text,label,seq_length,text_4mer,text_5mer,text_6mer,text_7mer,annotation,orig_index
AATATT ATATTG TATTGA ATTGAT TTGATG TGATGG GATGGT ATGGTT TGGTTA GGTTAT GTTATT TTATTT TATTTT ATTTTA TTTTAA TTTAAA TTAAAA TAAAAT AAAATA AAATAT AATATA ATATAT TATATT ATATTC TATTCT ATTCTA TTCTAA TCTAAG CTAAGC TAAGCA AAGCAC AGCACA GCACAC CACACG ACACGC CACGCC ACGCCT CGCCTA GCCTAT CCTATT CTATTA TATTAA ATTAAT TTAATT TAATTT AATTTA ATTTAG TTTAGG TTAGGG TAGGGC AGGGCG GGGCGT GGCGTG GCGTGA CGTGAT GTGATC TGATCT GATCTC ATCTCC TCTCCC CTCCCT TCCCTC CCCTCA CCTCAG CTCAGG TCAGGG CAGGGT AGGGTT GGGTTT GGTTTT GTTTTT TTTTTC TTTTCG TTTCGG TTCGGC TCGGCT CGGCTT GGCTTT GCTTTA CTTTAG TTTAGA TTAGAA TAGAAC AGAACC GAACCA AACCAT ACCATT CCATTG CATTGG ATTGGT TTGGTA TGGTAG GGTAGA GTAGAT TAGATT AGATTT GATTTG ATTTGC TTTGCC TTGCCA TGCCAA GCCAAT CCAATA CAATAG AATAGG ATAGGT TAGGTA AGGTAT GGTATT GTATTA TATTAA ATTAAC TTAACA TAACAT AACATC ACATCA CATCAC ATCACT TCACTA CACTAG ACTAGG CTAGGT TAGGTT AGGTTT GGTTTC GTTTCA TTTCAA TTCAAA TCAAAC CAAACT AAACTT AACTTT ACTTTA CTTTAC TTTACT TTACTT TACTTG ACTTGC CTTGCT TTGCTT TGCTTT GCTTTA,1,142,AATA ATAT TATT ATTG TTGA TGAT GATG ATGG TGGT GGTT GTTA TTAT TATT ATTT TTTT TTTA TTAA TAAA AAAA AAAT AATA ATAT TATA ATAT TATT ATTC TTCT TCTA CTAA TAAG AAGC AGCA GCAC CACA ACAC CACG ACGC CGCC GCCT CCTA CTAT TATT ATTA TTAA TAAT AATT ATTT TTTA TTAG TAGG AGGG GGGC GGCG GCGT CGTG GTGA TGAT GATC ATCT TCTC CTCC TCCC CCCT CCTC CTCA TCAG CAGG AGGG GGGT GGTT GTTT TTTT TTTT TTTC TTCG TCGG CGGC GGCT GCTT CTTT TTTA TTAG TAGA AGAA GAAC AACC ACCA CCAT CATT ATTG TTGG TGGT GGTA GTAG TAGA AGAT GATT ATTT TTTG TTGC TGCC GCCA CCAA CAAT AATA ATAG TAGG AGGT GGTA GTAT TATT ATTA TTAA TAAC AACA ACAT CATC ATCA TCAC CACT ACTA CTAG TAGG AGGT GGTT GTTT TTTC TTCA TCAA CAAA AAAC AACT ACTT CTTT TTTA TTAC TACT ACTT CTTG TTGC TGCT GCTT CTTT TTTA,AATAT ATATT TATTG ATTGA TTGAT TGATG GATGG ATGGT TGGTT GGTTA GTTAT TTATT TATTT ATTTT TTTTA TTTAA TTAAA TAAAA AAAAT AAATA AATAT ATATA TATAT ATATT TATTC ATTCT TTCTA TCTAA CTAAG TAAGC AAGCA AGCAC GCACA CACAC ACACG CACGC ACGCC CGCCT GCCTA CCTAT CTATT TATTA ATTAA TTAAT TAATT AATTT ATTTA TTTAG TTAGG TAGGG AGGGC GGGCG GGCGT GCGTG CGTGA GTGAT TGATC GATCT ATCTC TCTCC CTCCC TCCCT CCCTC CCTCA CTCAG TCAGG CAGGG AGGGT GGGTT GGTTT GTTTT TTTTT TTTTC TTTCG TTCGG TCGGC CGGCT GGCTT GCTTT CTTTA TTTAG TTAGA TAGAA AGAAC GAACC AACCA ACCAT CCATT CATTG ATTGG TTGGT TGGTA GGTAG GTAGA TAGAT AGATT GATTT ATTTG TTTGC TTGCC TGCCA GCCAA CCAAT CAATA AATAG ATAGG TAGGT AGGTA GGTAT GTATT TATTA ATTAA TTAAC TAACA AACAT ACATC CATCA ATCAC TCACT CACTA ACTAG CTAGG TAGGT AGGTT GGTTT GTTTC TTTCA TTCAA TCAAA CAAAC AAACT AACTT ACTTT CTTTA TTTAC TTACT TACTT ACTTG CTTGC TTGCT TGCTT GCTTT CTTTA,AATATT ATATTG TATTGA ATTGAT TTGATG TGATGG GATGGT ATGGTT TGGTTA GGTTAT GTTATT TTATTT TATTTT ATTTTA TTTTAA TTTAAA TTAAAA TAAAAT AAAATA AAATAT AATATA ATATAT TATATT ATATTC TATTCT ATTCTA TTCTAA TCTAAG CTAAGC TAAGCA AAGCAC AGCACA GCACAC CACACG ACACGC CACGCC ACGCCT CGCCTA GCCTAT CCTATT CTATTA TATTAA ATTAAT TTAATT TAATTT AATTTA ATTTAG TTTAGG TTAGGG TAGGGC AGGGCG GGGCGT GGCGTG GCGTGA CGTGAT GTGATC TGATCT GATCTC ATCTCC TCTCCC CTCCCT TCCCTC CCCTCA CCTCAG CTCAGG TCAGGG CAGGGT AGGGTT GGGTTT GGTTTT GTTTTT TTTTTC TTTTCG TTTCGG TTCGGC TCGGCT CGGCTT GGCTTT GCTTTA CTTTAG TTTAGA TTAGAA TAGAAC AGAACC GAACCA AACCAT ACCATT CCATTG CATTGG ATTGGT TTGGTA TGGTAG GGTAGA GTAGAT TAGATT AGATTT GATTTG ATTTGC TTTGCC TTGCCA TGCCAA GCCAAT CCAATA CAATAG AATAGG ATAGGT TAGGTA AGGTAT GGTATT GTATTA TATTAA ATTAAC TTAACA TAACAT AACATC ACATCA CATCAC ATCACT TCACTA CACTAG ACTAGG CTAGGT TAGGTT AGGTTT GGTTTC GTTTCA TTTCAA TTCAAA TCAAAC CAAACT AAACTT AACTTT ACTTTA CTTTAC TTTACT TTACTT TACTTG ACTTGC CTTGCT TTGCTT TGCTTT GCTTTA,AATATTG ATATTGA TATTGAT ATTGATG TTGATGG TGATGGT GATGGTT ATGGTTA TGGTTAT GGTTATT GTTATTT TTATTTT TATTTTA ATTTTAA TTTTAAA TTTAAAA TTAAAAT TAAAATA AAAATAT AAATATA AATATAT ATATATT TATATTC ATATTCT TATTCTA ATTCTAA TTCTAAG TCTAAGC CTAAGCA TAAGCAC AAGCACA AGCACAC GCACACG CACACGC ACACGCC CACGCCT ACGCCTA CGCCTAT GCCTATT CCTATTA CTATTAA TATTAAT ATTAATT TTAATTT TAATTTA AATTTAG ATTTAGG TTTAGGG TTAGGGC TAGGGCG AGGGCGT GGGCGTG GGCGTGA GCGTGAT CGTGATC GTGATCT TGATCTC GATCTCC ATCTCCC TCTCCCT CTCCCTC TCCCTCA CCCTCAG CCTCAGG CTCAGGG TCAGGGT CAGGGTT AGGGTTT GGGTTTT GGTTTTT GTTTTTC TTTTTCG TTTTCGG TTTCGGC TTCGGCT TCGGCTT CGGCTTT GGCTTTA GCTTTAG CTTTAGA TTTAGAA TTAGAAC TAGAACC AGAACCA GAACCAT AACCATT ACCATTG CCATTGG CATTGGT ATTGGTA TTGGTAG TGGTAGA GGTAGAT GTAGATT TAGATTT AGATTTG GATTTGC ATTTGCC TTTGCCA TTGCCAA TGCCAAT GCCAATA CCAATAG CAATAGG AATAGGT ATAGGTA TAGGTAT AGGTATT GGTATTA GTATTAA TATTAAC ATTAACA TTAACAT TAACATC AACATCA ACATCAC CATCACT ATCACTA TCACTAG CACTAGG ACTAGGT CTAGGTT TAGGTTT AGGTTTC GGTTTCA GTTTCAA TTTCAAA TTCAAAC TCAAACT CAAACTT AAACTTT AACTTTA ACTTTAC CTTTACT TTTACTT TTACTTG TACTTGC ACTTGCT CTTGCTT TTGCTTT TGCTTTA,"ID   SPIKE_SARS2             Reviewed;        1273 AA.
AC   P0DTC2;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Spike glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE            Short=S glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=E2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=Peplomer protein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S1 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2' {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Flags: Precursor;
GN   Name=S {ECO:0000255|HAMAP-Rule:MF_04099}; ORFNames=2;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   FUNCTION (SPIKE PROTEIN S1), AND CLEAVAGE BETWEEN S2 AND S2' BY HOST
RP   TMPRSS2.
RX   PubMed=32142651; DOI=10.1016/j.cell.2020.02.052;
RA   Hoffmann M., Kleine-Weber H., Schroeder S., Krueger N., Herrler T.,
RA   Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A.,
RA   Mueller M.A., Drosten C., Poehlmann S.;
RT   ""SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a
RT   clinically proven protease inhibitor."";
RL   Cell 181:1-10(2020).
RN   [3]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, FUNCTION, AND MUTAGENESIS OF
RP   681-PRO--ALA-684.
RX   PubMed=32362314; DOI=10.1016/j.molcel.2020.04.022;
RA   Hoffmann M., Kleine-Weber H., Poehlmann S.;
RT   ""A multibasic cleavage site in the Spike protein of SARS-CoV-2 is essential
RT   for infection of human lung cells."";
RL   Mol. Cell 78:779-784(2020).
RN   [4]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=32366695; DOI=10.1126/science.abb9983;
RA   Watanabe Y., Allen J.D., Wrapp D., McLellan J.S., Crispin M.;
RT   ""Site-specific glycan analysis of the SARS-CoV-2 spike."";
RL   Science 369:330-333(2020).
RN   [5]
RP   GLYCOSYLATION AT ASN-61; ASN-74; ASN-122; ASN-149; ASN-165; ASN-234;
RP   ASN-282; THR-323; SER-325; ASN-331; ASN-343; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1194, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=32363391; DOI=10.1093/glycob/cwaa042;
RA   Shajahan A., Supekar N.T., Gleinich A.S., Azadi P.;
RT   ""Deducing the N- and O- glycosylation profile of the spike protein of novel
RT   coronavirus SARS-CoV-2."";
RL   Glycobiology 30:981-988(2020).
RN   [6]
RP   VARIANT GLY-614.
RX   PubMed=32820179; DOI=10.1038/s41598-020-70827-z;
RA   Isabel S., Grana-Miraglia L., Gutierrez J.M., Bundalovic-Torma C.,
RA   Groves H.E., Isabel M.R., Eshaghi A., Patel S.N., Gubbay J.B., Poutanen T.,
RA   Guttman D.S., Poutanen S.M.;
RT   ""Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein
RT   mutation now documented worldwide."";
RL   Sci. Rep. 10:14031-14031(2020).
RN   [7]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=32697968; DOI=10.1016/j.cell.2020.06.043;
RG   Sheffield COVID-19 Genomics Group;
RA   Korber B., Fischer W.M., Gnanakaran S., Yoon H., Theiler J., Abfalterer W.,
RA   Hengartner N., Giorgi E.E., Bhattacharya T., Foley B., Hastie K.M.,
RA   Parker M.D., Partridge D.G., Evans C.M., Freeman T.M., de Silva T.I.,
RA   McDanal C., Perez L.G., Tang H., Moon-Walker A., Whelan S.P.,
RA   LaBranche C.C., Saphire E.O., Montefiori D.C.;
RT   ""Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases
RT   Infectivity of the COVID-19 Virus."";
RL   Cell 182:812-827(2020).
RN   [8]
RP   FUNCTION.
RX   PubMed=32817270; DOI=10.1126/science.abd5223;
RA   Turonova B., Sikora M., Schuermann C., Hagen W.J.H., Welsch S.,
RA   Blanc F.E.C., von Buelow S., Gecht M., Bagola K., Hoerner C.,
RA   van Zandbergen G., Landry J., de Azevedo N.T.D., Mosalaganti S.,
RA   Schwarz A., Covino R., Muehlebach M.D., Hummer G., Krijnse Locker J.,
RA   Beck M.;
RT   ""In situ structural analysis of SARS-CoV-2 spike reveals flexibility
RT   mediated by three hinges."";
RL   Science 370:203-208(2020).
RN   [9]
RP   GLYCOSYLATION.
RX   PubMed=32929138; DOI=10.1038/s41598-020-71748-7;
RA   Grant O.C., Montgomery D., Ito K., Woods R.J.;
RT   ""Analysis of the SARS-CoV-2 spike protein glycan shield reveals
RT   implications for immune recognition."";
RL   Sci. Rep. 10:14991-14991(2020).
RN   [10]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, IDENTIFICATION BY MASS SPECTROMETRY, SUBCELLULAR LOCATION, AND
RP   SUBUNIT.
RX   PubMed=32979942; DOI=10.1016/j.cell.2020.09.018;
RA   Yao H., Song Y., Chen Y., Wu N., Xu J., Sun C., Zhang J., Weng T.,
RA   Zhang Z., Wu Z., Cheng L., Shi D., Lu X., Lei J., Crispin M., Shi Y.,
RA   Li L., Li S.;
RT   ""Molecular Architecture of the SARS-CoV-2 Virus."";
RL   Cell 183:730-738(2020).
RN   [11]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=33106671; DOI=10.1038/s41586-020-2895-3;
RA   Plante J.A., Liu Y., Liu J., Xia H., Johnson B.A., Lokugamage K.G.,
RA   Zhang X., Muruato A.E., Zou J., Fontes-Garfias C.R., Mirchandani D.,
RA   Scharton D., Bilello J.P., Ku Z., An Z., Kalveram B., Freiberg A.N.,
RA   Menachery V.D., Xie X., Plante K.S., Weaver S.C., Shi P.Y.;
RT   ""Spike mutation D614G alters SARS-CoV-2 fitness."";
RL   Nature 592:116-121(2020).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Liverpool/REMRQ001/2020;
RX   PubMed=33082294; DOI=10.1126/science.abd3072;
RA   Daly J.L., Simonetti B., Klein K., Chen K.E., Williamson M.K.,
RA   Anton-Plagaro C., Shoemark D.K., Simon-Gracia L., Bauer M., Hollandi R.,
RA   Greber U.F., Horvath P., Sessions R.B., Helenius A., Hiscox J.A.,
RA   Teesalu T., Matthews D.A., Davidson A.D., Collins B.M., Cullen P.J.,
RA   Yamauchi Y.;
RT   ""Neuropilin-1 is a host factor for SARS-CoV-2 infection."";
RL   Science 370:861-865(2020).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Finland/1/2020;
RX   PubMed=33082293; DOI=10.1126/science.abd2985;
RA   Cantuti-Castelvetri L., Ojha R., Pedro L.D., Djannatian M., Franz J.,
RA   Kuivanen S., van der Meer F., Kallio K., Kaya T., Anastasina M., Smura T.,
RA   Levanov L., Szirovicza L., Tobi A., Kallio-Kokko H., Oesterlund P.,
RA   Joensuu M., Meunier F.A., Butcher S.J., Winkler M.S., Mollenhauer B.,
RA   Helenius A., Gokce O., Teesalu T., Hepojoki J., Vapalahti O.,
RA   Stadelmann C., Balistreri G., Simons M.;
RT   ""Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity."";
RL   Science 370:856-860(2020).
RN   [14]
RP   INTERACTION WITH HUMAN ITGA5 AND ITGB1.
RX   PubMed=33102950; DOI=10.1016/j.jacbts.2020.10.003;
RA   Beddingfield B.J., Iwanaga N., Chapagain P.P., Zheng W., Roy C.J., Hu T.Y.,
RA   Kolls J.K., Bix G.J.;
RT   ""The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2
RT   Infection."";
RL   JACC Basic Transl. Sci. 6:1-8(2021).
RN   [15]
RP   VARIANT GLY-614.
RX   PubMed=33184236; DOI=10.1126/science.abe8499;
RA   Hou Y.J., Chiba S., Halfmann P., Ehre C., Kuroda M., Dinnon K.H. III,
RA   Leist S.R., Schaefer A., Nakajima N., Takahashi K., Lee R.E.,
RA   Mascenik T.M., Graham R., Edwards C.E., Tse L.V., Okuda K., Markmann A.J.,
RA   Bartelt L., de Silva A., Margolis D.M., Boucher R.C., Randell S.H.,
RA   Suzuki T., Gralinski L.E., Kawaoka Y., Baric R.S.;
RT   ""SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and
RT   transmission in vivo."";
RL   Science 370:1464-1468(2020).
RN   [16]
RP   VARIANT GLY-614.
RX   PubMed=33417835; DOI=10.1016/j.celrep.2020.108630;
RA   Gobeil S.M., Janowska K., McDowell S., Mansouri K., Parks R., Manne K.,
RA   Stalls V., Kopp M.F., Henderson R., Edwards R.J., Haynes B.F., Acharya P.;
RT   ""D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease
RT   Cleavage at the S1/S2 Junction."";
RL   Cell Rep. 34:108630-108630(2021).
RN   [17]
RP   VARIANTS 69-VAL--PHE-70 DEL; LYS-144 DEL; TYR-501; ASP-570; GLY-614;
RP   HIS-681; ILE-716; ALA-982 AND HIS-1118.
RC   STRAIN=20I/501Y.V1, Alpha, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [18]
RP   VARIANT TYR-501.
RX   PubMed=32732280; DOI=10.1126/science.abc4730;
RA   Gu H., Chen Q., Yang G., He L., Fan H., Deng Y.Q., Wang Y., Teng Y.,
RA   Zhao Z., Cui Y., Li Y., Li X.F., Li J., Zhang N.N., Yang X., Chen S.,
RA   Guo Y., Zhao G., Wang X., Luo D.Y., Wang H., Yang X., Li Y., Han G., He Y.,
RA   Zhou X., Geng S., Sheng X., Jiang S., Sun S., Qin C.F., Zhou Y.;
RT   ""Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy."";
RL   Science 369:1603-1607(2020).
RN   [19]
RP   VARIANT GLY-614, AND MUTAGENESIS OF GLY-614.
RX   PubMed=33636719; DOI=10.1038/s41586-021-03361-1;
RA   Zhou B., Thi Nhu Thao T., Hoffmann D., Taddeo A., Ebert N., Labroussaa F.,
RA   Pohlmann A., King J., Steiner S., Kelly J.N., Portmann J., Halwe N.J.,
RA   Ulrich L., Trueeb B.S., Fan X., Hoffmann B., Wang L., Thomann L., Lin X.,
RA   Stalder H., Pozzi B., de Brot S., Jiang N., Cui D., Hossain J., Wilson M.,
RA   Keller M., Stark T.J., Barnes J.R., Dijkman R., Jores J., Benarafa C.,
RA   Wentworth D.E., Thiel V., Beer M.;
RT   ""SARS-CoV-2 spike D614G change enhances replication and transmission."";
RL   Nature 5920:122-127(2021).
RN   [20]
RP   MUTAGENESIS OF ASN-165; ASN-234; ASN-331; ASN-343; LEU-452; ALA-475;
RP   VAL-483; PHE-490 AND HIS-519.
RX   PubMed=32730807; DOI=10.1016/j.cell.2020.07.012;
RA   Li Q., Wu J., Nie J., Zhang L., Hao H., Liu S., Zhao C., Zhang Q., Liu H.,
RA   Nie L., Qin H., Wang M., Lu Q., Li X., Sun Q., Liu J., Zhang L., Li X.,
RA   Huang W., Wang Y.;
RT   ""The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and
RT   Antigenicity."";
RL   Cell 182:1284-1294(2020).
RN   [21]
RP   FUNCTION, CLEAVAGE BETWEEN S1 AND S2 BY HOST CTSL, AND INTERACTION WITH
RP   HUMAN ACE2.
RX   PubMed=32221306; DOI=10.1038/s41467-020-15562-9;
RA   Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Guo R., Chen T.,
RA   Hu J., Xiang Z., Mu Z., Chen X., Chen J., Hu K., Jin Q., Wang J., Qian Z.;
RT   ""Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and
RT   its immune cross-reactivity with SARS-CoV."";
RL   Nat. Commun. 11:1620-1620(2020).
RN   [22]
RP   INTERACTION WITH HUMAN ACE2.
RX   PubMed=33607086; DOI=10.1016/j.bpj.2021.02.007;
RA   Cao W., Dong C., Kim S., Hou D., Tai W., Du L., Im W., Zhang X.F.;
RT   ""Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2
RT   protein-protein interaction."";
RL   Biophys. J. 120:1011-1019(2021).
RN   [23]
RP   FUNCTION, AND CLEAVAGE BETWEEN S1 AND S2 BY HOST TMPRSS2.
RX   PubMed=33465165; DOI=10.1371/journal.ppat.1009212;
RA   Ou T., Mou H., Zhang L., Ojha A., Choe H., Farzan M.;
RT   ""Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated
RT   by TMPRSS2."";
RL   PLoS Pathog. 17:e1009212-e1009212(2021).
RN   [24]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH S PROTEIN.
RX   PubMed=33229438; DOI=10.1074/jbc.ra120.016175;
RA   Boson B., Legros V., Zhou B., Siret E., Mathieu C., Cosset F.L.,
RA   Lavillette D., Denolly S.;
RT   ""The SARS-CoV-2 Envelope and Membrane proteins modulate maturation and
RT   retention of the Spike protein, allowing assembly of virus-like
RT   particles."";
RL   J. Biol. Chem. 296:100111-100111(2020).
RN   [25]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, MUTAGENESIS OF ALA-684, AND FUNCTION (SPIKE PROTEIN S2').
RX   PubMed=32703818; DOI=10.26508/lsa.202000786;
RA   Bestle D., Heindl M.R., Limburg H., Van Lam van T., Pilgram O., Moulton H.,
RA   Stein D.A., Hardes K., Eickmann M., Dolnik O., Rohde C., Klenk H.D.,
RA   Garten W., Steinmetzer T., Boettcher-Friebertshaeuser E.;
RT   ""TMPRSS2 and furin are both essential for proteolytic activation of SARS-
RT   CoV-2 in human airway cells."";
RL   Life. Sci Alliance 3:1-14(2020).
RN   [26]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, CLEAVAGE BETWEEN S2 AND S2' BY HOST CSTL, AND FUNCTION (SPIKE
RP   PROTEIN S2').
RX   PubMed=34159616; DOI=10.15252/embj.2021107821;
RA   Koch J., Uckeley Z.M., Doldan P., Stanifer M., Boulant S., Lozach P.Y.;
RT   ""TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect
RT   host cells."";
RL   EMBO J. 40:1-20(2021).
RN   [27]
RP   VARIANTS PHE-18; ALA-80; GLY-215; ASN-417; LYS-484; TYR-501; GLY-614 AND
RP   VAL-701.
RC   STRAIN=20H/501Y.V2, B.1.351, and Beta;
RX   PubMed=33690265; DOI=10.1038/s41586-021-03402-9;
RA   Tegally H., Wilkinson E., Giovanetti M., Iranzadeh A., Fonseca V.,
RA   Giandhari J., Doolabh D., Pillay S., San E.J., Msomi N., Mlisana K.,
RA   von Gottberg A., Walaza S., Allam M., Ismail A., Mohale T., Glass A.J.,
RA   Engelbrecht S., Van Zyl G., Preiser W., Petruccione F., Sigal A.,
RA   Hardie D., Marais G., Hsiao M., Korsman S., Davies M.A., Tyers L.,
RA   Mudau I., York D., Maslo C., Goedhals D., Abrahams S., Laguda-Akingba O.,
RA   Alisoltani-Dehkordi A., Godzik A., Wibmer C.K., Sewell B.T., Lourenco J.,
RA   Alcantara L.C.J., Kosakovsky Pond S.L., Weaver S., Martin D.,
RA   Lessells R.J., Bhiman J.N., Williamson C., de Oliveira T.;
RT   ""Emergence of a SARS-CoV-2 variant of concern with mutations in spike
RT   glycoprotein."";
RL   Nature 592:438-443(2021).
RN   [28]
RP   POLYMORPHISM.
RX   PubMed=34142653; DOI=10.2807/1560-7917.es.2021.26.24.2100509;
RA   Campbell F., Archer B., Laurenson-Schafer H., Jinnai Y., Konings F.,
RA   Batra N., Pavlin B., Vandemaele K., Van Kerkhove M.D., Jombart T.,
RA   Morgan O., le Polain de Waroux O.;
RT   ""Increased transmissibility and global spread of SARS-CoV-2 variants of
RT   concern as at June 2021."";
RL   Eurosurveillance 26:0-0(2021).
RN   [29]
RP   VARIANTS ARG-452 AND PHE-453, AND MUTAGENESIS OF LEU-452; TYR-453 AND
RP   ASN-501.
RX   PubMed=34171266; DOI=10.1016/j.chom.2021.06.006;
RG   Genotype to Phenotype Japan (G2P-Japan) Consortium;
RA   Motozono C., Toyoda M., Zahradnik J., Saito A., Nasser H., Tan T.S.,
RA   Ngare I., Kimura I., Uriu K., Kosugi Y., Yue Y., Shimizu R., Ito J.,
RA   Torii S., Yonekawa A., Shimono N., Nagasaki Y., Minami R., Toya T.,
RA   Sekiya N., Fukuhara T., Matsuura Y., Schreiber G., Ikeda T., Nakagawa S.,
RA   Ueno T., Sato K.;
RT   ""SARS-CoV-2 spike L452R variant evades cellular immunity and increases
RT   infectivity."";
RL   Cell Host Microbe 0:0-0(2021).
RN   [30]
RP   VARIANT 69-VAL--PHE-70 DEL, AND MUTAGENESIS OF 69-HIS-VAL-70.
RX   PubMed=34166617; DOI=10.1016/j.celrep.2021.109292;
RG   COVID-19 Genomics UK (COG-UK) Consortium;
RA   Meng B., Kemp S.A., Papa G., Datir R., Ferreira I.A.T.M., Marelli S.,
RA   Harvey W.T., Lytras S., Mohamed A., Gallo G., Thakur N., Collier D.A.,
RA   Mlcochova P., Duncan L.M., Carabelli A.M., Kenyon J.C., Lever A.M.,
RA   De Marco A., Saliba C., Culap K., Cameroni E., Matheson N.J., Piccoli L.,
RA   Corti D., James L.C., Robertson D.L., Bailey D., Gupta R.K.;
RT   ""Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in
RT   the Alpha variant B.1.1.7."";
RL   Cell Rep. 35:109292-109292(2021).
RN   [31]
RP   VARIANTS ILE-13 AND CYS-152, POLYMORPHISM, AND MASS SPECTROMETRY (SIGNAL).
RX   PubMed=34210893; DOI=10.1126/science.abi7994;
RA   McCallum M., Bassi J., De Marco A., Chen A., Walls A.C., Di Iulio J.,
RA   Tortorici M.A., Navarro M.J., Silacci-Fregni C., Saliba C., Sprouse K.R.,
RA   Agostini M., Pinto D., Culap K., Bianchi S., Jaconi S., Cameroni E.,
RA   Bowen J.E., Tilles S.W., Pizzuto M.S., Guastalla S.B., Bona G.,
RA   Pellanda A.F., Garzoni C., Van Voorhis W.C., Rosen L.E., Snell G.,
RA   Telenti A., Virgin H.W., Piccoli L., Corti D., Veesler D.;
RT   ""SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern."";
RL   Science 373:648-654(2021).
RN   [32]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-1269 AND HIS-1271.
RX   PubMed=34504087; DOI=10.1038/s41467-021-25589-1;
RA   Cattin-Ortola J., Welch L.G., Maslen S.L., Papa G., James L.C., Munro S.;
RT   ""Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate
RT   expression at the cell surface and syncytia formation."";
RL   Nat. Commun. 12:5333-5333(2021).
RN   [33]
RP   PALMITOYLATION AT CYS-1235; CYS-1236; CYS-1240; CYS-1241; CYS-1243;
RP   CYS-1247; CYS-1248; CYS-1250; CYS-1253 AND CYS-1254.
RX   PubMed=34599882; DOI=10.1016/j.devcel.2021.09.016;
RA   Mesquita F.S., Abrami L., Sergeeva O., Turelli P., Qing E., Kunz B.,
RA   Raclot C., Paz Montoya J., Abriata L.A., Gallagher T., Dal Peraro M.,
RA   Trono D., D'Angelo G., van der Goot F.G.;
RT   ""S-acylation controls SARS-CoV-2 membrane lipid organization and enhances
RT   infectivity."";
RL   Dev. Cell 56:1-18(2021).
RN   [34] {ECO:0007744|PDB:6M17}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.90 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), DOMAIN, AND INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1).
RX   PubMed=32132184; DOI=10.1126/science.abb2762;
RA   Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q.;
RT   ""Structural basis for the recognition of the SARS-CoV-2 by full-length
RT   human ACE2."";
RL   Science 367:1444-1448(2020).
RN   [35]
RP   SUPERANTIGEN, AND DOMAIN.
RX   PubMed=32989130; DOI=10.1073/pnas.2010722117;
RA   Cheng M.H., Zhang S., Porritt R.A., Noval Rivas M., Paschold L.,
RA   Willscher E., Binder M., Arditi M., Bahar I.;
RT   ""Superantigenic character of an insert unique to SARS-CoV-2 spike supported
RT   by skewed TCR repertoire in patients with hyperinflammation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 117:25254-25262(2020).
RN   [36]
RP   INTERACTION WITH HUMAN BILIRUBIN, INTERACTION WITH HUMAN BILIVERDIN, AND
RP   MUTAGENESIS OF ASN-121 AND ARG-190.
RX   PubMed=33888467; DOI=10.1126/sciadv.abg7607;
RA   Rosa A., Pye V.E., Graham C., Muir L., Seow J., Ng K.W., Cook N.J.,
RA   Rees-Spear C., Parker E., Dos Santos M.S., Rosadas C., Susana A., Rhys H.,
RA   Nans A., Masino L., Roustan C., Christodoulou E., Ulferts R., Wrobel A.G.,
RA   Short C.E., Fertleman M., Sanders R.W., Heaney J., Spyer M., Kjaer S.,
RA   Riddell A., Malim M.H., Beale R., MacRae J.I., Taylor G.P., Nastouli E.,
RA   van Gils M.J., Rosenthal P.B., Pizzato M., McClure M.O., Tedder R.S.,
RA   Kassiotis G., McCoy L.E., Doores K.J., Cherepanov P.;
RT   ""SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity."";
RL   Sci. Adv. 7:0-0(2021).
RN   [37]
RP   BIOTECHNOLOGY, AND MUTAGENESIS OF 682-ARG--ARG-685 AND 986-LYS-VAL-987.
RX   PubMed=34322129; DOI=10.3389/fimmu.2021.701501;
RA   Martinez-Flores D., Zepeda-Cervantes J., Cruz-Resendiz A.,
RA   Aguirre-Sampieri S., Sampieri A., Vaca L.;
RT   ""SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of
RT   New Viral Variants."";
RL   Front. Immunol. 12:701501-701501(2021).
RN   [38]
RP   GLYCOSYLATION AT THR-676 AND THR-678 BY HOST GALNT1, AND MUTAGENESIS OF
RP   SER-673; THR-676; THR-678; SER-680 AND PRO-681.
RX   PubMed=34732583; DOI=10.1073/pnas.2109905118;
RA   Zhang L., Mann M., Syed Z.A., Reynolds H.M., Tian E., Samara N.L.,
RA   Zeldin D.C., Tabak L.A., Ten Hagen K.G.;
RT   ""Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [39]
RP   REVIEW, PROTEOLITIC PROCESSING, FUNCTION (SPIKE PROTEIN S2), AND FUNCTION
RP   (SPIKE PROTEIN S2').
RX   PubMed=34561887; DOI=10.1111/1348-0421.12945;
RA   Takeda M.;
RT   ""Proteolytic activation of SARS-CoV-2 spike protein."";
RL   Microbiol. Immunol. 66:15-23(2022).
RN   [40]
RP   INTERACTION WITH HOST MBL2.
RX   PubMed=35102342; DOI=10.1038/s41590-021-01114-w;
RA   Stravalaci M., Pagani I., Paraboschi E.M., Pedotti M., Doni A.,
RA   Scavello F., Mapelli S.N., Sironi M., Perucchini C., Varani L.,
RA   Matkovic M., Cavalli A., Cesana D., Gallina P., Pedemonte N., Capurro V.,
RA   Clementi N., Mancini N., Invernizzi P., Bayarri-Olmos R., Garred P.,
RA   Rappuoli R., Duga S., Bottazzi B., Uguccioni M., Asselta R., Vicenzi E.,
RA   Mantovani A., Garlanda C.;
RT   ""Recognition and inhibition of SARS-CoV-2 by humoral innate immunity
RT   pattern recognition molecules."";
RL   Nat. Immunol. 23:275-286(2022).
RN   [41]
RP   FUNCTION (SPIKE PROTEIN S1), AND INTERACTION WITH HOST INTEGRIN (SPIKE
RP   PROTEIN S1).
RX   PubMed=35150743; DOI=10.1016/j.jbc.2022.101710;
RA   Liu J., Lu F., Chen Y., Plow E., Qin J.;
RT   ""Integrin mediates cell entry of the SARS-CoV-2 virus independent of
RT   cellular receptor ACE2."";
RL   J. Biol. Chem. 1:101710-101710(2022).
RN   [42]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [43]
RP   SUBUNIT.
RX   PubMed=36735681; DOI=10.1371/journal.pbio.3001959;
RA   Shilts J., Crozier T.W.M., Teixeira-Silva A., Gabaev I., Gerber P.P.,
RA   Greenwood E.J.D., Watson S.J., Ortmann B.M., Gawden-Bone C.M., Pauzaite T.,
RA   Hoffmann M., Nathan J.A., Poehlmann S., Matheson N.J., Lehner P.J.,
RA   Wright G.J.;
RT   ""LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike
RT   protein."";
RL   PLoS Biol. 21:e3001959-e3001959(2023).
RN   [44]
RP   VARIANT ASN-405.
RX   PubMed=36851546; DOI=10.3390/v15020332;
RA   Bugatti A., Filippini F., Messali S., Giovanetti M., Ravelli C., Zani A.,
RA   Ciccozzi M., Caruso A., Caccuri F.;
RT   ""The D405N Mutation in the Spike Protein of SARS-CoV-2 Omicron BA.5
RT   Inhibits Spike/Integrins Interaction and Viral Infection of Human Lung
RT   Microvascular Endothelial Cells."";
RL   Viruses 15:0-0(2023).
RN   [45]
RP   MUTAGENESIS OF GLU-484.
RX   PubMed=37421949; DOI=10.1016/j.cell.2023.06.005;
RA   Baggen J., Jacquemyn M., Persoons L., Vanstreels E., Pye V.E., Wrobel A.G.,
RA   Calvaresi V., Martin S.R., Roustan C., Cronin N.B., Reading E.,
RA   Thibaut H.J., Vercruysse T., Maes P., De Smet F., Yee A., Nivitchanyong T.,
RA   Roell M., Franco-Hernandez N., Rhinn H., Mamchak A.A., Ah Young-Chapon M.,
RA   Brown E., Cherepanov P., Daelemans D.;
RT   ""TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry."";
RL   Cell 186:1-16(2023).
RN   [46] {ECO:0007744|PDB:6VSB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.46 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1), SUBUNIT, AND
RP   GLYCOSYLATION.
RX   PubMed=32075877; DOI=10.1126/science.abb2507;
RA   Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O.,
RA   Graham B.S., McLellan J.S.;
RT   ""Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation."";
RL   Science 367:1260-1263(2020).
RN   [47] {ECO:0007744|PDB:6VXX, ECO:0007744|PDB:6VYB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.80 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), SUBUNIT (SPIKE PROTEIN S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN
RP   S1), MUTAGENESIS OF 679-GLN--ALA-684, GLYCOSYLATION AT ASN-61; ASN-122;
RP   ASN-61; ASN-165; ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616;
RP   ASN-657; ASN-709; ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1134, AND
RP   DISULFIDE BOND.
RX   PubMed=32155444; DOI=10.1016/j.cell.2020.02.058;
RA   Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D.;
RT   ""Structure, function, and antigenicity of the SARS-CoV-2 spike
RT   glycoprotein."";
RL   Cell 180:1-12(2020).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2.
RX   PubMed=32225176; DOI=10.1038/s41586-020-2180-5;
RA   Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q.,
RA   Zhang L., Wang X.;
RT   ""Structure of the SARS-CoV-2 spike receptor-binding domain bound to the
RT   ACE2 receptor."";
RL   Nature 581:215-220(2020).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.68 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2, INTERACTION WITH HOST ACE2, AND MUTAGENESIS OF GLN-493 AND
RP   ASN-501.
RX   PubMed=32225175; DOI=10.1038/s41586-020-2179-y;
RA   Shang J., Ye G., Shi K., Wan Y., Luo C., Aihara H., Geng Q., Auerbach A.,
RA   Li F.;
RT   ""Structural basis of receptor recognition by SARS-CoV-2."";
RL   Nature 581:221-224(2020).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (3.08 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HUMAN ANTIBODY CR3022, AND DISULFIDE BOND.
RX   PubMed=32245784; DOI=10.1126/science.abb7269;
RA   Yuan M., Wu N.C., Zhu X., Lee C.D., So R.T.Y., Lv H., Mok C.K.P.,
RA   Wilson I.A.;
RT   ""A highly conserved cryptic epitope in the receptor-binding domains of
RT   SARS-CoV-2 and SARS-CoV."";
RL   Science 368:630-633(2020).
CC   -!- FUNCTION: [Spike protein S1]: Attaches the virion to the cell membrane
CC       by interacting with host receptor, initiating the infection. The major
CC       receptor is host ACE2 (PubMed:32142651, PubMed:32155444,
CC       PubMed:33607086). When S2/S2' has been cleaved, binding to the receptor
CC       triggers direct fusion at the cell membrane (PubMed:34561887). When
CC       S2/S2' has not been cleaved, binding to the receptor results in
CC       internalization of the virus by endocytosis leading to fusion of the
CC       virion membrane with the host endosomal membrane (PubMed:32075877,
CC       PubMed:32221306). Alternatively, may use NRP1/NRP2 (PubMed:33082294,
CC       PubMed:33082293) and integrin as entry receptors (PubMed:35150743). The
CC       use of NRP1/NRP2 receptors may explain the tropism of the virus in
CC       human olfactory epithelial cells, which express these molecules at high
CC       levels but ACE2 at low levels (PubMed:33082293). The stalk domain of S
CC       contains three hinges, giving the head unexpected orientational freedom
CC       (PubMed:32817270). {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32142651,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32817270, ECO:0000269|PubMed:33082293,
CC       ECO:0000269|PubMed:33082294, ECO:0000269|PubMed:35150743,
CC       ECO:0000303|PubMed:33082293, ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2]: Precursor of the fusion protein processed
CC       in the biosynthesis of the S protein and the formation of virus
CC       particle. Mediates fusion of the virion and cellular membranes by
CC       functioning as a class I viral fusion protein. Contains two viral
CC       fusion peptides that are unmasked after cleavage. The S2/S2' cleavage
CC       occurs during virus entry at the cell membrane by host TMPRSS2
CC       (PubMed:32142651) or during endocytosis by host CSTL (PubMed:32703818,
CC       PubMed:34159616). In either case, this triggers an extensive and
CC       irreversible conformational change leading to fusion of the viral
CC       envelope with the cellular cytoplasmic membrane, releasing viral
CC       genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the
CC       current model, the protein has at least three conformational states:
CC       pre-fusion native state, pre-hairpin intermediate state, and post-
CC       fusion hairpin state. During fusion of the viral and target cell
CC       membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-
CC       hairpins structure and position the fusion peptide in close proximity
CC       to the C-terminal region of the ectodomain. Formation of this structure
CC       appears to promote apposition and subsequent fusion of viral and target
CC       cell membranes. {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32703818, ECO:0000269|PubMed:34159616,
CC       ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2']: Subunit of the fusion protein that is
CC       processed upon entry into the host cell. Mediates fusion of the virion
CC       and cellular membranes by functioning as a class I viral fusion
CC       protein. Contains a viral fusion peptide that is unmasked after S2
CC       cleavage. This cleavage can occur at the cell membrane by host TMPRSS2
CC       or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616).
CC       In either case, this triggers an extensive and irreversible
CC       conformational change that leads to fusion of the viral envelope with
CC       the cellular cytoplasmic membrane, releasing viral genomic RNA into the
CC       host cell cytoplasm (PubMed:34561887). Under the current model, the
CC       protein has at least three conformational states: pre-fusion native
CC       state, pre-hairpin intermediate state, and post-fusion hairpin state.
CC       During fusion of the viral and target cell membranes, the coiled coil
CC       regions (heptad repeats) adopt a trimer-of-hairpins structure and
CC       position the fusion peptide in close proximity to the C-terminal region
CC       of the ectodomain. Formation of this structure appears to promote
CC       apposition and subsequent fusion of viral and target cell membranes.
CC       {ECO:0000255|HAMAP-Rule:MF_04099, ECO:0000269|PubMed:32703818,
CC       ECO:0000269|PubMed:34159616, ECO:0000305|PubMed:34561887}.
CC   -!- SUBUNIT: [Spike glycoprotein]: Homotrimer; each monomer consists of a
CC       S1 and a S2 subunit (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784). The resulting peplomers protrude from the virus
CC       surface as spikes (PubMed:32979942). Interacts with ORF3a protein and
CC       ORF7a protein (By similarity) (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784, PubMed:32979942). There are an average of 26 +/-15
CC       spike trimers at the surface of virion particles (PubMed:32979942).
CC       Binds to host MBL2 (PubMed:35102342). This binding occurs via glycans
CC       and inhibits viral infectivity. Inhibition is effective against alpha,
CC       beta, gamma, and delta variants (PubMed:35102342). {ECO:0000255|HAMAP-
CC       Rule:MF_04099, ECO:0000269|PubMed:32075877,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32245784,
CC       ECO:0000269|PubMed:32979942, ECO:0000269|PubMed:35102342}.
CC   -!- SUBUNIT: [Spike protein S1]: Binds to host ACE2 (PubMed:32075877,
CC       PubMed:32132184, PubMed:32155444, PubMed:32221306, PubMed:32225175,
CC       PubMed:32225176, PubMed:33607086). RBD also interacts with the N-linked
CC       glycan on 'Asn-90' of ACE2 (PubMed:33607086). Cleavage of S generates a
CC       polybasic C-terminal sequence on S1 that binds to host Neuropilin-1
CC       (NRP1) and Neuropilin-2 (NRP2) receptors (PubMed:33082293,
CC       PubMed:33082294). Interacts with host integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) and with ACE2 in complex with integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) (PubMed:33102950). May interact via cytoplasmic c-
CC       terminus with M protein (PubMed:33229438). May interact (via N-
CC       terminus) with host bilirubin and biliverdin, thereby preventing
CC       antibody binding to the SARS-CoV-2 spike NTD via an allosteric
CC       mechanism (PubMed:33888467). May interact with host LRRC15, thereby
CC       allowing attachment to host cells (PubMed:36735681).
CC       {ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32132184,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32225",4533
CTGGTG TGGTGT GGTGTG GTGTGC TGTGCT GTGCTG TGCTGG GCTGGT CTGGTA TGGTAC GGTACG GTACGC TACGCG ACGCGG CGCGGT GCGGTG CGGTGG GGTGGC GTGGCG TGGCGC GGCGCT GCGCTG CGCTGA GCTGAT CTGATG TGATGA GATGAA ATGAAG TGAAGC GAAGCC AAGCCG AGCCGC GCCGCG CCGCGC CGCGCT GCGCTT CGCTTC GCTTCG CTTCGG TTCGGC TCGGCT CGGCTA GGCTAC GCTACG CTACGA TACGAC ACGACG CGACGA GACGAC ACGACA CGACAG GACAGC ACAGCC CAGCCT AGCCTG GCCTGG CCTGGA CTGGAT TGGATG GGATGC GATGCC ATGCCT TGCCTT GCCTTC CCTTCG CTTCGG TTCGGC TCGGCG CGGCGT GGCGTG GCGTGC CGTGCA GTGCAC TGCACG GCACGG CACGGG ACGGGA CGGGAT GGGATC GGATCG GATCGG ATCGGC TCGGCG CGGCGG GGCGGC GCGGCA CGGCAT GGCATG GCATGG CATGGT ATGGTC TGGTCG GGTCGG GTCGGC TCGGCA CGGCAT GGCATG GCATGC CATGCT ATGCTG TGCTGC GCTGCT CTGCTG TGCTGA GCTGAC CTGACC TGACCG GACCGG ACCGGC CCGGCC CGGCCT GGCCTG GCCTGT CCTGTT CTGTTG TGTTGG GTTGGC TTGGCC TGGCCC GGCCCA GCCCAT CCCATG CCATGG CATGGC ATGGCG TGGCGC GGCGCG GCGCGC CGCGCT GCGCTT CGCTTT GCTTTC CTTTCC TTTCCG TTCCGC TCCGCC CCGCCA CGCCAC GCCACC CCACCA CACCAA ACCAAC CCAACG CAACGA AACGAC,2,145,CTGG TGGT GGTG GTGT TGTG GTGC TGCT GCTG CTGG TGGT GGTA GTAC TACG ACGC CGCG GCGG CGGT GGTG GTGG TGGC GGCG GCGC CGCT GCTG CTGA TGAT GATG ATGA TGAA GAAG AAGC AGCC GCCG CCGC CGCG GCGC CGCT GCTT CTTC TTCG TCGG CGGC GGCT GCTA CTAC TACG ACGA CGAC GACG ACGA CGAC GACA ACAG CAGC AGCC GCCT CCTG CTGG TGGA GGAT GATG ATGC TGCC GCCT CCTT CTTC TTCG TCGG CGGC GGCG GCGT CGTG GTGC TGCA GCAC CACG ACGG CGGG GGGA GGAT GATC ATCG TCGG CGGC GGCG GCGG CGGC GGCA GCAT CATG ATGG TGGT GGTC GTCG TCGG CGGC GGCA GCAT CATG ATGC TGCT GCTG CTGC TGCT GCTG CTGA TGAC GACC ACCG CCGG CGGC GGCC GCCT CCTG CTGT TGTT GTTG TTGG TGGC GGCC GCCC CCCA CCAT CATG ATGG TGGC GGCG GCGC CGCG GCGC CGCT GCTT CTTT TTTC TTCC TCCG CCGC CGCC GCCA CCAC CACC ACCA CCAA CAAC AACG ACGA CGAC,CTGGT TGGTG GGTGT GTGTG TGTGC GTGCT TGCTG GCTGG CTGGT TGGTA GGTAC GTACG TACGC ACGCG CGCGG GCGGT CGGTG GGTGG GTGGC TGGCG GGCGC GCGCT CGCTG GCTGA CTGAT TGATG GATGA ATGAA TGAAG GAAGC AAGCC AGCCG GCCGC CCGCG CGCGC GCGCT CGCTT GCTTC CTTCG TTCGG TCGGC CGGCT GGCTA GCTAC CTACG TACGA ACGAC CGACG GACGA ACGAC CGACA GACAG ACAGC CAGCC AGCCT GCCTG CCTGG CTGGA TGGAT GGATG GATGC ATGCC TGCCT GCCTT CCTTC CTTCG TTCGG TCGGC CGGCG GGCGT GCGTG CGTGC GTGCA TGCAC GCACG CACGG ACGGG CGGGA GGGAT GGATC GATCG ATCGG TCGGC CGGCG GGCGG GCGGC CGGCA GGCAT GCATG CATGG ATGGT TGGTC GGTCG GTCGG TCGGC CGGCA GGCAT GCATG CATGC ATGCT TGCTG GCTGC CTGCT TGCTG GCTGA CTGAC TGACC GACCG ACCGG CCGGC CGGCC GGCCT GCCTG CCTGT CTGTT TGTTG GTTGG TTGGC TGGCC GGCCC GCCCA CCCAT CCATG CATGG ATGGC TGGCG GGCGC GCGCG CGCGC GCGCT CGCTT GCTTT CTTTC TTTCC TTCCG TCCGC CCGCC CGCCA GCCAC CCACC CACCA ACCAA CCAAC CAACG AACGA ACGAC,CTGGTG TGGTGT GGTGTG GTGTGC TGTGCT GTGCTG TGCTGG GCTGGT CTGGTA TGGTAC GGTACG GTACGC TACGCG ACGCGG CGCGGT GCGGTG CGGTGG GGTGGC GTGGCG TGGCGC GGCGCT GCGCTG CGCTGA GCTGAT CTGATG TGATGA GATGAA ATGAAG TGAAGC GAAGCC AAGCCG AGCCGC GCCGCG CCGCGC CGCGCT GCGCTT CGCTTC GCTTCG CTTCGG TTCGGC TCGGCT CGGCTA GGCTAC GCTACG CTACGA TACGAC ACGACG CGACGA GACGAC ACGACA CGACAG GACAGC ACAGCC CAGCCT AGCCTG GCCTGG CCTGGA CTGGAT TGGATG GGATGC GATGCC ATGCCT TGCCTT GCCTTC CCTTCG CTTCGG TTCGGC TCGGCG CGGCGT GGCGTG GCGTGC CGTGCA GTGCAC TGCACG GCACGG CACGGG ACGGGA CGGGAT GGGATC GGATCG GATCGG ATCGGC TCGGCG CGGCGG GGCGGC GCGGCA CGGCAT GGCATG GCATGG CATGGT ATGGTC TGGTCG GGTCGG GTCGGC TCGGCA CGGCAT GGCATG GCATGC CATGCT ATGCTG TGCTGC GCTGCT CTGCTG TGCTGA GCTGAC CTGACC TGACCG GACCGG ACCGGC CCGGCC CGGCCT GGCCTG GCCTGT CCTGTT CTGTTG TGTTGG GTTGGC TTGGCC TGGCCC GGCCCA GCCCAT CCCATG CCATGG CATGGC ATGGCG TGGCGC GGCGCG GCGCGC CGCGCT GCGCTT CGCTTT GCTTTC CTTTCC TTTCCG TTCCGC TCCGCC CCGCCA CGCCAC GCCACC CCACCA CACCAA ACCAAC CCAACG CAACGA AACGAC,CTGGTGT TGGTGTG GGTGTGC GTGTGCT TGTGCTG GTGCTGG TGCTGGT GCTGGTA CTGGTAC TGGTACG GGTACGC GTACGCG TACGCGG ACGCGGT CGCGGTG GCGGTGG CGGTGGC GGTGGCG GTGGCGC TGGCGCT GGCGCTG GCGCTGA CGCTGAT GCTGATG CTGATGA TGATGAA GATGAAG ATGAAGC TGAAGCC GAAGCCG AAGCCGC AGCCGCG GCCGCGC CCGCGCT CGCGCTT GCGCTTC CGCTTCG GCTTCGG CTTCGGC TTCGGCT TCGGCTA CGGCTAC GGCTACG GCTACGA CTACGAC TACGACG ACGACGA CGACGAC GACGACA ACGACAG CGACAGC GACAGCC ACAGCCT CAGCCTG AGCCTGG GCCTGGA CCTGGAT CTGGATG TGGATGC GGATGCC GATGCCT ATGCCTT TGCCTTC GCCTTCG CCTTCGG CTTCGGC TTCGGCG TCGGCGT CGGCGTG GGCGTGC GCGTGCA CGTGCAC GTGCACG TGCACGG GCACGGG CACGGGA ACGGGAT CGGGATC GGGATCG GGATCGG GATCGGC ATCGGCG TCGGCGG CGGCGGC GGCGGCA GCGGCAT CGGCATG GGCATGG GCATGGT CATGGTC ATGGTCG TGGTCGG GGTCGGC GTCGGCA TCGGCAT CGGCATG GGCATGC GCATGCT CATGCTG ATGCTGC TGCTGCT GCTGCTG CTGCTGA TGCTGAC GCTGACC CTGACCG TGACCGG GACCGGC ACCGGCC CCGGCCT CGGCCTG GGCCTGT GCCTGTT CCTGTTG CTGTTGG TGTTGGC GTTGGCC TTGGCCC TGGCCCA GGCCCAT GCCCATG CCCATGG CCATGGC CATGGCG ATGGCGC TGGCGCG GGCGCGC GCGCGCT CGCGCTT GCGCTTT CGCTTTC GCTTTCC CTTTCCG TTTCCGC TTCCGCC TCCGCCA CCGCCAC CGCCACC GCCACCA CCACCAA CACCAAC ACCAACG CCAACGA CAACGAC,"ID   AMTB_BACSU              Reviewed;         404 AA.
AC   Q07429;
DT   01-OCT-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1994, sequence version 1.
DT   05-FEB-2025, entry version 156.
DE   RecName: Full=Ammonium transporter {ECO:0000303|PubMed:14600241};
DE   AltName: Full=Membrane protein NrgA {ECO:0000303|PubMed:8282685};
DE   AltName: Full=Protein AmtB {ECO:0000303|PubMed:14600241};
GN   Name=nrgA {ECO:0000303|PubMed:8282685};
GN   Synonyms=amtB {ECO:0000303|PubMed:14600241};
GN   OrderedLocusNames=BSU36510;
OS   Bacillus subtilis (strain 168).
OC   Bacteria; Bacillati; Bacillota; Bacilli; Bacillales; Bacillaceae; Bacillus.
OX   NCBI_TaxID=224308;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND SUBCELLULAR LOCATION.
RX   PubMed=8282685; DOI=10.1128/jb.176.1.108-114.1994;
RA   Wray L.V. Jr., Atkinson M.R., Fisher S.H.;
RT   ""The nitrogen-regulated Bacillus subtilis nrgAB operon encodes a membrane
RT   protein and a protein highly similar to the Escherichia coli glnB-encoded
RT   PII protein."";
RL   J. Bacteriol. 176:108-114(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=168;
RX   PubMed=9353933; DOI=10.1099/00221287-143-10-3313;
RA   Presecan E., Moszer I., Boursier L., Cruz Ramos H., De La Fuente V.,
RA   Hullo M.-F., Lelong C., Schleich S., Sekowska A., Song B.H., Villani G.,
RA   Kunst F., Danchin A., Glaser P.;
RT   ""The Bacillus subtilis genome from gerBC (311 degrees) to licR (334
RT   degrees)."";
RL   Microbiology 143:3313-3328(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=168;
RX   PubMed=9384377; DOI=10.1038/36786;
RA   Kunst F., Ogasawara N., Moszer I., Albertini A.M., Alloni G., Azevedo V.,
RA   Bertero M.G., Bessieres P., Bolotin A., Borchert S., Borriss R.,
RA   Boursier L., Brans A., Braun M., Brignell S.C., Bron S., Brouillet S.,
RA   Bruschi C.V., Caldwell B., Capuano V., Carter N.M., Choi S.-K.,
RA   Codani J.-J., Connerton I.F., Cummings N.J., Daniel R.A., Denizot F.,
RA   Devine K.M., Duesterhoeft A., Ehrlich S.D., Emmerson P.T., Entian K.-D.,
RA   Errington J., Fabret C., Ferrari E., Foulger D., Fritz C., Fujita M.,
RA   Fujita Y., Fuma S., Galizzi A., Galleron N., Ghim S.-Y., Glaser P.,
RA   Goffeau A., Golightly E.J., Grandi G., Guiseppi G., Guy B.J., Haga K.,
RA   Haiech J., Harwood C.R., Henaut A., Hilbert H., Holsappel S., Hosono S.,
RA   Hullo M.-F., Itaya M., Jones L.-M., Joris B., Karamata D., Kasahara Y.,
RA   Klaerr-Blanchard M., Klein C., Kobayashi Y., Koetter P., Koningstein G.,
RA   Krogh S., Kumano M., Kurita K., Lapidus A., Lardinois S., Lauber J.,
RA   Lazarevic V., Lee S.-M., Levine A., Liu H., Masuda S., Mauel C.,
RA   Medigue C., Medina N., Mellado R.P., Mizuno M., Moestl D., Nakai S.,
RA   Noback M., Noone D., O'Reilly M., Ogawa K., Ogiwara A., Oudega B.,
RA   Park S.-H., Parro V., Pohl T.M., Portetelle D., Porwollik S.,
RA   Prescott A.M., Presecan E., Pujic P., Purnelle B., Rapoport G., Rey M.,
RA   Reynolds S., Rieger M., Rivolta C., Rocha E., Roche B., Rose M., Sadaie Y.,
RA   Sato T., Scanlan E., Schleich S., Schroeter R., Scoffone F., Sekiguchi J.,
RA   Sekowska A., Seror S.J., Serror P., Shin B.-S., Soldo B., Sorokin A.,
RA   Tacconi E., Takagi T., Takahashi H., Takemaru K., Takeuchi M.,
RA   Tamakoshi A., Tanaka T., Terpstra P., Tognoni A., Tosato V., Uchiyama S.,
RA   Vandenbol M., Vannier F., Vassarotti A., Viari A., Wambutt R., Wedler E.,
RA   Wedler H., Weitzenegger T., Winters P., Wipat A., Yamamoto H., Yamane K.,
RA   Yasumoto K., Yata K., Yoshida K., Yoshikawa H.-F., Zumstein E.,
RA   Yoshikawa H., Danchin A.;
RT   ""The complete genome sequence of the Gram-positive bacterium Bacillus
RT   subtilis."";
RL   Nature 390:249-256(1997).
RN   [4]
RP   INDUCTION BY TNRA.
RC   STRAIN=168;
RX   PubMed=10864496; DOI=10.1006/jmbi.2000.3846;
RA   Wray L.V. Jr., Zalieckas J.M., Fisher S.H.;
RT   ""Purification and in vitro activities of the Bacillus subtilis TnrA
RT   transcription factor."";
RL   J. Mol. Biol. 300:29-40(2000).
RN   [5]
RP   FUNCTION, DISRUPTION PHENOTYPE, INDUCTION, AND SUBUNIT.
RC   STRAIN=168;
RX   PubMed=14600241; DOI=10.1099/mic.0.26512-0;
RA   Detsch C., Stuelke J.;
RT   ""Ammonium utilization in Bacillus subtilis: transport and regulatory
RT   functions of NrgA and NrgB."";
RL   Microbiology 149:3289-3297(2003).
RN   [6]
RP   INDUCTION BY TNRA.
RX   PubMed=12823818; DOI=10.1046/j.1365-2958.2003.03567.x;
RA   Yoshida K., Yamaguchi H., Kinehara M., Ohki Y.-H., Nakaura Y., Fujita Y.;
RT   ""Identification of additional TnrA-regulated genes of Bacillus subtilis
RT   associated with a TnrA box."";
RL   Mol. Microbiol. 49:157-165(2003).
RN   [7]
RP   FUNCTION, INTERACTION WITH GLNK AND TNRA, AND DISRUPTION PHENOTYPE.
RX   PubMed=17001076; DOI=10.1074/jbc.m607582200;
RA   Heinrich A., Woyda K., Brauburger K., Meiss G., Detsch C., Stuelke J.,
RA   Forchhammer K.;
RT   ""Interaction of the membrane-bound GlnK-AmtB complex with the master
RT   regulator of nitrogen metabolism TnrA in Bacillus subtilis."";
RL   J. Biol. Chem. 281:34909-34917(2006).
RN   [8]
RP   FUNCTION, INTERACTION WITH GLNK AND TNRA, AND DISRUPTION PHENOTYPE.
RX   PubMed=21435182; DOI=10.1111/j.1742-4658.2011.08102.x;
RA   Kayumov A., Heinrich A., Fedorova K., Ilinskaya O., Forchhammer K.;
RT   ""Interaction of the general transcription factor TnrA with the PII-like
RT   protein GlnK and glutamine synthetase in Bacillus subtilis."";
RL   FEBS J. 278:1779-1789(2011).
CC   -!- FUNCTION: Functions as an ammonium and methylammonium transporter in
CC       the absence of glutamine (PubMed:14600241). Required for ammonium
CC       utilization at low concentrations or at low pH values, when ammonium is
CC       the single nitrogen source (PubMed:14600241). Required for binding of
CC       NrgB to the membrane (PubMed:14600241). Interaction between GlnK-AmtB
CC       complex and TnrA protects TnrA from proteolytic degradation
CC       (PubMed:17001076, PubMed:21435182). {ECO:0000269|PubMed:14600241,
CC       ECO:0000269|PubMed:17001076, ECO:0000269|PubMed:21435182}.
CC   -!- SUBUNIT: Interacts with NrgB for a correct localization of the latter.
CC       GlnK-AmtB complex interacts with TnrA. {ECO:0000269|PubMed:17001076,
CC       ECO:0000269|PubMed:21435182, ECO:0000305|PubMed:14600241}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305|PubMed:8282685};
CC       Multi-pass membrane protein {ECO:0000305|PubMed:8282685}.
CC   -!- INDUCTION: The nrgAB operon is activated by TnrA (PubMed:12823818).
CC       NrgB is required for full induction of the operon under conditions of
CC       ammonium limitation (PubMed:10864496, PubMed:14600241).
CC       {ECO:0000269|PubMed:10864496, ECO:0000269|PubMed:12823818,
CC       ECO:0000269|PubMed:14600241}.
CC   -!- DISRUPTION PHENOTYPE: Cells grow poorly at pH 5.5 and not at all at pH
CC       5.0 with ammonium as their sole nitrogen source (PubMed:14600241). They
CC       are unable to transport the ammonium analog methylammonium, and thus
CC       probably also ammonium (PubMed:14600241). In the absence of nitrogen
CC       source, cells lacking this gene do not show degradation of TnrA, which
CC       is entirely soluble (PubMed:17001076, PubMed:21435182).
CC       {ECO:0000269|PubMed:14600241, ECO:0000269|PubMed:17001076,
CC       ECO:0000269|PubMed:21435182}.
CC   -!- SIMILARITY: Belongs to the ammonia transporter channel (TC 1.A.11.2)
CC       family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L03216; AAA17399.1; -; Unassigned_DNA.
DR   EMBL; Z82987; CAB05374.1; -; Genomic_DNA.
DR   EMBL; AL009126; CAB15668.1; -; Genomic_DNA.
DR   PIR; A36865; A36865.
DR   RefSeq; NP_391532.1; NC_000964.3.
DR   RefSeq; WP_003227757.1; NZ_OZ025638.1.
DR   AlphaFoldDB; Q07429; -.
DR   SMR; Q07429; -.
DR   STRING; 224308.BSU36510; -.
DR   PaxDb; 224308-BSU36510; -.
DR   EnsemblBacteria; CAB15668; CAB15668; BSU_36510.
DR   GeneID; 936933; -.
DR   KEGG; bsu:BSU36510; -.
DR   PATRIC; fig|224308.179.peg.3951; -.
DR   eggNOG; COG0004; Bacteria.
DR   InParanoid; Q07429; -.
DR   OrthoDB; 9814202at2; -.
DR   PhylomeDB; Q07429; -.
DR   BioCyc; BSUB:BSU36510-MONOMER; -.
DR   Proteomes; UP000001570; Chromosome.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0008519; F:ammonium channel activity; IBA:GO_Central.
DR   GO; GO:0072488; P:ammonium transmembrane transport; IBA:GO_Central.
DR   FunFam; 1.10.3430.10:FF:000007; Ammonium transporter; 1.
DR   Gene3D; 1.10.3430.10; Ammonium transporter AmtB like domains; 1.
DR   InterPro; IPR029020; Ammonium/urea_transptr.
DR   InterPro; IPR001905; Ammonium_transpt.
DR   InterPro; IPR018047; Ammonium_transpt_CS.
DR   InterPro; IPR024041; NH4_transpt_AmtB-like_dom.
DR   NCBIfam; TIGR00836; amt; 1.
DR   PANTHER; PTHR43029; AMMONIUM TRANSPORTER MEP2; 1.
DR   PANTHER; PTHR43029:SF10; AMMONIUM TRANSPORTER MEP2; 1.
DR   Pfam; PF00909; Ammonium_transp; 1.
DR   SUPFAM; SSF111352; Ammonium transporter; 1.
DR   PROSITE; PS01219; AMMONIUM_TRANSP; 1.
PE   1: Evidence at protein level;
KW   Ammonia transport; Cell membrane; Membrane; Reference proteome;
KW   Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..404
FT                   /note=""Ammonium transporter""
FT                   /id=""PRO_0000139760""
FT   TRANSMEM        7..27
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        44..64
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        96..116
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        125..145
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        158..178
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        227..247
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        254..274
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        277..297
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        352..372
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
SQ   SEQUENCE   404 AA;  42733 MW;  93A8C960ECAD2B9C CRC64;
     MQMGDTVFMF FCALLVWLMT PGLALFYGGM VKSKNVLSTA MHSFSSIAIV SIVWVLFGYT
     LAFAPGNSII GGLEWAGLKG VGFDPGDYSD TIPHSLFMMF QMTFAVLTTA IISGAFAERM
     RFGAFLLFSV LWASLVYTPV AHWVWGGGWI GQLGALDFAG GNVVHISSGV AGLVLAIVLG
     KRKDGTASSP HNLIYTFLGG ALIWFGWFGF NVGSALTLDG VAMYAFINTN TAAAAGIAGW
     ILVEWIINKK PTMLGAVSGA IAGLVAITPA AGFVTPFASI IIGIIGGAVC FWGVFSLKKK
     FGYDDALDAF GLHGIGGTWG GIATGLFATT SVNSAGADGL FYGDASLIWK QIVAIAATYV
     FVFIVTFVII KIVSLFLPLR ATEEEESLGL DLTMHGEKAY QDSM
//
",15455
TGCATC GCATCG CATCGC ATCGCC TCGCCC CGCCCT GCCCTC CCCTCG CCTCGC CTCGCG TCGCGC CGCGCT GCGCTC CGCTCG GCTCGC CTCGCC TCGCCC CGCCCT GCCCTC CCCTCG CCTCGA CTCGAG TCGAGC CGAGCC GAGCCG AGCCGA GCCGAA CCGAAG CGAAGA GAAGAT AAGATC AGATCA GATCAT ATCATC TCATCG CATCGT ATCGTC TCGTCG CGTCGC GTCGCC TCGCCG CGCCGA GCCGAC CCGACG CGACGA GACGAA ACGAAT CGAATC GAATCG AATCGG ATCGGT TCGGTT CGGTTT GGTTTC GTTTCC TTTCCG TTCCGC TCCGCG CCGCGC CGCGCT GCGCTG CGCTGG GCTGGA CTGGAC TGGACG GGACGT GACGTC ACGTCT CGTCTC GTCTCG TCTCGG CTCGGT TCGGTC CGGTCA GGTCAA GTCAAG TCAAGG CAAGGC AAGGCG AGGCGC GGCGCA GCGCAG CGCAGG GCAGGT CAGGTG AGGTGA GGTGAT GTGATC TGATCA GATCAA ATCAAC TCAACC CAACCT AACCTG ACCTGA CCTGAT CTGATG TGATGC GATGCT ATGCTC TGCTCG GCTCGA CTCGAT TCGATC CGATCT GATCTG ATCTGC TCTGCA CTGCAG TGCAGG GCAGGC CAGGCG AGGCGA GGCGAA GCGAAG CGAAGA GAAGAT AAGATG AGATGG GATGGG ATGGGG TGGGGC GGGGCT GGGCTC GGCTCG GCTCGC CTCGCC TCGCCT CGCCTA GCCTAT CCTATC CTATCT TATCTC ATCTCT TCTCTT CTCTTC TCTTCA CTTCAT TTCATC TCATCT CATCTC ATCTCC,2,142,TGCGCACA A G GCAT T CAA TGGATCCT C A ATATC TCG T TCTCGCGCC C CGCGCGCCCC C G GCGATCCCCC C C CC TCCCTCT  AG CCCCTCTCAA C C CTCTCTCGCG G T TCTCGCGCGC C C CGCGCGCGCG  GC CCGGT CGCGCGCTTGAT GG GGCTCTCTC C C CT AATCGG T TCTCGCGCGC GC  CGCGCCC GGT GCGCCCCCCC C CGTCAGGCCTCT T C CCCTCTC A TCAGCTCTCGG T TCTCGCGAGA A CC ACGAGAG GC GAGAGAGCGC C A ATAGCGCCCC C GCGAGCCCCGCG G CGCGCCGCGA CGCGAGAAAA A G GAGAAGCTG AAAG AGAGAAT TGA GA CT TC GG CG ATATCTG CA A T TCTCACATAT  CACATATCTC C AG CAT TCGG T TCTCGGT T C CGA TGTCTC C G GT CCTCGCG TCGCGCGC C CC CGCCCC C G GCGCCCCGG C GCCCGCGAA C CTCGAAC C G GAACGCG G A ACACGCGAGA C CGAA CAA G GAGAAAATCG T ACTCAATATCAT C A ATATCCG CCCTCGCGGGG  AG CGCGGGGTGT T G GGGGTGTT CCT G GTGTTTTTTT C C TTTTTC A TCAGGTTCT TCC C TCG TCCCCGCG  TGTT CGCGC TCC CGCGCGCGCG G G GCGCGCGCC C CGCGCGCTCT T G GCCTGTG G CGAACTGTGG TGTGGGGAGA A G GGGGAGACAC C G GAGACACGCG G A ACACGCGTGT T C CGCGTGTCTC C G GTGTCTCTCT T T TCTCTCTCTC C CGATCTCTCGC TG T TCTCGGA  CGCGCGT T G GGGGTTC C G GTGTCTCACA ATC TCTCACAATC A C CACAAAAGAG G A AAAAGAGGGG G A AGAGGGC C GGGCGCGAT G G GCGCGCGCC C CGCGCGCACA  ATGCACAGAG G C CACAGAGGGG G A AG TTTCGGT T GATGGTGTG G GT CCT GA A T TGTGAGCCAT TTC GATC ATCA CC AT TATCTCACA A T TCTCACAAAA A CCAAAC C A AAAACACCCC C AACCCCTCT T C CCCCTCTGTG G CCTG AAGA CC  TGTC GATAT GA GATGGCTG G AC GTGCC CCG G CTGCGCTGAAT G GCGCT CGTC  CTCTCTCGCG G TC TTCGCGAT GA CG GCGAGATTC T G GAGATATCTC C A ATCGTTCTCT T TTCTCTGTG G C CTCTGTGCGC C TTGCGCACA A G GCGCCAG G C CACGCCCCG A GTAGGGGCGC C GTC GGCAAGG G GCGCGCGAGA TC CGA CGA G GACT AAGAG G ACTCCG AGAGA A A AGAGAGATATC GAGATATGTCAG A ATATGCATGG G T TGTGGGGGGG CTC GGGGGGG G G GGGGGGGCGC C G GGATGAAGCT T G GCGCTCTCTC C C CTCG G T TCTCGCGCGC C C CGCGCCAGA TC G GCCCTTGAT C CCCCTC CTA A C CTCTATATAT T T TATATATCTC T G ATATCTCT AT TCTCTCTCGATCGG CTT GTCTCT TCTCTTTT T C CTCTTTTCTC C T TTTCACA  CGATCTCACATAT T C CACATATCTC C AA GTCTCT T T TCTCT GCC C CTCTCTCC, GTTCGCATAT GCCCCGCATTC C C CAATCTCGCG CCC ATT CTCGCGCGC C T TCTCGCGCGCCCC C C CGTCTGCCCCCCC CT  GCGCCCCCCT T C CCCGGCCTCTCTC C CCTCCCTGCACG G C CTCTCTCGCGCC T TCTCGCGCGCGG C CGCGCCCTCGCGC C GGCGCGCGCTCT AAGATGCGCGGTCTCC G GCGCTTCGCG G CGTCCTCGC C TCC AAT TCTCGCGCGCCGC TG  CGCGCGCCCCC GCGCCCCCCCTCT T C CCG ACTCTC AAT CCCCTCTCTCGCG G C CTCTCTCGCGAA T TCTCGCGAAG G C CGCGAGAGAGCGC C G GAGAGAGCGCCCC  AGGCTT GCCGCG G GGCCCCGCGAGA GAACCGCGA GCAA A C CGGAAAAGAG GG  GA CCAAGAGAGA  AT AA CTGATAT T AA AAGAGATATCTC C G TT GGATCTCACA A A ATATCTCACATAT T T TCTCACATATCTC C C CACATATCTCGGGCG A ATATCTCGCGTT T TCTGCTC TC C CCG  TCGTCTCGG G GTGTCCGCGC C TCGTC GCGC ACTT C C CGCGCGCCGCACG G G GCGCCCCGCGAGA A C CCCCGCGAGACAC  CGGGCGACACGCG G G GAGACACG AAA A ACACGCGAGGGG CA C TCCGAGAAC TAT T G GA GAAATCGTC AC AGAAATCTCGG A ATATCTCGCGGGG G T TCTCGCCCGGTGT T C CGCGGGGTGTTTT T G GGGGTTTTCC T G GTG GTTCTC C T TTTTTTCCCC C T TTTTCTCCATCCG AGG TCTCCTC TA  CCCCGCGC CG CGGCGCGCGCGC GGCGCGCGCTCT T C CGCGCGCTG G GCGCTCTGTGGGG G C CTCTGTGGGGAGA A T TGTGGGGATC AC C G GGGGAGACTTT GAGACACGCGTGT T AGCCACGCGTGACC C CGCGTGTCTCTCT  GTGTCTCT CCTC  TCTCTTCGG C CTTCGCGGG T TCCGGGGTGT C A GGAGCGTCTC C G GGA GTCATGCGTCTCACAAAA A T TCC CCAAT CAT  CACAAAAGAGGG GG A AAAAGAGGCG GC T CAGGGGCGC CG G G GGGCGCGCGC C G GCGCGCGCGCACA A C CGCGCGCATC G GC CGCACAGGCGGG AA  CACAGG TT A AGAGGGGTTG TCGGGTGTGTGAGA A G GTGTGTGAGATAT T T TGTGAACCGA C GGAAGATATCTCACA A A ATATCTCACCTAA A T TCTCACAAAACAC CT  CAAACACCCC C ACGAGATCCTCT T A ACCTGTG G C CCCCTCTGAAGGA A C CTCTGTGAAT T T TGTGAGATTG G G GAGATATGGC C A ATATGTCG TGGCTCTCTC C GTCACG G CAGACTCTCGTCTG TA T TCTCGCGAGATAT  CGCGAGATATCTC C G GAGATATCTCTA ATCTCTGTG G TGATTCTCTGTGCGC C CA GCTGTGCCTTA TGAATGCGCACAGAG G G GCGCACAGAGGGG G C CACAGAGGGGCGC C A AGAGGGGCGG CG G G GGGGCCGAGA  CT GCGCGGAAAA A C CGCGAGAAAAGAG G G GA TGAAGAGAGA  AG AAAGAGATT A AGAGAGAT CGTG G G GAATGAGGG A ATATGTGGGG  CGGG TGGGGGCTCGG G GGATGGGGGGGGCTC C GGGGGGCGCTCT AAG GGGGCGCTCTCTC C G GCGCTCTCTCGCG G C CTCTCTCGCGCC T TC GCGCCCC CGCGCCCCTCT T G GCGCCCAACTATGAA C CCGCGCTATATG CATC CTCTATATATCTC C T TATATATCTCTCT T A ATTCTAG C T TCTCTCTCTCTCT T C CTCTCTCTCA TT T T TCCGACTTTTCTC C C CTCTTTTCTCACA A T GATTCTCACATAT  TCTCACATTC C C CACATATC GGC GT A ATATCCTC TCTCTCTCTCC,CGCCTCCATATCC GA GGCAATCGTCG C CACATATCC TGC C AACGATC CGCGCGCCCC C TCGATCGCGCGCCCCCCC CGA CGCGCGCCTCACGTT GG TGCCCCCCGACTCC C CCCCCCCTCTCGGGCG G CGCACCTCTCTCGCGCGC C C CT CCTCGCGCGCGCG  TCCGCGCGCGCGC C C CGGCGCGCGCTCT  GCGCGCGCGCTTCTTC C C CGTC GCTC ATCGCG G G GCGCTCTCTCGCGC CAC C CTCTCTCGCGCGCCCC TCG TCTCGCGCGCCCC C CCCCGCCCCCTCGCT T GCCTTCGTC C C CCCCCCCTCTCTCGCG G CCCTCTCAAGCGAGTC CTCTCCCTCGAGAGAG ATC TCTCGCGAGAGAGCGC C C CGCGAGAGAGCGCCCC  GAA GAGCGCCCCGCG G A AGAGCGCCCCGCGAGCTA G GCGCCCGA GTACGA CTGGAAGGAAAAGAG G CTTCCGAGAA GAAGAGA  GA GAGAAAAGAGAAT T A AAAAGAGA GCTC C ACG AGAGATATCTCACGAA G GAGATATCTCACATAT T A ATTCACATATCTATC TTCACATATCTCGAT G CCATATCTCGCGTGT T A ATATCTCGCGTGTCTC C T TCTCGG GGTCTCGCG G C CGCGTGTCTCGGG GC C G AGTCGTCGGCCCC C TGCCTCGCGCGCCAAGG CCGCGCC GGCGACGCA G GCGCCCCGCTGGACAC CCGCGAGACTTCCG G CTCGCGAGACACGCGAGA A G GAACGCGAGAAAA CCT ACAAGG GGAAATCAT TGA CGCGAGAAATCC G GAGAAAATATCTCGCG G A AAAATTCGCGGGG G A ATATCTCGGGTGCTT T TCTCTCGGGGTGTTTT T C CGCTGGGTTCGTTTTT T G GGGGTGCATTCTC C GGAAGTTTTTTTCTCCCC C T TTTTTACGGTCCCGCG G T TTTTCTCCCCGCGCTCTC T TCTCCCCGCGCGCGCG G CGACCCGTGCGCGCGCGC  GG CGCGCGCGCGCGCTCT CTC GCGCGCGCGCTCTGTG G C CGCGCGCTCTGTGGCA  GCGCTTGGGGAGA A CAA CTGTGGGGAGACAC C T TG CCGGAGACACGCG G G GGGGAGACAA CGTCAAT GGAGTGCACGA GTC C A ACACGCGTGTCCCGACCT C CGCGTTCCGC CTCTC C G GTTCTCTCTCGG T TCCTCTCGCGGGG G C CTCTCTCGCGGGGTGT T TCGGGTCTC C C CGCGGGGTTCACA A G GGGGTATCTCACAAAA A GCTAA CTCACAAAAGAG G T TCTCACAAC CAGGGG G C CACAAAAGAGGGGCGC C AAAGAGGGGCGCGG A GTAGGGGCGCGCGCGC C G GGGGCGCGCGCGCACA A G GCGCGCGCGCACAGAG G C CGCGCCAGAGGGG CT  GCCAGAGGGGTGT GAA CACAGAGGGCGGTGG AGCGAGGGGTGTGTGAGA A GCCGGGTGTGTGAGATAT T GTCGGTGTGAGATATCTC C T TGTGAGATATCCA A G GAGATATCTCAGT  CTA A ATATCTCACAAAACAC C TG ACAAAACACCCC C C CACAAAACACCCCTCT T AAACACC CTCTGTG G A ACA AT CGA TCGCCTCTGTGAGATCG  CTCGGTGAGATTG G T TGAAGGATTGCGC  TG GAGATGCCCTGCT T A ATTGCGCTTC C T GTTGCGT CTCCCT AGG G GCGCTCG GA A C GCCTCTCGCGAGATAT T T TCTCGCGAGATATCTC  CG TCATCTCTCT T G ATGATAATTCTGCTTG TCA ATATCTCTGGCTGCGC C TTCTCTGTGCGCACA A CCTG CCGTTCAGAG G TC GTGCGCACAGAGGGG  GCGCACAGAGGGGCGC C CGC CAGAGGGGCGGTG A AGAGGGGCGCGCGAGA  GC GGGGCGCGCGAGAACGT GC AGCGACG TGAAG G C CGCGAGGTAGAGA  GAGAATCGAGAGATAT T C AACCGGATTG G AAGAGATATGTGGG G GAGATTGGGGGGG G A ATATGTGGGGGTCGGG G T TGTGGGGCGGGGGCGC GCA GGGGGGG  CTGCTCT T GCTTGGGGA CTCTC C G GGCTGGCTCTC CCCG G G GCGCTT G GCCGCGC C CGGGCTCTCGCGCGCCCC C T TCGTTCGC TCCCTCT T C CGTGCCCTCTATA A G GTGCCCCTCTATAT CCCCTCTATATATCTC GA  TGTATATCCTCT T TACGCATCTCTCTCTC CTC ATATCTCTCTCTCTCT T T TCTCTCTCTCTCTTTT T C CTCTCTCTCTT CGTC TCTC CTTCTCACA A CCTTTTCTCACATAT T T TTTTCTCACATATCTC C TTCACATATCTCGCT T A CACATTCTCTCC AATCTCTCTCTCC,CCC AGCAT GATCGAACCCGGCACATATCTCGCGCGC C C CAATCTCGCC C A ATATCTCGCGC CGCCCCC C TTC GCGCGCGCCCCCG CCGAT C CGCGCGCC GGCCTCTCTC C G GCCCCCCTT GTCGCG G C CCCCCCCTCTCTCGCGCGC C CCCTCTC CTCGCGCGCG G C CTCTCCAACGCTCACGCGC C T TCTCGCGCGCGCGCTCACGCCTA CGCGCGCGCTCGCTCTCTC C G TCGCGCGCGCTCCTTCGCG G C CGCGCGCTCTCTCGCGCGC C G GCTCGCT GCCCC AGA CTCTCTCGCGCGCCCCCCC C T TCTCGCGCGCCTGCCAACT G GCGCGCCCCTCTCTC C G GCGCCGAGCCTGA TCGCG G C CCCCCCCTCTCTCGGA A C CCCTCTCGCGAGAGAG G C CTCTCTCGCGAGCTAGCGC C T TCTCGCGAGAGGCCCC C C CGATGGAGAGCGCCCG G G GAATCAGCGCCCGAA A AGTCGGCCCCGCGAGAAGCCA G GCGCCCGAGCTAG CCT CCAT CGAAATAAGAGAGA TC AT CGAGAAAAGAGACCGT G GAGAAAAGAGAGATATC GCC AGCGAAGAGAGATTCACA A ATCGAGAATCTCACATAT T G GAGATATCTCACTCTC ATCCATATCTCGG T GCTCACATATCTCGCGTGCAT C AACATCCCTCGCGTGTCTC  ATATCTCGCGTGTCCG G TCAGC CCGTGTCTCGCGCGC GGC CGCGCGTCCGCGCCCC C G GTGTCTCGCGCGCCCG G T TCTCGGCGGCC GCCGAGA A CTCTCGCGCCCCGCGAGGGAC CGC GGGCCGACACGCG G C CCCCGGG GACACGCGATCAA C CGCGAGACACGCGAGAAAA GCA GAGACCG CGAGAAGAAT AACGCGAGAAAATCGCC CCC CGAGAAATC GAAATATCTCGCGGGG G A AAAATATCTCGCGGGGTT A ATATCCAGCGGGGTGTTTT G TCT TCGCGGGGTGTTAC TT T CCGGGGTGTTTC C GCCCAA TTTTTCCC C G GTGTTTTTTTCGTCCCGCG G T TTTTCTCCATGCGCGC C T TTGCGCAGGAACGCCG G T TCTCCGCACGCAGCCGCGC C C CCCCGCGCCA ATCGCTCT T C CGCGCGCGCGCGCTCTGTG G GTC GCGCGCGCTCTGTGGGG G C CGCGCCTGGA A G GCGCTCTGTGGGGATTTC C CT TGTGGGGAGACCG T T TGTGGGGACTC ACT CGT T G GGGGAGACACGCGTGTCTC C G GAACGCGTGTCCT T A ACCGTTCTTC C CGCTCGTGTCTCTGA TCGCG  CG ACCTCC TCTCTCGCGGGG G TT GTCTCTCTCGCGGCAAGT T CTCGCTCTCGCGGGGTGTC TCC T TCTCGCGGGGT GAGAC AA CGCGGGGTTCAAA TCA GGGGTGATACCAAGAG G G GTGTCTCACAAAAGAGGCGAG T TCCTCCCTAAGAGGGGCGC C CT CCAAAGGGGCGCGCG G A CAAAGAGGGGCTTCCGCGC C A AGAGGGCGCGCCCG GGGGCCGCGCAAAGG G GCGGCGCACAGAGGC CG C CGCGCA GCAGAGGGGTGT T G GCGCA TCCAAGGTTG G C CACAGAGGT GTGAGA A AGCAAGGGGTTGAAT GTGGGTGTGTGAGCCATCTC C G GTGTG CAGATATCTCACA A T TGTGAGATAGGAA A GATCGATATCGCTCAAAACAC C A ATATCTCAGGTG GACCCC C T TCTCACAACCTCT T C CAAACACCCCGCTGTG G AAACACCCCTCTGTGAGA A A GTACCCCTCTGTCAAT T CCCTCTGTGAGATATGTG G C CTCTGTGAGATC T TGTCGC TATGGATGCTCT CTCGAAGATTGCAG CTCA CC A ATCT TGCGCTCTCTCGCG G T TGTGCGCTCTCTGACGAGA A G GCGCTCTCTCGCGAGATAT T C CTCTCTCGCGAGATATCTC ACG TCTCGCGAGATATCTCTCT  CGCGAGATCTGT CG GATCGATATCCTGTGCGC C A ATATCTCTTGCGCACA A T TCTCTCTGCTGTCGAG G C CTCTGTGCGCACAGAGGGG G TCTGGT CAGAGGGGCGC C G GCTCGCAGAGGGGCGCGCG G CCAGAGGGGCGCGCGAGA A A AGAGGGGCGCGCGAGAAAA A G GGGCG GAGAAAAGAG G G GCGCGCGAGAAAAGGG GA A C CGCGACGCAAGAGAAT T G GAGAAGATATGTG G A AAAGAGATCCGTGC AGAGAGATATGTGGGGGGG G GGTCGATATGCTCGGGGGGGG G A ATATGTGGGACGGGGGCGC TCT TGTGGGGGGGG CTGCTCT  GGGGGGGGCGC CGCTCTC TAT GCGGGTCGGCTCTCTCGCG G G GGGGCGCTTCGCGCGC T T GCGAGCTCTCGCGCGAT CGC C CTCTCTCGC GGTTCCTCT C G TC AGCGCGCCGACTG TA A C CGCGCGCCCCTCTAC GAT GCCCCTCTATATATCTC C C CCCCTTATATCTCTCT T C CTCTATATATCTCTTGGTC C TTAT GATCTCGTTCT TCT A ATATCTCTCATTCTCTTTT T T TCTCTCTC CGCTTTC C C CTCTCTCTTTCTCACA  TCTCTCTTTTCTCAGCCCGTGGCTTCCATATCTC C T TTTTCTCACATATCTCTCT TCACATATCTCTCTCTC C CCATATCTCTTCC,"ID   GSIA_SALCH              Reviewed;         623 AA.
AC   Q57RB2;
DT   06-MAR-2007, integrated into UniProtKB/Swiss-Prot.
DT   06-MAR-2007, sequence version 2.
DT   05-FEB-2025, entry version 104.
DE   RecName: Full=Glutathione import ATP-binding protein GsiA {ECO:0000250|UniProtKB:P75796};
DE            EC=7.4.2.10 {ECO:0000250|UniProtKB:P75796};
GN   Name=gsiA {ECO:0000250|UniProtKB:P75796}; OrderedLocusNames=SCH_0843;
OS   Salmonella choleraesuis (strain SC-B67).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Enterobacterales;
OC   Enterobacteriaceae; Salmonella.
OX   NCBI_TaxID=321314;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=SC-B67;
RX   PubMed=15781495; DOI=10.1093/nar/gki297;
RA   Chiu C.-H., Tang P., Chu C., Hu S., Bao Q., Yu J., Chou Y.-Y., Wang H.-S.,
RA   Lee Y.-S.;
RT   ""The genome sequence of Salmonella enterica serovar Choleraesuis, a highly
RT   invasive and resistant zoonotic pathogen."";
RL   Nucleic Acids Res. 33:1690-1698(2005).
CC   -!- FUNCTION: Part of the ABC transporter complex GsiABCD involved in
CC       glutathione import. Responsible for energy coupling to the transport
CC       system. {ECO:0000250|UniProtKB:P75796}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=glutathione(out) + ATP + H2O = glutathione(in) + ADP +
CC         phosphate + H(+); Xref=Rhea:RHEA:29791, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:57925, ChEBI:CHEBI:456216; EC=7.4.2.10;
CC         Evidence={ECO:0000250|UniProtKB:P75796};
CC   -!- SUBUNIT: The complex is composed of two ATP-binding proteins (GsiA),
CC       two transmembrane proteins (GsiC and GsiD) and a solute-binding protein
CC       (GsiB). {ECO:0000250|UniProtKB:P75796}.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane
CC       {ECO:0000250|UniProtKB:P75796}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:P75796}.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. Glutathione
CC       importer (TC 3.A.1.5.11) family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAX64749.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AE017220; AAX64749.1; ALT_INIT; Genomic_DNA.
DR   RefSeq; WP_001120603.1; NC_006905.1.
DR   AlphaFoldDB; Q57RB2; -.
DR   SMR; Q57RB2; -.
DR   KEGG; sec:SCH_0843; -.
DR   HOGENOM; CLU_000604_86_2_6; -.
DR   Proteomes; UP000000538; Chromosome.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:InterPro.
DR   GO; GO:0015833; P:peptide transport; IEA:InterPro.
DR   GO; GO:0055085; P:transmembrane transport; IEA:UniProtKB-ARBA.
DR   CDD; cd03257; ABC_NikE_OppD_transporters; 2.
DR   FunFam; 3.40.50.300:FF:000016; Oligopeptide ABC transporter ATP-binding component; 2.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 2.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR050319; ABC_transp_ATP-bind.
DR   InterPro; IPR003439; ABC_transporter-like_ATP-bd.
DR   InterPro; IPR017871; ABC_transporter-like_CS.
DR   InterPro; IPR013563; Oligopep_ABC_C.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR43776:SF15; GLUTATHIONE IMPORT ATP-BINDING PROTEIN GSIA; 1.
DR   PANTHER; PTHR43776; TRANSPORT ATP-BINDING PROTEIN; 1.
DR   Pfam; PF00005; ABC_tran; 2.
DR   Pfam; PF08352; oligo_HPY; 2.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 2.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
PE   3: Inferred from homology;
KW   ATP-binding; Cell inner membrane; Cell membrane; Hydrolase; Membrane;
KW   Nucleotide-binding; Repeat; Translocase; Transport.
FT   CHAIN           1..623
FT                   /note=""Glutathione import ATP-binding protein GsiA""
FT                   /id=""PRO_0000280023""
FT   DOMAIN          15..269
FT                   /note=""ABC transporter 1""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00434""
FT   DOMAIN          325..564
FT                   /note=""ABC transporter 2""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00434""
FT   BINDING         49..56
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00434""
FT   BINDING         357..364
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00434""
SQ   SEQUENCE   623 AA;  69218 MW;  B7DA7DA38DDB1B76 CRC64;
     MPHSDELDSR DVLSVSGLNI AFHHEGQQVD AVRNVSLRLK RGETLAIVGE SGSGKSVTAL
     ALMRLIEQSG ANVRCGEMLL RRRNRQVIEL SEQSDAQMRR VRGADIAMIF QEPMTSLNPV
     FTVGEQIAES IRLHQRASHE EALAEAKRML DQVRIPESQA ILSRYPHQLS GGMRQRVMIA
     MALSCRPAVL IADEPTTALD VTIQAQILQL IKVLQQEMSM GVIFITHDMG VVADIADRVL
     VMYQGEAVET GSVEQIFHAP THPYTQTLLA AVPQLGAMRG HSLPRRFPLI SADEPALYES
     QIEQDTVVEG EPILQVRGLV TRFPLRSGLF NRVTREVHAV ENISFDLWPG ETLSLVGESG
     SGKSTTGRAL LRLVESRQGE IIFNGQRIDT LSAGKLQPLR RDIQCIFQDP YASLDPRQTV
     GYSIMEPLRI HGLGQGDAAA KRVAWLLERV GLRPEHAWRY PHEFSGGQRQ RICIARALAL
     NPKVIIADEA VSALDVSVRG QIINLLLDLQ REMGIAYLFI SHDMAVVERI SHRVAVMYLG
     QIVEMGPRRA VFENPQHPYT RKLMAAVPVA DPSRHRPRRV LLSDDIPSNI HKRGEETPAV
     SLQLVGPGHY VARPLQDNAL SRL
//
",34277
GAAGAT AAGATC AGATCT GATCTA ATCTAA TCTAAA CTAAAA TAAAAC AAAACC AAACCA AACCAG ACCAGT CCAGTC CAGTCT AGTCTC GTCTCT TCTCTG CTCTGA TCTGAA CTGAAG TGAAGA GAAGAA AAGAAG AGAAGT GAAGTA AAGTAG AGTAGT GTAGTG TAGTGG AGTGGA GTGGAA TGGAAA GGAAAA GAAAAT AAAATC AAATCC AATCCT ATCCTA TCCTAC CCTACC CTACCA TACCAT ACCATA CCATAC CATACA ATACAG TACAGA ACAGAA CAGAAA AGAAAG GAAAGA AAAGAC AAGACG AGACGT GACGTT ACGTTC CGTTCT GTTCTT TTCTTG TCTTGA CTTGAG TTGAGT TGAGTG GAGTGT AGTGTA GTGTAA TGTAAT GTAATG TAATGT AATGTG ATGTGA TGTGAA GTGAAA TGAAAA GAAAAC AAAACT AAACTA AACTAC ACTACC CTACCG TACCGA ACCGAA CCGAAG CGAAGT GAAGTT AAGTTG AGTTGT GTTGTA TTGTAG TGTAGG GTAGGA TAGGAG AGGAGA GGAGAC GAGACA AGACAT GACATT ACATTA CATTAT ATTATA TTATAC TATACT ATACTT TACTTA ACTTAA CTTAAA TTAAAC TAAACC AAACCA AACCAG ACCAGC CCAGCA CAGCAA AGCAAA GCAAAT CAAATA AAATAA AATAAT ATAATA TAATAG AATAGT ATAGTT TAGTTT AGTTTA GTTTAA TTTAAA TTAAAA TAAAAA AAAAAT AAAATT AAATTA AATTAC ATTACA TTACAG TACAGA ACAGAA CAGAAG AGAAGA GAAGAG AAGAGG AGAGGT GAGGTT,0,142,GAAG AAGA AGAT GATC ATCT TCTA CTAA TAAA AAAA AAAC AACC ACCA CCAG CAGT AGTC GTCT TCTC CTCT TCTG CTGA TGAA GAAG AAGA AGAA GAAG AAGT AGTA GTAG TAGT AGTG GTGG TGGA GGAA GAAA AAAA AAAT AATC ATCC TCCT CCTA CTAC TACC ACCA CCAT CATA ATAC TACA ACAG CAGA AGAA GAAA AAAG AAGA AGAC GACG ACGT CGTT GTTC TTCT TCTT CTTG TTGA TGAG GAGT AGTG GTGT TGTA GTAA TAAT AATG ATGT TGTG GTGA TGAA GAAA AAAA AAAC AACT ACTA CTAC TACC ACCG CCGA CGAA GAAG AAGT AGTT GTTG TTGT TGTA GTAG TAGG AGGA GGAG GAGA AGAC GACA ACAT CATT ATTA TTAT TATA ATAC TACT ACTT CTTA TTAA TAAA AAAC AACC ACCA CCAG CAGC AGCA GCAA CAAA AAAT AATA ATAA TAAT AATA ATAG TAGT AGTT GTTT TTTA TTAA TAAA AAAA AAAA AAAT AATT ATTA TTAC TACA ACAG CAGA AGAA GAAG AAGA AGAG GAGG AGGT GGTT,GAAGA AAGAT AGATC GATCT ATCTA TCTAA CTAAA TAAAA AAAAC AAACC AACCA ACCAG CCAGT CAGTC AGTCT GTCTC TCTCT CTCTG TCTGA CTGAA TGAAG GAAGA AAGAA AGAAG GAAGT AAGTA AGTAG GTAGT TAGTG AGTGG GTGGA TGGAA GGAAA GAAAA AAAAT AAATC AATCC ATCCT TCCTA CCTAC CTACC TACCA ACCAT CCATA CATAC ATACA TACAG ACAGA CAGAA AGAAA GAAAG AAAGA AAGAC AGACG GACGT ACGTT CGTTC GTTCT TTCTT TCTTG CTTGA TTGAG TGAGT GAGTG AGTGT GTGTA TGTAA GTAAT TAATG AATGT ATGTG TGTGA GTGAA TGAAA GAAAA AAAAC AAACT AACTA ACTAC CTACC TACCG ACCGA CCGAA CGAAG GAAGT AAGTT AGTTG GTTGT TTGTA TGTAG GTAGG TAGGA AGGAG GGAGA GAGAC AGACA GACAT ACATT CATTA ATTAT TTATA TATAC ATACT TACTT ACTTA CTTAA TTAAA TAAAC AAACC AACCA ACCAG CCAGC CAGCA AGCAA GCAAA CAAAT AAATA AATAA ATAAT TAATA AATAG ATAGT TAGTT AGTTT GTTTA TTTAA TTAAA TAAAA AAAAA AAAAT AAATT AATTA ATTAC TTACA TACAG ACAGA CAGAA AGAAG GAAGA AAGAG AGAGG GAGGT AGGTT,GAAGAT AAGATC AGATCT GATCTA ATCTAA TCTAAA CTAAAA TAAAAC AAAACC AAACCA AACCAG ACCAGT CCAGTC CAGTCT AGTCTC GTCTCT TCTCTG CTCTGA TCTGAA CTGAAG TGAAGA GAAGAA AAGAAG AGAAGT GAAGTA AAGTAG AGTAGT GTAGTG TAGTGG AGTGGA GTGGAA TGGAAA GGAAAA GAAAAT AAAATC AAATCC AATCCT ATCCTA TCCTAC CCTACC CTACCA TACCAT ACCATA CCATAC CATACA ATACAG TACAGA ACAGAA CAGAAA AGAAAG GAAAGA AAAGAC AAGACG AGACGT GACGTT ACGTTC CGTTCT GTTCTT TTCTTG TCTTGA CTTGAG TTGAGT TGAGTG GAGTGT AGTGTA GTGTAA TGTAAT GTAATG TAATGT AATGTG ATGTGA TGTGAA GTGAAA TGAAAA GAAAAC AAAACT AAACTA AACTAC ACTACC CTACCG TACCGA ACCGAA CCGAAG CGAAGT GAAGTT AAGTTG AGTTGT GTTGTA TTGTAG TGTAGG GTAGGA TAGGAG AGGAGA GGAGAC GAGACA AGACAT GACATT ACATTA CATTAT ATTATA TTATAC TATACT ATACTT TACTTA ACTTAA CTTAAA TTAAAC TAAACC AAACCA AACCAG ACCAGC CCAGCA CAGCAA AGCAAA GCAAAT CAAATA AAATAA AATAAT ATAATA TAATAG AATAGT ATAGTT TAGTTT AGTTTA GTTTAA TTTAAA TTAAAA TAAAAA AAAAAT AAAATT AAATTA AATTAC ATTACA TTACAG TACAGA ACAGAA CAGAAG AGAAGA GAAGAG AAGAGG AGAGGT GAGGTT,GAAGATC AAGATCT AGATCTA GATCTAA ATCTAAA TCTAAAA CTAAAAC TAAAACC AAAACCA AAACCAG AACCAGT ACCAGTC CCAGTCT CAGTCTC AGTCTCT GTCTCTG TCTCTGA CTCTGAA TCTGAAG CTGAAGA TGAAGAA GAAGAAG AAGAAGT AGAAGTA GAAGTAG AAGTAGT AGTAGTG GTAGTGG TAGTGGA AGTGGAA GTGGAAA TGGAAAA GGAAAAT GAAAATC AAAATCC AAATCCT AATCCTA ATCCTAC TCCTACC CCTACCA CTACCAT TACCATA ACCATAC CCATACA CATACAG ATACAGA TACAGAA ACAGAAA CAGAAAG AGAAAGA GAAAGAC AAAGACG AAGACGT AGACGTT GACGTTC ACGTTCT CGTTCTT GTTCTTG TTCTTGA TCTTGAG CTTGAGT TTGAGTG TGAGTGT GAGTGTA AGTGTAA GTGTAAT TGTAATG GTAATGT TAATGTG AATGTGA ATGTGAA TGTGAAA GTGAAAA TGAAAAC GAAAACT AAAACTA AAACTAC AACTACC ACTACCG CTACCGA TACCGAA ACCGAAG CCGAAGT CGAAGTT GAAGTTG AAGTTGT AGTTGTA GTTGTAG TTGTAGG TGTAGGA GTAGGAG TAGGAGA AGGAGAC GGAGACA GAGACAT AGACATT GACATTA ACATTAT CATTATA ATTATAC TTATACT TATACTT ATACTTA TACTTAA ACTTAAA CTTAAAC TTAAACC TAAACCA AAACCAG AACCAGC ACCAGCA CCAGCAA CAGCAAA AGCAAAT GCAAATA CAAATAA AAATAAT AATAATA ATAATAG TAATAGT AATAGTT ATAGTTT TAGTTTA AGTTTAA GTTTAAA TTTAAAA TTAAAAA TAAAAAT AAAAATT AAAATTA AAATTAC AATTACA ATTACAG TTACAGA TACAGAA ACAGAAG CAGAAGA AGAAGAG GAAGAGG AAGAGGT AGAGGTT,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",54731
ATTACT TTACTT TACTTC ACTTCA CTTCAG TTCAGG TCAGGT CAGGTG AGGTGA GGTGAT GTGATG TGATGG GATGGC ATGGCA TGGCAC GGCACA GCACAA CACAAC ACAACA CAACAA AACAAG ACAAGT CAAGTC AAGTCC AGTCCT GTCCTA TCCTAT CCTATT CTATTT TATTTC ATTTCT TTTCTG TTCTGA TCTGAA CTGAAC TGAACA GAACAT AACATG ACATGA CATGAC ATGACT TGACTA GACTAC ACTACC CTACCA TACCAG ACCAGA CCAGAT CAGATT AGATTG GATTGG ATTGGT TTGGTG TGGTGG GGTGGT GTGGTT TGGTTA GGTTAT GTTATA TTATAC TATACT ATACTG TACTGA ACTGAA CTGAAA TGAAAA GAAAAA AAAAAT AAAATG AAATGG AATGGG ATGGGA TGGGAA GGGAAT GGAATC GAATCT AATCTG ATCTGG TCTGGA CTGGAG TGGAGT GGAGTA GAGTAA AGTAAA GTAAAA,1,85,ATTA TTAC TACT ACTT CTTC TTCA TCAG CAGG AGGT GGTG GTGA TGAT GATG ATGG TGGC GGCA GCAC CACA ACAA CAAC AACA ACAA CAAG AAGT AGTC GTCC TCCT CCTA CTAT TATT ATTT TTTC TTCT TCTG CTGA TGAA GAAC AACA ACAT CATG ATGA TGAC GACT ACTA CTAC TACC ACCA CCAG CAGA AGAT GATT ATTG TTGG TGGT GGTG GTGG TGGT GGTT GTTA TTAT TATA ATAC TACT ACTG CTGA TGAA GAAA AAAA AAAA AAAT AATG ATGG TGGG GGGA GGAA GAAT AATC ATCT TCTG CTGG TGGA GGAG GAGT AGTA GTAA TAAA AAAA,ATTAC TTACT TACTT ACTTC CTTCA TTCAG TCAGG CAGGT AGGTG GGTGA GTGAT TGATG GATGG ATGGC TGGCA GGCAC GCACA CACAA ACAAC CAACA AACAA ACAAG CAAGT AAGTC AGTCC GTCCT TCCTA CCTAT CTATT TATTT ATTTC TTTCT TTCTG TCTGA CTGAA TGAAC GAACA AACAT ACATG CATGA ATGAC TGACT GACTA ACTAC CTACC TACCA ACCAG CCAGA CAGAT AGATT GATTG ATTGG TTGGT TGGTG GGTGG GTGGT TGGTT GGTTA GTTAT TTATA TATAC ATACT TACTG ACTGA CTGAA TGAAA GAAAA AAAAA AAAAT AAATG AATGG ATGGG TGGGA GGGAA GGAAT GAATC AATCT ATCTG TCTGG CTGGA TGGAG GGAGT GAGTA AGTAA GTAAA TAAAA,ATTACT TTACTT TACTTC ACTTCA CTTCAG TTCAGG TCAGGT CAGGTG AGGTGA GGTGAT GTGATG TGATGG GATGGC ATGGCA TGGCAC GGCACA GCACAA CACAAC ACAACA CAACAA AACAAG ACAAGT CAAGTC AAGTCC AGTCCT GTCCTA TCCTAT CCTATT CTATTT TATTTC ATTTCT TTTCTG TTCTGA TCTGAA CTGAAC TGAACA GAACAT AACATG ACATGA CATGAC ATGACT TGACTA GACTAC ACTACC CTACCA TACCAG ACCAGA CCAGAT CAGATT AGATTG GATTGG ATTGGT TTGGTG TGGTGG GGTGGT GTGGTT TGGTTA GGTTAT GTTATA TTATAC TATACT ATACTG TACTGA ACTGAA CTGAAA TGAAAA GAAAAA AAAAAT AAAATG AAATGG AATGGG ATGGGA TGGGAA GGGAAT GGAATC GAATCT AATCTG ATCTGG TCTGGA CTGGAG TGGAGT GGAGTA GAGTAA AGTAAA GTAAAA,ATTACTT TTACTTC TACTTCA ACTTCAG CTTCAGG TTCAGGT TCAGGTG CAGGTGA AGGTGAT GGTGATG GTGATGG TGATGGC GATGGCA ATGGCAC TGGCACA GGCACAA GCACAAC CACAACA ACAACAA CAACAAG AACAAGT ACAAGTC CAAGTCC AAGTCCT AGTCCTA GTCCTAT TCCTATT CCTATTT CTATTTC TATTTCT ATTTCTG TTTCTGA TTCTGAA TCTGAAC CTGAACA TGAACAT GAACATG AACATGA ACATGAC CATGACT ATGACTA TGACTAC GACTACC ACTACCA CTACCAG TACCAGA ACCAGAT CCAGATT CAGATTG AGATTGG GATTGGT ATTGGTG TTGGTGG TGGTGGT GGTGGTT GTGGTTA TGGTTAT GGTTATA GTTATAC TTATACT TATACTG ATACTGA TACTGAA ACTGAAA CTGAAAA TGAAAAA GAAAAAT AAAAATG AAAATGG AAATGGG AATGGGA ATGGGAA TGGGAAT GGGAATC GGAATCT GAATCTG AATCTGG ATCTGGA TCTGGAG CTGGAGT TGGAGTA GGAGTAA GAGTAAA AGTAAAA,"ID   AP3A_SARS2              Reviewed;         275 AA.
AC   P0DTC3;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 25.
DE   RecName: Full=ORF3a protein;
DE            Short=ORF3a;
DE   AltName: Full=Accessory protein 3a;
DE   AltName: Full=Protein 3a;
DE   AltName: Full=Protein U274;
DE   AltName: Full=Protein X1;
GN   ORFNames=3a;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   SUBCELLULAR LOCATION.
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [3]
RP   FUNCTION.
RX   PubMed=33157038; DOI=10.1016/j.cell.2020.10.039;
RA   Ghosh S., Dellibovi-Ragheb T.A., Kerviel A., Pak E., Qiu Q., Fisher M.,
RA   Takvorian P.M., Bleck C., Hsu V.W., Fehr A.R., Perlman S., Achar S.R.,
RA   Straus M.R., Whittaker G.R., de Haan C.A.M., Kehrl J., Altan-Bonnet G.,
RA   Altan-Bonnet N.;
RT   ""beta-Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic
RT   Secretory Pathway."";
RL   Cell 183:1520-1535(2020).
RN   [4]
RP   FUNCTION, INTERACTION WITH HOST VPS39, AND SUBCELLULAR LOCATION.
RX   PubMed=33422265; DOI=10.1016/j.devcel.2020.12.010;
RA   Miao G., Zhao H., Li Y., Ji M., Chen Y., Shi Y., Bi Y., Wang P., Zhang H.;
RT   ""ORF3a of the COVID-19 virus SARS-CoV-2 blocks HOPS complex-mediated
RT   assembly of the SNARE complex required for autolysosome formation."";
RL   Dev. Cell 56:427-442(2020).
RN   [5]
RP   FUNCTION, INTERACTION WITH HOST HMGB1 AND HOST HMOX1, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=35239449; DOI=10.1080/15548627.2022.2039992;
RA   Zhang X., Yang Z., Pan T., Long X., Sun Q., Wang P.H., Li X., Kuang E.;
RT   ""SARS-CoV-2 ORF3a induces RETREG1/FAM134B-dependent reticulophagy and
RT   triggers sequential ER stress and inflammatory responses during SARS-CoV-2
RT   infection."";
RL   Autophagy 0:0-0(2022).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.1 ANGSTROMS), FUNCTION, SUBUNIT,
RP   MUTAGENESIS OF 1-MET--LEU-41; 57-GLN-SER-58; GLN-57 AND GLN-116, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=34158638; DOI=10.1038/s41594-021-00619-0;
RA   Kern D.M., Sorum B., Mali S.S., Hoel C.M., Sridharan S., Remis J.P.,
RA   Toso D.B., Kotecha A., Bautista D.M., Brohawn S.G.;
RT   ""Cryo-EM structure of SARS-CoV-2 ORF3a in lipid nanodiscs."";
RL   Nat. Struct. Mol. Biol. 28:573-582(2021).
CC   -!- FUNCTION: Plays a role in viral egress via lysosomal trafficking
CC       (PubMed:33157038, PubMed:33422265). Forms homotetrameric ion channels
CC       (viroporins) localized at endosomes and lysosomes, that may induce
CC       deacidification of lysosomes, allowing safe egress of virions via
CC       lysosomal trafficking (PubMed:33157038, PubMed:33422265,
CC       PubMed:34158638). Also blocks autolysosome formation by binding and
CC       sequestering the host component VPS39 for homotypic fusion and protein
CC       sorting (HOPS) on late endosomes (PubMed:33422265). This prevents
CC       fusion of autophagosomes with lysosomes, disrupting autophagy and
CC       facilitating virus egress (PubMed:33422265). Induces host
CC       RETREG1/FAM134B-dependent reticulophagy by interacting with host HMGB1
CC       and enhancing the association between HMGB1 and host BECN1
CC       (PubMed:35239449). This induces endoplasmic reticulum stress and
CC       inflammatory responses and facilitates viral infection
CC       (PubMed:35239449). {ECO:0000269|PubMed:33157038,
CC       ECO:0000269|PubMed:33422265, ECO:0000269|PubMed:34158638,
CC       ECO:0000269|PubMed:35239449}.
CC   -!- SUBUNIT: Homodimer (PubMed:34158638), a subset forms homotetramer of
CC       two homodimers linked non covalently (PubMed:34158638). Interacts with
CC       M, S and E proteins. Also interacts with the accessory protein 7a (By
CC       similarity). Interacts with host VPS39, sequestering it on late
CC       endosomes (PubMed:33422265). Interacts with host HMGB1; the interaction
CC       enhances the association between HMGB1 and host BECN1, promoting
CC       reticulophagy (PubMed:35239449). Interacts with HMOX1; the interaction
CC       promotes ORF3A-induced autophagy but is unlikely to be involved in
CC       ORF3A-mediated induction of reticulophagy (PubMed:35239449).
CC       {ECO:0000250|UniProtKB:P59632, ECO:0000269|PubMed:33422265,
CC       ECO:0000269|PubMed:34158638, ECO:0000269|PubMed:35239449}.
CC   -!- INTERACTION:
CC       P0DTC3; P0DTC3: 3a; NbExp=4; IntAct=EBI-25475894, EBI-25475894;
CC       P0DTC3; P0DTD8: 7b; NbExp=3; IntAct=EBI-25475894, EBI-25475914;
CC       P0DTC3; Q9Y673: ALG5; Xeno; NbExp=4; IntAct=EBI-25475894, EBI-11725055;
CC       P0DTC3; Q01518: CAP1; Xeno; NbExp=3; IntAct=EBI-25475894, EBI-2808398;
CC       P0DTC3; P09601: HMOX1; Xeno; NbExp=4; IntAct=EBI-25475894, EBI-2806151;
CC       P0DTC3; Q12846: STX4; Xeno; NbExp=4; IntAct=EBI-25475894, EBI-744942;
CC       P0DTC3; Q8NBJ7: SUMF2; Xeno; NbExp=3; IntAct=EBI-25475894, EBI-723091;
CC       P0DTC3; Q9UH99: SUN2; Xeno; NbExp=3; IntAct=EBI-25475894, EBI-1044964;
CC       P0DTC3; Q9P2Y5: UVRAG; Xeno; NbExp=6; IntAct=EBI-25475894, EBI-2952704;
CC       P0DTC3; P51809: VAMP7; Xeno; NbExp=4; IntAct=EBI-25475894, EBI-1052205;
CC       P0DTC3; Q96JC1: VPS39; Xeno; NbExp=19; IntAct=EBI-25475894, EBI-1050197;
CC       P0DTC3; P49754: VPS41; Xeno; NbExp=4; IntAct=EBI-25475894, EBI-2130459;
CC       P0DTC3; Q8NAF0: ZNF579; Xeno; NbExp=2; IntAct=EBI-25475894, EBI-6164383;
CC   -!- SUBCELLULAR LOCATION: Virion {ECO:0000250|UniProtKB:P59632}. Host cell
CC       membrane {ECO:0000250|UniProtKB:P59632, ECO:0000269|PubMed:33060197,
CC       ECO:0000269|PubMed:34158638}; Multi-pass membrane protein
CC       {ECO:0000250|UniProtKB:P59632, ECO:0000269|PubMed:34158638}. Host
CC       endoplasmic reticulum membrane {ECO:0000269|PubMed:35239449}; Multi-
CC       pass membrane protein {ECO:0000269|PubMed:34158638}. Secreted
CC       {ECO:0000250|UniProtKB:P59632}. Host cytoplasm
CC       {ECO:0000250|UniProtKB:P59632, ECO:0000269|PubMed:33060197}. Host
CC       endosome {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:33422265}.
CC       Host lysosome {ECO:0000269|PubMed:33422265}. Note=The cell surface
CC       expressed protein can undergo endocytosis. The protein is secreted in
CC       association with membranous structures. {ECO:0000250|UniProtKB:P59632}.
CC   -!- DOMAIN: The second or the third transmembrane region are responsible
CC       for Golgi localization. {ECO:0000250|UniProtKB:P59632}.
CC   -!- PTM: Exists in both O-glycosylated and non-glycosylated forms. The
CC       glycosylated form is associated with the virion.
CC       {ECO:0000250|UniProtKB:P59632}.
CC   -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC       isolated in South Africa (November 2021). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC       isolated in Nigeria (November 2022). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC       isolated in United States (November 2022). It is the result of
CC       recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC       express ORF8. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43417.1; -; Genomic_RNA.
DR   PDB; 6XDC; EM; 2.90 A; A/B=1-275.
DR   PDB; 7KJR; EM; 2.08 A; A/B=1-275.
DR   PDB; 8EQJ; EM; 3.00 A; A/B=1-275.
DR   PDB; 8EQT; EM; 3.40 A; A/B=1-275.
DR   PDB; 8EQU; EM; 2.80 A; A/B=1-275.
DR   PDB; 8T5P; X-ray; 2.50 A; G/H/I=36-40.
DR   PDB; 8T5Q; X-ray; 1.90 A; G/H/I=36-40.
DR   PDBsum; 6XDC; -.
DR   PDBsum; 7KJR; -.
DR   PDBsum; 8EQJ; -.
DR   PDBsum; 8EQT; -.
DR   PDBsum; 8EQU; -.
DR   PDBsum; 8T5P; -.
DR   PDBsum; 8T5Q; -.
DR   EMDB; EMD-22136; -.
DR   EMDB; EMD-22898; -.
DR   EMDB; EMD-28538; -.
DR   EMDB; EMD-28545; -.
DR   EMDB; EMD-28546; -.
DR   SMR; P0DTC3; -.
DR   BioGRID; 4383868; 1267.
DR   ComplexPortal; CPX-6098; SARS-CoV-2 3a complex.
DR   IntAct; P0DTC3; 468.
DR   MINT; P0DTC3; -.
DR   TCDB; 1.A.57.1.5; the human sars coronavirus viroporin (sars-vp) family.
DR   GlyGen; P0DTC3; 2 sites.
DR   iPTMnet; P0DTC3; -.
DR   DNASU; 43740569; -.
DR   KEGG; vg:43740569; -.
DR   AGR; RefSeq:YP_009724391; -.
DR   Reactome; R-HSA-9694322; Virion Assembly and Release.
DR   Reactome; R-HSA-9694614; Attachment and Entry.
DR   Reactome; R-HSA-9694635; Translation of Structural Proteins.
DR   Reactome; R-HSA-9694719; Maturation of protein 3a.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9733458; Induction of Cell-Cell Fusion.
DR   Reactome; R-HSA-9754560; SARS-CoV-2 modulates autophagy.
DR   Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways.
DR   PRO; PR:P0DTC3; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0009898; C:cytoplasmic side of plasma membrane; IDA:DisProt.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0044165; C:host cell endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044174; C:host cell endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0044187; C:host cell lysosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0020002; C:host cell plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:ComplexPortal.
DR   GO; GO:0055036; C:virion membrane; TAS:Reactome.
DR   GO; GO:0005891; C:voltage-gated calcium channel complex; IPI:ComplexPortal.
DR   GO; GO:0008076; C:voltage-gated potassium channel complex; IPI:ComplexPortal.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0140677; F:molecular function activator activity; IMP:DisProt.
DR   GO; GO:0005216; F:monoatomic ion channel activity; IEA:InterPro.
DR   GO; GO:0039520; P:induction by virus of host autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0140883; P:induction by virus of host reticulophagy; IDA:UniProtKB.
DR   GO; GO:0098662; P:inorganic cation transmembrane transport; IDA:ComplexPortal.
DR   CDD; cd21648; SARS-CoV-like_ORF3a; 1.
DR   DisProt; DP03003; -.
DR   InterPro; IPR046446; a/bCoV_VIROPORIN_3A-like_CD.
DR   InterPro; IPR046445; a/bCoV_VIROPORIN_3A-like_TM.
DR   InterPro; IPR024407; Protein_3a_bCoV.
DR   Pfam; PF11289; bCoV_viroporin; 1.
DR   PROSITE; PS51967; COV_VIROPORIN_3A_CD; 1.
DR   PROSITE; PS51966; COV_VIROPORIN_3A_TM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Activation of host autophagy by virus; Glycoprotein;
KW   Host cell membrane; Host cytoplasm; Host endoplasmic reticulum;
KW   Host endosome; Host lysosome; Host membrane; Host-virus interaction;
KW   Ion channel; Ion transport; Membrane; Reference proteome; Secreted;
KW   Transmembrane; Transmembrane helix; Transport; Viral ion channel; Virion.
FT   CHAIN           1..275
FT                   /note=""ORF3a protein""
FT                   /id=""PRO_0000449650""
FT   TOPO_DOM        1..42
FT                   /note=""Extracellular""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   TRANSMEM        43..61
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   TOPO_DOM        62..67
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   TRANSMEM        68..93
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   TOPO_DOM        94..101
FT                   /note=""Extracellular""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   TRANSMEM        102..126
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   TOPO_DOM        127..275
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   DOMAIN          33..141
FT                   /note=""CoV 3a-like viroporin TM""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01311""
FT   DOMAIN          145..237
FT                   /note=""CoV 3a-like viroporin CD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01312""
FT   REGION          1..39
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000305|PubMed:35108439""
FT   REGION          239..275
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000305|PubMed:35108439""
FT   SITE            133
FT                   /note=""Involved in polymerization""
FT                   /evidence=""ECO:0000250|UniProtKB:P59632""
FT   CARBOHYD        32
FT                   /note=""O-linked (GalNAc...) threonine; by host""
FT                   /evidence=""ECO:0000250|UniProtKB:P59632""
FT   CARBOHYD        34
FT                   /note=""O-linked (GalNAc...) threonine; by host""
FT                   /evidence=""ECO:0000255""
FT   VARIANT         26
FT                   /note=""S -> L (in strain: Delta/B.1.617.2 and
FT                   Kappa/B.1.617.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         42
FT                   /note=""P -> L (in strain: Iota/B.1.526)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         57
FT                   /note=""Q -> H (in strain: Beta/B.1.351, Epsilon/B.1.429,
FT                   Iota/B.1.526 and Mu/B.1.621)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         171
FT                   /note=""S -> L (in strain: Beta/B.1.351)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         223
FT                   /note=""T -> I (in strain: Omicron/BA.2, Omicron/BA.2.12.1,
FT                   Omicron/BA.2.75, Omicron/BA.4, Omicron/BA.5,
FT                   Omicron/BQ.1.1, Omicron/XBB.1.5, Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         253
FT                   /note=""S -> P (in strain: Gamma/P.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         257
FT                   /note=""Missing (in strain: Mu/B.1.621)""
FT                   /evidence=""ECO:0000305""
FT   MUTAGEN         1..41
FT                   /note=""Missing: Partial loss of Ca(2+) and NMDG(+)
FT                   permeability. Increased localization at host plasma
FT                   membrane.""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   MUTAGEN         57..58
FT                   /note=""QS->EL: Partial loss of Ca(2+) and NMDG(+)
FT                   permeability.""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   MUTAGEN         57
FT                   /note=""Q->H: No effect on ion permeability.""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   MUTAGEN         116
FT                   /note=""Q->L: Partial loss of Ca(2+) and NMDG(+)
FT                   permeability.""
FT                   /evidence=""ECO:0000269|PubMed:34158638""
FT   HELIX           44..60
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   HELIX           68..99
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   HELIX           103..105
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   HELIX           106..133
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   HELIX           137..140
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   STRAND          144..150
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   STRAND          155..160
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   STRAND          165..172
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   STRAND          183..186
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   STRAND          189..192
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   STRAND          199..204
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   STRAND          209..218
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   HELIX           220..223
FT                   /evidence=""ECO:0007829|PDB:7KJR""
FT   STRAND          228..235
FT                   /evidence=""ECO:0007829|PDB:7KJR""
SQ   SEQUENCE   275 AA;  31123 MW;  4688E6D477E031C4 CRC64;
     MDLFMRIFTI GTVTLKQGEI KDATPSDFVR ATATIPIQAS LPFGWLIVGV ALLAVFQSAS
     KIITLKKRWQ LALSKGVHFV CNLLLLFVTV YSHLLLVAAG LEAPFLYLYA LVYFLQSINF
     VRIIMRLWLC WKCRSKNPLL YDANYFLCWH TNCYDYCIPY NSVTSSIVIT SGDGTTSPIS
     EHDYQIGGYT EKWESGVKDC VVLHSYFTSD YYQLYSTQLS TDTGVEHVTF FIYNKIVDEP
     EEHVQIHTID GSSGVVNPVM EPIYDEPTTT TSVPL
//
",29979
AGTAAA GTAAAC TAAACG AAACGA AACGAA ACGAAC CGAACT GAACTT AACTTC ACTTCT CTTCTC TTCTCC TCTCCT CTCCTG TCCTGC CCTGCT CTGCTA TGCTAG GCTAGA CTAGAA TAGAAT AGAATG GAATGG AATGGC ATGGCT TGGCTG GGCTGG GCTGGC CTGGCA TGGCAA GGCAAT GCAATG CAATGG AATGGC ATGGCG TGGCGG GGCGGG GCGGGG CGGGGA GGGGAT GGGATT GGATTG GATTGT ATTGTT TTGTTC TGTTCT GTTCTC TTCTCT TCTCTT CTCTTG TCTTGC CTTGCT TTGCTT TGCTTT GCTTTT CTTTTC TTTTCT TTTCTG TTCTGC TCTGCT CTGCTG TGCTGC GCTGCC CTGCCT TGCCTT GCCTTT CCTTTA CTTTAA TTTAAG TTAAGA TAAGAT AAGATT AGATTT GATTTA ATTTAA TTTAAC TTAACC TAACCA AACCAG ACCAGC CCAGCT CAGCTT AGCTTT GCTTTC CTTTCG TTTCGG TTCGGG TCGGGC CGGGCC GGGCCA GGCCAA GCCAAA CCAAAT CAAATG AAATGG AATGGC ATGGCT TGGCTG GGCTGG GCTGGT CTGGTA TGGTAA GGTAAA GTAAAG TAAAGG AAAGGG AAGGGC AGGGCC GGGCCA GGCCAC GCCACA CCACAA CACAAC ACAACA CAACAA AACAAC ACAACA CAACAA AACAAG ACAAGG CAAGGC AAGGCC AGGCCA GGCCAA GCCAAA CCAAAC CAAACT AAACTG AACTGT ACTGTC CTGTCA TGTCAC GTCACT TCACTA CACTAA ACTAAT CTAATA TAATAA AATAAA ATAAAA TAAAAC AAAACT,1,142,AGTTA A G GTA TTAAAA GTA TATAAAAAAA CTA AAAAAAACC A AAAACACGCG G A ACACGCGAGA A C CGCGAGAAA G GAGAAAACAC C A AAAACACTCT T A ACACTCTTTT T CGC TTCTC C TTTCTCTCT T TCT CTCAAT CTTGGCC TCCCCTCT T C CCCCTCTGTG  CTCTGTGC TGTAAGG T G CTGCTCTAC GA C CTCTATAGAG A C TA TGGA A A AGAGAGAATC A GGAAT T AAAATATGTG G A ATATGTGGGG G TTGGGGCGC C G GGT G GCGCTCTGTG G C CTCTGTTTG T TGGGCGC C TGC GGCGCACA A G GCGCACAAAA A C CACAAC CAT T A AAAATATGTG G A ATTGGGG G TTGGTTAGC C G GGTCA GCGCGCGGGG CGGGGGGG AC  GGGGGGGGC CACT GGTG GA A G GGGGATCTCA T G GAGATATTTT T A ATCTTTTGA AC A TTTTGTGTGT T TTAGGT GTTTT T G GTGTTT TC T TTTTCACCCT T T TCTCTTC C C CTCTCTCTCT TC  TCTCTCTTTT T C GCCTTGGGG T TTTTGTGCGC C T TGTGCGCT TCT G GCGCTCTTT C GCCTTTTTTT AATTCTTTTA CTG T T TTGATTTCTC C T TTAA TCTCT T TTTTGATCTGTT G C CTCTGTGCC T TGG CGCTCT T G AACTG CTG C CTCTGTGCGC C TAA TGCGCCCC C GTG CCTCT C T CCCCTATTTT CTT TCTT T T TTTTTGGCTA AA  TTTTATAAAA  CTTAAAAGAG G AGCTAAGAGAGA A A AGAGAGATAT T G GATTTATTTT T ATAAATTTTTTT  TTTTTTTATA A T TTTTATAA TGA T TA GTAACG GC A AAAACGG  ACAT CCATG A C CCCCACAGAG G C CACAGAGCC A AGAGCGCT GCCAACTGA AT C CTCTTTTT GGT T TTTTCTC  TTTTCAAGCG G TTCGACC CGCGGGG G G TAAA  CTC GTT GGCTA  GCGCCCA A C CCCCA CTA C CAGCTAA A AAATAT TGTAATATGTG G A ATTGGGG G T TGTGGGGCC G GGACTGCTCT T G GCGCTCTGGCCG CTC CTGGCTG T TGTGGGGTGT T G GGGGTGTATA A G GTGTATAAAA  TATAAAAAAA A A AAAAAAAGAG G A AATCGGG G AAGGGGGGG G G GGGGGGGCAAA GGGGC TTCC C G GCGCCCCACA A C CCCCACACAC C C CACACAT  GAACACAAGGCA C CACAAAACAC G T AAAACCA A A ACACACAAA TG T CACAAAACC A AAACACA TT  ACACACAAA C CACAAAG G A AAAAGAGGGGGG A AGAGGGGC GGGGCGCCCC CT  GCGCCCCACA A C CCCCACAAAA A C CACAAAAAAA A A TGAAAAACAC C A AAAACACTCT T A ACGGCCTTG C CTCTGTGTTGT TGA AGTCTG C G ATGTCTCACA A T TCG GCACAC GG  CACACG GCT T A ACACTCTATA CTCGGGA ATAAAA A T TATAA TTT A AAAATTA TG  ATATATAAAA A T TATGCGC AA T A AAAAACCAAA A A AAAAAAACAC C A AAAACACT,AGTGTATAAAA GTATAAAAAAA A T TAGCAAAAAC  AAAAAAACACGCG G A AAAACACGCGAGA A ATGTACGCGAGAAAA A C CGCGAGAAG AC GG TGAAAACACTCT T AAACTT T A ACACTTTCTC AAA CTCTTTTCTCTCT T TCAATTCTCTCTC TCTCTCTCTCCCC C C CTCTCTCCCCTCT T TCCTCTG AAG C CCCCTTGCGC C C CTACAGCTCT T T TGGCTCTATA A G GCGCTCTATAGAG  CTCTATAGGA A T TATAGAGAGAA AG CTGAAAT T GGAAAATATGTG G A AAAATATGTGGTTCG A ATATGTGGGGCGC C T TGTGGGGCGCTCT T G GGGGCGCTACCTG G GATGCTGTGGG CCAACTGTGG GCGC  TGTGGGGCGCATCAA G GGGGCTAACAAAA CG  GCGCA GTAT  CA TTAATATG AAG AGGCTGGGG G A ATATGTGCGGCGC C T TGTCTAAT TCCA G GATTGCGCGGGG G G GCCGGC TGG G C CGCGGGGGGGGACAG G GGCC  TGGGAGA A G GGGGGGGA TCCAA GGGGAGATATTTT T G GAGATTTGTG AC  ATATTTTGTGTGT T T TTTTGTGTGTTTT  TA TGTT AAGC G GTGTTTTCTCTCT T T TTTTCTCTCTCTC  TCTCTCTCTCTCTGGGGAGA AAT CCTTTT  TCTCTCTTTTGTG G C CTCTTTGC CCC T TTGGCTGCGCTT T TGTGCGCTCTTTT T G GCGCTCTTTT T C CTC GTTTTTTTT  TTTTTG TTTCTC C T TTTTTGGTTGGCT T T TTTTCTCTCTGTG G TTCTCTGC TGC C CGGGCTGTGCGCTCT TCT CAGCTGC TG G G GCCTGGC C C CTCTGTGCCC TGC TGTGCGCCCCTCT T G GCGCCCCTCTTTT T C CCCCTCTTTTT CTCTTTTTTTATA A T TTTA TTATAAAA AGG TTTTATAAAAGAG  GAT TTAAAAGC AA A AAAAGCTTGATAT T A TGAGAGATTT T G GAGATATTTTTC GT AATTGT TA A T TTTTATAAAA A T TTGGCTAAAACAC C T TAAA AACACCCC GA  AAACCCA TTA ACCTGCCACAGAAT CCCCACAGAGCC C CACAGA CGCTCT T A AGAGCGCTCTTT G GCTTTAAGT C GCTTCTC C T TTTTTTTCTCGCAC TTGG GG G TTCGGGCGGGGG  CGCGGG CTTACT C G GGGGGTTGGCCAC  AC GGGGCGCCCCACA  GCGCCCCACAATAAA CGC TGGCAAAAAAA A C CA CTAAAAATGC T A AAAAAAG ATG ATA ACG AATATGTGGGG G A ATTGGGGCGC C T AGTGGGGCGCTCT T GCTCGGCGCTCTGTG G GTTTGCTCTGGG G C CTCTGTGGAACGT T T TGTGGGGTGTATTTA G GGTTCCCATAAAA CAAGTAAAAAA A T TATAAAAATT AG G AAAAAAGAGGGG G A AAAGGGGGGG G A AGAGGGGGGGCGC C G GG CTGGCGCCAC CTT GGGGCCCACA A G GCGCCTTTGGGC C CCAA ACACA ACA CACACACAT GAA G A ACACACAAGGTAC C CTG AACACACA A A AAAACA CCAAAA  ACGG CAAAACCC C C CACAAACACA A A AAAACACACAAAA A A ACAACCAAAAGG C CACAAAAGAGGGG G A GG AAGGCAT AAT AGA TGGCGCCCC C G GGGGCGCCCCACA A G GCGCCGTACAACACA CCCAAAAAA A C CACAAC CAAC GGC A AAAAAAACACTCT T A AAAACACTCTGTG G A ACACTCTGTGTAAGT C CTCTGTGTGTCTC C T TGTGTGTCCA A G GTTCAAC C TAT ACTCT T CGGGCACACTCTATA A A ACACTCTATAAAA AGCCTAAATT T TAAATATATGGA A AAAATATATAAAA A A ATATATAAAAAAA A T TATAAAAAAAAAA A A AAAAAAACAC C A AAAAACTGACT,AGTGTATAAAAAAA A G GTGTATAAAAAAC C TTAAAAAACGCG G ACT AAAACGCA CAAA A AAAACACG AAGAAAA A A ACACGCGAAG AACGG C C CGCGAGAAAACACTA GT G GAGAAAACACTCTTTT T A AAAACACTTTCC A ACGGCCTTTCTCT G ATGGTTCTCTCTCTC GGAGCCTTCTCTCTCTCCCC  TCTCTTCCCCTCT TAA CTCTCAGCCCTCTGTG G T TCTCCCCTCTGTGCAA C C CCCCTTTCTGCGCTCT ATACTGGCTCTATA A TTGCGCTCTATAGAG G G GCGCTCTATAGAGAGA A CGG C CTGGAGAAACA T TATAGAGACC AT T A AGAGAGAAAATTG G G GAGAAAATATGGG G AAATATGGGCGC C A ATGGCGC CT T TTGGGGCTG GGCGGCGCTCTG CT TTG G GCGCTTAATGG GGTGTC CAC CTGTGGGGCGCACA AAATGGGCACAAAAGA G GGACTGCTAATAT  AA GCGCACAAAATATGTG G C CACAAAATATGTGGGG G A AATGCATGTGGCAAGC C A ATATGTGGGGCGCGCG G T TGTGGGGCCGGAC G G GGGGCGCGCGGGGGGG G GGCGCGGGGG CTG C CGCGGGGGGGGGGAGA  AA GGGGGGGGGGAGATAT GCC GGGGGC TGATATTTT T GGCCGGAGATAA TTGTG T A GATTCATTCCATGTGT T A ATATTTGCGTTTT T TTAATTGTGTGTTTTCC TCA TGTGTTG GTCTCT T GGGTGTTTCTCTCTC C T TTTTCA CCTCTCTCT T T TCTCTCTCTCTCTTTT T CCAACTCA GCTTTTGG T TCTCTCTTTTGTGCGC C C CTCTTTTGCT T T CCTTGTGCCTTTT T T TGGCTCTTTTTCACT GGCTCTTTTTTTTTT  CTTC CTTTTTTTT ATTC C TTTTTTTTTCTCTCT T TCA TTTTTCA ACTGTG G T TTTTCTCTCTATGCGC TTA TCTCTCTGAATCCACT T C CTCTGTGCGCTCTGTG G T TGTGCGCTCTGTGCGC C GGCTAACGC  GGGAAC C CTCTGGCCT T TGTGCGCCCTTCA  GCGCCCCTCTTT CTT T C CCCCTCTTTTTTTAA C CTTTTTTATAAAA A T GCTTTC TGCTAAGGAAG T TTTTATAAAAGAGAGA A T TATAAAAGAGAGATAT T A AAAAG AAGATATTTT GAT AGAGAGATATTTTTTT T G GAGATATTTTTTTATA A A ATATTTTT TTAA A T TTTTTTTATAAAACAC A TCTGTTATAAAACACCCC C T TAAG AACACCCCACA  AAAACACCC AG A ACACCCCACAGTCCGC  CCCCACAGAGCGCTCT GGCCAGAGCGCTCTTTT T A AGAGCGCTCTTTTTTT T G GCGCTCTTTTTTTCTC CTGACTCTTTTT TTTCGCG G T TTTTTTTCGG G T TTTTCTCGCGGGGGGG G T TCTCGCGGGGGGGCGC C C CGCGGGGGGGCCC AAA GGGGGGGCGCCCCAAAGTGG GGGGCGCCCCAGA C AA G GCGCCGCTCAAAAAAA  CCTTGGGCC GAATT C CACAA TGTG G A AAAAAGG ATGTGGG A AAAATATGGGCGC C A ATTGGGGCGCTCT A A TGTGGAGAGCTCTGTG G G GGGGCGCTCAAGGGGG G G TTGCTTGGT C CTCTGTGG GTGTATA A T TGTCTGGTGTAT CAA A G GGGGTGTATAAAA A GTAAGTACTGAAGAG G T TATAAAAAAAGAGGG AGGCAAAATTAGGGG T C AAAAGAGGGGGGGCGC CAG AGAGGGGGGGCGCCCC C G GGGGTGCCCCACA A G GGTTTGCCCCACACAC C G GC CTCCACACACACA A CAAC CTACACAAAA  GC CACACACACAAAAC CTC A ACACACAAAACACAAAAA C CACAAAA ACACAAGC A A AAAACACAAACAC C ATAAACACAAACATT A C CACAACCAACACTGAA A A AACAAAAG GTG A ACACACAA TTAGGG C CACAAAAGAGGGGCGCTAA AGGGCCCC C AGAAAAAGGCCCAA G GGGGCGCCCCA CTAA A G GCGCCGG CAAAAAAA TCT TTCCACAAAAAAACAC TGG CACAAAAAAACACTCT T A AAAGGCTGCTGTG G A AA ACACTCTGTGTGT T AAACACTCTGTGTTC C C CTCTGTGTGTCTCATGCA T TGTGTGTCTCACACAC  GTGTCTCACACT CCT T T TCTCACACACTCTATA A C CATT ACTTAAAA A A ACACTCTATAAAATAT T C CTTAAAATATATA A TTAAAATATA ACAA T TAATCACTAAAAATCTTTCTAAAAAAAAAA A T TACCT TGAACAC C ACGAAAAAAAAAC,AGTGTATAAAAAAACTTTAACTAAG AAACACGCG G T TATAAAAAAACACGCT AGCA A AAAAAACGAA A A AAAACCTTCGATTCAC C AAATACGCGAGAAACTCT T CTCTCGAGAAAACACTCTTTT T G GACGGAACACTCTTAACTC C ATCTAACCTTTTCCT T A ACACTCTTC GTCTCTCTC C C CTATTG ACTCTCCGCT TTTTCTCTCTCTCCCCTCT T T TCGGCCTC TGCCTATTG C CTCTCTCCCCTCTGCCTGC C T TCTTC CCTGCGCTCT T C CCCTGTGCGCTCA A C CTCTGTGCGCTCTATAGAG G T TGTGC GGTAGAGAGA A GGA GCTCTATAGAGAGAAA C CTTTCTAGAGAGAAAATTCCT T TATTTAGAGAAAATATGTG TTTAGAGAAATGTGGGG G G GAGAAA TATGTGGGGCGC C A AAAATATGTGGGGCGCTCT T AAACATGTGGGGCGCTTG ACA TGTGGGGCGCTCTGTGGGG G G GTGGCGCT TTTGGGGCGC  GG GCGCTCTGTGGGCACA A C CTTGGATAGCA TT TGAGGGGCGCACAAAATAT  GGGGCGCACAAAATTG G G GCGCACAAAAAATGTGGGG G C CACAAAATATGTGGGGC ACC TT TTGG AATCTCG G A ATATGCTAGGCGCGGAAG T TGTGGGGCGCGCGGGGGGG G G GGGGCTAGCGGGGGGGGGG G GGCCGCGCGGGGGGGGGGAGA A C CGCGGGGGGGGGGACACAT T G GGGGGGGAGATATTAAAT G GGGGGTAAGATTTGTG G G GGGGAGATATTTTGCTGT G GAGATATTGGCTT T A ATATTTGTGTTTC C T TTAACTGTGTTTTCTCTCT T T TGTGTTT TTCTAACTCTC C GGTTTTCTCTCTCGATAAGTTCGGCTCTCTT CAT T TCTCTCTCTCTCTTTTGTG  CTTTGTCTCTTTCTTGCGC C TCTCCTTTTGTGCGCTCT TTC CTCTTTTGGG GCTCTTTT T T TTTTGATAGCTCTTCA TT T T TG AACTTAC C TT G GCGGCACGTTTTTCTC ACT CTCTTTTT AACT GGCTTT AGTTT CGCTGG TTTTTTCTCTCTGTGCGC C T TTCTATCTTGCTGCGCTGCCT T TCTCTCTGTGCCTGTG G C CTCTGTGCGCTCTGTA C T TGACAGCTCTGGCCCC C G GCGCTCTGTGCGCCCCTCT T C CTCTGTGCGCCCCTCTTTT AAT TGTGCGCCCCTCTTTTTTT T G GCGCCCCTCTTTTTTTATA A CTGCCAATTTTTATAAAA CTC CTCTTTTTTTATGGAAGAG  TTTTATAAAAGAGA GCT TA TTTATAAAAGAGAGATAT T T TATAA TTAGAGATATTTT T A AAAAGAGAGATATTGCTT A AGGATC ATTTGTATA A G GATG TTTTTAT CAA A A ATATTTTTTTATAAAACAC C TCTGTTTTTATAAAACACCCC GCG TTTTATAAAACA GCCACAAA T TACTGA TCCACAGAG AAAGCTAACACCCCACAGAGCGC C A ACACCCCAGCTTAA CCCCACAGAGCGCTCTTTT T C CACCA TTCTTTTTTT  AGGA GCTCTTGTATTCTC C G GCTTTCTTTTTTTCGTACG G C CTTCGTTTT CTCG AAGG G T TTTTTTTCTAACGGGGGGG G T TTGGCTCGCGGGGGGGCGC C T TCCGGGGGTCCGCCCC C CCTGCGGGGGAA GCCCCACA A G GGGGGGGCGCCCCAAA TCT GCCAAAAAAA A GTTTGCCCCACAAAAAAT T CCCTCAGCAAAAAAATATGTG G C CACAAAAAAATATGTGGGG ATT AAAAAAATATGTGGGGCGC  CA AAAATATGTGGGGCAC CT T A ATATGTGGGGCGCTCTGTG G TTCGGGCGCTCTGTGGGG G G GGGTAGCTTGTGGTT G GCGCTTGGGGTTTTTA A C CTCTGTAAGGTTTATAAACC TGTGGGGTGTAGGACAAAA ACC GGCTTTAAAATAAGAG G GGCTGGCTAAAAAAAGAGGGG TAAAAAAAAAGGGGGTGCTTC AAAAGAAGTGGGGGGCGGC C A AAAAGAGGGGCGCCCC A A AGAGGGGGGGCCCACA  GGGGGGGCGCCCCACACAC C G GGGGCGCCCCACACACATTTA G GCGCCACACTAGGCA C CCCACACACAAAACC C CACACACACAAAACACAA A ACACAAAAAACG TCAAAA A C CAAACACACAAAACAC C ACGGAACG ACAATTCACACA C A ACACACAAAACACACAAA CC ACAAAACACACAATGCAG G A AAAACTGCCAAAAGAGGGG G AACAACAAGGGGCGC C C CACAAAAGAGGGGCGCCCC C A GTAAGAGGAATGCCCA A A AGAGGTGTGCCCCAAA A GC GGGCCT CCACAAAAAAA A G GCGCCCCACAAAAAAACAC C CCCACAAAAAAACACTCT T CTT CAAAAAAACACTCTGTG G A AAAAAAACACTCTGTGTGT  AAACTTGTGTCTC  ACACTCTGTGTGTCTCACA A C CTAACTGTGTCTCACACGCTC T TGTGTGTCCACACTT G AAGTCTCAACTCTAGC  TCTCACACCTATAA CACACACTCTATAAAATAT T A ACCTATAAAATATATA A C CTTGGTAAAATTGCTAAAA A TTAAAATAAAAA A A AAG TGGCAAAGTTA AATATAAAAA ATAC C T TATCGAAAAAAAACACT,"ID   NCAP_SARS2              Reviewed;         419 AA.
AC   P0DTC9;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Nucleoprotein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=N;
DE   AltName: Full=Nucleocapsid protein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=NC {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=Protein N {ECO:0000255|HAMAP-Rule:MF_04096};
GN   Name=N {ECO:0000255|HAMAP-Rule:MF_04096};
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   SUBCELLULAR LOCATION.
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [3] {ECO:0007744|PDB:6WZO, ECO:0007744|PDB:6WZQ}
RP   X-RAY CRYSTALLOGRAPHY (1.42 ANGSTROMS) OF 247-364, AND SUBUNIT.
RX   PubMed=32654247; DOI=10.1002/pro.3909;
RA   Ye Q., West A.M.V., Silletti S., Corbett K.D.;
RT   ""Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein."";
RL   Protein Sci. 29:1890-1901(2020).
RN   [4]
RP   REVIEW.
RX   PubMed=32974389; DOI=10.3389/fmolb.2020.00219;
RA   Nikolakaki E., Giannakouros T.;
RT   ""SR/RS Motifs as Critical Determinants of Coronavirus Life Cycle."";
RL   Front. Mol. Biosci. 7:219-219(2020).
RN   [5]
RP   VARIANTS LEU-3 AND PHE-235.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [6]
RP   FUNCTION, INTERACTION WITH HOST NLRP3, AND SUBCELLULAR LOCATION.
RX   PubMed=34341353; DOI=10.1038/s41467-021-25015-6;
RA   Pan P., Shen M., Yu Z., Ge W., Chen K., Tian M., Xiao F., Wang Z., Wang J.,
RA   Jia Y., Wang W., Wan P., Zhang J., Chen W., Lei Z., Chen X., Luo Z.,
RA   Zhang Q., Xu M., Li G., Li Y., Wu J.;
RT   ""SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce
RT   hyperinflammation."";
RL   Nat. Commun. 12:4664-4664(2021).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 41-174, AND MUTAGENESIS OF
RP   TYR-109.
RX   PubMed=32363136; DOI=10.1016/j.apsb.2020.04.009;
RA   Kang S., Yang M., Hong Z., Zhang L., Huang Z., Chen X., He S., Zhou Z.,
RA   Zhou Z., Chen Q., Yan Y., Zhang C., Shan H., Chen S.;
RT   ""Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain
RT   reveals potential unique drug targeting sites."";
RL   Acta Pharmacol. Sin. 10:1228-1238(2020).
RN   [8] {ECO:0007744|PDB:6YI3, ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT}
RP   STRUCTURE BY NMR OF 44-180, FUNCTION, AND MUTAGENESIS OF ARG-68; ARG-92;
RP   ILE-94; ARG-107; GLN-163; TYR-172 AND GLU-174.
RX   PubMed=33264373; DOI=10.1371/journal.ppat.1009100;
RA   Dinesh D.C., Chalupska D., Silhan J., Koutna E., Nencka R., Veverka V.,
RA   Boura E.;
RT   ""Structural basis of RNA recognition by the SARS-CoV-2 nucleocapsid
RT   phosphoprotein."";
RL   PLoS Pathog. 16:1-16(2020).
RN   [9]
RP   MUTAGENESIS OF SER-188 AND SER-206, AND PHOSPHORYLATION AT SER-206.
RX   PubMed=34593624; DOI=10.1073/pnas.2113401118;
RA   Liu X., Verma A., Garcia G. Jr., Ramage H., Lucas A., Myers R.L.,
RA   Michaelson J.J., Coryell W., Kumar A., Charney A.W., Kazanietz M.G.,
RA   Rader D.J., Ritchie M.D., Berrettini W.H., Schultz D.C., Cherry S.,
RA   Damoiseaux R., Arumugaswami V., Klein P.S.;
RT   ""Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:1-9(2021).
RN   [10]
RP   CLEAVAGE.
RX   PubMed=35922005; DOI=10.1038/s41586-022-05148-4;
RA   Chu H., Hou Y., Yang D., Wen L., Shuai H., Yoon C., Shi J., Chai Y.,
RA   Yuen T.T., Hu B., Li C., Zhao X., Wang Y., Huang X., Lee K.S., Luo C.,
RA   Cai J.P., Poon V.K., Chan C.C., Zhang A.J., Yuan S., Sit K.Y., Foo D.C.,
RA   Au W.K., Wong K.K., Zhou J., Kok K.H., Jin D.Y., Chan J.F., Yuen K.Y.;
RT   ""Coronaviruses exploit a host cysteine-aspartic protease for replication."";
RL   Nature 0:0-0(2022).
RN   [11]
RP   MUTAGENESIS OF 203-ARG-GLY-204 AND ARG-203, AND PHOSPHORYLATION.
RX   PubMed=35728038; DOI=10.1371/journal.ppat.1010627;
RA   Johnson B.A., Zhou Y., Lokugamage K.G., Vu M.N., Bopp N.,
RA   Crocquet-Valdes P.A., Kalveram B., Schindewolf C., Liu Y., Scharton D.,
RA   Plante J.A., Xie X., Aguilar P., Weaver S.C., Shi P.Y., Walker D.H.,
RA   Routh A.L., Plante K.S., Menachery V.D.;
RT   ""Nucleocapsid mutations in SARS-CoV-2 augment replication and
RT   pathogenesis."";
RL   PLoS Pathog. 18:e1010627-e1010627(2022).
RN   [12]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=35921414; DOI=10.1126/sciadv.abp9770;
RA   Lopez-Munoz A.D., Kosik I., Holly J., Yewdell J.W.;
RT   ""Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive
RT   immunity."";
RL   Sci. Adv. 8:eabp9770-eabp9770(2022).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=34901782; DOI=10.1016/j.isci.2021.103562;
RA   Nabeel-Shah S., Lee H., Ahmed N., Burke G.L., Farhangmehr S., Ashraf K.,
RA   Pu S., Braunschweig U., Zhong G., Wei H., Tang H., Yang J., Marcon E.,
RA   Blencowe B.J., Zhang Z., Greenblatt J.F.;
RT   ""SARS-CoV-2 nucleocapsid protein binds host mRNAs and attenuates stress
RT   granules to impair host stress response."";
RL   IScience 25:103562-103562(2022).
RN   [14]
RP   FUNCTION.
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [15] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 191-263, AND INTERACTION WITH NSP3.
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
CC   -!- FUNCTION: Packages the positive strand viral genome RNA into a helical
CC       ribonucleocapsid (RNP) and plays a fundamental role during virion
CC       assembly through its interactions with the viral genome and membrane
CC       protein M (PubMed:33264373). Plays an important role in enhancing the
CC       efficiency of subgenomic viral RNA transcription as well as viral
CC       replication. Attenuates the stress granules formation by reducing host
CC       G3BP1 access to host mRNAs under stress conditions (PubMed:34901782,
CC       PubMed:36534661). {ECO:0000269|PubMed:32974389,
CC       ECO:0000269|PubMed:33264373, ECO:0000269|PubMed:34901782,
CC       ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: May block host chemokine function in vivo, facilitating viral
CC       replication and transmission (PubMed:35921414). Acts by being secreted
CC       into the extracellular space where it competes to host chemokines for
CC       binding to host glycosaminoglycans (GAG) (PubMed:35921414).
CC       {ECO:0000269|PubMed:35921414}.
CC   -!- FUNCTION: May induce inflammasome responses in cultured cells and mice.
CC       Acts by interacting with host NLRP3 to facilitate inflammasome
CC       assembly, which induces cytokine release that may play a role in COVID
CC       lung injury. {ECO:0000269|PubMed:34341353}.
CC   -!- SUBUNIT: Homodimer, homotetramer, homooligomer with RNA
CC       (PubMed:32654247). Both monomeric and oligomeric forms interact with
CC       RNA. Interacts with protein M (By similarity). Interacts with protein E
CC       (By similarity). Interacts with NSP3; this interaction serves to tether
CC       the genome to the newly translated replicase-transcriptase complex at a
CC       very early stage of infection (PubMed:35044811). May interact with host
CC       NLRP3 (PubMed:34341353). {ECO:0000250|UniProtKB:P59595,
CC       ECO:0000255|HAMAP-Rule:MF_04096, ECO:0000269|PubMed:32654247,
CC       ECO:0000269|PubMed:34341353, ECO:0000269|PubMed:35044811}.
CC   -!- INTERACTION:
CC       P0DTC9; P0DTC4: E; NbExp=3; IntAct=EBI-25475856, EBI-25475850;
CC       P0DTC9; P0DTC5: M; NbExp=6; IntAct=EBI-25475856, EBI-25475853;
CC       P0DTC9; P0DTC9: N; NbExp=105; IntAct=EBI-25475856, EBI-25475856;
CC       P0DTC9; PRO_0000449621 [P0DTD1]: rep; NbExp=15; IntAct=EBI-25475856, EBI-25492388;
CC       P0DTC9; P78563: ADARB1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-2967304;
CC       P0DTC9; O15145: ARPC3; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-351829;
CC       P0DTC9; Q13895: BYSL; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-358049;
CC       P0DTC9; Q16543: CDC37; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-295634;
CC       P0DTC9; Q92793: CREBBP; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-81215;
CC       P0DTC9; Q92499: DDX1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-358474;
CC       P0DTC9; Q9NR30: DDX21; Xeno; NbExp=12; IntAct=EBI-25475856, EBI-357942;
CC       P0DTC9; P26196: DDX6; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-351257;
CC       P0DTC9; Q08426: EHHADH; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-2339219;
CC       P0DTC9; P19525: EIF2AK2; Xeno; NbExp=8; IntAct=EBI-25475856, EBI-640775;
CC       P0DTC9; Q14241: ELOA; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-742350;
CC       P0DTC9; Q13283: G3BP1; Xeno; NbExp=71; IntAct=EBI-25475856, EBI-1047359;
CC       P0DTC9; Q9UN86: G3BP2; Xeno; NbExp=37; IntAct=EBI-25475856, EBI-1044298;
CC       P0DTC9; P57764: GSDMD; Xeno; NbExp=13; IntAct=EBI-25475856, EBI-2798865;
CC       P0DTC9; P49841: GSK3B; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-373586;
CC       P0DTC9; P10412: H1-4; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-358163;
CC       P0DTC9; O14920: IKBKB; Xeno; NbExp=7; IntAct=EBI-25475856, EBI-81266;
CC       P0DTC9; Q92830: KAT2A; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-477622;
CC       P0DTC9; Q92831: KAT2B; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-477430;
CC       P0DTC9; Q07866: KLC1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-721019;
CC       P0DTC9; Q9H0B6: KLC2; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-726994;
CC       P0DTC9; Q9NSK0: KLC4; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-949319;
CC       P0DTC9; Q9NX58: LYAR; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-713507;
CC       P0DTC9; O43318: MAP3K7; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-358684;
CC       P0DTC9; Q9UBU8: MORF4L1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-399246;
CC       P0DTC9; Q15014: MORF4L2; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-399257;
CC       P0DTC9; Q9HCE1: MOV10; Xeno; NbExp=11; IntAct=EBI-25475856, EBI-1055820;
CC       P0DTC9; Q9HC36: MRM3; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-1045440;
CC       P0DTC9; O15226: NKRF; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-766011;
CC       P0DTC9; Q96P20: NLRP3; Xeno; NbExp=18; IntAct=EBI-25475856, EBI-6253230;
CC       P0DTC9; O15118: NPC1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-2368710;
CC       P0DTC9; Q96HA8: NTAQ1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-741158;
CC       P0DTC9; P11940: PABPC1; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-81531;
CC       P0DTC9; P62937: PPIA; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-437708;
CC       P0DTC9; O75569: PRKRA; Xeno; NbExp=8; IntAct=EBI-25475856, EBI-713955;
CC       P0DTC9; Q99873: PRMT1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-78738;
CC       P0DTC9; P61289: PSME3; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-355546;
CC       P0DTC9; P26022: PTX3; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-11574553;
CC       P0DTC9; P54727: RAD23B; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-954531;
CC       P0DTC9; O95786: RIGI; Xeno; NbExp=15; IntAct=EBI-25475856, EBI-995350;
CC       P0DTC9; P62899: RPL31; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-1053664;
CC       P0DTC9; P62753: RPS6; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-356625;
CC       P0DTC9; P37840: SNCA; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-985879;
CC       P0DTC9; Q96SB4: SRPK1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-539478;
CC       P0DTC9; P78362: SRPK2; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-593303;
CC       P0DTC9; P42224: STAT1; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-1057697;
CC       P0DTC9; P52630: STAT2; Xeno; NbExp=7; IntAct=EBI-25475856, EBI-1546963;
CC       P0DTC9; Q15633: TARBP2; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-978581;
CC       P0DTC9; Q14258: TRIM25; Xeno; NbExp=13; IntAct=EBI-25475856, EBI-2341129;
CC       P0DTC9; O60763: USO1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-356164;
CC       P0DTC9; Q93008: USP9X; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-302524;
CC   -!- SUBCELLULAR LOCATION: Virion {ECO:0000255|HAMAP-Rule:MF_04096}. Host
CC       cytoplasm {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:34341353}.
CC       Secreted {ECO:0000269|PubMed:35921414}. Host extracellular space
CC       {ECO:0000269|PubMed:35921414}. Note=Probably associates with ER-derived
CC       membranes where it participates in viral RNA synthesis and virus
CC       budding. When located inside the virion, complexed with the viral RNA.
CC       Can be secreted by unconventional protein secretion (UPS)
CC       (PubMed:35921414). When secreted, can bind to host glycosaminoglycans
CC       on infected and non infected cells (PubMed:35921414). Found in host
CC       cytoplasmic stress granules (PubMed:34901782). {ECO:0000255|HAMAP-
CC       Rule:MF_04096, ECO:0000269|PubMed:34901782,
CC       ECO:0000269|PubMed:35921414}.
CC   -!- PTM: ADP-ribosylated. The ADP-ribosylation is retained in the virion
CC       during infection. {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   -!- PTM: Phosphorylated on serine residues by host GSK3A and GSK3B
CC       (PubMed:34593624, PubMed:35728038). This promotes the solubility of
CC       homodimers that would otherwise aggregate (PubMed:32974389). Host
CC       phosphatase would dephosphorylate the protein during assembly at M
CC       bound membranes (PubMed:32974389). {ECO:0000269|PubMed:34593624,
CC       ECO:0000269|PubMed:35728038, ECO:0000305|PubMed:32974389}.
CC   -!- PTM: Proteolytically cleaved by host CASP6. The cleavage leads to two
CC       fragments and facilitates viral replication by inhibiting host IFN
CC       signaling. The two fragments may interact with IRF3 inhibiting its
CC       nuclear translocation after activation and reduce the expression of
CC       IFNB and IFN-stimulated genes. {ECO:0000269|PubMed:35922005}.
CC   -!- POLYMORPHISM: Variant Alpha/B.1.1.7 belongs to a lineage isolated first
CC       in United Kingdom (December 2020). It is also called Variant of Concern
CC       (VOC) 202012/01, Variant Under Investigation (VUI) 202012/01, 501Y.V1
CC       or 20B/501Y.V1. {ECO:0000305|PubMed:33413740}.
CC   -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC       isolated in South Africa (November 2021). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC       isolated in Nigeria (November 2022). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC       isolated in United States (November 2022). It is the result of
CC       recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC       express ORF8. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the betacoronavirus nucleocapsid protein family.
CC       {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43423.2; -; Genomic_RNA.
DR   PDB; 6M3M; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 6VYO; X-ray; 1.70 A; A/B/C/D=47-173.
DR   PDB; 6WJI; X-ray; 2.05 A; A/B/C/D/E/F=257-364.
DR   PDB; 6WKP; X-ray; 2.67 A; A/B/C/D=47-173.
DR   PDB; 6WZO; X-ray; 1.42 A; A/B/C/D=247-364.
DR   PDB; 6WZQ; X-ray; 1.45 A; A/B/C/D=247-364.
DR   PDB; 6YI3; NMR; -; A=44-180.
DR   PDB; 6YUN; X-ray; 1.44 A; A/B=249-364.
DR   PDB; 6ZCO; X-ray; 1.36 A; A=247-364.
DR   PDB; 7ACS; NMR; -; A=44-180.
DR   PDB; 7ACT; NMR; -; A=44-180.
DR   PDB; 7C22; X-ray; 2.00 A; A/B/C/D=248-364.
DR   PDB; 7CDZ; X-ray; 1.80 A; A/B/C/D=44-174.
DR   PDB; 7CE0; X-ray; 1.50 A; A/B/C/D=255-364.
DR   PDB; 7CR5; X-ray; 2.08 A; A=41-174.
DR   PDB; 7DE1; X-ray; 2.00 A; A/B=250-364.
DR   PDB; 7F2B; X-ray; 2.00 A; A/B=257-362.
DR   PDB; 7F2E; X-ray; 3.10 A; A/B/C/D/E/F/G/H/I/J/K/L=255-362.
DR   PDB; 7KGO; X-ray; 2.15 A; C=351-359.
DR   PDB; 7KGP; X-ray; 1.40 A; C=316-324.
DR   PDB; 7KGQ; X-ray; 1.34 A; C=222-230.
DR   PDB; 7KGR; X-ray; 1.55 A; C=159-167.
DR   PDB; 7KGS; X-ray; 1.58 A; C=138-146.
DR   PDB; 7KGT; X-ray; 1.90 A; C=226-234.
DR   PDB; 7LGD; X-ray; 2.88 A; E/F=105-113.
DR   PDB; 7LTU; X-ray; 1.12 A; A/B=217-222.
DR   PDB; 7LUX; X-ray; 1.30 A; A=217-222.
DR   PDB; 7LUZ; X-ray; 1.10 A; A=243-248.
DR   PDB; 7LV2; X-ray; 1.30 A; A=179-184.
DR   PDB; 7N0I; X-ray; 2.20 A; A/B/C/D/E/F/G/H=269-364.
DR   PDB; 7N0R; X-ray; 1.42 A; A/B=49-174.
DR   PDB; 7N3C; X-ray; 1.82 A; C=47-173.
DR   PDB; 7N3D; X-ray; 1.53 A; C=47-173.
DR   PDB; 7O05; X-ray; 1.94 A; A/B/C/D=247-364.
DR   PDB; 7O35; X-ray; 1.80 A; A/B/C/D=247-364.
DR   PDB; 7O36; X-ray; 2.00 A; A/B/C/D=247-364.
DR   PDB; 7PKU; NMR; -; B=191-263.
DR   PDB; 7QIK; X-ray; 2.01 A; E/F=193-200.
DR   PDB; 7QIP; X-ray; 2.65 A; C/D=201-210.
DR   PDB; 7R98; X-ray; 2.51 A; A/B/C=49-174.
DR   PDB; 7SD4; NMR; -; A=40-174.
DR   PDB; 7STR; X-ray; 1.50 A; C=47-173.
DR   PDB; 7STS; X-ray; 2.16 A; C/D=47-173.
DR   PDB; 7SUE; X-ray; 2.90 A; C/D/J/K=47-173.
DR   PDB; 7SUO; X-ray; 2.35 A; C/D=12-22.
DR   PDB; 7UW3; X-ray; 1.70 A; A/B/C/D=40-174.
DR   PDB; 7UXX; X-ray; 1.85 A; AAA/BBB/CCC/DDD/EEE/FFF=251-364.
DR   PDB; 7UXZ; X-ray; 1.73 A; AAA/BBB/CCC/DDD/EEE/FFF=251-364.
DR   PDB; 7VBD; X-ray; 1.94 A; A/B/C/D=48-174.
DR   PDB; 7VBE; X-ray; 1.59 A; A/B=257-364.
DR   PDB; 7VBF; X-ray; 1.30 A; A/B=255-364.
DR   PDB; 7VNU; X-ray; 1.95 A; A/B/C/D=47-174.
DR   PDB; 7WKJ; X-ray; 1.50 A; C=361-369.
DR   PDB; 7WZO; X-ray; 2.64 A; A=47-174.
DR   PDB; 7XWX; X-ray; 3.00 A; A/B/C/D/E/F/G/H=269-367.
DR   PDB; 7XWZ; X-ray; 2.25 A; A/B=48-172.
DR   PDB; 7XX1; X-ray; 1.90 A; A/B/C/D=49-173.
DR   PDB; 7XXK; X-ray; 2.00 A; A/B/C/D/E/F=248-364.
DR   PDB; 7YLB; X-ray; 2.41 A; A/B/C/D/G/H/J/K=247-364.
DR   PDB; 7YLD; X-ray; 2.80 A; A/B/C/D=47-174.
DR   PDB; 7ZIT; X-ray; 1.79 A; C/D=194-200.
DR   PDB; 8DNT; X-ray; 3.18 A; D/J/Q/X=222-230.
DR   PDB; 8FD5; EM; 4.57 A; A=1-419.
DR   PDB; 8FG2; EM; 6.00 A; A/B=1-419.
DR   PDB; 8IQJ; X-ray; 2.30 A; A/B/C/D=41-174.
DR   PDB; 8IV3; X-ray; 1.90 A; A/B/C/D=41-174.
DR   PDB; 8J6X; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 8TH1; X-ray; 1.80 A; E/F/G/H=1-25.
DR   PDB; 8TH5; X-ray; 2.62 A; K/L/M/N/O/P/Q=1-25.
DR   PDB; 8X1H; X-ray; 2.00 A; A/B/C/D=44-175.
DR   PDBsum; 6M3M; -.
DR   PDBsum; 6VYO; -.
DR   PDBsum; 6WJI; -.
DR   PDBsum; 6WKP; -.
DR   PDBsum; 6WZO; -.
DR   PDBsum; 6WZQ; -.
DR   PDBsum; 6YI3; -.
DR   PDBsum; 6YUN; -.
DR   PDBsum; 6ZCO; -.
DR   PDBsum; 7ACS; -.
DR   PDBsum; 7ACT; -.
DR   PDBsum; 7C22; -.
DR   PDBsum; 7CDZ; -.
DR   PDBsum; 7CE0; -.
DR   PDBsum; 7CR5; -.
DR   PDBsum; 7DE1; -.
DR   PDBsum; 7F2B; -.
DR   PDBsum; 7F2E; -.
DR   PDBsum; 7KGO; -.
DR   PDBsum; 7KGP; -.
DR   PDBsum; 7KGQ; -.
DR   PDBsum; 7KGR; -.
DR   PDBsum; 7KGS; -.
DR   PDBsum; 7KGT; -.
DR   PDBsum; 7LGD; -.
DR   PDBsum; 7LTU; -.
DR   PDBsum; 7LUX; -.
DR   PDBsum; 7LUZ; -.
DR   PDBsum; 7LV2; -.
DR   PDBsum; 7N0I; -.
DR   PDBsum; 7N0R; -.
DR   PDBsum; 7N3C; -.
DR   PDBsum; 7N3D; -.
DR   PDBsum; 7O05; -.
DR   PDBsum; 7O35; -.
DR   PDBsum; 7O36; -.
DR   PDBsum; 7PKU; -.
DR   PDBsum; 7QIK; -.
DR   PDBsum; 7QIP; -.
DR   PDBsum; 7R98; -.
DR   PDBsum; 7SD4; -.
DR   PDBsum; 7STR; -.
DR   PDBsum; 7STS; -.
DR   PDBsum; 7SUE; -.
DR   PDBsum; 7SUO; -.
DR   PDBsum; 7UW3; -.
DR   PDBsum; 7UXX; -.
DR   PDBsum; 7UXZ; -.
DR   PDBsum; 7VBD; -.
DR   PDBsum; 7VBE; -.
DR   PDBsum; 7VBF; -.
DR   PDBsum; 7VNU; -.
DR   PDBsum; 7WKJ; -.
DR   PDBsum; 7WZO; -.
DR   PDBsum; 7XWX; -.
DR   PDBsum; 7XWZ; -.
DR   PDBsum; 7XX1; -.
DR   PDBsum; 7XXK; -.
DR   PDBsum; 7YLB; -.
DR   PDBsum; 7YLD; -.
DR   PDBsum; 7ZIT; -.
DR   PDBsum; 8DNT; -.
DR   PDBsum; 8FD5; -.
DR   PDBsum; 8FG2; -.
DR   PDBsum; 8IQJ; -.
DR   PDBsum; 8IV3; -.
DR   PDBsum; 8J6X; -.
DR   PDBsum; 8TH1; -.
DR   PDBsum; 8TH5; -.
DR   PDBsum; 8X1H; -.
DR   BMRB; P0DTC9; -.
DR   EMDB; EMD-29002; -.
DR   EMDB; EMD-29072; -.
DR   SASBDB; P0DTC9; -.
DR   SMR; P0DTC9; -.
DR   BioGRID; 4383847; 1532.
DR   ComplexPortal; CPX-5686; SARS-CoV-2 nucleocapsid complex.
DR   IntAct; P0DTC9; 608.
DR   MINT; P0DTC9; -.
DR   ChEMBL; CHEMBL5169223; -.
DR   iPTMnet; P0DTC9; -.
DR   ABCD; P0DTC9; 27 sequenced antibodies.
DR   DNASU; 43740575; -.
DR   KEGG; vg:43740575; -.
DR   AGR; RefSeq:YP_009724397; -.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-168928; DDX58/IFIH1-mediated induction of interferon-alpha/beta.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-445989; TAK1-dependent IKK and NF-kappa-B activation.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-9020702; Interleukin-1 signaling.
DR   Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR   Reactome; R-HSA-9694322; Virion Assembly and Release.
DR   Reactome; R-HSA-9694614; Attachment and Entry.
DR   Reactome; R-HSA-9694631; Maturation of nucleoprotein.
DR   Reactome; R-HSA-9694635; Translation of Structural Proteins.
DR   Reactome; R-HSA-9694786; Transcription of SARS-CoV-2 sgRNAs.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9733458; Induction of Cell-Cell Fusion.
DR   Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways.
DR   SIGNOR; P0DTC9; -.
DR   PRO; PR:P0DTC9; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProt.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0044172; C:host cell endoplasmic reticulum-Golgi intermediate compartment; ISS:UniProtKB.
DR   GO; GO:0044177; C:host cell Golgi apparatus; ISS:UniProtKB.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0043655; C:host extracellular space; IEA:UniProtKB-SubCell.
DR   GO; GO:0043232; C:intracellular non-membrane-bounded organelle; IDA:DisProt.
DR   GO; GO:0042612; C:MHC class I protein complex; EXP:DisProt.
DR   GO; GO:1990904; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IPI:ComplexPortal.
DR   GO; GO:0019013; C:viral nucleocapsid; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0042288; F:MHC class I protein binding; EXP:DisProt.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; IDA:DisProt.
DR   GO; GO:0008266; F:poly(U) RNA binding; IMP:DisProt.
DR   GO; GO:0042803; F:protein homodimerization activity; EXP:DisProt.
DR   GO; GO:0140311; F:protein sequestering activity; IDA:UniProt.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProt.
DR   GO; GO:0035613; F:RNA stem-loop binding; IDA:DisProt.
DR   GO; GO:0039709; P:cytoplasmic capsid assembly; IDA:UniProt.
DR   GO; GO:0032688; P:negative regulation of interferon-beta production; IDA:ComplexPortal.
DR   GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; IDA:UniProtKB.
DR   GO; GO:0052572; P:response to host immune response; IDA:DisProt.
DR   GO; GO:0019074; P:viral RNA genome packaging; NAS:ComplexPortal.
DR   CDD; cd21595; CoV_N-CTD; 1.
DR   CDD; cd21554; CoV_N-NTD; 1.
DR   HAMAP; MF_04096; BETA_CORONA_NCAP; 1.
DR   InterPro; IPR044344; N_prot_C_CoV.
DR   InterPro; IPR044345; N_prot_N_CoV.
DR   InterPro; IPR043505; NCAP_bCoV.
DR   InterPro; IPR001218; Nucleocap_CoV.
DR   InterPro; IPR037179; Nucleocapsid_C.
DR   InterPro; IPR037195; Nucleocapsid_N.
DR   Pfam; PF00937; CoV_nucleocap; 1.
DR   PIRSF; PIRSF003888; Corona_nucleocap; 1.
DR   SUPFAM; SSF110304; Coronavirus RNA-binding domain; 1.
DR   SUPFAM; SSF103068; Nucleocapsid protein dimerization domain; 1.
DR   PROSITE; PS51929; COV_N_CTD; 1.
DR   PROSITE; PS51928; COV_N_NTD; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Host cytoplasm; Phosphoprotein;
KW   Reference proteome; Ribonucleoprotein; RNA-binding; Secreted;
KW   Transcription; Transcription regulation; Viral nucleoprotein; Virion.
FT   CHAIN           1..419
FT                   /note=""Nucleoprotein""
FT                   /id=""PRO_0000449656""
FT   DOMAIN          48..174
FT                   /note=""CoV N NTD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01276,
FT                   ECO:0000269|PubMed:32363136""
FT   DOMAIN          247..364
FT                   /note=""CoV N CTD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01277""
FT   REGION          1..51
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          41..186
FT                   /note=""RNA-binding""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   REGION          63..83
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          168..212
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          176..206
FT                   /note=""SR region""
FT                   /evidence=""ECO:0000305|PubMed:32974389""
FT   REGION          233..266
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          258..361
FT                   /note=""Dimerization""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   REGION          260..340
FT                   /note=""Putative NLRP3 binding""
FT                   /evidence=""ECO:0000269|PubMed:34341353""
FT   REGION          361..391
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          400..419
FT                   /note=""Tetramerization""
FT                   /evidence=""ECO:0000269|PubMed:32654247""
FT   MOTIF           256..264
FT                   /note=""Nuclear localization signal""
FT                   /evidence=""ECO:0000250|UniProtKB:P59595""
FT   COMPBIAS        1..11
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        21..31
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        367..378
FT                   /note=""Basic and acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   BINDING         92
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   BINDING         107
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   BINDING         149
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   SITE            399..402
FT                   /note=""Cleavage (by host CASP6)""
FT                   /evidence=""ECO:0000250|UniProtKB:P59595""
FT   MOD_RES         176
FT                   /note=""Phosphoserine; by host""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   MOD_RES         206
FT                   /note=""Phosphoserine; by host GSK3-alpha and GSK3-beta""
FT                   /evidence=""ECO:0000269|PubMed:34593624""
FT   VARIANT         2..3
FT                   /note=""SD -> Y (in strain: Eta/B.1.525)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         3
FT                   /note=""D -> L (in strain: Alpha/B.1.1.7)""
FT                   /evidence=""ECO:0000305|PubMed:33413740""
FT   VARIANT         12
FT                   /note=""A -> G (in strain: Eta/B.1.525)""
FT   VARIANT         13
FT                   /note=""P -> L (in strain: Lambda/C.37, Omicron/BA.1,
FT                   Omicron/BA.2, Omicron/BA.2.12.1, Omicron/BA.2.75,
FT                   Omicron/BA.4, Omicron/BA.5, Omicron/BQ.1.1,
FT                   Omicron/XBB.1.5, Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         31..33
FT                   /note=""Missing (in strain: Omicron/BA.1, Omicron/BA.2,
FT                   Omicron/BA.2.12.1, Omicron/BA.2.75, Omicron/BA.4,
FT                   Omicron/BA.5, Omicron/BQ.1.1, Omicron/XBB.1.5,
FT                   Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         63
FT                   /note=""D -> G (in strain: Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT  ",39652
CTTCAG TTCAGG TCAGGT CAGGTA AGGTAG GGTAGG GTAGGC TAGGCC AGGCCA GGCCAC GCCACC CCACCG CACCGC ACCGCG CCGCGC CGCGCC GCGCCG CGCCGC GCCGCG CCGCGG CGCGGA GCGGAG CGGAGT GGAGTT GAGTTC AGTTCT GTTCTA TTCTAC TCTACA CTACAA TACAAG ACAAGG CAAGGC AAGGCC AGGCCC GGCCCA GCCCAG CCCAGC CCAGCT CAGCTG AGCTGC GCTGCG CTGCGC TGCGCA GCGCAA CGCAAG GCAAGT CAAGTC AAGTCG AGTCGC GTCGCC TCGCCG CGCCGC GCCGCG CCGCGC CGCGCG GCGCGC CGCGCG GCGCGG CGCGGT GCGGTG CGGTGG GGTGGC GTGGCC TGGCCT GGCCTA GCCTAC CCTACC CTACCT TACCTG ACCTGA CCTGAA CTGAAG TGAAGG GAAGGG AAGGGG AGGGGC GGGGCG GGGCGT GGCGTG GCGTGG CGTGGC GTGGCC TGGCCT GGCCTG GCCTGA CCTGAC CTGACC TGACCG GACCGG ACCGGC CCGGCC CGGCCA GGCCAG GCCAGA CCAGAT CAGATC AGATCG GATCGC ATCGCC TCGCCG CGCCGC GCCGCC CCGCCC CGCCCG GCCCGC CCCGCT CCGCTT CGCTTC GCTTCG CTTCGG TTCGGC TCGGCC CGGCCT GGCCTG GCCTGG CCTGGG CTGGGC TGGGCT GGGCTA GGCTAC GCTACG CTACGC TACGCC ACGCCC CGCCCC GCCCCC CCCCCG CCCCGA CCCGAG CCGAGG CGAGGG GAGGGC AGGGCT GGGCTG GGCTGG GCTGGC CTGGCG TGGCGC GGCGCT GCGCTC CGCTCA GCTCAT CTCATT TCATTG,3,145,CTTC TTCA TCAG CAGG AGGT GGTA GTAG TAGG AGGC GGCC GCCA CCAC CACC ACCG CCGC CGCG GCGC CGCC GCCG CCGC CGCG GCGG CGGA GGAG GAGT AGTT GTTC TTCT TCTA CTAC TACA ACAA CAAG AAGG AGGC GGCC GCCC CCCA CCAG CAGC AGCT GCTG CTGC TGCG GCGC CGCA GCAA CAAG AAGT AGTC GTCG TCGC CGCC GCCG CCGC CGCG GCGC CGCG GCGC CGCG GCGG CGGT GGTG GTGG TGGC GGCC GCCT CCTA CTAC TACC ACCT CCTG CTGA TGAA GAAG AAGG AGGG GGGG GGGC GGCG GCGT CGTG GTGG TGGC GGCC GCCT CCTG CTGA TGAC GACC ACCG CCGG CGGC GGCC GCCA CCAG CAGA AGAT GATC ATCG TCGC CGCC GCCG CCGC CGCC GCCC CCCG CCGC CGCT GCTT CTTC TTCG TCGG CGGC GGCC GCCT CCTG CTGG TGGG GGGC GGCT GCTA CTAC TACG ACGC CGCC GCCC CCCC CCCC CCCG CCGA CGAG GAGG AGGG GGGC GGCT GCTG CTGG TGGC GGCG GCGC CGCT GCTC CTCA TCAT CATT ATTG,CTTCA TTCAG TCAGG CAGGT AGGTA GGTAG GTAGG TAGGC AGGCC GGCCA GCCAC CCACC CACCG ACCGC CCGCG CGCGC GCGCC CGCCG GCCGC CCGCG CGCGG GCGGA CGGAG GGAGT GAGTT AGTTC GTTCT TTCTA TCTAC CTACA TACAA ACAAG CAAGG AAGGC AGGCC GGCCC GCCCA CCCAG CCAGC CAGCT AGCTG GCTGC CTGCG TGCGC GCGCA CGCAA GCAAG CAAGT AAGTC AGTCG GTCGC TCGCC CGCCG GCCGC CCGCG CGCGC GCGCG CGCGC GCGCG CGCGG GCGGT CGGTG GGTGG GTGGC TGGCC GGCCT GCCTA CCTAC CTACC TACCT ACCTG CCTGA CTGAA TGAAG GAAGG AAGGG AGGGG GGGGC GGGCG GGCGT GCGTG CGTGG GTGGC TGGCC GGCCT GCCTG CCTGA CTGAC TGACC GACCG ACCGG CCGGC CGGCC GGCCA GCCAG CCAGA CAGAT AGATC GATCG ATCGC TCGCC CGCCG GCCGC CCGCC CGCCC GCCCG CCCGC CCGCT CGCTT GCTTC CTTCG TTCGG TCGGC CGGCC GGCCT GCCTG CCTGG CTGGG TGGGC GGGCT GGCTA GCTAC CTACG TACGC ACGCC CGCCC GCCCC CCCCC CCCCG CCCGA CCGAG CGAGG GAGGG AGGGC GGGCT GGCTG GCTGG CTGGC TGGCG GGCGC GCGCT CGCTC GCTCA CTCAT TCATT CATTG,CTTCAG TTCAGG TCAGGT CAGGTA AGGTAG GGTAGG GTAGGC TAGGCC AGGCCA GGCCAC GCCACC CCACCG CACCGC ACCGCG CCGCGC CGCGCC GCGCCG CGCCGC GCCGCG CCGCGG CGCGGA GCGGAG CGGAGT GGAGTT GAGTTC AGTTCT GTTCTA TTCTAC TCTACA CTACAA TACAAG ACAAGG CAAGGC AAGGCC AGGCCC GGCCCA GCCCAG CCCAGC CCAGCT CAGCTG AGCTGC GCTGCG CTGCGC TGCGCA GCGCAA CGCAAG GCAAGT CAAGTC AAGTCG AGTCGC GTCGCC TCGCCG CGCCGC GCCGCG CCGCGC CGCGCG GCGCGC CGCGCG GCGCGG CGCGGT GCGGTG CGGTGG GGTGGC GTGGCC TGGCCT GGCCTA GCCTAC CCTACC CTACCT TACCTG ACCTGA CCTGAA CTGAAG TGAAGG GAAGGG AAGGGG AGGGGC GGGGCG GGGCGT GGCGTG GCGTGG CGTGGC GTGGCC TGGCCT GGCCTG GCCTGA CCTGAC CTGACC TGACCG GACCGG ACCGGC CCGGCC CGGCCA GGCCAG GCCAGA CCAGAT CAGATC AGATCG GATCGC ATCGCC TCGCCG CGCCGC GCCGCC CCGCCC CGCCCG GCCCGC CCCGCT CCGCTT CGCTTC GCTTCG CTTCGG TTCGGC TCGGCC CGGCCT GGCCTG GCCTGG CCTGGG CTGGGC TGGGCT GGGCTA GGCTAC GCTACG CTACGC TACGCC ACGCCC CGCCCC GCCCCC CCCCCG CCCCGA CCCGAG CCGAGG CGAGGG GAGGGC AGGGCT GGGCTG GGCTGG GCTGGC CTGGCG TGGCGC GGCGCT GCGCTC CGCTCA GCTCAT CTCATT TCATTG,CTTCAGG TTCAGGT TCAGGTA CAGGTAG AGGTAGG GGTAGGC GTAGGCC TAGGCCA AGGCCAC GGCCACC GCCACCG CCACCGC CACCGCG ACCGCGC CCGCGCC CGCGCCG GCGCCGC CGCCGCG GCCGCGG CCGCGGA CGCGGAG GCGGAGT CGGAGTT GGAGTTC GAGTTCT AGTTCTA GTTCTAC TTCTACA TCTACAA CTACAAG TACAAGG ACAAGGC CAAGGCC AAGGCCC AGGCCCA GGCCCAG GCCCAGC CCCAGCT CCAGCTG CAGCTGC AGCTGCG GCTGCGC CTGCGCA TGCGCAA GCGCAAG CGCAAGT GCAAGTC CAAGTCG AAGTCGC AGTCGCC GTCGCCG TCGCCGC CGCCGCG GCCGCGC CCGCGCG CGCGCGC GCGCGCG CGCGCGG GCGCGGT CGCGGTG GCGGTGG CGGTGGC GGTGGCC GTGGCCT TGGCCTA GGCCTAC GCCTACC CCTACCT CTACCTG TACCTGA ACCTGAA CCTGAAG CTGAAGG TGAAGGG GAAGGGG AAGGGGC AGGGGCG GGGGCGT GGGCGTG GGCGTGG GCGTGGC CGTGGCC GTGGCCT TGGCCTG GGCCTGA GCCTGAC CCTGACC CTGACCG TGACCGG GACCGGC ACCGGCC CCGGCCA CGGCCAG GGCCAGA GCCAGAT CCAGATC CAGATCG AGATCGC GATCGCC ATCGCCG TCGCCGC CGCCGCC GCCGCCC CCGCCCG CGCCCGC GCCCGCT CCCGCTT CCGCTTC CGCTTCG GCTTCGG CTTCGGC TTCGGCC TCGGCCT CGGCCTG GGCCTGG GCCTGGG CCTGGGC CTGGGCT TGGGCTA GGGCTAC GGCTACG GCTACGC CTACGCC TACGCCC ACGCCCC CGCCCCC GCCCCCG CCCCCGA CCCCGAG CCCGAGG CCGAGGG CGAGGGC GAGGGCT AGGGCTG GGGCTGG GGCTGGC GCTGGCG CTGGCGC TGGCGCT GGCGCTC GCGCTCA CGCTCAT GCTCATT CTCATTG,"ID   DNAG_PSEPK              Reviewed;         660 AA.
AC   P0A118; O33470;
DT   01-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2005, sequence version 1.
DT   05-FEB-2025, entry version 112.
DE   RecName: Full=DNA primase {ECO:0000255|HAMAP-Rule:MF_00974};
DE            EC=2.7.7.101 {ECO:0000255|HAMAP-Rule:MF_00974};
GN   Name=dnaG {ECO:0000255|HAMAP-Rule:MF_00974};
GN   OrderedLocusNames=PP_0388;
OS   Pseudomonas putida (strain ATCC 47054 / DSM 6125 / CFBP 8728 / NCIMB 11950
OS   / KT2440).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Pseudomonadales;
OC   Pseudomonadaceae; Pseudomonas.
OX   NCBI_TaxID=160488;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 47054 / DSM 6125 / CFBP 8728 / NCIMB 11950 / KT2440;
RX   PubMed=12534463; DOI=10.1046/j.1462-2920.2002.00366.x;
RA   Nelson K.E., Weinel C., Paulsen I.T., Dodson R.J., Hilbert H.,
RA   Martins dos Santos V.A.P., Fouts D.E., Gill S.R., Pop M., Holmes M.,
RA   Brinkac L.M., Beanan M.J., DeBoy R.T., Daugherty S.C., Kolonay J.F.,
RA   Madupu R., Nelson W.C., White O., Peterson J.D., Khouri H.M., Hance I.,
RA   Chris Lee P., Holtzapple E.K., Scanlan D., Tran K., Moazzez A.,
RA   Utterback T.R., Rizzo M., Lee K., Kosack D., Moestl D., Wedler H.,
RA   Lauber J., Stjepandic D., Hoheisel J., Straetz M., Heim S., Kiewitz C.,
RA   Eisen J.A., Timmis K.N., Duesterhoeft A., Tuemmler B., Fraser C.M.;
RT   ""Complete genome sequence and comparative analysis of the metabolically
RT   versatile Pseudomonas putida KT2440."";
RL   Environ. Microbiol. 4:799-808(2002).
CC   -!- FUNCTION: RNA polymerase that catalyzes the synthesis of short RNA
CC       molecules used as primers for DNA polymerase during DNA replication.
CC       {ECO:0000255|HAMAP-Rule:MF_00974}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ssDNA + n NTP = ssDNA/pppN(pN)n-1 hybrid + (n-1) diphosphate.;
CC         EC=2.7.7.101; Evidence={ECO:0000255|HAMAP-Rule:MF_00974};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_00974};
CC       Note=Binds 1 zinc ion per monomer. {ECO:0000255|HAMAP-Rule:MF_00974};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_00974};
CC       Note=Binds two Mg(2+) per subunit. {ECO:0000255|HAMAP-Rule:MF_00974};
CC   -!- SUBUNIT: Monomer. Interacts with DnaB. {ECO:0000255|HAMAP-
CC       Rule:MF_00974}.
CC   -!- DOMAIN: Contains an N-terminal zinc-binding domain, a central core
CC       domain that contains the primase activity, and a C-terminal DnaB-
CC       binding domain. {ECO:0000255|HAMAP-Rule:MF_00974}.
CC   -!- SIMILARITY: Belongs to the DnaG primase family. {ECO:0000255|HAMAP-
CC       Rule:MF_00974}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AE015451; AAN66019.1; -; Genomic_DNA.
DR   RefSeq; NP_742555.1; NC_002947.4.
DR   RefSeq; WP_010951735.1; NC_002947.4.
DR   AlphaFoldDB; P0A118; -.
DR   SMR; P0A118; -.
DR   STRING; 160488.PP_0388; -.
DR   PaxDb; 160488-PP_0388; -.
DR   GeneID; 83677679; -.
DR   KEGG; ppu:PP_0388; -.
DR   PATRIC; fig|160488.4.peg.418; -.
DR   eggNOG; COG0358; Bacteria.
DR   HOGENOM; CLU_013501_5_4_6; -.
DR   OrthoDB; 9803773at2; -.
DR   PhylomeDB; P0A118; -.
DR   BioCyc; PPUT160488:G1G01-425-MONOMER; -.
DR   Proteomes; UP000000556; Chromosome.
DR   GO; GO:0005737; C:cytoplasm; IEA:TreeGrafter.
DR   GO; GO:0000428; C:DNA-directed RNA polymerase complex; IEA:UniProtKB-KW.
DR   GO; GO:1990077; C:primosome complex; IEA:UniProtKB-KW.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003896; F:DNA primase activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-UniRule.
DR   CDD; cd03364; TOPRIM_DnaG_primases; 1.
DR   FunFam; 3.40.1360.10:FF:000002; DNA primase; 1.
DR   FunFam; 3.90.580.10:FF:000001; DNA primase; 1.
DR   FunFam; 3.90.980.10:FF:000001; DNA primase; 1.
DR   Gene3D; 3.40.1360.10; -; 1.
DR   Gene3D; 3.90.980.10; DNA primase, catalytic core, N-terminal domain; 1.
DR   Gene3D; 1.10.860.10; DNAb Helicase, Chain A; 1.
DR   Gene3D; 1.20.50.20; DnaG, RNA polymerase domain, helical bundle; 1.
DR   Gene3D; 3.90.580.10; Zinc finger, CHC2-type domain; 1.
DR   HAMAP; MF_00974; DNA_primase_DnaG; 1.
DR   InterPro; IPR016136; DNA_helicase_N/primase_C.
DR   InterPro; IPR037068; DNA_primase_core_N_sf.
DR   InterPro; IPR019475; DNA_primase_DnaB-bd.
DR   InterPro; IPR006295; DNA_primase_DnaG.
DR   InterPro; IPR013173; DNA_primase_DnaG_DnaB-bd_dom.
DR   InterPro; IPR036977; DNA_primase_Znf_CHC2.
DR   InterPro; IPR030846; DnaG_bac.
DR   InterPro; IPR013264; DNAG_N.
DR   InterPro; IPR050219; DnaG_primase.
DR   InterPro; IPR034151; TOPRIM_DnaG_bac.
DR   InterPro; IPR006171; TOPRIM_dom.
DR   InterPro; IPR002694; Znf_CHC2.
DR   NCBIfam; TIGR01391; dnaG; 1.
DR   PANTHER; PTHR30313; DNA PRIMASE; 1.
DR   PANTHER; PTHR30313:SF2; DNA PRIMASE; 1.
DR   Pfam; PF10410; DnaB_bind; 1.
DR   Pfam; PF08278; DnaG_DnaB_bind; 1.
DR   Pfam; PF08275; DNAG_N; 1.
DR   Pfam; PF13155; Toprim_2; 1.
DR   Pfam; PF01807; zf-CHC2; 1.
DR   PIRSF; PIRSF002811; DnaG; 1.
DR   SMART; SM00766; DnaG_DnaB_bind; 1.
DR   SMART; SM00493; TOPRIM; 1.
DR   SMART; SM00400; ZnF_CHCC; 1.
DR   SUPFAM; SSF56731; DNA primase core; 1.
DR   SUPFAM; SSF117023; DNA primase DnaG, C-terminal domain; 1.
DR   SUPFAM; SSF57783; Zinc beta-ribbon; 1.
DR   PROSITE; PS50880; TOPRIM; 1.
PE   3: Inferred from homology;
KW   DNA replication; DNA-binding; DNA-directed RNA polymerase; Magnesium;
KW   Metal-binding; Nucleotidyltransferase; Primosome; Reference proteome;
KW   Transcription; Transferase; Zinc; Zinc-finger.
FT   CHAIN           1..660
FT                   /note=""DNA primase""
FT                   /id=""PRO_0000180513""
FT   DOMAIN          261..343
FT                   /note=""Toprim""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00974""
FT   ZN_FING         40..64
FT                   /note=""CHC2-type""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00974""
FT   REGION          94..115
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          425..449
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          476..519
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        97..110
FT                   /note=""Basic and acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        428..442
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        488..498
FT                   /note=""Basic and acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   BINDING         267
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""1""
FT                   /ligand_note=""catalytic""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00974""
FT   BINDING         311
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""1""
FT                   /ligand_note=""catalytic""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00974""
FT   BINDING         311
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00974""
FT   BINDING         313
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00974""
SQ   SEQUENCE   660 AA;  73830 MW;  0D9A88AAA2B81A9C CRC64;
     MAGLIPQSFI DDLINRLDIV DVVSSRVQLK KTGKNYSACC PFHKEKTPSF TVSPDKQFYY
     CFGCGAGGNA LGFVMDHDNL DFPQAVEELA RAAGMEVPRE QGRRDQKPRQ PTDSPLYPLL
     DAASEFYRQA LRSHPSRKAA VDYLKGRGLS GEIARDFGLG FAPPGWDNLL KHLGADTLQQ
     KVMIDAGLLI ENAESGKRYD RFRDRVMFPI RDSRGRIIAF GGRVLGDDKP KYLNSPETPV
     FHKGQELYGL YEARKHNRNL DEIIVVEGYM DVIALAQQGL RNAVATLGTA TSEEHLKRLF
     RVVPSVLFCF DGDQAGRKAA WRALESTLSN LQDGRRARFL FLPEGEDPDS LVRAEGTDAF
     MARINQHSQP LADYFFEQLG VEADPRSLEG KAHMATLAAP LIEKIPGANL RQLMRNRLKE
     ITGLDPQQVE QLAQQAPATS SMPDYDPGYD YDAMASYTPD YGDMPQHDYA PVHQEQAWKP
     NKGGSKKPWS DKPWDKNRKG GKPWQQRDEA PPRVPAPVEP PTLAALRTLL HHPLLAGKVE
     DASHFADEEH LYSQLLVALI EAAQKNPGLS SMQLIARWHG TEQGRLLRAL AEKEWLIVAD
     NLEQQFFDTI TSLSARQRER SLEQLLRKSR QSELTSEEKT QLLALLSRNV PAQTPTSSGA
//
",22030
ATGATC TGATCG GATCGA ATCGAC TCGACA CGACAT GACATC ACATCA CATCAA ATCAAA TCAAAA CAAAAA AAAAAC AAAACG AAACGT AACGTT ACGTTT CGTTTC GTTTCC TTTCCA TTCCAA TCCAAG CCAAGT CAAGTG AAGTGG AGTGGT GTGGTA TGGTAC GGTACG GTACGG TACGGC ACGGCA CGGCAG GGCAGC GCAGCT CAGCTT AGCTTC GCTTCC CTTCCA TTCCAG TCCAGG CCAGGT CAGGTG AGGTGC GGTGCT GTGCTG TGCTGA GCTGAC CTGACC TGACCG GACCGA ACCGAC CCGACT CGACTG GACTGC ACTGCA CTGCAC TGCACC GCACCA CACCAC ACCACC CCACCT CACCTC ACCTCC,2,64,ATGA TGAT GATC ATCG TCGA CGAC GACA ACAT CATC ATCA TCAA CAAA AAAA AAAA AAAC AACG ACGT CGTT GTTT TTTC TTCC TCCA CCAA CAAG AAGT AGTG GTGG TGGT GGTA GTAC TACG ACGG CGGC GGCA GCAG CAGC AGCT GCTT CTTC TTCC TCCA CCAG CAGG AGGT GGTG GTGC TGCT GCTG CTGA TGAC GACC ACCG CCGA CGAC GACT ACTG CTGC TGCA GCAC CACC ACCA CCAC CACC ACCT CCTC CTCC,ATGAT TGATC GATCG ATCGA TCGAC CGACA GACAT ACATC CATCA ATCAA TCAAA CAAAA AAAAA AAAAC AAACG AACGT ACGTT CGTTT GTTTC TTTCC TTCCA TCCAA CCAAG CAAGT AAGTG AGTGG GTGGT TGGTA GGTAC GTACG TACGG ACGGC CGGCA GGCAG GCAGC CAGCT AGCTT GCTTC CTTCC TTCCA TCCAG CCAGG CAGGT AGGTG GGTGC GTGCT TGCTG GCTGA CTGAC TGACC GACCG ACCGA CCGAC CGACT GACTG ACTGC CTGCA TGCAC GCACC CACCA ACCAC CCACC CACCT ACCTC CCTCC,ATGATC TGATCG GATCGA ATCGAC TCGACA CGACAT GACATC ACATCA CATCAA ATCAAA TCAAAA CAAAAA AAAAAC AAAACG AAACGT AACGTT ACGTTT CGTTTC GTTTCC TTTCCA TTCCAA TCCAAG CCAAGT CAAGTG AAGTGG AGTGGT GTGGTA TGGTAC GGTACG GTACGG TACGGC ACGGCA CGGCAG GGCAGC GCAGCT CAGCTT AGCTTC GCTTCC CTTCCA TTCCAG TCCAGG CCAGGT CAGGTG AGGTGC GGTGCT GTGCTG TGCTGA GCTGAC CTGACC TGACCG GACCGA ACCGAC CCGACT CGACTG GACTGC ACTGCA CTGCAC TGCACC GCACCA CACCAC ACCACC CCACCT CACCTC ACCTCC,ATGATCG TGATCGA GATCGAC ATCGACA TCGACAT CGACATC GACATCA ACATCAA CATCAAA ATCAAAA TCAAAAA CAAAAAC AAAAACG AAAACGT AAACGTT AACGTTT ACGTTTC CGTTTCC GTTTCCA TTTCCAA TTCCAAG TCCAAGT CCAAGTG CAAGTGG AAGTGGT AGTGGTA GTGGTAC TGGTACG GGTACGG GTACGGC TACGGCA ACGGCAG CGGCAGC GGCAGCT GCAGCTT CAGCTTC AGCTTCC GCTTCCA CTTCCAG TTCCAGG TCCAGGT CCAGGTG CAGGTGC AGGTGCT GGTGCTG GTGCTGA TGCTGAC GCTGACC CTGACCG TGACCGA GACCGAC ACCGACT CCGACTG CGACTGC GACTGCA ACTGCAC CTGCACC TGCACCA GCACCAC CACCACC ACCACCT CCACCTC CACCTCC,"ID   GLTL_ECO57              Reviewed;         241 AA.
AC   P0AAG4; P41076;
DT   11-OCT-2005, integrated into UniProtKB/Swiss-Prot.
DT   11-OCT-2005, sequence version 1.
DT   05-FEB-2025, entry version 119.
DE   RecName: Full=Glutamate/aspartate import ATP-binding protein GltL {ECO:0000250|UniProtKB:P0AAG3};
DE            EC=7.4.2.1 {ECO:0000250|UniProtKB:P0AAG3};
GN   Name=gltL; OrderedLocusNames=Z0802, ECs0691;
OS   Escherichia coli O157:H7.
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Enterobacterales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=83334;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=O157:H7 / EDL933 / ATCC 700927 / EHEC;
RX   PubMed=11206551; DOI=10.1038/35054089;
RA   Perna N.T., Plunkett G. III, Burland V., Mau B., Glasner J.D., Rose D.J.,
RA   Mayhew G.F., Evans P.S., Gregor J., Kirkpatrick H.A., Posfai G.,
RA   Hackett J., Klink S., Boutin A., Shao Y., Miller L., Grotbeck E.J.,
RA   Davis N.W., Lim A., Dimalanta E.T., Potamousis K., Apodaca J.,
RA   Anantharaman T.S., Lin J., Yen G., Schwartz D.C., Welch R.A.,
RA   Blattner F.R.;
RT   ""Genome sequence of enterohaemorrhagic Escherichia coli O157:H7."";
RL   Nature 409:529-533(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=O157:H7 / Sakai / RIMD 0509952 / EHEC;
RX   PubMed=11258796; DOI=10.1093/dnares/8.1.11;
RA   Hayashi T., Makino K., Ohnishi M., Kurokawa K., Ishii K., Yokoyama K.,
RA   Han C.-G., Ohtsubo E., Nakayama K., Murata T., Tanaka M., Tobe T., Iida T.,
RA   Takami H., Honda T., Sasakawa C., Ogasawara N., Yasunaga T., Kuhara S.,
RA   Shiba T., Hattori M., Shinagawa H.;
RT   ""Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and
RT   genomic comparison with a laboratory strain K-12."";
RL   DNA Res. 8:11-22(2001).
CC   -!- FUNCTION: Part of the ABC transporter complex GltIJKL involved in
CC       glutamate and aspartate uptake. Probably responsible for energy
CC       coupling to the transport system. {ECO:0000250|UniProtKB:P0AAG3}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a polar amino acid(out) + ATP + H2O = a polar amino acid(in) +
CC         ADP + phosphate + H(+); Xref=Rhea:RHEA:14673, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:62031, ChEBI:CHEBI:456216; EC=7.4.2.1;
CC         Evidence={ECO:0000250|UniProtKB:P0AAG3};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:14674;
CC         Evidence={ECO:0000250|UniProtKB:P0AAG3};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-glutamate(out) + ATP + H2O = L-glutamate(in) + ADP +
CC         phosphate + H(+); Xref=Rhea:RHEA:29035, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:29985, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000250|UniProtKB:P0AAG3};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:29036;
CC         Evidence={ECO:0000250|UniProtKB:P0AAG3};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-aspartate(out) + ATP + H2O = L-aspartate(in) + ADP +
CC         phosphate + H(+); Xref=Rhea:RHEA:29039, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:29991, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000250|UniProtKB:P0AAG3};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:29040;
CC         Evidence={ECO:0000250|UniProtKB:P0AAG3};
CC   -!- SUBUNIT: The complex is composed of two ATP-binding proteins (GltL),
CC       two transmembrane proteins (GltJ and GltK) and a solute-binding protein
CC       (GltI). {ECO:0000250|UniProtKB:P0AAG3}.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane
CC       {ECO:0000250|UniProtKB:P0AAG3}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:P0AAG3}.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AE005174; AAG54986.1; -; Genomic_DNA.
DR   EMBL; BA000007; BAB34114.1; -; Genomic_DNA.
DR   PIR; C90715; C90715.
DR   PIR; F85565; F85565.
DR   RefSeq; NP_308718.1; NC_002695.1.
DR   RefSeq; WP_000631384.1; NZ_VOAI01000012.1.
DR   AlphaFoldDB; P0AAG4; -.
DR   SMR; P0AAG4; -.
DR   STRING; 155864.Z0802; -.
DR   GeneID; 917052; -.
DR   GeneID; 93776830; -.
DR   KEGG; ece:Z0802; -.
DR   KEGG; ecs:ECs_0691; -.
DR   PATRIC; fig|386585.9.peg.805; -.
DR   eggNOG; COG1126; Bacteria.
DR   HOGENOM; CLU_000604_1_22_6; -.
DR   OMA; IFMDKGS; -.
DR   Proteomes; UP000000558; Chromosome.
DR   Proteomes; UP000002519; Chromosome.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:InterPro.
DR   GO; GO:0102013; F:ATPase-coupled L-glutamate tranmembrane transporter activity; IEA:RHEA.
DR   CDD; cd03262; ABC_HisP_GlnQ; 1.
DR   FunFam; 3.40.50.300:FF:000020; Amino acid ABC transporter ATP-binding component; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR030679; ABC_ATPase_HisP-typ.
DR   InterPro; IPR003439; ABC_transporter-like_ATP-bd.
DR   InterPro; IPR017871; ABC_transporter-like_CS.
DR   InterPro; IPR050086; MetN_ABC_transporter-like.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR43166; AMINO ACID IMPORT ATP-BINDING PROTEIN; 1.
DR   PANTHER; PTHR43166:SF9; GLUTAMATE_ASPARTATE IMPORT ATP-BINDING PROTEIN GLTL; 1.
DR   Pfam; PF00005; ABC_tran; 1.
DR   PIRSF; PIRSF039085; ABC_ATPase_HisP; 1.
DR   SMART; SM00382; AAA; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 1.
PE   3: Inferred from homology;
KW   Amino-acid transport; ATP-binding; Cell inner membrane; Cell membrane;
KW   Membrane; Nucleotide-binding; Reference proteome; Translocase; Transport.
FT   CHAIN           1..241
FT                   /note=""Glutamate/aspartate import ATP-binding protein GltL""
FT                   /id=""PRO_0000092336""
FT   DOMAIN          2..236
FT                   /note=""ABC transporter""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00434""
FT   BINDING         34..41
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00434""
SQ   SEQUENCE   241 AA;  26661 MW;  7643584D63FC424D CRC64;
     MITLKNVSKW YGHFQVLTDC STEVKKGEVV VVCGPSGSGK STLIKTVNGL EPVQQGEITV
     DGIVVNDKKT DLAKLRSRVG MVFQHFELFP HLSIIENLTL AQVKVLKRDK APAREKALKL
     LERVGLSAHA NKFPAQLSGG QQQRVAIARA LCMDPIAMLF DEPTSALDPE MINEVLDVMV
     ELANEGMTMM VVTHEMGFAR KVANRVIFMD EGKIVEDSPK DAFFDDPKSD RAKDFLAKIL
     H
//
",28110
ATCCTC TCCTCG CCTCGG CTCGGC TCGGCC CGGCCT GGCCTC GCCTCA CCTCAT CTCATC TCATCC CATCCC ATCCCG TCCCGC CCCGCT CCGCTC CGCTCG GCTCGT CTCGTG TCGTGA CGTGAC GTGACA TGACAG GACAGC ACAGCC CAGCCA AGCCAA GCCAAC CCAACG CAACGG AACGGC ACGGCG CGGCGC GGCGCC GCGCCG CGCCGC GCCGCC CCGCCA CGCCAT GCCATG CCATGG CATGGT ATGGTC TGGTCA GGTCAG GTCAGC TCAGCC CAGCCG AGCCGG GCCGGC CCGGCG CGGCGC GGCGCG GCGCGC CGCGCG GCGCGG CGCGGT GCGGTC CGGTCG GGTCGG GTCGGC TCGGCA CGGCAC GGCACT GCACTC CACTCC ACTCCC CTCCCG TCCCGT CCCGTC CCGTCT CGTCTT GTCTTC TCTTCG CTTCGC TTCGCC TCGCCG CGCCGG GCCGGA CCGGAA CGGAAT GGAATG GAATGC AATGCT ATGCTG TGCTGG GCTGGC CTGGCC TGGCCG GGCCGC GCCGCG CCGCGT CGCGTC GCGTCG CGTCGG GTCGGC TCGGCC CGGCCC GGCCCT GCCCTG CCCTGG CCTGGG CTGGGC TGGGCA GGGCAT GGCATT GCATTT CATTTT ATTTTC TTTTCC TTTCCT TTCCTC TCCTCA CCTCAT CTCATT TCATTC CATTCC ATTCCG TTCCGA TCCGAT CCGATG CGATGC GATGCT ATGCTG TGCTGT GCTGTA CTGTAC TGTACG GTACGT TACGTC ACGTCG CGTCGC GTCGCT TCGCTT CGCTTT GCTTTC CTTTCC TTTCCA TTCCAG TCCAGT CCAGTC CAGTCG AGTCGA GTCGAT TCGATG,2,145,ATCC TCCT CCTC CTCG TCGG CGGC GGCC GCCT CCTC CTCA TCAT CATC ATCC TCCC CCCG CCGC CGCT GCTC CTCG TCGT CGTG GTGA TGAC GACA ACAG CAGC AGCC GCCA CCAA CAAC AACG ACGG CGGC GGCG GCGC CGCC GCCG CCGC CGCC GCCA CCAT CATG ATGG TGGT GGTC GTCA TCAG CAGC AGCC GCCG CCGG CGGC GGCG GCGC CGCG GCGC CGCG GCGG CGGT GGTC GTCG TCGG CGGC GGCA GCAC CACT ACTC CTCC TCCC CCCG CCGT CGTC GTCT TCTT CTTC TTCG TCGC CGCC GCCG CCGG CGGA GGAA GAAT AATG ATGC TGCT GCTG CTGG TGGC GGCC GCCG CCGC CGCG GCGT CGTC GTCG TCGG CGGC GGCC GCCC CCCT CCTG CTGG TGGG GGGC GGCA GCAT CATT ATTT TTTT TTTC TTCC TCCT CCTC CTCA TCAT CATT ATTC TTCC TCCG CCGA CGAT GATG ATGC TGCT GCTG CTGT TGTA GTAC TACG ACGT CGTC GTCG TCGC CGCT GCTT CTTT TTTC TTCC TCCA CCAG CAGT AGTC GTCG TCGA CGAT GATG,ATCCT TCCTC CCTCG CTCGG TCGGC CGGCC GGCCT GCCTC CCTCA CTCAT TCATC CATCC ATCCC TCCCG CCCGC CCGCT CGCTC GCTCG CTCGT TCGTG CGTGA GTGAC TGACA GACAG ACAGC CAGCC AGCCA GCCAA CCAAC CAACG AACGG ACGGC CGGCG GGCGC GCGCC CGCCG GCCGC CCGCC CGCCA GCCAT CCATG CATGG ATGGT TGGTC GGTCA GTCAG TCAGC CAGCC AGCCG GCCGG CCGGC CGGCG GGCGC GCGCG CGCGC GCGCG CGCGG GCGGT CGGTC GGTCG GTCGG TCGGC CGGCA GGCAC GCACT CACTC ACTCC CTCCC TCCCG CCCGT CCGTC CGTCT GTCTT TCTTC CTTCG TTCGC TCGCC CGCCG GCCGG CCGGA CGGAA GGAAT GAATG AATGC ATGCT TGCTG GCTGG CTGGC TGGCC GGCCG GCCGC CCGCG CGCGT GCGTC CGTCG GTCGG TCGGC CGGCC GGCCC GCCCT CCCTG CCTGG CTGGG TGGGC GGGCA GGCAT GCATT CATTT ATTTT TTTTC TTTCC TTCCT TCCTC CCTCA CTCAT TCATT CATTC ATTCC TTCCG TCCGA CCGAT CGATG GATGC ATGCT TGCTG GCTGT CTGTA TGTAC GTACG TACGT ACGTC CGTCG GTCGC TCGCT CGCTT GCTTT CTTTC TTTCC TTCCA TCCAG CCAGT CAGTC AGTCG GTCGA TCGAT CGATG,ATCCTC TCCTCG CCTCGG CTCGGC TCGGCC CGGCCT GGCCTC GCCTCA CCTCAT CTCATC TCATCC CATCCC ATCCCG TCCCGC CCCGCT CCGCTC CGCTCG GCTCGT CTCGTG TCGTGA CGTGAC GTGACA TGACAG GACAGC ACAGCC CAGCCA AGCCAA GCCAAC CCAACG CAACGG AACGGC ACGGCG CGGCGC GGCGCC GCGCCG CGCCGC GCCGCC CCGCCA CGCCAT GCCATG CCATGG CATGGT ATGGTC TGGTCA GGTCAG GTCAGC TCAGCC CAGCCG AGCCGG GCCGGC CCGGCG CGGCGC GGCGCG GCGCGC CGCGCG GCGCGG CGCGGT GCGGTC CGGTCG GGTCGG GTCGGC TCGGCA CGGCAC GGCACT GCACTC CACTCC ACTCCC CTCCCG TCCCGT CCCGTC CCGTCT CGTCTT GTCTTC TCTTCG CTTCGC TTCGCC TCGCCG CGCCGG GCCGGA CCGGAA CGGAAT GGAATG GAATGC AATGCT ATGCTG TGCTGG GCTGGC CTGGCC TGGCCG GGCCGC GCCGCG CCGCGT CGCGTC GCGTCG CGTCGG GTCGGC TCGGCC CGGCCC GGCCCT GCCCTG CCCTGG CCTGGG CTGGGC TGGGCA GGGCAT GGCATT GCATTT CATTTT ATTTTC TTTTCC TTTCCT TTCCTC TCCTCA CCTCAT CTCATT TCATTC CATTCC ATTCCG TTCCGA TCCGAT CCGATG CGATGC GATGCT ATGCTG TGCTGT GCTGTA CTGTAC TGTACG GTACGT TACGTC ACGTCG CGTCGC GTCGCT TCGCTT CGCTTT GCTTTC CTTTCC TTTCCA TTCCAG TCCAGT CCAGTC CAGTCG AGTCGA GTCGAT TCGATG,ATCCTCG TCCTCGG CCTCGGC CTCGGCC TCGGCCT CGGCCTC GGCCTCA GCCTCAT CCTCATC CTCATCC TCATCCC CATCCCG ATCCCGC TCCCGCT CCCGCTC CCGCTCG CGCTCGT GCTCGTG CTCGTGA TCGTGAC CGTGACA GTGACAG TGACAGC GACAGCC ACAGCCA CAGCCAA AGCCAAC GCCAACG CCAACGG CAACGGC AACGGCG ACGGCGC CGGCGCC GGCGCCG GCGCCGC CGCCGCC GCCGCCA CCGCCAT CGCCATG GCCATGG CCATGGT CATGGTC ATGGTCA TGGTCAG GGTCAGC GTCAGCC TCAGCCG CAGCCGG AGCCGGC GCCGGCG CCGGCGC CGGCGCG GGCGCGC GCGCGCG CGCGCGG GCGCGGT CGCGGTC GCGGTCG CGGTCGG GGTCGGC GTCGGCA TCGGCAC CGGCACT GGCACTC GCACTCC CACTCCC ACTCCCG CTCCCGT TCCCGTC CCCGTCT CCGTCTT CGTCTTC GTCTTCG TCTTCGC CTTCGCC TTCGCCG TCGCCGG CGCCGGA GCCGGAA CCGGAAT CGGAATG GGAATGC GAATGCT AATGCTG ATGCTGG TGCTGGC GCTGGCC CTGGCCG TGGCCGC GGCCGCG GCCGCGT CCGCGTC CGCGTCG GCGTCGG CGTCGGC GTCGGCC TCGGCCC CGGCCCT GGCCCTG GCCCTGG CCCTGGG CCTGGGC CTGGGCA TGGGCAT GGGCATT GGCATTT GCATTTT CATTTTC ATTTTCC TTTTCCT TTTCCTC TTCCTCA TCCTCAT CCTCATT CTCATTC TCATTCC CATTCCG ATTCCGA TTCCGAT TCCGATG CCGATGC CGATGCT GATGCTG ATGCTGT TGCTGTA GCTGTAC CTGTACG TGTACGT GTACGTC TACGTCG ACGTCGC CGTCGCT GTCGCTT TCGCTTT CGCTTTC GCTTTCC CTTTCCA TTTCCAG TTCCAGT TCCAGTC CCAGTCG CAGTCGA AGTCGAT GTCGATG,"ID   BEPG_BRUSU              Reviewed;        1074 AA.
AC   Q8FWV9; G0KC75;
DT   19-JAN-2010, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2003, sequence version 1.
DT   05-FEB-2025, entry version 92.
DE   RecName: Full=Efflux pump membrane transporter BepG;
GN   Name=bepG; OrderedLocusNames=BRA0334, BS1330_II0331;
OS   Brucella suis biovar 1 (strain 1330).
OC   Bacteria; Pseudomonadota; Alphaproteobacteria; Hyphomicrobiales;
OC   Brucellaceae; Brucella/Ochrobactrum group; Brucella.
OX   NCBI_TaxID=204722;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=1330;
RX   PubMed=12271122; DOI=10.1073/pnas.192319099;
RA   Paulsen I.T., Seshadri R., Nelson K.E., Eisen J.A., Heidelberg J.F.,
RA   Read T.D., Dodson R.J., Umayam L.A., Brinkac L.M., Beanan M.J.,
RA   Daugherty S.C., DeBoy R.T., Durkin A.S., Kolonay J.F., Madupu R.,
RA   Nelson W.C., Ayodeji B., Kraul M., Shetty J., Malek J.A., Van Aken S.E.,
RA   Riedmuller S., Tettelin H., Gill S.R., White O., Salzberg S.L.,
RA   Hoover D.L., Lindler L.E., Halling S.M., Boyle S.M., Fraser C.M.;
RT   ""The Brucella suis genome reveals fundamental similarities between animal
RT   and plant pathogens and symbionts."";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:13148-13153(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=1330;
RX   PubMed=22038969; DOI=10.1128/jb.06181-11;
RA   Tae H., Shallom S., Settlage R., Preston D., Adams L.G., Garner H.R.;
RT   ""Revised genome sequence of Brucella suis 1330."";
RL   J. Bacteriol. 193:6410-6410(2011).
RN   [3]
RP   FUNCTION IN RESISTANCE, SUBUNIT, INDUCTION, AND DISRUPTION PHENOTYPE.
RC   STRAIN=1330;
RX   PubMed=19201794; DOI=10.1128/jb.01198-08;
RA   Martin F.A., Posadas D.M., Carrica M.C., Cravero S.L., O'Callaghan D.,
RA   Zorreguieta A.;
RT   ""Interplay between two RND systems mediating antimicrobial resistance in
RT   Brucella suis."";
RL   J. Bacteriol. 191:2530-2540(2009).
CC   -!- FUNCTION: May contribute to resistance to some drugs, such as
CC       deoxycholate, sodium dodecyl sulfate and nalidixic acid, in the absence
CC       of BepD and BepE. {ECO:0000269|PubMed:19201794}.
CC   -!- SUBUNIT: Probably part of a tripartite efflux pump, which is composed
CC       of an outer membrane efflux protein, an inner membrane protein and a
CC       protein that expands the periplasmic space. Could form a tripartite
CC       pump with BepC and BepF. {ECO:0000269|PubMed:19201794}.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane {ECO:0000305}; Multi-pass
CC       membrane protein {ECO:0000305}.
CC   -!- INDUCTION: Induced in the absence of BepDE.
CC       {ECO:0000269|PubMed:19201794}.
CC   -!- DISRUPTION PHENOTYPE: Shows no differences in the resistance profile to
CC       different dyes, detergents and antimicrobials.
CC       {ECO:0000269|PubMed:19201794}.
CC   -!- SIMILARITY: Belongs to the resistance-nodulation-cell division (RND)
CC       (TC 2.A.6) family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AE014292; AAN33534.1; -; Genomic_DNA.
DR   EMBL; CP002998; AEM19813.1; -; Genomic_DNA.
DR   RefSeq; WP_006191785.1; NZ_KN046805.1.
DR   AlphaFoldDB; Q8FWV9; -.
DR   SMR; Q8FWV9; -.
DR   GeneID; 45053393; -.
DR   KEGG; bms:BRA0334; -.
DR   KEGG; bsi:BS1330_II0331; -.
DR   PATRIC; fig|204722.22.peg.3114; -.
DR   HOGENOM; CLU_002755_1_1_5; -.
DR   PhylomeDB; Q8FWV9; -.
DR   Proteomes; UP000007104; Chromosome II.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0015562; F:efflux transmembrane transporter activity; IEA:InterPro.
DR   GO; GO:0042910; F:xenobiotic transmembrane transporter activity; IEA:TreeGrafter.
DR   FunFam; 1.20.1640.10:FF:000001; Efflux pump membrane transporter; 1.
DR   FunFam; 3.30.70.1430:FF:000001; Efflux pump membrane transporter; 1.
DR   Gene3D; 3.30.70.1430; Multidrug efflux transporter AcrB pore domain; 2.
DR   Gene3D; 3.30.70.1440; Multidrug efflux transporter AcrB pore domain; 1.
DR   Gene3D; 3.30.70.1320; Multidrug efflux transporter AcrB pore domain like; 1.
DR   Gene3D; 3.30.2090.10; Multidrug efflux transporter AcrB TolC docking domain, DN and DC subdomains; 2.
DR   Gene3D; 1.20.1640.10; Multidrug efflux transporter AcrB transmembrane domain; 2.
DR   InterPro; IPR027463; AcrB_DN_DC_subdom.
DR   InterPro; IPR001036; Acrflvin-R.
DR   InterPro; IPR004764; MdtF-like.
DR   NCBIfam; TIGR00915; 2A0602; 1.
DR   PANTHER; PTHR32063; -; 1.
DR   PANTHER; PTHR32063:SF76; EFFLUX PUMP MEMBRANE TRANSPORTER; 1.
DR   Pfam; PF00873; ACR_tran; 1.
DR   PRINTS; PR00702; ACRIFLAVINRP.
DR   SUPFAM; SSF82693; Multidrug efflux transporter AcrB pore domain, PN1, PN2, PC1 and PC2 subdomains; 3.
DR   SUPFAM; SSF82714; Multidrug efflux transporter AcrB TolC docking domain, DN and DC subdomains; 2.
DR   SUPFAM; SSF82866; Multidrug efflux transporter AcrB transmembrane domain; 2.
PE   1: Evidence at protein level;
KW   Cell inner membrane; Cell membrane; Membrane; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN           1..1074
FT                   /note=""Efflux pump membrane transporter BepG""
FT                   /id=""PRO_0000390651""
FT   TRANSMEM        13..33
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        342..362
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        368..388
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        395..415
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        444..464
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        478..498
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        540..560
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        876..896
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        898..918
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        930..950
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        975..995
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        1007..1027
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   REGION          1050..1074
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
SQ   SEQUENCE   1074 AA;  114902 MW;  79F0B440F8A96438 CRC64;
     MLSSVFINRP RLAIVIAIVI TLAGLIAVTR IPVAQFPDIV PPQVSVTATY PGASAETVEA
     AIAQPIEAQV NGVDDMIYMS STSGNNGTYT LTVTFKVGSD PNLNTVNVQN RVRLAEANLP
     QEVTRLGVTV KKQSSSFLQI ITLLSPDSRY DELFLNNYGV INVVDRLARV PGVGQAQSFG
     TFNYSMRIWF NTDALTSLNL TPNDIVNAIS SQNVQAAVGR LGAPPMTDQQ QIQLTLTTQG
     RLTDAKQFEN IIIRANPDGS SVRLKDVARV ELAAQSYDTI GRLNGKPASV IAVYQAPGSN
     AVAAAEGVRN VMEQLKQSFP AGLDYKITYD TTVFVSSTIH EVIKTLLEAF VLVVVVVFIF
     LGNFRATLIP TLAVPVSLIG TFAVLLVLGF SANTISLFAM ILAIGIVVDD AIVVVENVER
     VMAETGLPPK EAAKQAMQEI TAPIIAITLV LLSVFVPVAF IPGITGALYA QFALTVSVAM
     LISAINALTL SPALCGVFLK PHQGRKKSLY GRTMDKLSSG IEKISDGYAH IVRRLVRMAF
     LSIVLVAGLG AGAYFLNTIV PTGFLPEEDQ GLFFVQVNLP PAASQSRTAA VVSEIEADIT
     KMAGVADVTS VTGFSFIDGL AVSNAGLMIV TLKPLEERLK DNITVFDVIA EVNRRTAAIP
     SAVAITMNLP PILGLGSSGG FQYQLEDQEG QSPQQLASVA QGLVMAANQN PKLSRVFTTF
     ATDTPQLNLN IDRQKALSLG VSPNNIIQAL QSTLGGYFVN NFNTLGRTWQ VIIQGEQQDR
     KTVEDIYRIN VRSSHGDMVP LRSLVSVEER LGPLYITRYN NYRSASIQGN AAPGVSSGEA
     LAAMAQVSKT TLPSGYGYEW TGTALQELQA AGQTSMILAL AVLFAYLFLV ALYESWTIPV
     GVLLSVTAGL AGAMLALWIT GLSNDIYAQI GIVVLIALAS KNGILIVEFA KERREEGVPL
     EQAAIIGARQ RFRPVMMTSF AFILGLVPLV IAVGAAAASR RAVGTSVFGG MIAASAVGIF
     LIPMLYVVLE RVREWGHARI LRKPLYEEEK QEKADGDASG PTVPPTQPED RGLS
//
",34888
AACGCC ACGCCA CGCCAA GCCAAG CCAAGG CAAGGC AAGGCC AGGCCG GGCCGT GCCGTA CCGTAA CGTAAA GTAAAA TAAAAC AAAACC AAACCA AACCAG ACCAGC CCAGCG CAGCGG AGCGGA GCGGAT CGGATC GGATCC GATCCG ATCCGA TCCGAC CCGACC CGACCA GACCAT ACCATG CCATGG CATGGA ATGGAT TGGATG GGATGT GATGTT ATGTTT TGTTTA GTTTAT TTTATA TTATAC TATACT ATACTT TACTTT ACTTTT CTTTTA TTTTAT TTTATA TTATAG TATAGG ATAGGC TAGGCT AGGCTG GGCTGG GCTGGT CTGGTA TGGTAT GGTATT GTATTC TATTCT ATTCTG TTCTGA TCTGAC CTGACG TGACGA GACGAA ACGAAG CGAAGC GAAGCC AAGCCT AGCCTT GCCTTG CCTTGA CTTGAC TTGACT TGACTT GACTTC ACTTCC CTTCCG TTCCGC TCCGCC CCGCCT CGCCTA GCCTAT CCTATG CTATGA TATGAT ATGATT TGATTT GATTTT ATTTTA TTTTAA TTTAAT TTAATA TAATAC AATACC ATACCC TACCCC ACCCCC CCCCCG CCCCGT CCCGTT CCGTTA CGTTAC GTTACC TTACCG TACCGG ACCGGA CCGGAA CGGAAA GGAAAT GAAATA AAATAT AATATT ATATTA TATTAC ATTACC TTACCT TACCTT ACCTTT CCTTTT CTTTTA TTTTAT TTTATG TTATGC TATGCG ATGCGA TGCGAA GCGAAA CGAAAT GAAATG AAATGG AATGGG ATGGGG TGGGGA GGGGAA GGGAAT GGAATT,3,139,AACG ACGC CGCC GCCA CCAA CAAG AAGG AGGC GGCC GCCG CCGT CGTA GTAA TAAA AAAA AAAC AACC ACCA CCAG CAGC AGCG GCGG CGGA GGAT GATC ATCC TCCG CCGA CGAC GACC ACCA CCAT CATG ATGG TGGA GGAT GATG ATGT TGTT GTTT TTTA TTAT TATA ATAC TACT ACTT CTTT TTTT TTTA TTAT TATA ATAG TAGG AGGC GGCT GCTG CTGG TGGT GGTA GTAT TATT ATTC TTCT TCTG CTGA TGAC GACG ACGA CGAA GAAG AAGC AGCC GCCT CCTT CTTG TTGA TGAC GACT ACTT CTTC TTCC TCCG CCGC CGCC GCCT CCTA CTAT TATG ATGA TGAT GATT ATTT TTTT TTTA TTAA TAAT AATA ATAC TACC ACCC CCCC CCCC CCCG CCGT CGTT GTTA TTAC TACC ACCG CCGG CGGA GGAA GAAA AAAT AATA ATAT TATT ATTA TTAC TACC ACCT CCTT CTTT TTTT TTTA TTAT TATG ATGC TGCG GCGA CGAA GAAA AAAT AATG ATGG TGGG GGGG GGGA GGAA GAAT AATT,AACGC ACGCC CGCCA GCCAA CCAAG CAAGG AAGGC AGGCC GGCCG GCCGT CCGTA CGTAA GTAAA TAAAA AAAAC AAACC AACCA ACCAG CCAGC CAGCG AGCGG GCGGA CGGAT GGATC GATCC ATCCG TCCGA CCGAC CGACC GACCA ACCAT CCATG CATGG ATGGA TGGAT GGATG GATGT ATGTT TGTTT GTTTA TTTAT TTATA TATAC ATACT TACTT ACTTT CTTTT TTTTA TTTAT TTATA TATAG ATAGG TAGGC AGGCT GGCTG GCTGG CTGGT TGGTA GGTAT GTATT TATTC ATTCT TTCTG TCTGA CTGAC TGACG GACGA ACGAA CGAAG GAAGC AAGCC AGCCT GCCTT CCTTG CTTGA TTGAC TGACT GACTT ACTTC CTTCC TTCCG TCCGC CCGCC CGCCT GCCTA CCTAT CTATG TATGA ATGAT TGATT GATTT ATTTT TTTTA TTTAA TTAAT TAATA AATAC ATACC TACCC ACCCC CCCCC CCCCG CCCGT CCGTT CGTTA GTTAC TTACC TACCG ACCGG CCGGA CGGAA GGAAA GAAAT AAATA AATAT ATATT TATTA ATTAC TTACC TACCT ACCTT CCTTT CTTTT TTTTA TTTAT TTATG TATGC ATGCG TGCGA GCGAA CGAAA GAAAT AAATG AATGG ATGGG TGGGG GGGGA GGGAA GGAAT GAATT,AACGCC ACGCCA CGCCAA GCCAAG CCAAGG CAAGGC AAGGCC AGGCCG GGCCGT GCCGTA CCGTAA CGTAAA GTAAAA TAAAAC AAAACC AAACCA AACCAG ACCAGC CCAGCG CAGCGG AGCGGA GCGGAT CGGATC GGATCC GATCCG ATCCGA TCCGAC CCGACC CGACCA GACCAT ACCATG CCATGG CATGGA ATGGAT TGGATG GGATGT GATGTT ATGTTT TGTTTA GTTTAT TTTATA TTATAC TATACT ATACTT TACTTT ACTTTT CTTTTA TTTTAT TTTATA TTATAG TATAGG ATAGGC TAGGCT AGGCTG GGCTGG GCTGGT CTGGTA TGGTAT GGTATT GTATTC TATTCT ATTCTG TTCTGA TCTGAC CTGACG TGACGA GACGAA ACGAAG CGAAGC GAAGCC AAGCCT AGCCTT GCCTTG CCTTGA CTTGAC TTGACT TGACTT GACTTC ACTTCC CTTCCG TTCCGC TCCGCC CCGCCT CGCCTA GCCTAT CCTATG CTATGA TATGAT ATGATT TGATTT GATTTT ATTTTA TTTTAA TTTAAT TTAATA TAATAC AATACC ATACCC TACCCC ACCCCC CCCCCG CCCCGT CCCGTT CCGTTA CGTTAC GTTACC TTACCG TACCGG ACCGGA CCGGAA CGGAAA GGAAAT GAAATA AAATAT AATATT ATATTA TATTAC ATTACC TTACCT TACCTT ACCTTT CCTTTT CTTTTA TTTTAT TTTATG TTATGC TATGCG ATGCGA TGCGAA GCGAAA CGAAAT GAAATG AAATGG AATGGG ATGGGG TGGGGA GGGGAA GGGAAT GGAATT,AACGCCA ACGCCAA CGCCAAG GCCAAGG CCAAGGC CAAGGCC AAGGCCG AGGCCGT GGCCGTA GCCGTAA CCGTAAA CGTAAAA GTAAAAC TAAAACC AAAACCA AAACCAG AACCAGC ACCAGCG CCAGCGG CAGCGGA AGCGGAT GCGGATC CGGATCC GGATCCG GATCCGA ATCCGAC TCCGACC CCGACCA CGACCAT GACCATG ACCATGG CCATGGA CATGGAT ATGGATG TGGATGT GGATGTT GATGTTT ATGTTTA TGTTTAT GTTTATA TTTATAC TTATACT TATACTT ATACTTT TACTTTT ACTTTTA CTTTTAT TTTTATA TTTATAG TTATAGG TATAGGC ATAGGCT TAGGCTG AGGCTGG GGCTGGT GCTGGTA CTGGTAT TGGTATT GGTATTC GTATTCT TATTCTG ATTCTGA TTCTGAC TCTGACG CTGACGA TGACGAA GACGAAG ACGAAGC CGAAGCC GAAGCCT AAGCCTT AGCCTTG GCCTTGA CCTTGAC CTTGACT TTGACTT TGACTTC GACTTCC ACTTCCG CTTCCGC TTCCGCC TCCGCCT CCGCCTA CGCCTAT GCCTATG CCTATGA CTATGAT TATGATT ATGATTT TGATTTT GATTTTA ATTTTAA TTTTAAT TTTAATA TTAATAC TAATACC AATACCC ATACCCC TACCCCC ACCCCCG CCCCCGT CCCCGTT CCCGTTA CCGTTAC CGTTACC GTTACCG TTACCGG TACCGGA ACCGGAA CCGGAAA CGGAAAT GGAAATA GAAATAT AAATATT AATATTA ATATTAC TATTACC ATTACCT TTACCTT TACCTTT ACCTTTT CCTTTTA CTTTTAT TTTTATG TTTATGC TTATGCG TATGCGA ATGCGAA TGCGAAA GCGAAAT CGAAATG GAAATGG AAATGGG AATGGGG ATGGGGA TGGGGAA GGGGAAT GGGAATT,"ID   Y381_EVAC2              Reviewed;         664 AA.
AC   P0DJ98;
DT   14-DEC-2011, integrated into UniProtKB/Swiss-Prot.
DT   14-DEC-2011, sequence version 1.
DT   05-FEB-2025, entry version 23.
DE   RecName: Full=Putative membrane protein Bcell_0381;
GN   OrderedLocusNames=Bcell_0381;
OS   Evansella cellulosilytica (strain ATCC 21833 / DSM 2522 / FERM P-1141 / JCM
OS   9156 / N-4) (Bacillus cellulosilyticus).
OC   Bacteria; Bacillati; Bacillota; Bacilli; Bacillales; Bacillaceae;
OC   Evansella.
OX   NCBI_TaxID=649639;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 21833 / DSM 2522 / FERM P-1141 / JCM 9156 / N-4;
RA   Lucas S., Copeland A., Lapidus A., Cheng J.-F., Bruce D., Goodwin L.,
RA   Pitluck S., Chertkov O., Detter J.C., Han C., Tapia R., Land M., Hauser L.,
RA   Jeffries C., Kyrpides N., Ivanova N., Mikhailova N., Brumm P., Mead D.,
RA   Woyke T.;
RT   ""Complete sequence of Bacillus cellulosilyticus DSM 2522."";
RL   Submitted (DEC-2010) to the EMBL/GenBank/DDBJ databases.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Single-pass membrane
CC       protein {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP002394; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   AlphaFoldDB; P0DJ98; -.
DR   SMR; P0DJ98; -.
DR   Proteomes; UP000001401; Chromosome.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   Gene3D; 2.60.40.4270; Listeria-Bacteroides repeat domain; 4.
DR   InterPro; IPR025883; Cadherin-like_b_sandwich.
DR   InterPro; IPR013378; InlB-like_B-rpt.
DR   InterPro; IPR042229; Listeria/Bacterioides_rpt_sf.
DR   NCBIfam; TIGR02543; List_Bact_rpt; 4.
DR   Pfam; PF12733; Cadherin-like; 1.
DR   Pfam; PF09479; Flg_new; 4.
PE   4: Predicted;
KW   Cell membrane; Membrane; Reference proteome; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..664
FT                   /note=""Putative membrane protein Bcell_0381""
FT                   /id=""PRO_0000414220""
FT   TRANSMEM        636..656
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   REGION          588..622
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        588..616
FT                   /note=""Acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
SQ   SEQUENCE   664 AA;  75224 MW;  C2EF7E86A9B38081 CRC64;
     MTLYAKWEIN VYTVSFATNG GSKVSEVDAE FASLIEEPTP PEKEGHSFKG WYQDELLTEA
     WDFEVETITE NITLYAKWEI NVYTVSFESN GGSQVSEVEA EYGSSITEPV PPEKEGHSFL
     GWYQDELLTE AWDFETSTVS EDMILYAKWE INEYTVSFEL NGGSHVSEVE AEYGSTITEP
     APPEKEGHSF LGWYQDELHT EAWDFETDVI SENMTLYAQW SINNYDVHYD GNDYDSGEAP
     LTEAFAYDSE VTVAGQHTLG RNGYTFIGWN TERDGSGDQF EPGDTYRMGS EPLTLYAQWA
     SNNAKLSELV ISHGTLTPIF EADYAHYAVE VGHQVTSITI TPTLQDTRST VSISQNEAAS
     GEVSSAIPLE EGLNTIIIDI TAEDGSTYAY TVDVMRKVTD QFAQLTRESH FVTLDDEQIH
     MLDEEGTLRV DLQGELDDVT EVKFTQYQVQ LLQEKGAFVQ VVKEDLLVYI PFINFEPVKD
     LNITIQRQDY NIDTFAFADR SASAIYQLNI DQNGERISVF EHDIQLSFPV KNIGETNLEE
     LQVYYFNPDG QEWELIGGTY NNGYIHATTS HFSTFAVFHP DHLSVEDDVT QDENGEEKSE
     EDNKEEIVEE NTEEDNKEEK TIEAGEELPL TATRTYQFLL AGIIMLVGGS CIYVFYRRRN
     IMKT
//
",31256
GTTTTA TTTTAA TTTAAC TTAACA TAACAA AACAAC ACAACA CAACAA AACAAA ACAAAG CAAAGA AAAGAT AAGATA AGATAG GATAGC ATAGCA TAGCAC AGCACT GCACTT CACTTA ACTTAA CTTAAG TTAAGG TAAGGG AAGGGT AGGGTG GGGTGG GGTGGT GTGGTA TGGTAA GGTAAA GTAAAA TAAAAT AAAATT AAATTG AATTGT ATTGTT TTGTTA TGTTAA GTTAAT TTAATA TAATAA AATAAT ATAATT TAATTG AATTGG ATTGGT TTGGTT TGGTTG GGTTGA GTTGAA TTGAAG TGAAGC GAAGCA AAGCAG AGCAGT GCAGTT CAGTTA AGTTAA GTTAAT TTAATT,0,61,GTTT TTTT TTTA TTAA TAAC AACA ACAA CAAC AACA ACAA CAAA AAAG AAGA AGAT GATA ATAG TAGC AGCA GCAC CACT ACTT CTTA TTAA TAAG AAGG AGGG GGGT GGTG GTGG TGGT GGTA GTAA TAAA AAAA AAAT AATT ATTG TTGT TGTT GTTA TTAA TAAT AATA ATAA TAAT AATT ATTG TTGG TGGT GGTT GTTG TTGA TGAA GAAG AAGC AGCA GCAG CAGT AGTT GTTA TTAA TAAT AATT,GTTTT TTTTA TTTAA TTAAC TAACA AACAA ACAAC CAACA AACAA ACAAA CAAAG AAAGA AAGAT AGATA GATAG ATAGC TAGCA AGCAC GCACT CACTT ACTTA CTTAA TTAAG TAAGG AAGGG AGGGT GGGTG GGTGG GTGGT TGGTA GGTAA GTAAA TAAAA AAAAT AAATT AATTG ATTGT TTGTT TGTTA GTTAA TTAAT TAATA AATAA ATAAT TAATT AATTG ATTGG TTGGT TGGTT GGTTG GTTGA TTGAA TGAAG GAAGC AAGCA AGCAG GCAGT CAGTT AGTTA GTTAA TTAAT TAATT,GTTTTA TTTTAA TTTAAC TTAACA TAACAA AACAAC ACAACA CAACAA AACAAA ACAAAG CAAAGA AAAGAT AAGATA AGATAG GATAGC ATAGCA TAGCAC AGCACT GCACTT CACTTA ACTTAA CTTAAG TTAAGG TAAGGG AAGGGT AGGGTG GGGTGG GGTGGT GTGGTA TGGTAA GGTAAA GTAAAA TAAAAT AAAATT AAATTG AATTGT ATTGTT TTGTTA TGTTAA GTTAAT TTAATA TAATAA AATAAT ATAATT TAATTG AATTGG ATTGGT TTGGTT TGGTTG GGTTGA GTTGAA TTGAAG TGAAGC GAAGCA AAGCAG AGCAGT GCAGTT CAGTTA AGTTAA GTTAAT TTAATT,GTTTTAA TTTTAAC TTTAACA TTAACAA TAACAAC AACAACA ACAACAA CAACAAA AACAAAG ACAAAGA CAAAGAT AAAGATA AAGATAG AGATAGC GATAGCA ATAGCAC TAGCACT AGCACTT GCACTTA CACTTAA ACTTAAG CTTAAGG TTAAGGG TAAGGGT AAGGGTG AGGGTGG GGGTGGT GGTGGTA GTGGTAA TGGTAAA GGTAAAA GTAAAAT TAAAATT AAAATTG AAATTGT AATTGTT ATTGTTA TTGTTAA TGTTAAT GTTAATA TTAATAA TAATAAT AATAATT ATAATTG TAATTGG AATTGGT ATTGGTT TTGGTTG TGGTTGA GGTTGAA GTTGAAG TTGAAGC TGAAGCA GAAGCAG AAGCAGT AGCAGTT GCAGTTA CAGTTAA AGTTAAT GTTAATT,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",53761
CCGGTC CGGTCG GGTCGT GTCGTG TCGTGG CGTGGT GTGGTC TGGTCG GGTCGT GTCGTC TCGTCA CGTCAT GTCATG TCATGG CATGGG ATGGGC TGGGCC GGGCCA GGCCAC GCCACG CCACGT CACGTC ACGTCG CGTCGA GTCGAC TCGACC CGACCA GACCAC ACCACG CCACGG CACGGC ACGGCA CGGCAA GGCAAG GCAAGA CAAGAC AAGACG AGACGT GACGTC ACGTCG CGTCGC GTCGCT TCGCTG CGCTGC GCTGCT CTGCTC TGCTCG GCTCGA CTCGAC TCGACT CGACTA GACTAT ACTATA CTATAT TATATC ATATCC TATCCG ATCCGC TCCGCC CCGCCA CGCCAC GCCACG CCACGC CACGCG ACGCGA CGCGAA GCGAAG CGAAGG GAAGGT AAGGTC AGGTCG GGTCGC GTCGCG TCGCGG CGCGGC GCGGCT CGGCTG GGCTGG GCTGGC CTGGCG TGGCGA GGCGAG GCGAGG CGAGGC GAGGCC AGGCCG GGCCGG GCCGGC CCGGCG CGGCGG GGCGGC GCGGCA CGGCAT GGCATC GCATCA CATCAC ATCACG TCACGC CACGCA ACGCAG CGCAGC GCAGCA CAGCAT AGCATA GCATAT CATATC ATATCG TATCGG ATCGGC TCGGCG CGGCGC GGCGCT GCGCTT CGCTTA GCTTAC CTTACA TTACAC TACACC ACACCG CACCGT ACCGTC CCGTCG CGTCGA GTCGAG TCGAGA CGAGAT GAGATC AGATCA GATCAA ATCAAC TCAACG CAACGG AACGGC ACGGCC CGGCCA GGCCAG GCCAGC CCAGCC CAGCCC AGCCCA GCCCAT CCCATC,3,142,CCGG CGGT GGTC GTCG TCGT CGTG GTGG TGGT GGTC GTCG TCGT CGTC GTCA TCAT CATG ATGG TGGG GGGC GGCC GCCA CCAC CACG ACGT CGTC GTCG TCGA CGAC GACC ACCA CCAC CACG ACGG CGGC GGCA GCAA CAAG AAGA AGAC GACG ACGT CGTC GTCG TCGC CGCT GCTG CTGC TGCT GCTC CTCG TCGA CGAC GACT ACTA CTAT TATA ATAT TATC ATCC TCCG CCGC CGCC GCCA CCAC CACG ACGC CGCG GCGA CGAA GAAG AAGG AGGT GGTC GTCG TCGC CGCG GCGG CGGC GGCT GCTG CTGG TGGC GGCG GCGA CGAG GAGG AGGC GGCC GCCG CCGG CGGC GGCG GCGG CGGC GGCA GCAT CATC ATCA TCAC CACG ACGC CGCA GCAG CAGC AGCA GCAT CATA ATAT TATC ATCG TCGG CGGC GGCG GCGC CGCT GCTT CTTA TTAC TACA ACAC CACC ACCG CCGT CGTC GTCG TCGA CGAG GAGA AGAT GATC ATCA TCAA CAAC AACG ACGG CGGC GGCC GCCA CCAG CAGC AGCC GCCC CCCA CCAT CATC,CCGGT CGGTC GGTCG GTCGT TCGTG CGTGG GTGGT TGGTC GGTCG GTCGT TCGTC CGTCA GTCAT TCATG CATGG ATGGG TGGGC GGGCC GGCCA GCCAC CCACG CACGT ACGTC CGTCG GTCGA TCGAC CGACC GACCA ACCAC CCACG CACGG ACGGC CGGCA GGCAA GCAAG CAAGA AAGAC AGACG GACGT ACGTC CGTCG GTCGC TCGCT CGCTG GCTGC CTGCT TGCTC GCTCG CTCGA TCGAC CGACT GACTA ACTAT CTATA TATAT ATATC TATCC ATCCG TCCGC CCGCC CGCCA GCCAC CCACG CACGC ACGCG CGCGA GCGAA CGAAG GAAGG AAGGT AGGTC GGTCG GTCGC TCGCG CGCGG GCGGC CGGCT GGCTG GCTGG CTGGC TGGCG GGCGA GCGAG CGAGG GAGGC AGGCC GGCCG GCCGG CCGGC CGGCG GGCGG GCGGC CGGCA GGCAT GCATC CATCA ATCAC TCACG CACGC ACGCA CGCAG GCAGC CAGCA AGCAT GCATA CATAT ATATC TATCG ATCGG TCGGC CGGCG GGCGC GCGCT CGCTT GCTTA CTTAC TTACA TACAC ACACC CACCG ACCGT CCGTC CGTCG GTCGA TCGAG CGAGA GAGAT AGATC GATCA ATCAA TCAAC CAACG AACGG ACGGC CGGCC GGCCA GCCAG CCAGC CAGCC AGCCC GCCCA CCCAT CCATC,CCGGTC CGGTCG GGTCGT GTCGTG TCGTGG CGTGGT GTGGTC TGGTCG GGTCGT GTCGTC TCGTCA CGTCAT GTCATG TCATGG CATGGG ATGGGC TGGGCC GGGCCA GGCCAC GCCACG CCACGT CACGTC ACGTCG CGTCGA GTCGAC TCGACC CGACCA GACCAC ACCACG CCACGG CACGGC ACGGCA CGGCAA GGCAAG GCAAGA CAAGAC AAGACG AGACGT GACGTC ACGTCG CGTCGC GTCGCT TCGCTG CGCTGC GCTGCT CTGCTC TGCTCG GCTCGA CTCGAC TCGACT CGACTA GACTAT ACTATA CTATAT TATATC ATATCC TATCCG ATCCGC TCCGCC CCGCCA CGCCAC GCCACG CCACGC CACGCG ACGCGA CGCGAA GCGAAG CGAAGG GAAGGT AAGGTC AGGTCG GGTCGC GTCGCG TCGCGG CGCGGC GCGGCT CGGCTG GGCTGG GCTGGC CTGGCG TGGCGA GGCGAG GCGAGG CGAGGC GAGGCC AGGCCG GGCCGG GCCGGC CCGGCG CGGCGG GGCGGC GCGGCA CGGCAT GGCATC GCATCA CATCAC ATCACG TCACGC CACGCA ACGCAG CGCAGC GCAGCA CAGCAT AGCATA GCATAT CATATC ATATCG TATCGG ATCGGC TCGGCG CGGCGC GGCGCT GCGCTT CGCTTA GCTTAC CTTACA TTACAC TACACC ACACCG CACCGT ACCGTC CCGTCG CGTCGA GTCGAG TCGAGA CGAGAT GAGATC AGATCA GATCAA ATCAAC TCAACG CAACGG AACGGC ACGGCC CGGCCA GGCCAG GCCAGC CCAGCC CAGCCC AGCCCA GCCCAT CCCATC,CCGGTCG CGGTCGT GGTCGTG GTCGTGG TCGTGGT CGTGGTC GTGGTCG TGGTCGT GGTCGTC GTCGTCA TCGTCAT CGTCATG GTCATGG TCATGGG CATGGGC ATGGGCC TGGGCCA GGGCCAC GGCCACG GCCACGT CCACGTC CACGTCG ACGTCGA CGTCGAC GTCGACC TCGACCA CGACCAC GACCACG ACCACGG CCACGGC CACGGCA ACGGCAA CGGCAAG GGCAAGA GCAAGAC CAAGACG AAGACGT AGACGTC GACGTCG ACGTCGC CGTCGCT GTCGCTG TCGCTGC CGCTGCT GCTGCTC CTGCTCG TGCTCGA GCTCGAC CTCGACT TCGACTA CGACTAT GACTATA ACTATAT CTATATC TATATCC ATATCCG TATCCGC ATCCGCC TCCGCCA CCGCCAC CGCCACG GCCACGC CCACGCG CACGCGA ACGCGAA CGCGAAG GCGAAGG CGAAGGT GAAGGTC AAGGTCG AGGTCGC GGTCGCG GTCGCGG TCGCGGC CGCGGCT GCGGCTG CGGCTGG GGCTGGC GCTGGCG CTGGCGA TGGCGAG GGCGAGG GCGAGGC CGAGGCC GAGGCCG AGGCCGG GGCCGGC GCCGGCG CCGGCGG CGGCGGC GGCGGCA GCGGCAT CGGCATC GGCATCA GCATCAC CATCACG ATCACGC TCACGCA CACGCAG ACGCAGC CGCAGCA GCAGCAT CAGCATA AGCATAT GCATATC CATATCG ATATCGG TATCGGC ATCGGCG TCGGCGC CGGCGCT GGCGCTT GCGCTTA CGCTTAC GCTTACA CTTACAC TTACACC TACACCG ACACCGT CACCGTC ACCGTCG CCGTCGA CGTCGAG GTCGAGA TCGAGAT CGAGATC GAGATCA AGATCAA GATCAAC ATCAACG TCAACGG CAACGGC AACGGCC ACGGCCA CGGCCAG GGCCAGC GCCAGCC CCAGCCC CAGCCCA AGCCCAT GCCCATC,"ID   IF2_CELJU               Reviewed;         930 AA.
AC   B3PI96;
DT   24-MAR-2009, integrated into UniProtKB/Swiss-Prot.
DT   02-SEP-2008, sequence version 1.
DT   05-FEB-2025, entry version 96.
DE   RecName: Full=Translation initiation factor IF-2 {ECO:0000255|HAMAP-Rule:MF_00100};
GN   Name=infB {ECO:0000255|HAMAP-Rule:MF_00100};
GN   OrderedLocusNames=CJA_0436;
OS   Cellvibrio japonicus (strain Ueda107) (Pseudomonas fluorescens subsp.
OS   cellulosa).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Cellvibrionales;
OC   Cellvibrionaceae; Cellvibrio.
OX   NCBI_TaxID=498211;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Ueda107;
RX   PubMed=18556790; DOI=10.1128/jb.01701-07;
RA   DeBoy R.T., Mongodin E.F., Fouts D.E., Tailford L.E., Khouri H.,
RA   Emerson J.B., Mohamoud Y., Watkins K., Henrissat B., Gilbert H.J.,
RA   Nelson K.E.;
RT   ""Insights into plant cell wall degradation from the genome sequence of the
RT   soil bacterium Cellvibrio japonicus."";
RL   J. Bacteriol. 190:5455-5463(2008).
CC   -!- FUNCTION: One of the essential components for the initiation of protein
CC       synthesis. Protects formylmethionyl-tRNA from spontaneous hydrolysis
CC       and promotes its binding to the 30S ribosomal subunits. Also involved
CC       in the hydrolysis of GTP during the formation of the 70S ribosomal
CC       complex. {ECO:0000255|HAMAP-Rule:MF_00100}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000255|HAMAP-Rule:MF_00100}.
CC   -!- SIMILARITY: Belongs to the TRAFAC class translation factor GTPase
CC       superfamily. Classic translation factor GTPase family. IF-2 subfamily.
CC       {ECO:0000255|HAMAP-Rule:MF_00100}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP000934; ACE84775.1; -; Genomic_DNA.
DR   RefSeq; WP_012486117.1; NC_010995.1.
DR   AlphaFoldDB; B3PI96; -.
DR   SMR; B3PI96; -.
DR   STRING; 498211.CJA_0436; -.
DR   KEGG; cja:CJA_0436; -.
DR   eggNOG; COG0532; Bacteria.
DR   HOGENOM; CLU_006301_6_0_6; -.
DR   OrthoDB; 9811804at2; -.
DR   Proteomes; UP000001036; Chromosome.
DR   GO; GO:0005829; C:cytosol; IEA:TreeGrafter.
DR   GO; GO:0005525; F:GTP binding; IEA:UniProtKB-KW.
DR   GO; GO:0003924; F:GTPase activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0003743; F:translation initiation factor activity; IEA:UniProtKB-UniRule.
DR   CDD; cd01887; IF2_eIF5B; 1.
DR   CDD; cd03702; IF2_mtIF2_II; 1.
DR   CDD; cd03692; mtIF2_IVc; 1.
DR   FunFam; 2.40.30.10:FF:000007; Translation initiation factor IF-2; 1.
DR   FunFam; 2.40.30.10:FF:000008; Translation initiation factor IF-2; 1.
DR   FunFam; 3.40.50.10050:FF:000001; Translation initiation factor IF-2; 1.
DR   FunFam; 3.40.50.300:FF:000019; Translation initiation factor IF-2; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   Gene3D; 3.30.56.50; Putative DNA-binding domain, N-terminal subdomain of bacterial translation initiation factor IF2; 1.
DR   Gene3D; 2.40.30.10; Translation factors; 2.
DR   Gene3D; 3.40.50.10050; Translation initiation factor IF- 2, domain 3; 1.
DR   HAMAP; MF_00100_B; IF_2_B; 1.
DR   InterPro; IPR009061; DNA-bd_dom_put_sf.
DR   InterPro; IPR053905; EF-G-like_DII.
DR   InterPro; IPR013575; IF2_assoc_dom_bac.
DR   InterPro; IPR044145; IF2_II.
DR   InterPro; IPR006847; IF2_N.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR005225; Small_GTP-bd.
DR   InterPro; IPR000795; T_Tr_GTP-bd_dom.
DR   InterPro; IPR000178; TF_IF2_bacterial-like.
DR   InterPro; IPR015760; TIF_IF2.
DR   InterPro; IPR023115; TIF_IF2_dom3.
DR   InterPro; IPR036925; TIF_IF2_dom3_sf.
DR   InterPro; IPR009000; Transl_B-barrel_sf.
DR   NCBIfam; TIGR00487; IF-2; 1.
DR   NCBIfam; TIGR00231; small_GTP; 1.
DR   PANTHER; PTHR43381:SF5; TR-TYPE G DOMAIN-CONTAINING PROTEIN; 1.
DR   PANTHER; PTHR43381; TRANSLATION INITIATION FACTOR IF-2-RELATED; 1.
DR   Pfam; PF22042; EF-G_D2; 1.
DR   Pfam; PF00009; GTP_EFTU; 1.
DR   Pfam; PF11987; IF-2; 1.
DR   Pfam; PF08364; IF2_assoc; 1.
DR   Pfam; PF04760; IF2_N; 2.
DR   SUPFAM; SSF52156; Initiation factor IF2/eIF5b, domain 3; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   SUPFAM; SSF46955; Putative DNA-binding domain; 1.
DR   SUPFAM; SSF50447; Translation proteins; 2.
DR   PROSITE; PS51722; G_TR_2; 1.
DR   PROSITE; PS01176; IF2; 1.
PE   3: Inferred from homology;
KW   Cytoplasm; GTP-binding; Initiation factor; Nucleotide-binding;
KW   Protein biosynthesis; Reference proteome.
FT   CHAIN           1..930
FT                   /note=""Translation initiation factor IF-2""
FT                   /id=""PRO_1000093767""
FT   DOMAIN          431..600
FT                   /note=""tr-type G""
FT   REGION          160..179
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          208..301
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          440..447
FT                   /note=""G1""
FT                   /evidence=""ECO:0000250""
FT   REGION          465..469
FT                   /note=""G2""
FT                   /evidence=""ECO:0000250""
FT   REGION          486..489
FT                   /note=""G3""
FT                   /evidence=""ECO:0000250""
FT   REGION          540..543
FT                   /note=""G4""
FT                   /evidence=""ECO:0000250""
FT   REGION          576..578
FT                   /note=""G5""
FT                   /evidence=""ECO:0000250""
FT   COMPBIAS        208..227
FT                   /note=""Basic and acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        263..272
FT                   /note=""Basic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        288..301
FT                   /note=""Basic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   BINDING         440..447
FT                   /ligand=""GTP""
FT                   /ligand_id=""ChEBI:CHEBI:37565""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00100""
FT   BINDING         486..490
FT                   /ligand=""GTP""
FT                   /ligand_id=""ChEBI:CHEBI:37565""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00100""
FT   BINDING         540..543
FT                   /ligand=""GTP""
FT                   /ligand_id=""ChEBI:CHEBI:37565""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00100""
SQ   SEQUENCE   930 AA;  100715 MW;  E4DE42CEAB5E9694 CRC64;
     MAEVTVNELA TSIGAPVERL LKQMQEAGLQ HKTASAKVSD EEKQRLLAYL KGSHGEAAVE
     PRKITLQRKT TTTIKTGTGN AKKTVNVEVR KKRTYVKRED DVVDNTQAAQ SQEQDDELAS
     TVVEEVQQAE PSVVPVVDVA PEPEPEPVVE EVDVAAEEAE PVEAAVDTSA PTRFSFTDGI
     EEKRRAAIER RQAEEAARQA ELKAIEEAKR AAEEAKRTQP RAEKPADKSA AAGKGAKPDN
     RQPAKGKQAP VAVPVEREDA KHGHGHKKHH HGRNDDDFDD DSADRGNKRG AGKAVKKAAA
     PKKSSKIDLL DFVGDDSEDS DVLARRSHIR AHHKKNNKHA FKKPTTQIVH EIDIPETIAV
     SELAQRLTIK VGELIKRLMK MGVMASMNEQ IDQDTAVLIV EELGHKANLV SENDIEHALE
     KSLETAGELT TRAPVVTVMG HVDHGKTSLL DYIREAKVAA GEAGGITQHI GAYRVTTSRG
     EITFLDTPGH AAFTAMRARG AKATDVVILV VAADDGVMPQ TEEAIMHARA AEVPIVVAIN
     KCDKPSADPD RVTNELVAKG VIPEAYGGDT QFVQVSAHTG QGIDELLEAI SLQAEVLELT
     AVTNAAAKGV VIEARVDKGR GTVATVLVQQ GTLKQGDLIL AGQSYGRVRA MVNERGEQVK
     EAGPSTPVEI LGLDMPPSAG DDFVVLDDER KAREVAAFRA EKERKEKLAR FQAAKLENMF
     SNMEAGQKKT LTVVIKADVR GSLEAIQASL ADIGNDEVQV NVISSGIGGI TENDVNLAVT
     SGAIIVGFNV RADGATRRLA ETEGVDIRYY SIIYQLLDEV KAALSGMLDP ERVETIVGIA
     NVREVFNSPK FGQVAGCMVV EGTVYRNKPI RVLRDNVVIF TGELESLRRF KDDVNEVRNG
     FECGIGVKNY DVKVGDQIEV YEVKEVARQL
//
",58360
ATCGCT TCGCTC CGCTCC GCTCCA CTCCAG TCCAGG CCAGGG CAGGGC AGGGCA GGGCAA GGCAAA GCAAAC CAAACT AAACTG AACTGG ACTGGA CTGGAA TGGAAA GGAAAT GAAATA AAATAT AATATT ATATTG TATTGC ATTGCT TTGCTG TGCTGA GCTGAT CTGATT TGATTA GATTAT ATTATA TTATAA TATAAT ATAATT TAATTA AATTAT ATTATA TTATAA TATAAA ATAAAT TAAATT AAATTA AATTAC ATTACC TTACCA TACCAG ACCAGA CCAGAT CAGATG AGATGA GATGAT ATGATT TGATTT GATTTT ATTTTA TTTTAC TTTACA TTACAG TACAGG ACAGGC CAGGCT AGGCTG GGCTGC GCTGCG CTGCGT TGCGTT,1,67,ATCG TCGC CGCT GCTC CTCC TCCA CCAG CAGG AGGG GGGC GGCA GCAA CAAA AAAC AACT ACTG CTGG TGGA GGAA GAAA AAAT AATA ATAT TATT ATTG TTGC TGCT GCTG CTGA TGAT GATT ATTA TTAT TATA ATAA TAAT AATT ATTA TTAT TATA ATAA TAAA AAAT AATT ATTA TTAC TACC ACCA CCAG CAGA AGAT GATG ATGA TGAT GATT ATTT TTTT TTTA TTAC TACA ACAG CAGG AGGC GGCT GCTG CTGC TGCG GCGT CGTT,ATCGC TCGCT CGCTC GCTCC CTCCA TCCAG CCAGG CAGGG AGGGC GGGCA GGCAA GCAAA CAAAC AAACT AACTG ACTGG CTGGA TGGAA GGAAA GAAAT AAATA AATAT ATATT TATTG ATTGC TTGCT TGCTG GCTGA CTGAT TGATT GATTA ATTAT TTATA TATAA ATAAT TAATT AATTA ATTAT TTATA TATAA ATAAA TAAAT AAATT AATTA ATTAC TTACC TACCA ACCAG CCAGA CAGAT AGATG GATGA ATGAT TGATT GATTT ATTTT TTTTA TTTAC TTACA TACAG ACAGG CAGGC AGGCT GGCTG GCTGC CTGCG TGCGT GCGTT,ATCGCT TCGCTC CGCTCC GCTCCA CTCCAG TCCAGG CCAGGG CAGGGC AGGGCA GGGCAA GGCAAA GCAAAC CAAACT AAACTG AACTGG ACTGGA CTGGAA TGGAAA GGAAAT GAAATA AAATAT AATATT ATATTG TATTGC ATTGCT TTGCTG TGCTGA GCTGAT CTGATT TGATTA GATTAT ATTATA TTATAA TATAAT ATAATT TAATTA AATTAT ATTATA TTATAA TATAAA ATAAAT TAAATT AAATTA AATTAC ATTACC TTACCA TACCAG ACCAGA CCAGAT CAGATG AGATGA GATGAT ATGATT TGATTT GATTTT ATTTTA TTTTAC TTTACA TTACAG TACAGG ACAGGC CAGGCT AGGCTG GGCTGC GCTGCG CTGCGT TGCGTT,ATCGCTC TCGCTCC CGCTCCA GCTCCAG CTCCAGG TCCAGGG CCAGGGC CAGGGCA AGGGCAA GGGCAAA GGCAAAC GCAAACT CAAACTG AAACTGG AACTGGA ACTGGAA CTGGAAA TGGAAAT GGAAATA GAAATAT AAATATT AATATTG ATATTGC TATTGCT ATTGCTG TTGCTGA TGCTGAT GCTGATT CTGATTA TGATTAT GATTATA ATTATAA TTATAAT TATAATT ATAATTA TAATTAT AATTATA ATTATAA TTATAAA TATAAAT ATAAATT TAAATTA AAATTAC AATTACC ATTACCA TTACCAG TACCAGA ACCAGAT CCAGATG CAGATGA AGATGAT GATGATT ATGATTT TGATTTT GATTTTA ATTTTAC TTTTACA TTTACAG TTACAGG TACAGGC ACAGGCT CAGGCTG AGGCTGC GGCTGCG GCTGCGT CTGCGTT,"ID   SPIKE_SARS2             Reviewed;        1273 AA.
AC   P0DTC2;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Spike glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE            Short=S glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=E2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=Peplomer protein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S1 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2' {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Flags: Precursor;
GN   Name=S {ECO:0000255|HAMAP-Rule:MF_04099}; ORFNames=2;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   FUNCTION (SPIKE PROTEIN S1), AND CLEAVAGE BETWEEN S2 AND S2' BY HOST
RP   TMPRSS2.
RX   PubMed=32142651; DOI=10.1016/j.cell.2020.02.052;
RA   Hoffmann M., Kleine-Weber H., Schroeder S., Krueger N., Herrler T.,
RA   Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A.,
RA   Mueller M.A., Drosten C., Poehlmann S.;
RT   ""SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a
RT   clinically proven protease inhibitor."";
RL   Cell 181:1-10(2020).
RN   [3]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, FUNCTION, AND MUTAGENESIS OF
RP   681-PRO--ALA-684.
RX   PubMed=32362314; DOI=10.1016/j.molcel.2020.04.022;
RA   Hoffmann M., Kleine-Weber H., Poehlmann S.;
RT   ""A multibasic cleavage site in the Spike protein of SARS-CoV-2 is essential
RT   for infection of human lung cells."";
RL   Mol. Cell 78:779-784(2020).
RN   [4]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=32366695; DOI=10.1126/science.abb9983;
RA   Watanabe Y., Allen J.D., Wrapp D., McLellan J.S., Crispin M.;
RT   ""Site-specific glycan analysis of the SARS-CoV-2 spike."";
RL   Science 369:330-333(2020).
RN   [5]
RP   GLYCOSYLATION AT ASN-61; ASN-74; ASN-122; ASN-149; ASN-165; ASN-234;
RP   ASN-282; THR-323; SER-325; ASN-331; ASN-343; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1194, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=32363391; DOI=10.1093/glycob/cwaa042;
RA   Shajahan A., Supekar N.T., Gleinich A.S., Azadi P.;
RT   ""Deducing the N- and O- glycosylation profile of the spike protein of novel
RT   coronavirus SARS-CoV-2."";
RL   Glycobiology 30:981-988(2020).
RN   [6]
RP   VARIANT GLY-614.
RX   PubMed=32820179; DOI=10.1038/s41598-020-70827-z;
RA   Isabel S., Grana-Miraglia L., Gutierrez J.M., Bundalovic-Torma C.,
RA   Groves H.E., Isabel M.R., Eshaghi A., Patel S.N., Gubbay J.B., Poutanen T.,
RA   Guttman D.S., Poutanen S.M.;
RT   ""Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein
RT   mutation now documented worldwide."";
RL   Sci. Rep. 10:14031-14031(2020).
RN   [7]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=32697968; DOI=10.1016/j.cell.2020.06.043;
RG   Sheffield COVID-19 Genomics Group;
RA   Korber B., Fischer W.M., Gnanakaran S., Yoon H., Theiler J., Abfalterer W.,
RA   Hengartner N., Giorgi E.E., Bhattacharya T., Foley B., Hastie K.M.,
RA   Parker M.D., Partridge D.G., Evans C.M., Freeman T.M., de Silva T.I.,
RA   McDanal C., Perez L.G., Tang H., Moon-Walker A., Whelan S.P.,
RA   LaBranche C.C., Saphire E.O., Montefiori D.C.;
RT   ""Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases
RT   Infectivity of the COVID-19 Virus."";
RL   Cell 182:812-827(2020).
RN   [8]
RP   FUNCTION.
RX   PubMed=32817270; DOI=10.1126/science.abd5223;
RA   Turonova B., Sikora M., Schuermann C., Hagen W.J.H., Welsch S.,
RA   Blanc F.E.C., von Buelow S., Gecht M., Bagola K., Hoerner C.,
RA   van Zandbergen G., Landry J., de Azevedo N.T.D., Mosalaganti S.,
RA   Schwarz A., Covino R., Muehlebach M.D., Hummer G., Krijnse Locker J.,
RA   Beck M.;
RT   ""In situ structural analysis of SARS-CoV-2 spike reveals flexibility
RT   mediated by three hinges."";
RL   Science 370:203-208(2020).
RN   [9]
RP   GLYCOSYLATION.
RX   PubMed=32929138; DOI=10.1038/s41598-020-71748-7;
RA   Grant O.C., Montgomery D., Ito K., Woods R.J.;
RT   ""Analysis of the SARS-CoV-2 spike protein glycan shield reveals
RT   implications for immune recognition."";
RL   Sci. Rep. 10:14991-14991(2020).
RN   [10]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, IDENTIFICATION BY MASS SPECTROMETRY, SUBCELLULAR LOCATION, AND
RP   SUBUNIT.
RX   PubMed=32979942; DOI=10.1016/j.cell.2020.09.018;
RA   Yao H., Song Y., Chen Y., Wu N., Xu J., Sun C., Zhang J., Weng T.,
RA   Zhang Z., Wu Z., Cheng L., Shi D., Lu X., Lei J., Crispin M., Shi Y.,
RA   Li L., Li S.;
RT   ""Molecular Architecture of the SARS-CoV-2 Virus."";
RL   Cell 183:730-738(2020).
RN   [11]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=33106671; DOI=10.1038/s41586-020-2895-3;
RA   Plante J.A., Liu Y., Liu J., Xia H., Johnson B.A., Lokugamage K.G.,
RA   Zhang X., Muruato A.E., Zou J., Fontes-Garfias C.R., Mirchandani D.,
RA   Scharton D., Bilello J.P., Ku Z., An Z., Kalveram B., Freiberg A.N.,
RA   Menachery V.D., Xie X., Plante K.S., Weaver S.C., Shi P.Y.;
RT   ""Spike mutation D614G alters SARS-CoV-2 fitness."";
RL   Nature 592:116-121(2020).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Liverpool/REMRQ001/2020;
RX   PubMed=33082294; DOI=10.1126/science.abd3072;
RA   Daly J.L., Simonetti B., Klein K., Chen K.E., Williamson M.K.,
RA   Anton-Plagaro C., Shoemark D.K., Simon-Gracia L., Bauer M., Hollandi R.,
RA   Greber U.F., Horvath P., Sessions R.B., Helenius A., Hiscox J.A.,
RA   Teesalu T., Matthews D.A., Davidson A.D., Collins B.M., Cullen P.J.,
RA   Yamauchi Y.;
RT   ""Neuropilin-1 is a host factor for SARS-CoV-2 infection."";
RL   Science 370:861-865(2020).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Finland/1/2020;
RX   PubMed=33082293; DOI=10.1126/science.abd2985;
RA   Cantuti-Castelvetri L., Ojha R., Pedro L.D., Djannatian M., Franz J.,
RA   Kuivanen S., van der Meer F., Kallio K., Kaya T., Anastasina M., Smura T.,
RA   Levanov L., Szirovicza L., Tobi A., Kallio-Kokko H., Oesterlund P.,
RA   Joensuu M., Meunier F.A., Butcher S.J., Winkler M.S., Mollenhauer B.,
RA   Helenius A., Gokce O., Teesalu T., Hepojoki J., Vapalahti O.,
RA   Stadelmann C., Balistreri G., Simons M.;
RT   ""Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity."";
RL   Science 370:856-860(2020).
RN   [14]
RP   INTERACTION WITH HUMAN ITGA5 AND ITGB1.
RX   PubMed=33102950; DOI=10.1016/j.jacbts.2020.10.003;
RA   Beddingfield B.J., Iwanaga N., Chapagain P.P., Zheng W., Roy C.J., Hu T.Y.,
RA   Kolls J.K., Bix G.J.;
RT   ""The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2
RT   Infection."";
RL   JACC Basic Transl. Sci. 6:1-8(2021).
RN   [15]
RP   VARIANT GLY-614.
RX   PubMed=33184236; DOI=10.1126/science.abe8499;
RA   Hou Y.J., Chiba S., Halfmann P., Ehre C., Kuroda M., Dinnon K.H. III,
RA   Leist S.R., Schaefer A., Nakajima N., Takahashi K., Lee R.E.,
RA   Mascenik T.M., Graham R., Edwards C.E., Tse L.V., Okuda K., Markmann A.J.,
RA   Bartelt L., de Silva A., Margolis D.M., Boucher R.C., Randell S.H.,
RA   Suzuki T., Gralinski L.E., Kawaoka Y., Baric R.S.;
RT   ""SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and
RT   transmission in vivo."";
RL   Science 370:1464-1468(2020).
RN   [16]
RP   VARIANT GLY-614.
RX   PubMed=33417835; DOI=10.1016/j.celrep.2020.108630;
RA   Gobeil S.M., Janowska K., McDowell S., Mansouri K., Parks R., Manne K.,
RA   Stalls V., Kopp M.F., Henderson R., Edwards R.J., Haynes B.F., Acharya P.;
RT   ""D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease
RT   Cleavage at the S1/S2 Junction."";
RL   Cell Rep. 34:108630-108630(2021).
RN   [17]
RP   VARIANTS 69-VAL--PHE-70 DEL; LYS-144 DEL; TYR-501; ASP-570; GLY-614;
RP   HIS-681; ILE-716; ALA-982 AND HIS-1118.
RC   STRAIN=20I/501Y.V1, Alpha, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [18]
RP   VARIANT TYR-501.
RX   PubMed=32732280; DOI=10.1126/science.abc4730;
RA   Gu H., Chen Q., Yang G., He L., Fan H., Deng Y.Q., Wang Y., Teng Y.,
RA   Zhao Z., Cui Y., Li Y., Li X.F., Li J., Zhang N.N., Yang X., Chen S.,
RA   Guo Y., Zhao G., Wang X., Luo D.Y., Wang H., Yang X., Li Y., Han G., He Y.,
RA   Zhou X., Geng S., Sheng X., Jiang S., Sun S., Qin C.F., Zhou Y.;
RT   ""Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy."";
RL   Science 369:1603-1607(2020).
RN   [19]
RP   VARIANT GLY-614, AND MUTAGENESIS OF GLY-614.
RX   PubMed=33636719; DOI=10.1038/s41586-021-03361-1;
RA   Zhou B., Thi Nhu Thao T., Hoffmann D., Taddeo A., Ebert N., Labroussaa F.,
RA   Pohlmann A., King J., Steiner S., Kelly J.N., Portmann J., Halwe N.J.,
RA   Ulrich L., Trueeb B.S., Fan X., Hoffmann B., Wang L., Thomann L., Lin X.,
RA   Stalder H., Pozzi B., de Brot S., Jiang N., Cui D., Hossain J., Wilson M.,
RA   Keller M., Stark T.J., Barnes J.R., Dijkman R., Jores J., Benarafa C.,
RA   Wentworth D.E., Thiel V., Beer M.;
RT   ""SARS-CoV-2 spike D614G change enhances replication and transmission."";
RL   Nature 5920:122-127(2021).
RN   [20]
RP   MUTAGENESIS OF ASN-165; ASN-234; ASN-331; ASN-343; LEU-452; ALA-475;
RP   VAL-483; PHE-490 AND HIS-519.
RX   PubMed=32730807; DOI=10.1016/j.cell.2020.07.012;
RA   Li Q., Wu J., Nie J., Zhang L., Hao H., Liu S., Zhao C., Zhang Q., Liu H.,
RA   Nie L., Qin H., Wang M., Lu Q., Li X., Sun Q., Liu J., Zhang L., Li X.,
RA   Huang W., Wang Y.;
RT   ""The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and
RT   Antigenicity."";
RL   Cell 182:1284-1294(2020).
RN   [21]
RP   FUNCTION, CLEAVAGE BETWEEN S1 AND S2 BY HOST CTSL, AND INTERACTION WITH
RP   HUMAN ACE2.
RX   PubMed=32221306; DOI=10.1038/s41467-020-15562-9;
RA   Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Guo R., Chen T.,
RA   Hu J., Xiang Z., Mu Z., Chen X., Chen J., Hu K., Jin Q., Wang J., Qian Z.;
RT   ""Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and
RT   its immune cross-reactivity with SARS-CoV."";
RL   Nat. Commun. 11:1620-1620(2020).
RN   [22]
RP   INTERACTION WITH HUMAN ACE2.
RX   PubMed=33607086; DOI=10.1016/j.bpj.2021.02.007;
RA   Cao W., Dong C., Kim S., Hou D., Tai W., Du L., Im W., Zhang X.F.;
RT   ""Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2
RT   protein-protein interaction."";
RL   Biophys. J. 120:1011-1019(2021).
RN   [23]
RP   FUNCTION, AND CLEAVAGE BETWEEN S1 AND S2 BY HOST TMPRSS2.
RX   PubMed=33465165; DOI=10.1371/journal.ppat.1009212;
RA   Ou T., Mou H., Zhang L., Ojha A., Choe H., Farzan M.;
RT   ""Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated
RT   by TMPRSS2."";
RL   PLoS Pathog. 17:e1009212-e1009212(2021).
RN   [24]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH S PROTEIN.
RX   PubMed=33229438; DOI=10.1074/jbc.ra120.016175;
RA   Boson B., Legros V., Zhou B., Siret E., Mathieu C., Cosset F.L.,
RA   Lavillette D., Denolly S.;
RT   ""The SARS-CoV-2 Envelope and Membrane proteins modulate maturation and
RT   retention of the Spike protein, allowing assembly of virus-like
RT   particles."";
RL   J. Biol. Chem. 296:100111-100111(2020).
RN   [25]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, MUTAGENESIS OF ALA-684, AND FUNCTION (SPIKE PROTEIN S2').
RX   PubMed=32703818; DOI=10.26508/lsa.202000786;
RA   Bestle D., Heindl M.R., Limburg H., Van Lam van T., Pilgram O., Moulton H.,
RA   Stein D.A., Hardes K., Eickmann M., Dolnik O., Rohde C., Klenk H.D.,
RA   Garten W., Steinmetzer T., Boettcher-Friebertshaeuser E.;
RT   ""TMPRSS2 and furin are both essential for proteolytic activation of SARS-
RT   CoV-2 in human airway cells."";
RL   Life. Sci Alliance 3:1-14(2020).
RN   [26]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, CLEAVAGE BETWEEN S2 AND S2' BY HOST CSTL, AND FUNCTION (SPIKE
RP   PROTEIN S2').
RX   PubMed=34159616; DOI=10.15252/embj.2021107821;
RA   Koch J., Uckeley Z.M., Doldan P., Stanifer M., Boulant S., Lozach P.Y.;
RT   ""TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect
RT   host cells."";
RL   EMBO J. 40:1-20(2021).
RN   [27]
RP   VARIANTS PHE-18; ALA-80; GLY-215; ASN-417; LYS-484; TYR-501; GLY-614 AND
RP   VAL-701.
RC   STRAIN=20H/501Y.V2, B.1.351, and Beta;
RX   PubMed=33690265; DOI=10.1038/s41586-021-03402-9;
RA   Tegally H., Wilkinson E., Giovanetti M., Iranzadeh A., Fonseca V.,
RA   Giandhari J., Doolabh D., Pillay S., San E.J., Msomi N., Mlisana K.,
RA   von Gottberg A., Walaza S., Allam M., Ismail A., Mohale T., Glass A.J.,
RA   Engelbrecht S., Van Zyl G., Preiser W., Petruccione F., Sigal A.,
RA   Hardie D., Marais G., Hsiao M., Korsman S., Davies M.A., Tyers L.,
RA   Mudau I., York D., Maslo C., Goedhals D., Abrahams S., Laguda-Akingba O.,
RA   Alisoltani-Dehkordi A., Godzik A., Wibmer C.K., Sewell B.T., Lourenco J.,
RA   Alcantara L.C.J., Kosakovsky Pond S.L., Weaver S., Martin D.,
RA   Lessells R.J., Bhiman J.N., Williamson C., de Oliveira T.;
RT   ""Emergence of a SARS-CoV-2 variant of concern with mutations in spike
RT   glycoprotein."";
RL   Nature 592:438-443(2021).
RN   [28]
RP   POLYMORPHISM.
RX   PubMed=34142653; DOI=10.2807/1560-7917.es.2021.26.24.2100509;
RA   Campbell F., Archer B., Laurenson-Schafer H., Jinnai Y., Konings F.,
RA   Batra N., Pavlin B., Vandemaele K., Van Kerkhove M.D., Jombart T.,
RA   Morgan O., le Polain de Waroux O.;
RT   ""Increased transmissibility and global spread of SARS-CoV-2 variants of
RT   concern as at June 2021."";
RL   Eurosurveillance 26:0-0(2021).
RN   [29]
RP   VARIANTS ARG-452 AND PHE-453, AND MUTAGENESIS OF LEU-452; TYR-453 AND
RP   ASN-501.
RX   PubMed=34171266; DOI=10.1016/j.chom.2021.06.006;
RG   Genotype to Phenotype Japan (G2P-Japan) Consortium;
RA   Motozono C., Toyoda M., Zahradnik J., Saito A., Nasser H., Tan T.S.,
RA   Ngare I., Kimura I., Uriu K., Kosugi Y., Yue Y., Shimizu R., Ito J.,
RA   Torii S., Yonekawa A., Shimono N., Nagasaki Y., Minami R., Toya T.,
RA   Sekiya N., Fukuhara T., Matsuura Y., Schreiber G., Ikeda T., Nakagawa S.,
RA   Ueno T., Sato K.;
RT   ""SARS-CoV-2 spike L452R variant evades cellular immunity and increases
RT   infectivity."";
RL   Cell Host Microbe 0:0-0(2021).
RN   [30]
RP   VARIANT 69-VAL--PHE-70 DEL, AND MUTAGENESIS OF 69-HIS-VAL-70.
RX   PubMed=34166617; DOI=10.1016/j.celrep.2021.109292;
RG   COVID-19 Genomics UK (COG-UK) Consortium;
RA   Meng B., Kemp S.A., Papa G., Datir R., Ferreira I.A.T.M., Marelli S.,
RA   Harvey W.T., Lytras S., Mohamed A., Gallo G., Thakur N., Collier D.A.,
RA   Mlcochova P., Duncan L.M., Carabelli A.M., Kenyon J.C., Lever A.M.,
RA   De Marco A., Saliba C., Culap K., Cameroni E., Matheson N.J., Piccoli L.,
RA   Corti D., James L.C., Robertson D.L., Bailey D., Gupta R.K.;
RT   ""Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in
RT   the Alpha variant B.1.1.7."";
RL   Cell Rep. 35:109292-109292(2021).
RN   [31]
RP   VARIANTS ILE-13 AND CYS-152, POLYMORPHISM, AND MASS SPECTROMETRY (SIGNAL).
RX   PubMed=34210893; DOI=10.1126/science.abi7994;
RA   McCallum M., Bassi J., De Marco A., Chen A., Walls A.C., Di Iulio J.,
RA   Tortorici M.A., Navarro M.J., Silacci-Fregni C., Saliba C., Sprouse K.R.,
RA   Agostini M., Pinto D., Culap K., Bianchi S., Jaconi S., Cameroni E.,
RA   Bowen J.E., Tilles S.W., Pizzuto M.S., Guastalla S.B., Bona G.,
RA   Pellanda A.F., Garzoni C., Van Voorhis W.C., Rosen L.E., Snell G.,
RA   Telenti A., Virgin H.W., Piccoli L., Corti D., Veesler D.;
RT   ""SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern."";
RL   Science 373:648-654(2021).
RN   [32]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-1269 AND HIS-1271.
RX   PubMed=34504087; DOI=10.1038/s41467-021-25589-1;
RA   Cattin-Ortola J., Welch L.G., Maslen S.L., Papa G., James L.C., Munro S.;
RT   ""Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate
RT   expression at the cell surface and syncytia formation."";
RL   Nat. Commun. 12:5333-5333(2021).
RN   [33]
RP   PALMITOYLATION AT CYS-1235; CYS-1236; CYS-1240; CYS-1241; CYS-1243;
RP   CYS-1247; CYS-1248; CYS-1250; CYS-1253 AND CYS-1254.
RX   PubMed=34599882; DOI=10.1016/j.devcel.2021.09.016;
RA   Mesquita F.S., Abrami L., Sergeeva O., Turelli P., Qing E., Kunz B.,
RA   Raclot C., Paz Montoya J., Abriata L.A., Gallagher T., Dal Peraro M.,
RA   Trono D., D'Angelo G., van der Goot F.G.;
RT   ""S-acylation controls SARS-CoV-2 membrane lipid organization and enhances
RT   infectivity."";
RL   Dev. Cell 56:1-18(2021).
RN   [34] {ECO:0007744|PDB:6M17}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.90 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), DOMAIN, AND INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1).
RX   PubMed=32132184; DOI=10.1126/science.abb2762;
RA   Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q.;
RT   ""Structural basis for the recognition of the SARS-CoV-2 by full-length
RT   human ACE2."";
RL   Science 367:1444-1448(2020).
RN   [35]
RP   SUPERANTIGEN, AND DOMAIN.
RX   PubMed=32989130; DOI=10.1073/pnas.2010722117;
RA   Cheng M.H., Zhang S., Porritt R.A., Noval Rivas M., Paschold L.,
RA   Willscher E., Binder M., Arditi M., Bahar I.;
RT   ""Superantigenic character of an insert unique to SARS-CoV-2 spike supported
RT   by skewed TCR repertoire in patients with hyperinflammation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 117:25254-25262(2020).
RN   [36]
RP   INTERACTION WITH HUMAN BILIRUBIN, INTERACTION WITH HUMAN BILIVERDIN, AND
RP   MUTAGENESIS OF ASN-121 AND ARG-190.
RX   PubMed=33888467; DOI=10.1126/sciadv.abg7607;
RA   Rosa A., Pye V.E., Graham C., Muir L., Seow J., Ng K.W., Cook N.J.,
RA   Rees-Spear C., Parker E., Dos Santos M.S., Rosadas C., Susana A., Rhys H.,
RA   Nans A., Masino L., Roustan C., Christodoulou E., Ulferts R., Wrobel A.G.,
RA   Short C.E., Fertleman M., Sanders R.W., Heaney J., Spyer M., Kjaer S.,
RA   Riddell A., Malim M.H., Beale R., MacRae J.I., Taylor G.P., Nastouli E.,
RA   van Gils M.J., Rosenthal P.B., Pizzato M., McClure M.O., Tedder R.S.,
RA   Kassiotis G., McCoy L.E., Doores K.J., Cherepanov P.;
RT   ""SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity."";
RL   Sci. Adv. 7:0-0(2021).
RN   [37]
RP   BIOTECHNOLOGY, AND MUTAGENESIS OF 682-ARG--ARG-685 AND 986-LYS-VAL-987.
RX   PubMed=34322129; DOI=10.3389/fimmu.2021.701501;
RA   Martinez-Flores D., Zepeda-Cervantes J., Cruz-Resendiz A.,
RA   Aguirre-Sampieri S., Sampieri A., Vaca L.;
RT   ""SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of
RT   New Viral Variants."";
RL   Front. Immunol. 12:701501-701501(2021).
RN   [38]
RP   GLYCOSYLATION AT THR-676 AND THR-678 BY HOST GALNT1, AND MUTAGENESIS OF
RP   SER-673; THR-676; THR-678; SER-680 AND PRO-681.
RX   PubMed=34732583; DOI=10.1073/pnas.2109905118;
RA   Zhang L., Mann M., Syed Z.A., Reynolds H.M., Tian E., Samara N.L.,
RA   Zeldin D.C., Tabak L.A., Ten Hagen K.G.;
RT   ""Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [39]
RP   REVIEW, PROTEOLITIC PROCESSING, FUNCTION (SPIKE PROTEIN S2), AND FUNCTION
RP   (SPIKE PROTEIN S2').
RX   PubMed=34561887; DOI=10.1111/1348-0421.12945;
RA   Takeda M.;
RT   ""Proteolytic activation of SARS-CoV-2 spike protein."";
RL   Microbiol. Immunol. 66:15-23(2022).
RN   [40]
RP   INTERACTION WITH HOST MBL2.
RX   PubMed=35102342; DOI=10.1038/s41590-021-01114-w;
RA   Stravalaci M., Pagani I., Paraboschi E.M., Pedotti M., Doni A.,
RA   Scavello F., Mapelli S.N., Sironi M., Perucchini C., Varani L.,
RA   Matkovic M., Cavalli A., Cesana D., Gallina P., Pedemonte N., Capurro V.,
RA   Clementi N., Mancini N., Invernizzi P., Bayarri-Olmos R., Garred P.,
RA   Rappuoli R., Duga S., Bottazzi B., Uguccioni M., Asselta R., Vicenzi E.,
RA   Mantovani A., Garlanda C.;
RT   ""Recognition and inhibition of SARS-CoV-2 by humoral innate immunity
RT   pattern recognition molecules."";
RL   Nat. Immunol. 23:275-286(2022).
RN   [41]
RP   FUNCTION (SPIKE PROTEIN S1), AND INTERACTION WITH HOST INTEGRIN (SPIKE
RP   PROTEIN S1).
RX   PubMed=35150743; DOI=10.1016/j.jbc.2022.101710;
RA   Liu J., Lu F., Chen Y., Plow E., Qin J.;
RT   ""Integrin mediates cell entry of the SARS-CoV-2 virus independent of
RT   cellular receptor ACE2."";
RL   J. Biol. Chem. 1:101710-101710(2022).
RN   [42]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [43]
RP   SUBUNIT.
RX   PubMed=36735681; DOI=10.1371/journal.pbio.3001959;
RA   Shilts J., Crozier T.W.M., Teixeira-Silva A., Gabaev I., Gerber P.P.,
RA   Greenwood E.J.D., Watson S.J., Ortmann B.M., Gawden-Bone C.M., Pauzaite T.,
RA   Hoffmann M., Nathan J.A., Poehlmann S., Matheson N.J., Lehner P.J.,
RA   Wright G.J.;
RT   ""LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike
RT   protein."";
RL   PLoS Biol. 21:e3001959-e3001959(2023).
RN   [44]
RP   VARIANT ASN-405.
RX   PubMed=36851546; DOI=10.3390/v15020332;
RA   Bugatti A., Filippini F., Messali S., Giovanetti M., Ravelli C., Zani A.,
RA   Ciccozzi M., Caruso A., Caccuri F.;
RT   ""The D405N Mutation in the Spike Protein of SARS-CoV-2 Omicron BA.5
RT   Inhibits Spike/Integrins Interaction and Viral Infection of Human Lung
RT   Microvascular Endothelial Cells."";
RL   Viruses 15:0-0(2023).
RN   [45]
RP   MUTAGENESIS OF GLU-484.
RX   PubMed=37421949; DOI=10.1016/j.cell.2023.06.005;
RA   Baggen J., Jacquemyn M., Persoons L., Vanstreels E., Pye V.E., Wrobel A.G.,
RA   Calvaresi V., Martin S.R., Roustan C., Cronin N.B., Reading E.,
RA   Thibaut H.J., Vercruysse T., Maes P., De Smet F., Yee A., Nivitchanyong T.,
RA   Roell M., Franco-Hernandez N., Rhinn H., Mamchak A.A., Ah Young-Chapon M.,
RA   Brown E., Cherepanov P., Daelemans D.;
RT   ""TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry."";
RL   Cell 186:1-16(2023).
RN   [46] {ECO:0007744|PDB:6VSB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.46 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1), SUBUNIT, AND
RP   GLYCOSYLATION.
RX   PubMed=32075877; DOI=10.1126/science.abb2507;
RA   Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O.,
RA   Graham B.S., McLellan J.S.;
RT   ""Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation."";
RL   Science 367:1260-1263(2020).
RN   [47] {ECO:0007744|PDB:6VXX, ECO:0007744|PDB:6VYB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.80 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), SUBUNIT (SPIKE PROTEIN S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN
RP   S1), MUTAGENESIS OF 679-GLN--ALA-684, GLYCOSYLATION AT ASN-61; ASN-122;
RP   ASN-61; ASN-165; ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616;
RP   ASN-657; ASN-709; ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1134, AND
RP   DISULFIDE BOND.
RX   PubMed=32155444; DOI=10.1016/j.cell.2020.02.058;
RA   Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D.;
RT   ""Structure, function, and antigenicity of the SARS-CoV-2 spike
RT   glycoprotein."";
RL   Cell 180:1-12(2020).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2.
RX   PubMed=32225176; DOI=10.1038/s41586-020-2180-5;
RA   Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q.,
RA   Zhang L., Wang X.;
RT   ""Structure of the SARS-CoV-2 spike receptor-binding domain bound to the
RT   ACE2 receptor."";
RL   Nature 581:215-220(2020).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.68 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2, INTERACTION WITH HOST ACE2, AND MUTAGENESIS OF GLN-493 AND
RP   ASN-501.
RX   PubMed=32225175; DOI=10.1038/s41586-020-2179-y;
RA   Shang J., Ye G., Shi K., Wan Y., Luo C., Aihara H., Geng Q., Auerbach A.,
RA   Li F.;
RT   ""Structural basis of receptor recognition by SARS-CoV-2."";
RL   Nature 581:221-224(2020).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (3.08 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HUMAN ANTIBODY CR3022, AND DISULFIDE BOND.
RX   PubMed=32245784; DOI=10.1126/science.abb7269;
RA   Yuan M., Wu N.C., Zhu X., Lee C.D., So R.T.Y., Lv H., Mok C.K.P.,
RA   Wilson I.A.;
RT   ""A highly conserved cryptic epitope in the receptor-binding domains of
RT   SARS-CoV-2 and SARS-CoV."";
RL   Science 368:630-633(2020).
CC   -!- FUNCTION: [Spike protein S1]: Attaches the virion to the cell membrane
CC       by interacting with host receptor, initiating the infection. The major
CC       receptor is host ACE2 (PubMed:32142651, PubMed:32155444,
CC       PubMed:33607086). When S2/S2' has been cleaved, binding to the receptor
CC       triggers direct fusion at the cell membrane (PubMed:34561887). When
CC       S2/S2' has not been cleaved, binding to the receptor results in
CC       internalization of the virus by endocytosis leading to fusion of the
CC       virion membrane with the host endosomal membrane (PubMed:32075877,
CC       PubMed:32221306). Alternatively, may use NRP1/NRP2 (PubMed:33082294,
CC       PubMed:33082293) and integrin as entry receptors (PubMed:35150743). The
CC       use of NRP1/NRP2 receptors may explain the tropism of the virus in
CC       human olfactory epithelial cells, which express these molecules at high
CC       levels but ACE2 at low levels (PubMed:33082293). The stalk domain of S
CC       contains three hinges, giving the head unexpected orientational freedom
CC       (PubMed:32817270). {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32142651,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32817270, ECO:0000269|PubMed:33082293,
CC       ECO:0000269|PubMed:33082294, ECO:0000269|PubMed:35150743,
CC       ECO:0000303|PubMed:33082293, ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2]: Precursor of the fusion protein processed
CC       in the biosynthesis of the S protein and the formation of virus
CC       particle. Mediates fusion of the virion and cellular membranes by
CC       functioning as a class I viral fusion protein. Contains two viral
CC       fusion peptides that are unmasked after cleavage. The S2/S2' cleavage
CC       occurs during virus entry at the cell membrane by host TMPRSS2
CC       (PubMed:32142651) or during endocytosis by host CSTL (PubMed:32703818,
CC       PubMed:34159616). In either case, this triggers an extensive and
CC       irreversible conformational change leading to fusion of the viral
CC       envelope with the cellular cytoplasmic membrane, releasing viral
CC       genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the
CC       current model, the protein has at least three conformational states:
CC       pre-fusion native state, pre-hairpin intermediate state, and post-
CC       fusion hairpin state. During fusion of the viral and target cell
CC       membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-
CC       hairpins structure and position the fusion peptide in close proximity
CC       to the C-terminal region of the ectodomain. Formation of this structure
CC       appears to promote apposition and subsequent fusion of viral and target
CC       cell membranes. {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32703818, ECO:0000269|PubMed:34159616,
CC       ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2']: Subunit of the fusion protein that is
CC       processed upon entry into the host cell. Mediates fusion of the virion
CC       and cellular membranes by functioning as a class I viral fusion
CC       protein. Contains a viral fusion peptide that is unmasked after S2
CC       cleavage. This cleavage can occur at the cell membrane by host TMPRSS2
CC       or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616).
CC       In either case, this triggers an extensive and irreversible
CC       conformational change that leads to fusion of the viral envelope with
CC       the cellular cytoplasmic membrane, releasing viral genomic RNA into the
CC       host cell cytoplasm (PubMed:34561887). Under the current model, the
CC       protein has at least three conformational states: pre-fusion native
CC       state, pre-hairpin intermediate state, and post-fusion hairpin state.
CC       During fusion of the viral and target cell membranes, the coiled coil
CC       regions (heptad repeats) adopt a trimer-of-hairpins structure and
CC       position the fusion peptide in close proximity to the C-terminal region
CC       of the ectodomain. Formation of this structure appears to promote
CC       apposition and subsequent fusion of viral and target cell membranes.
CC       {ECO:0000255|HAMAP-Rule:MF_04099, ECO:0000269|PubMed:32703818,
CC       ECO:0000269|PubMed:34159616, ECO:0000305|PubMed:34561887}.
CC   -!- SUBUNIT: [Spike glycoprotein]: Homotrimer; each monomer consists of a
CC       S1 and a S2 subunit (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784). The resulting peplomers protrude from the virus
CC       surface as spikes (PubMed:32979942). Interacts with ORF3a protein and
CC       ORF7a protein (By similarity) (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784, PubMed:32979942). There are an average of 26 +/-15
CC       spike trimers at the surface of virion particles (PubMed:32979942).
CC       Binds to host MBL2 (PubMed:35102342). This binding occurs via glycans
CC       and inhibits viral infectivity. Inhibition is effective against alpha,
CC       beta, gamma, and delta variants (PubMed:35102342). {ECO:0000255|HAMAP-
CC       Rule:MF_04099, ECO:0000269|PubMed:32075877,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32245784,
CC       ECO:0000269|PubMed:32979942, ECO:0000269|PubMed:35102342}.
CC   -!- SUBUNIT: [Spike protein S1]: Binds to host ACE2 (PubMed:32075877,
CC       PubMed:32132184, PubMed:32155444, PubMed:32221306, PubMed:32225175,
CC       PubMed:32225176, PubMed:33607086). RBD also interacts with the N-linked
CC       glycan on 'Asn-90' of ACE2 (PubMed:33607086). Cleavage of S generates a
CC       polybasic C-terminal sequence on S1 that binds to host Neuropilin-1
CC       (NRP1) and Neuropilin-2 (NRP2) receptors (PubMed:33082293,
CC       PubMed:33082294). Interacts with host integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) and with ACE2 in complex with integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) (PubMed:33102950). May interact via cytoplasmic c-
CC       terminus with M protein (PubMed:33229438). May interact (via N-
CC       terminus) with host bilirubin and biliverdin, thereby preventing
CC       antibody binding to the SARS-CoV-2 spike NTD via an allosteric
CC       mechanism (PubMed:33888467). May interact with host LRRC15, thereby
CC       allowing attachment to host cells (PubMed:36735681).
CC       {ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32132184,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32225",11820
CTGGCG TGGCGA GGCGAG GCGAGC CGAGCA GAGCAG AGCAGT GCAGTT CAGTTG AGTTGT GTTGTC TTGTCT TGTCTG GTCTGG TCTGGA CTGGAT TGGATA GGATAT GATATC ATATCT TATCTC ATCTCC TCTCCG CTCCGA TCCGAT CCGATG CGATGG GATGGC ATGGCC TGGCCT GGCCTG GCCTGG CCTGGC CTGGCC TGGCCT GGCCTC GCCTCG CCTCGG CTCGGA TCGGAT CGGATC GGATCT GATCTT ATCTTC TCTTCG CTTCGG TTCGGC TCGGCA CGGCAT GGCATA GCATAT CATATC ATATCT TATCTT ATCTTG TCTTGC CTTGCA TTGCAG TGCAGG GCAGGC CAGGCT AGGCTT GGCTTC GCTTCC CTTCCG TTCCGG TCCGGG CCGGGG CGGGGT GGGGTC GGGTCA GGTCAG GTCAGC TCAGCG CAGCGC AGCGCA GCGCAC CGCACA GCACAG CACAGA ACAGAT CAGATT AGATTG GATTGA ATTGAG TTGAGC TGAGCT GAGCTC AGCTCA GCTCAG CTCAGC TCAGCC CAGCCA AGCCAG GCCAGT CCAGTT CAGTTG AGTTGC GTTGCC TTGCCC TGCCCT GCCCTT CCCTTA CCTTAT CTTATC TTATCT TATCTC ATCTCC TCTCCG CTCCGG TCCGGC CCGGCG CGGCGA GGCGAT GCGATT CGATTG GATTGA ATTGAG TTGAGA TGAGAT GAGATG AGATGC GATGCT ATGCTG TGCTGC GCTGCC CTGCCC TGCCCT GCCCTC CCCTCC CCTCCG CTCCGA TCCGAG CCGAGC CGAGCA GAGCAG AGCAGG GCAGGC CAGGCC AGGCCT GGCCTG GCCTGG CCTGGC CTGGCA TGGCAG,0,145,CTGG TGGC GGCG GCGA CGAG GAGC AGCA GCAG CAGT AGTT GTTG TTGT TGTC GTCT TCTG CTGG TGGA GGAT GATA ATAT TATC ATCT TCTC CTCC TCCG CCGA CGAT GATG ATGG TGGC GGCC GCCT CCTG CTGG TGGC GGCC GCCT CCTC CTCG TCGG CGGA GGAT GATC ATCT TCTT CTTC TTCG TCGG CGGC GGCA GCAT CATA ATAT TATC ATCT TCTT CTTG TTGC TGCA GCAG CAGG AGGC GGCT GCTT CTTC TTCC TCCG CCGG CGGG GGGG GGGT GGTC GTCA TCAG CAGC AGCG GCGC CGCA GCAC CACA ACAG CAGA AGAT GATT ATTG TTGA TGAG GAGC AGCT GCTC CTCA TCAG CAGC AGCC GCCA CCAG CAGT AGTT GTTG TTGC TGCC GCCC CCCT CCTT CTTA TTAT TATC ATCT TCTC CTCC TCCG CCGG CGGC GGCG GCGA CGAT GATT ATTG TTGA TGAG GAGA AGAT GATG ATGC TGCT GCTG CTGC TGCC GCCC CCCT CCTC CTCC TCCG CCGA CGAG GAGC AGCA GCAG CAGG AGGC GGCC GCCT CCTG CTGG TGGC GGCA GCAG,CTGGC TGGCG GGCGA GCGAG CGAGC GAGCA AGCAG GCAGT CAGTT AGTTG GTTGT TTGTC TGTCT GTCTG TCTGG CTGGA TGGAT GGATA GATAT ATATC TATCT ATCTC TCTCC CTCCG TCCGA CCGAT CGATG GATGG ATGGC TGGCC GGCCT GCCTG CCTGG CTGGC TGGCC GGCCT GCCTC CCTCG CTCGG TCGGA CGGAT GGATC GATCT ATCTT TCTTC CTTCG TTCGG TCGGC CGGCA GGCAT GCATA CATAT ATATC TATCT ATCTT TCTTG CTTGC TTGCA TGCAG GCAGG CAGGC AGGCT GGCTT GCTTC CTTCC TTCCG TCCGG CCGGG CGGGG GGGGT GGGTC GGTCA GTCAG TCAGC CAGCG AGCGC GCGCA CGCAC GCACA CACAG ACAGA CAGAT AGATT GATTG ATTGA TTGAG TGAGC GAGCT AGCTC GCTCA CTCAG TCAGC CAGCC AGCCA GCCAG CCAGT CAGTT AGTTG GTTGC TTGCC TGCCC GCCCT CCCTT CCTTA CTTAT TTATC TATCT ATCTC TCTCC CTCCG TCCGG CCGGC CGGCG GGCGA GCGAT CGATT GATTG ATTGA TTGAG TGAGA GAGAT AGATG GATGC ATGCT TGCTG GCTGC CTGCC TGCCC GCCCT CCCTC CCTCC CTCCG TCCGA CCGAG CGAGC GAGCA AGCAG GCAGG CAGGC AGGCC GGCCT GCCTG CCTGG CTGGC TGGCA GGCAG,CTGGCG TGGCGA GGCGAG GCGAGC CGAGCA GAGCAG AGCAGT GCAGTT CAGTTG AGTTGT GTTGTC TTGTCT TGTCTG GTCTGG TCTGGA CTGGAT TGGATA GGATAT GATATC ATATCT TATCTC ATCTCC TCTCCG CTCCGA TCCGAT CCGATG CGATGG GATGGC ATGGCC TGGCCT GGCCTG GCCTGG CCTGGC CTGGCC TGGCCT GGCCTC GCCTCG CCTCGG CTCGGA TCGGAT CGGATC GGATCT GATCTT ATCTTC TCTTCG CTTCGG TTCGGC TCGGCA CGGCAT GGCATA GCATAT CATATC ATATCT TATCTT ATCTTG TCTTGC CTTGCA TTGCAG TGCAGG GCAGGC CAGGCT AGGCTT GGCTTC GCTTCC CTTCCG TTCCGG TCCGGG CCGGGG CGGGGT GGGGTC GGGTCA GGTCAG GTCAGC TCAGCG CAGCGC AGCGCA GCGCAC CGCACA GCACAG CACAGA ACAGAT CAGATT AGATTG GATTGA ATTGAG TTGAGC TGAGCT GAGCTC AGCTCA GCTCAG CTCAGC TCAGCC CAGCCA AGCCAG GCCAGT CCAGTT CAGTTG AGTTGC GTTGCC TTGCCC TGCCCT GCCCTT CCCTTA CCTTAT CTTATC TTATCT TATCTC ATCTCC TCTCCG CTCCGG TCCGGC CCGGCG CGGCGA GGCGAT GCGATT CGATTG GATTGA ATTGAG TTGAGA TGAGAT GAGATG AGATGC GATGCT ATGCTG TGCTGC GCTGCC CTGCCC TGCCCT GCCCTC CCCTCC CCTCCG CTCCGA TCCGAG CCGAGC CGAGCA GAGCAG AGCAGG GCAGGC CAGGCC AGGCCT GGCCTG GCCTGG CCTGGC CTGGCA TGGCAG,CTGGCGA TGGCGAG GGCGAGC GCGAGCA CGAGCAG GAGCAGT AGCAGTT GCAGTTG CAGTTGT AGTTGTC GTTGTCT TTGTCTG TGTCTGG GTCTGGA TCTGGAT CTGGATA TGGATAT GGATATC GATATCT ATATCTC TATCTCC ATCTCCG TCTCCGA CTCCGAT TCCGATG CCGATGG CGATGGC GATGGCC ATGGCCT TGGCCTG GGCCTGG GCCTGGC CCTGGCC CTGGCCT TGGCCTC GGCCTCG GCCTCGG CCTCGGA CTCGGAT TCGGATC CGGATCT GGATCTT GATCTTC ATCTTCG TCTTCGG CTTCGGC TTCGGCA TCGGCAT CGGCATA GGCATAT GCATATC CATATCT ATATCTT TATCTTG ATCTTGC TCTTGCA CTTGCAG TTGCAGG TGCAGGC GCAGGCT CAGGCTT AGGCTTC GGCTTCC GCTTCCG CTTCCGG TTCCGGG TCCGGGG CCGGGGT CGGGGTC GGGGTCA GGGTCAG GGTCAGC GTCAGCG TCAGCGC CAGCGCA AGCGCAC GCGCACA CGCACAG GCACAGA CACAGAT ACAGATT CAGATTG AGATTGA GATTGAG ATTGAGC TTGAGCT TGAGCTC GAGCTCA AGCTCAG GCTCAGC CTCAGCC TCAGCCA CAGCCAG AGCCAGT GCCAGTT CCAGTTG CAGTTGC AGTTGCC GTTGCCC TTGCCCT TGCCCTT GCCCTTA CCCTTAT CCTTATC CTTATCT TTATCTC TATCTCC ATCTCCG TCTCCGG CTCCGGC TCCGGCG CCGGCGA CGGCGAT GGCGATT GCGATTG CGATTGA GATTGAG ATTGAGA TTGAGAT TGAGATG GAGATGC AGATGCT GATGCTG ATGCTGC TGCTGCC GCTGCCC CTGCCCT TGCCCTC GCCCTCC CCCTCCG CCTCCGA CTCCGAG TCCGAGC CCGAGCA CGAGCAG GAGCAGG AGCAGGC GCAGGCC CAGGCCT AGGCCTG GGCCTGG GCCTGGC CCTGGCA CTGGCAG,"ID   THIL_ECO57              Reviewed;         325 AA.
AC   Q8XE87; Q7AH12;
DT   20-DEC-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2002, sequence version 1.
DT   05-FEB-2025, entry version 127.
DE   RecName: Full=Thiamine-monophosphate kinase {ECO:0000255|HAMAP-Rule:MF_02128};
DE            Short=TMP kinase {ECO:0000255|HAMAP-Rule:MF_02128};
DE            Short=Thiamine-phosphate kinase {ECO:0000255|HAMAP-Rule:MF_02128};
DE            EC=2.7.4.16 {ECO:0000255|HAMAP-Rule:MF_02128};
GN   Name=thiL {ECO:0000255|HAMAP-Rule:MF_02128};
GN   OrderedLocusNames=Z0519, ECs0470;
OS   Escherichia coli O157:H7.
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Enterobacterales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=83334;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=O157:H7 / EDL933 / ATCC 700927 / EHEC;
RX   PubMed=11206551; DOI=10.1038/35054089;
RA   Perna N.T., Plunkett G. III, Burland V., Mau B., Glasner J.D., Rose D.J.,
RA   Mayhew G.F., Evans P.S., Gregor J., Kirkpatrick H.A., Posfai G.,
RA   Hackett J., Klink S., Boutin A., Shao Y., Miller L., Grotbeck E.J.,
RA   Davis N.W., Lim A., Dimalanta E.T., Potamousis K., Apodaca J.,
RA   Anantharaman T.S., Lin J., Yen G., Schwartz D.C., Welch R.A.,
RA   Blattner F.R.;
RT   ""Genome sequence of enterohaemorrhagic Escherichia coli O157:H7."";
RL   Nature 409:529-533(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=O157:H7 / Sakai / RIMD 0509952 / EHEC;
RX   PubMed=11258796; DOI=10.1093/dnares/8.1.11;
RA   Hayashi T., Makino K., Ohnishi M., Kurokawa K., Ishii K., Yokoyama K.,
RA   Han C.-G., Ohtsubo E., Nakayama K., Murata T., Tanaka M., Tobe T., Iida T.,
RA   Takami H., Honda T., Sasakawa C., Ogasawara N., Yasunaga T., Kuhara S.,
RA   Shiba T., Hattori M., Shinagawa H.;
RT   ""Complete genome sequence of enterohemorrhagic Escherichia coli O157:H7 and
RT   genomic comparison with a laboratory strain K-12."";
RL   DNA Res. 8:11-22(2001).
CC   -!- FUNCTION: Catalyzes the ATP-dependent phosphorylation of thiamine-
CC       monophosphate (TMP) to form thiamine-pyrophosphate (TPP), the active
CC       form of vitamin B1. {ECO:0000255|HAMAP-Rule:MF_02128}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=thiamine phosphate + ATP = thiamine diphosphate + ADP;
CC         Xref=Rhea:RHEA:15913, ChEBI:CHEBI:30616, ChEBI:CHEBI:37575,
CC         ChEBI:CHEBI:58937, ChEBI:CHEBI:456216; EC=2.7.4.16;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_02128};
CC   -!- PATHWAY: Cofactor biosynthesis; thiamine diphosphate biosynthesis;
CC       thiamine diphosphate from thiamine phosphate: step 1/1.
CC       {ECO:0000255|HAMAP-Rule:MF_02128}.
CC   -!- MISCELLANEOUS: Reaction mechanism of ThiL seems to utilize a direct,
CC       inline transfer of the gamma-phosphate of ATP to TMP rather than a
CC       phosphorylated enzyme intermediate. {ECO:0000255|HAMAP-Rule:MF_02128}.
CC   -!- SIMILARITY: Belongs to the thiamine-monophosphate kinase family.
CC       {ECO:0000255|HAMAP-Rule:MF_02128}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AE005174; AAG54766.1; -; Genomic_DNA.
DR   EMBL; BA000007; BAB33893.1; -; Genomic_DNA.
DR   PIR; B85538; B85538.
DR   PIR; F90687; F90687.
DR   RefSeq; NP_308497.1; NC_002695.1.
DR   RefSeq; WP_000742111.1; NZ_VOAI01000005.1.
DR   AlphaFoldDB; Q8XE87; -.
DR   SMR; Q8XE87; -.
DR   STRING; 155864.Z0519; -.
DR   GeneID; 914572; -.
DR   KEGG; ece:Z0519; -.
DR   KEGG; ecs:ECs_0470; -.
DR   PATRIC; fig|386585.9.peg.570; -.
DR   eggNOG; COG0611; Bacteria.
DR   HOGENOM; CLU_046964_3_0_6; -.
DR   OMA; HFRRDWS; -.
DR   UniPathway; UPA00060; UER00142.
DR   Proteomes; UP000000558; Chromosome.
DR   Proteomes; UP000002519; Chromosome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0009030; F:thiamine-phosphate kinase activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0009228; P:thiamine biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0009229; P:thiamine diphosphate biosynthetic process; IEA:UniProtKB-UniRule.
DR   CDD; cd02194; ThiL; 1.
DR   FunFam; 3.30.1330.10:FF:000008; Thiamine-monophosphate kinase; 1.
DR   FunFam; 3.90.650.10:FF:000012; Thiamine-monophosphate kinase; 1.
DR   Gene3D; 3.90.650.10; PurM-like C-terminal domain; 1.
DR   Gene3D; 3.30.1330.10; PurM-like, N-terminal domain; 1.
DR   HAMAP; MF_02128; TMP_kinase; 1.
DR   InterPro; IPR010918; PurM-like_C_dom.
DR   InterPro; IPR036676; PurM-like_C_sf.
DR   InterPro; IPR016188; PurM-like_N.
DR   InterPro; IPR036921; PurM-like_N_sf.
DR   InterPro; IPR006283; ThiL-like.
DR   NCBIfam; TIGR01379; thiL; 1.
DR   PANTHER; PTHR30270; THIAMINE-MONOPHOSPHATE KINASE; 1.
DR   PANTHER; PTHR30270:SF0; THIAMINE-MONOPHOSPHATE KINASE; 1.
DR   Pfam; PF00586; AIRS; 1.
DR   Pfam; PF02769; AIRS_C; 1.
DR   PIRSF; PIRSF005303; Thiam_monoph_kin; 1.
DR   SUPFAM; SSF56042; PurM C-terminal domain-like; 1.
DR   SUPFAM; SSF55326; PurM N-terminal domain-like; 1.
PE   3: Inferred from homology;
KW   ATP-binding; Kinase; Magnesium; Metal-binding; Nucleotide-binding;
KW   Reference proteome; Thiamine biosynthesis; Transferase.
FT   CHAIN           1..325
FT                   /note=""Thiamine-monophosphate kinase""
FT                   /id=""PRO_0000096195""
FT   BINDING         30
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""3""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_02128""
FT   BINDING         30
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""4""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_02128""
FT   BINDING         45
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""4""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_02128""
FT   BINDING         46
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_02128""
FT   BINDING         47
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_02128""
FT   BINDING         47
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_02128""
FT   BINDING         54
FT                   /ligand=""substrate""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_02128""
FT   BINDING         75
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_02128""
FT   BINDING         75
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""3""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_02128""
FT   BINDING         75
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""4""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_02128""
FT   BINDING         121..122
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_02128""
FT   BINDING         122
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_02128""
FT   BINDING         146
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_02128""
FT   BINDING         212
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""3""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_02128""
FT   BINDING         214
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_02128""
FT   BINDING         215
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""5""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_02128""
FT   BINDING         263
FT                   /ligand=""substrate""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_02128""
FT   BINDING         319
FT                   /ligand=""substrate""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_02128""
SQ   SEQUENCE   325 AA;  35041 MW;  53C5DCF55050EC07 CRC64;
     MACGEFSLIA RYFDRVRSSR LDVELGIGDD CALLNIPEKQ TLAISTDTLV AGNHFLPDID
     PADLAYKALA VNLSDLAAMG ADPAWLTLAL TLPDVDEAWL ESFSDSLFDL LNYYDMQLIG
     GDTTRGPLSM TLGIHGFVPM GRALTRSGAK PGDWIYVTGT PGDSAAGLAI LQNRLQVADA
     KDADYLIKRH LRPSPRILQG QALRDLANSA IDLSDGLISD LGHIVKASDC GARIDLALLP
     FSDALSRHVV PEQALRWALS GGEDYELCFT VPELNRGALD VALGHLGVPF TCIGQMTADI
     EGLCFIRDGE PVTLDWKGYD HFATP
//
",123
GATATT ATATTG TATTGA ATTGAT TTGATG TGATGC GATGCC ATGCCA TGCCAC GCCACA CCACAA CACAAT ACAATT CAATTG AATTGA ATTGAA TTGAAC TGAACG GAACGC AACGCT ACGCTT CGCTTA GCTTAA CTTAAC TTAACG TAACGC AACGCC ACGCCA CGCCAA GCCAAT CCAATC CAATCT AATCTT ATCTTA TCTTAG CTTAGA TTAGAA TAGAAC AGAACT GAACTC AACTCA ACTCAC CTCACC TCACCC CACCCC ACCCCT CCCCTG CCCTGA CCTGAT CTGATG TGATGA GATGAT ATGATA TGATAT GATATT ATATTG TATTGA ATTGAG TTGAGC TGAGCG GAGCGC AGCGCT GCGCTT CGCTTT GCTTTA CTTTAA TTTAAC TTAACA TAACAG AACAGT ACAGTC CAGTCG AGTCGT GTCGTA TCGTAT CGTATT GTATTA TATTAA ATTAAA TTAAAG TAAAGC AAAGCC AAGCCT AGCCTC GCCTCA CCTCAC CTCACG TCACGT CACGTA ACGTAA CGTAAA GTAAAA TAAAAC AAAACT AAACTG AACTGA ACTGAA CTGAAC TGAACG GAACGC,1,100,GATA ATAT TATT ATTG TTGA TGAT GATG ATGC TGCC GCCA CCAC CACA ACAA CAAT AATT ATTG TTGA TGAA GAAC AACG ACGC CGCT GCTT CTTA TTAA TAAC AACG ACGC CGCC GCCA CCAA CAAT AATC ATCT TCTT CTTA TTAG TAGA AGAA GAAC AACT ACTC CTCA TCAC CACC ACCC CCCC CCCT CCTG CTGA TGAT GATG ATGA TGAT GATA ATAT TATT ATTG TTGA TGAG GAGC AGCG GCGC CGCT GCTT CTTT TTTA TTAA TAAC AACA ACAG CAGT AGTC GTCG TCGT CGTA GTAT TATT ATTA TTAA TAAA AAAG AAGC AGCC GCCT CCTC CTCA TCAC CACG ACGT CGTA GTAA TAAA AAAA AAAC AACT ACTG CTGA TGAA GAAC AACG ACGC,GATAT ATATT TATTG ATTGA TTGAT TGATG GATGC ATGCC TGCCA GCCAC CCACA CACAA ACAAT CAATT AATTG ATTGA TTGAA TGAAC GAACG AACGC ACGCT CGCTT GCTTA CTTAA TTAAC TAACG AACGC ACGCC CGCCA GCCAA CCAAT CAATC AATCT ATCTT TCTTA CTTAG TTAGA TAGAA AGAAC GAACT AACTC ACTCA CTCAC TCACC CACCC ACCCC CCCCT CCCTG CCTGA CTGAT TGATG GATGA ATGAT TGATA GATAT ATATT TATTG ATTGA TTGAG TGAGC GAGCG AGCGC GCGCT CGCTT GCTTT CTTTA TTTAA TTAAC TAACA AACAG ACAGT CAGTC AGTCG GTCGT TCGTA CGTAT GTATT TATTA ATTAA TTAAA TAAAG AAAGC AAGCC AGCCT GCCTC CCTCA CTCAC TCACG CACGT ACGTA CGTAA GTAAA TAAAA AAAAC AAACT AACTG ACTGA CTGAA TGAAC GAACG AACGC,GATATT ATATTG TATTGA ATTGAT TTGATG TGATGC GATGCC ATGCCA TGCCAC GCCACA CCACAA CACAAT ACAATT CAATTG AATTGA ATTGAA TTGAAC TGAACG GAACGC AACGCT ACGCTT CGCTTA GCTTAA CTTAAC TTAACG TAACGC AACGCC ACGCCA CGCCAA GCCAAT CCAATC CAATCT AATCTT ATCTTA TCTTAG CTTAGA TTAGAA TAGAAC AGAACT GAACTC AACTCA ACTCAC CTCACC TCACCC CACCCC ACCCCT CCCCTG CCCTGA CCTGAT CTGATG TGATGA GATGAT ATGATA TGATAT GATATT ATATTG TATTGA ATTGAG TTGAGC TGAGCG GAGCGC AGCGCT GCGCTT CGCTTT GCTTTA CTTTAA TTTAAC TTAACA TAACAG AACAGT ACAGTC CAGTCG AGTCGT GTCGTA TCGTAT CGTATT GTATTA TATTAA ATTAAA TTAAAG TAAAGC AAAGCC AAGCCT AGCCTC GCCTCA CCTCAC CTCACG TCACGT CACGTA ACGTAA CGTAAA GTAAAA TAAAAC AAAACT AAACTG AACTGA ACTGAA CTGAAC TGAACG GAACGC,GATATTG ATATTGA TATTGAT ATTGATG TTGATGC TGATGCC GATGCCA ATGCCAC TGCCACA GCCACAA CCACAAT CACAATT ACAATTG CAATTGA AATTGAA ATTGAAC TTGAACG TGAACGC GAACGCT AACGCTT ACGCTTA CGCTTAA GCTTAAC CTTAACG TTAACGC TAACGCC AACGCCA ACGCCAA CGCCAAT GCCAATC CCAATCT CAATCTT AATCTTA ATCTTAG TCTTAGA CTTAGAA TTAGAAC TAGAACT AGAACTC GAACTCA AACTCAC ACTCACC CTCACCC TCACCCC CACCCCT ACCCCTG CCCCTGA CCCTGAT CCTGATG CTGATGA TGATGAT GATGATA ATGATAT TGATATT GATATTG ATATTGA TATTGAG ATTGAGC TTGAGCG TGAGCGC GAGCGCT AGCGCTT GCGCTTT CGCTTTA GCTTTAA CTTTAAC TTTAACA TTAACAG TAACAGT AACAGTC ACAGTCG CAGTCGT AGTCGTA GTCGTAT TCGTATT CGTATTA GTATTAA TATTAAA ATTAAAG TTAAAGC TAAAGCC AAAGCCT AAGCCTC AGCCTCA GCCTCAC CCTCACG CTCACGT TCACGTA CACGTAA ACGTAAA CGTAAAA GTAAAAC TAAAACT AAAACTG AAACTGA AACTGAA ACTGAAC CTGAACG TGAACGC,"ID   MRDA_ACIB2              Reviewed;         672 AA.
AC   D0C8Z9;
DT   27-NOV-2024, integrated into UniProtKB/Swiss-Prot.
DT   24-NOV-2009, sequence version 1.
DT   05-FEB-2025, entry version 71.
DE   RecName: Full=Peptidoglycan D,D-transpeptidase MrdA {ECO:0000255|HAMAP-Rule:MF_02081, ECO:0000305};
DE            EC=3.4.16.4 {ECO:0000255|HAMAP-Rule:MF_02081};
DE   AltName: Full=Class B penicillin-binding protein 2 {ECO:0000303|PubMed:36787358};
DE            Short=bPBP2 {ECO:0000303|PubMed:36787358};
DE   AltName: Full=Penicillin-binding protein 2 {ECO:0000255|HAMAP-Rule:MF_02081, ECO:0000303|PubMed:36787358};
DE            Short=PBP-2 {ECO:0000255|HAMAP-Rule:MF_02081};
DE            Short=PBP2 {ECO:0000303|PubMed:36787358};
GN   Name=mrdA {ECO:0000255|HAMAP-Rule:MF_02081,
GN   ECO:0000312|EMBL:EEX04163.1};
GN   ORFNames=HMPREF0010_01557 {ECO:0000312|EMBL:EEX04163.1};
OS   Acinetobacter baumannii (strain ATCC 19606 / DSM 30007 / JCM 6841 / CCUG
OS   19606 / CIP 70.34 / NBRC 109757 / NCIMB 12457 / NCTC 12156 / 81).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Moraxellales; Moraxellaceae;
OC   Acinetobacter; Acinetobacter calcoaceticus/baumannii complex.
OX   NCBI_TaxID=575584 {ECO:0000312|EMBL:EEX04163.1, ECO:0000312|Proteomes:UP000005740};
RN   [1] {ECO:0000312|Proteomes:UP000005740}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 19606 / DSM 30007 / JCM 6841 / CCUG 19606 / CIP 70.34 /
RC   NBRC 109757 / NCIMB 12457 / NCTC 12156 / 81
RC   {ECO:0000312|Proteomes:UP000005740};
RX   PubMed=23144699; DOI=10.1371/journal.pone.0046984;
RA   Peleg A.Y., de Breij A., Adams M.D., Cerqueira G.M., Mocali S.,
RA   Galardini M., Nibbering P.H., Earl A.M., Ward D.V., Paterson D.L.,
RA   Seifert H., Dijkshoorn L.;
RT   ""The success of Acinetobacter species; genetic, metabolic and virulence
RT   attributes."";
RL   PLoS ONE 7:E46984-E46984(2012).
RN   [2] {ECO:0007744|PDB:7ZG8}
RP   X-RAY CRYSTALLOGRAPHY (2.65 ANGSTROMS) OF 53-672 IN COMPLEX WITH ZN(2+),
RP   FUNCTION, COFACTOR, ACTIVITY REGULATION, SUBUNIT, DISRUPTION PHENOTYPE, AND
RP   MUTAGENESIS OF ASP-350; ASP-365; HIS-371 AND CYS-384.
RC   STRAIN=ATCC 17978 / DSM 105126 / CIP 53.77 / LMG 1025 / NCDC KC755 /
RC   5377, and ATCC 19606 / DSM 30007 / JCM 6841 / CCUG 19606 / CIP 70.34 /
RC   NBRC 109757 / NCIMB 12457 / NCTC 12156 / 81;
RX   PubMed=36787358; DOI=10.1073/pnas.2215237120;
RA   Micelli C., Dai Y., Raustad N., Isberg R.R., Dowson C.G., Lloyd A.J.,
RA   Geisinger E., Crow A., Roper D.I.;
RT   ""A conserved zinc-binding site in Acinetobacter baumannii PBP2 required for
RT   elongasome-directed bacterial cell shape."";
RL   Proc. Natl. Acad. Sci. U.S.A. 120:e2215237120-e2215237120(2023).
CC   -!- FUNCTION: Catalyzes cross-linking of the peptidoglycan cell wall (By
CC       similarity). Involved in the determination of the rod shape of the cell
CC       (PubMed:36787358). {ECO:0000255|HAMAP-Rule:MF_02081,
CC       ECO:0000269|PubMed:36787358}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Preferential cleavage: (Ac)2-L-Lys-D-Ala-|-D-Ala. Also
CC         transpeptidation of peptidyl-alanyl moieties that are N-acyl
CC         substituents of D-alanine.; EC=3.4.16.4; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_02081};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:36787358};
CC       Note=Binds one Zn(2+) ion per subunit. {ECO:0000269|PubMed:36787358};
CC   -!- ACTIVITY REGULATION: Inhibited by the beta-lactams sulbactam and
CC       piperacillin-tazobactam. {ECO:0000269|PubMed:36787358}.
CC   -!- PATHWAY: Cell wall biogenesis; peptidoglycan biosynthesis.
CC       {ECO:0000255|HAMAP-Rule:MF_02081}.
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:36787358}.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane {ECO:0000255|HAMAP-
CC       Rule:MF_02081}; Single-pass membrane protein {ECO:0000255|HAMAP-
CC       Rule:MF_02081}.
CC   -!- DISRUPTION PHENOTYPE: Viable under standard laboratory conditions.
CC       Spherical cell shape with increased maximal cell width.
CC       {ECO:0000269|PubMed:36787358}.
CC   -!- SIMILARITY: Belongs to the transpeptidase family. MrdA subfamily.
CC       {ECO:0000255|HAMAP-Rule:MF_02081}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; GG704573; EEX04163.1; -; Genomic_DNA.
DR   RefSeq; WP_000809155.1; NZ_MJHA01000009.1.
DR   PDB; 7ZG8; X-ray; 2.65 A; AAA/BBB=53-672.
DR   PDBsum; 7ZG8; -.
DR   AlphaFoldDB; D0C8Z9; -.
DR   SMR; D0C8Z9; -.
DR   GeneID; 92892983; -.
DR   PATRIC; fig|575584.18.peg.3049; -.
DR   UniPathway; UPA00219; -.
DR   Proteomes; UP000005740; Unassembled WGS sequence.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008658; F:penicillin binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0071972; F:peptidoglycan L,D-transpeptidase activity; IEA:TreeGrafter.
DR   GO; GO:0009002; F:serine-type D-Ala-D-Ala carboxypeptidase activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0071555; P:cell wall organization; IEA:UniProtKB-KW.
DR   GO; GO:0009252; P:peptidoglycan biosynthetic process; IEA:UniProtKB-UniRule.
DR   GO; GO:0006508; P:proteolysis; IEA:UniProtKB-KW.
DR   GO; GO:0008360; P:regulation of cell shape; IEA:UniProtKB-KW.
DR   FunFam; 3.40.710.10:FF:000024; Penicillin-binding protein 2; 1.
DR   Gene3D; 3.40.710.10; DD-peptidase/beta-lactamase superfamily; 1.
DR   Gene3D; 3.90.1310.10; Penicillin-binding protein 2a (Domain 2); 1.
DR   Gene3D; 3.30.1390.30; Penicillin-binding protein 2a, domain 3; 1.
DR   HAMAP; MF_02081; MrdA_transpept; 1.
DR   InterPro; IPR050515; Bact_Transpept/Beta-Lactamase.
DR   InterPro; IPR012338; Beta-lactam/transpept-like.
DR   InterPro; IPR005311; PBP_dimer.
DR   InterPro; IPR036138; PBP_dimer_sf.
DR   InterPro; IPR001460; PCN-bd_Tpept.
DR   InterPro; IPR017790; Penicillin-binding_protein_2.
DR   NCBIfam; TIGR03423; pbp2_mrdA; 1.
DR   PANTHER; PTHR30627; PEPTIDOGLYCAN D,D-TRANSPEPTIDASE; 1.
DR   PANTHER; PTHR30627:SF2; PEPTIDOGLYCAN D,D-TRANSPEPTIDASE MRDA; 1.
DR   Pfam; PF03717; PBP_dimer; 1.
DR   Pfam; PF00905; Transpeptidase; 1.
DR   SUPFAM; SSF56601; beta-lactamase/transpeptidase-like; 1.
DR   SUPFAM; SSF56519; Penicillin binding protein dimerisation domain; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Carboxypeptidase; Cell inner membrane; Cell membrane;
KW   Cell shape; Cell wall biogenesis/degradation; Hydrolase; Membrane;
KW   Metal-binding; Peptidoglycan synthesis; Protease; Reference proteome;
KW   Transmembrane; Transmembrane helix; Zinc.
FT   CHAIN           1..672
FT                   /note=""Peptidoglycan D,D-transpeptidase MrdA""
FT                   /id=""PRO_0000461383""
FT   TRANSMEM        21..41
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_02081""
FT   REGION          616..672
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   ACT_SITE        326
FT                   /note=""Acyl-ester intermediate""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_02081""
FT   BINDING         350
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /evidence=""ECO:0000269|PubMed:36787358,
FT                   ECO:0007744|PDB:7ZG8""
FT   BINDING         365
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /evidence=""ECO:0000269|PubMed:36787358,
FT                   ECO:0007744|PDB:7ZG8""
FT   BINDING         371
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /evidence=""ECO:0000269|PubMed:36787358,
FT                   ECO:0007744|PDB:7ZG8""
FT   BINDING         384
FT                   /ligand=""Zn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29105""
FT                   /evidence=""ECO:0000269|PubMed:36787358,
FT                   ECO:0007744|PDB:7ZG8""
FT   MUTAGEN         350
FT                   /note=""D->A: Decreased zinc-binding. Decreased structural
FT                   stability. Loss of short-rod shape coincident with
FT                   increased cell width. No effect on binding to fluorescent
FT                   beta-lactam bocillin. Lower minimum inhibitory
FT                   concentration (MIC) to the beta-lactams sulbactam and
FT                   piperacillin-tazobactam compared to wild-type.""
FT                   /evidence=""ECO:0000269|PubMed:36787358""
FT   MUTAGEN         365
FT                   /note=""D->A: Decreased zinc-binding. Decreased structural
FT                   stability. Loss of short-rod shape coincident with
FT                   increased cell width. No effect on binding to fluorescent
FT                   beta-lactam bocillin. Lower minimum inhibitory
FT                   concentration (MIC) to the beta-lactams sulbactam and
FT                   piperacillin-tazobactam compared to wild-type.""
FT                   /evidence=""ECO:0000269|PubMed:36787358""
FT   MUTAGEN         371
FT                   /note=""H->A: Decreased zinc-binding. Decreased structural
FT                   stability. Loss of short-rod shape coincident with
FT                   increased cell width. No effect on binding to fluorescent
FT                   beta-lactam bocillin. Lower minimum inhibitory
FT                   concentration (MIC) to the beta-lactams sulbactam and
FT                   piperacillin-tazobactam compared to wild-type.""
FT                   /evidence=""ECO:0000269|PubMed:36787358""
FT   MUTAGEN         384
FT                   /note=""C->A: Nearly complete loss of zinc-binding.
FT                   Decreased structural stability. Loss of short-rod shape
FT                   coincident with increased cell width. No effect on binding
FT                   to fluorescent beta-lactam bocillin. Lower minimum
FT                   inhibitory concentration (MIC) to the beta-lactams
FT                   sulbactam and piperacillin-tazobactam compared to
FT                   wild-type.""
FT                   /evidence=""ECO:0000269|PubMed:36787358""
SQ   SEQUENCE   672 AA;  74452 MW;  120BCF347A44C27B CRC64;
     MKQHFPLKDI QQEKRIYRGR IFFAVGLVII CLLVLASRYA YLQIFHYDEF STASDKNRIR
     LQPLPPARGY IYDRNGVLLA DNYPVFTATL SKADVENVDT VIEQLQPILE LTQEDVDRFK
     SRIKTARKTE RVAIKLNLTE TNIAKFSEVK YKFPGVRIET QMTRYYPHGD LFAHVIGYVG
     RINDKELKSI DKDLYAGTNL IGKIGVEKSY EDLLHGTPGY ESVEADAHSN ILRHLGRKDP
     TRGNDLYLSL DYGLQVVASQ QLAGRRGAIV AIDPRTGEIL ALVSSPSFNP NLFVTGINHK
     DYSSLRDNID QPLYNRAVQG VYPPGSTIKP MEAMGGLHYG IVDWATAISD PGYFHLPGDS
     HKFRDWKKTG HGIVNMHKAI IMSCDTYFYI LANQMGIDQM NQWMRQFGFG QKTGVDLPSE
     SEGLYPNPEW KMRTRKSKWM KGETISVSIG QGAFTATPLQ LAMATAITAN HGSHVVPHVL
     RATHGAKPFT VRNAPDGKIN FNGTDEDWVK MREAMIDVIQ SGTGRGIRTP LYQIAGKTGT
     AQVKSIAQGK RYNEAALSER QLDHGLFVGF APADKPEIAI AVIWENGRHG GSAAQLAKPV
     FDYWLLTRKK NPIRPANHQV NGGLMTAGIK PGELPSGNES ASSTPATSAP TSAAASTPQA
     TPTRPATNEV DE
//
",1413
ATGAAG TGAAGC GAAGCT AAGCTC AGCTCT GCTCTA CTCTAC TCTACA CTACAG TACAGC ACAGCT CAGCTT AGCTTT GCTTTT CTTTTT TTTTTC TTTTCC TTTCCG TTCCGC TCCGCA CCGCAG CGCAGC GCAGCG CAGCGG AGCGGC GCGGCA CGGCAC GGCACC GCACCT CACCTC ACCTCG CCTCGC CTCGCA TCGCAC CGCACC GCACCG CACCGC ACCGCC CCGCCT CGCCTG GCCTGC CCTGCG CTGCGC TGCGCA GCGCAT CGCATA GCATAG CATAGC ATAGCG TAGCGC AGCGCT GCGCTC CGCTCC GCTCCA CTCCAC TCCACC CCACCT CACCTC ACCTCA CCTCAA CTCAAG TCAAGG CAAGGG AAGGGC AGGGCC GGGCCT GGCCTC GCCTCA CCTCAC CTCACG TCACGC CACGCC ACGCCC CGCCCG GCCCGA CCCGAC CCGACT CGACTC GACTCC ACTCCC CTCCCT TCCCTG CCCTGC CCTGCC CTGCCG TGCCGG GCCGGT CCGGTG CGGTGG GGTGGA GTGGAT TGGATC GGATCT GATCTG ATCTGC TCTGCG CTGCGC TGCGCG GCGCGT CGCGTG GCGTGG CGTGGA GTGGAC TGGACG GGACGA GACGAG ACGAGC CGAGCA GAGCAG AGCAGG GCAGGC CAGGCA AGGCAC GGCACA GCACAG,0,115,ATGA TGAA GAAG AAGC AGCT GCTC CTCT TCTA CTAC TACA ACAG CAGC AGCT GCTT CTTT TTTT TTTT TTTC TTCC TCCG CCGC CGCA GCAG CAGC AGCG GCGG CGGC GGCA GCAC CACC ACCT CCTC CTCG TCGC CGCA GCAC CACC ACCG CCGC CGCC GCCT CCTG CTGC TGCG GCGC CGCA GCAT CATA ATAG TAGC AGCG GCGC CGCT GCTC CTCC TCCA CCAC CACC ACCT CCTC CTCA TCAA CAAG AAGG AGGG GGGC GGCC GCCT CCTC CTCA TCAC CACG ACGC CGCC GCCC CCCG CCGA CGAC GACT ACTC CTCC TCCC CCCT CCTG CTGC TGCC GCCG CCGG CGGT GGTG GTGG TGGA GGAT GATC ATCT TCTG CTGC TGCG GCGC CGCG GCGT CGTG GTGG TGGA GGAC GACG ACGA CGAG GAGC AGCA GCAG CAGG AGGC GGCA GCAC CACA ACAG,ATGAA TGAAG GAAGC AAGCT AGCTC GCTCT CTCTA TCTAC CTACA TACAG ACAGC CAGCT AGCTT GCTTT CTTTT TTTTT TTTTC TTTCC TTCCG TCCGC CCGCA CGCAG GCAGC CAGCG AGCGG GCGGC CGGCA GGCAC GCACC CACCT ACCTC CCTCG CTCGC TCGCA CGCAC GCACC CACCG ACCGC CCGCC CGCCT GCCTG CCTGC CTGCG TGCGC GCGCA CGCAT GCATA CATAG ATAGC TAGCG AGCGC GCGCT CGCTC GCTCC CTCCA TCCAC CCACC CACCT ACCTC CCTCA CTCAA TCAAG CAAGG AAGGG AGGGC GGGCC GGCCT GCCTC CCTCA CTCAC TCACG CACGC ACGCC CGCCC GCCCG CCCGA CCGAC CGACT GACTC ACTCC CTCCC TCCCT CCCTG CCTGC CTGCC TGCCG GCCGG CCGGT CGGTG GGTGG GTGGA TGGAT GGATC GATCT ATCTG TCTGC CTGCG TGCGC GCGCG CGCGT GCGTG CGTGG GTGGA TGGAC GGACG GACGA ACGAG CGAGC GAGCA AGCAG GCAGG CAGGC AGGCA GGCAC GCACA CACAG,ATGAAG TGAAGC GAAGCT AAGCTC AGCTCT GCTCTA CTCTAC TCTACA CTACAG TACAGC ACAGCT CAGCTT AGCTTT GCTTTT CTTTTT TTTTTC TTTTCC TTTCCG TTCCGC TCCGCA CCGCAG CGCAGC GCAGCG CAGCGG AGCGGC GCGGCA CGGCAC GGCACC GCACCT CACCTC ACCTCG CCTCGC CTCGCA TCGCAC CGCACC GCACCG CACCGC ACCGCC CCGCCT CGCCTG GCCTGC CCTGCG CTGCGC TGCGCA GCGCAT CGCATA GCATAG CATAGC ATAGCG TAGCGC AGCGCT GCGCTC CGCTCC GCTCCA CTCCAC TCCACC CCACCT CACCTC ACCTCA CCTCAA CTCAAG TCAAGG CAAGGG AAGGGC AGGGCC GGGCCT GGCCTC GCCTCA CCTCAC CTCACG TCACGC CACGCC ACGCCC CGCCCG GCCCGA CCCGAC CCGACT CGACTC GACTCC ACTCCC CTCCCT TCCCTG CCCTGC CCTGCC CTGCCG TGCCGG GCCGGT CCGGTG CGGTGG GGTGGA GTGGAT TGGATC GGATCT GATCTG ATCTGC TCTGCG CTGCGC TGCGCG GCGCGT CGCGTG GCGTGG CGTGGA GTGGAC TGGACG GGACGA GACGAG ACGAGC CGAGCA GAGCAG AGCAGG GCAGGC CAGGCA AGGCAC GGCACA GCACAG,ATGAAGC TGAAGCT GAAGCTC AAGCTCT AGCTCTA GCTCTAC CTCTACA TCTACAG CTACAGC TACAGCT ACAGCTT CAGCTTT AGCTTTT GCTTTTT CTTTTTC TTTTTCC TTTTCCG TTTCCGC TTCCGCA TCCGCAG CCGCAGC CGCAGCG GCAGCGG CAGCGGC AGCGGCA GCGGCAC CGGCACC GGCACCT GCACCTC CACCTCG ACCTCGC CCTCGCA CTCGCAC TCGCACC CGCACCG GCACCGC CACCGCC ACCGCCT CCGCCTG CGCCTGC GCCTGCG CCTGCGC CTGCGCA TGCGCAT GCGCATA CGCATAG GCATAGC CATAGCG ATAGCGC TAGCGCT AGCGCTC GCGCTCC CGCTCCA GCTCCAC CTCCACC TCCACCT CCACCTC CACCTCA ACCTCAA CCTCAAG CTCAAGG TCAAGGG CAAGGGC AAGGGCC AGGGCCT GGGCCTC GGCCTCA GCCTCAC CCTCACG CTCACGC TCACGCC CACGCCC ACGCCCG CGCCCGA GCCCGAC CCCGACT CCGACTC CGACTCC GACTCCC ACTCCCT CTCCCTG TCCCTGC CCCTGCC CCTGCCG CTGCCGG TGCCGGT GCCGGTG CCGGTGG CGGTGGA GGTGGAT GTGGATC TGGATCT GGATCTG GATCTGC ATCTGCG TCTGCGC CTGCGCG TGCGCGT GCGCGTG CGCGTGG GCGTGGA CGTGGAC GTGGACG TGGACGA GGACGAG GACGAGC ACGAGCA CGAGCAG GAGCAGG AGCAGGC GCAGGCA CAGGCAC AGGCACA GGCACAG,"ID   NAGK_RALSP              Reviewed;         192 AA.
AC   O86042;
DT   06-MAR-2013, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1998, sequence version 1.
DT   05-FEB-2025, entry version 71.
DE   RecName: Full=Fumarylpyruvate hydrolase {ECO:0000303|PubMed:11133965, ECO:0000312|EMBL:AAD12620.1};
DE            EC=3.7.1.20;
DE   AltName: Full=Naphthalene degradation protein K;
GN   Name=nagK {ECO:0000312|EMBL:AAD12620.1};
OS   Ralstonia sp.
OG   Plasmid pWWU2 {ECO:0000312|EMBL:AAD12620.1}.
OC   Bacteria; Pseudomonadota; Betaproteobacteria; Burkholderiales;
OC   Burkholderiaceae; Ralstonia.
OX   NCBI_TaxID=54061;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAD12620.1}
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], FUNCTION, CATALYTIC ACTIVITY, AND
RP   PATHWAY.
RC   STRAIN=U2 {ECO:0000312|EMBL:AAD12620.1};
RX   PubMed=11133965; DOI=10.1128/jb.183.2.700-708.2001;
RA   Zhou N.Y., Fuenmayor S.L., Williams P.A.;
RT   ""nag genes of Ralstonia (formerly Pseudomonas) sp. strain U2 encoding
RT   enzymes for gentisate catabolism."";
RL   J. Bacteriol. 183:700-708(2001).
CC   -!- FUNCTION: Involved in the catabolism of gentisate (2,5-
CC       dihydroxybenzoate) a key intermediates in the aerobic pathways for the
CC       metabolism of a large number of aromatic compoun such as naphthalene.
CC       Catalyzes the hydrolytic cleavage of fumarylpyruvate to form fumarate
CC       and pyruvate. {ECO:0000269|PubMed:11133965}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3-fumarylpyruvate + H2O = fumarate + pyruvate + H(+);
CC         Xref=Rhea:RHEA:26168, ChEBI:CHEBI:15361, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:16854, ChEBI:CHEBI:29806; EC=3.7.1.20;
CC         Evidence={ECO:0000269|PubMed:11133965};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- PATHWAY: Aromatic compound metabolism; naphthalene degradation.
CC       {ECO:0000269|PubMed:11133965}.
CC   -!- SIMILARITY: Belongs to the FAH family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF036940; AAD12620.1; -; Genomic_DNA.
DR   AlphaFoldDB; O86042; -.
DR   SMR; O86042; -.
DR   KEGG; ag:AAD12620; -.
DR   BioCyc; MetaCyc:MONOMER-14771; -.
DR   BRENDA; 3.7.1.20; 5275.
DR   UniPathway; UPA00082; -.
DR   GO; GO:0018773; F:acetylpyruvate hydrolase activity; IEA:TreeGrafter.
DR   GO; GO:0034545; F:fumarylpyruvate hydrolase activity; IDA:UniProtKB.
DR   GO; GO:0016823; F:hydrolase activity, acting on acid carbon-carbon bonds, in ketonic substances; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:1901170; P:naphthalene catabolic process; IDA:UniProtKB.
DR   Gene3D; 3.90.850.10; Fumarylacetoacetase-like, C-terminal domain; 1.
DR   InterPro; IPR011234; Fumarylacetoacetase-like_C.
DR   InterPro; IPR036663; Fumarylacetoacetase_C_sf.
DR   PANTHER; PTHR11820; ACYLPYRUVASE; 1.
DR   PANTHER; PTHR11820:SF90; FLUTATHIONE S-TRANSFERASE; 1.
DR   Pfam; PF01557; FAA_hydrolase; 1.
DR   SUPFAM; SSF56529; FAH; 1.
PE   1: Evidence at protein level;
KW   Aromatic hydrocarbons catabolism; Hydrolase; Metal-binding; Plasmid;
KW   Pyruvate.
FT   CHAIN           1..192
FT                   /note=""Fumarylpyruvate hydrolase""
FT                   /id=""PRO_0000421468""
FT   BINDING         41
FT                   /ligand=""a divalent metal cation""
FT                   /ligand_id=""ChEBI:CHEBI:60240""
FT                   /evidence=""ECO:0000250""
FT   BINDING         43
FT                   /ligand=""a divalent metal cation""
FT                   /ligand_id=""ChEBI:CHEBI:60240""
FT                   /evidence=""ECO:0000250""
FT   BINDING         72
FT                   /ligand=""a divalent metal cation""
FT                   /ligand_id=""ChEBI:CHEBI:60240""
FT                   /evidence=""ECO:0000250""
SQ   SEQUENCE   192 AA;  20886 MW;  661BD47519B61D45 CRC64;
     MGRPVDKSVE QAFYFTKSPQ TLVESGATVA YPPRTSNYHY EMELVLAIGK PGFRVSEDQA
     HELIYGYAAG LDMTRRDLQL VARDKGRPWD TGKDIEEGSV CSEIVPMQGV VVEQGAIALE
     VNGQTKQSSN VDKLIWNVRE IIADLSTYYH LQPGDLIYTG TPEGVGAVVA GDKIIGRVEG
     IAEISLTVGP AE
//
",951
CTCGCC TCGCCG CGCCGC GCCGCC CCGCCG CGCCGG GCCGGC CCGGCG CGGCGA GGCGAA GCGAAA CGAAAA GAAAAT AAAATC AAATCA AATCAC ATCACT TCACTA CACTAC ACTACA CTACAC TACACG ACACGC CACGCG ACGCGT CGCGTT GCGTTT CGTTTT GTTTTG TTTTGA TTTGAA TTGAAT TGAATT GAATTC AATTCA ATTCAA TTCAAC TCAACC CAACCG AACCGC ACCGCG CCGCGC CGCGCA GCGCAA CGCAAT GCAATC CAATCG AATCGA ATCGAG TCGAGG CGAGGA GAGGAC AGGACG GGACGG GACGGC ACGGCG CGGCGC GGCGCG GCGCGA CGCGAT GCGATC CGATCA GATCAC ATCACC TCACCA CACCAT ACCATT CCATTC CATTCT ATTCTG TTCTGC TCTGCA CTGCAG TGCAGC GCAGCC CAGCCC AGCCCG GCCCGA CCCGAC CCGACC CGACCT GACCTC ACCTCT CCTCTC CTCTCC TCTCCA CTCCAA TCCAAA CCAAAA CAAAAC AAAACC AAACCG AACCGG ACCGGC CCGGCG CGGCGG GGCGGC GCGGCA CGGCAT GGCATC GCATCA CATCAC ATCACC TCACCG CACCGA ACCGAA CCGAAG CGAAGC GAAGCG AAGCGC AGCGCT GCGCTG CGCTGC GCTGCG CTGCGC TGCGCG GCGCGT CGCGTC GCGTCG CGTCGC GTCGCC TCGCCG CGCCGC GCCGCC CCGCCA CGCCAT GCCATG CCATGG CATGGC ATGGCC TGGCCT GGCCTC GCCTCG CCTCGG CTCGGC TCGGCT CGGCTT GGCTTA GCTTAC CTTACA TTACAA TACAAA ACAAAC CAAACT AAACTG,0,145,CTCG TCGC CGCC GCCG CCGC CGCC GCCG CCGG CGGC GGCG GCGA CGAA GAAA AAAA AAAT AATC ATCA TCAC CACT ACTA CTAC TACA ACAC CACG ACGC CGCG GCGT CGTT GTTT TTTT TTTG TTGA TGAA GAAT AATT ATTC TTCA TCAA CAAC AACC ACCG CCGC CGCG GCGC CGCA GCAA CAAT AATC ATCG TCGA CGAG GAGG AGGA GGAC GACG ACGG CGGC GGCG GCGC CGCG GCGA CGAT GATC ATCA TCAC CACC ACCA CCAT CATT ATTC TTCT TCTG CTGC TGCA GCAG CAGC AGCC GCCC CCCG CCGA CGAC GACC ACCT CCTC CTCT TCTC CTCC TCCA CCAA CAAA AAAA AAAC AACC ACCG CCGG CGGC GGCG GCGG CGGC GGCA GCAT CATC ATCA TCAC CACC ACCG CCGA CGAA GAAG AAGC AGCG GCGC CGCT GCTG CTGC TGCG GCGC CGCG GCGT CGTC GTCG TCGC CGCC GCCG CCGC CGCC GCCA CCAT CATG ATGG TGGC GGCC GCCT CCTC CTCG TCGG CGGC GGCT GCTT CTTA TTAC TACA ACAA CAAA AAAC AACT ACTG,CTCGC TCGCC CGCCG GCCGC CCGCC CGCCG GCCGG CCGGC CGGCG GGCGA GCGAA CGAAA GAAAA AAAAT AAATC AATCA ATCAC TCACT CACTA ACTAC CTACA TACAC ACACG CACGC ACGCG CGCGT GCGTT CGTTT GTTTT TTTTG TTTGA TTGAA TGAAT GAATT AATTC ATTCA TTCAA TCAAC CAACC AACCG ACCGC CCGCG CGCGC GCGCA CGCAA GCAAT CAATC AATCG ATCGA TCGAG CGAGG GAGGA AGGAC GGACG GACGG ACGGC CGGCG GGCGC GCGCG CGCGA GCGAT CGATC GATCA ATCAC TCACC CACCA ACCAT CCATT CATTC ATTCT TTCTG TCTGC CTGCA TGCAG GCAGC CAGCC AGCCC GCCCG CCCGA CCGAC CGACC GACCT ACCTC CCTCT CTCTC TCTCC CTCCA TCCAA CCAAA CAAAA AAAAC AAACC AACCG ACCGG CCGGC CGGCG GGCGG GCGGC CGGCA GGCAT GCATC CATCA ATCAC TCACC CACCG ACCGA CCGAA CGAAG GAAGC AAGCG AGCGC GCGCT CGCTG GCTGC CTGCG TGCGC GCGCG CGCGT GCGTC CGTCG GTCGC TCGCC CGCCG GCCGC CCGCC CGCCA GCCAT CCATG CATGG ATGGC TGGCC GGCCT GCCTC CCTCG CTCGG TCGGC CGGCT GGCTT GCTTA CTTAC TTACA TACAA ACAAA CAAAC AAACT AACTG,CTCGCC TCGCCG CGCCGC GCCGCC CCGCCG CGCCGG GCCGGC CCGGCG CGGCGA GGCGAA GCGAAA CGAAAA GAAAAT AAAATC AAATCA AATCAC ATCACT TCACTA CACTAC ACTACA CTACAC TACACG ACACGC CACGCG ACGCGT CGCGTT GCGTTT CGTTTT GTTTTG TTTTGA TTTGAA TTGAAT TGAATT GAATTC AATTCA ATTCAA TTCAAC TCAACC CAACCG AACCGC ACCGCG CCGCGC CGCGCA GCGCAA CGCAAT GCAATC CAATCG AATCGA ATCGAG TCGAGG CGAGGA GAGGAC AGGACG GGACGG GACGGC ACGGCG CGGCGC GGCGCG GCGCGA CGCGAT GCGATC CGATCA GATCAC ATCACC TCACCA CACCAT ACCATT CCATTC CATTCT ATTCTG TTCTGC TCTGCA CTGCAG TGCAGC GCAGCC CAGCCC AGCCCG GCCCGA CCCGAC CCGACC CGACCT GACCTC ACCTCT CCTCTC CTCTCC TCTCCA CTCCAA TCCAAA CCAAAA CAAAAC AAAACC AAACCG AACCGG ACCGGC CCGGCG CGGCGG GGCGGC GCGGCA CGGCAT GGCATC GCATCA CATCAC ATCACC TCACCG CACCGA ACCGAA CCGAAG CGAAGC GAAGCG AAGCGC AGCGCT GCGCTG CGCTGC GCTGCG CTGCGC TGCGCG GCGCGT CGCGTC GCGTCG CGTCGC GTCGCC TCGCCG CGCCGC GCCGCC CCGCCA CGCCAT GCCATG CCATGG CATGGC ATGGCC TGGCCT GGCCTC GCCTCG CCTCGG CTCGGC TCGGCT CGGCTT GGCTTA GCTTAC CTTACA TTACAA TACAAA ACAAAC CAAACT AAACTG,CTCGCCG TCGCCGC CGCCGCC GCCGCCG CCGCCGG CGCCGGC GCCGGCG CCGGCGA CGGCGAA GGCGAAA GCGAAAA CGAAAAT GAAAATC AAAATCA AAATCAC AATCACT ATCACTA TCACTAC CACTACA ACTACAC CTACACG TACACGC ACACGCG CACGCGT ACGCGTT CGCGTTT GCGTTTT CGTTTTG GTTTTGA TTTTGAA TTTGAAT TTGAATT TGAATTC GAATTCA AATTCAA ATTCAAC TTCAACC TCAACCG CAACCGC AACCGCG ACCGCGC CCGCGCA CGCGCAA GCGCAAT CGCAATC GCAATCG CAATCGA AATCGAG ATCGAGG TCGAGGA CGAGGAC GAGGACG AGGACGG GGACGGC GACGGCG ACGGCGC CGGCGCG GGCGCGA GCGCGAT CGCGATC GCGATCA CGATCAC GATCACC ATCACCA TCACCAT CACCATT ACCATTC CCATTCT CATTCTG ATTCTGC TTCTGCA TCTGCAG CTGCAGC TGCAGCC GCAGCCC CAGCCCG AGCCCGA GCCCGAC CCCGACC CCGACCT CGACCTC GACCTCT ACCTCTC CCTCTCC CTCTCCA TCTCCAA CTCCAAA TCCAAAA CCAAAAC CAAAACC AAAACCG AAACCGG AACCGGC ACCGGCG CCGGCGG CGGCGGC GGCGGCA GCGGCAT CGGCATC GGCATCA GCATCAC CATCACC ATCACCG TCACCGA CACCGAA ACCGAAG CCGAAGC CGAAGCG GAAGCGC AAGCGCT AGCGCTG GCGCTGC CGCTGCG GCTGCGC CTGCGCG TGCGCGT GCGCGTC CGCGTCG GCGTCGC CGTCGCC GTCGCCG TCGCCGC CGCCGCC GCCGCCA CCGCCAT CGCCATG GCCATGG CCATGGC CATGGCC ATGGCCT TGGCCTC GGCCTCG GCCTCGG CCTCGGC CTCGGCT TCGGCTT CGGCTTA GGCTTAC GCTTACA CTTACAA TTACAAA TACAAAC ACAAACT CAAACTG,"ID   DGOD_RALPJ              Reviewed;         382 AA.
AC   B2UCA8;
DT   14-APR-2009, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-2008, sequence version 1.
DT   27-NOV-2024, entry version 104.
DE   RecName: Full=D-galactonate dehydratase {ECO:0000255|HAMAP-Rule:MF_01289};
DE            Short=GalD {ECO:0000255|HAMAP-Rule:MF_01289};
DE            EC=4.2.1.6 {ECO:0000255|HAMAP-Rule:MF_01289};
GN   Name=dgoD {ECO:0000255|HAMAP-Rule:MF_01289};
GN   OrderedLocusNames=Rpic_2990;
OS   Ralstonia pickettii (strain 12J).
OC   Bacteria; Pseudomonadota; Betaproteobacteria; Burkholderiales;
OC   Burkholderiaceae; Ralstonia.
OX   NCBI_TaxID=402626;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=12J;
RA   Lucas S., Copeland A., Lapidus A., Glavina del Rio T., Dalin E., Tice H.,
RA   Bruce D., Goodwin L., Pitluck S., Meincke L., Brettin T., Detter J.C.,
RA   Han C., Kuske C.R., Schmutz J., Larimer F., Land M., Hauser L.,
RA   Kyrpides N., Mikhailova N., Marsh T., Richardson P.;
RT   ""Complete sequence of chromosome 1 of Ralstonia pickettii 12J."";
RL   Submitted (MAY-2008) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Catalyzes the dehydration of D-galactonate to 2-keto-3-deoxy-
CC       D-galactonate. {ECO:0000255|HAMAP-Rule:MF_01289}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=D-galactonate = 2-dehydro-3-deoxy-D-galactonate + H2O;
CC         Xref=Rhea:RHEA:18649, ChEBI:CHEBI:12931, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:57989; EC=4.2.1.6; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_01289};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_01289};
CC       Note=Binds 1 Mg(2+) ion per subunit. {ECO:0000255|HAMAP-Rule:MF_01289};
CC   -!- PATHWAY: Carbohydrate acid metabolism; D-galactonate degradation; D-
CC       glyceraldehyde 3-phosphate and pyruvate from D-galactonate: step 1/3.
CC       {ECO:0000255|HAMAP-Rule:MF_01289}.
CC   -!- MISCELLANEOUS: Reaction proceeds via an anti dehydration.
CC       {ECO:0000255|HAMAP-Rule:MF_01289}.
CC   -!- SIMILARITY: Belongs to the mandelate racemase/muconate lactonizing
CC       enzyme family. GalD subfamily. {ECO:0000255|HAMAP-Rule:MF_01289}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP001068; ACD28113.1; -; Genomic_DNA.
DR   PDB; 3RR1; X-ray; 1.95 A; A/B=2-382.
DR   PDB; 3RRA; X-ray; 2.30 A; A/B=2-382.
DR   PDBsum; 3RR1; -.
DR   PDBsum; 3RRA; -.
DR   AlphaFoldDB; B2UCA8; -.
DR   SMR; B2UCA8; -.
DR   STRING; 402626.Rpic_2990; -.
DR   KEGG; rpi:Rpic_2990; -.
DR   PATRIC; fig|402626.5.peg.4126; -.
DR   eggNOG; COG4948; Bacteria.
DR   HOGENOM; CLU_030273_3_2_4; -.
DR   UniPathway; UPA00081; UER00518.
DR   EvolutionaryTrace; B2UCA8; -.
DR   GO; GO:0008869; F:galactonate dehydratase activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0009063; P:amino acid catabolic process; IEA:InterPro.
DR   GO; GO:0034194; P:D-galactonate catabolic process; IEA:UniProtKB-UniRule.
DR   CDD; cd03325; D-galactonate_dehydratase; 1.
DR   FunFam; 3.30.390.10:FF:000003; D-galactonate dehydratase; 1.
DR   Gene3D; 3.20.20.120; Enolase-like C-terminal domain; 1.
DR   Gene3D; 3.30.390.10; Enolase-like, N-terminal domain; 1.
DR   HAMAP; MF_01289; Galacton_dehydrat; 1.
DR   InterPro; IPR034593; DgoD-like.
DR   InterPro; IPR036849; Enolase-like_C_sf.
DR   InterPro; IPR029017; Enolase-like_N.
DR   InterPro; IPR029065; Enolase_C-like.
DR   InterPro; IPR023592; Galactonate_deHydtase.
DR   InterPro; IPR018110; Mandel_Rmase/mucon_lact_enz_CS.
DR   InterPro; IPR013342; Mandelate_racemase_C.
DR   InterPro; IPR013341; Mandelate_racemase_N_dom.
DR   PANTHER; PTHR48080:SF2; D-GALACTONATE DEHYDRATASE; 1.
DR   PANTHER; PTHR48080; D-GALACTONATE DEHYDRATASE-RELATED; 1.
DR   Pfam; PF13378; MR_MLE_C; 1.
DR   Pfam; PF02746; MR_MLE_N; 1.
DR   SFLD; SFLDF00003; D-galactonate_dehydratase; 1.
DR   SFLD; SFLDG00179; mandelate_racemase; 1.
DR   SMART; SM00922; MR_MLE; 1.
DR   SUPFAM; SSF51604; Enolase C-terminal domain-like; 1.
DR   SUPFAM; SSF54826; Enolase N-terminal domain-like; 1.
DR   PROSITE; PS00908; MR_MLE_1; 1.
DR   PROSITE; PS00909; MR_MLE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Lyase; Magnesium; Metal-binding.
FT   CHAIN           1..382
FT                   /note=""D-galactonate dehydratase""
FT                   /id=""PRO_1000140385""
FT   ACT_SITE        185
FT                   /note=""Proton donor""
FT                   /evidence=""ECO:0000250""
FT   ACT_SITE        285
FT                   /note=""Proton acceptor""
FT                   /evidence=""ECO:0000250""
FT   BINDING         183
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   BINDING         209
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   BINDING         235
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   SITE            258
FT                   /note=""Increases basicity of active site His""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   SITE            310
FT                   /note=""Transition state stabilizer""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   STRAND          3..11
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   TURN            12..14
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          15..22
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          27..30
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           38..48
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           49..51
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   TURN            52..54
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           60..69
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          71..73
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           77..98
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           102..105
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          114..119
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           125..137
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          142..147
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          150..152
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           157..172
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           175..177
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          178..183
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           190..200
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           201..203
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           218..224
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          231..233
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           240..249
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          253..255
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   TURN            259..263
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           264..276
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   TURN            277..279
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           290..302
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          309..311
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           323..326
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           330..333
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          345..347
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           354..362
FT                   /evidence=""ECO:0007829|PDB:3RR1""
SQ   SEQUENCE   382 AA;  42098 MW;  198F1A16BC5819F0 CRC64;
     MKITRLTTYR LPPRWMFLKV ETDEGVTGWG EPVIEGRART VEAAVHELSD YLIGQDPSRI
     NDLWQTMYRA GFYRGGPILM SAIAGIDQAL WDIKGKVLGV PVYELLGGLV RDKMRTYSWV
     GGDRPADVIA GMKALQAGGF DHFKLNGCEE MGIIDTSRAV DAAVARVAEI RSAFGNTVEF
     GLDFHGRVSA PMAKVLIKEL EPYRPLFIEE PVLAEQAETY ARLAAHTHLP IAAGERMFSR
     FDFKRVLEAG GVSILQPDLS HAGGITECVK IAAMAEAYDV ALAPHCPLGP IALAACLHVD
     FVSWNATLQE QSMGIHYNKG AELLDYVRNK ADFALEGGYI RPPRLPGLGV DIDEALVIER
     SKEAPDWRNP VWRHADGSVA EW
//
",260
ATGGAC TGGACC GGACCC GACCCC ACCCCA CCCCAA CCCAAA CCAAAA CAAAAT AAAATC AAATCA AATCAG ATCAGC TCAGCG CAGCGA AGCGAA GCGAAA CGAAAT GAAATG AAATGC AATGCA ATGCAC TGCACT GCACTC CACTCC ACTCCG CTCCGC TCCGCA CCGCAT CGCATT GCATTA CATTAC ATTACG TTACGT TACGTT ACGTTT CGTTTG GTTTGG TTTGGT TTGGTG TGGTGG GGTGGA GTGGAC TGGACC GGACCC GACCCT ACCCTC CCCTCA CCTCAG CTCAGA TCAGAT CAGATT AGATTC GATTCA ATTCAA TTCAAC TCAACT CAACTG AACTGG ACTGGC CTGGCA TGGCAG GGCAGT GCAGTA CAGTAA AGTAAC GTAACC TAACCA AACCAG ACCAGA CCAGAA CAGAAT AGAATG GAATGG AATGGT ATGGTG TGGTGG GGTGGG GTGGGG TGGGGC GGGGCG GGGCGC GGCGCG GCGCGA CGCGAT GCGATC CGATCA GATCAA ATCAAA TCAAAA CAAAAC AAAACA AAACAA AACAAC ACAACG CAACGT AACGTC ACGTCG CGTCGG GTCGGC TCGGCC CGGCCC GGCCCC GCCCCA CCCCAA CCCAAG CCAAGG CAAGGT AAGGTT AGGTTT GGTTTA GTTTAC,3,112,ATGG TGGA GGAC GACC ACCC CCCC CCCA CCAA CAAA AAAA AAAT AATC ATCA TCAG CAGC AGCG GCGA CGAA GAAA AAAT AATG ATGC TGCA GCAC CACT ACTC CTCC TCCG CCGC CGCA GCAT CATT ATTA TTAC TACG ACGT CGTT GTTT TTTG TTGG TGGT GGTG GTGG TGGA GGAC GACC ACCC CCCT CCTC CTCA TCAG CAGA AGAT GATT ATTC TTCA TCAA CAAC AACT ACTG CTGG TGGC GGCA GCAG CAGT AGTA GTAA TAAC AACC ACCA CCAG CAGA AGAA GAAT AATG ATGG TGGT GGTG GTGG TGGG GGGG GGGC GGCG GCGC CGCG GCGA CGAT GATC ATCA TCAA CAAA AAAA AAAC AACA ACAA CAAC AACG ACGT CGTC GTCG TCGG CGGC GGCC GCCC CCCC CCCA CCAA CAAG AAGG AGGT GGTT GTTT TTTA TTAC,ATGGA TGGAC GGACC GACCC ACCCC CCCCA CCCAA CCAAA CAAAA AAAAT AAATC AATCA ATCAG TCAGC CAGCG AGCGA GCGAA CGAAA GAAAT AAATG AATGC ATGCA TGCAC GCACT CACTC ACTCC CTCCG TCCGC CCGCA CGCAT GCATT CATTA ATTAC TTACG TACGT ACGTT CGTTT GTTTG TTTGG TTGGT TGGTG GGTGG GTGGA TGGAC GGACC GACCC ACCCT CCCTC CCTCA CTCAG TCAGA CAGAT AGATT GATTC ATTCA TTCAA TCAAC CAACT AACTG ACTGG CTGGC TGGCA GGCAG GCAGT CAGTA AGTAA GTAAC TAACC AACCA ACCAG CCAGA CAGAA AGAAT GAATG AATGG ATGGT TGGTG GGTGG GTGGG TGGGG GGGGC GGGCG GGCGC GCGCG CGCGA GCGAT CGATC GATCA ATCAA TCAAA CAAAA AAAAC AAACA AACAA ACAAC CAACG AACGT ACGTC CGTCG GTCGG TCGGC CGGCC GGCCC GCCCC CCCCA CCCAA CCAAG CAAGG AAGGT AGGTT GGTTT GTTTA TTTAC,ATGGAC TGGACC GGACCC GACCCC ACCCCA CCCCAA CCCAAA CCAAAA CAAAAT AAAATC AAATCA AATCAG ATCAGC TCAGCG CAGCGA AGCGAA GCGAAA CGAAAT GAAATG AAATGC AATGCA ATGCAC TGCACT GCACTC CACTCC ACTCCG CTCCGC TCCGCA CCGCAT CGCATT GCATTA CATTAC ATTACG TTACGT TACGTT ACGTTT CGTTTG GTTTGG TTTGGT TTGGTG TGGTGG GGTGGA GTGGAC TGGACC GGACCC GACCCT ACCCTC CCCTCA CCTCAG CTCAGA TCAGAT CAGATT AGATTC GATTCA ATTCAA TTCAAC TCAACT CAACTG AACTGG ACTGGC CTGGCA TGGCAG GGCAGT GCAGTA CAGTAA AGTAAC GTAACC TAACCA AACCAG ACCAGA CCAGAA CAGAAT AGAATG GAATGG AATGGT ATGGTG TGGTGG GGTGGG GTGGGG TGGGGC GGGGCG GGGCGC GGCGCG GCGCGA CGCGAT GCGATC CGATCA GATCAA ATCAAA TCAAAA CAAAAC AAAACA AAACAA AACAAC ACAACG CAACGT AACGTC ACGTCG CGTCGG GTCGGC TCGGCC CGGCCC GGCCCC GCCCCA CCCCAA CCCAAG CCAAGG CAAGGT AAGGTT AGGTTT GGTTTA GTTTAC,ATGGACC TGGACCC GGACCCC GACCCCA ACCCCAA CCCCAAA CCCAAAA CCAAAAT CAAAATC AAAATCA AAATCAG AATCAGC ATCAGCG TCAGCGA CAGCGAA AGCGAAA GCGAAAT CGAAATG GAAATGC AAATGCA AATGCAC ATGCACT TGCACTC GCACTCC CACTCCG ACTCCGC CTCCGCA TCCGCAT CCGCATT CGCATTA GCATTAC CATTACG ATTACGT TTACGTT TACGTTT ACGTTTG CGTTTGG GTTTGGT TTTGGTG TTGGTGG TGGTGGA GGTGGAC GTGGACC TGGACCC GGACCCT GACCCTC ACCCTCA CCCTCAG CCTCAGA CTCAGAT TCAGATT CAGATTC AGATTCA GATTCAA ATTCAAC TTCAACT TCAACTG CAACTGG AACTGGC ACTGGCA CTGGCAG TGGCAGT GGCAGTA GCAGTAA CAGTAAC AGTAACC GTAACCA TAACCAG AACCAGA ACCAGAA CCAGAAT CAGAATG AGAATGG GAATGGT AATGGTG ATGGTGG TGGTGGG GGTGGGG GTGGGGC TGGGGCG GGGGCGC GGGCGCG GGCGCGA GCGCGAT CGCGATC GCGATCA CGATCAA GATCAAA ATCAAAA TCAAAAC CAAAACA AAAACAA AAACAAC AACAACG ACAACGT CAACGTC AACGTCG ACGTCGG CGTCGGC GTCGGCC TCGGCCC CGGCCCC GGCCCCA GCCCCAA CCCCAAG CCCAAGG CCAAGGT CAAGGTT AAGGTTT AGGTTTA GGTTTAC,"ID   ORF9B_BCHK3             Reviewed;          97 AA.
AC   Q3LZX3;
DT   12-JUN-2007, integrated into UniProtKB/Swiss-Prot.
DT   25-OCT-2005, sequence version 1.
DT   02-OCT-2024, entry version 58.
DE   RecName: Full=Protein 9b;
DE   AltName: Full=Accessory protein 9b;
DE   AltName: Full=ORF-9b;
GN   ORFNames=9b;
OS   Bat coronavirus HKU3 (BtCoV) (SARS-like coronavirus HKU3).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=442736;
OH   NCBI_TaxID=89399; Rhinolophus sinicus (Chinese rufous horseshoe bat).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU3-1;
RX   PubMed=16169905; DOI=10.1073/pnas.0506735102;
RA   Lau S.K.P., Woo P.C.Y., Li K.S.M., Huang Y., Tsoi H.-W., Wong B.H.L.,
RA   Wong S.S.Y., Leung S.-Y., Chan K.-H., Yuen K.-Y.;
RT   ""Severe acute respiratory syndrome coronavirus-like virus in Chinese
RT   horseshoe bats."";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:14040-14045(2005).
CC   -!- SUBUNIT: Homodimer. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Host cytoplasmic vesicle membrane; Peripheral
CC       membrane protein. Host cytoplasm. Note=Binds non-covalently to
CC       intracellular lipid bilayers. {ECO:0000250}.
CC   -!- MISCELLANEOUS: The gene encoding this protein is included within the N
CC       gene (alternative ORF).
CC   -!- MISCELLANEOUS: Bat coronavirus HKU3 is highly similar to SARS-CoV
CC       (SARS-like).
CC   -!- SIMILARITY: Belongs to the coronavirus group 2 protein 9b family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; DQ022305; AAY88875.1; -; Genomic_RNA.
DR   SMR; Q3LZX3; -.
DR   Proteomes; UP000007450; Segment.
DR   GO; GO:0044162; C:host cell cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR   CDD; cd21955; SARS-CoV_ORF9b; 1.
DR   InterPro; IPR018542; Protein_9b_Betacoronavirus.
DR   InterPro; IPR037223; Protein_9b_SARS.
DR   Pfam; PF09399; bCoV_lipid_BD; 1.
DR   SUPFAM; SSF141666; SARS ORF9b-like; 1.
DR   PROSITE; PS51920; SARS_9B; 1.
PE   3: Inferred from homology;
KW   Host cytoplasm; Host cytoplasmic vesicle; Host membrane; Membrane.
FT   CHAIN           1..97
FT                   /note=""Protein 9b""
FT                   /id=""PRO_0000291325""
FT   DOMAIN          8..97
FT                   /note=""9b""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01268""
SQ   SEQUENCE   97 AA;  10723 MW;  1CAD2AFC3882E232 CRC64;
     MDPKVNVVPP ALHLVDPQIQ MTITRMEDAV VHDQNNAGPK VYPIILRLGS QLSLSMAKRN
     LDSLEARAFQ STPIVVKMTK LATTEELPDE FVVVTAK
//
",3456
GTCGAA TCGAAG CGAAGC GAAGCC AAGCCG AGCCGA GCCGAT CCGATG CGATGC GATGCT ATGCTG TGCTGC GCTGCT CTGCTG TGCTGT GCTGTG CTGTGA TGTGAC GTGACC TGACCG GACCGC ACCGCT CCGCTG CGCTGA GCTGAG CTGAGC TGAGCC GAGCCC AGCCCA GCCCAA CCCAAC CCAACG CAACGG AACGGC ACGGCT CGGCTT GGCTTT GCTTTA CTTTAT TTTATC TTATCG TATCGA ATCGAG TCGAGC CGAGCT GAGCTG AGCTGG GCTGGG CTGGGC TGGGCC GGGCCT GGCCTG GCCTGG CCTGGC CTGGCC TGGCCC GGCCCC GCCCCT CCCCTG CCCTGA CCTGAA CTGAAC TGAACT GAACTC AACTCG ACTCGT CTCGTG TCGTGC CGTGCA GTGCAA TGCAAG GCAAGC CAAGCC AAGCCG AGCCGT GCCGTG CCGTGG CGTGGC GTGGCT TGGCTG GGCTGA GCTGAT CTGATC TGATCT GATCTG ATCTGG TCTGGG CTGGGT TGGGTT GGGTTA GGTTAC GTTACA TTACAC TACACC ACACCC CACCCA ACCCAG CCCAGC CCAGCC CAGCCC AGCCCA GCCCAC CCCACC CCACCA CACCAG ACCAGC CCAGCG CAGCGT AGCGTG GCGTGC CGTGCA GTGCAG TGCAGC GCAGCT CAGCTC AGCTCA GCTCAA CTCAAG TCAAGG CAAGGC AAGGCG AGGCGA GGCGAT GCGATC CGATCC GATCCC ATCCCT TCCCTC CCCTCT CCTCTG CTCTGG TCTGGC CTGGCG TGGCGA GGCGAT GCGATG CGATGG GATGGG ATGGGC,3,139,GTC CTCG CT TCGCGAGA A C CGCGAGCCAA A GAG AAGAG CGA AAAGCGC C A AGGCCCC C GACTGCC CGCG G CC TCA A CGCACGAGATAT T G GATGGGG TG G A ATATGTGCGC C T TGGCTG TT G GCGCTCTGTG G CCG TGCGC AG  TGTGCT GCT T G GCGCTCTGTG G CTCGA CT T TG TGGTGTG G GGTGA TGA GTG TG CCC G GAGACAAGCC C AACC CTCG G CGGTCCGCGCGC C C CGCGCGCTCT T G GCGCTCTGTG G C CTA GTGAGA A T CCTGAGAGAG G G GAC AAACGC C A AGAGCCC C GATGGCCCCCCC C C CCCCCCCACA A CCCACAAAA  CACAAAACC A AAAGCACGCG  ACACGCGGGG G CCGGGC GC GG GGCT GT G GCGCTCTTGC  GG CTG GTTTTT T T TTTTTTTATA TGA TTTTATATAT T T TATATC GCC C A ATTCGCTGG T TCTCGCGAGAAA C CGCGAGAGG G GAGAGAGCGC C AAGCCT  GCGCTCTGTG G C CTTG TGGGG G T TGGGGG G GG GCGGCGC ATC GGGGCGCTCC  GCCCTT C CCCCTCTGCTGG C CTCTG GCGG G T TGTGGGGCTT C GT CGGCGCCCC C G TGGCCCCC CCCCCCC C CCCACCCCCTCT T C CCCCTCTGTG G C CTCTGTGAGA  TGTGAGAAA G GAGA AACAC  CCCTCAACACTCT T A AC GACTCTG C C CTCTC GCCG G T TCTCGCGTGT T CCCGCGTGTGTG G G GTGTGTGCGC C TTGCTGCGCAGAT GC CGCAAAA CTGCAAACCAG G A AAAAGAGCGC C A AGAGCGCCC G GCAAGCCG TGG C TGCCGCGTGT  CGCGTGTGTG G GA TTGGGG G TTGTTGGGGCGC C G GGGGCGCTCT T G GCGCTTG CCGCTGTGA TCA T TGTGAGAT GCGGGGATATCTC C A ATATCCT T T TCAAGCTGTG G C CTCTGTGGGG G T TGGGGG G GGGGTGT T G GG CCGTTTT T G GTGTTTTATA A T TTTTATACAC C T TATACACACA A A ACACACACAC C C CACACACCC A ACACCCCCCC C C CCCCCCCACA A CT GCCACAGAG G C CACAGAGCGC C A AGAGCCC C G GCGCCCCCCC C C CCCCCCA A C CCCCACACAC C C CACACACCTC C A ACACCCTCCA A C CCCCACAG GAG C CACAGAGCGC C A AGAGCCG TCGGATCGTGT T C CGCGTCC TG G G GT TGAT C TGGCTGCGCACA CTG GCGCACAGAG G CG ACAGAGCGC GAGT GAGCGCTCT  AGGCGGCT CCTC  CTCTCCGAA T TCCAACTTA CCAAAAGCCGG A AACGAAGGGG G A AGAGGGGCGC C G GGGGCGCGCG G G GCGCGG AGA A C CGCGAGATAT  AA GACA ATCTC C A ATATCTCCCC C T TCTCCCCCCC C C CCCCCCCTCT T CGACCCTCTCTC C C CTGATTCTT TGA TCTCTGTG G CCTGTGG GGG T TGTGGGGCGC C G GGGCGCG G G GCGCGTCTAT A C CGGATGA T GGCCATGTC G A ATTGGGG G TCG TGGGGGGG G G GGGGGGGC,GTCC GCGAGA  TCTCGCGAGAA TCGCTC ACGA GAAG G G GAGAAAAGTGAGC C A AAG CAGCGCC TGC A AGAGC TGCCGTCTGCA GCGCCCCGCGAG GA CAG CCGCGACAC CGCGAATGTG G GATCGATATGTGCGC C A ATATGTGCA CCT  CA TGTGCGCTCTGTG G G GCCTGTGCGC C CCTGTGCGCTCT CGAAGCTGCGCTCTGTG G G GCGCT AGTGTT C CTCTGTGTGTGTG  GTGCCCGCGTGTGACCCG TGTGTGAAT AC C C TGTGAGACACCCC C G GAGACACCCCGCG ATC ACACCCCGCGCC C CCCT TGTGACCT T CCGCGCTCTGG GGA CTGGCTCTGTGACG A C CTCTGTGAGAGAG GG  TGTGAGAGAGCGC TCG GAGAGAGCGCCCC C A AG TGGCCCCC CACCC GCGCCCCCCCACA A C CCCCCCCACAAAA A C CCCCACAAAACAC C C CACAA CTACGCG  GG AAAACACGCGGGG G A ACCGGGGCGC C CCGGCGTGCTC GAGCGGC CCCTTGGTT G GCGCTCTTCCTTT T C CTTTTTTATA A T TTTTT CCAT T T TTGGGTATTC C T TAATCCG G A ATTCGAGCA TTCGG CGAGAG G C CGCGAGAGAGCGC C G GAGAGAGCGCTCCCT A AG GACTGTG  GCTGGGG G CGATCTGTGGGGGG C CT TGTGGGGGGGCGC CTGGGGGGCGCCCC  GGGCCCCTCT AT  GCCCTCTGTG  CCCCTGG G C CTCC GGCGC  TGAAGGGCC G GGGGCGCCCC C G GCCCCCCCCC C C CCCCCGA CCTCT T CCCCCTGTG G CGCTCCTCTGTGAGA A C CTCTGTGAGAAAA  TGTG AACAC C G GAAACACTCCCT A AAAACACTCTCTC C A ACACTCTCTCGCG G C CTCTCTCGCGTGT T T TCTCGCGTGTGCGAG C CGGGCGTGTGCGC C G GTGTGT ACA A T TGTGCG GCAAAA A G GC ACCAAAAGAG G C CACAAAAGAGCGC C ATCCTGGAGCGCCCCCC AC AAGCGCCCCGG G GCGCCCCGCGTGT T C CCC GCGTGTGTG AAG CGCGTGTGG TG GTTAGTGTGGGC GTTTGGGGCGT CT T G GGGGCCTG GCG GGCTG GGA A C CTCTGTGAGAT GCT T TGGATG ATC C G GAGATATCCG CACTGC ATATCTCTCTGTG G TAA TCTCTGTGG GC CT GCCTG GTGG G T TGTGGGGTT G GGGGGGGTCC TT T G GGTT GTTTTATA A G GTGTTTTATACAC C T TTTTATACC TCA A T TATACCACAC  CG ACACACT ACCAGCC CCC T GCCCCC C AGCAACCCCCCCACA A C CCCCCCCACAGAG G C CCCCACAGA TGC C C CACAGAGCCCGCTGC A AGAGCGCCCCCCCG CTGCCCCCCCACA GCT CCCCAAC C CTTACCACACACCCC C C CACACACCCCACA A A ACACCCCACAGAG GG  CCCCACAGAGCC CT TCAGAGCGCGCG G AAGCGCGCGTGCTT G GCGCGCGTTG G C CGCGTGTGTGCGC CT  GTGTGTGCGCACA CC  TGTGCGCACAG CCG G GCGCACAGAGCGC C C CACAGAGCGCTCT T A AGAGCCTCTC C GG CGCTCTCTCACA A C GCCTCTCACAACCCA T TCTCAAAGAG G C CACAAAAGAGGGG G A AAAAGAGGGGCCTG AGAGGGGCGCGGA G G GGGGCGCGCGAGA A G GCGCGCGAGATGCTT C CGCGAGATAAGTC GCTGATATCTCCCC C A ATATC AAC GCC C T TCTCCCT CCTT C CCCT CCTTCTC T CCCCTCTCCT  CTCTCTCTCTGTG G T TCTCTCTGTGGGG G CG TCTGTGGGGCC T TGTGGGCGCG G G GGGGCGCGGA A GAT T TAACAT T C CGGATGCTTG TGAGATATGTGGGG G A ATATGTGGGGGGG G T TGTGGGGG,GTCTCGCGAGAAAA  TC TGACCAC AAGAG G C CGAAGAGCGC C G GAGCGAAGAGCGCCCC GA AAGAGCGCCCCGATGG A AGAGCCGACCGCGAGA A G GCACTCCGCGAGATAT T C CCAC CGAGATCG TG G C CGCGAGATATGTGCGC C G GAGATATGTGCGCTCT CCC ATATGTGCGCTCC TG TGG TGTGCGCTCTGTGCGC CGAGCTTCTTGGGCTCT T C CTCTGTGCGCTCTGCT CT TGCGCT CTTGTGT T GGCTCTGTGTGTGTG G C CTCTGTGTGTGTGAGA A T TGTGTGTGTGAGACAC GG CCCGTGTGAC TTGAGACACCCCGG G GAGACACCCCGCTGAA C ACCGCGCGCTGGCT C CCCCTCGCCTGTG G CGCACGCCTGCACGA GCTTGAGAGAG G CTG TGAGAGAGCGC  TGTGAGAGAGCGCCCC C G GAGCAAGCGCCCCCCC C AGATAGCGCC GTCCACA  GCAC CCCCCACAAGTGG A CCCCACAAAACAC C C CCAACCG CC  CACAAAACACGCGGC GTTA AAAACACGCGGGGCGC C A ACACGCGGGGCCT T C CGCGGGGCGCTCTTTT T GGGCGCTCTTTTTTT T G GCCTGCTTTTTTTATA A C CTCTTTTTTTATATAT T TTTTTTATATATCC T TTTTAAGCTCGCG G T TATATA GTCGCGAGA A A ATTCGCGAGCCAG G T TCTCG GCGAGAGCC CC C CGATCAGCGCTCT T G GAGAGAGCGCTCTGTG G AAGCGCTCTGCCTGG G G GCGCTCTGTGGGGGGG G C CTCTGTGAGGGGGCGC  TTTGGGGGGGCGCCCC C GCGTGGGGGCGCCCCTATCT G GGACCCCTTG G G GCGCCCTGTGGG C CCCCTCTGTGGGGCGC C CG CCTGTGGGGCGCCCC C T TGTGGGGCGAGCCCCCA GGGGCGCCT ACCCCC C G GCGCCCCTT C CCCCCCCCG TCACG C CCCCCCCTCTGTGGC AA C CCCCTCTGTGAGAAA C CTCTGTGACTG CTCCGAAC TGCTGGAAAT ACTT G GAGAAACTCTCTC C AC TGCCCTCTCGCG G A ACACTCTCGTGGT AACTCGCGTGTGCTGG T TC GCCGTGTGTGCC C CGCGTGTGTGCGATA G CAGTGTGCGG CAAGC  CCTGCCAAAAGAG G G GCGAGCAAAAGAGCGC C C CACAAAAGAGCGCCC A AAAGCGCCGCAG A AGATCGCCCCGCGTGT CAG GCGCCCCGCGTGTGTG G CCCGCGTTGGTGGTGC CTCGT GGTGGTGAGC C GG AGTGTGGGGCGCTCT T T TGTGGGCTCTGGC G G GTGCTGATTGAGA ATC GCCTGGGCGATAT T CCTGCTGTGAGATAGCTC  TGTGAGATATCTCTCT T G GAGATGAGTCTCGCTG A C ATACCTCTTGAGG G TGAATCTTGGGGGGCT GG CTCTGTGGGGTGCAT T TGTGGGGGGGTGTTTT T G GGGGT CTTTATA AGG GGGGTGTTG ATACGCCC G GTGTTTTATACACACA A TC TTTATACACATACC TAC CACTG CCCCTG ACACACGACCCCC C C CACACACCCCCCCACA A A ACACCACCC GCAGAG G C CCCCACAGAGCGC CTGA TCCACAGATCGCCCC C C CACAGAGCGCCCCCC GC AAGCGCCCCCCCAA G GCGCCCCCCAC TCGC  CCCCCCCACACACCCC C C CCCCATGAGCCCCACA A C CACACACCCCACAGAG G A ACACCCCACAGAGCCTC CCCCAT GAGCGCGCG  GTCAGAGCGCGGT T AGGCAGCGCGCGTAA TG G G GCGCGCGTGTGGG GC C C CGCGTGTGTGCCA A G GTGTGTGCGCACAGAG G T TGTGCGCACAGAGCGC GGG GCGCACAGAGCCT T C CAAGCCTCTC C A AGAGCGC TCACA A GTCGGCTG CTCAAA A CCTCTCACAAAAGAG G T TCTCACAAAAGAGGC C CACAAAAGA GGGCGC C A AAAAGAGGGGCGCGA GCT AGGGGCGCGCGAGA A G GGGGCCGAGATAACT G GCGCGCGA AGATCTC C C CGCGACA TCGCC CC  GAGATATCTCCCCCCC  ATTCCCCCCT T T TCTCCCCCCCTTC GG  CCCCCCCTCTCTCTG TCCTCTCTCTTG G C CTCTCTCTCTGGTGGG G T TCGAACTGTGCGGCGC ATC CTCTGTGGGGCGCGG T TGTGGGCGGCCGA A GG CGGCGAACGAAT T G GCGCGCGAGATATGTG  CGCGA CGCTGTGGGG G GGATATGTGGGGGGG G A ATATGTGGC GGGC,GTCTCGCGAGAAAAGAG G T TCTCGCGAGAAAAGTGCGC CAATA GAAAAGAGCGCCCC C G GAGAAAAGAGCGCCCCGCG G A AAAGCGCCCCGCGAATCA A AGAGCGCCCCGAGCTGGAT  GCGCCCCGCGAGATATGTG G C CCCGAGATATGTGCGC C CGCTGATATGAGCGCTCT T G GGTGCGCTCAAG A ATATGTGCGCTCTGTG C T TGTGCGCTCCATGCGCTACAT G GCCT CTGTGC TGCCATG  GCCTG CCGCTCTGCGA CG CCTGCGCTAGCTGTGTGTG G G GCGCTCTGTGTGTGT AGA A C CTCTG ATGTGTGAGACAC C T TGGTGTGAGACACCCC GTGG TGACACCTGGG T TGTGAGACACCGCACGCC G GAGACACCCC GCTCT TGA ACACCATCCGCGCTG CTG G C CCCGCGCTCTGGCTGA A CGCAGCTCTGTGAAG G GCCTGCTCTGTGAGAGGC CAG ACCTGCTGGAAAGCTT CC C T TGTGAGAGGCCTGCC GGAGAGCGCCCCCCCACA A A AGTCTGCCCCCCTGCAAA G GCGCCCCCCCAC CAACAC C C CCCCCCCACAAAACACGCG G CCG AGCCAACTTACGCGGG AG C CACAAAACACGGGCC A AAAACACGCGGGCTGCTT A ACACGCGGGGCGCTCTGTT T CGT CGGGGCGCTCTTTTTT G GGGGCTGACTTTTTTTAA G GCCTTTTTCC TATTTTTTACCGAT C T TTTTTTTATATATCTCGCG G TATCG GTATTCGCGAGA  TATATGA CGAGAGAG G A ATATCCGAGAGAGCCTGC T TCTCGCGAGAGAGCCGACT T C CGCGAGAGAGCGCTCCATG G G GAGAGAGCGCTCTGTGGGG GCCACCAGCGCTCTGCCGGGGGG G GCGAGCTCTGTGGGC AC  CTCTGTGGGGGGGCGCCCC C TGGCTGGGG TGTCCTCT T G GGGGGGGCGCCCCTCTGTGC GGGGCGCCCCTCTGTGGGG G G GCGCCCCTCTGTGGTCGC CCAACCTCTGTGG TGGCCCC  CTCTGTGGGCCCCCCC C T TGTGGGGCGCCCCCTTACCGC G GGGGCCGACCCCCCCCTT G GC AGAACTCGCTGG CCCCCCCCCTCTGC CGA  CCCCCCCTCTGTGAAA  CCCCTTGAGAAAACC C CTCTGTGAGAAG TACTCT T TGC GGCAACACTCTCTC C G GAGAAAACC CCTCTCGCG AAC CGCTCTCGCGTGT T A CTACTCTCT CCGTGTGTG G C CTTCGCGTGTGTGCACT TCCCCCGTGTGGCTCA A C CGCGTTGCGCACTGAT A G GTCC TGCTG CAAAAGAAC TGCC GCACAAAAGAGCGC C G GCGCA CCAAGAGCTTAC CCAAAAGAGCG ACCGTGCCCC AAAAGAGCGCCCCGCGTGT T A AGTGGGCCCCGAG GTGTG GC GCCCCGCGTAA TGGGGGG CAGCGGCCGTGTGTGGGGCGC C C CGCGTGTGCCAGGCCT T G GTGTGTGGGGCGCTCTGTG G T TGTGGGGCCTGTGAGA A G GGAGCGCTCTGTGAGATCAGT G GCGCTCTTTGAGATATCTC C C AGCTGGATATC TGCT T T TGTGAGATATCCAGCTGTG G G GAGATATCTCTCTGTGGGG TGTTCTCTGGATGGGGG G T TCTCTCTGTGGGGGGGTGT T C CTCTGTGGGGGGGTGTTT TTGGGGGGGTGTT CATA A G GGGGGCAGTACAC C GATGGGTGTTCCCTACACACA CGACACGTTTTATACACACACAC C TTTATACACACACACCCC GCG TATACACAA CCCCCC C A AC CGCACACCG ACCACA A C CACAC AGCCCCCATCT GTG A ACACCCCCCCACTGGC C C CCCCCCCACAGCGAGCCCC C C CCCCACGAGCCCC C CCAGAGCGCCGGCCCATGC AGAGCCCCCCACACTG C G GCGCCCCCCCACACACCCC ACT CCCCCCCA GTACCCTGGCGACC CCCACACCCCACAGCGTG C CACACACCCCACAGAGCGC C AACCCTGCAGAGCGCGCG G CC CT AAGCGCGCGTGT  CACAGAGCCA CGTGTGTG GG  CTAGCGCGCGTGTGTGCGC C G GCGCGGTGTTAGCACA A C CGCGTGTGTGCGCACAGAG G G GTGTGGG GCACAGGGCG GC T TGTGCGCAAA AGCGCTCT T G GCCCGCAGAGCGATTC C CTTACAGAGCA ACTCTCAA AGCCAGCGCTCTCTCACAAGTGA G GCGCTCTCTCACAAAAGAG G C CTCTCTCACAAAAGAGGTGCTGA TCTCACAAAAGAGGGGCGC C C CACAAC GGCGG A AAAAGAGGGGCCGAGA A A AGAGGGCGGATT G GGGGCGCGGCCGATATCTC C G GCGCGGAT TTTCCGTGC CCT A CATCTCCCC GGC GATCCCCCCCTCT  ATATCTCCCCCCCTCTCTC C T TCCCCCTCTCTT C CCCCCCCTCTCTCTGC  CCCCTCTCTCTTGACTCGC G C CTCTCTCTCTGGGCGC C T TCTCTCTGTGGGGCC TCG G C CTTGGGCGCGAGA A TGCTTGGGGCGCGCGAGATAT T G GGCCGGCGAGCGATTG G GG CGCGCGAGATATGTGG TGG C CGCGAGATATGTGGGGGTGC GAGATATGTGGGGGGGC,"ID   DDX56_MOUSE             Reviewed;         546 AA.
AC   Q9D0R4;
DT   23-JAN-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2001, sequence version 1.
DT   05-FEB-2025, entry version 174.
DE   RecName: Full=Probable ATP-dependent RNA helicase DDX56;
DE            EC=3.6.4.13;
DE   AltName: Full=ATP-dependent 61 kDa nucleolar RNA helicase;
DE   AltName: Full=DEAD box protein 56;
GN   Name=Ddx56; Synonyms=D11Ertd619e, Noh61;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=C57BL/6J; TISSUE=Embryo;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA   Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA   Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA   Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA   Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA   Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA   Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA   Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA   Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA   Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA   Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA   Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA   Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA   Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA   Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA   Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA   Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA   Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA   Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA   Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA   van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA   Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA   Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA   Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA   Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA   Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA   Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA   Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA   Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT   ""The transcriptional landscape of the mammalian genome."";
RL   Science 309:1559-1563(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=FVB/N; TISSUE=Salivary gland;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   ""The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC)."";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   FUNCTION, INTERACTION WITH SOX2 AND POU5F1, AND SUBCELLULAR LOCATION.
RX   PubMed=32703285; DOI=10.1186/s13287-020-01800-w;
RA   Wang J., Liu J., Ye M., Liu F., Wu S., Huang J., Shi G.;
RT   ""Ddx56 maintains proliferation of mouse embryonic stem cells via ribosome
RT   assembly and interaction with the Oct4/Sox2 complex."";
RL   Stem Cell Res Ther 11:314-314(2020).
CC   -!- FUNCTION: Nucleolar RNA helicase that plays a role in various
CC       biological processes including innate immunity, ribosome biogenesis or
CC       nucleolus organization. Plays an essential role in maintaining
CC       nucleolar integrity in planarian stem cells (PubMed:32703285).
CC       Maintains embryonic stem cells proliferation by conventional regulation
CC       of ribosome assembly and interaction with OCT4 and POU5F1 complex
CC       (PubMed:32703285). Regulates antiviral innate immunity by inhibiting
CC       the virus-triggered signaling nuclear translocation of IRF3.
CC       Mechanistically, acts by disrupting the interaction between IRF3 and
CC       importin IPO5. May play a role in later stages of the processing of the
CC       pre-ribosomal particles leading to mature 60S ribosomal subunits. Has
CC       intrinsic ATPase activity (By similarity).
CC       {ECO:0000250|UniProtKB:Q9NY93, ECO:0000269|PubMed:32703285}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O = ADP + phosphate + H(+); Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=3.6.4.13;
CC   -!- SUBUNIT: May form homooligomeric complexes. Interacts with IRF3 (By
CC       similarity). Interacts with OCT4 and POU5F1 (PubMed:32703285).
CC       {ECO:0000250|UniProtKB:Q9NY93, ECO:0000269|PubMed:32703285}.
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleolus {ECO:0000269|PubMed:32703285}.
CC   -!- SIMILARITY: Belongs to the DEAD box helicase family. DDX56/DBP9
CC       subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK011136; BAB27426.1; -; mRNA.
DR   EMBL; AK077514; BAC36839.1; -; mRNA.
DR   EMBL; BC018291; AAH18291.1; -; mRNA.
DR   CCDS; CCDS24414.1; -.
DR   RefSeq; NP_080814.1; NM_026538.3.
DR   AlphaFoldDB; Q9D0R4; -.
DR   SMR; Q9D0R4; -.
DR   BioGRID; 206632; 5.
DR   CORUM; Q9D0R4; -.
DR   IntAct; Q9D0R4; 1.
DR   STRING; 10090.ENSMUSP00000004507; -.
DR   iPTMnet; Q9D0R4; -.
DR   PhosphoSitePlus; Q9D0R4; -.
DR   PaxDb; 10090-ENSMUSP00000004507; -.
DR   ProteomicsDB; 279182; -.
DR   Pumba; Q9D0R4; -.
DR   Antibodypedia; 13419; 416 antibodies from 27 providers.
DR   DNASU; 52513; -.
DR   Ensembl; ENSMUST00000004507.11; ENSMUSP00000004507.5; ENSMUSG00000004393.11.
DR   GeneID; 52513; -.
DR   KEGG; mmu:52513; -.
DR   UCSC; uc007hyc.1; mouse.
DR   AGR; MGI:1277172; -.
DR   CTD; 54606; -.
DR   MGI; MGI:1277172; Ddx56.
DR   VEuPathDB; HostDB:ENSMUSG00000004393; -.
DR   eggNOG; KOG0346; Eukaryota.
DR   GeneTree; ENSGT00550000074946; -.
DR   HOGENOM; CLU_003041_17_1_1; -.
DR   InParanoid; Q9D0R4; -.
DR   OMA; NASEQCV; -.
DR   OrthoDB; 1191041at2759; -.
DR   PhylomeDB; Q9D0R4; -.
DR   TreeFam; TF300620; -.
DR   BioGRID-ORCS; 52513; 24 hits in 81 CRISPR screens.
DR   ChiTaRS; Ddx56; mouse.
DR   PRO; PR:Q9D0R4; -.
DR   Proteomes; UP000000589; Chromosome 11.
DR   RNAct; Q9D0R4; protein.
DR   Bgee; ENSMUSG00000004393; Expressed in otic placode and 253 other cell types or tissues.
DR   ExpressionAtlas; Q9D0R4; baseline and differential.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0005730; C:nucleolus; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:RHEA.
DR   GO; GO:0140849; F:ATP-dependent H2AZ histone chaperone activity; IEA:RHEA.
DR   GO; GO:0140665; F:ATP-dependent H3-H4 histone complex chaperone activity; IEA:RHEA.
DR   GO; GO:0140584; F:chromatin extrusion motor activity; IEA:RHEA.
DR   GO; GO:0061775; F:cohesin loader activity; IEA:RHEA.
DR   GO; GO:0003689; F:DNA clamp loader activity; IEA:RHEA.
DR   GO; GO:0140311; F:protein sequestering activity; IEA:Ensembl.
DR   GO; GO:0003724; F:RNA helicase activity; IEA:UniProtKB-EC.
DR   GO; GO:0035613; F:RNA stem-loop binding; IEA:Ensembl.
DR   GO; GO:0051607; P:defense response to virus; IEA:Ensembl.
DR   GO; GO:0044830; P:modulation by host of viral RNA genome replication; IEA:Ensembl.
DR   GO; GO:0032480; P:negative regulation of type I interferon production; IEA:Ensembl.
DR   GO; GO:0010976; P:positive regulation of neuron projection development; IEA:Ensembl.
DR   GO; GO:0006364; P:rRNA processing; IEA:UniProtKB-KW.
DR   CDD; cd17961; DEADc_DDX56; 1.
DR   CDD; cd18787; SF2_C_DEAD; 1.
DR   FunFam; 3.40.50.300:FF:000939; Probable ATP-dependent RNA helicase DDX56; 1.
DR   FunFam; 3.40.50.300:FF:001046; Probable ATP-dependent RNA helicase ddx56; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 2.
DR   InterPro; IPR011545; DEAD/DEAH_box_helicase_dom.
DR   InterPro; IPR050079; DEAD_box_RNA_helicase.
DR   InterPro; IPR014001; Helicase_ATP-bd.
DR   InterPro; IPR001650; Helicase_C-like.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR014014; RNA_helicase_DEAD_Q_motif.
DR   PANTHER; PTHR47959; ATP-DEPENDENT RNA HELICASE RHLE-RELATED; 1.
DR   PANTHER; PTHR47959:SF21; DEAD-BOX HELICASE 56; 1.
DR   Pfam; PF00270; DEAD; 1.
DR   Pfam; PF00271; Helicase_C; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SMART; SM00490; HELICc; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 2.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; 1.
DR   PROSITE; PS51195; Q_MOTIF; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Helicase; Hydrolase; Nucleotide-binding; Nucleus;
KW   Phosphoprotein; Reference proteome; Ribosome biogenesis; RNA-binding;
KW   rRNA processing.
FT   CHAIN           1..546
FT                   /note=""Probable ATP-dependent RNA helicase DDX56""
FT                   /id=""PRO_0000055059""
FT   DOMAIN          38..218
FT                   /note=""Helicase ATP-binding""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00541""
FT   DOMAIN          230..424
FT                   /note=""Helicase C-terminal""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00542""
FT   REGION          324..344
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          508..546
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   MOTIF           7..35
FT                   /note=""Q motif""
FT   MOTIF           166..169
FT                   /note=""DEAD box""
FT   COMPBIAS        325..334
FT                   /note=""Basic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        508..524
FT                   /note=""Basic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        532..546
FT                   /note=""Basic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   BINDING         51..58
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00541""
FT   MOD_RES         126
FT                   /note=""Phosphoserine""
FT                   /evidence=""ECO:0000250|UniProtKB:Q9NY93""
FT   MOD_RES         141
FT                   /note=""Phosphothreonine""
FT                   /evidence=""ECO:0000250|UniProtKB:Q9NY93""
SQ   SEQUENCE   546 AA;  61212 MW;  3C19F7354C29F9A1 CRC64;
     MEDQEALGFE HMGLDPRLLQ AVTDLGWSRP TLIQEKAIPL ALEGKDLLAR ARTGSGKTAA
     YAIPMLQSLL HKKATGPVME QAVRGLVLVP TKELARQAQA MIQQLAAYCA RDVRVANVSA
     AEDSASQRAV LMEKPDVVVG TPSRVLSHLQ QNTLKLRDSL ELLVVDEADL LFSFGFEDEL
     KSLLCHLPRI YQAFLMSATF NEDVQTLKEL VLHNPVTLKL QESQLPGPDQ LQQFQVVCET
     EEDKFLLLYA LLKLSLIRGK ALLFVNTLER GYRLRLFLEQ FSIPSCVLNG ELPLRSRCHI
     ISQFNQGLYD CVIATDAEIL GPQVKGKRRG RGSKGNKASD PESGVARGID FHHVSAVLNF
     DLPPTAEAYV HRAGRTARAN NPGIVLTFVL PAEQPFLGKI EDLLSGEGEA PILLPYQFQM
     EEIESFRYRC RDAMRSVTKQ AIREARLKEI KEELLHSEKL KTYFEDNPRD LQLLRHDLPL
     HPAVVKPHLG HVPDYLVPAA LRGLVHPRKK RRKVPFSRKA KKVKAQNPLR DFKHRGKKPK
     PAAKPS
//
",42281
CCCGTG CCGTGC CGTGCC GTGCCC TGCCCG GCCCGT CCCGTG CCGTGG CGTGGA GTGGAC TGGACC GGACCT GACCTG ACCTGG CCTGGT CTGGTC TGGTCA GGTCAC GTCACC TCACCG CACCGC ACCGCG CCGCGT CGCGTC GCGTCG CGTCGG GTCGGC TCGGCC CGGCCA GGCCAG GCCAGC CCAGCG CAGCGG AGCGGG GCGGGC CGGGCT GGGCTG GGCTGG GCTGGA CTGGAC TGGACC GGACCC GACCCA ACCCAC CCCACA CCACAC CACACA ACACAT CACATC ACATCA CATCAG ATCAGC TCAGCC CAGCCC AGCCCG GCCCGG CCCGGC CCGGCA CGGCAG GGCAGC GCAGCC CAGCCG AGCCGC GCCGCG CCGCGG CGCGGC GCGGCC CGGCCT GGCCTA GCCTAC CCTACC CTACCA TACCAG ACCAGA CCAGAG CAGAGC AGAGCG GAGCGA AGCGAA GCGAAC CGAACG GAACGC AACGCG ACGCGT CGCGTG GCGTGG CGTGGC GTGGCC TGGCCC GGCCCG GCCCGT CCCGTG CCGTGC CGTGCC GTGCCA TGCCAG GCCAGA CCAGAG CAGAGG AGAGGC GAGGCC AGGCCT GGCCTG GCCTGC CCTGCC CTGCCC TGCCCG GCCCGT CCCGTG CCGTGG CGTGGG GTGGGA TGGGAC GGGACA GGACAA GACAAG ACAAGT CAAGTG,2,118,CCCG CCGT CGTG GTGC TGCC GCCC CCCG CCGT CGTG GTGG TGGA GGAC GACC ACCT CCTG CTGG TGGT GGTC GTCA TCAC CACC ACCG CCGC CGCG GCGT CGTC GTCG TCGG CGGC GGCC GCCA CCAG CAGC AGCG GCGG CGGG GGGC GGCT GCTG CTGG TGGA GGAC GACC ACCC CCCA CCAC CACA ACAC CACA ACAT CATC ATCA TCAG CAGC AGCC GCCC CCCG CCGG CGGC GGCA GCAG CAGC AGCC GCCG CCGC CGCG GCGG CGGC GGCC GCCT CCTA CTAC TACC ACCA CCAG CAGA AGAG GAGC AGCG GCGA CGAA GAAC AACG ACGC CGCG GCGT CGTG GTGG TGGC GGCC GCCC CCCG CCGT CGTG GTGC TGCC GCCA CCAG CAGA AGAG GAGG AGGC GGCC GCCT CCTG CTGC TGCC GCCC CCCG CCGT CGTG GTGG TGGG GGGA GGAC GACA ACAA CAAG AAGT AGTG,CCCGT CCGTG CGTGC GTGCC TGCCC GCCCG CCCGT CCGTG CGTGG GTGGA TGGAC GGACC GACCT ACCTG CCTGG CTGGT TGGTC GGTCA GTCAC TCACC CACCG ACCGC CCGCG CGCGT GCGTC CGTCG GTCGG TCGGC CGGCC GGCCA GCCAG CCAGC CAGCG AGCGG GCGGG CGGGC GGGCT GGCTG GCTGG CTGGA TGGAC GGACC GACCC ACCCA CCCAC CCACA CACAC ACACA CACAT ACATC CATCA ATCAG TCAGC CAGCC AGCCC GCCCG CCCGG CCGGC CGGCA GGCAG GCAGC CAGCC AGCCG GCCGC CCGCG CGCGG GCGGC CGGCC GGCCT GCCTA CCTAC CTACC TACCA ACCAG CCAGA CAGAG AGAGC GAGCG AGCGA GCGAA CGAAC GAACG AACGC ACGCG CGCGT GCGTG CGTGG GTGGC TGGCC GGCCC GCCCG CCCGT CCGTG CGTGC GTGCC TGCCA GCCAG CCAGA CAGAG AGAGG GAGGC AGGCC GGCCT GCCTG CCTGC CTGCC TGCCC GCCCG CCCGT CCGTG CGTGG GTGGG TGGGA GGGAC GGACA GACAA ACAAG CAAGT AAGTG,CCCGTG CCGTGC CGTGCC GTGCCC TGCCCG GCCCGT CCCGTG CCGTGG CGTGGA GTGGAC TGGACC GGACCT GACCTG ACCTGG CCTGGT CTGGTC TGGTCA GGTCAC GTCACC TCACCG CACCGC ACCGCG CCGCGT CGCGTC GCGTCG CGTCGG GTCGGC TCGGCC CGGCCA GGCCAG GCCAGC CCAGCG CAGCGG AGCGGG GCGGGC CGGGCT GGGCTG GGCTGG GCTGGA CTGGAC TGGACC GGACCC GACCCA ACCCAC CCCACA CCACAC CACACA ACACAT CACATC ACATCA CATCAG ATCAGC TCAGCC CAGCCC AGCCCG GCCCGG CCCGGC CCGGCA CGGCAG GGCAGC GCAGCC CAGCCG AGCCGC GCCGCG CCGCGG CGCGGC GCGGCC CGGCCT GGCCTA GCCTAC CCTACC CTACCA TACCAG ACCAGA CCAGAG CAGAGC AGAGCG GAGCGA AGCGAA GCGAAC CGAACG GAACGC AACGCG ACGCGT CGCGTG GCGTGG CGTGGC GTGGCC TGGCCC GGCCCG GCCCGT CCCGTG CCGTGC CGTGCC GTGCCA TGCCAG GCCAGA CCAGAG CAGAGG AGAGGC GAGGCC AGGCCT GGCCTG GCCTGC CCTGCC CTGCCC TGCCCG GCCCGT CCCGTG CCGTGG CGTGGG GTGGGA TGGGAC GGGACA GGACAA GACAAG ACAAGT CAAGTG,CCCGTGC CCGTGCC CGTGCCC GTGCCCG TGCCCGT GCCCGTG CCCGTGG CCGTGGA CGTGGAC GTGGACC TGGACCT GGACCTG GACCTGG ACCTGGT CCTGGTC CTGGTCA TGGTCAC GGTCACC GTCACCG TCACCGC CACCGCG ACCGCGT CCGCGTC CGCGTCG GCGTCGG CGTCGGC GTCGGCC TCGGCCA CGGCCAG GGCCAGC GCCAGCG CCAGCGG CAGCGGG AGCGGGC GCGGGCT CGGGCTG GGGCTGG GGCTGGA GCTGGAC CTGGACC TGGACCC GGACCCA GACCCAC ACCCACA CCCACAC CCACACA CACACAT ACACATC CACATCA ACATCAG CATCAGC ATCAGCC TCAGCCC CAGCCCG AGCCCGG GCCCGGC CCCGGCA CCGGCAG CGGCAGC GGCAGCC GCAGCCG CAGCCGC AGCCGCG GCCGCGG CCGCGGC CGCGGCC GCGGCCT CGGCCTA GGCCTAC GCCTACC CCTACCA CTACCAG TACCAGA ACCAGAG CCAGAGC CAGAGCG AGAGCGA GAGCGAA AGCGAAC GCGAACG CGAACGC GAACGCG AACGCGT ACGCGTG CGCGTGG GCGTGGC CGTGGCC GTGGCCC TGGCCCG GGCCCGT GCCCGTG CCCGTGC CCGTGCC CGTGCCA GTGCCAG TGCCAGA GCCAGAG CCAGAGG CAGAGGC AGAGGCC GAGGCCT AGGCCTG GGCCTGC GCCTGCC CCTGCCC CTGCCCG TGCCCGT GCCCGTG CCCGTGG CCGTGGG CGTGGGA GTGGGAC TGGGACA GGGACAA GGACAAG GACAAGT ACAAGTG,"ID   KDPC_RALN1              Reviewed;         204 AA.
AC   Q8XU10;
DT   06-JUN-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2002, sequence version 1.
DT   05-FEB-2025, entry version 112.
DE   RecName: Full=Potassium-transporting ATPase KdpC subunit {ECO:0000255|HAMAP-Rule:MF_00276};
DE   AltName: Full=ATP phosphohydrolase [potassium-transporting] C chain {ECO:0000255|HAMAP-Rule:MF_00276};
DE   AltName: Full=Potassium-binding and translocating subunit C {ECO:0000255|HAMAP-Rule:MF_00276};
DE   AltName: Full=Potassium-translocating ATPase C chain {ECO:0000255|HAMAP-Rule:MF_00276};
GN   Name=kdpC {ECO:0000255|HAMAP-Rule:MF_00276};
GN   OrderedLocusNames=RSc3384; ORFNames=RS02658;
OS   Ralstonia nicotianae (strain ATCC BAA-1114 / GMI1000) (Ralstonia
OS   solanacearum).
OC   Bacteria; Pseudomonadota; Betaproteobacteria; Burkholderiales;
OC   Burkholderiaceae; Ralstonia; Ralstonia solanacearum species complex.
OX   NCBI_TaxID=267608;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC BAA-1114 / GMI1000;
RX   PubMed=11823852; DOI=10.1038/415497a;
RA   Salanoubat M., Genin S., Artiguenave F., Gouzy J., Mangenot S., Arlat M.,
RA   Billault A., Brottier P., Camus J.-C., Cattolico L., Chandler M.,
RA   Choisne N., Claudel-Renard C., Cunnac S., Demange N., Gaspin C., Lavie M.,
RA   Moisan A., Robert C., Saurin W., Schiex T., Siguier P., Thebault P.,
RA   Whalen M., Wincker P., Levy M., Weissenbach J., Boucher C.A.;
RT   ""Genome sequence of the plant pathogen Ralstonia solanacearum."";
RL   Nature 415:497-502(2002).
CC   -!- FUNCTION: Part of the high-affinity ATP-driven potassium transport (or
CC       Kdp) system, which catalyzes the hydrolysis of ATP coupled with the
CC       electrogenic transport of potassium into the cytoplasm. This subunit
CC       acts as a catalytic chaperone that increases the ATP-binding affinity
CC       of the ATP-hydrolyzing subunit KdpB by the formation of a transient
CC       KdpB/KdpC/ATP ternary complex. {ECO:0000255|HAMAP-Rule:MF_00276}.
CC   -!- SUBUNIT: The system is composed of three essential subunits: KdpA, KdpB
CC       and KdpC. {ECO:0000255|HAMAP-Rule:MF_00276}.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane {ECO:0000255|HAMAP-
CC       Rule:MF_00276}; Single-pass membrane protein {ECO:0000255|HAMAP-
CC       Rule:MF_00276}.
CC   -!- SIMILARITY: Belongs to the KdpC family. {ECO:0000255|HAMAP-
CC       Rule:MF_00276}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AL646052; CAD16881.1; -; Genomic_DNA.
DR   RefSeq; WP_011003265.1; NC_003295.1.
DR   AlphaFoldDB; Q8XU10; -.
DR   SMR; Q8XU10; -.
DR   STRING; 267608.RSc3384; -.
DR   EnsemblBacteria; CAD16881; CAD16881; RSc3384.
DR   KEGG; rso:RSc3384; -.
DR   PATRIC; fig|267608.8.peg.3436; -.
DR   eggNOG; COG2156; Bacteria.
DR   HOGENOM; CLU_077094_2_0_4; -.
DR   Proteomes; UP000001436; Chromosome.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0008556; F:P-type potassium transmembrane transporter activity; IEA:InterPro.
DR   HAMAP; MF_00276; KdpC; 1.
DR   InterPro; IPR003820; KdpC.
DR   NCBIfam; TIGR00681; kdpC; 1.
DR   PANTHER; PTHR30042; POTASSIUM-TRANSPORTING ATPASE C CHAIN; 1.
DR   PANTHER; PTHR30042:SF2; POTASSIUM-TRANSPORTING ATPASE KDPC SUBUNIT; 1.
DR   Pfam; PF02669; KdpC; 1.
DR   PIRSF; PIRSF001296; K_ATPase_KdpC; 1.
PE   3: Inferred from homology;
KW   ATP-binding; Cell inner membrane; Cell membrane; Ion transport; Membrane;
KW   Nucleotide-binding; Potassium; Potassium transport; Reference proteome;
KW   Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..204
FT                   /note=""Potassium-transporting ATPase KdpC subunit""
FT                   /id=""PRO_0000197004""
FT   TRANSMEM        21..41
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00276""
SQ   SEQUENCE   204 AA;  20754 MW;  67482B498D4A4594 CRC64;
     MATTTQPAHA EAPQQGGLLR AALVIFVGLS LVTGVLYPVV VTGIGKAAFP AQAGGSIIER
     GGKPVGSALI GQNFSEPQYF WGRLSATSPN PYNGAASSGS NLGPSNPALT DAAKARIAAL
     KEADPANTAP IPVDLVTASA SGLDPHISPA AAAYQVERVA RARHLPVERV KTLVAEHTTA
     PILGVFGEPV VNVLELNLGL GDLK
//
",27031
ATCTTC TCTTCG CTTCGT TTCGTG TCGTGG CGTGGA GTGGAT TGGATG GGATGG GATGGC ATGGCC TGGCCT GGCCTG GCCTGT CCTGTG CTGTGG TGTGGG GTGGGC TGGGCC GGGCCC GGCCCT GCCCTG CCCTGC CCTGCT CTGCTG TGCTGC GCTGCT CTGCTG TGCTGC GCTGCC CTGCCG TGCCGA GCCGAT CCGATC CGATCA GATCAT ATCATC TCATCA CATCAT ATCATC TCATCT CATCTT ATCTTG TCTTGG CTTGGT TTGGTG TGGTGG GGTGGG GTGGGC TGGGCC GGGCCT GGCCTG GCCTGC CCTGCG CTGCGC TGCGCA GCGCAG CGCAGT GCAGTG CAGTGG AGTGGC GTGGCA TGGCAT GGCATC GCATCT CATCTT ATCTTC TCTTCA CTTCAC TTCACC TCACCG CACCGC ACCGCG CCGCGA CGCGAC GCGACC CGACCG GACCGA ACCGAG CCGAGG CGAGGC GAGGCT AGGCTG GGCTGG GCTGGC CTGGCG TGGCGT GGCGTG GCGTGG CGTGGT GTGGTG TGGTGG GGTGGC GTGGCC TGGCCG GGCCGT GCCGTG CCGTGG CGTGGT GTGGTC TGGTCT GGTCTA GTCTAC TCTACG CTACGC TACGCC,2,106,C TG C TCGC CTTTT T C CTCTTTTCTC C T TTTTCTCGCG  TCTCGCGTTTCT C CGCGTGTGTG G G GTT TG T TGGGAGA A G GGGGAGAT GTT GGATATGG A ATATGTGGG TTGGGGCC GCCTAC GGTC G GCGCCCCTCT T C CCCCTTG  CTCTGGAGG GGTGCCGG GAT GTGTGGGG G T TGTGGGGGGG G GGGGGC GTG GGGGCGCCCC C G GCGCCCCCCC  CCCCCCCTT C CCCCTCTGTG A C CTCTGTGCTCTC T TGTGCGCTCT T GAGGGCTCTGTG G C CTCT GGTGC GT  TGGCTCT T G GCTG CTGTG  CTCTGTGC CAATC TGCCGCC C G GCGCCCCGCG G C CCCCGCGACC C ATCTGATAT T G GAGATG CTC C AATCATCTCACA A T TCTCACATT CCATATCTCTGGC ATATCTCACA A TGCTCATTCAAT  CACAT ATTC C A ATATCTCTCT T T TCTCTCTTTT T C CTCTTTTGTG G T TTTTGTGGGG G T TGTGGGGTATCT G GGCTGGTGTG GG  GTGTGTGGGG G T TGTGGGGGGG G G GGGGG CGGC C G GGGGCGCCA C GCCCTCT T CTC  GGCTGTG G C CTCTG GGGC C T TGTGCGCGCG G G GCGCGCGCGC C CGGCCGCGT CA A G GCCAGCACG C CACAGGACGT T A AGAGT TCG G GTTGGGG G T TGTGGGGCGCCC G GGC AGCACA A G GCGCACATAT T CGC GTGATCTC C A ATGT CGACT T T TC CCCTTTT T C CTCTTGT TC C T TTTTCTCACA A T TCTCACACAC C C CAGCAACCC A ACACCCCGCG  CCCCGCGCGC  CGCGCGCGCG G G GCGGTGA TCT CGCGAAC C G GAC GACCCC  CG ACACCTG CG G C CCGCCCGACTA CGTGGAG G GGT  GCGG G A AGGGCGC C G GGGGCGCTCT T G GCGCTCTGTG ATC CTCTGTGGGG G T TGTGGGGCGC GAC GGGGCGCGCG G GCGT CCT C CGGTGTG CCGCATTGGG T TGTGGCGAC TT G GGGGTGTGTG G G GTTGGGG G T TGTGGGGCGC C G GGGGCGCCCC C G GCGC CCGCG G CGT G GCGTGCCT C CGCGTGTGCGTG G GTC GTGGGG G T TGTGGTGCT G GGCC GTCTC C G GTGTCCT T T TCTCTGGTTA A C CTCTAG AGGCC T TATACACGCG TAC ACACGCGCGC C C CGGCC,ATCTCTTT T TTCTCTTTTCTC C C CTTTCCG G T TTT TC GGT  GC TCTCGCGTGTGTG G A CGCCCTGGGG G G GTGTGTGGGGAGA A TTGGGGA GCAT T G GGGGAGATATGGCTG G CCGAT GGTGGGG G A ATATGTGGGGCGC GC  TG GTGGCGCCCC C G GGGGCGCCCCTCT T G GCGCCCCTTG G C CCCCTTGTGT T C CTTGTGTGTG G T TGGTGTGGTC  GTTGGGGG GTG T TGTGGGGGGGCGC C G GGGGGGGC TCCC C GGGCGCCCCCCC CGT GCGCCCCCCCTCT T C TGTT CTGTG G C CCCCTCTGTGCGC C CCTGTGCGCTGAGT T TGTGCGCTCTGTG G G GCGCTTGCGAGC C CTCTGTGCGCTT TT T GATGCGCTTGGTG G G GCG GCTGTGCGC C CTGGCTGTGCGCCCGCC T TGGCCCCGCG G GGATCCGCGAGA A C CCATCCGAGCCAT T CCGAGATATCTC C GA GGATATCTCACA A A ATATCTCACATAT CT  TCTCACATATCTC C C CACATTCTTCACA A ACTTATCTTGCATT CT T TCTCACATATCC CCATATCTCTCT T A ATATCTCTCTTGTGT T TCTCTCTTTCATG G C CTCTTTTGTGGCATG T TTTTGTGGGT T T TGGGTGTGTG  GGGGTTGGGC G G GTGTGTGGGGGGG G T TGTGGGGGGGCGC CTG GGGGGGGCGATCC C G GGGCCCCT GAT G GCCCTCTGTG G C CCCCTCTGTGCGC C C CTCTGTGCGCGCG G TTG ACC GACGCAG C GT TGCGCT GCATACA C CGCGCGCACAGGC G G GCCAGAGTGT T C CACAGAGTCGA TGG CAGTGCCGG G G GTGTGTGGGGCGC C T TGTGGGGCGCACA  GGGGCGCACATAT T G GCGCACATATCTC CGC CAGG CCGTCTCT T A ATATCTCTCTTTT GCG TCATC ATTTCG G CTCTTTTCCA A T TTTCAGCTAC C T TCTCACACACCC C CACACTACCCGCG G AACCCCGCGCGC C C CCCCGGGCCG G C CGCGCGCGCGCGA A GGAGCGAGACAC C C CGGTGGACACCGTGC GCT TGCCCGCG G A CGACCGG CGAGA A C CCCCGCGAGCGG C CGGGCGG G GAGGGGCGC C A AGAGGGGCCT  GGGGCCACC CTG  GCGCTCTGGG G C CTCTGTGGGC C T TGTGGGGCCG G GG GGGCCGTGT T GC CGCGCGTGTGTG G CGGTGTGCGTCCG GGGTGTGGCGTGT TTC TGTGGGGTCC TG G G GGGGTGTGGG TG  GTGTGTGGC TC TCG C GT TGCCCCGCG G G GCGCCCCGCGTGT AT  CCCCGCGTGTGTG G C CGCGTCTATGGGG G G GTGTGTGGGGTGT T TGG TGGGGTGTCTC C GATGGGTGTCTCTCT T GGTCTCTCTATA A T TCCTAGG  CTGTGCA ACGCC G TTACAC CGC TGC A ACACGCC GCC,GTGTCTG CTTCTC C T TCTCTCTTTTCTCGCG G C CTCTTTTCTCGT T TTTTCTCGCGTGTGTG  TCTCGCGTGTGTGGGG G CTGCCGTGTGTGGGA GTC GTGTGTGGGGAGATAT T T TGTGGCC TGGATGTG G GGTGGATATGTGGGGGG G GAGATATGCTTGGCGC C A ATTGGGGC ATT CC T TGGATGCCCCTCT ATCGGCGCCCCTCTGTG  GCCCTCTGTGTGT T C CCCTGTGTGTGTG G CTCACTGTGTGTGTGGGG G T TGTGTTGGGGGGG G GC TATCTGGGGGGGCCTTC T TGTGGGGGGATGCCCC C G GGGG GGCCCCCC C G GGGGCGT CCCCCTCT T GGCCCCTCTGCCGG C CCCCTCTGTGCGC C C CCCCTCTGTGCGTGCT CC  CTCTGTGCGCTCTGTG G T TGTGCGCTCTGTGCGC C GGTGGCTCTGTGCCACCT T C CTTGCGCT CGG T TGTGCGCTCTGGC C G GCGCTCTGTGCGCCCC G A CTCTGTGCGCCCCGCG G T TGTGCGCCCCGCGAGA A G GCCTTCCGCGAGTGAT T C CCCCGCGAATCTC CTGTGGGGC GG GCG G GAGATATCTGGCT AT T A ATATCTCA GTATCTC GCC TCTCACATATCTCA GG CACATATCTCAAT T AGCCATCTCACATATCTC CTTTCACATATCTCTCT T CG CCATTCTGCCT A ATATCTCT TCTTGTG G T TCTCTCTTTTG GAGG G C CTGC CCGTGGGGTGCCT T TTTTGTGG GGTG G T TGGCGGGTGTGTGGG GGGTGTGTGGGGGGG G G GTGTGGC C TCGATGGGGGGGCGCCGCCC GGGGGGCGCCCCTCT GAG GGGGCGCCCCTCTGTG G G GCGCCCCTCTGACCGC C C CCTT C TTGCGCGCG G C CTCTGCGTGCGCGCGC C T TGTGCGCGCGCGCACA A G GCGCGCGCGCACAGG C GGCGCGCATACAGTGT T G GCAGTGTGTG G C CATCTAGTGTGTGGGG C C AGAGTGTGTGG GTGTGTCAGCACA A T TGTGGGCACATAT  GGGGCGCACATATCC GA GCATCA TCTCATT C CACATT GTCTCTTTT T A ATATCTCTCTTTTCTC G CC TTCTCTTTTC CTATCA C CTTGGTTCTCACACAC C T TTTTCTCACAC CGGGATGG TCTCATGGCCGCG G C CAGCTACCTTGCGCGC C A ACACCGCTGTGGCGCG C T CCCCGCGCGCGCGAGA A CTGG TG GTAC C G GCGCGCGAGACACCCC C C CGCGAGACCCTTG CG CA  GAGACCATCCGCGAGA CCT ACACCCCGCGAT GAG  CCCCGCGAGAGAGGGG G C CGCGAGAGAGGGGCGC TGGGAGAGGGCTCTG AGAGGGGCCCGCTGTG G G GGGCTCTGTGGGG GGCGCTCTGTGGGC C CT ATGGGGCGCGCG G T TGTGGGGCGCGCGT GCTGGTG GGCCGTGCTATCG GGG GCGCGTGTGTGGGG G C CGCGCTGGGGTGT T GGTGCACGGTACGG T TGTGGGGT GCTCAG GA CGGTGTGC TGGCC G GTTGCGGCGCCCC C TTGG GCGCCCCGCG G G GGGGCGCCCCGCGTGGTT G GCCC CCGCGTGTGTG  CA CCCCGTGCGTGCGAGG G C CGCGTGTGTGGGGTGT T G GTGTGTGGGT  GCTC CTG TGT GGGTGTCTCTCT  GGGGTGTCTCTCTATA A G GTGTCTCTCTATACAC CAG TCC TCTATACACGCG G C CTCTAACGCGC TC TATACGATC T,ATCTCTCTTTTC GACG  TCCTGCTTTTCT TCGTGT T C CTCTTTTCGTGCGTGTGTG G T TTT TTCGCGT TGTGGGG G T TCCGTGTGGGAGA A C CGCGTGTGTGGGGAGATAT  GC GTTGCTGGGGAGATATGTG G T TGTGGGGA CTATGGCCCG TG  GGC GATGGGCGC C G GAGATATGTGGGGCCC C A ATATGTGGCCCTGCCCTCT  TGTGGTGGCCTCTGTG G G GGGGCGCCTGT CAT G GCGCCATCCTGTGTGTGTG  CCCCTGATTGTGTGG C CTCTGTGTGTGTGGGG G T TGTGTGTGTGGGGGGGCG CC GTGGGGGGGCGCC TGC T TGTGGGGGGGCGCC GGCC  GGCCCGGCTACCCCCCTTGCT GTTCTGGGCCGGGCG CTGG G GCCCCCCTCTGTGCGC  CCCCCCAGCTGCT CAGCT T C CCCCTCTGGCTCTGTG GGT CTCT TGCGCTCTGTGCCG C TGCCTGCACCCTGTGCAGTCT T G GCGCTGTGTGGCTGTG G C CTCTGTGCGCTCTGTGCGC  TGTGCGCTCTGTGCGTGTGG GCGCTCTGTGCCCGCG G C CTCTGTCGGCCTCTCGAGA A T TGTGCGC CCGCGAGATT G GCGCCTCTCGAGATATCC C CCCCGCGACTGATCTCACA A CCGAG AGACTCATC AT T GTGCGATATCCAT GGTC C A ATATCTCACATATCTTGA T TCTCACATATCTCACGTTGGT CCACCATATCTCACATATCC AGT ATCCGCCATTCTTCTCT T T TCTCACATATCATCCTT GC CACATTCTCTTTG GAT ATCCGCTTTTGTGGGG G T TCTCTCTTTCAAT GGTGT  CTCTTTTGTGGGGTGTGG T TTTTGTGGGGTTGGGG G TTGGGGTGTGTGGGGGGG G G GGGGTGTGTGGGGGGGCGC GTGTGGGGGGGCCGACC C T TGGGGGGCGCCCCTCT T GGGGGGCGCCGCCCTGG GG G GGGGCGCCGCCCTGTGCGC  GCCCTTGCGCGCCTGC  CCCCTCTGGCGCGCGC C C CTCTGCCTTGGCGCGCAGTCA T TGTGCGCGCGCGCACAGAG G GT GGCGTCAGCAGCTGCTGT T C CGCGCGCACAGAGTGTGTG G G GCGCACAGAGTGTGTGGTCTG C CACCTAGTGTGTGGGC C A AGAGTTCGGGCGCAATCA GGTGTGGGGCGCACATAT T T TGTGGGGCGCACATTC GGA GGCGCGCACATATCTCTCT T GGCACATATCTCTCTTTT T CCAT CCCCGCTTG GCATC A ATTCTCTTTTCTCACA A T TCTCTCTTTTCTCACACAC C C CTCTTTTCTCAACCCC  TT GGTCAG GACCCCGCG G T TCTCAACCCCGCGCGC CACACCCCGCGCGCGCACG A ACACCCCGCGCGCGCGAGA A C CCCCGGGCCGAA GCGCGCGCGAGCGACCCC C GGGTGCGCGAGACGCTCCGCG G C CGCGAATCACCCCGCGAGAC GAGACACCCCGCCTGAGAG G A ACACCGCCCGAGAGAGGGG G CGGGCCGCGAAGGGGCGC C CCGAGAGAGGGGCGCTCT T G GAGAGAGGGGCGCTTCTTG GCC AGGGCGCTCTGTGGGG GT GGCGGCGCTCTGTGGGGCGC C G GCGCTCTGTGGGGCTGGGC G CGATCTGTGGGGCGCGCGTTCGT T TGTGGGGCGCGCGTGTGTG TTCG AGGCGCGCGTGTGGGCGG G G GCGCGCGTGTGTGGCTGGT T C CGGTGTGG GCGTGTG G G GTGTGTGGGGTGTGGG G TGACGGTGTGGCTGGCGC C G GGGGTGTGTGGCCGCC C G GTGTGGGCGCCCG G T TGTGGGGCCCGCATGT T G GGGGCCCGTGCG GTG TT GCCCCGCGTGTGGG G C CCCCGGTGGGTGT T C CGCGTGTGTGGGGTGTCC G GTGTGTGGGGTGTCTCTCTG ATCC TGGGGTGTCGG TA A G GGG CCA TCTCTATACAC C G GTGTCTCTCTAGCCGG G T TCTCTCTATACACGCGCGCCC C CTCTATACACGCGCGCC,"ID   YIAN_ECOLI              Reviewed;         425 AA.
AC   P37675; Q2M7P1; Q6BF20;
DT   01-OCT-1994, integrated into UniProtKB/Swiss-Prot.
DT   11-OCT-2004, sequence version 2.
DT   05-FEB-2025, entry version 155.
DE   RecName: Full=2,3-diketo-L-gulonate TRAP transporter large permease protein YiaN;
GN   Name=yiaN; OrderedLocusNames=b3578, JW5651;
OS   Escherichia coli (strain K12).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Enterobacterales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=83333;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=8041620; DOI=10.1093/nar/22.13.2576;
RA   Sofia H.J., Burland V., Daniels D.L., Plunkett G. III, Blattner F.R.;
RT   ""Analysis of the Escherichia coli genome. V. DNA sequence of the region
RT   from 76.0 to 81.5 minutes."";
RL   Nucleic Acids Res. 22:2576-2586(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=9278503; DOI=10.1126/science.277.5331.1453;
RA   Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,
RA   Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,
RA   Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J., Mau B.,
RA   Shao Y.;
RT   ""The complete genome sequence of Escherichia coli K-12."";
RL   Science 277:1453-1462(1997).
RN   [3]
RP   SEQUENCE REVISION.
RX   PubMed=16397293; DOI=10.1093/nar/gkj405;
RA   Riley M., Abe T., Arnaud M.B., Berlyn M.K.B., Blattner F.R.,
RA   Chaudhuri R.R., Glasner J.D., Horiuchi T., Keseler I.M., Kosuge T.,
RA   Mori H., Perna N.T., Plunkett G. III, Rudd K.E., Serres M.H., Thomas G.H.,
RA   Thomson N.R., Wishart D., Wanner B.L.;
RT   ""Escherichia coli K-12: a cooperatively developed annotation snapshot
RT   -- 2005."";
RL   Nucleic Acids Res. 34:1-9(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=16738553; DOI=10.1038/msb4100049;
RA   Hayashi K., Morooka N., Yamamoto Y., Fujita K., Isono K., Choi S.,
RA   Ohtsubo E., Baba T., Wanner B.L., Mori H., Horiuchi T.;
RT   ""Highly accurate genome sequences of Escherichia coli K-12 strains MG1655
RT   and W3110."";
RL   Mol. Syst. Biol. 2:E1-E5(2006).
RN   [5]
RP   PRELIMINARY FUNCTION.
RC   STRAIN=K12;
RX   PubMed=14668138; DOI=10.1080/09687680310001607369;
RA   Plantinga T.H., van der Does C., Badia J., Aguilar J., Konings W.N.,
RA   Driessen A.J.M.;
RT   ""Functional characterization of the Escherichia coli K-12 yiaMNO transport
RT   protein genes."";
RL   Mol. Membr. Biol. 21:51-57(2004).
RN   [6]
RP   DELETION STUDIES.
RC   STRAIN=K12;
RX   PubMed=15870475; DOI=10.1099/mic.0.27851-0;
RA   Plantinga T.H., van der Does C., Tomkiewicz D., van Keulen G.,
RA   Konings W.N., Driessen A.J.M.;
RT   ""Deletion of the yiaMNO transporter genes affects the growth
RT   characteristics of Escherichia coli K-12."";
RL   Microbiology 151:1683-1689(2005).
RN   [7]
RP   FUNCTION.
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=16385129; DOI=10.1099/mic.0.28334-0;
RA   Thomas G.H., Southworth T., Leon-Kempis M.R., Leech A., Kelly D.J.;
RT   ""Novel ligands for the extracellular solute receptors of two bacterial TRAP
RT   transporters."";
RL   Microbiology 152:187-198(2006).
CC   -!- FUNCTION: Part of the tripartite ATP-independent periplasmic (TRAP)
CC       transport system YiaMNO involved in the uptake of 2,3-diketo-L-
CC       gulonate. {ECO:0000269|PubMed:16385129}.
CC   -!- SUBUNIT: The complex comprises the extracytoplasmic solute receptor
CC       protein YiaO, and the two transmembrane proteins YiaM and YiaN.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane {ECO:0000305}; Multi-pass
CC       membrane protein {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the TRAP transporter large permease family.
CC       {ECO:0000305}.
CC   -!- CAUTION: Was originally proposed to be a subunit from an L-xylulose
CC       uptake system, but PubMed:16385129 shows that it does not bind L- or D-
CC       xylulose. {ECO:0000305|PubMed:14668138}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAB18555.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U00039; AAB18555.1; ALT_FRAME; Genomic_DNA.
DR   EMBL; U00096; AAT48194.1; -; Genomic_DNA.
DR   EMBL; AP009048; BAE77715.1; -; Genomic_DNA.
DR   PIR; S47799; S47799.
DR   RefSeq; WP_000279599.1; NZ_SSZK01000041.1.
DR   RefSeq; YP_026232.1; NC_000913.3.
DR   AlphaFoldDB; P37675; -.
DR   SMR; P37675; -.
DR   BioGRID; 4262549; 11.
DR   ComplexPortal; CPX-4681; YiaMNO tripartite ATP-independent periplasmic transporter complex.
DR   STRING; 511145.b3578; -.
DR   TCDB; 2.A.56.1.2; the tripartite atp-independent periplasmic transporter (trap-t) family.
DR   PaxDb; 511145-b3578; -.
DR   EnsemblBacteria; AAT48194; AAT48194; b3578.
DR   GeneID; 75204654; -.
DR   GeneID; 948092; -.
DR   KEGG; ecj:JW5651; -.
DR   KEGG; eco:b3578; -.
DR   KEGG; ecoc:C3026_19400; -.
DR   PATRIC; fig|1411691.4.peg.3134; -.
DR   EchoBASE; EB2190; -.
DR   eggNOG; COG1593; Bacteria.
DR   HOGENOM; CLU_019824_4_1_6; -.
DR   InParanoid; P37675; -.
DR   OMA; RMTAFVG; -.
DR   OrthoDB; 8627919at2; -.
DR   PhylomeDB; P37675; -.
DR   BioCyc; EcoCyc:EG12282-MONOMER; -.
DR   BioCyc; MetaCyc:EG12282-MONOMER; -.
DR   PRO; PR:P37675; -.
DR   Proteomes; UP000000318; Chromosome.
DR   Proteomes; UP000000625; Chromosome.
DR   GO; GO:0016020; C:membrane; NAS:ComplexPortal.
DR   GO; GO:0005886; C:plasma membrane; IDA:EcoCyc.
DR   GO; GO:0031317; C:tripartite ATP-independent periplasmic transporter complex; NAS:ComplexPortal.
DR   GO; GO:0015144; F:carbohydrate transmembrane transporter activity; IDA:EcoCyc.
DR   GO; GO:0022857; F:transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0034219; P:carbohydrate transmembrane transport; IDA:EcoCyc.
DR   GO; GO:1902075; P:cellular response to salt; NAS:ComplexPortal.
DR   GO; GO:1900190; P:regulation of single-species biofilm formation; NAS:ComplexPortal.
DR   InterPro; IPR010656; DctM.
DR   InterPro; IPR004681; TRAP_DctM.
DR   NCBIfam; TIGR00786; dctM; 1.
DR   PANTHER; PTHR33362:SF4; 2,3-DIKETO-L-GULONATE TRAP TRANSPORTER LARGE PERMEASE PROTEIN YIAN; 1.
DR   PANTHER; PTHR33362; SIALIC ACID TRAP TRANSPORTER PERMEASE PROTEIN SIAT-RELATED; 1.
DR   Pfam; PF06808; DctM; 1.
DR   PIRSF; PIRSF006066; HI0050; 1.
PE   3: Inferred from homology;
KW   Cell inner membrane; Cell membrane; Membrane; Reference proteome;
KW   Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..425
FT                   /note=""2,3-diketo-L-gulonate TRAP transporter large
FT                   permease protein YiaN""
FT                   /id=""PRO_0000169598""
FT   TRANSMEM        3..23
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        54..74
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        93..113
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        139..159
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        170..190
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        209..229
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        235..255
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        277..297
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        314..334
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        355..375
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        399..419
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
SQ   SEQUENCE   425 AA;  45368 MW;  4A90B9E035B1C98A CRC64;
     MAVLIFLGCL LGGIAIGLPI AWALLLCGAA LMFWLDMFDV QIMAQTLVNG ADSFSLLAIP
     FFVLAGEIMN AGGLSKRIVD LPMKLVGHKP GGLGYVGVLA AMIMASLSGS AVADTAAVAA
     LLVPMMRSAN YPVNRAAGLI ASGGIIAPII PPSIPFIIFG VSSGLSISKL FMAGIAPGMM
     MGATLMLTWW WQASRLNLPR QQKATMQEIW HSFVSGIWAL FLPVIIIGGF RSGLFTPTEA
     GAVAAFYALF VATVIYREMT FATLWHVLIG AAKTTSVVMF LVASAQVSAW LITIAELPMM
     VSDLLQPLVD SPRLLFIVIM VAILIVGMVM DLTPTVLILT PVLMPLVKEA GIDPIYFGVM
     FIINCSIGLI TPPIGNVLNV ISGVAKLKFD DAVRGVFPYV LVLYSLLVVF VFIPDLIILP
     LKWIN
//
",33282
TTCTTC TCTTCG CTTCGG TTCGGA TCGGAA CGGAAT GGAATG GAATGT AATGTC ATGTCG TGTCGC GTCGCG TCGCGC CGCGCA GCGCAT CGCATT GCATTG CATTGG ATTGGC TTGGCA TGGCAT GGCATG GCATGG CATGGA ATGGAA TGGAAG GGAAGT GAAGTC AAGTCA AGTCAC GTCACA TCACAC CACACC ACACCT CACCTT ACCTTC CCTTCG CTTCGG TTCGGG TCGGGA CGGGAA GGGAAC GGAACG GAACGT AACGTG ACGTGG CGTGGT GTGGTT TGGTTG GGTTGA GTTGAC TTGACC TGACCT GACCTA ACCTAC CCTACA CTACAC TACACA ACACAG CACAGG ACAGGT CAGGTG AGGTGC GGTGCC GTGCCA TGCCAT GCCATC CCATCA CATCAA ATCAAA TCAAAT CAAATT AAATTG AATTGG ATTGGA TTGGAT TGGATG GGATGA GATGAC ATGACA TGACAA GACAAA ACAAAG CAAAGA AAAGAT AAGATC AGATCC GATCCA ATCCAA TCCAAA CCAAAT CAAATT AAATTT AATTTC ATTTCA TTTCAA TTCAAA TCAAAG CAAAGA AAAGAT AAGATC AGATCA GATCAA ATCAAG TCAAGT CAAGTC AAGTCA AGTCAT GTCATT TCATTT CATTTT ATTTTG TTTTGC TTTGCT TTGCTG TGCTGA GCTGAA CTGAAT TGAATA GAATAA AATAAG ATAAGC TAAGCA AAGCAT AGCATA GCATAT CATATT ATATTG TATTGA ATTGAC TTGACG TGACGC GACGCA ACGCAT CGCATA GCATAC CATACA ATACAA TACAAA ACAAAA CAAAAC AAAACA AAACAT AACATT ACATTC,1,145,TTCTCTCT T TT CTCTCTTGATT C CT ACAT TG C T TTTTCTCG AAG T TCTCGCGGGG G C CGCGGGGAGA A G GGGGAGAAAA A G GAGAAAATAT  AAAATATGG AG AGT TGTGT T T TGTGTGTCATTC GA C AACG G T TCTCGCGCGC C C CGCGCGCGCG T G GCGCGCGCGC C C CGCGCGCACA A G GCGCACATAT C A ATCATCT TT T A ATATTTTGTG G T TTTTGTGGGG G TGGCGC C G GGGCCGCACA A G GCGCAATAAT T CCATATGTG G A ATATGTGGGG  AT TGTGGGGAGA A G GGGGAGAAAA A G GAGAAAG G A AAAGAAGTATGT A CCAGTGTCTC C GAT CA A T TCTCACACAC C CA ACA A A ACACACACAC C CACCT TC A ACTCAT C CCCCTCTTTT  TC CTCTTC TTC C T TTTTCTCGCG G T TCTCGCGG CGCGGGGGGG GG  GGGGGGA A G GGGGAGAAAA A G GAGAAAACAC  AAAACACGCG G A ACACG ATG T CGCGTGTGTG G G GTGTGTGGGG GT TGGGGTGT T G GGCA AAGTT T G GTGTTTTGTG C A TT TGTGAGA A T TGTGAGACAC C G GAACCCC CTAACCCCTAATT C CCCCTCTA AT CT ACTACAC C T TATACACACA A A TTATACACAC C C CACACACACA ACA ACACACAGAG G C CACAGG AAGGGGTGT T G GGGGTGTGC T GTT ATGCGC  TGTGCGGC TA GCGCCCCACA A CATGCCACATAT T C CAACAATCTC CT  ATATCC ACA A T TCGATCAAAA A C CACAAAAAAA A A AAAAACT AG T A AATA ATTTT GTGCATTTGGACG T TTTTGA CGG G T TGTGGGGAGA A G GGGGATCATTCT G GAG ATG G A ATATGTGAAATCAA TGTGAGACAC C G GAGACG ACA AAA ACGTCCAAAA  GT CAAAAAAAA A GT AAAAAGCAAT G A AAAAGAAGGA A A AGAGAGATG GGATTC C A ATATCTCCCC C TTCCCCA CCCCACAAAA A C CACAAAAA TTAAAAATT A AA TGATTTT T AATTTTTTT T T TTTTTTTCTC TGA TTTTCTCACA A T TCTCAAA A C CACAACC AA A A AAAAAGTTAG G TGTCAAGAGAGA GCA AGAGATT AT T G GAGATATCTC G T ATATCTCACA  TCTCAAA A C CACAAAAGAG G A AAAAGAGTGT T AACATC  GTGTCTCAGGTA T TCTATCATAT CATATTTT T ATA ATTTTTTT T T ACTTTTTTTT CC  TTTTTTTGTG A T TTTTGTGCGC C TAATTGCATTT G GCCTGTG G C CTCTGTGAGA G T TGTTCGAAAA A G GAGAAAATA AT A AAAATATATA  CAATATAAAA A TA ATCGAAGAG A G AAAAGAGCGC  AG AAGCA AG GCA ACATAT  CAATTACAGA A A ATTATAT AAA TATCAATTTT T A ATTC CATTG G TAA TTGTGAGA A T TGTGATC AC C G GAGACACGCG ACACTTACGCGCGC C C CG GCA GCGCAAGCATAT T C CACATCATTA A ACGTATATACAC C T TATACACACA A A ACCATA C CACAAAAAAA CG T TA ACAAAACAC T C AAACACA A A ACACATTGAT T C CACATTT  ATATTTTC,TTCCTTTT GGA TCTCTCTTTTCTC CTT CTCTTTTCTCGACAG T TTTTCTCGCGGACAG T TCTCGCGGGGAGA A C CGG GGAAAA A GT TGGAGAAAATAT CGG GAGAAATGG A AAAATATGCAA ATATGAG GTCTC C T TGGTCTCGCG G GTCAGTCTCGCGCT T TCTCGA AGCGCG G C AAACGGCGGCAGCGCGCAAGCA  CG GCCG CGTAT T G GCGCACATATTTT CATCATATTTTGTG G A ATATTTGGGG G T TTTTGTGGAG GC C T TGG AGGCGCACA A G GG TAGCAAT  AAC T GCCATATGTG G C CACATTGGGG G A ATATGTGGC TGA  TG TGTGGGGAGAAAA  GGGGAGAAAAGG G GAATTAAGAGTGT T A AAAAGAGTGTCC A AGGTCTCACA A G GTT TTCACACAC C T TCTCACACACACA A C CACACACACACAC C AACACACACCCC C CAGTACCCCTCT  ACACCCCTTT T C CCCCTCTTTC C CC CCA AGTG TTTCGG G T TCCGGGGGGG AAG CGCGGACAGA A G GGGGGGGAAA A G GGGGAGAAAACAC C G GAGAAAACACGCG G AT GAACCGCCGTGT T A ACACGCGTAGCTG C C CGCATGTGG AGG G G GTGTGTGGGGTGT T TA TTGGGGTGTTTT T G GGTT GTTTTGTG G G GTGTTTTGTGAGA A T TTTTGTGAGACAC C T TGTGA GG ACCC C G GAGACACCCCTTGCT A ACACCCCTCTATA A C CCCCTCTATACAC C C CTCTATACACACA  TATACGG CACAC T GACACACCA  CACACATACAGACGG A ACCG CAGAGGGG G C CACAGAGGGCAGT  AGAGGCATGTGTG G G GGGGTGTGTGCGC C G GTGTGCT GCCAT C T TGTGCGCCA TCA A G GCCCAAT A A CCCCACATT ATC G C CACATATCTCACA TTG ATCAAAA CAAAA A T TCTCACAAAAAAA TTTCAAAAACC T A AAGTCAATATTTT T A AAAATATTTTGTG TGG ATATTAATTGGGG G T TTTTGTGGGGAGA A TGGAGATAT T GGACGGAGATATGTG GGA GAGATATGA A ATATGTGAGACGGGC T TGTGA ACACACA A GAA AA CAC GAA A ACAAAAA A C CACAAAA GGCA A AAAAAGGTAGAGA A AAAG AAGATAT T A AGGATATCTC C G GAGATATCTCCC A ATATCTCCA T TCTCCCCACAAGACGGTCCACAAAAAAA A C CACAAAAATTGT A CGAAAATTTT  AAAATGAATTTT A ATATTTTTTTCTC  GCTTTTTCGC CA A TTGCTTCTCA GAAA  TT TCTCAAAAAA A C CACAAAAAAAGAG G AAAAAAGAGAT AA A AAAAGAGAAT T A AGAGAGATATCTC C G GAATCTCATGTA A ATACAATCAA A T TCTCACAAAAGAG G C CACAAAAGAGTGT T A AAG CTC C A AGCAAGTC GTCA A GTCACATAT T T TCTCACATATTGGTT CTG CATATTTTTTT T A ATATTTTTTTTTT T T TTTTT CATTGTG G T TTTTTTTGTGCGC  TTTTG TTGCTCT AAA TGTGCGCTCTGTG G G GCCTGA C CTCTGTGAGAAAA A T TGC GGAAAATAT T GCAAGAAAATATATA A ACGCTGTTAAA A ATATATAAAAGTGT TAAAGAGCGC C AAAGGCACA A A AGGTGCATAT AATA CCATATAATTA C CACATATATATAT T A ATATATATATTTT  GGTATATTTG TGG ATTTGTGACCA TTTTGTGAGACAC C T TGTGAGACACGCG G GGACAG TCAC ACAAACGCGCGCACA A C CGCGCGCACATCGCT G GCGCAT AATATA A C CACATATAAC C A ATATATACACACA A T TATACATCCAAAA CAT ACACACAAAAAAA A C CACAAAAAAAATCACGCAAAAAAAACAC C AAAAAACAC CA G AAGAAACACACATAT GA ACCACACATATTTT T C CAGCATA TTC,TCTCTTTTCTC AAA TCTCTCTTGCGTCGCG CGG CTCTTTTCTCGCGGGG G T TTTTCCGGG TA T TCTCGCGGCA GAAAA A C CGGGAGC AATAT T G GGGGAGAAACCATGTG G GCAGGAAAATCAGTGTGT T A AAAATATGTGTGTCTC C AGAAATGTGTGTCTCGCG  TGTGTGTCTCGAA GC C GGTTGTCTCGCGCGCGCG G T TCTCGGATGCGCAACGCTTCCGCGCACA A GGCGCGC ACCATT C CGCGCGCACATATTTT T G GCGCA CTAAATG G C CACATATTTTGTGGGG G A ATTTGTGGGGCC T TTTTGTGGT AGCACA A ATGGGGCGCACATAT T G GGGGCGCACATAAAG GGCACATATGTGGGG CCTGGTATGTGGGGAGA A A ATATGGGAGAAAA ATC TGTGGGGATC AAGAG G G GGGGAGAAAAGAGTGT ATC GA CTGTCAGTACATC CA  AAAAGAGTGTCTCATCAA A AGAGTGTCCACAC C G GTGTCTCACACACACA A TAG TCAATCCACAC C CA CCACACACACACCCC  CA ACT GCACA CCCTCT T C CACACACC TCCTTTT T A ACACCCCTCTTTTCC CGGAG CCTTTTCTCGCG G CCATCTTTTCTCG ACCAT TG TTTTCCGGGGGGG  TCTCGCGGGGGATTGA A C CGCGGGGGGGAGAACGCA GGGGGGAGAATTGAC C G GGAACACGCG G G GAGAAAACACGCGTGT T ATG AACCGTGTG AAG A ACACGCGTGTGTGGGG G C CGCGTGTGGGTGT T G GTGTGTGG GTTT T T TGTTGTG G G GGGGTGTTAC CAAGA ATC GTGTTTTGTGAGACAC C T TTCATTGAGACAATCC C T TGTCAACCCT T G GAATCACCCCTA A ACACCCCTCTAAGAAC C C CCCCTCTATACATGCA A CGAACTAA TACACACGTGC T TAAA CACACACA A AGCAACACACACAT GAG G C CACACACACAGAGGGG  ACACACAGAGGGGTGT  CA ATAGG CAAC G A AGAGGGGTGTGGC TGG GGGGTGTGTGCAGCC G GTGTGTGCGCCCCACA TT A ATGCGCCCCACATAT GCCCCACATTC  CCCCAT GGGATA  CACATATCTCAAA  ATTGGCA CAAAAAATAA T TCTCACAAAAAAATAT T CA CTGAAAAATTTT TGAAAAAATATTTTGTG G A AGAATATT ATTGGGG G A ATATTTTGGACGGAAGAA T TTTTGTGGATTCGCAT T T TGTGGGGAGATATGA A GGTGGGATATGGA A G GAGATATGTGAGACAC C A ATTGAGACACACA A T TGTGAACACAAACAA G GAGACACAAATC TAA A A ACACAAAAAAGAG G CGACTTGTAC AAAAAAAGAGAGATAT T A AAAAGAGAGATATCTC C AATTGATAAATCCCC C G GAGATATCTCCCCACA A AGGAATC TCCCAAA A TAAATCCCCACAAAAAACCCCAA TAATAT T C CACAAAAAAATATTTT T AAAAAATATTA T AAAATATTTTTTTCGAAC A ATATTTTTTTCCA A T TTTTTTTCTTTAA A T TTT ATCACAAAAATACA T TCATACAAACAAAGAG G C CACAAAAAAGAGA A A AAAAAAAGAGAGATAT TTG AAAAG TGGATA GTC C A AGGATATCCA A G GAGATATCTCACAAAA A T ATCACTCAAAGAG G T TCTCACAAAAGAGTGT T C CACAAAAGAGTAAGTC C A AAAAGAGTGTCTCAC A AGAGTGTCTCACATAT ACA GTGTCTCACATATTT T TCCAT CCTTTTT T C CACATTTTTTTTT T A ATATTTCATTTTTGTG G T TTTGCGC C T TTTTTTTGTGCGCTCT T T TTTTGTGCGCTCTGTG G T TGTGCGCTCTGTGAA G GCGCTCTGT A ATAA  CA CTCTGTG GAACAAAT T T TGTGAGAAAAT CAA G GAGAAAATTATAAGAA A A AAAATATATAAAAGTCCG A ATATATAAAAGGC C T TATAAAAGAGCGCAT CA A AATAA GCGCA AAAT TTC AAGCACATAA TA A G GCTCAGG TATAT T C CACATATAAACATTTT T A ATATATTGATTTTGTG G T TAGCATGAGA A AAACATTTTGTGAGACATAC T TTGGCACGG TAGATGACAACGC GAGACACGCGCGCACA A A ACCGCGCAAT CA  CGCGCGCACATTGGTA A G GCGCAATAAC  CACATTACACAA A GAATATACACACAAAA TAC TAGA ACACAAAAAAA A A ACACACAAAAAAAAAA A C CAAAATATAC C AAAAAAAAACACATTGA AAAAACACATAT T A AAACACAT AGTT T AG CACACATATTTTC,TTCTCTCTTTTCTCGCG G T TCTCTCTTTTCTCGCGGGG G C CTAATTTCTCGAGGGGAA AA TATC AATCGCGGG AGCAAA A T TCTCGGGAGAAAATAT GGA CG AAGGAAATATGTG G G GGGGAGAAAATATGTGTGT T G GAGAAAATATGTGTGTCTC TAT AAAATAAGTGTGTCTGGCG G ACTAATGTGTGTCCGCGC C TCA TGT ATTCGGA GCGCG G GGACGGCTCGCGCGCGCGCGC  TCTCGCGCGCGCGCCATATGA C CGCGCGCGCGCGG CATAT T G GCGCGCGCGCAT AATTTT T CATTCGCGCACATAC TTGG G GCGCACATCAATTGTGGG CCC CATATTTG AGGGGCC A AT GGTTGTGGGGCGCATTCACA TTTTGTGGGGCGCACATAT T T TGTGGTG GCACATATGTG G GATTGTCGCAAAGTGGGG G G GCAC CATCGG CAGA A C CACATATGTGGGGAGAAAA TTT ATCA GGAGAAAAGAG G T TGTGGGGAGAAAAGAGTATAT G GGGGAAGTGTCTC TTC GAGAAATGAGTGTCTCAGT CGGAAGAGTGTCTCACAA AGGTC ACCA A G GTGTCTCACACACACACAC CCAAAGATTCACACACACACC CAC CCACACACACCCTCT  ACACACACACCCCTCTTTT C T CACACACCCCTCTTTTCTC C AACAACCCCTCTTTTCTCGCA G C CCCCTCTTTCGCGGGG TAA CTCTTTTCTCGCGGGGGGG G T TTTTCTCGCGGGAAGGAGA A T TCTCGCGGGGGGGAGGGAA AAACAACGGGGTGGAGAAATT GGGGGGGAGAAAACGTTCG G GCGCT CGAAAACAGCCGTT GGC GCAACGCGTGTGTG G A AAAACACGCGTGTGTGGGG G A GAACGGTGTGGGGTAAGGGACGTTGGGGTGTTTTGT G GTGTGTGGAT TTGTG G T TGTGGGGTTTGTGA TT GGGTTTTGTGAGACAC C G GTGTTTTGTGAGACACCCC C T TT TGGACACCAAACT T T TGCTTGACACCATCAAATA A G ACGACACCGATA GT AAC C A ACACCAATCTATACACACA A CAT CCTCTATATGATAC C C CTCTAACACACACACA  TATACACACACACACAGAG G A ACACATGGACAAGAAGGGG G C CAACAGATCGGGGTA CT A ACACACAGTCG TGC ATG  CACAGAGGGGTGTGTGCC A AGAGGTGCGCCCC C G GGGTGTGCGCCCCACGCA G GTGTGTGCGCCCCACATAT T T TGGCCCCACATATCTC C GATTGCCT CCATTCACA ATCTCAATCAA A CA ACCT TTTCACAAGT AA  CA ATCCTTCACAAAAAAATAT T T TCCAAAAAATTTT T C CACAAAAAAT ATTTTGTTG GCAAAAATAGATTGTGGGG G A AAAATATTTTGTGG CGGA A A ATTTGCACGGACCTAT T TA ATTGGGAATGTG  TGCA GGAATGTGAGA CTAGCAGGAGATATGTGAGACAC C G GACAGATGTGAGACACACA A A ATATGTG A TAA A T TGTGA GTACACAAAAAA AA G GAGACCAAAAAAAGGAAG A ACACACAAAAAA AAGAGA A C CATTTAAAAAGAGAGATAT T A AAAAAAAGGATCAATC AAGAGAGATATCTCCCC  GCCAGGATATCTCCCCACA A G GAACAATCTCCCCACAAAA A AGTCATCTCCCCAAAAAA A T TCTCCCCAAAAAATAT T C CCCAAAAACATATTTT GGACAAC GATTTT T A AAAAACAATTCTC AAG AAAATATTTTTTGGTCACA AA  ATATTTTCTCA CGAA A T TTATATTCTCAAAAAA  TTTTCTCACAAAG G T TCCAAAAAAAGA C CACAAAAAATA CGGATAT GCA AATGAAAGAGAGATATCTC C A AAATCTCACA A A AGAGAGATATCCAA GGA GGATATCACGATTAAGAG G AATCTCAAAGAGTGT T T TCTCACAAAAGTGAGTCC C CACAAAAGAGTGTCTCACA GA  AAATGTCACATAATTAC AGAGTGTCTCACATATTTT T G GTGTCTCAATTAGATT T T TCGATCATATTA ATTTTT T C CAATTATTTTTTTTTTGTG GGAATTTTTTTTGC C T TTTTTTTTT GGCTCT T TGA TTTTTGTGCGCTCTGTG G T TTCATTGCGCTCTGTGAGA A T TGTGCGCTCTGTGAGAAAA A G GCGCTCTGTGAGAAAATAT T C CTCTGTGAGAAAATTA AACA CTGAGAAAATATATAAAA A G GAAG AATATAG CAAGAG G AAATATATAAAAGAGCGC GTG ATTAAAAGAGCGCACG A T TATAA TCAGCGCACAT CCT ATTCAAGGCACATATATA A AAGCGCACATATATACGGT AAGCACATGT TATTCATT T C CACATAAGTATATTGACG ATTTC AATTTTGTGAGA A T TATATTTGTGAGACGCAC A ATATTTTGTGATCA TTTTGAGTGACACGCGCGC AAAGACACGCGCGCACA A G GAGACACGAA GAACATAT T A ACACGCGCGCAATAA C CGGAACATATATACAC C G GCGCACATATATACACACA TGA CACATATATACACACAAAA A A AT ATTACACACAAATAAA A T TAT AACAAC CCTAAAAA A A ACACACAAAAAAAAAACAC  CACAAAAAAAAACACA  TT AAAAAAAAAACACACATAT TAC AAAAAAACACACATATTTT T A AAACACAT AGTTC,"ID   NCAP_SARS2              Reviewed;         419 AA.
AC   P0DTC9;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Nucleoprotein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=N;
DE   AltName: Full=Nucleocapsid protein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=NC {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=Protein N {ECO:0000255|HAMAP-Rule:MF_04096};
GN   Name=N {ECO:0000255|HAMAP-Rule:MF_04096};
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   SUBCELLULAR LOCATION.
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [3] {ECO:0007744|PDB:6WZO, ECO:0007744|PDB:6WZQ}
RP   X-RAY CRYSTALLOGRAPHY (1.42 ANGSTROMS) OF 247-364, AND SUBUNIT.
RX   PubMed=32654247; DOI=10.1002/pro.3909;
RA   Ye Q., West A.M.V., Silletti S., Corbett K.D.;
RT   ""Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein."";
RL   Protein Sci. 29:1890-1901(2020).
RN   [4]
RP   REVIEW.
RX   PubMed=32974389; DOI=10.3389/fmolb.2020.00219;
RA   Nikolakaki E., Giannakouros T.;
RT   ""SR/RS Motifs as Critical Determinants of Coronavirus Life Cycle."";
RL   Front. Mol. Biosci. 7:219-219(2020).
RN   [5]
RP   VARIANTS LEU-3 AND PHE-235.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [6]
RP   FUNCTION, INTERACTION WITH HOST NLRP3, AND SUBCELLULAR LOCATION.
RX   PubMed=34341353; DOI=10.1038/s41467-021-25015-6;
RA   Pan P., Shen M., Yu Z., Ge W., Chen K., Tian M., Xiao F., Wang Z., Wang J.,
RA   Jia Y., Wang W., Wan P., Zhang J., Chen W., Lei Z., Chen X., Luo Z.,
RA   Zhang Q., Xu M., Li G., Li Y., Wu J.;
RT   ""SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce
RT   hyperinflammation."";
RL   Nat. Commun. 12:4664-4664(2021).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 41-174, AND MUTAGENESIS OF
RP   TYR-109.
RX   PubMed=32363136; DOI=10.1016/j.apsb.2020.04.009;
RA   Kang S., Yang M., Hong Z., Zhang L., Huang Z., Chen X., He S., Zhou Z.,
RA   Zhou Z., Chen Q., Yan Y., Zhang C., Shan H., Chen S.;
RT   ""Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain
RT   reveals potential unique drug targeting sites."";
RL   Acta Pharmacol. Sin. 10:1228-1238(2020).
RN   [8] {ECO:0007744|PDB:6YI3, ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT}
RP   STRUCTURE BY NMR OF 44-180, FUNCTION, AND MUTAGENESIS OF ARG-68; ARG-92;
RP   ILE-94; ARG-107; GLN-163; TYR-172 AND GLU-174.
RX   PubMed=33264373; DOI=10.1371/journal.ppat.1009100;
RA   Dinesh D.C., Chalupska D., Silhan J., Koutna E., Nencka R., Veverka V.,
RA   Boura E.;
RT   ""Structural basis of RNA recognition by the SARS-CoV-2 nucleocapsid
RT   phosphoprotein."";
RL   PLoS Pathog. 16:1-16(2020).
RN   [9]
RP   MUTAGENESIS OF SER-188 AND SER-206, AND PHOSPHORYLATION AT SER-206.
RX   PubMed=34593624; DOI=10.1073/pnas.2113401118;
RA   Liu X., Verma A., Garcia G. Jr., Ramage H., Lucas A., Myers R.L.,
RA   Michaelson J.J., Coryell W., Kumar A., Charney A.W., Kazanietz M.G.,
RA   Rader D.J., Ritchie M.D., Berrettini W.H., Schultz D.C., Cherry S.,
RA   Damoiseaux R., Arumugaswami V., Klein P.S.;
RT   ""Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:1-9(2021).
RN   [10]
RP   CLEAVAGE.
RX   PubMed=35922005; DOI=10.1038/s41586-022-05148-4;
RA   Chu H., Hou Y., Yang D., Wen L., Shuai H., Yoon C., Shi J., Chai Y.,
RA   Yuen T.T., Hu B., Li C., Zhao X., Wang Y., Huang X., Lee K.S., Luo C.,
RA   Cai J.P., Poon V.K., Chan C.C., Zhang A.J., Yuan S., Sit K.Y., Foo D.C.,
RA   Au W.K., Wong K.K., Zhou J., Kok K.H., Jin D.Y., Chan J.F., Yuen K.Y.;
RT   ""Coronaviruses exploit a host cysteine-aspartic protease for replication."";
RL   Nature 0:0-0(2022).
RN   [11]
RP   MUTAGENESIS OF 203-ARG-GLY-204 AND ARG-203, AND PHOSPHORYLATION.
RX   PubMed=35728038; DOI=10.1371/journal.ppat.1010627;
RA   Johnson B.A., Zhou Y., Lokugamage K.G., Vu M.N., Bopp N.,
RA   Crocquet-Valdes P.A., Kalveram B., Schindewolf C., Liu Y., Scharton D.,
RA   Plante J.A., Xie X., Aguilar P., Weaver S.C., Shi P.Y., Walker D.H.,
RA   Routh A.L., Plante K.S., Menachery V.D.;
RT   ""Nucleocapsid mutations in SARS-CoV-2 augment replication and
RT   pathogenesis."";
RL   PLoS Pathog. 18:e1010627-e1010627(2022).
RN   [12]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=35921414; DOI=10.1126/sciadv.abp9770;
RA   Lopez-Munoz A.D., Kosik I., Holly J., Yewdell J.W.;
RT   ""Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive
RT   immunity."";
RL   Sci. Adv. 8:eabp9770-eabp9770(2022).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=34901782; DOI=10.1016/j.isci.2021.103562;
RA   Nabeel-Shah S., Lee H., Ahmed N., Burke G.L., Farhangmehr S., Ashraf K.,
RA   Pu S., Braunschweig U., Zhong G., Wei H., Tang H., Yang J., Marcon E.,
RA   Blencowe B.J., Zhang Z., Greenblatt J.F.;
RT   ""SARS-CoV-2 nucleocapsid protein binds host mRNAs and attenuates stress
RT   granules to impair host stress response."";
RL   IScience 25:103562-103562(2022).
RN   [14]
RP   FUNCTION.
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [15] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 191-263, AND INTERACTION WITH NSP3.
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
CC   -!- FUNCTION: Packages the positive strand viral genome RNA into a helical
CC       ribonucleocapsid (RNP) and plays a fundamental role during virion
CC       assembly through its interactions with the viral genome and membrane
CC       protein M (PubMed:33264373). Plays an important role in enhancing the
CC       efficiency of subgenomic viral RNA transcription as well as viral
CC       replication. Attenuates the stress granules formation by reducing host
CC       G3BP1 access to host mRNAs under stress conditions (PubMed:34901782,
CC       PubMed:36534661). {ECO:0000269|PubMed:32974389,
CC       ECO:0000269|PubMed:33264373, ECO:0000269|PubMed:34901782,
CC       ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: May block host chemokine function in vivo, facilitating viral
CC       replication and transmission (PubMed:35921414). Acts by being secreted
CC       into the extracellular space where it competes to host chemokines for
CC       binding to host glycosaminoglycans (GAG) (PubMed:35921414).
CC       {ECO:0000269|PubMed:35921414}.
CC   -!- FUNCTION: May induce inflammasome responses in cultured cells and mice.
CC       Acts by interacting with host NLRP3 to facilitate inflammasome
CC       assembly, which induces cytokine release that may play a role in COVID
CC       lung injury. {ECO:0000269|PubMed:34341353}.
CC   -!- SUBUNIT: Homodimer, homotetramer, homooligomer with RNA
CC       (PubMed:32654247). Both monomeric and oligomeric forms interact with
CC       RNA. Interacts with protein M (By similarity). Interacts with protein E
CC       (By similarity). Interacts with NSP3; this interaction serves to tether
CC       the genome to the newly translated replicase-transcriptase complex at a
CC       very early stage of infection (PubMed:35044811). May interact with host
CC       NLRP3 (PubMed:34341353). {ECO:0000250|UniProtKB:P59595,
CC       ECO:0000255|HAMAP-Rule:MF_04096, ECO:0000269|PubMed:32654247,
CC       ECO:0000269|PubMed:34341353, ECO:0000269|PubMed:35044811}.
CC   -!- INTERACTION:
CC       P0DTC9; P0DTC4: E; NbExp=3; IntAct=EBI-25475856, EBI-25475850;
CC       P0DTC9; P0DTC5: M; NbExp=6; IntAct=EBI-25475856, EBI-25475853;
CC       P0DTC9; P0DTC9: N; NbExp=105; IntAct=EBI-25475856, EBI-25475856;
CC       P0DTC9; PRO_0000449621 [P0DTD1]: rep; NbExp=15; IntAct=EBI-25475856, EBI-25492388;
CC       P0DTC9; P78563: ADARB1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-2967304;
CC       P0DTC9; O15145: ARPC3; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-351829;
CC       P0DTC9; Q13895: BYSL; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-358049;
CC       P0DTC9; Q16543: CDC37; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-295634;
CC       P0DTC9; Q92793: CREBBP; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-81215;
CC       P0DTC9; Q92499: DDX1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-358474;
CC       P0DTC9; Q9NR30: DDX21; Xeno; NbExp=12; IntAct=EBI-25475856, EBI-357942;
CC       P0DTC9; P26196: DDX6; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-351257;
CC       P0DTC9; Q08426: EHHADH; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-2339219;
CC       P0DTC9; P19525: EIF2AK2; Xeno; NbExp=8; IntAct=EBI-25475856, EBI-640775;
CC       P0DTC9; Q14241: ELOA; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-742350;
CC       P0DTC9; Q13283: G3BP1; Xeno; NbExp=71; IntAct=EBI-25475856, EBI-1047359;
CC       P0DTC9; Q9UN86: G3BP2; Xeno; NbExp=37; IntAct=EBI-25475856, EBI-1044298;
CC       P0DTC9; P57764: GSDMD; Xeno; NbExp=13; IntAct=EBI-25475856, EBI-2798865;
CC       P0DTC9; P49841: GSK3B; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-373586;
CC       P0DTC9; P10412: H1-4; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-358163;
CC       P0DTC9; O14920: IKBKB; Xeno; NbExp=7; IntAct=EBI-25475856, EBI-81266;
CC       P0DTC9; Q92830: KAT2A; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-477622;
CC       P0DTC9; Q92831: KAT2B; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-477430;
CC       P0DTC9; Q07866: KLC1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-721019;
CC       P0DTC9; Q9H0B6: KLC2; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-726994;
CC       P0DTC9; Q9NSK0: KLC4; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-949319;
CC       P0DTC9; Q9NX58: LYAR; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-713507;
CC       P0DTC9; O43318: MAP3K7; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-358684;
CC       P0DTC9; Q9UBU8: MORF4L1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-399246;
CC       P0DTC9; Q15014: MORF4L2; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-399257;
CC       P0DTC9; Q9HCE1: MOV10; Xeno; NbExp=11; IntAct=EBI-25475856, EBI-1055820;
CC       P0DTC9; Q9HC36: MRM3; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-1045440;
CC       P0DTC9; O15226: NKRF; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-766011;
CC       P0DTC9; Q96P20: NLRP3; Xeno; NbExp=18; IntAct=EBI-25475856, EBI-6253230;
CC       P0DTC9; O15118: NPC1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-2368710;
CC       P0DTC9; Q96HA8: NTAQ1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-741158;
CC       P0DTC9; P11940: PABPC1; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-81531;
CC       P0DTC9; P62937: PPIA; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-437708;
CC       P0DTC9; O75569: PRKRA; Xeno; NbExp=8; IntAct=EBI-25475856, EBI-713955;
CC       P0DTC9; Q99873: PRMT1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-78738;
CC       P0DTC9; P61289: PSME3; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-355546;
CC       P0DTC9; P26022: PTX3; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-11574553;
CC       P0DTC9; P54727: RAD23B; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-954531;
CC       P0DTC9; O95786: RIGI; Xeno; NbExp=15; IntAct=EBI-25475856, EBI-995350;
CC       P0DTC9; P62899: RPL31; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-1053664;
CC       P0DTC9; P62753: RPS6; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-356625;
CC       P0DTC9; P37840: SNCA; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-985879;
CC       P0DTC9; Q96SB4: SRPK1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-539478;
CC       P0DTC9; P78362: SRPK2; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-593303;
CC       P0DTC9; P42224: STAT1; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-1057697;
CC       P0DTC9; P52630: STAT2; Xeno; NbExp=7; IntAct=EBI-25475856, EBI-1546963;
CC       P0DTC9; Q15633: TARBP2; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-978581;
CC       P0DTC9; Q14258: TRIM25; Xeno; NbExp=13; IntAct=EBI-25475856, EBI-2341129;
CC       P0DTC9; O60763: USO1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-356164;
CC       P0DTC9; Q93008: USP9X; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-302524;
CC   -!- SUBCELLULAR LOCATION: Virion {ECO:0000255|HAMAP-Rule:MF_04096}. Host
CC       cytoplasm {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:34341353}.
CC       Secreted {ECO:0000269|PubMed:35921414}. Host extracellular space
CC       {ECO:0000269|PubMed:35921414}. Note=Probably associates with ER-derived
CC       membranes where it participates in viral RNA synthesis and virus
CC       budding. When located inside the virion, complexed with the viral RNA.
CC       Can be secreted by unconventional protein secretion (UPS)
CC       (PubMed:35921414). When secreted, can bind to host glycosaminoglycans
CC       on infected and non infected cells (PubMed:35921414). Found in host
CC       cytoplasmic stress granules (PubMed:34901782). {ECO:0000255|HAMAP-
CC       Rule:MF_04096, ECO:0000269|PubMed:34901782,
CC       ECO:0000269|PubMed:35921414}.
CC   -!- PTM: ADP-ribosylated. The ADP-ribosylation is retained in the virion
CC       during infection. {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   -!- PTM: Phosphorylated on serine residues by host GSK3A and GSK3B
CC       (PubMed:34593624, PubMed:35728038). This promotes the solubility of
CC       homodimers that would otherwise aggregate (PubMed:32974389). Host
CC       phosphatase would dephosphorylate the protein during assembly at M
CC       bound membranes (PubMed:32974389). {ECO:0000269|PubMed:34593624,
CC       ECO:0000269|PubMed:35728038, ECO:0000305|PubMed:32974389}.
CC   -!- PTM: Proteolytically cleaved by host CASP6. The cleavage leads to two
CC       fragments and facilitates viral replication by inhibiting host IFN
CC       signaling. The two fragments may interact with IRF3 inhibiting its
CC       nuclear translocation after activation and reduce the expression of
CC       IFNB and IFN-stimulated genes. {ECO:0000269|PubMed:35922005}.
CC   -!- POLYMORPHISM: Variant Alpha/B.1.1.7 belongs to a lineage isolated first
CC       in United Kingdom (December 2020). It is also called Variant of Concern
CC       (VOC) 202012/01, Variant Under Investigation (VUI) 202012/01, 501Y.V1
CC       or 20B/501Y.V1. {ECO:0000305|PubMed:33413740}.
CC   -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC       isolated in South Africa (November 2021). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC       isolated in Nigeria (November 2022). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC       isolated in United States (November 2022). It is the result of
CC       recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC       express ORF8. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the betacoronavirus nucleocapsid protein family.
CC       {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43423.2; -; Genomic_RNA.
DR   PDB; 6M3M; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 6VYO; X-ray; 1.70 A; A/B/C/D=47-173.
DR   PDB; 6WJI; X-ray; 2.05 A; A/B/C/D/E/F=257-364.
DR   PDB; 6WKP; X-ray; 2.67 A; A/B/C/D=47-173.
DR   PDB; 6WZO; X-ray; 1.42 A; A/B/C/D=247-364.
DR   PDB; 6WZQ; X-ray; 1.45 A; A/B/C/D=247-364.
DR   PDB; 6YI3; NMR; -; A=44-180.
DR   PDB; 6YUN; X-ray; 1.44 A; A/B=249-364.
DR   PDB; 6ZCO; X-ray; 1.36 A; A=247-364.
DR   PDB; 7ACS; NMR; -; A=44-180.
DR   PDB; 7ACT; NMR; -; A=44-180.
DR   PDB; 7C22; X-ray; 2.00 A; A/B/C/D=248-364.
DR   PDB; 7CDZ; X-ray; 1.80 A; A/B/C/D=44-174.
DR   PDB; 7CE0; X-ray; 1.50 A; A/B/C/D=255-364.
DR   PDB; 7CR5; X-ray; 2.08 A; A=41-174.
DR   PDB; 7DE1; X-ray; 2.00 A; A/B=250-364.
DR   PDB; 7F2B; X-ray; 2.00 A; A/B=257-362.
DR   PDB; 7F2E; X-ray; 3.10 A; A/B/C/D/E/F/G/H/I/J/K/L=255-362.
DR   PDB; 7KGO; X-ray; 2.15 A; C=351-359.
DR   PDB; 7KGP; X-ray; 1.40 A; C=316-324.
DR   PDB; 7KGQ; X-ray; 1.34 A; C=222-230.
DR   PDB; 7KGR; X-ray; 1.55 A; C=159-167.
DR   PDB; 7KGS; X-ray; 1.58 A; C=138-146.
DR   PDB; 7KGT; X-ray; 1.90 A; C=226-234.
DR   PDB; 7LGD; X-ray; 2.88 A; E/F=105-113.
DR   PDB; 7LTU; X-ray; 1.12 A; A/B=217-222.
DR   PDB; 7LUX; X-ray; 1.30 A; A=217-222.
DR   PDB; 7LUZ; X-ray; 1.10 A; A=243-248.
DR   PDB; 7LV2; X-ray; 1.30 A; A=179-184.
DR   PDB; 7N0I; X-ray; 2.20 A; A/B/C/D/E/F/G/H=269-364.
DR   PDB; 7N0R; X-ray; 1.42 A; A/B=49-174.
DR   PDB; 7N3C; X-ray; 1.82 A; C=47-173.
DR   PDB; 7N3D; X-ray; 1.53 A; C=47-173.
DR   PDB; 7O05; X-ray; 1.94 A; A/B/C/D=247-364.
DR   PDB; 7O35; X-ray; 1.80 A; A/B/C/D=247-364.
DR   PDB; 7O36; X-ray; 2.00 A; A/B/C/D=247-364.
DR   PDB; 7PKU; NMR; -; B=191-263.
DR   PDB; 7QIK; X-ray; 2.01 A; E/F=193-200.
DR   PDB; 7QIP; X-ray; 2.65 A; C/D=201-210.
DR   PDB; 7R98; X-ray; 2.51 A; A/B/C=49-174.
DR   PDB; 7SD4; NMR; -; A=40-174.
DR   PDB; 7STR; X-ray; 1.50 A; C=47-173.
DR   PDB; 7STS; X-ray; 2.16 A; C/D=47-173.
DR   PDB; 7SUE; X-ray; 2.90 A; C/D/J/K=47-173.
DR   PDB; 7SUO; X-ray; 2.35 A; C/D=12-22.
DR   PDB; 7UW3; X-ray; 1.70 A; A/B/C/D=40-174.
DR   PDB; 7UXX; X-ray; 1.85 A; AAA/BBB/CCC/DDD/EEE/FFF=251-364.
DR   PDB; 7UXZ; X-ray; 1.73 A; AAA/BBB/CCC/DDD/EEE/FFF=251-364.
DR   PDB; 7VBD; X-ray; 1.94 A; A/B/C/D=48-174.
DR   PDB; 7VBE; X-ray; 1.59 A; A/B=257-364.
DR   PDB; 7VBF; X-ray; 1.30 A; A/B=255-364.
DR   PDB; 7VNU; X-ray; 1.95 A; A/B/C/D=47-174.
DR   PDB; 7WKJ; X-ray; 1.50 A; C=361-369.
DR   PDB; 7WZO; X-ray; 2.64 A; A=47-174.
DR   PDB; 7XWX; X-ray; 3.00 A; A/B/C/D/E/F/G/H=269-367.
DR   PDB; 7XWZ; X-ray; 2.25 A; A/B=48-172.
DR   PDB; 7XX1; X-ray; 1.90 A; A/B/C/D=49-173.
DR   PDB; 7XXK; X-ray; 2.00 A; A/B/C/D/E/F=248-364.
DR   PDB; 7YLB; X-ray; 2.41 A; A/B/C/D/G/H/J/K=247-364.
DR   PDB; 7YLD; X-ray; 2.80 A; A/B/C/D=47-174.
DR   PDB; 7ZIT; X-ray; 1.79 A; C/D=194-200.
DR   PDB; 8DNT; X-ray; 3.18 A; D/J/Q/X=222-230.
DR   PDB; 8FD5; EM; 4.57 A; A=1-419.
DR   PDB; 8FG2; EM; 6.00 A; A/B=1-419.
DR   PDB; 8IQJ; X-ray; 2.30 A; A/B/C/D=41-174.
DR   PDB; 8IV3; X-ray; 1.90 A; A/B/C/D=41-174.
DR   PDB; 8J6X; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 8TH1; X-ray; 1.80 A; E/F/G/H=1-25.
DR   PDB; 8TH5; X-ray; 2.62 A; K/L/M/N/O/P/Q=1-25.
DR   PDB; 8X1H; X-ray; 2.00 A; A/B/C/D=44-175.
DR   PDBsum; 6M3M; -.
DR   PDBsum; 6VYO; -.
DR   PDBsum; 6WJI; -.
DR   PDBsum; 6WKP; -.
DR   PDBsum; 6WZO; -.
DR   PDBsum; 6WZQ; -.
DR   PDBsum; 6YI3; -.
DR   PDBsum; 6YUN; -.
DR   PDBsum; 6ZCO; -.
DR   PDBsum; 7ACS; -.
DR   PDBsum; 7ACT; -.
DR   PDBsum; 7C22; -.
DR   PDBsum; 7CDZ; -.
DR   PDBsum; 7CE0; -.
DR   PDBsum; 7CR5; -.
DR   PDBsum; 7DE1; -.
DR   PDBsum; 7F2B; -.
DR   PDBsum; 7F2E; -.
DR   PDBsum; 7KGO; -.
DR   PDBsum; 7KGP; -.
DR   PDBsum; 7KGQ; -.
DR   PDBsum; 7KGR; -.
DR   PDBsum; 7KGS; -.
DR   PDBsum; 7KGT; -.
DR   PDBsum; 7LGD; -.
DR   PDBsum; 7LTU; -.
DR   PDBsum; 7LUX; -.
DR   PDBsum; 7LUZ; -.
DR   PDBsum; 7LV2; -.
DR   PDBsum; 7N0I; -.
DR   PDBsum; 7N0R; -.
DR   PDBsum; 7N3C; -.
DR   PDBsum; 7N3D; -.
DR   PDBsum; 7O05; -.
DR   PDBsum; 7O35; -.
DR   PDBsum; 7O36; -.
DR   PDBsum; 7PKU; -.
DR   PDBsum; 7QIK; -.
DR   PDBsum; 7QIP; -.
DR   PDBsum; 7R98; -.
DR   PDBsum; 7SD4; -.
DR   PDBsum; 7STR; -.
DR   PDBsum; 7STS; -.
DR   PDBsum; 7SUE; -.
DR   PDBsum; 7SUO; -.
DR   PDBsum; 7UW3; -.
DR   PDBsum; 7UXX; -.
DR   PDBsum; 7UXZ; -.
DR   PDBsum; 7VBD; -.
DR   PDBsum; 7VBE; -.
DR   PDBsum; 7VBF; -.
DR   PDBsum; 7VNU; -.
DR   PDBsum; 7WKJ; -.
DR   PDBsum; 7WZO; -.
DR   PDBsum; 7XWX; -.
DR   PDBsum; 7XWZ; -.
DR   PDBsum; 7XX1; -.
DR   PDBsum; 7XXK; -.
DR   PDBsum; 7YLB; -.
DR   PDBsum; 7YLD; -.
DR   PDBsum; 7ZIT; -.
DR   PDBsum; 8DNT; -.
DR   PDBsum; 8FD5; -.
DR   PDBsum; 8FG2; -.
DR   PDBsum; 8IQJ; -.
DR   PDBsum; 8IV3; -.
DR   PDBsum; 8J6X; -.
DR   PDBsum; 8TH1; -.
DR   PDBsum; 8TH5; -.
DR   PDBsum; 8X1H; -.
DR   BMRB; P0DTC9; -.
DR   EMDB; EMD-29002; -.
DR   EMDB; EMD-29072; -.
DR   SASBDB; P0DTC9; -.
DR   SMR; P0DTC9; -.
DR   BioGRID; 4383847; 1532.
DR   ComplexPortal; CPX-5686; SARS-CoV-2 nucleocapsid complex.
DR   IntAct; P0DTC9; 608.
DR   MINT; P0DTC9; -.
DR   ChEMBL; CHEMBL5169223; -.
DR   iPTMnet; P0DTC9; -.
DR   ABCD; P0DTC9; 27 sequenced antibodies.
DR   DNASU; 43740575; -.
DR   KEGG; vg:43740575; -.
DR   AGR; RefSeq:YP_009724397; -.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-168928; DDX58/IFIH1-mediated induction of interferon-alpha/beta.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-445989; TAK1-dependent IKK and NF-kappa-B activation.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-9020702; Interleukin-1 signaling.
DR   Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR   Reactome; R-HSA-9694322; Virion Assembly and Release.
DR   Reactome; R-HSA-9694614; Attachment and Entry.
DR   Reactome; R-HSA-9694631; Maturation of nucleoprotein.
DR   Reactome; R-HSA-9694635; Translation of Structural Proteins.
DR   Reactome; R-HSA-9694786; Transcription of SARS-CoV-2 sgRNAs.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9733458; Induction of Cell-Cell Fusion.
DR   Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways.
DR   SIGNOR; P0DTC9; -.
DR   PRO; PR:P0DTC9; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProt.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0044172; C:host cell endoplasmic reticulum-Golgi intermediate compartment; ISS:UniProtKB.
DR   GO; GO:0044177; C:host cell Golgi apparatus; ISS:UniProtKB.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0043655; C:host extracellular space; IEA:UniProtKB-SubCell.
DR   GO; GO:0043232; C:intracellular non-membrane-bounded organelle; IDA:DisProt.
DR   GO; GO:0042612; C:MHC class I protein complex; EXP:DisProt.
DR   GO; GO:1990904; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IPI:ComplexPortal.
DR   GO; GO:0019013; C:viral nucleocapsid; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0042288; F:MHC class I protein binding; EXP:DisProt.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; IDA:DisProt.
DR   GO; GO:0008266; F:poly(U) RNA binding; IMP:DisProt.
DR   GO; GO:0042803; F:protein homodimerization activity; EXP:DisProt.
DR   GO; GO:0140311; F:protein sequestering activity; IDA:UniProt.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProt.
DR   GO; GO:0035613; F:RNA stem-loop binding; IDA:DisProt.
DR   GO; GO:0039709; P:cytoplasmic capsid assembly; IDA:UniProt.
DR   GO; GO:0032688; P:negative regulation of interferon-beta production; IDA:ComplexPortal.
DR   GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; IDA:UniProtKB.
DR   GO; GO:0052572; P:response to host immune response; IDA:DisProt.
DR   GO; GO:0019074; P:viral RNA genome packaging; NAS:ComplexPortal.
DR   CDD; cd21595; CoV_N-CTD; 1.
DR   CDD; cd21554; CoV_N-NTD; 1.
DR   HAMAP; MF_04096; BETA_CORONA_NCAP; 1.
DR   InterPro; IPR044344; N_prot_C_CoV.
DR   InterPro; IPR044345; N_prot_N_CoV.
DR   InterPro; IPR043505; NCAP_bCoV.
DR   InterPro; IPR001218; Nucleocap_CoV.
DR   InterPro; IPR037179; Nucleocapsid_C.
DR   InterPro; IPR037195; Nucleocapsid_N.
DR   Pfam; PF00937; CoV_nucleocap; 1.
DR   PIRSF; PIRSF003888; Corona_nucleocap; 1.
DR   SUPFAM; SSF110304; Coronavirus RNA-binding domain; 1.
DR   SUPFAM; SSF103068; Nucleocapsid protein dimerization domain; 1.
DR   PROSITE; PS51929; COV_N_CTD; 1.
DR   PROSITE; PS51928; COV_N_NTD; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Host cytoplasm; Phosphoprotein;
KW   Reference proteome; Ribonucleoprotein; RNA-binding; Secreted;
KW   Transcription; Transcription regulation; Viral nucleoprotein; Virion.
FT   CHAIN           1..419
FT                   /note=""Nucleoprotein""
FT                   /id=""PRO_0000449656""
FT   DOMAIN          48..174
FT                   /note=""CoV N NTD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01276,
FT                   ECO:0000269|PubMed:32363136""
FT   DOMAIN          247..364
FT                   /note=""CoV N CTD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01277""
FT   REGION          1..51
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          41..186
FT                   /note=""RNA-binding""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   REGION          63..83
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          168..212
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          176..206
FT                   /note=""SR region""
FT                   /evidence=""ECO:0000305|PubMed:32974389""
FT   REGION          233..266
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          258..361
FT                   /note=""Dimerization""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   REGION          260..340
FT                   /note=""Putative NLRP3 binding""
FT                   /evidence=""ECO:0000269|PubMed:34341353""
FT   REGION          361..391
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          400..419
FT                   /note=""Tetramerization""
FT                   /evidence=""ECO:0000269|PubMed:32654247""
FT   MOTIF           256..264
FT                   /note=""Nuclear localization signal""
FT                   /evidence=""ECO:0000250|UniProtKB:P59595""
FT   COMPBIAS        1..11
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        21..31
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        367..378
FT                   /note=""Basic and acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   BINDING         92
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   BINDING         107
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   BINDING         149
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   SITE            399..402
FT                   /note=""Cleavage (by host CASP6)""
FT                   /evidence=""ECO:0000250|UniProtKB:P59595""
FT   MOD_RES         176
FT                   /note=""Phosphoserine; by host""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   MOD_RES         206
FT                   /note=""Phosphoserine; by host GSK3-alpha and GSK3-beta""
FT                   /evidence=""ECO:0000269|PubMed:34593624""
FT   VARIANT         2..3
FT                   /note=""SD -> Y (in strain: Eta/B.1.525)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         3
FT                   /note=""D -> L (in strain: Alpha/B.1.1.7)""
FT                   /evidence=""ECO:0000305|PubMed:33413740""
FT   VARIANT         12
FT                   /note=""A -> G (in strain: Eta/B.1.525)""
FT   VARIANT         13
FT                   /note=""P -> L (in strain: Lambda/C.37, Omicron/BA.1,
FT                   Omicron/BA.2, Omicron/BA.2.12.1, Omicron/BA.2.75,
FT                   Omicron/BA.4, Omicron/BA.5, Omicron/BQ.1.1,
FT                   Omicron/XBB.1.5, Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         31..33
FT                   /note=""Missing (in strain: Omicron/BA.1, Omicron/BA.2,
FT                   Omicron/BA.2.12.1, Omicron/BA.2.75, Omicron/BA.4,
FT                   Omicron/BA.5, Omicron/BQ.1.1, Omicron/XBB.1.5,
FT                   Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         63
FT                   /note=""D -> G (in strain: Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT  ",64328
GTGTTC TGTTCC GTTCCA TTCCAG TCCAGA CCAGAC CAGACA AGACAT GACATT ACATTC CATTCC ATTCCG TTCCGT TCCGTA CCGTAA CGTAAC GTAACG TAACGC AACGCA ACGCAT CGCATG GCATGG CATGGA ATGGAA TGGAAG GGAAGA GAAGAT AAGATC AGATCC GATCCC ATCCCC TCCCCG CCCCGA CCCGAG CCGAGC CGAGCT GAGCTT AGCTTA GCTTAA CTTAAA TTAAAA TAAAAA AAAAAT AAAATC AAATCG AATCGT ATCGTC TCGTCT CGTCTC GTCTCC TCTCCT CTCCTG TCCTGT CCTGTT CTGTTC TGTTCA GTTCAC TTCACG TCACGC CACGCT ACGCTG CGCTGG GCTGGC CTGGCG TGGCGA GGCGAT GCGATC CGATCC GATCCT ATCCTC TCCTCG CCTCGT CTCGTG TCGTGG CGTGGT GTGGTG TGGTGT GGTGTA GTGTAT TGTATC GTATCG TATCGT ATCGTT TCGTTT CGTTTG GTTTGG TTTGGG TTGGGC TGGGCT GGGCTG GGCTGT GCTGTG CTGTGC TGTGCT GTGCTA TGCTAT GCTATC CTATCC TATCCC ATCCCC TCCCCA CCCCAT CCCATG,1,103,GTGT TGTT GTTC TTCC TCCA CCAG CAGA AGAC GACA ACAT CATT ATTC TTCC TCCG CCGT CGTA GTAA TAAC AACG ACGC CGCA GCAT CATG ATGG TGGA GGAA GAAG AAGA AGAT GATC ATCC TCCC CCCC CCCG CCGA CGAG GAGC AGCT GCTT CTTA TTAA TAAA AAAA AAAA AAAT AATC ATCG TCGT CGTC GTCT TCTC CTCC TCCT CCTG CTGT TGTT GTTC TTCA TCAC CACG ACGC CGCT GCTG CTGG TGGC GGCG GCGA CGAT GATC ATCC TCCT CCTC CTCG TCGT CGTG GTGG TGGT GGTG GTGT TGTA GTAT TATC ATCG TCGT CGTT GTTT TTTG TTGG TGGG GGGC GGCT GCTG CTGT TGTG GTGC TGCT GCTA CTAT TATC ATCC TCCC CCCC CCCA CCAT CATG,GTGTT TGTTC GTTCC TTCCA TCCAG CCAGA CAGAC AGACA GACAT ACATT CATTC ATTCC TTCCG TCCGT CCGTA CGTAA GTAAC TAACG AACGC ACGCA CGCAT GCATG CATGG ATGGA TGGAA GGAAG GAAGA AAGAT AGATC GATCC ATCCC TCCCC CCCCG CCCGA CCGAG CGAGC GAGCT AGCTT GCTTA CTTAA TTAAA TAAAA AAAAA AAAAT AAATC AATCG ATCGT TCGTC CGTCT GTCTC TCTCC CTCCT TCCTG CCTGT CTGTT TGTTC GTTCA TTCAC TCACG CACGC ACGCT CGCTG GCTGG CTGGC TGGCG GGCGA GCGAT CGATC GATCC ATCCT TCCTC CCTCG CTCGT TCGTG CGTGG GTGGT TGGTG GGTGT GTGTA TGTAT GTATC TATCG ATCGT TCGTT CGTTT GTTTG TTTGG TTGGG TGGGC GGGCT GGCTG GCTGT CTGTG TGTGC GTGCT TGCTA GCTAT CTATC TATCC ATCCC TCCCC CCCCA CCCAT CCATG,GTGTTC TGTTCC GTTCCA TTCCAG TCCAGA CCAGAC CAGACA AGACAT GACATT ACATTC CATTCC ATTCCG TTCCGT TCCGTA CCGTAA CGTAAC GTAACG TAACGC AACGCA ACGCAT CGCATG GCATGG CATGGA ATGGAA TGGAAG GGAAGA GAAGAT AAGATC AGATCC GATCCC ATCCCC TCCCCG CCCCGA CCCGAG CCGAGC CGAGCT GAGCTT AGCTTA GCTTAA CTTAAA TTAAAA TAAAAA AAAAAT AAAATC AAATCG AATCGT ATCGTC TCGTCT CGTCTC GTCTCC TCTCCT CTCCTG TCCTGT CCTGTT CTGTTC TGTTCA GTTCAC TTCACG TCACGC CACGCT ACGCTG CGCTGG GCTGGC CTGGCG TGGCGA GGCGAT GCGATC CGATCC GATCCT ATCCTC TCCTCG CCTCGT CTCGTG TCGTGG CGTGGT GTGGTG TGGTGT GGTGTA GTGTAT TGTATC GTATCG TATCGT ATCGTT TCGTTT CGTTTG GTTTGG TTTGGG TTGGGC TGGGCT GGGCTG GGCTGT GCTGTG CTGTGC TGTGCT GTGCTA TGCTAT GCTATC CTATCC TATCCC ATCCCC TCCCCA CCCCAT CCCATG,GTGTTCC TGTTCCA GTTCCAG TTCCAGA TCCAGAC CCAGACA CAGACAT AGACATT GACATTC ACATTCC CATTCCG ATTCCGT TTCCGTA TCCGTAA CCGTAAC CGTAACG GTAACGC TAACGCA AACGCAT ACGCATG CGCATGG GCATGGA CATGGAA ATGGAAG TGGAAGA GGAAGAT GAAGATC AAGATCC AGATCCC GATCCCC ATCCCCG TCCCCGA CCCCGAG CCCGAGC CCGAGCT CGAGCTT GAGCTTA AGCTTAA GCTTAAA CTTAAAA TTAAAAA TAAAAAT AAAAATC AAAATCG AAATCGT AATCGTC ATCGTCT TCGTCTC CGTCTCC GTCTCCT TCTCCTG CTCCTGT TCCTGTT CCTGTTC CTGTTCA TGTTCAC GTTCACG TTCACGC TCACGCT CACGCTG ACGCTGG CGCTGGC GCTGGCG CTGGCGA TGGCGAT GGCGATC GCGATCC CGATCCT GATCCTC ATCCTCG TCCTCGT CCTCGTG CTCGTGG TCGTGGT CGTGGTG GTGGTGT TGGTGTA GGTGTAT GTGTATC TGTATCG GTATCGT TATCGTT ATCGTTT TCGTTTG CGTTTGG GTTTGGG TTTGGGC TTGGGCT TGGGCTG GGGCTGT GGCTGTG GCTGTGC CTGTGCT TGTGCTA GTGCTAT TGCTATC GCTATCC CTATCCC TATCCCC ATCCCCA TCCCCAT CCCCATG,"ID   RL15_AGARV              Reviewed;         146 AA.
AC   C4ZBT7;
DT   22-SEP-2009, integrated into UniProtKB/Swiss-Prot.
DT   28-JUL-2009, sequence version 1.
DT   05-FEB-2025, entry version 69.
DE   RecName: Full=Large ribosomal subunit protein uL15 {ECO:0000255|HAMAP-Rule:MF_01341};
DE   AltName: Full=50S ribosomal protein L15 {ECO:0000305};
GN   Name=rplO {ECO:0000255|HAMAP-Rule:MF_01341};
GN   OrderedLocusNames=EUBREC_0436;
OS   Agathobacter rectalis (strain ATCC 33656 / DSM 3377 / JCM 17463 / KCTC 5835
OS   / VPI 0990) (Eubacterium rectale).
OC   Bacteria; Bacillati; Bacillota; Clostridia; Lachnospirales;
OC   Lachnospiraceae; Agathobacter.
OX   NCBI_TaxID=515619;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 33656 / DSM 3377 / JCM 17463 / KCTC 5835 / LMG 30912 / VPI
RC   0990;
RX   PubMed=19321416; DOI=10.1073/pnas.0901529106;
RA   Mahowald M.A., Rey F.E., Seedorf H., Turnbaugh P.J., Fulton R.S.,
RA   Wollam A., Shah N., Wang C., Magrini V., Wilson R.K., Cantarel B.L.,
RA   Coutinho P.M., Henrissat B., Crock L.W., Russell A., Verberkmoes N.C.,
RA   Hettich R.L., Gordon J.I.;
RT   ""Characterizing a model human gut microbiota composed of members of its two
RT   dominant bacterial phyla."";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:5859-5864(2009).
CC   -!- FUNCTION: Binds to the 23S rRNA. {ECO:0000255|HAMAP-Rule:MF_01341}.
CC   -!- SUBUNIT: Part of the 50S ribosomal subunit. {ECO:0000255|HAMAP-
CC       Rule:MF_01341}.
CC   -!- SIMILARITY: Belongs to the universal ribosomal protein uL15 family.
CC       {ECO:0000255|HAMAP-Rule:MF_01341}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP001107; ACR74227.1; -; Genomic_DNA.
DR   RefSeq; WP_012741344.1; NZ_CAXSYD010000003.1.
DR   AlphaFoldDB; C4ZBT7; -.
DR   SMR; C4ZBT7; -.
DR   STRING; 515619.EUBREC_0436; -.
DR   PaxDb; 515619-EUBREC_0436; -.
DR   GeneID; 86987347; -.
DR   KEGG; ere:EUBREC_0436; -.
DR   HOGENOM; CLU_055188_4_2_9; -.
DR   Proteomes; UP000001477; Chromosome.
DR   GO; GO:0022625; C:cytosolic large ribosomal subunit; IEA:TreeGrafter.
DR   GO; GO:0019843; F:rRNA binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0003735; F:structural constituent of ribosome; IEA:InterPro.
DR   GO; GO:0006412; P:translation; IEA:UniProtKB-UniRule.
DR   Gene3D; 3.100.10.10; -; 1.
DR   HAMAP; MF_01341; Ribosomal_uL15; 1.
DR   InterPro; IPR030878; Ribosomal_uL15.
DR   InterPro; IPR021131; Ribosomal_uL15/eL18.
DR   InterPro; IPR036227; Ribosomal_uL15/eL18_sf.
DR   InterPro; IPR005749; Ribosomal_uL15_bac-type.
DR   InterPro; IPR001196; Ribosomal_uL15_CS.
DR   NCBIfam; TIGR01071; rplO_bact; 1.
DR   PANTHER; PTHR12934; 50S RIBOSOMAL PROTEIN L15; 1.
DR   PANTHER; PTHR12934:SF11; LARGE RIBOSOMAL SUBUNIT PROTEIN UL15M; 1.
DR   Pfam; PF00828; Ribosomal_L27A; 1.
DR   SUPFAM; SSF52080; Ribosomal proteins L15p and L18e; 1.
DR   PROSITE; PS00475; RIBOSOMAL_L15; 1.
PE   3: Inferred from homology;
KW   Ribonucleoprotein; Ribosomal protein; RNA-binding; rRNA-binding.
FT   CHAIN           1..146
FT                   /note=""Large ribosomal subunit protein uL15""
FT                   /id=""PRO_1000214704""
FT   REGION          1..57
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
SQ   SEQUENCE   146 AA;  15518 MW;  9259776D89A8E84E CRC64;
     MDLSNLKAAE GSVHSDNFRR GRGHGSGNGK TAGKGHKGQK ARSGAPRPGF EGGQMPLYRR
     LPKRGFKNRN TLTIVPINLS ALERFDNDAV VSVETLIEAG IVKNPRDGVK ILGNGELTKK
     LTVQANAFSA SAKEKIEALG GKAEVI
//
",58245
ATGTAC TGTACT GTACTC TACTCA ACTCAT CTCATT TCATTC CATTCG ATTCGT TTCGTT TCGTTT CGTTTC GTTTCG TTTCGG TTCGGA TCGGAA CGGAAG GGAAGA GAAGAG AAGAGA AGAGAT GAGATA AGATAG GATAGG ATAGGT TAGGTA AGGTAC GGTACG GTACGT TACGTT ACGTTA CGTTAA GTTAAT TTAATA TAATAG AATAGT ATAGTT TAGTTA AGTTAA GTTAAT TTAATA TAATAG AATAGC ATAGCG TAGCGT AGCGTA GCGTAC CGTACT GTACTT TACTTC ACTTCT CTTCTT TTCTTT TCTTTT CTTTTT TTTTTC TTTTCT TTTCTT TTCTTG TCTTGC CTTGCT TTGCTT TGCTTT GCTTTC CTTTCG TTTCGT TTCGTG TCGTGG CGTGGT GTGGTA TGGTAT GGTATT GTATTC TATTCT ATTCTT TTCTTG TCTTGC CTTGCT TTGCTA TGCTAG GCTAGT CTAGTT TAGTTA AGTTAC GTTACA TTACAC TACACT ACACTA CACTAG ACTAGC CTAGCC TAGCCA AGCCAT GCCATC CCATCC CATCCT ATCCTT TCCTTA CCTTAC CTTACT,1,100,ATGT TGTA GTAC TACT ACTC CTCA TCAT CATT ATTC TTCG TCGT CGTT GTTT TTTC TTCG TCGG CGGA GGAA GAAG AAGA AGAG GAGA AGAT GATA ATAG TAGG AGGT GGTA GTAC TACG ACGT CGTT GTTA TTAA TAAT AATA ATAG TAGT AGTT GTTA TTAA TAAT AATA ATAG TAGC AGCG GCGT CGTA GTAC TACT ACTT CTTC TTCT TCTT CTTT TTTT TTTT TTTC TTCT TCTT CTTG TTGC TGCT GCTT CTTT TTTC TTCG TCGT CGTG GTGG TGGT GGTA GTAT TATT ATTC TTCT TCTT CTTG TTGC TGCT GCTA CTAG TAGT AGTT GTTA TTAC TACA ACAC CACT ACTA CTAG TAGC AGCC GCCA CCAT CATC ATCC TCCT CCTT CTTA TTAC TACT,ATGTA TGTAC GTACT TACTC ACTCA CTCAT TCATT CATTC ATTCG TTCGT TCGTT CGTTT GTTTC TTTCG TTCGG TCGGA CGGAA GGAAG GAAGA AAGAG AGAGA GAGAT AGATA GATAG ATAGG TAGGT AGGTA GGTAC GTACG TACGT ACGTT CGTTA GTTAA TTAAT TAATA AATAG ATAGT TAGTT AGTTA GTTAA TTAAT TAATA AATAG ATAGC TAGCG AGCGT GCGTA CGTAC GTACT TACTT ACTTC CTTCT TTCTT TCTTT CTTTT TTTTT TTTTC TTTCT TTCTT TCTTG CTTGC TTGCT TGCTT GCTTT CTTTC TTTCG TTCGT TCGTG CGTGG GTGGT TGGTA GGTAT GTATT TATTC ATTCT TTCTT TCTTG CTTGC TTGCT TGCTA GCTAG CTAGT TAGTT AGTTA GTTAC TTACA TACAC ACACT CACTA ACTAG CTAGC TAGCC AGCCA GCCAT CCATC CATCC ATCCT TCCTT CCTTA CTTAC TTACT,ATGTAC TGTACT GTACTC TACTCA ACTCAT CTCATT TCATTC CATTCG ATTCGT TTCGTT TCGTTT CGTTTC GTTTCG TTTCGG TTCGGA TCGGAA CGGAAG GGAAGA GAAGAG AAGAGA AGAGAT GAGATA AGATAG GATAGG ATAGGT TAGGTA AGGTAC GGTACG GTACGT TACGTT ACGTTA CGTTAA GTTAAT TTAATA TAATAG AATAGT ATAGTT TAGTTA AGTTAA GTTAAT TTAATA TAATAG AATAGC ATAGCG TAGCGT AGCGTA GCGTAC CGTACT GTACTT TACTTC ACTTCT CTTCTT TTCTTT TCTTTT CTTTTT TTTTTC TTTTCT TTTCTT TTCTTG TCTTGC CTTGCT TTGCTT TGCTTT GCTTTC CTTTCG TTTCGT TTCGTG TCGTGG CGTGGT GTGGTA TGGTAT GGTATT GTATTC TATTCT ATTCTT TTCTTG TCTTGC CTTGCT TTGCTA TGCTAG GCTAGT CTAGTT TAGTTA AGTTAC GTTACA TTACAC TACACT ACACTA CACTAG ACTAGC CTAGCC TAGCCA AGCCAT GCCATC CCATCC CATCCT ATCCTT TCCTTA CCTTAC CTTACT,ATGTACT TGTACTC GTACTCA TACTCAT ACTCATT CTCATTC TCATTCG CATTCGT ATTCGTT TTCGTTT TCGTTTC CGTTTCG GTTTCGG TTTCGGA TTCGGAA TCGGAAG CGGAAGA GGAAGAG GAAGAGA AAGAGAT AGAGATA GAGATAG AGATAGG GATAGGT ATAGGTA TAGGTAC AGGTACG GGTACGT GTACGTT TACGTTA ACGTTAA CGTTAAT GTTAATA TTAATAG TAATAGT AATAGTT ATAGTTA TAGTTAA AGTTAAT GTTAATA TTAATAG TAATAGC AATAGCG ATAGCGT TAGCGTA AGCGTAC GCGTACT CGTACTT GTACTTC TACTTCT ACTTCTT CTTCTTT TTCTTTT TCTTTTT CTTTTTC TTTTTCT TTTTCTT TTTCTTG TTCTTGC TCTTGCT CTTGCTT TTGCTTT TGCTTTC GCTTTCG CTTTCGT TTTCGTG TTCGTGG TCGTGGT CGTGGTA GTGGTAT TGGTATT GGTATTC GTATTCT TATTCTT ATTCTTG TTCTTGC TCTTGCT CTTGCTA TTGCTAG TGCTAGT GCTAGTT CTAGTTA TAGTTAC AGTTACA GTTACAC TTACACT TACACTA ACACTAG CACTAGC ACTAGCC CTAGCCA TAGCCAT AGCCATC GCCATCC CCATCCT CATCCTT ATCCTTA TCCTTAC CCTTACT,"ID   VEMP_SARS2              Reviewed;          75 AA.
AC   P0DTC4;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Envelope small membrane protein {ECO:0000255|HAMAP-Rule:MF_04204};
DE            Short=E;
DE            Short=sM protein {ECO:0000255|HAMAP-Rule:MF_04204};
GN   Name=E {ECO:0000255|HAMAP-Rule:MF_04204}; ORFNames=4;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   FUNCTION, AND INTERACTION WITH HUMAN PALS1/MPP5.
RX   PubMed=32891874; DOI=10.1016/j.micinf.2020.08.006;
RA   De Maio F., Lo Cascio E., Babini G., Sali M., Della Longa S., Tilocca B.,
RA   Roncada P., Arcovito A., Sanguinetti M., Scambia G., Urbani A.;
RT   ""Improved binding of SARS-CoV-2 Envelope protein to tight junction-
RT   associated PALS1 could play a key role in COVID-19 pathogenesis."";
RL   Microbes Infect. 22:592-597(2020).
RN   [3]
RP   TOPOLOGY.
RX   PubMed=32898469; DOI=10.1098/rsob.200209;
RA   Duart G., Garcia-Murria M.J., Grau B., Acosta-Caceres J.M.,
RA   Martinez-Gil L., Mingarro I.;
RT   ""SARS-CoV-2 envelope protein topology in eukaryotic membranes."";
RL   Open Biol. 10:200209-200209(2020).
RN   [4]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [5]
RP   STRUCTURE BY NMR OF 8-38, SUBUNIT, SUBCELLULAR LOCATION, AND TOPOLOGY.
RX   PubMed=33177698; DOI=10.1038/s41594-020-00536-8;
RA   Mandala V.S., McKay M.J., Shcherbakov A.A., Dregni A.J., Kolocouris A.,
RA   Hong M.;
RT   ""Structure and drug binding of the SARS-CoV-2 envelope protein
RT   transmembrane domain in lipid bilayers."";
RL   Nat. Struct. Mol. Biol. 27:1202-1208(2020).
RN   [6]
RP   FUNCTION.
RX   PubMed=33229438; DOI=10.1074/jbc.ra120.016175;
RA   Boson B., Legros V., Zhou B., Siret E., Mathieu C., Cosset F.L.,
RA   Lavillette D., Denolly S.;
RT   ""The SARS-CoV-2 Envelope and Membrane proteins modulate maturation and
RT   retention of the Spike protein, allowing assembly of virus-like
RT   particles."";
RL   J. Biol. Chem. 296:100111-100111(2020).
RN   [7] {ECO:0007744|PDB:7QCR, ECO:0007744|PDB:7QCS, ECO:0007744|PDB:7QCT}
RP   X-RAY CRYSTALLOGRAPHY (2.28 ANGSTROMS) OF 64-75, INTERACTION WITH HOST
RP   PALS1/MPP5, INTERACTION WITH HOST TJP1/ZO1, INTERACTION WITH HOST LNX2,
RP   INTERACTION WITH HOST PARD3, INTERACTION WITH HOST AFDN/MLLT4, AND
RP   MUTAGENESIS OF PRO-71.
RX   PubMed=35283834; DOI=10.3389/fmicb.2022.829094;
RA   Zhu Y., Alvarez F., Wolff N., Mechaly A., Brule S., Neitthoffer B.,
RA   Etienne-Manneville S., Haouz A., Boeda B., Caillet-Saguy C.;
RT   ""Interactions of Severe Acute Respiratory Syndrome Coronavirus 2 Protein E
RT   With Cell Junctions and Polarity PSD-95/Dlg/ZO-1-Containing Proteins."";
RL   Front. Microbiol. 13:829094-829094(2022).
CC   -!- FUNCTION: Plays a central role in virus morphogenesis and assembly.
CC       Acts as a viroporin and self-assembles in host membranes forming
CC       pentameric protein-lipid pores that allow ion transport. Also plays a
CC       role in the induction of apoptosis (By similarity). Regulates the
CC       localization of S protein at cis-Golgi, the place of virus budding
CC       (PubMed:33229438). May act by slowing down the cell secretory pathway
CC       (PubMed:33229438). May interfere with tight-junction stability by
CC       interacting with host MPP5. This would result in disruption of
CC       epithelial barriers, thereby amplifying inflammatory processes
CC       (PubMed:32891874). {ECO:0000255|HAMAP-Rule:MF_04204,
CC       ECO:0000269|PubMed:33229438, ECO:0000303|PubMed:32891874}.
CC   -!- SUBUNIT: Homopentamer (PubMed:33177698). Interacts via C-terminus PDM
CC       domain with PDZ domain-containing host proteins such as PALS1/MPP5
CC       (PubMed:32891874, PubMed:35283834), TJP1/ZO1 (PubMed:35283834), LNX2
CC       (PubMed:35283834), PARD3 (PubMed:35283834), and AFDN/MLLT4
CC       (PubMed:35283834). This may lead to disruption of tight junctions
CC       between epithelial cells (PubMed:32891874). Interacts with membrane
CC       protein M in the budding compartment of the host cell, which is located
CC       between endoplasmic reticulum and the Golgi complex. Interacts with
CC       Nucleoprotein (By similarity). {ECO:0000250|UniProtKB:P59637,
CC       ECO:0000255|HAMAP-Rule:MF_04204, ECO:0000269|PubMed:33177698,
CC       ECO:0000269|PubMed:35283834, ECO:0000303|PubMed:32891874}.
CC   -!- INTERACTION:
CC       P0DTC4; P0DTD8: 7b; NbExp=5; IntAct=EBI-25475850, EBI-25475914;
CC       P0DTC4; P0DTC4: E; NbExp=6; IntAct=EBI-25475850, EBI-25475850;
CC       P0DTC4; P0DTC5: M; NbExp=5; IntAct=EBI-25475850, EBI-25475853;
CC       P0DTC4; P0DTC9: N; NbExp=3; IntAct=EBI-25475850, EBI-25475856;
CC       P0DTC4; O95429: BAG4; Xeno; NbExp=3; IntAct=EBI-25475850, EBI-2949658;
CC       P0DTC4; PRO_0000018590 [Q07021]: C1QBP; Xeno; NbExp=2; IntAct=EBI-25475850, EBI-14032968;
CC       P0DTC4; Q8N3R9: PALS1; Xeno; NbExp=6; IntAct=EBI-25475850, EBI-2513978;
CC       P0DTC4; O75360: PROP1; Xeno; NbExp=3; IntAct=EBI-25475850, EBI-9027467;
CC       P0DTC4; P61165: TMEM258; Xeno; NbExp=3; IntAct=EBI-25475850, EBI-12019210;
CC       P0DTC4; Q86VM9: ZC3H18; Xeno; NbExp=3; IntAct=EBI-25475850, EBI-1045965;
CC   -!- SUBCELLULAR LOCATION: Host Golgi apparatus membrane {ECO:0000255|HAMAP-
CC       Rule:MF_04204}; Single-pass type III membrane protein
CC       {ECO:0000255|HAMAP-Rule:MF_04204, ECO:0000269|PubMed:32898469,
CC       ECO:0000269|PubMed:33177698}. Note=The cytoplasmic tail functions as a
CC       Golgi complex-targeting signal. {ECO:0000255|HAMAP-Rule:MF_04204}.
CC   -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC       isolated in South Africa (November 2021). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC       isolated in Nigeria (November 2022). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC       isolated in United States (November 2022). It is the result of
CC       recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC       express ORF8. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the betacoronaviruses E protein family.
CC       {ECO:0000255|HAMAP-Rule:MF_04204}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43418.1; -; Genomic_RNA.
DR   PDB; 7K3G; NMR; -; A/B/C/D/E=8-38.
DR   PDB; 7M4R; EM; 3.65 A; C=58-75.
DR   PDB; 7NTK; X-ray; 1.90 A; C/E/G/H=68-75.
DR   PDB; 7QCR; X-ray; 2.28 A; C/D=64-75.
DR   PDB; 7QCS; X-ray; 2.80 A; C/D=64-75.
DR   PDB; 7QCT; X-ray; 3.20 A; C/D=64-75.
DR   PDB; 7TUQ; X-ray; 2.68 A; C=60-68.
DR   PDB; 7TV0; X-ray; 2.60 A; E/G=53-64.
DR   PDB; 8SUZ; NMR; -; A/B/C/D/E=8-38.
DR   PDB; 8U1T; NMR; -; A/B=12-37.
DR   PDBsum; 7K3G; -.
DR   PDBsum; 7M4R; -.
DR   PDBsum; 7NTK; -.
DR   PDBsum; 7QCR; -.
DR   PDBsum; 7QCS; -.
DR   PDBsum; 7QCT; -.
DR   PDBsum; 7TUQ; -.
DR   PDBsum; 7TV0; -.
DR   PDBsum; 8SUZ; -.
DR   PDBsum; 8U1T; -.
DR   BMRB; P0DTC4; -.
DR   EMDB; EMD-23665; -.
DR   SMR; P0DTC4; -.
DR   BioGRID; 4383845; 1097.
DR   IntAct; P0DTC4; 71.
DR   MINT; P0DTC4; -.
DR   TCDB; 1.A.65.1.7; the coronavirus viroporin e protein (viroporin e) family.
DR   ABCD; P0DTC4; 9 sequenced antibodies.
DR   KEGG; vg:43740570; -.
DR   AGR; RefSeq:YP_009724392; -.
DR   Reactome; R-HSA-191650; Regulation of gap junction activity.
DR   Reactome; R-HSA-420029; Tight junction interactions.
DR   Reactome; R-HSA-9694322; Virion Assembly and Release.
DR   Reactome; R-HSA-9694493; Maturation of protein E.
DR   Reactome; R-HSA-9694614; Attachment and Entry.
DR   Reactome; R-HSA-9694635; Translation of Structural Proteins.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9705677; SARS-CoV-2 targets PDZ proteins in cell-cell junction.
DR   Reactome; R-HSA-9733458; Induction of Cell-Cell Fusion.
DR   PRO; PR:P0DTC4; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0005793; C:endoplasmic reticulum-Golgi intermediate compartment; ISS:UniProt.
DR   GO; GO:0044178; C:host cell Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-UniRule.
DR   GO; GO:0055036; C:virion membrane; TAS:Reactome.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0005216; F:monoatomic ion channel activity; IDA:UniProt.
DR   GO; GO:0039660; F:structural constituent of virion; IDA:UniProt.
DR   GO; GO:0039709; P:cytoplasmic capsid assembly; IDA:UniProt.
DR   GO; GO:0140975; P:disruption of cellular anatomical structure in another organism; IEA:UniProtKB-UniRule.
DR   GO; GO:0046760; P:viral budding from Golgi membrane; IEA:UniProtKB-UniRule.
DR   CDD; cd21536; SARS-CoV-2_E; 1.
DR   Gene3D; 6.10.250.1810; -; 1.
DR   HAMAP; MF_04204; BETA_CORONA_E; 1.
DR   InterPro; IPR043506; E_protein_bCoV.
DR   InterPro; IPR003873; E_protein_CoV.
DR   InterPro; IPR044377; E_SARS-CoV-2.
DR   Pfam; PF02723; CoV_E; 1.
DR   PROSITE; PS51926; COV_E; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Apoptosis; Host Golgi apparatus; Host membrane; Membrane;
KW   Reference proteome; Transmembrane; Transmembrane helix.
FT   CHAIN           1..75
FT                   /note=""Envelope small membrane protein""
FT                   /id=""PRO_0000449651""
FT   TOPO_DOM        1..13
FT                   /note=""Virion surface""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04204,
FT                   ECO:0000305|PubMed:32898469""
FT   TRANSMEM        14..34
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04204,
FT                   ECO:0000269|PubMed:33177698, ECO:0000305|PubMed:32898469""
FT   TOPO_DOM        35..75
FT                   /note=""Intravirion""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04204,
FT                   ECO:0000305|PubMed:32898469""
FT   REGION          61..75
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000305|PubMed:35108439""
FT   MOTIF           72..75
FT                   /note=""PDZ-binding; required for interaction with human
FT                   MPP5""
FT                   /evidence=""ECO:0000250|UniProtKB:P59637""
FT   VARIANT         9
FT                   /note=""T -> I (in strain: Omicron/BA.1, Omicron/BA.2,
FT                   Omicron/BA.2.12.1, Omicron/BA.2.75, Omicron/BA.4,
FT                   Omicron/BA.5, Omicron/BQ.1.1, Omicron/XBB.1.5)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         11
FT                   /note=""T -> A (in strain: Omicron/XBB.1.5, Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         21
FT                   /note=""L -> F (in strain: Eta/B.1.525)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         71
FT                   /note=""P -> L (in strain: Beta/B.1.351)""
FT                   /evidence=""ECO:0000305""
FT   MUTAGEN         71
FT                   /note=""P->L: Complete loss of interaction with host PARD3
FT                   and MLLT4. Partial loss of interaction with host ZO1.""
FT                   /evidence=""ECO:0000269|PubMed:35283834""
FT   HELIX           11..18
FT                   /evidence=""ECO:0007829|PDB:7K3G""
FT   HELIX           19..21
FT                   /evidence=""ECO:0007829|PDB:7K3G""
FT   HELIX           22..36
FT                   /evidence=""ECO:0007829|PDB:7K3G""
FT   HELIX           56..62
FT                   /evidence=""ECO:0007829|PDB:7TV0""
FT   STRAND          72..75
FT                   /evidence=""ECO:0007829|PDB:7QCT""
SQ   SEQUENCE   75 AA;  8365 MW;  5C431BD2AA1B6B99 CRC64;
     MYSFVSEETG TLIVNSVLLF LAFVVFLLVT LAILTALRLC AYCCNIVNVS LVKPSFYVYS
     RVKNLNSSRV PDLLV
//
",49082
CCTACA CTACAC TACACT ACACTA CACTAG ACTAGT CTAGTG TAGTGA AGTGAC GTGACA TGACAC GACACA ACACAT CACATG ACATGA CATGAG ATGAGC TGAGCA GAGCAC AGCACT GCACTA CACTAT ACTATG CTATGT TATGTT ATGTTA TGTTAG GTTAGA TTAGAA TAGAAT AGAATA GAATAG AATAGC ATAGCT TAGCTG AGCTGG GCTGGC CTGGCT TGGCTT GGCTTA GCTTAT CTTATA TTATAC TATACC ATACCC TACCCA ACCCAA CCCAAC CCAACA CAACAC AACACT ACACTC CACTCA ACTCAA CTCAAT TCAATT CAATTG AATTGC ATTGCT TTGCTC TGCTCA GCTCAG CTCAGA TCAGAT,0,64,CCTA CTAC TACA ACAC CACT ACTA CTAG TAGT AGTG GTGA TGAC GACA ACAC CACA ACAT CATG ATGA TGAG GAGC AGCA GCAC CACT ACTA CTAT TATG ATGT TGTT GTTA TTAG TAGA AGAA GAAT AATA ATAG TAGC AGCT GCTG CTGG TGGC GGCT GCTT CTTA TTAT TATA ATAC TACC ACCC CCCA CCAA CAAC AACA ACAC CACT ACTC CTCA TCAA CAAT AATT ATTG TTGC TGCT GCTC CTCA TCAG CAGA AGAT,CCTAC CTACA TACAC ACACT CACTA ACTAG CTAGT TAGTG AGTGA GTGAC TGACA GACAC ACACA CACAT ACATG CATGA ATGAG TGAGC GAGCA AGCAC GCACT CACTA ACTAT CTATG TATGT ATGTT TGTTA GTTAG TTAGA TAGAA AGAAT GAATA AATAG ATAGC TAGCT AGCTG GCTGG CTGGC TGGCT GGCTT GCTTA CTTAT TTATA TATAC ATACC TACCC ACCCA CCCAA CCAAC CAACA AACAC ACACT CACTC ACTCA CTCAA TCAAT CAATT AATTG ATTGC TTGCT TGCTC GCTCA CTCAG TCAGA CAGAT,CCTACA CTACAC TACACT ACACTA CACTAG ACTAGT CTAGTG TAGTGA AGTGAC GTGACA TGACAC GACACA ACACAT CACATG ACATGA CATGAG ATGAGC TGAGCA GAGCAC AGCACT GCACTA CACTAT ACTATG CTATGT TATGTT ATGTTA TGTTAG GTTAGA TTAGAA TAGAAT AGAATA GAATAG AATAGC ATAGCT TAGCTG AGCTGG GCTGGC CTGGCT TGGCTT GGCTTA GCTTAT CTTATA TTATAC TATACC ATACCC TACCCA ACCCAA CCCAAC CCAACA CAACAC AACACT ACACTC CACTCA ACTCAA CTCAAT TCAATT CAATTG AATTGC ATTGCT TTGCTC TGCTCA GCTCAG CTCAGA TCAGAT,CCTACAC CTACACT TACACTA ACACTAG CACTAGT ACTAGTG CTAGTGA TAGTGAC AGTGACA GTGACAC TGACACA GACACAT ACACATG CACATGA ACATGAG CATGAGC ATGAGCA TGAGCAC GAGCACT AGCACTA GCACTAT CACTATG ACTATGT CTATGTT TATGTTA ATGTTAG TGTTAGA GTTAGAA TTAGAAT TAGAATA AGAATAG GAATAGC AATAGCT ATAGCTG TAGCTGG AGCTGGC GCTGGCT CTGGCTT TGGCTTA GGCTTAT GCTTATA CTTATAC TTATACC TATACCC ATACCCA TACCCAA ACCCAAC CCCAACA CCAACAC CAACACT AACACTC ACACTCA CACTCAA ACTCAAT CTCAATT TCAATTG CAATTGC AATTGCT ATTGCTC TTGCTCA TGCTCAG GCTCAGA CTCAGAT,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",18919
GTTACA TTACAG TACAGC ACAGCG CAGCGT AGCGTA GCGTAT CGTATA GTATAA TATAAT ATAATG TAATGG AATGGT ATGGTT TGGTTA GGTTAT GTTATC TTATCT TATCTT ATCTTA TCTTAC CTTACT TTACTT TACTTC ACTTCT CTTCTT TTCTTC TCTTCT CTTCTT TTCTTC TCTTCT CTTCTA TTCTAA TCTAAA CTAAAA TAAAAC AAAACA AAACAC AACACC ACACCT CACCTG ACCTGA CCTGAA CTGAAG TGAAGA GAAGAA AAGAAC AGAACA GAACAT AACATT ACATTT CATTTT ATTTTA TTTTAT TTTATT TTATTG TATTGA ATTGAA TTGAAA TGAAAC GAAACC AAACCA AACCAT ACCATC CCATCT CATCTC ATCTCA TCTCAC CTCACT TCACTT CACTTG ACTTGC CTTGCT TTGCTG TGCTGG GCTGGT CTGGTT TGGTTC GGTTCC GTTCCT TTCCTA TCCTAT CCTATA CTATAA TATAAA ATAAAG TAAAGA AAAGAT AAGATT AGATTG GATTGG ATTGGT TTGGTC TGGTCC GGTCCT GTCCTA TCCTAT CCTATT CTATTC TATTCT ATTCTG TTCTGG TCTGGA CTGGAC TGGACA GGACAA GACAAT ACAATC CAATCT AATCTA ATCTAC TCTACA CTACAC TACACA ACACAA CACAAC ACAACT CAACTA AACTAG ACTAGG CTAGGT TAGGTA AGGTAT GGTATA GTATAG TATAGA ATAGAA TAGAAT AGAATT GAATTT AATTTC ATTTCT TTTCTT TTCTTA TCTTAA CTTAAG,0,136,GTTA TTAC TACA ACAG CAGC AGCG GCGT CGTA GTAT TATA ATAA TAAT AATG ATGG TGGT GGTT GTTA TTAT TATC ATCT TCTT CTTA TTAC TACT ACTT CTTC TTCT TCTT CTTC TTCT TCTT CTTC TTCT TCTA CTAA TAAA AAAA AAAC AACA ACAC CACC ACCT CCTG CTGA TGAA GAAG AAGA AGAA GAAC AACA ACAT CATT ATTT TTTT TTTA TTAT TATT ATTG TTGA TGAA GAAA AAAC AACC ACCA CCAT CATC ATCT TCTC CTCA TCAC CACT ACTT CTTG TTGC TGCT GCTG CTGG TGGT GGTT GTTC TTCC TCCT CCTA CTAT TATA ATAA TAAA AAAG AAGA AGAT GATT ATTG TTGG TGGT GGTC GTCC TCCT CCTA CTAT TATT ATTC TTCT TCTG CTGG TGGA GGAC GACA ACAA CAAT AATC ATCT TCTA CTAC TACA ACAC CACA ACAA CAAC AACT ACTA CTAG TAGG AGGT GGTA GTAT TATA ATAG TAGA AGAA GAAT AATT ATTT TTTC TTCT TCTT CTTA TTAA TAAG,GTTAC TTACA TACAG ACAGC CAGCG AGCGT GCGTA CGTAT GTATA TATAA ATAAT TAATG AATGG ATGGT TGGTT GGTTA GTTAT TTATC TATCT ATCTT TCTTA CTTAC TTACT TACTT ACTTC CTTCT TTCTT TCTTC CTTCT TTCTT TCTTC CTTCT TTCTA TCTAA CTAAA TAAAA AAAAC AAACA AACAC ACACC CACCT ACCTG CCTGA CTGAA TGAAG GAAGA AAGAA AGAAC GAACA AACAT ACATT CATTT ATTTT TTTTA TTTAT TTATT TATTG ATTGA TTGAA TGAAA GAAAC AAACC AACCA ACCAT CCATC CATCT ATCTC TCTCA CTCAC TCACT CACTT ACTTG CTTGC TTGCT TGCTG GCTGG CTGGT TGGTT GGTTC GTTCC TTCCT TCCTA CCTAT CTATA TATAA ATAAA TAAAG AAAGA AAGAT AGATT GATTG ATTGG TTGGT TGGTC GGTCC GTCCT TCCTA CCTAT CTATT TATTC ATTCT TTCTG TCTGG CTGGA TGGAC GGACA GACAA ACAAT CAATC AATCT ATCTA TCTAC CTACA TACAC ACACA CACAA ACAAC CAACT AACTA ACTAG CTAGG TAGGT AGGTA GGTAT GTATA TATAG ATAGA TAGAA AGAAT GAATT AATTT ATTTC TTTCT TTCTT TCTTA CTTAA TTAAG,GTTACA TTACAG TACAGC ACAGCG CAGCGT AGCGTA GCGTAT CGTATA GTATAA TATAAT ATAATG TAATGG AATGGT ATGGTT TGGTTA GGTTAT GTTATC TTATCT TATCTT ATCTTA TCTTAC CTTACT TTACTT TACTTC ACTTCT CTTCTT TTCTTC TCTTCT CTTCTT TTCTTC TCTTCT CTTCTA TTCTAA TCTAAA CTAAAA TAAAAC AAAACA AAACAC AACACC ACACCT CACCTG ACCTGA CCTGAA CTGAAG TGAAGA GAAGAA AAGAAC AGAACA GAACAT AACATT ACATTT CATTTT ATTTTA TTTTAT TTTATT TTATTG TATTGA ATTGAA TTGAAA TGAAAC GAAACC AAACCA AACCAT ACCATC CCATCT CATCTC ATCTCA TCTCAC CTCACT TCACTT CACTTG ACTTGC CTTGCT TTGCTG TGCTGG GCTGGT CTGGTT TGGTTC GGTTCC GTTCCT TTCCTA TCCTAT CCTATA CTATAA TATAAA ATAAAG TAAAGA AAAGAT AAGATT AGATTG GATTGG ATTGGT TTGGTC TGGTCC GGTCCT GTCCTA TCCTAT CCTATT CTATTC TATTCT ATTCTG TTCTGG TCTGGA CTGGAC TGGACA GGACAA GACAAT ACAATC CAATCT AATCTA ATCTAC TCTACA CTACAC TACACA ACACAA CACAAC ACAACT CAACTA AACTAG ACTAGG CTAGGT TAGGTA AGGTAT GGTATA GTATAG TATAGA ATAGAA TAGAAT AGAATT GAATTT AATTTC ATTTCT TTTCTT TTCTTA TCTTAA CTTAAG,GTTACAG TTACAGC TACAGCG ACAGCGT CAGCGTA AGCGTAT GCGTATA CGTATAA GTATAAT TATAATG ATAATGG TAATGGT AATGGTT ATGGTTA TGGTTAT GGTTATC GTTATCT TTATCTT TATCTTA ATCTTAC TCTTACT CTTACTT TTACTTC TACTTCT ACTTCTT CTTCTTC TTCTTCT TCTTCTT CTTCTTC TTCTTCT TCTTCTA CTTCTAA TTCTAAA TCTAAAA CTAAAAC TAAAACA AAAACAC AAACACC AACACCT ACACCTG CACCTGA ACCTGAA CCTGAAG CTGAAGA TGAAGAA GAAGAAC AAGAACA AGAACAT GAACATT AACATTT ACATTTT CATTTTA ATTTTAT TTTTATT TTTATTG TTATTGA TATTGAA ATTGAAA TTGAAAC TGAAACC GAAACCA AAACCAT AACCATC ACCATCT CCATCTC CATCTCA ATCTCAC TCTCACT CTCACTT TCACTTG CACTTGC ACTTGCT CTTGCTG TTGCTGG TGCTGGT GCTGGTT CTGGTTC TGGTTCC GGTTCCT GTTCCTA TTCCTAT TCCTATA CCTATAA CTATAAA TATAAAG ATAAAGA TAAAGAT AAAGATT AAGATTG AGATTGG GATTGGT ATTGGTC TTGGTCC TGGTCCT GGTCCTA GTCCTAT TCCTATT CCTATTC CTATTCT TATTCTG ATTCTGG TTCTGGA TCTGGAC CTGGACA TGGACAA GGACAAT GACAATC ACAATCT CAATCTA AATCTAC ATCTACA TCTACAC CTACACA TACACAA ACACAAC CACAACT ACAACTA CAACTAG AACTAGG ACTAGGT CTAGGTA TAGGTAT AGGTATA GGTATAG GTATAGA TATAGAA ATAGAAT TAGAATT AGAATTT GAATTTC AATTTCT ATTTCTT TTTCTTA TTCTTAA TCTTAAG,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",1843
CCAACA CAACAG AACAGT ACAGTG CAGTGG AGTGGT GTGGTT TGGTTG GGTTGT GTTGTT TTGTTA TGTTAA GTTAAT TTAATG TAATGC AATGCA ATGCAG TGCAGC GCAGCC CAGCCA AGCCAA GCCAAT CCAATG CAATGT AATGTT ATGTTT TGTTTA GTTTAC TTTACC TTACCT TACCTT ACCTTA CCTTAA CTTAAA TTAAAC TAAACA AAACAT AACATG ACATGG CATGGA ATGGAG TGGAGG GGAGGA GAGGAG AGGAGG GGAGGT GAGGTG AGGTGT GGTGTT GTGTTG TGTTGC GTTGCA TTGCAG TGCAGG GCAGGA CAGGAG AGGAGC GGAGCC GAGCCT AGCCTT GCCTTA CCTTAA CTTAAA TTAAAT TAAATA AAATAA AATAAG ATAAGG TAAGGC AAGGCT AGGCTA GGCTAC GCTACT CTACTA TACTAA ACTAAC CTAACA TAACAA AACAAT ACAATG CAATGC AATGCC ATGCCA TGCCAT GCCATG CCATGC CATGCA ATGCAA TGCAAG GCAAGT CAAGTT AAGTTG AGTTGA GTTGAA TTGAAT TGAATC GAATCT AATCTG ATCTGA TCTGAT CTGATG TGATGA GATGAT ATGATT TGATTA GATTAC ATTACA TTACAT TACATA ACATAG CATAGC ATAGCT TAGCTA AGCTAC GCTACT CTACTA TACTAA ACTAAT CTAATG TAATGG AATGGA ATGGAC TGGACC GGACCA GACCAC ACCACT CCACTT CACTTA ACTTAA CTTAAA TTAAAG TAAAGT AAAGTG AAGTGG AGTGGG GTGGGT TGGGTG GGGTGG GGTGGT GTGGTA TGGTAG GGTAGT,0,142,CCAA CAAC AACA ACAG CAGT AGTG GTGG TGGT GGTT GTTG TTGT TGTT GTTA TTAA TAAT AATG ATGC TGCA GCAG CAGC AGCC GCCA CCAA CAAT AATG ATGT TGTT GTTT TTTA TTAC TACC ACCT CCTT CTTA TTAA TAAA AAAC AACA ACAT CATG ATGG TGGA GGAG GAGG AGGA GGAG GAGG AGGT GGTG GTGT TGTT GTTG TTGC TGCA GCAG CAGG AGGA GGAG GAGC AGCC GCCT CCTT CTTA TTAA TAAA AAAT AATA ATAA TAAG AAGG AGGC GGCT GCTA CTAC TACT ACTA CTAA TAAC AACA ACAA CAAT AATG ATGC TGCC GCCA CCAT CATG ATGC TGCA GCAA CAAG AAGT AGTT GTTG TTGA TGAA GAAT AATC ATCT TCTG CTGA TGAT GATG ATGA TGAT GATT ATTA TTAC TACA ACAT CATA ATAG TAGC AGCT GCTA CTAC TACT ACTA CTAA TAAT AATG ATGG TGGA GGAC GACC ACCA CCAC CACT ACTT CTTA TTAA TAAA AAAG AAGT AGTG GTGG TGGG GGGT GGTG GTGG TGGT GGTA GTAG TAGT,CCAAC CAACA AACAG ACAGT CAGTG AGTGG GTGGT TGGTT GGTTG GTTGT TTGTT TGTTA GTTAA TTAAT TAATG AATGC ATGCA TGCAG GCAGC CAGCC AGCCA GCCAA CCAAT CAATG AATGT ATGTT TGTTT GTTTA TTTAC TTACC TACCT ACCTT CCTTA CTTAA TTAAA TAAAC AAACA AACAT ACATG CATGG ATGGA TGGAG GGAGG GAGGA AGGAG GGAGG GAGGT AGGTG GGTGT GTGTT TGTTG GTTGC TTGCA TGCAG GCAGG CAGGA AGGAG GGAGC GAGCC AGCCT GCCTT CCTTA CTTAA TTAAA TAAAT AAATA AATAA ATAAG TAAGG AAGGC AGGCT GGCTA GCTAC CTACT TACTA ACTAA CTAAC TAACA AACAA ACAAT CAATG AATGC ATGCC TGCCA GCCAT CCATG CATGC ATGCA TGCAA GCAAG CAAGT AAGTT AGTTG GTTGA TTGAA TGAAT GAATC AATCT ATCTG TCTGA CTGAT TGATG GATGA ATGAT TGATT GATTA ATTAC TTACA TACAT ACATA CATAG ATAGC TAGCT AGCTA GCTAC CTACT TACTA ACTAA CTAAT TAATG AATGG ATGGA TGGAC GGACC GACCA ACCAC CCACT CACTT ACTTA CTTAA TTAAA TAAAG AAAGT AAGTG AGTGG GTGGG TGGGT GGGTG GGTGG GTGGT TGGTA GGTAG GTAGT,CCAACA CAACAG AACAGT ACAGTG CAGTGG AGTGGT GTGGTT TGGTTG GGTTGT GTTGTT TTGTTA TGTTAA GTTAAT TTAATG TAATGC AATGCA ATGCAG TGCAGC GCAGCC CAGCCA AGCCAA GCCAAT CCAATG CAATGT AATGTT ATGTTT TGTTTA GTTTAC TTTACC TTACCT TACCTT ACCTTA CCTTAA CTTAAA TTAAAC TAAACA AAACAT AACATG ACATGG CATGGA ATGGAG TGGAGG GGAGGA GAGGAG AGGAGG GGAGGT GAGGTG AGGTGT GGTGTT GTGTTG TGTTGC GTTGCA TTGCAG TGCAGG GCAGGA CAGGAG AGGAGC GGAGCC GAGCCT AGCCTT GCCTTA CCTTAA CTTAAA TTAAAT TAAATA AAATAA AATAAG ATAAGG TAAGGC AAGGCT AGGCTA GGCTAC GCTACT CTACTA TACTAA ACTAAC CTAACA TAACAA AACAAT ACAATG CAATGC AATGCC ATGCCA TGCCAT GCCATG CCATGC CATGCA ATGCAA TGCAAG GCAAGT CAAGTT AAGTTG AGTTGA GTTGAA TTGAAT TGAATC GAATCT AATCTG ATCTGA TCTGAT CTGATG TGATGA GATGAT ATGATT TGATTA GATTAC ATTACA TTACAT TACATA ACATAG CATAGC ATAGCT TAGCTA AGCTAC GCTACT CTACTA TACTAA ACTAAT CTAATG TAATGG AATGGA ATGGAC TGGACC GGACCA GACCAC ACCACT CCACTT CACTTA ACTTAA CTTAAA TTAAAG TAAAGT AAAGTG AAGTGG AGTGGG GTGGGT TGGGTG GGGTGG GGTGGT GTGGTA TGGTAG GGTAGT,CCAACAG CAACAGT AACAGTG ACAGTGG CAGTGGT AGTGGTT GTGGTTG TGGTTGT GGTTGTT GTTGTTA TTGTTAA TGTTAAT GTTAATG TTAATGC TAATGCA AATGCAG ATGCAGC TGCAGCC GCAGCCA CAGCCAA AGCCAAT GCCAATG CCAATGT CAATGTT AATGTTT ATGTTTA TGTTTAC GTTTACC TTTACCT TTACCTT TACCTTA ACCTTAA CCTTAAA CTTAAAC TTAAACA TAAACAT AAACATG AACATGG ACATGGA CATGGAG ATGGAGG TGGAGGA GGAGGAG GAGGAGG AGGAGGT GGAGGTG GAGGTGT AGGTGTT GGTGTTG GTGTTGC TGTTGCA GTTGCAG TTGCAGG TGCAGGA GCAGGAG CAGGAGC AGGAGCC GGAGCCT GAGCCTT AGCCTTA GCCTTAA CCTTAAA CTTAAAT TTAAATA TAAATAA AAATAAG AATAAGG ATAAGGC TAAGGCT AAGGCTA AGGCTAC GGCTACT GCTACTA CTACTAA TACTAAC ACTAACA CTAACAA TAACAAT AACAATG ACAATGC CAATGCC AATGCCA ATGCCAT TGCCATG GCCATGC CCATGCA CATGCAA ATGCAAG TGCAAGT GCAAGTT CAAGTTG AAGTTGA AGTTGAA GTTGAAT TTGAATC TGAATCT GAATCTG AATCTGA ATCTGAT TCTGATG CTGATGA TGATGAT GATGATT ATGATTA TGATTAC GATTACA ATTACAT TTACATA TACATAG ACATAGC CATAGCT ATAGCTA TAGCTAC AGCTACT GCTACTA CTACTAA TACTAAT ACTAATG CTAATGG TAATGGA AATGGAC ATGGACC TGGACCA GGACCAC GACCACT ACCACTT CCACTTA CACTTAA ACTTAAA CTTAAAG TTAAAGT TAAAGTG AAAGTGG AAGTGGG AGTGGGT GTGGGTG TGGGTGG GGGTGGT GGTGGTA GTGGTAG TGGTAGT,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",3491
TTAGGC TAGGCA AGGCAC GGCACT GCACTC CACTCC ACTCCT CTCCTT TCCTTC CCTTCT CTTCTT TTCTTA TCTTAC CTTACT TTACTG TACTGT ACTGTA CTGTAC TGTACT GTACTG TACTGG ACTGGT CTGGTT TGGTTA GGTTAC GTTACA TTACAG TACAGA ACAGAG CAGAGA AGAGAA GAGAAG AGAAGG GAAGGC AAGGCT AGGCTA GGCTAT GCTATT CTATTT TATTTG ATTTGA TTTGAA TTGAAC TGAACT GAACTC AACTCT ACTCTA CTCTAC TCTACT CTACTA TACTAA ACTAAT CTAATG TAATGC AATGCT ATGCTG TGCTGA GCTGAC CTGACT TGACTC GACTCT ACTCTT CTCTTA TCTTAT CTTATA TTATAC TATACA ATACAC TACACA ACACAT CACATC ACATCC CATCCG ATCCGA TCCGAC CCGACG CGACGC GACGCT ACGCTG CGCTGC GCTGCC CTGCCG TGCCGA GCCGAC CCGACG CGACGA GACGAA ACGAAG CGAAGA GAAGAG AAGAGG AGAGGA GAGGAA AGGAAA GGAAAG GAAAGA AAAGAC AAGACA AGACAC GACACC ACACCC CACCCC ACCCCT CCCCTG CCCTGT CCTGTC CTGTCG TGTCGC GTCGCT TCGCTT CGCTTA GCTTAT CTTATA TTATAC TATACC ATACCC TACCCA ACCCAT CCCATC CCATCT CATCTG ATCTGA TCTGAC CTGACG TGACGC GACGCT ACGCTA CGCTAA GCTAAC CTAACG TAACGA AACGAC ACGACG CGACGA GACGAA ACGAAT CGAATA GAATAG AATAGA ATAGAG TAGAGA AGAGAA,0,142,TTAG TAGG AGGC GGCA GCAC CACT ACTC CTCC TCCT CCTT CTTC TTCT TCTT CTTA TTAC TACT ACTG CTGT TGTA GTAC TACT ACTG CTGG TGGT GGTT GTTA TTAC TACA ACAG CAGA AGAG GAGA AGAA GAAG AAGG AGGC GGCT GCTA CTAT TATT ATTT TTTG TTGA TGAA GAAC AACT ACTC CTCT TCTA CTAC TACT ACTA CTAA TAAT AATG ATGC TGCT GCTG CTGA TGAC GACT ACTC CTCT TCTT CTTA TTAT TATA ATAC TACA ACAC CACA ACAT CATC ATCC TCCG CCGA CGAC GACG ACGC CGCT GCTG CTGC TGCC GCCG CCGA CGAC GACG ACGA CGAA GAAG AAGA AGAG GAGG AGGA GGAA GAAA AAAG AAGA AGAC GACA ACAC CACC ACCC CCCC CCCT CCTG CTGT TGTC GTCG TCGC CGCT GCTT CTTA TTAT TATA ATAC TACC ACCC CCCA CCAT CATC ATCT TCTG CTGA TGAC GACG ACGC CGCT GCTA CTAA TAAC AACG ACGA CGAC GACG ACGA CGAA GAAT AATA ATAG TAGA AGAG GAGA AGAA,TTAGG TAGGC AGGCA GGCAC GCACT CACTC ACTCC CTCCT TCCTT CCTTC CTTCT TTCTT TCTTA CTTAC TTACT TACTG ACTGT CTGTA TGTAC GTACT TACTG ACTGG CTGGT TGGTT GGTTA GTTAC TTACA TACAG ACAGA CAGAG AGAGA GAGAA AGAAG GAAGG AAGGC AGGCT GGCTA GCTAT CTATT TATTT ATTTG TTTGA TTGAA TGAAC GAACT AACTC ACTCT CTCTA TCTAC CTACT TACTA ACTAA CTAAT TAATG AATGC ATGCT TGCTG GCTGA CTGAC TGACT GACTC ACTCT CTCTT TCTTA CTTAT TTATA TATAC ATACA TACAC ACACA CACAT ACATC CATCC ATCCG TCCGA CCGAC CGACG GACGC ACGCT CGCTG GCTGC CTGCC TGCCG GCCGA CCGAC CGACG GACGA ACGAA CGAAG GAAGA AAGAG AGAGG GAGGA AGGAA GGAAA GAAAG AAAGA AAGAC AGACA GACAC ACACC CACCC ACCCC CCCCT CCCTG CCTGT CTGTC TGTCG GTCGC TCGCT CGCTT GCTTA CTTAT TTATA TATAC ATACC TACCC ACCCA CCCAT CCATC CATCT ATCTG TCTGA CTGAC TGACG GACGC ACGCT CGCTA GCTAA CTAAC TAACG AACGA ACGAC CGACG GACGA ACGAA CGAAT GAATA AATAG ATAGA TAGAG AGAGA GAGAA,TTAGGC TAGGCA AGGCAC GGCACT GCACTC CACTCC ACTCCT CTCCTT TCCTTC CCTTCT CTTCTT TTCTTA TCTTAC CTTACT TTACTG TACTGT ACTGTA CTGTAC TGTACT GTACTG TACTGG ACTGGT CTGGTT TGGTTA GGTTAC GTTACA TTACAG TACAGA ACAGAG CAGAGA AGAGAA GAGAAG AGAAGG GAAGGC AAGGCT AGGCTA GGCTAT GCTATT CTATTT TATTTG ATTTGA TTTGAA TTGAAC TGAACT GAACTC AACTCT ACTCTA CTCTAC TCTACT CTACTA TACTAA ACTAAT CTAATG TAATGC AATGCT ATGCTG TGCTGA GCTGAC CTGACT TGACTC GACTCT ACTCTT CTCTTA TCTTAT CTTATA TTATAC TATACA ATACAC TACACA ACACAT CACATC ACATCC CATCCG ATCCGA TCCGAC CCGACG CGACGC GACGCT ACGCTG CGCTGC GCTGCC CTGCCG TGCCGA GCCGAC CCGACG CGACGA GACGAA ACGAAG CGAAGA GAAGAG AAGAGG AGAGGA GAGGAA AGGAAA GGAAAG GAAAGA AAAGAC AAGACA AGACAC GACACC ACACCC CACCCC ACCCCT CCCCTG CCCTGT CCTGTC CTGTCG TGTCGC GTCGCT TCGCTT CGCTTA GCTTAT CTTATA TTATAC TATACC ATACCC TACCCA ACCCAT CCCATC CCATCT CATCTG ATCTGA TCTGAC CTGACG TGACGC GACGCT ACGCTA CGCTAA GCTAAC CTAACG TAACGA AACGAC ACGACG CGACGA GACGAA ACGAAT CGAATA GAATAG AATAGA ATAGAG TAGAGA AGAGAA,TTAGGCA TAGGCAC AGGCACT GGCACTC GCACTCC CACTCCT ACTCCTT CTCCTTC TCCTTCT CCTTCTT CTTCTTA TTCTTAC TCTTACT CTTACTG TTACTGT TACTGTA ACTGTAC CTGTACT TGTACTG GTACTGG TACTGGT ACTGGTT CTGGTTA TGGTTAC GGTTACA GTTACAG TTACAGA TACAGAG ACAGAGA CAGAGAA AGAGAAG GAGAAGG AGAAGGC GAAGGCT AAGGCTA AGGCTAT GGCTATT GCTATTT CTATTTG TATTTGA ATTTGAA TTTGAAC TTGAACT TGAACTC GAACTCT AACTCTA ACTCTAC CTCTACT TCTACTA CTACTAA TACTAAT ACTAATG CTAATGC TAATGCT AATGCTG ATGCTGA TGCTGAC GCTGACT CTGACTC TGACTCT GACTCTT ACTCTTA CTCTTAT TCTTATA CTTATAC TTATACA TATACAC ATACACA TACACAT ACACATC CACATCC ACATCCG CATCCGA ATCCGAC TCCGACG CCGACGC CGACGCT GACGCTG ACGCTGC CGCTGCC GCTGCCG CTGCCGA TGCCGAC GCCGACG CCGACGA CGACGAA GACGAAG ACGAAGA CGAAGAG GAAGAGG AAGAGGA AGAGGAA GAGGAAA AGGAAAG GGAAAGA GAAAGAC AAAGACA AAGACAC AGACACC GACACCC ACACCCC CACCCCT ACCCCTG CCCCTGT CCCTGTC CCTGTCG CTGTCGC TGTCGCT GTCGCTT TCGCTTA CGCTTAT GCTTATA CTTATAC TTATACC TATACCC ATACCCA TACCCAT ACCCATC CCCATCT CCATCTG CATCTGA ATCTGAC TCTGACG CTGACGC TGACGCT GACGCTA ACGCTAA CGCTAAC GCTAACG CTAACGA TAACGAC AACGACG ACGACGA CGACGAA GACGAAT ACGAATA CGAATAG GAATAGA AATAGAG ATAGAGA TAGAGAA,"ID   R1A_SARS2               Reviewed;        4405 AA.
AC   P0DTC1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1a;
DE            Short=pp1a;
DE   AltName: Full=ORF1a polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69;
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=RNA-capping enzyme subunit nsp9;
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=Non-structural protein 11;
DE              Short=nsp11;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [5]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [6]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [7]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (NON-STRUCTURAL PROTEIN 10),
RP   MUTAGENESIS OF ASN-4141 AND ASN-4142, AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [8]
RP   REVIEW, SUBUNIT (NON-STRUCTURAL PROTEIN 7), AND SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [9]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [10]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [11]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN
RP   COMPLEX WITH ALPHA-KETOAMIDE INHIBITORS, SUBUNIT (3C-LIKE PROTEINASE NSP5),
RP   ACTIVE SITE, AND ACTIVITY REGULATION.
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE APOENZYME AND
RP   IN COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5), AND CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7 AND NON-STRUCTURAL PROTEIN 8, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 7), AND
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [16]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7 AND NON-STRUCTURAL PROTEIN 8, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 7), AND
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [18]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7 AND NON-STRUCTURAL PROTEIN 8, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 7), AND
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION OF NON-STRUCTURAL PROTEIN 3.
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [20]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7 AND NON-STRUCTURAL PROTEIN 8 IN COMPLEX WITH ZINC ION, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), AND FUNCTION (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), CATALYTIC ACTIVITY (NON-STRUCTURAL
RP   PROTEIN 3), ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 3), AND MUTAGENESIS
RP   OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [22]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [23]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [24]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   AND INTERACTION WITH HOST TBK1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [25]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), AND SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [26]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [27]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [28]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9 AND NON-STRUCTURAL
RP   PROTEIN 10, AND SUBUNIT (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [29]
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
CC   -!- FUNCTION: [Replicase polyprotein 1a]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by nsp3 and nsp4, while nsp6 zippers
CC       ER membranes and connects to lipid droplets (PubMed:35551511).
CC       {ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [3C-like proteinase nsp5]: Cleaves the C-terminus of
CC       replicase polyprotein at 11 sites (PubMed:32321856). Recognizes
CC       substrates containing the core sequence [ILMVF]-Q-|-[SGACN]
CC       (PubMed:32198291, PubMed:32272481). May cleave human NLRP1 in lung
CC       epithelial cells, thereby activating the NLRP1 inflammasome pathway
CC       (PubMed:35594856). May cleave human GSDMD, triggering alternative
CC       GSDME-mediated epithelial cell death upon activation of the NLRP1
CC       inflammasome, which may enhance the release interleukins 1B, 6, 16 and
CC       18 (PubMed:35594856). Also able to bind an ADP-ribose-1''-phosphate
CC       (ADRP) (PubMed:32198291, PubMed:32272481).
CC       {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481,
CC       ECO:0000269|PubMed:32321856, ECO:0000269|PubMed:32680882,
CC       ECO:0000269|PubMed:35594856}.
CC   -!- FUNCTION: [Non-structural protein 6]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by nsp3 and nsp4, while nsp6 zippers
CC       ER membranes and connects to lipid droplets (LDs) (PubMed:35551511).
CC       LDs are consumed during DMV formation (PubMed:35551511). Binds to host
CC       TBK1 without affecting TBK1 phosphorylation; the interaction with TBK1
CC       decreases IRF3 phosphorylation, which leads to reduced IFN-beta
CC       production (PubMed:32979938). {ECO:0000269|PubMed:32979938,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 7]: Plays a role in viral RNA
CC       synthesis (PubMed:32277040, PubMed:32358203, PubMed:32438371,
CC       PubMed:32526208). Forms a hexadecamer with nsp8 (8 subunits of each)
CC       that may participate in viral replication by acting as a primase.
CC       Alternatively, may synthesize substantially longer products than
CC       oligonucleotide primers (By similarity). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32277040, ECO:0000269|PubMed:32358203,
CC       ECO:0000269|PubMed:32438371, ECO:0000269|PubMed:32526208}.
CC   -!- FUNCTION: [Non-structural protein 8]: Plays a role in viral RNA
CC       synthesis (PubMed:32277040, PubMed:32358203, PubMed:32438371,
CC       PubMed:32526208). Forms a hexadecamer with nsp7 (8 subunits of each)
CC       that may participate in viral replication by acting as a primase.
CC       Alternatively, may synthesize substantially longer products than
CC       oligonucleotide primers (By similarity). Interacts with ribosome signal
CC       recognition particle RNA (SRP) (PubMed:33080218). Together with NSP9,
CC       suppress protein integration into the cell membrane, thereby disrupting
CC       host immune defenses (PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32277040, ECO:0000269|PubMed:32358203,
CC       ECO:0000269|PubMed:32438371, ECO:0000269|PubMed:32526208,
CC       ECO:0000269|PubMed:33080218}.
CC   -!- FUNCTION: [RNA-capping enzyme subunit nsp9]: Catalytic subunit of viral
CC       RNA capping enzyme which catalyzes the RNA guanylyltransferase reaction
CC       for genomic and sub-genomic RNAs (PubMed:35944563). The kinase-like
CC       NiRAN domain of NSP12 transfers RNA to the amino terminus of NSP9,
CC       forming a covalent RNA-protein intermediate (PubMed:35944563).
CC       Subsequently, the NiRAN domain transfers RNA to GDP, forming the core
CC       cap structure GpppA-RNA (PubMed:35944563). The NSP14 and NSP16
CC       methyltransferases then add methyl groups to form functional cap
CC       structures (PubMed:35944563). Interacts with ribosome signal
CC       recognition particle RNA (SRP) (PubMed:33080218). Together with NSP8,
CC       suppress protein integration into the cell membrane, thereby disrupting
CC       host immune defenses (PubMed:33080218). {ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:35944563}.
CC   -!- FUNCTION: [Non-structural protein 10]: Plays a pivotal role in viral
CC       transcription by stimulating both nsp14 3'-5' exoribonuclease (By
CC       similarity) and nsp16 2'-O-methyltransferase activities
CC       (PubMed:35944563). Therefore plays an essential role in viral mRNAs cap
CC       methylation. {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:35944563}.
CC   -!- CATALYTIC ACTIVITY: [Papain-like protease nsp3]:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12; Evidence={ECO:0000269|PubMed:32726803};
CC   -!- CATALYTIC ACTIVITY: [3C-like proteinase nsp5]:
CC       Reaction=TSAVLQ-|-SGFRK-NH2 and SGVTFQ-|-GKFKK the two peptides
CC         corresponding to the two self-cleavage sites of the SARS 3C-like
CC         proteinase are the two most reactive peptide substrates. The enzyme
CC         exhibits a strong preference for substrates containing Gln at P1
CC         position and Leu at P2 position.; EC=3.4.22.69;
CC         Evidence={ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481,
CC         ECO:0000269|PubMed:32321856};
CC   -!- CATALYTIC ACTIVITY: [RNA-capping enzyme subunit nsp9]:
CC       Reaction=a 5'-end diphospho-ribonucleoside in mRNA + GTP + H(+) = a 5'-
CC         end (5'-triphosphoguanosine)-ribonucleoside in mRNA + diphosphate;
CC         Xref=Rhea:RHEA:67012, Rhea:RHEA-COMP:17165, Rhea:RHEA-COMP:17166,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:33019, ChEBI:CHEBI:37565,
CC         ChEBI:CHEBI:167616, ChEBI:CHEBI:167617; EC=2.7.7.50;
CC         Evidence={ECO:0000269|PubMed:35944563};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:67014;
CC         Evidence={ECO:0000269|PubMed:35944563};
CC   -!- ACTIVITY REGULATION: [Non-structural protein 6]: Inhibited ex vivo by
CC       K22. It may shift NSP6 zippering activity towards the nuclear envelope,
CC       thereby impairing formation of the NSP6-compartment necessary for viral
CC       transcription/replication. {ECO:0000269|PubMed:35551511}.
CC   -!- ACTIVITY REGULATION: [Papain-like protease nsp3]: Inhibited in vitro by
CC       GRL-0617. {ECO:0000269|PubMed:32726803}.
CC   -!- ACTIVITY REGULATION: [3C-like proteinase nsp5]: Inhibited by pyridone-
CC       containing alpha-ketoamides compounds 13a and 13b. In turn, alpha-
CC       ketoamide 13b (tert-butyl (1-((S)-1-(((S)-4-(benzylamino)-3,4-dioxo-1-
CC       ((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-3-cyclopropyl-1-oxopropan-
CC       2-yl)-2-oxo-1,2-dihydropyridin-3-yl)carbamate) inhibits SARS-CoV-2
CC       replication in human lung cells (PubMed:32198291). Inhibited ex vivo by
CC       michael acceptor inhibitor N3 (PubMed:32272481). Inhibited ex vivo by
CC       compound 11a and 11b (PubMed:32321856). {ECO:0000269|PubM",9267
GAATTA AATTAC ATTACT TTACTG TACTGC ACTGCA CTGCAA TGCAAA GCAAAA CAAAAT AAAATG AAATGG AATGGT ATGGTA TGGTAT GGTATG GTATGA TATGAA ATGAAT TGAATG GAATGG AATGGA ATGGAC TGGACG GGACGT GACGTA ACGTAC CGTACC GTACCA TACCAT ACCATA CCATAT CATATT ATATTG TATTGG ATTGGG TTGGGT TGGGTA GGGTAG GGTAGT GTAGTG TAGTGC AGTGCT GTGCTT TGCTTT GCTTTA CTTTAT TTTATT TTATTA TATTAG ATTAGA TTAGAA TAGAAG AGAAGA GAAGAT AAGATG AGATGA GATGAA ATGAAT TGAATT GAATTT AATTTA ATTTAC TTTACA TTACAC TACACC ACACCT CACCTT ACCTTT CCTTTT CTTTTG TTTTGA TTTGAT TTGATG TGATGT GATGTT ATGTTG TGTTGT GTTGTT TTGTTA TGTTAG GTTAGA TTAGAC TAGACA AGACAA GACAAT ACAATG CAATGC AATGCT ATGCTC TGCTCA,0,91,GAAT AATT ATTA TTAC TACT ACTG CTGC TGCA GCAA CAAA AAAA AAAT AATG ATGG TGGT GGTA GTAT TATG ATGA TGAA GAAT AATG ATGG TGGA GGAC GACG ACGT CGTA GTAC TACC ACCA CCAT CATA ATAT TATT ATTG TTGG TGGG GGGT GGTA GTAG TAGT AGTG GTGC TGCT GCTT CTTT TTTA TTAT TATT ATTA TTAG TAGA AGAA GAAG AAGA AGAT GATG ATGA TGAA GAAT AATT ATTT TTTA TTAC TACA ACAC CACC ACCT CCTT CTTT TTTT TTTG TTGA TGAT GATG ATGT TGTT GTTG TTGT TGTT GTTA TTAG TAGA AGAC GACA ACAA CAAT AATG ATGC TGCT GCTC CTCA,GAATT AATTA ATTAC TTACT TACTG ACTGC CTGCA TGCAA GCAAA CAAAA AAAAT AAATG AATGG ATGGT TGGTA GGTAT GTATG TATGA ATGAA TGAAT GAATG AATGG ATGGA TGGAC GGACG GACGT ACGTA CGTAC GTACC TACCA ACCAT CCATA CATAT ATATT TATTG ATTGG TTGGG TGGGT GGGTA GGTAG GTAGT TAGTG AGTGC GTGCT TGCTT GCTTT CTTTA TTTAT TTATT TATTA ATTAG TTAGA TAGAA AGAAG GAAGA AAGAT AGATG GATGA ATGAA TGAAT GAATT AATTT ATTTA TTTAC TTACA TACAC ACACC CACCT ACCTT CCTTT CTTTT TTTTG TTTGA TTGAT TGATG GATGT ATGTT TGTTG GTTGT TTGTT TGTTA GTTAG TTAGA TAGAC AGACA GACAA ACAAT CAATG AATGC ATGCT TGCTC GCTCA,GAATTA AATTAC ATTACT TTACTG TACTGC ACTGCA CTGCAA TGCAAA GCAAAA CAAAAT AAAATG AAATGG AATGGT ATGGTA TGGTAT GGTATG GTATGA TATGAA ATGAAT TGAATG GAATGG AATGGA ATGGAC TGGACG GGACGT GACGTA ACGTAC CGTACC GTACCA TACCAT ACCATA CCATAT CATATT ATATTG TATTGG ATTGGG TTGGGT TGGGTA GGGTAG GGTAGT GTAGTG TAGTGC AGTGCT GTGCTT TGCTTT GCTTTA CTTTAT TTTATT TTATTA TATTAG ATTAGA TTAGAA TAGAAG AGAAGA GAAGAT AAGATG AGATGA GATGAA ATGAAT TGAATT GAATTT AATTTA ATTTAC TTTACA TTACAC TACACC ACACCT CACCTT ACCTTT CCTTTT CTTTTG TTTTGA TTTGAT TTGATG TGATGT GATGTT ATGTTG TGTTGT GTTGTT TTGTTA TGTTAG GTTAGA TTAGAC TAGACA AGACAA GACAAT ACAATG CAATGC AATGCT ATGCTC TGCTCA,GAATTAC AATTACT ATTACTG TTACTGC TACTGCA ACTGCAA CTGCAAA TGCAAAA GCAAAAT CAAAATG AAAATGG AAATGGT AATGGTA ATGGTAT TGGTATG GGTATGA GTATGAA TATGAAT ATGAATG TGAATGG GAATGGA AATGGAC ATGGACG TGGACGT GGACGTA GACGTAC ACGTACC CGTACCA GTACCAT TACCATA ACCATAT CCATATT CATATTG ATATTGG TATTGGG ATTGGGT TTGGGTA TGGGTAG GGGTAGT GGTAGTG GTAGTGC TAGTGCT AGTGCTT GTGCTTT TGCTTTA GCTTTAT CTTTATT TTTATTA TTATTAG TATTAGA ATTAGAA TTAGAAG TAGAAGA AGAAGAT GAAGATG AAGATGA AGATGAA GATGAAT ATGAATT TGAATTT GAATTTA AATTTAC ATTTACA TTTACAC TTACACC TACACCT ACACCTT CACCTTT ACCTTTT CCTTTTG CTTTTGA TTTTGAT TTTGATG TTGATGT TGATGTT GATGTTG ATGTTGT TGTTGTT GTTGTTA TTGTTAG TGTTAGA GTTAGAC TTAGACA TAGACAA AGACAAT GACAATG ACAATGC CAATGCT AATGCTC ATGCTCA,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",880
GTTAAG TTAAGA TAAGAT AAGATG AGATGT GATGTT ATGTTG TGTTGT GTTGTG TTGTGT TGTGTA GTGTAC TGTACA GTACAC TACACA ACACAC CACACA ACACAC CACACT ACACTG CACTGG ACTGGT CTGGTA TGGTAC GGTACT GTACTG TACTGG ACTGGT CTGGTC TGGTCA GGTCAG GTCAGG TCAGGC CAGGCA AGGCAA GGCAAT GCAATA CAATAA AATAAC ATAACA TAACAG AACAGT ACAGTT CAGTTA AGTTAC GTTACA TTACAC TACACC ACACCG CACCGG ACCGGA CCGGAA CGGAAG GGAAGC GAAGCC AAGCCA AGCCAA GCCAAT CCAATA CAATAT AATATG ATATGG TATGGA ATGGAT TGGATC GGATCA GATCAA ATCAAG TCAAGA CAAGAA AAGAAT AGAATC GAATCC AATCCT ATCCTT TCCTTT CCTTTG CTTTGG TTTGGT TTGGTG TGGTGG GGTGGT GTGGTG TGGTGC GGTGCA GTGCAT TGCATC GCATCG CATCGT ATCGTG TCGTGT CGTGTT GTGTTG TGTTGT GTTGTC TTGTCT TGTCTG GTCTGT TCTGTA CTGTAC TGTACT GTACTG TACTGC ACTGCC CTGCCG TGCCGT GCCGTT CCGTTG CGTTGC GTTGCC TTGCCA TGCCAC GCCACA CCACAT CACATA ACATAG CATAGA ATAGAT TAGATC AGATCA GATCAT ATCATC TCATCC CATCCA ATCCAA TCCAAA CCAAAT CAAATC AAATCC AATCCT ATCCTA TCCTAA CCTAAA CTAAAG TAAAGG AAAGGA AAGGAT AGGATT GGATTT GATTTT ATTTTG TTTTGT,0,142,GTTA TTAA TAAG AAGA AGAT GATG ATGT TGTT GTTG TTGT TGTG GTGT TGTA GTAC TACA ACAC CACA ACAC CACA ACAC CACT ACTG CTGG TGGT GGTA GTAC TACT ACTG CTGG TGGT GGTC GTCA TCAG CAGG AGGC GGCA GCAA CAAT AATA ATAA TAAC AACA ACAG CAGT AGTT GTTA TTAC TACA ACAC CACC ACCG CCGG CGGA GGAA GAAG AAGC AGCC GCCA CCAA CAAT AATA ATAT TATG ATGG TGGA GGAT GATC ATCA TCAA CAAG AAGA AGAA GAAT AATC ATCC TCCT CCTT CTTT TTTG TTGG TGGT GGTG GTGG TGGT GGTG GTGC TGCA GCAT CATC ATCG TCGT CGTG GTGT TGTT GTTG TTGT TGTC GTCT TCTG CTGT TGTA GTAC TACT ACTG CTGC TGCC GCCG CCGT CGTT GTTG TTGC TGCC GCCA CCAC CACA ACAT CATA ATAG TAGA AGAT GATC ATCA TCAT CATC ATCC TCCA CCAA CAAA AAAT AATC ATCC TCCT CCTA CTAA TAAA AAAG AAGG AGGA GGAT GATT ATTT TTTT TTTG TTGT,GTTAA TTAAG TAAGA AAGAT AGATG GATGT ATGTT TGTTG GTTGT TTGTG TGTGT GTGTA TGTAC GTACA TACAC ACACA CACAC ACACA CACAC ACACT CACTG ACTGG CTGGT TGGTA GGTAC GTACT TACTG ACTGG CTGGT TGGTC GGTCA GTCAG TCAGG CAGGC AGGCA GGCAA GCAAT CAATA AATAA ATAAC TAACA AACAG ACAGT CAGTT AGTTA GTTAC TTACA TACAC ACACC CACCG ACCGG CCGGA CGGAA GGAAG GAAGC AAGCC AGCCA GCCAA CCAAT CAATA AATAT ATATG TATGG ATGGA TGGAT GGATC GATCA ATCAA TCAAG CAAGA AAGAA AGAAT GAATC AATCC ATCCT TCCTT CCTTT CTTTG TTTGG TTGGT TGGTG GGTGG GTGGT TGGTG GGTGC GTGCA TGCAT GCATC CATCG ATCGT TCGTG CGTGT GTGTT TGTTG GTTGT TTGTC TGTCT GTCTG TCTGT CTGTA TGTAC GTACT TACTG ACTGC CTGCC TGCCG GCCGT CCGTT CGTTG GTTGC TTGCC TGCCA GCCAC CCACA CACAT ACATA CATAG ATAGA TAGAT AGATC GATCA ATCAT TCATC CATCC ATCCA TCCAA CCAAA CAAAT AAATC AATCC ATCCT TCCTA CCTAA CTAAA TAAAG AAAGG AAGGA AGGAT GGATT GATTT ATTTT TTTTG TTTGT,GTTAAG TTAAGA TAAGAT AAGATG AGATGT GATGTT ATGTTG TGTTGT GTTGTG TTGTGT TGTGTA GTGTAC TGTACA GTACAC TACACA ACACAC CACACA ACACAC CACACT ACACTG CACTGG ACTGGT CTGGTA TGGTAC GGTACT GTACTG TACTGG ACTGGT CTGGTC TGGTCA GGTCAG GTCAGG TCAGGC CAGGCA AGGCAA GGCAAT GCAATA CAATAA AATAAC ATAACA TAACAG AACAGT ACAGTT CAGTTA AGTTAC GTTACA TTACAC TACACC ACACCG CACCGG ACCGGA CCGGAA CGGAAG GGAAGC GAAGCC AAGCCA AGCCAA GCCAAT CCAATA CAATAT AATATG ATATGG TATGGA ATGGAT TGGATC GGATCA GATCAA ATCAAG TCAAGA CAAGAA AAGAAT AGAATC GAATCC AATCCT ATCCTT TCCTTT CCTTTG CTTTGG TTTGGT TTGGTG TGGTGG GGTGGT GTGGTG TGGTGC GGTGCA GTGCAT TGCATC GCATCG CATCGT ATCGTG TCGTGT CGTGTT GTGTTG TGTTGT GTTGTC TTGTCT TGTCTG GTCTGT TCTGTA CTGTAC TGTACT GTACTG TACTGC ACTGCC CTGCCG TGCCGT GCCGTT CCGTTG CGTTGC GTTGCC TTGCCA TGCCAC GCCACA CCACAT CACATA ACATAG CATAGA ATAGAT TAGATC AGATCA GATCAT ATCATC TCATCC CATCCA ATCCAA TCCAAA CCAAAT CAAATC AAATCC AATCCT ATCCTA TCCTAA CCTAAA CTAAAG TAAAGG AAAGGA AAGGAT AGGATT GGATTT GATTTT ATTTTG TTTTGT,GTTAAGA TTAAGAT TAAGATG AAGATGT AGATGTT GATGTTG ATGTTGT TGTTGTG GTTGTGT TTGTGTA TGTGTAC GTGTACA TGTACAC GTACACA TACACAC ACACACA CACACAC ACACACT CACACTG ACACTGG CACTGGT ACTGGTA CTGGTAC TGGTACT GGTACTG GTACTGG TACTGGT ACTGGTC CTGGTCA TGGTCAG GGTCAGG GTCAGGC TCAGGCA CAGGCAA AGGCAAT GGCAATA GCAATAA CAATAAC AATAACA ATAACAG TAACAGT AACAGTT ACAGTTA CAGTTAC AGTTACA GTTACAC TTACACC TACACCG ACACCGG CACCGGA ACCGGAA CCGGAAG CGGAAGC GGAAGCC GAAGCCA AAGCCAA AGCCAAT GCCAATA CCAATAT CAATATG AATATGG ATATGGA TATGGAT ATGGATC TGGATCA GGATCAA GATCAAG ATCAAGA TCAAGAA CAAGAAT AAGAATC AGAATCC GAATCCT AATCCTT ATCCTTT TCCTTTG CCTTTGG CTTTGGT TTTGGTG TTGGTGG TGGTGGT GGTGGTG GTGGTGC TGGTGCA GGTGCAT GTGCATC TGCATCG GCATCGT CATCGTG ATCGTGT TCGTGTT CGTGTTG GTGTTGT TGTTGTC GTTGTCT TTGTCTG TGTCTGT GTCTGTA TCTGTAC CTGTACT TGTACTG GTACTGC TACTGCC ACTGCCG CTGCCGT TGCCGTT GCCGTTG CCGTTGC CGTTGCC GTTGCCA TTGCCAC TGCCACA GCCACAT CCACATA CACATAG ACATAGA CATAGAT ATAGATC TAGATCA AGATCAT GATCATC ATCATCC TCATCCA CATCCAA ATCCAAA TCCAAAT CCAAATC CAAATCC AAATCCT AATCCTA ATCCTAA TCCTAAA CCTAAAG CTAAAGG TAAAGGA AAAGGAT AAGGATT AGGATTT GGATTTT GATTTTG ATTTTGT,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",8
ACTATA CTATAG TATAGG ATAGGT TAGGTC AGGTCC GGTCCA GTCCAG TCCAGA CCAGAC CAGACA AGACAT GACATG ACATGT CATGTT ATGTTC TGTTCC GTTCCT TTCCTC TCCTCG CCTCGG CTCGGA TCGGAA CGGAAC GGAACT GAACTT AACTTG ACTTGT CTTGTC TTGTCG TGTCGG GTCGGC TCGGCG CGGCGT GGCGTT GCGTTG CGTTGT GTTGTC TTGTCC TGTCCT GTCCTG TCCTGC CCTGCT CTGCTG TGCTGA GCTGAA CTGAAA TGAAAT GAAATT AAATTG AATTGT ATTGTT TTGTTG TGTTGA GTTGAC TTGACA TGACAC GACACT ACACTG CACTGT ACTGTG CTGTGA TGTGAG GTGAGT TGAGTG GAGTGC AGTGCT GTGCTT TGCTTT GCTTTG CTTTGG TTTGGT TTGGTT TGGTTT GGTTTA GTTTAT TTTATG TTATGA TATGAT ATGATA TGATAA GATAAT ATAATA TAATAA AATAAG ATAAGC TAAGCT AAGCTT AGCTTA GCTTAA CTTAAA TTAAAG TAAAGC AAAGCA AAGCAC AGCACA GCACAT CACATA ACATAA CATAAA ATAAAG TAAAGA AAAGAC AAGACA AGACAA GACAAA ACAAAT CAAATC AAATCA AATCAG ATCAGC TCAGCT CAGCTC AGCTCA GCTCAA CTCAAT TCAATG CAATGC AATGCT ATGCTT TGCTTT GCTTTA CTTTAA TTTAAA TTAAAA TAAAAT AAAATG AAATGT AATGTT ATGTTT TGTTTT GTTTTA TTTTAT TTTATA TTATAA TATAAG ATAAGG TAAGGG AAGGGT AGGGTG GGGTGT GGTGTT GTGTTA TGTTAT GTTATC,0,145,ACTA CTAT TATA ATAG TAGG AGGT GGTC GTCC TCCA CCAG CAGA AGAC GACA ACAT CATG ATGT TGTT GTTC TTCC TCCT CCTC CTCG TCGG CGGA GGAA GAAC AACT ACTT CTTG TTGT TGTC GTCG TCGG CGGC GGCG GCGT CGTT GTTG TTGT TGTC GTCC TCCT CCTG CTGC TGCT GCTG CTGA TGAA GAAA AAAT AATT ATTG TTGT TGTT GTTG TTGA TGAC GACA ACAC CACT ACTG CTGT TGTG GTGA TGAG GAGT AGTG GTGC TGCT GCTT CTTT TTTG TTGG TGGT GGTT GTTT TTTA TTAT TATG ATGA TGAT GATA ATAA TAAT AATA ATAA TAAG AAGC AGCT GCTT CTTA TTAA TAAA AAAG AAGC AGCA GCAC CACA ACAT CATA ATAA TAAA AAAG AAGA AGAC GACA ACAA CAAA AAAT AATC ATCA TCAG CAGC AGCT GCTC CTCA TCAA CAAT AATG ATGC TGCT GCTT CTTT TTTA TTAA TAAA AAAA AAAT AATG ATGT TGTT GTTT TTTT TTTA TTAT TATA ATAA TAAG AAGG AGGG GGGT GGTG GTGT TGTT GTTA TTAT TATC,ACTAT CTATA TATAG ATAGG TAGGT AGGTC GGTCC GTCCA TCCAG CCAGA CAGAC AGACA GACAT ACATG CATGT ATGTT TGTTC GTTCC TTCCT TCCTC CCTCG CTCGG TCGGA CGGAA GGAAC GAACT AACTT ACTTG CTTGT TTGTC TGTCG GTCGG TCGGC CGGCG GGCGT GCGTT CGTTG GTTGT TTGTC TGTCC GTCCT TCCTG CCTGC CTGCT TGCTG GCTGA CTGAA TGAAA GAAAT AAATT AATTG ATTGT TTGTT TGTTG GTTGA TTGAC TGACA GACAC ACACT CACTG ACTGT CTGTG TGTGA GTGAG TGAGT GAGTG AGTGC GTGCT TGCTT GCTTT CTTTG TTTGG TTGGT TGGTT GGTTT GTTTA TTTAT TTATG TATGA ATGAT TGATA GATAA ATAAT TAATA AATAA ATAAG TAAGC AAGCT AGCTT GCTTA CTTAA TTAAA TAAAG AAAGC AAGCA AGCAC GCACA CACAT ACATA CATAA ATAAA TAAAG AAAGA AAGAC AGACA GACAA ACAAA CAAAT AAATC AATCA ATCAG TCAGC CAGCT AGCTC GCTCA CTCAA TCAAT CAATG AATGC ATGCT TGCTT GCTTT CTTTA TTTAA TTAAA TAAAA AAAAT AAATG AATGT ATGTT TGTTT GTTTT TTTTA TTTAT TTATA TATAA ATAAG TAAGG AAGGG AGGGT GGGTG GGTGT GTGTT TGTTA GTTAT TTATC,ACTATA CTATAG TATAGG ATAGGT TAGGTC AGGTCC GGTCCA GTCCAG TCCAGA CCAGAC CAGACA AGACAT GACATG ACATGT CATGTT ATGTTC TGTTCC GTTCCT TTCCTC TCCTCG CCTCGG CTCGGA TCGGAA CGGAAC GGAACT GAACTT AACTTG ACTTGT CTTGTC TTGTCG TGTCGG GTCGGC TCGGCG CGGCGT GGCGTT GCGTTG CGTTGT GTTGTC TTGTCC TGTCCT GTCCTG TCCTGC CCTGCT CTGCTG TGCTGA GCTGAA CTGAAA TGAAAT GAAATT AAATTG AATTGT ATTGTT TTGTTG TGTTGA GTTGAC TTGACA TGACAC GACACT ACACTG CACTGT ACTGTG CTGTGA TGTGAG GTGAGT TGAGTG GAGTGC AGTGCT GTGCTT TGCTTT GCTTTG CTTTGG TTTGGT TTGGTT TGGTTT GGTTTA GTTTAT TTTATG TTATGA TATGAT ATGATA TGATAA GATAAT ATAATA TAATAA AATAAG ATAAGC TAAGCT AAGCTT AGCTTA GCTTAA CTTAAA TTAAAG TAAAGC AAAGCA AAGCAC AGCACA GCACAT CACATA ACATAA CATAAA ATAAAG TAAAGA AAAGAC AAGACA AGACAA GACAAA ACAAAT CAAATC AAATCA AATCAG ATCAGC TCAGCT CAGCTC AGCTCA GCTCAA CTCAAT TCAATG CAATGC AATGCT ATGCTT TGCTTT GCTTTA CTTTAA TTTAAA TTAAAA TAAAAT AAAATG AAATGT AATGTT ATGTTT TGTTTT GTTTTA TTTTAT TTTATA TTATAA TATAAG ATAAGG TAAGGG AAGGGT AGGGTG GGGTGT GGTGTT GTGTTA TGTTAT GTTATC,ACTATAG CTATAGG TATAGGT ATAGGTC TAGGTCC AGGTCCA GGTCCAG GTCCAGA TCCAGAC CCAGACA CAGACAT AGACATG GACATGT ACATGTT CATGTTC ATGTTCC TGTTCCT GTTCCTC TTCCTCG TCCTCGG CCTCGGA CTCGGAA TCGGAAC CGGAACT GGAACTT GAACTTG AACTTGT ACTTGTC CTTGTCG TTGTCGG TGTCGGC GTCGGCG TCGGCGT CGGCGTT GGCGTTG GCGTTGT CGTTGTC GTTGTCC TTGTCCT TGTCCTG GTCCTGC TCCTGCT CCTGCTG CTGCTGA TGCTGAA GCTGAAA CTGAAAT TGAAATT GAAATTG AAATTGT AATTGTT ATTGTTG TTGTTGA TGTTGAC GTTGACA TTGACAC TGACACT GACACTG ACACTGT CACTGTG ACTGTGA CTGTGAG TGTGAGT GTGAGTG TGAGTGC GAGTGCT AGTGCTT GTGCTTT TGCTTTG GCTTTGG CTTTGGT TTTGGTT TTGGTTT TGGTTTA GGTTTAT GTTTATG TTTATGA TTATGAT TATGATA ATGATAA TGATAAT GATAATA ATAATAA TAATAAG AATAAGC ATAAGCT TAAGCTT AAGCTTA AGCTTAA GCTTAAA CTTAAAG TTAAAGC TAAAGCA AAAGCAC AAGCACA AGCACAT GCACATA CACATAA ACATAAA CATAAAG ATAAAGA TAAAGAC AAAGACA AAGACAA AGACAAA GACAAAT ACAAATC CAAATCA AAATCAG AATCAGC ATCAGCT TCAGCTC CAGCTCA AGCTCAA GCTCAAT CTCAATG TCAATGC CAATGCT AATGCTT ATGCTTT TGCTTTA GCTTTAA CTTTAAA TTTAAAA TTAAAAT TAAAATG AAAATGT AAATGTT AATGTTT ATGTTTT TGTTTTA GTTTTAT TTTTATA TTTATAA TTATAAG TATAAGG ATAAGGG TAAGGGT AAGGGTG AGGGTGT GGGTGTT GGTGTTA GTGTTAT TGTTATC,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",0
CGTGTA GTGTAG TGTAGC GTAGCA TAGCAG AGCAGG GCAGGT CAGGTG AGGTGA GGTGAC GTGACT TGACTC GACTCA ACTCAG CTCAGG TCAGGT CAGGTT AGGTTT GGTTTT GTTTTG TTTTGC TTTGCT TTGCTG TGCTGC GCTGCA CTGCAT TGCATA GCATAC CATACA ATACAG TACAGT ACAGTC CAGTCG AGTCGC GTCGCT TCGCTA CGCTAC GCTACA CTACAG TACAGG ACAGGA CAGGAT AGGATT GGATTG GATTGG ATTGGC TTGGCA TGGCAA GGCAAC GCAACT CAACTA AACTAT ACTATA CTATAA TATAAA ATAAAT TAAATT AAATTA AATTAA ATTAAA TTAAAC TAAACA AAACAC AACACA ACACAG CACAGA ACAGAC CAGACC AGACCA GACCAT ACCATT CCATTC CATTCC ATTCCA TTCCAG TCCAGT CCAGTA CAGTAG AGTAGC GTAGCA TAGCAG AGCAGT GCAGTG CAGTGA AGTGAC GTGACA TGACAA GACAAT ACAATA CAATAT AATATT,1,91,CGTGTGG G GTGTGTGTGT TG  TGTGTGTATA A G GTGTAAG G T TAGGCAGCGC C A AGGCACA  GCGCACAG CAG C CACAGAGGGG  AGAGGGGTGT T G GGGGTT ATG G G GTGTGTGAG GTTA TGTGAGACAC C G GAGACACTTGGA G ACACTTC GT TTTTCACA A T TCTCACAGAG  CACAGAGGGG G AAGGCCAT GTTGATTGTTTT T G GTGTTAGCTT T T TTTTTT TA CTTGTG G T TTTTGTGCGC C T TGTGCAT GAC GCGCTCTGTG G C CTCTGTGCGC  TGTGCGCACA GCAGTGT AT CT ACATATATA A A ATATATACACAC T TAACACA CAG ACAC CAGG C CAA AGT T A AGAGTGTCTC GA GTCTCGCG G T TCTCGCGCGC C CCGCGCTCT T GTAGGCTCTA CTCTATACAC C T TATACACACA A A ACCAGAG G C CACAGACAGG AGA AGAGGGGAGA CAG GGGGAGATA A AT GAGATGGTTT T A ATATTTTGT TG T TTCT GG G T TGTGGGGCGC C G GGTAGGCACA A AGCA TAAA CAAAACAC C A AAACTCT T A ACACTCTATA  CTCTATATT TC ATA ATAA A ATATAAG AA A T TAG CAAAAA GTAGTAAT T A AAAATATTTT AT T GATTA TA T TTTTATAAAA A T TATAAAAAAA A A AAAAAAACAC  TA AAAACACAA A ACACACACTTCC C CACACACACA G C ACACACAGAG TAA CATA AGAGA A A AGATTGACAC C G GAGACCTCCC C A ACACCGGTCA A C CCCCACATAT CA  CAATTTT T A ATATTAC TC C T TTTTCCC C T TCTCCCCACA A CA GCCACAGAG  CACAGAGTGT GTG AGT ATATA G GT AATAGAG G T TA GCAGCGC C A AGTTTT CA G GCGCAA GTAAG C CACAGAGTC C AGAGTGTGTG GA CATTGA GTA T TGTGAGACC G GAT GCA AT  ACCAAAA  TT CACAAAATAAA CA AAAATATATA A A ATATATACAT T TCAATATG A,CGTGTGTGTGT T GA AGTGTGTGTATA GTA TGTGTGTATAGATAG G GTGTAATTACCGC AGGAATTAG ACGCAA A AGAGCGCACAGAG G G GCGCACAGAGGG TG CACTCAGAGGGGTG C AGCAGGTGTG G G GGGGTGTGTGAA TA G GTGTGAGAGACAC  TGTGAGACACTCT T G GAGAC CACTCTC C AAGCACTCTCTCACA A C CTCTCTCATA AG GTCTTTTCACAGAGGA TG C CACAGAGGGGTGT T A AGAGGGGTGTTCAC GGGGTGTTTTTTT T G GTGTTTTT TCT TATATTTTTTAG TG G T TTTTTGC TGCGC C T TTTTGTGCAGTCT T T TGTGCGCTCTGTG G G GCGCTCTGTGCGC C C CTCTGTGCGCAGA  TGTGCGCACATAT T G GCCATATATA A C CACATATATACAC  GT ATTACACACA A T TATACCAGAG G C ACACAAT AGTGT CCA CACAGAGTGG C A AGAGTGTCTTACG G G GTGTCTCGCGCGC C TTCCTCGCGCGCTCT TGG CGGCTCTAA A GCCTATACAC C C CTAT TACACACA A TGCTTACACACAGAG G A ACACACAGTAAGG  CAAGGGGAGA AAC AGAGGGGAAT T G GGGGAGATATTTT ACA GAGATTTGCT G AAA TTGTGGGG G T TTTGGGGCC TT CGGCGCACA A G GGGGC TACAAAA A G GCCAAA GAC  TT AGCAACACACTTG T A AAAACACTCTATA A A ACACTCTATATCAGT C CTCTATATATATA GG  TATATAG TAAAA A A ATATATAAAAAAA A T TATAAAAAAATCTAT A AAAAAAATATTTT AGTAATTAGTTAA A ATATTTTAAGTA T TTTCGTAAAAAAA  TAC TAACAC C A AAAAAAACCA A A AAAACACACACAC  ACACA CAACACA A C CAAACACACAGAG G A ACT GCAGAGACAGA CCAGAGAGACAC C ATGAGACACCCC C G GAGACCA  GT ACAGCCCAGTAAT T C CCATTT C CACATATTTTCTC C A ATATTTCCCC C T TTTTCTCCCA CCA TCT CCAGAG G A CC TCCAGAGTGT T C CAGCTGTATA A A AG AAAG TAGG G GTA TTAGAGCGC C T TATAGAGCGCACA A A AGAGCGCATTGG G GCGCAGGTAGTGT T CCAGCAAGTGTG GT  AGAGTGTGTGAGA A GC AGTGTGAGACAC TA  TGTGAGACACACA A G GAGACACA ATA A ACACACAAAATTT AA AATC CCAGA A AAGCAATATATAT T A ATATATATATT,CGTTGTGTATA A G GTGTGGTCCA AG G TTTTGTATAGAGCATAC G GTGTATAGAGCGCATAGA TTTTTAGAGCGCACAGAG G A AGAGCGCACAGTGAA G GCGCACAGAGCGGTCCAT C CAGT GGTGTGTG G ATTATGAGA A G GGGGTGTGAGGAC C G GTA CTGAGACACTCT T T TGTGAGACACTCTCA CC G GAGACACTCTCTCACA A A ACCTCTCACAGAG ATAA TTCACAGAGGGG G T TCATACAGAGGGGTCAGT C CACAGAGGGGTGTTTT T A AGAGGGGTGTT TATT T G GGGGTGTTTTTTTTTT  GTGTTCC TGTTTGGT G T TTTTTTTTTTGTGCGCAC TCAGTTTTTGTGCGCTCT T T TTTTG ACGCTCTGTG AGGCAGTGCGCTTATGC C G GCAAACTGTGCGCAATAA C CTCTGTGCGCATTAAT T T TGGCACATATATA GG  GCGCATAGGC TACAC C C CACATGTC GAACACA A ATACCAGAG CAG TATACACA TGTG T ATGCCAGAGTATATC C CCA G TAGTGTAAGTCG G A AGAGTGTCTCGCGCGC C GGTCCGCGCTACAT TTCGCGCACCCTATA A C CGCGCGCTCTATACAC C G GCGCTCTATACACACA TC CTATACACAAG G T TATACACAAGGGG G A ACACACAGGGACAGA C CAGT AGGGGAACAAT T A AGAGGTTCGATATTTT T G GGGGAATTTTGTG G GGATATTTTGTGGAAAG A ATATTTTGTGGGGCGC  TT CCTGGGGCGCACA AG TATGGCGCATGTA G GGGGCGCACAAAACC G GCGCACAAAACACTCT  CACAAAACTA A A AAAACGT CTAAT T A ACACTCTA CTTA A C CTAC CAGCAGTAAAA G T TAATATAAGCTAA A A ATTAAGG AATAT T T TATAAAAAAATATTTT T A AAAAAAATATTTTATA A A AAAATATTTTATAAAA A A ATCATTAAACAAA AAA TTGGTTAAAAACTATCC TATAAAAAAACACACA A AAAAAACACACACAC C AACCAACACACA A A ACACACACACACAGCAGG CGATCAGAGAGA A ATATAC C C CATGGAGAGACGCTAGTC A AG CAGACCCACA A G GAGACACCCATAT T A AC AACCACATATTTT TTGCCACATTTCTC C C CACATATTTCCTTTC AATTGGATCCCCA CAA TGACTTCCCACAGAG G T TCTCCACTCAGAGTGT T C CCCCACAGCC GTATA GTG CACAGTCGGTATAG TGG AAGTGTATAGA TGC C G GTGTATAGAGCGCACA CTC TAAGCGCACAGAG G A AGAGCGCACAGAGTTCAT G GCGC AGTGTGTG G C CAGA AGTGTGTGAGA A A AGGTGTGA TTAC C G GTCAATGAGACACACA A TTGAGACACACAAAA A G GAGACACA ATAATAT T A ACA TGTGAATATATA A CCAAAATATA ACAT T A AAAATATATATATT,ATTCACTGTGTATAGG G GTGTGTAGAGCGC C T TGATT CT GGAGCGCAACAA G GTGTAG AAGCGCACAGAG G T TAAGCGCACAGAGGGG G A AGAGCGCACAGCCAGGTA TT G GCGCAC CAGTGTGTG G C CAAGGAATGTGTGAGA A ATTGTT GGTGTGCAGGAC GGGGTGTGTGACT T G GTGTGATAGACACTCTCTC C T TGTGAGACACTCTCCA  AC GA CTACTCTCAG G A ACTGCTCACAGAGGGG G CGTACTCTCACAGAGGGGTGT T T TCTCACAGAGGGGTGTTTT T C CACAGAGGGGTGTTTTTTT T A AGAGGGGTGTTTTTTT  GGGTTAT GT TG G GCA TAGTTTTTTTTG AAC T TTTTTTTTTTGTGCGTGTAAT TAGTTTTTTGTGCCTGTG G T TTTTGTGCCTGTGCGC C T TGGCTCTGTGCCAGCA A G GCGCTCTGACTGCAG AAT T CCTGTGCGCACATAGGGATA T TGTGCGCACATATATACAC C G GCGCACATATATACACACA A C CACATTACACACAGTAGT GATATACACACAGAGTGT T T TA GGACACAGAGTGTCC A ACACAAGTGTCTCGG C CA AG TTGTCAACCGCGC C A AGAGTGTCCGCGCTCT T G GT CACGCGCTCTATA TGC TCTCGGCTAC C C CGCGCGCTTACACACA GCTCTATACACACAGAG TTT CTTACACAATAGG G T TATACACACAGAGGTAGGA  ACACACAGAGGAC GATAT T CCAGAGGTA ATTTCCT A AGAGGGGAGATATT AGTG G GTACGGAGATATTTTATGGGG A G GAGATATTTTGTGGTTTGC C A ATCAATTGTGGGGCGCACA ACT TTTTGTGGGGCGCACAAAA A T TGTGGGGCGCAATTAACAC C GTAGAACCAAGCAA TCT T GAACGCAAACACTCTATA A CCAA CAACTTATTATACAT A AAAACACTCTACT TGAA A ACACTAGCTATATATAAAA A C CTCTATATATATAAAAAAA A T TATATATATAAAAAA GGACT A ATTTCTATAAACGCATTTT T T TATAAAAAAATATTTTATA A AAAAATTGCAAACAA A A AAAATATTTTGTAAAAAAA A A ATATTTTATAAAACGGAC T TT TATAAAAATAACA CA GT TCCTAAAAAAACACACACCAAC AGC AAAAACACACACACACA  AATCGACAGTGACACAGAG CATT GTG CACACATGAAGAGA A C CAACACAGAGAGACG GACACAGAGAGACACCCC C C CACAGAGAGACACCCCACA A A AGAGAACCCATAT  AC GAGACACCCCACATCAGTT T A ACACCCCAATTTTCC C CCCCACATTGTTTCAGGCC CAGCATATTTTC TACCAAATA A ATCGTATATCCCCACAGAG G T TTTTCTCCCCACAGAGTGT T T TCTCCCCACAGAGTGTATA A C CCCCAATTAGTAGCGTTAG G C CACAGAGTGTAGC C A AGAGTGTATAGAGTGCA GTA GTCGGTATAGAGCGCACAGAG G TTTAAGCGCACAGG CT ACAGCTATTACAGAGTGTGACAG G GCGCACAGAGGGTGTGAGA A CGTCGCTTGAGACAC C A AGAGTGTGTGAACACA A G GTTGAGACTTTAC AA A T TGTGAGACCAAAATT G GAGACACACAAAATATATA A AACAAATATACTAAT T C CACAAAATATATATATT,"ID   VME1_SARS2              Reviewed;         222 AA.
AC   P0DTC5;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Membrane protein {ECO:0000255|HAMAP-Rule:MF_04202};
DE            Short=M;
DE   AltName: Full=E1 glycoprotein {ECO:0000255|HAMAP-Rule:MF_04202};
DE   AltName: Full=Matrix glycoprotein {ECO:0000255|HAMAP-Rule:MF_04202};
DE   AltName: Full=Membrane glycoprotein {ECO:0000255|HAMAP-Rule:MF_04202};
GN   ORFNames=M;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   SUBCELLULAR LOCATION.
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [3]
RP   INTERACTION WITH S PROTEIN, AND FUNCTION.
RX   PubMed=33229438; DOI=10.1074/jbc.ra120.016175;
RA   Boson B., Legros V., Zhou B., Siret E., Mathieu C., Cosset F.L.,
RA   Lavillette D., Denolly S.;
RT   ""The SARS-CoV-2 Envelope and Membrane proteins modulate maturation and
RT   retention of the Spike protein, allowing assembly of virus-like
RT   particles."";
RL   J. Biol. Chem. 296:100111-100111(2020).
RN   [4]
RP   GLYCOSYLATION AT ASN-5, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=38666819; DOI=10.3390/biology13040207;
RA   Schwarze M., Volke D., Rojas Echeverri J.C., Schick R., Lakowa N.,
RA   Gruenewald T., Wolf J., Borte S., Scholz M., Krizsan A., Hoffmann R.;
RT   ""Influence of Mutations and N-Glycosylation Sites in the Receptor-Binding
RT   Domain (RBD) and the Membrane Protein of SARS-CoV-2 Variants of Concern on
RT   Antibody Binding in ELISA."";
RL   Biology 13:1-21(2024).
RN   [5] {ECO:0007744|PDB:8CTK}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.52 ANGSTROMS), TOPOLOGY, AND
RP   GLYCOSYLATION AT ASN-5.
RX   PubMed=36264056; DOI=10.7554/elife.81702;
RA   Dolan K.A., Dutta M., Kern D.M., Kotecha A., Voth G.A., Brohawn S.G.;
RT   ""Structure of SARS-CoV-2 M protein in lipid nanodiscs."";
RL   Elife 11:1-16(2022).
RN   [6] {ECO:0007744|PDB:7VGR, ECO:0007744|PDB:7VGS}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.70 ANGSTROMS), SUBUNIT, MUTAGENESIS OF
RP   42-ARG--ARG-44, AND GLYCOSYLATION AT ASN-5.
RX   PubMed=35931673; DOI=10.1038/s41467-022-32019-3;
RA   Zhang Z., Nomura N., Muramoto Y., Ekimoto T., Uemura T., Liu K., Yui M.,
RA   Kono N., Aoki J., Ikeguchi M., Noda T., Iwata S., Ohto U., Shimizu T.;
RT   ""Structure of SARS-CoV-2 membrane protein essential for virus assembly."";
RL   Nat. Commun. 13:1-12(2022).
CC   -!- FUNCTION: Component of the viral envelope that plays a central role in
CC       virus morphogenesis and assembly via its interactions with other viral
CC       proteins (By similarity). Regulates the localization of S protein at
CC       cis-Golgi, the place of virus budding (PubMed:33229438). May act by
CC       binding cytoplasmic c-terminus of S (PubMed:33229438).
CC       {ECO:0000255|HAMAP-Rule:MF_04202, ECO:0000255|PROSITE-ProRule:PRU01275,
CC       ECO:0000269|PubMed:33229438}.
CC   -!- SUBUNIT: Homomultimer (PubMed:35931673). Interacts with envelope E
CC       protein in the budding compartment of the host cell, which is located
CC       between endoplasmic reticulum and the Golgi complex (By similarity).
CC       Forms a complex with S proteins (PubMed:33229438). Interacts with
CC       nucleocapsid N protein. This interaction probably participates in RNA
CC       packaging into the virus (PubMed:35931673). Interacts with the
CC       accessory proteins 3a and 7a (By similarity).
CC       {ECO:0000250|UniProtKB:P59596, ECO:0000255|HAMAP-Rule:MF_04202,
CC       ECO:0000269|PubMed:33229438, ECO:0000269|PubMed:35931673}.
CC   -!- INTERACTION:
CC       P0DTC5; P0DTD8: 7b; NbExp=4; IntAct=EBI-25475853, EBI-25475914;
CC       P0DTC5; P0DTC4: E; NbExp=5; IntAct=EBI-25475853, EBI-25475850;
CC       P0DTC5; P0DTC5: M; NbExp=4; IntAct=EBI-25475853, EBI-25475853;
CC       P0DTC5; P0DTC9: N; NbExp=6; IntAct=EBI-25475853, EBI-25475856;
CC       P0DTC5; Q9BYX4: IFIH1; Xeno; NbExp=3; IntAct=EBI-25475853, EBI-6115771;
CC       P0DTC5; Q7Z434: MAVS; Xeno; NbExp=11; IntAct=EBI-25475853, EBI-995373;
CC       P0DTC5; O00487: PSMD14; Xeno; NbExp=2; IntAct=EBI-25475853, EBI-722193;
CC       P0DTC5; Q9UHD2: TBK1; Xeno; NbExp=10; IntAct=EBI-25475853, EBI-356402;
CC   -!- SUBCELLULAR LOCATION: Virion membrane {ECO:0000255|HAMAP-
CC       Rule:MF_04202}; Multi-pass membrane protein {ECO:0000255|HAMAP-
CC       Rule:MF_04202}. Host Golgi apparatus membrane {ECO:0000255|HAMAP-
CC       Rule:MF_04202, ECO:0000269|PubMed:33060197}; Multi-pass membrane
CC       protein {ECO:0000255|HAMAP-Rule:MF_04202}. Host membrane
CC       {ECO:0000269|PubMed:33060197}; Multi-pass membrane protein.
CC       Note=Largely embedded in the lipid bilayer. {ECO:0000255|HAMAP-
CC       Rule:MF_04202}.
CC   -!- PTM: Glycosylated at N-terminus by host. {ECO:0000269|PubMed:35931673,
CC       ECO:0000269|PubMed:36264056, ECO:0000269|PubMed:38666819}.
CC   -!- POLYMORPHISM: Variant Delta/B.1.617.2 belongs to a lineage first
CC       isolated in India (October 2020) and is also called G/478K.V1. It has
CC       an estimated 97% increase of transmissibility. {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC       isolated in South Africa (November 2021). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC       isolated in Nigeria (November 2022). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC       isolated in United States (November 2022). It is the result of
CC       recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC       express ORF8. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the betacoronaviruses M protein family.
CC       {ECO:0000255|HAMAP-Rule:MF_04202}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43419.1; -; Genomic_RNA.
DR   PDB; 7VGR; EM; 2.70 A; A/B=1-222.
DR   PDB; 7VGS; EM; 2.80 A; A/B=1-222.
DR   PDB; 8CME; X-ray; 2.26 A; C/F/I=176-190.
DR   PDB; 8CTK; EM; 3.52 A; A/B=1-222.
DR   PDBsum; 7VGR; -.
DR   PDBsum; 7VGS; -.
DR   PDBsum; 8CME; -.
DR   PDBsum; 8CTK; -.
DR   EMDB; EMD-26993; -.
DR   EMDB; EMD-31977; -.
DR   EMDB; EMD-31978; -.
DR   SMR; P0DTC5; -.
DR   BioGRID; 4383846; 2055.
DR   IntAct; P0DTC5; 270.
DR   MINT; P0DTC5; -.
DR   TCDB; 1.A.117.1.2; the coronavirus membrane matrix-protein (m-protein) family.
DR   GlyGen; P0DTC5; 1 site.
DR   iPTMnet; P0DTC5; -.
DR   ABCD; P0DTC5; 10 sequenced antibodies.
DR   DNASU; 43740571; -.
DR   KEGG; vg:43740571; -.
DR   AGR; RefSeq:YP_009724393; -.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-918233; TRAF3-dependent IRF activation pathway.
DR   Reactome; R-HSA-9694322; Virion Assembly and Release.
DR   Reactome; R-HSA-9694594; Maturation of protein M.
DR   Reactome; R-HSA-9694614; Attachment and Entry.
DR   Reactome; R-HSA-9694635; Translation of Structural Proteins.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9733458; Induction of Cell-Cell Fusion.
DR   Reactome; R-HSA-9754560; SARS-CoV-2 modulates autophagy.
DR   Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways.
DR   SIGNOR; P0DTC5; -.
DR   PRO; PR:P0DTC5; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0005793; C:endoplasmic reticulum-Golgi intermediate compartment; ISS:UniProt.
DR   GO; GO:0044178; C:host cell Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; TAS:Reactome.
DR   GO; GO:0019031; C:viral envelope; IEA:UniProtKB-UniRule.
DR   GO; GO:0055036; C:virion membrane; TAS:Reactome.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0140311; F:protein sequestering activity; IDA:UniProt.
DR   GO; GO:0039660; F:structural constituent of virion; IDA:UniProt.
DR   GO; GO:0039709; P:cytoplasmic capsid assembly; IDA:UniProt.
DR   GO; GO:0039545; P:symbiont-mediated suppression of host cytoplasmic pattern recognition receptor signaling pathway via inhibition of MAVS activity; IDA:UniProt.
DR   GO; GO:0019049; P:virus-mediated perturbation of host defense response; IEA:UniProtKB-KW.
DR   CDD; cd21569; SARS-like-CoV_M; 1.
DR   HAMAP; MF_04202; BETA_CORONA_M; 1.
DR   InterPro; IPR002574; M_CoV.
DR   InterPro; IPR044361; M_SARS-like-CoV.
DR   Pfam; PF01635; CoV_M; 1.
DR   PROSITE; PS51927; COV_M; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Glycoprotein; Host Golgi apparatus; Host membrane;
KW   Host-virus interaction; Membrane; Reference proteome; Transmembrane;
KW   Transmembrane helix; Viral envelope protein; Viral immunoevasion;
KW   Viral matrix protein; Virion.
FT   CHAIN           1..222
FT                   /note=""Membrane protein""
FT                   /id=""PRO_0000449652""
FT   TOPO_DOM        2..16
FT                   /note=""Virion surface""
FT                   /evidence=""ECO:0000269|PubMed:36264056""
FT   TRANSMEM        17..36
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:36264056""
FT   TOPO_DOM        37..44
FT                   /note=""Intravirion""
FT                   /evidence=""ECO:0000269|PubMed:36264056""
FT   TRANSMEM        45..70
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:36264056""
FT   TOPO_DOM        71..75
FT                   /note=""Virion surface""
FT                   /evidence=""ECO:0000269|PubMed:36264056""
FT   TRANSMEM        76..105
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:36264056""
FT   TOPO_DOM        106..222
FT                   /note=""Intravirion""
FT                   /evidence=""ECO:0000269|PubMed:36264056""
FT   CARBOHYD        5
FT                   /note=""N-linked (GlcNAc...) asparagine; by host""
FT                   /evidence=""ECO:0000269|PubMed:35931673,
FT                   ECO:0000269|PubMed:36264056, ECO:0000269|PubMed:38666819""
FT   VARIANT         3
FT                   /note=""D -> G (in strain: Omicron/BA.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         3
FT                   /note=""D -> N (in strain: Omicron/BA.5, Omicron/BQ.1.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         19
FT                   /note=""Q -> E (in strain: Omicron/BA.1, Omicron/BA.2,
FT                   Omicron/BA.2.12.1, Omicron/BA.2.75, Omicron/BA.4,
FT                   Omicron/BA.5, Omicron/BQ.1.1, Omicron/XBB.1.5,
FT                   Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         63
FT                   /note=""A -> T (in strain: Omicron/BA.1, Omicron/BA.2,
FT                   Omicron/BA.2.12.1, Omicron/BA.2.75, Omicron/BA.4,
FT                   Omicron/BA.5, Omicron/BQ.1.1, Omicron/XBB.1.5,
FT                   Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         82
FT                   /note=""I -> T (in strain: Eta/B.1.525 and Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   MUTAGEN         42..44
FT                   /note=""RNR->ANA: Partial loss of N-RNA binding.""
FT                   /evidence=""ECO:0000269|PubMed:35931673""
FT   HELIX           11..36
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   TURN            40..42
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   HELIX           44..70
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   HELIX           77..105
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   HELIX           109..112
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   STRAND          117..135
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   STRAND          138..140
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   TURN            145..147
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   STRAND          149..151
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   STRAND          154..157
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   STRAND          167..170
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   STRAND          172..174
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   STRAND          177..182
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   STRAND          188..190
FT                   /evidence=""ECO:0007829|PDB:7VGR""
FT   STRAND          195..200
FT                   /evidence=""ECO:0007829|PDB:7VGR""
SQ   SEQUENCE   222 AA;  25147 MW;  ED44D84C3BB9A6DB CRC64;
     MADSNGTITV EELKKLLEQW NLVIGFLFLT WICLLQFAYA NRNRFLYIIK LIFLWLLWPV
     TLACFVLAAV YRINWITGGI AIAMACLVGL MWLSYFIASF RLFARTRSMW SFNPETNILL
     NVPLHGTILT RPLLESELVI GAVILRGHLR IAGHHLGRCD IKDLPKEITV ATSRTLSYYK
     LGASQRVAGD SGFAAYSRYR IGNYKLNTDH SSSSDNIALL VQ
//
",19967
CGCAAA GCAAAG CAAAGC AAAGCC AAGCCG AGCCGG GCCGGG CCGGGC CGGGCC GGGCCG GGCCGC GCCGCT CCGCTG CGCTGC GCTGCT CTGCTG TGCTGA GCTGAT CTGATC TGATCC GATCCC ATCCCG TCCCGG CCCGGG CCGGGG CGGGGG GGGGGC GGGGCG GGGCGA GGCGAC GCGACG CGACGC GACGCT ACGCTG CGCTGG GCTGGC CTGGCG TGGCGA GGCGAC GCGACC CGACCT GACCTT ACCTTC CCTTCT CTTCTT TTCTTC TCTTCA CTTCAT TTCATC TCATCA CATCAA ATCAAC TCAACA CAACAC AACACC ACACCT CACCTC ACCTCG CCTCGA CTCGAT TCGATC CGATCA GATCAC ATCACC TCACCA CACCAG ACCAGC CCAGCT CAGCTC AGCTCC GCTCCG CTCCGC TCCGCC CCGCCG CGCCGG GCCGGC CCGGCT CGGCTG GGCTGT GCTGTT CTGTTC TGTTCG GTTCGG TTCGGC TCGGCG CGGCGG GGCGGC GCGGCG CGGCGG GGCGGT GCGGTC CGGTCG GGTCGG GTCGGT TCGGTT CGGTTC GGTTCG GTTCGA TTCGAT TCGATC CGATCC GATCCT ATCCTG TCCTGA CCTGAT CTGATC TGATCC GATCCC ATCCCG TCCCGA CCCGAT CCGATC CGATCA GATCAT ATCATG TCATGC CATGCT ATGCTT TGCTTT GCTTTC CTTTCG TTTCGG TTCGGC TCGGCC CGGCCG GGCCGG GCCGGG CCGGGG CGGGGT GGGGTG GGGTGC GGTGCA GTGCAT TGCATC GCATCC CATCCG ATCCGG TCCGGC CCGGCC CGGCCG GGCCGA GCCGAA CCGAAA CGAAAG GAAAGC,2,145,CGCA GCAA CAAA AAAG AAGC AGCC GCCG CCGG CGGG GGGC GGCC GCCG CCGC CGCT GCTG CTGC TGCT GCTG CTGA TGAT GATC ATCC TCCC CCCG CCGG CGGG GGGG GGGG GGGC GGCG GCGA CGAC GACG ACGC CGCT GCTG CTGG TGGC GGCG GCGA CGAC GACC ACCT CCTT CTTC TTCT TCTT CTTC TTCA TCAT CATC ATCA TCAA CAAC AACA ACAC CACC ACCT CCTC CTCG TCGA CGAT GATC ATCA TCAC CACC ACCA CCAG CAGC AGCT GCTC CTCC TCCG CCGC CGCC GCCG CCGG CGGC GGCT GCTG CTGT TGTT GTTC TTCG TCGG CGGC GGCG GCGG CGGC GGCG GCGG CGGT GGTC GTCG TCGG CGGT GGTT GTTC TTCG TCGA CGAT GATC ATCC TCCT CCTG CTGA TGAT GATC ATCC TCCC CCCG CCGA CGAT GATC ATCA TCAT CATG ATGC TGCT GCTT CTTT TTTC TTCG TCGG CGGC GGCC GCCG CCGG CGGG GGGG GGGT GGTG GTGC TGCA GCAT CATC ATCC TCCG CCGG CGGC GGCC GCCG CCGA CGAA GAAA AAAG AAGC,CGCAA GCAAA CAAAG AAAGC AAGCC AGCCG GCCGG CCGGG CGGGC GGGCC GGCCG GCCGC CCGCT CGCTG GCTGC CTGCT TGCTG GCTGA CTGAT TGATC GATCC ATCCC TCCCG CCCGG CCGGG CGGGG GGGGG GGGGC GGGCG GGCGA GCGAC CGACG GACGC ACGCT CGCTG GCTGG CTGGC TGGCG GGCGA GCGAC CGACC GACCT ACCTT CCTTC CTTCT TTCTT TCTTC CTTCA TTCAT TCATC CATCA ATCAA TCAAC CAACA AACAC ACACC CACCT ACCTC CCTCG CTCGA TCGAT CGATC GATCA ATCAC TCACC CACCA ACCAG CCAGC CAGCT AGCTC GCTCC CTCCG TCCGC CCGCC CGCCG GCCGG CCGGC CGGCT GGCTG GCTGT CTGTT TGTTC GTTCG TTCGG TCGGC CGGCG GGCGG GCGGC CGGCG GGCGG GCGGT CGGTC GGTCG GTCGG TCGGT CGGTT GGTTC GTTCG TTCGA TCGAT CGATC GATCC ATCCT TCCTG CCTGA CTGAT TGATC GATCC ATCCC TCCCG CCCGA CCGAT CGATC GATCA ATCAT TCATG CATGC ATGCT TGCTT GCTTT CTTTC TTTCG TTCGG TCGGC CGGCC GGCCG GCCGG CCGGG CGGGG GGGGT GGGTG GGTGC GTGCA TGCAT GCATC CATCC ATCCG TCCGG CCGGC CGGCC GGCCG GCCGA CCGAA CGAAA GAAAG AAAGC,CGCAAA GCAAAG CAAAGC AAAGCC AAGCCG AGCCGG GCCGGG CCGGGC CGGGCC GGGCCG GGCCGC GCCGCT CCGCTG CGCTGC GCTGCT CTGCTG TGCTGA GCTGAT CTGATC TGATCC GATCCC ATCCCG TCCCGG CCCGGG CCGGGG CGGGGG GGGGGC GGGGCG GGGCGA GGCGAC GCGACG CGACGC GACGCT ACGCTG CGCTGG GCTGGC CTGGCG TGGCGA GGCGAC GCGACC CGACCT GACCTT ACCTTC CCTTCT CTTCTT TTCTTC TCTTCA CTTCAT TTCATC TCATCA CATCAA ATCAAC TCAACA CAACAC AACACC ACACCT CACCTC ACCTCG CCTCGA CTCGAT TCGATC CGATCA GATCAC ATCACC TCACCA CACCAG ACCAGC CCAGCT CAGCTC AGCTCC GCTCCG CTCCGC TCCGCC CCGCCG CGCCGG GCCGGC CCGGCT CGGCTG GGCTGT GCTGTT CTGTTC TGTTCG GTTCGG TTCGGC TCGGCG CGGCGG GGCGGC GCGGCG CGGCGG GGCGGT GCGGTC CGGTCG GGTCGG GTCGGT TCGGTT CGGTTC GGTTCG GTTCGA TTCGAT TCGATC CGATCC GATCCT ATCCTG TCCTGA CCTGAT CTGATC TGATCC GATCCC ATCCCG TCCCGA CCCGAT CCGATC CGATCA GATCAT ATCATG TCATGC CATGCT ATGCTT TGCTTT GCTTTC CTTTCG TTTCGG TTCGGC TCGGCC CGGCCG GGCCGG GCCGGG CCGGGG CGGGGT GGGGTG GGGTGC GGTGCA GTGCAT TGCATC GCATCC CATCCG ATCCGG TCCGGC CCGGCC CGGCCG GGCCGA GCCGAA CCGAAA CGAAAG GAAAGC,CGCAAAG GCAAAGC CAAAGCC AAAGCCG AAGCCGG AGCCGGG GCCGGGC CCGGGCC CGGGCCG GGGCCGC GGCCGCT GCCGCTG CCGCTGC CGCTGCT GCTGCTG CTGCTGA TGCTGAT GCTGATC CTGATCC TGATCCC GATCCCG ATCCCGG TCCCGGG CCCGGGG CCGGGGG CGGGGGC GGGGGCG GGGGCGA GGGCGAC GGCGACG GCGACGC CGACGCT GACGCTG ACGCTGG CGCTGGC GCTGGCG CTGGCGA TGGCGAC GGCGACC GCGACCT CGACCTT GACCTTC ACCTTCT CCTTCTT CTTCTTC TTCTTCA TCTTCAT CTTCATC TTCATCA TCATCAA CATCAAC ATCAACA TCAACAC CAACACC AACACCT ACACCTC CACCTCG ACCTCGA CCTCGAT CTCGATC TCGATCA CGATCAC GATCACC ATCACCA TCACCAG CACCAGC ACCAGCT CCAGCTC CAGCTCC AGCTCCG GCTCCGC CTCCGCC TCCGCCG CCGCCGG CGCCGGC GCCGGCT CCGGCTG CGGCTGT GGCTGTT GCTGTTC CTGTTCG TGTTCGG GTTCGGC TTCGGCG TCGGCGG CGGCGGC GGCGGCG GCGGCGG CGGCGGT GGCGGTC GCGGTCG CGGTCGG GGTCGGT GTCGGTT TCGGTTC CGGTTCG GGTTCGA GTTCGAT TTCGATC TCGATCC CGATCCT GATCCTG ATCCTGA TCCTGAT CCTGATC CTGATCC TGATCCC GATCCCG ATCCCGA TCCCGAT CCCGATC CCGATCA CGATCAT GATCATG ATCATGC TCATGCT CATGCTT ATGCTTT TGCTTTC GCTTTCG CTTTCGG TTTCGGC TTCGGCC TCGGCCG CGGCCGG GGCCGGG GCCGGGG CCGGGGT CGGGGTG GGGGTGC GGGTGCA GGTGCAT GTGCATC TGCATCC GCATCCG CATCCGG ATCCGGC TCCGGCC CCGGCCG CGGCCGA GGCCGAA GCCGAAA CCGAAAG CGAAAGC,"ID   Y586_HAEIN              Reviewed;         145 AA.
AC   P44019;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   24-JUL-2024, entry version 93.
DE   RecName: Full=Putative uncharacterized transporter HI_0586;
GN   OrderedLocusNames=HI_0586;
OS   Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Pasteurellales;
OC   Pasteurellaceae; Haemophilus.
OX   NCBI_TaxID=71421;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 51907 / DSM 11121 / KW20 / Rd;
RX   PubMed=7542800; DOI=10.1126/science.7542800;
RA   Fleischmann R.D., Adams M.D., White O., Clayton R.A., Kirkness E.F.,
RA   Kerlavage A.R., Bult C.J., Tomb J.-F., Dougherty B.A., Merrick J.M.,
RA   McKenney K., Sutton G.G., FitzHugh W., Fields C.A., Gocayne J.D.,
RA   Scott J.D., Shirley R., Liu L.-I., Glodek A., Kelley J.M., Weidman J.F.,
RA   Phillips C.A., Spriggs T., Hedblom E., Cotton M.D., Utterback T.R.,
RA   Hanna M.C., Nguyen D.T., Saudek D.M., Brandon R.C., Fine L.D.,
RA   Fritchman J.L., Fuhrmann J.L., Geoghagen N.S.M., Gnehm C.L., McDonald L.A.,
RA   Small K.V., Fraser C.M., Smith H.O., Venter J.C.;
RT   ""Whole-genome random sequencing and assembly of Haemophilus influenzae
RT   Rd."";
RL   Science 269:496-512(1995).
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Multi-pass membrane
CC       protein {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the DcuC/DcuD transporter (TC 2.A.61) family.
CC       {ECO:0000305}.
CC   -!- CAUTION: Could be the product of a pseudogene. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L42023; AAC22250.1; -; Genomic_DNA.
DR   PIR; A64010; A64010.
DR   AlphaFoldDB; P44019; -.
DR   SMR; P44019; -.
DR   STRING; 71421.HI_0586; -.
DR   EnsemblBacteria; AAC22250; AAC22250; HI_0586.
DR   KEGG; hin:HI_0586; -.
DR   eggNOG; COG3069; Bacteria.
DR   HOGENOM; CLU_1784149_0_0_6; -.
DR   Proteomes; UP000000579; Chromosome.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0015556; F:C4-dicarboxylate transmembrane transporter activity; IEA:InterPro.
DR   InterPro; IPR004669; C4_dicarb_anaerob_car.
DR   NCBIfam; NF037994; DcuC_1; 1.
PE   5: Uncertain;
KW   Cell membrane; Membrane; Reference proteome; Transmembrane;
KW   Transmembrane helix.
FT   CHAIN           1..145
FT                   /note=""Putative uncharacterized transporter HI_0586""
FT                   /id=""PRO_0000201634""
FT   TRANSMEM        1..21
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        28..48
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        54..74
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        96..116
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
SQ   SEQUENCE   145 AA;  15226 MW;  211213504489AA7D CRC64;
     MELFKSIVAV IGIIATIYFL IKKAETRTVL IGVGLIMSIL TLNPMGALDA FAKSMTSGGL
     IMAICSSMGF AYVMKYTQCD THLVHLLTKP LSGLKFFLIP IATIITFFIN IAIPSAAGCA
     AAVGATLIPV LKSAGVRPAT AGQLF
//
",24755
ATGGAC TGGACC GGACCC GACCCC ACCCCA CCCCAA CCCAAA CCAAAA CAAAAT AAAATC AAATCA AATCAG ATCAGC TCAGCG CAGCGA AGCGAA GCGAAA CGAAAT GAAATG AAATGC AATGCA ATGCAC TGCACT GCACTC CACTCC ACTCCG CTCCGC TCCGCA CCGCAT CGCATT GCATTA CATTAC ATTACG TTACGT TACGTT ACGTTT CGTTTG GTTTGG TTTGGT TTGGTG TGGTGG GGTGGA GTGGAC TGGACC GGACCC GACCCT ACCCTC CCCTCA CCTCAG CTCAGA TCAGAT CAGATT AGATTC GATTCA ATTCAA TTCAAC TCAACT CAACTG AACTGG ACTGGC CTGGCA TGGCAG GGCAGT GCAGTA CAGTAA AGTAAC GTAACC TAACCA AACCAG ACCAGA CCAGAA CAGAAT AGAATG GAATGG AATGGT ATGGTG TGGTGG GGTGGG GTGGGG TGGGGC GGGGCG GGGCGC GGCGCG GCGCGA CGCGAT GCGATC CGATCA GATCAA ATCAAA TCAAAA CAAAAC AAAACA AAACAA AACAAC ACAACG CAACGT AACGTC ACGTCG CGTCGG GTCGGC TCGGCC CGGCCC GGCCCC GCCCCA CCCCAA CCCAAG CCAAGG CAAGGT AAGGTT AGGTTT GGTTTA GTTTAC,3,112,ATGG TGGA GGAC GACC ACCC CCCC CCCA CCAA CAAA AAAA AAAT AATC ATCA TCAG CAGC AGCG GCGA CGAA GAAA AAAT AATG ATGC TGCA GCAC CACT ACTC CTCC TCCG CCGC CGCA GCAT CATT ATTA TTAC TACG ACGT CGTT GTTT TTTG TTGG TGGT GGTG GTGG TGGA GGAC GACC ACCC CCCT CCTC CTCA TCAG CAGA AGAT GATT ATTC TTCA TCAA CAAC AACT ACTG CTGG TGGC GGCA GCAG CAGT AGTA GTAA TAAC AACC ACCA CCAG CAGA AGAA GAAT AATG ATGG TGGT GGTG GTGG TGGG GGGG GGGC GGCG GCGC CGCG GCGA CGAT GATC ATCA TCAA CAAA AAAA AAAC AACA ACAA CAAC AACG ACGT CGTC GTCG TCGG CGGC GGCC GCCC CCCC CCCA CCAA CAAG AAGG AGGT GGTT GTTT TTTA TTAC,ATGGA TGGAC GGACC GACCC ACCCC CCCCA CCCAA CCAAA CAAAA AAAAT AAATC AATCA ATCAG TCAGC CAGCG AGCGA GCGAA CGAAA GAAAT AAATG AATGC ATGCA TGCAC GCACT CACTC ACTCC CTCCG TCCGC CCGCA CGCAT GCATT CATTA ATTAC TTACG TACGT ACGTT CGTTT GTTTG TTTGG TTGGT TGGTG GGTGG GTGGA TGGAC GGACC GACCC ACCCT CCCTC CCTCA CTCAG TCAGA CAGAT AGATT GATTC ATTCA TTCAA TCAAC CAACT AACTG ACTGG CTGGC TGGCA GGCAG GCAGT CAGTA AGTAA GTAAC TAACC AACCA ACCAG CCAGA CAGAA AGAAT GAATG AATGG ATGGT TGGTG GGTGG GTGGG TGGGG GGGGC GGGCG GGCGC GCGCG CGCGA GCGAT CGATC GATCA ATCAA TCAAA CAAAA AAAAC AAACA AACAA ACAAC CAACG AACGT ACGTC CGTCG GTCGG TCGGC CGGCC GGCCC GCCCC CCCCA CCCAA CCAAG CAAGG AAGGT AGGTT GGTTT GTTTA TTTAC,ATGGAC TGGACC GGACCC GACCCC ACCCCA CCCCAA CCCAAA CCAAAA CAAAAT AAAATC AAATCA AATCAG ATCAGC TCAGCG CAGCGA AGCGAA GCGAAA CGAAAT GAAATG AAATGC AATGCA ATGCAC TGCACT GCACTC CACTCC ACTCCG CTCCGC TCCGCA CCGCAT CGCATT GCATTA CATTAC ATTACG TTACGT TACGTT ACGTTT CGTTTG GTTTGG TTTGGT TTGGTG TGGTGG GGTGGA GTGGAC TGGACC GGACCC GACCCT ACCCTC CCCTCA CCTCAG CTCAGA TCAGAT CAGATT AGATTC GATTCA ATTCAA TTCAAC TCAACT CAACTG AACTGG ACTGGC CTGGCA TGGCAG GGCAGT GCAGTA CAGTAA AGTAAC GTAACC TAACCA AACCAG ACCAGA CCAGAA CAGAAT AGAATG GAATGG AATGGT ATGGTG TGGTGG GGTGGG GTGGGG TGGGGC GGGGCG GGGCGC GGCGCG GCGCGA CGCGAT GCGATC CGATCA GATCAA ATCAAA TCAAAA CAAAAC AAAACA AAACAA AACAAC ACAACG CAACGT AACGTC ACGTCG CGTCGG GTCGGC TCGGCC CGGCCC GGCCCC GCCCCA CCCCAA CCCAAG CCAAGG CAAGGT AAGGTT AGGTTT GGTTTA GTTTAC,ATGGACC TGGACCC GGACCCC GACCCCA ACCCCAA CCCCAAA CCCAAAA CCAAAAT CAAAATC AAAATCA AAATCAG AATCAGC ATCAGCG TCAGCGA CAGCGAA AGCGAAA GCGAAAT CGAAATG GAAATGC AAATGCA AATGCAC ATGCACT TGCACTC GCACTCC CACTCCG ACTCCGC CTCCGCA TCCGCAT CCGCATT CGCATTA GCATTAC CATTACG ATTACGT TTACGTT TACGTTT ACGTTTG CGTTTGG GTTTGGT TTTGGTG TTGGTGG TGGTGGA GGTGGAC GTGGACC TGGACCC GGACCCT GACCCTC ACCCTCA CCCTCAG CCTCAGA CTCAGAT TCAGATT CAGATTC AGATTCA GATTCAA ATTCAAC TTCAACT TCAACTG CAACTGG AACTGGC ACTGGCA CTGGCAG TGGCAGT GGCAGTA GCAGTAA CAGTAAC AGTAACC GTAACCA TAACCAG AACCAGA ACCAGAA CCAGAAT CAGAATG AGAATGG GAATGGT AATGGTG ATGGTGG TGGTGGG GGTGGGG GTGGGGC TGGGGCG GGGGCGC GGGCGCG GGCGCGA GCGCGAT CGCGATC GCGATCA CGATCAA GATCAAA ATCAAAA TCAAAAC CAAAACA AAAACAA AAACAAC AACAACG ACAACGT CAACGTC AACGTCG ACGTCGG CGTCGGC GTCGGCC TCGGCCC CGGCCCC GGCCCCA GCCCCAA CCCCAAG CCCAAGG CCAAGGT CAAGGTT AAGGTTT AGGTTTA GGTTTAC,"ID   ORF9B_BCHK3             Reviewed;          97 AA.
AC   Q3LZX3;
DT   12-JUN-2007, integrated into UniProtKB/Swiss-Prot.
DT   25-OCT-2005, sequence version 1.
DT   02-OCT-2024, entry version 58.
DE   RecName: Full=Protein 9b;
DE   AltName: Full=Accessory protein 9b;
DE   AltName: Full=ORF-9b;
GN   ORFNames=9b;
OS   Bat coronavirus HKU3 (BtCoV) (SARS-like coronavirus HKU3).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=442736;
OH   NCBI_TaxID=89399; Rhinolophus sinicus (Chinese rufous horseshoe bat).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU3-1;
RX   PubMed=16169905; DOI=10.1073/pnas.0506735102;
RA   Lau S.K.P., Woo P.C.Y., Li K.S.M., Huang Y., Tsoi H.-W., Wong B.H.L.,
RA   Wong S.S.Y., Leung S.-Y., Chan K.-H., Yuen K.-Y.;
RT   ""Severe acute respiratory syndrome coronavirus-like virus in Chinese
RT   horseshoe bats."";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:14040-14045(2005).
CC   -!- SUBUNIT: Homodimer. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Host cytoplasmic vesicle membrane; Peripheral
CC       membrane protein. Host cytoplasm. Note=Binds non-covalently to
CC       intracellular lipid bilayers. {ECO:0000250}.
CC   -!- MISCELLANEOUS: The gene encoding this protein is included within the N
CC       gene (alternative ORF).
CC   -!- MISCELLANEOUS: Bat coronavirus HKU3 is highly similar to SARS-CoV
CC       (SARS-like).
CC   -!- SIMILARITY: Belongs to the coronavirus group 2 protein 9b family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; DQ022305; AAY88875.1; -; Genomic_RNA.
DR   SMR; Q3LZX3; -.
DR   Proteomes; UP000007450; Segment.
DR   GO; GO:0044162; C:host cell cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR   CDD; cd21955; SARS-CoV_ORF9b; 1.
DR   InterPro; IPR018542; Protein_9b_Betacoronavirus.
DR   InterPro; IPR037223; Protein_9b_SARS.
DR   Pfam; PF09399; bCoV_lipid_BD; 1.
DR   SUPFAM; SSF141666; SARS ORF9b-like; 1.
DR   PROSITE; PS51920; SARS_9B; 1.
PE   3: Inferred from homology;
KW   Host cytoplasm; Host cytoplasmic vesicle; Host membrane; Membrane.
FT   CHAIN           1..97
FT                   /note=""Protein 9b""
FT                   /id=""PRO_0000291325""
FT   DOMAIN          8..97
FT                   /note=""9b""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01268""
SQ   SEQUENCE   97 AA;  10723 MW;  1CAD2AFC3882E232 CRC64;
     MDPKVNVVPP ALHLVDPQIQ MTITRMEDAV VHDQNNAGPK VYPIILRLGS QLSLSMAKRN
     LDSLEARAFQ STPIVVKMTK LATTEELPDE FVVVTAK
//
",3456
CACCAA ACCAAA CCAAAC CAAACT AAACTA AACTAT ACTATA CTATAT TATATA ATATAC TATACA ATACAA TACAAA ACAAAT CAAATT AAATTA AATTAC ATTACA TTACAA TACAAC ACAACA CAACAT AACATA ACATAA CATAAT ATAATA TAATAC AATACA ATACAG TACAGC ACAGCA CAGCAG AGCAGC GCAGCC CAGCCC AGCCCA GCCCAT CCCATT CCATTT CATTTA ATTTAC TTTACA TTACAG TACAGG ACAGGG CAGGGA AGGGAG GGGAGC GGAGCC GAGCCG AGCCGG GCCGGA CCGGAC CGGACA GGACAC GACACG ACACGT CACGTT ACGTTG CGTTGT GTTGTA TTGTAG TGTAGA GTAGAC TAGACT AGACTC GACTCT ACTCTG CTCTGA TCTGAC CTGACA TGACAG GACAGA ACAGAG CAGAGT AGAGTT GAGTTG AGTTGT GTTGTC TTGTCA TGTCAG GTCAGT TCAGTG CAGTGT AGTGTA GTGTAA TGTAAC GTAACC TAACCG AACCGG ACCGGC CCGGCG CGGCGT GGCGTA GCGTAC CGTACA GTACAG TACAGA ACAGAT CAGATC AGATCG GATCGG ATCGGT TCGGTT CGGTTC GGTTCC GTTCCA TTCCAT TCCATC CCATCA CATCAG ATCAGC TCAGCA CAGCAG AGCAGA GCAGAC CAGACC AGACCA GACCAG ACCAGG CCAGGC CAGGCG AGGCGA GGCGAG GCGAGG CGAGGG GAGGGA AGGGAA GGGAAG GGAAGT GAAGTG AAGTGC AGTGCA GTGCAG TGCAGT GCAGTA CAGTAA AGTAAG GTAAGG TAAGGA AAGGAG AGGAGC GGAGCG GAGCGA AGCGAT,3,145,CACC ACCA CCAA CAAA AAAC AACT ACTA CTAT TATA ATAT TATA ATAC TACA ACAA CAAA AAAT AATT ATTA TTAC TACA ACAA CAAC AACA ACAT CATA ATAA TAAT AATA ATAC TACA ACAG CAGC AGCA GCAG CAGC AGCC GCCC CCCA CCAT CATT ATTT TTTA TTAC TACA ACAG CAGG AGGG GGGA GGAG GAGC AGCC GCCG CCGG CGGA GGAC GACA ACAC CACG ACGT CGTT GTTG TTGT TGTA GTAG TAGA AGAC GACT ACTC CTCT TCTG CTGA TGAC GACA ACAG CAGA AGAG GAGT AGTT GTTG TTGT TGTC GTCA TCAG CAGT AGTG GTGT TGTA GTAA TAAC AACC ACCG CCGG CGGC GGCG GCGT CGTA GTAC TACA ACAG CAGA AGAT GATC ATCG TCGG CGGT GGTT GTTC TTCC TCCA CCAT CATC ATCA TCAG CAGC AGCA GCAG CAGA AGAC GACC ACCA CCAG CAGG AGGC GGCG GCGA CGAG GAGG AGGG GGGA GGAA GAAG AAGT AGTG GTGC TGCA GCAG CAGT AGTA GTAA TAAG AAGG AGGA GGAG GAGC AGCG GCGA CGAT,CACCA ACCAA CCAAA CAAAC AAACT AACTA ACTAT CTATA TATAT ATATA TATAC ATACA TACAA ACAAA CAAAT AAATT AATTA ATTAC TTACA TACAA ACAAC CAACA AACAT ACATA CATAA ATAAT TAATA AATAC ATACA TACAG ACAGC CAGCA AGCAG GCAGC CAGCC AGCCC GCCCA CCCAT CCATT CATTT ATTTA TTTAC TTACA TACAG ACAGG CAGGG AGGGA GGGAG GGAGC GAGCC AGCCG GCCGG CCGGA CGGAC GGACA GACAC ACACG CACGT ACGTT CGTTG GTTGT TTGTA TGTAG GTAGA TAGAC AGACT GACTC ACTCT CTCTG TCTGA CTGAC TGACA GACAG ACAGA CAGAG AGAGT GAGTT AGTTG GTTGT TTGTC TGTCA GTCAG TCAGT CAGTG AGTGT GTGTA TGTAA GTAAC TAACC AACCG ACCGG CCGGC CGGCG GGCGT GCGTA CGTAC GTACA TACAG ACAGA CAGAT AGATC GATCG ATCGG TCGGT CGGTT GGTTC GTTCC TTCCA TCCAT CCATC CATCA ATCAG TCAGC CAGCA AGCAG GCAGA CAGAC AGACC GACCA ACCAG CCAGG CAGGC AGGCG GGCGA GCGAG CGAGG GAGGG AGGGA GGGAA GGAAG GAAGT AAGTG AGTGC GTGCA TGCAG GCAGT CAGTA AGTAA GTAAG TAAGG AAGGA AGGAG GGAGC GAGCG AGCGA GCGAT,CACCAA ACCAAA CCAAAC CAAACT AAACTA AACTAT ACTATA CTATAT TATATA ATATAC TATACA ATACAA TACAAA ACAAAT CAAATT AAATTA AATTAC ATTACA TTACAA TACAAC ACAACA CAACAT AACATA ACATAA CATAAT ATAATA TAATAC AATACA ATACAG TACAGC ACAGCA CAGCAG AGCAGC GCAGCC CAGCCC AGCCCA GCCCAT CCCATT CCATTT CATTTA ATTTAC TTTACA TTACAG TACAGG ACAGGG CAGGGA AGGGAG GGGAGC GGAGCC GAGCCG AGCCGG GCCGGA CCGGAC CGGACA GGACAC GACACG ACACGT CACGTT ACGTTG CGTTGT GTTGTA TTGTAG TGTAGA GTAGAC TAGACT AGACTC GACTCT ACTCTG CTCTGA TCTGAC CTGACA TGACAG GACAGA ACAGAG CAGAGT AGAGTT GAGTTG AGTTGT GTTGTC TTGTCA TGTCAG GTCAGT TCAGTG CAGTGT AGTGTA GTGTAA TGTAAC GTAACC TAACCG AACCGG ACCGGC CCGGCG CGGCGT GGCGTA GCGTAC CGTACA GTACAG TACAGA ACAGAT CAGATC AGATCG GATCGG ATCGGT TCGGTT CGGTTC GGTTCC GTTCCA TTCCAT TCCATC CCATCA CATCAG ATCAGC TCAGCA CAGCAG AGCAGA GCAGAC CAGACC AGACCA GACCAG ACCAGG CCAGGC CAGGCG AGGCGA GGCGAG GCGAGG CGAGGG GAGGGA AGGGAA GGGAAG GGAAGT GAAGTG AAGTGC AGTGCA GTGCAG TGCAGT GCAGTA CAGTAA AGTAAG GTAAGG TAAGGA AAGGAG AGGAGC GGAGCG GAGCGA AGCGAT,CACCAAA ACCAAAC CCAAACT CAAACTA AAACTAT AACTATA ACTATAT CTATATA TATATAC ATATACA TATACAA ATACAAA TACAAAT ACAAATT CAAATTA AAATTAC AATTACA ATTACAA TTACAAC TACAACA ACAACAT CAACATA AACATAA ACATAAT CATAATA ATAATAC TAATACA AATACAG ATACAGC TACAGCA ACAGCAG CAGCAGC AGCAGCC GCAGCCC CAGCCCA AGCCCAT GCCCATT CCCATTT CCATTTA CATTTAC ATTTACA TTTACAG TTACAGG TACAGGG ACAGGGA CAGGGAG AGGGAGC GGGAGCC GGAGCCG GAGCCGG AGCCGGA GCCGGAC CCGGACA CGGACAC GGACACG GACACGT ACACGTT CACGTTG ACGTTGT CGTTGTA GTTGTAG TTGTAGA TGTAGAC GTAGACT TAGACTC AGACTCT GACTCTG ACTCTGA CTCTGAC TCTGACA CTGACAG TGACAGA GACAGAG ACAGAGT CAGAGTT AGAGTTG GAGTTGT AGTTGTC GTTGTCA TTGTCAG TGTCAGT GTCAGTG TCAGTGT CAGTGTA AGTGTAA GTGTAAC TGTAACC GTAACCG TAACCGG AACCGGC ACCGGCG CCGGCGT CGGCGTA GGCGTAC GCGTACA CGTACAG GTACAGA TACAGAT ACAGATC CAGATCG AGATCGG GATCGGT ATCGGTT TCGGTTC CGGTTCC GGTTCCA GTTCCAT TTCCATC TCCATCA CCATCAG CATCAGC ATCAGCA TCAGCAG CAGCAGA AGCAGAC GCAGACC CAGACCA AGACCAG GACCAGG ACCAGGC CCAGGCG CAGGCGA AGGCGAG GGCGAGG GCGAGGG CGAGGGA GAGGGAA AGGGAAG GGGAAGT GGAAGTG GAAGTGC AAGTGCA AGTGCAG GTGCAGT TGCAGTA GCAGTAA CAGTAAG AGTAAGG GTAAGGA TAAGGAG AAGGAGC AGGAGCG GGAGCGA GAGCGAT,"ID   GBLP_CHLRE              Reviewed;         318 AA.
AC   P25387;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1992, sequence version 1.
DT   05-FEB-2025, entry version 127.
DE   RecName: Full=Small ribosomal subunit protein RACK1 {ECO:0000305};
DE   AltName: Full=Guanine nucleotide-binding protein subunit beta-like protein;
GN   Name=GBLP;
OS   Chlamydomonas reinhardtii (Chlamydomonas smithii).
OC   Eukaryota; Viridiplantae; Chlorophyta; core chlorophytes; Chlorophyceae;
OC   CS clade; Chlamydomonadales; Chlamydomonadaceae; Chlamydomonas.
OX   NCBI_TaxID=3055;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=21gr / CC-1690;
RX   PubMed=2116589; DOI=10.1007/bf00259410;
RA   Schloss J.A.;
RT   ""A Chlamydomonas gene encodes a G protein beta subunit-like polypeptide."";
RL   Mol. Gen. Genet. 221:443-452(1990).
CC   -!- DEVELOPMENTAL STAGE: Constitutively expressed during the cell cycle and
CC       flagella regeneration.
CC   -!- SIMILARITY: Belongs to the WD repeat G protein beta family. Ribosomal
CC       protein RACK1 subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X53574; CAA37638.1; -; Genomic_DNA.
DR   PIR; S11904; S11904.
DR   RefSeq; XP_001698065.1; XM_001698013.1.
DR   AlphaFoldDB; P25387; -.
DR   SMR; P25387; -.
DR   PaxDb; 3055-EDO99650; -.
DR   ProMEX; P25387; -.
DR   EnsemblPlants; PNW82333; PNW82333; CHLRE_06g278222v5.
DR   GeneID; 5723548; -.
DR   Gramene; PNW82333; PNW82333; CHLRE_06g278222v5.
DR   KEGG; cre:CHLRE_06g278222v5; -.
DR   eggNOG; KOG0279; Eukaryota.
DR   HOGENOM; CLU_000288_57_7_1; -.
DR   OMA; AQVPYCV; -.
DR   OrthoDB; 7875889at2759; -.
DR   GO; GO:1990904; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0005840; C:ribosome; IEA:UniProtKB-KW.
DR   GO; GO:0043022; F:ribosome binding; IEA:InterPro.
DR   GO; GO:0045182; F:translation regulator activity; IEA:InterPro.
DR   CDD; cd00200; WD40; 1.
DR   FunFam; 2.130.10.10:FF:000018; Receptor for activated C kinase 1; 1.
DR   Gene3D; 2.130.10.10; YVTN repeat-like/Quinoprotein amine dehydrogenase; 1.
DR   InterPro; IPR020472; G-protein_beta_WD-40_rep.
DR   InterPro; IPR045223; RACK1-like.
DR   InterPro; IPR015943; WD40/YVTN_repeat-like_dom_sf.
DR   InterPro; IPR019775; WD40_repeat_CS.
DR   InterPro; IPR036322; WD40_repeat_dom_sf.
DR   InterPro; IPR001680; WD40_rpt.
DR   PANTHER; PTHR19868; RECEPTOR FOR ACTIVATED PROTEIN KINASE C RACK1; 1.
DR   Pfam; PF00400; WD40; 7.
DR   PRINTS; PR00320; GPROTEINBRPT.
DR   SMART; SM00320; WD40; 7.
DR   SUPFAM; SSF50978; WD40 repeat-like; 1.
DR   PROSITE; PS00678; WD_REPEATS_1; 5.
DR   PROSITE; PS50082; WD_REPEATS_2; 6.
DR   PROSITE; PS50294; WD_REPEATS_REGION; 1.
PE   2: Evidence at transcript level;
KW   Repeat; Ribonucleoprotein; Ribosomal protein; WD repeat.
FT   CHAIN           1..318
FT                   /note=""Small ribosomal subunit protein RACK1""
FT                   /id=""PRO_0000127750""
FT   REPEAT          13..45
FT                   /note=""WD 1""
FT   REPEAT          62..92
FT                   /note=""WD 2""
FT   REPEAT          104..134
FT                   /note=""WD 3""
FT   REPEAT          148..180
FT                   /note=""WD 4""
FT   REPEAT          192..222
FT                   /note=""WD 5""
FT   REPEAT          233..262
FT                   /note=""WD 6""
FT   REPEAT          283..313
FT                   /note=""WD 7""
SQ   SEQUENCE   318 AA;  35145 MW;  F545C3534D83B778 CRC64;
     MAETLTLRAT LKGHTNWVTA IATPLDPSSN TLLSASRDKS VLVWELERSE SNYGYARKAL
     RGHSHFVQDV VISSDGQFCL TGSWDGTLRL WDLNTGTTTR RFVGHTKDVL SVAFSVDNRQ
     IVSGSRDKTI KLWNTLGECK YTIGEPEGHT EWVSCVRFSP MTTNPIIVSG GWDKMVKVWN
     LTNCKLKNNL VGHHGYVNTV TVSPDGSLCA SGGKDGIAML WDLAEGKRLY SLDAGDVIHC
     LCFSPNRYWL CAATQSSIKI WDLESKSIVD DLRPEFNITS KKAQVPYCVS LAWSADGSTL
     YSGYTDGQIR VWAVGHSL
//
",55397
CTCGCC TCGCCG CGCCGC GCCGCC CCGCCG CGCCGG GCCGGC CCGGCG CGGCGA GGCGAA GCGAAA CGAAAA GAAAAT AAAATC AAATCA AATCAC ATCACT TCACTA CACTAC ACTACA CTACAC TACACG ACACGC CACGCG ACGCGT CGCGTT GCGTTT CGTTTT GTTTTG TTTTGA TTTGAA TTGAAT TGAATT GAATTC AATTCA ATTCAA TTCAAC TCAACC CAACCG AACCGC ACCGCG CCGCGC CGCGCA GCGCAA CGCAAT GCAATC CAATCG AATCGA ATCGAG TCGAGG CGAGGA GAGGAC AGGACG GGACGG GACGGC ACGGCG CGGCGC GGCGCG GCGCGA CGCGAT GCGATC CGATCA GATCAC ATCACC TCACCA CACCAT ACCATT CCATTC CATTCT ATTCTG TTCTGC TCTGCA CTGCAG TGCAGC GCAGCC CAGCCC AGCCCG GCCCGA CCCGAC CCGACC CGACCT GACCTC ACCTCT CCTCTC CTCTCC TCTCCA CTCCAA TCCAAA CCAAAA CAAAAC AAAACC AAACCG AACCGG ACCGGC CCGGCG CGGCGG GGCGGC GCGGCA CGGCAT GGCATC GCATCA CATCAC ATCACC TCACCG CACCGA ACCGAA CCGAAG CGAAGC GAAGCG AAGCGC AGCGCT GCGCTG CGCTGC GCTGCG CTGCGC TGCGCG GCGCGT CGCGTC GCGTCG CGTCGC GTCGCC TCGCCG CGCCGC GCCGCC CCGCCA CGCCAT GCCATG CCATGG CATGGC ATGGCC TGGCCT GGCCTC GCCTCG CCTCGG CTCGGC TCGGCT CGGCTT GGCTTA GCTTAC CTTACA TTACAA TACAAA ACAAAC CAAACT AAACTG,0,145,CTCG TCGC CGCC GCCG CCGC CGCC GCCG CCGG CGGC GGCG GCGA CGAA GAAA AAAA AAAT AATC ATCA TCAC CACT ACTA CTAC TACA ACAC CACG ACGC CGCG GCGT CGTT GTTT TTTT TTTG TTGA TGAA GAAT AATT ATTC TTCA TCAA CAAC AACC ACCG CCGC CGCG GCGC CGCA GCAA CAAT AATC ATCG TCGA CGAG GAGG AGGA GGAC GACG ACGG CGGC GGCG GCGC CGCG GCGA CGAT GATC ATCA TCAC CACC ACCA CCAT CATT ATTC TTCT TCTG CTGC TGCA GCAG CAGC AGCC GCCC CCCG CCGA CGAC GACC ACCT CCTC CTCT TCTC CTCC TCCA CCAA CAAA AAAA AAAC AACC ACCG CCGG CGGC GGCG GCGG CGGC GGCA GCAT CATC ATCA TCAC CACC ACCG CCGA CGAA GAAG AAGC AGCG GCGC CGCT GCTG CTGC TGCG GCGC CGCG GCGT CGTC GTCG TCGC CGCC GCCG CCGC CGCC GCCA CCAT CATG ATGG TGGC GGCC GCCT CCTC CTCG TCGG CGGC GGCT GCTT CTTA TTAC TACA ACAA CAAA AAAC AACT ACTG,CTCGC TCGCC CGCCG GCCGC CCGCC CGCCG GCCGG CCGGC CGGCG GGCGA GCGAA CGAAA GAAAA AAAAT AAATC AATCA ATCAC TCACT CACTA ACTAC CTACA TACAC ACACG CACGC ACGCG CGCGT GCGTT CGTTT GTTTT TTTTG TTTGA TTGAA TGAAT GAATT AATTC ATTCA TTCAA TCAAC CAACC AACCG ACCGC CCGCG CGCGC GCGCA CGCAA GCAAT CAATC AATCG ATCGA TCGAG CGAGG GAGGA AGGAC GGACG GACGG ACGGC CGGCG GGCGC GCGCG CGCGA GCGAT CGATC GATCA ATCAC TCACC CACCA ACCAT CCATT CATTC ATTCT TTCTG TCTGC CTGCA TGCAG GCAGC CAGCC AGCCC GCCCG CCCGA CCGAC CGACC GACCT ACCTC CCTCT CTCTC TCTCC CTCCA TCCAA CCAAA CAAAA AAAAC AAACC AACCG ACCGG CCGGC CGGCG GGCGG GCGGC CGGCA GGCAT GCATC CATCA ATCAC TCACC CACCG ACCGA CCGAA CGAAG GAAGC AAGCG AGCGC GCGCT CGCTG GCTGC CTGCG TGCGC GCGCG CGCGT GCGTC CGTCG GTCGC TCGCC CGCCG GCCGC CCGCC CGCCA GCCAT CCATG CATGG ATGGC TGGCC GGCCT GCCTC CCTCG CTCGG TCGGC CGGCT GGCTT GCTTA CTTAC TTACA TACAA ACAAA CAAAC AAACT AACTG,CTCGCC TCGCCG CGCCGC GCCGCC CCGCCG CGCCGG GCCGGC CCGGCG CGGCGA GGCGAA GCGAAA CGAAAA GAAAAT AAAATC AAATCA AATCAC ATCACT TCACTA CACTAC ACTACA CTACAC TACACG ACACGC CACGCG ACGCGT CGCGTT GCGTTT CGTTTT GTTTTG TTTTGA TTTGAA TTGAAT TGAATT GAATTC AATTCA ATTCAA TTCAAC TCAACC CAACCG AACCGC ACCGCG CCGCGC CGCGCA GCGCAA CGCAAT GCAATC CAATCG AATCGA ATCGAG TCGAGG CGAGGA GAGGAC AGGACG GGACGG GACGGC ACGGCG CGGCGC GGCGCG GCGCGA CGCGAT GCGATC CGATCA GATCAC ATCACC TCACCA CACCAT ACCATT CCATTC CATTCT ATTCTG TTCTGC TCTGCA CTGCAG TGCAGC GCAGCC CAGCCC AGCCCG GCCCGA CCCGAC CCGACC CGACCT GACCTC ACCTCT CCTCTC CTCTCC TCTCCA CTCCAA TCCAAA CCAAAA CAAAAC AAAACC AAACCG AACCGG ACCGGC CCGGCG CGGCGG GGCGGC GCGGCA CGGCAT GGCATC GCATCA CATCAC ATCACC TCACCG CACCGA ACCGAA CCGAAG CGAAGC GAAGCG AAGCGC AGCGCT GCGCTG CGCTGC GCTGCG CTGCGC TGCGCG GCGCGT CGCGTC GCGTCG CGTCGC GTCGCC TCGCCG CGCCGC GCCGCC CCGCCA CGCCAT GCCATG CCATGG CATGGC ATGGCC TGGCCT GGCCTC GCCTCG CCTCGG CTCGGC TCGGCT CGGCTT GGCTTA GCTTAC CTTACA TTACAA TACAAA ACAAAC CAAACT AAACTG,CTCGCCG TCGCCGC CGCCGCC GCCGCCG CCGCCGG CGCCGGC GCCGGCG CCGGCGA CGGCGAA GGCGAAA GCGAAAA CGAAAAT GAAAATC AAAATCA AAATCAC AATCACT ATCACTA TCACTAC CACTACA ACTACAC CTACACG TACACGC ACACGCG CACGCGT ACGCGTT CGCGTTT GCGTTTT CGTTTTG GTTTTGA TTTTGAA TTTGAAT TTGAATT TGAATTC GAATTCA AATTCAA ATTCAAC TTCAACC TCAACCG CAACCGC AACCGCG ACCGCGC CCGCGCA CGCGCAA GCGCAAT CGCAATC GCAATCG CAATCGA AATCGAG ATCGAGG TCGAGGA CGAGGAC GAGGACG AGGACGG GGACGGC GACGGCG ACGGCGC CGGCGCG GGCGCGA GCGCGAT CGCGATC GCGATCA CGATCAC GATCACC ATCACCA TCACCAT CACCATT ACCATTC CCATTCT CATTCTG ATTCTGC TTCTGCA TCTGCAG CTGCAGC TGCAGCC GCAGCCC CAGCCCG AGCCCGA GCCCGAC CCCGACC CCGACCT CGACCTC GACCTCT ACCTCTC CCTCTCC CTCTCCA TCTCCAA CTCCAAA TCCAAAA CCAAAAC CAAAACC AAAACCG AAACCGG AACCGGC ACCGGCG CCGGCGG CGGCGGC GGCGGCA GCGGCAT CGGCATC GGCATCA GCATCAC CATCACC ATCACCG TCACCGA CACCGAA ACCGAAG CCGAAGC CGAAGCG GAAGCGC AAGCGCT AGCGCTG GCGCTGC CGCTGCG GCTGCGC CTGCGCG TGCGCGT GCGCGTC CGCGTCG GCGTCGC CGTCGCC GTCGCCG TCGCCGC CGCCGCC GCCGCCA CCGCCAT CGCCATG GCCATGG CCATGGC CATGGCC ATGGCCT TGGCCTC GGCCTCG GCCTCGG CCTCGGC CTCGGCT TCGGCTT CGGCTTA GGCTTAC GCTTACA CTTACAA TTACAAA TACAAAC ACAAACT CAAACTG,"ID   DGOD_RALPJ              Reviewed;         382 AA.
AC   B2UCA8;
DT   14-APR-2009, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-2008, sequence version 1.
DT   27-NOV-2024, entry version 104.
DE   RecName: Full=D-galactonate dehydratase {ECO:0000255|HAMAP-Rule:MF_01289};
DE            Short=GalD {ECO:0000255|HAMAP-Rule:MF_01289};
DE            EC=4.2.1.6 {ECO:0000255|HAMAP-Rule:MF_01289};
GN   Name=dgoD {ECO:0000255|HAMAP-Rule:MF_01289};
GN   OrderedLocusNames=Rpic_2990;
OS   Ralstonia pickettii (strain 12J).
OC   Bacteria; Pseudomonadota; Betaproteobacteria; Burkholderiales;
OC   Burkholderiaceae; Ralstonia.
OX   NCBI_TaxID=402626;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=12J;
RA   Lucas S., Copeland A., Lapidus A., Glavina del Rio T., Dalin E., Tice H.,
RA   Bruce D., Goodwin L., Pitluck S., Meincke L., Brettin T., Detter J.C.,
RA   Han C., Kuske C.R., Schmutz J., Larimer F., Land M., Hauser L.,
RA   Kyrpides N., Mikhailova N., Marsh T., Richardson P.;
RT   ""Complete sequence of chromosome 1 of Ralstonia pickettii 12J."";
RL   Submitted (MAY-2008) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Catalyzes the dehydration of D-galactonate to 2-keto-3-deoxy-
CC       D-galactonate. {ECO:0000255|HAMAP-Rule:MF_01289}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=D-galactonate = 2-dehydro-3-deoxy-D-galactonate + H2O;
CC         Xref=Rhea:RHEA:18649, ChEBI:CHEBI:12931, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:57989; EC=4.2.1.6; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_01289};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_01289};
CC       Note=Binds 1 Mg(2+) ion per subunit. {ECO:0000255|HAMAP-Rule:MF_01289};
CC   -!- PATHWAY: Carbohydrate acid metabolism; D-galactonate degradation; D-
CC       glyceraldehyde 3-phosphate and pyruvate from D-galactonate: step 1/3.
CC       {ECO:0000255|HAMAP-Rule:MF_01289}.
CC   -!- MISCELLANEOUS: Reaction proceeds via an anti dehydration.
CC       {ECO:0000255|HAMAP-Rule:MF_01289}.
CC   -!- SIMILARITY: Belongs to the mandelate racemase/muconate lactonizing
CC       enzyme family. GalD subfamily. {ECO:0000255|HAMAP-Rule:MF_01289}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP001068; ACD28113.1; -; Genomic_DNA.
DR   PDB; 3RR1; X-ray; 1.95 A; A/B=2-382.
DR   PDB; 3RRA; X-ray; 2.30 A; A/B=2-382.
DR   PDBsum; 3RR1; -.
DR   PDBsum; 3RRA; -.
DR   AlphaFoldDB; B2UCA8; -.
DR   SMR; B2UCA8; -.
DR   STRING; 402626.Rpic_2990; -.
DR   KEGG; rpi:Rpic_2990; -.
DR   PATRIC; fig|402626.5.peg.4126; -.
DR   eggNOG; COG4948; Bacteria.
DR   HOGENOM; CLU_030273_3_2_4; -.
DR   UniPathway; UPA00081; UER00518.
DR   EvolutionaryTrace; B2UCA8; -.
DR   GO; GO:0008869; F:galactonate dehydratase activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0009063; P:amino acid catabolic process; IEA:InterPro.
DR   GO; GO:0034194; P:D-galactonate catabolic process; IEA:UniProtKB-UniRule.
DR   CDD; cd03325; D-galactonate_dehydratase; 1.
DR   FunFam; 3.30.390.10:FF:000003; D-galactonate dehydratase; 1.
DR   Gene3D; 3.20.20.120; Enolase-like C-terminal domain; 1.
DR   Gene3D; 3.30.390.10; Enolase-like, N-terminal domain; 1.
DR   HAMAP; MF_01289; Galacton_dehydrat; 1.
DR   InterPro; IPR034593; DgoD-like.
DR   InterPro; IPR036849; Enolase-like_C_sf.
DR   InterPro; IPR029017; Enolase-like_N.
DR   InterPro; IPR029065; Enolase_C-like.
DR   InterPro; IPR023592; Galactonate_deHydtase.
DR   InterPro; IPR018110; Mandel_Rmase/mucon_lact_enz_CS.
DR   InterPro; IPR013342; Mandelate_racemase_C.
DR   InterPro; IPR013341; Mandelate_racemase_N_dom.
DR   PANTHER; PTHR48080:SF2; D-GALACTONATE DEHYDRATASE; 1.
DR   PANTHER; PTHR48080; D-GALACTONATE DEHYDRATASE-RELATED; 1.
DR   Pfam; PF13378; MR_MLE_C; 1.
DR   Pfam; PF02746; MR_MLE_N; 1.
DR   SFLD; SFLDF00003; D-galactonate_dehydratase; 1.
DR   SFLD; SFLDG00179; mandelate_racemase; 1.
DR   SMART; SM00922; MR_MLE; 1.
DR   SUPFAM; SSF51604; Enolase C-terminal domain-like; 1.
DR   SUPFAM; SSF54826; Enolase N-terminal domain-like; 1.
DR   PROSITE; PS00908; MR_MLE_1; 1.
DR   PROSITE; PS00909; MR_MLE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Lyase; Magnesium; Metal-binding.
FT   CHAIN           1..382
FT                   /note=""D-galactonate dehydratase""
FT                   /id=""PRO_1000140385""
FT   ACT_SITE        185
FT                   /note=""Proton donor""
FT                   /evidence=""ECO:0000250""
FT   ACT_SITE        285
FT                   /note=""Proton acceptor""
FT                   /evidence=""ECO:0000250""
FT   BINDING         183
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   BINDING         209
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   BINDING         235
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   SITE            258
FT                   /note=""Increases basicity of active site His""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   SITE            310
FT                   /note=""Transition state stabilizer""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   STRAND          3..11
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   TURN            12..14
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          15..22
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          27..30
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           38..48
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           49..51
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   TURN            52..54
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           60..69
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          71..73
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           77..98
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           102..105
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          114..119
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           125..137
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          142..147
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          150..152
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           157..172
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           175..177
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          178..183
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           190..200
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           201..203
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           218..224
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          231..233
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           240..249
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          253..255
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   TURN            259..263
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           264..276
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   TURN            277..279
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           290..302
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          309..311
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           323..326
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           330..333
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          345..347
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           354..362
FT                   /evidence=""ECO:0007829|PDB:3RR1""
SQ   SEQUENCE   382 AA;  42098 MW;  198F1A16BC5819F0 CRC64;
     MKITRLTTYR LPPRWMFLKV ETDEGVTGWG EPVIEGRART VEAAVHELSD YLIGQDPSRI
     NDLWQTMYRA GFYRGGPILM SAIAGIDQAL WDIKGKVLGV PVYELLGGLV RDKMRTYSWV
     GGDRPADVIA GMKALQAGGF DHFKLNGCEE MGIIDTSRAV DAAVARVAEI RSAFGNTVEF
     GLDFHGRVSA PMAKVLIKEL EPYRPLFIEE PVLAEQAETY ARLAAHTHLP IAAGERMFSR
     FDFKRVLEAG GVSILQPDLS HAGGITECVK IAAMAEAYDV ALAPHCPLGP IALAACLHVD
     FVSWNATLQE QSMGIHYNKG AELLDYVRNK ADFALEGGYI RPPRLPGLGV DIDEALVIER
     SKEAPDWRNP VWRHADGSVA EW
//
",260
GTGGTG TGGTGA GGTGAA GTGAAG TGAAGC GAAGCT AAGCTC AGCTCA GCTCAC CTCACC TCACCG CACCGA ACCGAT CCGATT CGATTA GATTAC ATTACG TTACGA TACGAG ACGAGA CGAGAA GAGAAT AGAATC GAATCC AATCCG ATCCGC TCCGCG CCGCGC CGCGCA GCGCAC CGCACC GCACCG CACCGA ACCGAC CCGACA CGACAC GACACG ACACGA CACGAT ACGATC CGATCT GATCTA ATCTAC TCTACG CTACGA TACGAG ACGAGG CGAGGA GAGGAC AGGACA GGACAG GACAGT ACAGTC CAGTCT AGTCTC GTCTCA TCTCAT CTCATC TCATCA CATCAT ATCATG TCATGA CATGAA ATGAAA TGAAAC GAAACT AAACTG AACTGT ACTGTT CTGTTC TGTTCG GTTCGT TTCGTG TCGTGT CGTGTT GTGTTT TGTTTC GTTTCA TTTCAG TTCAGT TCAGTT CAGTTT AGTTTG GTTTGT TTTGTC TTGTCA TGTCAA GTCAAC TCAACT CAACTC AACTCG ACTCGT CTCGTA TCGTAC CGTACG GTACGC TACGCC ACGCCT CGCCTC GCCTCG CCTCGT CTCGTT TCGTTC CGTTCT GTTCTT TTCTTT TCTTTT CTTTTT TTTTTC TTTTCT TTTCTT TTCTTG TCTTGG CTTGGC TTGGCG TGGCGT GGCGTT GCGTTC CGTTCA GTTCAT TTCATT,2,121,GTGG TGGT GGTG GTGA TGAA GAAG AAGC AGCT GCTC CTCA TCAC CACC ACCG CCGA CGAT GATT ATTA TTAC TACG ACGA CGAG GAGA AGAA GAAT AATC ATCC TCCG CCGC CGCG GCGC CGCA GCAC CACC ACCG CCGA CGAC GACA ACAC CACG ACGA CGAT GATC ATCT TCTA CTAC TACG ACGA CGAG GAGG AGGA GGAC GACA ACAG CAGT AGTC GTCT TCTC CTCA TCAT CATC ATCA TCAT CATG ATGA TGAA GAAA AAAC AACT ACTG CTGT TGTT GTTC TTCG TCGT CGTG GTGT TGTT GTTT TTTC TTCA TCAG CAGT AGTT GTTT TTTG TTGT TGTC GTCA TCAA CAAC AACT ACTC CTCG TCGT CGTA GTAC TACG ACGC CGCC GCCT CCTC CTCG TCGT CGTT GTTC TTCT TCTT CTTT TTTT TTTT TTTC TTCT TCTT CTTG TTGG TGGC GGCG GCGT CGTT GTTC TTCA TCAT CATT,GTGGT TGGTG GGTGA GTGAA TGAAG GAAGC AAGCT AGCTC GCTCA CTCAC TCACC CACCG ACCGA CCGAT CGATT GATTA ATTAC TTACG TACGA ACGAG CGAGA GAGAA AGAAT GAATC AATCC ATCCG TCCGC CCGCG CGCGC GCGCA CGCAC GCACC CACCG ACCGA CCGAC CGACA GACAC ACACG CACGA ACGAT CGATC GATCT ATCTA TCTAC CTACG TACGA ACGAG CGAGG GAGGA AGGAC GGACA GACAG ACAGT CAGTC AGTCT GTCTC TCTCA CTCAT TCATC CATCA ATCAT TCATG CATGA ATGAA TGAAA GAAAC AAACT AACTG ACTGT CTGTT TGTTC GTTCG TTCGT TCGTG CGTGT GTGTT TGTTT GTTTC TTTCA TTCAG TCAGT CAGTT AGTTT GTTTG TTTGT TTGTC TGTCA GTCAA TCAAC CAACT AACTC ACTCG CTCGT TCGTA CGTAC GTACG TACGC ACGCC CGCCT GCCTC CCTCG CTCGT TCGTT CGTTC GTTCT TTCTT TCTTT CTTTT TTTTT TTTTC TTTCT TTCTT TCTTG CTTGG TTGGC TGGCG GGCGT GCGTT CGTTC GTTCA TTCAT TCATT,GTGGTG TGGTGA GGTGAA GTGAAG TGAAGC GAAGCT AAGCTC AGCTCA GCTCAC CTCACC TCACCG CACCGA ACCGAT CCGATT CGATTA GATTAC ATTACG TTACGA TACGAG ACGAGA CGAGAA GAGAAT AGAATC GAATCC AATCCG ATCCGC TCCGCG CCGCGC CGCGCA GCGCAC CGCACC GCACCG CACCGA ACCGAC CCGACA CGACAC GACACG ACACGA CACGAT ACGATC CGATCT GATCTA ATCTAC TCTACG CTACGA TACGAG ACGAGG CGAGGA GAGGAC AGGACA GGACAG GACAGT ACAGTC CAGTCT AGTCTC GTCTCA TCTCAT CTCATC TCATCA CATCAT ATCATG TCATGA CATGAA ATGAAA TGAAAC GAAACT AAACTG AACTGT ACTGTT CTGTTC TGTTCG GTTCGT TTCGTG TCGTGT CGTGTT GTGTTT TGTTTC GTTTCA TTTCAG TTCAGT TCAGTT CAGTTT AGTTTG GTTTGT TTTGTC TTGTCA TGTCAA GTCAAC TCAACT CAACTC AACTCG ACTCGT CTCGTA TCGTAC CGTACG GTACGC TACGCC ACGCCT CGCCTC GCCTCG CCTCGT CTCGTT TCGTTC CGTTCT GTTCTT TTCTTT TCTTTT CTTTTT TTTTTC TTTTCT TTTCTT TTCTTG TCTTGG CTTGGC TTGGCG TGGCGT GGCGTT GCGTTC CGTTCA GTTCAT TTCATT,GTGGTGA TGGTGAA GGTGAAG GTGAAGC TGAAGCT GAAGCTC AAGCTCA AGCTCAC GCTCACC CTCACCG TCACCGA CACCGAT ACCGATT CCGATTA CGATTAC GATTACG ATTACGA TTACGAG TACGAGA ACGAGAA CGAGAAT GAGAATC AGAATCC GAATCCG AATCCGC ATCCGCG TCCGCGC CCGCGCA CGCGCAC GCGCACC CGCACCG GCACCGA CACCGAC ACCGACA CCGACAC CGACACG GACACGA ACACGAT CACGATC ACGATCT CGATCTA GATCTAC ATCTACG TCTACGA CTACGAG TACGAGG ACGAGGA CGAGGAC GAGGACA AGGACAG GGACAGT GACAGTC ACAGTCT CAGTCTC AGTCTCA GTCTCAT TCTCATC CTCATCA TCATCAT CATCATG ATCATGA TCATGAA CATGAAA ATGAAAC TGAAACT GAAACTG AAACTGT AACTGTT ACTGTTC CTGTTCG TGTTCGT GTTCGTG TTCGTGT TCGTGTT CGTGTTT GTGTTTC TGTTTCA GTTTCAG TTTCAGT TTCAGTT TCAGTTT CAGTTTG AGTTTGT GTTTGTC TTTGTCA TTGTCAA TGTCAAC GTCAACT TCAACTC CAACTCG AACTCGT ACTCGTA CTCGTAC TCGTACG CGTACGC GTACGCC TACGCCT ACGCCTC CGCCTCG GCCTCGT CCTCGTT CTCGTTC TCGTTCT CGTTCTT GTTCTTT TTCTTTT TCTTTTT CTTTTTC TTTTTCT TTTTCTT TTTCTTG TTCTTGG TCTTGGC CTTGGCG TTGGCGT TGGCGTT GGCGTTC GCGTTCA CGTTCAT GTTCATT,"ID   ANO6_MOUSE              Reviewed;         911 AA.
AC   Q6P9J9; Q8C242;
DT   13-SEP-2005, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   05-FEB-2025, entry version 152.
DE   RecName: Full=Anoctamin-6;
DE   AltName: Full=Small-conductance calcium-activated nonselective cation channel;
DE            Short=SCAN channel;
DE   AltName: Full=Transmembrane protein 16F;
GN   Name=Ano6;
GN   Synonyms=Tmem16f {ECO:0000303|PubMed:21107324,
GN   ECO:0000303|PubMed:30785399};
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   STRAIN=C57BL/6J; TISSUE=Dendritic cell;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA   Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA   Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA   Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA   Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA   Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA   Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA   Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA   Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA   Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA   Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA   Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA   Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA   Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA   Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA   Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA   Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA   Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA   Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA   Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA   van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA   Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA   Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA   Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA   Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA   Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA   Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA   Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA   Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT   ""The transcriptional landscape of the mammalian genome."";
RL   Science 309:1559-1563(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   STRAIN=C57BL/6J; TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   ""The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC)."";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   DEVELOPMENTAL STAGE.
RX   PubMed=18729231; DOI=10.1002/dvdy.21676;
RA   Rock J.R., Harfe B.D.;
RT   ""Expression of TMEM16 paralogs during murine embryogenesis."";
RL   Dev. Dyn. 237:2566-2574(2008).
RN   [4]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-494; ASN-785 AND ASN-803.
RC   TISSUE=Myoblast;
RX   PubMed=19656770; DOI=10.1074/mcp.m900195-mcp200;
RA   Gundry R.L., Raginski K., Tarasova Y., Tchernyshyov I., Bausch-Fluck D.,
RA   Elliott S.T., Boheler K.R., Van Eyk J.E., Wollscheid B.;
RT   ""The mouse C2C12 myoblast cell surface N-linked glycoproteome:
RT   identification, glycosite occupancy, and membrane orientation."";
RL   Mol. Cell. Proteomics 8:2555-2569(2009).
RN   [5]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brown adipose tissue, Kidney, Lung, Pancreas, and Spleen;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   ""A tissue-specific atlas of mouse protein phosphorylation and expression."";
RL   Cell 143:1174-1189(2010).
RN   [6]
RP   TISSUE SPECIFICITY.
RX   PubMed=20056604; DOI=10.1074/jbc.m109.065367;
RA   Schreiber R., Uliyakina I., Kongsuphol P., Warth R., Mirza M.,
RA   Martins J.R., Kunzelmann K.;
RT   ""Expression and function of epithelial anoctamins."";
RL   J. Biol. Chem. 285:7838-7845(2010).
RN   [7]
RP   FUNCTION.
RX   PubMed=21107324; DOI=10.1038/nature09583;
RA   Suzuki J., Umeda M., Sims P.J., Nagata S.;
RT   ""Calcium-dependent phospholipid scrambling by TMEM16F."";
RL   Nature 468:834-838(2010).
RN   [8]
RP   ABSENCE OF CALCIUM-ACTIVATED CHLORIDE CHANNEL ACTIVITY.
RX   PubMed=22075693; DOI=10.1152/ajpcell.00140.2011;
RA   Duran C., Qu Z., Osunkoya A.O., Cui Y., Hartzell H.C.;
RT   ""ANOs 3-7 in the anoctamin/Tmem16 Cl- channel family are intracellular
RT   proteins."";
RL   Am. J. Physiol. 302:C482-C493(2012).
RN   [9]
RP   FUNCTION, DISRUPTION PHENOTYPE, ACTIVITY REGULATION, AND MUTAGENESIS OF
RP   ASP-409; GLN-559 AND GLU-667.
RX   PubMed=23021219; DOI=10.1016/j.cell.2012.07.036;
RA   Yang H., Kim A., David T., Palmer D., Jin T., Tien J., Huang F., Cheng T.,
RA   Coughlin S.R., Jan Y.N., Jan L.Y.;
RT   ""TMEM16F forms a Ca(2+)-activated cation channel required for lipid
RT   scrambling in platelets during blood coagulation."";
RL   Cell 151:111-122(2012).
RN   [10]
RP   REVIEW.
RX   PubMed=22302790; DOI=10.1113/expphysiol.2011.058214;
RA   Winpenny J.P., Gray M.A.;
RT   ""The anoctamin (TMEM16) gene family: calcium-activated chloride channels
RT   come of age."";
RL   Exp. Physiol. 97:175-176(2012).
RN   [11]
RP   REVIEW, AND FUNCTION.
RX   PubMed=21908539; DOI=10.1113/expphysiol.2011.058206;
RA   Kunzelmann K., Schreiber R., Kmit A., Jantarajit W., Martins J.R.,
RA   Faria D., Kongsuphol P., Ousingsawat J., Tian Y.;
RT   ""Expression and function of epithelial anoctamins."";
RL   Exp. Physiol. 97:184-192(2012).
RN   [12]
RP   FUNCTION, AND TRANSPORTER ACTIVITY.
RX   PubMed=23532839; DOI=10.1074/jbc.m113.457937;
RA   Suzuki J., Fujii T., Imao T., Ishihara K., Kuba H., Nagata S.;
RT   ""Calcium-dependent phospholipid scramblase activity of TMEM16 protein
RT   family members."";
RL   J. Biol. Chem. 288:13305-13316(2013).
RN   [13]
RP   FUNCTION, DISRUPTION PHENOTYPE, AND TISSUE SPECIFICITY.
RX   PubMed=22936354; DOI=10.1002/jbmr.1751;
RA   Ehlen H.W., Chinenkova M., Moser M., Munter H.M., Krause Y., Gross S.,
RA   Brachvogel B., Wuelling M., Kornak U., Vortkamp A.;
RT   ""Inactivation of Anoctamin-6/Tmem16f, a regulator of phosphatidylserine
RT   scrambling in osteoblasts, leads to decreased mineral deposition in
RT   skeletal tissues."";
RL   J. Bone Miner. Res. 28:246-259(2013).
RN   [14]
RP   FUNCTION, TRANSPORTER ACTIVITY, AND MUTAGENESIS OF ASP-409; PHE-518;
RP   TYR-563; ILE-612 AND ASP-703.
RX   PubMed=31015464; DOI=10.1038/s41467-019-09778-7;
RA   Le T., Jia Z., Le S.C., Zhang Y., Chen J., Yang H.;
RT   ""An inner activation gate controls TMEM16F phospholipid scrambling."";
RL   Nat. Commun. 10:1846-1846(2019).
RN   [15] {ECO:0007744|PDB:6QP6, ECO:0007744|PDB:6QPB, ECO:0007744|PDB:6QPC, ECO:0007744|PDB:6QPI}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.20 ANGSTROMS), FUNCTION, SUBUNIT,
RP   SUBCELLULAR LOCATION, TOPOLOGY, DISULFIDE BONDS, AND MUTAGENESIS OF
RP   ARG-478; GLY-615; GLU-624 AND GLU-667.
RX   PubMed=30785399; DOI=10.7554/elife.44365;
RA   Alvadia C., Lim N.K., Clerico Mosina V., Oostergetel G.T., Dutzler R.,
RA   Paulino C.;
RT   ""Cryo-EM structures and functional characterization of the murine lipid
RT   scramblase TMEM16F."";
RL   Elife 8:0-0(2019).
CC   -!- FUNCTION: Small-conductance calcium-activated nonselective cation
CC       (SCAN) channel which acts as a regulator of phospholipid scrambling in
CC       platelets, osteoblasts and fetal thymocytes. Phospholipid scrambling
CC       results in surface exposure of phosphatidylserine which in platelets is
CC       essential to trigger the clotting system whereas in osteoblasts is
CC       essential for the deposition of hydroxyapatite during bone
CC       mineralization. Has calcium-dependent phospholipid scramblase activity;
CC       scrambles phosphatidylserine, phosphatidylcholine and
CC       galactosylceramide. Can generate outwardly rectifying chloride channel
CC       currents in airway epithelial cells and Jurkat T lymphocytes.
CC       {ECO:0000269|PubMed:21107324, ECO:0000269|PubMed:21908539,
CC       ECO:0000269|PubMed:22936354, ECO:0000269|PubMed:23021219,
CC       ECO:0000269|PubMed:23532839, ECO:0000269|PubMed:30785399,
CC       ECO:0000269|PubMed:31015464}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-L-serine(in) = a 1,2-diacyl-
CC         sn-glycero-3-phospho-L-serine(out); Xref=Rhea:RHEA:38663,
CC         ChEBI:CHEBI:57262; Evidence={ECO:0000269|PubMed:23532839,
CC         ECO:0000269|PubMed:31015464};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:38664;
CC         Evidence={ECO:0000305|PubMed:23532839};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a beta-D-galactosyl-(1<->1')-N-acylsphing-4-enine(out) = a
CC         beta-D-galactosyl-(1<->1')-N-acylsphing-4-enine(in);
CC         Xref=Rhea:RHEA:38899, ChEBI:CHEBI:18390;
CC         Evidence={ECO:0000269|PubMed:23532839};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:38900;
CC         Evidence={ECO:0000305|PubMed:23532839};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phosphocholine(in) = a 1,2-diacyl-
CC         sn-glycero-3-phosphocholine(out); Xref=Rhea:RHEA:38571,
CC         ChEBI:CHEBI:57643; Evidence={ECO:0000269|PubMed:23532839};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:38573;
CC         Evidence={ECO:0000305|PubMed:23532839};
CC   -!- ACTIVITY REGULATION: Exhibits synergistic gating by Ca(2+) and voltage.
CC       Inhibited by some non-specific cation channel blockers such as:
CC       ruthenium red, 2-aminoethyl diphenylborinate (2APB), gadolinium and
CC       cadmium ions. {ECO:0000269|PubMed:23021219}.
CC   -!- SUBUNIT: Homodimer. {ECO:0000269|PubMed:30785399}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:30785399};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:30785399}. Note=Shows
CC       an intracellular localization. {ECO:0000250|UniProtKB:Q4KMQ2}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q6P9J9-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q6P9J9-2; Sequence=VSP_015654, VSP_015655;
CC   -!- TISSUE SPECIFICITY: Predominant expression seen in epithelial tissues.
CC       Also found in skeletal system where it is primarily expressed in
CC       osteoblasts. {ECO:0000269|PubMed:20056604,
CC       ECO:0000269|PubMed:22936354}.
CC   -!- DEVELOPMENTAL STAGE: At 14.5 dpc, expressed in lung epithelium and
CC       mesenchyme. At 16.5 dpc, expressed in esophageal epithelium and
CC       mesenchyme. In the caudal digestive tract, detected in small intestine
CC       epithelium at 14.5 dpc. Also detected at 14.5 dpc in epithelium and
CC       mesenchyme of trachea, ovary, kidney and stomach. In the developing
CC       skeleton, expressed in developing rib perichondria at 14.5 dpc. Also
CC       expressed in the neural tube and dorsal root ganglia at 14.5 dpc. In
CC       developing skin, expression is restricted to basal layers of the
CC       epidermis at 16.5 dpc. {ECO:0000269|PubMed:18729231}.
CC   -!- DISRUPTION PHENOTYPE: Mice are viable and fertile, and display no major
CC       morphological defects. They exhibit deficiencies in Ca(2+)-dependent
CC       phospholipid scramblase activity in platelets and defects in blood
CC       coagulation (PubMed:23021219). They also show reduced skeleton size and
CC       skeletal deformities. {ECO:0000269|PubMed:22936354,
CC       ECO:0000269|PubMed:23021219}.
CC   -!- MISCELLANEOUS: The term 'anoctamin' was coined because these channels
CC       are anion selective and are predicted to have eight (OCT) transmembrane
CC       segments. There is some dissatisfaction in the field with the Ano
CC       nomenclature because it is not certain that all the members of this
CC       family are anion channels or have the 8-transmembrane topology.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the anoctamin family. {ECO:0000305}.
CC   -!- CAUTION: Contains ten transmembrane regions, not eight as predicted.
CC       {ECO:0000269|PubMed:30785399}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK089300; BAC40833.1; -; mRNA.
DR   EMBL; BC060732; AAH60732.1; -; mRNA.
DR   CCDS; CCDS37184.1; -. [Q6P9J9-1]
DR   RefSeq; NP_001240742.1; NM_001253813.1.
DR   RefSeq; NP_780553.2; NM_175344.4. [Q6P9J9-1]
DR   PDB; 6P46; EM; 3.50 A; A/B=1-911.
DR   PDB; 6P47; EM; 3.90 A; A/B=1-911.
DR   PDB; 6P48; EM; 3.20 A; A/B=1-911.
DR   PDB; 6P49; EM; 3.30 A; A/B=1-911.
DR   PDB; 6QP6; EM; 3.20 A; A/B=1-911.
DR   PDB; 6QPB; EM; 3.60 A; A/B=1-911.
DR   PDB; 6QPC; EM; 3.50 A; A/B=1-911.
DR   PDB; 6QPI; EM; 3.30 A; A/B=1-911.
DR   PDB; 8B8G; EM; 3.39 A; A/B=1-911.
DR   PDB; 8B8J; EM; 2.96 A; A/B=1-911.
DR   PDB; 8B8K; EM; 3.01 A; A/B=1-911.
DR   PDB; 8B8M; EM; 3.49 A; A/B=1-911.
DR   PDB; 8B8Q; EM; 2.94 A; A/B=1-911.
DR   PDB; 8BC0; EM; 3.09 A; A/B=1-911.
DR   PDB; 8BC1; EM; 2.93 A; A/B=1-911.
DR   PDB; 8SUN; EM; 3.12 A; A/B=52-871.
DR   PDB; 8SUR; EM; 3.10 A; A/B=52-871.
DR   PDB; 8TAG; EM; 3.20 A; A/B=52-871.
DR   PDB; 8TAI; EM; 3.10 A; A/B=52-871.
DR   PDB; 8TAL; EM; 3.20 A; A/B=52-871.
DR   PDBsum; 6P46; -.
DR   PDBsum; 6P47; -.
DR   PDBsum; 6P48; -.
DR   PDBsum; 6P49; -.
DR   PDBsum; 6QP6; -.
DR   PDBsum; 6QPB; -.
DR   PDBsum; 6QPC; -.
DR   PDBsum; 6QPI; -.
DR   PDBsum; 8B8G; -.
DR   PDBsum; 8B8J; -.
DR   PDBsum; 8B8K; -.
DR   PDBsum; 8B8M; -.
DR   PDBsum; 8B8Q; -.
DR   PDBsum; 8BC0; -.
DR   PDBsum; 8BC1; -.
DR   PDBsum; 8SUN; -.
DR   PDBsum; 8SUR; -.
DR   PDBsum; 8TAG; -.
DR   PDBsum; 8TAI; -.
DR   PDBsum; 8TAL; -.
DR   AlphaFoldDB; Q6P9J9; -.
DR   EMDB; EMD-15913; -.
DR   EMDB; EMD-15914; -.
DR   EMDB; EMD-15916; -.
DR   EMDB; EMD-15917; -.
DR   EMDB; EMD-15919; -.
DR   EMDB; EMD-15958; -.
DR   EMDB; EMD-20244; -.
DR   EMDB; EMD-20245; -.
DR   EMDB; EMD-20246; -.
DR   EMDB; EMD-20247; -.
DR   EMDB; EMD-40768; -.
DR   EMDB; EMD-40776; -.
DR   EMDB; EMD-41134; -.
DR   EMDB; EMD-41136; -.
DR   EMDB; EMD-41137; -.
DR   EMDB; EMD-4611; -.
DR   EMDB; EMD-4612; -.
DR   EMDB; EMD-4613; -.
DR   EMDB; EMD-4614; -.
DR   SMR; Q6P9J9; -.
DR   BioGRID; 222904; 1.
DR   STRING; 10090.ENSMUSP00000071770; -.
DR   SwissLipids; SLP:000000373; -.
DR   MoonProt; Q6P9J9; -.
DR   GlyCosmos; Q6P9J9; 6 sites, No reported glycans.
DR   GlyGen; Q6P9J9; 7 sites, 3 N-linked glycans (3 sites), 1 O-linked glycan (1 site).
DR   iPTMnet; Q6P9J9; -.
DR   PhosphoSitePlus; Q6P9J9; -.
DR   SwissPalm; Q6P9J9; -.
DR   jPOST; Q6P9J9; -.
DR   PaxDb; 10090-ENSMUSP00000071770; -.
DR   PeptideAtlas; Q6P9J9; -.
DR   ProteomicsDB; 281994; -. [Q6P9J9-1]
DR   ProteomicsDB; 281995; -. [Q6P9J9-2]
DR   Pumba; Q6P9J9; -.
DR   ABCD; Q6P9J9; 1 sequenced antibody.
DR   Antibodypedia; 42608; 154 antibodies from 22 providers.
DR   Ensembl; ENSMUST00000071874.8; ENSMUSP00000071770.7; ENSMUSG00000064210.8. [Q6P9J9-1]
DR   GeneID; 105722; -.
DR   KEGG; mmu:105722; -.
DR   UCSC; uc007xju.2; mouse. [Q6P9J9-1]
DR   AGR; MGI:2145890; -.
DR   CTD; 196527; -.
DR   MGI; MGI:2145890; Ano6.
DR   VEuPathDB; HostDB:ENSMUSG00000064210; -.
DR   eggNOG; KOG2514; Eukaryota.
DR   GeneTree; ENSGT00940000158969; -.
DR   HOGENOM; CLU_006685_1_3_1; -.
DR   InParanoid; Q6P9J9; -.
DR   OMA; PYAVREQ; -.
DR   OrthoDB; 296386at2759; -.
DR   PhylomeDB; Q6P9J9; -.
DR   TreeFam; TF314265; -.
DR   Reactome; R-MMU-2672351; Stimuli-sensing channels.
DR   Reactome; R-MMU-6798695; Neutrophil degranulation.
DR   BioGRID-ORCS; 105722; 3 hits in 78 CRISPR screens.
DR   ChiTaRS; Ano6; mouse.
DR   PRO; PR:Q6P9J9; -.
DR   Proteomes; UP000000589; Chromosome 15.
DR   RNAct; Q6P9J9; protein.
DR   Bgee; ENSMUSG00000064210; Expressed in otolith organ and 256 other cell types or tissues.
DR   ExpressionAtlas; Q6P9J9; baseline and differential.
DR   GO; GO:0034707; C:chloride channel complex; IEA:UniProtKB-KW.
DR   GO; GO:0098981; C:cholinergic synapse; IDA:SynGO.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0097060; C:synaptic membrane; IDA:SynGO.
DR   GO; GO:0005227; F:calcium-activated cation channel activity; IDA:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:MGI.
DR   GO; GO:0005229; F:intracellularly calcium-gated chloride channel activity; IDA:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0017128; F:phospholipid scramblase activity; IDA:UniProtKB.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0005244; F:voltage-gated monoatomic ion channel activity; IDA:UniProtKB.
DR   GO; GO:0032060; P:bleb assembly; IMP:UniProtKB.
DR   GO; GO:0007596; P:blood coagulation; IMP:UniProtKB.
DR   GO; GO:0035630; P:bone mineralization involved in bone maturation; IMP:MGI.
DR   GO; GO:0061591; P:calcium activated galactosylceramide scrambling; IDA:MGI.
DR   GO; GO:0061590; P:calcium activated phosphatidylcholine scrambling; IDA:MGI.
DR   GO; GO:0061589; P:calcium activated phosphatidylserine scrambling; IDA:MGI.
DR   GO; GO:0061588; P:calcium activated phospholipid scrambling; IMP:MGI.
DR   GO; GO:0070588; P:calcium ion transmembrane transport; IGI:UniProtKB.
DR   GO; GO:1902476; P:chloride transmembrane transport; IDA:UniProtKB.
DR   GO; GO:0006821; P:chloride transport; IDA:MGI.
DR   GO; GO:0002407; P:dendritic cell chemotaxis; IMP:MGI.
DR   GO; GO:0051649; P:establishment of localization in cell; IDA:MGI.
DR   GO; GO:0045794; P:negative regulation of cell volume; IMP:UniProtKB.
DR   GO; GO:0045332; P:phospholipid translocation; IDA:UniProtKB.
DR   GO; GO:0017121; P:plasma membrane phospholipid scrambling; IMP:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0030501; P:positive regulation of bone mineralization; IMP:UniProtKB.
DR   GO; GO:0034767; P:positive regulation of monoatomic ion transmembrane transport; IMP:UniProtKB.
DR   GO; GO:0090026; P:positive regulation of monocyte chemotaxis; IMP:UniProtKB.
DR   GO; GO:0060100; P:positive regulation of phagocytosis, engulfment; IMP:UniProtKB.
DR   GO; GO:1903766; P:positive regulation of potassium ion export across plasma membrane; ISS:BHF-UCL.
DR   GO; GO:0035590; P:purinergic nucleotide receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0060078; P:regulation of postsynaptic membrane potential; IDA:SynGO.
DR   InterPro; IPR032394; Anoct_dimer.
DR   InterPro; IPR007632; Anoctamin.
DR   InterPro; IPR049452; Anoctamin_TM.
DR   PANTHER; PTHR12308; ANOCTAMIN; 1.
DR   PANTHER; PTHR12308:SF21; ANOCTAMIN-6; 1.
DR   Pfam; PF16178; Anoct_dimer; 1.
DR   Pfam; PF04547; Anoctamin; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Calcium; Cell membrane; Chloride;
KW   Chloride channel; Disulfide bond; Glycoprotein; Ion channel; Ion transport;
KW   Lipid transport; Membrane; Metal-binding; Reference proteome;
KW   Transmembrane; Transmembrane helix; Transport; Voltage-gated channel.
FT   CHAIN           1..911
FT                   /note=""Anoctamin-6""
FT                   /id=""PRO_0000191758""
FT   TOPO_DOM        1..301
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TRANSMEM        302..322
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TOPO_DOM        323..376
FT                   /note=""Extracellular""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TRANSMEM        377..397
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TOPO_DOM        398..456
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TRANSMEM        457..477
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TOPO_DOM        478..510
FT                   /note=""Extracellular""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TRANSMEM        511..531
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TOPO_DOM        532..552
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TRANSMEM        553..573
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TOPO_DOM        574..602
FT                   /note=""Extracellular""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TRANSMEM        603..622
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TOPO_DOM        623..664
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TRANSMEM        665..685
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TRANSMEM        686..706
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TOPO_DOM        707..723
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TRANSMEM        724..744
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TOPO_DOM        745..837
FT                   /note=""Extracellular""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TRANSMEM        838..858
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   TOPO_DOM        859..911
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   BINDING         624
FT                   /ligand=""Ca(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29108""
FT                   /evidence=""ECO:0000305|PubMed:30785399""
FT   BINDING         667
FT                   /ligand=""Ca(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29108""
FT                   /evidence=""ECO:0000305|PubMed:30785399""
FT   BINDING         670
FT                   /ligand=""Ca(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29108""
FT                   /evidence=""ECO:0000305|PubMed:30785399""
FT   CARBOHYD        330
FT                   /note=""N-linked (GlcNAc...) asparagine""
FT                   /evidence=""ECO:0000255""
FT   CARBOHYD        362
FT                   /note=""N-linked (GlcNAc...) asparagine""
FT                   /evidence=""ECO:0000255""
FT   CARBOHYD        494
FT                   /note=""N-linked (GlcNAc...) asparagine""
FT                   /evidence=""ECO:0000269|PubMed:19656770""
FT   CARBOHYD        778
FT                   /note=""N-linked (GlcNAc...) asparagine""
FT                   /evidence=""ECO:0000255""
FT   CARBOHYD        785
FT                   /note=""N-linked (GlcNAc...) asparagine""
FT                   /evidence=""ECO:0000269|PubMed:19656770""
FT   CARBOHYD        803
FT                   /note=""N-linked (GlcNAc...) asparagine""
FT                   /evidence=""ECO:0000269|PubMed:19656770""
FT   DISULFID        331..372
FT                   /evidence=""ECO:0000269|PubMed:30785399,
FT                   ECO:0007744|PDB:6QP6, ECO:0007744|PDB:6QPC""
FT   DISULFID        338..365
FT                   /evidence=""ECO:0000269|PubMed:30785399,
FT                   ECO:0007744|PDB:6QP6, ECO:0007744|PDB:6QPB,
FT                   ECO:0007744|PDB:6QPC""
FT   DISULFID        349..807
FT                   /evidence=""ECO:0000269|PubMed:30785399,
FT                   ECO:0007744|PDB:6QP6, ECO:0007744|PDB:6QPB,
FT                   ECO:0007744|PDB:6QPC""
FT   DISULFID        352..356
FT                   /evidence=""ECO:0000269|PubMed:30785399,
FT                   ECO:0007744|PDB:6QPC""
FT   DISULFID        596..601
FT                   /evidence=""ECO:0000269|PubMed:30785399,
FT                   ECO:0007744|PDB:6QP6, ECO:0007744|PDB:6QPB,
FT                   ECO:0007744|PDB:6QPC""
FT   VAR_SEQ         1..427
FT                   /note=""Missing (in isoform 2)""
FT                   /evidence=""ECO:0000303|PubMed:16141072""
FT                   /id=""VSP_015654""
FT   VAR_SEQ         428..436
FT                   /note=""NHVVINEIT -> MALMAESLC (in isoform 2)""
FT                   /evidence=""ECO:0000303|PubMed:16141072""
FT                   /id=""VSP_015655""
FT   MUTAGEN         370
FT                   /note=""K->A: No effect on lipid scramblase activity.""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   MUTAGEN         409
FT                   /note=""D->G: Increased speed of phospholipid scrambling.""
FT                   /evidence=""ECO:0000269|PubMed:31015464""
FT   MUTAGEN         409
FT                   /note=""D->G: Reduced channel activity and sensitivity to
FT                   Ca(2+).""
FT                   /evidence=""ECO:0000269|PubMed:23021219""
FT   MUTAGEN         478
FT                   /note=""R->A: Decreased lipid scramblase and ion channel
FT                   activity. Requires lower calcium levels for activation of
FT                   ion channel activity.""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   MUTAGEN         518
FT                   /note=""F->A: Increased speed of phospholipid scrambling.
FT                   Constitutive scramblase activity at basal cytosolic calcium
FT                   levels; when associated with A-563 and A-612.""
FT                   /evidence=""ECO:0000269|PubMed:31015464""
FT   MUTAGEN         518
FT                   /note=""F->E,K,Q: Constitutive lipid scramblase activity at
FT                   basal cytosolic calcium levels.""
FT                   /evidence=""ECO:0000269|PubMed:31015464""
FT   MUTAGEN         518
FT                   /note=""F->L: Decreased lipid scramblase activity.""
FT                   /evidence=""ECO:0000269|PubMed:31015464""
FT   MUTAGEN         518
FT                   /note=""F->W: Slightly increased lipid scramblase activity.""
FT                   /evidence=""ECO:0000269|PubMed:31015464""
FT   MUTAGEN         559
FT                   /note=""Q->K: Moderately decreased sensitivity to activation
FT                   by calcium.""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   MUTAGEN         559
FT                   /note=""Q->K: Slower channel activation. Increased
FT                   permeability to chloride ions.""
FT                   /evidence=""ECO:0000269|PubMed:23021219""
FT   MUTAGEN         563
FT                   /note=""Y->A: Increased speed of phospholipid scrambling.
FT                   Requires lower calcium levels for activation of scramblase
FT                   and ion channel activity. Constitutive scramblase activity
FT                   at basal cytosolic calcium levels; when associated with
FT                   A-518 and A-612.""
FT                   /evidence=""ECO:0000269|PubMed:31015464""
FT   MUTAGEN         563
FT                   /note=""Y->K,Q: Constitutive lipid scramblase activity at
FT                   basal cytosolic calcium levels.""
FT                   /evidence=""ECO:0000269|PubMed:31015464""
FT   MUTAGEN         563
FT                   /note=""Y->S: No effect on lipid scramblase activity.""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   MUTAGEN         563
FT                   /note=""Y->W: Loss of lipid scramblase activity.""
FT                   /evidence=""ECO:0000269|PubMed:31015464""
FT   MUTAGEN         612
FT                   /note=""I->A: Increased speed of phospholipid scrambling.
FT                   Constitutive scramblase activity at basal cytosolic calcium
FT                   levels; when associated with A-518 and A-563.""
FT                   /evidence=""ECO:0000269|PubMed:31015464""
FT   MUTAGEN         612
FT                   /note=""I->E,K: Constitutive lipid scramblase activity at
FT                   basal cytosolic calcium levels.""
FT                   /evidence=""ECO:0000269|PubMed:31015464""
FT   MUTAGEN         612
FT                   /note=""I->W: Decreased lipid scramblase activity.""
FT                   /evidence=""ECO:0000269|PubMed:31015464""
FT   MUTAGEN         615
FT                   /note=""G->A: Requires lower calcium levels for activation
FT                   of scramblase and ion channel activity.""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   MUTAGEN         623
FT                   /note=""Q->F: No effect on lipid scramblase activity.""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   MUTAGEN         624
FT                   /note=""E->Q: Expected to disrupt calcium binding. Loss of
FT                   scramblase and ion channel activity.""
FT                   /evidence=""ECO:0000269|PubMed:30785399""
FT   MUTAGEN         667
FT                   /note=""E->Q: Requires much higher calcium levels for the
FT                   activation of scramblase and ion channel activity.""
FT                   /evidence=""ECO:0000269|PubMed:23021219,
FT                   ECO:0000269|PubMed:30785399""
FT   MUTAGEN         703
FT                   /note=""D->R: Expected to disrupt calcium binding. Loss of
FT                   scramblase activity.""
FT                   /evidence=""ECO:0000269|PubMed:31015464""
FT   STRAND          45..47
FT                   /evidence=""ECO:0007829|PDB:6QP6""
FT   STRAND          67..70
FT                   /evidence=""ECO:0007829|PDB:6QP6""
FT   STRAND          73..76
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   HELIX           91..103
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   STRAND          111..116
FT                   /evidence=""ECO:0007829|PDB:6QP6""
FT   STRAND          121..129
FT                   /evidence=""ECO:0007829|PDB:6QP6""
FT   TURN            137..141
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   STRAND          146..148
FT                   /evidence=""ECO:0007829|PDB:6QP6""
FT   STRAND          188..192
FT                   /evidence=""ECO:0007829|PDB:6QP6""
FT   HELIX           206..219
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   HELIX           234..238
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   STRAND          243..247
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   STRAND          253..255
FT                   /evidence=""ECO:0007829|PDB:6QP6""
FT   STRAND          260..262
FT                   /evidence=""ECO:0007829|PDB:6QP6""
FT   HELIX           268..271
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   TURN            272..274
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   HELIX           276..278
FT                   /evidence=""ECO:0007829|PDB:6QP6""
FT   STRAND          279..281
FT                   /evidence=""ECO:0007829|PDB:6QP6""
FT   HELIX           286..289
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   TURN            290..296
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   HELIX           297..309
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   HELIX           312..325
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   STRAND          327..329
FT                   /evidence=""ECO:0007829|PDB:6P46""
FT   STRAND          330..335
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   TURN            336..338
FT                   /evidence=""ECO:0007829|PDB:6P48""
FT   TURN       ",44137
CTGCGT TGCGTC GCGTCA CGTCAG GTCAGA TCAGAA CAGAAT AGAATG GAATGA AATGAC ATGACG TGACGT GACGTG ACGTGG CGTGGA GTGGAG TGGAGT GGAGTA GAGTAT AGTATT GTATTC TATTCC ATTCCG TTCCGT TCCGTC CCGTCG CGTCGT GTCGTC TCGTCA CGTCAA GTCAAA TCAAAA CAAAAA AAAAAC AAAACA AAACAC AACACC ACACCC CACCCT ACCCTG CCCTGA CCTGAC CTGACC TGACCC GACCCG ACCCGC CCCGCT CCGCTT CGCTTT GCTTTG CTTTGC TTTGCG TTGCGC TGCGCT GCGCTC CGCTCA GCTCAA CTCAAG TCAAGG CAAGGA AAGGAC AGGACG GGACGT GACGTC ACGTCG CGTCGG GTCGGT TCGGTC CGGTCT GGTCTC GTCTCG TCTCGA CTCGAG TCGAGG CGAGGC GAGGCA AGGCAA GGCAAT GCAATG CAATGA AATGAG ATGAGT TGAGTG GAGTGA AGTGAT GTGATC TGATCT GATCTG ATCTGC TCTGCT CTGCTC TGCTCA GCTCAA CTCAAT TCAATG CAATGG AATGGT ATGGTA TGGTAC GGTACG GTACGA TACGAC ACGACT CGACTT GACTTC ACTTCG CTTCGC TTCGCT TCGCTC CGCTCG GCTCGC CTCGCA TCGCAA CGCAAC GCAACC CAACCA AACCAG ACCAGC CCAGCA CAGCAC AGCACG GCACGG CACGGC ACGGCC CGGCCG GGCCGA GCCGAT CCGATC CGATCC GATCCG ATCCGA TCCGAT CCGATC CGATCG GATCGT ATCGTC TCGTCC CGTCCC GTCCCG TCCCGA CCCGAT CCGATC,1,142,CTGC TGCG GCGT CGTC GTCA TCAG CAGA AGAA GAAT AATG ATGA TGAC GACG ACGT CGTG GTGG TGGA GGAG GAGT AGTA GTAT TATT ATTC TTCC TCCG CCGT CGTC GTCG TCGT CGTC GTCA TCAA CAAA AAAA AAAA AAAC AACA ACAC CACC ACCC CCCT CCTG CTGA TGAC GACC ACCC CCCG CCGC CGCT GCTT CTTT TTTG TTGC TGCG GCGC CGCT GCTC CTCA TCAA CAAG AAGG AGGA GGAC GACG ACGT CGTC GTCG TCGG CGGT GGTC GTCT TCTC CTCG TCGA CGAG GAGG AGGC GGCA GCAA CAAT AATG ATGA TGAG GAGT AGTG GTGA TGAT GATC ATCT TCTG CTGC TGCT GCTC CTCA TCAA CAAT AATG ATGG TGGT GGTA GTAC TACG ACGA CGAC GACT ACTT CTTC TTCG TCGC CGCT GCTC CTCG TCGC CGCA GCAA CAAC AACC ACCA CCAG CAGC AGCA GCAC CACG ACGG CGGC GGCC GCCG CCGA CGAT GATC ATCC TCCG CCGA CGAT GATC ATCG TCGT CGTC GTCC TCCC CCCG CCGA CGAT GATC,CTGCG TGCGT GCGTC CGTCA GTCAG TCAGA CAGAA AGAAT GAATG AATGA ATGAC TGACG GACGT ACGTG CGTGG GTGGA TGGAG GGAGT GAGTA AGTAT GTATT TATTC ATTCC TTCCG TCCGT CCGTC CGTCG GTCGT TCGTC CGTCA GTCAA TCAAA CAAAA AAAAA AAAAC AAACA AACAC ACACC CACCC ACCCT CCCTG CCTGA CTGAC TGACC GACCC ACCCG CCCGC CCGCT CGCTT GCTTT CTTTG TTTGC TTGCG TGCGC GCGCT CGCTC GCTCA CTCAA TCAAG CAAGG AAGGA AGGAC GGACG GACGT ACGTC CGTCG GTCGG TCGGT CGGTC GGTCT GTCTC TCTCG CTCGA TCGAG CGAGG GAGGC AGGCA GGCAA GCAAT CAATG AATGA ATGAG TGAGT GAGTG AGTGA GTGAT TGATC GATCT ATCTG TCTGC CTGCT TGCTC GCTCA CTCAA TCAAT CAATG AATGG ATGGT TGGTA GGTAC GTACG TACGA ACGAC CGACT GACTT ACTTC CTTCG TTCGC TCGCT CGCTC GCTCG CTCGC TCGCA CGCAA GCAAC CAACC AACCA ACCAG CCAGC CAGCA AGCAC GCACG CACGG ACGGC CGGCC GGCCG GCCGA CCGAT CGATC GATCC ATCCG TCCGA CCGAT CGATC GATCG ATCGT TCGTC CGTCC GTCCC TCCCG CCCGA CCGAT CGATC,CTGCGT TGCGTC GCGTCA CGTCAG GTCAGA TCAGAA CAGAAT AGAATG GAATGA AATGAC ATGACG TGACGT GACGTG ACGTGG CGTGGA GTGGAG TGGAGT GGAGTA GAGTAT AGTATT GTATTC TATTCC ATTCCG TTCCGT TCCGTC CCGTCG CGTCGT GTCGTC TCGTCA CGTCAA GTCAAA TCAAAA CAAAAA AAAAAC AAAACA AAACAC AACACC ACACCC CACCCT ACCCTG CCCTGA CCTGAC CTGACC TGACCC GACCCG ACCCGC CCCGCT CCGCTT CGCTTT GCTTTG CTTTGC TTTGCG TTGCGC TGCGCT GCGCTC CGCTCA GCTCAA CTCAAG TCAAGG CAAGGA AAGGAC AGGACG GGACGT GACGTC ACGTCG CGTCGG GTCGGT TCGGTC CGGTCT GGTCTC GTCTCG TCTCGA CTCGAG TCGAGG CGAGGC GAGGCA AGGCAA GGCAAT GCAATG CAATGA AATGAG ATGAGT TGAGTG GAGTGA AGTGAT GTGATC TGATCT GATCTG ATCTGC TCTGCT CTGCTC TGCTCA GCTCAA CTCAAT TCAATG CAATGG AATGGT ATGGTA TGGTAC GGTACG GTACGA TACGAC ACGACT CGACTT GACTTC ACTTCG CTTCGC TTCGCT TCGCTC CGCTCG GCTCGC CTCGCA TCGCAA CGCAAC GCAACC CAACCA AACCAG ACCAGC CCAGCA CAGCAC AGCACG GCACGG CACGGC ACGGCC CGGCCG GGCCGA GCCGAT CCGATC CGATCC GATCCG ATCCGA TCCGAT CCGATC CGATCG GATCGT ATCGTC TCGTCC CGTCCC GTCCCG TCCCGA CCCGAT CCGATC,CTGCGTC TGCGTCA GCGTCAG CGTCAGA GTCAGAA TCAGAAT CAGAATG AGAATGA GAATGAC AATGACG ATGACGT TGACGTG GACGTGG ACGTGGA CGTGGAG GTGGAGT TGGAGTA GGAGTAT GAGTATT AGTATTC GTATTCC TATTCCG ATTCCGT TTCCGTC TCCGTCG CCGTCGT CGTCGTC GTCGTCA TCGTCAA CGTCAAA GTCAAAA TCAAAAA CAAAAAC AAAAACA AAAACAC AAACACC AACACCC ACACCCT CACCCTG ACCCTGA CCCTGAC CCTGACC CTGACCC TGACCCG GACCCGC ACCCGCT CCCGCTT CCGCTTT CGCTTTG GCTTTGC CTTTGCG TTTGCGC TTGCGCT TGCGCTC GCGCTCA CGCTCAA GCTCAAG CTCAAGG TCAAGGA CAAGGAC AAGGACG AGGACGT GGACGTC GACGTCG ACGTCGG CGTCGGT GTCGGTC TCGGTCT CGGTCTC GGTCTCG GTCTCGA TCTCGAG CTCGAGG TCGAGGC CGAGGCA GAGGCAA AGGCAAT GGCAATG GCAATGA CAATGAG AATGAGT ATGAGTG TGAGTGA GAGTGAT AGTGATC GTGATCT TGATCTG GATCTGC ATCTGCT TCTGCTC CTGCTCA TGCTCAA GCTCAAT CTCAATG TCAATGG CAATGGT AATGGTA ATGGTAC TGGTACG GGTACGA GTACGAC TACGACT ACGACTT CGACTTC GACTTCG ACTTCGC CTTCGCT TTCGCTC TCGCTCG CGCTCGC GCTCGCA CTCGCAA TCGCAAC CGCAACC GCAACCA CAACCAG AACCAGC ACCAGCA CCAGCAC CAGCACG AGCACGG GCACGGC CACGGCC ACGGCCG CGGCCGA GGCCGAT GCCGATC CCGATCC CGATCCG GATCCGA ATCCGAT TCCGATC CCGATCG CGATCGT GATCGTC ATCGTCC TCGTCCC CGTCCCG GTCCCGA TCCCGAT CCCGATC,"ID   RL10_STRAW              Reviewed;         176 AA.
AC   Q82DQ7;
DT   15-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2003, sequence version 1.
DT   05-FEB-2025, entry version 104.
DE   RecName: Full=Large ribosomal subunit protein uL10 {ECO:0000255|HAMAP-Rule:MF_00362};
DE   AltName: Full=50S ribosomal protein L10 {ECO:0000305};
GN   Name=rplJ {ECO:0000255|HAMAP-Rule:MF_00362};
GN   OrderedLocusNames=SAV_4912;
OS   Streptomyces avermitilis (strain ATCC 31267 / DSM 46492 / JCM 5070 / NBRC
OS   14893 / NCIMB 12804 / NRRL 8165 / MA-4680).
OC   Bacteria; Bacillati; Actinomycetota; Actinomycetes; Kitasatosporales;
OC   Streptomycetaceae; Streptomyces.
OX   NCBI_TaxID=227882;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 31267 / DSM 46492 / JCM 5070 / NBRC 14893 / NCIMB 12804 /
RC   NRRL 8165 / MA-4680;
RX   PubMed=11572948; DOI=10.1073/pnas.211433198;
RA   Omura S., Ikeda H., Ishikawa J., Hanamoto A., Takahashi C., Shinose M.,
RA   Takahashi Y., Horikawa H., Nakazawa H., Osonoe T., Kikuchi H., Shiba T.,
RA   Sakaki Y., Hattori M.;
RT   ""Genome sequence of an industrial microorganism Streptomyces avermitilis:
RT   deducing the ability of producing secondary metabolites."";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:12215-12220(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 31267 / DSM 46492 / JCM 5070 / NBRC 14893 / NCIMB 12804 /
RC   NRRL 8165 / MA-4680;
RX   PubMed=12692562; DOI=10.1038/nbt820;
RA   Ikeda H., Ishikawa J., Hanamoto A., Shinose M., Kikuchi H., Shiba T.,
RA   Sakaki Y., Hattori M., Omura S.;
RT   ""Complete genome sequence and comparative analysis of the industrial
RT   microorganism Streptomyces avermitilis."";
RL   Nat. Biotechnol. 21:526-531(2003).
CC   -!- FUNCTION: Forms part of the ribosomal stalk, playing a central role in
CC       the interaction of the ribosome with GTP-bound translation factors.
CC       {ECO:0000255|HAMAP-Rule:MF_00362}.
CC   -!- SUBUNIT: Part of the ribosomal stalk of the 50S ribosomal subunit. The
CC       N-terminus interacts with L11 and the large rRNA to form the base of
CC       the stalk. The C-terminus forms an elongated spine to which L12 dimers
CC       bind in a sequential fashion forming a multimeric L10(L12)X complex.
CC       {ECO:0000255|HAMAP-Rule:MF_00362}.
CC   -!- SIMILARITY: Belongs to the universal ribosomal protein uL10 family.
CC       {ECO:0000255|HAMAP-Rule:MF_00362}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BA000030; BAC72624.1; -; Genomic_DNA.
DR   RefSeq; WP_010986331.1; NZ_JZJK01000077.1.
DR   AlphaFoldDB; Q82DQ7; -.
DR   SMR; Q82DQ7; -.
DR   GeneID; 41541996; -.
DR   KEGG; sma:SAVERM_4912; -.
DR   eggNOG; COG0244; Bacteria.
DR   HOGENOM; CLU_092227_1_0_11; -.
DR   OrthoDB; 3186107at2; -.
DR   Proteomes; UP000000428; Chromosome.
DR   GO; GO:0015934; C:large ribosomal subunit; IEA:InterPro.
DR   GO; GO:0070180; F:large ribosomal subunit rRNA binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0003735; F:structural constituent of ribosome; IEA:InterPro.
DR   GO; GO:0006412; P:translation; IEA:UniProtKB-UniRule.
DR   CDD; cd05797; Ribosomal_L10; 1.
DR   FunFam; 3.30.70.1730:FF:000003; 50S ribosomal protein L10; 1.
DR   Gene3D; 3.30.70.1730; -; 1.
DR   Gene3D; 6.10.250.290; -; 1.
DR   HAMAP; MF_00362; Ribosomal_uL10; 1.
DR   InterPro; IPR001790; Ribosomal_uL10.
DR   InterPro; IPR043141; Ribosomal_uL10-like_sf.
DR   InterPro; IPR022973; Ribosomal_uL10_bac.
DR   InterPro; IPR047865; Ribosomal_uL10_bac_type.
DR   InterPro; IPR002363; Ribosomal_uL10_CS_bac.
DR   PANTHER; PTHR11560; 39S RIBOSOMAL PROTEIN L10, MITOCHONDRIAL; 1.
DR   Pfam; PF00466; Ribosomal_L10; 1.
DR   SUPFAM; SSF160369; Ribosomal protein L10-like; 1.
DR   PROSITE; PS01109; RIBOSOMAL_L10; 1.
PE   3: Inferred from homology;
KW   Reference proteome; Ribonucleoprotein; Ribosomal protein; RNA-binding;
KW   rRNA-binding.
FT   CHAIN           1..176
FT                   /note=""Large ribosomal subunit protein uL10""
FT                   /id=""PRO_0000154718""
SQ   SEQUENCE   176 AA;  18542 MW;  17C7CC56546F9112 CRC64;
     MARPDKAAAV AELADQFRSS NAAVLTEYRG LTVAQLKTLR RSLGEDAQYA VVKNTLTKIA
     ANEAGINTLD DLFNGPTAVA FITGDPVVSA KGLRDFAKDN PNLVIKGGVL DGKALSADEI
     KKLADLESRE VLLAKLAGAF KGKQSQAASL FQALPSKFVR TAEALRAKKA EQGGAE
//
",24654
CTCTAC TCTACG CTACGA TACGAC ACGACG CGACGA GACGAG ACGAGC CGAGCT GAGCTC AGCTCG GCTCGC CTCGCC TCGCCA CGCCAC GCCACC CCACCG CACCGT ACCGTC CCGTCC CGTCCT GTCCTC TCCTCA CCTCAA CTCAAG TCAAGT CAAGTC AAGTCC AGTCCG GTCCGC TCCGCC CCGCCC CGCCCT GCCCTT CCCTTG CCTTGG CTTGGC TTGGCA TGGCAG GGCAGC GCAGCC CAGCCA AGCCAG GCCAGC CCAGCA CAGCAG AGCAGG GCAGGG CAGGGC AGGGCG GGGCGC GGCGCC GCGCCA CGCCAA GCCAAC CCAACA CAACAT AACATG ACATGA CATGAG ATGAGC TGAGCC GAGCCT AGCCTG GCCTGT CCTGTA CTGTAC TGTACA GTACAC TACACC ACACCG CACCGA ACCGAG CCGAGC CGAGCT GAGCTC AGCTCG GCTCGG CTCGGC TCGGCG CGGCGT GGCGTC GCGTCC CGTCCA GTCCAG TCCAGT CCAGTA CAGTAC AGTACG GTACGC TACGCC ACGCCA CGCCAA GCCAAG CCAAGC CAAGCA AAGCAC AGCACA GCACAA CACAAG ACAAGC CAAGCC AAGCCC AGCCCG GCCCGA CCCGAG CCGAGA CGAGAA GAGAAG AGAAGC GAAGCT AAGCTG AGCTGC GCTGCT CTGCTG TGCTGG GCTGGA CTGGAG TGGAGC GGAGCA GAGCAC AGCACA GCACAT CACATC ACATCA CATCAA ATCAAG TCAAGA CAAGAT AAGATG AGATGC GATGCA ATGCAC TGCACA GCACAC CACACG ACACGA CACGAA ACGAAG CGAAGA GAAGAA AAGAAG AGAAGA GAAGAT AAGATC,1,145,CTCTCTCT T T TCTGCTA A C CTTACAC C TTACACGG A ACGGCCGAGA A C CGCGATCCAC C G GAGACACGCG G AC CCGAGA A CC CCGAGAGAG G G GAGAGAGCGC C A AGAGCGCTCT T GG CGCTCTCTC C C CTCTCTCGCG G T TCCGCGC  CG CCGCC AG GCGCCCCACA A C CC CTTACC CCACCC C AACCCG G CCTGCCGCGTGT T CGC CGTGTCTC AGT GTCC  TC TCTCCCT T C TCCCTCTCTC C C CTTCCTCAA T TCCAAAA A C CACAAAAGAG G A AAC GGT T A AGAGTGTCTC C GGTCTCCCC C TC TTCCCCGCG AC  CCCCGCGCC C CGCATCC CC  GCGCCCCCA CC C CCCCCCCTCT T CCGCCCTCTTTT T C CTCTTTG G T TTTTGTGGG T TGTGGTG GC C GA TACGGCACA  GCGCACAGAAGG CCAGGC C A AGAGCGCCCC C G GCGCCCCACA A C CCCCACAGAG G C CACAGAGCGC  AGAGCGCA AGA G GCGCACAG CACAGAGGGG G A AGAGGGGGGC G GAGAGGGGGCC AC G GGGGCGCGCG GCA GCGCGCGCGC  CGCGCGCCCC C G GCGCCCA  GCA C CCCCA CCGAA CACAAAACAA C AC AACAA AACACATAT T C CACATATGAT G A ATATGTGAGA C G TGTGACA TCAC G GAGAGAGCGC C AGAGAGCGCC CCC G GCCCT CCCCTGC ACGG CCCACTGTGTGT T T TGGTATA  GTGTATACAC C T TATACACACA G A ACACAAC  CAACCCC C A ACGAGG CGC  GC CCCCGCGAGA A CCGAGAGAG G C GAGAGAGCGC C A AGG GGCTCT T G GCGCTCTCTC C C CTCTCTCGCG G T CCTCGCGGGG G C CGCGGGGCGC CGA GGGGCGCGCG G G GCGCGCGT CGCGTGTCAGC GTGTCGACCC  TCTCCCCA AAA CGT CCACAGAG G C CACAGAGTC CT A AGCGCGTATA A G GTGTATGTAC C T TAAC  CA ACACGCGCGC C C CGCAAGCCCC C G GCGCCCCACA CC CGCCCACAAAA A C CACAAAG G ACA AC AGCGC G G AGAGC CGCA A GCA GCACCG CACACACACA AT  ACACACAAA C CACAAAAGAG G AAGC CGAAC AGAGCAGACC C G GCC CCCCC C CCCCCCCGCG  CCCGAGA A C CGCGAGAGAG G G GAACC GGGA A A AGAGAGAAAA A G GAGAAAAGAG  AAAAGAGCCG C AAGCGCTCT T G GCGCTCTGG C CTCTGTGCGC C T TGCTAGCTCT T G GCGCTTG G G CTCTGTGGGG G T TGTGGGGAGA A G GGGGAGAGAG G G GAAGCGC C A CA CCGCACA A G GCGCACACAC  CACACACACA A A ACACAAGTAT T C CACATTC C A ATTCACA A T TCAG CAAAA A C AGCAAAAGAG  AAAAGAGAGA  AG ACA ACA  GAGATATGTG G A ATATGTGCGC C TTGCAAGA G CAGCACACAC CG ACACA A A ACACACACAC C C CAACGCG G A ACTG CGAGA A C CGC GGAAAA A G GAAA CA AG  AAAAGGCCA A AGAGAGAAAA A G GAGAAAAGGG G A AAAAGAGAGA A AAGAGATGGCT G GAGATATC,CCATCTCTATA C G TCTCTCTATACCACC CCTATACACGT CG T TATACCGAGA A AC CACGCGAGACAC C C CGACAGCCACGCG G G GAGACACGGA A A ACACGCGAGAGAG G C CGA AGC C G GAGAGAGCCT T A AGAGCCTCTC C GGCTCTCTCGCG G CCAACTCTCGCGCGC C T TCCGCGCC CTC C CGCGCGCCCCACA A GGCCCCACAC TGC C CCCCACACACCCC C C CACACACCCCGGCTG A ACACCCCGCGTGT T CCACCCGGTCTC C CCGTGTCTCC CCC G GTGTCTCCCCTCT CAGG CTCCCCTAG A GC C CCCTCTCAA C CTCTCTCAAGGAC ATG TCTCACAAAG G C CACAAAGTGT T A AACAAAGTGTC CGC AAGTGTCTCCCC C G GTGTCGCCCCGCG G T TCTCCCCGCGCGC C C CCCCGCGCAG CC C C CGCGCTCCCCCCC GAAGCCCCCCT CG GCAAA CCTCTTT CCC CCTCTTTTG TGG C CTCTTTTGTGGGG G T TTTTGTGGGGCGC C TAAGGGCGCACA A G GGGGCGCA GCAG G G GCT GCAGAGCGC C CCAGCCTGC CC C A AGGCCCA  GCGCCCCACAGAG G C CCCAGGC  AC CACAGAGCGCACA A A AGAGCGCAATCCTC GCGCACAGAGGGG G C CAAC GAGGGGGG G A AGGGGGGCGC T A GGGGGGGCGCGCG  CC GGAG GCGGC  GC GCGCGATGGCCCC C C CGCGCGCCCCACA A G GCGCCAAGAA CT  CCCCACAAAACC C CACAAAACACACA A A GCAACACACATAT C G ACCATGGCTG G C CACAT GTTGAGA A A ATCGCTGAGAGAG G TTG TGAGAGAGCGC C G GAGAGAGCGCCCC C A AGAGCGCCGCCA CGCACAGGACAGCTG A T CCCCTCGATGTACAT CCC CTGTGTGTAA TAA TGTGTAAC C G GTGTATACACACA  TATACCGACACAC C A ACACACACACCT TC C AAACCCTCGAAG A ACACCCCGCGACA A C CCCCGCGAGAGGCAG C CGCGAGAGAGCGCCC G GAGAGGCTCT T A AGAGCCG CCGCGAC G GCGCTCTCTCGCG CAT CTCACTCGCGGGG G T TCTCGCGGGGCGCTC C CGCGGGGCGCGCG G G GGA TGCGCGTGT T G GCGCGCGTGTCCA  CGCGTGTCTCCCC C GGTAGTCTCCCCAC CAAG TCTCCCCACAGAG G C CCCCACAGAGT AAC G CACAGGTAA A AGAGTATGACGAC T A GTGTATACACGCG G TTACACGCGCGC C AACGCGCGCCCC C C CGCGCCCA TGTC  GCGCCCCA CTAA A C CCCCACAAAG G C CACAACA AGCGC C A AAAAGGGCAGCCTG AGATGGCACACT TC G GCGCACACGA A CT CCACCAACCCA A ACACACAA GGAG G C CACAAAAGAGCGC  TGAAGAGCGCCCC C AAGCGCCGAGCC C G GCGCCCCCCCGCG  CCCCCCCGCGAGA A CCCGCGAGAG TC CGCGAGAGAGAGA A G GAAGAGAAACGAGACG AAGAG G G GAGAAAAGAGCGC CAC CAAAGCT T A AGAGCGCTCTGAAGG GCTGGCTCTGTGCGC C C CTCTGGCTGCTCC  TGTGCTG G G CAGCTCTGTGGGG G C CTTGGGA A T TGTGGCA AG TGGGGAAGGAGC GCC G GAGAGCCCC GCA A A AGGCA CCAC GCA GCCACACAAAGA C CAC ACATAT  ACCATCAGTC C C CAG CATCTCACA A A ATATCCAAAA  TCTCACAAAAGAG G C CACAATG GA A A AAAAGAGAGATAT C G AGAGAGATATGG G GAGATATGTGCGC C A ATAGCGCACA A TCA TGCGCAAC AC  GCGCACTCCA A C CACACCACAC C A ACACACACACGCG G C CACACACGTC GA A A AC AGCGAGAAAA A CTC AAGG G GAGAAAGAGA A A AAAAGAGAGAAAA A A AGAGAGAAA TAG G G GAGAAAAGAGAGA A A AAAAGAGAGATAT T A AGAGAGATATC,CTCTCT ACTACAC C T TCTCTCTATACACGCG G C CTCTATACACGCGAGA A T TATACACGCGA CAAC C AAGCACG GAGACACGCG G C CGCAAGACACGCGAGA A G GAACGCGAGAGCGAG A ACACGGAGGAGAGCGC C C CGCGAAGCCT T G GAAGCGCTCTCTC C AAGCGCTCTCTCGG G GCGCTCTCTCGCGCGC C CCTCCTCTCGGCCCC C TTCGGA GC CCACA A CG GCGCC GCAACACAC C G GCGCCCCA GCACCCC C CCTGCCACACACCCG G CCATACCCCGCTATGCT A ACC TCCGAGTGTCTC C C CCCCGGTCTCCCC C C CGC GTCCCCTCT T G GTCTGTCCCACAGCTC C T TCTCCCCTCTCCA TGG CCCCTCTCTCAA CA C CTCTCAAGAG G T TCTCACAAAGTGT T CTCACAAAAGCGTGTCTC C A AA CAGTCTCCCC ACG AGGGC GCTCCCAGCG G G CAGTCTCCA CCGCGC C T TCTCCCCGCGCGCCCC C CATGCCGCGCC CCAGCGCGCCGCTCCT ACT G GCACACCCCTTATCT C CCCCT CCTTGTG G C CTCCTTTGTGGGG G C CCCTTTTGTGGGGC TTTTGTGGGGCGCACA A T TGTGGGGCGCACAGAG G G GGGGCGCACAGAGCGC C G ATCAGAGCGCCC CGACCCGAGCGCC CACA A A AGAGCAG GCGCAGAG  CGCA GCCCCAGG C C CCGAACAGAGCGCAA CGATCAGGCAAG G A AGCC GCACAGAGG GCGCACAGAGGGGGGG  CACAGGAGGGGGGCGC C A AGAGGGGGGGCGCGCG  GGGGGGGCGCGCGCGC C G GGGGCCCAGCCAA  CC TACGCGCCCCAA C CGCGCGCCCCAGAGAA A G GCGCCCCACAAAACAC C C CCCCACAAGAAACAGTAA C GTGCAAACACACATAT T A AAAACACAGCCTG G ACGTACACATATGGA AAGGAGCATATGGAGG AGCA CCTGAGAGGCCC T TGTGAAGCAAGC G GAGAGCTCGCC GCT A AG GCGCCCCTGTCTG G G GCGCCCCTA CGT T C CCCCTCTTTGTGAGTA A C CTCTGATCGTATACAC C T TGTGTCA TACGA A G GTGTATACACACACAC C TAGCTACG TA AAGCC A ACA CCACACCCG CTCCACACCCCGCGAACCCT ACCCCGCGACAA CCCCGCGAGAG ACGC C CGAAGAGGCTCT CGAGTAAGCGCTCTCTC C A AGAGCGCT CTTCGCG G G GCGCTCTCTCGCGCG C CTG CTCGCGGGC C T TCTCGCGGGGCGCGCG G C CGCGGGGCGCGCGTGT T G GGGGCGCGCGTGTCTC CCG GCGCGCGTGTCTCCCC C C CGAGGCGGCCACA A G GTGTCTCCAG CAGAG CAC TCTCCCCACAGAGTGT C GCCACAGAGTGTATA  CACAGAGTGTATACAC C A AGAGTGTATACACGCG G G GTCAATACACGCGCGC ACC TATACACGCGCCC CGACGCCCACA CAACGCGCCCCACAAAA A G GCGCCGTACAC CGG C CCCAAAGCGC C C CACAAAAGAGCGCAA A AA TGAGCGCACACAC C A AGAGCCGACACACACA A G GCGCACACACACAAAAGA C CACCTACACAAAAGG A ACACACAAAAGAGCGC C CCCACAAAAGAGCGCCCC C AAAGAGCGCCCCCGCTC A AGAGCGCCCCCC GCG G G GCGCCCCCCCGCGAGA A C CCCCCCCGCGA CAAG G C CCCCGCGAGAGAGAGCCA CAG GAGAGAGAAAA  GAGAGAGACCAAAGG A AGAGAGAAACAAGCGC C G GAAAGAGCGCTCT  AAAAGAGCCCCCTGG A AGAGCGCTCTTTGCGC GTCCACGCTCTGTGCGCTCT T C CTCTGTGCGCTTG CAC TGTGCGCTCTGG GCTGTGGGGACGCA C CTCTGTGGGGACGTG TTCCGGAGAGGCCA GGGAGAGAGCGCACA A G GACGA CGGCAAAGAC C A AGAGCGCACACACAAC A G GCGCACACACAAAGT C CAG TACACATATCC A ACACACATTGTTCACA TGT CACATATCTCACAAAA A A AT CG CACAAAG G T TCTCACCAAAGAGAGA A C CACAAAAGAGA CAAT T A AAAG AGAGATATGTG G A AGGATATGTGCGC C GGATATGTGCGCACA A A ATATGGT GCAAC C TAAGTGCGCAAGCCA A G GCGCAACACACCA  CACACACACACACGCG G A ACACACACACGCGAGA A C CACACC ACGAAACAA A A ACACG ACGAAAAGAG G CGC CGAGAAAAGAGAGA  GG GAGAACC CC AA A A AAAAGAGAGAAAAGGCC AGAGATT TGAAGAGA  GAAGACTGAT T A AAAAGAGAGATATC,CTCTCTTG ACGCAGG TCG TCTTACACGCGAG AA CCTATACACGCTGGACAC C T TATG ACGACG GTACGAAG ACACGT GACGCGAGA AGCGC CGAACGGAGAG G G GAGACACGCGACTGAGCGC C A ACGCCGAGAGCCT T CCGAATCAGCTC CTCTC C GCACCTGAGCGCTCTCTCGCG GA  GAAGCCTCTCGCGCGC CAT GCGAGCTCCGCGCCA CC C CTCTCTCGCGCAGCCCACA  TCTCGCGCGCCCCACACAC C C CGCGCCATCCAGATACCGCCC GGCCCCAACCCCGCG G CCCACAC GCCCGCGTAGCT CC GCACCTCCCGCGTG ACAC AC CTGAACGTTCCCC C C CCCCGCGTGTCTCCCC CT  CGCGTGTCTCCCCTCTCTC C G GTGTCCCTCTCTCACA A T TCTCCCCTCTCG ACAAAA A C CCCCTCAAAAGAG G C GACAAAAGAGTGT T T TCAG AAGAGTGTCAAGC C CACAAAAGAGTGTCTCCCC C A AAAAGAGTGTCTCCCCGCG G ATGAAGTGTCGCACGCGC CCT CGTCCCGACGCGCCCC  TCTCCCCG ACGCCCCCC C CCCCGACAGCCCCCCCTCT T C CGCGAGCCCCCCCTCTTTT  GCGCCCCCCCTCTTTTGTG G C CCCCCCCTCTTTTGTGGGG G C CCCCTCTTTTGTGGGGCC CACCCTTTTGTGGCC GCACA TTGGGCGCACGAAG G TGC TGGGGCTGCCAGAGCGC C G GGGGCGCACAGGCCCC C G GCGCACAGAGCGCCCCACA A C CACAGAGCACGCAAAG G A AGAGCGCCCCACAGAGCGC C G GCCCACAGC GGCACCGA C CCCCACAGAGCGGCTACAG G CTCCCAGGCACAGAGGGCAGCAAGCGCACAGAGGGGGGG G G GCGCACAGA AGGGGGCC C CACAGAGGGGGTGCGCGCG G A AGGGGGGCGCGCGCGC  GGGGGGCGCGCGCAC G GGGGCGCGGCCCCAAGAGCTGCGCGCGCCCCACAAAA A C CGCGCGCCCCAGAGC GGCCCCACAAAACACACA A C CCCCACAAAACACA TCAT T C CACAAAACACACACATGCTAG A AATCAACAG CATGTGAGA A A ACACACATATGTGAGAGCCGTGC CACATATGTGAGAGAGCGC C A ATCATTGAGAGAGCGCCGCTC T TGGAGAGCGCCCCTCT T G GAGCCAGCGCCCCTTG G A AGGCCGCCGACGCTTGTGT T G GCCCTCTGTGTGTATA A CGC CCTTGTGTAAC C CCTGTGTGTATACACACG A T TGTGTGTATACCA CACAC AGCCATGTATACACACACACCCC C T TACTCACACACACCCCGCG G A ACACA GAACCCCGCGAGA A C CACAGACCCCGCCGC AACCCCGCGAGAGAGCGC CGA CCCCGCGAGAGAGCGCTCT T C CGCGAGAGAGCC CCTCTC C GAACCC ACCTCGGCCG A AGAGCGCTCTCTCGCGGGG G G GCGCTCTC GCCGGGC TGCC TCG TCGCGGGGCGCGCG G T TCTCGCGGGGCGCGCGTGT T C CGCGGGGCGCGCGTGTCTC C G GGGGCGCGCGTGTCTCCCC C G GCGCGCGTGTCTCCCCAACAA C CGCGTGTCTCCCCACAGAG G GCGCGCTTCCCA CAGAGTGT T T TCTCCCCAAGTGTATA GT  CCCCACACAGTTACAC C CAAGCAGTACACGG AGTATACCGA GTGC C GGTAACGCGCGCCCC  CT TATACCGCGCCCCACA A A ACACGCGCGCCCCACAAAA A C CGCGCGCCCCACAAAAGAG G G GCGCCCCAAAGAGCCTGC C CCCAAAAGAGCGCACA A C CACAAAAGAGCGCACACAC AG  AAAAGAGCGCACACACACA  AGGCAAG ACACAAAA A G GCGCACACACACAAAAGAG G C CACACACAAGAAAGGC C A ACACACAAAAGGCTGAGCCTC C CACAAAAGAGCCCCCC T C AAAGCGCCCCCCACG A AGGCCCCCCCGCGAGA  GC GCCC CCCCCGCGAAG  CCCCCCCGGCTGAGGA CAC CCCA CGAGAGAGAGAAA CGTCCGAGAGCAGA AAAG GAGAGAGAGAAAAGAGCGC C A AGAGAGAAAAGA CGCTCT GCATCAGAAAAGAGCGCTCTGTG G A AATC AGCGCTCTGTCCC A AGAGCGCTCTGTGCA GCT T G CGGCTGAGGGCGCTCTGTG GC  CTCTGTGCGCTCTGTGGGG  TGTGCAGAGC TGGGGAGA A G GCCTGTGGGGAGAGAG G C CTCTGTGGAC GAG AGCTGC T TGTGGGGAGAGAGCGCACA A G GGGGAAGCGCACACC GGAGAGCGCACACACAA A AGTC ACACATAT AGCGCACACACACATATCGTCC C CACACACACATATCTCACA  CA ACACAC GATCTCACAAA C CAATGATCAACCAAAAGTCAG A ATTCACAAAAGAGAGA A T TCTCACAAAAGAGAC A CACAAAAGAGAGATATGTACG A AAAAGAGAGATC CGGC CCC AAGCAGAGATATGTGCCA A G GAGATATGCATGCAATGTGCGG CACACACA A T TGTGCT GCACACACACC GACCGCACACCGCCACACGCG G C CAACACACACGCGCGA A A ACACACACACGCAGGAAAA A C CACACACGCGAGAAAAGAG G ACGCACGCGAGAAAAGAGAGA A C CGCGAGAAAAGA CGAAAA A G GACCGAAGAGAGAAAAGAG  AAAAGCCAGAAAAGAGAGA GAAAGAGAAAGA GTAT T G AGGAACAACAAGATGAG,"ID   CLH1_ORYSJ              Reviewed;        1708 AA.
AC   Q2RBN7;
DT   16-NOV-2011, integrated into UniProtKB/Swiss-Prot.
DT   24-JAN-2006, sequence version 1.
DT   05-FEB-2025, entry version 102.
DE   RecName: Full=Clathrin heavy chain 1;
GN   OrderedLocusNames=Os11g0104900, LOC_Os11g01380;
OS   Oryza sativa subsp. japonica (Rice).
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliopsida; Liliopsida; Poales; Poaceae; BOP clade;
OC   Oryzoideae; Oryzeae; Oryzinae; Oryza; Oryza sativa.
OX   NCBI_TaxID=39947;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=cv. Nipponbare;
RX   PubMed=16188032; DOI=10.1186/1741-7007-3-20;
RG   The rice chromosomes 11 and 12 sequencing consortia;
RT   ""The sequence of rice chromosomes 11 and 12, rich in disease resistance
RT   genes and recent gene duplications."";
RL   BMC Biol. 3:20-20(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=cv. Nipponbare;
RX   PubMed=16100779; DOI=10.1038/nature03895;
RG   International rice genome sequencing project (IRGSP);
RT   ""The map-based sequence of the rice genome."";
RL   Nature 436:793-800(2005).
RN   [3]
RP   GENOME REANNOTATION.
RC   STRAIN=cv. Nipponbare;
RX   PubMed=18089549; DOI=10.1093/nar/gkm978;
RG   The rice annotation project (RAP);
RT   ""The rice annotation project database (RAP-DB): 2008 update."";
RL   Nucleic Acids Res. 36:D1028-D1033(2008).
RN   [4]
RP   GENOME REANNOTATION.
RC   STRAIN=cv. Nipponbare;
RX   PubMed=24280374; DOI=10.1186/1939-8433-6-4;
RA   Kawahara Y., de la Bastide M., Hamilton J.P., Kanamori H., McCombie W.R.,
RA   Ouyang S., Schwartz D.C., Tanaka T., Wu J., Zhou S., Childs K.L.,
RA   Davidson R.M., Lin H., Quesada-Ocampo L., Vaillancourt B., Sakai H.,
RA   Lee S.S., Kim J., Numa H., Itoh T., Buell C.R., Matsumoto T.;
RT   ""Improvement of the Oryza sativa Nipponbare reference genome using next
RT   generation sequence and optical map data."";
RL   Rice 6:4-4(2013).
CC   -!- FUNCTION: Clathrin is the major protein of the polyhedral coat of
CC       coated pits and vesicles.
CC   -!- SUBUNIT: Clathrin triskelions, composed of 3 heavy chains and 3 light
CC       chains, are the basic subunits of the clathrin coat. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasmic vesicle membrane {ECO:0000250};
CC       Peripheral membrane protein {ECO:0000250}; Cytoplasmic side
CC       {ECO:0000250}. Membrane, coated pit {ECO:0000250}; Peripheral membrane
CC       protein {ECO:0000250}; Cytoplasmic side {ECO:0000250}. Note=Cytoplasmic
CC       face of coated pits and vesicles. {ECO:0000250}.
CC   -!- DOMAIN: The C-terminal third of the heavy chains forms the hub of the
CC       triskelion. This region contains the trimerization domain and the
CC       light-chain binding domain involved in the assembly of the clathrin
CC       lattice.
CC   -!- DOMAIN: The N-terminal seven-bladed beta-propeller is formed by WD40-
CC       like repeats, and projects inward from the polyhedral outer clathrin
CC       coat. It constitutes a major protein-protein interaction node (By
CC       similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the clathrin heavy chain family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; DP000010; ABA91061.1; -; Genomic_DNA.
DR   EMBL; AP008217; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AP014967; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   RefSeq; XP_015616901.1; XM_015761415.1.
DR   AlphaFoldDB; Q2RBN7; -.
DR   SMR; Q2RBN7; -.
DR   STRING; 39947.Q2RBN7; -.
DR   PaxDb; 39947-Q2RBN7; -.
DR   EnsemblPlants; Os11t0104900-01; Os11t0104900-01; Os11g0104900.
DR   GeneID; 4349546; -.
DR   Gramene; Os11t0104900-01; Os11t0104900-01; Os11g0104900.
DR   KEGG; osa:4349546; -.
DR   eggNOG; KOG0985; Eukaryota.
DR   HOGENOM; CLU_002136_1_0_1; -.
DR   InParanoid; Q2RBN7; -.
DR   OrthoDB; 1853790at2759; -.
DR   Proteomes; UP000000763; Chromosome 11.
DR   Proteomes; UP000059680; Chromosome 11.
DR   GO; GO:0030132; C:clathrin coat of coated pit; IEA:InterPro.
DR   GO; GO:0030130; C:clathrin coat of trans-Golgi network vesicle; IEA:InterPro.
DR   GO; GO:0071439; C:clathrin complex; IBA:GO_Central.
DR   GO; GO:0032051; F:clathrin light chain binding; IBA:GO_Central.
DR   GO; GO:0005198; F:structural molecule activity; IEA:InterPro.
DR   GO; GO:0006886; P:intracellular protein transport; IEA:InterPro.
DR   GO; GO:0006898; P:receptor-mediated endocytosis; IBA:GO_Central.
DR   FunFam; 1.25.40.10:FF:000001; Clathrin heavy chain; 1.
DR   FunFam; 1.25.40.10:FF:000002; Clathrin heavy chain; 1.
DR   FunFam; 1.25.40.10:FF:000005; Clathrin heavy chain; 1.
DR   FunFam; 1.25.40.10:FF:000686; Clathrin heavy chain; 1.
DR   FunFam; 1.25.40.730:FF:000002; Clathrin heavy chain; 1.
DR   FunFam; 2.130.10.110:FF:000002; Clathrin heavy chain; 1.
DR   Gene3D; 1.25.40.730; -; 1.
DR   Gene3D; 2.130.10.110; Clathrin heavy-chain terminal domain; 1.
DR   Gene3D; 1.25.40.10; Tetratricopeptide repeat domain; 3.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR000547; Clathrin_H-chain/VPS_repeat.
DR   InterPro; IPR015348; Clathrin_H-chain_linker_core.
DR   InterPro; IPR016025; Clathrin_H-chain_N.
DR   InterPro; IPR022365; Clathrin_H-chain_propeller_rpt.
DR   InterPro; IPR016341; Clathrin_heavy_chain.
DR   InterPro; IPR011990; TPR-like_helical_dom_sf.
DR   PANTHER; PTHR10292:SF1; CLATHRIN HEAVY CHAIN; 1.
DR   PANTHER; PTHR10292; CLATHRIN HEAVY CHAIN RELATED; 1.
DR   Pfam; PF00637; Clathrin; 7.
DR   Pfam; PF09268; Clathrin-link; 1.
DR   Pfam; PF13838; Clathrin_H_link; 1.
DR   Pfam; PF01394; Clathrin_propel; 2.
DR   PIRSF; PIRSF002290; Clathrin_H_chain; 1.
DR   SMART; SM00299; CLH; 7.
DR   SUPFAM; SSF48371; ARM repeat; 5.
DR   SUPFAM; SSF50989; Clathrin heavy-chain terminal domain; 1.
DR   PROSITE; PS50236; CHCR; 7.
PE   3: Inferred from homology;
KW   Coated pit; Cytoplasmic vesicle; Membrane; Reference proteome; Repeat.
FT   CHAIN           1..1708
FT                   /note=""Clathrin heavy chain 1""
FT                   /id=""PRO_0000414015""
FT   REPEAT          551..697
FT                   /note=""CHCR 1""
FT   REPEAT          700..842
FT                   /note=""CHCR 2""
FT   REPEAT          847..986
FT                   /note=""CHCR 3""
FT   REPEAT          993..1138
FT                   /note=""CHCR 4""
FT   REPEAT          1142..1283
FT                   /note=""CHCR 5""
FT   REPEAT          1288..1434
FT                   /note=""CHCR 6""
FT   REPEAT          1437..1580
FT                   /note=""CHCR 7""
FT   REGION          1..492
FT                   /note=""Globular terminal domain""
FT                   /evidence=""ECO:0000250""
FT   REGION          25..67
FT                   /note=""WD40-like repeat 1""
FT   REGION          68..113
FT                   /note=""WD40-like repeat 2""
FT   REGION          114..155
FT                   /note=""WD40-like repeat 3""
FT   REGION          156..205
FT                   /note=""WD40-like repeat 4""
FT   REGION          206..270
FT                   /note=""WD40-like repeat 5""
FT   REGION          271..314
FT                   /note=""WD40-like repeat 6""
FT   REGION          315..343
FT                   /note=""WD40-like repeat 7""
FT   REGION          462..478
FT                   /note=""Binding site for the uncoating ATPase, involved in
FT                   lattice disassembly""
FT                   /evidence=""ECO:0000250""
FT   REGION          493..536
FT                   /note=""Flexible linker""
FT                   /evidence=""ECO:0000250""
FT   REGION          537..1708
FT                   /note=""Heavy chain arm""
FT                   /evidence=""ECO:0000250""
FT   REGION          537..648
FT                   /note=""Distal segment""
FT                   /evidence=""ECO:0000250""
FT   REGION          653..1708
FT                   /note=""Proximal segment""
FT                   /evidence=""ECO:0000250""
FT   REGION          1227..1536
FT                   /note=""Involved in binding clathrin light chain""
FT                   /evidence=""ECO:0000250""
FT   REGION          1564..1708
FT                   /note=""Trimerization""
FT                   /evidence=""ECO:0000250""
SQ   SEQUENCE   1708 AA;  193346 MW;  15217B973A965E59 CRC64;
     MAAANAPIAM REALTLTSLG IAPQFVTFTH VTMESEKYIC VRETSPQNSV VIVDMAMPAQ
     PLRRPITADS ALMNPNTRIL ALKAQIPGTT QDHLQIFNIE AKTKIKSHQM PEQVVFWKWI
     TPKLLGLVTQ TSVYHWSIEG DSEPAKMFDR TANLANNQII NYRCDPSEKW LVLIGIAPGA
     PERPQLVKGN MQLFSVDQQR SQALEAHAAS FASFKVVGNE NPSTLICFAS KTTNAGQITS
     KLHVIELGAQ PGKPGFSKKQ ADLFFPPDFQ DDFPVAMQIS QKYGLIYVIT KLGLLFVYDL
     ETAAAVYRNR ISPDPIFLTA ESSASGGFYA INRRGQVLHA TVNDATIVPF VSSQLNNLEL
     AVNLAKRANL PGAENLVVQR FQELFAQTKY KEAAELAAES PQGLLRTPET VAKFQSVPVQ
     AGQTPPLLQY FGTLLTRGKL NAYESLELSR LVVNQNKKNL LENWLAEDKL ECSEELGDLV
     KTVDNDLALK IYIKARATPK VVAAFAERRE FDKILIYSKQ VGYTPDYLFL LQTILRTDPQ
     GAVNFALMMS QMEGGCPVDY NTITDLFLQR NMIREATAFL LDVLKPNLPE HAFLQTKVLE
     INLVTYPNVA DAILANGMFS HYDRPRVAQL CEKAGLYLRA LQHYTELPDI KRVMVNTHAI
     EPQALVEFFG TLSREWALEC MKDLLLVNLR GNLQIVVQAA KEYSEQLGVD ACIKLFEQFK
     SYEGLYFFLG AYLSSSEDPD IHFKYIEAAA RTGQIKEVER VTRESNFYDA EKTKNFLMEA
     KLPDARPLIN VCDRFGFVPD LTHYLYTNNM LRYIEGYVQK VNPGNAPLVV GQLLDDECPE
     DFIKGLILSV RSLLPVEPLV DECEKRNRLR LLTQFLEHLV SEGSQDVHVH NALGKIIIDS
     NNNPEHFLTT NPFYDSRVVG KYCEKRDPTL AVVAYRRGQC DDELINVTNK NSLFKLQARY
     VVERMDGDLW DKVLQPENEY RRQLIDQVVS TALPESKSPE QVSAAVKAFM TADLPHELIE
     LLEKIVLQNS AFSGNFNLQN LLILTAIKAD PSRVMDYVNR LDNFDGPAVG EVAVEAQLFE
     EAFAIFKKFN LNVQAVNVLL DNIRSIERAE EFAFRVEEDA VWSQVAKAQL REGLVSEAIE
     SFIRADDATH FLDVIRAAEE ANVYDDLVKY LLMVRQKARE PKVDGELIFA YAKIDRLSDI
     EEFILMPNVA NLQNVGDRLY DEELYEAAKI IYAFISNWAK LAVTLVKLKQ FQGAVDAARK
     ANSAKTWKEV CFACVDAEEF RLAQICGLNI IVQVDDLEEV SEYYQNRGCF NELISLMESG
     LGLERAHMGI FTELGVLYAR YRPEKLMEHI KLFSTRLNIP KLIRACDEQQ HWKELTYLYI
     QYDEFDNAAT TIMNHSPDAW DHMQFKDVAV KVANVELYYK AVHFYLQEHP DLINDLLNVL
     ALRLDHTRVV DIMRKAGQLH LVKPYMVAVQ SNNVSAVNEA LNELYVEEED YERLRESVDM
     HDNFDQIGLA QKLEKHELLE MRRIAAYIYK KAGRWKQSIA LSKKDNMYKD CMETCSQSGD
     RELSEDLLVY FIEQGKKECF ASCLFICYDL IRADVALELA WMNNMVDFAF PYLLQFIREY
     TSKVDELVKD RIESQNEVRA KEKEEKDLVA QQNMYAQLLP LALPAPPGMG GPPPPMGMPG
     MPPMGGMGMP PMGPGPMPAY GMPPMGSY
//
",40367
GCGGCT CGGCTG GGCTGA GCTGAC CTGACA TGACAA GACAAA ACAAAT CAAATC AAATCA AATCAG ATCAGG TCAGGC CAGGCC AGGCCG GGCCGA GCCGAA CCGAAC CGAACC GAACCC AACCCG ACCCGT CCCGTG CCGTGC CGTGCC GTGCCC TGCCCG GCCCGC CCCGCG CCGCGA CGCGAA GCGAAT CGAATT GAATTT AATTTG ATTTGC TTTGCG TTGCGT TGCGTT GCGTTG CGTTGC GTTGCA TTGCAG TGCAGG GCAGGC CAGGCG AGGCGC GGCGCT GCGCTG CGCTGT GCTGTA CTGTAC TGTACC GTACCA TACCAA ACCAAC CCAACA CAACAC AACACC ACACCT CACCTG ACCTGG CCTGGT CTGGTG TGGTGG GGTGGG GTGGGC TGGGCC GGGCCG GGCCGC GCCGCA CCGCAA CGCAAC GCAACG CAACGA AACGAG ACGAGC CGAGCC GAGCCT AGCCTG GCCTGC CCTGCC CTGCCG TGCCGA GCCGAC CCGACA CGACAT GACATC ACATCG CATCGA ATCGAC TCGACC CGACCT GACCTG ACCTGT CCTGTT CTGTTC TGTTCA GTTCAC TTCACC TCACCC CACCCG ACCCGC CCCGCG CCGCGA CGCGAC GCGACC CGACCT GACCTG ACCTGA CCTGAG CTGAGC TGAGCG GAGCGG AGCGGC GCGGCT CGGCTT GGCTTT GCTTTC CTTTCA TTTCAC TTCACA TCACAA CACAAG ACAAGT CAAGTG AAGTGC AGTGCG GTGCGA TGCGAC GCGACA CGACAG GACAGC ACAGCG CAGCGC AGCGCC GCGCCC CGCCCA GCCCAC CCCACT CCACTA CACTAC ACTACG CTACGA TACGAT,3,145,GCGG CGGC GGCT GCTG CTGA TGAC GACA ACAA CAAA AAAT AATC ATCA TCAG CAGG AGGC GGCC GCCG CCGA CGAA GAAC AACC ACCC CCCG CCGT CGTG GTGC TGCC GCCC CCCG CCGC CGCG GCGA CGAA GAAT AATT ATTT TTTG TTGC TGCG GCGT CGTT GTTG TTGC TGCA GCAG CAGG AGGC GGCG GCGC CGCT GCTG CTGT TGTA GTAC TACC ACCA CCAA CAAC AACA ACAC CACC ACCT CCTG CTGG TGGT GGTG GTGG TGGG GGGC GGCC GCCG CCGC CGCA GCAA CAAC AACG ACGA CGAG GAGC AGCC GCCT CCTG CTGC TGCC GCCG CCGA CGAC GACA ACAT CATC ATCG TCGA CGAC GACC ACCT CCTG CTGT TGTT GTTC TTCA TCAC CACC ACCC CCCG CCGC CGCG GCGA CGAC GACC ACCT CCTG CTGA TGAG GAGC AGCG GCGG CGGC GGCT GCTT CTTT TTTC TTCA TCAC CACA ACAA CAAG AAGT AGTG GTGC TGCG GCGA CGAC GACA ACAG CAGC AGCG GCGC CGCC GCCC CCCA CCAC CACT ACTA CTAC TACG ACGA CGAT,GCGGC CGGCT GGCTG GCTGA CTGAC TGACA GACAA ACAAA CAAAT AAATC AATCA ATCAG TCAGG CAGGC AGGCC GGCCG GCCGA CCGAA CGAAC GAACC AACCC ACCCG CCCGT CCGTG CGTGC GTGCC TGCCC GCCCG CCCGC CCGCG CGCGA GCGAA CGAAT GAATT AATTT ATTTG TTTGC TTGCG TGCGT GCGTT CGTTG GTTGC TTGCA TGCAG GCAGG CAGGC AGGCG GGCGC GCGCT CGCTG GCTGT CTGTA TGTAC GTACC TACCA ACCAA CCAAC CAACA AACAC ACACC CACCT ACCTG CCTGG CTGGT TGGTG GGTGG GTGGG TGGGC GGGCC GGCCG GCCGC CCGCA CGCAA GCAAC CAACG AACGA ACGAG CGAGC GAGCC AGCCT GCCTG CCTGC CTGCC TGCCG GCCGA CCGAC CGACA GACAT ACATC CATCG ATCGA TCGAC CGACC GACCT ACCTG CCTGT CTGTT TGTTC GTTCA TTCAC TCACC CACCC ACCCG CCCGC CCGCG CGCGA GCGAC CGACC GACCT ACCTG CCTGA CTGAG TGAGC GAGCG AGCGG GCGGC CGGCT GGCTT GCTTT CTTTC TTTCA TTCAC TCACA CACAA ACAAG CAAGT AAGTG AGTGC GTGCG TGCGA GCGAC CGACA GACAG ACAGC CAGCG AGCGC GCGCC CGCCC GCCCA CCCAC CCACT CACTA ACTAC CTACG TACGA ACGAT,GCGGCT CGGCTG GGCTGA GCTGAC CTGACA TGACAA GACAAA ACAAAT CAAATC AAATCA AATCAG ATCAGG TCAGGC CAGGCC AGGCCG GGCCGA GCCGAA CCGAAC CGAACC GAACCC AACCCG ACCCGT CCCGTG CCGTGC CGTGCC GTGCCC TGCCCG GCCCGC CCCGCG CCGCGA CGCGAA GCGAAT CGAATT GAATTT AATTTG ATTTGC TTTGCG TTGCGT TGCGTT GCGTTG CGTTGC GTTGCA TTGCAG TGCAGG GCAGGC CAGGCG AGGCGC GGCGCT GCGCTG CGCTGT GCTGTA CTGTAC TGTACC GTACCA TACCAA ACCAAC CCAACA CAACAC AACACC ACACCT CACCTG ACCTGG CCTGGT CTGGTG TGGTGG GGTGGG GTGGGC TGGGCC GGGCCG GGCCGC GCCGCA CCGCAA CGCAAC GCAACG CAACGA AACGAG ACGAGC CGAGCC GAGCCT AGCCTG GCCTGC CCTGCC CTGCCG TGCCGA GCCGAC CCGACA CGACAT GACATC ACATCG CATCGA ATCGAC TCGACC CGACCT GACCTG ACCTGT CCTGTT CTGTTC TGTTCA GTTCAC TTCACC TCACCC CACCCG ACCCGC CCCGCG CCGCGA CGCGAC GCGACC CGACCT GACCTG ACCTGA CCTGAG CTGAGC TGAGCG GAGCGG AGCGGC GCGGCT CGGCTT GGCTTT GCTTTC CTTTCA TTTCAC TTCACA TCACAA CACAAG ACAAGT CAAGTG AAGTGC AGTGCG GTGCGA TGCGAC GCGACA CGACAG GACAGC ACAGCG CAGCGC AGCGCC GCGCCC CGCCCA GCCCAC CCCACT CCACTA CACTAC ACTACG CTACGA TACGAT,GCGGCTG CGGCTGA GGCTGAC GCTGACA CTGACAA TGACAAA GACAAAT ACAAATC CAAATCA AAATCAG AATCAGG ATCAGGC TCAGGCC CAGGCCG AGGCCGA GGCCGAA GCCGAAC CCGAACC CGAACCC GAACCCG AACCCGT ACCCGTG CCCGTGC CCGTGCC CGTGCCC GTGCCCG TGCCCGC GCCCGCG CCCGCGA CCGCGAA CGCGAAT GCGAATT CGAATTT GAATTTG AATTTGC ATTTGCG TTTGCGT TTGCGTT TGCGTTG GCGTTGC CGTTGCA GTTGCAG TTGCAGG TGCAGGC GCAGGCG CAGGCGC AGGCGCT GGCGCTG GCGCTGT CGCTGTA GCTGTAC CTGTACC TGTACCA GTACCAA TACCAAC ACCAACA CCAACAC CAACACC AACACCT ACACCTG CACCTGG ACCTGGT CCTGGTG CTGGTGG TGGTGGG GGTGGGC GTGGGCC TGGGCCG GGGCCGC GGCCGCA GCCGCAA CCGCAAC CGCAACG GCAACGA CAACGAG AACGAGC ACGAGCC CGAGCCT GAGCCTG AGCCTGC GCCTGCC CCTGCCG CTGCCGA TGCCGAC GCCGACA CCGACAT CGACATC GACATCG ACATCGA CATCGAC ATCGACC TCGACCT CGACCTG GACCTGT ACCTGTT CCTGTTC CTGTTCA TGTTCAC GTTCACC TTCACCC TCACCCG CACCCGC ACCCGCG CCCGCGA CCGCGAC CGCGACC GCGACCT CGACCTG GACCTGA ACCTGAG CCTGAGC CTGAGCG TGAGCGG GAGCGGC AGCGGCT GCGGCTT CGGCTTT GGCTTTC GCTTTCA CTTTCAC TTTCACA TTCACAA TCACAAG CACAAGT ACAAGTG CAAGTGC AAGTGCG AGTGCGA GTGCGAC TGCGACA GCGACAG CGACAGC GACAGCG ACAGCGC CAGCGCC AGCGCCC GCGCCCA CGCCCAC GCCCACT CCCACTA CCACTAC CACTACG ACTACGA CTACGAT,"ID   NUSB_POLSJ              Reviewed;         187 AA.
AC   Q129J0;
DT   12-DEC-2006, integrated into UniProtKB/Swiss-Prot.
DT   22-AUG-2006, sequence version 1.
DT   29-MAY-2024, entry version 89.
DE   RecName: Full=Transcription antitermination protein NusB {ECO:0000255|HAMAP-Rule:MF_00073};
DE   AltName: Full=Antitermination factor NusB {ECO:0000255|HAMAP-Rule:MF_00073};
GN   Name=nusB {ECO:0000255|HAMAP-Rule:MF_00073};
GN   OrderedLocusNames=Bpro_2887;
OS   Polaromonas sp. (strain JS666 / ATCC BAA-500).
OC   Bacteria; Pseudomonadota; Betaproteobacteria; Burkholderiales;
OC   Comamonadaceae; Polaromonas.
OX   NCBI_TaxID=296591;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=JS666 / ATCC BAA-500;
RX   PubMed=18723656; DOI=10.1128/aem.00197-08;
RA   Mattes T.E., Alexander A.K., Richardson P.M., Munk A.C., Han C.S.,
RA   Stothard P., Coleman N.V.;
RT   ""The genome of Polaromonas sp. strain JS666: insights into the evolution of
RT   a hydrocarbon- and xenobiotic-degrading bacterium, and features of
RT   relevance to biotechnology."";
RL   Appl. Environ. Microbiol. 74:6405-6416(2008).
CC   -!- FUNCTION: Involved in transcription antitermination. Required for
CC       transcription of ribosomal RNA (rRNA) genes. Binds specifically to the
CC       boxA antiterminator sequence of the ribosomal RNA (rrn) operons.
CC       {ECO:0000255|HAMAP-Rule:MF_00073}.
CC   -!- SIMILARITY: Belongs to the NusB family. {ECO:0000255|HAMAP-
CC       Rule:MF_00073}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP000316; ABE44802.1; -; Genomic_DNA.
DR   AlphaFoldDB; Q129J0; -.
DR   SMR; Q129J0; -.
DR   STRING; 296591.Bpro_2887; -.
DR   KEGG; pol:Bpro_2887; -.
DR   eggNOG; COG0781; Bacteria.
DR   HOGENOM; CLU_087843_4_1_4; -.
DR   Proteomes; UP000001983; Chromosome.
DR   GO; GO:0005829; C:cytosol; IEA:TreeGrafter.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0006353; P:DNA-templated transcription termination; IEA:UniProtKB-UniRule.
DR   GO; GO:0031564; P:transcription antitermination; IEA:UniProtKB-KW.
DR   Gene3D; 1.10.940.10; NusB-like; 1.
DR   HAMAP; MF_00073; NusB; 1.
DR   InterPro; IPR035926; NusB-like_sf.
DR   InterPro; IPR011605; NusB_fam.
DR   InterPro; IPR006027; NusB_RsmB_TIM44.
DR   NCBIfam; TIGR01951; nusB; 1.
DR   PANTHER; PTHR11078:SF3; ANTITERMINATION NUSB DOMAIN-CONTAINING PROTEIN; 1.
DR   PANTHER; PTHR11078; N UTILIZATION SUBSTANCE PROTEIN B-RELATED; 1.
DR   Pfam; PF01029; NusB; 1.
DR   SUPFAM; SSF48013; NusB-like; 1.
PE   3: Inferred from homology;
KW   Reference proteome; RNA-binding; Transcription;
KW   Transcription antitermination; Transcription regulation.
FT   CHAIN           1..187
FT                   /note=""Transcription antitermination protein NusB""
FT                   /id=""PRO_0000265559""
FT   REGION          20..41
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
SQ   SEQUENCE   187 AA;  20754 MW;  68F5B713B6EDE2F1 CRC64;
     MHKPLFQKTF ITNRRFMAEP LNKPKRPPQI RTGLTDTGVK KAADKSARTR AREFALQALY
     QHLVGRNDAD SIDAFTRDLV GFHKADSAHY DALLHGCIEG ASALDAVITP LLDRPMAEIS
     PVEHAVLWMG AYEFRQCLDV PYRVVINECI ELAKAFGGTD GHKYVNGVLH KMAPSLRAAE
     VAADQTK
//
",55708
ATTCTG TTCTGT TCTGTG CTGTGC TGTGCC GTGCCT TGCCTG GCCTGC CCTGCT CTGCTC TGCTCG GCTCGA CTCGAG TCGAGT CGAGTC GAGTCC AGTCCA GTCCAT TCCATG CCATGA CATGAC ATGACG TGACGT GACGTC ACGTCC CGTCCG GTCCGG TCCGGC CCGGCA CGGCAG GGCAGC GCAGCT CAGCTA AGCTAC GCTACC CTACCG TACCGG ACCGGC CCGGCT CGGCTC GGCTCG GCTCGA CTCGAC TCGACG CGACGG GACGGT ACGGTG CGGTGA GGTGAA GTGAAG TGAAGC GAAGCG AAGCGG AGCGGT GCGGTA CGGTAC GGTACA GTACAG TACAGG ACAGGG CAGGGT AGGGTC GGGTCT GGTCTT GTCTTC TCTTCA CTTCAG TTCAGG TCAGGA CAGGAT AGGATG GGATGC GATGCC ATGCCG TGCCGC GCCGCG CCGCGC CGCGCT GCGCTG CGCTGA GCTGAC CTGACG TGACGC GACGCT ACGCTG CGCTGC GCTGCG CTGCGC TGCGCC GCGCCG CGCCGT GCCGTC CCGTCG CGTCGC GTCGCC TCGCCG CGCCGC GCCGCA CCGCAC CGCACG GCACGC CACGCT ACGCTG CGCTGG GCTGGG CTGGGG TGGGGT GGGGTT GGGTTT GGTTTG GTTTGT TTTGTC TTGTCT TGTCTT GTCTTC TCTTCC CTTCCA TTCCAG TCCAGT CCAGTT CAGTTC AGTTCC GTTCCA TTCCAC TCCACC CCACCA CACCAC ACCACC CCACCT CACCTG ACCTGC CCTGCT CTGCTG TGCTGC GCTGCC CTGCCC TGCCCG GCCCGC CCCGCG CCGCGT CGCGTT GCGTTC CGTTCT GTTCTC TTCTCG,2,145,ATTC TTCT TCTG CTGT TGTG GTGC TGCC GCCT CCTG CTGC TGCT GCTC CTCG TCGA CGAG GAGT AGTC GTCC TCCA CCAT CATG ATGA TGAC GACG ACGT CGTC GTCC TCCG CCGG CGGC GGCA GCAG CAGC AGCT GCTA CTAC TACC ACCG CCGG CGGC GGCT GCTC CTCG TCGA CGAC GACG ACGG CGGT GGTG GTGA TGAA GAAG AAGC AGCG GCGG CGGT GGTA GTAC TACA ACAG CAGG AGGG GGGT GGTC GTCT TCTT CTTC TTCA TCAG CAGG AGGA GGAT GATG ATGC TGCC GCCG CCGC CGCG GCGC CGCT GCTG CTGA TGAC GACG ACGC CGCT GCTG CTGC TGCG GCGC CGCC GCCG CCGT CGTC GTCG TCGC CGCC GCCG CCGC CGCA GCAC CACG ACGC CGCT GCTG CTGG TGGG GGGG GGGT GGTT GTTT TTTG TTGT TGTC GTCT TCTT CTTC TTCC TCCA CCAG CAGT AGTT GTTC TTCC TCCA CCAC CACC ACCA CCAC CACC ACCT CCTG CTGC TGCT GCTG CTGC TGCC GCCC CCCG CCGC CGCG GCGT CGTT GTTC TTCT TCTC CTCG,ATTCT TTCTG TCTGT CTGTG TGTGC GTGCC TGCCT GCCTG CCTGC CTGCT TGCTC GCTCG CTCGA TCGAG CGAGT GAGTC AGTCC GTCCA TCCAT CCATG CATGA ATGAC TGACG GACGT ACGTC CGTCC GTCCG TCCGG CCGGC CGGCA GGCAG GCAGC CAGCT AGCTA GCTAC CTACC TACCG ACCGG CCGGC CGGCT GGCTC GCTCG CTCGA TCGAC CGACG GACGG ACGGT CGGTG GGTGA GTGAA TGAAG GAAGC AAGCG AGCGG GCGGT CGGTA GGTAC GTACA TACAG ACAGG CAGGG AGGGT GGGTC GGTCT GTCTT TCTTC CTTCA TTCAG TCAGG CAGGA AGGAT GGATG GATGC ATGCC TGCCG GCCGC CCGCG CGCGC GCGCT CGCTG GCTGA CTGAC TGACG GACGC ACGCT CGCTG GCTGC CTGCG TGCGC GCGCC CGCCG GCCGT CCGTC CGTCG GTCGC TCGCC CGCCG GCCGC CCGCA CGCAC GCACG CACGC ACGCT CGCTG GCTGG CTGGG TGGGG GGGGT GGGTT GGTTT GTTTG TTTGT TTGTC TGTCT GTCTT TCTTC CTTCC TTCCA TCCAG CCAGT CAGTT AGTTC GTTCC TTCCA TCCAC CCACC CACCA ACCAC CCACC CACCT ACCTG CCTGC CTGCT TGCTG GCTGC CTGCC TGCCC GCCCG CCCGC CCGCG CGCGT GCGTT CGTTC GTTCT TTCTC TCTCG,ATTCTG TTCTGT TCTGTG CTGTGC TGTGCC GTGCCT TGCCTG GCCTGC CCTGCT CTGCTC TGCTCG GCTCGA CTCGAG TCGAGT CGAGTC GAGTCC AGTCCA GTCCAT TCCATG CCATGA CATGAC ATGACG TGACGT GACGTC ACGTCC CGTCCG GTCCGG TCCGGC CCGGCA CGGCAG GGCAGC GCAGCT CAGCTA AGCTAC GCTACC CTACCG TACCGG ACCGGC CCGGCT CGGCTC GGCTCG GCTCGA CTCGAC TCGACG CGACGG GACGGT ACGGTG CGGTGA GGTGAA GTGAAG TGAAGC GAAGCG AAGCGG AGCGGT GCGGTA CGGTAC GGTACA GTACAG TACAGG ACAGGG CAGGGT AGGGTC GGGTCT GGTCTT GTCTTC TCTTCA CTTCAG TTCAGG TCAGGA CAGGAT AGGATG GGATGC GATGCC ATGCCG TGCCGC GCCGCG CCGCGC CGCGCT GCGCTG CGCTGA GCTGAC CTGACG TGACGC GACGCT ACGCTG CGCTGC GCTGCG CTGCGC TGCGCC GCGCCG CGCCGT GCCGTC CCGTCG CGTCGC GTCGCC TCGCCG CGCCGC GCCGCA CCGCAC CGCACG GCACGC CACGCT ACGCTG CGCTGG GCTGGG CTGGGG TGGGGT GGGGTT GGGTTT GGTTTG GTTTGT TTTGTC TTGTCT TGTCTT GTCTTC TCTTCC CTTCCA TTCCAG TCCAGT CCAGTT CAGTTC AGTTCC GTTCCA TTCCAC TCCACC CCACCA CACCAC ACCACC CCACCT CACCTG ACCTGC CCTGCT CTGCTG TGCTGC GCTGCC CTGCCC TGCCCG GCCCGC CCCGCG CCGCGT CGCGTT GCGTTC CGTTCT GTTCTC TTCTCG,ATTCTGT TTCTGTG TCTGTGC CTGTGCC TGTGCCT GTGCCTG TGCCTGC GCCTGCT CCTGCTC CTGCTCG TGCTCGA GCTCGAG CTCGAGT TCGAGTC CGAGTCC GAGTCCA AGTCCAT GTCCATG TCCATGA CCATGAC CATGACG ATGACGT TGACGTC GACGTCC ACGTCCG CGTCCGG GTCCGGC TCCGGCA CCGGCAG CGGCAGC GGCAGCT GCAGCTA CAGCTAC AGCTACC GCTACCG CTACCGG TACCGGC ACCGGCT CCGGCTC CGGCTCG GGCTCGA GCTCGAC CTCGACG TCGACGG CGACGGT GACGGTG ACGGTGA CGGTGAA GGTGAAG GTGAAGC TGAAGCG GAAGCGG AAGCGGT AGCGGTA GCGGTAC CGGTACA GGTACAG GTACAGG TACAGGG ACAGGGT CAGGGTC AGGGTCT GGGTCTT GGTCTTC GTCTTCA TCTTCAG CTTCAGG TTCAGGA TCAGGAT CAGGATG AGGATGC GGATGCC GATGCCG ATGCCGC TGCCGCG GCCGCGC CCGCGCT CGCGCTG GCGCTGA CGCTGAC GCTGACG CTGACGC TGACGCT GACGCTG ACGCTGC CGCTGCG GCTGCGC CTGCGCC TGCGCCG GCGCCGT CGCCGTC GCCGTCG CCGTCGC CGTCGCC GTCGCCG TCGCCGC CGCCGCA GCCGCAC CCGCACG CGCACGC GCACGCT CACGCTG ACGCTGG CGCTGGG GCTGGGG CTGGGGT TGGGGTT GGGGTTT GGGTTTG GGTTTGT GTTTGTC TTTGTCT TTGTCTT TGTCTTC GTCTTCC TCTTCCA CTTCCAG TTCCAGT TCCAGTT CCAGTTC CAGTTCC AGTTCCA GTTCCAC TTCCACC TCCACCA CCACCAC CACCACC ACCACCT CCACCTG CACCTGC ACCTGCT CCTGCTG CTGCTGC TGCTGCC GCTGCCC CTGCCCG TGCCCGC GCCCGCG CCCGCGT CCGCGTT CGCGTTC GCGTTCT CGTTCTC GTTCTCG,"ID   LOLD_BORA1              Reviewed;         230 AA.
AC   Q2L219;
DT   23-JAN-2007, integrated into UniProtKB/Swiss-Prot.
DT   07-MAR-2006, sequence version 1.
DT   05-FEB-2025, entry version 105.
DE   RecName: Full=Lipoprotein-releasing system ATP-binding protein LolD {ECO:0000255|HAMAP-Rule:MF_01708};
DE            EC=7.6.2.- {ECO:0000255|HAMAP-Rule:MF_01708};
GN   Name=lolD {ECO:0000255|HAMAP-Rule:MF_01708};
GN   OrderedLocusNames=BAV1523;
OS   Bordetella avium (strain 197N).
OC   Bacteria; Pseudomonadota; Betaproteobacteria; Burkholderiales;
OC   Alcaligenaceae; Bordetella.
OX   NCBI_TaxID=360910;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=197N;
RX   PubMed=16885469; DOI=10.1128/jb.01927-05;
RA   Sebaihia M., Preston A., Maskell D.J., Kuzmiak H., Connell T.D., King N.D.,
RA   Orndorff P.E., Miyamoto D.M., Thomson N.R., Harris D., Goble A., Lord A.,
RA   Murphy L., Quail M.A., Rutter S., Squares R., Squares S., Woodward J.,
RA   Parkhill J., Temple L.M.;
RT   ""Comparison of the genome sequence of the poultry pathogen Bordetella avium
RT   with those of B. bronchiseptica, B. pertussis, and B. parapertussis reveals
RT   extensive diversity in surface structures associated with host
RT   interaction."";
RL   J. Bacteriol. 188:6002-6015(2006).
CC   -!- FUNCTION: Part of the ABC transporter complex LolCDE involved in the
CC       translocation of mature outer membrane-directed lipoproteins, from the
CC       inner membrane to the periplasmic chaperone, LolA. Responsible for the
CC       formation of the LolA-lipoprotein complex in an ATP-dependent manner.
CC       {ECO:0000255|HAMAP-Rule:MF_01708}.
CC   -!- SUBUNIT: The complex is composed of two ATP-binding proteins (LolD) and
CC       two transmembrane proteins (LolC and LolE). {ECO:0000255|HAMAP-
CC       Rule:MF_01708}.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane {ECO:0000255|HAMAP-
CC       Rule:MF_01708}; Peripheral membrane protein {ECO:0000255|HAMAP-
CC       Rule:MF_01708}.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily. Lipoprotein
CC       translocase (TC 3.A.1.125) family. {ECO:0000255|HAMAP-Rule:MF_01708}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AM167904; CAJ49136.1; -; Genomic_DNA.
DR   RefSeq; WP_012417200.1; NC_010645.1.
DR   AlphaFoldDB; Q2L219; -.
DR   SMR; Q2L219; -.
DR   STRING; 360910.BAV1523; -.
DR   GeneID; 92935412; -.
DR   KEGG; bav:BAV1523; -.
DR   eggNOG; COG1136; Bacteria.
DR   HOGENOM; CLU_000604_1_22_4; -.
DR   OrthoDB; 9802264at2; -.
DR   Proteomes; UP000001977; Chromosome.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:InterPro.
DR   GO; GO:0022857; F:transmembrane transporter activity; IEA:TreeGrafter.
DR   GO; GO:0044874; P:lipoprotein localization to outer membrane; IEA:TreeGrafter.
DR   GO; GO:0089705; P:protein localization to outer membrane; IEA:TreeGrafter.
DR   CDD; cd03255; ABC_MJ0796_LolCDE_FtsE; 1.
DR   FunFam; 3.40.50.300:FF:000230; Lipoprotein-releasing system ATP-binding protein LolD; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR003439; ABC_transporter-like_ATP-bd.
DR   InterPro; IPR017871; ABC_transporter-like_CS.
DR   InterPro; IPR015854; ABC_transpr_LolD-like.
DR   InterPro; IPR017911; MacB-like_ATP-bd.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR24220; IMPORT ATP-BINDING PROTEIN; 1.
DR   PANTHER; PTHR24220:SF689; LIPOPROTEIN-RELEASING SYSTEM ATP-BINDING PROTEIN LOLD; 1.
DR   Pfam; PF00005; ABC_tran; 1.
DR   SMART; SM00382; AAA; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 1.
DR   PROSITE; PS51244; LOLD; 1.
PE   3: Inferred from homology;
KW   ATP-binding; Cell inner membrane; Cell membrane; Membrane;
KW   Nucleotide-binding; Reference proteome; Translocase; Transport.
FT   CHAIN           1..230
FT                   /note=""Lipoprotein-releasing system ATP-binding protein
FT                   LolD""
FT                   /id=""PRO_0000272062""
FT   DOMAIN          10..228
FT                   /note=""ABC transporter""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01708""
FT   BINDING         46..53
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01708""
SQ   SEQUENCE   230 AA;  24749 MW;  02DB3670014CB7D2 CRC64;
     MTDTSLQAAL RAEHLSKVYD EGPARIQVLD DVSLTVARGE MVAIVGASGS GKSTLLHILG
     LLDVPTSGSL VVDGTATEGL SEARKSAVRN RSLGFVYQFH HLLPEFSALD NVAMPLIVRR
     MDRDQARLQA REVLGLVGLA AREGHYPGQL SGGERQRVAL ARALVTRPAC VLADEPTGNL
     DRQTAQNMFE LLSRVNRESG TAFAIVTHDP ELAARADRQL HMANGRLLPG
//
",30451
AGTCGC GTCGCA TCGCAA CGCAAC GCAACA CAACAG AACAGT ACAGTT CAGTTC AGTTCA GTTCAA TTCAAG TCAAGA CAAGAA AAGAAA AGAAAT GAAATT AAATTC AATTCA ATTCAA TTCAAC TCAACT CAACTC AACTCC ACTCCA CTCCAG TCCAGG CCAGGC CAGGCA AGGCAG GGCAGC GCAGCA CAGCAG AGCAGT GCAGTA CAGTAA AGTAAA GTAAAC TAAACG AAACGA AACGAA ACGAAC CGAACT GAACTT AACTTC ACTTCT CTTCTC TTCTCC TCTCCT CTCCTG TCCTGC CCTGCT CTGCTA TGCTAG GCTAGA CTAGAA TAGAAT AGAATG GAATGG AATGGC ATGGCT TGGCTG GGCTGG GCTGGC CTGGCA TGGCAA GGCAAT GCAATG CAATGG AATGGC ATGGCG TGGCGG GGCGGT GCGGTG CGGTGA GGTGAT GTGATG TGATGC GATGCT ATGCTG TGCTGC GCTGCT CTGCTC TGCTCT GCTCTT CTCTTG TCTTGC CTTGCT TTGCTT TGCTTT GCTTTG CTTTGC TTTGCT TTGCTG TGCTGC GCTGCT CTGCTG TGCTGC GCTGCT CTGCTT TGCTTG GCTTGA CTTGAT TTGATA TGATAG GATAGA ATAGAT TAGATT AGATTG GATTGA ATTGAA TTGAAC TGAACC GAACCA AACCAG ACCAGC CCAGCT CAGCTT AGCTTG GCTTGT CTTGTG TTGTGC TGTGCT GTGCTG TGCTGT GCTGTC CTGTCT TGTCTC GTCTCT TCTCTT CTCTTA TCTTAT CTTATA TTATAC TATACA ATACAC TACACA ACACAC CACACT ACACTT CACTTC ACTTCC CTTCCG TTCCGG TCCGGG,1,145,AGTC GTCG TCGC CGCA GCAA CAAC AACA ACAG CAGT AGTT GTTC TTCA TCAA CAAG AAGA AGAA GAAA AAAT AATT ATTC TTCA TCAA CAAC AACT ACTC CTCC TCCA CCAG CAGG AGGC GGCA GCAG CAGC AGCA GCAG CAGT AGTA GTAA TAAA AAAC AACG ACGA CGAA GAAC AACT ACTT CTTC TTCT TCTC CTCC TCCT CCTG CTGC TGCT GCTA CTAG TAGA AGAA GAAT AATG ATGG TGGC GGCT GCTG CTGG TGGC GGCA GCAA CAAT AATG ATGG TGGC GGCG GCGG CGGT GGTG GTGA TGAT GATG ATGC TGCT GCTG CTGC TGCT GCTC CTCT TCTT CTTG TTGC TGCT GCTT CTTT TTTG TTGC TGCT GCTG CTGC TGCT GCTG CTGC TGCT GCTT CTTG TTGA TGAT GATA ATAG TAGA AGAT GATT ATTG TTGA TGAA GAAC AACC ACCA CCAG CAGC AGCT GCTT CTTG TTGT TGTG GTGC TGCT GCTG CTGT TGTC GTCT TCTC CTCT TCTT CTTA TTAT TATA ATAC TACA ACAC CACA ACAC CACT ACTT CTTC TTCC TCCG CCGG CGGG,AGTCG GTCGC TCGCA CGCAA GCAAC CAACA AACAG ACAGT CAGTT AGTTC GTTCA TTCAA TCAAG CAAGA AAGAA AGAAA GAAAT AAATT AATTC ATTCA TTCAA TCAAC CAACT AACTC ACTCC CTCCA TCCAG CCAGG CAGGC AGGCA GGCAG GCAGC CAGCA AGCAG GCAGT CAGTA AGTAA GTAAA TAAAC AAACG AACGA ACGAA CGAAC GAACT AACTT ACTTC CTTCT TTCTC TCTCC CTCCT TCCTG CCTGC CTGCT TGCTA GCTAG CTAGA TAGAA AGAAT GAATG AATGG ATGGC TGGCT GGCTG GCTGG CTGGC TGGCA GGCAA GCAAT CAATG AATGG ATGGC TGGCG GGCGG GCGGT CGGTG GGTGA GTGAT TGATG GATGC ATGCT TGCTG GCTGC CTGCT TGCTC GCTCT CTCTT TCTTG CTTGC TTGCT TGCTT GCTTT CTTTG TTTGC TTGCT TGCTG GCTGC CTGCT TGCTG GCTGC CTGCT TGCTT GCTTG CTTGA TTGAT TGATA GATAG ATAGA TAGAT AGATT GATTG ATTGA TTGAA TGAAC GAACC AACCA ACCAG CCAGC CAGCT AGCTT GCTTG CTTGT TTGTG TGTGC GTGCT TGCTG GCTGT CTGTC TGTCT GTCTC TCTCT CTCTT TCTTA CTTAT TTATA TATAC ATACA TACAC ACACA CACAC ACACT CACTT ACTTC CTTCC TTCCG TCCGG CCGGG,AGTCGC GTCGCA TCGCAA CGCAAC GCAACA CAACAG AACAGT ACAGTT CAGTTC AGTTCA GTTCAA TTCAAG TCAAGA CAAGAA AAGAAA AGAAAT GAAATT AAATTC AATTCA ATTCAA TTCAAC TCAACT CAACTC AACTCC ACTCCA CTCCAG TCCAGG CCAGGC CAGGCA AGGCAG GGCAGC GCAGCA CAGCAG AGCAGT GCAGTA CAGTAA AGTAAA GTAAAC TAAACG AAACGA AACGAA ACGAAC CGAACT GAACTT AACTTC ACTTCT CTTCTC TTCTCC TCTCCT CTCCTG TCCTGC CCTGCT CTGCTA TGCTAG GCTAGA CTAGAA TAGAAT AGAATG GAATGG AATGGC ATGGCT TGGCTG GGCTGG GCTGGC CTGGCA TGGCAA GGCAAT GCAATG CAATGG AATGGC ATGGCG TGGCGG GGCGGT GCGGTG CGGTGA GGTGAT GTGATG TGATGC GATGCT ATGCTG TGCTGC GCTGCT CTGCTC TGCTCT GCTCTT CTCTTG TCTTGC CTTGCT TTGCTT TGCTTT GCTTTG CTTTGC TTTGCT TTGCTG TGCTGC GCTGCT CTGCTG TGCTGC GCTGCT CTGCTT TGCTTG GCTTGA CTTGAT TTGATA TGATAG GATAGA ATAGAT TAGATT AGATTG GATTGA ATTGAA TTGAAC TGAACC GAACCA AACCAG ACCAGC CCAGCT CAGCTT AGCTTG GCTTGT CTTGTG TTGTGC TGTGCT GTGCTG TGCTGT GCTGTC CTGTCT TGTCTC GTCTCT TCTCTT CTCTTA TCTTAT CTTATA TTATAC TATACA ATACAC TACACA ACACAC CACACT ACACTT CACTTC ACTTCC CTTCCG TTCCGG TCCGGG,AGTCGCA GTCGCAA TCGCAAC CGCAACA GCAACAG CAACAGT AACAGTT ACAGTTC CAGTTCA AGTTCAA GTTCAAG TTCAAGA TCAAGAA CAAGAAA AAGAAAT AGAAATT GAAATTC AAATTCA AATTCAA ATTCAAC TTCAACT TCAACTC CAACTCC AACTCCA ACTCCAG CTCCAGG TCCAGGC CCAGGCA CAGGCAG AGGCAGC GGCAGCA GCAGCAG CAGCAGT AGCAGTA GCAGTAA CAGTAAA AGTAAAC GTAAACG TAAACGA AAACGAA AACGAAC ACGAACT CGAACTT GAACTTC AACTTCT ACTTCTC CTTCTCC TTCTCCT TCTCCTG CTCCTGC TCCTGCT CCTGCTA CTGCTAG TGCTAGA GCTAGAA CTAGAAT TAGAATG AGAATGG GAATGGC AATGGCT ATGGCTG TGGCTGG GGCTGGC GCTGGCA CTGGCAA TGGCAAT GGCAATG GCAATGG CAATGGC AATGGCG ATGGCGG TGGCGGT GGCGGTG GCGGTGA CGGTGAT GGTGATG GTGATGC TGATGCT GATGCTG ATGCTGC TGCTGCT GCTGCTC CTGCTCT TGCTCTT GCTCTTG CTCTTGC TCTTGCT CTTGCTT TTGCTTT TGCTTTG GCTTTGC CTTTGCT TTTGCTG TTGCTGC TGCTGCT GCTGCTG CTGCTGC TGCTGCT GCTGCTT CTGCTTG TGCTTGA GCTTGAT CTTGATA TTGATAG TGATAGA GATAGAT ATAGATT TAGATTG AGATTGA GATTGAA ATTGAAC TTGAACC TGAACCA GAACCAG AACCAGC ACCAGCT CCAGCTT CAGCTTG AGCTTGT GCTTGTG CTTGTGC TTGTGCT TGTGCTG GTGCTGT TGCTGTC GCTGTCT CTGTCTC TGTCTCT GTCTCTT TCTCTTA CTCTTAT TCTTATA CTTATAC TTATACA TATACAC ATACACA TACACAC ACACACT CACACTT ACACTTC CACTTCC ACTTCCG CTTCCGG TTCCGGG,"ID   NCAP_SARS2              Reviewed;         419 AA.
AC   P0DTC9;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Nucleoprotein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=N;
DE   AltName: Full=Nucleocapsid protein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=NC {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=Protein N {ECO:0000255|HAMAP-Rule:MF_04096};
GN   Name=N {ECO:0000255|HAMAP-Rule:MF_04096};
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   SUBCELLULAR LOCATION.
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [3] {ECO:0007744|PDB:6WZO, ECO:0007744|PDB:6WZQ}
RP   X-RAY CRYSTALLOGRAPHY (1.42 ANGSTROMS) OF 247-364, AND SUBUNIT.
RX   PubMed=32654247; DOI=10.1002/pro.3909;
RA   Ye Q., West A.M.V., Silletti S., Corbett K.D.;
RT   ""Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein."";
RL   Protein Sci. 29:1890-1901(2020).
RN   [4]
RP   REVIEW.
RX   PubMed=32974389; DOI=10.3389/fmolb.2020.00219;
RA   Nikolakaki E., Giannakouros T.;
RT   ""SR/RS Motifs as Critical Determinants of Coronavirus Life Cycle."";
RL   Front. Mol. Biosci. 7:219-219(2020).
RN   [5]
RP   VARIANTS LEU-3 AND PHE-235.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [6]
RP   FUNCTION, INTERACTION WITH HOST NLRP3, AND SUBCELLULAR LOCATION.
RX   PubMed=34341353; DOI=10.1038/s41467-021-25015-6;
RA   Pan P., Shen M., Yu Z., Ge W., Chen K., Tian M., Xiao F., Wang Z., Wang J.,
RA   Jia Y., Wang W., Wan P., Zhang J., Chen W., Lei Z., Chen X., Luo Z.,
RA   Zhang Q., Xu M., Li G., Li Y., Wu J.;
RT   ""SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce
RT   hyperinflammation."";
RL   Nat. Commun. 12:4664-4664(2021).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 41-174, AND MUTAGENESIS OF
RP   TYR-109.
RX   PubMed=32363136; DOI=10.1016/j.apsb.2020.04.009;
RA   Kang S., Yang M., Hong Z., Zhang L., Huang Z., Chen X., He S., Zhou Z.,
RA   Zhou Z., Chen Q., Yan Y., Zhang C., Shan H., Chen S.;
RT   ""Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain
RT   reveals potential unique drug targeting sites."";
RL   Acta Pharmacol. Sin. 10:1228-1238(2020).
RN   [8] {ECO:0007744|PDB:6YI3, ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT}
RP   STRUCTURE BY NMR OF 44-180, FUNCTION, AND MUTAGENESIS OF ARG-68; ARG-92;
RP   ILE-94; ARG-107; GLN-163; TYR-172 AND GLU-174.
RX   PubMed=33264373; DOI=10.1371/journal.ppat.1009100;
RA   Dinesh D.C., Chalupska D., Silhan J., Koutna E., Nencka R., Veverka V.,
RA   Boura E.;
RT   ""Structural basis of RNA recognition by the SARS-CoV-2 nucleocapsid
RT   phosphoprotein."";
RL   PLoS Pathog. 16:1-16(2020).
RN   [9]
RP   MUTAGENESIS OF SER-188 AND SER-206, AND PHOSPHORYLATION AT SER-206.
RX   PubMed=34593624; DOI=10.1073/pnas.2113401118;
RA   Liu X., Verma A., Garcia G. Jr., Ramage H., Lucas A., Myers R.L.,
RA   Michaelson J.J., Coryell W., Kumar A., Charney A.W., Kazanietz M.G.,
RA   Rader D.J., Ritchie M.D., Berrettini W.H., Schultz D.C., Cherry S.,
RA   Damoiseaux R., Arumugaswami V., Klein P.S.;
RT   ""Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:1-9(2021).
RN   [10]
RP   CLEAVAGE.
RX   PubMed=35922005; DOI=10.1038/s41586-022-05148-4;
RA   Chu H., Hou Y., Yang D., Wen L., Shuai H., Yoon C., Shi J., Chai Y.,
RA   Yuen T.T., Hu B., Li C., Zhao X., Wang Y., Huang X., Lee K.S., Luo C.,
RA   Cai J.P., Poon V.K., Chan C.C., Zhang A.J., Yuan S., Sit K.Y., Foo D.C.,
RA   Au W.K., Wong K.K., Zhou J., Kok K.H., Jin D.Y., Chan J.F., Yuen K.Y.;
RT   ""Coronaviruses exploit a host cysteine-aspartic protease for replication."";
RL   Nature 0:0-0(2022).
RN   [11]
RP   MUTAGENESIS OF 203-ARG-GLY-204 AND ARG-203, AND PHOSPHORYLATION.
RX   PubMed=35728038; DOI=10.1371/journal.ppat.1010627;
RA   Johnson B.A., Zhou Y., Lokugamage K.G., Vu M.N., Bopp N.,
RA   Crocquet-Valdes P.A., Kalveram B., Schindewolf C., Liu Y., Scharton D.,
RA   Plante J.A., Xie X., Aguilar P., Weaver S.C., Shi P.Y., Walker D.H.,
RA   Routh A.L., Plante K.S., Menachery V.D.;
RT   ""Nucleocapsid mutations in SARS-CoV-2 augment replication and
RT   pathogenesis."";
RL   PLoS Pathog. 18:e1010627-e1010627(2022).
RN   [12]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=35921414; DOI=10.1126/sciadv.abp9770;
RA   Lopez-Munoz A.D., Kosik I., Holly J., Yewdell J.W.;
RT   ""Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive
RT   immunity."";
RL   Sci. Adv. 8:eabp9770-eabp9770(2022).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=34901782; DOI=10.1016/j.isci.2021.103562;
RA   Nabeel-Shah S., Lee H., Ahmed N., Burke G.L., Farhangmehr S., Ashraf K.,
RA   Pu S., Braunschweig U., Zhong G., Wei H., Tang H., Yang J., Marcon E.,
RA   Blencowe B.J., Zhang Z., Greenblatt J.F.;
RT   ""SARS-CoV-2 nucleocapsid protein binds host mRNAs and attenuates stress
RT   granules to impair host stress response."";
RL   IScience 25:103562-103562(2022).
RN   [14]
RP   FUNCTION.
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [15] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 191-263, AND INTERACTION WITH NSP3.
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
CC   -!- FUNCTION: Packages the positive strand viral genome RNA into a helical
CC       ribonucleocapsid (RNP) and plays a fundamental role during virion
CC       assembly through its interactions with the viral genome and membrane
CC       protein M (PubMed:33264373). Plays an important role in enhancing the
CC       efficiency of subgenomic viral RNA transcription as well as viral
CC       replication. Attenuates the stress granules formation by reducing host
CC       G3BP1 access to host mRNAs under stress conditions (PubMed:34901782,
CC       PubMed:36534661). {ECO:0000269|PubMed:32974389,
CC       ECO:0000269|PubMed:33264373, ECO:0000269|PubMed:34901782,
CC       ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: May block host chemokine function in vivo, facilitating viral
CC       replication and transmission (PubMed:35921414). Acts by being secreted
CC       into the extracellular space where it competes to host chemokines for
CC       binding to host glycosaminoglycans (GAG) (PubMed:35921414).
CC       {ECO:0000269|PubMed:35921414}.
CC   -!- FUNCTION: May induce inflammasome responses in cultured cells and mice.
CC       Acts by interacting with host NLRP3 to facilitate inflammasome
CC       assembly, which induces cytokine release that may play a role in COVID
CC       lung injury. {ECO:0000269|PubMed:34341353}.
CC   -!- SUBUNIT: Homodimer, homotetramer, homooligomer with RNA
CC       (PubMed:32654247). Both monomeric and oligomeric forms interact with
CC       RNA. Interacts with protein M (By similarity). Interacts with protein E
CC       (By similarity). Interacts with NSP3; this interaction serves to tether
CC       the genome to the newly translated replicase-transcriptase complex at a
CC       very early stage of infection (PubMed:35044811). May interact with host
CC       NLRP3 (PubMed:34341353). {ECO:0000250|UniProtKB:P59595,
CC       ECO:0000255|HAMAP-Rule:MF_04096, ECO:0000269|PubMed:32654247,
CC       ECO:0000269|PubMed:34341353, ECO:0000269|PubMed:35044811}.
CC   -!- INTERACTION:
CC       P0DTC9; P0DTC4: E; NbExp=3; IntAct=EBI-25475856, EBI-25475850;
CC       P0DTC9; P0DTC5: M; NbExp=6; IntAct=EBI-25475856, EBI-25475853;
CC       P0DTC9; P0DTC9: N; NbExp=105; IntAct=EBI-25475856, EBI-25475856;
CC       P0DTC9; PRO_0000449621 [P0DTD1]: rep; NbExp=15; IntAct=EBI-25475856, EBI-25492388;
CC       P0DTC9; P78563: ADARB1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-2967304;
CC       P0DTC9; O15145: ARPC3; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-351829;
CC       P0DTC9; Q13895: BYSL; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-358049;
CC       P0DTC9; Q16543: CDC37; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-295634;
CC       P0DTC9; Q92793: CREBBP; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-81215;
CC       P0DTC9; Q92499: DDX1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-358474;
CC       P0DTC9; Q9NR30: DDX21; Xeno; NbExp=12; IntAct=EBI-25475856, EBI-357942;
CC       P0DTC9; P26196: DDX6; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-351257;
CC       P0DTC9; Q08426: EHHADH; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-2339219;
CC       P0DTC9; P19525: EIF2AK2; Xeno; NbExp=8; IntAct=EBI-25475856, EBI-640775;
CC       P0DTC9; Q14241: ELOA; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-742350;
CC       P0DTC9; Q13283: G3BP1; Xeno; NbExp=71; IntAct=EBI-25475856, EBI-1047359;
CC       P0DTC9; Q9UN86: G3BP2; Xeno; NbExp=37; IntAct=EBI-25475856, EBI-1044298;
CC       P0DTC9; P57764: GSDMD; Xeno; NbExp=13; IntAct=EBI-25475856, EBI-2798865;
CC       P0DTC9; P49841: GSK3B; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-373586;
CC       P0DTC9; P10412: H1-4; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-358163;
CC       P0DTC9; O14920: IKBKB; Xeno; NbExp=7; IntAct=EBI-25475856, EBI-81266;
CC       P0DTC9; Q92830: KAT2A; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-477622;
CC       P0DTC9; Q92831: KAT2B; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-477430;
CC       P0DTC9; Q07866: KLC1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-721019;
CC       P0DTC9; Q9H0B6: KLC2; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-726994;
CC       P0DTC9; Q9NSK0: KLC4; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-949319;
CC       P0DTC9; Q9NX58: LYAR; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-713507;
CC       P0DTC9; O43318: MAP3K7; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-358684;
CC       P0DTC9; Q9UBU8: MORF4L1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-399246;
CC       P0DTC9; Q15014: MORF4L2; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-399257;
CC       P0DTC9; Q9HCE1: MOV10; Xeno; NbExp=11; IntAct=EBI-25475856, EBI-1055820;
CC       P0DTC9; Q9HC36: MRM3; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-1045440;
CC       P0DTC9; O15226: NKRF; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-766011;
CC       P0DTC9; Q96P20: NLRP3; Xeno; NbExp=18; IntAct=EBI-25475856, EBI-6253230;
CC       P0DTC9; O15118: NPC1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-2368710;
CC       P0DTC9; Q96HA8: NTAQ1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-741158;
CC       P0DTC9; P11940: PABPC1; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-81531;
CC       P0DTC9; P62937: PPIA; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-437708;
CC       P0DTC9; O75569: PRKRA; Xeno; NbExp=8; IntAct=EBI-25475856, EBI-713955;
CC       P0DTC9; Q99873: PRMT1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-78738;
CC       P0DTC9; P61289: PSME3; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-355546;
CC       P0DTC9; P26022: PTX3; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-11574553;
CC       P0DTC9; P54727: RAD23B; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-954531;
CC       P0DTC9; O95786: RIGI; Xeno; NbExp=15; IntAct=EBI-25475856, EBI-995350;
CC       P0DTC9; P62899: RPL31; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-1053664;
CC       P0DTC9; P62753: RPS6; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-356625;
CC       P0DTC9; P37840: SNCA; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-985879;
CC       P0DTC9; Q96SB4: SRPK1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-539478;
CC       P0DTC9; P78362: SRPK2; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-593303;
CC       P0DTC9; P42224: STAT1; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-1057697;
CC       P0DTC9; P52630: STAT2; Xeno; NbExp=7; IntAct=EBI-25475856, EBI-1546963;
CC       P0DTC9; Q15633: TARBP2; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-978581;
CC       P0DTC9; Q14258: TRIM25; Xeno; NbExp=13; IntAct=EBI-25475856, EBI-2341129;
CC       P0DTC9; O60763: USO1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-356164;
CC       P0DTC9; Q93008: USP9X; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-302524;
CC   -!- SUBCELLULAR LOCATION: Virion {ECO:0000255|HAMAP-Rule:MF_04096}. Host
CC       cytoplasm {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:34341353}.
CC       Secreted {ECO:0000269|PubMed:35921414}. Host extracellular space
CC       {ECO:0000269|PubMed:35921414}. Note=Probably associates with ER-derived
CC       membranes where it participates in viral RNA synthesis and virus
CC       budding. When located inside the virion, complexed with the viral RNA.
CC       Can be secreted by unconventional protein secretion (UPS)
CC       (PubMed:35921414). When secreted, can bind to host glycosaminoglycans
CC       on infected and non infected cells (PubMed:35921414). Found in host
CC       cytoplasmic stress granules (PubMed:34901782). {ECO:0000255|HAMAP-
CC       Rule:MF_04096, ECO:0000269|PubMed:34901782,
CC       ECO:0000269|PubMed:35921414}.
CC   -!- PTM: ADP-ribosylated. The ADP-ribosylation is retained in the virion
CC       during infection. {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   -!- PTM: Phosphorylated on serine residues by host GSK3A and GSK3B
CC       (PubMed:34593624, PubMed:35728038). This promotes the solubility of
CC       homodimers that would otherwise aggregate (PubMed:32974389). Host
CC       phosphatase would dephosphorylate the protein during assembly at M
CC       bound membranes (PubMed:32974389). {ECO:0000269|PubMed:34593624,
CC       ECO:0000269|PubMed:35728038, ECO:0000305|PubMed:32974389}.
CC   -!- PTM: Proteolytically cleaved by host CASP6. The cleavage leads to two
CC       fragments and facilitates viral replication by inhibiting host IFN
CC       signaling. The two fragments may interact with IRF3 inhibiting its
CC       nuclear translocation after activation and reduce the expression of
CC       IFNB and IFN-stimulated genes. {ECO:0000269|PubMed:35922005}.
CC   -!- POLYMORPHISM: Variant Alpha/B.1.1.7 belongs to a lineage isolated first
CC       in United Kingdom (December 2020). It is also called Variant of Concern
CC       (VOC) 202012/01, Variant Under Investigation (VUI) 202012/01, 501Y.V1
CC       or 20B/501Y.V1. {ECO:0000305|PubMed:33413740}.
CC   -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC       isolated in South Africa (November 2021). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC       isolated in Nigeria (November 2022). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC       isolated in United States (November 2022). It is the result of
CC       recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC       express ORF8. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the betacoronavirus nucleocapsid protein family.
CC       {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43423.2; -; Genomic_RNA.
DR   PDB; 6M3M; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 6VYO; X-ray; 1.70 A; A/B/C/D=47-173.
DR   PDB; 6WJI; X-ray; 2.05 A; A/B/C/D/E/F=257-364.
DR   PDB; 6WKP; X-ray; 2.67 A; A/B/C/D=47-173.
DR   PDB; 6WZO; X-ray; 1.42 A; A/B/C/D=247-364.
DR   PDB; 6WZQ; X-ray; 1.45 A; A/B/C/D=247-364.
DR   PDB; 6YI3; NMR; -; A=44-180.
DR   PDB; 6YUN; X-ray; 1.44 A; A/B=249-364.
DR   PDB; 6ZCO; X-ray; 1.36 A; A=247-364.
DR   PDB; 7ACS; NMR; -; A=44-180.
DR   PDB; 7ACT; NMR; -; A=44-180.
DR   PDB; 7C22; X-ray; 2.00 A; A/B/C/D=248-364.
DR   PDB; 7CDZ; X-ray; 1.80 A; A/B/C/D=44-174.
DR   PDB; 7CE0; X-ray; 1.50 A; A/B/C/D=255-364.
DR   PDB; 7CR5; X-ray; 2.08 A; A=41-174.
DR   PDB; 7DE1; X-ray; 2.00 A; A/B=250-364.
DR   PDB; 7F2B; X-ray; 2.00 A; A/B=257-362.
DR   PDB; 7F2E; X-ray; 3.10 A; A/B/C/D/E/F/G/H/I/J/K/L=255-362.
DR   PDB; 7KGO; X-ray; 2.15 A; C=351-359.
DR   PDB; 7KGP; X-ray; 1.40 A; C=316-324.
DR   PDB; 7KGQ; X-ray; 1.34 A; C=222-230.
DR   PDB; 7KGR; X-ray; 1.55 A; C=159-167.
DR   PDB; 7KGS; X-ray; 1.58 A; C=138-146.
DR   PDB; 7KGT; X-ray; 1.90 A; C=226-234.
DR   PDB; 7LGD; X-ray; 2.88 A; E/F=105-113.
DR   PDB; 7LTU; X-ray; 1.12 A; A/B=217-222.
DR   PDB; 7LUX; X-ray; 1.30 A; A=217-222.
DR   PDB; 7LUZ; X-ray; 1.10 A; A=243-248.
DR   PDB; 7LV2; X-ray; 1.30 A; A=179-184.
DR   PDB; 7N0I; X-ray; 2.20 A; A/B/C/D/E/F/G/H=269-364.
DR   PDB; 7N0R; X-ray; 1.42 A; A/B=49-174.
DR   PDB; 7N3C; X-ray; 1.82 A; C=47-173.
DR   PDB; 7N3D; X-ray; 1.53 A; C=47-173.
DR   PDB; 7O05; X-ray; 1.94 A; A/B/C/D=247-364.
DR   PDB; 7O35; X-ray; 1.80 A; A/B/C/D=247-364.
DR   PDB; 7O36; X-ray; 2.00 A; A/B/C/D=247-364.
DR   PDB; 7PKU; NMR; -; B=191-263.
DR   PDB; 7QIK; X-ray; 2.01 A; E/F=193-200.
DR   PDB; 7QIP; X-ray; 2.65 A; C/D=201-210.
DR   PDB; 7R98; X-ray; 2.51 A; A/B/C=49-174.
DR   PDB; 7SD4; NMR; -; A=40-174.
DR   PDB; 7STR; X-ray; 1.50 A; C=47-173.
DR   PDB; 7STS; X-ray; 2.16 A; C/D=47-173.
DR   PDB; 7SUE; X-ray; 2.90 A; C/D/J/K=47-173.
DR   PDB; 7SUO; X-ray; 2.35 A; C/D=12-22.
DR   PDB; 7UW3; X-ray; 1.70 A; A/B/C/D=40-174.
DR   PDB; 7UXX; X-ray; 1.85 A; AAA/BBB/CCC/DDD/EEE/FFF=251-364.
DR   PDB; 7UXZ; X-ray; 1.73 A; AAA/BBB/CCC/DDD/EEE/FFF=251-364.
DR   PDB; 7VBD; X-ray; 1.94 A; A/B/C/D=48-174.
DR   PDB; 7VBE; X-ray; 1.59 A; A/B=257-364.
DR   PDB; 7VBF; X-ray; 1.30 A; A/B=255-364.
DR   PDB; 7VNU; X-ray; 1.95 A; A/B/C/D=47-174.
DR   PDB; 7WKJ; X-ray; 1.50 A; C=361-369.
DR   PDB; 7WZO; X-ray; 2.64 A; A=47-174.
DR   PDB; 7XWX; X-ray; 3.00 A; A/B/C/D/E/F/G/H=269-367.
DR   PDB; 7XWZ; X-ray; 2.25 A; A/B=48-172.
DR   PDB; 7XX1; X-ray; 1.90 A; A/B/C/D=49-173.
DR   PDB; 7XXK; X-ray; 2.00 A; A/B/C/D/E/F=248-364.
DR   PDB; 7YLB; X-ray; 2.41 A; A/B/C/D/G/H/J/K=247-364.
DR   PDB; 7YLD; X-ray; 2.80 A; A/B/C/D=47-174.
DR   PDB; 7ZIT; X-ray; 1.79 A; C/D=194-200.
DR   PDB; 8DNT; X-ray; 3.18 A; D/J/Q/X=222-230.
DR   PDB; 8FD5; EM; 4.57 A; A=1-419.
DR   PDB; 8FG2; EM; 6.00 A; A/B=1-419.
DR   PDB; 8IQJ; X-ray; 2.30 A; A/B/C/D=41-174.
DR   PDB; 8IV3; X-ray; 1.90 A; A/B/C/D=41-174.
DR   PDB; 8J6X; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 8TH1; X-ray; 1.80 A; E/F/G/H=1-25.
DR   PDB; 8TH5; X-ray; 2.62 A; K/L/M/N/O/P/Q=1-25.
DR   PDB; 8X1H; X-ray; 2.00 A; A/B/C/D=44-175.
DR   PDBsum; 6M3M; -.
DR   PDBsum; 6VYO; -.
DR   PDBsum; 6WJI; -.
DR   PDBsum; 6WKP; -.
DR   PDBsum; 6WZO; -.
DR   PDBsum; 6WZQ; -.
DR   PDBsum; 6YI3; -.
DR   PDBsum; 6YUN; -.
DR   PDBsum; 6ZCO; -.
DR   PDBsum; 7ACS; -.
DR   PDBsum; 7ACT; -.
DR   PDBsum; 7C22; -.
DR   PDBsum; 7CDZ; -.
DR   PDBsum; 7CE0; -.
DR   PDBsum; 7CR5; -.
DR   PDBsum; 7DE1; -.
DR   PDBsum; 7F2B; -.
DR   PDBsum; 7F2E; -.
DR   PDBsum; 7KGO; -.
DR   PDBsum; 7KGP; -.
DR   PDBsum; 7KGQ; -.
DR   PDBsum; 7KGR; -.
DR   PDBsum; 7KGS; -.
DR   PDBsum; 7KGT; -.
DR   PDBsum; 7LGD; -.
DR   PDBsum; 7LTU; -.
DR   PDBsum; 7LUX; -.
DR   PDBsum; 7LUZ; -.
DR   PDBsum; 7LV2; -.
DR   PDBsum; 7N0I; -.
DR   PDBsum; 7N0R; -.
DR   PDBsum; 7N3C; -.
DR   PDBsum; 7N3D; -.
DR   PDBsum; 7O05; -.
DR   PDBsum; 7O35; -.
DR   PDBsum; 7O36; -.
DR   PDBsum; 7PKU; -.
DR   PDBsum; 7QIK; -.
DR   PDBsum; 7QIP; -.
DR   PDBsum; 7R98; -.
DR   PDBsum; 7SD4; -.
DR   PDBsum; 7STR; -.
DR   PDBsum; 7STS; -.
DR   PDBsum; 7SUE; -.
DR   PDBsum; 7SUO; -.
DR   PDBsum; 7UW3; -.
DR   PDBsum; 7UXX; -.
DR   PDBsum; 7UXZ; -.
DR   PDBsum; 7VBD; -.
DR   PDBsum; 7VBE; -.
DR   PDBsum; 7VBF; -.
DR   PDBsum; 7VNU; -.
DR   PDBsum; 7WKJ; -.
DR   PDBsum; 7WZO; -.
DR   PDBsum; 7XWX; -.
DR   PDBsum; 7XWZ; -.
DR   PDBsum; 7XX1; -.
DR   PDBsum; 7XXK; -.
DR   PDBsum; 7YLB; -.
DR   PDBsum; 7YLD; -.
DR   PDBsum; 7ZIT; -.
DR   PDBsum; 8DNT; -.
DR   PDBsum; 8FD5; -.
DR   PDBsum; 8FG2; -.
DR   PDBsum; 8IQJ; -.
DR   PDBsum; 8IV3; -.
DR   PDBsum; 8J6X; -.
DR   PDBsum; 8TH1; -.
DR   PDBsum; 8TH5; -.
DR   PDBsum; 8X1H; -.
DR   BMRB; P0DTC9; -.
DR   EMDB; EMD-29002; -.
DR   EMDB; EMD-29072; -.
DR   SASBDB; P0DTC9; -.
DR   SMR; P0DTC9; -.
DR   BioGRID; 4383847; 1532.
DR   ComplexPortal; CPX-5686; SARS-CoV-2 nucleocapsid complex.
DR   IntAct; P0DTC9; 608.
DR   MINT; P0DTC9; -.
DR   ChEMBL; CHEMBL5169223; -.
DR   iPTMnet; P0DTC9; -.
DR   ABCD; P0DTC9; 27 sequenced antibodies.
DR   DNASU; 43740575; -.
DR   KEGG; vg:43740575; -.
DR   AGR; RefSeq:YP_009724397; -.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-168928; DDX58/IFIH1-mediated induction of interferon-alpha/beta.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-445989; TAK1-dependent IKK and NF-kappa-B activation.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-9020702; Interleukin-1 signaling.
DR   Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR   Reactome; R-HSA-9694322; Virion Assembly and Release.
DR   Reactome; R-HSA-9694614; Attachment and Entry.
DR   Reactome; R-HSA-9694631; Maturation of nucleoprotein.
DR   Reactome; R-HSA-9694635; Translation of Structural Proteins.
DR   Reactome; R-HSA-9694786; Transcription of SARS-CoV-2 sgRNAs.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9733458; Induction of Cell-Cell Fusion.
DR   Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways.
DR   SIGNOR; P0DTC9; -.
DR   PRO; PR:P0DTC9; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProt.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0044172; C:host cell endoplasmic reticulum-Golgi intermediate compartment; ISS:UniProtKB.
DR   GO; GO:0044177; C:host cell Golgi apparatus; ISS:UniProtKB.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0043655; C:host extracellular space; IEA:UniProtKB-SubCell.
DR   GO; GO:0043232; C:intracellular non-membrane-bounded organelle; IDA:DisProt.
DR   GO; GO:0042612; C:MHC class I protein complex; EXP:DisProt.
DR   GO; GO:1990904; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IPI:ComplexPortal.
DR   GO; GO:0019013; C:viral nucleocapsid; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0042288; F:MHC class I protein binding; EXP:DisProt.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; IDA:DisProt.
DR   GO; GO:0008266; F:poly(U) RNA binding; IMP:DisProt.
DR   GO; GO:0042803; F:protein homodimerization activity; EXP:DisProt.
DR   GO; GO:0140311; F:protein sequestering activity; IDA:UniProt.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProt.
DR   GO; GO:0035613; F:RNA stem-loop binding; IDA:DisProt.
DR   GO; GO:0039709; P:cytoplasmic capsid assembly; IDA:UniProt.
DR   GO; GO:0032688; P:negative regulation of interferon-beta production; IDA:ComplexPortal.
DR   GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; IDA:UniProtKB.
DR   GO; GO:0052572; P:response to host immune response; IDA:DisProt.
DR   GO; GO:0019074; P:viral RNA genome packaging; NAS:ComplexPortal.
DR   CDD; cd21595; CoV_N-CTD; 1.
DR   CDD; cd21554; CoV_N-NTD; 1.
DR   HAMAP; MF_04096; BETA_CORONA_NCAP; 1.
DR   InterPro; IPR044344; N_prot_C_CoV.
DR   InterPro; IPR044345; N_prot_N_CoV.
DR   InterPro; IPR043505; NCAP_bCoV.
DR   InterPro; IPR001218; Nucleocap_CoV.
DR   InterPro; IPR037179; Nucleocapsid_C.
DR   InterPro; IPR037195; Nucleocapsid_N.
DR   Pfam; PF00937; CoV_nucleocap; 1.
DR   PIRSF; PIRSF003888; Corona_nucleocap; 1.
DR   SUPFAM; SSF110304; Coronavirus RNA-binding domain; 1.
DR   SUPFAM; SSF103068; Nucleocapsid protein dimerization domain; 1.
DR   PROSITE; PS51929; COV_N_CTD; 1.
DR   PROSITE; PS51928; COV_N_NTD; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Host cytoplasm; Phosphoprotein;
KW   Reference proteome; Ribonucleoprotein; RNA-binding; Secreted;
KW   Transcription; Transcription regulation; Viral nucleoprotein; Virion.
FT   CHAIN           1..419
FT                   /note=""Nucleoprotein""
FT                   /id=""PRO_0000449656""
FT   DOMAIN          48..174
FT                   /note=""CoV N NTD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01276,
FT                   ECO:0000269|PubMed:32363136""
FT   DOMAIN          247..364
FT                   /note=""CoV N CTD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01277""
FT   REGION          1..51
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          41..186
FT                   /note=""RNA-binding""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   REGION          63..83
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          168..212
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          176..206
FT                   /note=""SR region""
FT                   /evidence=""ECO:0000305|PubMed:32974389""
FT   REGION          233..266
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          258..361
FT                   /note=""Dimerization""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   REGION          260..340
FT                   /note=""Putative NLRP3 binding""
FT                   /evidence=""ECO:0000269|PubMed:34341353""
FT   REGION          361..391
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          400..419
FT                   /note=""Tetramerization""
FT                   /evidence=""ECO:0000269|PubMed:32654247""
FT   MOTIF           256..264
FT                   /note=""Nuclear localization signal""
FT                   /evidence=""ECO:0000250|UniProtKB:P59595""
FT   COMPBIAS        1..11
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        21..31
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        367..378
FT                   /note=""Basic and acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   BINDING         92
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   BINDING         107
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   BINDING         149
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   SITE            399..402
FT                   /note=""Cleavage (by host CASP6)""
FT                   /evidence=""ECO:0000250|UniProtKB:P59595""
FT   MOD_RES         176
FT                   /note=""Phosphoserine; by host""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   MOD_RES         206
FT                   /note=""Phosphoserine; by host GSK3-alpha and GSK3-beta""
FT                   /evidence=""ECO:0000269|PubMed:34593624""
FT   VARIANT         2..3
FT                   /note=""SD -> Y (in strain: Eta/B.1.525)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         3
FT                   /note=""D -> L (in strain: Alpha/B.1.1.7)""
FT                   /evidence=""ECO:0000305|PubMed:33413740""
FT   VARIANT         12
FT                   /note=""A -> G (in strain: Eta/B.1.525)""
FT   VARIANT         13
FT                   /note=""P -> L (in strain: Lambda/C.37, Omicron/BA.1,
FT                   Omicron/BA.2, Omicron/BA.2.12.1, Omicron/BA.2.75,
FT                   Omicron/BA.4, Omicron/BA.5, Omicron/BQ.1.1,
FT                   Omicron/XBB.1.5, Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         31..33
FT                   /note=""Missing (in strain: Omicron/BA.1, Omicron/BA.2,
FT                   Omicron/BA.2.12.1, Omicron/BA.2.75, Omicron/BA.4,
FT                   Omicron/BA.5, Omicron/BQ.1.1, Omicron/XBB.1.5,
FT                   Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         63
FT                   /note=""D -> G (in strain: Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT  ",33408
GGCAAC GCAACG CAACGA AACGAC ACGACA CGACAA GACAAT ACAATG CAATGT AATGTG ATGTGG TGTGGT GTGGTA TGGTAA GGTAAC GTAACT TAACTG AACTGT ACTGTA CTGTAA TGTAAA GTAAAG TAAAGG AAAGGG AAGGGG AGGGGC GGGGCC GGGCCT GGCCTA GCCTAA CCTAAA CTAAAG TAAAGG AAAGGA AAGGAG AGGAGA GGAGAA GAGAAC AGAACT GAACTG AACTGA ACTGAA CTGAAA TGAAAG GAAAGA AAAGAA AAGAAG AGAAGC GAAGCC AAGCCA AGCCAT GCCATC CCATCG CATCGA ATCGAC TCGACA CGACAG GACAGG ACAGGG CAGGGA AGGGAT GGGATA GGATAT GATATT ATATTA TATTAC ATTACT TTACTG TACTGT ACTGTA CTGTAA TGTAAC GTAACC TAACCG AACCGT ACCGTT CCGTTA CGTTAA GTTAAA TTAAAG TAAAGA AAAGAC AAGACG AGACGG GACGGC ACGGCC CGGCCA GGCCAG GCCAGG CCAGGT CAGGTA AGGTAA GGTAAA GTAAAT TAAATT AAATTT AATTTT ATTTTG TTTTGC TTTGCA TTGCAC TGCACG GCACGC CACGCC ACGCCC CGCCCT GCCCTA CCCTAC CCTACA CTACAG TACAGA ACAGAT CAGATC AGATCA GATCAG ATCAGA TCAGAT CAGATT AGATTC GATTCG ATTCGT TTCGTC TCGTCA CGTCAC GTCACC TCACCG CACCGT ACCGTG CCGTGC CGTGCC GTGCCA TGCCAT GCCATG CCATGC CATGCA ATGCAC TGCACG GCACGG CACGGC ACGGCC CGGCCT GGCCTG GCCTGT CCTGTA CTGTAC,1,145,GGCA GCAA CAAC AACG ACGA CGAC GACA ACAA CAAT AATG ATGT TGTG GTGG TGGT GGTA GTAA TAAC AACT ACTG CTGT TGTA GTAA TAAA AAAG AAGG AGGG GGGG GGGC GGCC GCCT CCTA CTAA TAAA AAAG AAGG AGGA GGAG GAGA AGAA GAAC AACT ACTG CTGA TGAA GAAA AAAG AAGA AGAA GAAG AAGC AGCC GCCA CCAT CATC ATCG TCGA CGAC GACA ACAG CAGG AGGG GGGA GGAT GATA ATAT TATT ATTA TTAC TACT ACTG CTGT TGTA GTAA TAAC AACC ACCG CCGT CGTT GTTA TTAA TAAA AAAG AAGA AGAC GACG ACGG CGGC GGCC GCCA CCAG CAGG AGGT GGTA GTAA TAAA AAAT AATT ATTT TTTT TTTG TTGC TGCA GCAC CACG ACGC CGCC GCCC CCCT CCTA CTAC TACA ACAG CAGA AGAT GATC ATCA TCAG CAGA AGAT GATT ATTC TTCG TCGT CGTC GTCA TCAC CACC ACCG CCGT CGTG GTGC TGCC GCCA CCAT CATG ATGC TGCA GCAC CACG ACGG CGGC GGCC GCCT CCTG CTGT TGTA GTAC,GGCAA GCAAC CAACG AACGA ACGAC CGACA GACAA ACAAT CAATG AATGT ATGTG TGTGG GTGGT TGGTA GGTAA GTAAC TAACT AACTG ACTGT CTGTA TGTAA GTAAA TAAAG AAAGG AAGGG AGGGG GGGGC GGGCC GGCCT GCCTA CCTAA CTAAA TAAAG AAAGG AAGGA AGGAG GGAGA GAGAA AGAAC GAACT AACTG ACTGA CTGAA TGAAA GAAAG AAAGA AAGAA AGAAG GAAGC AAGCC AGCCA GCCAT CCATC CATCG ATCGA TCGAC CGACA GACAG ACAGG CAGGG AGGGA GGGAT GGATA GATAT ATATT TATTA ATTAC TTACT TACTG ACTGT CTGTA TGTAA GTAAC TAACC AACCG ACCGT CCGTT CGTTA GTTAA TTAAA TAAAG AAAGA AAGAC AGACG GACGG ACGGC CGGCC GGCCA GCCAG CCAGG CAGGT AGGTA GGTAA GTAAA TAAAT AAATT AATTT ATTTT TTTTG TTTGC TTGCA TGCAC GCACG CACGC ACGCC CGCCC GCCCT CCCTA CCTAC CTACA TACAG ACAGA CAGAT AGATC GATCA ATCAG TCAGA CAGAT AGATT GATTC ATTCG TTCGT TCGTC CGTCA GTCAC TCACC CACCG ACCGT CCGTG CGTGC GTGCC TGCCA GCCAT CCATG CATGC ATGCA TGCAC GCACG CACGG ACGGC CGGCC GGCCT GCCTG CCTGT CTGTA TGTAC,GGCAAC GCAACG CAACGA AACGAC ACGACA CGACAA GACAAT ACAATG CAATGT AATGTG ATGTGG TGTGGT GTGGTA TGGTAA GGTAAC GTAACT TAACTG AACTGT ACTGTA CTGTAA TGTAAA GTAAAG TAAAGG AAAGGG AAGGGG AGGGGC GGGGCC GGGCCT GGCCTA GCCTAA CCTAAA CTAAAG TAAAGG AAAGGA AAGGAG AGGAGA GGAGAA GAGAAC AGAACT GAACTG AACTGA ACTGAA CTGAAA TGAAAG GAAAGA AAAGAA AAGAAG AGAAGC GAAGCC AAGCCA AGCCAT GCCATC CCATCG CATCGA ATCGAC TCGACA CGACAG GACAGG ACAGGG CAGGGA AGGGAT GGGATA GGATAT GATATT ATATTA TATTAC ATTACT TTACTG TACTGT ACTGTA CTGTAA TGTAAC GTAACC TAACCG AACCGT ACCGTT CCGTTA CGTTAA GTTAAA TTAAAG TAAAGA AAAGAC AAGACG AGACGG GACGGC ACGGCC CGGCCA GGCCAG GCCAGG CCAGGT CAGGTA AGGTAA GGTAAA GTAAAT TAAATT AAATTT AATTTT ATTTTG TTTTGC TTTGCA TTGCAC TGCACG GCACGC CACGCC ACGCCC CGCCCT GCCCTA CCCTAC CCTACA CTACAG TACAGA ACAGAT CAGATC AGATCA GATCAG ATCAGA TCAGAT CAGATT AGATTC GATTCG ATTCGT TTCGTC TCGTCA CGTCAC GTCACC TCACCG CACCGT ACCGTG CCGTGC CGTGCC GTGCCA TGCCAT GCCATG CCATGC CATGCA ATGCAC TGCACG GCACGG CACGGC ACGGCC CGGCCT GGCCTG GCCTGT CCTGTA CTGTAC,GGCAACG GCAACGA CAACGAC AACGACA ACGACAA CGACAAT GACAATG ACAATGT CAATGTG AATGTGG ATGTGGT TGTGGTA GTGGTAA TGGTAAC GGTAACT GTAACTG TAACTGT AACTGTA ACTGTAA CTGTAAA TGTAAAG GTAAAGG TAAAGGG AAAGGGG AAGGGGC AGGGGCC GGGGCCT GGGCCTA GGCCTAA GCCTAAA CCTAAAG CTAAAGG TAAAGGA AAAGGAG AAGGAGA AGGAGAA GGAGAAC GAGAACT AGAACTG GAACTGA AACTGAA ACTGAAA CTGAAAG TGAAAGA GAAAGAA AAAGAAG AAGAAGC AGAAGCC GAAGCCA AAGCCAT AGCCATC GCCATCG CCATCGA CATCGAC ATCGACA TCGACAG CGACAGG GACAGGG ACAGGGA CAGGGAT AGGGATA GGGATAT GGATATT GATATTA ATATTAC TATTACT ATTACTG TTACTGT TACTGTA ACTGTAA CTGTAAC TGTAACC GTAACCG TAACCGT AACCGTT ACCGTTA CCGTTAA CGTTAAA GTTAAAG TTAAAGA TAAAGAC AAAGACG AAGACGG AGACGGC GACGGCC ACGGCCA CGGCCAG GGCCAGG GCCAGGT CCAGGTA CAGGTAA AGGTAAA GGTAAAT GTAAATT TAAATTT AAATTTT AATTTTG ATTTTGC TTTTGCA TTTGCAC TTGCACG TGCACGC GCACGCC CACGCCC ACGCCCT CGCCCTA GCCCTAC CCCTACA CCTACAG CTACAGA TACAGAT ACAGATC CAGATCA AGATCAG GATCAGA ATCAGAT TCAGATT CAGATTC AGATTCG GATTCGT ATTCGTC TTCGTCA TCGTCAC CGTCACC GTCACCG TCACCGT CACCGTG ACCGTGC CCGTGCC CGTGCCA GTGCCAT TGCCATG GCCATGC CCATGCA CATGCAC ATGCACG TGCACGG GCACGGC CACGGCC ACGGCCT CGGCCTG GGCCTGT GCCTGTA CCTGTAC,"ID   RL6_CLOP1               Reviewed;         179 AA.
AC   Q0TMR1;
DT   28-NOV-2006, integrated into UniProtKB/Swiss-Prot.
DT   05-SEP-2006, sequence version 1.
DT   05-FEB-2025, entry version 97.
DE   RecName: Full=Large ribosomal subunit protein uL6 {ECO:0000255|HAMAP-Rule:MF_01365};
DE   AltName: Full=50S ribosomal protein L6 {ECO:0000305};
GN   Name=rplF {ECO:0000255|HAMAP-Rule:MF_01365};
GN   OrderedLocusNames=CPF_2699;
OS   Clostridium perfringens (strain ATCC 13124 / DSM 756 / JCM 1290 / NCIMB
OS   6125 / NCTC 8237 / Type A).
OC   Bacteria; Bacillati; Bacillota; Clostridia; Eubacteriales; Clostridiaceae;
OC   Clostridium.
OX   NCBI_TaxID=195103;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 13124 / DSM 756 / JCM 1290 / NCIMB 6125 / NCTC 8237 / S
RC   107 / Type A;
RX   PubMed=16825665; DOI=10.1101/gr.5238106;
RA   Myers G.S.A., Rasko D.A., Cheung J.K., Ravel J., Seshadri R., DeBoy R.T.,
RA   Ren Q., Varga J., Awad M.M., Brinkac L.M., Daugherty S.C., Haft D.H.,
RA   Dodson R.J., Madupu R., Nelson W.C., Rosovitz M.J., Sullivan S.A.,
RA   Khouri H., Dimitrov G.I., Watkins K.L., Mulligan S., Benton J., Radune D.,
RA   Fisher D.J., Atkins H.S., Hiscox T., Jost B.H., Billington S.J.,
RA   Songer J.G., McClane B.A., Titball R.W., Rood J.I., Melville S.B.,
RA   Paulsen I.T.;
RT   ""Skewed genomic variability in strains of the toxigenic bacterial pathogen,
RT   Clostridium perfringens."";
RL   Genome Res. 16:1031-1040(2006).
CC   -!- FUNCTION: This protein binds to the 23S rRNA, and is important in its
CC       secondary structure. It is located near the subunit interface in the
CC       base of the L7/L12 stalk, and near the tRNA binding site of the
CC       peptidyltransferase center. {ECO:0000255|HAMAP-Rule:MF_01365}.
CC   -!- SUBUNIT: Part of the 50S ribosomal subunit. {ECO:0000255|HAMAP-
CC       Rule:MF_01365}.
CC   -!- SIMILARITY: Belongs to the universal ribosomal protein uL6 family.
CC       {ECO:0000255|HAMAP-Rule:MF_01365}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP000246; ABG83096.1; -; Genomic_DNA.
DR   RefSeq; WP_003454268.1; NC_008261.1.
DR   AlphaFoldDB; Q0TMR1; -.
DR   SMR; Q0TMR1; -.
DR   STRING; 195103.CPF_2699; -.
DR   PaxDb; 195103-CPF_2699; -.
DR   GeneID; 93001024; -.
DR   KEGG; cpf:CPF_2699; -.
DR   eggNOG; COG0097; Bacteria.
DR   HOGENOM; CLU_065464_1_2_9; -.
DR   Proteomes; UP000001823; Chromosome.
DR   GO; GO:0022625; C:cytosolic large ribosomal subunit; IEA:TreeGrafter.
DR   GO; GO:0019843; F:rRNA binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0003735; F:structural constituent of ribosome; IEA:InterPro.
DR   GO; GO:0002181; P:cytoplasmic translation; IEA:TreeGrafter.
DR   FunFam; 3.90.930.12:FF:000001; 50S ribosomal protein L6; 1.
DR   FunFam; 3.90.930.12:FF:000002; 50S ribosomal protein L6; 1.
DR   Gene3D; 3.90.930.12; Ribosomal protein L6, alpha-beta domain; 2.
DR   HAMAP; MF_01365_B; Ribosomal_uL6_B; 1.
DR   InterPro; IPR000702; Ribosomal_uL6-like.
DR   InterPro; IPR036789; Ribosomal_uL6-like_a/b-dom_sf.
DR   InterPro; IPR020040; Ribosomal_uL6_a/b-dom.
DR   InterPro; IPR019906; Ribosomal_uL6_bac-type.
DR   InterPro; IPR002358; Ribosomal_uL6_CS.
DR   NCBIfam; TIGR03654; L6_bact; 1.
DR   PANTHER; PTHR11655; 60S/50S RIBOSOMAL PROTEIN L6/L9; 1.
DR   PANTHER; PTHR11655:SF14; LARGE RIBOSOMAL SUBUNIT PROTEIN UL6M; 1.
DR   Pfam; PF00347; Ribosomal_L6; 2.
DR   PIRSF; PIRSF002162; Ribosomal_L6; 1.
DR   PRINTS; PR00059; RIBOSOMALL6.
DR   SUPFAM; SSF56053; Ribosomal protein L6; 2.
DR   PROSITE; PS00525; RIBOSOMAL_L6_1; 1.
PE   3: Inferred from homology;
KW   Ribonucleoprotein; Ribosomal protein; RNA-binding; rRNA-binding.
FT   CHAIN           1..179
FT                   /note=""Large ribosomal subunit protein uL6""
FT                   /id=""PRO_0000260851""
SQ   SEQUENCE   179 AA;  19381 MW;  9576BCD700043E2F CRC64;
     MSRVGKMPIA IPAGVTVTVT PENVVTVKGP KGELVKAMHK DINIAVEDAQ VVVTRPSDVK
     EHRALHGLTR ALLNNMVVGV SQGFSKTLEL NGVGYRAQLQ GKKLVMNLGY SHPVEVEAVD
     GVDFKLDGTT KVIVEGIDKE KVGAVAANIR SWRKPEPYKG KGIKYSDEVI RRKEGKTGK
//
",3779
ACCTAC CCTACC CTACCT TACCTT ACCTTG CCTTGA CTTGAA TTGAAG TGAAGG GAAGGT AAGGTC AGGTCC GGTCCT GTCCTG TCCTGT CCTGTT CTGTTA TGTTAG GTTAGA TTAGAG TAGAGT AGAGTG GAGTGG AGTGGT GTGGTA TGGTAA GGTAAC GTAACA TAACAA AACAAC ACAACT CAACTA AACTAT ACTATT CTATTG TATTGA ATTGAT TTGATT TGATTC GATTCT ATTCTG TTCTGA TCTGAG CTGAGT TGAGTA GAGTAC AGTACA GTACAG TACAGT ACAGTA CAGTAG AGTAGG GTAGGC TAGGCA AGGCAC GGCACG GCACGG CACGGC ACGGCG CGGCGC GGCGCG GCGCGT CGCGTG GCGTGT CGTGTG GTGTGA TGTGAA GTGAAG TGAAGG GAAGGA AAGGAT AGGATC GGATCA GATCAA ATCAAA TCAAAA CAAAAA AAAAAC AAAACA AAACAG AACAGG ACAGGT CAGGTG AGGTGA GGTGAA GTGAAG TGAAGG GAAGGT AAGGTG AGGTGT GGTGTA GTGTAT TGTATC GTATCT TATCTA ATCTAC TCTACT CTACTA TACTAG ACTAGT CTAGTG TAGTGG AGTGGT GTGGTA TGGTAG GGTAGA GTAGAT TAGATG AGATGG GATGGG ATGGGT TGGGTA GGGTAC GGTACT GTACTT TACTTA ACTTAA CTTAAC TTAACA TAACAA AACAAT ACAATG CAATGA AATGAA ATGAAT TGAATA GAATAA,0,127,ACCT CCTA CTAC TACC ACCT CCTT CTTG TTGA TGAA GAAG AAGG AGGT GGTC GTCC TCCT CCTG CTGT TGTT GTTA TTAG TAGA AGAG GAGT AGTG GTGG TGGT GGTA GTAA TAAC AACA ACAA CAAC AACT ACTA CTAT TATT ATTG TTGA TGAT GATT ATTC TTCT TCTG CTGA TGAG GAGT AGTA GTAC TACA ACAG CAGT AGTA GTAG TAGG AGGC GGCA GCAC CACG ACGG CGGC GGCG GCGC CGCG GCGT CGTG GTGT TGTG GTGA TGAA GAAG AAGG AGGA GGAT GATC ATCA TCAA CAAA AAAA AAAA AAAC AACA ACAG CAGG AGGT GGTG GTGA TGAA GAAG AAGG AGGT GGTG GTGT TGTA GTAT TATC ATCT TCTA CTAC TACT ACTA CTAG TAGT AGTG GTGG TGGT GGTA GTAG TAGA AGAT GATG ATGG TGGG GGGT GGTA GTAC TACT ACTT CTTA TTAA TAAC AACA ACAA CAAT AATG ATGA TGAA GAAT AATA ATAA,ACCTA CCTAC CTACC TACCT ACCTT CCTTG CTTGA TTGAA TGAAG GAAGG AAGGT AGGTC GGTCC GTCCT TCCTG CCTGT CTGTT TGTTA GTTAG TTAGA TAGAG AGAGT GAGTG AGTGG GTGGT TGGTA GGTAA GTAAC TAACA AACAA ACAAC CAACT AACTA ACTAT CTATT TATTG ATTGA TTGAT TGATT GATTC ATTCT TTCTG TCTGA CTGAG TGAGT GAGTA AGTAC GTACA TACAG ACAGT CAGTA AGTAG GTAGG TAGGC AGGCA GGCAC GCACG CACGG ACGGC CGGCG GGCGC GCGCG CGCGT GCGTG CGTGT GTGTG TGTGA GTGAA TGAAG GAAGG AAGGA AGGAT GGATC GATCA ATCAA TCAAA CAAAA AAAAA AAAAC AAACA AACAG ACAGG CAGGT AGGTG GGTGA GTGAA TGAAG GAAGG AAGGT AGGTG GGTGT GTGTA TGTAT GTATC TATCT ATCTA TCTAC CTACT TACTA ACTAG CTAGT TAGTG AGTGG GTGGT TGGTA GGTAG GTAGA TAGAT AGATG GATGG ATGGG TGGGT GGGTA GGTAC GTACT TACTT ACTTA CTTAA TTAAC TAACA AACAA ACAAT CAATG AATGA ATGAA TGAAT GAATA AATAA,ACCTAC CCTACC CTACCT TACCTT ACCTTG CCTTGA CTTGAA TTGAAG TGAAGG GAAGGT AAGGTC AGGTCC GGTCCT GTCCTG TCCTGT CCTGTT CTGTTA TGTTAG GTTAGA TTAGAG TAGAGT AGAGTG GAGTGG AGTGGT GTGGTA TGGTAA GGTAAC GTAACA TAACAA AACAAC ACAACT CAACTA AACTAT ACTATT CTATTG TATTGA ATTGAT TTGATT TGATTC GATTCT ATTCTG TTCTGA TCTGAG CTGAGT TGAGTA GAGTAC AGTACA GTACAG TACAGT ACAGTA CAGTAG AGTAGG GTAGGC TAGGCA AGGCAC GGCACG GCACGG CACGGC ACGGCG CGGCGC GGCGCG GCGCGT CGCGTG GCGTGT CGTGTG GTGTGA TGTGAA GTGAAG TGAAGG GAAGGA AAGGAT AGGATC GGATCA GATCAA ATCAAA TCAAAA CAAAAA AAAAAC AAAACA AAACAG AACAGG ACAGGT CAGGTG AGGTGA GGTGAA GTGAAG TGAAGG GAAGGT AAGGTG AGGTGT GGTGTA GTGTAT TGTATC GTATCT TATCTA ATCTAC TCTACT CTACTA TACTAG ACTAGT CTAGTG TAGTGG AGTGGT GTGGTA TGGTAG GGTAGA GTAGAT TAGATG AGATGG GATGGG ATGGGT TGGGTA GGGTAC GGTACT GTACTT TACTTA ACTTAA CTTAAC TTAACA TAACAA AACAAT ACAATG CAATGA AATGAA ATGAAT TGAATA GAATAA,ACCTACC CCTACCT CTACCTT TACCTTG ACCTTGA CCTTGAA CTTGAAG TTGAAGG TGAAGGT GAAGGTC AAGGTCC AGGTCCT GGTCCTG GTCCTGT TCCTGTT CCTGTTA CTGTTAG TGTTAGA GTTAGAG TTAGAGT TAGAGTG AGAGTGG GAGTGGT AGTGGTA GTGGTAA TGGTAAC GGTAACA GTAACAA TAACAAC AACAACT ACAACTA CAACTAT AACTATT ACTATTG CTATTGA TATTGAT ATTGATT TTGATTC TGATTCT GATTCTG ATTCTGA TTCTGAG TCTGAGT CTGAGTA TGAGTAC GAGTACA AGTACAG GTACAGT TACAGTA ACAGTAG CAGTAGG AGTAGGC GTAGGCA TAGGCAC AGGCACG GGCACGG GCACGGC CACGGCG ACGGCGC CGGCGCG GGCGCGT GCGCGTG CGCGTGT GCGTGTG CGTGTGA GTGTGAA TGTGAAG GTGAAGG TGAAGGA GAAGGAT AAGGATC AGGATCA GGATCAA GATCAAA ATCAAAA TCAAAAA CAAAAAC AAAAACA AAAACAG AAACAGG AACAGGT ACAGGTG CAGGTGA AGGTGAA GGTGAAG GTGAAGG TGAAGGT GAAGGTG AAGGTGT AGGTGTA GGTGTAT GTGTATC TGTATCT GTATCTA TATCTAC ATCTACT TCTACTA CTACTAG TACTAGT ACTAGTG CTAGTGG TAGTGGT AGTGGTA GTGGTAG TGGTAGA GGTAGAT GTAGATG TAGATGG AGATGGG GATGGGT ATGGGTA TGGGTAC GGGTACT GGTACTT GTACTTA TACTTAA ACTTAAC CTTAACA TTAACAA TAACAAT AACAATG ACAATGA CAATGAA AATGAAT ATGAATA TGAATAA,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",41245
AAGCAG AGCAGA GCAGAT CAGATG AGATGC GATGCC ATGCCT TGCCTA GCCTAC CCTACA CTACAT TACATC ACATCA CATCAC ATCACT TCACTC CACTCA ACTCAT CTCATT TCATTA CATTAG ATTAGC TTAGCA TAGCAT AGCATT GCATTA CATTAT ATTATG TTATGA TATGAT ATGATG TGATGA GATGAC ATGACG TGACGG GACGGC ACGGCA CGGCAA GGCAAC GCAACT CAACTA AACTAC ACTACA CTACAA TACAAC ACAACG CAACGC AACGCA ACGCAG CGCAGA GCAGAA CAGAAT AGAATA GAATAC AATACT ATACTC TACTCA ACTCAG CTCAGG TCAGGA CAGGAC AGGACA GGACAC GACACC ACACCA CACCAA ACCAAG CCAAGA CAAGAA AAGAAG AGAAGT GAAGTC AAGTCG AGTCGC GTCGCA TCGCAG CGCAGG GCAGGA CAGGAC AGGACC GGACCT GACCTG ACCTGG CCTGGT CTGGTC TGGTCA GGTCAT GTCATG TCATGA CATGAA ATGAAG TGAAGC GAAGCT AAGCTG AGCTGT GCTGTC CTGTCA TGTCAA GTCAAA TCAAAC CAAACT AAACTC AACTCG ACTCGA CTCGAT TCGATG CGATGA GATGAA ATGAAT TGAATG GAATGA AATGAA ATGAAG TGAAGT GAAGTA AAGTAG AGTAGT GTAGTT TAGTTC AGTTCA GTTCAA TTCAAA TCAAAT CAAATC AAATCA AATCAC ATCACC TCACCA CACCAG ACCAGC CCAGCG CAGCGT AGCGTG GCGTGC CGTGCT GTGCTG TGCTGA GCTGAC CTGACA TGACAA GACAAT ACAATG CAATGA AATGAT ATGATC,2,145,AAGC AGCA GCAG CAGA AGAT GATG ATGC TGCC GCCT CCTA CTAC TACA ACAT CATC ATCA TCAC CACT ACTC CTCA TCAT CATT ATTA TTAG TAGC AGCA GCAT CATT ATTA TTAT TATG ATGA TGAT GATG ATGA TGAC GACG ACGG CGGC GGCA GCAA CAAC AACT ACTA CTAC TACA ACAA CAAC AACG ACGC CGCA GCAG CAGA AGAA GAAT AATA ATAC TACT ACTC CTCA TCAG CAGG AGGA GGAC GACA ACAC CACC ACCA CCAA CAAG AAGA AGAA GAAG AAGT AGTC GTCG TCGC CGCA GCAG CAGG AGGA GGAC GACC ACCT CCTG CTGG TGGT GGTC GTCA TCAT CATG ATGA TGAA GAAG AAGC AGCT GCTG CTGT TGTC GTCA TCAA CAAA AAAC AACT ACTC CTCG TCGA CGAT GATG ATGA TGAA GAAT AATG ATGA TGAA GAAG AAGT AGTA GTAG TAGT AGTT GTTC TTCA TCAA CAAA AAAT AATC ATCA TCAC CACC ACCA CCAG CAGC AGCG GCGT CGTG GTGC TGCT GCTG CTGA TGAC GACA ACAA CAAT AATG ATGA TGAT GATC,AAGCA AGCAG GCAGA CAGAT AGATG GATGC ATGCC TGCCT GCCTA CCTAC CTACA TACAT ACATC CATCA ATCAC TCACT CACTC ACTCA CTCAT TCATT CATTA ATTAG TTAGC TAGCA AGCAT GCATT CATTA ATTAT TTATG TATGA ATGAT TGATG GATGA ATGAC TGACG GACGG ACGGC CGGCA GGCAA GCAAC CAACT AACTA ACTAC CTACA TACAA ACAAC CAACG AACGC ACGCA CGCAG GCAGA CAGAA AGAAT GAATA AATAC ATACT TACTC ACTCA CTCAG TCAGG CAGGA AGGAC GGACA GACAC ACACC CACCA ACCAA CCAAG CAAGA AAGAA AGAAG GAAGT AAGTC AGTCG GTCGC TCGCA CGCAG GCAGG CAGGA AGGAC GGACC GACCT ACCTG CCTGG CTGGT TGGTC GGTCA GTCAT TCATG CATGA ATGAA TGAAG GAAGC AAGCT AGCTG GCTGT CTGTC TGTCA GTCAA TCAAA CAAAC AAACT AACTC ACTCG CTCGA TCGAT CGATG GATGA ATGAA TGAAT GAATG AATGA ATGAA TGAAG GAAGT AAGTA AGTAG GTAGT TAGTT AGTTC GTTCA TTCAA TCAAA CAAAT AAATC AATCA ATCAC TCACC CACCA ACCAG CCAGC CAGCG AGCGT GCGTG CGTGC GTGCT TGCTG GCTGA CTGAC TGACA GACAA ACAAT CAATG AATGA ATGAT TGATC,AAGCAG AGCAGA GCAGAT CAGATG AGATGC GATGCC ATGCCT TGCCTA GCCTAC CCTACA CTACAT TACATC ACATCA CATCAC ATCACT TCACTC CACTCA ACTCAT CTCATT TCATTA CATTAG ATTAGC TTAGCA TAGCAT AGCATT GCATTA CATTAT ATTATG TTATGA TATGAT ATGATG TGATGA GATGAC ATGACG TGACGG GACGGC ACGGCA CGGCAA GGCAAC GCAACT CAACTA AACTAC ACTACA CTACAA TACAAC ACAACG CAACGC AACGCA ACGCAG CGCAGA GCAGAA CAGAAT AGAATA GAATAC AATACT ATACTC TACTCA ACTCAG CTCAGG TCAGGA CAGGAC AGGACA GGACAC GACACC ACACCA CACCAA ACCAAG CCAAGA CAAGAA AAGAAG AGAAGT GAAGTC AAGTCG AGTCGC GTCGCA TCGCAG CGCAGG GCAGGA CAGGAC AGGACC GGACCT GACCTG ACCTGG CCTGGT CTGGTC TGGTCA GGTCAT GTCATG TCATGA CATGAA ATGAAG TGAAGC GAAGCT AAGCTG AGCTGT GCTGTC CTGTCA TGTCAA GTCAAA TCAAAC CAAACT AAACTC AACTCG ACTCGA CTCGAT TCGATG CGATGA GATGAA ATGAAT TGAATG GAATGA AATGAA ATGAAG TGAAGT GAAGTA AAGTAG AGTAGT GTAGTT TAGTTC AGTTCA GTTCAA TTCAAA TCAAAT CAAATC AAATCA AATCAC ATCACC TCACCA CACCAG ACCAGC CCAGCG CAGCGT AGCGTG GCGTGC CGTGCT GTGCTG TGCTGA GCTGAC CTGACA TGACAA GACAAT ACAATG CAATGA AATGAT ATGATC,AAGCAGA AGCAGAT GCAGATG CAGATGC AGATGCC GATGCCT ATGCCTA TGCCTAC GCCTACA CCTACAT CTACATC TACATCA ACATCAC CATCACT ATCACTC TCACTCA CACTCAT ACTCATT CTCATTA TCATTAG CATTAGC ATTAGCA TTAGCAT TAGCATT AGCATTA GCATTAT CATTATG ATTATGA TTATGAT TATGATG ATGATGA TGATGAC GATGACG ATGACGG TGACGGC GACGGCA ACGGCAA CGGCAAC GGCAACT GCAACTA CAACTAC AACTACA ACTACAA CTACAAC TACAACG ACAACGC CAACGCA AACGCAG ACGCAGA CGCAGAA GCAGAAT CAGAATA AGAATAC GAATACT AATACTC ATACTCA TACTCAG ACTCAGG CTCAGGA TCAGGAC CAGGACA AGGACAC GGACACC GACACCA ACACCAA CACCAAG ACCAAGA CCAAGAA CAAGAAG AAGAAGT AGAAGTC GAAGTCG AAGTCGC AGTCGCA GTCGCAG TCGCAGG CGCAGGA GCAGGAC CAGGACC AGGACCT GGACCTG GACCTGG ACCTGGT CCTGGTC CTGGTCA TGGTCAT GGTCATG GTCATGA TCATGAA CATGAAG ATGAAGC TGAAGCT GAAGCTG AAGCTGT AGCTGTC GCTGTCA CTGTCAA TGTCAAA GTCAAAC TCAAACT CAAACTC AAACTCG AACTCGA ACTCGAT CTCGATG TCGATGA CGATGAA GATGAAT ATGAATG TGAATGA GAATGAA AATGAAG ATGAAGT TGAAGTA GAAGTAG AAGTAGT AGTAGTT GTAGTTC TAGTTCA AGTTCAA GTTCAAA TTCAAAT TCAAATC CAAATCA AAATCAC AATCACC ATCACCA TCACCAG CACCAGC ACCAGCG CCAGCGT CAGCGTG AGCGTGC GCGTGCT CGTGCTG GTGCTGA TGCTGAC GCTGACA CTGACAA TGACAAT GACAATG ACAATGA CAATGAT AATGATC,"ID   RGT1_YEAS1              Reviewed;        1170 AA.
AC   B3LR49;
DT   03-MAY-2011, integrated into UniProtKB/Swiss-Prot.
DT   02-SEP-2008, sequence version 1.
DT   05-FEB-2025, entry version 68.
DE   RecName: Full=Glucose transport transcription regulator RGT1;
DE   AltName: Full=Restores glucose transport protein 1;
GN   Name=RGT1; ORFNames=SCRG_03981;
OS   Saccharomyces cerevisiae (strain RM11-1a) (Baker's yeast).
OC   Eukaryota; Fungi; Dikarya; Ascomycota; Saccharomycotina; Saccharomycetes;
OC   Saccharomycetales; Saccharomycetaceae; Saccharomyces.
OX   NCBI_TaxID=285006;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=RM11-1a;
RG   The Broad Institute Genome Sequencing Platform;
RA   Birren B.W., Lander E.S., Galagan J.E., Nusbaum C., Devon K., Cuomo C.,
RA   Jaffe D.B., Butler J., Alvarez P., Gnerre S., Grabherr M., Kleber M.,
RA   Mauceli E.W., Brockman W., MacCallum I.A., Rounsley S., Young S.K.,
RA   LaButti K., Pushparaj V., DeCaprio D., Crawford M., Koehrsen M., Engels R.,
RA   Montgomery P., Pearson M., Howarth C., Larson L., Luoma S., White J.,
RA   O'Leary S., Kodira C.D., Zeng Q., Yandava C., Alvarado L., Pratt S.,
RA   Kruglyak L.;
RT   ""Annotation of the Saccharomyces cerevisiae RM11-1a genome."";
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Glucose-responsive transcription factor that regulates
CC       expression of several glucose transporter (HXT) genes in response to
CC       glucose. In the absence of glucose, it functions as a transcriptional
CC       repressor, whereas high concentrations of glucose cause it to function
CC       as a transcriptional activator. In cells growing on low levels of
CC       glucose, has a neutral role, neither repressing nor activating
CC       transcription. Binds the consensus binding site sequence 5'-CGGANNA-3',
CC       of which multiple copies are present in all HXT promoters regulated by
CC       RGT1 (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00227}.
CC       Cytoplasm {ECO:0000250}.
CC   -!- PTM: Glucose-induced phosphorylation regulates the DNA-binding
CC       activity. Hyperphosphorylation in cells growing on high levels of
CC       glucose does prevents DNA-binding and dephosphorylation restores DNA-
CC       binding ability (By similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the EDS1/RGT1 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CH408051; EDV13052.1; -; Genomic_DNA.
DR   AlphaFoldDB; B3LR49; -.
DR   HOGENOM; CLU_006525_0_0_1; -.
DR   OrthoDB; 39552at4893; -.
DR   Proteomes; UP000008335; Unassembled WGS sequence.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   CDD; cd00067; GAL4; 1.
DR   Gene3D; 4.10.240.10; Zn(2)-C6 fungal-type DNA-binding domain; 1.
DR   InterPro; IPR050797; Carb_Metab_Trans_Reg.
DR   InterPro; IPR036864; Zn2-C6_fun-type_DNA-bd_sf.
DR   InterPro; IPR001138; Zn2Cys6_DnaBD.
DR   PANTHER; PTHR31668:SF26; GLUCOSE TRANSPORT TRANSCRIPTION REGULATOR RGT1-RELATED; 1.
DR   PANTHER; PTHR31668; GLUCOSE TRANSPORT TRANSCRIPTION REGULATOR RGT1-RELATED-RELATED; 1.
DR   Pfam; PF00172; Zn_clus; 1.
DR   SMART; SM00066; GAL4; 1.
DR   SUPFAM; SSF57701; Zn2/Cys6 DNA-binding domain; 1.
DR   PROSITE; PS00463; ZN2_CY6_FUNGAL_1; 1.
DR   PROSITE; PS50048; ZN2_CY6_FUNGAL_2; 1.
PE   3: Inferred from homology;
KW   Activator; Cytoplasm; DNA-binding; Metal-binding; Nucleus; Phosphoprotein;
KW   Repressor; Transcription; Transcription regulation; Zinc.
FT   CHAIN           1..1170
FT                   /note=""Glucose transport transcription regulator RGT1""
FT                   /id=""PRO_0000408017""
FT   DNA_BIND        47..76
FT                   /note=""Zn(2)-C6 fungal-type""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00227""
FT   REGION          1..46
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          77..149
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          226..254
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          269..288
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          293..323
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          384..506
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          944..977
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        1..22
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        99..108
FT                   /note=""Basic and acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        139..149
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        271..280
FT                   /note=""Basic and acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        411..422
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        445..457
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        473..488
FT                   /note=""Basic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        493..506
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   MOD_RES         202
FT                   /note=""Phosphoserine""
FT                   /evidence=""ECO:0000250|UniProtKB:P32862""
FT   MOD_RES         205
FT                   /note=""Phosphoserine""
FT                   /evidence=""ECO:0000250|UniProtKB:P32862""
FT   MOD_RES         208
FT                   /note=""Phosphoserine""
FT                   /evidence=""ECO:0000250|UniProtKB:P32862""
FT   MOD_RES         229
FT                   /note=""Phosphoserine""
FT                   /evidence=""ECO:0000250|UniProtKB:P32862""
FT   MOD_RES         283
FT                   /note=""Phosphoserine""
FT                   /evidence=""ECO:0000250|UniProtKB:P32862""
FT   MOD_RES         284
FT                   /note=""Phosphoserine""
FT                   /evidence=""ECO:0000250|UniProtKB:P32862""
FT   MOD_RES         410
FT                   /note=""Phosphoserine""
FT                   /evidence=""ECO:0000250|UniProtKB:P32862""
FT   MOD_RES         414
FT                   /note=""Phosphoserine""
FT                   /evidence=""ECO:0000250|UniProtKB:P32862""
FT   MOD_RES         1130
FT                   /note=""Phosphoserine""
FT                   /evidence=""ECO:0000250|UniProtKB:P32862""
SQ   SEQUENCE   1170 AA;  128240 MW;  2063178C29F8128C CRC64;
     MNELNTVSTN SSDSTKNGGT SNSPDDMDSA AAASHAIKKR TKASRACDQC RKKKIKCDYK
     DEKGVCSNCQ RNGDRCSFDR VPLKRGPSKG YTRSTSHPRT NEIQDHNNSR SYNTFDNSNN
     TLNNNTGNSG DNGINSNTVP STPSRSNSVL LPPLTQYIPQ AGGIPPSFQN PAIQSTMPAG
     NIGQQQFWKV PYHEFQHQRK GSIDSLQSDI SVRTLNPNEQ LSYNTVQQSP ITNKHTNDSG
     NANGSVTGSG SASGSGGYWS FIRTSGLLAP TDDHNGEQTR RSSSIPSLLR NTSNSLLLGG
     QPQLPPPQQQ SQPQAHQQKL QQGQNLYSYS QFSQQQPYNP SISSFGQFAA NGFHSRQGSV
     ASEAMSPSAP AMFTSTSTNP VNVAQQTQRP QGQQVPQFSS ELDGNKRRQS APVSVTLSTD
     RLNGNENNNG EINNNNGSNN SGSSKDTSQH SQESVTTPAA LEASSPGSTP QRSTKKRRKS
     YVSKKTKPKR DSSISITSKD SAHPMTTSST IAYGQISDVD LIDTYYEFIH VGFPIIPLNK
     TTLTSDLLLV NTQPISNIHE VNSYVILWFR NSLELLVRVA LKQKPGGKFF DNIVGVALSP
     SNDNNKAGFT TATARDDAEK TRRDSHNEVQ DTLEVQSVFI AALNECFQKI VDIHPKFREN
     NDQISPKIKV IYLSTFILLN YILAFVGYDN SFVLGMSVTI FNEFKLYKLL LFPEPDINDV
     KPPVDEEVST GNGNTKTSEF EIGSESAGHM NPSNSPNSMD ENISHYSVLF KRLYVLLSVF
     DSLQSCAFGG PKLLNISIQG STERFFSNDL GSKWCLEQSQ LRLKSVLQSL KLGELMSELT
     RNRISMNGNR KPGFDITNSS SLLSEYVETQ PLSVAQLFCK LLIGKHNFIN CLLSLYDSEA
     GVYSDLTLDL SSKIADSLCS LISIILQVLT LILRLNPTNS IDFNYRPPNP PANNPTVQEG
     PSAMGSSPVA GNLSAAPPSE GNPDFYKKLL GLKQDTGTIL SDLCRGIISP FAIAILHEVY
     NITELVKQMP TSLISIMMTA TTTQNTQDTK KSQDLVMKLS NSMNEVVQIT SVLTMIKPFK
     IFEHELNKPI MSLTGGLSST TRNDVMWPKS GQGLRESSVM KTLLDERRTS GTQPTTAPVA
     AEEPRLENVA LENFVSIGWK LLDDSELGWY
//
",2553
ATGCCC TGCCCG GCCCGA CCCGAT CCGATA CGATAA GATAAT ATAATG TAATGC AATGCA ATGCAC TGCACC GCACCC CACCCC ACCCCT CCCCTA CCCTAA CCTAAA CTAAAT TAAATC AAATCA AATCAG ATCAGC TCAGCG CAGCGA AGCGAA GCGAAA CGAAAT GAAATG AAATGC AATGCA ATGCAC TGCACT GCACTC CACTCC ACTCCG CTCCGC TCCGCA CCGCAT CGCATT GCATTA CATTAC ATTACG TTACGT TACGTT ACGTTT CGTTTG GTTTGG TTTGGA TTGGAG TGGAGG GGAGGA GAGGAC AGGACC GGACCC GACCCT ACCCTC CCCTCA CCTCAG CTCAGA TCAGAT CAGATT AGATTC GATTCA ATTCAA TTCAAC TCAACT CAACTG AACTGG ACTGGC CTGGCA TGGCAG GGCAGT GCAGTA CAGTAA AGTAAC GTAACC TAACCA AACCAG ACCAGA CCAGAA CAGAAT AGAATG GAATGC AATGCT ATGCTG TGCTGG GCTGGG CTGGGG TGGGGC GGGGCT GGGCTG GGCTGT GCTGTC CTGTCC TGTCCC GTCCCT TCCCTT CCCTTC CCTTCT CTTCTA TTCTAC TCTACA CTACAC TACACA ACACAT CACATC ACATCT CATCTG ATCTGT TCTGTC CTGTCC TGTCCC GTCCCC TCCCCG CCCCGC CCCGCC CCGCCG CGCCGA GCCGAT CCGATG CGATGA GATGAT ATGATC TGATCG GATCGT ATCGTC TCGTCC CGTCCG GTCCGC TCCGCG CCGCGC CGCGCT GCGCTC CGCTCT GCTCTT CTCTTA TCTTAC CTTACA,1,139,ATGC TGCC GCCC CCCG CCGA CGAT GATA ATAA TAAT AATG ATGC TGCA GCAC CACC ACCC CCCC CCCT CCTA CTAA TAAA AAAT AATC ATCA TCAG CAGC AGCG GCGA CGAA GAAA AAAT AATG ATGC TGCA GCAC CACT ACTC CTCC TCCG CCGC CGCA GCAT CATT ATTA TTAC TACG ACGT CGTT GTTT TTTG TTGG TGGA GGAG GAGG AGGA GGAC GACC ACCC CCCT CCTC CTCA TCAG CAGA AGAT GATT ATTC TTCA TCAA CAAC AACT ACTG CTGG TGGC GGCA GCAG CAGT AGTA GTAA TAAC AACC ACCA CCAG CAGA AGAA GAAT AATG ATGC TGCT GCTG CTGG TGGG GGGG GGGC GGCT GCTG CTGT TGTC GTCC TCCC CCCT CCTT CTTC TTCT TCTA CTAC TACA ACAC CACA ACAT CATC ATCT TCTG CTGT TGTC GTCC TCCC CCCC CCCG CCGC CGCC GCCG CCGA CGAT GATG ATGA TGAT GATC ATCG TCGT CGTC GTCC TCCG CCGC CGCG GCGC CGCT GCTC CTCT TCTT CTTA TTAC TACA,ATGCC TGCCC GCCCG CCCGA CCGAT CGATA GATAA ATAAT TAATG AATGC ATGCA TGCAC GCACC CACCC ACCCC CCCCT CCCTA CCTAA CTAAA TAAAT AAATC AATCA ATCAG TCAGC CAGCG AGCGA GCGAA CGAAA GAAAT AAATG AATGC ATGCA TGCAC GCACT CACTC ACTCC CTCCG TCCGC CCGCA CGCAT GCATT CATTA ATTAC TTACG TACGT ACGTT CGTTT GTTTG TTTGG TTGGA TGGAG GGAGG GAGGA AGGAC GGACC GACCC ACCCT CCCTC CCTCA CTCAG TCAGA CAGAT AGATT GATTC ATTCA TTCAA TCAAC CAACT AACTG ACTGG CTGGC TGGCA GGCAG GCAGT CAGTA AGTAA GTAAC TAACC AACCA ACCAG CCAGA CAGAA AGAAT GAATG AATGC ATGCT TGCTG GCTGG CTGGG TGGGG GGGGC GGGCT GGCTG GCTGT CTGTC TGTCC GTCCC TCCCT CCCTT CCTTC CTTCT TTCTA TCTAC CTACA TACAC ACACA CACAT ACATC CATCT ATCTG TCTGT CTGTC TGTCC GTCCC TCCCC CCCCG CCCGC CCGCC CGCCG GCCGA CCGAT CGATG GATGA ATGAT TGATC GATCG ATCGT TCGTC CGTCC GTCCG TCCGC CCGCG CGCGC GCGCT CGCTC GCTCT CTCTT TCTTA CTTAC TTACA,ATGCCC TGCCCG GCCCGA CCCGAT CCGATA CGATAA GATAAT ATAATG TAATGC AATGCA ATGCAC TGCACC GCACCC CACCCC ACCCCT CCCCTA CCCTAA CCTAAA CTAAAT TAAATC AAATCA AATCAG ATCAGC TCAGCG CAGCGA AGCGAA GCGAAA CGAAAT GAAATG AAATGC AATGCA ATGCAC TGCACT GCACTC CACTCC ACTCCG CTCCGC TCCGCA CCGCAT CGCATT GCATTA CATTAC ATTACG TTACGT TACGTT ACGTTT CGTTTG GTTTGG TTTGGA TTGGAG TGGAGG GGAGGA GAGGAC AGGACC GGACCC GACCCT ACCCTC CCCTCA CCTCAG CTCAGA TCAGAT CAGATT AGATTC GATTCA ATTCAA TTCAAC TCAACT CAACTG AACTGG ACTGGC CTGGCA TGGCAG GGCAGT GCAGTA CAGTAA AGTAAC GTAACC TAACCA AACCAG ACCAGA CCAGAA CAGAAT AGAATG GAATGC AATGCT ATGCTG TGCTGG GCTGGG CTGGGG TGGGGC GGGGCT GGGCTG GGCTGT GCTGTC CTGTCC TGTCCC GTCCCT TCCCTT CCCTTC CCTTCT CTTCTA TTCTAC TCTACA CTACAC TACACA ACACAT CACATC ACATCT CATCTG ATCTGT TCTGTC CTGTCC TGTCCC GTCCCC TCCCCG CCCCGC CCCGCC CCGCCG CGCCGA GCCGAT CCGATG CGATGA GATGAT ATGATC TGATCG GATCGT ATCGTC TCGTCC CGTCCG GTCCGC TCCGCG CCGCGC CGCGCT GCGCTC CGCTCT GCTCTT CTCTTA TCTTAC CTTACA,ATGCCCG TGCCCGA GCCCGAT CCCGATA CCGATAA CGATAAT GATAATG ATAATGC TAATGCA AATGCAC ATGCACC TGCACCC GCACCCC CACCCCT ACCCCTA CCCCTAA CCCTAAA CCTAAAT CTAAATC TAAATCA AAATCAG AATCAGC ATCAGCG TCAGCGA CAGCGAA AGCGAAA GCGAAAT CGAAATG GAAATGC AAATGCA AATGCAC ATGCACT TGCACTC GCACTCC CACTCCG ACTCCGC CTCCGCA TCCGCAT CCGCATT CGCATTA GCATTAC CATTACG ATTACGT TTACGTT TACGTTT ACGTTTG CGTTTGG GTTTGGA TTTGGAG TTGGAGG TGGAGGA GGAGGAC GAGGACC AGGACCC GGACCCT GACCCTC ACCCTCA CCCTCAG CCTCAGA CTCAGAT TCAGATT CAGATTC AGATTCA GATTCAA ATTCAAC TTCAACT TCAACTG CAACTGG AACTGGC ACTGGCA CTGGCAG TGGCAGT GGCAGTA GCAGTAA CAGTAAC AGTAACC GTAACCA TAACCAG AACCAGA ACCAGAA CCAGAAT CAGAATG AGAATGC GAATGCT AATGCTG ATGCTGG TGCTGGG GCTGGGG CTGGGGC TGGGGCT GGGGCTG GGGCTGT GGCTGTC GCTGTCC CTGTCCC TGTCCCT GTCCCTT TCCCTTC CCCTTCT CCTTCTA CTTCTAC TTCTACA TCTACAC CTACACA TACACAT ACACATC CACATCT ACATCTG CATCTGT ATCTGTC TCTGTCC CTGTCCC TGTCCCC GTCCCCG TCCCCGC CCCCGCC CCCGCCG CCGCCGA CGCCGAT GCCGATG CCGATGA CGATGAT GATGATC ATGATCG TGATCGT GATCGTC ATCGTCC TCGTCCG CGTCCGC GTCCGCG TCCGCGC CCGCGCT CGCGCTC GCGCTCT CGCTCTT GCTCTTA CTCTTAC TCTTACA,"ID   NCAP_SARS2              Reviewed;         419 AA.
AC   P0DTC9;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Nucleoprotein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=N;
DE   AltName: Full=Nucleocapsid protein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=NC {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=Protein N {ECO:0000255|HAMAP-Rule:MF_04096};
GN   Name=N {ECO:0000255|HAMAP-Rule:MF_04096};
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   SUBCELLULAR LOCATION.
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [3] {ECO:0007744|PDB:6WZO, ECO:0007744|PDB:6WZQ}
RP   X-RAY CRYSTALLOGRAPHY (1.42 ANGSTROMS) OF 247-364, AND SUBUNIT.
RX   PubMed=32654247; DOI=10.1002/pro.3909;
RA   Ye Q., West A.M.V., Silletti S., Corbett K.D.;
RT   ""Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein."";
RL   Protein Sci. 29:1890-1901(2020).
RN   [4]
RP   REVIEW.
RX   PubMed=32974389; DOI=10.3389/fmolb.2020.00219;
RA   Nikolakaki E., Giannakouros T.;
RT   ""SR/RS Motifs as Critical Determinants of Coronavirus Life Cycle."";
RL   Front. Mol. Biosci. 7:219-219(2020).
RN   [5]
RP   VARIANTS LEU-3 AND PHE-235.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [6]
RP   FUNCTION, INTERACTION WITH HOST NLRP3, AND SUBCELLULAR LOCATION.
RX   PubMed=34341353; DOI=10.1038/s41467-021-25015-6;
RA   Pan P., Shen M., Yu Z., Ge W., Chen K., Tian M., Xiao F., Wang Z., Wang J.,
RA   Jia Y., Wang W., Wan P., Zhang J., Chen W., Lei Z., Chen X., Luo Z.,
RA   Zhang Q., Xu M., Li G., Li Y., Wu J.;
RT   ""SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce
RT   hyperinflammation."";
RL   Nat. Commun. 12:4664-4664(2021).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 41-174, AND MUTAGENESIS OF
RP   TYR-109.
RX   PubMed=32363136; DOI=10.1016/j.apsb.2020.04.009;
RA   Kang S., Yang M., Hong Z., Zhang L., Huang Z., Chen X., He S., Zhou Z.,
RA   Zhou Z., Chen Q., Yan Y., Zhang C., Shan H., Chen S.;
RT   ""Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain
RT   reveals potential unique drug targeting sites."";
RL   Acta Pharmacol. Sin. 10:1228-1238(2020).
RN   [8] {ECO:0007744|PDB:6YI3, ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT}
RP   STRUCTURE BY NMR OF 44-180, FUNCTION, AND MUTAGENESIS OF ARG-68; ARG-92;
RP   ILE-94; ARG-107; GLN-163; TYR-172 AND GLU-174.
RX   PubMed=33264373; DOI=10.1371/journal.ppat.1009100;
RA   Dinesh D.C., Chalupska D., Silhan J., Koutna E., Nencka R., Veverka V.,
RA   Boura E.;
RT   ""Structural basis of RNA recognition by the SARS-CoV-2 nucleocapsid
RT   phosphoprotein."";
RL   PLoS Pathog. 16:1-16(2020).
RN   [9]
RP   MUTAGENESIS OF SER-188 AND SER-206, AND PHOSPHORYLATION AT SER-206.
RX   PubMed=34593624; DOI=10.1073/pnas.2113401118;
RA   Liu X., Verma A., Garcia G. Jr., Ramage H., Lucas A., Myers R.L.,
RA   Michaelson J.J., Coryell W., Kumar A., Charney A.W., Kazanietz M.G.,
RA   Rader D.J., Ritchie M.D., Berrettini W.H., Schultz D.C., Cherry S.,
RA   Damoiseaux R., Arumugaswami V., Klein P.S.;
RT   ""Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:1-9(2021).
RN   [10]
RP   CLEAVAGE.
RX   PubMed=35922005; DOI=10.1038/s41586-022-05148-4;
RA   Chu H., Hou Y., Yang D., Wen L., Shuai H., Yoon C., Shi J., Chai Y.,
RA   Yuen T.T., Hu B., Li C., Zhao X., Wang Y., Huang X., Lee K.S., Luo C.,
RA   Cai J.P., Poon V.K., Chan C.C., Zhang A.J., Yuan S., Sit K.Y., Foo D.C.,
RA   Au W.K., Wong K.K., Zhou J., Kok K.H., Jin D.Y., Chan J.F., Yuen K.Y.;
RT   ""Coronaviruses exploit a host cysteine-aspartic protease for replication."";
RL   Nature 0:0-0(2022).
RN   [11]
RP   MUTAGENESIS OF 203-ARG-GLY-204 AND ARG-203, AND PHOSPHORYLATION.
RX   PubMed=35728038; DOI=10.1371/journal.ppat.1010627;
RA   Johnson B.A., Zhou Y., Lokugamage K.G., Vu M.N., Bopp N.,
RA   Crocquet-Valdes P.A., Kalveram B., Schindewolf C., Liu Y., Scharton D.,
RA   Plante J.A., Xie X., Aguilar P., Weaver S.C., Shi P.Y., Walker D.H.,
RA   Routh A.L., Plante K.S., Menachery V.D.;
RT   ""Nucleocapsid mutations in SARS-CoV-2 augment replication and
RT   pathogenesis."";
RL   PLoS Pathog. 18:e1010627-e1010627(2022).
RN   [12]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=35921414; DOI=10.1126/sciadv.abp9770;
RA   Lopez-Munoz A.D., Kosik I., Holly J., Yewdell J.W.;
RT   ""Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive
RT   immunity."";
RL   Sci. Adv. 8:eabp9770-eabp9770(2022).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=34901782; DOI=10.1016/j.isci.2021.103562;
RA   Nabeel-Shah S., Lee H., Ahmed N., Burke G.L., Farhangmehr S., Ashraf K.,
RA   Pu S., Braunschweig U., Zhong G., Wei H., Tang H., Yang J., Marcon E.,
RA   Blencowe B.J., Zhang Z., Greenblatt J.F.;
RT   ""SARS-CoV-2 nucleocapsid protein binds host mRNAs and attenuates stress
RT   granules to impair host stress response."";
RL   IScience 25:103562-103562(2022).
RN   [14]
RP   FUNCTION.
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [15] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 191-263, AND INTERACTION WITH NSP3.
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
CC   -!- FUNCTION: Packages the positive strand viral genome RNA into a helical
CC       ribonucleocapsid (RNP) and plays a fundamental role during virion
CC       assembly through its interactions with the viral genome and membrane
CC       protein M (PubMed:33264373). Plays an important role in enhancing the
CC       efficiency of subgenomic viral RNA transcription as well as viral
CC       replication. Attenuates the stress granules formation by reducing host
CC       G3BP1 access to host mRNAs under stress conditions (PubMed:34901782,
CC       PubMed:36534661). {ECO:0000269|PubMed:32974389,
CC       ECO:0000269|PubMed:33264373, ECO:0000269|PubMed:34901782,
CC       ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: May block host chemokine function in vivo, facilitating viral
CC       replication and transmission (PubMed:35921414). Acts by being secreted
CC       into the extracellular space where it competes to host chemokines for
CC       binding to host glycosaminoglycans (GAG) (PubMed:35921414).
CC       {ECO:0000269|PubMed:35921414}.
CC   -!- FUNCTION: May induce inflammasome responses in cultured cells and mice.
CC       Acts by interacting with host NLRP3 to facilitate inflammasome
CC       assembly, which induces cytokine release that may play a role in COVID
CC       lung injury. {ECO:0000269|PubMed:34341353}.
CC   -!- SUBUNIT: Homodimer, homotetramer, homooligomer with RNA
CC       (PubMed:32654247). Both monomeric and oligomeric forms interact with
CC       RNA. Interacts with protein M (By similarity). Interacts with protein E
CC       (By similarity). Interacts with NSP3; this interaction serves to tether
CC       the genome to the newly translated replicase-transcriptase complex at a
CC       very early stage of infection (PubMed:35044811). May interact with host
CC       NLRP3 (PubMed:34341353). {ECO:0000250|UniProtKB:P59595,
CC       ECO:0000255|HAMAP-Rule:MF_04096, ECO:0000269|PubMed:32654247,
CC       ECO:0000269|PubMed:34341353, ECO:0000269|PubMed:35044811}.
CC   -!- INTERACTION:
CC       P0DTC9; P0DTC4: E; NbExp=3; IntAct=EBI-25475856, EBI-25475850;
CC       P0DTC9; P0DTC5: M; NbExp=6; IntAct=EBI-25475856, EBI-25475853;
CC       P0DTC9; P0DTC9: N; NbExp=105; IntAct=EBI-25475856, EBI-25475856;
CC       P0DTC9; PRO_0000449621 [P0DTD1]: rep; NbExp=15; IntAct=EBI-25475856, EBI-25492388;
CC       P0DTC9; P78563: ADARB1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-2967304;
CC       P0DTC9; O15145: ARPC3; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-351829;
CC       P0DTC9; Q13895: BYSL; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-358049;
CC       P0DTC9; Q16543: CDC37; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-295634;
CC       P0DTC9; Q92793: CREBBP; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-81215;
CC       P0DTC9; Q92499: DDX1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-358474;
CC       P0DTC9; Q9NR30: DDX21; Xeno; NbExp=12; IntAct=EBI-25475856, EBI-357942;
CC       P0DTC9; P26196: DDX6; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-351257;
CC       P0DTC9; Q08426: EHHADH; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-2339219;
CC       P0DTC9; P19525: EIF2AK2; Xeno; NbExp=8; IntAct=EBI-25475856, EBI-640775;
CC       P0DTC9; Q14241: ELOA; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-742350;
CC       P0DTC9; Q13283: G3BP1; Xeno; NbExp=71; IntAct=EBI-25475856, EBI-1047359;
CC       P0DTC9; Q9UN86: G3BP2; Xeno; NbExp=37; IntAct=EBI-25475856, EBI-1044298;
CC       P0DTC9; P57764: GSDMD; Xeno; NbExp=13; IntAct=EBI-25475856, EBI-2798865;
CC       P0DTC9; P49841: GSK3B; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-373586;
CC       P0DTC9; P10412: H1-4; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-358163;
CC       P0DTC9; O14920: IKBKB; Xeno; NbExp=7; IntAct=EBI-25475856, EBI-81266;
CC       P0DTC9; Q92830: KAT2A; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-477622;
CC       P0DTC9; Q92831: KAT2B; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-477430;
CC       P0DTC9; Q07866: KLC1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-721019;
CC       P0DTC9; Q9H0B6: KLC2; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-726994;
CC       P0DTC9; Q9NSK0: KLC4; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-949319;
CC       P0DTC9; Q9NX58: LYAR; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-713507;
CC       P0DTC9; O43318: MAP3K7; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-358684;
CC       P0DTC9; Q9UBU8: MORF4L1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-399246;
CC       P0DTC9; Q15014: MORF4L2; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-399257;
CC       P0DTC9; Q9HCE1: MOV10; Xeno; NbExp=11; IntAct=EBI-25475856, EBI-1055820;
CC       P0DTC9; Q9HC36: MRM3; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-1045440;
CC       P0DTC9; O15226: NKRF; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-766011;
CC       P0DTC9; Q96P20: NLRP3; Xeno; NbExp=18; IntAct=EBI-25475856, EBI-6253230;
CC       P0DTC9; O15118: NPC1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-2368710;
CC       P0DTC9; Q96HA8: NTAQ1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-741158;
CC       P0DTC9; P11940: PABPC1; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-81531;
CC       P0DTC9; P62937: PPIA; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-437708;
CC       P0DTC9; O75569: PRKRA; Xeno; NbExp=8; IntAct=EBI-25475856, EBI-713955;
CC       P0DTC9; Q99873: PRMT1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-78738;
CC       P0DTC9; P61289: PSME3; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-355546;
CC       P0DTC9; P26022: PTX3; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-11574553;
CC       P0DTC9; P54727: RAD23B; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-954531;
CC       P0DTC9; O95786: RIGI; Xeno; NbExp=15; IntAct=EBI-25475856, EBI-995350;
CC       P0DTC9; P62899: RPL31; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-1053664;
CC       P0DTC9; P62753: RPS6; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-356625;
CC       P0DTC9; P37840: SNCA; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-985879;
CC       P0DTC9; Q96SB4: SRPK1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-539478;
CC       P0DTC9; P78362: SRPK2; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-593303;
CC       P0DTC9; P42224: STAT1; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-1057697;
CC       P0DTC9; P52630: STAT2; Xeno; NbExp=7; IntAct=EBI-25475856, EBI-1546963;
CC       P0DTC9; Q15633: TARBP2; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-978581;
CC       P0DTC9; Q14258: TRIM25; Xeno; NbExp=13; IntAct=EBI-25475856, EBI-2341129;
CC       P0DTC9; O60763: USO1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-356164;
CC       P0DTC9; Q93008: USP9X; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-302524;
CC   -!- SUBCELLULAR LOCATION: Virion {ECO:0000255|HAMAP-Rule:MF_04096}. Host
CC       cytoplasm {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:34341353}.
CC       Secreted {ECO:0000269|PubMed:35921414}. Host extracellular space
CC       {ECO:0000269|PubMed:35921414}. Note=Probably associates with ER-derived
CC       membranes where it participates in viral RNA synthesis and virus
CC       budding. When located inside the virion, complexed with the viral RNA.
CC       Can be secreted by unconventional protein secretion (UPS)
CC       (PubMed:35921414). When secreted, can bind to host glycosaminoglycans
CC       on infected and non infected cells (PubMed:35921414). Found in host
CC       cytoplasmic stress granules (PubMed:34901782). {ECO:0000255|HAMAP-
CC       Rule:MF_04096, ECO:0000269|PubMed:34901782,
CC       ECO:0000269|PubMed:35921414}.
CC   -!- PTM: ADP-ribosylated. The ADP-ribosylation is retained in the virion
CC       during infection. {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   -!- PTM: Phosphorylated on serine residues by host GSK3A and GSK3B
CC       (PubMed:34593624, PubMed:35728038). This promotes the solubility of
CC       homodimers that would otherwise aggregate (PubMed:32974389). Host
CC       phosphatase would dephosphorylate the protein during assembly at M
CC       bound membranes (PubMed:32974389). {ECO:0000269|PubMed:34593624,
CC       ECO:0000269|PubMed:35728038, ECO:0000305|PubMed:32974389}.
CC   -!- PTM: Proteolytically cleaved by host CASP6. The cleavage leads to two
CC       fragments and facilitates viral replication by inhibiting host IFN
CC       signaling. The two fragments may interact with IRF3 inhibiting its
CC       nuclear translocation after activation and reduce the expression of
CC       IFNB and IFN-stimulated genes. {ECO:0000269|PubMed:35922005}.
CC   -!- POLYMORPHISM: Variant Alpha/B.1.1.7 belongs to a lineage isolated first
CC       in United Kingdom (December 2020). It is also called Variant of Concern
CC       (VOC) 202012/01, Variant Under Investigation (VUI) 202012/01, 501Y.V1
CC       or 20B/501Y.V1. {ECO:0000305|PubMed:33413740}.
CC   -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC       isolated in South Africa (November 2021). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC       isolated in Nigeria (November 2022). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC       isolated in United States (November 2022). It is the result of
CC       recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC       express ORF8. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the betacoronavirus nucleocapsid protein family.
CC       {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43423.2; -; Genomic_RNA.
DR   PDB; 6M3M; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 6VYO; X-ray; 1.70 A; A/B/C/D=47-173.
DR   PDB; 6WJI; X-ray; 2.05 A; A/B/C/D/E/F=257-364.
DR   PDB; 6WKP; X-ray; 2.67 A; A/B/C/D=47-173.
DR   PDB; 6WZO; X-ray; 1.42 A; A/B/C/D=247-364.
DR   PDB; 6WZQ; X-ray; 1.45 A; A/B/C/D=247-364.
DR   PDB; 6YI3; NMR; -; A=44-180.
DR   PDB; 6YUN; X-ray; 1.44 A; A/B=249-364.
DR   PDB; 6ZCO; X-ray; 1.36 A; A=247-364.
DR   PDB; 7ACS; NMR; -; A=44-180.
DR   PDB; 7ACT; NMR; -; A=44-180.
DR   PDB; 7C22; X-ray; 2.00 A; A/B/C/D=248-364.
DR   PDB; 7CDZ; X-ray; 1.80 A; A/B/C/D=44-174.
DR   PDB; 7CE0; X-ray; 1.50 A; A/B/C/D=255-364.
DR   PDB; 7CR5; X-ray; 2.08 A; A=41-174.
DR   PDB; 7DE1; X-ray; 2.00 A; A/B=250-364.
DR   PDB; 7F2B; X-ray; 2.00 A; A/B=257-362.
DR   PDB; 7F2E; X-ray; 3.10 A; A/B/C/D/E/F/G/H/I/J/K/L=255-362.
DR   PDB; 7KGO; X-ray; 2.15 A; C=351-359.
DR   PDB; 7KGP; X-ray; 1.40 A; C=316-324.
DR   PDB; 7KGQ; X-ray; 1.34 A; C=222-230.
DR   PDB; 7KGR; X-ray; 1.55 A; C=159-167.
DR   PDB; 7KGS; X-ray; 1.58 A; C=138-146.
DR   PDB; 7KGT; X-ray; 1.90 A; C=226-234.
DR   PDB; 7LGD; X-ray; 2.88 A; E/F=105-113.
DR   PDB; 7LTU; X-ray; 1.12 A; A/B=217-222.
DR   PDB; 7LUX; X-ray; 1.30 A; A=217-222.
DR   PDB; 7LUZ; X-ray; 1.10 A; A=243-248.
DR   PDB; 7LV2; X-ray; 1.30 A; A=179-184.
DR   PDB; 7N0I; X-ray; 2.20 A; A/B/C/D/E/F/G/H=269-364.
DR   PDB; 7N0R; X-ray; 1.42 A; A/B=49-174.
DR   PDB; 7N3C; X-ray; 1.82 A; C=47-173.
DR   PDB; 7N3D; X-ray; 1.53 A; C=47-173.
DR   PDB; 7O05; X-ray; 1.94 A; A/B/C/D=247-364.
DR   PDB; 7O35; X-ray; 1.80 A; A/B/C/D=247-364.
DR   PDB; 7O36; X-ray; 2.00 A; A/B/C/D=247-364.
DR   PDB; 7PKU; NMR; -; B=191-263.
DR   PDB; 7QIK; X-ray; 2.01 A; E/F=193-200.
DR   PDB; 7QIP; X-ray; 2.65 A; C/D=201-210.
DR   PDB; 7R98; X-ray; 2.51 A; A/B/C=49-174.
DR   PDB; 7SD4; NMR; -; A=40-174.
DR   PDB; 7STR; X-ray; 1.50 A; C=47-173.
DR   PDB; 7STS; X-ray; 2.16 A; C/D=47-173.
DR   PDB; 7SUE; X-ray; 2.90 A; C/D/J/K=47-173.
DR   PDB; 7SUO; X-ray; 2.35 A; C/D=12-22.
DR   PDB; 7UW3; X-ray; 1.70 A; A/B/C/D=40-174.
DR   PDB; 7UXX; X-ray; 1.85 A; AAA/BBB/CCC/DDD/EEE/FFF=251-364.
DR   PDB; 7UXZ; X-ray; 1.73 A; AAA/BBB/CCC/DDD/EEE/FFF=251-364.
DR   PDB; 7VBD; X-ray; 1.94 A; A/B/C/D=48-174.
DR   PDB; 7VBE; X-ray; 1.59 A; A/B=257-364.
DR   PDB; 7VBF; X-ray; 1.30 A; A/B=255-364.
DR   PDB; 7VNU; X-ray; 1.95 A; A/B/C/D=47-174.
DR   PDB; 7WKJ; X-ray; 1.50 A; C=361-369.
DR   PDB; 7WZO; X-ray; 2.64 A; A=47-174.
DR   PDB; 7XWX; X-ray; 3.00 A; A/B/C/D/E/F/G/H=269-367.
DR   PDB; 7XWZ; X-ray; 2.25 A; A/B=48-172.
DR   PDB; 7XX1; X-ray; 1.90 A; A/B/C/D=49-173.
DR   PDB; 7XXK; X-ray; 2.00 A; A/B/C/D/E/F=248-364.
DR   PDB; 7YLB; X-ray; 2.41 A; A/B/C/D/G/H/J/K=247-364.
DR   PDB; 7YLD; X-ray; 2.80 A; A/B/C/D=47-174.
DR   PDB; 7ZIT; X-ray; 1.79 A; C/D=194-200.
DR   PDB; 8DNT; X-ray; 3.18 A; D/J/Q/X=222-230.
DR   PDB; 8FD5; EM; 4.57 A; A=1-419.
DR   PDB; 8FG2; EM; 6.00 A; A/B=1-419.
DR   PDB; 8IQJ; X-ray; 2.30 A; A/B/C/D=41-174.
DR   PDB; 8IV3; X-ray; 1.90 A; A/B/C/D=41-174.
DR   PDB; 8J6X; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 8TH1; X-ray; 1.80 A; E/F/G/H=1-25.
DR   PDB; 8TH5; X-ray; 2.62 A; K/L/M/N/O/P/Q=1-25.
DR   PDB; 8X1H; X-ray; 2.00 A; A/B/C/D=44-175.
DR   PDBsum; 6M3M; -.
DR   PDBsum; 6VYO; -.
DR   PDBsum; 6WJI; -.
DR   PDBsum; 6WKP; -.
DR   PDBsum; 6WZO; -.
DR   PDBsum; 6WZQ; -.
DR   PDBsum; 6YI3; -.
DR   PDBsum; 6YUN; -.
DR   PDBsum; 6ZCO; -.
DR   PDBsum; 7ACS; -.
DR   PDBsum; 7ACT; -.
DR   PDBsum; 7C22; -.
DR   PDBsum; 7CDZ; -.
DR   PDBsum; 7CE0; -.
DR   PDBsum; 7CR5; -.
DR   PDBsum; 7DE1; -.
DR   PDBsum; 7F2B; -.
DR   PDBsum; 7F2E; -.
DR   PDBsum; 7KGO; -.
DR   PDBsum; 7KGP; -.
DR   PDBsum; 7KGQ; -.
DR   PDBsum; 7KGR; -.
DR   PDBsum; 7KGS; -.
DR   PDBsum; 7KGT; -.
DR   PDBsum; 7LGD; -.
DR   PDBsum; 7LTU; -.
DR   PDBsum; 7LUX; -.
DR   PDBsum; 7LUZ; -.
DR   PDBsum; 7LV2; -.
DR   PDBsum; 7N0I; -.
DR   PDBsum; 7N0R; -.
DR   PDBsum; 7N3C; -.
DR   PDBsum; 7N3D; -.
DR   PDBsum; 7O05; -.
DR   PDBsum; 7O35; -.
DR   PDBsum; 7O36; -.
DR   PDBsum; 7PKU; -.
DR   PDBsum; 7QIK; -.
DR   PDBsum; 7QIP; -.
DR   PDBsum; 7R98; -.
DR   PDBsum; 7SD4; -.
DR   PDBsum; 7STR; -.
DR   PDBsum; 7STS; -.
DR   PDBsum; 7SUE; -.
DR   PDBsum; 7SUO; -.
DR   PDBsum; 7UW3; -.
DR   PDBsum; 7UXX; -.
DR   PDBsum; 7UXZ; -.
DR   PDBsum; 7VBD; -.
DR   PDBsum; 7VBE; -.
DR   PDBsum; 7VBF; -.
DR   PDBsum; 7VNU; -.
DR   PDBsum; 7WKJ; -.
DR   PDBsum; 7WZO; -.
DR   PDBsum; 7XWX; -.
DR   PDBsum; 7XWZ; -.
DR   PDBsum; 7XX1; -.
DR   PDBsum; 7XXK; -.
DR   PDBsum; 7YLB; -.
DR   PDBsum; 7YLD; -.
DR   PDBsum; 7ZIT; -.
DR   PDBsum; 8DNT; -.
DR   PDBsum; 8FD5; -.
DR   PDBsum; 8FG2; -.
DR   PDBsum; 8IQJ; -.
DR   PDBsum; 8IV3; -.
DR   PDBsum; 8J6X; -.
DR   PDBsum; 8TH1; -.
DR   PDBsum; 8TH5; -.
DR   PDBsum; 8X1H; -.
DR   BMRB; P0DTC9; -.
DR   EMDB; EMD-29002; -.
DR   EMDB; EMD-29072; -.
DR   SASBDB; P0DTC9; -.
DR   SMR; P0DTC9; -.
DR   BioGRID; 4383847; 1532.
DR   ComplexPortal; CPX-5686; SARS-CoV-2 nucleocapsid complex.
DR   IntAct; P0DTC9; 608.
DR   MINT; P0DTC9; -.
DR   ChEMBL; CHEMBL5169223; -.
DR   iPTMnet; P0DTC9; -.
DR   ABCD; P0DTC9; 27 sequenced antibodies.
DR   DNASU; 43740575; -.
DR   KEGG; vg:43740575; -.
DR   AGR; RefSeq:YP_009724397; -.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-168928; DDX58/IFIH1-mediated induction of interferon-alpha/beta.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-445989; TAK1-dependent IKK and NF-kappa-B activation.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-9020702; Interleukin-1 signaling.
DR   Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR   Reactome; R-HSA-9694322; Virion Assembly and Release.
DR   Reactome; R-HSA-9694614; Attachment and Entry.
DR   Reactome; R-HSA-9694631; Maturation of nucleoprotein.
DR   Reactome; R-HSA-9694635; Translation of Structural Proteins.
DR   Reactome; R-HSA-9694786; Transcription of SARS-CoV-2 sgRNAs.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9733458; Induction of Cell-Cell Fusion.
DR   Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways.
DR   SIGNOR; P0DTC9; -.
DR   PRO; PR:P0DTC9; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProt.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0044172; C:host cell endoplasmic reticulum-Golgi intermediate compartment; ISS:UniProtKB.
DR   GO; GO:0044177; C:host cell Golgi apparatus; ISS:UniProtKB.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0043655; C:host extracellular space; IEA:UniProtKB-SubCell.
DR   GO; GO:0043232; C:intracellular non-membrane-bounded organelle; IDA:DisProt.
DR   GO; GO:0042612; C:MHC class I protein complex; EXP:DisProt.
DR   GO; GO:1990904; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IPI:ComplexPortal.
DR   GO; GO:0019013; C:viral nucleocapsid; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0042288; F:MHC class I protein binding; EXP:DisProt.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; IDA:DisProt.
DR   GO; GO:0008266; F:poly(U) RNA binding; IMP:DisProt.
DR   GO; GO:0042803; F:protein homodimerization activity; EXP:DisProt.
DR   GO; GO:0140311; F:protein sequestering activity; IDA:UniProt.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProt.
DR   GO; GO:0035613; F:RNA stem-loop binding; IDA:DisProt.
DR   GO; GO:0039709; P:cytoplasmic capsid assembly; IDA:UniProt.
DR   GO; GO:0032688; P:negative regulation of interferon-beta production; IDA:ComplexPortal.
DR   GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; IDA:UniProtKB.
DR   GO; GO:0052572; P:response to host immune response; IDA:DisProt.
DR   GO; GO:0019074; P:viral RNA genome packaging; NAS:ComplexPortal.
DR   CDD; cd21595; CoV_N-CTD; 1.
DR   CDD; cd21554; CoV_N-NTD; 1.
DR   HAMAP; MF_04096; BETA_CORONA_NCAP; 1.
DR   InterPro; IPR044344; N_prot_C_CoV.
DR   InterPro; IPR044345; N_prot_N_CoV.
DR   InterPro; IPR043505; NCAP_bCoV.
DR   InterPro; IPR001218; Nucleocap_CoV.
DR   InterPro; IPR037179; Nucleocapsid_C.
DR   InterPro; IPR037195; Nucleocapsid_N.
DR   Pfam; PF00937; CoV_nucleocap; 1.
DR   PIRSF; PIRSF003888; Corona_nucleocap; 1.
DR   SUPFAM; SSF110304; Coronavirus RNA-binding domain; 1.
DR   SUPFAM; SSF103068; Nucleocapsid protein dimerization domain; 1.
DR   PROSITE; PS51929; COV_N_CTD; 1.
DR   PROSITE; PS51928; COV_N_NTD; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Host cytoplasm; Phosphoprotein;
KW   Reference proteome; Ribonucleoprotein; RNA-binding; Secreted;
KW   Transcription; Transcription regulation; Viral nucleoprotein; Virion.
FT   CHAIN           1..419
FT                   /note=""Nucleoprotein""
FT                   /id=""PRO_0000449656""
FT   DOMAIN          48..174
FT                   /note=""CoV N NTD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01276,
FT                   ECO:0000269|PubMed:32363136""
FT   DOMAIN          247..364
FT                   /note=""CoV N CTD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01277""
FT   REGION          1..51
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          41..186
FT                   /note=""RNA-binding""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   REGION          63..83
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          168..212
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          176..206
FT                   /note=""SR region""
FT                   /evidence=""ECO:0000305|PubMed:32974389""
FT   REGION          233..266
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          258..361
FT                   /note=""Dimerization""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   REGION          260..340
FT                   /note=""Putative NLRP3 binding""
FT                   /evidence=""ECO:0000269|PubMed:34341353""
FT   REGION          361..391
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          400..419
FT                   /note=""Tetramerization""
FT                   /evidence=""ECO:0000269|PubMed:32654247""
FT   MOTIF           256..264
FT                   /note=""Nuclear localization signal""
FT                   /evidence=""ECO:0000250|UniProtKB:P59595""
FT   COMPBIAS        1..11
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        21..31
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        367..378
FT                   /note=""Basic and acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   BINDING         92
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   BINDING         107
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   BINDING         149
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   SITE            399..402
FT                   /note=""Cleavage (by host CASP6)""
FT                   /evidence=""ECO:0000250|UniProtKB:P59595""
FT   MOD_RES         176
FT                   /note=""Phosphoserine; by host""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   MOD_RES         206
FT                   /note=""Phosphoserine; by host GSK3-alpha and GSK3-beta""
FT                   /evidence=""ECO:0000269|PubMed:34593624""
FT   VARIANT         2..3
FT                   /note=""SD -> Y (in strain: Eta/B.1.525)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         3
FT                   /note=""D -> L (in strain: Alpha/B.1.1.7)""
FT                   /evidence=""ECO:0000305|PubMed:33413740""
FT   VARIANT         12
FT                   /note=""A -> G (in strain: Eta/B.1.525)""
FT   VARIANT         13
FT                   /note=""P -> L (in strain: Lambda/C.37, Omicron/BA.1,
FT                   Omicron/BA.2, Omicron/BA.2.12.1, Omicron/BA.2.75,
FT                   Omicron/BA.4, Omicron/BA.5, Omicron/BQ.1.1,
FT                   Omicron/XBB.1.5, Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         31..33
FT                   /note=""Missing (in strain: Omicron/BA.1, Omicron/BA.2,
FT                   Omicron/BA.2.12.1, Omicron/BA.2.75, Omicron/BA.4,
FT                   Omicron/BA.5, Omicron/BQ.1.1, Omicron/XBB.1.5,
FT                   Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         63
FT                   /note=""D -> G (in strain: Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT  ",5950
GCTGTT CTGTTA TGTTAT GTTATG TTATGT TATGTC ATGTCT TGTCTT GTCTTT TCTTTA CTTTAA TTTAAA TTAAAA TAAAAG AAAAGA AAAGAA AAGAAG AGAAGG GAAGGT AAGGTC AGGTCA GGTCAA GTCAAA TCAAAT CAAATC AAATCA AATCAA ATCAAT TCAATG CAATGA AATGAT ATGATA TGATAT GATATG ATATGA TATGAT ATGATT TGATTT GATTTT ATTTTA TTTTAT TTTATC TTATCT TATCTC ATCTCT TCTCTT CTCTTC TCTTCT CTTCTT TTCTTA TCTTAG CTTAGT TTAGTA TAGTAA AGTAAA GTAAAG TAAAGG AAAGGT AAGGTA AGGTAG GGTAGA,0,61,GCTG CTGT TGTT GTTA TTAT TATG ATGT TGTC GTCT TCTT CTTT TTTA TTAA TAAA AAAA AAAG AAGA AGAA GAAG AAGG AGGT GGTC GTCA TCAA CAAA AAAT AATC ATCA TCAA CAAT AATG ATGA TGAT GATA ATAT TATG ATGA TGAT GATT ATTT TTTT TTTA TTAT TATC ATCT TCTC CTCT TCTT CTTC TTCT TCTT CTTA TTAG TAGT AGTA GTAA TAAA AAAG AAGG AGGT GGTA GTAG TAGA,GCTGT CTGTT TGTTA GTTAT TTATG TATGT ATGTC TGTCT GTCTT TCTTT CTTTA TTTAA TTAAA TAAAA AAAAG AAAGA AAGAA AGAAG GAAGG AAGGT AGGTC GGTCA GTCAA TCAAA CAAAT AAATC AATCA ATCAA TCAAT CAATG AATGA ATGAT TGATA GATAT ATATG TATGA ATGAT TGATT GATTT ATTTT TTTTA TTTAT TTATC TATCT ATCTC TCTCT CTCTT TCTTC CTTCT TTCTT TCTTA CTTAG TTAGT TAGTA AGTAA GTAAA TAAAG AAAGG AAGGT AGGTA GGTAG GTAGA,GCTGTT CTGTTA TGTTAT GTTATG TTATGT TATGTC ATGTCT TGTCTT GTCTTT TCTTTA CTTTAA TTTAAA TTAAAA TAAAAG AAAAGA AAAGAA AAGAAG AGAAGG GAAGGT AAGGTC AGGTCA GGTCAA GTCAAA TCAAAT CAAATC AAATCA AATCAA ATCAAT TCAATG CAATGA AATGAT ATGATA TGATAT GATATG ATATGA TATGAT ATGATT TGATTT GATTTT ATTTTA TTTTAT TTTATC TTATCT TATCTC ATCTCT TCTCTT CTCTTC TCTTCT CTTCTT TTCTTA TCTTAG CTTAGT TTAGTA TAGTAA AGTAAA GTAAAG TAAAGG AAAGGT AAGGTA AGGTAG GGTAGA,GCTGTTA CTGTTAT TGTTATG GTTATGT TTATGTC TATGTCT ATGTCTT TGTCTTT GTCTTTA TCTTTAA CTTTAAA TTTAAAA TTAAAAG TAAAAGA AAAAGAA AAAGAAG AAGAAGG AGAAGGT GAAGGTC AAGGTCA AGGTCAA GGTCAAA GTCAAAT TCAAATC CAAATCA AAATCAA AATCAAT ATCAATG TCAATGA CAATGAT AATGATA ATGATAT TGATATG GATATGA ATATGAT TATGATT ATGATTT TGATTTT GATTTTA ATTTTAT TTTTATC TTTATCT TTATCTC TATCTCT ATCTCTT TCTCTTC CTCTTCT TCTTCTT CTTCTTA TTCTTAG TCTTAGT CTTAGTA TTAGTAA TAGTAAA AGTAAAG GTAAAGG TAAAGGT AAAGGTA AAGGTAG AGGTAGA,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",21855
GTTTTT TTTTTG TTTTGT TTTGTA TTGTAA TGTAAC GTAACA TAACAG AACAGG ACAGGT CAGGTT AGGTTC GGTTCC GTTCCG TTCCGA TCCGAT CCGATA CGATAC GATACA ATACAT TACATC ACATCA CATCAT ATCATC TCATCC CATCCA ATCCAA TCCAAT CCAATG CAATGC AATGCT ATGCTT TGCTTT GCTTTG CTTTGT TTTGTT TTGTTC TGTTCT GTTCTG TTCTGT TCTGTA CTGTAA TGTAAT GTAATA TAATAC AATACG ATACGC TACGCA ACGCAA CGCAAA GCAAAA CAAAAG AAAAGG AAAGGC AAGGCA AGGCAA GGCAAC GCAACG CAACGG AACGGC ACGGCG CGGCGG GGCGGT GCGGTT CGGTTT GGTTTC GTTTCG TTTCGA TTCGAT TCGATT CGATTG GATTGG ATTGGG TTGGGG TGGGGT GGGGTT GGGTTT GGTTTC GTTTCC TTTCCC TTCCCC TCCCCG CCCCGG CCCGGT CCGGTC CGGTCA GGTCAT GTCATT TCATTC CATTCA ATTCAC TTCACG TCACGT CACGTT ACGTTG CGTTGC GTTGCG TTGCGG TGCGGC GCGGCC CGGCCC GGCCCA GCCCAT CCCATA CCATAT CATATT ATATTT TATTTC ATTTCC TTTCCG TTCCGG TCCGGA CCGGAG CGGAGG GGAGGG GAGGGG AGGGGG GGGGGG GGGGGG GGGGGT GGGGTT GGGTTG GGTTGG GTTGGT TTGGTA TGGTAA GGTAAA GTAAAA TAAAAA AAAAAG AAAAGC AAAGCT AAGCTT AGCTTT GCTTTC CTTTCA TTTCAC TTCACC TCACCC CACCCT ACCCTG CCCTGC,2,142,GTTT TTTT TTTT TTTG TTGT TGTA GTAA TAAC AACA ACAG CAGG AGGT GGTT GTTC TTCC TCCG CCGA CGAT GATA ATAC TACA ACAT CATC ATCA TCAT CATC ATCC TCCA CCAA CAAT AATG ATGC TGCT GCTT CTTT TTTG TTGT TGTT GTTC TTCT TCTG CTGT TGTA GTAA TAAT AATA ATAC TACG ACGC CGCA GCAA CAAA AAAA AAAG AAGG AGGC GGCA GCAA CAAC AACG ACGG CGGC GGCG GCGG CGGT GGTT GTTT TTTC TTCG TCGA CGAT GATT ATTG TTGG TGGG GGGG GGGT GGTT GTTT TTTC TTCC TCCC CCCC CCCG CCGG CGGT GGTC GTCA TCAT CATT ATTC TTCA TCAC CACG ACGT CGTT GTTG TTGC TGCG GCGG CGGC GGCC GCCC CCCA CCAT CATA ATAT TATT ATTT TTTC TTCC TCCG CCGG CGGA GGAG GAGG AGGG GGGG GGGG GGGG GGGG GGGT GGTT GTTG TTGG TGGT GGTA GTAA TAAA AAAA AAAA AAAG AAGC AGCT GCTT CTTT TTTC TTCA TCAC CACC ACCC CCCT CCTG CTGC,GTTTT TTTTT TTTTG TTTGT TTGTA TGTAA GTAAC TAACA AACAG ACAGG CAGGT AGGTT GGTTC GTTCC TTCCG TCCGA CCGAT CGATA GATAC ATACA TACAT ACATC CATCA ATCAT TCATC CATCC ATCCA TCCAA CCAAT CAATG AATGC ATGCT TGCTT GCTTT CTTTG TTTGT TTGTT TGTTC GTTCT TTCTG TCTGT CTGTA TGTAA GTAAT TAATA AATAC ATACG TACGC ACGCA CGCAA GCAAA CAAAA AAAAG AAAGG AAGGC AGGCA GGCAA GCAAC CAACG AACGG ACGGC CGGCG GGCGG GCGGT CGGTT GGTTT GTTTC TTTCG TTCGA TCGAT CGATT GATTG ATTGG TTGGG TGGGG GGGGT GGGTT GGTTT GTTTC TTTCC TTCCC TCCCC CCCCG CCCGG CCGGT CGGTC GGTCA GTCAT TCATT CATTC ATTCA TTCAC TCACG CACGT ACGTT CGTTG GTTGC TTGCG TGCGG GCGGC CGGCC GGCCC GCCCA CCCAT CCATA CATAT ATATT TATTT ATTTC TTTCC TTCCG TCCGG CCGGA CGGAG GGAGG GAGGG AGGGG GGGGG GGGGG GGGGG GGGGT GGGTT GGTTG GTTGG TTGGT TGGTA GGTAA GTAAA TAAAA AAAAA AAAAG AAAGC AAGCT AGCTT GCTTT CTTTC TTTCA TTCAC TCACC CACCC ACCCT CCCTG CCTGC,GTTTTT TTTTTG TTTTGT TTTGTA TTGTAA TGTAAC GTAACA TAACAG AACAGG ACAGGT CAGGTT AGGTTC GGTTCC GTTCCG TTCCGA TCCGAT CCGATA CGATAC GATACA ATACAT TACATC ACATCA CATCAT ATCATC TCATCC CATCCA ATCCAA TCCAAT CCAATG CAATGC AATGCT ATGCTT TGCTTT GCTTTG CTTTGT TTTGTT TTGTTC TGTTCT GTTCTG TTCTGT TCTGTA CTGTAA TGTAAT GTAATA TAATAC AATACG ATACGC TACGCA ACGCAA CGCAAA GCAAAA CAAAAG AAAAGG AAAGGC AAGGCA AGGCAA GGCAAC GCAACG CAACGG AACGGC ACGGCG CGGCGG GGCGGT GCGGTT CGGTTT GGTTTC GTTTCG TTTCGA TTCGAT TCGATT CGATTG GATTGG ATTGGG TTGGGG TGGGGT GGGGTT GGGTTT GGTTTC GTTTCC TTTCCC TTCCCC TCCCCG CCCCGG CCCGGT CCGGTC CGGTCA GGTCAT GTCATT TCATTC CATTCA ATTCAC TTCACG TCACGT CACGTT ACGTTG CGTTGC GTTGCG TTGCGG TGCGGC GCGGCC CGGCCC GGCCCA GCCCAT CCCATA CCATAT CATATT ATATTT TATTTC ATTTCC TTTCCG TTCCGG TCCGGA CCGGAG CGGAGG GGAGGG GAGGGG AGGGGG GGGGGG GGGGGG GGGGGT GGGGTT GGGTTG GGTTGG GTTGGT TTGGTA TGGTAA GGTAAA GTAAAA TAAAAA AAAAAG AAAAGC AAAGCT AAGCTT AGCTTT GCTTTC CTTTCA TTTCAC TTCACC TCACCC CACCCT ACCCTG CCCTGC,GTTTTTG TTTTTGT TTTTGTA TTTGTAA TTGTAAC TGTAACA GTAACAG TAACAGG AACAGGT ACAGGTT CAGGTTC AGGTTCC GGTTCCG GTTCCGA TTCCGAT TCCGATA CCGATAC CGATACA GATACAT ATACATC TACATCA ACATCAT CATCATC ATCATCC TCATCCA CATCCAA ATCCAAT TCCAATG CCAATGC CAATGCT AATGCTT ATGCTTT TGCTTTG GCTTTGT CTTTGTT TTTGTTC TTGTTCT TGTTCTG GTTCTGT TTCTGTA TCTGTAA CTGTAAT TGTAATA GTAATAC TAATACG AATACGC ATACGCA TACGCAA ACGCAAA CGCAAAA GCAAAAG CAAAAGG AAAAGGC AAAGGCA AAGGCAA AGGCAAC GGCAACG GCAACGG CAACGGC AACGGCG ACGGCGG CGGCGGT GGCGGTT GCGGTTT CGGTTTC GGTTTCG GTTTCGA TTTCGAT TTCGATT TCGATTG CGATTGG GATTGGG ATTGGGG TTGGGGT TGGGGTT GGGGTTT GGGTTTC GGTTTCC GTTTCCC TTTCCCC TTCCCCG TCCCCGG CCCCGGT CCCGGTC CCGGTCA CGGTCAT GGTCATT GTCATTC TCATTCA CATTCAC ATTCACG TTCACGT TCACGTT CACGTTG ACGTTGC CGTTGCG GTTGCGG TTGCGGC TGCGGCC GCGGCCC CGGCCCA GGCCCAT GCCCATA CCCATAT CCATATT CATATTT ATATTTC TATTTCC ATTTCCG TTTCCGG TTCCGGA TCCGGAG CCGGAGG CGGAGGG GGAGGGG GAGGGGG AGGGGGG GGGGGGG GGGGGGT GGGGGTT GGGGTTG GGGTTGG GGTTGGT GTTGGTA TTGGTAA TGGTAAA GGTAAAA GTAAAAA TAAAAAG AAAAAGC AAAAGCT AAAGCTT AAGCTTT AGCTTTC GCTTTCA CTTTCAC TTTCACC TTCACCC TCACCCT CACCCTG ACCCTGC,"ID   LUTP_BACSU              Reviewed;         563 AA.
AC   P71067;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   05-FEB-2025, entry version 126.
DE   RecName: Full=L-lactate permease;
GN   Name=lutP; Synonyms=yvfH; OrderedLocusNames=BSU34190;
OS   Bacillus subtilis (strain 168).
OC   Bacteria; Bacillati; Bacillota; Bacilli; Bacillales; Bacillaceae; Bacillus.
OX   NCBI_TaxID=224308;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=168;
RA   Denizot F.;
RL   Submitted (APR-1997) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=168;
RX   PubMed=9384377; DOI=10.1038/36786;
RA   Kunst F., Ogasawara N., Moszer I., Albertini A.M., Alloni G., Azevedo V.,
RA   Bertero M.G., Bessieres P., Bolotin A., Borchert S., Borriss R.,
RA   Boursier L., Brans A., Braun M., Brignell S.C., Bron S., Brouillet S.,
RA   Bruschi C.V., Caldwell B., Capuano V., Carter N.M., Choi S.-K.,
RA   Codani J.-J., Connerton I.F., Cummings N.J., Daniel R.A., Denizot F.,
RA   Devine K.M., Duesterhoeft A., Ehrlich S.D., Emmerson P.T., Entian K.-D.,
RA   Errington J., Fabret C., Ferrari E., Foulger D., Fritz C., Fujita M.,
RA   Fujita Y., Fuma S., Galizzi A., Galleron N., Ghim S.-Y., Glaser P.,
RA   Goffeau A., Golightly E.J., Grandi G., Guiseppi G., Guy B.J., Haga K.,
RA   Haiech J., Harwood C.R., Henaut A., Hilbert H., Holsappel S., Hosono S.,
RA   Hullo M.-F., Itaya M., Jones L.-M., Joris B., Karamata D., Kasahara Y.,
RA   Klaerr-Blanchard M., Klein C., Kobayashi Y., Koetter P., Koningstein G.,
RA   Krogh S., Kumano M., Kurita K., Lapidus A., Lardinois S., Lauber J.,
RA   Lazarevic V., Lee S.-M., Levine A., Liu H., Masuda S., Mauel C.,
RA   Medigue C., Medina N., Mellado R.P., Mizuno M., Moestl D., Nakai S.,
RA   Noback M., Noone D., O'Reilly M., Ogawa K., Ogiwara A., Oudega B.,
RA   Park S.-H., Parro V., Pohl T.M., Portetelle D., Porwollik S.,
RA   Prescott A.M., Presecan E., Pujic P., Purnelle B., Rapoport G., Rey M.,
RA   Reynolds S., Rieger M., Rivolta C., Rocha E., Roche B., Rose M., Sadaie Y.,
RA   Sato T., Scanlan E., Schleich S., Schroeter R., Scoffone F., Sekiguchi J.,
RA   Sekowska A., Seror S.J., Serror P., Shin B.-S., Soldo B., Sorokin A.,
RA   Tacconi E., Takagi T., Takahashi H., Takemaru K., Takeuchi M.,
RA   Tamakoshi A., Tanaka T., Terpstra P., Tognoni A., Tosato V., Uchiyama S.,
RA   Vandenbol M., Vannier F., Vassarotti A., Viari A., Wambutt R., Wedler E.,
RA   Wedler H., Weitzenegger T., Winters P., Wipat A., Yamamoto H., Yamane K.,
RA   Yasumoto K., Yata K., Yoshida K., Yoshikawa H.-F., Zumstein E.,
RA   Yoshikawa H., Danchin A.;
RT   ""The complete genome sequence of the Gram-positive bacterium Bacillus
RT   subtilis."";
RL   Nature 390:249-256(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 51-563.
RC   STRAIN=168;
RX   PubMed=8969506; DOI=10.1099/13500872-142-11-3089;
RA   Fabret C., Quentin Y., Chapal N., Guiseppi A., Haiech J., Denizot F.;
RT   ""Integrated mapping and sequencing of a 115 kb DNA fragment from Bacillus
RT   subtilis: sequence analysis of a 21 kb segment containing the sigL locus."";
RL   Microbiology 142:3089-3096(1996).
RN   [4]
RP   FUNCTION AS A LACTATE PERMEASE, AND DISRUPTION PHENOTYPE.
RC   STRAIN=3610;
RX   PubMed=19201793; DOI=10.1128/jb.01464-08;
RA   Chai Y., Kolter R., Losick R.;
RT   ""A widely conserved gene cluster required for lactate utilization in
RT   Bacillus subtilis and its involvement in biofilm formation."";
RL   J. Bacteriol. 191:2423-2430(2009).
CC   -!- FUNCTION: Is the principal permease for the uptake of L-lactate in
CC       B.subtilis. {ECO:0000269|PubMed:19201793}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Multi-pass membrane
CC       protein {ECO:0000305}.
CC   -!- DISRUPTION PHENOTYPE: Cells lacking this gene are markedly impaired
CC       (but not totally blocked) in growth on L-lactate minimal medium but not
CC       impaired in growth on glucose minimal medium.
CC       {ECO:0000269|PubMed:19201793}.
CC   -!- SIMILARITY: Belongs to the lactate permease family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Z94043; CAB08002.1; -; Genomic_DNA.
DR   EMBL; AL009126; CAB15424.1; -; Genomic_DNA.
DR   EMBL; Z71928; CAA96486.1; -; Genomic_DNA.
DR   PIR; A70038; A70038.
DR   RefSeq; NP_391299.1; NC_000964.3.
DR   RefSeq; WP_003228275.1; NZ_OZ025638.1.
DR   AlphaFoldDB; P71067; -.
DR   STRING; 224308.BSU34190; -.
DR   TCDB; 2.A.14.1.3; the lactate permease (lctp) family.
DR   PaxDb; 224308-BSU34190; -.
DR   EnsemblBacteria; CAB15424; CAB15424; BSU_34190.
DR   GeneID; 936322; -.
DR   KEGG; bsu:BSU34190; -.
DR   PATRIC; fig|224308.179.peg.3706; -.
DR   eggNOG; COG1620; Bacteria.
DR   InParanoid; P71067; -.
DR   OrthoDB; 9761056at2; -.
DR   PhylomeDB; P71067; -.
DR   BioCyc; BSUB:BSU34190-MONOMER; -.
DR   Proteomes; UP000001570; Chromosome.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0015129; F:lactate transmembrane transporter activity; IEA:InterPro.
DR   GO; GO:0015295; F:solute:proton symporter activity; IBA:GO_Central.
DR   InterPro; IPR003804; Lactate_perm.
DR   NCBIfam; TIGR00795; lctP; 1.
DR   PANTHER; PTHR30003:SF0; GLYCOLATE PERMEASE GLCA-RELATED; 1.
DR   PANTHER; PTHR30003; L-LACTATE PERMEASE; 1.
DR   Pfam; PF02652; Lactate_perm; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Membrane; Reference proteome; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN           1..563
FT                   /note=""L-lactate permease""
FT                   /id=""PRO_0000210381""
FT   TRANSMEM        14..34
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        37..57
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        73..93
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        131..151
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        157..177
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        194..214
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        220..240
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        249..269
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        304..324
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        381..401
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        419..439
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        448..468
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        506..526
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        542..562
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
SQ   SEQUENCE   563 AA;  59762 MW;  E3B0983059B19B08 CRC64;
     MQWTQAYTPI GGNLLLSALA ALVPIIFFFW ALAIKRMKGY TAGLATLGIA LIIAVLVYRM
     PAEKALMSAT QGAVYGLLPI GWIIVTSVFL YKITVKTGQF DIIRSSVLSI TDDRRLQALL
     IAFSFGAFLE GAAGFGAPVA ISAALLVGLG FNPLYAAGIC LIANTAPVAF GAIGIPITAV
     EGPTGIPAME ISQMVGRQLP FLSVFIPLYL IIIMSGFRKA LEIWPAILVS GVSFAVVQYL
     SSNFLGPELP DVLSALVSMA ALAVFLKWWK PKTTFRFAGE QESAASIETA RTNPAAPAYR
     GGQIFKAWSP FLLLTAMISV WGIPSVKSAL TGHYEGSAVF LKWLNAVGEK LTFSPGVPFL
     NNQIVNADGT PIEAVYKLEV LGSAGTAILI AAVLSKFITA ISWKDWGTVF KETVQELKLP
     ILTIASVVGF AYVTNSSGMS TTLGMTLALT GSMFTFFSPV LGWLGVFITG SDTSANLLFG
     NLQKVTALSV GMDPVLSVAA NSSGGVTGKM ISPQSIAVAC AAVGLAGKES DLFRFTIKHS
     LFLLLLVCII TFLQHHVFSW MIP
//
",39914
CTGTTG TGTTGG GTTGGA TTGGAA TGGAAC GGAACA GAACAG AACAGC ACAGCT CAGCTG AGCTGG GCTGGC CTGGCC TGGCCG GGCCGC GCCGCG CCGCGC CGCGCT GCGCTG CGCTGA GCTGAT CTGATT TGATTG GATTGA ATTGAG TTGAGC TGAGCA GAGCAT AGCATC GCATCG CATCGC ATCGCC TCGCCT CGCCTC GCCTCT CCTCTT CTCTTG TCTTGC CTTGCC TTGCCG TGCCGT GCCGTT CCGTTC CGTTCA GTTCAT TTCATC TCATCC CATCCC ATCCCT TCCCTA CCCTAG CCTAGC CTAGCA TAGCAA AGCAAA GCAAAG CAAAGG AAAGGC AAGGCT AGGCTC GGCTCG GCTCGG CTCGGT TCGGTT CGGTTG GGTTGG GTTGGG TTGGGG TGGGGC GGGGCC GGGCCA GGCCAG GCCAGC CCAGCG CAGCGG AGCGGC GCGGCG CGGCGA GGCGAT GCGATT CGATTT GATTTG ATTTGA TTTGAC TTGACG TGACGC GACGCC ACGCCG CGCCGC GCCGCT CCGCTG CGCTGT GCTGTC CTGTCC TGTCCT GTCCTA TCCTAT,3,97,CTGT TGTT GTTG TTGG TGGA GGAA GAAC AACA ACAG CAGC AGCT GCTG CTGG TGGC GGCC GCCG CCGC CGCG GCGC CGCT GCTG CTGA TGAT GATT ATTG TTGA TGAG GAGC AGCA GCAT CATC ATCG TCGC CGCC GCCT CCTC CTCT TCTT CTTG TTGC TGCC GCCG CCGT CGTT GTTC TTCA TCAT CATC ATCC TCCC CCCT CCTA CTAG TAGC AGCA GCAA CAAA AAAG AAGG AGGC GGCT GCTC CTCG TCGG CGGT GGTT GTTG TTGG TGGG GGGG GGGC GGCC GCCA CCAG CAGC AGCG GCGG CGGC GGCG GCGA CGAT GATT ATTT TTTG TTGA TGAC GACG ACGC CGCC GCCG CCGC CGCT GCTG CTGT TGTC GTCC TCCT CCTA CTAT,CTGTT TGTTG GTTGG TTGGA TGGAA GGAAC GAACA AACAG ACAGC CAGCT AGCTG GCTGG CTGGC TGGCC GGCCG GCCGC CCGCG CGCGC GCGCT CGCTG GCTGA CTGAT TGATT GATTG ATTGA TTGAG TGAGC GAGCA AGCAT GCATC CATCG ATCGC TCGCC CGCCT GCCTC CCTCT CTCTT TCTTG CTTGC TTGCC TGCCG GCCGT CCGTT CGTTC GTTCA TTCAT TCATC CATCC ATCCC TCCCT CCCTA CCTAG CTAGC TAGCA AGCAA GCAAA CAAAG AAAGG AAGGC AGGCT GGCTC GCTCG CTCGG TCGGT CGGTT GGTTG GTTGG TTGGG TGGGG GGGGC GGGCC GGCCA GCCAG CCAGC CAGCG AGCGG GCGGC CGGCG GGCGA GCGAT CGATT GATTT ATTTG TTTGA TTGAC TGACG GACGC ACGCC CGCCG GCCGC CCGCT CGCTG GCTGT CTGTC TGTCC GTCCT TCCTA CCTAT,CTGTTG TGTTGG GTTGGA TTGGAA TGGAAC GGAACA GAACAG AACAGC ACAGCT CAGCTG AGCTGG GCTGGC CTGGCC TGGCCG GGCCGC GCCGCG CCGCGC CGCGCT GCGCTG CGCTGA GCTGAT CTGATT TGATTG GATTGA ATTGAG TTGAGC TGAGCA GAGCAT AGCATC GCATCG CATCGC ATCGCC TCGCCT CGCCTC GCCTCT CCTCTT CTCTTG TCTTGC CTTGCC TTGCCG TGCCGT GCCGTT CCGTTC CGTTCA GTTCAT TTCATC TCATCC CATCCC ATCCCT TCCCTA CCCTAG CCTAGC CTAGCA TAGCAA AGCAAA GCAAAG CAAAGG AAAGGC AAGGCT AGGCTC GGCTCG GCTCGG CTCGGT TCGGTT CGGTTG GGTTGG GTTGGG TTGGGG TGGGGC GGGGCC GGGCCA GGCCAG GCCAGC CCAGCG CAGCGG AGCGGC GCGGCG CGGCGA GGCGAT GCGATT CGATTT GATTTG ATTTGA TTTGAC TTGACG TGACGC GACGCC ACGCCG CGCCGC GCCGCT CCGCTG CGCTGT GCTGTC CTGTCC TGTCCT GTCCTA TCCTAT,CTGTTGG TGTTGGA GTTGGAA TTGGAAC TGGAACA GGAACAG GAACAGC AACAGCT ACAGCTG CAGCTGG AGCTGGC GCTGGCC CTGGCCG TGGCCGC GGCCGCG GCCGCGC CCGCGCT CGCGCTG GCGCTGA CGCTGAT GCTGATT CTGATTG TGATTGA GATTGAG ATTGAGC TTGAGCA TGAGCAT GAGCATC AGCATCG GCATCGC CATCGCC ATCGCCT TCGCCTC CGCCTCT GCCTCTT CCTCTTG CTCTTGC TCTTGCC CTTGCCG TTGCCGT TGCCGTT GCCGTTC CCGTTCA CGTTCAT GTTCATC TTCATCC TCATCCC CATCCCT ATCCCTA TCCCTAG CCCTAGC CCTAGCA CTAGCAA TAGCAAA AGCAAAG GCAAAGG CAAAGGC AAAGGCT AAGGCTC AGGCTCG GGCTCGG GCTCGGT CTCGGTT TCGGTTG CGGTTGG GGTTGGG GTTGGGG TTGGGGC TGGGGCC GGGGCCA GGGCCAG GGCCAGC GCCAGCG CCAGCGG CAGCGGC AGCGGCG GCGGCGA CGGCGAT GGCGATT GCGATTT CGATTTG GATTTGA ATTTGAC TTTGACG TTGACGC TGACGCC GACGCCG ACGCCGC CGCCGCT GCCGCTG CCGCTGT CGCTGTC GCTGTCC CTGTCCT TGTCCTA GTCCTAT,"ID   HUTH_BACVZ              Reviewed;         512 AA.
AC   A7ZAE4;
DT   20-MAY-2008, integrated into UniProtKB/Swiss-Prot.
DT   20-MAY-2008, sequence version 2.
DT   05-FEB-2025, entry version 98.
DE   RecName: Full=Histidine ammonia-lyase {ECO:0000255|HAMAP-Rule:MF_00229};
DE            Short=Histidase {ECO:0000255|HAMAP-Rule:MF_00229};
DE            EC=4.3.1.3 {ECO:0000255|HAMAP-Rule:MF_00229};
GN   Name=hutH {ECO:0000255|HAMAP-Rule:MF_00229};
GN   OrderedLocusNames=RBAM_036410;
OS   Bacillus velezensis (strain DSM 23117 / BGSC 10A6 / LMG 26770 / FZB42)
OS   (Bacillus amyloliquefaciens subsp. plantarum).
OC   Bacteria; Bacillati; Bacillota; Bacilli; Bacillales; Bacillaceae; Bacillus;
OC   Bacillus amyloliquefaciens group.
OX   NCBI_TaxID=326423;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=DSM 23117 / BGSC 10A6 / LMG 26770 / FZB42;
RX   PubMed=17704766; DOI=10.1038/nbt1325;
RA   Chen X.H., Koumoutsi A., Scholz R., Eisenreich A., Schneider K.,
RA   Heinemeyer I., Morgenstern B., Voss B., Hess W.R., Reva O., Junge H.,
RA   Voigt B., Jungblut P.R., Vater J., Suessmuth R., Liesegang H.,
RA   Strittmatter A., Gottschalk G., Borriss R.;
RT   ""Comparative analysis of the complete genome sequence of the plant growth-
RT   promoting bacterium Bacillus amyloliquefaciens FZB42."";
RL   Nat. Biotechnol. 25:1007-1014(2007).
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-histidine = trans-urocanate + NH4(+); Xref=Rhea:RHEA:21232,
CC         ChEBI:CHEBI:17771, ChEBI:CHEBI:28938, ChEBI:CHEBI:57595; EC=4.3.1.3;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_00229};
CC   -!- PATHWAY: Amino-acid degradation; L-histidine degradation into L-
CC       glutamate; N-formimidoyl-L-glutamate from L-histidine: step 1/3.
CC       {ECO:0000255|HAMAP-Rule:MF_00229}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000255|HAMAP-Rule:MF_00229}.
CC   -!- PTM: Contains an active site 4-methylidene-imidazol-5-one (MIO), which
CC       is formed autocatalytically by cyclization and dehydration of residues
CC       Ala-Ser-Gly. {ECO:0000255|HAMAP-Rule:MF_00229}.
CC   -!- SIMILARITY: Belongs to the PAL/histidase family. {ECO:0000255|HAMAP-
CC       Rule:MF_00229}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=ABS75970.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP000560; ABS75970.1; ALT_INIT; Genomic_DNA.
DR   RefSeq; WP_041482230.1; NC_009725.2.
DR   AlphaFoldDB; A7ZAE4; -.
DR   SMR; A7ZAE4; -.
DR   GeneID; 93082781; -.
DR   KEGG; bay:RBAM_036410; -.
DR   HOGENOM; CLU_014801_4_0_9; -.
DR   UniPathway; UPA00379; UER00549.
DR   Proteomes; UP000001120; Chromosome.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0004397; F:histidine ammonia-lyase activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0019556; P:L-histidine catabolic process to glutamate and formamide; IEA:UniProtKB-UniPathway.
DR   GO; GO:0019557; P:L-histidine catabolic process to glutamate and formate; IEA:UniProtKB-UniPathway.
DR   CDD; cd00332; PAL-HAL; 1.
DR   FunFam; 1.10.275.10:FF:000008; Histidine ammonia-lyase; 1.
DR   FunFam; 1.20.200.10:FF:000003; Histidine ammonia-lyase; 1.
DR   Gene3D; 1.20.200.10; Fumarase/aspartase (Central domain); 1.
DR   Gene3D; 1.10.275.10; Fumarase/aspartase (N-terminal domain); 1.
DR   HAMAP; MF_00229; His_ammonia_lyase; 1.
DR   InterPro; IPR001106; Aromatic_Lyase.
DR   InterPro; IPR024083; Fumarase/histidase_N.
DR   InterPro; IPR005921; HutH.
DR   InterPro; IPR008948; L-Aspartase-like.
DR   InterPro; IPR022313; Phe/His_NH3-lyase_AS.
DR   NCBIfam; TIGR01225; hutH; 1.
DR   PANTHER; PTHR10362; HISTIDINE AMMONIA-LYASE; 1.
DR   Pfam; PF00221; Lyase_aromatic; 1.
DR   SUPFAM; SSF48557; L-aspartase-like; 1.
DR   PROSITE; PS00488; PAL_HISTIDASE; 1.
PE   3: Inferred from homology;
KW   Cytoplasm; Histidine metabolism; Lyase.
FT   CHAIN           1..512
FT                   /note=""Histidine ammonia-lyase""
FT                   /id=""PRO_0000336583""
FT   MOD_RES         142
FT                   /note=""2,3-didehydroalanine (Ser)""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00229""
FT   CROSSLNK        141..143
FT                   /note=""5-imidazolinone (Ala-Gly)""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00229""
SQ   SEQUENCE   512 AA;  56317 MW;  365FAB2EADA7E8D3 CRC64;
     MVTLDGSSLT TADAQRVLFD FEEVQASAES MERVKKSRAA VERIVQEEKT IYGITTGFGK
     FSDVLIQKED AADLQLNLIL SHACGVGDPF PESVSRAMLL LRANALLKGF SGVRTELIDQ
     LLAYLNHRIH PVIPQQGSLG ASGDLAPLSH LALALIGQGE VFYEGARMPT AHALEQTNLQ
     PAVLTSKEGL ALINGTQAMT AMGLIAYLEA EKLAYQSERI ASLTIEGLQG IIDAFDEDIH
     AARGYQEQMD VAERIRYYLS DSKLTTVQGE LRVQDAYSIR CIPQVHGASW QTLAYVKEKL
     EIEMNAATDN PLIFEDGAKI ISGGNFHGQP IAFAMDFLKV AAAELANISE RRIERLVNPQ
     LNDLPPFLSP QPGLQSGAMI MQYAAASLVS ENKTLAHPAS VDSIPSSANQ EDHVSMGTIA
     SRHAYQIIAN TRRVLAVEAI CALQAVEYRG EEHCASYTKQ LYHEMRNIVP SIQEDRVFSY
     DIEHLSDWLK KESFLPNEHH QKLMTNEGGL TR
//
",12333
CTGACT TGACTT GACTTT ACTTTC CTTTCG TTTCGG TTCGGA TCGGAG CGGAGC GGAGCC GAGCCG AGCCGT GCCGTG CCGTGG CGTGGC GTGGCA TGGCAC GGCACT GCACTG CACTGG ACTGGC CTGGCA TGGCAT GGCATT GCATTT CATTTA ATTTAT TTTATC TTATCG TATCGG ATCGGC TCGGCA CGGCAT GGCATG GCATGA CATGAG ATGAGT TGAGTG GAGTGA AGTGAC GTGACA TGACAC GACACC ACACCC CACCCA ACCCAT CCCATG CCATGA CATGAT ATGATA TGATAT GATATG ATATGG TATGGC ATGGCC TGGCCT GGCCTT GCCTTG CCTTGG CTTGGC TTGGCA TGGCAT GGCATC GCATCC CATCCA ATCCAA TCCAAC CCAACC CAACCG AACCGC ACCGCT CCGCTA CGCTAT GCTATT CTATTA TATTAC ATTACT TTACTC TACTCA ACTCAC CTCACT TCACTG CACTGG ACTGGC CTGGCG TGGCGG GGCGGT GCGGTG CGGTGG GGTGGT GTGGTC TGGTCT GGTCTT GTCTTG TCTTGA CTTGAT TTGATT TGATTA GATTAT ATTATC TTATCT TATCTA ATCTAC TCTACT CTACTG TACTGG ACTGGC CTGGCT TGGCTG GGCTGG GCTGGC CTGGCC TGGCCA GGCCAC GCCACC CCACCT CACCTT ACCTTC CCTTCA CTTCAT TTCATT TCATTT CATTTC ATTTCA TTTCAC TTCACT TCACTG CACTGA ACTGAA CTGAAA TGAAAG GAAAGG AAAGGC AAGGCA AGGCAT GGCATG GCATGG CATGGG ATGGGC TGGGCT GGGCTG GGCTGG,2,142,CTGA TGAC GACT ACTT CTTT TTTC TTCG TCGG CGGA GGAG GAGC AGCC GCCG CCGT CGTG GTGG TGGC GGCA GCAC CACT ACTG CTGG TGGC GGCA GCAT CATT ATTT TTTA TTAT TATC ATCG TCGG CGGC GGCA GCAT CATG ATGA TGAG GAGT AGTG GTGA TGAC GACA ACAC CACC ACCC CCCA CCAT CATG ATGA TGAT GATA ATAT TATG ATGG TGGC GGCC GCCT CCTT CTTG TTGG TGGC GGCA GCAT CATC ATCC TCCA CCAA CAAC AACC ACCG CCGC CGCT GCTA CTAT TATT ATTA TTAC TACT ACTC CTCA TCAC CACT ACTG CTGG TGGC GGCG GCGG CGGT GGTG GTGG TGGT GGTC GTCT TCTT CTTG TTGA TGAT GATT ATTA TTAT TATC ATCT TCTA CTAC TACT ACTG CTGG TGGC GGCT GCTG CTGG TGGC GGCC GCCA CCAC CACC ACCT CCTT CTTC TTCA TCAT CATT ATTT TTTC TTCA TCAC CACT ACTG CTGA TGAA GAAA AAAG AAGG AGGC GGCA GCAT CATG ATGG TGGG GGGC GGCT GCTG CTGG,CTGAC TGACT GACTT ACTTT CTTTC TTTCG TTCGG TCGGA CGGAG GGAGC GAGCC AGCCG GCCGT CCGTG CGTGG GTGGC TGGCA GGCAC GCACT CACTG ACTGG CTGGC TGGCA GGCAT GCATT CATTT ATTTA TTTAT TTATC TATCG ATCGG TCGGC CGGCA GGCAT GCATG CATGA ATGAG TGAGT GAGTG AGTGA GTGAC TGACA GACAC ACACC CACCC ACCCA CCCAT CCATG CATGA ATGAT TGATA GATAT ATATG TATGG ATGGC TGGCC GGCCT GCCTT CCTTG CTTGG TTGGC TGGCA GGCAT GCATC CATCC ATCCA TCCAA CCAAC CAACC AACCG ACCGC CCGCT CGCTA GCTAT CTATT TATTA ATTAC TTACT TACTC ACTCA CTCAC TCACT CACTG ACTGG CTGGC TGGCG GGCGG GCGGT CGGTG GGTGG GTGGT TGGTC GGTCT GTCTT TCTTG CTTGA TTGAT TGATT GATTA ATTAT TTATC TATCT ATCTA TCTAC CTACT TACTG ACTGG CTGGC TGGCT GGCTG GCTGG CTGGC TGGCC GGCCA GCCAC CCACC CACCT ACCTT CCTTC CTTCA TTCAT TCATT CATTT ATTTC TTTCA TTCAC TCACT CACTG ACTGA CTGAA TGAAA GAAAG AAAGG AAGGC AGGCA GGCAT GCATG CATGG ATGGG TGGGC GGGCT GGCTG GCTGG,CTGACT TGACTT GACTTT ACTTTC CTTTCG TTTCGG TTCGGA TCGGAG CGGAGC GGAGCC GAGCCG AGCCGT GCCGTG CCGTGG CGTGGC GTGGCA TGGCAC GGCACT GCACTG CACTGG ACTGGC CTGGCA TGGCAT GGCATT GCATTT CATTTA ATTTAT TTTATC TTATCG TATCGG ATCGGC TCGGCA CGGCAT GGCATG GCATGA CATGAG ATGAGT TGAGTG GAGTGA AGTGAC GTGACA TGACAC GACACC ACACCC CACCCA ACCCAT CCCATG CCATGA CATGAT ATGATA TGATAT GATATG ATATGG TATGGC ATGGCC TGGCCT GGCCTT GCCTTG CCTTGG CTTGGC TTGGCA TGGCAT GGCATC GCATCC CATCCA ATCCAA TCCAAC CCAACC CAACCG AACCGC ACCGCT CCGCTA CGCTAT GCTATT CTATTA TATTAC ATTACT TTACTC TACTCA ACTCAC CTCACT TCACTG CACTGG ACTGGC CTGGCG TGGCGG GGCGGT GCGGTG CGGTGG GGTGGT GTGGTC TGGTCT GGTCTT GTCTTG TCTTGA CTTGAT TTGATT TGATTA GATTAT ATTATC TTATCT TATCTA ATCTAC TCTACT CTACTG TACTGG ACTGGC CTGGCT TGGCTG GGCTGG GCTGGC CTGGCC TGGCCA GGCCAC GCCACC CCACCT CACCTT ACCTTC CCTTCA CTTCAT TTCATT TCATTT CATTTC ATTTCA TTTCAC TTCACT TCACTG CACTGA ACTGAA CTGAAA TGAAAG GAAAGG AAAGGC AAGGCA AGGCAT GGCATG GCATGG CATGGG ATGGGC TGGGCT GGGCTG GGCTGG,CTGACTT TGACTTT GACTTTC ACTTTCG CTTTCGG TTTCGGA TTCGGAG TCGGAGC CGGAGCC GGAGCCG GAGCCGT AGCCGTG GCCGTGG CCGTGGC CGTGGCA GTGGCAC TGGCACT GGCACTG GCACTGG CACTGGC ACTGGCA CTGGCAT TGGCATT GGCATTT GCATTTA CATTTAT ATTTATC TTTATCG TTATCGG TATCGGC ATCGGCA TCGGCAT CGGCATG GGCATGA GCATGAG CATGAGT ATGAGTG TGAGTGA GAGTGAC AGTGACA GTGACAC TGACACC GACACCC ACACCCA CACCCAT ACCCATG CCCATGA CCATGAT CATGATA ATGATAT TGATATG GATATGG ATATGGC TATGGCC ATGGCCT TGGCCTT GGCCTTG GCCTTGG CCTTGGC CTTGGCA TTGGCAT TGGCATC GGCATCC GCATCCA CATCCAA ATCCAAC TCCAACC CCAACCG CAACCGC AACCGCT ACCGCTA CCGCTAT CGCTATT GCTATTA CTATTAC TATTACT ATTACTC TTACTCA TACTCAC ACTCACT CTCACTG TCACTGG CACTGGC ACTGGCG CTGGCGG TGGCGGT GGCGGTG GCGGTGG CGGTGGT GGTGGTC GTGGTCT TGGTCTT GGTCTTG GTCTTGA TCTTGAT CTTGATT TTGATTA TGATTAT GATTATC ATTATCT TTATCTA TATCTAC ATCTACT TCTACTG CTACTGG TACTGGC ACTGGCT CTGGCTG TGGCTGG GGCTGGC GCTGGCC CTGGCCA TGGCCAC GGCCACC GCCACCT CCACCTT CACCTTC ACCTTCA CCTTCAT CTTCATT TTCATTT TCATTTC CATTTCA ATTTCAC TTTCACT TTCACTG TCACTGA CACTGAA ACTGAAA CTGAAAG TGAAAGG GAAAGGC AAAGGCA AAGGCAT AGGCATG GGCATGG GCATGGG CATGGGC ATGGGCT TGGGCTG GGGCTGG,"ID   Y1691_LEGPH             Reviewed;         464 AA.
AC   P37034; Q5ZUV1;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-2005, sequence version 2.
DT   05-FEB-2025, entry version 105.
DE   RecName: Full=Uncharacterized transporter lpg1691;
GN   OrderedLocusNames=lpg1691;
OS   Legionella pneumophila subsp. pneumophila (strain Philadelphia 1 / ATCC
OS   33152 / DSM 7513).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Legionellales;
OC   Legionellaceae; Legionella.
OX   NCBI_TaxID=272624;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Philadelphia 1 / ATCC 33152 / DSM 7513;
RX   PubMed=15448271; DOI=10.1126/science.1099776;
RA   Chien M., Morozova I., Shi S., Sheng H., Chen J., Gomez S.M., Asamani G.,
RA   Hill K., Nuara J., Feder M., Rineer J., Greenberg J.J., Steshenko V.,
RA   Park S.H., Zhao B., Teplitskaya E., Edwards J.R., Pampou S., Georghiou A.,
RA   Chou I.-C., Iannuccilli W., Ulz M.E., Kim D.H., Geringer-Sameth A.,
RA   Goldsberry C., Morozov P., Fischer S.G., Segal G., Qu X., Rzhetsky A.,
RA   Zhang P., Cayanis E., De Jong P.J., Ju J., Kalachikov S., Shuman H.A.,
RA   Russo J.J.;
RT   ""The genomic sequence of the accidental pathogen Legionella pneumophila."";
RL   Science 305:1966-1968(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-57.
RX   PubMed=8366052; DOI=10.1128/jb.175.17.5666-5676.1993;
RA   Mengaud J.M., Horwitz M.A.;
RT   ""The major iron-containing protein of Legionella pneumophila is an
RT   aconitase homologous with the human iron-responsive element-binding
RT   protein."";
RL   J. Bacteriol. 175:5666-5676(1993).
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Multi-pass membrane
CC       protein {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the amino acid-polyamine-organocation (APC)
CC       superfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AE017354; AAU27771.1; -; Genomic_DNA.
DR   EMBL; L22081; AAA25296.1; -; Genomic_DNA.
DR   PIR; C48642; C48642.
DR   RefSeq; WP_010947418.1; NC_002942.5.
DR   RefSeq; YP_095718.1; NC_002942.5.
DR   AlphaFoldDB; P37034; -.
DR   SMR; P37034; -.
DR   STRING; 272624.lpg1691; -.
DR   PaxDb; 272624-lpg1691; -.
DR   GeneID; 57035682; -.
DR   KEGG; lpn:lpg1691; -.
DR   PATRIC; fig|272624.6.peg.1772; -.
DR   eggNOG; COG0531; Bacteria.
DR   HOGENOM; CLU_020854_4_2_6; -.
DR   OrthoDB; 3185104at2; -.
DR   Proteomes; UP000000609; Chromosome.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0022857; F:transmembrane transporter activity; IEA:InterPro.
DR   Gene3D; 1.20.1740.10; Amino acid/polyamine transporter I; 1.
DR   InterPro; IPR002293; AA/rel_permease1.
DR   InterPro; IPR050367; APC_superfamily.
DR   PANTHER; PTHR42770; AMINO ACID TRANSPORTER-RELATED; 1.
DR   PANTHER; PTHR42770:SF15; GLUTAMATE_GAMMA-AMINOBUTYRATE ANTIPORTER-RELATED; 1.
DR   Pfam; PF13520; AA_permease_2; 1.
DR   PIRSF; PIRSF006060; AA_transporter; 1.
PE   3: Inferred from homology;
KW   Cell membrane; Membrane; Reference proteome; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN           1..464
FT                   /note=""Uncharacterized transporter lpg1691""
FT                   /id=""PRO_0000054223""
FT   TRANSMEM        7..27
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        37..57
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        94..114
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        121..141
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        153..173
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        196..216
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        231..251
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        282..302
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        329..349
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        359..379
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        401..421
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        432..452
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
SQ   SEQUENCE   464 AA;  50778 MW;  AB835A4CCC9CF06D CRC64;
     MNHSKKVLNV FSLVMINVIA VDSLRTLPIS AKLGFSLVFY YIFAALTFFI PVALVAAELA
     TAYPNTGGIY VWVREAFGRR AGFITIWLQW IYNVVWYPTM LAFIAATLSY LIAPHLGNNK
     FYLLGTALTL FWVFTFLNCF GMKLSSIVSI IGASIGTLLP MIVIIVLGAV WIFQDRPVAV
     NYPTTWLPDF SSLGNLSLFS AVLFGLIGME MSAVHAEEVK NPQRDYPKAL FYSALLIIST
     LSLGSLAIVI VVPNDSLSVV SGLVDAYAIF FNSYNMPWMT SVIAVLIILG GLSGVSAWII
     GPTKGLLVSA RDGSLPALFS RVNKYGSPVA ILLTQGVIFT VLSTVFILLD SINAAYWVLS
     DLSAQMALLV YIMMFAAAIK LRYSKPEQPR GYTIPGGNLV MSLISGIGII CCIAAMIVGF
     IPPSQIPIKN VFLFECFLIG GLILFVFIPW LFAKKHDEQL CSEE
//
",44674
ACTCAA CTCAAA TCAAAT CAAATG AAATGA AATGAT ATGATC TGATCG GATCGT ATCGTT TCGTTA CGTTAC GTTACT TTACTA TACTAC ACTACC CTACCC TACCCC ACCCCA CCCCAG CCCAGA CCAGAA CAGAAA AGAAAA GAAAAG AAAAGT AAAGTG AAGTGG AGTGGG GTGGGA TGGGAT GGGATG GGATGT GATGTT ATGTTA TGTTAT GTTATT TTATTA TATTAC ATTACT TTACTC TACTCG ACTCGT CTCGTA TCGTAA CGTAAA GTAAAA TAAAAG AAAAGT AAAGTA AAGTAA AGTAAT GTAATG TAATGA AATGAT ATGATG TGATGG GATGGA ATGGAT TGGATC GGATCA GATCAT ATCATT TCATTA CATTAC ATTACT TTACTT TACTTT ACTTTC CTTTCC TTTCCC TTCCCT TCCCTC CCCTCG CCTCGT CTCGTT TCGTTA CGTTAA GTTAAG TTAAGC TAAGCT AAGCTC AGCTCC GCTCCT CTCCTC TCCTCA CCTCAT CTCATC TCATCA CATCAT ATCATT TCATTG CATTGA ATTGAT TTGATG TGATGA GATGAA ATGAAA TGAAAT GAAATC AAATCC AATCCA ATCCAT TCCATC CCATCT CATCTC ATCTCC TCTCCT CTCCTT TCCTTC CCTTCA CTTCAT TTCATG TCATGA CATGAA ATGAAG TGAAGA GAAGAT AAGATC AGATCG GATCGT ATCGTG TCGTGG CGTGGT GTGGTC TGGTCC GGTCCA GTCCAG TCCAGT CCAGTG CAGTGT AGTGTT GTGTTA TGTTAG GTTAGA TTAGAA TAGAAA AGAAAC GAAACC AAACCA AACCAT ACCATT CCATTG CATTGT ATTGTG,3,145,ACTC CTCA TCAA CAAA AAAT AATG ATGA TGAT GATC ATCG TCGT CGTT GTTA TTAC TACT ACTA CTAC TACC ACCC CCCC CCCA CCAG CAGA AGAA GAAA AAAA AAAG AAGT AGTG GTGG TGGG GGGA GGAT GATG ATGT TGTT GTTA TTAT TATT ATTA TTAC TACT ACTC CTCG TCGT CGTA GTAA TAAA AAAA AAAG AAGT AGTA GTAA TAAT AATG ATGA TGAT GATG ATGG TGGA GGAT GATC ATCA TCAT CATT ATTA TTAC TACT ACTT CTTT TTTC TTCC TCCC CCCT CCTC CTCG TCGT CGTT GTTA TTAA TAAG AAGC AGCT GCTC CTCC TCCT CCTC CTCA TCAT CATC ATCA TCAT CATT ATTG TTGA TGAT GATG ATGA TGAA GAAA AAAT AATC ATCC TCCA CCAT CATC ATCT TCTC CTCC TCCT CCTT CTTC TTCA TCAT CATG ATGA TGAA GAAG AAGA AGAT GATC ATCG TCGT CGTG GTGG TGGT GGTC GTCC TCCA CCAG CAGT AGTG GTGT TGTT GTTA TTAG TAGA AGAA GAAA AAAC AACC ACCA CCAT CATT ATTG TTGT TGTG,ACTCA CTCAA TCAAA CAAAT AAATG AATGA ATGAT TGATC GATCG ATCGT TCGTT CGTTA GTTAC TTACT TACTA ACTAC CTACC TACCC ACCCC CCCCA CCCAG CCAGA CAGAA AGAAA GAAAA AAAAG AAAGT AAGTG AGTGG GTGGG TGGGA GGGAT GGATG GATGT ATGTT TGTTA GTTAT TTATT TATTA ATTAC TTACT TACTC ACTCG CTCGT TCGTA CGTAA GTAAA TAAAA AAAAG AAAGT AAGTA AGTAA GTAAT TAATG AATGA ATGAT TGATG GATGG ATGGA TGGAT GGATC GATCA ATCAT TCATT CATTA ATTAC TTACT TACTT ACTTT CTTTC TTTCC TTCCC TCCCT CCCTC CCTCG CTCGT TCGTT CGTTA GTTAA TTAAG TAAGC AAGCT AGCTC GCTCC CTCCT TCCTC CCTCA CTCAT TCATC CATCA ATCAT TCATT CATTG ATTGA TTGAT TGATG GATGA ATGAA TGAAA GAAAT AAATC AATCC ATCCA TCCAT CCATC CATCT ATCTC TCTCC CTCCT TCCTT CCTTC CTTCA TTCAT TCATG CATGA ATGAA TGAAG GAAGA AAGAT AGATC GATCG ATCGT TCGTG CGTGG GTGGT TGGTC GGTCC GTCCA TCCAG CCAGT CAGTG AGTGT GTGTT TGTTA GTTAG TTAGA TAGAA AGAAA GAAAC AAACC AACCA ACCAT CCATT CATTG ATTGT TTGTG,ACTCAA CTCAAA TCAAAT CAAATG AAATGA AATGAT ATGATC TGATCG GATCGT ATCGTT TCGTTA CGTTAC GTTACT TTACTA TACTAC ACTACC CTACCC TACCCC ACCCCA CCCCAG CCCAGA CCAGAA CAGAAA AGAAAA GAAAAG AAAAGT AAAGTG AAGTGG AGTGGG GTGGGA TGGGAT GGGATG GGATGT GATGTT ATGTTA TGTTAT GTTATT TTATTA TATTAC ATTACT TTACTC TACTCG ACTCGT CTCGTA TCGTAA CGTAAA GTAAAA TAAAAG AAAAGT AAAGTA AAGTAA AGTAAT GTAATG TAATGA AATGAT ATGATG TGATGG GATGGA ATGGAT TGGATC GGATCA GATCAT ATCATT TCATTA CATTAC ATTACT TTACTT TACTTT ACTTTC CTTTCC TTTCCC TTCCCT TCCCTC CCCTCG CCTCGT CTCGTT TCGTTA CGTTAA GTTAAG TTAAGC TAAGCT AAGCTC AGCTCC GCTCCT CTCCTC TCCTCA CCTCAT CTCATC TCATCA CATCAT ATCATT TCATTG CATTGA ATTGAT TTGATG TGATGA GATGAA ATGAAA TGAAAT GAAATC AAATCC AATCCA ATCCAT TCCATC CCATCT CATCTC ATCTCC TCTCCT CTCCTT TCCTTC CCTTCA CTTCAT TTCATG TCATGA CATGAA ATGAAG TGAAGA GAAGAT AAGATC AGATCG GATCGT ATCGTG TCGTGG CGTGGT GTGGTC TGGTCC GGTCCA GTCCAG TCCAGT CCAGTG CAGTGT AGTGTT GTGTTA TGTTAG GTTAGA TTAGAA TAGAAA AGAAAC GAAACC AAACCA AACCAT ACCATT CCATTG CATTGT ATTGTG,ACTCAAA CTCAAAT TCAAATG CAAATGA AAATGAT AATGATC ATGATCG TGATCGT GATCGTT ATCGTTA TCGTTAC CGTTACT GTTACTA TTACTAC TACTACC ACTACCC CTACCCC TACCCCA ACCCCAG CCCCAGA CCCAGAA CCAGAAA CAGAAAA AGAAAAG GAAAAGT AAAAGTG AAAGTGG AAGTGGG AGTGGGA GTGGGAT TGGGATG GGGATGT GGATGTT GATGTTA ATGTTAT TGTTATT GTTATTA TTATTAC TATTACT ATTACTC TTACTCG TACTCGT ACTCGTA CTCGTAA TCGTAAA CGTAAAA GTAAAAG TAAAAGT AAAAGTA AAAGTAA AAGTAAT AGTAATG GTAATGA TAATGAT AATGATG ATGATGG TGATGGA GATGGAT ATGGATC TGGATCA GGATCAT GATCATT ATCATTA TCATTAC CATTACT ATTACTT TTACTTT TACTTTC ACTTTCC CTTTCCC TTTCCCT TTCCCTC TCCCTCG CCCTCGT CCTCGTT CTCGTTA TCGTTAA CGTTAAG GTTAAGC TTAAGCT TAAGCTC AAGCTCC AGCTCCT GCTCCTC CTCCTCA TCCTCAT CCTCATC CTCATCA TCATCAT CATCATT ATCATTG TCATTGA CATTGAT ATTGATG TTGATGA TGATGAA GATGAAA ATGAAAT TGAAATC GAAATCC AAATCCA AATCCAT ATCCATC TCCATCT CCATCTC CATCTCC ATCTCCT TCTCCTT CTCCTTC TCCTTCA CCTTCAT CTTCATG TTCATGA TCATGAA CATGAAG ATGAAGA TGAAGAT GAAGATC AAGATCG AGATCGT GATCGTG ATCGTGG TCGTGGT CGTGGTC GTGGTCC TGGTCCA GGTCCAG GTCCAGT TCCAGTG CCAGTGT CAGTGTT AGTGTTA GTGTTAG TGTTAGA GTTAGAA TTAGAAA TAGAAAC AGAAACC GAAACCA AAACCAT AACCATT ACCATTG CCATTGT CATTGTG,"ID   ASCC3_YEAST             Reviewed;        1967 AA.
AC   P53327; D6VV48;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   21-SEP-2011, sequence version 2.
DT   05-FEB-2025, entry version 191.
DE   RecName: Full=RQC trigger complex helicase SLH1 {ECO:0000303|PubMed:28757607};
DE            EC=3.6.4.13 {ECO:0000305|PubMed:28757607, ECO:0000305|PubMed:30893611, ECO:0000305|PubMed:32203490};
DE   AltName: Full=Antiviral helicase SLH1;
DE   AltName: Full=SKI2-like helicase 1;
GN   Name=SLH1 {ECO:0000303|PubMed:10922069};
GN   Synonyms=RQT2 {ECO:0000303|PubMed:28757607};
GN   OrderedLocusNames=YGR271W {ECO:0000312|SGD:S000003503};
GN   ORFNames=G9365;
OS   Saccharomyces cerevisiae (strain ATCC 204508 / S288c) (Baker's yeast).
OC   Eukaryota; Fungi; Dikarya; Ascomycota; Saccharomycotina; Saccharomycetes;
OC   Saccharomycetales; Saccharomycetaceae; Saccharomyces.
OX   NCBI_TaxID=559292;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=ATCC 96604 / S288c / FY1679;
RX   PubMed=9133744;
RX   DOI=10.1002/(sici)1097-0061(19970330)13:4<391::aid-yea92>3.0.co;2-q;
RA   Martegani E., Vanoni M., Mauri I., Rudoni S., Saliola M., Alberghina L.;
RT   ""Identification of gene encoding a putative RNA-helicase, homologous to
RT   SKI2, in chromosome VII of Saccharomyces cerevisiae."";
RL   Yeast 13:391-397(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 204508 / S288c;
RX   PubMed=9169869; DOI=10.1038/387s081;
RA   Tettelin H., Agostoni-Carbone M.L., Albermann K., Albers M., Arroyo J.,
RA   Backes U., Barreiros T., Bertani I., Bjourson A.J., Brueckner M.,
RA   Bruschi C.V., Carignani G., Castagnoli L., Cerdan E., Clemente M.L.,
RA   Coblenz A., Coglievina M., Coissac E., Defoor E., Del Bino S., Delius H.,
RA   Delneri D., de Wergifosse P., Dujon B., Durand P., Entian K.-D., Eraso P.,
RA   Escribano V., Fabiani L., Fartmann B., Feroli F., Feuermann M.,
RA   Frontali L., Garcia-Gonzalez M., Garcia-Saez M.I., Goffeau A.,
RA   Guerreiro P., Hani J., Hansen M., Hebling U., Hernandez K., Heumann K.,
RA   Hilger F., Hofmann B., Indge K.J., James C.M., Klima R., Koetter P.,
RA   Kramer B., Kramer W., Lauquin G., Leuther H., Louis E.J., Maillier E.,
RA   Marconi A., Martegani E., Mazon M.J., Mazzoni C., McReynolds A.D.K.,
RA   Melchioretto P., Mewes H.-W., Minenkova O., Mueller-Auer S., Nawrocki A.,
RA   Netter P., Neu R., Nombela C., Oliver S.G., Panzeri L., Paoluzi S.,
RA   Plevani P., Portetelle D., Portillo F., Potier S., Purnelle B., Rieger M.,
RA   Riles L., Rinaldi T., Robben J., Rodrigues-Pousada C.,
RA   Rodriguez-Belmonte E., Rodriguez-Torres A.M., Rose M., Ruzzi M.,
RA   Saliola M., Sanchez-Perez M., Schaefer B., Schaefer M., Scharfe M.,
RA   Schmidheini T., Schreer A., Skala J., Souciet J.-L., Steensma H.Y.,
RA   Talla E., Thierry A., Vandenbol M., van der Aart Q.J.M., Van Dyck L.,
RA   Vanoni M., Verhasselt P., Voet M., Volckaert G., Wambutt R., Watson M.D.,
RA   Weber N., Wedler E., Wedler H., Wipfli P., Wolf K., Wright L.F.,
RA   Zaccaria P., Zimmermann M., Zollner A., Kleine K.;
RT   ""The nucleotide sequence of Saccharomyces cerevisiae chromosome VII."";
RL   Nature 387:81-84(1997).
RN   [3]
RP   GENOME REANNOTATION, AND SEQUENCE REVISION TO 51; 193 AND 438.
RC   STRAIN=ATCC 204508 / S288c;
RX   PubMed=24374639; DOI=10.1534/g3.113.008995;
RA   Engel S.R., Dietrich F.S., Fisk D.G., Binkley G., Balakrishnan R.,
RA   Costanzo M.C., Dwight S.S., Hitz B.C., Karra K., Nash R.S., Weng S.,
RA   Wong E.D., Lloyd P., Skrzypek M.S., Miyasato S.R., Simison M., Cherry J.M.;
RT   ""The reference genome sequence of Saccharomyces cerevisiae: Then and now."";
RL   G3 (Bethesda) 4:389-398(2014).
RN   [4]
RP   FUNCTION.
RX   PubMed=10922069; DOI=10.1073/pnas.97.16.9133;
RA   Searfoss A.M., Wickner R.B.;
RT   ""3' poly(A) is dispensable for translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:9133-9137(2000).
RN   [5]
RP   FUNCTION.
RX   PubMed=11438647; DOI=10.1128/mcb.21.15.4900-4908.2001;
RA   Searfoss A., Dever T.E., Wickner R.;
RT   ""Linking the 3' poly(A) tail to the subunit joining step of translation
RT   initiation: relations of Pab1p, eukaryotic translation initiation factor 5b
RT   (Fun12p), and Ski2p-Slh1p."";
RL   Mol. Cell. Biol. 21:4900-4908(2001).
RN   [6]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RX   PubMed=14562095; DOI=10.1038/nature02026;
RA   Huh W.-K., Falvo J.V., Gerke L.C., Carroll A.S., Howson R.W.,
RA   Weissman J.S., O'Shea E.K.;
RT   ""Global analysis of protein localization in budding yeast."";
RL   Nature 425:686-691(2003).
RN   [7]
RP   LEVEL OF PROTEIN EXPRESSION [LARGE SCALE ANALYSIS].
RX   PubMed=14562106; DOI=10.1038/nature02046;
RA   Ghaemmaghami S., Huh W.-K., Bower K., Howson R.W., Belle A., Dephoure N.,
RA   O'Shea E.K., Weissman J.S.;
RT   ""Global analysis of protein expression in yeast."";
RL   Nature 425:737-741(2003).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, IDENTIFICATION IN THE RQT COMPLEX,
RP   INTERACTION WITH CUE3; RQT4 AND HEL2, DISRUPTION PHENOTYPE, AND MUTAGENESIS
RP   OF LYS-316.
RX   PubMed=28757607; DOI=10.1038/s41467-017-00188-1;
RA   Matsuo Y., Ikeuchi K., Saeki Y., Iwasaki S., Schmidt C., Udagawa T.,
RA   Sato F., Tsuchiya H., Becker T., Tanaka K., Ingolia N.T., Beckmann R.,
RA   Inada T.;
RT   ""Ubiquitination of stalled ribosome triggers ribosome-associated quality
RT   control."";
RL   Nat. Commun. 8:159-159(2017).
RN   [9]
RP   FUNCTION, INTERACTION WITH HEL2, AND DISRUPTION PHENOTYPE.
RX   PubMed=28223409; DOI=10.1261/rna.060897.117;
RA   Sitron C.S., Park J.H., Brandman O.;
RT   ""Asc1, Hel2, and Slh1 couple translation arrest to nascent chain
RT   degradation."";
RL   RNA 23:798-810(2017).
RN   [10]
RP   FUNCTION, CATALYTIC ACTIVITY, AND MUTAGENESIS OF LYS-316.
RX   PubMed=30893611; DOI=10.1016/j.celrep.2019.02.067;
RA   Sugiyama T., Li S., Kato M., Ikeuchi K., Ichimura A., Matsuo Y., Inada T.;
RT   ""Sequential ubiquitination of ribosomal protein uS3 triggers the
RT   degradation of non-functional 18S rRNA."";
RL   Cell Rep. 26:3400-3415(2019).
RN   [11]
RP   FUNCTION, CATALYTIC ACTIVITY, IDENTIFICATION IN THE RQT COMPLEX, AND
RP   MUTAGENESIS OF LYS-316.
RX   PubMed=32203490; DOI=10.1038/s41594-020-0393-9;
RA   Matsuo Y., Tesina P., Nakajima S., Mizuno M., Endo A., Buschauer R.,
RA   Cheng J., Shounai O., Ikeuchi K., Saeki Y., Becker T., Beckmann R.,
RA   Inada T.;
RT   ""RQT complex dissociates ribosomes collided on endogenous RQC substrate
RT   SDD1."";
RL   Nat. Struct. Mol. Biol. 27:323-332(2020).
CC   -!- FUNCTION: Involved in activation of the ribosome quality control (RQC)
CC       pathway, a pathway that degrades nascent peptide chains during
CC       problematic translation (PubMed:28223409, PubMed:28757607,
CC       PubMed:30893611, PubMed:32203490). Drives the splitting of stalled
CC       ribosomes that are polyubiquitinated in a HEL2-dependent manner, as
CC       part of the ribosome quality control trigger (RQT) complex
CC       (PubMed:28757607, PubMed:30893611, PubMed:32203490). Also represses the
CC       translation of non-poly(A) mRNAs together with SKI2 (PubMed:10922069).
CC       May block translation by inhibiting translation initiation factor 5B
CC       (FUN12) action on mRNAs lacking a 3' poly(A) structure
CC       (PubMed:11438647). Involved in antiviral defense, preventing L-A dsRNA
CC       virus propagation by specifically blocking translation of viral mRNAs
CC       (PubMed:10922069). {ECO:0000269|PubMed:10922069,
CC       ECO:0000269|PubMed:11438647, ECO:0000269|PubMed:28223409,
CC       ECO:0000269|PubMed:28757607, ECO:0000269|PubMed:30893611,
CC       ECO:0000269|PubMed:32203490}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O = ADP + phosphate + H(+); Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=3.6.4.13;
CC         Evidence={ECO:0000305|PubMed:28757607, ECO:0000305|PubMed:30893611,
CC         ECO:0000305|PubMed:32203490};
CC   -!- SUBUNIT: Component of the RQT (ribosome quality control trigger)
CC       complex, composed of SLH1, CUE3, and RQT4 (PubMed:28757607,
CC       PubMed:32203490). Interacts with CUE3 (PubMed:28757607). Interacts with
CC       RQT4 (PubMed:28757607). Interacts with HEL2 (PubMed:28223409,
CC       PubMed:28757607). Associates with translating ribosomes
CC       (PubMed:28757607). {ECO:0000269|PubMed:28223409,
CC       ECO:0000269|PubMed:28757607, ECO:0000269|PubMed:32203490}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:14562095}.
CC   -!- DISRUPTION PHENOTYPE: Defective activation of the ribosome quality
CC       control (RQC) pathway (PubMed:28223409, PubMed:28757607). Mildly
CC       defective ribosome stalling induced by RNA arrest sequences
CC       (PubMed:28223409). Sensitive to anisomycin (stalls ribosomes in the
CC       rotated state) (PubMed:28757607). {ECO:0000269|PubMed:28223409,
CC       ECO:0000269|PubMed:28757607}.
CC   -!- MISCELLANEOUS: Present with 486 molecules/cell in log phase SD medium.
CC       {ECO:0000269|PubMed:14562106}.
CC   -!- SIMILARITY: Belongs to the helicase family. SKI2 subfamily.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U35242; AAC49699.1; -; Genomic_DNA.
DR   EMBL; Z73056; CAA97301.1; -; Genomic_DNA.
DR   EMBL; BK006941; DAA08359.2; -; Genomic_DNA.
DR   PIR; S64604; S64604.
DR   RefSeq; NP_011787.4; NM_001181400.4.
DR   PDB; 7ZPQ; EM; 3.47 A; CA=1-1967.
DR   PDB; 7ZRS; EM; 4.80 A; CA=1-1967.
DR   PDB; 7ZUW; EM; 4.30 A; CA=1-1967.
DR   PDBsum; 7ZPQ; -.
DR   PDBsum; 7ZRS; -.
DR   PDBsum; 7ZUW; -.
DR   AlphaFoldDB; P53327; -.
DR   EMDB; EMD-14921; -.
DR   EMDB; EMD-14978; -.
DR   SMR; P53327; -.
DR   BioGRID; 33520; 171.
DR   ComplexPortal; CPX-6643; RQT ribosome-associated quality control trigger complex.
DR   DIP; DIP-5563N; -.
DR   IntAct; P53327; 13.
DR   MINT; P53327; -.
DR   STRING; 4932.YGR271W; -.
DR   iPTMnet; P53327; -.
DR   PaxDb; 4932-YGR271W; -.
DR   PeptideAtlas; P53327; -.
DR   EnsemblFungi; YGR271W_mRNA; YGR271W; YGR271W.
DR   GeneID; 853187; -.
DR   KEGG; sce:YGR271W; -.
DR   AGR; SGD:S000003503; -.
DR   SGD; S000003503; SLH1.
DR   VEuPathDB; FungiDB:YGR271W; -.
DR   eggNOG; KOG0952; Eukaryota.
DR   GeneTree; ENSGT00940000155377; -.
DR   HOGENOM; CLU_000335_1_0_1; -.
DR   InParanoid; P53327; -.
DR   OMA; MCSATEF; -.
DR   OrthoDB; 5575at2759; -.
DR   BioCyc; YEAST:G3O-30937-MONOMER; -.
DR   BioGRID-ORCS; 853187; 0 hits in 10 CRISPR screens.
DR   PRO; PR:P53327; -.
DR   Proteomes; UP000002311; Chromosome VII.
DR   RNAct; P53327; protein.
DR   GO; GO:0005737; C:cytoplasm; HDA:SGD.
DR   GO; GO:0010494; C:cytoplasmic stress granule; HDA:SGD.
DR   GO; GO:0022626; C:cytosolic ribosome; IDA:UniProt.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IDA:UniProtKB.
DR   GO; GO:0140849; F:ATP-dependent H2AZ histone chaperone activity; IEA:RHEA.
DR   GO; GO:0140665; F:ATP-dependent H3-H4 histone complex chaperone activity; IEA:RHEA.
DR   GO; GO:0140584; F:chromatin extrusion motor activity; IEA:RHEA.
DR   GO; GO:0061775; F:cohesin loader activity; IEA:RHEA.
DR   GO; GO:0003689; F:DNA clamp loader activity; IEA:RHEA.
DR   GO; GO:0004386; F:helicase activity; IMP:UniProtKB.
DR   GO; GO:0003729; F:mRNA binding; HDA:SGD.
DR   GO; GO:0003724; F:RNA helicase activity; ISS:SGD.
DR   GO; GO:0002181; P:cytoplasmic translation; IGI:SGD.
DR   GO; GO:0051607; P:defense response to virus; IEA:UniProtKB-KW.
DR   GO; GO:0006417; P:regulation of translation; IMP:SGD.
DR   GO; GO:0072344; P:rescue of stalled ribosome; IDA:UniProt.
DR   GO; GO:0032790; P:ribosome disassembly; IDA:UniProtKB.
DR   GO; GO:1990116; P:ribosome-associated ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   CDD; cd18020; DEXHc_ASCC3_1; 1.
DR   CDD; cd18022; DEXHc_ASCC3_2; 1.
DR   CDD; cd18795; SF2_C_Ski2; 2.
DR   FunFam; 3.40.50.300:FF:000198; Activating signal cointegrator 1 complex subunit; 1.
DR   FunFam; 1.10.3380.10:FF:000002; Activating signal cointegrator 1 complex subunit 3; 1.
DR   FunFam; 3.40.50.300:FF:000231; Activating signal cointegrator 1 complex subunit 3; 1.
DR   FunFam; 2.60.40.150:FF:000241; Antiviral helicase SLH1; 1.
DR   FunFam; 3.40.50.300:FF:000102; RNA helicase, activating signal cointegrator 1; 1.
DR   FunFam; 1.10.10.10:FF:000012; U5 small nuclear ribonucleoprotein helicase; 1.
DR   FunFam; 1.10.10.10:FF:000024; U5 small nuclear ribonucleoprotein helicase; 1.
DR   FunFam; 1.10.150.20:FF:000004; U5 small nuclear ribonucleoprotein helicase; 1.
DR   FunFam; 1.10.3380.10:FF:000001; U5 small nuclear ribonucleoprotein helicase; 1.
DR   FunFam; 3.40.50.300:FF:000062; U5 small nuclear ribonucleoprotein helicase; 1.
DR   Gene3D; 1.10.150.20; 5' to 3' exonuclease, C-terminal subdomain; 1.
DR   Gene3D; 2.60.40.150; C2 domain; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 4.
DR   Gene3D; 1.10.3380.10; Sec63 N-terminal domain-like domain; 2.
DR   Gene3D; 1.10.10.10; Winged helix-like DNA-binding domain superfamily/Winged helix DNA-binding domain; 2.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR011545; DEAD/DEAH_box_helicase_dom.
DR   InterPro; IPR050474; Hel308_SKI2-like.
DR   InterPro; IPR014001; Helicase_ATP-bd.
DR   InterPro; IPR001650; Helicase_C-like.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR004179; Sec63-dom.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   PANTHER; PTHR47961:SF13; ACTIVATING SIGNAL COINTEGRATOR 1 COMPLEX SUBUNIT 3; 1.
DR   PANTHER; PTHR47961; DNA POLYMERASE THETA, PUTATIVE (AFU_ORTHOLOGUE AFUA_1G05260)-RELATED; 1.
DR   Pfam; PF00270; DEAD; 2.
DR   Pfam; PF00271; Helicase_C; 2.
DR   Pfam; PF02889; Sec63; 2.
DR   PIRSF; PIRSF039073; BRR2; 1.
DR   SMART; SM00382; AAA; 2.
DR   SMART; SM00487; DEXDc; 2.
DR   SMART; SM00490; HELICc; 2.
DR   SMART; SM00973; Sec63; 2.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 4.
DR   SUPFAM; SSF158702; Sec63 N-terminal domain-like; 2.
DR   SUPFAM; SSF46785; Winged helix' DNA-binding domain; 2.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 2.
DR   PROSITE; PS51194; HELICASE_CTER; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Antiviral defense; ATP-binding; Cytoplasm; Helicase;
KW   Hydrolase; Nucleotide-binding; Reference proteome; Repeat.
FT   CHAIN           1..1967
FT                   /note=""RQC trigger complex helicase SLH1""
FT                   /id=""PRO_0000102085""
FT   DOMAIN          297..485
FT                   /note=""Helicase ATP-binding 1""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00541""
FT   DOMAIN          516..735
FT                   /note=""Helicase C-terminal 1""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00542""
FT   DOMAIN          795..1100
FT                   /note=""SEC63 1""
FT   DOMAIN          1149..1324
FT                   /note=""Helicase ATP-binding 2""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00541""
FT   DOMAIN          1355..1550
FT                   /note=""Helicase C-terminal 2""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00542""
FT   DOMAIN          1626..1776
FT                   /note=""SEC63 2""
FT   MOTIF           427..430
FT                   /note=""DEVH box""
FT   MOTIF           1266..1269
FT                   /note=""DEAH box""
FT   BINDING         310..317
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00541""
FT   BINDING         1162..1169
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00541""
FT   MUTAGEN         316
FT                   /note=""K->R: Abolishes splitting of stalled ribosomes.
FT                   Defective activation of the ribosome quality control (RQC)
FT                   pathway. Does not affect the association of the RQT complex
FT                   with ribosomes.""
FT                   /evidence=""ECO:0000269|PubMed:28757607,
FT                   ECO:0000269|PubMed:30893611, ECO:0000269|PubMed:32203490""
FT   CONFLICT        27
FT                   /note=""F -> L (in Ref. 1; AAC49699)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        51
FT                   /note=""Q -> P (in Ref. 1; AAC49699 and 2; CAA97301)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        193
FT                   /note=""K -> E (in Ref. 1; AAC49699 and 2; CAA97301)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        438
FT                   /note=""S -> P (in Ref. 1; AAC49699 and 2; CAA97301)""
FT                   /evidence=""ECO:0000305""
SQ   SEQUENCE   1967 AA;  224850 MW;  249DF515AEE511A1 CRC64;
     MSTEYSADSS KSFMIAMQSM IDTSQTFNLD RSKISLPDFD DELKKVQKDE QNQRTELTVL
     SQDRNDWDDI FEEFKDISFA QLQSIIDSYK TKNAVAVYKK IGKLINEAET TLSSNVLLET
     VLQMVYKHQK QELEKELLDF LGTGNIDLVS LLLQHRRMIV ATPIETTILL IKNAVNSTPE
     FLTQQDIRNQ VLKSAEDAKN RKLNPATKII KYPHVFRKYE AGSTTAMAFA GQKFTLPVGT
     TRMSYNTHEE IIIPAADQAS NKNYLYTKLL KISDLDHFCK TVFPYETLNQ IQSLVYPVAY
     KTNENMLICA PTGAGKTDIA LLTIINTIKQ FSVVNGENEI DIQYDDFKVI YVAPLKALAA
     EIVDKFSKKL APFNIQVREL TGDMQLTKAE ILATQVIVTT PEKWDVVTRK ANGDNDLVSK
     VKLLIIDEVH LLHEDRGSVI ETLVARTLRQ VESSQSMIRI IGLSATLPNF MDVADFLGVN
     RQIGMFYFDQ SFRPKPLEQQ LLGCRGKAGS RQSKENIDKV AYDKLSEMIQ RGYQVMVFVH
     SRKETVKSAR NFIKLAESNH EVDLFAPDPI EKDKYSRSLV KNRDKDMKEI FQFGFGIHHA
     GMARSDRNLT EKMFKDGAIK VLCCTATLAW GVNLPADCVI IKGTQVYDSK KGGFIDLGIS
     DVIQIFGRGG RPGFGSANGT GILCTSNDRL DHYVSLITQQ HPIESRFGSK LVDNLNAEIS
     LGSVTNVDEA IEWLGYTYMF VRMRKNPFTY GIDWEEIAND PQLYERRRKM IVVAARRLHA
     LQMIVFDEVS MHFIAKDLGR VSSDFYLLNE SVEIFNQMCD PRATEADVLS MISMSSEFDG
     IKFREEESKE LKRLSDESVE CQIGSQLDTP QGKANVLLQA YISQTRIFDS ALSSDSNYVA
     QNSVRICRAL FLIGVNRRWG KFSNVMLNIC KSIEKRLWAF DHPLCQFDLP ENIIRRIRDT
     KPSMEHLLEL EADELGELVH NKKAGSRLYK ILSRFPKINI EAEIFPITTN VMRIHIALGP
     DFVWDSRIHG DAQFFWVFVE ESDKSQILHF EKFILNRRQL NNQHEMDFMI PLSDPLPPQV
     VVKVVSDTWI GCESTHAISF QHLIRPFNET LQTKLLKLRP LPTSALQNPL IESIYPFKYF
     NPMQTMTFYT LYNTNENAFV GSPTGSGKTI VAELAIWHAF KTFPGKKIVY IAPMKALVRE
     RVDDWRKKIT PVTGDKVVEL TGDSLPDPKD VHDATIVITT PEKFDGISRN WQTRKFVQDV
     SLIIMDEIHL LASDRGPILE MIVSRMNYIS SQTKQPVRLL GMSTAVSNAY DMAGWLGVKD
     HGLYNFPSSV RPVPLKMYID GFPDNLAFCP LMKTMNKPVF MAIKQHSPDK PALIFVASRR
     QTRLTALDLI HLCGMEDNPR RFLNIDDEEE LQYYLSQVTD DTLKLSLQFG IGLHHAGLVQ
     KDRSISHQLF QKNKIQILIA TSTLAWGVNL PAHLVIIKGT QFFDAKIEGY RDMDLTDILQ
     MMGRAGRPAY DTTGTAIVYT KESKKMFYKH FLNVGFPVES SLHKVLDDHL GAEITSGSIT
     NKQEALDFLS WTFLFRRAHH NPTYYGIEDD TSTAGVSEHL SSLIDSTLEN LRESQCVLLH
     GDDIVATPFL SISSYYYISH LTIRQLLKQI HDHATFQEVL RWLSLAVEYN ELPVRGGEII
     MNEEMSQQSR YSVESTFTDE FELPMWDPHV KTFLLLQAHL SRVDLPIADY IQDTVSVLDQ
     SLRILQAYID VASELGYFHT VLTMIKMMQC IKQGYWYEDD PVSVLPGLQL RRIKDYTFSE
     QGFIEMTPQQ KKKKLLTLEE IGRFGYKKLL NVFDQLTFGM TESEDTKKRF VSVCQRLPVL
     EGMKFEEQEN NEVLTFYSKH LSSKHNNGFE VYCDKFPKIQ KELWFLIGHK GDELLMIKRC
     QPKQMNKEVI IHCDLFIPEE IRGEELQFSL INDALGLRYD MVHKLIS
//
",44538
TGGTAT GGTATT GTATTT TATTTC ATTTCT TTTCTA TTCTAC TCTACT CTACTA TACTAC ACTACC CTACCT TACCTA ACCTAG CCTAGG CTAGGA TAGGAA AGGAAC GGAACT GAACTG AACTGG ACTGGG CTGGGC TGGGCC GGGCCA GGCCAG GCCAGA CCAGAA CAGAAG AGAAGC GAAGCT AAGCTG AGCTGG GCTGGA CTGGAC TGGACT GGACTT GACTTC ACTTCC CTTCCC TTCCCT TCCCTA CCCTAT CCTATG CTATGG TATGGT ATGGTG TGGTGC GGTGCT GTGCTA TGCTAA GCTAAC CTAACA TAACAA AACAAA ACAAAG CAAAGA AAAGAC AAGACG AGACGG GACGGC ACGGCA CGGCAT GGCATC GCATCA CATCAT ATCATA TCATAT CATATG ATATGG TATGGG ATGGGT TGGGTT GGGTTG GGTTGC GTTGCA TTGCAA TGCAAC GCAACT CAACTG AACTGA ACTGAG CTGAGG TGAGGG GAGGGA AGGGAG GGGAGC GGAGCC GAGCCT AGCCTT GCCTTG CCTTGA CTTGAA TTGAAT TGAATA GAATAC AATACA ATACAC TACACC ACACCA CACCAA ACCAAA CCAAAA CAAAAA AAAAAA AAAAAT AAAATC AAATCA AATCAC ATCACA TCACAT CACATT ACATTG CATTGG ATTGGC TTGGCA TGGCAC GGCACC GCACCC CACCCG ACCCGC CCCGCA CCGCAA CGCAAT GCAATC CAATCC AATCCT ATCCTG TCCTGC CCTGCT CTGCTA TGCTAA GCTAAC,1,133,TGGT GGTA GTAT TATT ATTT TTTC TTCT TCTA CTAC TACT ACTA CTAC TACC ACCT CCTA CTAG TAGG AGGA GGAA GAAC AACT ACTG CTGG TGGG GGGC GGCC GCCA CCAG CAGA AGAA GAAG AAGC AGCT GCTG CTGG TGGA GGAC GACT ACTT CTTC TTCC TCCC CCCT CCTA CTAT TATG ATGG TGGT GGTG GTGC TGCT GCTA CTAA TAAC AACA ACAA CAAA AAAG AAGA AGAC GACG ACGG CGGC GGCA GCAT CATC ATCA TCAT CATA ATAT TATG ATGG TGGG GGGT GGTT GTTG TTGC TGCA GCAA CAAC AACT ACTG CTGA TGAG GAGG AGGG GGGA GGAG GAGC AGCC GCCT CCTT CTTG TTGA TGAA GAAT AATA ATAC TACA ACAC CACC ACCA CCAA CAAA AAAA AAAA AAAA AAAT AATC ATCA TCAC CACA ACAT CATT ATTG TTGG TGGC GGCA GCAC CACC ACCC CCCG CCGC CGCA GCAA CAAT AATC ATCC TCCT CCTG CTGC TGCT GCTA CTAA TAAC,TGGTA GGTAT GTATT TATTT ATTTC TTTCT TTCTA TCTAC CTACT TACTA ACTAC CTACC TACCT ACCTA CCTAG CTAGG TAGGA AGGAA GGAAC GAACT AACTG ACTGG CTGGG TGGGC GGGCC GGCCA GCCAG CCAGA CAGAA AGAAG GAAGC AAGCT AGCTG GCTGG CTGGA TGGAC GGACT GACTT ACTTC CTTCC TTCCC TCCCT CCCTA CCTAT CTATG TATGG ATGGT TGGTG GGTGC GTGCT TGCTA GCTAA CTAAC TAACA AACAA ACAAA CAAAG AAAGA AAGAC AGACG GACGG ACGGC CGGCA GGCAT GCATC CATCA ATCAT TCATA CATAT ATATG TATGG ATGGG TGGGT GGGTT GGTTG GTTGC TTGCA TGCAA GCAAC CAACT AACTG ACTGA CTGAG TGAGG GAGGG AGGGA GGGAG GGAGC GAGCC AGCCT GCCTT CCTTG CTTGA TTGAA TGAAT GAATA AATAC ATACA TACAC ACACC CACCA ACCAA CCAAA CAAAA AAAAA AAAAA AAAAT AAATC AATCA ATCAC TCACA CACAT ACATT CATTG ATTGG TTGGC TGGCA GGCAC GCACC CACCC ACCCG CCCGC CCGCA CGCAA GCAAT CAATC AATCC ATCCT TCCTG CCTGC CTGCT TGCTA GCTAA CTAAC,TGGTAT GGTATT GTATTT TATTTC ATTTCT TTTCTA TTCTAC TCTACT CTACTA TACTAC ACTACC CTACCT TACCTA ACCTAG CCTAGG CTAGGA TAGGAA AGGAAC GGAACT GAACTG AACTGG ACTGGG CTGGGC TGGGCC GGGCCA GGCCAG GCCAGA CCAGAA CAGAAG AGAAGC GAAGCT AAGCTG AGCTGG GCTGGA CTGGAC TGGACT GGACTT GACTTC ACTTCC CTTCCC TTCCCT TCCCTA CCCTAT CCTATG CTATGG TATGGT ATGGTG TGGTGC GGTGCT GTGCTA TGCTAA GCTAAC CTAACA TAACAA AACAAA ACAAAG CAAAGA AAAGAC AAGACG AGACGG GACGGC ACGGCA CGGCAT GGCATC GCATCA CATCAT ATCATA TCATAT CATATG ATATGG TATGGG ATGGGT TGGGTT GGGTTG GGTTGC GTTGCA TTGCAA TGCAAC GCAACT CAACTG AACTGA ACTGAG CTGAGG TGAGGG GAGGGA AGGGAG GGGAGC GGAGCC GAGCCT AGCCTT GCCTTG CCTTGA CTTGAA TTGAAT TGAATA GAATAC AATACA ATACAC TACACC ACACCA CACCAA ACCAAA CCAAAA CAAAAA AAAAAA AAAAAT AAAATC AAATCA AATCAC ATCACA TCACAT CACATT ACATTG CATTGG ATTGGC TTGGCA TGGCAC GGCACC GCACCC CACCCG ACCCGC CCCGCA CCGCAA CGCAAT GCAATC CAATCC AATCCT ATCCTG TCCTGC CCTGCT CTGCTA TGCTAA GCTAAC,TGGTATT GGTATTT GTATTTC TATTTCT ATTTCTA TTTCTAC TTCTACT TCTACTA CTACTAC TACTACC ACTACCT CTACCTA TACCTAG ACCTAGG CCTAGGA CTAGGAA TAGGAAC AGGAACT GGAACTG GAACTGG AACTGGG ACTGGGC CTGGGCC TGGGCCA GGGCCAG GGCCAGA GCCAGAA CCAGAAG CAGAAGC AGAAGCT GAAGCTG AAGCTGG AGCTGGA GCTGGAC CTGGACT TGGACTT GGACTTC GACTTCC ACTTCCC CTTCCCT TTCCCTA TCCCTAT CCCTATG CCTATGG CTATGGT TATGGTG ATGGTGC TGGTGCT GGTGCTA GTGCTAA TGCTAAC GCTAACA CTAACAA TAACAAA AACAAAG ACAAAGA CAAAGAC AAAGACG AAGACGG AGACGGC GACGGCA ACGGCAT CGGCATC GGCATCA GCATCAT CATCATA ATCATAT TCATATG CATATGG ATATGGG TATGGGT ATGGGTT TGGGTTG GGGTTGC GGTTGCA GTTGCAA TTGCAAC TGCAACT GCAACTG CAACTGA AACTGAG ACTGAGG CTGAGGG TGAGGGA GAGGGAG AGGGAGC GGGAGCC GGAGCCT GAGCCTT AGCCTTG GCCTTGA CCTTGAA CTTGAAT TTGAATA TGAATAC GAATACA AATACAC ATACACC TACACCA ACACCAA CACCAAA ACCAAAA CCAAAAA CAAAAAA AAAAAAT AAAAATC AAAATCA AAATCAC AATCACA ATCACAT TCACATT CACATTG ACATTGG CATTGGC ATTGGCA TTGGCAC TGGCACC GGCACCC GCACCCG CACCCGC ACCCGCA CCCGCAA CCGCAAT CGCAATC GCAATCC CAATCCT AATCCTG ATCCTGC TCCTGCT CCTGCTA CTGCTAA TGCTAAC,"ID   NCAP_SARS2              Reviewed;         419 AA.
AC   P0DTC9;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Nucleoprotein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=N;
DE   AltName: Full=Nucleocapsid protein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=NC {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=Protein N {ECO:0000255|HAMAP-Rule:MF_04096};
GN   Name=N {ECO:0000255|HAMAP-Rule:MF_04096};
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   SUBCELLULAR LOCATION.
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [3] {ECO:0007744|PDB:6WZO, ECO:0007744|PDB:6WZQ}
RP   X-RAY CRYSTALLOGRAPHY (1.42 ANGSTROMS) OF 247-364, AND SUBUNIT.
RX   PubMed=32654247; DOI=10.1002/pro.3909;
RA   Ye Q., West A.M.V., Silletti S., Corbett K.D.;
RT   ""Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein."";
RL   Protein Sci. 29:1890-1901(2020).
RN   [4]
RP   REVIEW.
RX   PubMed=32974389; DOI=10.3389/fmolb.2020.00219;
RA   Nikolakaki E., Giannakouros T.;
RT   ""SR/RS Motifs as Critical Determinants of Coronavirus Life Cycle."";
RL   Front. Mol. Biosci. 7:219-219(2020).
RN   [5]
RP   VARIANTS LEU-3 AND PHE-235.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [6]
RP   FUNCTION, INTERACTION WITH HOST NLRP3, AND SUBCELLULAR LOCATION.
RX   PubMed=34341353; DOI=10.1038/s41467-021-25015-6;
RA   Pan P., Shen M., Yu Z., Ge W., Chen K., Tian M., Xiao F., Wang Z., Wang J.,
RA   Jia Y., Wang W., Wan P., Zhang J., Chen W., Lei Z., Chen X., Luo Z.,
RA   Zhang Q., Xu M., Li G., Li Y., Wu J.;
RT   ""SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce
RT   hyperinflammation."";
RL   Nat. Commun. 12:4664-4664(2021).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 41-174, AND MUTAGENESIS OF
RP   TYR-109.
RX   PubMed=32363136; DOI=10.1016/j.apsb.2020.04.009;
RA   Kang S., Yang M., Hong Z., Zhang L., Huang Z., Chen X., He S., Zhou Z.,
RA   Zhou Z., Chen Q., Yan Y., Zhang C., Shan H., Chen S.;
RT   ""Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain
RT   reveals potential unique drug targeting sites."";
RL   Acta Pharmacol. Sin. 10:1228-1238(2020).
RN   [8] {ECO:0007744|PDB:6YI3, ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT}
RP   STRUCTURE BY NMR OF 44-180, FUNCTION, AND MUTAGENESIS OF ARG-68; ARG-92;
RP   ILE-94; ARG-107; GLN-163; TYR-172 AND GLU-174.
RX   PubMed=33264373; DOI=10.1371/journal.ppat.1009100;
RA   Dinesh D.C., Chalupska D., Silhan J., Koutna E., Nencka R., Veverka V.,
RA   Boura E.;
RT   ""Structural basis of RNA recognition by the SARS-CoV-2 nucleocapsid
RT   phosphoprotein."";
RL   PLoS Pathog. 16:1-16(2020).
RN   [9]
RP   MUTAGENESIS OF SER-188 AND SER-206, AND PHOSPHORYLATION AT SER-206.
RX   PubMed=34593624; DOI=10.1073/pnas.2113401118;
RA   Liu X., Verma A., Garcia G. Jr., Ramage H., Lucas A., Myers R.L.,
RA   Michaelson J.J., Coryell W., Kumar A., Charney A.W., Kazanietz M.G.,
RA   Rader D.J., Ritchie M.D., Berrettini W.H., Schultz D.C., Cherry S.,
RA   Damoiseaux R., Arumugaswami V., Klein P.S.;
RT   ""Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:1-9(2021).
RN   [10]
RP   CLEAVAGE.
RX   PubMed=35922005; DOI=10.1038/s41586-022-05148-4;
RA   Chu H., Hou Y., Yang D., Wen L., Shuai H., Yoon C., Shi J., Chai Y.,
RA   Yuen T.T., Hu B., Li C., Zhao X., Wang Y., Huang X., Lee K.S., Luo C.,
RA   Cai J.P., Poon V.K., Chan C.C., Zhang A.J., Yuan S., Sit K.Y., Foo D.C.,
RA   Au W.K., Wong K.K., Zhou J., Kok K.H., Jin D.Y., Chan J.F., Yuen K.Y.;
RT   ""Coronaviruses exploit a host cysteine-aspartic protease for replication."";
RL   Nature 0:0-0(2022).
RN   [11]
RP   MUTAGENESIS OF 203-ARG-GLY-204 AND ARG-203, AND PHOSPHORYLATION.
RX   PubMed=35728038; DOI=10.1371/journal.ppat.1010627;
RA   Johnson B.A., Zhou Y., Lokugamage K.G., Vu M.N., Bopp N.,
RA   Crocquet-Valdes P.A., Kalveram B., Schindewolf C., Liu Y., Scharton D.,
RA   Plante J.A., Xie X., Aguilar P., Weaver S.C., Shi P.Y., Walker D.H.,
RA   Routh A.L., Plante K.S., Menachery V.D.;
RT   ""Nucleocapsid mutations in SARS-CoV-2 augment replication and
RT   pathogenesis."";
RL   PLoS Pathog. 18:e1010627-e1010627(2022).
RN   [12]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=35921414; DOI=10.1126/sciadv.abp9770;
RA   Lopez-Munoz A.D., Kosik I., Holly J., Yewdell J.W.;
RT   ""Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive
RT   immunity."";
RL   Sci. Adv. 8:eabp9770-eabp9770(2022).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=34901782; DOI=10.1016/j.isci.2021.103562;
RA   Nabeel-Shah S., Lee H., Ahmed N., Burke G.L., Farhangmehr S., Ashraf K.,
RA   Pu S., Braunschweig U., Zhong G., Wei H., Tang H., Yang J., Marcon E.,
RA   Blencowe B.J., Zhang Z., Greenblatt J.F.;
RT   ""SARS-CoV-2 nucleocapsid protein binds host mRNAs and attenuates stress
RT   granules to impair host stress response."";
RL   IScience 25:103562-103562(2022).
RN   [14]
RP   FUNCTION.
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [15] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 191-263, AND INTERACTION WITH NSP3.
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
CC   -!- FUNCTION: Packages the positive strand viral genome RNA into a helical
CC       ribonucleocapsid (RNP) and plays a fundamental role during virion
CC       assembly through its interactions with the viral genome and membrane
CC       protein M (PubMed:33264373). Plays an important role in enhancing the
CC       efficiency of subgenomic viral RNA transcription as well as viral
CC       replication. Attenuates the stress granules formation by reducing host
CC       G3BP1 access to host mRNAs under stress conditions (PubMed:34901782,
CC       PubMed:36534661). {ECO:0000269|PubMed:32974389,
CC       ECO:0000269|PubMed:33264373, ECO:0000269|PubMed:34901782,
CC       ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: May block host chemokine function in vivo, facilitating viral
CC       replication and transmission (PubMed:35921414). Acts by being secreted
CC       into the extracellular space where it competes to host chemokines for
CC       binding to host glycosaminoglycans (GAG) (PubMed:35921414).
CC       {ECO:0000269|PubMed:35921414}.
CC   -!- FUNCTION: May induce inflammasome responses in cultured cells and mice.
CC       Acts by interacting with host NLRP3 to facilitate inflammasome
CC       assembly, which induces cytokine release that may play a role in COVID
CC       lung injury. {ECO:0000269|PubMed:34341353}.
CC   -!- SUBUNIT: Homodimer, homotetramer, homooligomer with RNA
CC       (PubMed:32654247). Both monomeric and oligomeric forms interact with
CC       RNA. Interacts with protein M (By similarity). Interacts with protein E
CC       (By similarity). Interacts with NSP3; this interaction serves to tether
CC       the genome to the newly translated replicase-transcriptase complex at a
CC       very early stage of infection (PubMed:35044811). May interact with host
CC       NLRP3 (PubMed:34341353). {ECO:0000250|UniProtKB:P59595,
CC       ECO:0000255|HAMAP-Rule:MF_04096, ECO:0000269|PubMed:32654247,
CC       ECO:0000269|PubMed:34341353, ECO:0000269|PubMed:35044811}.
CC   -!- INTERACTION:
CC       P0DTC9; P0DTC4: E; NbExp=3; IntAct=EBI-25475856, EBI-25475850;
CC       P0DTC9; P0DTC5: M; NbExp=6; IntAct=EBI-25475856, EBI-25475853;
CC       P0DTC9; P0DTC9: N; NbExp=105; IntAct=EBI-25475856, EBI-25475856;
CC       P0DTC9; PRO_0000449621 [P0DTD1]: rep; NbExp=15; IntAct=EBI-25475856, EBI-25492388;
CC       P0DTC9; P78563: ADARB1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-2967304;
CC       P0DTC9; O15145: ARPC3; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-351829;
CC       P0DTC9; Q13895: BYSL; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-358049;
CC       P0DTC9; Q16543: CDC37; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-295634;
CC       P0DTC9; Q92793: CREBBP; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-81215;
CC       P0DTC9; Q92499: DDX1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-358474;
CC       P0DTC9; Q9NR30: DDX21; Xeno; NbExp=12; IntAct=EBI-25475856, EBI-357942;
CC       P0DTC9; P26196: DDX6; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-351257;
CC       P0DTC9; Q08426: EHHADH; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-2339219;
CC       P0DTC9; P19525: EIF2AK2; Xeno; NbExp=8; IntAct=EBI-25475856, EBI-640775;
CC       P0DTC9; Q14241: ELOA; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-742350;
CC       P0DTC9; Q13283: G3BP1; Xeno; NbExp=71; IntAct=EBI-25475856, EBI-1047359;
CC       P0DTC9; Q9UN86: G3BP2; Xeno; NbExp=37; IntAct=EBI-25475856, EBI-1044298;
CC       P0DTC9; P57764: GSDMD; Xeno; NbExp=13; IntAct=EBI-25475856, EBI-2798865;
CC       P0DTC9; P49841: GSK3B; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-373586;
CC       P0DTC9; P10412: H1-4; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-358163;
CC       P0DTC9; O14920: IKBKB; Xeno; NbExp=7; IntAct=EBI-25475856, EBI-81266;
CC       P0DTC9; Q92830: KAT2A; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-477622;
CC       P0DTC9; Q92831: KAT2B; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-477430;
CC       P0DTC9; Q07866: KLC1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-721019;
CC       P0DTC9; Q9H0B6: KLC2; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-726994;
CC       P0DTC9; Q9NSK0: KLC4; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-949319;
CC       P0DTC9; Q9NX58: LYAR; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-713507;
CC       P0DTC9; O43318: MAP3K7; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-358684;
CC       P0DTC9; Q9UBU8: MORF4L1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-399246;
CC       P0DTC9; Q15014: MORF4L2; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-399257;
CC       P0DTC9; Q9HCE1: MOV10; Xeno; NbExp=11; IntAct=EBI-25475856, EBI-1055820;
CC       P0DTC9; Q9HC36: MRM3; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-1045440;
CC       P0DTC9; O15226: NKRF; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-766011;
CC       P0DTC9; Q96P20: NLRP3; Xeno; NbExp=18; IntAct=EBI-25475856, EBI-6253230;
CC       P0DTC9; O15118: NPC1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-2368710;
CC       P0DTC9; Q96HA8: NTAQ1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-741158;
CC       P0DTC9; P11940: PABPC1; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-81531;
CC       P0DTC9; P62937: PPIA; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-437708;
CC       P0DTC9; O75569: PRKRA; Xeno; NbExp=8; IntAct=EBI-25475856, EBI-713955;
CC       P0DTC9; Q99873: PRMT1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-78738;
CC       P0DTC9; P61289: PSME3; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-355546;
CC       P0DTC9; P26022: PTX3; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-11574553;
CC       P0DTC9; P54727: RAD23B; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-954531;
CC       P0DTC9; O95786: RIGI; Xeno; NbExp=15; IntAct=EBI-25475856, EBI-995350;
CC       P0DTC9; P62899: RPL31; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-1053664;
CC       P0DTC9; P62753: RPS6; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-356625;
CC       P0DTC9; P37840: SNCA; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-985879;
CC       P0DTC9; Q96SB4: SRPK1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-539478;
CC       P0DTC9; P78362: SRPK2; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-593303;
CC       P0DTC9; P42224: STAT1; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-1057697;
CC       P0DTC9; P52630: STAT2; Xeno; NbExp=7; IntAct=EBI-25475856, EBI-1546963;
CC       P0DTC9; Q15633: TARBP2; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-978581;
CC       P0DTC9; Q14258: TRIM25; Xeno; NbExp=13; IntAct=EBI-25475856, EBI-2341129;
CC       P0DTC9; O60763: USO1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-356164;
CC       P0DTC9; Q93008: USP9X; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-302524;
CC   -!- SUBCELLULAR LOCATION: Virion {ECO:0000255|HAMAP-Rule:MF_04096}. Host
CC       cytoplasm {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:34341353}.
CC       Secreted {ECO:0000269|PubMed:35921414}. Host extracellular space
CC       {ECO:0000269|PubMed:35921414}. Note=Probably associates with ER-derived
CC       membranes where it participates in viral RNA synthesis and virus
CC       budding. When located inside the virion, complexed with the viral RNA.
CC       Can be secreted by unconventional protein secretion (UPS)
CC       (PubMed:35921414). When secreted, can bind to host glycosaminoglycans
CC       on infected and non infected cells (PubMed:35921414). Found in host
CC       cytoplasmic stress granules (PubMed:34901782). {ECO:0000255|HAMAP-
CC       Rule:MF_04096, ECO:0000269|PubMed:34901782,
CC       ECO:0000269|PubMed:35921414}.
CC   -!- PTM: ADP-ribosylated. The ADP-ribosylation is retained in the virion
CC       during infection. {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   -!- PTM: Phosphorylated on serine residues by host GSK3A and GSK3B
CC       (PubMed:34593624, PubMed:35728038). This promotes the solubility of
CC       homodimers that would otherwise aggregate (PubMed:32974389). Host
CC       phosphatase would dephosphorylate the protein during assembly at M
CC       bound membranes (PubMed:32974389). {ECO:0000269|PubMed:34593624,
CC       ECO:0000269|PubMed:35728038, ECO:0000305|PubMed:32974389}.
CC   -!- PTM: Proteolytically cleaved by host CASP6. The cleavage leads to two
CC       fragments and facilitates viral replication by inhibiting host IFN
CC       signaling. The two fragments may interact with IRF3 inhibiting its
CC       nuclear translocation after activation and reduce the expression of
CC       IFNB and IFN-stimulated genes. {ECO:0000269|PubMed:35922005}.
CC   -!- POLYMORPHISM: Variant Alpha/B.1.1.7 belongs to a lineage isolated first
CC       in United Kingdom (December 2020). It is also called Variant of Concern
CC       (VOC) 202012/01, Variant Under Investigation (VUI) 202012/01, 501Y.V1
CC       or 20B/501Y.V1. {ECO:0000305|PubMed:33413740}.
CC   -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC       isolated in South Africa (November 2021). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC       isolated in Nigeria (November 2022). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC       isolated in United States (November 2022). It is the result of
CC       recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC       express ORF8. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the betacoronavirus nucleocapsid protein family.
CC       {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43423.2; -; Genomic_RNA.
DR   PDB; 6M3M; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 6VYO; X-ray; 1.70 A; A/B/C/D=47-173.
DR   PDB; 6WJI; X-ray; 2.05 A; A/B/C/D/E/F=257-364.
DR   PDB; 6WKP; X-ray; 2.67 A; A/B/C/D=47-173.
DR   PDB; 6WZO; X-ray; 1.42 A; A/B/C/D=247-364.
DR   PDB; 6WZQ; X-ray; 1.45 A; A/B/C/D=247-364.
DR   PDB; 6YI3; NMR; -; A=44-180.
DR   PDB; 6YUN; X-ray; 1.44 A; A/B=249-364.
DR   PDB; 6ZCO; X-ray; 1.36 A; A=247-364.
DR   PDB; 7ACS; NMR; -; A=44-180.
DR   PDB; 7ACT; NMR; -; A=44-180.
DR   PDB; 7C22; X-ray; 2.00 A; A/B/C/D=248-364.
DR   PDB; 7CDZ; X-ray; 1.80 A; A/B/C/D=44-174.
DR   PDB; 7CE0; X-ray; 1.50 A; A/B/C/D=255-364.
DR   PDB; 7CR5; X-ray; 2.08 A; A=41-174.
DR   PDB; 7DE1; X-ray; 2.00 A; A/B=250-364.
DR   PDB; 7F2B; X-ray; 2.00 A; A/B=257-362.
DR   PDB; 7F2E; X-ray; 3.10 A; A/B/C/D/E/F/G/H/I/J/K/L=255-362.
DR   PDB; 7KGO; X-ray; 2.15 A; C=351-359.
DR   PDB; 7KGP; X-ray; 1.40 A; C=316-324.
DR   PDB; 7KGQ; X-ray; 1.34 A; C=222-230.
DR   PDB; 7KGR; X-ray; 1.55 A; C=159-167.
DR   PDB; 7KGS; X-ray; 1.58 A; C=138-146.
DR   PDB; 7KGT; X-ray; 1.90 A; C=226-234.
DR   PDB; 7LGD; X-ray; 2.88 A; E/F=105-113.
DR   PDB; 7LTU; X-ray; 1.12 A; A/B=217-222.
DR   PDB; 7LUX; X-ray; 1.30 A; A=217-222.
DR   PDB; 7LUZ; X-ray; 1.10 A; A=243-248.
DR   PDB; 7LV2; X-ray; 1.30 A; A=179-184.
DR   PDB; 7N0I; X-ray; 2.20 A; A/B/C/D/E/F/G/H=269-364.
DR   PDB; 7N0R; X-ray; 1.42 A; A/B=49-174.
DR   PDB; 7N3C; X-ray; 1.82 A; C=47-173.
DR   PDB; 7N3D; X-ray; 1.53 A; C=47-173.
DR   PDB; 7O05; X-ray; 1.94 A; A/B/C/D=247-364.
DR   PDB; 7O35; X-ray; 1.80 A; A/B/C/D=247-364.
DR   PDB; 7O36; X-ray; 2.00 A; A/B/C/D=247-364.
DR   PDB; 7PKU; NMR; -; B=191-263.
DR   PDB; 7QIK; X-ray; 2.01 A; E/F=193-200.
DR   PDB; 7QIP; X-ray; 2.65 A; C/D=201-210.
DR   PDB; 7R98; X-ray; 2.51 A; A/B/C=49-174.
DR   PDB; 7SD4; NMR; -; A=40-174.
DR   PDB; 7STR; X-ray; 1.50 A; C=47-173.
DR   PDB; 7STS; X-ray; 2.16 A; C/D=47-173.
DR   PDB; 7SUE; X-ray; 2.90 A; C/D/J/K=47-173.
DR   PDB; 7SUO; X-ray; 2.35 A; C/D=12-22.
DR   PDB; 7UW3; X-ray; 1.70 A; A/B/C/D=40-174.
DR   PDB; 7UXX; X-ray; 1.85 A; AAA/BBB/CCC/DDD/EEE/FFF=251-364.
DR   PDB; 7UXZ; X-ray; 1.73 A; AAA/BBB/CCC/DDD/EEE/FFF=251-364.
DR   PDB; 7VBD; X-ray; 1.94 A; A/B/C/D=48-174.
DR   PDB; 7VBE; X-ray; 1.59 A; A/B=257-364.
DR   PDB; 7VBF; X-ray; 1.30 A; A/B=255-364.
DR   PDB; 7VNU; X-ray; 1.95 A; A/B/C/D=47-174.
DR   PDB; 7WKJ; X-ray; 1.50 A; C=361-369.
DR   PDB; 7WZO; X-ray; 2.64 A; A=47-174.
DR   PDB; 7XWX; X-ray; 3.00 A; A/B/C/D/E/F/G/H=269-367.
DR   PDB; 7XWZ; X-ray; 2.25 A; A/B=48-172.
DR   PDB; 7XX1; X-ray; 1.90 A; A/B/C/D=49-173.
DR   PDB; 7XXK; X-ray; 2.00 A; A/B/C/D/E/F=248-364.
DR   PDB; 7YLB; X-ray; 2.41 A; A/B/C/D/G/H/J/K=247-364.
DR   PDB; 7YLD; X-ray; 2.80 A; A/B/C/D=47-174.
DR   PDB; 7ZIT; X-ray; 1.79 A; C/D=194-200.
DR   PDB; 8DNT; X-ray; 3.18 A; D/J/Q/X=222-230.
DR   PDB; 8FD5; EM; 4.57 A; A=1-419.
DR   PDB; 8FG2; EM; 6.00 A; A/B=1-419.
DR   PDB; 8IQJ; X-ray; 2.30 A; A/B/C/D=41-174.
DR   PDB; 8IV3; X-ray; 1.90 A; A/B/C/D=41-174.
DR   PDB; 8J6X; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 8TH1; X-ray; 1.80 A; E/F/G/H=1-25.
DR   PDB; 8TH5; X-ray; 2.62 A; K/L/M/N/O/P/Q=1-25.
DR   PDB; 8X1H; X-ray; 2.00 A; A/B/C/D=44-175.
DR   PDBsum; 6M3M; -.
DR   PDBsum; 6VYO; -.
DR   PDBsum; 6WJI; -.
DR   PDBsum; 6WKP; -.
DR   PDBsum; 6WZO; -.
DR   PDBsum; 6WZQ; -.
DR   PDBsum; 6YI3; -.
DR   PDBsum; 6YUN; -.
DR   PDBsum; 6ZCO; -.
DR   PDBsum; 7ACS; -.
DR   PDBsum; 7ACT; -.
DR   PDBsum; 7C22; -.
DR   PDBsum; 7CDZ; -.
DR   PDBsum; 7CE0; -.
DR   PDBsum; 7CR5; -.
DR   PDBsum; 7DE1; -.
DR   PDBsum; 7F2B; -.
DR   PDBsum; 7F2E; -.
DR   PDBsum; 7KGO; -.
DR   PDBsum; 7KGP; -.
DR   PDBsum; 7KGQ; -.
DR   PDBsum; 7KGR; -.
DR   PDBsum; 7KGS; -.
DR   PDBsum; 7KGT; -.
DR   PDBsum; 7LGD; -.
DR   PDBsum; 7LTU; -.
DR   PDBsum; 7LUX; -.
DR   PDBsum; 7LUZ; -.
DR   PDBsum; 7LV2; -.
DR   PDBsum; 7N0I; -.
DR   PDBsum; 7N0R; -.
DR   PDBsum; 7N3C; -.
DR   PDBsum; 7N3D; -.
DR   PDBsum; 7O05; -.
DR   PDBsum; 7O35; -.
DR   PDBsum; 7O36; -.
DR   PDBsum; 7PKU; -.
DR   PDBsum; 7QIK; -.
DR   PDBsum; 7QIP; -.
DR   PDBsum; 7R98; -.
DR   PDBsum; 7SD4; -.
DR   PDBsum; 7STR; -.
DR   PDBsum; 7STS; -.
DR   PDBsum; 7SUE; -.
DR   PDBsum; 7SUO; -.
DR   PDBsum; 7UW3; -.
DR   PDBsum; 7UXX; -.
DR   PDBsum; 7UXZ; -.
DR   PDBsum; 7VBD; -.
DR   PDBsum; 7VBE; -.
DR   PDBsum; 7VBF; -.
DR   PDBsum; 7VNU; -.
DR   PDBsum; 7WKJ; -.
DR   PDBsum; 7WZO; -.
DR   PDBsum; 7XWX; -.
DR   PDBsum; 7XWZ; -.
DR   PDBsum; 7XX1; -.
DR   PDBsum; 7XXK; -.
DR   PDBsum; 7YLB; -.
DR   PDBsum; 7YLD; -.
DR   PDBsum; 7ZIT; -.
DR   PDBsum; 8DNT; -.
DR   PDBsum; 8FD5; -.
DR   PDBsum; 8FG2; -.
DR   PDBsum; 8IQJ; -.
DR   PDBsum; 8IV3; -.
DR   PDBsum; 8J6X; -.
DR   PDBsum; 8TH1; -.
DR   PDBsum; 8TH5; -.
DR   PDBsum; 8X1H; -.
DR   BMRB; P0DTC9; -.
DR   EMDB; EMD-29002; -.
DR   EMDB; EMD-29072; -.
DR   SASBDB; P0DTC9; -.
DR   SMR; P0DTC9; -.
DR   BioGRID; 4383847; 1532.
DR   ComplexPortal; CPX-5686; SARS-CoV-2 nucleocapsid complex.
DR   IntAct; P0DTC9; 608.
DR   MINT; P0DTC9; -.
DR   ChEMBL; CHEMBL5169223; -.
DR   iPTMnet; P0DTC9; -.
DR   ABCD; P0DTC9; 27 sequenced antibodies.
DR   DNASU; 43740575; -.
DR   KEGG; vg:43740575; -.
DR   AGR; RefSeq:YP_009724397; -.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-168928; DDX58/IFIH1-mediated induction of interferon-alpha/beta.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-445989; TAK1-dependent IKK and NF-kappa-B activation.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-9020702; Interleukin-1 signaling.
DR   Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR   Reactome; R-HSA-9694322; Virion Assembly and Release.
DR   Reactome; R-HSA-9694614; Attachment and Entry.
DR   Reactome; R-HSA-9694631; Maturation of nucleoprotein.
DR   Reactome; R-HSA-9694635; Translation of Structural Proteins.
DR   Reactome; R-HSA-9694786; Transcription of SARS-CoV-2 sgRNAs.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9733458; Induction of Cell-Cell Fusion.
DR   Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways.
DR   SIGNOR; P0DTC9; -.
DR   PRO; PR:P0DTC9; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProt.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0044172; C:host cell endoplasmic reticulum-Golgi intermediate compartment; ISS:UniProtKB.
DR   GO; GO:0044177; C:host cell Golgi apparatus; ISS:UniProtKB.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0043655; C:host extracellular space; IEA:UniProtKB-SubCell.
DR   GO; GO:0043232; C:intracellular non-membrane-bounded organelle; IDA:DisProt.
DR   GO; GO:0042612; C:MHC class I protein complex; EXP:DisProt.
DR   GO; GO:1990904; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IPI:ComplexPortal.
DR   GO; GO:0019013; C:viral nucleocapsid; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0042288; F:MHC class I protein binding; EXP:DisProt.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; IDA:DisProt.
DR   GO; GO:0008266; F:poly(U) RNA binding; IMP:DisProt.
DR   GO; GO:0042803; F:protein homodimerization activity; EXP:DisProt.
DR   GO; GO:0140311; F:protein sequestering activity; IDA:UniProt.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProt.
DR   GO; GO:0035613; F:RNA stem-loop binding; IDA:DisProt.
DR   GO; GO:0039709; P:cytoplasmic capsid assembly; IDA:UniProt.
DR   GO; GO:0032688; P:negative regulation of interferon-beta production; IDA:ComplexPortal.
DR   GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; IDA:UniProtKB.
DR   GO; GO:0052572; P:response to host immune response; IDA:DisProt.
DR   GO; GO:0019074; P:viral RNA genome packaging; NAS:ComplexPortal.
DR   CDD; cd21595; CoV_N-CTD; 1.
DR   CDD; cd21554; CoV_N-NTD; 1.
DR   HAMAP; MF_04096; BETA_CORONA_NCAP; 1.
DR   InterPro; IPR044344; N_prot_C_CoV.
DR   InterPro; IPR044345; N_prot_N_CoV.
DR   InterPro; IPR043505; NCAP_bCoV.
DR   InterPro; IPR001218; Nucleocap_CoV.
DR   InterPro; IPR037179; Nucleocapsid_C.
DR   InterPro; IPR037195; Nucleocapsid_N.
DR   Pfam; PF00937; CoV_nucleocap; 1.
DR   PIRSF; PIRSF003888; Corona_nucleocap; 1.
DR   SUPFAM; SSF110304; Coronavirus RNA-binding domain; 1.
DR   SUPFAM; SSF103068; Nucleocapsid protein dimerization domain; 1.
DR   PROSITE; PS51929; COV_N_CTD; 1.
DR   PROSITE; PS51928; COV_N_NTD; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Host cytoplasm; Phosphoprotein;
KW   Reference proteome; Ribonucleoprotein; RNA-binding; Secreted;
KW   Transcription; Transcription regulation; Viral nucleoprotein; Virion.
FT   CHAIN           1..419
FT                   /note=""Nucleoprotein""
FT                   /id=""PRO_0000449656""
FT   DOMAIN          48..174
FT                   /note=""CoV N NTD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01276,
FT                   ECO:0000269|PubMed:32363136""
FT   DOMAIN          247..364
FT                   /note=""CoV N CTD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01277""
FT   REGION          1..51
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          41..186
FT                   /note=""RNA-binding""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   REGION          63..83
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          168..212
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          176..206
FT                   /note=""SR region""
FT                   /evidence=""ECO:0000305|PubMed:32974389""
FT   REGION          233..266
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          258..361
FT                   /note=""Dimerization""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   REGION          260..340
FT                   /note=""Putative NLRP3 binding""
FT                   /evidence=""ECO:0000269|PubMed:34341353""
FT   REGION          361..391
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          400..419
FT                   /note=""Tetramerization""
FT                   /evidence=""ECO:0000269|PubMed:32654247""
FT   MOTIF           256..264
FT                   /note=""Nuclear localization signal""
FT                   /evidence=""ECO:0000250|UniProtKB:P59595""
FT   COMPBIAS        1..11
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        21..31
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        367..378
FT                   /note=""Basic and acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   BINDING         92
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   BINDING         107
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   BINDING         149
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   SITE            399..402
FT                   /note=""Cleavage (by host CASP6)""
FT                   /evidence=""ECO:0000250|UniProtKB:P59595""
FT   MOD_RES         176
FT                   /note=""Phosphoserine; by host""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   MOD_RES         206
FT                   /note=""Phosphoserine; by host GSK3-alpha and GSK3-beta""
FT                   /evidence=""ECO:0000269|PubMed:34593624""
FT   VARIANT         2..3
FT                   /note=""SD -> Y (in strain: Eta/B.1.525)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         3
FT                   /note=""D -> L (in strain: Alpha/B.1.1.7)""
FT                   /evidence=""ECO:0000305|PubMed:33413740""
FT   VARIANT         12
FT                   /note=""A -> G (in strain: Eta/B.1.525)""
FT   VARIANT         13
FT                   /note=""P -> L (in strain: Lambda/C.37, Omicron/BA.1,
FT                   Omicron/BA.2, Omicron/BA.2.12.1, Omicron/BA.2.75,
FT                   Omicron/BA.4, Omicron/BA.5, Omicron/BQ.1.1,
FT                   Omicron/XBB.1.5, Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         31..33
FT                   /note=""Missing (in strain: Omicron/BA.1, Omicron/BA.2,
FT                   Omicron/BA.2.12.1, Omicron/BA.2.75, Omicron/BA.4,
FT                   Omicron/BA.5, Omicron/BQ.1.1, Omicron/XBB.1.5,
FT                   Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         63
FT                   /note=""D -> G (in strain: Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT  ",4145
GTGAAG TGAAGC GAAGCT AAGCTG AGCTGG GCTGGG CTGGGT TGGGTT GGGTTA GGTTAT GTTATC TTATCT TATCTG ATCTGC TCTGCA CTGCAG TGCAGT GCAGTC CAGTCC AGTCCC GTCCCA TCCCAG CCCAGC CCAGCG CAGCGT AGCGTG GCGTGG CGTGGC GTGGCA TGGCAA GGCAAG GCAAGA CAAGAA AAGAAT AGAATG GAATGG AATGGC ATGGCG TGGCGG GGCGGG GCGGGA CGGGAT GGGATC GGATCC GATCCG ATCCGC TCCGCA CCGCAT CGCATG GCATGG CATGGC ATGGCC TGGCCT GGCCTG GCCTGT CCTGTT CTGTTC TGTTCC GTTCCC TTCCCC TCCCCT CCCCTG CCCTGA CCTGAG CTGAGA TGAGAG GAGAGC AGAGCG GAGCGT AGCGTG GCGTGA CGTGAA GTGAAC TGAACA GAACAT AACATA ACATAG CATAGG ATAGGC TAGGCC AGGCCA GGCCAG GCCAGG CCAGGG CAGGGG AGGGGA GGGGAT GGGATC GGATCC GATCCG ATCCGG TCCGGG CCGGGC CGGGCG GGGCGC GGCGCT GCGCTG CGCTGG GCTGGA CTGGAA TGGAAG GGAAGG GAAGGC,3,103,GTGA TGAA GAAG AAGC AGCT GCTG CTGG TGGG GGGT GGTT GTTA TTAT TATC ATCT TCTG CTGC TGCA GCAG CAGT AGTC GTCC TCCC CCCA CCAG CAGC AGCG GCGT CGTG GTGG TGGC GGCA GCAA CAAG AAGA AGAA GAAT AATG ATGG TGGC GGCG GCGG CGGG GGGA GGAT GATC ATCC TCCG CCGC CGCA GCAT CATG ATGG TGGC GGCC GCCT CCTG CTGT TGTT GTTC TTCC TCCC CCCC CCCT CCTG CTGA TGAG GAGA AGAG GAGC AGCG GCGT CGTG GTGA TGAA GAAC AACA ACAT CATA ATAG TAGG AGGC GGCC GCCA CCAG CAGG AGGG GGGG GGGA GGAT GATC ATCC TCCG CCGG CGGG GGGC GGCG GCGC CGCT GCTG CTGG TGGA GGAA GAAG AAGG AGGC,GTGAA TGAAG GAAGC AAGCT AGCTG GCTGG CTGGG TGGGT GGGTT GGTTA GTTAT TTATC TATCT ATCTG TCTGC CTGCA TGCAG GCAGT CAGTC AGTCC GTCCC TCCCA CCCAG CCAGC CAGCG AGCGT GCGTG CGTGG GTGGC TGGCA GGCAA GCAAG CAAGA AAGAA AGAAT GAATG AATGG ATGGC TGGCG GGCGG GCGGG CGGGA GGGAT GGATC GATCC ATCCG TCCGC CCGCA CGCAT GCATG CATGG ATGGC TGGCC GGCCT GCCTG CCTGT CTGTT TGTTC GTTCC TTCCC TCCCC CCCCT CCCTG CCTGA CTGAG TGAGA GAGAG AGAGC GAGCG AGCGT GCGTG CGTGA GTGAA TGAAC GAACA AACAT ACATA CATAG ATAGG TAGGC AGGCC GGCCA GCCAG CCAGG CAGGG AGGGG GGGGA GGGAT GGATC GATCC ATCCG TCCGG CCGGG CGGGC GGGCG GGCGC GCGCT CGCTG GCTGG CTGGA TGGAA GGAAG GAAGG AAGGC,GTGAAG TGAAGC GAAGCT AAGCTG AGCTGG GCTGGG CTGGGT TGGGTT GGGTTA GGTTAT GTTATC TTATCT TATCTG ATCTGC TCTGCA CTGCAG TGCAGT GCAGTC CAGTCC AGTCCC GTCCCA TCCCAG CCCAGC CCAGCG CAGCGT AGCGTG GCGTGG CGTGGC GTGGCA TGGCAA GGCAAG GCAAGA CAAGAA AAGAAT AGAATG GAATGG AATGGC ATGGCG TGGCGG GGCGGG GCGGGA CGGGAT GGGATC GGATCC GATCCG ATCCGC TCCGCA CCGCAT CGCATG GCATGG CATGGC ATGGCC TGGCCT GGCCTG GCCTGT CCTGTT CTGTTC TGTTCC GTTCCC TTCCCC TCCCCT CCCCTG CCCTGA CCTGAG CTGAGA TGAGAG GAGAGC AGAGCG GAGCGT AGCGTG GCGTGA CGTGAA GTGAAC TGAACA GAACAT AACATA ACATAG CATAGG ATAGGC TAGGCC AGGCCA GGCCAG GCCAGG CCAGGG CAGGGG AGGGGA GGGGAT GGGATC GGATCC GATCCG ATCCGG TCCGGG CCGGGC CGGGCG GGGCGC GGCGCT GCGCTG CGCTGG GCTGGA CTGGAA TGGAAG GGAAGG GAAGGC,GTGAAGC TGAAGCT GAAGCTG AAGCTGG AGCTGGG GCTGGGT CTGGGTT TGGGTTA GGGTTAT GGTTATC GTTATCT TTATCTG TATCTGC ATCTGCA TCTGCAG CTGCAGT TGCAGTC GCAGTCC CAGTCCC AGTCCCA GTCCCAG TCCCAGC CCCAGCG CCAGCGT CAGCGTG AGCGTGG GCGTGGC CGTGGCA GTGGCAA TGGCAAG GGCAAGA GCAAGAA CAAGAAT AAGAATG AGAATGG GAATGGC AATGGCG ATGGCGG TGGCGGG GGCGGGA GCGGGAT CGGGATC GGGATCC GGATCCG GATCCGC ATCCGCA TCCGCAT CCGCATG CGCATGG GCATGGC CATGGCC ATGGCCT TGGCCTG GGCCTGT GCCTGTT CCTGTTC CTGTTCC TGTTCCC GTTCCCC TTCCCCT TCCCCTG CCCCTGA CCCTGAG CCTGAGA CTGAGAG TGAGAGC GAGAGCG AGAGCGT GAGCGTG AGCGTGA GCGTGAA CGTGAAC GTGAACA TGAACAT GAACATA AACATAG ACATAGG CATAGGC ATAGGCC TAGGCCA AGGCCAG GGCCAGG GCCAGGG CCAGGGG CAGGGGA AGGGGAT GGGGATC GGGATCC GGATCCG GATCCGG ATCCGGG TCCGGGC CCGGGCG CGGGCGC GGGCGCT GGCGCTG GCGCTGG CGCTGGA GCTGGAA CTGGAAG TGGAAGG GGAAGGC,"ID   NSRR_BACLD              Reviewed;         143 AA.
AC   Q65M01; Q62XD8;
DT   09-JAN-2007, integrated into UniProtKB/Swiss-Prot.
DT   25-OCT-2004, sequence version 1.
DT   05-FEB-2025, entry version 116.
DE   RecName: Full=HTH-type transcriptional regulator NsrR;
GN   Name=nsrR; OrderedLocusNames=BLi01005, BL02858;
OS   Bacillus licheniformis (strain ATCC 14580 / DSM 13 / JCM 2505 / CCUG 7422 /
OS   NBRC 12200 / NCIMB 9375 / NCTC 10341 / NRRL NRS-1264 / Gibson 46).
OC   Bacteria; Bacillati; Bacillota; Bacilli; Bacillales; Bacillaceae; Bacillus.
OX   NCBI_TaxID=279010;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 14580 / DSM 13 / JCM 2505 / CCUG 7422 / NBRC 12200 / NCIMB
RC   9375 / NCTC 10341 / NRRL NRS-1264 / Gibson 46;
RX   PubMed=15383718; DOI=10.1159/000079829;
RA   Veith B., Herzberg C., Steckel S., Feesche J., Maurer K.H., Ehrenreich P.,
RA   Baeumer S., Henne A., Liesegang H., Merkl R., Ehrenreich A., Gottschalk G.;
RT   ""The complete genome sequence of Bacillus licheniformis DSM13, an organism
RT   with great industrial potential."";
RL   J. Mol. Microbiol. Biotechnol. 7:204-211(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 14580 / DSM 13 / JCM 2505 / CCUG 7422 / NBRC 12200 / NCIMB
RC   9375 / NCTC 10341 / NRRL NRS-1264 / Gibson 46;
RX   PubMed=15461803; DOI=10.1186/gb-2004-5-10-r77;
RA   Rey M.W., Ramaiya P., Nelson B.A., Brody-Karpin S.D., Zaretsky E.J.,
RA   Tang M., Lopez de Leon A., Xiang H., Gusti V., Clausen I.G., Olsen P.B.,
RA   Rasmussen M.D., Andersen J.T., Joergensen P.L., Larsen T.S., Sorokin A.,
RA   Bolotin A., Lapidus A., Galleron N., Ehrlich S.D., Berka R.M.;
RT   ""Complete genome sequence of the industrial bacterium Bacillus
RT   licheniformis and comparisons with closely related Bacillus species."";
RL   Genome Biol. 5:R77.1-R77.12(2004).
CC   -!- FUNCTION: Nitric oxide-responsive transcriptional regulator.
CC       {ECO:0000250}.
CC   -!- COFACTOR:
CC       Name=[2Fe-2S] cluster; Xref=ChEBI:CHEBI:190135; Evidence={ECO:0000305};
CC       Note=Binds 1 [2Fe-2S] cluster per subunit. {ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AE017333; AAU39913.3; -; Genomic_DNA.
DR   EMBL; CP000002; AAU22570.1; -; Genomic_DNA.
DR   RefSeq; WP_003180105.1; NC_006322.1.
DR   AlphaFoldDB; Q65M01; -.
DR   SMR; Q65M01; -.
DR   STRING; 279010.BL02858; -.
DR   GeneID; 92862419; -.
DR   KEGG; bld:BLi01005; -.
DR   KEGG; bli:BL02858; -.
DR   eggNOG; COG1959; Bacteria.
DR   HOGENOM; CLU_107144_2_1_9; -.
DR   Proteomes; UP000000606; Chromosome.
DR   GO; GO:0005829; C:cytosol; IEA:TreeGrafter.
DR   GO; GO:0051537; F:2 iron, 2 sulfur cluster binding; IEA:UniProtKB-KW.
DR   GO; GO:0003677; F:DNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IEA:TreeGrafter.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   Gene3D; 1.10.10.10; Winged helix-like DNA-binding domain superfamily/Winged helix DNA-binding domain; 1.
DR   InterPro; IPR030489; TR_Rrf2-type_CS.
DR   InterPro; IPR000944; Tscrpt_reg_Rrf2.
DR   InterPro; IPR036388; WH-like_DNA-bd_sf.
DR   InterPro; IPR036390; WH_DNA-bd_sf.
DR   NCBIfam; TIGR00738; rrf2_super; 1.
DR   PANTHER; PTHR33221:SF4; HTH-TYPE TRANSCRIPTIONAL REPRESSOR NSRR; 1.
DR   PANTHER; PTHR33221; WINGED HELIX-TURN-HELIX TRANSCRIPTIONAL REGULATOR, RRF2 FAMILY; 1.
DR   Pfam; PF02082; Rrf2; 1.
DR   SUPFAM; SSF46785; Winged helix' DNA-binding domain; 1.
DR   PROSITE; PS01332; HTH_RRF2_1; 1.
DR   PROSITE; PS51197; HTH_RRF2_2; 1.
PE   3: Inferred from homology;
KW   2Fe-2S; DNA-binding; Iron; Iron-sulfur; Metal-binding; Reference proteome;
KW   Transcription; Transcription regulation.
FT   CHAIN           1..143
FT                   /note=""HTH-type transcriptional regulator NsrR""
FT                   /id=""PRO_0000271133""
FT   DOMAIN          2..133
FT                   /note=""HTH rrf2-type""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00540""
FT   DNA_BIND        28..51
FT                   /note=""H-T-H motif""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00540""
FT   BINDING         92
FT                   /ligand=""[2Fe-2S] cluster""
FT                   /ligand_id=""ChEBI:CHEBI:190135""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00540""
FT   BINDING         100
FT                   /ligand=""[2Fe-2S] cluster""
FT                   /ligand_id=""ChEBI:CHEBI:190135""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00540""
FT   BINDING         106
FT                   /ligand=""[2Fe-2S] cluster""
FT                   /ligand_id=""ChEBI:CHEBI:190135""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00540""
SQ   SEQUENCE   143 AA;  16280 MW;  81CBC28EEC12851E CRC64;
     MKLTNYTDYS LRVLIFLATK NSNELVNIKD IADSYSISKN HLMKVIYELG KLGYVETIRG
     RNGGIRLGKA PELINIGEVI RHTEDDFNLV ECFNGEKNHC ILSPICGLKH VLNKALSAYL
     DVLDQYTLQD IIMNQDHIRK LLS
//
",22762
CTGAAA TGAAAG GAAAGG AAAGGC AAGGCG AGGCGT GGCGTG GCGTGA CGTGAC GTGACT TGACTT GACTTA ACTTAC CTTACC TTACCG TACCGC ACCGCG CCGCGC CGCGCC GCGCCG CGCCGT GCCGTG CCGTGG CGTGGG GTGGGT TGGGTG GGGTGC GGTGCC GTGCCG TGCCGC GCCGCC CCGCCG CGCCGC GCCGCA CCGCAC CGCACT GCACTG CACTGC ACTGCT CTGCTG TGCTGC GCTGCG CTGCGC TGCGCC GCGCCG CGCCGC GCCGCA CCGCAA CGCAAC GCAACC CAACCT AACCTG ACCTGG CCTGGC CTGGCC TGGCCA GGCCAT GCCATT CCATTT CATTTA ATTTAT TTTATG TTATGG TATGGG ATGGGC TGGGCT GGGCTT GGCTTG GCTTGG CTTGGG TTGGGG TGGGGG GGGGGC GGGGCA GGGCAT GGCATG GCATGG CATGGT ATGGTG TGGTGG GGTGGT GTGGTG TGGTGC GGTGCC GTGCCA TGCCAT GCCATT CCATTC CATTCA ATTCAT TTCATT TCATTG CATTGG ATTGGC TTGGCA TGGCAT GGCATC GCATCA CATCAA ATCAAG TCAAGT CAAGTT AAGTTG AGTTGA GTTGAT TTGATT TGATTG GATTGA ATTGAC TTGACA TGACAT GACATG ACATGG CATGGT ATGGTG TGGTGC GGTGCT GTGCTG TGCTGG GCTGGC CTGGCC TGGCCG GGCCGC GCCGCA CCGCAG CGCAGC GCAGCC CAGCCG AGCCGG GCCGGG,2,130,CTGA TGAA GAAA AAAG AAGG AGGC GGCG GCGT CGTG GTGA TGAC GACT ACTT CTTA TTAC TACC ACCG CCGC CGCG GCGC CGCC GCCG CCGT CGTG GTGG TGGG GGGT GGTG GTGC TGCC GCCG CCGC CGCC GCCG CCGC CGCA GCAC CACT ACTG CTGC TGCT GCTG CTGC TGCG GCGC CGCC GCCG CCGC CGCA GCAA CAAC AACC ACCT CCTG CTGG TGGC GGCC GCCA CCAT CATT ATTT TTTA TTAT TATG ATGG TGGG GGGC GGCT GCTT CTTG TTGG TGGG GGGG GGGG GGGC GGCA GCAT CATG ATGG TGGT GGTG GTGG TGGT GGTG GTGC TGCC GCCA CCAT CATT ATTC TTCA TCAT CATT ATTG TTGG TGGC GGCA GCAT CATC ATCA TCAA CAAG AAGT AGTT GTTG TTGA TGAT GATT ATTG TTGA TGAC GACA ACAT CATG ATGG TGGT GGTG GTGC TGCT GCTG CTGG TGGC GGCC GCCG CCGC CGCA GCAG CAGC AGCC GCCG CCGG CGGG,CTGAA TGAAA GAAAG AAAGG AAGGC AGGCG GGCGT GCGTG CGTGA GTGAC TGACT GACTT ACTTA CTTAC TTACC TACCG ACCGC CCGCG CGCGC GCGCC CGCCG GCCGT CCGTG CGTGG GTGGG TGGGT GGGTG GGTGC GTGCC TGCCG GCCGC CCGCC CGCCG GCCGC CCGCA CGCAC GCACT CACTG ACTGC CTGCT TGCTG GCTGC CTGCG TGCGC GCGCC CGCCG GCCGC CCGCA CGCAA GCAAC CAACC AACCT ACCTG CCTGG CTGGC TGGCC GGCCA GCCAT CCATT CATTT ATTTA TTTAT TTATG TATGG ATGGG TGGGC GGGCT GGCTT GCTTG CTTGG TTGGG TGGGG GGGGG GGGGC GGGCA GGCAT GCATG CATGG ATGGT TGGTG GGTGG GTGGT TGGTG GGTGC GTGCC TGCCA GCCAT CCATT CATTC ATTCA TTCAT TCATT CATTG ATTGG TTGGC TGGCA GGCAT GCATC CATCA ATCAA TCAAG CAAGT AAGTT AGTTG GTTGA TTGAT TGATT GATTG ATTGA TTGAC TGACA GACAT ACATG CATGG ATGGT TGGTG GGTGC GTGCT TGCTG GCTGG CTGGC TGGCC GGCCG GCCGC CCGCA CGCAG GCAGC CAGCC AGCCG GCCGG CCGGG,CTGAAA TGAAAG GAAAGG AAAGGC AAGGCG AGGCGT GGCGTG GCGTGA CGTGAC GTGACT TGACTT GACTTA ACTTAC CTTACC TTACCG TACCGC ACCGCG CCGCGC CGCGCC GCGCCG CGCCGT GCCGTG CCGTGG CGTGGG GTGGGT TGGGTG GGGTGC GGTGCC GTGCCG TGCCGC GCCGCC CCGCCG CGCCGC GCCGCA CCGCAC CGCACT GCACTG CACTGC ACTGCT CTGCTG TGCTGC GCTGCG CTGCGC TGCGCC GCGCCG CGCCGC GCCGCA CCGCAA CGCAAC GCAACC CAACCT AACCTG ACCTGG CCTGGC CTGGCC TGGCCA GGCCAT GCCATT CCATTT CATTTA ATTTAT TTTATG TTATGG TATGGG ATGGGC TGGGCT GGGCTT GGCTTG GCTTGG CTTGGG TTGGGG TGGGGG GGGGGC GGGGCA GGGCAT GGCATG GCATGG CATGGT ATGGTG TGGTGG GGTGGT GTGGTG TGGTGC GGTGCC GTGCCA TGCCAT GCCATT CCATTC CATTCA ATTCAT TTCATT TCATTG CATTGG ATTGGC TTGGCA TGGCAT GGCATC GCATCA CATCAA ATCAAG TCAAGT CAAGTT AAGTTG AGTTGA GTTGAT TTGATT TGATTG GATTGA ATTGAC TTGACA TGACAT GACATG ACATGG CATGGT ATGGTG TGGTGC GGTGCT GTGCTG TGCTGG GCTGGC CTGGCC TGGCCG GGCCGC GCCGCA CCGCAG CGCAGC GCAGCC CAGCCG AGCCGG GCCGGG,CTGAAAG TGAAAGG GAAAGGC AAAGGCG AAGGCGT AGGCGTG GGCGTGA GCGTGAC CGTGACT GTGACTT TGACTTA GACTTAC ACTTACC CTTACCG TTACCGC TACCGCG ACCGCGC CCGCGCC CGCGCCG GCGCCGT CGCCGTG GCCGTGG CCGTGGG CGTGGGT GTGGGTG TGGGTGC GGGTGCC GGTGCCG GTGCCGC TGCCGCC GCCGCCG CCGCCGC CGCCGCA GCCGCAC CCGCACT CGCACTG GCACTGC CACTGCT ACTGCTG CTGCTGC TGCTGCG GCTGCGC CTGCGCC TGCGCCG GCGCCGC CGCCGCA GCCGCAA CCGCAAC CGCAACC GCAACCT CAACCTG AACCTGG ACCTGGC CCTGGCC CTGGCCA TGGCCAT GGCCATT GCCATTT CCATTTA CATTTAT ATTTATG TTTATGG TTATGGG TATGGGC ATGGGCT TGGGCTT GGGCTTG GGCTTGG GCTTGGG CTTGGGG TTGGGGG TGGGGGC GGGGGCA GGGGCAT GGGCATG GGCATGG GCATGGT CATGGTG ATGGTGG TGGTGGT GGTGGTG GTGGTGC TGGTGCC GGTGCCA GTGCCAT TGCCATT GCCATTC CCATTCA CATTCAT ATTCATT TTCATTG TCATTGG CATTGGC ATTGGCA TTGGCAT TGGCATC GGCATCA GCATCAA CATCAAG ATCAAGT TCAAGTT CAAGTTG AAGTTGA AGTTGAT GTTGATT TTGATTG TGATTGA GATTGAC ATTGACA TTGACAT TGACATG GACATGG ACATGGT CATGGTG ATGGTGC TGGTGCT GGTGCTG GTGCTGG TGCTGGC GCTGGCC CTGGCCG TGGCCGC GGCCGCA GCCGCAG CCGCAGC CGCAGCC GCAGCCG CAGCCGG AGCCGGG,"ID   KDPB_DECAR              Reviewed;         688 AA.
AC   Q47H39;
DT   15-JAN-2008, integrated into UniProtKB/Swiss-Prot.
DT   13-SEP-2005, sequence version 1.
DT   27-NOV-2024, entry version 118.
DE   RecName: Full=Potassium-transporting ATPase ATP-binding subunit {ECO:0000255|HAMAP-Rule:MF_00285};
DE            EC=7.2.2.6 {ECO:0000255|HAMAP-Rule:MF_00285};
DE   AltName: Full=ATP phosphohydrolase [potassium-transporting] B chain {ECO:0000255|HAMAP-Rule:MF_00285};
DE   AltName: Full=Potassium-binding and translocating subunit B {ECO:0000255|HAMAP-Rule:MF_00285};
DE   AltName: Full=Potassium-translocating ATPase B chain {ECO:0000255|HAMAP-Rule:MF_00285};
GN   Name=kdpB {ECO:0000255|HAMAP-Rule:MF_00285};
GN   OrderedLocusNames=Daro_1086;
OS   Dechloromonas aromatica (strain RCB).
OC   Bacteria; Pseudomonadota; Betaproteobacteria; Rhodocyclales; Azonexaceae;
OC   Dechloromonas.
OX   NCBI_TaxID=159087;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=RCB;
RX   PubMed=19650930; DOI=10.1186/1471-2164-10-351;
RA   Salinero K.K., Keller K., Feil W.S., Feil H., Trong S., Di Bartolo G.,
RA   Lapidus A.;
RT   ""Metabolic analysis of the soil microbe Dechloromonas aromatica str. RCB:
RT   indications of a surprisingly complex life-style and cryptic anaerobic
RT   pathways for aromatic degradation."";
RL   BMC Genomics 10:351-351(2009).
CC   -!- FUNCTION: Part of the high-affinity ATP-driven potassium transport (or
CC       Kdp) system, which catalyzes the hydrolysis of ATP coupled with the
CC       electrogenic transport of potassium into the cytoplasm. This subunit is
CC       responsible for energy coupling to the transport system and for the
CC       release of the potassium ions to the cytoplasm. {ECO:0000255|HAMAP-
CC       Rule:MF_00285}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=K(+)(out) + ATP + H2O = K(+)(in) + ADP + phosphate + H(+);
CC         Xref=Rhea:RHEA:16777, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:29103, ChEBI:CHEBI:30616, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:456216; EC=7.2.2.6; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_00285};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:16778;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_00285};
CC   -!- SUBUNIT: The system is composed of three essential subunits: KdpA, KdpB
CC       and KdpC. {ECO:0000255|HAMAP-Rule:MF_00285}.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane {ECO:0000255|HAMAP-
CC       Rule:MF_00285}; Multi-pass membrane protein {ECO:0000255|HAMAP-
CC       Rule:MF_00285}.
CC   -!- SIMILARITY: Belongs to the cation transport ATPase (P-type) (TC 3.A.3)
CC       family. Type IA subfamily. {ECO:0000255|HAMAP-Rule:MF_00285}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP000089; AAZ45842.1; -; Genomic_DNA.
DR   AlphaFoldDB; Q47H39; -.
DR   SMR; Q47H39; -.
DR   STRING; 159087.Daro_1086; -.
DR   KEGG; dar:Daro_1086; -.
DR   eggNOG; COG2216; Bacteria.
DR   HOGENOM; CLU_025728_2_0_4; -.
DR   OrthoDB; 9814270at2; -.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:InterPro.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0008556; F:P-type potassium transmembrane transporter activity; IEA:UniProtKB-UniRule.
DR   CDD; cd02078; P-type_ATPase_K; 1.
DR   FunFam; 2.70.150.10:FF:000010; Potassium-transporting ATPase ATP-binding subunit; 1.
DR   FunFam; 3.40.1110.10:FF:000007; Potassium-transporting ATPase ATP-binding subunit; 1.
DR   Gene3D; 3.40.1110.10; Calcium-transporting ATPase, cytoplasmic domain N; 1.
DR   Gene3D; 2.70.150.10; Calcium-transporting ATPase, cytoplasmic transduction domain A; 1.
DR   Gene3D; 3.40.50.1000; HAD superfamily/HAD-like; 1.
DR   HAMAP; MF_00285; KdpB; 1.
DR   InterPro; IPR023299; ATPase_P-typ_cyto_dom_N.
DR   InterPro; IPR018303; ATPase_P-typ_P_site.
DR   InterPro; IPR023298; ATPase_P-typ_TM_dom_sf.
DR   InterPro; IPR008250; ATPase_P-typ_transduc_dom_A_sf.
DR   InterPro; IPR036412; HAD-like_sf.
DR   InterPro; IPR023214; HAD_sf.
DR   InterPro; IPR006391; P-type_ATPase_bsu_IA.
DR   InterPro; IPR001757; P_typ_ATPase.
DR   InterPro; IPR044492; P_typ_ATPase_HD_dom.
DR   NCBIfam; TIGR01494; ATPase_P-type; 2.
DR   NCBIfam; TIGR01497; kdpB; 1.
DR   PANTHER; PTHR43743; POTASSIUM-TRANSPORTING ATPASE ATP-BINDING SUBUNIT; 1.
DR   PANTHER; PTHR43743:SF1; POTASSIUM-TRANSPORTING ATPASE ATP-BINDING SUBUNIT; 1.
DR   Pfam; PF00122; E1-E2_ATPase; 1.
DR   Pfam; PF00702; Hydrolase; 1.
DR   PRINTS; PR00119; CATATPASE.
DR   SFLD; SFLDS00003; Haloacid_Dehalogenase; 1.
DR   SFLD; SFLDF00027; p-type_atpase; 1.
DR   SUPFAM; SSF81653; Calcium ATPase, transduction domain A; 1.
DR   SUPFAM; SSF81665; Calcium ATPase, transmembrane domain M; 1.
DR   SUPFAM; SSF56784; HAD-like; 1.
DR   PROSITE; PS00154; ATPASE_E1_E2; 1.
PE   3: Inferred from homology;
KW   ATP-binding; Cell inner membrane; Cell membrane; Ion transport; Magnesium;
KW   Membrane; Metal-binding; Nucleotide-binding; Phosphoprotein; Potassium;
KW   Potassium transport; Translocase; Transmembrane; Transmembrane helix;
KW   Transport.
FT   CHAIN           1..688
FT                   /note=""Potassium-transporting ATPase ATP-binding subunit""
FT                   /id=""PRO_1000022437""
FT   TRANSMEM        35..55
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00285""
FT   TRANSMEM        62..82
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00285""
FT   TRANSMEM        219..239
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00285""
FT   TRANSMEM        260..280
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00285""
FT   TRANSMEM        594..614
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00285""
FT   TRANSMEM        622..642
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00285""
FT   TRANSMEM        668..688
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00285""
FT   ACT_SITE        313
FT                   /note=""4-aspartylphosphate intermediate""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00285""
FT   BINDING         350
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00285""
FT   BINDING         354
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00285""
FT   BINDING         383..390
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00285""
FT   BINDING         401
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00285""
FT   BINDING         524
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00285""
FT   BINDING         528
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00285""
SQ   SEQUENCE   688 AA;  72581 MW;  ABFC1DFF2389933B CRC64;
     MTRKTFTLFD PTLALPAIAD AFRKLNPAVQ WRNPVMFVVY VGSILTTILW VQALGGQGEA
     PAGFILAITI WLWFTVLFAN FAEALAEGRS KAQAASLRGL KKETWAKKLA EPRFGAQWQM
     TPAADLRKGD VIVVQAQETI PADGEVIEGV ASVDESAITG ESAPVIRESG GDFSAVTGGT
     RVLSDWIVVR VTVNPGETFV DRMIAMVENA KRQKTPNEIA LTILLVALTI VFLGVIVTLL
     PFSMFSVEVA GAGTPISITV LIALLVCLIP TTIAGLLSAI GVAGMSRMMQ ANVIATSGRA
     VEAAGDVDVL LMDKTGTITL GNRQASVFLP ADGVSEAELA DAAQLASLAD ETPEGRSIVV
     LAKQRFQLRE RDIHALDAHF VHFSAHTRMS GVDMAGRQVR KGAADAIRKH VEALGGKFPA
     SVSGYVDEVA RRGSTPLVVA DGTRVMGVIE LKDIVKGGIK ERFAELRKMG IKTVMVTGDN
     RVTAAAIAAE AGVDDFLSEA TPEAKLALIR KYQAEGRLVA MTGDGTNDAP ALAQADVAVA
     MNTGTQAAKE AGNMVDLDSN PTKLIEVVET GKQMLMTRGS LTTFSIANDI AKYFAIIPAA
     FVTTYPQLAA LNVMGLASPA SAILSAVIFN ALIIVFLIPL ALKGVKYRPL GAATLLRQNL
     AIYGLGGVIV PFIGIKLIDL AIAAVGLA
//
",27088
AGTGCT GTGCTG TGCTGA GCTGAA CTGAAC TGAACA GAACAA AACAAA ACAAAT CAAATG AAATGC AATGCT ATGCTG TGCTGC GCTGCA CTGCAA TGCAAG GCAAGG CAAGGT AAGGTC AGGTCG GGTCGC GTCGCG TCGCGC CGCGCT GCGCTG CGCTGC GCTGCA CTGCAG TGCAGG GCAGGC CAGGCG AGGCGT GGCGTT GCGTTA CGTTAA GTTAAC TTAACA TAACAT AACATT ACATTG CATTGT ATTGTT TTGTTA TGTTAC GTTACC TTACCT TACCTC ACCTCA CCTCAG CTCAGG TCAGGT CAGGTC AGGTCA GGTCAG GTCAGC TCAGCC CAGCCT AGCCTG GCCTGG CCTGGC CTGGCG TGGCGC GGCGCA GCGCAG CGCAGG GCAGGT CAGGTA AGGTAG GGTAGT GTAGTA TAGTAA AGTAAT GTAATG TAATGT AATGTT ATGTTC TGTTCG GTTCGT TTCGTA TCGTAT CGTATT GTATTC TATTCG ATTCGA TTCGAG TCGAGG CGAGGA GAGGAA AGGAAT GGAATT GAATTA AATTAC ATTACT TTACTT TACTTC ACTTCT CTTCTT TTCTTT TCTTTC CTTTCG TTTCGG TTCGGT TCGGTA CGGTAA GGTAAC GTAACG TAACGT AACGTG ACGTGG CGTGGA GTGGAC TGGACC GGACCC GACCCT ACCCTC CCCTCT CCTCTT CTCTTT TCTTTA CTTTAT TTTATA TTATAT TATATC ATATCA TATCAT ATCATT TCATTG CATTGA ATTGAT TTGATG TGATGG GATGGG ATGGGG TGGGGT GGGGTT GGGTTC GGTTCA GTTCAG TTCAGG TCAGGG CAGGGA,3,142,AGTG GTGC TGCT GCTG CTGA TGAA GAAC AACA ACAA CAAA AAAT AATG ATGC TGCT GCTG CTGC TGCA GCAA CAAG AAGG AGGT GGTC GTCG TCGC CGCG GCGC CGCT GCTG CTGC TGCA GCAG CAGG AGGC GGCG GCGT CGTT GTTA TTAA TAAC AACA ACAT CATT ATTG TTGT TGTT GTTA TTAC TACC ACCT CCTC CTCA TCAG CAGG AGGT GGTC GTCA TCAG CAGC AGCC GCCT CCTG CTGG TGGC GGCG GCGC CGCA GCAG CAGG AGGT GGTA GTAG TAGT AGTA GTAA TAAT AATG ATGT TGTT GTTC TTCG TCGT CGTA GTAT TATT ATTC TTCG TCGA CGAG GAGG AGGA GGAA GAAT AATT ATTA TTAC TACT ACTT CTTC TTCT TCTT CTTT TTTC TTCG TCGG CGGT GGTA GTAA TAAC AACG ACGT CGTG GTGG TGGA GGAC GACC ACCC CCCT CCTC CTCT TCTT CTTT TTTA TTAT TATA ATAT TATC ATCA TCAT CATT ATTG TTGA TGAT GATG ATGG TGGG GGGG GGGT GGTT GTTC TTCA TCAG CAGG AGGG GGGA,AGTGC GTGCT TGCTG GCTGA CTGAA TGAAC GAACA AACAA ACAAA CAAAT AAATG AATGC ATGCT TGCTG GCTGC CTGCA TGCAA GCAAG CAAGG AAGGT AGGTC GGTCG GTCGC TCGCG CGCGC GCGCT CGCTG GCTGC CTGCA TGCAG GCAGG CAGGC AGGCG GGCGT GCGTT CGTTA GTTAA TTAAC TAACA AACAT ACATT CATTG ATTGT TTGTT TGTTA GTTAC TTACC TACCT ACCTC CCTCA CTCAG TCAGG CAGGT AGGTC GGTCA GTCAG TCAGC CAGCC AGCCT GCCTG CCTGG CTGGC TGGCG GGCGC GCGCA CGCAG GCAGG CAGGT AGGTA GGTAG GTAGT TAGTA AGTAA GTAAT TAATG AATGT ATGTT TGTTC GTTCG TTCGT TCGTA CGTAT GTATT TATTC ATTCG TTCGA TCGAG CGAGG GAGGA AGGAA GGAAT GAATT AATTA ATTAC TTACT TACTT ACTTC CTTCT TTCTT TCTTT CTTTC TTTCG TTCGG TCGGT CGGTA GGTAA GTAAC TAACG AACGT ACGTG CGTGG GTGGA TGGAC GGACC GACCC ACCCT CCCTC CCTCT CTCTT TCTTT CTTTA TTTAT TTATA TATAT ATATC TATCA ATCAT TCATT CATTG ATTGA TTGAT TGATG GATGG ATGGG TGGGG GGGGT GGGTT GGTTC GTTCA TTCAG TCAGG CAGGG AGGGA,AGTGCT GTGCTG TGCTGA GCTGAA CTGAAC TGAACA GAACAA AACAAA ACAAAT CAAATG AAATGC AATGCT ATGCTG TGCTGC GCTGCA CTGCAA TGCAAG GCAAGG CAAGGT AAGGTC AGGTCG GGTCGC GTCGCG TCGCGC CGCGCT GCGCTG CGCTGC GCTGCA CTGCAG TGCAGG GCAGGC CAGGCG AGGCGT GGCGTT GCGTTA CGTTAA GTTAAC TTAACA TAACAT AACATT ACATTG CATTGT ATTGTT TTGTTA TGTTAC GTTACC TTACCT TACCTC ACCTCA CCTCAG CTCAGG TCAGGT CAGGTC AGGTCA GGTCAG GTCAGC TCAGCC CAGCCT AGCCTG GCCTGG CCTGGC CTGGCG TGGCGC GGCGCA GCGCAG CGCAGG GCAGGT CAGGTA AGGTAG GGTAGT GTAGTA TAGTAA AGTAAT GTAATG TAATGT AATGTT ATGTTC TGTTCG GTTCGT TTCGTA TCGTAT CGTATT GTATTC TATTCG ATTCGA TTCGAG TCGAGG CGAGGA GAGGAA AGGAAT GGAATT GAATTA AATTAC ATTACT TTACTT TACTTC ACTTCT CTTCTT TTCTTT TCTTTC CTTTCG TTTCGG TTCGGT TCGGTA CGGTAA GGTAAC GTAACG TAACGT AACGTG ACGTGG CGTGGA GTGGAC TGGACC GGACCC GACCCT ACCCTC CCCTCT CCTCTT CTCTTT TCTTTA CTTTAT TTTATA TTATAT TATATC ATATCA TATCAT ATCATT TCATTG CATTGA ATTGAT TTGATG TGATGG GATGGG ATGGGG TGGGGT GGGGTT GGGTTC GGTTCA GTTCAG TTCAGG TCAGGG CAGGGA,AGTGCTG GTGCTGA TGCTGAA GCTGAAC CTGAACA TGAACAA GAACAAA AACAAAT ACAAATG CAAATGC AAATGCT AATGCTG ATGCTGC TGCTGCA GCTGCAA CTGCAAG TGCAAGG GCAAGGT CAAGGTC AAGGTCG AGGTCGC GGTCGCG GTCGCGC TCGCGCT CGCGCTG GCGCTGC CGCTGCA GCTGCAG CTGCAGG TGCAGGC GCAGGCG CAGGCGT AGGCGTT GGCGTTA GCGTTAA CGTTAAC GTTAACA TTAACAT TAACATT AACATTG ACATTGT CATTGTT ATTGTTA TTGTTAC TGTTACC GTTACCT TTACCTC TACCTCA ACCTCAG CCTCAGG CTCAGGT TCAGGTC CAGGTCA AGGTCAG GGTCAGC GTCAGCC TCAGCCT CAGCCTG AGCCTGG GCCTGGC CCTGGCG CTGGCGC TGGCGCA GGCGCAG GCGCAGG CGCAGGT GCAGGTA CAGGTAG AGGTAGT GGTAGTA GTAGTAA TAGTAAT AGTAATG GTAATGT TAATGTT AATGTTC ATGTTCG TGTTCGT GTTCGTA TTCGTAT TCGTATT CGTATTC GTATTCG TATTCGA ATTCGAG TTCGAGG TCGAGGA CGAGGAA GAGGAAT AGGAATT GGAATTA GAATTAC AATTACT ATTACTT TTACTTC TACTTCT ACTTCTT CTTCTTT TTCTTTC TCTTTCG CTTTCGG TTTCGGT TTCGGTA TCGGTAA CGGTAAC GGTAACG GTAACGT TAACGTG AACGTGG ACGTGGA CGTGGAC GTGGACC TGGACCC GGACCCT GACCCTC ACCCTCT CCCTCTT CCTCTTT CTCTTTA TCTTTAT CTTTATA TTTATAT TTATATC TATATCA ATATCAT TATCATT ATCATTG TCATTGA CATTGAT ATTGATG TTGATGG TGATGGG GATGGGG ATGGGGT TGGGGTT GGGGTTC GGGTTCA GGTTCAG GTTCAGG TTCAGGG TCAGGGA,"ID   PLH3_FORAG              Reviewed;        1001 AA.
AC   T2KPJ3;
DT   16-OCT-2019, integrated into UniProtKB/Swiss-Prot.
DT   13-NOV-2013, sequence version 1.
DT   05-FEB-2025, entry version 47.
DE   RecName: Full=TonB-dependent receptor P3 {ECO:0000303|PubMed:31285597};
DE            Short=P3_TBDR {ECO:0000303|PubMed:31285597};
DE   AltName: Full=Polysaccharide utilization locus H protein P3 {ECO:0000303|PubMed:31285597};
DE            Short=PUL H protein P3;
DE   Flags: Precursor;
GN   ORFNames=BN863_21920;
OS   Formosa agariphila (strain DSM 15362 / KCTC 12365 / LMG 23005 / KMM 3901 /
OS   M-2Alg 35-1).
OC   Bacteria; Bacteroidota; Flavobacteriia; Flavobacteriales;
OC   Flavobacteriaceae; Formosa.
OX   NCBI_TaxID=1347342;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=DSM 15362 / KCTC 12365 / LMG 23005 / KMM 3901 / M-2Alg 35-1;
RX   PubMed=23995932; DOI=10.1128/aem.01937-13;
RA   Mann A.J., Hahnke R.L., Huang S., Werner J., Xing P., Barbeyron T.,
RA   Huettel B., Stueber K., Reinhardt R., Harder J., Gloeckner F.O.,
RA   Amann R.I., Teeling H.;
RT   ""The genome of the alga-associated marine flavobacterium Formosa agariphila
RT   KMM 3901T reveals a broad potential for degradation of algal
RT   polysaccharides."";
RL   Appl. Environ. Microbiol. 79:6813-6822(2013).
RN   [2]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=31285597; DOI=10.1038/s41589-019-0311-9;
RA   Reisky L., Prechoux A., Zuehlke M.K., Baeumgen M., Robb C.S., Gerlach N.,
RA   Roret T., Stanetty C., Larocque R., Michel G., Song T., Markert S.,
RA   Unfried F., Mihovilovic M.D., Trautwein-Schult A., Becher D., Schweder T.,
RA   Bornscheuer U.T., Hehemann J.H.;
RT   ""A marine bacterial enzymatic cascade degrades the algal polysaccharide
RT   ulvan."";
RL   Nat. Chem. Biol. 15:803-812(2019).
CC   -!- FUNCTION: TonB-dependent receptor probably involved in ulvan
CC       degradation (Probable). Ulvan is the main polysaccharide component of
CC       the Ulvales (green seaweed) cell wall. It is composed of disaccharide
CC       building blocks comprising 3-sulfated rhamnose (Rha3S) linked to D-
CC       glucuronic acid (GlcA), L-iduronic acid (IduA), or D-xylose (Xyl)
CC       (Probable). The TonB-dependent receptor may mediate transport of ulvan
CC       oligosaccharides from the surface of the outer membrane to the
CC       periplasm for subsequent degradation (By similarity).
CC       {ECO:0000250|UniProtKB:Q8A1G2, ECO:0000305|PubMed:31285597}.
CC   -!- SUBCELLULAR LOCATION: Cell outer membrane
CC       {ECO:0000250|UniProtKB:Q8A1G2, ECO:0000255|PROSITE-ProRule:PRU01360};
CC       Multi-pass membrane protein {ECO:0000250|UniProtKB:Q8A1G2,
CC       ECO:0000255|PROSITE-ProRule:PRU01360}.
CC   -!- INDUCTION: By ulvan and rhamnose. {ECO:0000269|PubMed:31285597}.
CC   -!- SIMILARITY: Belongs to the TonB-dependent receptor family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; HG315671; CDF79904.1; -; Genomic_DNA.
DR   AlphaFoldDB; T2KPJ3; -.
DR   SMR; T2KPJ3; -.
DR   STRING; 1347342.BN863_21920; -.
DR   PATRIC; fig|1347342.6.peg.2199; -.
DR   eggNOG; COG4771; Bacteria.
DR   HOGENOM; CLU_004317_0_2_10; -.
DR   OrthoDB; 9768177at2; -.
DR   Proteomes; UP000016160; Chromosome.
DR   GO; GO:0009279; C:cell outer membrane; IEA:UniProtKB-SubCell.
DR   Gene3D; 2.60.40.1120; Carboxypeptidase-like, regulatory domain; 1.
DR   Gene3D; 2.40.170.20; TonB-dependent receptor, beta-barrel domain; 1.
DR   Gene3D; 2.170.130.10; TonB-dependent receptor, plug domain; 1.
DR   InterPro; IPR008969; CarboxyPept-like_regulatory.
DR   InterPro; IPR012910; Plug_dom.
DR   InterPro; IPR037066; Plug_dom_sf.
DR   InterPro; IPR023996; TonB-dep_OMP_SusC/RagA.
DR   InterPro; IPR023997; TonB-dep_OMP_SusC/RagA_CS.
DR   InterPro; IPR039426; TonB-dep_rcpt-like.
DR   InterPro; IPR000531; TonB-dep_rcpt_b-brl.
DR   InterPro; IPR036942; TonB_rcpt_b-brl_sf.
DR   NCBIfam; TIGR04056; OMP_RagA_SusC; 1.
DR   NCBIfam; TIGR04057; SusC_RagA_signa; 1.
DR   Pfam; PF13715; CarbopepD_reg_2; 1.
DR   Pfam; PF07715; Plug; 1.
DR   Pfam; PF00593; TonB_dep_Rec_b-barrel; 1.
DR   SUPFAM; SSF49464; Carboxypeptidase regulatory domain-like; 1.
DR   SUPFAM; SSF56935; Porins; 1.
DR   PROSITE; PS52016; TONB_DEPENDENT_REC_3; 1.
PE   2: Evidence at transcript level;
KW   Cell outer membrane; Membrane; Receptor; Reference proteome; Signal;
KW   TonB box; Transmembrane; Transmembrane beta strand; Transport.
FT   SIGNAL          1..26
FT                   /evidence=""ECO:0000255""
FT   CHAIN           27..1001
FT                   /note=""TonB-dependent receptor P3""
FT                   /id=""PRO_5004602761""
FT   DOMAIN          120..232
FT                   /note=""TBDR plug""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01360""
FT   DOMAIN          238..1001
FT                   /note=""TBDR beta-barrel""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01360""
FT   MOTIF           109..116
FT                   /note=""TonB box""
FT                   /evidence=""ECO:0000255""
FT   MOTIF           984..1001
FT                   /note=""TonB C-terminal box""
FT                   /evidence=""ECO:0000255""
SQ   SEQUENCE   1001 AA;  109272 MW;  FF33747DE549D3E5 CRC64;
     MTTKNNKQLK SVLFMFLLLI GAYVKAQEKN VSGTVTSSED GMMLPGVNII VKGTASGTTS
     DFDGNYNIEV PDSNAILQFN YLGFVTQEIK VGAQTNISVV LQVDQNELEE IVVIGYGTVK
     KSDVSGSVSS VKSAELTAYP TVSAEQALQG RAAGVQVQSN NGGEPGAPIK VRIRGGTSIN
     ASSDALIVVD GFVGASMPAP QDIASMEVLK DASATAIYGS RGANGVIMVT TKKGTSSKPT
     LELNTSYSLQ HVNNTIDLLD ADEFATYRQA YSENYVQGPA NTDWQDEIYT TGSISNTQLA
     FSGGSDNSKY YISGNYFAQD GVVINSNLER FTILSNVDVD ITKRFKVGLN VFGGRSTKDG
     VSTQAQTGGT GGGDVISSAY RFAPDLGIYN ADGTYTINSL GDDIDNPYAL ATESVDERKA
     DTYRANFYAA YEFIDGLEFK TTFGFSSENT QIGKFKPTTI LAGAGVGGEA TFEYRNTTNT
     LSENYLTYNK SFGAHNLSLL GGYSYQKVQN EGAFAGARSF VTNEVSYRNL EGGAVTMQPS
     SYLNETELVS VFGRVNYEYA SKYIFTFTAR RDGSSNFSKN NKYAFFPSGA IAWNMAKENF
     LKDSNTITTW KWRASYGATG NPSISPYETL AKFSSVYAVV GDQQVNGVVL TDFANDNLKW
     ETSKQLDLGL DVALFDNRLE LSFDYYTIKT EDLLFPRPLP EYSGVSSQIQ NIGELENKGY
     EFSINSRNIT NQDFTWSTAF NFSRNKNKMV KLPDGDDLFI DSAPGHFLQR QTQILREGEA
     IGSFYGYEYK GVYQGGNFPE GTATLSGDSD PGGELFADLD GNGEISTADR KIIGDPTPDF
     TMGFNNDLRY KNFDMNLFFQ ASVGGEILNY TLLELGSGAA NSTADMVNAW SPTNTNTDVP
     RPAVREKRIT SRYVYDGSYV RLKNLSFGYN LPESFLGKTG LQTVRLYVSG QNLLTFTDYP
     GADPEANYRN DNNQRSNTNI GLDYGSYPNV RTFTMGLNMK F
//
",425
ACTAAA CTAAAG TAAAGA AAAGAA AAGAAG AGAAGG GAAGGT AAGGTG AGGTGC GGTGCC GTGCCA TGCCAC GCCACT CCACTA CACTAC ACTACT CTACTT TACTTG ACTTGT CTTGTG TTGTGG TGTGGT GTGGTT TGGTTA GGTTAC GTTACT TTACTT TACTTA ACTTAC CTTACC TTACCC TACCCC ACCCCA CCCCAA CCCAAA CCAAAA CAAAAT AAAATG AAATGC AATGCT ATGCTG TGCTGT GCTGTT CTGTTG TGTTGT GTTGTT TTGTTA TGTTAA GTTAAA TTAAAA TAAAAT AAAATT AAATTT AATTTA ATTTAT TTTATT TTATTG TATTGT ATTGTC TTGTCC TGTCCA GTCCAG TCCAGC CCAGCA CAGCAT AGCATG GCATGT CATGTC ATGTCA TGTCAC GTCACA TCACAA CACAAT ACAATT CAATTC AATTCA ATTCAG TTCAGA TCAGAA CAGAAG AGAAGT GAAGTA AAGTAG AGTAGG GTAGGA TAGGAC AGGACC GGACCT GACCTG ACCTGA CCTGAG CTGAGC TGAGCA GAGCAT AGCATA GCATAG CATAGT ATAGTC TAGTCT AGTCTT GTCTTG TCTTGC CTTGCC TTGCCG TGCCGA GCCGAA CCGAAT CGAATA GAATAC AATACC ATACCA TACCAT ACCATA CCATAA CATAAT ATAATG TAATGA AATGAA ATGAAT TGAATC GAATCT AATCTG ATCTGG TCTGGC CTGGCT TGGCTT GGCTTG GCTTGA CTTGAA TTGAAA TGAAAA GAAAAC AAAACC AAACCA AACCAT ACCATT,0,136,ACTA CTAA TAAA AAAG AAGA AGAA GAAG AAGG AGGT GGTG GTGC TGCC GCCA CCAC CACT ACTA CTAC TACT ACTT CTTG TTGT TGTG GTGG TGGT GGTT GTTA TTAC TACT ACTT CTTA TTAC TACC ACCC CCCC CCCA CCAA CAAA AAAA AAAT AATG ATGC TGCT GCTG CTGT TGTT GTTG TTGT TGTT GTTA TTAA TAAA AAAA AAAT AATT ATTT TTTA TTAT TATT ATTG TTGT TGTC GTCC TCCA CCAG CAGC AGCA GCAT CATG ATGT TGTC GTCA TCAC CACA ACAA CAAT AATT ATTC TTCA TCAG CAGA AGAA GAAG AAGT AGTA GTAG TAGG AGGA GGAC GACC ACCT CCTG CTGA TGAG GAGC AGCA GCAT CATA ATAG TAGT AGTC GTCT TCTT CTTG TTGC TGCC GCCG CCGA CGAA GAAT AATA ATAC TACC ACCA CCAT CATA ATAA TAAT AATG ATGA TGAA GAAT AATC ATCT TCTG CTGG TGGC GGCT GCTT CTTG TTGA TGAA GAAA AAAA AAAC AACC ACCA CCAT CATT,ACTAA CTAAA TAAAG AAAGA AAGAA AGAAG GAAGG AAGGT AGGTG GGTGC GTGCC TGCCA GCCAC CCACT CACTA ACTAC CTACT TACTT ACTTG CTTGT TTGTG TGTGG GTGGT TGGTT GGTTA GTTAC TTACT TACTT ACTTA CTTAC TTACC TACCC ACCCC CCCCA CCCAA CCAAA CAAAA AAAAT AAATG AATGC ATGCT TGCTG GCTGT CTGTT TGTTG GTTGT TTGTT TGTTA GTTAA TTAAA TAAAA AAAAT AAATT AATTT ATTTA TTTAT TTATT TATTG ATTGT TTGTC TGTCC GTCCA TCCAG CCAGC CAGCA AGCAT GCATG CATGT ATGTC TGTCA GTCAC TCACA CACAA ACAAT CAATT AATTC ATTCA TTCAG TCAGA CAGAA AGAAG GAAGT AAGTA AGTAG GTAGG TAGGA AGGAC GGACC GACCT ACCTG CCTGA CTGAG TGAGC GAGCA AGCAT GCATA CATAG ATAGT TAGTC AGTCT GTCTT TCTTG CTTGC TTGCC TGCCG GCCGA CCGAA CGAAT GAATA AATAC ATACC TACCA ACCAT CCATA CATAA ATAAT TAATG AATGA ATGAA TGAAT GAATC AATCT ATCTG TCTGG CTGGC TGGCT GGCTT GCTTG CTTGA TTGAA TGAAA GAAAA AAAAC AAACC AACCA ACCAT CCATT,ACTAAA CTAAAG TAAAGA AAAGAA AAGAAG AGAAGG GAAGGT AAGGTG AGGTGC GGTGCC GTGCCA TGCCAC GCCACT CCACTA CACTAC ACTACT CTACTT TACTTG ACTTGT CTTGTG TTGTGG TGTGGT GTGGTT TGGTTA GGTTAC GTTACT TTACTT TACTTA ACTTAC CTTACC TTACCC TACCCC ACCCCA CCCCAA CCCAAA CCAAAA CAAAAT AAAATG AAATGC AATGCT ATGCTG TGCTGT GCTGTT CTGTTG TGTTGT GTTGTT TTGTTA TGTTAA GTTAAA TTAAAA TAAAAT AAAATT AAATTT AATTTA ATTTAT TTTATT TTATTG TATTGT ATTGTC TTGTCC TGTCCA GTCCAG TCCAGC CCAGCA CAGCAT AGCATG GCATGT CATGTC ATGTCA TGTCAC GTCACA TCACAA CACAAT ACAATT CAATTC AATTCA ATTCAG TTCAGA TCAGAA CAGAAG AGAAGT GAAGTA AAGTAG AGTAGG GTAGGA TAGGAC AGGACC GGACCT GACCTG ACCTGA CCTGAG CTGAGC TGAGCA GAGCAT AGCATA GCATAG CATAGT ATAGTC TAGTCT AGTCTT GTCTTG TCTTGC CTTGCC TTGCCG TGCCGA GCCGAA CCGAAT CGAATA GAATAC AATACC ATACCA TACCAT ACCATA CCATAA CATAAT ATAATG TAATGA AATGAA ATGAAT TGAATC GAATCT AATCTG ATCTGG TCTGGC CTGGCT TGGCTT GGCTTG GCTTGA CTTGAA TTGAAA TGAAAA GAAAAC AAAACC AAACCA AACCAT ACCATT,ACTAAAG CTAAAGA TAAAGAA AAAGAAG AAGAAGG AGAAGGT GAAGGTG AAGGTGC AGGTGCC GGTGCCA GTGCCAC TGCCACT GCCACTA CCACTAC CACTACT ACTACTT CTACTTG TACTTGT ACTTGTG CTTGTGG TTGTGGT TGTGGTT GTGGTTA TGGTTAC GGTTACT GTTACTT TTACTTA TACTTAC ACTTACC CTTACCC TTACCCC TACCCCA ACCCCAA CCCCAAA CCCAAAA CCAAAAT CAAAATG AAAATGC AAATGCT AATGCTG ATGCTGT TGCTGTT GCTGTTG CTGTTGT TGTTGTT GTTGTTA TTGTTAA TGTTAAA GTTAAAA TTAAAAT TAAAATT AAAATTT AAATTTA AATTTAT ATTTATT TTTATTG TTATTGT TATTGTC ATTGTCC TTGTCCA TGTCCAG GTCCAGC TCCAGCA CCAGCAT CAGCATG AGCATGT GCATGTC CATGTCA ATGTCAC TGTCACA GTCACAA TCACAAT CACAATT ACAATTC CAATTCA AATTCAG ATTCAGA TTCAGAA TCAGAAG CAGAAGT AGAAGTA GAAGTAG AAGTAGG AGTAGGA GTAGGAC TAGGACC AGGACCT GGACCTG GACCTGA ACCTGAG CCTGAGC CTGAGCA TGAGCAT GAGCATA AGCATAG GCATAGT CATAGTC ATAGTCT TAGTCTT AGTCTTG GTCTTGC TCTTGCC CTTGCCG TTGCCGA TGCCGAA GCCGAAT CCGAATA CGAATAC GAATACC AATACCA ATACCAT TACCATA ACCATAA CCATAAT CATAATG ATAATGA TAATGAA AATGAAT ATGAATC TGAATCT GAATCTG AATCTGG ATCTGGC TCTGGCT CTGGCTT TGGCTTG GGCTTGA GCTTGAA CTTGAAA TTGAAAA TGAAAAC GAAAACC AAAACCA AAACCAT AACCATT,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",606
AACTGC ACTGCA CTGCAC TGCACA GCACAG CACAGG ACAGGA CAGGAG AGGAGT GGAGTC GAGTCC AGTCCC GTCCCA TCCCAG CCCAGT CCAGTT CAGTTG AGTTGA GTTGAT TTGATA TGATAT GATATT ATATTC TATTCA ATTCAT TTCATG TCATGC CATGCA ATGCAG TGCAGA GCAGAT CAGATC AGATCA GATCAA ATCAAC TCAACT CAACTT AACTTA ACTTAC CTTACT TTACTC TACTCC ACTCCT CTCCTG TCCTGC CCTGCT CTGCTT TGCTTG GCTTGG CTTGGC TTGGCG TGGCGT GGCGTG GCGTGT CGTGTT GTGTTT TGTTTA GTTTAT TTTATT TTATTC TATTCG ATTCGA TTCGAC TCGACA CGACAG GACAGG ACAGGT CAGGTG AGGTGC GGTGCT GTGCTA TGCTAA GCTAAT CTAATA TAATAT AATATT ATATTA TATTAA ATTAAT TTAATC TAATCA AATCAA ATCAAA TCAAAC CAAACA AAACAC AACACG ACACGG CACGGG ACGGGC CGGGCA GGGCAG GGCAGG GCAGGA CAGGAT AGGATA GGATAT GATATT ATATTT TATTTA ATTTAA TTTAAT TTAATA TAATAG AATAGG ATAGGG TAGGGA AGGGAC GGGACT GGACTG GACTGA ACTGAA CTGAAT TGAATA GAATAT AATATG ATATGT TATGTC ATGTCA TGTCAA GTCAAC TCAACA CAACAA AACAAC ACAACT CAACTC AACTCA ACTCAG CTCAGA TCAGAT CAGATG AGATGA GATGAG ATGAGT TGAGTG GAGTGG AGTGGG GTGGGA TGGGAC GGGACA GGACAT GACATA ACATAG CATAGC ATAGCC,1,145,AACT ACTG CTGC TGCA GCAC CACA ACAG CAGG AGGA GGAG GAGT AGTC GTCC TCCC CCCA CCAG CAGT AGTT GTTG TTGA TGAT GATA ATAT TATT ATTC TTCA TCAT CATG ATGC TGCA GCAG CAGA AGAT GATC ATCA TCAA CAAC AACT ACTT CTTA TTAC TACT ACTC CTCC TCCT CCTG CTGC TGCT GCTT CTTG TTGG TGGC GGCG GCGT CGTG GTGT TGTT GTTT TTTA TTAT TATT ATTC TTCG TCGA CGAC GACA ACAG CAGG AGGT GGTG GTGC TGCT GCTA CTAA TAAT AATA ATAT TATT ATTA TTAA TAAT AATC ATCA TCAA CAAA AAAC AACA ACAC CACG ACGG CGGG GGGC GGCA GCAG CAGG AGGA GGAT GATA ATAT TATT ATTT TTTA TTAA TAAT AATA ATAG TAGG AGGG GGGA GGAC GACT ACTG CTGA TGAA GAAT AATA ATAT TATG ATGT TGTC GTCA TCAA CAAC AACA ACAA CAAC AACT ACTC CTCA TCAG CAGA AGAT GATG ATGA TGAG GAGT AGTG GTGG TGGG GGGA GGAC GACA ACAT CATA ATAG TAGC AGCC,AACTG ACTGC CTGCA TGCAC GCACA CACAG ACAGG CAGGA AGGAG GGAGT GAGTC AGTCC GTCCC TCCCA CCCAG CCAGT CAGTT AGTTG GTTGA TTGAT TGATA GATAT ATATT TATTC ATTCA TTCAT TCATG CATGC ATGCA TGCAG GCAGA CAGAT AGATC GATCA ATCAA TCAAC CAACT AACTT ACTTA CTTAC TTACT TACTC ACTCC CTCCT TCCTG CCTGC CTGCT TGCTT GCTTG CTTGG TTGGC TGGCG GGCGT GCGTG CGTGT GTGTT TGTTT GTTTA TTTAT TTATT TATTC ATTCG TTCGA TCGAC CGACA GACAG ACAGG CAGGT AGGTG GGTGC GTGCT TGCTA GCTAA CTAAT TAATA AATAT ATATT TATTA ATTAA TTAAT TAATC AATCA ATCAA TCAAA CAAAC AAACA AACAC ACACG CACGG ACGGG CGGGC GGGCA GGCAG GCAGG CAGGA AGGAT GGATA GATAT ATATT TATTT ATTTA TTTAA TTAAT TAATA AATAG ATAGG TAGGG AGGGA GGGAC GGACT GACTG ACTGA CTGAA TGAAT GAATA AATAT ATATG TATGT ATGTC TGTCA GTCAA TCAAC CAACA AACAA ACAAC CAACT AACTC ACTCA CTCAG TCAGA CAGAT AGATG GATGA ATGAG TGAGT GAGTG AGTGG GTGGG TGGGA GGGAC GGACA GACAT ACATA CATAG ATAGC TAGCC,AACTGC ACTGCA CTGCAC TGCACA GCACAG CACAGG ACAGGA CAGGAG AGGAGT GGAGTC GAGTCC AGTCCC GTCCCA TCCCAG CCCAGT CCAGTT CAGTTG AGTTGA GTTGAT TTGATA TGATAT GATATT ATATTC TATTCA ATTCAT TTCATG TCATGC CATGCA ATGCAG TGCAGA GCAGAT CAGATC AGATCA GATCAA ATCAAC TCAACT CAACTT AACTTA ACTTAC CTTACT TTACTC TACTCC ACTCCT CTCCTG TCCTGC CCTGCT CTGCTT TGCTTG GCTTGG CTTGGC TTGGCG TGGCGT GGCGTG GCGTGT CGTGTT GTGTTT TGTTTA GTTTAT TTTATT TTATTC TATTCG ATTCGA TTCGAC TCGACA CGACAG GACAGG ACAGGT CAGGTG AGGTGC GGTGCT GTGCTA TGCTAA GCTAAT CTAATA TAATAT AATATT ATATTA TATTAA ATTAAT TTAATC TAATCA AATCAA ATCAAA TCAAAC CAAACA AAACAC AACACG ACACGG CACGGG ACGGGC CGGGCA GGGCAG GGCAGG GCAGGA CAGGAT AGGATA GGATAT GATATT ATATTT TATTTA ATTTAA TTTAAT TTAATA TAATAG AATAGG ATAGGG TAGGGA AGGGAC GGGACT GGACTG GACTGA ACTGAA CTGAAT TGAATA GAATAT AATATG ATATGT TATGTC ATGTCA TGTCAA GTCAAC TCAACA CAACAA AACAAC ACAACT CAACTC AACTCA ACTCAG CTCAGA TCAGAT CAGATG AGATGA GATGAG ATGAGT TGAGTG GAGTGG AGTGGG GTGGGA TGGGAC GGGACA GGACAT GACATA ACATAG CATAGC ATAGCC,AACTGCA ACTGCAC CTGCACA TGCACAG GCACAGG CACAGGA ACAGGAG CAGGAGT AGGAGTC GGAGTCC GAGTCCC AGTCCCA GTCCCAG TCCCAGT CCCAGTT CCAGTTG CAGTTGA AGTTGAT GTTGATA TTGATAT TGATATT GATATTC ATATTCA TATTCAT ATTCATG TTCATGC TCATGCA CATGCAG ATGCAGA TGCAGAT GCAGATC CAGATCA AGATCAA GATCAAC ATCAACT TCAACTT CAACTTA AACTTAC ACTTACT CTTACTC TTACTCC TACTCCT ACTCCTG CTCCTGC TCCTGCT CCTGCTT CTGCTTG TGCTTGG GCTTGGC CTTGGCG TTGGCGT TGGCGTG GGCGTGT GCGTGTT CGTGTTT GTGTTTA TGTTTAT GTTTATT TTTATTC TTATTCG TATTCGA ATTCGAC TTCGACA TCGACAG CGACAGG GACAGGT ACAGGTG CAGGTGC AGGTGCT GGTGCTA GTGCTAA TGCTAAT GCTAATA CTAATAT TAATATT AATATTA ATATTAA TATTAAT ATTAATC TTAATCA TAATCAA AATCAAA ATCAAAC TCAAACA CAAACAC AAACACG AACACGG ACACGGG CACGGGC ACGGGCA CGGGCAG GGGCAGG GGCAGGA GCAGGAT CAGGATA AGGATAT GGATATT GATATTT ATATTTA TATTTAA ATTTAAT TTTAATA TTAATAG TAATAGG AATAGGG ATAGGGA TAGGGAC AGGGACT GGGACTG GGACTGA GACTGAA ACTGAAT CTGAATA TGAATAT GAATATG AATATGT ATATGTC TATGTCA ATGTCAA TGTCAAC GTCAACA TCAACAA CAACAAC AACAACT ACAACTC CAACTCA AACTCAG ACTCAGA CTCAGAT TCAGATG CAGATGA AGATGAG GATGAGT ATGAGTG TGAGTGG GAGTGGG AGTGGGA GTGGGAC TGGGACA GGGACAT GGACATA GACATAG ACATAGC CATAGCC,"ID   SPIKE_SARS2             Reviewed;        1273 AA.
AC   P0DTC2;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Spike glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE            Short=S glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=E2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=Peplomer protein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S1 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2' {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Flags: Precursor;
GN   Name=S {ECO:0000255|HAMAP-Rule:MF_04099}; ORFNames=2;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   FUNCTION (SPIKE PROTEIN S1), AND CLEAVAGE BETWEEN S2 AND S2' BY HOST
RP   TMPRSS2.
RX   PubMed=32142651; DOI=10.1016/j.cell.2020.02.052;
RA   Hoffmann M., Kleine-Weber H., Schroeder S., Krueger N., Herrler T.,
RA   Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A.,
RA   Mueller M.A., Drosten C., Poehlmann S.;
RT   ""SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a
RT   clinically proven protease inhibitor."";
RL   Cell 181:1-10(2020).
RN   [3]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, FUNCTION, AND MUTAGENESIS OF
RP   681-PRO--ALA-684.
RX   PubMed=32362314; DOI=10.1016/j.molcel.2020.04.022;
RA   Hoffmann M., Kleine-Weber H., Poehlmann S.;
RT   ""A multibasic cleavage site in the Spike protein of SARS-CoV-2 is essential
RT   for infection of human lung cells."";
RL   Mol. Cell 78:779-784(2020).
RN   [4]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=32366695; DOI=10.1126/science.abb9983;
RA   Watanabe Y., Allen J.D., Wrapp D., McLellan J.S., Crispin M.;
RT   ""Site-specific glycan analysis of the SARS-CoV-2 spike."";
RL   Science 369:330-333(2020).
RN   [5]
RP   GLYCOSYLATION AT ASN-61; ASN-74; ASN-122; ASN-149; ASN-165; ASN-234;
RP   ASN-282; THR-323; SER-325; ASN-331; ASN-343; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1194, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=32363391; DOI=10.1093/glycob/cwaa042;
RA   Shajahan A., Supekar N.T., Gleinich A.S., Azadi P.;
RT   ""Deducing the N- and O- glycosylation profile of the spike protein of novel
RT   coronavirus SARS-CoV-2."";
RL   Glycobiology 30:981-988(2020).
RN   [6]
RP   VARIANT GLY-614.
RX   PubMed=32820179; DOI=10.1038/s41598-020-70827-z;
RA   Isabel S., Grana-Miraglia L., Gutierrez J.M., Bundalovic-Torma C.,
RA   Groves H.E., Isabel M.R., Eshaghi A., Patel S.N., Gubbay J.B., Poutanen T.,
RA   Guttman D.S., Poutanen S.M.;
RT   ""Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein
RT   mutation now documented worldwide."";
RL   Sci. Rep. 10:14031-14031(2020).
RN   [7]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=32697968; DOI=10.1016/j.cell.2020.06.043;
RG   Sheffield COVID-19 Genomics Group;
RA   Korber B., Fischer W.M., Gnanakaran S., Yoon H., Theiler J., Abfalterer W.,
RA   Hengartner N., Giorgi E.E., Bhattacharya T., Foley B., Hastie K.M.,
RA   Parker M.D., Partridge D.G., Evans C.M., Freeman T.M., de Silva T.I.,
RA   McDanal C., Perez L.G., Tang H., Moon-Walker A., Whelan S.P.,
RA   LaBranche C.C., Saphire E.O., Montefiori D.C.;
RT   ""Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases
RT   Infectivity of the COVID-19 Virus."";
RL   Cell 182:812-827(2020).
RN   [8]
RP   FUNCTION.
RX   PubMed=32817270; DOI=10.1126/science.abd5223;
RA   Turonova B., Sikora M., Schuermann C., Hagen W.J.H., Welsch S.,
RA   Blanc F.E.C., von Buelow S., Gecht M., Bagola K., Hoerner C.,
RA   van Zandbergen G., Landry J., de Azevedo N.T.D., Mosalaganti S.,
RA   Schwarz A., Covino R., Muehlebach M.D., Hummer G., Krijnse Locker J.,
RA   Beck M.;
RT   ""In situ structural analysis of SARS-CoV-2 spike reveals flexibility
RT   mediated by three hinges."";
RL   Science 370:203-208(2020).
RN   [9]
RP   GLYCOSYLATION.
RX   PubMed=32929138; DOI=10.1038/s41598-020-71748-7;
RA   Grant O.C., Montgomery D., Ito K., Woods R.J.;
RT   ""Analysis of the SARS-CoV-2 spike protein glycan shield reveals
RT   implications for immune recognition."";
RL   Sci. Rep. 10:14991-14991(2020).
RN   [10]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, IDENTIFICATION BY MASS SPECTROMETRY, SUBCELLULAR LOCATION, AND
RP   SUBUNIT.
RX   PubMed=32979942; DOI=10.1016/j.cell.2020.09.018;
RA   Yao H., Song Y., Chen Y., Wu N., Xu J., Sun C., Zhang J., Weng T.,
RA   Zhang Z., Wu Z., Cheng L., Shi D., Lu X., Lei J., Crispin M., Shi Y.,
RA   Li L., Li S.;
RT   ""Molecular Architecture of the SARS-CoV-2 Virus."";
RL   Cell 183:730-738(2020).
RN   [11]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=33106671; DOI=10.1038/s41586-020-2895-3;
RA   Plante J.A., Liu Y., Liu J., Xia H., Johnson B.A., Lokugamage K.G.,
RA   Zhang X., Muruato A.E., Zou J., Fontes-Garfias C.R., Mirchandani D.,
RA   Scharton D., Bilello J.P., Ku Z., An Z., Kalveram B., Freiberg A.N.,
RA   Menachery V.D., Xie X., Plante K.S., Weaver S.C., Shi P.Y.;
RT   ""Spike mutation D614G alters SARS-CoV-2 fitness."";
RL   Nature 592:116-121(2020).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Liverpool/REMRQ001/2020;
RX   PubMed=33082294; DOI=10.1126/science.abd3072;
RA   Daly J.L., Simonetti B., Klein K., Chen K.E., Williamson M.K.,
RA   Anton-Plagaro C., Shoemark D.K., Simon-Gracia L., Bauer M., Hollandi R.,
RA   Greber U.F., Horvath P., Sessions R.B., Helenius A., Hiscox J.A.,
RA   Teesalu T., Matthews D.A., Davidson A.D., Collins B.M., Cullen P.J.,
RA   Yamauchi Y.;
RT   ""Neuropilin-1 is a host factor for SARS-CoV-2 infection."";
RL   Science 370:861-865(2020).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Finland/1/2020;
RX   PubMed=33082293; DOI=10.1126/science.abd2985;
RA   Cantuti-Castelvetri L., Ojha R., Pedro L.D., Djannatian M., Franz J.,
RA   Kuivanen S., van der Meer F., Kallio K., Kaya T., Anastasina M., Smura T.,
RA   Levanov L., Szirovicza L., Tobi A., Kallio-Kokko H., Oesterlund P.,
RA   Joensuu M., Meunier F.A., Butcher S.J., Winkler M.S., Mollenhauer B.,
RA   Helenius A., Gokce O., Teesalu T., Hepojoki J., Vapalahti O.,
RA   Stadelmann C., Balistreri G., Simons M.;
RT   ""Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity."";
RL   Science 370:856-860(2020).
RN   [14]
RP   INTERACTION WITH HUMAN ITGA5 AND ITGB1.
RX   PubMed=33102950; DOI=10.1016/j.jacbts.2020.10.003;
RA   Beddingfield B.J., Iwanaga N., Chapagain P.P., Zheng W., Roy C.J., Hu T.Y.,
RA   Kolls J.K., Bix G.J.;
RT   ""The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2
RT   Infection."";
RL   JACC Basic Transl. Sci. 6:1-8(2021).
RN   [15]
RP   VARIANT GLY-614.
RX   PubMed=33184236; DOI=10.1126/science.abe8499;
RA   Hou Y.J., Chiba S., Halfmann P., Ehre C., Kuroda M., Dinnon K.H. III,
RA   Leist S.R., Schaefer A., Nakajima N., Takahashi K., Lee R.E.,
RA   Mascenik T.M., Graham R., Edwards C.E., Tse L.V., Okuda K., Markmann A.J.,
RA   Bartelt L., de Silva A., Margolis D.M., Boucher R.C., Randell S.H.,
RA   Suzuki T., Gralinski L.E., Kawaoka Y., Baric R.S.;
RT   ""SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and
RT   transmission in vivo."";
RL   Science 370:1464-1468(2020).
RN   [16]
RP   VARIANT GLY-614.
RX   PubMed=33417835; DOI=10.1016/j.celrep.2020.108630;
RA   Gobeil S.M., Janowska K., McDowell S., Mansouri K., Parks R., Manne K.,
RA   Stalls V., Kopp M.F., Henderson R., Edwards R.J., Haynes B.F., Acharya P.;
RT   ""D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease
RT   Cleavage at the S1/S2 Junction."";
RL   Cell Rep. 34:108630-108630(2021).
RN   [17]
RP   VARIANTS 69-VAL--PHE-70 DEL; LYS-144 DEL; TYR-501; ASP-570; GLY-614;
RP   HIS-681; ILE-716; ALA-982 AND HIS-1118.
RC   STRAIN=20I/501Y.V1, Alpha, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [18]
RP   VARIANT TYR-501.
RX   PubMed=32732280; DOI=10.1126/science.abc4730;
RA   Gu H., Chen Q., Yang G., He L., Fan H., Deng Y.Q., Wang Y., Teng Y.,
RA   Zhao Z., Cui Y., Li Y., Li X.F., Li J., Zhang N.N., Yang X., Chen S.,
RA   Guo Y., Zhao G., Wang X., Luo D.Y., Wang H., Yang X., Li Y., Han G., He Y.,
RA   Zhou X., Geng S., Sheng X., Jiang S., Sun S., Qin C.F., Zhou Y.;
RT   ""Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy."";
RL   Science 369:1603-1607(2020).
RN   [19]
RP   VARIANT GLY-614, AND MUTAGENESIS OF GLY-614.
RX   PubMed=33636719; DOI=10.1038/s41586-021-03361-1;
RA   Zhou B., Thi Nhu Thao T., Hoffmann D., Taddeo A., Ebert N., Labroussaa F.,
RA   Pohlmann A., King J., Steiner S., Kelly J.N., Portmann J., Halwe N.J.,
RA   Ulrich L., Trueeb B.S., Fan X., Hoffmann B., Wang L., Thomann L., Lin X.,
RA   Stalder H., Pozzi B., de Brot S., Jiang N., Cui D., Hossain J., Wilson M.,
RA   Keller M., Stark T.J., Barnes J.R., Dijkman R., Jores J., Benarafa C.,
RA   Wentworth D.E., Thiel V., Beer M.;
RT   ""SARS-CoV-2 spike D614G change enhances replication and transmission."";
RL   Nature 5920:122-127(2021).
RN   [20]
RP   MUTAGENESIS OF ASN-165; ASN-234; ASN-331; ASN-343; LEU-452; ALA-475;
RP   VAL-483; PHE-490 AND HIS-519.
RX   PubMed=32730807; DOI=10.1016/j.cell.2020.07.012;
RA   Li Q., Wu J., Nie J., Zhang L., Hao H., Liu S., Zhao C., Zhang Q., Liu H.,
RA   Nie L., Qin H., Wang M., Lu Q., Li X., Sun Q., Liu J., Zhang L., Li X.,
RA   Huang W., Wang Y.;
RT   ""The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and
RT   Antigenicity."";
RL   Cell 182:1284-1294(2020).
RN   [21]
RP   FUNCTION, CLEAVAGE BETWEEN S1 AND S2 BY HOST CTSL, AND INTERACTION WITH
RP   HUMAN ACE2.
RX   PubMed=32221306; DOI=10.1038/s41467-020-15562-9;
RA   Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Guo R., Chen T.,
RA   Hu J., Xiang Z., Mu Z., Chen X., Chen J., Hu K., Jin Q., Wang J., Qian Z.;
RT   ""Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and
RT   its immune cross-reactivity with SARS-CoV."";
RL   Nat. Commun. 11:1620-1620(2020).
RN   [22]
RP   INTERACTION WITH HUMAN ACE2.
RX   PubMed=33607086; DOI=10.1016/j.bpj.2021.02.007;
RA   Cao W., Dong C., Kim S., Hou D., Tai W., Du L., Im W., Zhang X.F.;
RT   ""Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2
RT   protein-protein interaction."";
RL   Biophys. J. 120:1011-1019(2021).
RN   [23]
RP   FUNCTION, AND CLEAVAGE BETWEEN S1 AND S2 BY HOST TMPRSS2.
RX   PubMed=33465165; DOI=10.1371/journal.ppat.1009212;
RA   Ou T., Mou H., Zhang L., Ojha A., Choe H., Farzan M.;
RT   ""Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated
RT   by TMPRSS2."";
RL   PLoS Pathog. 17:e1009212-e1009212(2021).
RN   [24]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH S PROTEIN.
RX   PubMed=33229438; DOI=10.1074/jbc.ra120.016175;
RA   Boson B., Legros V., Zhou B., Siret E., Mathieu C., Cosset F.L.,
RA   Lavillette D., Denolly S.;
RT   ""The SARS-CoV-2 Envelope and Membrane proteins modulate maturation and
RT   retention of the Spike protein, allowing assembly of virus-like
RT   particles."";
RL   J. Biol. Chem. 296:100111-100111(2020).
RN   [25]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, MUTAGENESIS OF ALA-684, AND FUNCTION (SPIKE PROTEIN S2').
RX   PubMed=32703818; DOI=10.26508/lsa.202000786;
RA   Bestle D., Heindl M.R., Limburg H., Van Lam van T., Pilgram O., Moulton H.,
RA   Stein D.A., Hardes K., Eickmann M., Dolnik O., Rohde C., Klenk H.D.,
RA   Garten W., Steinmetzer T., Boettcher-Friebertshaeuser E.;
RT   ""TMPRSS2 and furin are both essential for proteolytic activation of SARS-
RT   CoV-2 in human airway cells."";
RL   Life. Sci Alliance 3:1-14(2020).
RN   [26]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, CLEAVAGE BETWEEN S2 AND S2' BY HOST CSTL, AND FUNCTION (SPIKE
RP   PROTEIN S2').
RX   PubMed=34159616; DOI=10.15252/embj.2021107821;
RA   Koch J., Uckeley Z.M., Doldan P., Stanifer M., Boulant S., Lozach P.Y.;
RT   ""TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect
RT   host cells."";
RL   EMBO J. 40:1-20(2021).
RN   [27]
RP   VARIANTS PHE-18; ALA-80; GLY-215; ASN-417; LYS-484; TYR-501; GLY-614 AND
RP   VAL-701.
RC   STRAIN=20H/501Y.V2, B.1.351, and Beta;
RX   PubMed=33690265; DOI=10.1038/s41586-021-03402-9;
RA   Tegally H., Wilkinson E., Giovanetti M., Iranzadeh A., Fonseca V.,
RA   Giandhari J., Doolabh D., Pillay S., San E.J., Msomi N., Mlisana K.,
RA   von Gottberg A., Walaza S., Allam M., Ismail A., Mohale T., Glass A.J.,
RA   Engelbrecht S., Van Zyl G., Preiser W., Petruccione F., Sigal A.,
RA   Hardie D., Marais G., Hsiao M., Korsman S., Davies M.A., Tyers L.,
RA   Mudau I., York D., Maslo C., Goedhals D., Abrahams S., Laguda-Akingba O.,
RA   Alisoltani-Dehkordi A., Godzik A., Wibmer C.K., Sewell B.T., Lourenco J.,
RA   Alcantara L.C.J., Kosakovsky Pond S.L., Weaver S., Martin D.,
RA   Lessells R.J., Bhiman J.N., Williamson C., de Oliveira T.;
RT   ""Emergence of a SARS-CoV-2 variant of concern with mutations in spike
RT   glycoprotein."";
RL   Nature 592:438-443(2021).
RN   [28]
RP   POLYMORPHISM.
RX   PubMed=34142653; DOI=10.2807/1560-7917.es.2021.26.24.2100509;
RA   Campbell F., Archer B., Laurenson-Schafer H., Jinnai Y., Konings F.,
RA   Batra N., Pavlin B., Vandemaele K., Van Kerkhove M.D., Jombart T.,
RA   Morgan O., le Polain de Waroux O.;
RT   ""Increased transmissibility and global spread of SARS-CoV-2 variants of
RT   concern as at June 2021."";
RL   Eurosurveillance 26:0-0(2021).
RN   [29]
RP   VARIANTS ARG-452 AND PHE-453, AND MUTAGENESIS OF LEU-452; TYR-453 AND
RP   ASN-501.
RX   PubMed=34171266; DOI=10.1016/j.chom.2021.06.006;
RG   Genotype to Phenotype Japan (G2P-Japan) Consortium;
RA   Motozono C., Toyoda M., Zahradnik J., Saito A., Nasser H., Tan T.S.,
RA   Ngare I., Kimura I., Uriu K., Kosugi Y., Yue Y., Shimizu R., Ito J.,
RA   Torii S., Yonekawa A., Shimono N., Nagasaki Y., Minami R., Toya T.,
RA   Sekiya N., Fukuhara T., Matsuura Y., Schreiber G., Ikeda T., Nakagawa S.,
RA   Ueno T., Sato K.;
RT   ""SARS-CoV-2 spike L452R variant evades cellular immunity and increases
RT   infectivity."";
RL   Cell Host Microbe 0:0-0(2021).
RN   [30]
RP   VARIANT 69-VAL--PHE-70 DEL, AND MUTAGENESIS OF 69-HIS-VAL-70.
RX   PubMed=34166617; DOI=10.1016/j.celrep.2021.109292;
RG   COVID-19 Genomics UK (COG-UK) Consortium;
RA   Meng B., Kemp S.A., Papa G., Datir R., Ferreira I.A.T.M., Marelli S.,
RA   Harvey W.T., Lytras S., Mohamed A., Gallo G., Thakur N., Collier D.A.,
RA   Mlcochova P., Duncan L.M., Carabelli A.M., Kenyon J.C., Lever A.M.,
RA   De Marco A., Saliba C., Culap K., Cameroni E., Matheson N.J., Piccoli L.,
RA   Corti D., James L.C., Robertson D.L., Bailey D., Gupta R.K.;
RT   ""Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in
RT   the Alpha variant B.1.1.7."";
RL   Cell Rep. 35:109292-109292(2021).
RN   [31]
RP   VARIANTS ILE-13 AND CYS-152, POLYMORPHISM, AND MASS SPECTROMETRY (SIGNAL).
RX   PubMed=34210893; DOI=10.1126/science.abi7994;
RA   McCallum M., Bassi J., De Marco A., Chen A., Walls A.C., Di Iulio J.,
RA   Tortorici M.A., Navarro M.J., Silacci-Fregni C., Saliba C., Sprouse K.R.,
RA   Agostini M., Pinto D., Culap K., Bianchi S., Jaconi S., Cameroni E.,
RA   Bowen J.E., Tilles S.W., Pizzuto M.S., Guastalla S.B., Bona G.,
RA   Pellanda A.F., Garzoni C., Van Voorhis W.C., Rosen L.E., Snell G.,
RA   Telenti A., Virgin H.W., Piccoli L., Corti D., Veesler D.;
RT   ""SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern."";
RL   Science 373:648-654(2021).
RN   [32]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-1269 AND HIS-1271.
RX   PubMed=34504087; DOI=10.1038/s41467-021-25589-1;
RA   Cattin-Ortola J., Welch L.G., Maslen S.L., Papa G., James L.C., Munro S.;
RT   ""Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate
RT   expression at the cell surface and syncytia formation."";
RL   Nat. Commun. 12:5333-5333(2021).
RN   [33]
RP   PALMITOYLATION AT CYS-1235; CYS-1236; CYS-1240; CYS-1241; CYS-1243;
RP   CYS-1247; CYS-1248; CYS-1250; CYS-1253 AND CYS-1254.
RX   PubMed=34599882; DOI=10.1016/j.devcel.2021.09.016;
RA   Mesquita F.S., Abrami L., Sergeeva O., Turelli P., Qing E., Kunz B.,
RA   Raclot C., Paz Montoya J., Abriata L.A., Gallagher T., Dal Peraro M.,
RA   Trono D., D'Angelo G., van der Goot F.G.;
RT   ""S-acylation controls SARS-CoV-2 membrane lipid organization and enhances
RT   infectivity."";
RL   Dev. Cell 56:1-18(2021).
RN   [34] {ECO:0007744|PDB:6M17}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.90 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), DOMAIN, AND INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1).
RX   PubMed=32132184; DOI=10.1126/science.abb2762;
RA   Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q.;
RT   ""Structural basis for the recognition of the SARS-CoV-2 by full-length
RT   human ACE2."";
RL   Science 367:1444-1448(2020).
RN   [35]
RP   SUPERANTIGEN, AND DOMAIN.
RX   PubMed=32989130; DOI=10.1073/pnas.2010722117;
RA   Cheng M.H., Zhang S., Porritt R.A., Noval Rivas M., Paschold L.,
RA   Willscher E., Binder M., Arditi M., Bahar I.;
RT   ""Superantigenic character of an insert unique to SARS-CoV-2 spike supported
RT   by skewed TCR repertoire in patients with hyperinflammation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 117:25254-25262(2020).
RN   [36]
RP   INTERACTION WITH HUMAN BILIRUBIN, INTERACTION WITH HUMAN BILIVERDIN, AND
RP   MUTAGENESIS OF ASN-121 AND ARG-190.
RX   PubMed=33888467; DOI=10.1126/sciadv.abg7607;
RA   Rosa A., Pye V.E., Graham C., Muir L., Seow J., Ng K.W., Cook N.J.,
RA   Rees-Spear C., Parker E., Dos Santos M.S., Rosadas C., Susana A., Rhys H.,
RA   Nans A., Masino L., Roustan C., Christodoulou E., Ulferts R., Wrobel A.G.,
RA   Short C.E., Fertleman M., Sanders R.W., Heaney J., Spyer M., Kjaer S.,
RA   Riddell A., Malim M.H., Beale R., MacRae J.I., Taylor G.P., Nastouli E.,
RA   van Gils M.J., Rosenthal P.B., Pizzato M., McClure M.O., Tedder R.S.,
RA   Kassiotis G., McCoy L.E., Doores K.J., Cherepanov P.;
RT   ""SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity."";
RL   Sci. Adv. 7:0-0(2021).
RN   [37]
RP   BIOTECHNOLOGY, AND MUTAGENESIS OF 682-ARG--ARG-685 AND 986-LYS-VAL-987.
RX   PubMed=34322129; DOI=10.3389/fimmu.2021.701501;
RA   Martinez-Flores D., Zepeda-Cervantes J., Cruz-Resendiz A.,
RA   Aguirre-Sampieri S., Sampieri A., Vaca L.;
RT   ""SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of
RT   New Viral Variants."";
RL   Front. Immunol. 12:701501-701501(2021).
RN   [38]
RP   GLYCOSYLATION AT THR-676 AND THR-678 BY HOST GALNT1, AND MUTAGENESIS OF
RP   SER-673; THR-676; THR-678; SER-680 AND PRO-681.
RX   PubMed=34732583; DOI=10.1073/pnas.2109905118;
RA   Zhang L., Mann M., Syed Z.A., Reynolds H.M., Tian E., Samara N.L.,
RA   Zeldin D.C., Tabak L.A., Ten Hagen K.G.;
RT   ""Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [39]
RP   REVIEW, PROTEOLITIC PROCESSING, FUNCTION (SPIKE PROTEIN S2), AND FUNCTION
RP   (SPIKE PROTEIN S2').
RX   PubMed=34561887; DOI=10.1111/1348-0421.12945;
RA   Takeda M.;
RT   ""Proteolytic activation of SARS-CoV-2 spike protein."";
RL   Microbiol. Immunol. 66:15-23(2022).
RN   [40]
RP   INTERACTION WITH HOST MBL2.
RX   PubMed=35102342; DOI=10.1038/s41590-021-01114-w;
RA   Stravalaci M., Pagani I., Paraboschi E.M., Pedotti M., Doni A.,
RA   Scavello F., Mapelli S.N., Sironi M., Perucchini C., Varani L.,
RA   Matkovic M., Cavalli A., Cesana D., Gallina P., Pedemonte N., Capurro V.,
RA   Clementi N., Mancini N., Invernizzi P., Bayarri-Olmos R., Garred P.,
RA   Rappuoli R., Duga S., Bottazzi B., Uguccioni M., Asselta R., Vicenzi E.,
RA   Mantovani A., Garlanda C.;
RT   ""Recognition and inhibition of SARS-CoV-2 by humoral innate immunity
RT   pattern recognition molecules."";
RL   Nat. Immunol. 23:275-286(2022).
RN   [41]
RP   FUNCTION (SPIKE PROTEIN S1), AND INTERACTION WITH HOST INTEGRIN (SPIKE
RP   PROTEIN S1).
RX   PubMed=35150743; DOI=10.1016/j.jbc.2022.101710;
RA   Liu J., Lu F., Chen Y., Plow E., Qin J.;
RT   ""Integrin mediates cell entry of the SARS-CoV-2 virus independent of
RT   cellular receptor ACE2."";
RL   J. Biol. Chem. 1:101710-101710(2022).
RN   [42]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [43]
RP   SUBUNIT.
RX   PubMed=36735681; DOI=10.1371/journal.pbio.3001959;
RA   Shilts J., Crozier T.W.M., Teixeira-Silva A., Gabaev I., Gerber P.P.,
RA   Greenwood E.J.D., Watson S.J., Ortmann B.M., Gawden-Bone C.M., Pauzaite T.,
RA   Hoffmann M., Nathan J.A., Poehlmann S., Matheson N.J., Lehner P.J.,
RA   Wright G.J.;
RT   ""LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike
RT   protein."";
RL   PLoS Biol. 21:e3001959-e3001959(2023).
RN   [44]
RP   VARIANT ASN-405.
RX   PubMed=36851546; DOI=10.3390/v15020332;
RA   Bugatti A., Filippini F., Messali S., Giovanetti M., Ravelli C., Zani A.,
RA   Ciccozzi M., Caruso A., Caccuri F.;
RT   ""The D405N Mutation in the Spike Protein of SARS-CoV-2 Omicron BA.5
RT   Inhibits Spike/Integrins Interaction and Viral Infection of Human Lung
RT   Microvascular Endothelial Cells."";
RL   Viruses 15:0-0(2023).
RN   [45]
RP   MUTAGENESIS OF GLU-484.
RX   PubMed=37421949; DOI=10.1016/j.cell.2023.06.005;
RA   Baggen J., Jacquemyn M., Persoons L., Vanstreels E., Pye V.E., Wrobel A.G.,
RA   Calvaresi V., Martin S.R., Roustan C., Cronin N.B., Reading E.,
RA   Thibaut H.J., Vercruysse T., Maes P., De Smet F., Yee A., Nivitchanyong T.,
RA   Roell M., Franco-Hernandez N., Rhinn H., Mamchak A.A., Ah Young-Chapon M.,
RA   Brown E., Cherepanov P., Daelemans D.;
RT   ""TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry."";
RL   Cell 186:1-16(2023).
RN   [46] {ECO:0007744|PDB:6VSB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.46 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1), SUBUNIT, AND
RP   GLYCOSYLATION.
RX   PubMed=32075877; DOI=10.1126/science.abb2507;
RA   Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O.,
RA   Graham B.S., McLellan J.S.;
RT   ""Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation."";
RL   Science 367:1260-1263(2020).
RN   [47] {ECO:0007744|PDB:6VXX, ECO:0007744|PDB:6VYB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.80 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), SUBUNIT (SPIKE PROTEIN S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN
RP   S1), MUTAGENESIS OF 679-GLN--ALA-684, GLYCOSYLATION AT ASN-61; ASN-122;
RP   ASN-61; ASN-165; ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616;
RP   ASN-657; ASN-709; ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1134, AND
RP   DISULFIDE BOND.
RX   PubMed=32155444; DOI=10.1016/j.cell.2020.02.058;
RA   Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D.;
RT   ""Structure, function, and antigenicity of the SARS-CoV-2 spike
RT   glycoprotein."";
RL   Cell 180:1-12(2020).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2.
RX   PubMed=32225176; DOI=10.1038/s41586-020-2180-5;
RA   Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q.,
RA   Zhang L., Wang X.;
RT   ""Structure of the SARS-CoV-2 spike receptor-binding domain bound to the
RT   ACE2 receptor."";
RL   Nature 581:215-220(2020).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.68 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2, INTERACTION WITH HOST ACE2, AND MUTAGENESIS OF GLN-493 AND
RP   ASN-501.
RX   PubMed=32225175; DOI=10.1038/s41586-020-2179-y;
RA   Shang J., Ye G., Shi K., Wan Y., Luo C., Aihara H., Geng Q., Auerbach A.,
RA   Li F.;
RT   ""Structural basis of receptor recognition by SARS-CoV-2."";
RL   Nature 581:221-224(2020).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (3.08 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HUMAN ANTIBODY CR3022, AND DISULFIDE BOND.
RX   PubMed=32245784; DOI=10.1126/science.abb7269;
RA   Yuan M., Wu N.C., Zhu X., Lee C.D., So R.T.Y., Lv H., Mok C.K.P.,
RA   Wilson I.A.;
RT   ""A highly conserved cryptic epitope in the receptor-binding domains of
RT   SARS-CoV-2 and SARS-CoV."";
RL   Science 368:630-633(2020).
CC   -!- FUNCTION: [Spike protein S1]: Attaches the virion to the cell membrane
CC       by interacting with host receptor, initiating the infection. The major
CC       receptor is host ACE2 (PubMed:32142651, PubMed:32155444,
CC       PubMed:33607086). When S2/S2' has been cleaved, binding to the receptor
CC       triggers direct fusion at the cell membrane (PubMed:34561887). When
CC       S2/S2' has not been cleaved, binding to the receptor results in
CC       internalization of the virus by endocytosis leading to fusion of the
CC       virion membrane with the host endosomal membrane (PubMed:32075877,
CC       PubMed:32221306). Alternatively, may use NRP1/NRP2 (PubMed:33082294,
CC       PubMed:33082293) and integrin as entry receptors (PubMed:35150743). The
CC       use of NRP1/NRP2 receptors may explain the tropism of the virus in
CC       human olfactory epithelial cells, which express these molecules at high
CC       levels but ACE2 at low levels (PubMed:33082293). The stalk domain of S
CC       contains three hinges, giving the head unexpected orientational freedom
CC       (PubMed:32817270). {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32142651,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32817270, ECO:0000269|PubMed:33082293,
CC       ECO:0000269|PubMed:33082294, ECO:0000269|PubMed:35150743,
CC       ECO:0000303|PubMed:33082293, ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2]: Precursor of the fusion protein processed
CC       in the biosynthesis of the S protein and the formation of virus
CC       particle. Mediates fusion of the virion and cellular membranes by
CC       functioning as a class I viral fusion protein. Contains two viral
CC       fusion peptides that are unmasked after cleavage. The S2/S2' cleavage
CC       occurs during virus entry at the cell membrane by host TMPRSS2
CC       (PubMed:32142651) or during endocytosis by host CSTL (PubMed:32703818,
CC       PubMed:34159616). In either case, this triggers an extensive and
CC       irreversible conformational change leading to fusion of the viral
CC       envelope with the cellular cytoplasmic membrane, releasing viral
CC       genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the
CC       current model, the protein has at least three conformational states:
CC       pre-fusion native state, pre-hairpin intermediate state, and post-
CC       fusion hairpin state. During fusion of the viral and target cell
CC       membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-
CC       hairpins structure and position the fusion peptide in close proximity
CC       to the C-terminal region of the ectodomain. Formation of this structure
CC       appears to promote apposition and subsequent fusion of viral and target
CC       cell membranes. {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32703818, ECO:0000269|PubMed:34159616,
CC       ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2']: Subunit of the fusion protein that is
CC       processed upon entry into the host cell. Mediates fusion of the virion
CC       and cellular membranes by functioning as a class I viral fusion
CC       protein. Contains a viral fusion peptide that is unmasked after S2
CC       cleavage. This cleavage can occur at the cell membrane by host TMPRSS2
CC       or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616).
CC       In either case, this triggers an extensive and irreversible
CC       conformational change that leads to fusion of the viral envelope with
CC       the cellular cytoplasmic membrane, releasing viral genomic RNA into the
CC       host cell cytoplasm (PubMed:34561887). Under the current model, the
CC       protein has at least three conformational states: pre-fusion native
CC       state, pre-hairpin intermediate state, and post-fusion hairpin state.
CC       During fusion of the viral and target cell membranes, the coiled coil
CC       regions (heptad repeats) adopt a trimer-of-hairpins structure and
CC       position the fusion peptide in close proximity to the C-terminal region
CC       of the ectodomain. Formation of this structure appears to promote
CC       apposition and subsequent fusion of viral and target cell membranes.
CC       {ECO:0000255|HAMAP-Rule:MF_04099, ECO:0000269|PubMed:32703818,
CC       ECO:0000269|PubMed:34159616, ECO:0000305|PubMed:34561887}.
CC   -!- SUBUNIT: [Spike glycoprotein]: Homotrimer; each monomer consists of a
CC       S1 and a S2 subunit (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784). The resulting peplomers protrude from the virus
CC       surface as spikes (PubMed:32979942). Interacts with ORF3a protein and
CC       ORF7a protein (By similarity) (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784, PubMed:32979942). There are an average of 26 +/-15
CC       spike trimers at the surface of virion particles (PubMed:32979942).
CC       Binds to host MBL2 (PubMed:35102342). This binding occurs via glycans
CC       and inhibits viral infectivity. Inhibition is effective against alpha,
CC       beta, gamma, and delta variants (PubMed:35102342). {ECO:0000255|HAMAP-
CC       Rule:MF_04099, ECO:0000269|PubMed:32075877,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32245784,
CC       ECO:0000269|PubMed:32979942, ECO:0000269|PubMed:35102342}.
CC   -!- SUBUNIT: [Spike protein S1]: Binds to host ACE2 (PubMed:32075877,
CC       PubMed:32132184, PubMed:32155444, PubMed:32221306, PubMed:32225175,
CC       PubMed:32225176, PubMed:33607086). RBD also interacts with the N-linked
CC       glycan on 'Asn-90' of ACE2 (PubMed:33607086). Cleavage of S generates a
CC       polybasic C-terminal sequence on S1 that binds to host Neuropilin-1
CC       (NRP1) and Neuropilin-2 (NRP2) receptors (PubMed:33082293,
CC       PubMed:33082294). Interacts with host integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) and with ACE2 in complex with integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) (PubMed:33102950). May interact via cytoplasmic c-
CC       terminus with M protein (PubMed:33229438). May interact (via N-
CC       terminus) with host bilirubin and biliverdin, thereby preventing
CC       antibody binding to the SARS-CoV-2 spike NTD via an allosteric
CC       mechanism (PubMed:33888467). May interact with host LRRC15, thereby
CC       allowing attachment to host cells (PubMed:36735681).
CC       {ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32132184,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32225",4677
CTGAGT TGAGTC GAGTCT AGTCTC GTCTCT TCTCTG CTCTGC TCTGCT CTGCTG TGCTGG GCTGGA CTGGAG TGGAGA GGAGAC GAGACA AGACAG GACAGC ACAGCG CAGCGC AGCGCC GCGCCC CGCCCC GCCCCC CCCCCA CCCCAT CCCATC CCATCA CATCAT ATCATT TCATTA CATTAT ATTATG TTATGC TATGCC ATGCCA TGCCAT GCCATT CCATTC CATTCG ATTCGT TTCGTG TCGTGC CGTGCA GTGCAG TGCAGG GCAGGT CAGGTC AGGTCG GGTCGG GTCGGA TCGGAA CGGAAC GGAACT GAACTT AACTTA ACTTAC CTTACC TTACCC TACCCG ACCCGA CCCGAC CCGACA CGACAA GACAAG ACAAGG CAAGGA AAGGAA AGGAAT GGAATT GAATTT AATTTC ATTTCG TTTCGC TTCGCT TCGCTA CGCTAC GCTACC CTACCT TACCTT ACCTTA CCTTAG CTTAGG TTAGGA TAGGAC AGGACC GGACCG GACCGT ACCGTT CCGTTA CGTTAT GTTATT TTATTG TATTGT ATTGTT TTGTTA TGTTAC GTTACG TTACGG TACGGC ACGGCC CGGCCG GGCCGC GCCGCC CCGCCG CGCCGT GCCGTT CCGTTT CGTTTA GTTTAC TTTACT TTACTG TACTGG ACTGGG CTGGGG TGGGGC GGGGCT GGGCTT GGCTTC GCTTCG CTTCGA TTCGAT TCGATC CGATCA GATCAA ATCAAG TCAAGA CAAGAG AAGAGC AGAGCT GAGCTT AGCTTC GCTTCG CTTCGC TTCGCT TCGCTT CGCTTA GCTTAC CTTACG TTACGC TACGCT ACGCTA CGCTAA,3,142,CTGA TGAG GAGT AGTC GTCT TCTC CTCT TCTG CTGC TGCT GCTG CTGG TGGA GGAG GAGA AGAC GACA ACAG CAGC AGCG GCGC CGCC GCCC CCCC CCCC CCCA CCAT CATC ATCA TCAT CATT ATTA TTAT TATG ATGC TGCC GCCA CCAT CATT ATTC TTCG TCGT CGTG GTGC TGCA GCAG CAGG AGGT GGTC GTCG TCGG CGGA GGAA GAAC AACT ACTT CTTA TTAC TACC ACCC CCCG CCGA CGAC GACA ACAA CAAG AAGG AGGA GGAA GAAT AATT ATTT TTTC TTCG TCGC CGCT GCTA CTAC TACC ACCT CCTT CTTA TTAG TAGG AGGA GGAC GACC ACCG CCGT CGTT GTTA TTAT TATT ATTG TTGT TGTT GTTA TTAC TACG ACGG CGGC GGCC GCCG CCGC CGCC GCCG CCGT CGTT GTTT TTTA TTAC TACT ACTG CTGG TGGG GGGG GGGC GGCT GCTT CTTC TTCG TCGA CGAT GATC ATCA TCAA CAAG AAGA AGAG GAGC AGCT GCTT CTTC TTCG TCGC CGCT GCTT CTTA TTAC TACG ACGC CGCT GCTA CTAA,CTGAG TGAGT GAGTC AGTCT GTCTC TCTCT CTCTG TCTGC CTGCT TGCTG GCTGG CTGGA TGGAG GGAGA GAGAC AGACA GACAG ACAGC CAGCG AGCGC GCGCC CGCCC GCCCC CCCCC CCCCA CCCAT CCATC CATCA ATCAT TCATT CATTA ATTAT TTATG TATGC ATGCC TGCCA GCCAT CCATT CATTC ATTCG TTCGT TCGTG CGTGC GTGCA TGCAG GCAGG CAGGT AGGTC GGTCG GTCGG TCGGA CGGAA GGAAC GAACT AACTT ACTTA CTTAC TTACC TACCC ACCCG CCCGA CCGAC CGACA GACAA ACAAG CAAGG AAGGA AGGAA GGAAT GAATT AATTT ATTTC TTTCG TTCGC TCGCT CGCTA GCTAC CTACC TACCT ACCTT CCTTA CTTAG TTAGG TAGGA AGGAC GGACC GACCG ACCGT CCGTT CGTTA GTTAT TTATT TATTG ATTGT TTGTT TGTTA GTTAC TTACG TACGG ACGGC CGGCC GGCCG GCCGC CCGCC CGCCG GCCGT CCGTT CGTTT GTTTA TTTAC TTACT TACTG ACTGG CTGGG TGGGG GGGGC GGGCT GGCTT GCTTC CTTCG TTCGA TCGAT CGATC GATCA ATCAA TCAAG CAAGA AAGAG AGAGC GAGCT AGCTT GCTTC CTTCG TTCGC TCGCT CGCTT GCTTA CTTAC TTACG TACGC ACGCT CGCTA GCTAA,CTGAGT TGAGTC GAGTCT AGTCTC GTCTCT TCTCTG CTCTGC TCTGCT CTGCTG TGCTGG GCTGGA CTGGAG TGGAGA GGAGAC GAGACA AGACAG GACAGC ACAGCG CAGCGC AGCGCC GCGCCC CGCCCC GCCCCC CCCCCA CCCCAT CCCATC CCATCA CATCAT ATCATT TCATTA CATTAT ATTATG TTATGC TATGCC ATGCCA TGCCAT GCCATT CCATTC CATTCG ATTCGT TTCGTG TCGTGC CGTGCA GTGCAG TGCAGG GCAGGT CAGGTC AGGTCG GGTCGG GTCGGA TCGGAA CGGAAC GGAACT GAACTT AACTTA ACTTAC CTTACC TTACCC TACCCG ACCCGA CCCGAC CCGACA CGACAA GACAAG ACAAGG CAAGGA AAGGAA AGGAAT GGAATT GAATTT AATTTC ATTTCG TTTCGC TTCGCT TCGCTA CGCTAC GCTACC CTACCT TACCTT ACCTTA CCTTAG CTTAGG TTAGGA TAGGAC AGGACC GGACCG GACCGT ACCGTT CCGTTA CGTTAT GTTATT TTATTG TATTGT ATTGTT TTGTTA TGTTAC GTTACG TTACGG TACGGC ACGGCC CGGCCG GGCCGC GCCGCC CCGCCG CGCCGT GCCGTT CCGTTT CGTTTA GTTTAC TTTACT TTACTG TACTGG ACTGGG CTGGGG TGGGGC GGGGCT GGGCTT GGCTTC GCTTCG CTTCGA TTCGAT TCGATC CGATCA GATCAA ATCAAG TCAAGA CAAGAG AAGAGC AGAGCT GAGCTT AGCTTC GCTTCG CTTCGC TTCGCT TCGCTT CGCTTA GCTTAC CTTACG TTACGC TACGCT ACGCTA CGCTAA,CTGAGTC TGAGTCT GAGTCTC AGTCTCT GTCTCTG TCTCTGC CTCTGCT TCTGCTG CTGCTGG TGCTGGA GCTGGAG CTGGAGA TGGAGAC GGAGACA GAGACAG AGACAGC GACAGCG ACAGCGC CAGCGCC AGCGCCC GCGCCCC CGCCCCC GCCCCCA CCCCCAT CCCCATC CCCATCA CCATCAT CATCATT ATCATTA TCATTAT CATTATG ATTATGC TTATGCC TATGCCA ATGCCAT TGCCATT GCCATTC CCATTCG CATTCGT ATTCGTG TTCGTGC TCGTGCA CGTGCAG GTGCAGG TGCAGGT GCAGGTC CAGGTCG AGGTCGG GGTCGGA GTCGGAA TCGGAAC CGGAACT GGAACTT GAACTTA AACTTAC ACTTACC CTTACCC TTACCCG TACCCGA ACCCGAC CCCGACA CCGACAA CGACAAG GACAAGG ACAAGGA CAAGGAA AAGGAAT AGGAATT GGAATTT GAATTTC AATTTCG ATTTCGC TTTCGCT TTCGCTA TCGCTAC CGCTACC GCTACCT CTACCTT TACCTTA ACCTTAG CCTTAGG CTTAGGA TTAGGAC TAGGACC AGGACCG GGACCGT GACCGTT ACCGTTA CCGTTAT CGTTATT GTTATTG TTATTGT TATTGTT ATTGTTA TTGTTAC TGTTACG GTTACGG TTACGGC TACGGCC ACGGCCG CGGCCGC GGCCGCC GCCGCCG CCGCCGT CGCCGTT GCCGTTT CCGTTTA CGTTTAC GTTTACT TTTACTG TTACTGG TACTGGG ACTGGGG CTGGGGC TGGGGCT GGGGCTT GGGCTTC GGCTTCG GCTTCGA CTTCGAT TTCGATC TCGATCA CGATCAA GATCAAG ATCAAGA TCAAGAG CAAGAGC AAGAGCT AGAGCTT GAGCTTC AGCTTCG GCTTCGC CTTCGCT TTCGCTT TCGCTTA CGCTTAC GCTTACG CTTACGC TTACGCT TACGCTA ACGCTAA,"ID   YCX91_PHAAO             Reviewed;          91 AA.
AC   Q3BAI2;
DT   25-JUL-2006, integrated into UniProtKB/Swiss-Prot.
DT   22-NOV-2005, sequence version 1.
DT   05-FEB-2025, entry version 27.
DE   RecName: Full=Uncharacterized protein ORF91;
OS   Phalaenopsis aphrodite subsp. formosana (Moth orchid).
OG   Plastid; Chloroplast.
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliopsida; Liliopsida; Asparagales; Orchidaceae;
OC   Epidendroideae; Vandeae; Aeridinae; Phalaenopsis.
OX   NCBI_TaxID=308872;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=cv. Taisugar TS-97;
RX   PubMed=16207935; DOI=10.1093/molbev/msj029;
RA   Chang C.-C., Lin H.-C., Lin I.-P., Chow T.-Y., Chen H.-H., Chen W.-H.,
RA   Cheng C.-H., Lin C.-Y., Liu S.-M., Chang C.-C., Chaw S.-M.;
RT   ""The chloroplast genome of Phalaenopsis aphrodite (Orchidaceae):
RT   comparative analysis of evolutionary rate with that of grasses and its
RT   phylogenetic implications."";
RL   Mol. Biol. Evol. 23:279-291(2006).
CC   -!- SUBCELLULAR LOCATION: Plastid, chloroplast.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY916449; AAW82572.1; -; Genomic_DNA.
DR   RefSeq; YP_358636.1; NC_007499.1.
DR   AlphaFoldDB; Q3BAI2; -.
DR   GeneID; 3741793; -.
DR   GO; GO:0009507; C:chloroplast; IEA:UniProtKB-SubCell.
DR   AntiFam; ANF00025; Antisense to 23S rRNA.
PE   4: Predicted;
KW   Chloroplast; Plastid.
FT   CHAIN           1..91
FT                   /note=""Uncharacterized protein ORF91""
FT                   /id=""PRO_0000246135""
SQ   SEQUENCE   91 AA;  10596 MW;  C770491A1FF96EE8 CRC64;
     MQVVRIFTDM SISPSLSPRQ CPDRYAFRAG RNLPDKEFRY LRTVLVTAAV HRGFGRRLPC
     HQVTNFLDLP ALGRRQPPYM VLRLCGDLCF W
//
",2187
CAATTG AATTGT ATTGTT TTGTTA TGTTAC GTTACC TTACCT TACCTT ACCTTA CCTTAT CTTATG TTATGA TATGAG ATGAGG TGAGGC GAGGCG AGGCGA GGCGAA GCGAAT CGAATA GAATAG AATAGC ATAGCG TAGCGC AGCGCT GCGCTG CGCTGC GCTGCG CTGCGC TGCGCA GCGCAG CGCAGG GCAGGC CAGGCA AGGCAG GGCAGG GCAGGT CAGGTG AGGTGG GGTGGC GTGGCG TGGCGA GGCGAT GCGATC CGATCC GATCCC ATCCCT TCCCTT CCCTTC CCTTCC CTTCCG TTCCGT TCCGTG CCGTGT CGTGTG GTGTGA TGTGAT GTGATC TGATCG GATCGT ATCGTA TCGTAG CGTAGG GTAGGC TAGGCG AGGCGA GGCGAT GCGATT CGATTT GATTTT ATTTTG TTTTGT TTTGTA TTGTAA TGTAAC GTAACA TAACAA AACAAC ACAACA CAACAG AACAGA ACAGAA CAGAAG AGAAGA GAAGAC AAGACG AGACGG GACGGT ACGGTA CGGTAC GGTACG GTACGG TACGGG ACGGGT CGGGTA GGGTAT GGTATT GTATTG TATTGT ATTGTG TTGTGC TGTGCA GTGCAT TGCATA GCATAC CATACC ATACCG TACCGC ACCGCT CCGCTC CGCTCC GCTCCG CTCCGG TCCGGC CCGGCA CGGCAT GGCATT GCATTT CATTTG ATTTGG TTTGGT TTGGTG TGGTGC GGTGCG GTGCGG TGCGGA GCGGAT CGGATG GGATGA GATGAC ATGACT TGACTA GACTAC ACTACA CTACAA TACAAA ACAAAG CAAAGT AAAGTG AAGTGG AGTGGG GTGGGA TGGGAC GGGACA GGACAG,1,145,CAAT AATT ATTG TTGT TGTT GTTA TTAC TACC ACCT CCTT CTTA TTAT TATG ATGA TGAG GAGG AGGC GGCG GCGA CGAA GAAT AATA ATAG TAGC AGCG GCGC CGCT GCTG CTGC TGCG GCGC CGCA GCAG CAGG AGGC GGCA GCAG CAGG AGGT GGTG GTGG TGGC GGCG GCGA CGAT GATC ATCC TCCC CCCT CCTT CTTC TTCC TCCG CCGT CGTG GTGT TGTG GTGA TGAT GATC ATCG TCGT CGTA GTAG TAGG AGGC GGCG GCGA CGAT GATT ATTT TTTT TTTG TTGT TGTA GTAA TAAC AACA ACAA CAAC AACA ACAG CAGA AGAA GAAG AAGA AGAC GACG ACGG CGGT GGTA GTAC TACG ACGG CGGG GGGT GGTA GTAT TATT ATTG TTGT TGTG GTGC TGCA GCAT CATA ATAC TACC ACCG CCGC CGCT GCTC CTCC TCCG CCGG CGGC GGCA GCAT CATT ATTT TTTG TTGG TGGT GGTG GTGC TGCG GCGG CGGA GGAT GATG ATGA TGAC GACT ACTA CTAC TACA ACAA CAAA AAAG AAGT AGTG GTGG TGGG GGGA GGAC GACA ACAG,CAATT AATTG ATTGT TTGTT TGTTA GTTAC TTACC TACCT ACCTT CCTTA CTTAT TTATG TATGA ATGAG TGAGG GAGGC AGGCG GGCGA GCGAA CGAAT GAATA AATAG ATAGC TAGCG AGCGC GCGCT CGCTG GCTGC CTGCG TGCGC GCGCA CGCAG GCAGG CAGGC AGGCA GGCAG GCAGG CAGGT AGGTG GGTGG GTGGC TGGCG GGCGA GCGAT CGATC GATCC ATCCC TCCCT CCCTT CCTTC CTTCC TTCCG TCCGT CCGTG CGTGT GTGTG TGTGA GTGAT TGATC GATCG ATCGT TCGTA CGTAG GTAGG TAGGC AGGCG GGCGA GCGAT CGATT GATTT ATTTT TTTTG TTTGT TTGTA TGTAA GTAAC TAACA AACAA ACAAC CAACA AACAG ACAGA CAGAA AGAAG GAAGA AAGAC AGACG GACGG ACGGT CGGTA GGTAC GTACG TACGG ACGGG CGGGT GGGTA GGTAT GTATT TATTG ATTGT TTGTG TGTGC GTGCA TGCAT GCATA CATAC ATACC TACCG ACCGC CCGCT CGCTC GCTCC CTCCG TCCGG CCGGC CGGCA GGCAT GCATT CATTT ATTTG TTTGG TTGGT TGGTG GGTGC GTGCG TGCGG GCGGA CGGAT GGATG GATGA ATGAC TGACT GACTA ACTAC CTACA TACAA ACAAA CAAAG AAAGT AAGTG AGTGG GTGGG TGGGA GGGAC GGACA GACAG,CAATTG AATTGT ATTGTT TTGTTA TGTTAC GTTACC TTACCT TACCTT ACCTTA CCTTAT CTTATG TTATGA TATGAG ATGAGG TGAGGC GAGGCG AGGCGA GGCGAA GCGAAT CGAATA GAATAG AATAGC ATAGCG TAGCGC AGCGCT GCGCTG CGCTGC GCTGCG CTGCGC TGCGCA GCGCAG CGCAGG GCAGGC CAGGCA AGGCAG GGCAGG GCAGGT CAGGTG AGGTGG GGTGGC GTGGCG TGGCGA GGCGAT GCGATC CGATCC GATCCC ATCCCT TCCCTT CCCTTC CCTTCC CTTCCG TTCCGT TCCGTG CCGTGT CGTGTG GTGTGA TGTGAT GTGATC TGATCG GATCGT ATCGTA TCGTAG CGTAGG GTAGGC TAGGCG AGGCGA GGCGAT GCGATT CGATTT GATTTT ATTTTG TTTTGT TTTGTA TTGTAA TGTAAC GTAACA TAACAA AACAAC ACAACA CAACAG AACAGA ACAGAA CAGAAG AGAAGA GAAGAC AAGACG AGACGG GACGGT ACGGTA CGGTAC GGTACG GTACGG TACGGG ACGGGT CGGGTA GGGTAT GGTATT GTATTG TATTGT ATTGTG TTGTGC TGTGCA GTGCAT TGCATA GCATAC CATACC ATACCG TACCGC ACCGCT CCGCTC CGCTCC GCTCCG CTCCGG TCCGGC CCGGCA CGGCAT GGCATT GCATTT CATTTG ATTTGG TTTGGT TTGGTG TGGTGC GGTGCG GTGCGG TGCGGA GCGGAT CGGATG GGATGA GATGAC ATGACT TGACTA GACTAC ACTACA CTACAA TACAAA ACAAAG CAAAGT AAAGTG AAGTGG AGTGGG GTGGGA TGGGAC GGGACA GGACAG,CAATTGT AATTGTT ATTGTTA TTGTTAC TGTTACC GTTACCT TTACCTT TACCTTA ACCTTAT CCTTATG CTTATGA TTATGAG TATGAGG ATGAGGC TGAGGCG GAGGCGA AGGCGAA GGCGAAT GCGAATA CGAATAG GAATAGC AATAGCG ATAGCGC TAGCGCT AGCGCTG GCGCTGC CGCTGCG GCTGCGC CTGCGCA TGCGCAG GCGCAGG CGCAGGC GCAGGCA CAGGCAG AGGCAGG GGCAGGT GCAGGTG CAGGTGG AGGTGGC GGTGGCG GTGGCGA TGGCGAT GGCGATC GCGATCC CGATCCC GATCCCT ATCCCTT TCCCTTC CCCTTCC CCTTCCG CTTCCGT TTCCGTG TCCGTGT CCGTGTG CGTGTGA GTGTGAT TGTGATC GTGATCG TGATCGT GATCGTA ATCGTAG TCGTAGG CGTAGGC GTAGGCG TAGGCGA AGGCGAT GGCGATT GCGATTT CGATTTT GATTTTG ATTTTGT TTTTGTA TTTGTAA TTGTAAC TGTAACA GTAACAA TAACAAC AACAACA ACAACAG CAACAGA AACAGAA ACAGAAG CAGAAGA AGAAGAC GAAGACG AAGACGG AGACGGT GACGGTA ACGGTAC CGGTACG GGTACGG GTACGGG TACGGGT ACGGGTA CGGGTAT GGGTATT GGTATTG GTATTGT TATTGTG ATTGTGC TTGTGCA TGTGCAT GTGCATA TGCATAC GCATACC CATACCG ATACCGC TACCGCT ACCGCTC CCGCTCC CGCTCCG GCTCCGG CTCCGGC TCCGGCA CCGGCAT CGGCATT GGCATTT GCATTTG CATTTGG ATTTGGT TTTGGTG TTGGTGC TGGTGCG GGTGCGG GTGCGGA TGCGGAT GCGGATG CGGATGA GGATGAC GATGACT ATGACTA TGACTAC GACTACA ACTACAA CTACAAA TACAAAG ACAAAGT CAAAGTG AAAGTGG AAGTGGG AGTGGGA GTGGGAC TGGGACA GGGACAG,"ID   SYI_TREDE               Reviewed;        1100 AA.
AC   Q73JB2;
DT   20-DEC-2005, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   05-FEB-2025, entry version 118.
DE   RecName: Full=Isoleucine--tRNA ligase {ECO:0000255|HAMAP-Rule:MF_02003};
DE            EC=6.1.1.5 {ECO:0000255|HAMAP-Rule:MF_02003};
DE   AltName: Full=Isoleucyl-tRNA synthetase {ECO:0000255|HAMAP-Rule:MF_02003};
DE            Short=IleRS {ECO:0000255|HAMAP-Rule:MF_02003};
GN   Name=ileS {ECO:0000255|HAMAP-Rule:MF_02003};
GN   OrderedLocusNames=TDE_2663;
OS   Treponema denticola (strain ATCC 35405 / DSM 14222 / CIP 103919 / JCM 8153
OS   / KCTC 15104).
OC   Bacteria; Spirochaetota; Spirochaetia; Spirochaetales; Treponemataceae;
OC   Treponema.
OX   NCBI_TaxID=243275;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 35405 / DSM 14222 / CIP 103919 / JCM 8153 / KCTC 15104;
RX   PubMed=15064399; DOI=10.1073/pnas.0307639101;
RA   Seshadri R., Myers G.S.A., Tettelin H., Eisen J.A., Heidelberg J.F.,
RA   Dodson R.J., Davidsen T.M., DeBoy R.T., Fouts D.E., Haft D.H., Selengut J.,
RA   Ren Q., Brinkac L.M., Madupu R., Kolonay J.F., Durkin S.A., Daugherty S.C.,
RA   Shetty J., Shvartsbeyn A., Gebregeorgis E., Geer K., Tsegaye G.,
RA   Malek J.A., Ayodeji B., Shatsman S., McLeod M.P., Smajs D., Howell J.K.,
RA   Pal S., Amin A., Vashisth P., McNeill T.Z., Xiang Q., Sodergren E.,
RA   Baca E., Weinstock G.M., Norris S.J., Fraser C.M., Paulsen I.T.;
RT   ""Comparison of the genome of the oral pathogen Treponema denticola with
RT   other spirochete genomes."";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:5646-5651(2004).
CC   -!- FUNCTION: Catalyzes the attachment of isoleucine to tRNA(Ile). As IleRS
CC       can inadvertently accommodate and process structurally similar amino
CC       acids such as valine, to avoid such errors it has two additional
CC       distinct tRNA(Ile)-dependent editing activities. One activity is
CC       designated as 'pretransfer' editing and involves the hydrolysis of
CC       activated Val-AMP. The other activity is designated 'posttransfer'
CC       editing and involves deacylation of mischarged Val-tRNA(Ile).
CC       {ECO:0000255|HAMAP-Rule:MF_02003}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=tRNA(Ile) + L-isoleucine + ATP = L-isoleucyl-tRNA(Ile) + AMP +
CC         diphosphate; Xref=Rhea:RHEA:11060, Rhea:RHEA-COMP:9666, Rhea:RHEA-
CC         COMP:9695, ChEBI:CHEBI:30616, ChEBI:CHEBI:33019, ChEBI:CHEBI:58045,
CC         ChEBI:CHEBI:78442, ChEBI:CHEBI:78528, ChEBI:CHEBI:456215; EC=6.1.1.5;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_02003};
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_02003};
CC   -!- SUBUNIT: Monomer. {ECO:0000255|HAMAP-Rule:MF_02003}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000255|HAMAP-Rule:MF_02003}.
CC   -!- DOMAIN: IleRS has two distinct active sites: one for aminoacylation and
CC       one for editing. The misactivated valine is translocated from the
CC       active site to the editing site, which sterically excludes the
CC       correctly activated isoleucine. The single editing site contains two
CC       valyl binding pockets, one specific for each substrate (Val-AMP or Val-
CC       tRNA(Ile)). {ECO:0000255|HAMAP-Rule:MF_02003}.
CC   -!- SIMILARITY: Belongs to the class-I aminoacyl-tRNA synthetase family.
CC       IleS type 2 subfamily. {ECO:0000255|HAMAP-Rule:MF_02003}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AE017226; AAS13180.1; -; Genomic_DNA.
DR   RefSeq; NP_973261.1; NC_002967.9.
DR   RefSeq; WP_002680710.1; NC_002967.9.
DR   AlphaFoldDB; Q73JB2; -.
DR   SMR; Q73JB2; -.
DR   STRING; 243275.TDE_2663; -.
DR   PaxDb; 243275-TDE_2663; -.
DR   GeneID; 2741108; -.
DR   KEGG; tde:TDE_2663; -.
DR   PATRIC; fig|243275.7.peg.2517; -.
DR   eggNOG; COG0060; Bacteria.
DR   HOGENOM; CLU_001493_1_1_12; -.
DR   OrthoDB; 9810365at2; -.
DR   Proteomes; UP000008212; Chromosome.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0002161; F:aminoacyl-tRNA editing activity; IEA:InterPro.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0004822; F:isoleucine-tRNA ligase activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0000049; F:tRNA binding; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0006428; P:isoleucyl-tRNA aminoacylation; IEA:UniProtKB-UniRule.
DR   CDD; cd07961; Anticodon_Ia_Ile_ABEc; 1.
DR   CDD; cd00818; IleRS_core; 1.
DR   FunFam; 3.40.50.620:FF:000063; Isoleucine--tRNA ligase; 1.
DR   FunFam; 3.40.50.620:FF:000133; Isoleucyl-tRNA synthetase, cytoplasmic; 1.
DR   Gene3D; 3.40.50.620; HUPs; 2.
DR   Gene3D; 1.10.730.10; Isoleucyl-tRNA Synthetase, Domain 1; 1.
DR   HAMAP; MF_02003; Ile_tRNA_synth_type2; 1.
DR   InterPro; IPR002300; aa-tRNA-synth_Ia.
DR   InterPro; IPR033709; Anticodon_Ile_ABEc.
DR   InterPro; IPR002301; Ile-tRNA-ligase.
DR   InterPro; IPR023586; Ile-tRNA-ligase_type2.
DR   InterPro; IPR013155; M/V/L/I-tRNA-synth_anticd-bd.
DR   InterPro; IPR014729; Rossmann-like_a/b/a_fold.
DR   InterPro; IPR009080; tRNAsynth_Ia_anticodon-bd.
DR   InterPro; IPR009008; Val/Leu/Ile-tRNA-synth_edit.
DR   NCBIfam; TIGR00392; ileS; 1.
DR   PANTHER; PTHR42780:SF1; ISOLEUCINE--TRNA LIGASE, CYTOPLASMIC; 1.
DR   PANTHER; PTHR42780; SOLEUCYL-TRNA SYNTHETASE; 1.
DR   Pfam; PF08264; Anticodon_1; 1.
DR   Pfam; PF19302; DUF5915; 1.
DR   Pfam; PF00133; tRNA-synt_1; 1.
DR   PRINTS; PR00984; TRNASYNTHILE.
DR   SUPFAM; SSF47323; Anticodon-binding domain of a subclass of class I aminoacyl-tRNA synthetases; 1.
DR   SUPFAM; SSF52374; Nucleotidylyl transferase; 1.
DR   SUPFAM; SSF50677; ValRS/IleRS/LeuRS editing domain; 1.
PE   3: Inferred from homology;
KW   Aminoacyl-tRNA synthetase; ATP-binding; Cytoplasm; Ligase; Metal-binding;
KW   Nucleotide-binding; Protein biosynthesis; Reference proteome; Zinc.
FT   CHAIN           1..1100
FT                   /note=""Isoleucine--tRNA ligase""
FT                   /id=""PRO_0000098568""
FT   MOTIF           48..58
FT                   /note=""'HIGH' region""
FT   MOTIF           626..630
FT                   /note=""'KMSKS' region""
FT   BINDING         629
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_02003""
SQ   SEQUENCE   1100 AA;  125760 MW;  90A17F4C6F320E8D CRC64;
     MYKPVDPKVD FAKQEEDVLK FWEKNDVFKK SVSSRDGRDN YIFFDGPPFA TGLPHFGHFV
     PGTIKDIIPR YKTMKGFRVE RRFGWDCHGL PVENLIEKEL GLNSKTDIEK YGIDKFNEAC
     RASVLRYVKE WKQTITRLGR WVDFENDYKT MEPAFMESIW WVMKSLWEKG LLYEGYYILP
     YCPRCSTVLS NHELNLGGYK DVHDPAITVR FKTLSPVKTS PAGKAFEGKN ALPSDTYLLA
     WTTTPWTLPS NLGLAVGADI DYALIEYDGA HYIMAVPRLE AYFAKSGKEE AKEYKLIWTK
     KGAELEGLRY EPLFPYFKNL AADENGKNAE AGQGAFRVLI GDFVTTEDGT GIVHTAPGFG
     EDDNRIFKDT GVPTVCPVDA ECKFTHEVSD YQGLFVKDAD KQIMERLKTE GKLFKKAQIL
     HSYPHCWRCS SPLIYRAVAS WFVSVTKIKD KLLNANSKIN WQPDHIKTGR FGKWLEGARD
     WAISRNRYWG NPIPIWKCPD CGETICVGSR EELKELSGVF PEDMHKHFVD KISIPCKKCG
     GTMKRVSEVL DCWFESGSMP YAQQHYPFEN KEHFEKNFPA DFISEGLDQT RGWFYTLTIL
     AAALFDEPAF KNCIVNGLVL AEDGKKMSKS LRNYTDPNEV IKQFGADALR LFLMNSNVVK
     ADDLKYSDEG VRDVLKGILI PFWNSYSFYI TYANIDGVKP PHNAKVDGKD EGVEEFLAKL
     NNPLDLWILS VTEKLVADVT EALDKYDLSQ AIPPMVEYID LLNNWYIRRS RRRFWKSEND
     GDKSQAYETL YRALKKFSLV AAPVVPFITE SIWQNLRTES DALSIHLADY PDYNEKIRNS
     ELEFKMKTVQ KAVSMGRALR YQFNLKIRQP LKAVEIVTLN PEEKRVLLEM EESIIEELNV
     KEVIFHEKED ELVEYSAKAN FKVLGKELGP LMKKAAAIIE QMNSSEIQNI MEGATLSIDI
     EGKSVEITAD KIVINRIEKA SLKIVNEGTL TVGLNTELTE ELLMEGYIRD LVRGIQTLRK
     ECGLDVTDRI KLYLSASQKN ADNKELEKAF ELFKDYVCDE TLTVQSSWLK TGELTKLGSI
     KTSLVEAGDY EWEIGIEKNN
//
",45814
GCCCTG CCCTGG CCTGGC CTGGCC TGGCCG GGCCGC GCCGCC CCGCCA CGCCAA GCCAAC CCAACG CAACGC AACGCT ACGCTG CGCTGC GCTGCA CTGCAC TGCACA GCACAC CACACG ACACGA CACGAG ACGAGC CGAGCT GAGCTG AGCTGC GCTGCG CTGCGC TGCGCA GCGCAC CGCACG GCACGC CACGCC ACGCCG CGCCGC GCCGCT CCGCTG CGCTGG GCTGGC CTGGCC TGGCCA GGCCAC GCCACA CCACAG CACAGT ACAGTG CAGTGC AGTGCG GTGCGC TGCGCC GCGCCT CGCCTG GCCTGC CCTGCA CTGCAC TGCACC GCACCT CACCTG ACCTGC CCTGCA CTGCAA TGCAAA GCAAAC CAAACA AAACAG AACAGC ACAGCG CAGCGC AGCGCT GCGCTC CGCTCG GCTCGG CTCGGC TCGGCC CGGCCA GGCCAC GCCACG CCACGG CACGGG ACGGGC CGGGCA GGGCAG GGCAGG GCAGGC CAGGCA AGGCAC GGCACA GCACAG CACAGG ACAGGC CAGGCC AGGCCG GGCCGC GCCGCA CCGCAC CGCACG GCACGA CACGAG ACGAGA CGAGAG GAGAGG AGAGGG GAGGGC AGGGCT GGGCTT GGCTTG GCTTGC CTTGCA TTGCAC TGCACG GCACGA CACGAG ACGAGG CGAGGC GAGGCA AGGCAC GGCACT GCACTC CACTCC ACTCCA CTCCAT TCCATT CCATTC CATTCA ATTCAC TTCACT TCACTG CACTGG ACTGGA CTGGAG TGGAGC GGAGCG GAGCGC AGCGCC GCGCCT CGCCTC GCCTCA CCTCAG CTCAGC TCAGCC CAGCCG AGCCGT GCCGTC CCGTCG CGTCGC,3,145,GCCC CCCT CCTG CTGG TGGC GGCC GCCG CCGC CGCC GCCA CCAA CAAC AACG ACGC CGCT GCTG CTGC TGCA GCAC CACA ACAC CACG ACGA CGAG GAGC AGCT GCTG CTGC TGCG GCGC CGCA GCAC CACG ACGC CGCC GCCG CCGC CGCT GCTG CTGG TGGC GGCC GCCA CCAC CACA ACAG CAGT AGTG GTGC TGCG GCGC CGCC GCCT CCTG CTGC TGCA GCAC CACC ACCT CCTG CTGC TGCA GCAA CAAA AAAC AACA ACAG CAGC AGCG GCGC CGCT GCTC CTCG TCGG CGGC GGCC GCCA CCAC CACG ACGG CGGG GGGC GGCA GCAG CAGG AGGC GGCA GCAC CACA ACAG CAGG AGGC GGCC GCCG CCGC CGCA GCAC CACG ACGA CGAG GAGA AGAG GAGG AGGG GGGC GGCT GCTT CTTG TTGC TGCA GCAC CACG ACGA CGAG GAGG AGGC GGCA GCAC CACT ACTC CTCC TCCA CCAT CATT ATTC TTCA TCAC CACT ACTG CTGG TGGA GGAG GAGC AGCG GCGC CGCC GCCT CCTC CTCA TCAG CAGC AGCC GCCG CCGT CGTC GTCG TCGC,GCCCT CCCTG CCTGG CTGGC TGGCC GGCCG GCCGC CCGCC CGCCA GCCAA CCAAC CAACG AACGC ACGCT CGCTG GCTGC CTGCA TGCAC GCACA CACAC ACACG CACGA ACGAG CGAGC GAGCT AGCTG GCTGC CTGCG TGCGC GCGCA CGCAC GCACG CACGC ACGCC CGCCG GCCGC CCGCT CGCTG GCTGG CTGGC TGGCC GGCCA GCCAC CCACA CACAG ACAGT CAGTG AGTGC GTGCG TGCGC GCGCC CGCCT GCCTG CCTGC CTGCA TGCAC GCACC CACCT ACCTG CCTGC CTGCA TGCAA GCAAA CAAAC AAACA AACAG ACAGC CAGCG AGCGC GCGCT CGCTC GCTCG CTCGG TCGGC CGGCC GGCCA GCCAC CCACG CACGG ACGGG CGGGC GGGCA GGCAG GCAGG CAGGC AGGCA GGCAC GCACA CACAG ACAGG CAGGC AGGCC GGCCG GCCGC CCGCA CGCAC GCACG CACGA ACGAG CGAGA GAGAG AGAGG GAGGG AGGGC GGGCT GGCTT GCTTG CTTGC TTGCA TGCAC GCACG CACGA ACGAG CGAGG GAGGC AGGCA GGCAC GCACT CACTC ACTCC CTCCA TCCAT CCATT CATTC ATTCA TTCAC TCACT CACTG ACTGG CTGGA TGGAG GGAGC GAGCG AGCGC GCGCC CGCCT GCCTC CCTCA CTCAG TCAGC CAGCC AGCCG GCCGT CCGTC CGTCG GTCGC,GCCCTG CCCTGG CCTGGC CTGGCC TGGCCG GGCCGC GCCGCC CCGCCA CGCCAA GCCAAC CCAACG CAACGC AACGCT ACGCTG CGCTGC GCTGCA CTGCAC TGCACA GCACAC CACACG ACACGA CACGAG ACGAGC CGAGCT GAGCTG AGCTGC GCTGCG CTGCGC TGCGCA GCGCAC CGCACG GCACGC CACGCC ACGCCG CGCCGC GCCGCT CCGCTG CGCTGG GCTGGC CTGGCC TGGCCA GGCCAC GCCACA CCACAG CACAGT ACAGTG CAGTGC AGTGCG GTGCGC TGCGCC GCGCCT CGCCTG GCCTGC CCTGCA CTGCAC TGCACC GCACCT CACCTG ACCTGC CCTGCA CTGCAA TGCAAA GCAAAC CAAACA AAACAG AACAGC ACAGCG CAGCGC AGCGCT GCGCTC CGCTCG GCTCGG CTCGGC TCGGCC CGGCCA GGCCAC GCCACG CCACGG CACGGG ACGGGC CGGGCA GGGCAG GGCAGG GCAGGC CAGGCA AGGCAC GGCACA GCACAG CACAGG ACAGGC CAGGCC AGGCCG GGCCGC GCCGCA CCGCAC CGCACG GCACGA CACGAG ACGAGA CGAGAG GAGAGG AGAGGG GAGGGC AGGGCT GGGCTT GGCTTG GCTTGC CTTGCA TTGCAC TGCACG GCACGA CACGAG ACGAGG CGAGGC GAGGCA AGGCAC GGCACT GCACTC CACTCC ACTCCA CTCCAT TCCATT CCATTC CATTCA ATTCAC TTCACT TCACTG CACTGG ACTGGA CTGGAG TGGAGC GGAGCG GAGCGC AGCGCC GCGCCT CGCCTC GCCTCA CCTCAG CTCAGC TCAGCC CAGCCG AGCCGT GCCGTC CCGTCG CGTCGC,GCCCTGG CCCTGGC CCTGGCC CTGGCCG TGGCCGC GGCCGCC GCCGCCA CCGCCAA CGCCAAC GCCAACG CCAACGC CAACGCT AACGCTG ACGCTGC CGCTGCA GCTGCAC CTGCACA TGCACAC GCACACG CACACGA ACACGAG CACGAGC ACGAGCT CGAGCTG GAGCTGC AGCTGCG GCTGCGC CTGCGCA TGCGCAC GCGCACG CGCACGC GCACGCC CACGCCG ACGCCGC CGCCGCT GCCGCTG CCGCTGG CGCTGGC GCTGGCC CTGGCCA TGGCCAC GGCCACA GCCACAG CCACAGT CACAGTG ACAGTGC CAGTGCG AGTGCGC GTGCGCC TGCGCCT GCGCCTG CGCCTGC GCCTGCA CCTGCAC CTGCACC TGCACCT GCACCTG CACCTGC ACCTGCA CCTGCAA CTGCAAA TGCAAAC GCAAACA CAAACAG AAACAGC AACAGCG ACAGCGC CAGCGCT AGCGCTC GCGCTCG CGCTCGG GCTCGGC CTCGGCC TCGGCCA CGGCCAC GGCCACG GCCACGG CCACGGG CACGGGC ACGGGCA CGGGCAG GGGCAGG GGCAGGC GCAGGCA CAGGCAC AGGCACA GGCACAG GCACAGG CACAGGC ACAGGCC CAGGCCG AGGCCGC GGCCGCA GCCGCAC CCGCACG CGCACGA GCACGAG CACGAGA ACGAGAG CGAGAGG GAGAGGG AGAGGGC GAGGGCT AGGGCTT GGGCTTG GGCTTGC GCTTGCA CTTGCAC TTGCACG TGCACGA GCACGAG CACGAGG ACGAGGC CGAGGCA GAGGCAC AGGCACT GGCACTC GCACTCC CACTCCA ACTCCAT CTCCATT TCCATTC CCATTCA CATTCAC ATTCACT TTCACTG TCACTGG CACTGGA ACTGGAG CTGGAGC TGGAGCG GGAGCGC GAGCGCC AGCGCCT GCGCCTC CGCCTCA GCCTCAG CCTCAGC CTCAGCC TCAGCCG CAGCCGT AGCCGTC GCCGTCG CCGTCGC,"ID   BASS_ECOLI              Reviewed;         363 AA.
AC   P30844; Q2M6J2;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1993, sequence version 1.
DT   27-NOV-2024, entry version 191.
DE   RecName: Full=Sensor protein BasS;
DE            EC=2.7.13.3;
GN   Name=basS; Synonyms=pmrB; OrderedLocusNames=b4112, JW4073;
OS   Escherichia coli (strain K12).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Enterobacterales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=83333;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=K12;
RX   PubMed=8282725; DOI=10.1093/oxfordjournals.jbchem.a124180;
RA   Nagasawa S., Ishige K., Mizuno T.;
RT   ""Novel members of the two-component signal transduction genes in
RT   Escherichia coli."";
RL   J. Biochem. 114:350-357(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=7610040; DOI=10.1093/nar/23.12.2105;
RA   Burland V.D., Plunkett G. III, Sofia H.J., Daniels D.L., Blattner F.R.;
RT   ""Analysis of the Escherichia coli genome VI: DNA sequence of the region
RT   from 92.8 through 100 minutes."";
RL   Nucleic Acids Res. 23:2105-2119(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=9278503; DOI=10.1126/science.277.5331.1453;
RA   Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,
RA   Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,
RA   Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J., Mau B.,
RA   Shao Y.;
RT   ""The complete genome sequence of Escherichia coli K-12."";
RL   Science 277:1453-1462(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=16738553; DOI=10.1038/msb4100049;
RA   Hayashi K., Morooka N., Yamamoto Y., Fujita K., Isono K., Choi S.,
RA   Ohtsubo E., Baba T., Wanner B.L., Mori H., Horiuchi T.;
RT   ""Highly accurate genome sequences of Escherichia coli K-12 strains MG1655
RT   and W3110."";
RL   Mol. Syst. Biol. 2:E1-E5(2006).
RN   [5]
RP   FUNCTION, AND AUTOPHOSPHORYLATION.
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=15522865; DOI=10.1074/jbc.m410104200;
RA   Yamamoto K., Hirao K., Oshima T., Aiba H., Utsumi R., Ishihama A.;
RT   ""Functional characterization in vitro of all two-component signal
RT   transduction systems from Escherichia coli."";
RL   J. Biol. Chem. 280:1448-1456(2005).
RN   [6]
RP   TOPOLOGY [LARGE SCALE ANALYSIS].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=15919996; DOI=10.1126/science.1109730;
RA   Daley D.O., Rapp M., Granseth E., Melen K., Drew D., von Heijne G.;
RT   ""Global topology analysis of the Escherichia coli inner membrane
RT   proteome."";
RL   Science 308:1321-1323(2005).
CC   -!- FUNCTION: Member of the two-component regulatory system BasS/BasR
CC       Autophosphorylates and activates BasR by phosphorylation.
CC       {ECO:0000269|PubMed:15522865}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + protein L-histidine = ADP + protein N-phospho-L-
CC         histidine.; EC=2.7.13.3;
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane; Multi-pass membrane protein.
CC   -!- INDUCTION: The eptA-basRS operon is positively autoregulated by BasR
CC       under high iron or aluminum concentration conditions. {ECO:0000250}.
CC   -!- PTM: Autophosphorylated.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D14055; BAA03144.1; -; Genomic_DNA.
DR   EMBL; U14003; AAA97011.1; -; Genomic_DNA.
DR   EMBL; U00096; AAC77073.1; -; Genomic_DNA.
DR   EMBL; AP009048; BAE78114.1; -; Genomic_DNA.
DR   PIR; JX0285; JX0285.
DR   RefSeq; NP_418536.1; NC_000913.3.
DR   AlphaFoldDB; P30844; -.
DR   SMR; P30844; -.
DR   BioGRID; 4263084; 7.
DR   DIP; DIP-9202N; -.
DR   IntAct; P30844; 4.
DR   STRING; 511145.b4112; -.
DR   jPOST; P30844; -.
DR   PaxDb; 511145-b4112; -.
DR   EnsemblBacteria; AAC77073; AAC77073; b4112.
DR   GeneID; 948632; -.
DR   KEGG; ecj:JW4073; -.
DR   KEGG; eco:b4112; -.
DR   KEGG; ecoc:C3026_22220; -.
DR   PATRIC; fig|83333.103.peg.419; -.
DR   EchoBASE; EB1571; -.
DR   eggNOG; COG0642; Bacteria.
DR   HOGENOM; CLU_000445_89_37_6; -.
DR   InParanoid; P30844; -.
DR   OMA; QLISVFW; -.
DR   OrthoDB; 9809766at2; -.
DR   PhylomeDB; P30844; -.
DR   BioCyc; EcoCyc:BASS-MONOMER; -.
DR   BioCyc; MetaCyc:BASS-MONOMER; -.
DR   BRENDA; 2.7.13.3; 2026.
DR   PRO; PR:P30844; -.
DR   Proteomes; UP000000318; Chromosome.
DR   Proteomes; UP000000625; Chromosome.
DR   GO; GO:0005886; C:plasma membrane; IDA:EcoCyc.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004721; F:phosphoprotein phosphatase activity; IDA:EcoCyc.
DR   GO; GO:0000155; F:phosphorelay sensor kinase activity; IDA:EcoCyc.
DR   GO; GO:0004673; F:protein histidine kinase activity; IDA:EcoCyc.
DR   GO; GO:0000160; P:phosphorelay signal transduction system; IBA:GO_Central.
DR   GO; GO:0010041; P:response to iron(III) ion; IDA:EcoCyc.
DR   GO; GO:0010043; P:response to zinc ion; IEP:EcoCyc.
DR   GO; GO:0007165; P:signal transduction; IDA:EcoCyc.
DR   CDD; cd16940; HATPase_BasS-like; 1.
DR   CDD; cd00082; HisKA; 1.
DR   FunFam; 1.10.287.130:FF:000026; Two-component system sensor histidine kinase PmrB; 1.
DR   Gene3D; 1.10.287.130; -; 1.
DR   Gene3D; 6.10.340.10; -; 1.
DR   Gene3D; 3.30.565.10; Histidine kinase-like ATPase, C-terminal domain; 1.
DR   InterPro; IPR003660; HAMP_dom.
DR   InterPro; IPR036890; HATPase_C_sf.
DR   InterPro; IPR003594; HATPase_dom.
DR   InterPro; IPR005467; His_kinase_dom.
DR   InterPro; IPR003661; HisK_dim/P_dom.
DR   InterPro; IPR036097; HisK_dim/P_sf.
DR   InterPro; IPR004358; Sig_transdc_His_kin-like_C.
DR   InterPro; IPR050428; TCS_sensor_his_kinase.
DR   PANTHER; PTHR45436; SENSOR HISTIDINE KINASE YKOH; 1.
DR   PANTHER; PTHR45436:SF7; SENSOR PROTEIN BASS; 1.
DR   Pfam; PF02518; HATPase_c; 1.
DR   Pfam; PF00512; HisKA; 1.
DR   PRINTS; PR00344; BCTRLSENSOR.
DR   SMART; SM00304; HAMP; 1.
DR   SMART; SM00387; HATPase_c; 1.
DR   SMART; SM00388; HisKA; 1.
DR   SUPFAM; SSF55874; ATPase domain of HSP90 chaperone/DNA topoisomerase II/histidine kinase; 1.
DR   SUPFAM; SSF47384; Homodimeric domain of signal transducing histidine kinase; 1.
DR   PROSITE; PS50885; HAMP; 1.
DR   PROSITE; PS50109; HIS_KIN; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Cell inner membrane; Cell membrane; Kinase; Membrane;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome; Transferase;
KW   Transmembrane; Transmembrane helix; Two-component regulatory system.
FT   CHAIN           1..363
FT                   /note=""Sensor protein BasS""
FT                   /id=""PRO_0000074701""
FT   TOPO_DOM        1..13
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        14..34
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TOPO_DOM        35..64
FT                   /note=""Periplasmic""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        65..88
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TOPO_DOM        89..363
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000255""
FT   DOMAIN          89..141
FT                   /note=""HAMP""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00102""
FT   DOMAIN          149..357
FT                   /note=""Histidine kinase""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00107""
FT   MOD_RES         152
FT                   /note=""Phosphohistidine; by autocatalysis""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00107""
SQ   SEQUENCE   363 AA;  41029 MW;  A390AAB9EB425750 CRC64;
     MHFLRRPISL RQRLILTIGA ILLVFELISV FWLWHESTEQ IQLFEQALRD NRNNDRHIMR
     EIREAVASLI VPGVFMVSLT LFICYQAVRR ITRPLAELQK ELEARTADNL TPIAIHSATL
     EIEAVVSALN DLVSRLTSTL DNERLFTADV AHELRTPLAG VRLHLELLAK THHIDVAPLV
     ARLDQMMESV SQLLQLARAG QSFSSGNYQH VKLLEDVILP SYDELSTMLD QRQQTLLLPE
     SAADITVQGD ATLLRMLLRN LVENAHRYSP QGSNIMIKLQ EDDGAVMAVE DEGPGIDESK
     CGELSKAFVR MDSRYGGIGL GLSIVSRITQ LHHGQFFLQN RQETSGTRAW VRLKKDQYVA
     NQI
//
",26760
CGGTAT GGTATT GTATTT TATTTA ATTTAA TTTAAC TTAACC TAACCG AACCGA ACCGAC CCGACA CGACAA GACAAG ACAAGG CAAGGA AAGGAA AGGAAT GGAATT GAATTT AATTTC ATTTCG TTTCGC TTCGCT TCGCTA CGCTAC GCTACC CTACCT TACCTT ACCTTA CCTTAG CTTAGG TTAGGA TAGGAC AGGACC GGACCG GACCGT ACCGTT CCGTTA CGTTAT GTTATA TTATAG TATAGT ATAGTT TAGTTA AGTTAC GTTACG TTACGG TACGGC ACGGCC CGGCCG GGCCGC GCCGCC CCGCCG CGCCGT GCCGTT CCGTTT CGTTTA GTTTAC TTTACT TTACTC TACTCG ACTCGG CTCGGG TCGGGC CGGGCT GGGCTT GGCTTC GCTTCA CTTCAA TTCAAT TCAATC CAATCA AATCAA ATCAAA TCAAAT CAAATG AAATGC AATGCT ATGCTT TGCTTC GCTTCG CTTCGC TTCGCT TCGCTT CGCTTG GCTTGC CTTGCG TTGCGC TGCGCT GCGCTG CGCTGA,3,91,CGGT GGTA GTAT TATT ATTT TTTA TTAA TAAC AACC ACCG CCGA CGAC GACA ACAA CAAG AAGG AGGA GGAA GAAT AATT ATTT TTTC TTCG TCGC CGCT GCTA CTAC TACC ACCT CCTT CTTA TTAG TAGG AGGA GGAC GACC ACCG CCGT CGTT GTTA TTAT TATA ATAG TAGT AGTT GTTA TTAC TACG ACGG CGGC GGCC GCCG CCGC CGCC GCCG CCGT CGTT GTTT TTTA TTAC TACT ACTC CTCG TCGG CGGG GGGC GGCT GCTT CTTC TTCA TCAA CAAT AATC ATCA TCAA CAAA AAAT AATG ATGC TGCT GCTT CTTC TTCG TCGC CGCT GCTT CTTG TTGC TGCG GCGC CGCT GCTG CTGA,CGGTA GGTAT GTATT TATTT ATTTA TTTAA TTAAC TAACC AACCG ACCGA CCGAC CGACA GACAA ACAAG CAAGG AAGGA AGGAA GGAAT GAATT AATTT ATTTC TTTCG TTCGC TCGCT CGCTA GCTAC CTACC TACCT ACCTT CCTTA CTTAG TTAGG TAGGA AGGAC GGACC GACCG ACCGT CCGTT CGTTA GTTAT TTATA TATAG ATAGT TAGTT AGTTA GTTAC TTACG TACGG ACGGC CGGCC GGCCG GCCGC CCGCC CGCCG GCCGT CCGTT CGTTT GTTTA TTTAC TTACT TACTC ACTCG CTCGG TCGGG CGGGC GGGCT GGCTT GCTTC CTTCA TTCAA TCAAT CAATC AATCA ATCAA TCAAA CAAAT AAATG AATGC ATGCT TGCTT GCTTC CTTCG TTCGC TCGCT CGCTT GCTTG CTTGC TTGCG TGCGC GCGCT CGCTG GCTGA,CGGTAT GGTATT GTATTT TATTTA ATTTAA TTTAAC TTAACC TAACCG AACCGA ACCGAC CCGACA CGACAA GACAAG ACAAGG CAAGGA AAGGAA AGGAAT GGAATT GAATTT AATTTC ATTTCG TTTCGC TTCGCT TCGCTA CGCTAC GCTACC CTACCT TACCTT ACCTTA CCTTAG CTTAGG TTAGGA TAGGAC AGGACC GGACCG GACCGT ACCGTT CCGTTA CGTTAT GTTATA TTATAG TATAGT ATAGTT TAGTTA AGTTAC GTTACG TTACGG TACGGC ACGGCC CGGCCG GGCCGC GCCGCC CCGCCG CGCCGT GCCGTT CCGTTT CGTTTA GTTTAC TTTACT TTACTC TACTCG ACTCGG CTCGGG TCGGGC CGGGCT GGGCTT GGCTTC GCTTCA CTTCAA TTCAAT TCAATC CAATCA AATCAA ATCAAA TCAAAT CAAATG AAATGC AATGCT ATGCTT TGCTTC GCTTCG CTTCGC TTCGCT TCGCTT CGCTTG GCTTGC CTTGCG TTGCGC TGCGCT GCGCTG CGCTGA,CGGTATT GGTATTT GTATTTA TATTTAA ATTTAAC TTTAACC TTAACCG TAACCGA AACCGAC ACCGACA CCGACAA CGACAAG GACAAGG ACAAGGA CAAGGAA AAGGAAT AGGAATT GGAATTT GAATTTC AATTTCG ATTTCGC TTTCGCT TTCGCTA TCGCTAC CGCTACC GCTACCT CTACCTT TACCTTA ACCTTAG CCTTAGG CTTAGGA TTAGGAC TAGGACC AGGACCG GGACCGT GACCGTT ACCGTTA CCGTTAT CGTTATA GTTATAG TTATAGT TATAGTT ATAGTTA TAGTTAC AGTTACG GTTACGG TTACGGC TACGGCC ACGGCCG CGGCCGC GGCCGCC GCCGCCG CCGCCGT CGCCGTT GCCGTTT CCGTTTA CGTTTAC GTTTACT TTTACTC TTACTCG TACTCGG ACTCGGG CTCGGGC TCGGGCT CGGGCTT GGGCTTC GGCTTCA GCTTCAA CTTCAAT TTCAATC TCAATCA CAATCAA AATCAAA ATCAAAT TCAAATG CAAATGC AAATGCT AATGCTT ATGCTTC TGCTTCG GCTTCGC CTTCGCT TTCGCTT TCGCTTG CGCTTGC GCTTGCG CTTGCGC TTGCGCT TGCGCTG GCGCTGA,"ID   YCX91_PHAAO             Reviewed;          91 AA.
AC   Q3BAI2;
DT   25-JUL-2006, integrated into UniProtKB/Swiss-Prot.
DT   22-NOV-2005, sequence version 1.
DT   05-FEB-2025, entry version 27.
DE   RecName: Full=Uncharacterized protein ORF91;
OS   Phalaenopsis aphrodite subsp. formosana (Moth orchid).
OG   Plastid; Chloroplast.
OC   Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC   Spermatophyta; Magnoliopsida; Liliopsida; Asparagales; Orchidaceae;
OC   Epidendroideae; Vandeae; Aeridinae; Phalaenopsis.
OX   NCBI_TaxID=308872;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=cv. Taisugar TS-97;
RX   PubMed=16207935; DOI=10.1093/molbev/msj029;
RA   Chang C.-C., Lin H.-C., Lin I.-P., Chow T.-Y., Chen H.-H., Chen W.-H.,
RA   Cheng C.-H., Lin C.-Y., Liu S.-M., Chang C.-C., Chaw S.-M.;
RT   ""The chloroplast genome of Phalaenopsis aphrodite (Orchidaceae):
RT   comparative analysis of evolutionary rate with that of grasses and its
RT   phylogenetic implications."";
RL   Mol. Biol. Evol. 23:279-291(2006).
CC   -!- SUBCELLULAR LOCATION: Plastid, chloroplast.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY916449; AAW82572.1; -; Genomic_DNA.
DR   RefSeq; YP_358636.1; NC_007499.1.
DR   AlphaFoldDB; Q3BAI2; -.
DR   GeneID; 3741793; -.
DR   GO; GO:0009507; C:chloroplast; IEA:UniProtKB-SubCell.
DR   AntiFam; ANF00025; Antisense to 23S rRNA.
PE   4: Predicted;
KW   Chloroplast; Plastid.
FT   CHAIN           1..91
FT                   /note=""Uncharacterized protein ORF91""
FT                   /id=""PRO_0000246135""
SQ   SEQUENCE   91 AA;  10596 MW;  C770491A1FF96EE8 CRC64;
     MQVVRIFTDM SISPSLSPRQ CPDRYAFRAG RNLPDKEFRY LRTVLVTAAV HRGFGRRLPC
     HQVTNFLDLP ALGRRQPPYM VLRLCGDLCF W
//
",15273
CAATAT AATATG ATATGA TATGAG ATGAGT TGAGTA GAGTAT AGTATG GTATGG TATGGT ATGGTA TGGTAC GGTACT GTACTG TACTGA ACTGAA CTGAAG TGAAGA GAAGAT AAGATG AGATGA GATGAT ATGATT TGATTA GATTAC ATTACC TTACCA TACCAA ACCAAG CCAAGG CAAGGT AAGGTA AGGTAA GGTAAA GTAAAC TAAACC AAACCT AACCTT ACCTTT CCTTTG CTTTGG TTTGGA TTGGAA TGGAAT GGAATT GAATTT AATTTG ATTTGG TTTGGT TTGGTG TGGTGC GGTGCC GTGCCA TGCCAC GCCACT CCACTT CACTTC ACTTCT CTTCTG TTCTGC TCTGCT CTGCTG TGCTGC GCTGCT CTGCTC TGCTCT GCTCTT CTCTTC TCTTCA CTTCAA TTCAAC TCAACC CAACCT AACCTG ACCTGA CCTGAA CTGAAG TGAAGA GAAGAA AAGAAG AGAAGA GAAGAG AAGAGC AGAGCA GAGCAA AGCAAG GCAAGA CAAGAA AAGAAG AGAAGA GAAGAA AAGAAG AGAAGA GAAGAT AAGATT AGATTG GATTGG ATTGGT TTGGTT TGGTTA GGTTAG GTTAGA TTAGAT TAGATG AGATGA GATGAT ATGATG TGATGA GATGAT ATGATA TGATAG GATAGT ATAGTC TAGTCC AGTCCT GTCCTG TCCTGT CCTGTC CTGTCT TGTCTC GTCTCT TCTCTT CTCTTA TCTTAT CTTATA TTATAC TATACA ATACAC TACACA ACACAT CACATT ACATTC CATTCC ATTCCG TTCCGA TCCGAG CCGAGC CGAGCC GAGCCC AGCCCA GCCCAC CCCACG CCACGA CACGAG ACGAGA,0,145,CAAT AATA ATAT TATG ATGA TGAG GAGT AGTA GTAT TATG ATGG TGGT GGTA GTAC TACT ACTG CTGA TGAA GAAG AAGA AGAT GATG ATGA TGAT GATT ATTA TTAC TACC ACCA CCAA CAAG AAGG AGGT GGTA GTAA TAAA AAAC AACC ACCT CCTT CTTT TTTG TTGG TGGA GGAA GAAT AATT ATTT TTTG TTGG TGGT GGTG GTGC TGCC GCCA CCAC CACT ACTT CTTC TTCT TCTG CTGC TGCT GCTG CTGC TGCT GCTC CTCT TCTT CTTC TTCA TCAA CAAC AACC ACCT CCTG CTGA TGAA GAAG AAGA AGAA GAAG AAGA AGAG GAGC AGCA GCAA CAAG AAGA AGAA GAAG AAGA AGAA GAAG AAGA AGAT GATT ATTG TTGG TGGT GGTT GTTA TTAG TAGA AGAT GATG ATGA TGAT GATG ATGA TGAT GATA ATAG TAGT AGTC GTCC TCCT CCTG CTGT TGTC GTCT TCTC CTCT TCTT CTTA TTAT TATA ATAC TACA ACAC CACA ACAT CATT ATTC TTCC TCCG CCGA CGAG GAGC AGCC GCCC CCCA CCAC CACG ACGA CGAG GAGA,CAATA AATAT ATATG TATGA ATGAG TGAGT GAGTA AGTAT GTATG TATGG ATGGT TGGTA GGTAC GTACT TACTG ACTGA CTGAA TGAAG GAAGA AAGAT AGATG GATGA ATGAT TGATT GATTA ATTAC TTACC TACCA ACCAA CCAAG CAAGG AAGGT AGGTA GGTAA GTAAA TAAAC AAACC AACCT ACCTT CCTTT CTTTG TTTGG TTGGA TGGAA GGAAT GAATT AATTT ATTTG TTTGG TTGGT TGGTG GGTGC GTGCC TGCCA GCCAC CCACT CACTT ACTTC CTTCT TTCTG TCTGC CTGCT TGCTG GCTGC CTGCT TGCTC GCTCT CTCTT TCTTC CTTCA TTCAA TCAAC CAACC AACCT ACCTG CCTGA CTGAA TGAAG GAAGA AAGAA AGAAG GAAGA AAGAG AGAGC GAGCA AGCAA GCAAG CAAGA AAGAA AGAAG GAAGA AAGAA AGAAG GAAGA AAGAT AGATT GATTG ATTGG TTGGT TGGTT GGTTA GTTAG TTAGA TAGAT AGATG GATGA ATGAT TGATG GATGA ATGAT TGATA GATAG ATAGT TAGTC AGTCC GTCCT TCCTG CCTGT CTGTC TGTCT GTCTC TCTCT CTCTT TCTTA CTTAT TTATA TATAC ATACA TACAC ACACA CACAT ACATT CATTC ATTCC TTCCG TCCGA CCGAG CGAGC GAGCC AGCCC GCCCA CCCAC CCACG CACGA ACGAG CGAGA,CAATAT AATATG ATATGA TATGAG ATGAGT TGAGTA GAGTAT AGTATG GTATGG TATGGT ATGGTA TGGTAC GGTACT GTACTG TACTGA ACTGAA CTGAAG TGAAGA GAAGAT AAGATG AGATGA GATGAT ATGATT TGATTA GATTAC ATTACC TTACCA TACCAA ACCAAG CCAAGG CAAGGT AAGGTA AGGTAA GGTAAA GTAAAC TAAACC AAACCT AACCTT ACCTTT CCTTTG CTTTGG TTTGGA TTGGAA TGGAAT GGAATT GAATTT AATTTG ATTTGG TTTGGT TTGGTG TGGTGC GGTGCC GTGCCA TGCCAC GCCACT CCACTT CACTTC ACTTCT CTTCTG TTCTGC TCTGCT CTGCTG TGCTGC GCTGCT CTGCTC TGCTCT GCTCTT CTCTTC TCTTCA CTTCAA TTCAAC TCAACC CAACCT AACCTG ACCTGA CCTGAA CTGAAG TGAAGA GAAGAA AAGAAG AGAAGA GAAGAG AAGAGC AGAGCA GAGCAA AGCAAG GCAAGA CAAGAA AAGAAG AGAAGA GAAGAA AAGAAG AGAAGA GAAGAT AAGATT AGATTG GATTGG ATTGGT TTGGTT TGGTTA GGTTAG GTTAGA TTAGAT TAGATG AGATGA GATGAT ATGATG TGATGA GATGAT ATGATA TGATAG GATAGT ATAGTC TAGTCC AGTCCT GTCCTG TCCTGT CCTGTC CTGTCT TGTCTC GTCTCT TCTCTT CTCTTA TCTTAT CTTATA TTATAC TATACA ATACAC TACACA ACACAT CACATT ACATTC CATTCC ATTCCG TTCCGA TCCGAG CCGAGC CGAGCC GAGCCC AGCCCA GCCCAC CCCACG CCACGA CACGAG ACGAGA,CAATATG AATATGA ATATGAG TATGAGT ATGAGTA TGAGTAT GAGTATG AGTATGG GTATGGT TATGGTA ATGGTAC TGGTACT GGTACTG GTACTGA TACTGAA ACTGAAG CTGAAGA TGAAGAT GAAGATG AAGATGA AGATGAT GATGATT ATGATTA TGATTAC GATTACC ATTACCA TTACCAA TACCAAG ACCAAGG CCAAGGT CAAGGTA AAGGTAA AGGTAAA GGTAAAC GTAAACC TAAACCT AAACCTT AACCTTT ACCTTTG CCTTTGG CTTTGGA TTTGGAA TTGGAAT TGGAATT GGAATTT GAATTTG AATTTGG ATTTGGT TTTGGTG TTGGTGC TGGTGCC GGTGCCA GTGCCAC TGCCACT GCCACTT CCACTTC CACTTCT ACTTCTG CTTCTGC TTCTGCT TCTGCTG CTGCTGC TGCTGCT GCTGCTC CTGCTCT TGCTCTT GCTCTTC CTCTTCA TCTTCAA CTTCAAC TTCAACC TCAACCT CAACCTG AACCTGA ACCTGAA CCTGAAG CTGAAGA TGAAGAA GAAGAAG AAGAAGA AGAAGAG GAAGAGC AAGAGCA AGAGCAA GAGCAAG AGCAAGA GCAAGAA CAAGAAG AAGAAGA AGAAGAA GAAGAAG AAGAAGA AGAAGAT GAAGATT AAGATTG AGATTGG GATTGGT ATTGGTT TTGGTTA TGGTTAG GGTTAGA GTTAGAT TTAGATG TAGATGA AGATGAT GATGATG ATGATGA TGATGAT GATGATA ATGATAG TGATAGT GATAGTC ATAGTCC TAGTCCT AGTCCTG GTCCTGT TCCTGTC CCTGTCT CTGTCTC TGTCTCT GTCTCTT TCTCTTA CTCTTAT TCTTATA CTTATAC TTATACA TATACAC ATACACA TACACAT ACACATT CACATTC ACATTCC CATTCCG ATTCCGA TTCCGAG TCCGAGC CCGAGCC CGAGCCC GAGCCCA AGCCCAC GCCCACG CCCACGA CCACGAG CACGAGA,"ID   R1A_SARS                Reviewed;        4382 AA.
AC   P0C6U8; P59641;
DT   10-JUN-2008, integrated into UniProtKB/Swiss-Prot.
DT   10-JUN-2008, sequence version 1.
DT   05-FEB-2025, entry version 124.
DE   RecName: Full=Replicase polyprotein 1a;
DE            Short=pp1a;
DE   AltName: Full=ORF1a polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3;
DE              Short=PL-PRO;
DE              EC=3.4.19.12 {ECO:0000269|PubMed:17692280};
DE              EC=3.4.22.- {ECO:0000269|PubMed:12917450, ECO:0000269|PubMed:16306590, ECO:0000269|PubMed:17692280};
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:12917450};
DE     AltName: Full=Main protease;
DE              Short=Mpro;
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=RNA-capping enzyme subunit nsp9;
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE              EC=2.7.7.50;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=Non-structural protein 11;
DE              Short=nsp11;
GN   ORFNames=1a;
OS   Severe acute respiratory syndrome coronavirus (SARS-CoV).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus.
OX   NCBI_TaxID=694009;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
OH   NCBI_TaxID=9675; Paguma larvata (Masked palm civet).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Urbani;
RX   PubMed=12730500; DOI=10.1126/science.1085952;
RA   Rota P.A., Oberste M.S., Monroe S.S., Nix W.A., Campagnoli R.,
RA   Icenogle J.P., Penaranda S., Bankamp B., Maher K., Chen M.-H., Tong S.,
RA   Tamin A., Lowe L., Frace M., DeRisi J.L., Chen Q., Wang D., Erdman D.D.,
RA   Peret T.C.T., Burns C., Ksiazek T.G., Rollin P.E., Sanchez A., Liffick S.,
RA   Holloway B., Limor J., McCaustland K., Olsen-Rasmussen M., Fouchier R.,
RA   Guenther S., Osterhaus A.D.M.E., Drosten C., Pallansch M.A., Anderson L.J.,
RA   Bellini W.J.;
RT   ""Characterization of a novel coronavirus associated with severe acute
RT   respiratory syndrome."";
RL   Science 300:1394-1399(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Tor2;
RX   PubMed=12730501; DOI=10.1126/science.1085953;
RA   Marra M.A., Jones S.J.M., Astell C.R., Holt R.A., Brooks-Wilson A.,
RA   Butterfield Y.S.N., Khattra J., Asano J.K., Barber S.A., Chan S.Y.,
RA   Cloutier A., Coughlin S.M., Freeman D., Girn N., Griffith O.L., Leach S.R.,
RA   Mayo M., McDonald H., Montgomery S.B., Pandoh P.K., Petrescu A.S.,
RA   Robertson A.G., Schein J.E., Siddiqui A., Smailus D.E., Stott J.M.,
RA   Yang G.S., Plummer F., Andonov A., Artsob H., Bastien N., Bernard K.,
RA   Booth T.F., Bowness D., Czub M., Drebot M., Fernando L., Flick R.,
RA   Garbutt M., Gray M., Grolla A., Jones S., Feldmann H., Meyers A.,
RA   Kabani A., Li Y., Normand S., Stroher U., Tipples G.A., Tyler S.,
RA   Vogrig R., Ward D., Watson B., Brunham R.C., Krajden M., Petric M.,
RA   Skowronski D.M., Upton C., Roper R.L.;
RT   ""The genome sequence of the SARS-associated coronavirus."";
RL   Science 300:1399-1404(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate CUHK-Su10, and Isolate CUHK-W1;
RX   PubMed=12853594; DOI=10.1056/nejm200307103490216;
RA   Tsui S.K.W., Chim S.S.C., Lo Y.M.D.;
RT   ""Coronavirus genomic-sequence variations and the epidemiology of the severe
RT   acute respiratory syndrome."";
RL   N. Engl. J. Med. 349:187-188(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate GZ50, Isolate SZ16, and Isolate SZ3;
RX   PubMed=12958366; DOI=10.1126/science.1087139;
RA   Guan Y., Zheng B.J., He Y.Q., Liu X.L., Zhuang Z.X., Cheung C.L., Luo S.W.,
RA   Li P.H., Zhang L.J., Guan Y.J., Butt K.M., Wong K.L., Chan K.W., Lim W.,
RA   Shortridge K.F., Yuen K.Y., Peiris J.S.M., Poon L.L.M.;
RT   ""Isolation and characterization of viruses related to the SARS coronavirus
RT   from animals in southern China."";
RL   Science 302:276-278(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU-39849;
RX   PubMed=12876307; DOI=10.1177/15353702-0322807-13;
RA   Zeng F.Y., Chan C.W., Chan M.N., Chen J.D., Chow K.Y.C., Hon C.C.C.,
RA   Hui R.K.H., Li J., Li V.Y.Y., Wang C.Y., Wang P.Y., Guan Y., Zheng B.,
RA   Poon L.L.M., Chan K.H., Yuen K.Y., Peiris J.S.M., Leung F.C.;
RT   ""The complete genome sequence of severe acute respiratory syndrome
RT   coronavirus strain HKU-39849 (HK-39)."";
RL   Exp. Biol. Med. 228:866-873(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Sin2500, Isolate Sin2677, Isolate Sin2679, Isolate
RC   Sin2748, and Isolate sin2774;
RX   PubMed=12781537; DOI=10.1016/s0140-6736(03)13414-9;
RA   Ruan Y., Wei C.L., Ling A.E., Vega V.B., Thoreau H., Se Thoe S.Y.,
RA   Chia J.-M., Ng P., Chiu K.P., Lim L., Zhang T., Chan K.P., Oon L.E.L.,
RA   Ng M.L., Leo S.Y., Ng L.F.P., Ren E.C., Stanton L.W., Long P.M., Liu E.T.;
RT   ""Comparative full-length genome sequence analysis of 14 SARS coronavirus
RT   isolates and common mutations associated with putative origins of
RT   infection."";
RL   Lancet 361:1779-1785(2003).
RN   [7]
RP   ERRATUM OF PUBMED:12781537.
RA   Ruan Y., Wei C.L., Ling A.E., Vega V.B., Thoreau H., Se Thoe S.Y.,
RA   Chia J.-M., Ng P., Chiu K.P., Lim L., Zhang T., Chan K.P., Oon L.E.L.,
RA   Ng M.L., Leo S.Y., Ng L.F.P., Ren E.C., Stanton L.W., Long P.M., Liu E.T.;
RL   Lancet 361:1832-1832(2003).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate ZJ01;
RX   PubMed=14527350;
RA   Li L., Wang Z., Lu Y., Bao Q., Chen S., Wu N., Cheng S., Weng J., Zhang Y.,
RA   Yan J., Mei L., Wang X., Zhu H., Yu Y., Zhang M., Li M., Yao J., Lu Q.,
RA   Yao P., Bo X., Wo J., Wang S., Hu S.;
RT   ""Severe acute respiratory syndrome-associated coronavirus genotype and its
RT   characterization."";
RL   Chin. Med. J. 116:1288-1292(2003).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate BJ01, Isolate BJ02, Isolate BJ03, Isolate BJ04, and
RC   Isolate GD01;
RA   Qin E., Zhu Q., Yu M., Fan B., Chang G., Si B., Yang B., Peng W., Jiang T.,
RA   Liu B., Deng Y., Liu H., Zhang Y., Wang C., Li Y., Gan Y., Li X., Lu F.,
RA   Tan G., Yang R., Cao W.S., Wang J., Chen W., Cong L., Deng Y., Dong W.,
RA   Han Y., Hu W., Lei M., Li C., Li G., Li G., Li H., Li S., Li S., Li W.,
RA   Li W., Lin W., Liu J., Liu Z., Lu H., Ni P., Qi Q., Sun Y., Tang L.,
RA   Tong Z., Wang J., Wang X., Wu Q., Xi Y., Xu Z., Yang L., Ye C., Ye J.,
RA   Zhang B., Zhang F., Zhang J., Zhang X., Zhou J., Yang H.;
RL   Submitted (APR-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TW1;
RA   Yeh S.-H., Kao C.-L., Tsai C.-Y., Liu C.-J., Chen D.-S., Chen P.-J.;
RT   ""The complete genome of SARS coronavirus clone TW1."";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate FRA;
RX   PubMed=14645828; DOI=10.1126/science.302.5650.1504b;
RA   Eickmann M., Becker S., Klenk H.-D., Doerr H.W., Stadler K., Censini S.,
RA   Guidotti S., Masignani V., Scarselli M., Mora M., Donati C., Han J.H.,
RA   Song H.C., Abrignani S., Covacci A., Rappuoli R.;
RT   ""Phylogeny of the SARS coronavirus."";
RL   Science 302:1504-1505(2003).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Frankfurt-1;
RA   Thiel V., Hertzig T., Putics A., Ivanov K.A., Schelle B., Bayer S.,
RA   Scheiner B., Weinand H., Weissbrich B., Ziebuhr J.;
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWC;
RA   Yang J.-Y., Lin J.-H., Chiu S.-C., Wang S.-F., Lee S.C., Lin Y.-C.,
RA   Hsu C.-K., Chen H.-Y., Chang J.G., Chen P.-J., Su I.-J.;
RT   ""Genomic sequence of SARS isolate from the first fatal case in Taiwan."";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Shanghai QXC1;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RT   ""Analysis of SARS coronavirus genome in Shanghai isolates."";
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [15]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HSR 1;
RA   Canducci F., Clementi M., Poli G., Vicenzi E.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [16]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate Taiwan TC1, Isolate Taiwan TC2, and Isolate Taiwan TC3;
RA   Chang J.-G.C., Lin T.-H., Chen C.-M., Lin C.-S., Chan W.-L., Shih M.-C.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [17]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate TWH, Isolate TWJ, Isolate TWK, Isolate TWS, and Isolate
RC   TWY;
RA   Shu H.Y., Wu K.M., Tsai S.F.;
RL   Submitted (JUL-2003) to the EMBL/GenBank/DDBJ databases.
RN   [18]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate AS;
RA   Balotta C., Corvasce S., Violin M., Galli M., Moroni M., Vigevani G.M.,
RA   Ruan Y.J., Salemi M.;
RL   Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
RN   [19]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate ZJ01;
RA   Wang Z., Cheng S., Zhang Y.;
RL   Submitted (NOV-2003) to the EMBL/GenBank/DDBJ databases.
RN   [20]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA] OF 1-507 AND 1655-4382.
RC   STRAIN=Isolate Shanghai LY;
RA   Yuan Z., Zhang X., Hu Y., Lan S., Wang H., Zhou Z., Wen Y.;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [21]
RP   PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A), CATALYTIC ACTIVITY
RP   (3C-LIKE PROTEINASE NSP5), AND CATALYTIC ACTIVITY (PAPAIN-LIKE PROTEASE
RP   NSP3).
RX   PubMed=12917450; DOI=10.1099/vir.0.19424-0;
RA   Thiel V., Ivanov K.A., Putics A., Hertzig T., Schelle B., Bayer S.,
RA   Weissbrich B., Snijder E.J., Rabenau H., Doerr H.W., Gorbalenya A.E.,
RA   Ziebuhr J.;
RT   ""Mechanisms and enzymes involved in SARS coronavirus genome expression."";
RL   J. Gen. Virol. 84:2305-2315(2003).
RN   [22]
RP   PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A).
RX   PubMed=15331731; DOI=10.1128/jvi.78.18.9977-9986.2004;
RA   Prentice E., McAuliffe J., Lu X., Subbarao K., Denison M.R.;
RT   ""Identification and characterization of severe acute respiratory syndrome
RT   coronavirus replicase proteins."";
RL   J. Virol. 78:9977-9986(2004).
RN   [23]
RP   PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A).
RC   STRAIN=Isolate Urbani;
RX   PubMed=15564471; DOI=10.1128/jvi.78.24.13600-13612.2004;
RA   Harcourt B.H., Jukneliene D., Kanjanahaluethai A., Bechill J.,
RA   Severson K.M., Smith C.M., Rota P.A., Baker S.C.;
RT   ""Identification of severe acute respiratory syndrome coronavirus replicase
RT   products and characterization of papain-like protease activity."";
RL   J. Virol. 78:13600-13612(2004).
RN   [24]
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), AND BIOPHYSICOCHEMICAL PROPERTIES (3C-LIKE PROTEINASE NSP5).
RX   PubMed=14561748; DOI=10.1074/jbc.m310875200;
RA   Fan K., Wei P., Feng Q., Chen S., Huang C., Ma L., Lai B., Pei J., Liu Y.,
RA   Chen J., Lai L.;
RT   ""Biosynthesis, purification, and substrate specificity of severe acute
RT   respiratory syndrome coronavirus 3C-like proteinase."";
RL   J. Biol. Chem. 279:1637-1642(2004).
RN   [25]
RP   CATALYTIC ACTIVITY (PAPAIN-LIKE PROTEASE NSP3), FUNCTION (PAPAIN-LIKE
RP   PROTEASE NSP3), PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A),
RP   COFACTOR (PAPAIN-LIKE PROTEASE NSP3), MUTAGENESIS OF CYS-1651; CYS-1688;
RP   CYS-1729; CYS-1732; CYS-1764; CYS-1766 AND ASP-1826, AND ACTIVE SITE
RP   (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=16306590; DOI=10.1128/jvi.79.24.15189-15198.2005;
RA   Barretto N., Jukneliene D., Ratia K., Chen Z., Mesecar A.D., Baker S.C.;
RT   ""The papain-like protease of severe acute respiratory syndrome coronavirus
RT   has deubiquitinating activity."";
RL   J. Virol. 79:15189-15198(2005).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=16226257; DOI=10.1016/j.febslet.2005.09.075;
RA   Lin C.W., Tsai F.J., Wan L., Lai C.C., Lin K.H., Hsieh T.H., Shiu S.Y.,
RA   Li J.Y.;
RT   ""Binding interaction of SARS coronavirus 3CL(pro) protease with vacuolar-H+
RT   ATPase G1 subunit."";
RL   FEBS Lett. 579:6089-6094(2005).
RN   [27]
RP   SUBUNIT (3C-LIKE PROTEINASE NSP5).
RX   PubMed=15507456; DOI=10.1074/jbc.m408211200;
RA   Chen S., Chen L., Tan J., Chen J., Du L., Sun T., Shen J., Chen K.,
RA   Jiang H., Shen X.;
RT   ""Severe acute respiratory syndrome coronavirus 3C-like proteinase N
RT   terminus is indispensable for proteolytic activity but not for enzyme
RT   dimerization. Biochemical and thermodynamic investigation in conjunction
RT   with molecular dynamics simulations."";
RL   J. Biol. Chem. 280:164-173(2005).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=17024178; DOI=10.1038/sj.emboj.7601368;
RA   Imbert I., Guillemot J.-C., Bourhis J.-M., Bussetta C., Coutard B.,
RA   Egloff M.-P., Ferron F., Gorbalenya A.E., Canard B.;
RT   ""A second, non-canonical RNA-dependent RNA polymerase in SARS
RT   coronavirus."";
RL   EMBO J. 25:4933-4942(2006).
RN   [29]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3).
RX   PubMed=17692280; DOI=10.1016/j.abb.2007.07.006;
RA   Lindner H.A., Lytvyn V., Qi H., Lachance P., Ziomek E., Menard R.;
RT   ""Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus
RT   papain-like protease."";
RL   Arch. Biochem. Biophys. 466:8-14(2007).
RN   [30]
RP   INTERACTION WITH ORF6 PROTEIN (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=17532020; DOI=10.1016/j.virol.2007.04.029;
RA   Kumar P., Gunalan V., Liu B., Chow V.T., Druce J., Birch C., Catton M.,
RA   Fielding B.C., Tan Y.J., Lal S.K.;
RT   ""The nonstructural protein 8 (nsp8) of the SARS coronavirus interacts with
RT   its ORF6 accessory protein."";
RL   Virology 366:293-303(2007).
RN   [31]
RP   TOPOLOGY (PAPAIN-LIKE PROTEASE NSP3), TOPOLOGY (NON-STRUCTURAL PROTEIN 4),
RP   AND TOPOLOGY (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=18842706; DOI=10.1128/jvi.01219-08;
RA   Oostra M., Hagemeijer M.C., van Gent M., Bekker C.P., te Lintelo E.G.,
RA   Rottier P.J., de Haan C.A.;
RT   ""Topology and membrane anchoring of the coronavirus replication complex:
RT   not all hydrophobic domains of nsp3 and nsp6 are membrane spanning."";
RL   J. Virol. 82:12392-12405(2008).
RN   [32]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=19369340; DOI=10.1128/jvi.02220-08;
RA   Frieman M., Ratia K., Johnston R.E., Mesecar A.D., Baric R.S.;
RT   ""Severe acute respiratory syndrome coronavirus papain-like protease
RT   ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and
RT   NF-kappaB signaling."";
RL   J. Virol. 83:6689-6705(2009).
RN   [33]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), AND INTERACTION WITH HOST PHB AND PHB2
RP   (NON-STRUCTURAL PROTEIN 2).
RX   PubMed=19640993; DOI=10.1128/jvi.00842-09;
RA   Cornillez-Ty C.T., Liao L., Yates J.R., Kuhn P., Buchmeier M.J.;
RT   ""Severe acute respiratory syndrome coronavirus nonstructural protein 2
RT   interacts with a host protein complex involved in mitochondrial biogenesis
RT   and intracellular signaling."";
RL   J. Virol. 83:10314-10318(2009).
RN   [34]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=19153232; DOI=10.1128/jvi.01505-08;
RA   Miknis Z.J., Donaldson E.F., Umland T.C., Rimmer R.A., Baric R.S.,
RA   Schultz L.W.;
RT   ""Severe acute respiratory syndrome coronavirus nsp9 dimerization is
RT   essential for efficient viral growth."";
RL   J. Virol. 83:3007-3018(2009).
RN   [35]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=22174690; DOI=10.1371/journal.ppat.1002433;
RA   Huang C., Lokugamage K.G., Rozovics J.M., Narayanan K., Semler B.L.,
RA   Makino S.;
RT   ""SARS coronavirus nsp1 protein induces template-dependent endonucleolytic
RT   cleavage of mRNAs: viral mRNAs are resistant to nsp1-induced RNA
RT   cleavage."";
RL   PLoS Pathog. 7:E1002433-E1002433(2011).
RN   [36]
RP   INTERACTION WITH PAPAIN-LIKE PROTEASE NSP3 (NON-STRUCTURAL PROTEIN 4),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 4), AND INTERACTION WITH
RP   NON-STRUCTURAL PROTEIN 6 (NON-STRUCTURAL PROTEIN 4).
RX   PubMed=21345958; DOI=10.1128/jvi.00042-11;
RA   Hagemeijer M.C., Ulasli M., Vonk A.M., Reggiori F., Rottier P.J.,
RA   de Haan C.A.;
RT   ""Mobility and interactions of coronavirus nonstructural protein 4."";
RL   J. Virol. 85:4572-4577(2011).
RN   [37]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=23035226; DOI=10.1128/jvi.01958-12;
RA   Lokugamage K.G., Narayanan K., Huang C., Makino S.;
RT   ""Severe acute respiratory syndrome coronavirus protein nsp1 is a novel
RT   eukaryotic translation inhibitor that represses multiple steps of
RT   translation initiation."";
RL   J. Virol. 86:13598-13608(2012).
RN   [38]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 7), AND FUNCTION (NON-STRUCTURAL PROTEIN
RP   8).
RX   PubMed=22039154; DOI=10.1093/nar/gkr893;
RA   te Velthuis A.J., van den Worm S.H., Snijder E.J.;
RT   ""The SARS-coronavirus nsp7+nsp8 complex is a unique multimeric RNA
RT   polymerase capable of both de novo initiation and primer extension."";
RL   Nucleic Acids Res. 40:1737-1747(2012).
RN   [39]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 10), AND INTERACTION WITH PROOFREADING
RP   EXORIBONUCLEASE NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=22635272; DOI=10.1073/pnas.1201130109;
RA   Bouvet M., Imbert I., Subissi L., Gluais L., Canard B., Decroly E.;
RT   ""RNA 3'-end mismatch excision by the severe acute respiratory syndrome
RT   coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex."";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:9372-9377(2012).
RN   [40]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 4), FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND FUNCTION
RP   (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=23943763; DOI=10.1128/mbio.00524-13;
RA   Angelini M.M., Akhlaghpour M., Neuman B.W., Buchmeier M.J.;
RT   ""Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4,
RT   and 6 induce double-membrane vesicles."";
RL   MBio 4:0-0(2013).
RN   [41]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=24991833; DOI=10.4161/auto.29309;
RA   Cottam E.M., Whelband M.C., Wileman T.;
RT   ""Coronavirus NSP6 restricts autophagosome expansion."";
RL   Autophagy 10:1426-1441(2014).
RN   [42]
RP   REVIEW.
RX   PubMed=24410069; DOI=10.1089/dna.2013.2304;
RA   Angelini M.M., Neuman B.W., Buchmeier M.J.;
RT   ""Untangling membrane rearrangement in the nidovirales."";
RL   DNA Cell Biol. 33:122-127(2014).
RN   [43]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=24622840; DOI=10.1007/s13238-014-0026-3;
RA   Chen X., Yang X., Zheng Y., Yang Y., Xing Y., Chen Z.;
RT   ""SARS coronavirus papain-like protease inhibits the type I interferon
RT   signaling pathway through interaction with the STING-TRAF3-TBK1 complex."";
RL   Protein Cell 5:369-381(2014).
RN   [44]
RP   INTERACTION WITH NUP93 (HOST TRANSLATION INHIBITOR NSP1), AND FUNCTION
RP   (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=30943371; DOI=10.1139/bcb-2018-0394;
RA   Gomez G.N., Abrar F., Dodhia M.P., Gonzalez F.G., Nag A.;
RT   ""SARS coronavirus protein nsp1 disrupts localization of Nup93 from the
RT   nuclear pore complex."";
RL   Biochem. Cell Biol. 97:758-766(2019).
RN   [45]
RP   PROTEOLYTIC CLEAVAGE (ISOFORM REPLICASE POLYPROTEIN 1A), MASS SPECTROMETRY
RP   (NON-STRUCTURAL PROTEIN 8), MASS SPECTROMETRY (NON-STRUCTURAL PROTEIN 9),
RP   AND MASS SPECTROMETRY (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=32083638; DOI=10.1042/bcj20200029;
RA   Krichel B., Falke S., Hilgenfeld R., Redecke L., Uetrecht C.;
RT   ""Processing of the SARS-CoV pp1a/ab nsp7-10 region."";
RL   Biochem. J. 477:1009-1019(2020).
RN   [46]
RP   3D-STRUCTURE MODELING OF 3241-3540, AND CHARACTERIZATION (3C-LIKE
RP   PROTEINASE NSP5).
RX   PubMed=12746549; DOI=10.1126/science.1085658;
RA   Anand K., Ziebuhr J., Wadhwani P., Mesters J.R., Hilgenfeld R.;
RT   ""Coronavirus main proteinase (3CLpro) structure: basis for design of anti-
RT   SARS drugs."";
RL   Science 300:1763-1767(2003).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 4118-4230 (NON-STRUCTURAL PROTEIN
RP   9).
RC   STRAIN=Isolate Frankfurt-1;
RX   PubMed=12925794; DOI=10.1107/s0907444903016779;
RA   Campanacci V., Egloff M.-P., Longhi S., Ferron F., Rancurel C.,
RA   Salomoni A., Durousseau C., Tocque F., Bremond N., Dobbe J.C.,
RA   Snijder E.J., Canard B., Cambillau C.;
RT   ""Structural genomics of the SARS coronavirus: cloning, expression,
RT   crystallization and preliminary crystallographic study of the Nsp9
RT   protein."";
RL   Acta Crystallogr. D 59:1628-1631(2003).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 4118-4230.
RX   PubMed=15007178; DOI=10.1073/pnas.0307877101;
RA   Egloff M.-P., Ferron F., Campanacci V., Longhi S., Rancurel C.,
RA   Dutartre H., Snijder E.J., Gorbalenya A.E., Cambillau C., Canard B.;
RT   ""The severe acute respiratory syndrome-coronavirus replicative protein nsp9
RT   is a single-stranded RNA-binding subunit unique in the RNA virus world."";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:3792-3796(2004).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 4107-4230.
RX   PubMed=14962394; DOI=10.1016/j.str.2004.01.016;
RA   Sutton G., Fry E., Carter L., Sainsbury S., Walter T., Nettleship J.,
RA   Berrow N., Owens R., Gilbert R., Davidson A., Siddell S., Poon L.L.M.,
RA   Diprose J., Alderton D., Walsh M., Grimes J.M., Stuart D.I.;
RT   ""The nsp9 replicase protein of SARS-coronavirus, structure and functional
RT   insights."";
RL   Structure 12:341-353(2004).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 3837-4117 AND 3920-4117,
RP   INTERACTION WITH NON-STRUCTURAL PROTEIN 7 (NON-STRUCTURAL PROTEIN 8), AND
RP   INTERACTION WITH NON-STRUCTURAL PROTEIN 8 (NON-STRUCTURAL PROTEIN 7).
RX   PubMed=16228002; DOI=10.1038/nsmb999;
RA   Zhai Y., Sun F., Li X., Pang H., Xu X., Bartlam M., Rao Z.;
RT   ""Insights into SARS-CoV transcription and replication from the structure of
RT   the nsp7-nsp8 hexadecamer."";
RL   Nat. Struct. Mol. Biol. 12:980-986(2005).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (1.4 ANGSTROMS) OF 1002-1176.
RX   PubMed=16271890; DOI=10.1016/j.str.2005.07.022;
RA   Saikatendu K.S., Joseph J.S., Subramanian V., Clayton T., Griffith M.,
RA   Moy K., Velasquez J., Neuman B.W., Buchmeier M.J., Stevens R.C., Kuhn P.;
RT   ""Structural basis of severe acute respiratory syndrome coronavirus ADP-
RT   ribose-1''-phosphate dephosphorylation by a conserved domain of nsP3."";
RL   Structure 13:1665-1675(2005).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 1541-1854.
RX   PubMed=16581910; DOI=10.1073/pnas.0510851103;
RA   Ratia K., Saikatendu K.S., Santarsiero B.D., Barretto N., Baker S.C.,
RA   Stevens R.C., Mesecar A.D.;
RT   ""Severe acute respiratory syndrome coronavirus papain-like protease:
RT   structure of a viral deubiquitinating enzyme."";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:5717-5722(2006).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 4240-4362.
RC   STRAIN=Isolate Tor2;
RX   PubMed=16873246; DOI=10.1128/jvi.00467-06;
RA   Joseph J.S., Saikatendu K.S., Subramanian V., Neuman B.W., Brooun A.,
RA   Griffith M., Moy K., Yadav M.K., Velasquez J., Buchmeier M.J.,
RA   Stevens R.C., Kuhn P.;
RT   ""Crystal structure of nonstructural protein 10 from the severe acute
RT   respiratory syndrome coronavirus reveals a novel fold with two zinc-binding
RT   motifs."";
RL   J. Virol. 80:7894-7901(2006).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 4231-4378.
RX   PubMed=16873247; DOI=10.1128/jvi.00483-06;
RA   Su D., Lou Z., Sun F., Zhai Y., Yang H., Zhang R., Joachimiak A.,
RA   Zhang X.C., Bartlam M., Rao Z.;
RT   ""Dodecamer structure of severe acute respiratory syndrome coronavirus
RT   nonstructural protein nsp10."";
RL   J. Virol. 80:7902-7908(2006).
RN   [55]
RP   STRUCTURE BY NMR OF 13-127.
RX   PubMed=17202208; DOI=10.1128/jvi.01939-06;
RA   Almeida M.S., Johnson M.A., Herrmann T., Geralt M., Wuthrich K.;
RT   ""Novel beta-barrel fold in the nuclear magnetic resonance structure of the
RT   replicase nonstructural protein 1 from the severe acute respiratory
RT   syndrome coronavirus."";
RL   J. Virol. 81:3151-3161(2007).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3241-3546.
RG   RIKEN structural genomics initiative (RSGI);
RT   ""Crystal structure of Sars coronavirus main proteinase(3CLPRO)."";
RL   Submitted (JUL-2007) to the PDB data bank.
CC   -!- FUNCTION: [Isoform Replicase polyprotein 1a]: Multifunctional protein
CC       involved in the transcription and replication of viral RNAs. Contains
CC       the proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000305}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by interacting with the 40S ribosomal subunit. The nsp1-40S ribosome
CC       complex further induces an endonucleolytic cleavage near the 5'UTR of
CC       host mRNAs, targeting them for degradation. Viral mRNAs are not
CC       susceptible to nsp1-mediated endonucleolytic RNA cleavage thanks to the
CC       presence of a 5'-end leader sequence and are therefore protected from
CC       degradation. By suppressing host gene expression, nsp1 facilitates
CC       efficient viral gene expression in infected cells and evasion from host
CC       immune response (PubMed:23035226). May disrupt nuclear pore function by
CC       binding and displacing host NUP93 (PubMed:30943371).
CC       {ECO:0000269|PubMed:23035226, ECO:0000269|PubMed:30943371}.
CC   -!- FUNCTION: [Non-structural protein 2]: May play a role in the modulation
CC       of host cell survival signaling pathway by interacting with host PHB
CC       and PHB2 (PubMed:19640993). Indeed, these two proteins play a role in
CC       maintaining the functional integrity of the mitochondria and protecting
CC       cells from various stresses (PubMed:19640993).
CC       {ECO:0000269|PubMed:19640993}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. In addition,
CC       PL-PRO possesses a deubiquitinating/deISGylating activity and processes
CC       both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:17692280). Plays a role in host membrane
CC       rearrangement that leads to creation of cytoplasmic double-membrane
CC       vesicles (DMV) necessary for viral replication (PubMed:23943763). Nsp3,
CC       nsp4 and nsp6 together are sufficient to form DMV (PubMed:23943763,
CC       PubMed:24410069). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:19369340, PubMed:24622840).
CC       Prevents also host NF-kappa-B signaling (PubMed:19369340,
CC       PubMed:24622840). {ECO:0000269|PubMed:16271890,
CC       ECO:0000269|PubMed:17692280, ECO:0000269|PubMed:19369340,
CC       ECO:0000269|PubMed:23943763, ECO:0000269|PubMed:24622840,
CC       ECO:0000303|PubMed:24410069}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in host membrane
CC       rearrangement that leads to creation of cytoplasmic double-membrane
CC       vesicles (DMV) necessary for viral replication (PubMed:23943763,
CC       PubMed:24410069). Alone appears incapable to induce membrane curvature,
CC       but together with nsp3 is able to induce paired membranes
CC       (PubMed:23943763). Nsp3, nsp4 and nsp6 together are sufficient to form
CC       DMV (PubMed:23943763, PubMed:24410069). {ECO:0000269|PubMed:23943763,
CC       ECO:0000303|PubMed:24410069}.
CC   -!- FUNCTION: [3C-like proteinase nsp5]: Cleaves the C-terminus of
CC       replicase polyprotein at 11 sites. Recognizes substrates containing the
CC       core sequence [ILMVF]-Q-|-[SGACN]. Also able to bind an ADP-ribose-1''-
CC       phosphate (ADRP). May cleave host ATP6V1G1 thereby modifying host
CC       vacuoles intracellular pH. {ECO:0000255|PROSITE-ProRule:PRU00772,
CC       ECO:0000269|PubMed:16226257}.
CC   -!- FUNCTION: [Non-structural protein 6]: Plays a role in host membrane
CC       rearrangement that leads to creation of cytoplasmic double-membrane
CC       vesicles (DMV) necessary for viral replication (PubMed:23943763). Nsp3,
CC       nsp4 and nsp6 together are sufficient to form DMV (PubMed:23943763,
CC       PubMed:24410069). Plays a role in the initial induction of
CC       autophagosomes from host endoplasmic reticulum. Later, limits the
CC       expansion of these phagosomes that are no longer able to deliver viral
CC       components to lysosomes (PubMed:24991833).
CC       {ECO:0000269|PubMed:23943763, ECO:0000269|PubMed:24991833,
CC       ECO:0000303|PubMed:24410069}.
CC   -!- FUNCTION: [Non-structural protein 7]: Forms a hexadecamer with nsp8 (8
CC       subunits of each) that may participate in viral replication by acting
CC       as a primase. Alternatively, may synthesize substantially longer
CC       products than oligonucleotide primers. {ECO:0000269|PubMed:22039154}.
CC   -!- FUNCTION: [Non-structural protein 8]: Forms a hexadecamer with nsp7 (8
CC       subunits of each) that may participate in viral replication by acting
CC       as a primase. Alternatively, may synthesize substantially longer
CC       products than oligonucleotide primers. {ECO:0000269|PubMed:22039154}.
CC   -!- FUNCTION: [RNA-capping enzyme subunit nsp9]: Catalytic subunit of viral
CC       RNA capping enzyme which catalyzes the RNA guanylyltransferase reaction
CC       for genomic and sub-genomic RNAs. The kinase-like NiRAN domain of NSP12
CC       transfers RNA to the amino terminus of NSP9, forming a covalent RNA-
CC       protein intermediate. Subsequently, the NiRAN domain transfers RNA to
CC       GDP, forming the core cap structure GpppA-RNA. The NSP14 and NSP16
CC       methyltransferases then add methyl groups to form functional cap
CC       structures. {ECO:0000250|UniProtKB:P0DTC1,
CC       ECO:0000269|PubMed:19153232}.
CC   -!- FUNCTION: [Non-structural protein 10]: Plays a pivotal role in viral
CC       transcription by stimulating both nsp14 3'-5' exoribonuclease and nsp16
CC       2'-O-methyltransferase activities. Therefore plays an essential role in
CC       viral mRNAs cap methylation. {ECO:0000269|PubMed:22635272}.
CC   -!- CATALYTIC ACTIVITY: [3C-like proteinase nsp5]:
CC       Reaction=TSAVLQ-|-SGFRK-NH2 and SGVTFQ-|-GKFKK the two peptides
CC         corresponding to the two self-cleavage sites of the SARS 3C-like
CC         proteinase are the two most reactive peptide substrates. The enzyme
CC         exhibits a strong preference for substrates containing Gln at P1
CC         position and Leu at P2 position.; EC=3.4.22.69;
CC         Evidence={ECO:0000269|PubMed:12917450, ECO:0000269|PubMed:14561748};
CC   -!- CATALYTIC ACTIVITY: [Papain-like protease nsp3]:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12; Evidence={ECO:0000269|PubMed:12917450,
CC         ECO:0000269|PubMed:17692280};
CC   -!- CATALYTIC ACTIVITY: [RNA-capping enzyme subunit nsp9]:
CC       Reaction=a 5'-end diphospho-ribonuc",52854
CTAACC TAACCA AACCAG ACCAGA CCAGAA CAGAAA AGAAAG GAAAGC AAAGCG AAGCGT AGCGTG GCGTGC CGTGCA GTGCAA TGCAAG GCAAGC CAAGCA AAGCAG AGCAGA GCAGAT CAGATT AGATTT GATTTG ATTTGG TTTGGA TTGGAC TGGACG GGACGC GACGCG ACGCGT CGCGTA GCGTAA CGTAAG GTAAGA TAAGAT AAGATC AGATCG GATCGT ATCGTC TCGTCG CGTCGG GTCGGC TCGGCA CGGCAG GGCAGC GCAGCG CAGCGT AGCGTC GCGTCA CGTCAG GTCAGA TCAGAT CAGATG AGATGT GATGTG ATGTGT TGTGTA GTGTAT TGTATA GTATAA TATAAA ATAAAG TAAAGA AAAGAG AAGAGA AGAGAC GAGACA AGACAG GACAGC ACAGCT CAGCTC AGCTCC GCTCCT CTCCTA TCCTAC CCTACT CTACTT TACTTG ACTTGG CTTGGC TTGGCG TGGCGT GGCGTG GCGTGT CGTGTT GTGTTT TGTTTA GTTTAT TTTATT TTATTC TATTCT ATTCTA TTCTAC TCTACA CTACAG TACAGG ACAGGT CAGGTT AGGTTC GGTTCT GTTCTA TTCTAA TCTAAT CTAATG TAATGT AATGTT ATGTTT TGTTTT GTTTTT TTTTTC TTTTCA TTTCAA TTCAAA TCAAAC CAAACA AAACAC AACACG ACACGT CACGTG ACGTGC CGTGCA GTGCAG TGCAGG GCAGGC CAGGCT AGGCTG GGCTGT GCTGTT CTGTTT TGTTTA GTTTAA TTTAAT TTAATA TAATAG AATAGG ATAGGG TAGGGG AGGGGC GGGGCT GGGCTG GGCTGA GCTGAA,1,142,CTATAAAAAA T TAAACAC C A AAAACACCCC C A ACACCCCACA A C CCCCAAG G CTGT GGAGAA ATGGAGAGAAAA A G GAGAAAA A A AACCTAAGAG G A AAAAGAGCGC C A AGAGCGCGCG  GCCGTT C CGAGAGTGTG G G GTGTGTGCAAT TGTGCGCACA A G GCGCACAAAA A C CACAAAAGAG  TC AAAAGAGCGTAC A AGAGCGCACA A G GCCAGCAGAG G C CAAGAGA A A AGAGAGATAT  AGG AGATATTTT T A ATCT TTT GAT T TTTTTTTGTG G TGA TTG AGGG G T TGTGGGGAGA A G GGGGAGACAC C G GAGACCG G A ACACGTA GC C C CGCGCGCGCG G G TG GACGTGT T C CGCGTGGCTA A G GTGC TAAAA A T GCTAAAAGAG G A AAAAGA TGA A A AGAGAGATAT T GTT GATATCCA C A ATTG TCGCG G T TCTCGCGTGT T C CGCGTG TC GGTCTCGCG G T TCTCGCGGGG G C CGCGGGGCGC C G GGGC GCACA A G GCGCACAGAG G C CAGCAC AGC C A AGAGCGCGCG G G GCGCGCGTGT T C CGCGTGTCTG C G GTGTCTCACA A T TCTCATG AG G C CACAGAGAGA A A AGGC T G GAGATATGTC G AATGTGTGT T T TGTGTGTGTTTG G GT CATGTGT T T TG GCGTACTAA G GTGTATATAT TGT TATATATATA GAC ATATATAAAA A T TATAAAAAAA A A AAAAAAAGG A AAAAGAGAGA  AGAGAGAGAG AAC GAGAGAGAGA TA  AGG GA AAC C G GAGACACACA A A ACCAGAG CAGAGCAGC AGGCTATTAAT GCA CCTCTC C C CTCTCTCCCC C T TCTCCCT T C CCCCTCTATA A C CTCTATACAC  GG TATACACTCT T A ACACT GTTT T C CTTTGTC G T TTGTTGG T T TGTGGGGC TT GGGGCGCGT AG G GCGCGCGTGT  TT CGCGTGTGCAGG GC TGTGTGTGT T T GCGTCT GCTTGTTTTTTA T GC GCTTTTAA AA T TTTTATATAT T T TATAT CTTT  ATT TTTCTC  TA TTTTCCT T T TCTCTCTATA GCTATTCGCTACAC C T TATACACACA A A ACACACAGAG  CACAGAGGGCTT GAGGGGTGT T GCAGGGTGTTTT T G GTGTTTTCTC C T TTC TTCTCT T TG ATCTTT A C CT TCTAAAA A T TATAAGC AT CG  AAAATATGGCG ATATG CAT T TGTT T GTA TGGTTTTT T T TTTTTTT ATTT CTG TTTTT T T TTTTCTC  GT TTTTCTCACA A TTCACAAA C CACAAAA AA GT  AAAAAAA AC  AAAACACACA A A ACACACACAC C CGTGACGCG G A ACCGTGT  AT CGCGTTG G GA GGTGTGCAGAC TTGCGCATG  CA GCGCACAGAG G C CACAGAGGGG G A TTAGGC TGC C G GGGGCGCTCT T GGTAGCTCTGTAATTTCTG TGGT T TTGTTGTGTTTT T T GTGTTTTTTT T T TTTTTTTA GTA T TTTTATAGG GAGA TATAAT GAT T AATATA A AT CATATAAAG G T TATAGAGGGG G A AGAGGGGGGG G G GGGGGGGGGG CAC GGGGCGGCC GGGCG ACT TGTCTGATCG C CTTGAGA A T TGTGAGAA,CTATAAAACAC TTC TAGACAACACCCC C A TGAACACCCCACA CAG ACACCCCAGTTG C CCCCACAGAGAA CACGCAGAGAGAAGCTA A AGAGAA TAAAAA A G GAGAAAAGAG G A AAAAAAAGAGCGC ATTAAGAGCGCGCA CA GACG GCGTGT T G GCGCGCGTGTGTG G CTC GTGTGCAT AGACA A T TGTGCGCAAA A G GCGCACAAGATAG G C CACAAAAGAGCGC GTTAAGAGCGCAA A AGGT GCACAGAG  GCGCAAGAATAA GGATAT T AAGAAAGATTG GT G GAGATA CTTTTT T A ATTTGTTTTTGTG G T TTTTTATTTGGGG G TGC TTGTGGGGAGA A T TGTGGGGAGACAC GGAGACACGGCG GATAA CACGCGC  ACACGCGCGCGCG ATTCGCGCGTT AGCCA GCGCGTGT TA A C CGCGTGTA CGAA A G GTAACAAGAG G T TA TAAGAGA A A AAAAGAGAGATCGTT AGA  TCGATTC C G GAGATATCTCGCG G A ATATCTCGGTTGTTTCGCGTGTCTGCCGTG CTCGCG G G GTG GTCGGG  TCCGGGGCGC C C CGCGGGGCGCA GGGGCGCAA AG CG G GCCCTCAGAGCGC C C CACAGAGCGCGCG G A AGAGCGCGCGTGT T G GCAT GTCTC C C CGCGTGTCTCACAG GTGTCTCACAGAG G TTCACAGTCA AGATT CAT ATGCGATAT T A AGAGAGTCATGTG G GGATATGTGTGT T A ATATGTGTTG  TGTGTGTGGTAT G GTGTGTGTTCTA C TGTGTGTATATGAC GTTATATATA A T TATATGA TAATGAAAG ATATATAAAAAAA A T TATAAAAAA AAG G A AAAAAAAGAGAGA A A AAAAGAGAGAGAG G AG GAGAGAGAGAGA A GGAGGGTC A AGAGAGACACACA A G GAT GACACAGAG G A ACACACAGAGCA TC CC ACAGAGCGCTCT CT ATAAGCCTCC GAA CTCTCCCC C C CTCTCTCCCCTCT  ACTT TCCCCTCTACG  CGGCACTATACACAC C CTCTATACT AT T TATACGTCTTA TGT A ACACTCTTGTAGG  CTCTTTTGTGGGG  TTTGGGGCGC C T AATGGGGCGCGCG  GGGGCGCGCGTG GT G GCGCGGTGTG G C CGCGTGTGTGTGT T G GTTGTGT TT T T TGTGTC ATTTTT T G GTGTTTTTA CTA A T TTTT TTAAT T T TTTATTTTTT T T TATATATTTTGTC C A ATA TTTCAG CT T T TTTTCACACTATA A TAGATA CTATACAC C C CTCTATAC GCTAA AACAGT TACACAGGG G C CAAGGGT T A AGAGGCGTT G GGGGTGTTTTCC G GTTTCTCTCT T T TTTTCTCTCTATA A T CGTCTCTATAAA C CTCTATAAAATAT T T TATAA TCATGTG  AAAATATGTGTT A ATATGTGTGTTTTTT TTGTGTTTTTTT T G GTAG TTTTTTTT T T TTTTTTTTTTTTT GT  TTTTTTTCTC C TTACC TTCACA GC  TTTTCAGAAA A T TCTCACAAAAAAA A C CACAAAAAAC C A AAAAAAACTCT AGA A AAAACCACAC C A ACAC CACAA CG G C CACAGACGCGTGT CAG ACACGC AGTGTG G CTAACGTGTG TC TTC G GTGTGGCACG A T TGGCTCAGAG TT  GCGCACAGAGGGG G C CACACAGGGGCGC  CA AGGGCGCTCT T G GGGGCGCTCTGTG T TGCTCTGTGTGT T C CTCTGTGTCGTT TTT TGTGTTTTTTT T GGTTTTATA AC  TTTTTTTATAAACGA T TTCTTAATAT  TATAAAAT AGTA A A AAAATATATAGTCTG A ATATATAGAGGGG G T TAAGGGGGACTG AAGGGGGGGGGG GATGGGGGGGGCCT C G GGGGGGCTGC T G GGGGCGCTTG G G GCGCACTGAA TTACTGTGAGAA,TAAAACACCCC C T TATAAAG ACCCCACA A A AAAACCCACAGG AGGCACCCCACAGAGAGA A C CCCACCAGAGAAA CAG CACAGAGAGAAAAAAA A A AGAGAGAAAAAAAGG G GAGAAAAAAGCGC C A AAAAAAAGAGCGCGCG AG GGCGG GCGCGTTTTT A AGAGCGTGTG CTAGCGCGTGTGTGCGTTC CAA CGTGTGTGCCGTCA A G GT TATGCGCACAAAA A T TGTGCTAACAAAAGAG TCC GCGCA AAAGCGC C C CACAAAGCGCACA A A AAAAGAGCGCACAGAG G A AGAGC TTGCGTATA G GTGCACAGGATAT T C CACAGGATATTCT T AGG AGAGATATTTT T GG AGATATTTTTTTGTG G A ATATTTTTTCACTAGG G T TTTTTTTGTGGGGAGA A T TTTTGG GGACC T TGTGGGGAGACACGCG TGG GGGCAGACACGCGCGC GACACGCGCGCGCG G AACGCGCTGTCGTGT T CCGCGCGCGTGTAAGCA G GCGCGCGTGTAGCAAA A C GTGTAAAGAG G G GTGTATAAAAGAGAGA GC  TATAAAAGAGAGATAT T A AAT TAGAGATATCTC C AAATAGAGATATCCGTCG G G GAATCTCGCGT CG ATTGTTCGCGTGTCTC C T TCTCGCGTGTCTCGG CCGTGTCTCG GGAGA GTGTCTCGCGGGC  TCTCGCGGGGCGCACA A CT ACGGGGCGCAA CG AG G GGGGCCAG CAGC CTGGCACAGAGCAGGCG G C CACAGAGCCGTGT TCT AGAGCTG GCGGTCTC C G GCGCGGTCTTGCTGA CCGTGTCTCA CGATG GCGTCTCACAGAGAGA A T TCTCACAGAGATT AT T C CACAGGG GATG GGTGG AAGAT AGGGTGTGT GCTGATATGGTGTG G A ATTGTTGTGTGATCGT T T TGTGTGCGGC TA GTTGTGTGTGTATATAT T T TGTGTGTATATATATA G A GTGTAGA ATATAAAA A T TAAT GGGTAAAAAAA A AATAAAAAAGAG G T TATAAAAAAAGAGAGA A AAAAAAGAGAGAGAG G AAAGAGAGAGAGAGA A A AGAGAGAGC TAC C G GAGAGAGATTTACACA A AAGAACACAGAACG G GAACACAGCACA TC AACACAGAGCGCTCT T C CAAGCGCTAA C A AGATTTT CTCTCC TTC G GCGCTTATTCCCCTCT T C CTTCCCCTCTATA  TCG GCCTCTAGT AC C C CCCCTAGGACTCT  CT GCTACACTCTTTT ATATACACTTT TTGTG G A ACACTCTTTTGTGGGG G C CTCTTCTGTGGGGCGC CTC TTTGTGGCCTCCG  TGTGG ACGCGCGTGT T G GGGGCCAGCAGGTGG G GCGCGCGTGTGTGTGT T C CGCGTTGT GATT T G GTGATTGTGTTTTTTT T T TGTGTGTTTTTTTATA  GTGTTGACTTACTC ACT TTTTTTATATAGCGATTTT TATTATATATTTTCTC C T TTTATTCTCT T A ATATTTCTTA A T TTTTCTCTCTATACAC  TC CGCTATACACACA A CTT CTATACACACAGAG G T TATACACACAGAGG AGG A ACACACAGAGGGGTGT T C CACGTAGGGGTGTTTT T A AGCTAGGTGTTTTCCG C GCGGGGTGTTTTCTCTCAAACACGT GTTTCTCTCTATA  TTTTCTCTTAAAA A T TCGCTCTATAAAATT CCTATAAATGGTTG T TATAAAATATGTGTTACT A AAAATATGTGTTG TT GAT ATATGTGTGTTTTTTT T T TGTGTGTTTTTCTTT G GTGTTTTTTTTTTT CTT TTTTTTTTTTTTCTTTC T TTTTTTGTTTCCA GTA TTTTTTTCTCACAAAG A TTTCTCACAAAAAC TA T TCTCAGCTAAAAC C C CACAATAAAACACACA A A AAAAAAACCTACACAC C A AAAACT GAGCACGCG TATACACCAACGGCAGT T C CACACACGCGTGTGTG G A ACACGCGTGTGTGCGC C C CGCGTGTGA TGCACA A G GTGTGTGCGCACAGAG G T TGTGCGCACAGAGGGG G G GCGGACAGAGGGGCGC C CTA CAGAGGGGCGCTATAT A AGAT GGCGCTCTGTG G G GG AAT GC GT TGT T G GCGCTCTGTGTTGCTT T C CT GGATG TATTTTT T T TGTGTGTTGT TTATA A GGTTTTTTAAAA A TGCATTTTTATAAAATAGGAAGATATTAAAAAATCT TA A T TATAAAATGTGTAGAG G A AGTAGGG  GA ATATATAGAGGGGGGG G TGTTTAGGCGATAGGGAAGA G AGAGGGGGATGGGCGC  GGGGGGGGGGCTCTCT CTGGGGGGCGCTCTGTG G G GGGGCCA TGAA G GCGCTTTGTGAGAA,CTAATGAACACCCCACA A T GGACCCCACAGG AACCCCACAGAGA AC GGCCACAGAATAA TAT CCCCACAGAGAGAAAAAA C CACAGAGAATCAAAAAGAG  AGAGAGAAAAGAGCGTTC G GAGATAAAAAGAGCGCGCG  AAAAAAAGAGCGCGCGTT AGTCAAGAGCCGTGTGTG  AGGCGCGTTGCGC GAC GCGCGCG GTGTGCGCACA A C CGCGTGTGTGCGCACAAAA A GA AGTGGTTGCACAAGG AG TGCGCACAAAAGAGCGC  GCGCACAATAAAGCGCACA A C CACAAACTAGCGCATTCAG G A AAAAGACGGCAAGAGA A A AGAGCGCACAGAGAGATAT AG  GCGCACAGAGAGATATTTT T C CACAGAGAGATATTTTTTT T A TTAGAGATATTTTTG GATAGATATTTTTTTGAGCG A ATATTTTTTTGGCGGGAGA  TA TTTTTTTGA GGGAC T TTTTGAT GGA ATACGTGT GT TGTGGC GACGCGCGC GGAAT CGCGCGCG G GGACACGTGGCGTACCT A ACACGGCGCAACTGTA A C CGGCGCGTGTATAAAA A G GCGCGCGTCT TAAAAGAG G CA TCGTGTATAAAAGATGGA A GGTCGTATAAAAGAGAGATAT G T TATAAA GAGAGATAGATC C A AAAAGAGAGATATCA CCAGG A AGAGAGATATCCGTT G GAGATATCTCGGTCTC C AGCTATCTCG TTGTCTCGCG G T TCTCGCGTGTCTCGCGGGG G C CGGTCTCGCGGGC C G GT AATCGGGCGCACA TCGCGGGCACAGG C CGGGCTTTCAGAGCGC C G GGGGCGCACG AGCA ACG G G GCGCACAGAGCAATCGTGT T C CAG ACTTGCGGAC GT AGAGC CACGTGTCTCA TC GCAC CGTGTCTCACAGG C CGCGTGTCTCACAGAGAGA AAG GTGTCTA  TTAGAGAAT TGTTAATAGAGATTAATG  CACAGAGAGATATGTGTGT TTT AGAGAGATATGTATGTGTG G G GA TCTC TGTGTGTGTGT T A ATATGTGTGTGGTATA A TACGTGTGTGTGTGTATGTAT T G GTTAGGGCGTATATATAGT TGTTTTTATTGGTAA GTGTATATTAAAA A T TATATAAGAAAAAGAG G A ATATAGTGAAAAAGAGAGA A T TATAAAAGAGA ACAG G A AAAAATTCAGAGAGAGAGT  AAAAGAGA TAAGAGT C A AGAGAGAGAGAGACACAA G GAGAGAGAGACACACAG TG AGAGACGTACACAGAGCGC C G GAGACACATAAT AGAGACACAGAGCGCTACAATG CACAGAGCGCTCT TCCCC C A AGCTAGCTCTCTCCCCTCT T G GCGCTCTCTCCCCTCTAA C CTCTCCCTCTATACGCG TCCTACCTTCCTACACTCTCT C CCCCTAGCTACACTCTTTT T C CTCTATACACTCTTTTGA TG T GATACACTCTTTTGTGGGG G AAAGAGCTTGTGGGGCGC  CTCTTTTGTGGGGCGCGCG T T TTTTGTGGGGCGCGCGTGT T T TGTGGTGCGCGGTGGTG GGGGCGCGGTGTGTGT T G GCGCGCGTGTGTGTTT T C CGCGTTAATGTGTTTTTTT T GGTGTGTGTTTTTTTATA A T TGTGTTGCTTTTTATCGGACT G GTGTTTTTTTATATATTTT T T TTTTAATT TCTC C TTCTTTATATATTTTCTCTCT T TGAGTATATTTTCTCTTA TCAA A ATATTGAA AACTATACAC CTA TTAAC TTCTATACCTCCA A TA GTCTCAGAG G C CTCTATACACACAGAGGAAGCACTACA TCAGAGGGT T A ACCAG TGGGTGC TT T C CACAGAGGGGTGTTTC C ACAGAGGGGTTTCTCTGTAT G GGAAGCTATA A G GTGTTTTCTCTCTATAAA T TTACATCTCTATAAGAAT TAAACTATGGCAGATGTG G CCTATAAAATATGTGTGAC TATGGAATATGTGTGTTTT T A AAAATTGTGTTG AT A ATATGTGTGTTTTTTTTTT T TG ATGTGTTTTTTTTTTTTT T G GTGTTTTTTTTTTTTTCTC  TTGTATTTTTCTCACA T TCGTTTTTTTTCACGTAA ACATTATTTTTCTCACAAAAAAA A T TTTTCTCAAAAAACAC C T TCTCACAAAAAAACACAA C CACAATCTACACACAC C ATCTAAAAACACACACCGTG A AAAACCAGCACACGCGTT A ACACA TAACGCGTGTGTG G C CACACACGCGTGTGTGCGC C A ACTCTCGTGTGTGCGCACA A CCGTGTGGGCAAACAGAG G G GTGTGTGCGCACAGAGGGG G T TGTGCAGGGC C G GCGCACAGAGGGCTCT GCGCAGAGGGGCGCTGTATG AGG AGAGGGGCGCTTGTTG T G GGGGCGCTCTGTT GGC GCGCTCTGGTTTTTTT T C CTCTGTGTTCAT ATTATA A T TGTGTGTTTTTTAAA G GTGTTTTTTTAAATAT T T TTTAAAATTA A TTTATTATAAGCGATATAGAG G T TATAAAATTAGGG G A AAAATATATAGAGGGGGGG G AGACATATAGAT GGGGGGGG G T TACGTAGGGGGGGGGC C A AGAGGGGGGGGGGCGCTCT T GAACGGGGGGTAA ATCTGTG G G GGGGGGGCGCTCTGTGAGA  GGCG GCTCTGAGA,"ID   SPIKE_SARS2             Reviewed;        1273 AA.
AC   P0DTC2;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Spike glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE            Short=S glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=E2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=Peplomer protein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S1 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2' {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Flags: Precursor;
GN   Name=S {ECO:0000255|HAMAP-Rule:MF_04099}; ORFNames=2;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   FUNCTION (SPIKE PROTEIN S1), AND CLEAVAGE BETWEEN S2 AND S2' BY HOST
RP   TMPRSS2.
RX   PubMed=32142651; DOI=10.1016/j.cell.2020.02.052;
RA   Hoffmann M., Kleine-Weber H., Schroeder S., Krueger N., Herrler T.,
RA   Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A.,
RA   Mueller M.A., Drosten C., Poehlmann S.;
RT   ""SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a
RT   clinically proven protease inhibitor."";
RL   Cell 181:1-10(2020).
RN   [3]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, FUNCTION, AND MUTAGENESIS OF
RP   681-PRO--ALA-684.
RX   PubMed=32362314; DOI=10.1016/j.molcel.2020.04.022;
RA   Hoffmann M., Kleine-Weber H., Poehlmann S.;
RT   ""A multibasic cleavage site in the Spike protein of SARS-CoV-2 is essential
RT   for infection of human lung cells."";
RL   Mol. Cell 78:779-784(2020).
RN   [4]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=32366695; DOI=10.1126/science.abb9983;
RA   Watanabe Y., Allen J.D., Wrapp D., McLellan J.S., Crispin M.;
RT   ""Site-specific glycan analysis of the SARS-CoV-2 spike."";
RL   Science 369:330-333(2020).
RN   [5]
RP   GLYCOSYLATION AT ASN-61; ASN-74; ASN-122; ASN-149; ASN-165; ASN-234;
RP   ASN-282; THR-323; SER-325; ASN-331; ASN-343; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1194, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=32363391; DOI=10.1093/glycob/cwaa042;
RA   Shajahan A., Supekar N.T., Gleinich A.S., Azadi P.;
RT   ""Deducing the N- and O- glycosylation profile of the spike protein of novel
RT   coronavirus SARS-CoV-2."";
RL   Glycobiology 30:981-988(2020).
RN   [6]
RP   VARIANT GLY-614.
RX   PubMed=32820179; DOI=10.1038/s41598-020-70827-z;
RA   Isabel S., Grana-Miraglia L., Gutierrez J.M., Bundalovic-Torma C.,
RA   Groves H.E., Isabel M.R., Eshaghi A., Patel S.N., Gubbay J.B., Poutanen T.,
RA   Guttman D.S., Poutanen S.M.;
RT   ""Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein
RT   mutation now documented worldwide."";
RL   Sci. Rep. 10:14031-14031(2020).
RN   [7]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=32697968; DOI=10.1016/j.cell.2020.06.043;
RG   Sheffield COVID-19 Genomics Group;
RA   Korber B., Fischer W.M., Gnanakaran S., Yoon H., Theiler J., Abfalterer W.,
RA   Hengartner N., Giorgi E.E., Bhattacharya T., Foley B., Hastie K.M.,
RA   Parker M.D., Partridge D.G., Evans C.M., Freeman T.M., de Silva T.I.,
RA   McDanal C., Perez L.G., Tang H., Moon-Walker A., Whelan S.P.,
RA   LaBranche C.C., Saphire E.O., Montefiori D.C.;
RT   ""Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases
RT   Infectivity of the COVID-19 Virus."";
RL   Cell 182:812-827(2020).
RN   [8]
RP   FUNCTION.
RX   PubMed=32817270; DOI=10.1126/science.abd5223;
RA   Turonova B., Sikora M., Schuermann C., Hagen W.J.H., Welsch S.,
RA   Blanc F.E.C., von Buelow S., Gecht M., Bagola K., Hoerner C.,
RA   van Zandbergen G., Landry J., de Azevedo N.T.D., Mosalaganti S.,
RA   Schwarz A., Covino R., Muehlebach M.D., Hummer G., Krijnse Locker J.,
RA   Beck M.;
RT   ""In situ structural analysis of SARS-CoV-2 spike reveals flexibility
RT   mediated by three hinges."";
RL   Science 370:203-208(2020).
RN   [9]
RP   GLYCOSYLATION.
RX   PubMed=32929138; DOI=10.1038/s41598-020-71748-7;
RA   Grant O.C., Montgomery D., Ito K., Woods R.J.;
RT   ""Analysis of the SARS-CoV-2 spike protein glycan shield reveals
RT   implications for immune recognition."";
RL   Sci. Rep. 10:14991-14991(2020).
RN   [10]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, IDENTIFICATION BY MASS SPECTROMETRY, SUBCELLULAR LOCATION, AND
RP   SUBUNIT.
RX   PubMed=32979942; DOI=10.1016/j.cell.2020.09.018;
RA   Yao H., Song Y., Chen Y., Wu N., Xu J., Sun C., Zhang J., Weng T.,
RA   Zhang Z., Wu Z., Cheng L., Shi D., Lu X., Lei J., Crispin M., Shi Y.,
RA   Li L., Li S.;
RT   ""Molecular Architecture of the SARS-CoV-2 Virus."";
RL   Cell 183:730-738(2020).
RN   [11]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=33106671; DOI=10.1038/s41586-020-2895-3;
RA   Plante J.A., Liu Y., Liu J., Xia H., Johnson B.A., Lokugamage K.G.,
RA   Zhang X., Muruato A.E., Zou J., Fontes-Garfias C.R., Mirchandani D.,
RA   Scharton D., Bilello J.P., Ku Z., An Z., Kalveram B., Freiberg A.N.,
RA   Menachery V.D., Xie X., Plante K.S., Weaver S.C., Shi P.Y.;
RT   ""Spike mutation D614G alters SARS-CoV-2 fitness."";
RL   Nature 592:116-121(2020).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Liverpool/REMRQ001/2020;
RX   PubMed=33082294; DOI=10.1126/science.abd3072;
RA   Daly J.L., Simonetti B., Klein K., Chen K.E., Williamson M.K.,
RA   Anton-Plagaro C., Shoemark D.K., Simon-Gracia L., Bauer M., Hollandi R.,
RA   Greber U.F., Horvath P., Sessions R.B., Helenius A., Hiscox J.A.,
RA   Teesalu T., Matthews D.A., Davidson A.D., Collins B.M., Cullen P.J.,
RA   Yamauchi Y.;
RT   ""Neuropilin-1 is a host factor for SARS-CoV-2 infection."";
RL   Science 370:861-865(2020).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Finland/1/2020;
RX   PubMed=33082293; DOI=10.1126/science.abd2985;
RA   Cantuti-Castelvetri L., Ojha R., Pedro L.D., Djannatian M., Franz J.,
RA   Kuivanen S., van der Meer F., Kallio K., Kaya T., Anastasina M., Smura T.,
RA   Levanov L., Szirovicza L., Tobi A., Kallio-Kokko H., Oesterlund P.,
RA   Joensuu M., Meunier F.A., Butcher S.J., Winkler M.S., Mollenhauer B.,
RA   Helenius A., Gokce O., Teesalu T., Hepojoki J., Vapalahti O.,
RA   Stadelmann C., Balistreri G., Simons M.;
RT   ""Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity."";
RL   Science 370:856-860(2020).
RN   [14]
RP   INTERACTION WITH HUMAN ITGA5 AND ITGB1.
RX   PubMed=33102950; DOI=10.1016/j.jacbts.2020.10.003;
RA   Beddingfield B.J., Iwanaga N., Chapagain P.P., Zheng W., Roy C.J., Hu T.Y.,
RA   Kolls J.K., Bix G.J.;
RT   ""The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2
RT   Infection."";
RL   JACC Basic Transl. Sci. 6:1-8(2021).
RN   [15]
RP   VARIANT GLY-614.
RX   PubMed=33184236; DOI=10.1126/science.abe8499;
RA   Hou Y.J., Chiba S., Halfmann P., Ehre C., Kuroda M., Dinnon K.H. III,
RA   Leist S.R., Schaefer A., Nakajima N., Takahashi K., Lee R.E.,
RA   Mascenik T.M., Graham R., Edwards C.E., Tse L.V., Okuda K., Markmann A.J.,
RA   Bartelt L., de Silva A., Margolis D.M., Boucher R.C., Randell S.H.,
RA   Suzuki T., Gralinski L.E., Kawaoka Y., Baric R.S.;
RT   ""SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and
RT   transmission in vivo."";
RL   Science 370:1464-1468(2020).
RN   [16]
RP   VARIANT GLY-614.
RX   PubMed=33417835; DOI=10.1016/j.celrep.2020.108630;
RA   Gobeil S.M., Janowska K., McDowell S., Mansouri K., Parks R., Manne K.,
RA   Stalls V., Kopp M.F., Henderson R., Edwards R.J., Haynes B.F., Acharya P.;
RT   ""D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease
RT   Cleavage at the S1/S2 Junction."";
RL   Cell Rep. 34:108630-108630(2021).
RN   [17]
RP   VARIANTS 69-VAL--PHE-70 DEL; LYS-144 DEL; TYR-501; ASP-570; GLY-614;
RP   HIS-681; ILE-716; ALA-982 AND HIS-1118.
RC   STRAIN=20I/501Y.V1, Alpha, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [18]
RP   VARIANT TYR-501.
RX   PubMed=32732280; DOI=10.1126/science.abc4730;
RA   Gu H., Chen Q., Yang G., He L., Fan H., Deng Y.Q., Wang Y., Teng Y.,
RA   Zhao Z., Cui Y., Li Y., Li X.F., Li J., Zhang N.N., Yang X., Chen S.,
RA   Guo Y., Zhao G., Wang X., Luo D.Y., Wang H., Yang X., Li Y., Han G., He Y.,
RA   Zhou X., Geng S., Sheng X., Jiang S., Sun S., Qin C.F., Zhou Y.;
RT   ""Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy."";
RL   Science 369:1603-1607(2020).
RN   [19]
RP   VARIANT GLY-614, AND MUTAGENESIS OF GLY-614.
RX   PubMed=33636719; DOI=10.1038/s41586-021-03361-1;
RA   Zhou B., Thi Nhu Thao T., Hoffmann D., Taddeo A., Ebert N., Labroussaa F.,
RA   Pohlmann A., King J., Steiner S., Kelly J.N., Portmann J., Halwe N.J.,
RA   Ulrich L., Trueeb B.S., Fan X., Hoffmann B., Wang L., Thomann L., Lin X.,
RA   Stalder H., Pozzi B., de Brot S., Jiang N., Cui D., Hossain J., Wilson M.,
RA   Keller M., Stark T.J., Barnes J.R., Dijkman R., Jores J., Benarafa C.,
RA   Wentworth D.E., Thiel V., Beer M.;
RT   ""SARS-CoV-2 spike D614G change enhances replication and transmission."";
RL   Nature 5920:122-127(2021).
RN   [20]
RP   MUTAGENESIS OF ASN-165; ASN-234; ASN-331; ASN-343; LEU-452; ALA-475;
RP   VAL-483; PHE-490 AND HIS-519.
RX   PubMed=32730807; DOI=10.1016/j.cell.2020.07.012;
RA   Li Q., Wu J., Nie J., Zhang L., Hao H., Liu S., Zhao C., Zhang Q., Liu H.,
RA   Nie L., Qin H., Wang M., Lu Q., Li X., Sun Q., Liu J., Zhang L., Li X.,
RA   Huang W., Wang Y.;
RT   ""The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and
RT   Antigenicity."";
RL   Cell 182:1284-1294(2020).
RN   [21]
RP   FUNCTION, CLEAVAGE BETWEEN S1 AND S2 BY HOST CTSL, AND INTERACTION WITH
RP   HUMAN ACE2.
RX   PubMed=32221306; DOI=10.1038/s41467-020-15562-9;
RA   Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Guo R., Chen T.,
RA   Hu J., Xiang Z., Mu Z., Chen X., Chen J., Hu K., Jin Q., Wang J., Qian Z.;
RT   ""Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and
RT   its immune cross-reactivity with SARS-CoV."";
RL   Nat. Commun. 11:1620-1620(2020).
RN   [22]
RP   INTERACTION WITH HUMAN ACE2.
RX   PubMed=33607086; DOI=10.1016/j.bpj.2021.02.007;
RA   Cao W., Dong C., Kim S., Hou D., Tai W., Du L., Im W., Zhang X.F.;
RT   ""Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2
RT   protein-protein interaction."";
RL   Biophys. J. 120:1011-1019(2021).
RN   [23]
RP   FUNCTION, AND CLEAVAGE BETWEEN S1 AND S2 BY HOST TMPRSS2.
RX   PubMed=33465165; DOI=10.1371/journal.ppat.1009212;
RA   Ou T., Mou H., Zhang L., Ojha A., Choe H., Farzan M.;
RT   ""Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated
RT   by TMPRSS2."";
RL   PLoS Pathog. 17:e1009212-e1009212(2021).
RN   [24]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH S PROTEIN.
RX   PubMed=33229438; DOI=10.1074/jbc.ra120.016175;
RA   Boson B., Legros V., Zhou B., Siret E., Mathieu C., Cosset F.L.,
RA   Lavillette D., Denolly S.;
RT   ""The SARS-CoV-2 Envelope and Membrane proteins modulate maturation and
RT   retention of the Spike protein, allowing assembly of virus-like
RT   particles."";
RL   J. Biol. Chem. 296:100111-100111(2020).
RN   [25]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, MUTAGENESIS OF ALA-684, AND FUNCTION (SPIKE PROTEIN S2').
RX   PubMed=32703818; DOI=10.26508/lsa.202000786;
RA   Bestle D., Heindl M.R., Limburg H., Van Lam van T., Pilgram O., Moulton H.,
RA   Stein D.A., Hardes K., Eickmann M., Dolnik O., Rohde C., Klenk H.D.,
RA   Garten W., Steinmetzer T., Boettcher-Friebertshaeuser E.;
RT   ""TMPRSS2 and furin are both essential for proteolytic activation of SARS-
RT   CoV-2 in human airway cells."";
RL   Life. Sci Alliance 3:1-14(2020).
RN   [26]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, CLEAVAGE BETWEEN S2 AND S2' BY HOST CSTL, AND FUNCTION (SPIKE
RP   PROTEIN S2').
RX   PubMed=34159616; DOI=10.15252/embj.2021107821;
RA   Koch J., Uckeley Z.M., Doldan P., Stanifer M., Boulant S., Lozach P.Y.;
RT   ""TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect
RT   host cells."";
RL   EMBO J. 40:1-20(2021).
RN   [27]
RP   VARIANTS PHE-18; ALA-80; GLY-215; ASN-417; LYS-484; TYR-501; GLY-614 AND
RP   VAL-701.
RC   STRAIN=20H/501Y.V2, B.1.351, and Beta;
RX   PubMed=33690265; DOI=10.1038/s41586-021-03402-9;
RA   Tegally H., Wilkinson E., Giovanetti M., Iranzadeh A., Fonseca V.,
RA   Giandhari J., Doolabh D., Pillay S., San E.J., Msomi N., Mlisana K.,
RA   von Gottberg A., Walaza S., Allam M., Ismail A., Mohale T., Glass A.J.,
RA   Engelbrecht S., Van Zyl G., Preiser W., Petruccione F., Sigal A.,
RA   Hardie D., Marais G., Hsiao M., Korsman S., Davies M.A., Tyers L.,
RA   Mudau I., York D., Maslo C., Goedhals D., Abrahams S., Laguda-Akingba O.,
RA   Alisoltani-Dehkordi A., Godzik A., Wibmer C.K., Sewell B.T., Lourenco J.,
RA   Alcantara L.C.J., Kosakovsky Pond S.L., Weaver S., Martin D.,
RA   Lessells R.J., Bhiman J.N., Williamson C., de Oliveira T.;
RT   ""Emergence of a SARS-CoV-2 variant of concern with mutations in spike
RT   glycoprotein."";
RL   Nature 592:438-443(2021).
RN   [28]
RP   POLYMORPHISM.
RX   PubMed=34142653; DOI=10.2807/1560-7917.es.2021.26.24.2100509;
RA   Campbell F., Archer B., Laurenson-Schafer H., Jinnai Y., Konings F.,
RA   Batra N., Pavlin B., Vandemaele K., Van Kerkhove M.D., Jombart T.,
RA   Morgan O., le Polain de Waroux O.;
RT   ""Increased transmissibility and global spread of SARS-CoV-2 variants of
RT   concern as at June 2021."";
RL   Eurosurveillance 26:0-0(2021).
RN   [29]
RP   VARIANTS ARG-452 AND PHE-453, AND MUTAGENESIS OF LEU-452; TYR-453 AND
RP   ASN-501.
RX   PubMed=34171266; DOI=10.1016/j.chom.2021.06.006;
RG   Genotype to Phenotype Japan (G2P-Japan) Consortium;
RA   Motozono C., Toyoda M., Zahradnik J., Saito A., Nasser H., Tan T.S.,
RA   Ngare I., Kimura I., Uriu K., Kosugi Y., Yue Y., Shimizu R., Ito J.,
RA   Torii S., Yonekawa A., Shimono N., Nagasaki Y., Minami R., Toya T.,
RA   Sekiya N., Fukuhara T., Matsuura Y., Schreiber G., Ikeda T., Nakagawa S.,
RA   Ueno T., Sato K.;
RT   ""SARS-CoV-2 spike L452R variant evades cellular immunity and increases
RT   infectivity."";
RL   Cell Host Microbe 0:0-0(2021).
RN   [30]
RP   VARIANT 69-VAL--PHE-70 DEL, AND MUTAGENESIS OF 69-HIS-VAL-70.
RX   PubMed=34166617; DOI=10.1016/j.celrep.2021.109292;
RG   COVID-19 Genomics UK (COG-UK) Consortium;
RA   Meng B., Kemp S.A., Papa G., Datir R., Ferreira I.A.T.M., Marelli S.,
RA   Harvey W.T., Lytras S., Mohamed A., Gallo G., Thakur N., Collier D.A.,
RA   Mlcochova P., Duncan L.M., Carabelli A.M., Kenyon J.C., Lever A.M.,
RA   De Marco A., Saliba C., Culap K., Cameroni E., Matheson N.J., Piccoli L.,
RA   Corti D., James L.C., Robertson D.L., Bailey D., Gupta R.K.;
RT   ""Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in
RT   the Alpha variant B.1.1.7."";
RL   Cell Rep. 35:109292-109292(2021).
RN   [31]
RP   VARIANTS ILE-13 AND CYS-152, POLYMORPHISM, AND MASS SPECTROMETRY (SIGNAL).
RX   PubMed=34210893; DOI=10.1126/science.abi7994;
RA   McCallum M., Bassi J., De Marco A., Chen A., Walls A.C., Di Iulio J.,
RA   Tortorici M.A., Navarro M.J., Silacci-Fregni C., Saliba C., Sprouse K.R.,
RA   Agostini M., Pinto D., Culap K., Bianchi S., Jaconi S., Cameroni E.,
RA   Bowen J.E., Tilles S.W., Pizzuto M.S., Guastalla S.B., Bona G.,
RA   Pellanda A.F., Garzoni C., Van Voorhis W.C., Rosen L.E., Snell G.,
RA   Telenti A., Virgin H.W., Piccoli L., Corti D., Veesler D.;
RT   ""SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern."";
RL   Science 373:648-654(2021).
RN   [32]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-1269 AND HIS-1271.
RX   PubMed=34504087; DOI=10.1038/s41467-021-25589-1;
RA   Cattin-Ortola J., Welch L.G., Maslen S.L., Papa G., James L.C., Munro S.;
RT   ""Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate
RT   expression at the cell surface and syncytia formation."";
RL   Nat. Commun. 12:5333-5333(2021).
RN   [33]
RP   PALMITOYLATION AT CYS-1235; CYS-1236; CYS-1240; CYS-1241; CYS-1243;
RP   CYS-1247; CYS-1248; CYS-1250; CYS-1253 AND CYS-1254.
RX   PubMed=34599882; DOI=10.1016/j.devcel.2021.09.016;
RA   Mesquita F.S., Abrami L., Sergeeva O., Turelli P., Qing E., Kunz B.,
RA   Raclot C., Paz Montoya J., Abriata L.A., Gallagher T., Dal Peraro M.,
RA   Trono D., D'Angelo G., van der Goot F.G.;
RT   ""S-acylation controls SARS-CoV-2 membrane lipid organization and enhances
RT   infectivity."";
RL   Dev. Cell 56:1-18(2021).
RN   [34] {ECO:0007744|PDB:6M17}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.90 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), DOMAIN, AND INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1).
RX   PubMed=32132184; DOI=10.1126/science.abb2762;
RA   Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q.;
RT   ""Structural basis for the recognition of the SARS-CoV-2 by full-length
RT   human ACE2."";
RL   Science 367:1444-1448(2020).
RN   [35]
RP   SUPERANTIGEN, AND DOMAIN.
RX   PubMed=32989130; DOI=10.1073/pnas.2010722117;
RA   Cheng M.H., Zhang S., Porritt R.A., Noval Rivas M., Paschold L.,
RA   Willscher E., Binder M., Arditi M., Bahar I.;
RT   ""Superantigenic character of an insert unique to SARS-CoV-2 spike supported
RT   by skewed TCR repertoire in patients with hyperinflammation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 117:25254-25262(2020).
RN   [36]
RP   INTERACTION WITH HUMAN BILIRUBIN, INTERACTION WITH HUMAN BILIVERDIN, AND
RP   MUTAGENESIS OF ASN-121 AND ARG-190.
RX   PubMed=33888467; DOI=10.1126/sciadv.abg7607;
RA   Rosa A., Pye V.E., Graham C., Muir L., Seow J., Ng K.W., Cook N.J.,
RA   Rees-Spear C., Parker E., Dos Santos M.S., Rosadas C., Susana A., Rhys H.,
RA   Nans A., Masino L., Roustan C., Christodoulou E., Ulferts R., Wrobel A.G.,
RA   Short C.E., Fertleman M., Sanders R.W., Heaney J., Spyer M., Kjaer S.,
RA   Riddell A., Malim M.H., Beale R., MacRae J.I., Taylor G.P., Nastouli E.,
RA   van Gils M.J., Rosenthal P.B., Pizzato M., McClure M.O., Tedder R.S.,
RA   Kassiotis G., McCoy L.E., Doores K.J., Cherepanov P.;
RT   ""SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity."";
RL   Sci. Adv. 7:0-0(2021).
RN   [37]
RP   BIOTECHNOLOGY, AND MUTAGENESIS OF 682-ARG--ARG-685 AND 986-LYS-VAL-987.
RX   PubMed=34322129; DOI=10.3389/fimmu.2021.701501;
RA   Martinez-Flores D., Zepeda-Cervantes J., Cruz-Resendiz A.,
RA   Aguirre-Sampieri S., Sampieri A., Vaca L.;
RT   ""SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of
RT   New Viral Variants."";
RL   Front. Immunol. 12:701501-701501(2021).
RN   [38]
RP   GLYCOSYLATION AT THR-676 AND THR-678 BY HOST GALNT1, AND MUTAGENESIS OF
RP   SER-673; THR-676; THR-678; SER-680 AND PRO-681.
RX   PubMed=34732583; DOI=10.1073/pnas.2109905118;
RA   Zhang L., Mann M., Syed Z.A., Reynolds H.M., Tian E., Samara N.L.,
RA   Zeldin D.C., Tabak L.A., Ten Hagen K.G.;
RT   ""Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [39]
RP   REVIEW, PROTEOLITIC PROCESSING, FUNCTION (SPIKE PROTEIN S2), AND FUNCTION
RP   (SPIKE PROTEIN S2').
RX   PubMed=34561887; DOI=10.1111/1348-0421.12945;
RA   Takeda M.;
RT   ""Proteolytic activation of SARS-CoV-2 spike protein."";
RL   Microbiol. Immunol. 66:15-23(2022).
RN   [40]
RP   INTERACTION WITH HOST MBL2.
RX   PubMed=35102342; DOI=10.1038/s41590-021-01114-w;
RA   Stravalaci M., Pagani I., Paraboschi E.M., Pedotti M., Doni A.,
RA   Scavello F., Mapelli S.N., Sironi M., Perucchini C., Varani L.,
RA   Matkovic M., Cavalli A., Cesana D., Gallina P., Pedemonte N., Capurro V.,
RA   Clementi N., Mancini N., Invernizzi P., Bayarri-Olmos R., Garred P.,
RA   Rappuoli R., Duga S., Bottazzi B., Uguccioni M., Asselta R., Vicenzi E.,
RA   Mantovani A., Garlanda C.;
RT   ""Recognition and inhibition of SARS-CoV-2 by humoral innate immunity
RT   pattern recognition molecules."";
RL   Nat. Immunol. 23:275-286(2022).
RN   [41]
RP   FUNCTION (SPIKE PROTEIN S1), AND INTERACTION WITH HOST INTEGRIN (SPIKE
RP   PROTEIN S1).
RX   PubMed=35150743; DOI=10.1016/j.jbc.2022.101710;
RA   Liu J., Lu F., Chen Y., Plow E., Qin J.;
RT   ""Integrin mediates cell entry of the SARS-CoV-2 virus independent of
RT   cellular receptor ACE2."";
RL   J. Biol. Chem. 1:101710-101710(2022).
RN   [42]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [43]
RP   SUBUNIT.
RX   PubMed=36735681; DOI=10.1371/journal.pbio.3001959;
RA   Shilts J., Crozier T.W.M., Teixeira-Silva A., Gabaev I., Gerber P.P.,
RA   Greenwood E.J.D., Watson S.J., Ortmann B.M., Gawden-Bone C.M., Pauzaite T.,
RA   Hoffmann M., Nathan J.A., Poehlmann S., Matheson N.J., Lehner P.J.,
RA   Wright G.J.;
RT   ""LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike
RT   protein."";
RL   PLoS Biol. 21:e3001959-e3001959(2023).
RN   [44]
RP   VARIANT ASN-405.
RX   PubMed=36851546; DOI=10.3390/v15020332;
RA   Bugatti A., Filippini F., Messali S., Giovanetti M., Ravelli C., Zani A.,
RA   Ciccozzi M., Caruso A., Caccuri F.;
RT   ""The D405N Mutation in the Spike Protein of SARS-CoV-2 Omicron BA.5
RT   Inhibits Spike/Integrins Interaction and Viral Infection of Human Lung
RT   Microvascular Endothelial Cells."";
RL   Viruses 15:0-0(2023).
RN   [45]
RP   MUTAGENESIS OF GLU-484.
RX   PubMed=37421949; DOI=10.1016/j.cell.2023.06.005;
RA   Baggen J., Jacquemyn M., Persoons L., Vanstreels E., Pye V.E., Wrobel A.G.,
RA   Calvaresi V., Martin S.R., Roustan C., Cronin N.B., Reading E.,
RA   Thibaut H.J., Vercruysse T., Maes P., De Smet F., Yee A., Nivitchanyong T.,
RA   Roell M., Franco-Hernandez N., Rhinn H., Mamchak A.A., Ah Young-Chapon M.,
RA   Brown E., Cherepanov P., Daelemans D.;
RT   ""TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry."";
RL   Cell 186:1-16(2023).
RN   [46] {ECO:0007744|PDB:6VSB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.46 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1), SUBUNIT, AND
RP   GLYCOSYLATION.
RX   PubMed=32075877; DOI=10.1126/science.abb2507;
RA   Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O.,
RA   Graham B.S., McLellan J.S.;
RT   ""Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation."";
RL   Science 367:1260-1263(2020).
RN   [47] {ECO:0007744|PDB:6VXX, ECO:0007744|PDB:6VYB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.80 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), SUBUNIT (SPIKE PROTEIN S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN
RP   S1), MUTAGENESIS OF 679-GLN--ALA-684, GLYCOSYLATION AT ASN-61; ASN-122;
RP   ASN-61; ASN-165; ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616;
RP   ASN-657; ASN-709; ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1134, AND
RP   DISULFIDE BOND.
RX   PubMed=32155444; DOI=10.1016/j.cell.2020.02.058;
RA   Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D.;
RT   ""Structure, function, and antigenicity of the SARS-CoV-2 spike
RT   glycoprotein."";
RL   Cell 180:1-12(2020).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2.
RX   PubMed=32225176; DOI=10.1038/s41586-020-2180-5;
RA   Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q.,
RA   Zhang L., Wang X.;
RT   ""Structure of the SARS-CoV-2 spike receptor-binding domain bound to the
RT   ACE2 receptor."";
RL   Nature 581:215-220(2020).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.68 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2, INTERACTION WITH HOST ACE2, AND MUTAGENESIS OF GLN-493 AND
RP   ASN-501.
RX   PubMed=32225175; DOI=10.1038/s41586-020-2179-y;
RA   Shang J., Ye G., Shi K., Wan Y., Luo C., Aihara H., Geng Q., Auerbach A.,
RA   Li F.;
RT   ""Structural basis of receptor recognition by SARS-CoV-2."";
RL   Nature 581:221-224(2020).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (3.08 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HUMAN ANTIBODY CR3022, AND DISULFIDE BOND.
RX   PubMed=32245784; DOI=10.1126/science.abb7269;
RA   Yuan M., Wu N.C., Zhu X., Lee C.D., So R.T.Y., Lv H., Mok C.K.P.,
RA   Wilson I.A.;
RT   ""A highly conserved cryptic epitope in the receptor-binding domains of
RT   SARS-CoV-2 and SARS-CoV."";
RL   Science 368:630-633(2020).
CC   -!- FUNCTION: [Spike protein S1]: Attaches the virion to the cell membrane
CC       by interacting with host receptor, initiating the infection. The major
CC       receptor is host ACE2 (PubMed:32142651, PubMed:32155444,
CC       PubMed:33607086). When S2/S2' has been cleaved, binding to the receptor
CC       triggers direct fusion at the cell membrane (PubMed:34561887). When
CC       S2/S2' has not been cleaved, binding to the receptor results in
CC       internalization of the virus by endocytosis leading to fusion of the
CC       virion membrane with the host endosomal membrane (PubMed:32075877,
CC       PubMed:32221306). Alternatively, may use NRP1/NRP2 (PubMed:33082294,
CC       PubMed:33082293) and integrin as entry receptors (PubMed:35150743). The
CC       use of NRP1/NRP2 receptors may explain the tropism of the virus in
CC       human olfactory epithelial cells, which express these molecules at high
CC       levels but ACE2 at low levels (PubMed:33082293). The stalk domain of S
CC       contains three hinges, giving the head unexpected orientational freedom
CC       (PubMed:32817270). {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32142651,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32817270, ECO:0000269|PubMed:33082293,
CC       ECO:0000269|PubMed:33082294, ECO:0000269|PubMed:35150743,
CC       ECO:0000303|PubMed:33082293, ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2]: Precursor of the fusion protein processed
CC       in the biosynthesis of the S protein and the formation of virus
CC       particle. Mediates fusion of the virion and cellular membranes by
CC       functioning as a class I viral fusion protein. Contains two viral
CC       fusion peptides that are unmasked after cleavage. The S2/S2' cleavage
CC       occurs during virus entry at the cell membrane by host TMPRSS2
CC       (PubMed:32142651) or during endocytosis by host CSTL (PubMed:32703818,
CC       PubMed:34159616). In either case, this triggers an extensive and
CC       irreversible conformational change leading to fusion of the viral
CC       envelope with the cellular cytoplasmic membrane, releasing viral
CC       genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the
CC       current model, the protein has at least three conformational states:
CC       pre-fusion native state, pre-hairpin intermediate state, and post-
CC       fusion hairpin state. During fusion of the viral and target cell
CC       membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-
CC       hairpins structure and position the fusion peptide in close proximity
CC       to the C-terminal region of the ectodomain. Formation of this structure
CC       appears to promote apposition and subsequent fusion of viral and target
CC       cell membranes. {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32703818, ECO:0000269|PubMed:34159616,
CC       ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2']: Subunit of the fusion protein that is
CC       processed upon entry into the host cell. Mediates fusion of the virion
CC       and cellular membranes by functioning as a class I viral fusion
CC       protein. Contains a viral fusion peptide that is unmasked after S2
CC       cleavage. This cleavage can occur at the cell membrane by host TMPRSS2
CC       or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616).
CC       In either case, this triggers an extensive and irreversible
CC       conformational change that leads to fusion of the viral envelope with
CC       the cellular cytoplasmic membrane, releasing viral genomic RNA into the
CC       host cell cytoplasm (PubMed:34561887). Under the current model, the
CC       protein has at least three conformational states: pre-fusion native
CC       state, pre-hairpin intermediate state, and post-fusion hairpin state.
CC       During fusion of the viral and target cell membranes, the coiled coil
CC       regions (heptad repeats) adopt a trimer-of-hairpins structure and
CC       position the fusion peptide in close proximity to the C-terminal region
CC       of the ectodomain. Formation of this structure appears to promote
CC       apposition and subsequent fusion of viral and target cell membranes.
CC       {ECO:0000255|HAMAP-Rule:MF_04099, ECO:0000269|PubMed:32703818,
CC       ECO:0000269|PubMed:34159616, ECO:0000305|PubMed:34561887}.
CC   -!- SUBUNIT: [Spike glycoprotein]: Homotrimer; each monomer consists of a
CC       S1 and a S2 subunit (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784). The resulting peplomers protrude from the virus
CC       surface as spikes (PubMed:32979942). Interacts with ORF3a protein and
CC       ORF7a protein (By similarity) (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784, PubMed:32979942). There are an average of 26 +/-15
CC       spike trimers at the surface of virion particles (PubMed:32979942).
CC       Binds to host MBL2 (PubMed:35102342). This binding occurs via glycans
CC       and inhibits viral infectivity. Inhibition is effective against alpha,
CC       beta, gamma, and delta variants (PubMed:35102342). {ECO:0000255|HAMAP-
CC       Rule:MF_04099, ECO:0000269|PubMed:32075877,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32245784,
CC       ECO:0000269|PubMed:32979942, ECO:0000269|PubMed:35102342}.
CC   -!- SUBUNIT: [Spike protein S1]: Binds to host ACE2 (PubMed:32075877,
CC       PubMed:32132184, PubMed:32155444, PubMed:32221306, PubMed:32225175,
CC       PubMed:32225176, PubMed:33607086). RBD also interacts with the N-linked
CC       glycan on 'Asn-90' of ACE2 (PubMed:33607086). Cleavage of S generates a
CC       polybasic C-terminal sequence on S1 that binds to host Neuropilin-1
CC       (NRP1) and Neuropilin-2 (NRP2) receptors (PubMed:33082293,
CC       PubMed:33082294). Interacts with host integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) and with ACE2 in complex with integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) (PubMed:33102950). May interact via cytoplasmic c-
CC       terminus with M protein (PubMed:33229438). May interact (via N-
CC       terminus) with host bilirubin and biliverdin, thereby preventing
CC       antibody binding to the SARS-CoV-2 spike NTD via an allosteric
CC       mechanism (PubMed:33888467). May interact with host LRRC15, thereby
CC       allowing attachment to host cells (PubMed:36735681).
CC       {ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32132184,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32225",51888
CATTGA ATTGAG TTGAGA TGAGAA GAGAAA AGAAAT GAAATT AAATTA AATTAA ATTAAA TTAAAA TAAAAT AAAATT AAATTA AATTAC ATTACT TTACTA TACTAT ACTATG CTATGG TATGGA ATGGAT TGGATT GGATTT GATTTA ATTTAC TTTACA TTACAA TACAAA ACAAAG CAAAGC AAAGCA AAGCAT AGCATA GCATAA CATAAA ATAAAG TAAAGA AAAGAA AAGAAC AGAACA GAACAG AACAGA ACAGAT CAGATT AGATTC GATTCG ATTCGG TTCGGC TCGGCA CGGCAT GGCATC GCATCA CATCAT ATCATT TCATTG CATTGG ATTGGT TTGGTA TGGTAA GGTAAC GTAACT TAACTC AACTCC ACTCCC CTCCCC TCCCCC CCCCCG CCCCGC CCCGCT CCGCTC CGCTCT GCTCTC CTCTCA TCTCAA CTCAAT TCAATC CAATCA AATCAT ATCATG TCATGC CATGCA ATGCAT TGCATT GCATTG CATTGA ATTGAA TTGAAT TGAATA GAATAC AATACA ATACAG TACAGC ACAGCA CAGCAG AGCAGC GCAGCG CAGCGC AGCGCA GCGCAG CGCAGG GCAGGT CAGGTG AGGTGG GGTGGC GTGGCG TGGCGG GGCGGC GCGGCT CGGCTA GGCTAC GCTACC CTACCG TACCGA ACCGAT CCGATC CGATCT GATCTC ATCTCA TCTCAC CTCACC TCACCG CACCGT ACCGTG CCGTGT CGTGTT GTGTTA TGTTAA GTTAAT TTAATT TAATTG AATTGT ATTGTG TTGTGG TGTGGG GTGGGG TGGGGG GGGGGA GGGGAA GGGAAA GGAAAG GAAAGT,1,142,CATT ATTG TTGA TGAG GAGA AGAA GAAA AAAT AATT ATTA TTAA TAAA AAAA AAAT AATT ATTA TTAC TACT ACTA CTAT TATG ATGG TGGA GGAT GATT ATTT TTTA TTAC TACA ACAA CAAA AAAG AAGC AGCA GCAT CATA ATAA TAAA AAAG AAGA AGAA GAAC AACA ACAG CAGA AGAT GATT ATTC TTCG TCGG CGGC GGCA GCAT CATC ATCA TCAT CATT ATTG TTGG TGGT GGTA GTAA TAAC AACT ACTC CTCC TCCC CCCC CCCC CCCG CCGC CGCT GCTC CTCT TCTC CTCA TCAA CAAT AATC ATCA TCAT CATG ATGC TGCA GCAT CATT ATTG TTGA TGAA GAAT AATA ATAC TACA ACAG CAGC AGCA GCAG CAGC AGCG GCGC CGCA GCAG CAGG AGGT GGTG GTGG TGGC GGCG GCGG CGGC GGCT GCTA CTAC TACC ACCG CCGA CGAT GATC ATCT TCTC CTCA TCAC CACC ACCG CCGT CGTG GTGT TGTT GTTA TTAA TAAT AATT ATTG TTGT TGTG GTGG TGGG GGGG GGGG GGGA GGAA GAAA AAAG AAGT,CATTG ATTGA TTGAG TGAGA GAGAA AGAAA GAAAT AAATT AATTA ATTAA TTAAA TAAAA AAAAT AAATT AATTA ATTAC TTACT TACTA ACTAT CTATG TATGG ATGGA TGGAT GGATT GATTT ATTTA TTTAC TTACA TACAA ACAAA CAAAG AAAGC AAGCA AGCAT GCATA CATAA ATAAA TAAAG AAAGA AAGAA AGAAC GAACA AACAG ACAGA CAGAT AGATT GATTC ATTCG TTCGG TCGGC CGGCA GGCAT GCATC CATCA ATCAT TCATT CATTG ATTGG TTGGT TGGTA GGTAA GTAAC TAACT AACTC ACTCC CTCCC TCCCC CCCCC CCCCG CCCGC CCGCT CGCTC GCTCT CTCTC TCTCA CTCAA TCAAT CAATC AATCA ATCAT TCATG CATGC ATGCA TGCAT GCATT CATTG ATTGA TTGAA TGAAT GAATA AATAC ATACA TACAG ACAGC CAGCA AGCAG GCAGC CAGCG AGCGC GCGCA CGCAG GCAGG CAGGT AGGTG GGTGG GTGGC TGGCG GGCGG GCGGC CGGCT GGCTA GCTAC CTACC TACCG ACCGA CCGAT CGATC GATCT ATCTC TCTCA CTCAC TCACC CACCG ACCGT CCGTG CGTGT GTGTT TGTTA GTTAA TTAAT TAATT AATTG ATTGT TTGTG TGTGG GTGGG TGGGG GGGGG GGGGA GGGAA GGAAA GAAAG AAAGT,CATTGA ATTGAG TTGAGA TGAGAA GAGAAA AGAAAT GAAATT AAATTA AATTAA ATTAAA TTAAAA TAAAAT AAAATT AAATTA AATTAC ATTACT TTACTA TACTAT ACTATG CTATGG TATGGA ATGGAT TGGATT GGATTT GATTTA ATTTAC TTTACA TTACAA TACAAA ACAAAG CAAAGC AAAGCA AAGCAT AGCATA GCATAA CATAAA ATAAAG TAAAGA AAAGAA AAGAAC AGAACA GAACAG AACAGA ACAGAT CAGATT AGATTC GATTCG ATTCGG TTCGGC TCGGCA CGGCAT GGCATC GCATCA CATCAT ATCATT TCATTG CATTGG ATTGGT TTGGTA TGGTAA GGTAAC GTAACT TAACTC AACTCC ACTCCC CTCCCC TCCCCC CCCCCG CCCCGC CCCGCT CCGCTC CGCTCT GCTCTC CTCTCA TCTCAA CTCAAT TCAATC CAATCA AATCAT ATCATG TCATGC CATGCA ATGCAT TGCATT GCATTG CATTGA ATTGAA TTGAAT TGAATA GAATAC AATACA ATACAG TACAGC ACAGCA CAGCAG AGCAGC GCAGCG CAGCGC AGCGCA GCGCAG CGCAGG GCAGGT CAGGTG AGGTGG GGTGGC GTGGCG TGGCGG GGCGGC GCGGCT CGGCTA GGCTAC GCTACC CTACCG TACCGA ACCGAT CCGATC CGATCT GATCTC ATCTCA TCTCAC CTCACC TCACCG CACCGT ACCGTG CCGTGT CGTGTT GTGTTA TGTTAA GTTAAT TTAATT TAATTG AATTGT ATTGTG TTGTGG TGTGGG GTGGGG TGGGGG GGGGGA GGGGAA GGGAAA GGAAAG GAAAGT,CATTGAG ATTGAGA TTGAGAA TGAGAAA GAGAAAT AGAAATT GAAATTA AAATTAA AATTAAA ATTAAAA TTAAAAT TAAAATT AAAATTA AAATTAC AATTACT ATTACTA TTACTAT TACTATG ACTATGG CTATGGA TATGGAT ATGGATT TGGATTT GGATTTA GATTTAC ATTTACA TTTACAA TTACAAA TACAAAG ACAAAGC CAAAGCA AAAGCAT AAGCATA AGCATAA GCATAAA CATAAAG ATAAAGA TAAAGAA AAAGAAC AAGAACA AGAACAG GAACAGA AACAGAT ACAGATT CAGATTC AGATTCG GATTCGG ATTCGGC TTCGGCA TCGGCAT CGGCATC GGCATCA GCATCAT CATCATT ATCATTG TCATTGG CATTGGT ATTGGTA TTGGTAA TGGTAAC GGTAACT GTAACTC TAACTCC AACTCCC ACTCCCC CTCCCCC TCCCCCG CCCCCGC CCCCGCT CCCGCTC CCGCTCT CGCTCTC GCTCTCA CTCTCAA TCTCAAT CTCAATC TCAATCA CAATCAT AATCATG ATCATGC TCATGCA CATGCAT ATGCATT TGCATTG GCATTGA CATTGAA ATTGAAT TTGAATA TGAATAC GAATACA AATACAG ATACAGC TACAGCA ACAGCAG CAGCAGC AGCAGCG GCAGCGC CAGCGCA AGCGCAG GCGCAGG CGCAGGT GCAGGTG CAGGTGG AGGTGGC GGTGGCG GTGGCGG TGGCGGC GGCGGCT GCGGCTA CGGCTAC GGCTACC GCTACCG CTACCGA TACCGAT ACCGATC CCGATCT CGATCTC GATCTCA ATCTCAC TCTCACC CTCACCG TCACCGT CACCGTG ACCGTGT CCGTGTT CGTGTTA GTGTTAA TGTTAAT GTTAATT TTAATTG TAATTGT AATTGTG ATTGTGG TTGTGGG TGTGGGG GTGGGGG TGGGGGA GGGGGAA GGGGAAA GGGAAAG GGAAAGT,"ID   GLRR_ECOLI              Reviewed;         444 AA.
AC   P0AFU4; P21712; P77512;
DT   20-DEC-2005, integrated into UniProtKB/Swiss-Prot.
DT   20-DEC-2005, sequence version 1.
DT   05-FEB-2025, entry version 140.
DE   RecName: Full=Transcriptional regulatory protein GlrR;
GN   Name=glrR; Synonyms=yfhA; OrderedLocusNames=b2554, JW2538;
OS   Escherichia coli (strain K12).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Enterobacterales;
OC   Enterobacteriaceae; Escherichia.
OX   NCBI_TaxID=83333;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=8226691; DOI=10.1128/jb.175.22.7441-7449.1993;
RA   Liu J., Magasanik B.;
RT   ""The glnB region of the Escherichia coli chromosome."";
RL   J. Bacteriol. 175:7441-7449(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=9205837; DOI=10.1093/dnares/4.2.91;
RA   Yamamoto Y., Aiba H., Baba T., Hayashi K., Inada T., Isono K., Itoh T.,
RA   Kimura S., Kitagawa M., Makino K., Miki T., Mitsuhashi N., Mizobuchi K.,
RA   Mori H., Nakade S., Nakamura Y., Nashimoto H., Oshima T., Oyama S.,
RA   Saito N., Sampei G., Satoh Y., Sivasundaram S., Tagami H., Takahashi H.,
RA   Takeda J., Takemoto K., Uehara K., Wada C., Yamagata S., Horiuchi T.;
RT   ""Construction of a contiguous 874-kb sequence of the Escherichia coli-K12
RT   genome corresponding to 50.0-68.8 min on the linkage map and analysis of
RT   its sequence features."";
RL   DNA Res. 4:91-113(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / MG1655 / ATCC 47076;
RX   PubMed=9278503; DOI=10.1126/science.277.5331.1453;
RA   Blattner F.R., Plunkett G. III, Bloch C.A., Perna N.T., Burland V.,
RA   Riley M., Collado-Vides J., Glasner J.D., Rode C.K., Mayhew G.F.,
RA   Gregor J., Davis N.W., Kirkpatrick H.A., Goeden M.A., Rose D.J., Mau B.,
RA   Shao Y.;
RT   ""The complete genome sequence of Escherichia coli K-12."";
RL   Science 277:1453-1462(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=16738553; DOI=10.1038/msb4100049;
RA   Hayashi K., Morooka N., Yamamoto Y., Fujita K., Isono K., Choi S.,
RA   Ohtsubo E., Baba T., Wanner B.L., Mori H., Horiuchi T.;
RT   ""Highly accurate genome sequences of Escherichia coli K-12 strains MG1655
RT   and W3110."";
RL   Mol. Syst. Biol. 2:E1-E5(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 288-444.
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=8412694; DOI=10.1111/j.1365-2958.1993.tb01706.x;
RA   van Heeswijk W.C., Rabenberg M., Westerhoff H.V., Kahn D.D.;
RT   ""The genes of the glutamine synthetase adenylylation cascade are not
RT   regulated by nitrogen in Escherichia coli."";
RL   Mol. Microbiol. 9:443-458(1993).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 404-444.
RC   STRAIN=K12;
RX   PubMed=2034230; DOI=10.1007/bf00273586;
RA   Vasudevan S.G., Armarego W.L.F., Shaw D.C., Lilley P.E., Dixon N.E.,
RA   Poole R.K.;
RT   ""Isolation and nucleotide sequence of the hmp gene that encodes a
RT   haemoglobin-like protein in Escherichia coli K-12."";
RL   Mol. Gen. Genet. 226:49-58(1991).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 419-444.
RX   PubMed=2885322; DOI=10.1016/s0021-9258(18)47469-8;
RA   Son H.S., Rhee S.G.;
RT   ""Cascade control of Escherichia coli glutamine synthetase. Purification and
RT   properties of PII protein and nucleotide sequence of its structural gene."";
RL   J. Biol. Chem. 262:8690-8695(1987).
RN   [8]
RP   PHOSPHORYLATION.
RC   STRAIN=K12 / W3110 / ATCC 27325 / DSM 5911;
RX   PubMed=15522865; DOI=10.1074/jbc.m410104200;
RA   Yamamoto K., Hirao K., Oshima T., Aiba H., Utsumi R., Ishihama A.;
RT   ""Functional characterization in vitro of all two-component signal
RT   transduction systems from Escherichia coli."";
RL   J. Biol. Chem. 280:1448-1456(2005).
RN   [9]
RP   FUNCTION, DNA-BINDING, DISRUPTION PHENOTYPE, AND GENE NAME.
RX   PubMed=19843219; DOI=10.1111/j.1365-2958.2009.06918.x;
RA   Reichenbach B., Gopel Y., Gorke B.;
RT   ""Dual control by perfectly overlapping sigma 54- and sigma 70-promoters
RT   adjusts small RNA GlmY expression to different environmental signals."";
RL   Mol. Microbiol. 74:1054-1070(2009).
CC   -!- FUNCTION: Member of the two-component regulatory system GlrR/GlrK that
CC       up-regulates transcription of the glmY sRNA when cells enter the
CC       stationary growth phase. Regulates glmY transcription by binding to
CC       three conserved sites in the purL-glmY intergenic region.
CC       {ECO:0000269|PubMed:19843219}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000305}.
CC   -!- PTM: Phosphorylated by GlrK. {ECO:0000269|PubMed:15522865}.
CC   -!- DISRUPTION PHENOTYPE: Mutants show decreased amounts of glmY.
CC       {ECO:0000269|PubMed:19843219}.
CC   -!- MISCELLANEOUS: Not required for the regulation of the glmY-glmZ-glmS
CC       regulatory cascade by glucosamine-6-phosphate depletion.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA79816.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; S67014; AAB28778.1; -; Genomic_DNA.
DR   EMBL; U00096; AAC75607.1; -; Genomic_DNA.
DR   EMBL; AP009048; BAA16462.1; -; Genomic_DNA.
DR   EMBL; Z21843; CAA79889.1; -; Genomic_DNA.
DR   EMBL; M16778; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; U36841; AAA79816.1; ALT_INIT; Genomic_DNA.
DR   PIR; A65033; A65033.
DR   RefSeq; NP_417049.1; NC_000913.3.
DR   RefSeq; WP_001295369.1; NZ_LN832404.1.
DR   AlphaFoldDB; P0AFU4; -.
DR   SMR; P0AFU4; -.
DR   BioGRID; 4259202; 117.
DR   BioGRID; 851381; 2.
DR   DIP; DIP-12044N; -.
DR   IntAct; P0AFU4; 9.
DR   STRING; 511145.b2554; -.
DR   iPTMnet; P0AFU4; -.
DR   jPOST; P0AFU4; -.
DR   PaxDb; 511145-b2554; -.
DR   EnsemblBacteria; AAC75607; AAC75607; b2554.
DR   GeneID; 93774581; -.
DR   GeneID; 947042; -.
DR   KEGG; ecj:JW2538; -.
DR   KEGG; eco:b2554; -.
DR   KEGG; ecoc:C3026_14140; -.
DR   PATRIC; fig|1411691.4.peg.4180; -.
DR   EchoBASE; EB1262; -.
DR   eggNOG; COG2204; Bacteria.
DR   HOGENOM; CLU_000445_0_6_6; -.
DR   InParanoid; P0AFU4; -.
DR   OMA; DRNRTEF; -.
DR   OrthoDB; 9804019at2; -.
DR   PhylomeDB; P0AFU4; -.
DR   BioCyc; EcoCyc:EG11285-MONOMER; -.
DR   PRO; PR:P0AFU4; -.
DR   Proteomes; UP000000318; Chromosome.
DR   Proteomes; UP000000625; Chromosome.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:InterPro.
DR   GO; GO:0000987; F:cis-regulatory region sequence-specific DNA binding; IDA:EcoCyc.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:EcoCyc.
DR   GO; GO:0000156; F:phosphorelay response regulator activity; IMP:EcoCyc.
DR   GO; GO:0006351; P:DNA-templated transcription; IDA:EcoCyc.
DR   GO; GO:0000160; P:phosphorelay signal transduction system; IMP:EcoCyc.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IMP:EcoCyc.
DR   CDD; cd00009; AAA; 1.
DR   FunFam; 3.40.50.300:FF:000006; DNA-binding transcriptional regulator NtrC; 1.
DR   FunFam; 3.40.50.2300:FF:000167; Two-component response regulator GlrR; 1.
DR   FunFam; 1.10.10.60:FF:000111; Two-component system response regulator GlrR; 1.
DR   FunFam; 1.10.8.60:FF:000034; Two-component system response regulator GlrR; 1.
DR   Gene3D; 1.10.8.60; -; 1.
DR   Gene3D; 3.40.50.2300; -; 1.
DR   Gene3D; 1.10.10.60; Homeodomain-like; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR011006; CheY-like_superfamily.
DR   InterPro; IPR009057; Homeodomain-like_sf.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR001789; Sig_transdc_resp-reg_receiver.
DR   InterPro; IPR002078; Sigma_54_int.
DR   InterPro; IPR025662; Sigma_54_int_dom_ATP-bd_1.
DR   InterPro; IPR025943; Sigma_54_int_dom_ATP-bd_2.
DR   InterPro; IPR025944; Sigma_54_int_dom_CS.
DR   PANTHER; PTHR32071; TRANSCRIPTIONAL REGULATORY PROTEIN; 1.
DR   PANTHER; PTHR32071:SF116; TRANSCRIPTIONAL REGULATORY PROTEIN GLRR; 1.
DR   Pfam; PF00072; Response_reg; 1.
DR   Pfam; PF00158; Sigma54_activat; 1.
DR   SMART; SM00382; AAA; 1.
DR   SMART; SM00448; REC; 1.
DR   SUPFAM; SSF52172; CheY-like; 1.
DR   SUPFAM; SSF46689; Homeodomain-like; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   PROSITE; PS50110; RESPONSE_REGULATORY; 1.
DR   PROSITE; PS00675; SIGMA54_INTERACT_1; 1.
DR   PROSITE; PS00676; SIGMA54_INTERACT_2; 1.
DR   PROSITE; PS00688; SIGMA54_INTERACT_3; 1.
DR   PROSITE; PS50045; SIGMA54_INTERACT_4; 1.
PE   1: Evidence at protein level;
KW   ATP-binding; Cytoplasm; DNA-binding; Nucleotide-binding; Phosphoprotein;
KW   Reference proteome; Transcription; Transcription regulation;
KW   Two-component regulatory system.
FT   CHAIN           1..444
FT                   /note=""Transcriptional regulatory protein GlrR""
FT                   /id=""PRO_0000081377""
FT   DOMAIN          7..121
FT                   /note=""Response regulatory""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00169""
FT   DOMAIN          136..366
FT                   /note=""Sigma-54 factor interaction""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00193""
FT   DNA_BIND        414..433
FT                   /note=""H-T-H motif""
FT                   /evidence=""ECO:0000255""
FT   BINDING         164..171
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00193""
FT   BINDING         227..236
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00193""
FT   MOD_RES         56
FT                   /note=""4-aspartylphosphate""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00169""
FT   CONFLICT        106
FT                   /note=""K -> N (in Ref. 1; AAB28778)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        309..310
FT                   /note=""ER -> DG (in Ref. 1; AAB28778)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        327..328
FT                   /note=""ER -> DG (in Ref. 1; AAB28778)""
FT                   /evidence=""ECO:0000305""
SQ   SEQUENCE   444 AA;  49148 MW;  6553C027DE5513EF CRC64;
     MSHKPAHLLL VDDDPGLLKL LGLRLTSEGY SVVTAESGAE GLRVLNREKV DLVISDLRMD
     EMDGMQLFAE IQKVQPGMPV IILTAHGSIP DAVAATQQGV FSFLTKPVDK DALYQAIDDA
     LEQSAPATDE RWREAIVTRS PLMLRLLEQA RLVAQSDVSV LINGQSGTGK EIFAQAIHNA
     SPRNSKPFIA INCGALPEQL LESELFGHAR GAFTGAVSNR EGLFQAAEGG TLFLDEIGDM
     PAPLQVKLLR VLQERKVRPL GSNRDIDINV RIISATHRDL PKAMARGEFR EDLYYRLNVV
     SLKIPALAER TEDIPLLANH LLRQAAERHK PFVRAFSTDA MKRLMTASWP GNVRQLVNVI
     EQCVALTSSP VISDALVEQA LEGENTALPT FVEARNQFEL NYLRKLLQIT KGNVTHAARM
     AGRNRTEFYK LLSRHELDAN DFKE
//
",43676
CTCAAA TCAAAG CAAAGG AAAGGC AAGGCG AGGCGA GGCGAG GCGAGG CGAGGA GAGGAT AGGATT GGATTG GATTGG ATTGGT TTGGTA TGGTAT GGTATG GTATGA TATGAG ATGAGA TGAGAA GAGAAA AGAAAA GAAAAA AAAAAA AAAAAT AAAATT AAATTC AATTCA ATTCAT TTCATC TCATCC CATCCC ATCCCG TCCCGC CCCGCG CCGCGG CGCGGA GCGGAT CGGATC GGATCT GATCTC ATCTCG TCTCGC CTCGCC TCGCCG CGCCGC GCCGCT CCGCTC CGCTCA GCTCAC CTCACG TCACGC CACGCT ACGCTC CGCTCG GCTCGG CTCGGG TCGGGG CGGGGC GGGGCG GGGCGC GGCGCT GCGCTC CGCTCC GCTCCT CTCCTC TCCTCT CCTCTT CTCTTC,2,70,TCACA  TCTCACAAG TTCC CACAAAAAAA A A AAATGAAGAG G A AAAAGAGGC CG A AGAGGGGCGC C GC TGCGCG G GAATGCGCGAGA A CAAAAG G GAA GAGAGGGG G A AGAGGGGAGA GA  GGGGAGAT CGCCG GAC CATTT A ATATTTTGG T TTTTGTGGGG G T TGTGGGGTGT T G GGGGTGTATA A G GTGTATATAT T T TATATATGTG  ATCCCTGACC AA  TGTGACG AG G G GAAGAGA A A AGAGAAA A G GAGAACGA GAT TAAACA A A AACC AAAAA A ACTCAAAAAAAA A A AAAAAAATAT T ATCCCG ATTTT  GC ATATTTTCTC C T TTTTCTCAA TA T TCTCACATC CT C CACATTC C A ATATCTCCCGG TCA CAAACC C C CCCCGCG G C CCCCGCGCGC GAT CGCGCGCG GC GCGCGGG G C CGGGAA G GGGGAGATAT T G GAGATATCG AC A ATATCTCTCT T T TCTCTGG TC C C CTCTCTCGCG AA  TCTCGGC AT  CGCGCGCCAAAC G GCGCCT GCG G C ACCCGCGC CCC C CGCGCCT T GCTTGCTCTCTC C C CTCTCTCACA A T TCTCACACAC C C CACACACGCG G AACGGC GC C C CGCGCGCTCT T G GCGCTCTCTC GG  CTCTCTCGGAGG T TCTCGCGGGG G C CGCGGGGG AA GGGGGGGGGG G G GGGGGGGCGC C G GGGGCGCGCG G GT AGCGCT  AAC CAT GCTCT T G GCGCTCTCTC C C CTTCCCC  GG TC AACCTCT GC CCTCTCTC C C CTCTCTCTCGCCGC TCTCTCTTTT T C CT GCTTC,CTCTCACAAAA A TTCACAAAAAAA A A CACAAAAGAG G ACGCAAAAAGAGGAAAG A AA AAAGGGGCGC C AGGCGCGCG A C GGGGCGCGCGAGA A G GCATGAGGATTGGACGAGAGAGGGG C CGAGC T ACGA A AAGGGATAT T G GGGGAATTTT T G GATCTTTGTG TTG ATCGGAAA CGG T TTTTGCGCGGTGT T T TGTGGGGTGTATA  GG GGGGTTATAT T G GTGA TATTG G TTATATGATCGTAA A ATCGCTGAGAGAG G CT CTGAA GAGAGA A G GAGAGAGAAA A A AGAGAGAAAAAA G GAGAAAAAAAAA C AAAAAAAAAAAAA  CTAAGAAAGG AAAAA A AGCCGATAAAAATAT T A AATGGAATATTTT AT  AAATTTTCTC C A ATATTTTCTCACA A T TTA ATCACATAT T T TCTCACATTGATC C CT CGCGATCTCCCC C A ATATCTCCCCCCC CGA TCTCCCCCCCGCG G C CC CGCCGCGCGC C C CCCCG AAGCGCG  CGGCGG AGG G G GCGCGCGGGA A CGG CGGGGAGATT A GGGGAGATATCTC C G GAGATTCTCT T A ATATCTCTCTCC T TCGATCTCCACCG G CTTCCTCTCGCGCGC C T TC GGGCCCC CCCCGCCCGCG G GTC GCCCCGCGCGAGC CCCGCGCGCTCT T C CGCGCGCTCTCTC C G GCGCTCTCTCACA G G CTCTCTCACACAC C T TCTCACACACGCG G CTCGACGCGCC AGGAG CCGCGCTCT  TG CGCGCGCTCTCTC C G GCGCTCTCTCGCG G T CTCTCTCGCGCG T TCTCGCGGGGGGG G C CGGC GGGGGGGG G GGAGGGGGGCC GTCGGGGGGCGCGCG G GGGCGCGCGCGC C G GCCATTGGGCTCT T C CGGG GCTCTCTC C GGCTCTCTCCCC G G CTCTCCCTCT T TTCCCCTCTCC CCCTCTCTCTATCTCTCTTTT T T TCTCTCTTTTC,CTCTCACAAAAAAA A TT CTCACAAAAAATCAG G C CACAAAAAGG G A AAAAAAAGC AGGCGC C ATGGAAGAGGTTCGCGCG G A AGCACGGCGCGCGAGA A GCGCGGCCGAC GG GCGCCTCGAGAAAG C CGCGAGAGAGGGGAGA A G GAGAGG TGGAGATAT T A AGAGGGGAGATATTTT T GAAGGATGATGGGTTGG G GAGGAAAATTGTGGG A ATATTTTGTGGGGTGT TTGGGTGTATA  AAGGTGTATATAT GGTGTATATATGTG G G GT TCTATATGTGAGA A T TAATGTATTGAGAGAG G A ATATGTGAAA TCAGA A T TGGGCGAGAGAGAAAA A GT AAGAGAAAAAGAGA A AGAGAGAAAAAAAAAGG GAGAAAAAATTAA TCCAGGAAA GG TCAA A A AACGGAAAAAAAATAT GAG AAAAAAAAAATATTTT T A AAAAATTCTTCTC C AAATATTATT TTA A ATATTTTCTCACATAT CA CA GGCTCACATAAGTC C TTGGAGACATATCTCCCC C C CACATATCTCCCCCCC AGG ATATCTCCCCCCCGCG G TGTATCCCCCCCGCGCGC C CCCCCCGCGCGCGCG G C CCCCG GGGCGCGGGG  CGGCGGGAGA A G GCGCGAAAGGAGATCT T C CGCGGGGAGATATCTC C GGGAGATATCTCTCT T G GAG TTCTCTCC A ATATCTCTCTCCG G T TCTCTCTCTCGCC GC C C CTACGTCGCGCGCCCC C T TCTCGGCC GC CGCGCGGCCCGCGC GCCTCGCCCCGCGCGCTCT  TCTCACCGCGCGCTCTCTC C C CGCGCGCTCTCTCAT TA G GCGCTCTCTCATC AC  CTCTCCACCTCCG AGG TCTCACTCACGCGCGC C C CACACACGGCTCT T A ACACGGCGGCTCTCCTT CGGCTGCTCTCTCGCG G GCG CGCTCGCGGGG G C CTCTCTCGCGGGGGGG ATC TCTCGCGGGGGGGGGG G CCGGGGGGGGTGAGC AAA AAGGGGGCGCGCG G G GGGGGGCCCGCGC C G GGT CGCGCGCGCTCT T G GCGCGGG GCTCTCTC C C CGCGCGCTC GTCCCGCCTC GCGCTCGAA ACCTCT T C CTTCCCCT GCTC C T TCTCCCCTCTCTCTGGC CCCCTCACTCTC CT C CTCTCTCTCTTTTC,CTCCAAAAAAAGAG G T TCGCTAAAGCGAGGGG G C CAAAAAAGAGGGGCCCGC A AAAAAAAGGGGGGCGCGCG  AACGCGGGGCGCGAGA A A AGAGGGGCGCGCGAGAGAG CGG GGGGCGCGCGAGAGAGGGG G G GCGCGCGAGAGAGGGGAA C CGCGAAAATCAGATT G GAGC CGCGA TCCATTTT  AGGTAGGAGATATTTTGC TG G GGGGAGATATTTTGTGGGG G G GAGATATTTTGTGGGGTGT  ATATTG GTGGGTAGTATA ATTCAAAAATGGGGTGTATATAT T T TGATGTATATGTG AA  GGAGGCGCTGAGGAA G GTGTATATATGTGAGAGAG G T TAATGTGAGAGAGAC TCC GGTTGAGAGGAAAA A T TGTGAGAGAGAGAAAAAA G GAAGAGAATTGA CA A AGAGAGAAAAAAAAT GA GTCGGAAAAAAAAAAAGAGGCGA A AAAAAAAAAAAAAAAATAT T AAAAAAAAAAAATA TTT T A AAAAAAAAAATATTCGGTC C A AAAAAAATATTTTCTCACA A A AAAATATTTTCTCAGG AT T A ATGGCTTCTCAATCTC TG  TTTTCCTCCATATCTCCCC  TCTTGCATATCTCCCC C CCATTCCCCCCCGTC G A ATATCTCCAGGCCGCGCC T TCCCCCCGCGCAA CG G C CCCCCCCGCGCAAGTCTGG G C CCGC CGCGCGCGGA CGA GGA CGCGCCGGGGAAT T GC CGCG TTGGAGATATCTC C CCGGGGAATCTCTCT AGG GGGGAATCTCTCTCTC CGC GAGATTCTTCA GACG G A ATATCTCGCGCGC C T TCTCTCTCTCGCACGCCCC C C CTCTCCGCCG G T TCTCGGC C C CGCGCGCCCCGCGCGCTCT T G GCGCCCCGGCTCTCC C CCCCGGGTGCTCTCTCACA  CGCGCGCTCTCTT CACAC C G GCGCTCTCTCACGCACGCG G C CTCTCAGGCACACGCGCGC C T TCTCACACACGGCTCT T C CACACACGC GGCTCTCC A ACACGCGCC GCTCG C CGCGCCTCTCGCGGCATG G GCGCTCTCTCGCGGGGGGG  CTCTCTCGTTCGGGGGGGG G T TCTCGT GGGGGGCGC C CCCTCGGGGGGGGGGCCG G GGGGGGGGGCGCGCGCGAGC G GG CGGGCGCGCGCCT T G GGGGCGCGCGCTCACTCTC GCTCGCGCGCGCGCTCTCTCC CGCGCCTCTCCATTCT AAA GCGCTCTCCATCCTCTCTC  GCCTCTCCCCTTCTCT T T TCCCTCTCCGGCTTTCAT C CCTCTCTTTTC,"ID   ARSB_BACSU              Reviewed;         346 AA.
AC   P45946;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   07-JUL-2009, sequence version 2.
DT   05-FEB-2025, entry version 137.
DE   RecName: Full=Arsenite resistance protein ArsB;
GN   Name=arsB; Synonyms=yqcL; OrderedLocusNames=BSU25790;
OS   Bacillus subtilis (strain 168).
OC   Bacteria; Bacillati; Bacillota; Bacilli; Bacillales; Bacillaceae; Bacillus.
OX   NCBI_TaxID=224308;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=168 / JH642;
RX   PubMed=7704261; DOI=10.1099/13500872-141-2-323;
RA   Takemaru K., Mizuno M., Sato T., Takeuchi M., Kobayashi Y.;
RT   ""Complete nucleotide sequence of a skin element excised by DNA
RT   rearrangement during sporulation in Bacillus subtilis."";
RL   Microbiology 141:323-327(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=168 / JH642;
RX   PubMed=8969508; DOI=10.1099/13500872-142-11-3103;
RA   Mizuno M., Masuda S., Takemaru K., Hosono S., Sato T., Takeuchi M.,
RA   Kobayashi Y.;
RT   ""Systematic sequencing of the 283 kb 210 degrees-232 degrees region of the
RT   Bacillus subtilis genome containing the skin element and many sporulation
RT   genes."";
RL   Microbiology 142:3103-3111(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=168;
RX   PubMed=9384377; DOI=10.1038/36786;
RA   Kunst F., Ogasawara N., Moszer I., Albertini A.M., Alloni G., Azevedo V.,
RA   Bertero M.G., Bessieres P., Bolotin A., Borchert S., Borriss R.,
RA   Boursier L., Brans A., Braun M., Brignell S.C., Bron S., Brouillet S.,
RA   Bruschi C.V., Caldwell B., Capuano V., Carter N.M., Choi S.-K.,
RA   Codani J.-J., Connerton I.F., Cummings N.J., Daniel R.A., Denizot F.,
RA   Devine K.M., Duesterhoeft A., Ehrlich S.D., Emmerson P.T., Entian K.-D.,
RA   Errington J., Fabret C., Ferrari E., Foulger D., Fritz C., Fujita M.,
RA   Fujita Y., Fuma S., Galizzi A., Galleron N., Ghim S.-Y., Glaser P.,
RA   Goffeau A., Golightly E.J., Grandi G., Guiseppi G., Guy B.J., Haga K.,
RA   Haiech J., Harwood C.R., Henaut A., Hilbert H., Holsappel S., Hosono S.,
RA   Hullo M.-F., Itaya M., Jones L.-M., Joris B., Karamata D., Kasahara Y.,
RA   Klaerr-Blanchard M., Klein C., Kobayashi Y., Koetter P., Koningstein G.,
RA   Krogh S., Kumano M., Kurita K., Lapidus A., Lardinois S., Lauber J.,
RA   Lazarevic V., Lee S.-M., Levine A., Liu H., Masuda S., Mauel C.,
RA   Medigue C., Medina N., Mellado R.P., Mizuno M., Moestl D., Nakai S.,
RA   Noback M., Noone D., O'Reilly M., Ogawa K., Ogiwara A., Oudega B.,
RA   Park S.-H., Parro V., Pohl T.M., Portetelle D., Porwollik S.,
RA   Prescott A.M., Presecan E., Pujic P., Purnelle B., Rapoport G., Rey M.,
RA   Reynolds S., Rieger M., Rivolta C., Rocha E., Roche B., Rose M., Sadaie Y.,
RA   Sato T., Scanlan E., Schleich S., Schroeter R., Scoffone F., Sekiguchi J.,
RA   Sekowska A., Seror S.J., Serror P., Shin B.-S., Soldo B., Sorokin A.,
RA   Tacconi E., Takagi T., Takahashi H., Takemaru K., Takeuchi M.,
RA   Tamakoshi A., Tanaka T., Terpstra P., Tognoni A., Tosato V., Uchiyama S.,
RA   Vandenbol M., Vannier F., Vassarotti A., Viari A., Wambutt R., Wedler E.,
RA   Wedler H., Weitzenegger T., Winters P., Wipat A., Yamamoto H., Yamane K.,
RA   Yasumoto K., Yata K., Yoshida K., Yoshikawa H.-F., Zumstein E.,
RA   Yoshikawa H., Danchin A.;
RT   ""The complete genome sequence of the Gram-positive bacterium Bacillus
RT   subtilis."";
RL   Nature 390:249-256(1997).
RN   [4]
RP   SEQUENCE REVISION TO 152.
RX   PubMed=19383706; DOI=10.1099/mic.0.027839-0;
RA   Barbe V., Cruveiller S., Kunst F., Lenoble P., Meurice G., Sekowska A.,
RA   Vallenet D., Wang T., Moszer I., Medigue C., Danchin A.;
RT   ""From a consortium sequence to a unified sequence: the Bacillus subtilis
RT   168 reference genome a decade later."";
RL   Microbiology 155:1758-1775(2009).
RN   [5]
RP   IDENTIFICATION.
RX   PubMed=7489895; DOI=10.1016/0378-1119(95)00636-k;
RA   Medigue C., Moszer I., Viari A., Danchin A.;
RT   ""Analysis of a Bacillus subtilis genome fragment using a co-operative
RT   computer system prototype."";
RL   Gene 165:GC37-GC51(1995).
RN   [6]
RP   ROLE IN ARSENIC RESISTANCE.
RX   PubMed=9537360; DOI=10.1128/jb.180.7.1655-1661.1998;
RA   Sato T., Kobayashi Y.;
RT   ""The ars operon in the skin element of Bacillus subtilis confers resistance
RT   to arsenate and arsenite."";
RL   J. Bacteriol. 180:1655-1661(1998).
CC   -!- FUNCTION: Seems to confer resistance to arsenite by allowing cells to
CC       extrude this compound. Could be part of an arsenite extrusion pump.
CC       {ECO:0000269|PubMed:9537360}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Multi-pass membrane
CC       protein {ECO:0000305}.
CC   -!- MISCELLANEOUS: Deletion of the arsB gene results in both an
CC       aresenite- and arsenate-sensitive phenotype in the absence of IPTG.
CC   -!- SIMILARITY: Belongs to the arsenical resistance-3 (ACR3) (TC 2.A.59)
CC       family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; D32216; BAA06969.1; -; Genomic_DNA.
DR   EMBL; D84432; BAA12433.1; -; Genomic_DNA.
DR   EMBL; AL009126; CAB14520.2; -; Genomic_DNA.
DR   PIR; B69950; B69950.
DR   RefSeq; NP_390456.2; NC_000964.3.
DR   RefSeq; WP_004398718.1; NZ_OZ025638.1.
DR   AlphaFoldDB; P45946; -.
DR   SMR; P45946; -.
DR   STRING; 224308.BSU25790; -.
DR   TCDB; 2.A.59.1.2; the arsenical resistance-3 (acr3) family.
DR   PaxDb; 224308-BSU25790; -.
DR   EnsemblBacteria; CAB14520; CAB14520; BSU_25790.
DR   GeneID; 937800; -.
DR   KEGG; bsu:BSU25790; -.
DR   PATRIC; fig|224308.179.peg.2803; -.
DR   eggNOG; COG0798; Bacteria.
DR   InParanoid; P45946; -.
DR   OrthoDB; 9771457at2; -.
DR   PhylomeDB; P45946; -.
DR   BioCyc; BSUB:BSU25790-MONOMER; -.
DR   BioCyc; MetaCyc:BSU25790-MONOMER; -.
DR   Proteomes; UP000001570; Chromosome.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0015104; F:antimonite transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0015297; F:antiporter activity; IBA:GO_Central.
DR   GO; GO:0015105; F:arsenite transmembrane transporter activity; IBA:GO_Central.
DR   GO; GO:0015699; P:antimonite transmembrane transport; IBA:GO_Central.
DR   GO; GO:0015700; P:arsenite transport; IBA:GO_Central.
DR   GO; GO:0046685; P:response to arsenic-containing substance; IEA:UniProtKB-KW.
DR   FunFam; 1.20.1530.20:FF:000009; Arsenite transporter, ACR3 family; 1.
DR   Gene3D; 1.20.1530.20; -; 1.
DR   InterPro; IPR004706; Arsenical-R_Acr3.
DR   InterPro; IPR002657; BilAc:Na_symport/Acr3.
DR   InterPro; IPR038770; Na+/solute_symporter_sf.
DR   NCBIfam; TIGR00832; acr3; 1.
DR   PANTHER; PTHR43057:SF1; ARSENICAL-RESISTANCE PROTEIN 3; 1.
DR   PANTHER; PTHR43057; ARSENITE EFFLUX TRANSPORTER; 1.
DR   Pfam; PF01758; SBF; 1.
DR   PIRSF; PIRSF005508; Acr3; 1.
PE   3: Inferred from homology;
KW   Arsenical resistance; Cell membrane; Membrane; Reference proteome;
KW   Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..346
FT                   /note=""Arsenite resistance protein ArsB""
FT                   /id=""PRO_0000201482""
FT   TRANSMEM        13..33
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        41..61
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        82..102
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        106..126
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        140..160
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        184..204
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        216..236
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        253..273
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        285..307
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        318..338
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   CONFLICT        152
FT                   /note=""F -> S (in Ref. 1; BAA06969 and 2; BAA12433)""
FT                   /evidence=""ECO:0000305""
SQ   SEQUENCE   346 AA;  38312 MW;  05739D0B768A8644 CRC64;
     MKRLSFLDRY LTIWIFLAMA LGIGLGFIFP SFVGGLNKLQ VGTTSIPLAI GLVLMMYPPL
     AKVRYEEIGR VFKDIKVLIL SLVQNWIIGP TLMFILAIIF LPDKPEYMIG LIMIGLARCI
     AMVIVWNDLS KGDTEYAAGL VAFNSIFQML FFSVYAYIFV TVIPQWLGME GAVVNITMAE
     VAKSVFIYLG VPFIAGMVTR YIFVKVKGKE WYEKVFIPKI SPITLIALLF TIIVMFSLKG
     DVIVSLPLDV VRVAIPLLIY FVLMFFVSFF LGKKIGANYA VTTTLAFTAG SNNFELAIAV
     AVGVFGIHSG AAFAAVIGPL VEVPVMIALV KVALWFQRKY FGSHSM
//
",378
GACAAG ACAAGG CAAGGC AAGGCG AGGCGA GGCGAA GCGAAG CGAAGC GAAGCG AAGCGG AGCGGA GCGGAT CGGATA GGATAC GATACT ATACTC TACTCG ACTCGG CTCGGC TCGGCG CGGCGA GGCGAG GCGAGA CGAGAC GAGACG AGACGC GACGCA ACGCAA CGCAAA GCAAAC CAAACC AAACCG AACCGT ACCGTG CCGTGC CGTGCA GTGCAG TGCAGA GCAGAC CAGACC AGACCG GACCGG ACCGGC CCGGCC CGGCCT GGCCTT GCCTTG CCTTGC CTTGCG TTGCGG TGCGGG GCGGGG CGGGGC GGGGCT GGGCTC GGCTCG GCTCGA CTCGAC TCGACA CGACAC GACACC ACACCC CACCCA ACCCAG CCCAGG CCAGGA CAGGAC AGGACG GGACGG GACGGC ACGGCT CGGCTG GGCTGC GCTGCA CTGCAA TGCAAG GCAAGC CAAGCG AAGCGA AGCGAT GCGATT CGATTG GATTGG ATTGGC TTGGCG TGGCGA GGCGAA GCGAAT CGAATG GAATGC AATGCA ATGCAA TGCAAT GCAATG CAATGT AATGTG ATGTGG TGTGGA GTGGAA TGGAAT GGAATG GAATGC AATGCG ATGCGT TGCGTG GCGTGC CGTGCG GTGCGA TGCGAG GCGAGA CGAGAC GAGACA AGACAT GACATG ACATGA,1,115,GACA ACAA CAAG AAGG AGGC GGCG GCGA CGAA GAAG AAGC AGCG GCGG CGGA GGAT GATA ATAC TACT ACTC CTCG TCGG CGGC GGCG GCGA CGAG GAGA AGAC GACG ACGC CGCA GCAA CAAA AAAC AACC ACCG CCGT CGTG GTGC TGCA GCAG CAGA AGAC GACC ACCG CCGG CGGC GGCC GCCT CCTT CTTG TTGC TGCG GCGG CGGG GGGG GGGC GGCT GCTC CTCG TCGA CGAC GACA ACAC CACC ACCC CCCA CCAG CAGG AGGA GGAC GACG ACGG CGGC GGCT GCTG CTGC TGCA GCAA CAAG AAGC AGCG GCGA CGAT GATT ATTG TTGG TGGC GGCG GCGA CGAA GAAT AATG ATGC TGCA GCAA CAAT AATG ATGT TGTG GTGG TGGA GGAA GAAT AATG ATGC TGCG GCGT CGTG GTGC TGCG GCGA CGAG GAGA AGAC GACA ACAT CATG ATGA,GACAA ACAAG CAAGG AAGGC AGGCG GGCGA GCGAA CGAAG GAAGC AAGCG AGCGG GCGGA CGGAT GGATA GATAC ATACT TACTC ACTCG CTCGG TCGGC CGGCG GGCGA GCGAG CGAGA GAGAC AGACG GACGC ACGCA CGCAA GCAAA CAAAC AAACC AACCG ACCGT CCGTG CGTGC GTGCA TGCAG GCAGA CAGAC AGACC GACCG ACCGG CCGGC CGGCC GGCCT GCCTT CCTTG CTTGC TTGCG TGCGG GCGGG CGGGG GGGGC GGGCT GGCTC GCTCG CTCGA TCGAC CGACA GACAC ACACC CACCC ACCCA CCCAG CCAGG CAGGA AGGAC GGACG GACGG ACGGC CGGCT GGCTG GCTGC CTGCA TGCAA GCAAG CAAGC AAGCG AGCGA GCGAT CGATT GATTG ATTGG TTGGC TGGCG GGCGA GCGAA CGAAT GAATG AATGC ATGCA TGCAA GCAAT CAATG AATGT ATGTG TGTGG GTGGA TGGAA GGAAT GAATG AATGC ATGCG TGCGT GCGTG CGTGC GTGCG TGCGA GCGAG CGAGA GAGAC AGACA GACAT ACATG CATGA,GACAAG ACAAGG CAAGGC AAGGCG AGGCGA GGCGAA GCGAAG CGAAGC GAAGCG AAGCGG AGCGGA GCGGAT CGGATA GGATAC GATACT ATACTC TACTCG ACTCGG CTCGGC TCGGCG CGGCGA GGCGAG GCGAGA CGAGAC GAGACG AGACGC GACGCA ACGCAA CGCAAA GCAAAC CAAACC AAACCG AACCGT ACCGTG CCGTGC CGTGCA GTGCAG TGCAGA GCAGAC CAGACC AGACCG GACCGG ACCGGC CCGGCC CGGCCT GGCCTT GCCTTG CCTTGC CTTGCG TTGCGG TGCGGG GCGGGG CGGGGC GGGGCT GGGCTC GGCTCG GCTCGA CTCGAC TCGACA CGACAC GACACC ACACCC CACCCA ACCCAG CCCAGG CCAGGA CAGGAC AGGACG GGACGG GACGGC ACGGCT CGGCTG GGCTGC GCTGCA CTGCAA TGCAAG GCAAGC CAAGCG AAGCGA AGCGAT GCGATT CGATTG GATTGG ATTGGC TTGGCG TGGCGA GGCGAA GCGAAT CGAATG GAATGC AATGCA ATGCAA TGCAAT GCAATG CAATGT AATGTG ATGTGG TGTGGA GTGGAA TGGAAT GGAATG GAATGC AATGCG ATGCGT TGCGTG GCGTGC CGTGCG GTGCGA TGCGAG GCGAGA CGAGAC GAGACA AGACAT GACATG ACATGA,GACAAGG ACAAGGC CAAGGCG AAGGCGA AGGCGAA GGCGAAG GCGAAGC CGAAGCG GAAGCGG AAGCGGA AGCGGAT GCGGATA CGGATAC GGATACT GATACTC ATACTCG TACTCGG ACTCGGC CTCGGCG TCGGCGA CGGCGAG GGCGAGA GCGAGAC CGAGACG GAGACGC AGACGCA GACGCAA ACGCAAA CGCAAAC GCAAACC CAAACCG AAACCGT AACCGTG ACCGTGC CCGTGCA CGTGCAG GTGCAGA TGCAGAC GCAGACC CAGACCG AGACCGG GACCGGC ACCGGCC CCGGCCT CGGCCTT GGCCTTG GCCTTGC CCTTGCG CTTGCGG TTGCGGG TGCGGGG GCGGGGC CGGGGCT GGGGCTC GGGCTCG GGCTCGA GCTCGAC CTCGACA TCGACAC CGACACC GACACCC ACACCCA CACCCAG ACCCAGG CCCAGGA CCAGGAC CAGGACG AGGACGG GGACGGC GACGGCT ACGGCTG CGGCTGC GGCTGCA GCTGCAA CTGCAAG TGCAAGC GCAAGCG CAAGCGA AAGCGAT AGCGATT GCGATTG CGATTGG GATTGGC ATTGGCG TTGGCGA TGGCGAA GGCGAAT GCGAATG CGAATGC GAATGCA AATGCAA ATGCAAT TGCAATG GCAATGT CAATGTG AATGTGG ATGTGGA TGTGGAA GTGGAAT TGGAATG GGAATGC GAATGCG AATGCGT ATGCGTG TGCGTGC GCGTGCG CGTGCGA GTGCGAG TGCGAGA GCGAGAC CGAGACA GAGACAT AGACATG GACATGA,"ID   HMPD_RHILO              Reviewed;         234 AA.
AC   Q988D0;
DT   20-JUN-2018, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2001, sequence version 1.
DT   27-NOV-2024, entry version 119.
DE   RecName: Full=3-hydroxy-2-methylpyridine-4,5-dicarboxylate 4-decarboxylase {ECO:0000303|PubMed:17973403};
DE            Short=HMPDdc {ECO:0000303|PubMed:17973403};
DE            EC=4.1.1.51 {ECO:0000269|PubMed:17973403};
GN   OrderedLocusNames=mlr6791 {ECO:0000312|EMBL:BAB53020.1};
OS   Mesorhizobium japonicum (strain LMG 29417 / CECT 9101 / MAFF 303099)
OS   (Mesorhizobium loti (strain MAFF 303099)).
OC   Bacteria; Pseudomonadota; Alphaproteobacteria; Hyphomicrobiales;
OC   Phyllobacteriaceae; Mesorhizobium.
OX   NCBI_TaxID=266835;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=LMG 29417 / CECT 9101 / MAFF 303099;
RX   PubMed=11214968; DOI=10.1093/dnares/7.6.331;
RA   Kaneko T., Nakamura Y., Sato S., Asamizu E., Kato T., Sasamoto S.,
RA   Watanabe A., Idesawa K., Ishikawa A., Kawashima K., Kimura T., Kishida Y.,
RA   Kiyokawa C., Kohara M., Matsumoto M., Matsuno A., Mochizuki Y.,
RA   Nakayama S., Nakazaki N., Shimpo S., Sugimoto M., Takeuchi C., Yamada M.,
RA   Tabata S.;
RT   ""Complete genome structure of the nitrogen-fixing symbiotic bacterium
RT   Mesorhizobium loti."";
RL   DNA Res. 7:331-338(2000).
RN   [2]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) IN COMPLEX WITH MANGANESE ION,
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, COFACTOR,
RP   SUBUNIT, ACTIVE SITE, REACTION MECHANISM, AND PATHWAY.
RC   STRAIN=LMG 29417 / CECT 9101 / MAFF 303099;
RX   PubMed=17973403; DOI=10.1021/bi701439j;
RA   Mukherjee T., McCulloch K.M., Ealick S.E., Begley T.P.;
RT   ""Gene identification and structural characterization of the pyridoxal 5'-
RT   phosphate degradative protein 3-hydroxy-2-methylpyridine-4,5-dicarboxylate
RT   decarboxylase from mesorhizobium loti MAFF303099."";
RL   Biochemistry 46:13606-13615(2007).
CC   -!- FUNCTION: Involved in the catabolism of pyridoxal 5-phosphate (Vitamin
CC       B6). Catalyzes the decarboxylation of 3-hydroxy-2-methylpyridine-4,5-
CC       dicarboxylate to yield 3-hydroxy-2-methylpyridine-5-carboxylate. The
CC       decarboxylation proceeds by an aldolase-like mechanism in which the
CC       binding of the substrate frees Glu-73 residue from its interaction with
CC       manganese ion replacing it by an interaction with the hydroxyl group
CC       from the substrate. Glu-73 residue then provides the proton for the
CC       keto-enol tautomerization. The decarboxylation reaction is analogous to
CC       the retroaldol reaction except that it does not need a base as the
CC       carboxylate is likely to be deprotonated under the reaction conditions.
CC       {ECO:0000269|PubMed:17973403}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=5-hydroxy-6-methylpyridine-3,4-dicarboxylate + H(+) = 3-
CC         hydroxy-2-methylpyridine-5-carboxylate + CO2; Xref=Rhea:RHEA:13669,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:16526, ChEBI:CHEBI:57528,
CC         ChEBI:CHEBI:77620; EC=4.1.1.51;
CC         Evidence={ECO:0000269|PubMed:17973403};
CC   -!- COFACTOR:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:17973403};
CC       Note=Binds 1 manganese ion per subunit. {ECO:0000269|PubMed:17973403};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=366 uM for 3-hydroxy-2-methylpyridine-4,5-dicarboxylate
CC         {ECO:0000269|PubMed:17973403};
CC         Note=kcat is 0.6 sec(-1) for
CC         3-hydroxy-2-methylpyridine-4,5-dicarboxylate as substrate.
CC         {ECO:0000269|PubMed:17973403};
CC   -!- PATHWAY: Cofactor degradation; B6 vitamer degradation.
CC       {ECO:0000305|PubMed:17973403}.
CC   -!- SUBUNIT: Homotetramer. {ECO:0000269|PubMed:17973403}.
CC   -!- SIMILARITY: Belongs to the aldolase class II family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BA000012; BAB53020.1; -; Genomic_DNA.
DR   PDB; 2Z7B; X-ray; 1.90 A; A=1-234.
DR   PDBsum; 2Z7B; -.
DR   AlphaFoldDB; Q988D0; -.
DR   SMR; Q988D0; -.
DR   KEGG; mlo:mlr6791; -.
DR   eggNOG; COG0235; Bacteria.
DR   HOGENOM; CLU_006033_2_2_5; -.
DR   BioCyc; MetaCyc:MONOMER-20512; -.
DR   UniPathway; UPA00192; -.
DR   EvolutionaryTrace; Q988D0; -.
DR   Proteomes; UP000000552; Chromosome.
DR   GO; GO:0005829; C:cytosol; IEA:TreeGrafter.
DR   GO; GO:0047431; F:3-hydroxy-2-methylpyridine-4,5-dicarboxylate 4-decarboxylase activity; IDA:UniProtKB.
DR   GO; GO:0016832; F:aldehyde-lyase activity; IEA:TreeGrafter.
DR   GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB.
DR   GO; GO:0019323; P:pentose catabolic process; IEA:TreeGrafter.
DR   GO; GO:0042820; P:vitamin B6 catabolic process; IDA:UniProtKB.
DR   FunFam; 3.40.225.10:FF:000019; 3-hydroxy-2-methylpyridine-4,5-dicarboxylic acid decarboxylase; 1.
DR   Gene3D; 3.40.225.10; Class II aldolase/adducin N-terminal domain; 1.
DR   InterPro; IPR050197; Aldolase_class_II_sugar_metab.
DR   InterPro; IPR001303; Aldolase_II/adducin_N.
DR   InterPro; IPR036409; Aldolase_II/adducin_N_sf.
DR   PANTHER; PTHR22789:SF0; 3-OXO-TETRONATE 4-PHOSPHATE DECARBOXYLASE-RELATED; 1.
DR   PANTHER; PTHR22789; FUCULOSE PHOSPHATE ALDOLASE; 1.
DR   Pfam; PF00596; Aldolase_II; 1.
DR   SMART; SM01007; Aldolase_II; 1.
DR   SUPFAM; SSF53639; AraD/HMP-PK domain-like; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Lyase; Manganese; Metal-binding.
FT   CHAIN           1..234
FT                   /note=""3-hydroxy-2-methylpyridine-4,5-dicarboxylate 4-
FT                   decarboxylase""
FT                   /id=""PRO_0000444598""
FT   ACT_SITE        73
FT                   /note=""Proton acceptor/donor""
FT                   /evidence=""ECO:0000305|PubMed:17973403""
FT   BINDING         73
FT                   /ligand=""Mn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29035""
FT                   /ligand_note=""catalytic""
FT                   /evidence=""ECO:0000269|PubMed:17973403,
FT                   ECO:0007744|PDB:2Z7B""
FT   BINDING         92
FT                   /ligand=""Mn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29035""
FT                   /ligand_note=""catalytic""
FT                   /evidence=""ECO:0000269|PubMed:17973403,
FT                   ECO:0007744|PDB:2Z7B""
FT   BINDING         94
FT                   /ligand=""Mn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29035""
FT                   /ligand_note=""catalytic""
FT                   /evidence=""ECO:0000269|PubMed:17973403,
FT                   ECO:0007744|PDB:2Z7B""
FT   BINDING         163
FT                   /ligand=""Mn(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:29035""
FT                   /ligand_note=""catalytic""
FT                   /evidence=""ECO:0000269|PubMed:17973403,
FT                   ECO:0007744|PDB:2Z7B""
FT   HELIX           1..18
FT                   /evidence=""ECO:0007829|PDB:2Z7B""
FT   STRAND          27..31
FT                   /evidence=""ECO:0007829|PDB:2Z7B""
FT   STRAND          38..42
FT                   /evidence=""ECO:0007829|PDB:2Z7B""
FT   HELIX           47..49
FT                   /evidence=""ECO:0007829|PDB:2Z7B""
FT   HELIX           52..54
FT                   /evidence=""ECO:0007829|PDB:2Z7B""
FT   STRAND          55..59
FT                   /evidence=""ECO:0007829|PDB:2Z7B""
FT   HELIX           74..83
FT                   /evidence=""ECO:0007829|PDB:2Z7B""
FT   STRAND          89..93
FT                   /evidence=""ECO:0007829|PDB:2Z7B""
FT   TURN            96..98
FT                   /evidence=""ECO:0007829|PDB:2Z7B""
FT   HELIX           99..102
FT                   /evidence=""ECO:0007829|PDB:2Z7B""
FT   STRAND          103..106
FT                   /evidence=""ECO:0007829|PDB:2Z7B""
FT   HELIX           113..118
FT                   /evidence=""ECO:0007829|PDB:2Z7B""
FT   HELIX           128..131
FT                   /evidence=""ECO:0007829|PDB:2Z7B""
FT   HELIX           142..152
FT                   /evidence=""ECO:0007829|PDB:2Z7B""
FT   STRAND          155..160
FT                   /evidence=""ECO:0007829|PDB:2Z7B""
FT   TURN            161..163
FT                   /evidence=""ECO:0007829|PDB:2Z7B""
FT   STRAND          164..171
FT                   /evidence=""ECO:0007829|PDB:2Z7B""
FT   HELIX           172..193
FT                   /evidence=""ECO:0007829|PDB:2Z7B""
FT   HELIX           203..209
FT                   /evidence=""ECO:0007829|PDB:2Z7B""
FT   HELIX           216..230
FT                   /evidence=""ECO:0007829|PDB:2Z7B""
SQ   SEQUENCE   234 AA;  25939 MW;  76E7783A748E0F24 CRC64;
     MRRKVFEELV TATKILLNEG IMDTFGHISA RDPEDPASFF LAQKLAPSLI TVDDIQRFNL
     DGETSDNRPS YLERYIHSEI YKTRPDVQCV LHTHSPAVLP YCFVDTPLRP VTHMGAFIGE
     SVPVYEIRDK HGDETDLFGG SPDVCADIAE SLGSQTVVLM ARHGVVNVGK SVREVVFRAF
     YLEQEAAALT AGLKIGNVKY LSPGEIKTAG KLVGAQIDRG WNHWSQRLRQ AGLA
//
",45540
TTAACA TAACAT AACATT ACATTA CATTAG ATTAGC TTAGCT TAGCTG AGCTGT GCTGTA CTGTAC TGTACC GTACCC TACCCT ACCCTA CCCTAT CCTATA CTATAA TATAAT ATAATA TAATAT AATATG ATATGA TATGAG ATGAGA TGAGAG GAGAGT AGAGTT GAGTTA AGTTAT GTTATA TTATAC TATACA ATACAT TACATT ACATTT CATTTT ATTTTG TTTTGG TTTGGT TTGGTG TGGTGC GGTGCT GTGCTG TGCTGG GCTGGT CTGGTT TGGTTC GGTTCT GTTCTG TTCTGA TCTGAT CTGATA TGATAA GATAAA ATAAAG TAAAGG AAAGGA AAGGAG AGGAGT GGAGTT GAGTTG AGTTGC GTTGCA TTGCAC TGCACC GCACCA CACCAG ACCAGG CCAGGT CAGGTA AGGTAC GGTACA GTACAG TACAGC ACAGCT CAGCTG AGCTGT GCTGTT CTGTTT TGTTTT GTTTTA TTTTAA TTTAAG TTAAGA TAAGAC AAGACA AGACAG GACAGT ACAGTG CAGTGG AGTGGT GTGGTT TGGTTC GGTTCT GTTCTG TTCTGT TCTGTC CTGTCT TGTCTC GTCTCT TCTCTT CTCTTA TCTTAT CTTATA TTATAC TATACA ATACAC TACACA ACACAT CACATT ACATTC CATTCC ATTCCG TTCCGA TCCGAG CCGAGC CGAGCC GAGCCC AGCCCA GCCCAC CCCACG CCACGA CACGAG ACGAGA CGAGAC GAGACT AGACTC GACTCC ACTCCT CTCCTG TCCTGA CCTGAG CTGAGC TGAGCA GAGCAT AGCATC GCATCT CATCTC ATCTCG TCTCGT CTCGTA,0,142,TTAA TAAC AACA ACAT CATT ATTA TTAG TAGC AGCT GCTG CTGT TGTA GTAC TACC ACCC CCCT CCTA CTAT TATA ATAA TAAT AATA ATAT TATG ATGA TGAG GAGA AGAG GAGT AGTT GTTA TTAT TATA ATAC TACA ACAT CATT ATTT TTTT TTTG TTGG TGGT GGTG GTGC TGCT GCTG CTGG TGGT GGTT GTTC TTCT TCTG CTGA TGAT GATA ATAA TAAA AAAG AAGG AGGA GGAG GAGT AGTT GTTG TTGC TGCA GCAC CACC ACCA CCAG CAGG AGGT GGTA GTAC TACA ACAG CAGC AGCT GCTG CTGT TGTT GTTT TTTT TTTA TTAA TAAG AAGA AGAC GACA ACAG CAGT AGTG GTGG TGGT GGTT GTTC TTCT TCTG CTGT TGTC GTCT TCTC CTCT TCTT CTTA TTAT TATA ATAC TACA ACAC CACA ACAT CATT ATTC TTCC TCCG CCGA CGAG GAGC AGCC GCCC CCCA CCAC CACG ACGA CGAG GAGA AGAC GACT ACTC CTCC TCCT CCTG CTGA TGAG GAGC AGCA GCAT CATC ATCT TCTC CTCG TCGT CGTA,TTAAC TAACA AACAT ACATT CATTA ATTAG TTAGC TAGCT AGCTG GCTGT CTGTA TGTAC GTACC TACCC ACCCT CCCTA CCTAT CTATA TATAA ATAAT TAATA AATAT ATATG TATGA ATGAG TGAGA GAGAG AGAGT GAGTT AGTTA GTTAT TTATA TATAC ATACA TACAT ACATT CATTT ATTTT TTTTG TTTGG TTGGT TGGTG GGTGC GTGCT TGCTG GCTGG CTGGT TGGTT GGTTC GTTCT TTCTG TCTGA CTGAT TGATA GATAA ATAAA TAAAG AAAGG AAGGA AGGAG GGAGT GAGTT AGTTG GTTGC TTGCA TGCAC GCACC CACCA ACCAG CCAGG CAGGT AGGTA GGTAC GTACA TACAG ACAGC CAGCT AGCTG GCTGT CTGTT TGTTT GTTTT TTTTA TTTAA TTAAG TAAGA AAGAC AGACA GACAG ACAGT CAGTG AGTGG GTGGT TGGTT GGTTC GTTCT TTCTG TCTGT CTGTC TGTCT GTCTC TCTCT CTCTT TCTTA CTTAT TTATA TATAC ATACA TACAC ACACA CACAT ACATT CATTC ATTCC TTCCG TCCGA CCGAG CGAGC GAGCC AGCCC GCCCA CCCAC CCACG CACGA ACGAG CGAGA GAGAC AGACT GACTC ACTCC CTCCT TCCTG CCTGA CTGAG TGAGC GAGCA AGCAT GCATC CATCT ATCTC TCTCG CTCGT TCGTA,TTAACA TAACAT AACATT ACATTA CATTAG ATTAGC TTAGCT TAGCTG AGCTGT GCTGTA CTGTAC TGTACC GTACCC TACCCT ACCCTA CCCTAT CCTATA CTATAA TATAAT ATAATA TAATAT AATATG ATATGA TATGAG ATGAGA TGAGAG GAGAGT AGAGTT GAGTTA AGTTAT GTTATA TTATAC TATACA ATACAT TACATT ACATTT CATTTT ATTTTG TTTTGG TTTGGT TTGGTG TGGTGC GGTGCT GTGCTG TGCTGG GCTGGT CTGGTT TGGTTC GGTTCT GTTCTG TTCTGA TCTGAT CTGATA TGATAA GATAAA ATAAAG TAAAGG AAAGGA AAGGAG AGGAGT GGAGTT GAGTTG AGTTGC GTTGCA TTGCAC TGCACC GCACCA CACCAG ACCAGG CCAGGT CAGGTA AGGTAC GGTACA GTACAG TACAGC ACAGCT CAGCTG AGCTGT GCTGTT CTGTTT TGTTTT GTTTTA TTTTAA TTTAAG TTAAGA TAAGAC AAGACA AGACAG GACAGT ACAGTG CAGTGG AGTGGT GTGGTT TGGTTC GGTTCT GTTCTG TTCTGT TCTGTC CTGTCT TGTCTC GTCTCT TCTCTT CTCTTA TCTTAT CTTATA TTATAC TATACA ATACAC TACACA ACACAT CACATT ACATTC CATTCC ATTCCG TTCCGA TCCGAG CCGAGC CGAGCC GAGCCC AGCCCA GCCCAC CCCACG CCACGA CACGAG ACGAGA CGAGAC GAGACT AGACTC GACTCC ACTCCT CTCCTG TCCTGA CCTGAG CTGAGC TGAGCA GAGCAT AGCATC GCATCT CATCTC ATCTCG TCTCGT CTCGTA,TTAACAT TAACATT AACATTA ACATTAG CATTAGC ATTAGCT TTAGCTG TAGCTGT AGCTGTA GCTGTAC CTGTACC TGTACCC GTACCCT TACCCTA ACCCTAT CCCTATA CCTATAA CTATAAT TATAATA ATAATAT TAATATG AATATGA ATATGAG TATGAGA ATGAGAG TGAGAGT GAGAGTT AGAGTTA GAGTTAT AGTTATA GTTATAC TTATACA TATACAT ATACATT TACATTT ACATTTT CATTTTG ATTTTGG TTTTGGT TTTGGTG TTGGTGC TGGTGCT GGTGCTG GTGCTGG TGCTGGT GCTGGTT CTGGTTC TGGTTCT GGTTCTG GTTCTGA TTCTGAT TCTGATA CTGATAA TGATAAA GATAAAG ATAAAGG TAAAGGA AAAGGAG AAGGAGT AGGAGTT GGAGTTG GAGTTGC AGTTGCA GTTGCAC TTGCACC TGCACCA GCACCAG CACCAGG ACCAGGT CCAGGTA CAGGTAC AGGTACA GGTACAG GTACAGC TACAGCT ACAGCTG CAGCTGT AGCTGTT GCTGTTT CTGTTTT TGTTTTA GTTTTAA TTTTAAG TTTAAGA TTAAGAC TAAGACA AAGACAG AGACAGT GACAGTG ACAGTGG CAGTGGT AGTGGTT GTGGTTC TGGTTCT GGTTCTG GTTCTGT TTCTGTC TCTGTCT CTGTCTC TGTCTCT GTCTCTT TCTCTTA CTCTTAT TCTTATA CTTATAC TTATACA TATACAC ATACACA TACACAT ACACATT CACATTC ACATTCC CATTCCG ATTCCGA TTCCGAG TCCGAGC CCGAGCC CGAGCCC GAGCCCA AGCCCAC GCCCACG CCCACGA CCACGAG CACGAGA ACGAGAC CGAGACT GAGACTC AGACTCC GACTCCT ACTCCTG CTCCTGA TCCTGAG CCTGAGC CTGAGCA TGAGCAT GAGCATC AGCATCT GCATCTC CATCTCG ATCTCGT TCTCGTA,"ID   R1AB_BCHK3              Reviewed;        7067 AA.
AC   P0C6W2; Q3LZX2;
DT   10-JUN-2008, integrated into UniProtKB/Swiss-Prot.
DT   10-JUN-2008, sequence version 1.
DT   05-FEB-2025, entry version 109.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE              Short=nsp1;
DE     AltName: Full=Leader protein;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like proteinase nsp3;
DE              Short=PL-PRO;
DE              EC=3.4.19.12;
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.-;
DE     AltName: Full=nsp5;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9;
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE     AltName: Full=p12;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50;
DE     AltName: Full=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              Short=ExoN;
DE              EC=2.1.1.56;
DE              EC=3.1.13.-;
DE     AltName: Full=nsp14;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.-;
DE     AltName: Full=NendoU;
DE     AltName: Full=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Bat coronavirus HKU3 (BtCoV) (SARS-like coronavirus HKU3).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=442736;
OH   NCBI_TaxID=89399; Rhinolophus sinicus (Chinese rufous horseshoe bat).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU3-1;
RX   PubMed=16169905; DOI=10.1073/pnas.0506735102;
RA   Lau S.K.P., Woo P.C.Y., Li K.S.M., Huang Y., Tsoi H.-W., Wong B.H.L.,
RA   Wong S.S.Y., Leung S.-Y., Chan K.-H., Yuen K.-Y.;
RT   ""Severe acute respiratory syndrome coronavirus-like virus in Chinese
RT   horseshoe bats."";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:14040-14045(2005).
CC   -!- FUNCTION: The replicase polyprotein of coronaviruses is a
CC       multifunctional protein: it contains the activities necessary for the
CC       transcription of negative stranded RNA, leader RNA, subgenomic mRNAs
CC       and progeny virion RNA as well as proteinases responsible for the
CC       cleavage of the polyprotein into functional products.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by interacting with the 40S ribosomal subunit. The nsp1-40S ribosome
CC       complex further induces an endonucleolytic cleavage near the 5'UTR of
CC       host mRNAs, targeting them for degradation. Viral mRNAs are not
CC       susceptible to nsp1-mediated endonucleolytic RNA cleavage thanks to the
CC       presence of a 5'-end leader sequence and are therefore protected from
CC       degradation. By suppressing host gene expression, nsp1 facilitates
CC       efficient viral gene expression in infected cells and evasion from host
CC       immune response. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Non-structural protein 2]: May play a role in the modulation
CC       of host cell survival signaling pathway by interacting with host PHB
CC       and PHB2. Indeed, these two proteins play a role in maintaining the
CC       functional integrity of the mitochondria and protecting cells from
CC       various stresses. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Papain-like proteinase nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. In addition,
CC       PL-PRO possesses a deubiquitinating/deISGylating activity and processes
CC       both 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates. Participates together with nsp4 in the assembly of virally-
CC       induced cytoplasmic double-membrane vesicles necessary for viral
CC       replication. Antagonizes innate immune induction of type I interferon
CC       by blocking the phosphorylation, dimerization and subsequent nuclear
CC       translocation of host IRF3. Prevents also host NF-kappa-B signaling.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Non-structural protein 4]: Participates in the assembly of
CC       virally-induced cytoplasmic double-membrane vesicles necessary for
CC       viral replication. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [3C-like proteinase nsp5]: Cleaves the C-terminus of
CC       replicase polyprotein at 11 sites. Recognizes substrates containing the
CC       core sequence [ILMVF]-Q-|-[SGACN]. Also able to bind an ADP-ribose-1''-
CC       phosphate (ADRP). {ECO:0000250|UniProtKB:P0C6X7, ECO:0000255|PROSITE-
CC       ProRule:PRU00772}.
CC   -!- FUNCTION: [Non-structural protein 6]: Plays a role in the initial
CC       induction of autophagosomes from host endoplasmic reticulum. Later,
CC       limits the expansion of these phagosomes that are no longer able to
CC       deliver viral components to lysosomes. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Non-structural protein 7]: Forms a hexadecamer with nsp8 (8
CC       subunits of each) that may participate in viral replication by acting
CC       as a primase. Alternatively, may synthesize substantially longer
CC       products than oligonucleotide primers. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Non-structural protein 8]: Forms a hexadecamer with nsp7 (8
CC       subunits of each) that may participate in viral replication by acting
CC       as a primase. Alternatively, may synthesize substantially longer
CC       products than oligonucleotide primers. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Viral protein genome-linked nsp9]: Forms a primer, NSP9-pU,
CC       which is utilized by the polymerase for the initiation of RNA chains.
CC       Interacts with ribosome signal recognition particle RNA (SRP). Together
CC       with NSP8, suppress protein integration into the cell membrane, thereby
CC       disrupting host immune defenses. {ECO:0000250|UniProtKB:P0DTD1}.
CC   -!- FUNCTION: [Non-structural protein 10]: Plays a pivotal role in viral
CC       transcription by stimulating both nsp14 3'-5' exoribonuclease and nsp16
CC       2'-O-methyltransferase activities. Therefore plays an essential role in
CC       viral mRNAs cap methylation. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [RNA-directed RNA polymerase nsp12]: RNA-directed RNA
CC       polymerase that catalyzes the transcription of viral genomic and
CC       subgenomic RNAs. Acts in complex with nsp7 and nsp8 to transcribe both
CC       the minus and positive strands of genomic RNA. The kinase-like NiRAN
CC       domain of NSP12 attaches one or more nucleotides to the amino terminus
CC       of NSP9, forming a covalent RNA-protein intermediate that serves as
CC       transcription/replication primer. Subgenomic RNAs (sgRNAs) are formed
CC       by discontinuous transcription: The polymerase has the ability to pause
CC       at transcription-regulating sequences (TRS) and jump to the leader TRS,
CC       resulting in a major deletion. This creates a series of subgenomic RNAs
CC       that are replicated, transcribed and translated. In addition, Nsp12 is
CC       a subunit of the viral RNA capping enzyme that catalyzes the RNA
CC       guanylyltransferase reaction for genomic and sub-genomic RNAs.
CC       Subsequently, the NiRAN domain transfers RNA to GDP, and forms the core
CC       cap structure GpppA-RNA. {ECO:0000250|UniProtKB:P0DTD1}.
CC   -!- FUNCTION: [Helicase nsp13]: Multi-functional protein with a zinc-
CC       binding domain in N-terminus displaying RNA and DNA duplex-unwinding
CC       activities with 5' to 3' polarity. Activity of helicase is dependent on
CC       magnesium. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Guanine-N7 methyltransferase nsp14]: Plays a role in viral
CC       RNA synthesis through two distinct activities. The N7-guanine
CC       methyltransferase activity plays a role in the formation of the cap
CC       structure GpppA-RNA. The proofreading exoribonuclease reduces the
CC       sensitivity of the virus to RNA mutagens during replication. This
CC       activity acts on both ssRNA and dsRNA in a 3'-5' direction.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Uridylate-specific endoribonuclease nsp15]: Plays a role in
CC       viral transcription/replication and prevents the simultaneous
CC       activation of host cell dsRNA sensors, such as MDA5/IFIH1, OAS, and PKR
CC       (By similarity). Acts by degrading the 5'-polyuridines generated during
CC       replication of the poly(A) region of viral genomic and subgenomic RNAs.
CC       Catalyzes a two-step reaction in which a 2'3'-cyclic phosphate (2'3'-
CC       cP) is first generated by 2'-O transesterification, which is then
CC       hydrolyzed to a 3'-phosphate (3'-P) (By similarity). If not degraded,
CC       poly(U) RNA would hybridize with poly(A) RNA tails and activate host
CC       dsRNA sensors (By similarity). {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [2'-O-methyltransferase nsp16]: Methyltransferase that
CC       mediates mRNA cap 2'-O-ribose methylation to the 5'-cap structure of
CC       viral mRNAs. N7-methyl guanosine cap is a prerequisite for binding of
CC       nsp16. Therefore plays an essential role in viral mRNAs cap methylation
CC       which is essential to evade immune system.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- CATALYTIC ACTIVITY: [RNA-directed RNA polymerase nsp12]:
CC       Reaction=RNA(n) + a ribonucleoside 5'-triphosphate = RNA(n+1) +
CC         diphosphate; Xref=Rhea:RHEA:21248, Rhea:RHEA-COMP:14527, Rhea:RHEA-
CC         COMP:17342, ChEBI:CHEBI:33019, ChEBI:CHEBI:61557, ChEBI:CHEBI:140395;
CC         EC=2.7.7.48; Evidence={ECO:0000255|PROSITE-ProRule:PRU00539};
CC   -!- CATALYTIC ACTIVITY: [Helicase nsp13]:
CC       Reaction=ATP + H2O = ADP + phosphate + H(+); Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=3.6.4.12;
CC   -!- CATALYTIC ACTIVITY: [Helicase nsp13]:
CC       Reaction=ATP + H2O = ADP + phosphate + H(+); Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=3.6.4.13;
CC   -!- CATALYTIC ACTIVITY: [Papain-like proteinase nsp3]:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12;
CC   -!- CATALYTIC ACTIVITY: [2'-O-methyltransferase nsp16]:
CC       Reaction=a 5'-end (N(7)-methyl 5'-triphosphoguanosine)-ribonucleoside
CC         in mRNA + S-adenosyl-L-methionine = a 5'-end (N(7)-methyl 5'-
CC         triphosphoguanosine)-(2'-O-methyl-ribonucleoside) in mRNA + S-
CC         adenosyl-L-homocysteine + H(+); Xref=Rhea:RHEA:67020, Rhea:RHEA-
CC         COMP:17167, Rhea:RHEA-COMP:17168, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:57856, ChEBI:CHEBI:59789, ChEBI:CHEBI:156461,
CC         ChEBI:CHEBI:167609; EC=2.1.1.57;
CC         Evidence={ECO:0000250|UniProtKB:P0C6X7};
CC   -!- CATALYTIC ACTIVITY: [Uridylate-specific endoribonuclease nsp15]:
CC       Reaction=uridylyl-uridylyl-ribonucleotide-RNA = a 3'-end uridylyl-
CC         2',3'-cyclophospho-uridine-RNA + a 5'-end dephospho-ribonucleoside-
CC         RNA; Xref=Rhea:RHEA:67732, Rhea:RHEA-COMP:13936, Rhea:RHEA-
CC         COMP:17334, Rhea:RHEA-COMP:17335, ChEBI:CHEBI:138284,
CC         ChEBI:CHEBI:173079, ChEBI:CHEBI:173080;
CC         Evidence={ECO:0000250|UniProtKB:P0C6X7};
CC   -!- CATALYTIC ACTIVITY: [RNA-directed RNA polymerase nsp12]:
CC       Reaction=a 5'-end diphospho-ribonucleoside in mRNA + GTP + H(+) = a 5'-
CC         end (5'-triphosphoguanosine)-ribonucleoside in mRNA + diphosphate;
CC         Xref=Rhea:RHEA:67012, Rhea:RHEA-COMP:17165, Rhea:RHEA-COMP:17166,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:33019, ChEBI:CHEBI:37565,
CC         ChEBI:CHEBI:167616, ChEBI:CHEBI:167617; EC=2.7.7.50;
CC         Evidence={ECO:0000250|UniProtKB:P0DTD1};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:67013;
CC         Evidence={ECO:0000250|UniProtKB:P0DTD1};
CC   -!- CATALYTIC ACTIVITY: [Guanine-N7 methyltransferase nsp14]:
CC       Reaction=a 5'-end (5'-triphosphoguanosine)-ribonucleoside in mRNA + S-
CC         adenosyl-L-methionine = a 5'-end (N(7)-methyl 5'-
CC         triphosphoguanosine)-ribonucleoside in mRNA + S-adenosyl-L-
CC         homocysteine; Xref=Rhea:RHEA:67008, Rhea:RHEA-COMP:17166, Rhea:RHEA-
CC         COMP:17167, ChEBI:CHEBI:57856, ChEBI:CHEBI:59789, ChEBI:CHEBI:156461,
CC         ChEBI:CHEBI:167617; EC=2.1.1.56;
CC         Evidence={ECO:0000250|UniProtKB:P0C6X7};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:67009;
CC         Evidence={ECO:0000250|UniProtKB:P0C6X7};
CC   -!- COFACTOR: [Uridylate-specific endoribonuclease nsp15]:
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000250|UniProtKB:P0C6X7};
CC       Note=Likely affects Nsp15 binding to RNA.
CC       {ECO:0000250|UniProtKB:P0C6X7};
CC   -!- COFACTOR: [RNA-directed RNA polymerase nsp12]:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000250|UniProtKB:P0DTD1};
CC   -!- SUBUNIT: [Non-structural protein 2]: Interacts with host PHB and PHB2.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBUNIT: [Non-structural protein 4]: Interacts with papain-like
CC       protease nsp3 and non-structural protein 6.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBUNIT: [3C-like proteinase nsp5]: Monomer. Homodimer. Only the
CC       homodimer shows catalytic activity. {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBUNIT: [Non-structural protein 7]: Interacts with nsp8 and nsp12 to
CC       form the replication-transcription complex (RTC): nsp12, nsp7, two
CC       subunits of nsp8, and up to two subunits of nsp13.
CC       {ECO:0000250|UniProtKB:P0DTD1}.
CC   -!- SUBUNIT: [Non-structural protein 8]: Interacts with nsp7, nsp13 and
CC       nsp12 to form the replication-transcription complex (RTC): nsp12, nsp7,
CC       two subunits of nsp8, and up to two subunits of nsp13.
CC       {ECO:0000250|UniProtKB:P0DTD1}.
CC   -!- SUBUNIT: [Viral protein genome-linked nsp9]: Interacts with nsp12.
CC       {ECO:0000250|UniProtKB:P0DTD1}.
CC   -!- SUBUNIT: [Non-structural protein 10]: Interacts with proofreading
CC       exoribonuclease nsp14 and 2'-O-methyltransferase nsp16; these
CC       interactions enhance nsp14 and nsp16 enzymatic activities.
CC       {ECO:0000250|UniProtKB:P0DTD1}.
CC   -!- SUBUNIT: [RNA-directed RNA polymerase nsp12]: Interacts with nsp7 and
CC       nsp8 to form the replication-transcription complex (RTC): nsp12, nsp7,
CC       two subunits of nsp8, and up to two subunits of nsp13. Interacts with
CC       nsp9. {ECO:0000250|UniProtKB:P0DTD1}.
CC   -!- SUBUNIT: [Helicase nsp13]: Interacts with nsp8 to form the replication-
CC       transcription complex (RTC): nsp12, nsp7, two subunits of nsp8, and up
CC       to two subunits of nsp13. {ECO:0000250|UniProtKB:P0DTD1}.
CC   -!- SUBCELLULAR LOCATION: [Papain-like proteinase nsp3]: Host membrane;
CC       Multi-pass membrane protein. Host cytoplasm
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 4]: Host membrane; Multi-
CC       pass membrane protein. Host cytoplasm. Note=Localizes in virally-
CC       induced cytoplasmic double-membrane vesicles.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 6]: Host membrane
CC       {ECO:0000305}; Multi-pass membrane protein {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 7]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250}. Note=nsp7, nsp8, nsp9 and nsp10 are
CC       localized in cytoplasmic foci, largely perinuclear. Late in infection,
CC       they merge into confluent complexes (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 8]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250}. Note=nsp7, nsp8, nsp9 and nsp10 are
CC       localized in cytoplasmic foci, largely perinuclear. Late in infection,
CC       they merge into confluent complexes (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Viral protein genome-linked nsp9]: Host
CC       cytoplasm, host perinuclear region {ECO:0000250}. Note=nsp7, nsp8, nsp9
CC       and nsp10 are localized in cytoplasmic foci, largely perinuclear. Late
CC       in infection, they merge into confluent complexes (By similarity).
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Non-structural protein 10]: Host cytoplasm, host
CC       perinuclear region {ECO:0000250}. Note=nsp7, nsp8, nsp9 and nsp10 are
CC       localized in cytoplasmic foci, largely perinuclear. Late in infection,
CC       they merge into confluent complexes (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Helicase nsp13]: Host endoplasmic reticulum-
CC       Golgi intermediate compartment {ECO:0000305}. Note=The helicase
CC       interacts with the N protein in membranous complexes and colocalizes
CC       with sites of synthesis of new viral RNA. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Uridylate-specific endoribonuclease nsp15]: Host
CC       cytoplasm, host perinuclear region {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Ribosomal frameshifting; Named isoforms=2;
CC       Name=Replicase polyprotein 1ab; Synonyms=pp1ab;
CC         IsoId=P0C6W2-1; Sequence=Displayed;
CC       Name=Replicase polyprotein 1a; Synonyms=pp1a, ORF1a polyprotein;
CC         IsoId=P0C6F8-1; Sequence=External;
CC   -!- DOMAIN: The hydrophobic domains (HD) could mediate the membrane
CC       association of the replication complex and thereby alter the
CC       architecture of the host cell membrane. {ECO:0000250}.
CC   -!- PTM: Specific enzymatic cleavages in vivo by its own proteases yield
CC       mature proteins. 3CL-PRO and PL-PRO proteinases are autocatalytically
CC       processed (By similarity). {ECO:0000250}.
CC   -!- MISCELLANEOUS: Bat coronavirus HKU3 is highly similar to SARS-CoV
CC       (SARS-like).
CC   -!- MISCELLANEOUS: [Isoform Replicase polyprotein 1ab]: Produced by -1
CC       ribosomal frameshifting at the 1a-1b genes boundary.
CC   -!- SIMILARITY: Belongs to the coronaviruses polyprotein 1ab family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; DQ022305; AAY88865.2; -; Genomic_RNA.
DR   BMRB; P0C6W2; -.
DR   SMR; P0C6W2; -.
DR   MEROPS; C16.009; -.
DR   MEROPS; C30.005; -.
DR   Proteomes; UP000007450; Segment.
DR   GO; GO:0044172; C:host cell endoplasmic reticulum-Golgi intermediate compartment; IEA:UniProtKB-SubCell.
DR   GO; GO:0033644; C:host cell membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR   GO; GO:0000175; F:3'-5'-RNA exonuclease activity; IEA:InterPro.
DR   GO; GO:0043139; F:5'-3' DNA helicase activity; IEA:TreeGrafter.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:RHEA.
DR   GO; GO:0140849; F:ATP-dependent H2AZ histone chaperone activity; IEA:RHEA.
DR   GO; GO:0140665; F:ATP-dependent H3-H4 histone complex chaperone activity; IEA:RHEA.
DR   GO; GO:0140584; F:chromatin extrusion motor activity; IEA:RHEA.
DR   GO; GO:0061775; F:cohesin loader activity; IEA:RHEA.
DR   GO; GO:0004843; F:cysteine-type deubiquitinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IEA:InterPro.
DR   GO; GO:0003689; F:DNA clamp loader activity; IEA:RHEA.
DR   GO; GO:0036121; F:double-stranded DNA helicase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004519; F:endonuclease activity; IEA:UniProtKB-KW.
DR   GO; GO:0061749; F:forked DNA-dependent helicase activity; IEA:UniProtKB-EC.
DR   GO; GO:0009378; F:four-way junction helicase activity; IEA:UniProtKB-EC.
DR   GO; GO:0002151; F:G-quadruplex RNA binding; IEA:InterPro.
DR   GO; GO:0016829; F:lyase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004483; F:mRNA (nucleoside-2'-O-)-methyltransferase activity; IEA:InterPro.
DR   GO; GO:0004482; F:mRNA 5'-cap (guanine-N7-)-methyltransferase activity; IEA:InterPro.
DR   GO; GO:0008242; F:omega peptidase activity; IEA:InterPro.
DR   GO; GO:0003724; F:RNA helicase activity; IEA:UniProtKB-EC.
DR   GO; GO:0003968; F:RNA-dependent RNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:1990518; F:single-stranded 3'-5' DNA helicase activity; IEA:UniProtKB-EC.
DR   GO; GO:0003727; F:single-stranded RNA binding; IEA:InterPro.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0006351; P:DNA-templated transcription; IEA:InterPro.
DR   GO; GO:0039520; P:induction by virus of host autophagy; IEA:UniProtKB-KW.
DR   GO; GO:0006508; P:proteolysis; IEA:UniProtKB-KW.
DR   GO; GO:0039595; P:symbiont-mediated degradation of host mRNA; IEA:UniProtKB-KW.
DR   GO; GO:0039648; P:symbiont-mediated perturbation of host ubiquitin-like protein modification; IEA:UniProtKB-KW.
DR   GO; GO:0039657; P:symbiont-mediated suppression of host gene expression; IEA:UniProtKB-KW.
DR   GO; GO:0039579; P:symbiont-mediated suppression of host ISG15-protein conjugation; IEA:UniProtKB-KW.
DR   GO; GO:0085034; P:symbiont-mediated suppression of host NF-kappaB cascade; IEA:UniProtKB-KW.
DR   GO; GO:0039502; P:symbiont-mediated suppression of host type I interferon-mediated signaling pathway; IEA:UniProtKB-KW.
DR   GO; GO:0019082; P:viral protein processing; IEA:InterPro.
DR   GO; GO:0039694; P:viral RNA genome replication; IEA:InterPro.
DR   GO; GO:0075523; P:viral translational frameshifting; IEA:UniProtKB-KW.
DR   GO; GO:0019049; P:virus-mediated perturbation of host defense response; IEA:UniProtKB-KW.
DR   CDD; cd21409; 1B_cv_Nsp13-like; 1.
DR   CDD; cd21560; betaCoV-Nsp6; 1.
DR   CDD; cd21722; betaCoV_Nsp13-helicase; 1.
DR   CDD; cd21659; betaCoV_Nsp14; 1.
DR   CDD; cd21516; betaCoV_Nsp2_SARS-like; 1.
DR   CDD; cd21666; betaCoV_Nsp5_Mpro; 1.
DR   CDD; cd21827; betaCoV_Nsp7; 1.
DR   CDD; cd21831; betaCoV_Nsp8; 1.
DR   CDD; cd21898; betaCoV_Nsp9; 1.
DR   CDD; cd21732; betaCoV_PLPro; 1.
DR   CDD; cd20762; capping_2-OMTase_Nidovirales; 1.
DR   CDD; cd21872; CoV_Nsp10; 1.
DR   CDD; cd21473; cv_Nsp4_TM; 1.
DR   CDD; cd21167; M_alpha_beta_cv_Nsp15-like; 1.
DR   CDD; cd21563; Macro_cv_SUD-M_Nsp3-like; 1.
DR   CDD; cd21562; Macro_cv_SUD-N_Nsp3-like; 1.
DR   CDD; cd21557; Macro_X_Nsp3-like; 1.
DR   CDD; cd21161; NendoU_cv_Nsp15-like; 1.
DR   CDD; cd21171; NTD_alpha_betaCoV_Nsp15-like; 1.
DR   CDD; cd22662; SARS-CoV-like_Nsp1_C; 1.
DR   CDD; cd21796; SARS-CoV-like_Nsp1_N; 1.
DR   CDD; cd21814; SARS-CoV-like_Nsp3_betaSM; 1.
DR   CDD; cd21822; SARS-CoV-like_Nsp3_NAB; 1.
DR   CDD; cd21591; SARS-CoV-like_RdRp; 1.
DR   CDD; cd21689; stalk_CoV_Nsp13-like; 1.
DR   CDD; cd21525; SUD_C_SARS-CoV_Nsp3; 1.
DR   CDD; cd21717; TM_Y_SARS-CoV-like_Nsp3_C; 1.
DR   CDD; cd21467; Ubl1_cv_Nsp3_N-like; 1.
DR   CDD; cd21401; ZBD_cv_Nsp13-like; 1.
DR   FunFam; 1.10.8.370:FF:000001; Orf1a polyprotein; 1.
DR   FunFam; 2.40.10.250:FF:000001; Orf1a polyprotein; 1.
DR   FunFam; 3.40.220.30:FF:000001; Orf1a polyprotein; 1.
DR   FunFam; 3.30.160.820:FF:000001; Orf1ab polyprotein; 1.
DR   FunFam; 3.40.50.150:FF:000162; Orf1ab polyprotein; 1.
DR   FunFam; 3.40.50.300:FF:001105; Orf1ab polyprotein; 1.
DR   FunFam; 3.40.50.300:FF:001139; Orf1ab polyprotein; 1.
DR   FunFam; 1.10.150.420:FF:000001; Replicase polyprotein; 1.
DR   FunFam; 1.10.1840.10:FF:000001; Replicase polyprotein 1a; 1.
DR   FunFam; 1.10.8.1190:FF:000001; Replicase polyprotein 1a; 1.
DR   FunFam; 2.40.10.10:FF:000033; Replicase polyprotein 1a; 1.
DR   FunFam; 3.40.50.11580:FF:000001; Replicase polyprotein 1ab; 1.
DR   Gene3D; 1.10.8.1190; -; 1.
DR   Gene3D; 2.60.120.1680; -; 1.
DR   Gene3D; 3.10.20.350; -; 1.
DR   Gene3D; 3.10.20.540; -; 1.
DR   Gene3D; 3.40.50.11580; -; 1.
DR   Gene3D; 6.10.140.2090; -; 1.
DR   Gene3D; 1.10.150.420; Coronavirus nonstructural protein 4 C-terminus; 1.
DR   Gene3D; 3.40.30.150; Coronavirus polyprotein cleavage domain; 1.
DR   Gene3D; 3.40.220.10; Leucine Aminopeptidase, subunit E, domain 1; 1.
DR   Gene3D; 1.10.1840.10; main proteinase (3clpro) structure, domain 3; 1.
DR   Gene3D; 3.30.160.820; Nsp15 N-terminal domain-like; 1.
DR   Gene3D; 3.40.220.20; Nsp3, SUD-M subdomain; 1.
DR   Gene3D; 3.40.220.30; Nsp3, SUD-N subdomain; 1.
DR   Gene3D; 1.10.8.370; nsp7 replicase; 1.
DR   Gene3D; 3.30.70.3540; Nsp8 replicase, head domain; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 2.
DR   Gene3D; 2.40.10.250; Replicase NSP9; 1.
DR   Gene3D; 3.40.50.11020; Replicase polyprotein, nucleic acid-binding domain; 1.
DR   Gene3D; 2.40.10.10; Trypsin-like serine proteases; 2.
DR   Gene3D; 3.40.50.150; Vaccinia Virus protein VP39; 1.
DR   InterPro; IPR027351; (+)RNA_virus_helicase_core_dom.
DR   InterPro; IPR046443; a/bCoV_NSP1_glob.
DR   InterPro; IPR046440; AV_NSP11N_COV_NSP15M.
DR   InterPro; IPR046442; bCoV_NSP1_C.
DR   InterPro; IPR050534; Coronavir_polyprotein_1ab.
DR   InterPro; IPR043608; CoV_NSP15_M.
DR   InterPro; IPR043606; CoV_NSP15_N.
DR   InterPro; IPR043613; CoV_NSP2_C.
DR   InterPro; IPR047573; CoV_NSP2_M.
DR   InterPro; IPR049894; COV_NSP3_3ECTO.
DR   InterPro; IPR043611; CoV_NSP3_C.
DR   InterPro; IPR047566; CoV_NSP3_Y.
DR   InterPro; IPR032505; CoV_NSP4_C.
DR   InterPro; IPR043612; CoV_NSP4_N.
DR   InterPro; IPR043502; DNA/RNA_pol_sf.
DR   InterPro; IPR041679; DNA2/NAM7-like_C.
DR   InterPro; IPR022733; DPUP_SUD_C_bCoV.
DR   InterPro; IPR037227; EndoU-like.
DR   InterPro; IPR002589; Macro_dom.
DR   InterPro; IPR043472; Macro_dom-like.
DR   InterPro; IPR044371; Macro_X_NSP3-like.
DR   InterPro; IPR046435; N7_MTase_CoV.
DR   InterPro; IPR043609; NendoU_nidovirus.
DR   InterPro; IPR044863; NIRAN.
DR   InterPro; IPR046438; NIV_2_O_MTASE.
DR   InterPro; IPR046436; NIV_EXON.
DR   InterPro; IPR036333; NSP10_sf_CoV.
DR   InterPro; IPR047570; NSP12_IF_CoV.
DR   InterPro; IPR044343; NSP13_1B_dom_CoV.
DR   InterPro; IPR048673; NSP13_stalk_CoV.
DR   InterPro; IPR048672; NSP13_ZBD_CoV.
DR   InterPro; IPR027352; NSP13_ZBD_CoV-like.
DR   InterPro; IPR044315; NSP14_betaCoV.
DR   InterPro; IPR009466; NSP14_CoV.
DR   InterPro; IPR044330; NSP15_alpha_betaCoV_N.
DR   InterPro; IPR044322; NSP15_M_alpha_beta_CoV.
DR   InterPro; IPR043174; NSP15_middle_sf.
DR   InterPro; IPR042515; NSP15_N_CoV.
DR   InterPro; IPR044401; NSP15_NendoU_CoV.
DR   InterPro; IPR009461; NSP16_CoV-like.
DR   InterPro; IPR021590; NSP1_glob_bCoV.
DR   InterPro; IPR038030; NSP1_glob_sf_bCoV.
DR   InterPro; IPR043615; NSP2_N_CoV.
DR   InterPro; IPR044389; NSP2_SARS-CoV-like.
DR   InterPro; IPR024375; NSP3_bCoV.
DR   InterPro; IPR047567; NSP3_G2M_bCoV.
DR   InterPro; IPR024358; NSP3_N_bCoV.
DR   InterPro; IPR032592; NSP3_NAB_bCoV.
DR   InterPro; IPR042570; NSP3_NAB_bCoV_sf.
DR   InterPro; IPR038166; NSP3_PL2pro_sf_bCoV.
DR   InterPro; IPR038400; NSP3_SUD-M_sf_bCoV.
DR   InterPro; IPR044864; NSP3_SUD-N_bCoV.
DR   InterPro; IPR044374; NSP3_SUD-N_SARS-CoV.
DR   InterPro; IPR043478; NSP3_SUD-N_sf_bCoV.
DR   InterPro; IPR044357; NSP3_Ubl1_dom_CoV.
DR   InterPro; IPR044353; Nsp3_Ubl2_dom_CoV.
DR   InterPro; IPR038083; NSP3A-like.
DR   InterPro; IPR038123; NSP4_C_sf_CoV.
DR   InterPro; IPR044367; NSP6_betaCoV.
DR   InterPro; IPR043610; NSP6_CoV.
DR   InterPro; IPR014828; NSP7_CoV.
DR   InterPro; IPR037204; NSP7_sf_CoV.
DR   InterPro; IPR014829; NSP8_CoV.
DR   InterPro; IPR037230; NSP8_sf_CoV.
DR   InterPro; IPR014822; NSP9_CoV.
DR   InterPro; IPR036499; NSP9_sf_CoV.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR013016; Peptidase_C16_CoV.
DR   InterPro; IPR008740; Peptidase_C30_CoV.
DR   InterPro; IPR043477; Peptidase_C30_dom3_CoV.
DR   InterPro; IPR009003; Peptidase_S1_PA.
DR   InterPro; IPR043504; Peptidase_S1_PA_chymotrypsin.
DR   InterPro; IPR043177; PLpro_N_sf_CoV.
DR   InterPro; IPR043503; PLpro_palm_finger_dom_CoV.
DR   InterPro; IPR043178; PLpro_thumb_sf_CoV.
DR   InterPro; IPR046441; RdRp_CoV.
DR   InterPro; IPR009469; RdRp_N_CoV.
DR   InterPro; IPR044351; RdRp_SARS-CoV-like.
DR   InterPro; IPR001205; RNA-dir_pol_C.
DR   InterPro; IPR007094; RNA-dir_pol_PSvirus.
DR   InterPro; IPR018995; RNA_synth_NSP10_CoV.
DR   InterPro; IPR029063; SAM-dependent_MTases_sf.
DR   PANTHER; PTHR43788; DNA2/NAM7 HELICASE FAMILY MEMBER; 1.
DR   PANTHER; PTHR43788:SF16; HELICASE WITH ZINC FINGER 2; 1.
DR   Pfam; PF13087; AAA_12; 1.
DR   Pfam; PF16251; bCoV_NAB; 1.
DR   Pfam; PF11501; bCoV_NSP1; 1.
DR   Pfam; PF12379; bCoV_NSP3_N; 1.
DR   Pfam; PF12124; bCoV_SUD_C; 1.
DR   Pfam; PF11633; bCoV_SUD_M; 1.
DR   Pfam; PF06471; CoV_ExoN; 1.
DR   Pfam; PF06460; CoV_Methyltr_2; 1.
DR   Pfam; PF09401; CoV_NSP10; 1.
DR   Pfam; PF20631; CoV_NSP13_1B; 1.
DR   Pfam; PF20633; CoV_NSP13_stalk; 1.
DR   Pfam; PF20632; CoV_NSP13_ZBD; 1.
DR   Pfam; PF19215; CoV_NSP15_C; 1.
DR   Pfam; PF19216; CoV_NSP15_M; 1.
DR   Pfam; PF19219; CoV_NSP15_N; 1.
DR   Pfam; PF19212; CoV_NSP2_C; 1.
DR   Pfam; PF19211; CoV_NSP2_N; 1.
DR   Pfam; PF19218; CoV_NSP3_C; 1.
DR   Pfam; PF16348; CoV_NSP4_C; 1.
DR   Pfam; PF19217; CoV_NSP4_N; 1.
DR   Pfam; PF19213; CoV_NSP6; 1.
DR   Pfam; PF08716; CoV_NSP7; 1.
DR   Pfam; PF08717; CoV_NSP8; 1.
DR   Pfam; PF08710; CoV_NSP9; 1.
DR   Pfam; PF08715; CoV_peptidase; 1.
DR   Pfam; PF06478; CoV_RPol_N; 1.
DR   Pfam; PF01661; Macro; 1.
DR   Pfam; PF05409; Peptidase_C30; 1.
DR   Pfam; PF00680; RdRP_1; 1.
DR   SMART; SM00506; A1pp; 1.
DR   SUPFAM; SSF144246; Coronavirus NSP10-like; 1.
DR   SUPFAM; SSF140367; Coronavirus NSP7-like; 1.
DR   SUPFAM; SSF143076; Coronavirus NSP8-like; 1.
DR   SUPFAM; SSF56672; DNA/RNA polymerases; 1.
DR   SUPFAM; SSF142877; EndoU-like; 1.
DR   SUPFAM; SSF52949; Macro domain-like; 1.
DR   SUPFAM; SSF159936; NSP3A-like; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   SUPFAM; SSF101816; Replicase NSP9; 1.
DR   SUPFAM; SSF53335; S-adenosyl-L-methionine-dependent methyltransferases; 1.
DR   SUPFAM; SSF160099; SARS Nsp1-like; 1.
DR   SUPFAM; SSF50494; Trypsin-like serine proteases; 1.
DR   PROSITE; PS51961; AV_NSP11N_COV_NSP15M; 1.
DR   PROSITE; PS51963; BCOV_NSP1_C; 1.
DR   PROSITE; PS51942; BCOV_NSP3C_C; 1.
DR   PROSITE; PS51941; BCOV_NSP3C_M; 1.
DR   PROSITE; PS51994; BCOV_NSP3E_G2M; 1.
DR   PROSITE; PS51945; BCOV_NSP3E_NAB; 1.
DR   PROSITE; PS51993; COV_3ECTO; 1.
DR   PROSITE; PS51952; COV_EXON_MTASE_COACT; 1.
DR   PROSITE; PS51954; COV_N7_MTASE; 1.
DR   PROSITE; PS51962; COV_NSP1; 1.
DR   PROSITE; PS52000; COV_NSP12_IF; 1.
DR   PROSITE; PS51948; COV_NSP12_RDRP; 1.
DR   PROSITE; PS51960; COV_NSP15_NTD; 1.
DR   PROSITE; PS51991; COV_NSP2_C; 1.
DR   PROSITE; PS51990; COV_NSP2_M; 1.
DR   PROSITE; PS51989; COV_NSP2_N; 1.
DR   P",52909
CCCGCG CCGCGG CGCGGC GCGGCT CGGCTG GGCTGC GCTGCC CTGCCG TGCCGG GCCGGC CCGGCA CGGCAA GGCAAG GCAAGA CAAGAG AAGAGC AGAGCA GAGCAC AGCACC GCACCT CACCTG ACCTGC CCTGCT CTGCTA TGCTAC GCTACC CTACCA TACCAG ACCAGA CCAGAT CAGATC AGATCC GATCCT ATCCTG TCCTGG CCTGGC CTGGCC TGGCCA GGCCAA GCCAAT CCAATC CAATCT AATCTG ATCTGA TCTGAT CTGATG TGATGA GATGAC ATGACC TGACCA GACCAA ACCAAC CCAACT CAACTT AACTTG ACTTGC CTTGCG TTGCGC TGCGCG GCGCGA CGCGAG GCGAGA CGAGAA GAGAAG AGAAGG GAAGGG AAGGGC AGGGCT GGGCTC GGCTCT GCTCTC CTCTCC TCTCCG CTCCGA TCCGAA CCGAAT CGAATC GAATCA AATCAG ATCAGG TCAGGA CAGGAG AGGAGT GGAGTT GAGTTC AGTTCC GTTCCA TTCCAG TCCAGC CCAGCG CAGCGC AGCGCG GCGCGT CGCGTG GCGTGC CGTGCG GTGCGG TGCGGT GCGGTT CGGTTC GGTTCC GTTCCA TTCCAG TCCAGA CCAGAT CAGATC AGATCC GATCCT ATCCTC TCCTCA CCTCAA CTCAAC TCAACC CAACCC AACCCG ACCCGA CCCGAA CCGAAG CGAAGT GAAGTG AAGTGC AGTGCA GTGCAT TGCATC GCATCA CATCAG ATCAGC TCAGCA CAGCAT AGCATG GCATGG CATGGG ATGGGC TGGGCG GGGCGA GGCGAG GCGAGT CGAGTT GAGTTG AGTTGT GTTGTA TTGTAT,3,142,CCCG CCGC CGCG GCGG CGGC GGCT GCTG CTGC TGCC GCCG CCGG CGGC GGCA GCAA CAAG AAGA AGAG GAGC AGCA GCAC CACC ACCT CCTG CTGC TGCT GCTA CTAC TACC ACCA CCAG CAGA AGAT GATC ATCC TCCT CCTG CTGG TGGC GGCC GCCA CCAA CAAT AATC ATCT TCTG CTGA TGAT GATG ATGA TGAC GACC ACCA CCAA CAAC AACT ACTT CTTG TTGC TGCG GCGC CGCG GCGA CGAG GAGA AGAA GAAG AAGG AGGG GGGC GGCT GCTC CTCT TCTC CTCC TCCG CCGA CGAA GAAT AATC ATCA TCAG CAGG AGGA GGAG GAGT AGTT GTTC TTCC TCCA CCAG CAGC AGCG GCGC CGCG GCGT CGTG GTGC TGCG GCGG CGGT GGTT GTTC TTCC TCCA CCAG CAGA AGAT GATC ATCC TCCT CCTC CTCA TCAA CAAC AACC ACCC CCCG CCGA CGAA GAAG AAGT AGTG GTGC TGCA GCAT CATC ATCA TCAG CAGC AGCA GCAT CATG ATGG TGGG GGGC GGCG GCGA CGAG GAGT AGTT GTTG TTGT TGTA GTAT,CCCGC CCGCG CGCGG GCGGC CGGCT GGCTG GCTGC CTGCC TGCCG GCCGG CCGGC CGGCA GGCAA GCAAG CAAGA AAGAG AGAGC GAGCA AGCAC GCACC CACCT ACCTG CCTGC CTGCT TGCTA GCTAC CTACC TACCA ACCAG CCAGA CAGAT AGATC GATCC ATCCT TCCTG CCTGG CTGGC TGGCC GGCCA GCCAA CCAAT CAATC AATCT ATCTG TCTGA CTGAT TGATG GATGA ATGAC TGACC GACCA ACCAA CCAAC CAACT AACTT ACTTG CTTGC TTGCG TGCGC GCGCG CGCGA GCGAG CGAGA GAGAA AGAAG GAAGG AAGGG AGGGC GGGCT GGCTC GCTCT CTCTC TCTCC CTCCG TCCGA CCGAA CGAAT GAATC AATCA ATCAG TCAGG CAGGA AGGAG GGAGT GAGTT AGTTC GTTCC TTCCA TCCAG CCAGC CAGCG AGCGC GCGCG CGCGT GCGTG CGTGC GTGCG TGCGG GCGGT CGGTT GGTTC GTTCC TTCCA TCCAG CCAGA CAGAT AGATC GATCC ATCCT TCCTC CCTCA CTCAA TCAAC CAACC AACCC ACCCG CCCGA CCGAA CGAAG GAAGT AAGTG AGTGC GTGCA TGCAT GCATC CATCA ATCAG TCAGC CAGCA AGCAT GCATG CATGG ATGGG TGGGC GGGCG GGCGA GCGAG CGAGT GAGTT AGTTG GTTGT TTGTA TGTAT,CCCGCG CCGCGG CGCGGC GCGGCT CGGCTG GGCTGC GCTGCC CTGCCG TGCCGG GCCGGC CCGGCA CGGCAA GGCAAG GCAAGA CAAGAG AAGAGC AGAGCA GAGCAC AGCACC GCACCT CACCTG ACCTGC CCTGCT CTGCTA TGCTAC GCTACC CTACCA TACCAG ACCAGA CCAGAT CAGATC AGATCC GATCCT ATCCTG TCCTGG CCTGGC CTGGCC TGGCCA GGCCAA GCCAAT CCAATC CAATCT AATCTG ATCTGA TCTGAT CTGATG TGATGA GATGAC ATGACC TGACCA GACCAA ACCAAC CCAACT CAACTT AACTTG ACTTGC CTTGCG TTGCGC TGCGCG GCGCGA CGCGAG GCGAGA CGAGAA GAGAAG AGAAGG GAAGGG AAGGGC AGGGCT GGGCTC GGCTCT GCTCTC CTCTCC TCTCCG CTCCGA TCCGAA CCGAAT CGAATC GAATCA AATCAG ATCAGG TCAGGA CAGGAG AGGAGT GGAGTT GAGTTC AGTTCC GTTCCA TTCCAG TCCAGC CCAGCG CAGCGC AGCGCG GCGCGT CGCGTG GCGTGC CGTGCG GTGCGG TGCGGT GCGGTT CGGTTC GGTTCC GTTCCA TTCCAG TCCAGA CCAGAT CAGATC AGATCC GATCCT ATCCTC TCCTCA CCTCAA CTCAAC TCAACC CAACCC AACCCG ACCCGA CCCGAA CCGAAG CGAAGT GAAGTG AAGTGC AGTGCA GTGCAT TGCATC GCATCA CATCAG ATCAGC TCAGCA CAGCAT AGCATG GCATGG CATGGG ATGGGC TGGGCG GGGCGA GGCGAG GCGAGT CGAGTT GAGTTG AGTTGT GTTGTA TTGTAT,CCCGCGG CCGCGGC CGCGGCT GCGGCTG CGGCTGC GGCTGCC GCTGCCG CTGCCGG TGCCGGC GCCGGCA CCGGCAA CGGCAAG GGCAAGA GCAAGAG CAAGAGC AAGAGCA AGAGCAC GAGCACC AGCACCT GCACCTG CACCTGC ACCTGCT CCTGCTA CTGCTAC TGCTACC GCTACCA CTACCAG TACCAGA ACCAGAT CCAGATC CAGATCC AGATCCT GATCCTG ATCCTGG TCCTGGC CCTGGCC CTGGCCA TGGCCAA GGCCAAT GCCAATC CCAATCT CAATCTG AATCTGA ATCTGAT TCTGATG CTGATGA TGATGAC GATGACC ATGACCA TGACCAA GACCAAC ACCAACT CCAACTT CAACTTG AACTTGC ACTTGCG CTTGCGC TTGCGCG TGCGCGA GCGCGAG CGCGAGA GCGAGAA CGAGAAG GAGAAGG AGAAGGG GAAGGGC AAGGGCT AGGGCTC GGGCTCT GGCTCTC GCTCTCC CTCTCCG TCTCCGA CTCCGAA TCCGAAT CCGAATC CGAATCA GAATCAG AATCAGG ATCAGGA TCAGGAG CAGGAGT AGGAGTT GGAGTTC GAGTTCC AGTTCCA GTTCCAG TTCCAGC TCCAGCG CCAGCGC CAGCGCG AGCGCGT GCGCGTG CGCGTGC GCGTGCG CGTGCGG GTGCGGT TGCGGTT GCGGTTC CGGTTCC GGTTCCA GTTCCAG TTCCAGA TCCAGAT CCAGATC CAGATCC AGATCCT GATCCTC ATCCTCA TCCTCAA CCTCAAC CTCAACC TCAACCC CAACCCG AACCCGA ACCCGAA CCCGAAG CCGAAGT CGAAGTG GAAGTGC AAGTGCA AGTGCAT GTGCATC TGCATCA GCATCAG CATCAGC ATCAGCA TCAGCAT CAGCATG AGCATGG GCATGGG CATGGGC ATGGGCG TGGGCGA GGGCGAG GGCGAGT GCGAGTT CGAGTTG GAGTTGT AGTTGTA GTTGTAT,"ID   DYH6_HUMAN              Reviewed;        4158 AA.
AC   Q9C0G6; A0PJN9; B5MEE0; B7ZL99; O95493; Q53QZ1; Q53TE5; Q8N1W6; Q92861;
AC   Q96BL6; Q9H030; Q9H5E1;
DT   05-FEB-2008, integrated into UniProtKB/Swiss-Prot.
DT   05-FEB-2008, sequence version 3.
DT   05-FEB-2025, entry version 161.
DE   RecName: Full=Dynein axonemal heavy chain 6 {ECO:0000305};
DE   AltName: Full=Axonemal beta dynein heavy chain 6;
DE   AltName: Full=Ciliary dynein heavy chain 6;
GN   Name=DNAH6 {ECO:0000312|HGNC:HGNC:2951};
GN   Synonyms=DNAHC6, DNHL1, HL2, KIAA1697;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 3573-4158 (ISOFORM 1).
RC   TISSUE=Amygdala, and Lung;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   ""Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs."";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Lymph node;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   ""The full-ORF clone resource of the German cDNA consortium."";
RL   BMC Genomics 8:399-399(2007).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   ""Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4."";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), NUCLEOTIDE SEQUENCE
RP   [LARGE SCALE MRNA] OF 1925-4158 (ISOFORM 4), AND NUCLEOTIDE SEQUENCE [LARGE
RP   SCALE MRNA] OF 2578-4158 (ISOFORM 1).
RC   TISSUE=Brain, and Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   ""The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC)."";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1448-1527 (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=8812413; DOI=10.1006/geno.1996.0422;
RA   Vaughan K.T., Mikami A., Paschal B.M., Holzbaur E.L.F., Hughes S.M.,
RA   Echeverri C.J., Moore K.J., Gilbert D.J., Copeland N.G., Jenkins N.A.,
RA   Vallee R.B.;
RT   ""Multiple mouse chromosomal loci for dynein-based motility."";
RL   Genomics 36:29-38(1996).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1476-1576 (ISOFORM 1), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Nasal polyp;
RX   PubMed=11175280; DOI=10.1038/sj.ejhg.5200555;
RA   Maiti A.K., Mattei M.-G., Jorissen M., Volz A., Zeigler A., Bouvagnet P.;
RT   ""Identification, tissue specific expression, and chromosomal localisation
RT   of several human dynein heavy chain genes."";
RL   Eur. J. Hum. Genet. 8:923-932(2000).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1977-4158 (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=11214970; DOI=10.1093/dnares/7.6.347;
RA   Nagase T., Kikuno R., Hattori A., Kondo Y., Okumura K., Ohara O.;
RT   ""Prediction of the coding sequences of unidentified human genes. XIX. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro."";
RL   DNA Res. 7:347-355(2000).
RN   [9]
RP   SEQUENCE REVISION.
RA   Ohara O., Nagase T., Kikuno R.;
RL   Submitted (AUG-2005) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   TISSUE SPECIFICITY, AND VARIANT GLN-3471.
RX   PubMed=28206990; DOI=10.1038/gim.2016.225;
RA   Gershoni M., Hauser R., Yogev L., Lehavi O., Azem F., Yavetz H.,
RA   Pietrokovski S., Kleiman S.E.;
RT   ""A familial study of azoospermic men identifies three novel causative
RT   mutations in three new human azoospermia genes."";
RL   Genet. Med. 19:998-1006(2017).
CC   -!- FUNCTION: Force generating protein of respiratory cilia. Produces force
CC       towards the minus ends of microtubules. Dynein has ATPase activity; the
CC       force-producing power stroke is thought to occur on release of ADP (By
CC       similarity). {ECO:0000250}.
CC   -!- SUBUNIT: The dynein complex consists of at least two heavy chains and a
CC       number of intermediate and light chains. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, cilium axoneme
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q9C0G6-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9C0G6-2; Sequence=VSP_031122, VSP_031129, VSP_031130;
CC       Name=3;
CC         IsoId=Q9C0G6-3; Sequence=VSP_031123, VSP_031124, VSP_031125;
CC       Name=4;
CC         IsoId=Q9C0G6-4; Sequence=VSP_031126, VSP_031127, VSP_031128;
CC   -!- TISSUE SPECIFICITY: Expressed in several tissues, including brain,
CC       pituitary, testis and trachea, with highest levels in testis.
CC       {ECO:0000269|PubMed:11175280, ECO:0000269|PubMed:28206990}.
CC   -!- DOMAIN: Dynein heavy chains probably consist of an N-terminal stem
CC       (which binds cargo and interacts with other dynein components), and the
CC       head or motor domain. The motor contains six tandemly-linked AAA
CC       domains in the head, which form a ring. A stalk-like structure (formed
CC       by two of the coiled coil domains) protrudes between AAA 4 and AAA 5
CC       and terminates in a microtubule-binding site. A seventh domain may also
CC       contribute to this ring; it is not clear whether the N-terminus or the
CC       C-terminus forms this extra domain. There are four well-conserved and
CC       two non-conserved ATPase sites, one per AAA domain. Probably only one
CC       of these (within AAA 1) actually hydrolyzes ATP, the others may serve a
CC       regulatory function (By similarity). {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the dynein heavy chain family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH15442.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAX93115.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC       Sequence=BAB15685.1; Type=Frameshift; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK027182; BAB15685.1; ALT_FRAME; mRNA.
DR   EMBL; AK094676; BAC04400.1; -; mRNA.
DR   EMBL; AL512706; CAC21651.1; -; mRNA.
DR   EMBL; AC010087; AAX93108.1; -; Genomic_DNA.
DR   EMBL; AC096770; AAY24108.1; -; Genomic_DNA.
DR   EMBL; AC098975; AAX93115.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; AC109827; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471053; EAW99557.1; -; Genomic_DNA.
DR   EMBL; BC015442; AAH15442.1; ALT_INIT; mRNA.
DR   EMBL; BC104884; AAI04885.1; -; mRNA.
DR   EMBL; BC113424; AAI13425.1; -; mRNA.
DR   EMBL; BC117259; AAI17260.1; -; mRNA.
DR   EMBL; BC143666; AAI43667.1; -; mRNA.
DR   EMBL; U61736; AAC50700.1; -; mRNA.
DR   EMBL; AJ132086; CAA10559.1; -; mRNA.
DR   EMBL; AB051484; BAB21788.2; -; mRNA.
DR   CCDS; CCDS46348.1; -. [Q9C0G6-1]
DR   RefSeq; NP_001361.1; NM_001370.1. [Q9C0G6-1]
DR   RefSeq; XP_006712019.1; XM_006711956.2. [Q9C0G6-1]
DR   RefSeq; XP_011530951.1; XM_011532649.2. [Q9C0G6-1]
DR   RefSeq; XP_011530952.1; XM_011532650.2. [Q9C0G6-1]
DR   PDB; 8J07; EM; 4.10 A; g5=1-4158.
DR   PDBsum; 8J07; -.
DR   EMDB; EMD-35888; -.
DR   SMR; Q9C0G6; -.
DR   BioGRID; 108107; 29.
DR   IntAct; Q9C0G6; 7.
DR   STRING; 9606.ENSP00000374045; -.
DR   iPTMnet; Q9C0G6; -.
DR   PhosphoSitePlus; Q9C0G6; -.
DR   BioMuta; DNAH6; -.
DR   DMDM; 166922150; -.
DR   jPOST; Q9C0G6; -.
DR   MassIVE; Q9C0G6; -.
DR   PaxDb; 9606-ENSP00000374045; -.
DR   PeptideAtlas; Q9C0G6; -.
DR   ProteomicsDB; 80034; -. [Q9C0G6-1]
DR   ProteomicsDB; 80035; -. [Q9C0G6-2]
DR   ProteomicsDB; 80036; -. [Q9C0G6-3]
DR   ProteomicsDB; 80037; -. [Q9C0G6-4]
DR   Antibodypedia; 31722; 87 antibodies from 17 providers.
DR   DNASU; 1768; -.
DR   Ensembl; ENST00000389394.8; ENSP00000374045.3; ENSG00000115423.19. [Q9C0G6-1]
DR   GeneID; 1768; -.
DR   KEGG; hsa:1768; -.
DR   MANE-Select; ENST00000389394.8; ENSP00000374045.3; NM_001370.2; NP_001361.1.
DR   UCSC; uc002sor.4; human. [Q9C0G6-1]
DR   AGR; HGNC:2951; -.
DR   CTD; 1768; -.
DR   DisGeNET; 1768; -.
DR   GeneCards; DNAH6; -.
DR   HGNC; HGNC:2951; DNAH6.
DR   HPA; ENSG00000115423; Tissue enhanced (choroid plexus, fallopian tube).
DR   MalaCards; DNAH6; -.
DR   MIM; 603336; gene.
DR   neXtProt; NX_Q9C0G6; -.
DR   OpenTargets; ENSG00000115423; -.
DR   PharmGKB; PA27404; -.
DR   VEuPathDB; HostDB:ENSG00000115423; -.
DR   eggNOG; KOG3595; Eukaryota.
DR   GeneTree; ENSGT00940000154761; -.
DR   HOGENOM; CLU_000038_0_0_1; -.
DR   InParanoid; Q9C0G6; -.
DR   OMA; VESFDWQ; -.
DR   OrthoDB; 5593012at2759; -.
DR   PhylomeDB; Q9C0G6; -.
DR   TreeFam; TF352520; -.
DR   PathwayCommons; Q9C0G6; -.
DR   SignaLink; Q9C0G6; -.
DR   BioGRID-ORCS; 1768; 15 hits in 1153 CRISPR screens.
DR   ChiTaRS; DNAH6; human.
DR   GenomeRNAi; 1768; -.
DR   Pharos; Q9C0G6; Tdark.
DR   PRO; PR:Q9C0G6; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q9C0G6; protein.
DR   Bgee; ENSG00000115423; Expressed in epithelium of bronchus and 130 other cell types or tissues.
DR   GO; GO:0097729; C:9+2 motile cilium; IBA:GO_Central.
DR   GO; GO:0005930; C:axoneme; IEA:UniProtKB-ARBA.
DR   GO; GO:0030286; C:dynein complex; IBA:GO_Central.
DR   GO; GO:0005874; C:microtubule; IEA:UniProtKB-KW.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:InterPro.
DR   GO; GO:0045505; F:dynein intermediate chain binding; IBA:GO_Central.
DR   GO; GO:0051959; F:dynein light intermediate chain binding; IBA:GO_Central.
DR   GO; GO:0008569; F:minus-end-directed microtubule motor activity; IBA:GO_Central.
DR   GO; GO:0060294; P:cilium movement involved in cell motility; IBA:GO_Central.
DR   CDD; cd00009; AAA; 1.
DR   FunFam; 1.10.287.2620:FF:000001; Cytoplasmic dynein heavy chain 1; 1.
DR   FunFam; 1.20.920.30:FF:000002; Dynein axonemal heavy chain 3; 1.
DR   FunFam; 1.10.8.1220:FF:000001; Dynein axonemal heavy chain 5; 1.
DR   FunFam; 1.10.8.710:FF:000004; Dynein axonemal heavy chain 6; 1.
DR   FunFam; 1.10.8.720:FF:000007; Dynein axonemal heavy chain 6; 1.
DR   FunFam; 1.20.140.100:FF:000004; Dynein axonemal heavy chain 6; 1.
DR   FunFam; 3.10.490.20:FF:000005; Dynein axonemal heavy chain 6; 1.
DR   FunFam; 3.20.180.20:FF:000004; Dynein axonemal heavy chain 6; 1.
DR   FunFam; 3.40.50.300:FF:001143; Dynein axonemal heavy chain 6; 1.
DR   FunFam; 3.40.50.300:FF:002141; Dynein heavy chain; 1.
DR   FunFam; 3.40.50.300:FF:000223; Dynein heavy chain 3, axonemal; 1.
DR   FunFam; 3.40.50.300:FF:000063; dynein heavy chain 6, axonemal; 1.
DR   FunFam; 1.10.472.130:FF:000015; Dynein heavy chain 7; 1.
DR   FunFam; 1.20.1270.280:FF:000009; Dynein, axonemal, heavy chain 6; 1.
DR   FunFam; 1.20.58.1120:FF:000011; Dynein, axonemal, heavy chain 6; 1.
DR   FunFam; 1.20.920.20:FF:000006; Dynein, axonemal, heavy chain 6; 1.
DR   FunFam; 3.40.50.300:FF:000362; Dynein, axonemal, heavy chain 6; 1.
DR   Gene3D; 1.10.287.2620; -; 1.
DR   Gene3D; 1.10.8.1220; -; 1.
DR   Gene3D; 1.10.8.710; -; 1.
DR   Gene3D; 1.20.1270.280; -; 1.
DR   Gene3D; 1.20.58.1120; -; 1.
DR   Gene3D; 1.20.920.20; -; 1.
DR   Gene3D; 1.20.920.30; -; 1.
DR   Gene3D; 3.10.490.20; -; 1.
DR   Gene3D; 6.10.140.1060; -; 1.
DR   Gene3D; 1.20.140.100; Dynein heavy chain, N-terminal domain 2; 1.
DR   Gene3D; 3.20.180.20; Dynein heavy chain, N-terminal domain 2; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 5.
DR   Gene3D; 1.10.8.720; Region D6 of dynein motor; 1.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR035699; AAA_6.
DR   InterPro; IPR035706; AAA_9.
DR   InterPro; IPR041658; AAA_lid_11.
DR   InterPro; IPR042219; AAA_lid_11_sf.
DR   InterPro; IPR026983; DHC.
DR   InterPro; IPR041589; DNAH3_AAA_lid_1.
DR   InterPro; IPR042222; Dynein_2_N.
DR   InterPro; IPR043157; Dynein_AAA1S.
DR   InterPro; IPR041466; Dynein_AAA5_ext.
DR   InterPro; IPR041228; Dynein_C.
DR   InterPro; IPR043160; Dynein_C_barrel.
DR   InterPro; IPR024743; Dynein_HC_stalk.
DR   InterPro; IPR024317; Dynein_heavy_chain_D4_dom.
DR   InterPro; IPR004273; Dynein_heavy_D6_P-loop.
DR   InterPro; IPR013602; Dynein_heavy_linker.
DR   InterPro; IPR042228; Dynein_linker_3.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR22878:SF67; DYNEIN AXONEMAL HEAVY CHAIN 6; 1.
DR   PANTHER; PTHR22878; DYNEIN HEAVY CHAIN 6, AXONEMAL-LIKE-RELATED; 1.
DR   Pfam; PF12774; AAA_6; 1.
DR   Pfam; PF12775; AAA_7; 1.
DR   Pfam; PF12780; AAA_8; 1.
DR   Pfam; PF12781; AAA_9; 1.
DR   Pfam; PF17857; AAA_lid_1; 1.
DR   Pfam; PF18198; AAA_lid_11; 1.
DR   Pfam; PF08393; DHC_N2; 1.
DR   Pfam; PF17852; Dynein_AAA_lid; 1.
DR   Pfam; PF18199; Dynein_C; 1.
DR   Pfam; PF03028; Dynein_heavy; 1.
DR   Pfam; PF12777; MT; 1.
DR   SMART; SM00382; AAA; 4.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 4.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Cell projection; Cilium;
KW   Coiled coil; Cytoplasm; Cytoskeleton; Dynein; Microtubule; Motor protein;
KW   Nucleotide-binding; Proteomics identification; Reference proteome; Repeat.
FT   CHAIN           1..4158
FT                   /note=""Dynein axonemal heavy chain 6""
FT                   /id=""PRO_0000317665""
FT   REGION          1..1433
FT                   /note=""Stem""
FT                   /evidence=""ECO:0000250""
FT   REGION          1434..1655
FT                   /note=""AAA 1""
FT                   /evidence=""ECO:0000250""
FT   REGION          1715..1948
FT                   /note=""AAA 2""
FT                   /evidence=""ECO:0000250""
FT   REGION          2058..2306
FT                   /note=""AAA 3""
FT                   /evidence=""ECO:0000250""
FT   REGION          2408..2659
FT                   /note=""AAA 4""
FT                   /evidence=""ECO:0000250""
FT   REGION          2676..2961
FT                   /note=""Stalk""
FT                   /evidence=""ECO:0000250""
FT   REGION          3042..3272
FT                   /note=""AAA 5""
FT                   /evidence=""ECO:0000250""
FT   REGION          3509..3730
FT                   /note=""AAA 6""
FT                   /evidence=""ECO:0000250""
FT   COILED          805..859
FT                   /evidence=""ECO:0000255""
FT   COILED          2901..2996
FT                   /evidence=""ECO:0000255""
FT   BINDING         192..199
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255""
FT   BINDING         1472..1479
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255""
FT   BINDING         1753..1760
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255""
FT   BINDING         2096..2103
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255""
FT   BINDING         2447..2454
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255""
FT   VAR_SEQ         1..3241
FT                   /note=""Missing (in isoform 2)""
FT                   /evidence=""ECO:0000303|PubMed:17974005""
FT                   /id=""VSP_031122""
FT   VAR_SEQ         1..421
FT                   /note=""Missing (in isoform 3)""
FT                   /evidence=""ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334""
FT                   /id=""VSP_031123""
FT   VAR_SEQ         828..829
FT                   /note=""DP -> VS (in isoform 3)""
FT                   /evidence=""ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334""
FT                   /id=""VSP_031124""
FT   VAR_SEQ         830..4158
FT                   /note=""Missing (in isoform 3)""
FT                   /evidence=""ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334""
FT                   /id=""VSP_031125""
FT   VAR_SEQ         2306..2355
FT                   /note=""GILQCDPGTIREEIQIFRLFCHECQRVFHDRLINNEDKHYFHVILTEMAN
FT                   -> D (in isoform 4)""
FT                   /evidence=""ECO:0000303|PubMed:15489334""
FT                   /id=""VSP_031126""
FT   VAR_SEQ         2561..2579
FT                   /note=""FQYFISKVRQKLHIVLCMS -> GCARVVMWLYHKNVSSPFI (in
FT                   isoform 4)""
FT                   /evidence=""ECO:0000303|PubMed:15489334""
FT                   /id=""VSP_031127""
FT   VAR_SEQ         2580..4158
FT                   /note=""Missing (in isoform 4)""
FT                   /evidence=""ECO:0000303|PubMed:15489334""
FT                   /id=""VSP_031128""
FT   VAR_SEQ         3828..3833
FT                   /note=""YKETST -> VCGLSS (in isoform 2)""
FT                   /evidence=""ECO:0000303|PubMed:17974005""
FT                   /id=""VSP_031129""
FT   VAR_SEQ         3834..4158
FT                   /note=""Missing (in isoform 2)""
FT                   /evidence=""ECO:0000303|PubMed:17974005""
FT                   /id=""VSP_031130""
FT   VARIANT         3471
FT                   /note=""H -> Q (found in a patient with azoospermia;
FT                   uncertain significance; dbSNP:rs61731722)""
FT                   /evidence=""ECO:0000269|PubMed:28206990""
FT                   /id=""VAR_080035""
FT   CONFLICT        1504
FT                   /note=""Y -> C (in Ref. 7; CAA10559)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        1521
FT                   /note=""C -> G (in Ref. 6; AAC50700)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        3716
FT                   /note=""F -> S (in Ref. 1; BAB15685)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        3965
FT                   /note=""K -> R (in Ref. 1; BAB15685)""
FT                   /evidence=""ECO:0000305""
FT   CONFLICT        4151
FT                   /note=""A -> V (in Ref. 1; BAB15685)""
FT                   /evidence=""ECO:0000305""
SQ   SEQUENCE   4158 AA;  475983 MW;  8ADAA07BC375F683 CRC64;
     MTFRATDSEF DLTNIEEYAE NSALSRLNNI KAKQRVSYVT STENESDTQI LTFRHITKAQ
     EKTRKRQQPI KLEPLPVLKV YQDHKQPEYI HEQNRFQLMT AGIIKRPVSI AKKSFATSST
     QFLEHQDAVK KMQIHRPYVE VFSPSPPKLP HTGIGKRGLF GTRSSAYPKY TFHDREEVVK
     ANIRDPLQII KIIRENEHLG FLYMIPAVPR SSIEYDTYNL KVVSYENINK NDYYTISQRA
     VTHIYNEDIE FIEIDRWEQE YLYHRELTKI PIFSLFRKWK AFSVWRKNVR SKKITGCQKS
     LQKNLFIVNP HLRPALLKIN ELCYHLSFMG LCYIEKCHTY TLQEFKAAQV IRLAEVTERL
     GEFRNEAKYV VRRACRFALR AAGFVPDDCA FGPFEDYHKV QSSGSFINTP HELPTYGDSE
     KMTYTEQASK RHYCMRLTCF IRLNDYLIEN TMHILTVNAV NSLLNHLTDK LKRTPSADVI
     QKWITEEKPE VPDKKGTLMV EKQEEDESLI PMFLTELMLT VQSLLFEPSL EDFLDGILGA
     VNHCQNTVLS VPNLVPDSYF DAFTSPYINN KLEGKTCGTG PSLAAVFEDD KNFHTIISQI
     KETIQAAFES ARIYAATFEK FQIFFKENES LDLQALKLQE PDINFFSEQL EKYHKQHKDA
     VALRPTRNVG LLLIDTRLLR EKLIPSPLRC LEVLNFMLPR QSKKKVDAII FEAQDAEYKL
     EFVPTTTTEY VHSLLFLDEI QERIESLEDE GNIVTQMYKL MEQYQVPTPP EDFAVFATMK
     PSIVAVRNAI DKSVGDRESS IKQFCVHLGS DLEELNNEVN EVKLQAQDPQ ILDISADQDK
     IRLILNNLQS VLADLQKRAF QYKSYQKNFK VEVSKFEALE EVSAELKLKQ LLWDSFSEWD
     KLQQEWLKSK FDCLDPEVLN GQVSKYAKFV TQLEKGLPPN SVVPQLKYKV EKMKEKLPVI
     IDLRNPTLKA RHWAAIEQTV DATLVDAEIP LTLERLSQLH VFDFGQEIQD ISGQASGEAA
     LEAILKKVED SWKTTEFVIL PHRDSKDVFI LGGTDDIQVL LDDSTINVAT LASSRYLGPL
     KTRVDEWQKQ LALFNQTLEE WLTCQRNWLY LESIFNAPDI QRQLPAEAKM FLQVDKSWKE
     IMRKVNRLPN ALRAATQPGL LETFQNNNAL LDQIQKCLEA YLESKRVIFP RFYFLSNDEL
     LEILAQTRNP QAVQPHLRKC FDSISKLEFA LMPPAEGKIP GIDGEPEKVY TNDILAMLSP
     EGERVSLGKG LKARGNVEEW LGKVEEAMFT SLRRLCKAAI ADYQGKLRTD WVVAGHPSQV
     ILTVSQIMWC RDLTECLETE HSNHIQALKN FEKVNFERLN ALAAIVQGSL PKLHRNILTA
     LITIDVHARD IVTELVQSKV ETVESFDWQR QLRYYWDIDL DNCVARMALS QYTYGYEYLG
     ACPRLVITPL TDRCYLCLMG ALQLDLGGAP AGPAGTGKTE TTKDLAKALA IQCVVFNCSD
     GLDYKMMGRF FSGLAQSGAW CCFDEFNRID IEVLSVIAQQ LITIRNAKAA KLSRFMFEGR
     EIKLVMTCAA FITMNPGYAG RTELPDNLKA LFRPFAMMVP NYALIAEVIL YSEGFESSKI
     LARKMTQMYK LCSEQLSQQD HYDFGMRAVK SVLVMAGSLK RENPDLNEDV VLIRALQDSN
     LPKFLTDDAL LFSGIISDLF PGVQIPEHDY GILQSTIVDV MNRQNLQPEM CMVRKVIQFY
     ETMLVRHGVM LVGPTGGGKT TVYRILAETL GNLQKLGIEN SFYQAVKTYV LNPKSITMGE
     LYGEVNNLTL EWKDGLMALS VRAAVNDTSE DHKWIISDGP VDALWIENMN TVLDDNKMLC
     LANSERIKLT PQIHMLFEVQ DLRVASPATV SRCGMVFVDP EELKWMPYVK TWMKGISKKL
     TEETQEYILN LFQRYVDEGL HFINKKCSQA IPQVDISKVT TLCCLLESLI LGKDGVNLAM
     EQTKLNTILC QTFVFCYLWS LGGNLTENYY DSFDTFIRTQ FDDNPDARLP NSGDLWSIHM
     DFDTKRLDPW ERIIPTFKYN RDVPFFEMLV PTTDTVRYGY LMEKLLAVKH SVLFTGITGV
     GKSVIAKGLL NKIQESAGYV PVYLNFSAQT SSARTQEIIE SKLERKRKNI LGAPGNKRIV
     IFVDDLNMPR LDRYGSQPPI ELLRQYQDFG GFYDRNKLFW KEIQDVTIIS ACAPPGGGRN
     PVTPRFIRHF SMLCLPMPSE HSLKQIFQAI LNGFLSDFPP AVKQTASSIV EASVEIYNKM
     SVDLLPTPAK SHYVFNLRDL SKCVQGILQC DPGTIREEIQ IFRLFCHECQ RVFHDRLINN
     EDKHYFHVIL TEMANKHFGI AIDLEYFLNK PIIFGDFIKF GADKADRIYD DMPDIEKTAN
     VLQDYLDDYN LTNPKEVKLV FFQDAIEHVS RIARMIRQER GNALLVGVGG TGKQSLTRLA
     AHICGYKCLQ IELSRGYNYD SFHEDLRKLY KMAGVEDKNM VFLFTDTQIV VEEFLEDINN
     ILNSGEVPNL FEKDELEQVL AATRPRAKEV GISEGNRDEV FQYFISKVRQ KLHIVLCMSP
     VGEAFRSRCR MFPSLVNCCT IDWFVQWPRE ALLSVSKTFF SQVDAGNEEL KEKLPLMCVN
     VHLSVSSMAE RYYNELRRRY YTTPTSYLEL INLYLSMLSE KRKQIISARD RVKNGLTKLL
     ETNILVDKMK LDLSALEPVL LAKSEDVEAL MEKLAVDQES ADQVRNTVQE DEATAKVKAE
     ETQAIADDAQ RDLDEALPAL DAANKALDSL DKADISEIRV FTKPPDLVMT VMEAISILLN
     AKPDWPSAKQ LLGDSNFLKR LLEYDKENIK PQILAKLQKY INNPDFVPEK VEKVSKACKS
     MCMWVRAMDL YSRVVKVVEP KRQKLRAAQA ELDITMATLR EKQALLRQVE DQIQALQDEY
     DKGVNEKESL AKTMALTKAR LVRAGKLTAA LEDEQVRWEE SIQKFEEEIS NITGNVFIAA
     ACVAYYGAFT AQYRQSLIEC WIQDCQSLEI PIDPSFSLIN ILGDPYEIRQ WNTDGLPRDL
     ISTENGILVT QGRRWPLMID PQDQANRWIR NKESKSGLKI IKLTDSNFLR ILENSIRLGL
     PVLLEELKET LDPALEPILL KQIFISGGRL LIRLGDSDID YDKNFRFYMT TKMPNPHYLP
     EVCIKVTIIN FTVTKSGLED QLLSDVVRLE KPRLEEQRIK LIVRINTDKN QLKTIEEKIL
     RMLFTSEGNI LDNEELIDTL QDSKITSGAI KTRLEEAEST EQMINVAREK YRPVATQGSV
     MYFVIASLSE IDPMYQYSLK YFKQLFNTTI ETSVKTENLQ QRLDVLLEQT LLTAYVNVSR
     GLFEQHKLIY SFMLCVEMMR QQGTLSDAEW NFFLRGSAGL EKERPPKPEA PWLPTATWFA
     CCDLEESFPV FHGLTQNILS HPISIRLGSF ETYINPQKWE GYSKMKHEDK HMRQEKEAAH
     QDPWSAGLSS FHKLILIKCC KEEKVVFALT DFVIENLGKQ FIETPPVDLP TLYQDMSCNT
     PLVFILSTGS DPMGAFQRFA RESGYSERVQ SISLGQGQGP IAEKMVKDAM KSGNWVFLQN
     CHLAVSWMLA MEELIKTFTD PDSAIKDTFR LFLSSMPSNT FPVTVLQNSV KVTNEPPKGL
     RANIRRAFTE MTPSFFEENI LGKKWRQIIF GICFFHAIIQ ERKKFGPLGW NICYEFNDSD
     RECALLNLKL YCKEGKIPWD ALIYITGEIT YGGRVTDSWD QRCLRTILKR FFSPETLEED
     YKYSESGIYF APMADSLQEF KDYIENLPLI DDPEIFGMHE NANLVFQYKE TSTLINTILE
     VQPRSSTGGE GKSNDEIVQE LVASVQTRVP EKLEMEGASE SLFVKDLQGR LNSLTTVLGQ
     EVDRFNNLLK LIHTSLETLN KAIAGFVVMS EEMEKVYNSF LNNQVPALWS NTAYPSLKPL
     GSWVKDLILR TSFVDLWLKR GQPKSYWISG FFFPQGFLTG TLQNHARKYN LPIDELSFKY
     SVIPTYRDQA AVIEAAKTVQ FGQELPMDME LPSPEDGVLV HGMFMDASRW DDKEMVIEDA
     LPGQMNPVLP VVHFEPQQNY KPSPTLYHCP LYKTGARAGT LSTTGHSTNF VVTVLLPSKR
     SKDYWIAKGS ALLCQLSE
//
",55686
ACGTGG CGTGGG GTGGGC TGGGCG GGGCGC GGCGCG GCGCGT CGCGTT GCGTTA CGTTAT GTTATC TTATCA TATCAG ATCAGG TCAGGT CAGGTG AGGTGG GGTGGC GTGGCC TGGCCC GGCCCG GCCCGT CCCGTG CCGTGC CGTGCG GTGCGG TGCGGT GCGGTC CGGTCA GGTCAT GTCATG TCATGC CATGCA ATGCAC TGCACA GCACAA CACAAA ACAAAG CAAAGA AAAGAA AAGAAT AGAATT GAATTG AATTGC ATTGCT TTGCTG TGCTGG GCTGGA CTGGAG TGGAGC GGAGCC GAGCCG AGCCGC GCCGCG CCGCGC CGCGCC GCGCCT CGCCTG GCCTGG CCTGGA CTGGAT TGGATC GGATCT GATCTG ATCTGG TCTGGC CTGGCC TGGCCG GGCCGC GCCGCA CCGCAG CGCAGC GCAGCG CAGCGG AGCGGT GCGGTG CGGTGT GGTGTC GTGTCT TGTCTG GTCTGC TCTGCG CTGCGG TGCGGC GCGGCC CGGCCT GGCCTT GCCTTG CCTTGG CTTGGC TTGGCC TGGCCG GGCCGA GCCGAC CCGACG CGACGA GACGAG ACGAGC CGAGCC GAGCCG AGCCGG GCCGGC CCGGCG CGGCGC GGCGCT GCGCTG CGCTGG GCTGGC CTGGCC TGGCCA GGCCAG GCCAGC CCAGCA CAGCAG AGCAGC GCAGCA CAGCAA AGCAAA GCAAAC CAAACC AAACCA AACCAC ACCACG CCACGC CACGCT ACGCTT CGCTTG GCTTGC CTTGCC TTGCCG TGCCGT GCCGTG CCGTGG CGTGGC GTGGCG TGGCGC GGCGCG GCGCGG CGCGGG GCGGGC CGGGCT GGGCTG GGCTGG GCTGGG CTGGGA,3,145,ACGT CGTG GTGG TGGG GGGC GGCG GCGC CGCG GCGT CGTT GTTA TTAT TATC ATCA TCAG CAGG AGGT GGTG GTGG TGGC GGCC GCCC CCCG CCGT CGTG GTGC TGCG GCGG CGGT GGTC GTCA TCAT CATG ATGC TGCA GCAC CACA ACAA CAAA AAAG AAGA AGAA GAAT AATT ATTG TTGC TGCT GCTG CTGG TGGA GGAG GAGC AGCC GCCG CCGC CGCG GCGC CGCC GCCT CCTG CTGG TGGA GGAT GATC ATCT TCTG CTGG TGGC GGCC GCCG CCGC CGCA GCAG CAGC AGCG GCGG CGGT GGTG GTGT TGTC GTCT TCTG CTGC TGCG GCGG CGGC GGCC GCCT CCTT CTTG TTGG TGGC GGCC GCCG CCGA CGAC GACG ACGA CGAG GAGC AGCC GCCG CCGG CGGC GGCG GCGC CGCT GCTG CTGG TGGC GGCC GCCA CCAG CAGC AGCA GCAG CAGC AGCA GCAA CAAA AAAC AACC ACCA CCAC CACG ACGC CGCT GCTT CTTG TTGC TGCC GCCG CCGT CGTG GTGG TGGC GGCG GCGC CGCG GCGG CGGG GGGC GGCT GCTG CTGG TGGG GGGA,ACGTG CGTGG GTGGG TGGGC GGGCG GGCGC GCGCG CGCGT GCGTT CGTTA GTTAT TTATC TATCA ATCAG TCAGG CAGGT AGGTG GGTGG GTGGC TGGCC GGCCC GCCCG CCCGT CCGTG CGTGC GTGCG TGCGG GCGGT CGGTC GGTCA GTCAT TCATG CATGC ATGCA TGCAC GCACA CACAA ACAAA CAAAG AAAGA AAGAA AGAAT GAATT AATTG ATTGC TTGCT TGCTG GCTGG CTGGA TGGAG GGAGC GAGCC AGCCG GCCGC CCGCG CGCGC GCGCC CGCCT GCCTG CCTGG CTGGA TGGAT GGATC GATCT ATCTG TCTGG CTGGC TGGCC GGCCG GCCGC CCGCA CGCAG GCAGC CAGCG AGCGG GCGGT CGGTG GGTGT GTGTC TGTCT GTCTG TCTGC CTGCG TGCGG GCGGC CGGCC GGCCT GCCTT CCTTG CTTGG TTGGC TGGCC GGCCG GCCGA CCGAC CGACG GACGA ACGAG CGAGC GAGCC AGCCG GCCGG CCGGC CGGCG GGCGC GCGCT CGCTG GCTGG CTGGC TGGCC GGCCA GCCAG CCAGC CAGCA AGCAG GCAGC CAGCA AGCAA GCAAA CAAAC AAACC AACCA ACCAC CCACG CACGC ACGCT CGCTT GCTTG CTTGC TTGCC TGCCG GCCGT CCGTG CGTGG GTGGC TGGCG GGCGC GCGCG CGCGG GCGGG CGGGC GGGCT GGCTG GCTGG CTGGG TGGGA,ACGTGG CGTGGG GTGGGC TGGGCG GGGCGC GGCGCG GCGCGT CGCGTT GCGTTA CGTTAT GTTATC TTATCA TATCAG ATCAGG TCAGGT CAGGTG AGGTGG GGTGGC GTGGCC TGGCCC GGCCCG GCCCGT CCCGTG CCGTGC CGTGCG GTGCGG TGCGGT GCGGTC CGGTCA GGTCAT GTCATG TCATGC CATGCA ATGCAC TGCACA GCACAA CACAAA ACAAAG CAAAGA AAAGAA AAGAAT AGAATT GAATTG AATTGC ATTGCT TTGCTG TGCTGG GCTGGA CTGGAG TGGAGC GGAGCC GAGCCG AGCCGC GCCGCG CCGCGC CGCGCC GCGCCT CGCCTG GCCTGG CCTGGA CTGGAT TGGATC GGATCT GATCTG ATCTGG TCTGGC CTGGCC TGGCCG GGCCGC GCCGCA CCGCAG CGCAGC GCAGCG CAGCGG AGCGGT GCGGTG CGGTGT GGTGTC GTGTCT TGTCTG GTCTGC TCTGCG CTGCGG TGCGGC GCGGCC CGGCCT GGCCTT GCCTTG CCTTGG CTTGGC TTGGCC TGGCCG GGCCGA GCCGAC CCGACG CGACGA GACGAG ACGAGC CGAGCC GAGCCG AGCCGG GCCGGC CCGGCG CGGCGC GGCGCT GCGCTG CGCTGG GCTGGC CTGGCC TGGCCA GGCCAG GCCAGC CCAGCA CAGCAG AGCAGC GCAGCA CAGCAA AGCAAA GCAAAC CAAACC AAACCA AACCAC ACCACG CCACGC CACGCT ACGCTT CGCTTG GCTTGC CTTGCC TTGCCG TGCCGT GCCGTG CCGTGG CGTGGC GTGGCG TGGCGC GGCGCG GCGCGG CGCGGG GCGGGC CGGGCT GGGCTG GGCTGG GCTGGG CTGGGA,ACGTGGG CGTGGGC GTGGGCG TGGGCGC GGGCGCG GGCGCGT GCGCGTT CGCGTTA GCGTTAT CGTTATC GTTATCA TTATCAG TATCAGG ATCAGGT TCAGGTG CAGGTGG AGGTGGC GGTGGCC GTGGCCC TGGCCCG GGCCCGT GCCCGTG CCCGTGC CCGTGCG CGTGCGG GTGCGGT TGCGGTC GCGGTCA CGGTCAT GGTCATG GTCATGC TCATGCA CATGCAC ATGCACA TGCACAA GCACAAA CACAAAG ACAAAGA CAAAGAA AAAGAAT AAGAATT AGAATTG GAATTGC AATTGCT ATTGCTG TTGCTGG TGCTGGA GCTGGAG CTGGAGC TGGAGCC GGAGCCG GAGCCGC AGCCGCG GCCGCGC CCGCGCC CGCGCCT GCGCCTG CGCCTGG GCCTGGA CCTGGAT CTGGATC TGGATCT GGATCTG GATCTGG ATCTGGC TCTGGCC CTGGCCG TGGCCGC GGCCGCA GCCGCAG CCGCAGC CGCAGCG GCAGCGG CAGCGGT AGCGGTG GCGGTGT CGGTGTC GGTGTCT GTGTCTG TGTCTGC GTCTGCG TCTGCGG CTGCGGC TGCGGCC GCGGCCT CGGCCTT GGCCTTG GCCTTGG CCTTGGC CTTGGCC TTGGCCG TGGCCGA GGCCGAC GCCGACG CCGACGA CGACGAG GACGAGC ACGAGCC CGAGCCG GAGCCGG AGCCGGC GCCGGCG CCGGCGC CGGCGCT GGCGCTG GCGCTGG CGCTGGC GCTGGCC CTGGCCA TGGCCAG GGCCAGC GCCAGCA CCAGCAG CAGCAGC AGCAGCA GCAGCAA CAGCAAA AGCAAAC GCAAACC CAAACCA AAACCAC AACCACG ACCACGC CCACGCT CACGCTT ACGCTTG CGCTTGC GCTTGCC CTTGCCG TTGCCGT TGCCGTG GCCGTGG CCGTGGC CGTGGCG GTGGCGC TGGCGCG GGCGCGG GCGCGGG CGCGGGC GCGGGCT CGGGCTG GGGCTGG GGCTGGG GCTGGGA,"ID   MUCA_PSEAE              Reviewed;         194 AA.
AC   P38107;
DT   01-OCT-1994, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1994, sequence version 1.
DT   05-FEB-2025, entry version 129.
DE   RecName: Full=Sigma factor AlgU negative regulatory protein;
GN   Name=mucA; OrderedLocusNames=PA0763;
OS   Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM
OS   14847 / LMG 12228 / 1C / PRS 101 / PAO1).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Pseudomonadales;
OC   Pseudomonadaceae; Pseudomonas.
OX   NCBI_TaxID=208964;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 /
RC   1C / PRS 101 / PAO1;
RX   PubMed=8412698; DOI=10.1111/j.1365-2958.1993.tb01711.x;
RA   Martin D.W., Schurr M.J., Mudd M.H., Deretic V.;
RT   ""Differentiation of Pseudomonas aeruginosa into the alginate-producing
RT   form: inactivation of mucB causes conversion to mucoidy."";
RL   Mol. Microbiol. 9:497-506(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=PAO381, and PAO568;
RX   PubMed=8378309; DOI=10.1073/pnas.90.18.8377;
RA   Martin D.W., Schurr M.J., Mudd M.H., Govan J.R.W., Holloway B.W.,
RA   Deretic V.;
RT   ""Mechanism of conversion to mucoidy in Pseudomonas aeruginosa infecting
RT   cystic fibrosis patients."";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:8377-8381(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 /
RC   1C / PRS 101 / PAO1;
RX   PubMed=10984043; DOI=10.1038/35023079;
RA   Stover C.K., Pham X.-Q.T., Erwin A.L., Mizoguchi S.D., Warrener P.,
RA   Hickey M.J., Brinkman F.S.L., Hufnagle W.O., Kowalik D.J., Lagrou M.,
RA   Garber R.L., Goltry L., Tolentino E., Westbrock-Wadman S., Yuan Y.,
RA   Brody L.L., Coulter S.N., Folger K.R., Kas A., Larbig K., Lim R.M.,
RA   Smith K.A., Spencer D.H., Wong G.K.-S., Wu Z., Paulsen I.T., Reizer J.,
RA   Saier M.H. Jr., Hancock R.E.W., Lory S., Olson M.V.;
RT   ""Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic
RT   pathogen."";
RL   Nature 406:959-964(2000).
CC   -!- FUNCTION: Negative regulator of the sigma factor AlgU. Plays a role in
CC       the differentiation of P.aeruginosa into the alginate-producing form.
CC       Inactivation of mucA causes a switch from the non-mucoid to mucoid
CC       state resulting in constitutive expression of alginate biosynthetic
CC       genes.
CC   -!- INTERACTION:
CC       P38107; Q9HVX1: algW; NbExp=3; IntAct=EBI-6406981, EBI-6407097;
CC       P38107; P38108: mucB; NbExp=4; IntAct=EBI-6406981, EBI-6406975;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Single-pass membrane
CC       protein {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the RseA family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L14760; AAA87629.1; -; Genomic_DNA.
DR   EMBL; U49151; AAC43715.1; -; Genomic_DNA.
DR   EMBL; AE004091; AAG04152.1; -; Genomic_DNA.
DR   PIR; S36207; S36207.
DR   RefSeq; NP_249454.1; NC_002516.2.
DR   RefSeq; WP_003101958.1; NZ_QZGE01000007.1.
DR   PDB; 6IN7; X-ray; 1.96 A; A=1-80.
DR   PDB; 6IN9; X-ray; 1.80 A; C/D=106-194.
DR   PDB; 6JAU; X-ray; 1.91 A; B=106-194.
DR   PDB; 8Z6G; X-ray; 2.10 A; A/C/E=1-80.
DR   PDBsum; 6IN7; -.
DR   PDBsum; 6IN9; -.
DR   PDBsum; 6JAU; -.
DR   PDBsum; 8Z6G; -.
DR   AlphaFoldDB; P38107; -.
DR   SMR; P38107; -.
DR   IntAct; P38107; 3.
DR   STRING; 208964.PA0763; -.
DR   PaxDb; 208964-PA0763; -.
DR   GeneID; 879357; -.
DR   KEGG; pae:PA0763; -.
DR   PATRIC; fig|208964.12.peg.793; -.
DR   PseudoCAP; PA0763; -.
DR   HOGENOM; CLU_105872_1_0_6; -.
DR   InParanoid; P38107; -.
DR   OrthoDB; 5734981at2; -.
DR   PhylomeDB; P38107; -.
DR   BioCyc; PAER208964:G1FZ6-776-MONOMER; -.
DR   Proteomes; UP000002438; Chromosome.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016989; F:sigma factor antagonist activity; IMP:PseudoCAP.
DR   GO; GO:0042121; P:alginic acid biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0032885; P:regulation of polysaccharide biosynthetic process; IMP:PseudoCAP.
DR   CDD; cd16328; RseA_N; 1.
DR   FunFam; 1.10.10.880:FF:000002; Sigma factor AlgU regulatory protein MucA; 1.
DR   Gene3D; 1.10.10.880; Anti sigma-E protein RseA, N-terminal domain; 1.
DR   InterPro; IPR052383; Anti-sigma-E_RseA-like.
DR   InterPro; IPR005573; Anti-sigma_E_RseA_C.
DR   InterPro; IPR005572; Anti-sigma_E_RseA_N.
DR   InterPro; IPR036147; Anti-sigma_E_RseA_N_sf.
DR   PANTHER; PTHR38104; -; 1.
DR   PANTHER; PTHR38104:SF1; ANTI-SIGMA-E FACTOR RSEA; 1.
DR   Pfam; PF03873; RseA_C; 1.
DR   Pfam; PF03872; RseA_N; 1.
DR   SUPFAM; SSF89069; N-terminal, cytoplasmic domain of anti-sigmaE factor RseA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alginate biosynthesis; Cell membrane; Membrane;
KW   Reference proteome; Transmembrane; Transmembrane helix.
FT   CHAIN           1..194
FT                   /note=""Sigma factor AlgU negative regulatory protein""
FT                   /id=""PRO_0000096642""
FT   TRANSMEM        89..105
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   HELIX           3..14
FT                   /evidence=""ECO:0007829|PDB:6IN7""
FT   HELIX           20..32
FT                   /evidence=""ECO:0007829|PDB:6IN7""
FT   HELIX           34..50
FT                   /evidence=""ECO:0007829|PDB:6IN7""
FT   HELIX           62..70
FT                   /evidence=""ECO:0007829|PDB:6IN7""
FT   HELIX           153..160
FT                   /evidence=""ECO:0007829|PDB:6IN9""
FT   HELIX           163..177
FT                   /evidence=""ECO:0007829|PDB:6IN9""
FT   HELIX           183..189
FT                   /evidence=""ECO:0007829|PDB:6IN9""
SQ   SEQUENCE   194 AA;  20999 MW;  421755F4F113769B CRC64;
     MSREALQETL SAVMDNEADE LELRRVLAAC GEDAELRSTW SRYQLARSVM HREPTLPKLD
     IAAAVSAALA DEAAPPKAEK GPWRMVGRLA VAASVTLAVL AGVRLYNQND ALPQMAQQGT
     TPQIALPQVK GPAVLAGYSE EQGAPQVITN SSSSDTRWHE QRLPIYLRQH VQQSAVSGTE
     SALPYARAAS LENR
//
",1314
CGCAGC GCAGCC CAGCCT AGCCTG GCCTGC CCTGCG CTGCGT TGCGTG GCGTGA CGTGAG GTGAGC TGAGCG GAGCGC AGCGCA GCGCAT CGCATG GCATGG CATGGT ATGGTG TGGTGG GGTGGA GTGGAG TGGAGC GGAGCT GAGCTG AGCTGG GCTGGG CTGGGT TGGGTC GGGTCG GGTCGC GTCGCA TCGCAG CGCAGT GCAGTT CAGTTG AGTTGC GTTGCG TTGCGT TGCGTA GCGTAC CGTACA GTACAC TACACC ACACCC CACCCG ACCCGG CCCGGA CCGGAC CGGACT GGACTA GACTAC ACTACC CTACCG TACCGC ACCGCA CCGCAC CGCACC GCACCG CACCGG ACCGGC CCGGCG CGGCGG GGCGGT GCGGTG CGGTGT GGTGTC GTGTCA TGTCAT GTCATC TCATCA CATCAT ATCATG TCATGG CATGGC ATGGCG TGGCGC GGCGCC GCGCCG CGCCGT GCCGTG CCGTGG CGTGGG GTGGGG TGGGGG GGGGGG GGGGGC GGGGCG GGGCGC GGCGCT GCGCTG CGCTGG GCTGGG CTGGGA TGGGAG GGGAGA GGAGAG GAGAGT AGAGTT GAGTTC AGTTCA GTTCAT TTCATG TCATGG CATGGG ATGGGG TGGGGC GGGGCG GGGCGC GGCGCA GCGCAA CGCAAC GCAACA CAACAA AACAAA ACAAAC CAAACT AAACTC AACTCG ACTCGA CTCGAC TCGACA CGACAC GACACC ACACCA CACCAT ACCATG CCATGA CATGAT ATGATT TGATTG GATTGG ATTGGC TTGGCT TGGCTG GGCTGT GCTGTG CTGTGC TGTGCC GTGCCA TGCCAG GCCAGC,3,142,CGCCA A GCT GCACAGAG G C CAGGTGC CGC AGAGCCC C G GCGCCCCTCT T C CCCCTCTGTG ACC CT GCTGCGC C T TGTGCGCGCG  GCGCGCGTGT GG  ACCGTGTGTG G GGTGTGAGA  TGTGAGAGAG  CC GAGAGGC C A AGAGCGCGT CG GGGGGCGGCGGC  AT CGCGCGCACA G G GCGCACATAT T C CACATATG ACG A GAATGTGGGG G T TCTGGGGTGT T G GGGGT GTTG G G GTGTGTGGGG G T TGTGGGGAGA A G GGGGAGAGAG  CGG CGAG ACGC C A AGAGCGCTCT T G CGGCTCTGTG G C CTCTGCA GG G T TGTGGGGGGG G G GG CGGT T G GGGGTGTCTC C G GTGTCTCGCG GTG TC CCCGCGC C C CGGT GCATGGTC  GCGCACAGAG G CCGGCAGAGTGT T A AGAGTGTT CA GTGTTTTGTG ACCTTGTGCGC C T TGTGC AACG GTC GCCGTGT T CAC CGTTGTTA A G GTGTATACGGCC T ACTACACACA AC  TAACATCAAC C C CACACACCT CC A ACG TCCCCC TGG CCCCGCCGCG G CC CCCGGG G C CGCGGGGAGA A GGGAGACTG C CGACACTT ATG ACTTA  TG CTCTATACAC C G TATACACCCC C A ACACCCCGCG GCCGC C C GCCGCGCACA A GGCACACA AC CT GCACG CCC C AACCCCGCG G C CCCCCCGGGG G CCGGGGCGC GG  GGGGCGCGCG G G GCGCGCGGGG G CCGG GCT G GGGGTGTGTG G G GTGC TGTTCGT T TGTGTGTCTC C G GTG GTCACA A T TCCACCATAT T C CACATGCGTC C A ATATCTCACA A TTCAAT CC TGACATATGG AATGTGGGG C G TGGGCC G GGGGCGCGCG G G GCCGCGC  CGCGCGCCCC C GCTG GGCCGCG G CG GCCGCGTGT  CGCGTGTGG G GTGTGC CGG G T TGTGG GCCAG GGGGGGGGGG  GC GGGGGGGGCG G G GGGGGGGGC GGGGTTCGC C G GGGGCATCCG G G GCGCGCGCGC C CG GCGCGCTT G GCGCTCTGTG  GA CTCTGTGGGG G TC ATGGGGGGG G G GGGGGGGAGA A G GGGGAACAG G GAAGA CAAGAGAGAG G G GAGAGAGTCGC AGAGTGTTTT  GTGTTGGCTC C T TTTTCTCACA A T TCTCACATAT T CCTGATGC GG A ATTGGGG  TGTGGT CGG G G GGGGGGGGGG G G GGGGGGGCGC C T GGAC CGCCG G G GCGCGCGCGC C C CG CGGCACA GAT GCGCAA C AGCAAAACAC C AGCGAACCA A AGCCGAGCAAAA A C CAAAAAA  AA TGAACAC C A AAAACA GT A CGACTCTCA GC C CTCTCTCGCG G T TCTCGCGAGA A C CGCGAGACAC  GAGACACAA A ACACACATAC C C CACACCC C A ACACCCCACA A C CCGCGCATAT T C CACATATGTG G A ATATG CAGA A T TGTGAGATAT  GAA GATTTT T A ATATTTTGG T TTTTGTGGGG G T TGGGCGC G T GGGGCCT  GCGCT CATG G C CTCTGTGTGT T T TGGTATG G GGGTGTGTGCGC C TAAAGCCCC C G GCAGCCCA GGA C CCCCACAGAG  CAGG AGC,CGCGCAAG G G GCTGCCAGAGCCGTC CCAGGCCCC C A AGAGCGCCCCTCT T G GCGCCCCTTG G C CCCCTTC GC  CTCTGCT GCG GGG T TGT GGCGGT T G GCGCGCGTGTG TGG C CGGTGGG A GA G GTGTGTGAGAGGTAG T TGCACAGCGC C GG CAGCAAACG  AGGGGGCGCGCGC C G GCGCGCGCC TCA A C CGCGCGCACATAT GT  GCGCACATATGTG CGC CACATATGTGGGG G AC GATGTGGGGTT TTGTTGGGGTGTGTG G G GGGGTGTGTGGG G GTGGA GGA T TGGGAAG G G GGGAGAGCGC C G GAGTTAGCGCTCT T A AGAGCA CCTGTG G G GCTCAT TTGGGG G C CTCTGGTGGGGG T TGTGGGGGGGTGT GCA GGAGCGGTGTCTGCC G GGGGTGTCTCGCG G G GGGTCTCGCGCGC C TTCGGCAGGGA C CGCGCGCACAGGC G G GCGCAAGTGT T C CACAGAGTGTTGC T AAGTGTTTTGTG G G GTGTTGC C T TTTTGTGCGCGCG G TTG TGCGCGCGTGT T G GCGCGGTATA GCTTT CGTTACAC GGTGTAACACA A T TATACACACACAC ATTCACACCCC C C CACACACCCCCCC C AACCCCCCCGG CC GCCCCCGCGGGG G C CCCCGGGAGA A C CGCGGGGA GGAC TTC GGGGAGACACTGGA GAGCCACTTA  ACACTCCGTACCATC C CTCTATACACCGGA TATACACCCCGCCATGGACCGAGCGCTT C C CCCGCGCAG GA C CGCGCGCACACAC C GGCACACACC CG CATGAACCCCGG AACCCCGCGGGG G C CCCCGCGGGGCGC T G CG GTGCTCG G GGGCGCGCGGGG G GA ACGGGGTT GT C CGGACGTGTG G G GGGGTGTGTG GT C C GTGTG TGGAGTC C T TGTGTTCACA A G GTTCACG T CCTGTC TCACATTCATC C C CAATCTCACA  GGATCTCACATAT T T TCAC ATGTG  CACATATGTGGGG G AATGTGGGGCGGGT G TGTGGGGCCG G GGCGGGCGCGG CC G GCGCGCGCGCCCC GG C CCGCGAGCCGCG  GCGCCCTACGTGT AT  CCCCGACCGTGTG  GA CGGC TGAGG G GCGCTGGAG GG G T TGTGGGGGG GGA GGGGGGGGGG G GGGG GGGGGGGG G GGGGCGCGC C G GGGGCGCGCG CA CG AC GCGC G GCGCGTGGGGCCT  CGCGCGGGTG G G GCGCTCTGTGGGG G C CTCTGTGGGGGGG G T TGTGGA CGA A G GTGCTGGAGTCAG G G GGGGAGAGAGAGA  GAGAGAGAATTA AG A AGAGAGACAGTGT TGC GACGAAGTGTT CGT A AGAGTC GTTCTC  AT GTGTTCCGTCACA A T TTTTCGCTCATAT T T TCATCCATATGTG G C CACATATGG AGG G A ATATGTGGGGGGG G TTGGGGGGGGGTGG G GGGGGGGGGC  CCCA GGCGCGCATG G GGGGCCGCGC AG  GCGCGGGCGCACA A C CGCGCGCAGCAAA A G GCGCACAAAACAC C C CAACACA A ACAAAACCAAAA AG  ACACACCGAA GGG CAGAT GG CC AAAAAAACACTCT AACACTCTC TCC A ACCTCTCGCG G CCTCTCGGAGGA A T TCTCGCGAGACC C CGCGAGACACACA  GAGACACACACAC C AACACACCGTCC C C CACACCCACA  GC ACCATAT  GGCCACATATGTG G C CACATATGTGA ATATGTGAGATAT T T TGTGA AAATTTGCT G GAGATGAGTTGTG G A AT ACTTGTGGG T TTTTGTGGGGCGC C T TGTGGGCTCT T G GGGGCGCTCTGTG G G GCGCTCTGTGTGT T C CTCTGTGTGTGTGTG T TGTGTTGCGC C GCGGGTGTGCGCCCC C T TGCAAGCCCG CA A G GCCCACAGC GG CCCACAGAGC,CGCGCAGGG AGGC C G GCGCACAGAGCGCCCC AGCGCCCCTCT T A AGAGCGCCCTG GTTG G G GCGCCACCCTGTGCGC C C CCCCTCTGTGCGGGCG G C CTCTGTGCGCGCGTGT T T TGTGCGCGCGTGTGTG G G GCGCGCGTCTATGGC C CGCGTGTGTGAGAGAG G GGTGCGGGAG GCGC C T TGGAGAGCGCGT TG G GAGAGAGCGCGGC C A AGTGGGCGCGCGCACA A GGG GCGCGCGCA ACAT T C CGCGCGCACATGCTG G GCGCACATATGTGAGG GT GGGCATCGCTGGGGTGT  ATCGCGGTGTGCCAGCATGGGGTGTGTGGG G GGGGTG GTGGGGAGA A G GTGTGAGCGGAGAGG T TGGGAGAGAGCGC  GGGGAGAGAGCGCTT G GAGAGGCTGCTCTGTG  GT CGAGCGCTCTGACTGG G G GCGCT CGTGGGGGGG G C CTCTGCAAGGGGGTCACT T TGTGGGGGCC GTCTC C G CCGGGGGTGTCTCG TGG G GGGGTGTCAGAGC C GGTCTCGCA A T TCTCGCGCGCACAGAG G C CGG T GCAGTAGCC ACAGAGTGTTTT T CGGGCAGAGTGTTTTGTG G AAGCAGTGTTTTGTGCGC  GTCCGTTGTGCGCGCG G T TTTTGTGCGCGCGTGT T T TGTGCGCGCGTGTATA A G GCGCGCGTGTAAC C C CGCGTGTATACACACA A G GTGTATACACAAC C T TATACGCACACACCGCAC A ACACCCCCCC C C CA GGGCGCG CCTACCGGCCGGGG G C GGCCCCCGGA A C CCGTGTGAGGAGACAC C C CGCGGGGACCAACTCT T GGGAATGACTCTATA CCAGACGGGCCGTACAC C A ACGGGCTATACACCTGGC C CTCTATACACCCCGCG G T TATACACCCCGCGCGC C A ACACCGTTCA A C CCCCGCGCGCACACAC C C CGCGCCACACCGG C GGCA GAACCCCGCG  CACACCCTCCGCGGGTT ACACCCCGCGGGGCGC C CCATCCGGGCGGCCG G CCGG AGGGCGCGCGGGGGGGC GGGGCGCGCGGGGTT G GCGCGCGGGGTGTGTG G CAC CGGGGTGTGTGTGT T G GGGGTGTGTGTGTCTC C G GTGTG GAGTCTCAA T CATGTGTCCATAT T G GTGTCTCAGGGATCTC C T TCTCAATCTCACA A C CACATTCAAT T A ATATCTG  CCATGTG G T TCTCACATTGGGG G C CACATATGTGGGGCGC  ATAAATGGGGCGCGCG G T TGCGAGGCGCGGAGC G GGCC GGGG GC G GCCCCA CGCCCCGATGG CTGGCGCGCCCCGGT T GGCCCCGCGTGTGTG G C CCCCGCGTGTGTGGGG GGA CGCGTGTGCATGG G GCTGGTGCAT GCGG  TGTGGGGGGGGGG G GGGGGGG CAGGGGG CG  GGGGGGGGGGGGGCGC C G GGCAGGGGCGGGCGCG G G GGGCGCCCGCGCGCC G GGGGCGCGATGGCTCT T GGCGCGCGCGG AT AG C CGCGCGCTCTGTGGGG GCTCTGTGGG C CTCTGTGGGGGGGAGA A T TGGGGGGAGAGAG G G GGGGGGGAGAGAGAGA A G GGGGAAGAGAGAG G GGGCGAGAGAGAGAGTGT TG  AGCGCGAGAGTGTTTT T G GAGAGAGTG ATTCTC C A AGAGTGTTTCACA A G GTGTTTTCCATAT T T TTTTCTCAGTGTG G T TCTCACATATGTGGGG  CACATATGTGGGGGGG G A AT CGGGGCC  TGGGGGCCGGCGC C GGGGACTGGCGCGCG G G GGGGGGGCGCTGC C G GGTGGCGCACACA A G GCGCGCGCCAAAA A CCTGCGCGCATGGAACAC C G GCACACAAACACA CGCAACCC TG A CA A AAAACACA GAAAAAA A ATCGCAAAAAACT CGGA  CACAAAAAAACACTCT T A AAATGAACGCTCTCTC GCAAACCTC GCCG G A ACACTCTCTCGCGAGA A CCTCTGGGACAC C T TCTCGCGAGACACACA AA  CGCGAGACACACACAC CACTGTGACACACACACCCC C A ACACACACACCTG CA A C CACACC GCATG GT AACCAT CATTG  CC GAATGGA A C CAGGGTGAGATAT T A ATATGTGAGATATTTT CG  TGGATATTTTGTG G GCATGATTTGG A ATTTGGGCGC C T TTTTGGGCACTCT T T TGTGGGGCATG GCG GACCGGCAGCCTGGT T GCAAGCTCTGTGTGTGTCAG C CTCTGTGTGTGTGCGC C TCG TGTGTGTGCAG GGTC GG ATGCGCCCCACA  TGTGCGCCGACCAGAG G GCAGGCCCCACAGAGC,GTCC CCAGG GACAGCGC GGCACAG CGGCCCCTCT  CACAGAGCGCCCCTCTGTG G AGT AGCGCCCCTTGGTGCAACC G GCGCCCTGTGCGCGCG G C CCCCTG CTGCCGTGT T C CTCTGTGC GTGCGGTGGGCG T TGTGCG GGG GTGCTAGA C A GCGCGCGTGTGTGAGAGCAAG CCCGCGTGTGTGAGAGAGCGC C G GTGTGTGA AGAGCGCGCG  TGTGAATGAGCGCGC G GACGTAGCGCGCGCGCACGTA AAC GCGCGCGCACATAT T G GCGCGCGCCCCATGTG G C CGCGCGCACATAT GG G G GCGA ATGTGGGGTGT T C CACATATGTGGGGTGCGCGCG A ATATGTGGGGTGTGTGGGG G T TGTGGGGTGTGTGGGTGGA A GCA GGTTGGGGAGAGTCGGGG GTGTGGTGGGAGAGAGCGC C T TGCTGGGAGAGAGCCT  GGGGAGAGAGCGCTCTGTG G GGCCGAGAGCGCTTGCTGGCGTG AGAGGCTCTGTGGGGGGG G G GCGCTCTGTGGGGGGT T C CTCTGTGGGGG CTGTCTC  TGGGCGGGCATGTCTCGCG G GA AGGTGTCTCGCGCGC C G GGTCAGTCTCGCACGCACA A GGTCTCGGCACAGAG G T TCTCGCGCGCACAGGT T CAGCCGCGCAAGTGTTTT GAG GCGCACAGAGTGTTTTGTG G C CACAGCATTGCC AGCA AACA TTGCTGCG G GGTTTTGTGCCGTGT  TTTTGTGCGCGCGTGTATA A T TGTGCGCGCGTGTATACGCG TT GCGCGCGTGTATACACACA A C CGGTATACCACAC C G GTGTATACACACACACCCC C T GAACACACACCGC CC C A ACCGCACCCCCCCGG C CAACCCCCCCGCGGGG  ACCCCCCGCGGGGAGA A C CCCCGGATGACAC  CCCCGCGGGGAGACACTT C CGCGGGGAGACCTATA A G GGGGAGACACTCTAAGATGGCATGACCTAACCCC C A ACACTTACCCGCG G C CTAC TACACCCCGCGCGC C T TATACACCCCGCGCGCACA A AAGAACCCCGCGCGCAA TAC C C CCCCGCGC AGCACACCCC C C CGCGCCACACCCG G GGCAACCCCGCGGGG G C CA TGCG GA GGCC A ACCGCAGTGCGCG G C CCCCG GAGGCGCGAACG CG GGGCGCGCGGGGT CGT GCACGGCGCGCGGGGTGTGTG AGT GCGCGCGGGGTGTGTGTGT T CCGTGGTGTGTGTGTCTC C G GGGTGTGTGTCTCACA A G GTGGATGTCGCTGTCATT T TGTGTGTCTCACATATCTC C G GTGTCTCAATCTCA GGA T TCTCACATATC GGCATAT T C CAATCTCATACATGGGAG A ATATCTCACAT GGTGGGG G T TCTCAGGTATGTGGGGCGC GCTGT ATGTGGGGCGTGCG G A TCATGTGGGGCG TCGCGC C T TGTGGTGGT GGCGGGCCC C GGGTGGCCGTCGCGG CCGCCGG G GCGCGCGC GAGCCT CCGCGCCCA GTGG G GCGCCCCGC CGTGGTGGCCCTG CCCCGCGTGTGGG GGGGG G C CGGAGTGGGGGGG AT  GTTGGGGGGGGGGGGG GCG TGGGGGGGGGGGG C A GGGGGGGGGGGGGGGGCGC C G GGGGGGGGGGGCT CG TCAGGGGGGGCGCGCGC C G GGGGGGGCCGCCGCGAGT G GGGGCGCGCGCGCTCTGTG G G GCGCGCGC CAATGGG G CGT CGCGCTA GGGGGG G G GCGCTCTGTGGGGGGGAGA A C CTCTGGCCGGGGGAGAGAG G T TGTGGGGGTG GAGAGAGA A GGGGGGAGAGAGA CAAG G G GGGGAGAG ACGAGAGTGT GTT GAGAGAC T GAGTGTTTT T A AGAGAGAGAGTGTTTTCCGCC G GAGAGAGTGTTTTCTCACA A AAGTGTTTTC GGCATCGGT GT GTTCTCACATATGTG G TC GGC TCACATCTGTGGTGGG T ATTCAACCGCTTGGGGGG CCATATGC GGGGGG G A ATATGTGGGGGG GGGCACCC T TGTGGGGGGGGGGCGCGCG G GGGAGGGGGGGGCGCGCGCGC C G GGGGGGCCGCGCGCGCACA A GATGGGCGCGCGCGCACAAAA A G GCCTACCGGCAAACC C CGTC CAAGC ACACACA G GCGCAAG AACACACAAAA A CGAGCAAAACACACAAAAAAA A A AAAACACACAAAAAAACAGCCTG ACACACAAAAAAACACTCT  CACCTAACACTCTCTC C ACC AAAAACACTCTCTCGCG G A AAACTCTCCGAGCAGGG ACACTTCGGACAC C C CTCTCAG CCAGACCA CACGGTTCGCGAGACACACACAC C C CGCGAACACACACCCC C GCGGGACCACACCCCAA A ACACA GGACCCCACATAT T C CAGTTGC CCACATTACTG G A ACCGACATATGTGAG GA C CCCCACATATGTGAAT T C CACATTGAGATATTTT T A ATATGTGAGATTTGTG G TGTTTGAGATATTTTGTGGAGC GAGATATTTTGTGGGGCGC CGG ATTTGTGGGCTT T TTTTGTGGTG GCTCTGTG TGG TGGGCGCTCTGTGT AGGCG GGGGCGCTCTGTGTGTGTG G G GCGCTCTGTGTGTGTGCGCAGGTCTGTCAGTGTGC GGCC C T TGTGTGTGTGCGCCCCACA A GGCGGTGTGCGCCCCACAGAG G T TGTGCCCACAGAGC,"ID   OLSB_RHOCB              Reviewed;         259 AA.
AC   D5AQD6;
DT   07-APR-2021, integrated into UniProtKB/Swiss-Prot.
DT   15-JUN-2010, sequence version 1.
DT   05-FEB-2025, entry version 53.
DE   RecName: Full=L-ornithine N(alpha)-acyltransferase {ECO:0000305};
DE            EC=2.3.2.30 {ECO:0000250|UniProtKB:Q92SJ1};
GN   Name=olsB {ECO:0000303|PubMed:16856942};
GN   OrderedLocusNames=RCAP_rcc02998 {ECO:0000312|EMBL:ADE86725.1};
OS   Rhodobacter capsulatus (strain ATCC BAA-309 / NBRC 16581 / SB1003).
OC   Bacteria; Pseudomonadota; Alphaproteobacteria; Rhodobacterales;
OC   Rhodobacter group; Rhodobacter.
OX   NCBI_TaxID=272942;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC BAA-309 / NBRC 16581 / SB1003;
RX   PubMed=20418398; DOI=10.1128/jb.00366-10;
RA   Strnad H., Lapidus A., Paces J., Ulbrich P., Vlcek C., Paces V.,
RA   Haselkorn R.;
RT   ""Complete genome sequence of the photosynthetic purple nonsulfur bacterium
RT   Rhodobacter capsulatus SB 1003."";
RL   J. Bacteriol. 192:3545-3546(2010).
RN   [2]
RP   FUNCTION, PATHWAY, AND DISRUPTION PHENOTYPE.
RC   STRAIN=MT1131;
RX   PubMed=16856942; DOI=10.1111/j.1365-2958.2006.05253.x;
RA   Aygun-Sunar S., Mandaci S., Koch H.G., Murray I.V., Goldfine H., Daldal F.;
RT   ""Ornithine lipid is required for optimal steady-state amounts of c-type
RT   cytochromes in Rhodobacter capsulatus."";
RL   Mol. Microbiol. 61:418-435(2006).
CC   -!- FUNCTION: Catalyzes the first step in the biosynthesis of ornithine
CC       lipids, which are phosphorus-free membrane lipids (Probable). Catalyzes
CC       the 3-hydroxyacyl-acyl carrier protein-dependent acylation of ornithine
CC       to form lyso-ornithine lipid (LOL) (By similarity).
CC       {ECO:0000250|UniProtKB:Q92SJ1, ECO:0000305|PubMed:16856942}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a (3R)-hydroxyacyl-[ACP] + L-ornithine = a lyso-ornithine
CC         lipid + holo-[ACP] + H(+); Xref=Rhea:RHEA:20633, Rhea:RHEA-COMP:9685,
CC         Rhea:RHEA-COMP:9945, ChEBI:CHEBI:15378, ChEBI:CHEBI:46911,
CC         ChEBI:CHEBI:64479, ChEBI:CHEBI:78827, ChEBI:CHEBI:138482;
CC         EC=2.3.2.30; Evidence={ECO:0000250|UniProtKB:Q92SJ1};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:20634;
CC         Evidence={ECO:0000250|UniProtKB:Q92SJ1};
CC   -!- PATHWAY: Lipid metabolism. {ECO:0000269|PubMed:16856942}.
CC   -!- DISRUPTION PHENOTYPE: Mutant lacking this gene is unable to produce
CC       ornithine lipids. {ECO:0000269|PubMed:16856942}.
CC   -!- SIMILARITY: Belongs to the acetyltransferase family. OlsB subfamily.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP001312; ADE86725.1; -; Genomic_DNA.
DR   RefSeq; WP_013068698.1; NC_014034.1.
DR   AlphaFoldDB; D5AQD6; -.
DR   SMR; D5AQD6; -.
DR   STRING; 272942.RCAP_rcc02998; -.
DR   GeneID; 31491793; -.
DR   KEGG; rcp:RCAP_rcc02998; -.
DR   eggNOG; COG3176; Bacteria.
DR   HOGENOM; CLU_058962_1_1_5; -.
DR   OrthoDB; 9787072at2; -.
DR   Proteomes; UP000002361; Chromosome.
DR   GO; GO:0043810; F:ornithine-acyl [acyl carrier protein] N-acyltransferase activity; IEA:UniProtKB-EC.
DR   GO; GO:0006629; P:lipid metabolic process; IEA:UniProtKB-KW.
DR   Gene3D; 3.40.630.30; -; 1.
DR   InterPro; IPR016181; Acyl_CoA_acyltransferase.
DR   InterPro; IPR052351; Ornithine_N-alpha-AT.
DR   PANTHER; PTHR37323; GCN5-RELATED N-ACETYLTRANSFERASE; 1.
DR   PANTHER; PTHR37323:SF1; L-ORNITHINE N(ALPHA)-ACYLTRANSFERASE; 1.
DR   Pfam; PF13444; Acetyltransf_5; 1.
DR   SUPFAM; SSF55729; Acyl-CoA N-acyltransferases (Nat); 1.
PE   3: Inferred from homology;
KW   Acyltransferase; Lipid biosynthesis; Lipid metabolism; Reference proteome;
KW   Transferase.
FT   CHAIN           1..259
FT                   /note=""L-ornithine N(alpha)-acyltransferase""
FT                   /id=""PRO_0000452114""
SQ   SEQUENCE   259 AA;  29315 MW;  D8273E969114CF9B CRC64;
     MAAAPLSYEI RLARDAQEIR ASQRLRYAVF VEELGGAGPL IDHENRLEAD EFDPLYDHLV
     LIDATKPEED LDRVVAAYRL LRSDRAAEIG RFYCDAEYDL TPLRASGRRL LELGRSCVHP
     DHRGGAAMLM LWNALADYVL AHEIEILFGV ASFHGTDVAA LQQPLAWLHH HHLAPEGLRP
     RARQFQRMDL VAKEALDRRA ALDAMPNLIK AYLRLGGFVG EGAFVDRPFN TTDVMLLMDT
     QAMSEKHREF YTRRVEGRG
//
",40364
AAGAAA AGAAAT GAAATC AAATCT AATCTG ATCTGC TCTGCT CTGCTG TGCTGC GCTGCT CTGCTG TGCTGA GCTGAG CTGAGG TGAGGC GAGGCT AGGCTT GGCTTC GCTTCT CTTCTA TTCTAA TCTAAG CTAAGA TAAGAA AAGAAG AGAAGC GAAGCC AAGCCT AGCCTC GCCTCG CCTCGG CTCGGC TCGGCA CGGCAA GGCAAA GCAAAA CAAAAA AAAAAC AAAACG AAACGT AACGTA ACGTAC CGTACT GTACTG TACTGC ACTGCC CTGCCA TGCCAC GCCACT CCACTA CACTAA ACTAAA CTAAAG TAAAGC AAAGCA AAGCAT AGCATA GCATAC CATACA ATACAA TACAAT ACAATG CAATGT AATGTA ATGTAA TGTAAC GTAACA TAACAC AACACA ACACAA CACAAG ACAAGC CAAGCT AAGCTT AGCTTT GCTTTC CTTTCG TTTCGG TTCGGC TCGGCA CGGCAG GGCAGA GCAGAC CAGACG AGACGT GACGTG ACGTGG CGTGGT GTGGTC TGGTCC GGTCCA GTCCAG TCCAGA CCAGAA CAGAAC AGAACA GAACAA AACAAA ACAAAC CAAACC AAACCC AACCCA ACCCAA CCCAAG CCAAGG CAAGGA AAGGAA AGGAAA GGAAAT GAAATT AAATTT AATTTT ATTTTG TTTTGG TTTGGG TTGGGG TGGGGA GGGGAC GGGACC GGACCA GACCAG ACCAGG CCAGGA CAGGAA AGGAAC GGAACT GAACTA AACTAA ACTAAT CTAATC TAATCA AATCAG ATCAGA TCAGAC CAGACA AGACAA GACAAG ACAAGG CAAGGA AAGGAA AGGAAC GGAACT,1,142,AAGA AGAA GAAA AAAT AATC ATCT TCTG CTGC TGCT GCTG CTGC TGCT GCTG CTGA TGAG GAGG AGGC GGCT GCTT CTTC TTCT TCTA CTAA TAAG AAGA AGAA GAAG AAGC AGCC GCCT CCTC CTCG TCGG CGGC GGCA GCAA CAAA AAAA AAAA AAAC AACG ACGT CGTA GTAC TACT ACTG CTGC TGCC GCCA CCAC CACT ACTA CTAA TAAA AAAG AAGC AGCA GCAT CATA ATAC TACA ACAA CAAT AATG ATGT TGTA GTAA TAAC AACA ACAC CACA ACAA CAAG AAGC AGCT GCTT CTTT TTTC TTCG TCGG CGGC GGCA GCAG CAGA AGAC GACG ACGT CGTG GTGG TGGT GGTC GTCC TCCA CCAG CAGA AGAA GAAC AACA ACAA CAAA AAAC AACC ACCC CCCA CCAA CAAG AAGG AGGA GGAA GAAA AAAT AATT ATTT TTTT TTTG TTGG TGGG GGGG GGGA GGAC GACC ACCA CCAG CAGG AGGA GGAA GAAC AACT ACTA CTAA TAAT AATC ATCA TCAG CAGA AGAC GACA ACAA CAAG AAGG AGGA GGAA GAAC AACT,AAGAA AGAAA GAAAT AAATC AATCT ATCTG TCTGC CTGCT TGCTG GCTGC CTGCT TGCTG GCTGA CTGAG TGAGG GAGGC AGGCT GGCTT GCTTC CTTCT TTCTA TCTAA CTAAG TAAGA AAGAA AGAAG GAAGC AAGCC AGCCT GCCTC CCTCG CTCGG TCGGC CGGCA GGCAA GCAAA CAAAA AAAAA AAAAC AAACG AACGT ACGTA CGTAC GTACT TACTG ACTGC CTGCC TGCCA GCCAC CCACT CACTA ACTAA CTAAA TAAAG AAAGC AAGCA AGCAT GCATA CATAC ATACA TACAA ACAAT CAATG AATGT ATGTA TGTAA GTAAC TAACA AACAC ACACA CACAA ACAAG CAAGC AAGCT AGCTT GCTTT CTTTC TTTCG TTCGG TCGGC CGGCA GGCAG GCAGA CAGAC AGACG GACGT ACGTG CGTGG GTGGT TGGTC GGTCC GTCCA TCCAG CCAGA CAGAA AGAAC GAACA AACAA ACAAA CAAAC AAACC AACCC ACCCA CCCAA CCAAG CAAGG AAGGA AGGAA GGAAA GAAAT AAATT AATTT ATTTT TTTTG TTTGG TTGGG TGGGG GGGGA GGGAC GGACC GACCA ACCAG CCAGG CAGGA AGGAA GGAAC GAACT AACTA ACTAA CTAAT TAATC AATCA ATCAG TCAGA CAGAC AGACA GACAA ACAAG CAAGG AAGGA AGGAA GGAAC GAACT,AAGAAA AGAAAT GAAATC AAATCT AATCTG ATCTGC TCTGCT CTGCTG TGCTGC GCTGCT CTGCTG TGCTGA GCTGAG CTGAGG TGAGGC GAGGCT AGGCTT GGCTTC GCTTCT CTTCTA TTCTAA TCTAAG CTAAGA TAAGAA AAGAAG AGAAGC GAAGCC AAGCCT AGCCTC GCCTCG CCTCGG CTCGGC TCGGCA CGGCAA GGCAAA GCAAAA CAAAAA AAAAAC AAAACG AAACGT AACGTA ACGTAC CGTACT GTACTG TACTGC ACTGCC CTGCCA TGCCAC GCCACT CCACTA CACTAA ACTAAA CTAAAG TAAAGC AAAGCA AAGCAT AGCATA GCATAC CATACA ATACAA TACAAT ACAATG CAATGT AATGTA ATGTAA TGTAAC GTAACA TAACAC AACACA ACACAA CACAAG ACAAGC CAAGCT AAGCTT AGCTTT GCTTTC CTTTCG TTTCGG TTCGGC TCGGCA CGGCAG GGCAGA GCAGAC CAGACG AGACGT GACGTG ACGTGG CGTGGT GTGGTC TGGTCC GGTCCA GTCCAG TCCAGA CCAGAA CAGAAC AGAACA GAACAA AACAAA ACAAAC CAAACC AAACCC AACCCA ACCCAA CCCAAG CCAAGG CAAGGA AAGGAA AGGAAA GGAAAT GAAATT AAATTT AATTTT ATTTTG TTTTGG TTTGGG TTGGGG TGGGGA GGGGAC GGGACC GGACCA GACCAG ACCAGG CCAGGA CAGGAA AGGAAC GGAACT GAACTA AACTAA ACTAAT CTAATC TAATCA AATCAG ATCAGA TCAGAC CAGACA AGACAA GACAAG ACAAGG CAAGGA AAGGAA AGGAAC GGAACT,AAGAAAT AGAAATC GAAATCT AAATCTG AATCTGC ATCTGCT TCTGCTG CTGCTGC TGCTGCT GCTGCTG CTGCTGA TGCTGAG GCTGAGG CTGAGGC TGAGGCT GAGGCTT AGGCTTC GGCTTCT GCTTCTA CTTCTAA TTCTAAG TCTAAGA CTAAGAA TAAGAAG AAGAAGC AGAAGCC GAAGCCT AAGCCTC AGCCTCG GCCTCGG CCTCGGC CTCGGCA TCGGCAA CGGCAAA GGCAAAA GCAAAAA CAAAAAC AAAAACG AAAACGT AAACGTA AACGTAC ACGTACT CGTACTG GTACTGC TACTGCC ACTGCCA CTGCCAC TGCCACT GCCACTA CCACTAA CACTAAA ACTAAAG CTAAAGC TAAAGCA AAAGCAT AAGCATA AGCATAC GCATACA CATACAA ATACAAT TACAATG ACAATGT CAATGTA AATGTAA ATGTAAC TGTAACA GTAACAC TAACACA AACACAA ACACAAG CACAAGC ACAAGCT CAAGCTT AAGCTTT AGCTTTC GCTTTCG CTTTCGG TTTCGGC TTCGGCA TCGGCAG CGGCAGA GGCAGAC GCAGACG CAGACGT AGACGTG GACGTGG ACGTGGT CGTGGTC GTGGTCC TGGTCCA GGTCCAG GTCCAGA TCCAGAA CCAGAAC CAGAACA AGAACAA GAACAAA AACAAAC ACAAACC CAAACCC AAACCCA AACCCAA ACCCAAG CCCAAGG CCAAGGA CAAGGAA AAGGAAA AGGAAAT GGAAATT GAAATTT AAATTTT AATTTTG ATTTTGG TTTTGGG TTTGGGG TTGGGGA TGGGGAC GGGGACC GGGACCA GGACCAG GACCAGG ACCAGGA CCAGGAA CAGGAAC AGGAACT GGAACTA GAACTAA AACTAAT ACTAATC CTAATCA TAATCAG AATCAGA ATCAGAC TCAGACA CAGACAA AGACAAG GACAAGG ACAAGGA CAAGGAA AAGGAAC AGGAACT,"ID   NCAP_SARS2              Reviewed;         419 AA.
AC   P0DTC9;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Nucleoprotein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=N;
DE   AltName: Full=Nucleocapsid protein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=NC {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=Protein N {ECO:0000255|HAMAP-Rule:MF_04096};
GN   Name=N {ECO:0000255|HAMAP-Rule:MF_04096};
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   SUBCELLULAR LOCATION.
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [3] {ECO:0007744|PDB:6WZO, ECO:0007744|PDB:6WZQ}
RP   X-RAY CRYSTALLOGRAPHY (1.42 ANGSTROMS) OF 247-364, AND SUBUNIT.
RX   PubMed=32654247; DOI=10.1002/pro.3909;
RA   Ye Q., West A.M.V., Silletti S., Corbett K.D.;
RT   ""Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein."";
RL   Protein Sci. 29:1890-1901(2020).
RN   [4]
RP   REVIEW.
RX   PubMed=32974389; DOI=10.3389/fmolb.2020.00219;
RA   Nikolakaki E., Giannakouros T.;
RT   ""SR/RS Motifs as Critical Determinants of Coronavirus Life Cycle."";
RL   Front. Mol. Biosci. 7:219-219(2020).
RN   [5]
RP   VARIANTS LEU-3 AND PHE-235.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [6]
RP   FUNCTION, INTERACTION WITH HOST NLRP3, AND SUBCELLULAR LOCATION.
RX   PubMed=34341353; DOI=10.1038/s41467-021-25015-6;
RA   Pan P., Shen M., Yu Z., Ge W., Chen K., Tian M., Xiao F., Wang Z., Wang J.,
RA   Jia Y., Wang W., Wan P., Zhang J., Chen W., Lei Z., Chen X., Luo Z.,
RA   Zhang Q., Xu M., Li G., Li Y., Wu J.;
RT   ""SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce
RT   hyperinflammation."";
RL   Nat. Commun. 12:4664-4664(2021).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 41-174, AND MUTAGENESIS OF
RP   TYR-109.
RX   PubMed=32363136; DOI=10.1016/j.apsb.2020.04.009;
RA   Kang S., Yang M., Hong Z., Zhang L., Huang Z., Chen X., He S., Zhou Z.,
RA   Zhou Z., Chen Q., Yan Y., Zhang C., Shan H., Chen S.;
RT   ""Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain
RT   reveals potential unique drug targeting sites."";
RL   Acta Pharmacol. Sin. 10:1228-1238(2020).
RN   [8] {ECO:0007744|PDB:6YI3, ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT}
RP   STRUCTURE BY NMR OF 44-180, FUNCTION, AND MUTAGENESIS OF ARG-68; ARG-92;
RP   ILE-94; ARG-107; GLN-163; TYR-172 AND GLU-174.
RX   PubMed=33264373; DOI=10.1371/journal.ppat.1009100;
RA   Dinesh D.C., Chalupska D., Silhan J., Koutna E., Nencka R., Veverka V.,
RA   Boura E.;
RT   ""Structural basis of RNA recognition by the SARS-CoV-2 nucleocapsid
RT   phosphoprotein."";
RL   PLoS Pathog. 16:1-16(2020).
RN   [9]
RP   MUTAGENESIS OF SER-188 AND SER-206, AND PHOSPHORYLATION AT SER-206.
RX   PubMed=34593624; DOI=10.1073/pnas.2113401118;
RA   Liu X., Verma A., Garcia G. Jr., Ramage H., Lucas A., Myers R.L.,
RA   Michaelson J.J., Coryell W., Kumar A., Charney A.W., Kazanietz M.G.,
RA   Rader D.J., Ritchie M.D., Berrettini W.H., Schultz D.C., Cherry S.,
RA   Damoiseaux R., Arumugaswami V., Klein P.S.;
RT   ""Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:1-9(2021).
RN   [10]
RP   CLEAVAGE.
RX   PubMed=35922005; DOI=10.1038/s41586-022-05148-4;
RA   Chu H., Hou Y., Yang D., Wen L., Shuai H., Yoon C., Shi J., Chai Y.,
RA   Yuen T.T., Hu B., Li C., Zhao X., Wang Y., Huang X., Lee K.S., Luo C.,
RA   Cai J.P., Poon V.K., Chan C.C., Zhang A.J., Yuan S., Sit K.Y., Foo D.C.,
RA   Au W.K., Wong K.K., Zhou J., Kok K.H., Jin D.Y., Chan J.F., Yuen K.Y.;
RT   ""Coronaviruses exploit a host cysteine-aspartic protease for replication."";
RL   Nature 0:0-0(2022).
RN   [11]
RP   MUTAGENESIS OF 203-ARG-GLY-204 AND ARG-203, AND PHOSPHORYLATION.
RX   PubMed=35728038; DOI=10.1371/journal.ppat.1010627;
RA   Johnson B.A., Zhou Y., Lokugamage K.G., Vu M.N., Bopp N.,
RA   Crocquet-Valdes P.A., Kalveram B., Schindewolf C., Liu Y., Scharton D.,
RA   Plante J.A., Xie X., Aguilar P., Weaver S.C., Shi P.Y., Walker D.H.,
RA   Routh A.L., Plante K.S., Menachery V.D.;
RT   ""Nucleocapsid mutations in SARS-CoV-2 augment replication and
RT   pathogenesis."";
RL   PLoS Pathog. 18:e1010627-e1010627(2022).
RN   [12]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=35921414; DOI=10.1126/sciadv.abp9770;
RA   Lopez-Munoz A.D., Kosik I., Holly J., Yewdell J.W.;
RT   ""Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive
RT   immunity."";
RL   Sci. Adv. 8:eabp9770-eabp9770(2022).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=34901782; DOI=10.1016/j.isci.2021.103562;
RA   Nabeel-Shah S., Lee H., Ahmed N., Burke G.L., Farhangmehr S., Ashraf K.,
RA   Pu S., Braunschweig U., Zhong G., Wei H., Tang H., Yang J., Marcon E.,
RA   Blencowe B.J., Zhang Z., Greenblatt J.F.;
RT   ""SARS-CoV-2 nucleocapsid protein binds host mRNAs and attenuates stress
RT   granules to impair host stress response."";
RL   IScience 25:103562-103562(2022).
RN   [14]
RP   FUNCTION.
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [15] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 191-263, AND INTERACTION WITH NSP3.
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
CC   -!- FUNCTION: Packages the positive strand viral genome RNA into a helical
CC       ribonucleocapsid (RNP) and plays a fundamental role during virion
CC       assembly through its interactions with the viral genome and membrane
CC       protein M (PubMed:33264373). Plays an important role in enhancing the
CC       efficiency of subgenomic viral RNA transcription as well as viral
CC       replication. Attenuates the stress granules formation by reducing host
CC       G3BP1 access to host mRNAs under stress conditions (PubMed:34901782,
CC       PubMed:36534661). {ECO:0000269|PubMed:32974389,
CC       ECO:0000269|PubMed:33264373, ECO:0000269|PubMed:34901782,
CC       ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: May block host chemokine function in vivo, facilitating viral
CC       replication and transmission (PubMed:35921414). Acts by being secreted
CC       into the extracellular space where it competes to host chemokines for
CC       binding to host glycosaminoglycans (GAG) (PubMed:35921414).
CC       {ECO:0000269|PubMed:35921414}.
CC   -!- FUNCTION: May induce inflammasome responses in cultured cells and mice.
CC       Acts by interacting with host NLRP3 to facilitate inflammasome
CC       assembly, which induces cytokine release that may play a role in COVID
CC       lung injury. {ECO:0000269|PubMed:34341353}.
CC   -!- SUBUNIT: Homodimer, homotetramer, homooligomer with RNA
CC       (PubMed:32654247). Both monomeric and oligomeric forms interact with
CC       RNA. Interacts with protein M (By similarity). Interacts with protein E
CC       (By similarity). Interacts with NSP3; this interaction serves to tether
CC       the genome to the newly translated replicase-transcriptase complex at a
CC       very early stage of infection (PubMed:35044811). May interact with host
CC       NLRP3 (PubMed:34341353). {ECO:0000250|UniProtKB:P59595,
CC       ECO:0000255|HAMAP-Rule:MF_04096, ECO:0000269|PubMed:32654247,
CC       ECO:0000269|PubMed:34341353, ECO:0000269|PubMed:35044811}.
CC   -!- INTERACTION:
CC       P0DTC9; P0DTC4: E; NbExp=3; IntAct=EBI-25475856, EBI-25475850;
CC       P0DTC9; P0DTC5: M; NbExp=6; IntAct=EBI-25475856, EBI-25475853;
CC       P0DTC9; P0DTC9: N; NbExp=105; IntAct=EBI-25475856, EBI-25475856;
CC       P0DTC9; PRO_0000449621 [P0DTD1]: rep; NbExp=15; IntAct=EBI-25475856, EBI-25492388;
CC       P0DTC9; P78563: ADARB1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-2967304;
CC       P0DTC9; O15145: ARPC3; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-351829;
CC       P0DTC9; Q13895: BYSL; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-358049;
CC       P0DTC9; Q16543: CDC37; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-295634;
CC       P0DTC9; Q92793: CREBBP; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-81215;
CC       P0DTC9; Q92499: DDX1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-358474;
CC       P0DTC9; Q9NR30: DDX21; Xeno; NbExp=12; IntAct=EBI-25475856, EBI-357942;
CC       P0DTC9; P26196: DDX6; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-351257;
CC       P0DTC9; Q08426: EHHADH; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-2339219;
CC       P0DTC9; P19525: EIF2AK2; Xeno; NbExp=8; IntAct=EBI-25475856, EBI-640775;
CC       P0DTC9; Q14241: ELOA; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-742350;
CC       P0DTC9; Q13283: G3BP1; Xeno; NbExp=71; IntAct=EBI-25475856, EBI-1047359;
CC       P0DTC9; Q9UN86: G3BP2; Xeno; NbExp=37; IntAct=EBI-25475856, EBI-1044298;
CC       P0DTC9; P57764: GSDMD; Xeno; NbExp=13; IntAct=EBI-25475856, EBI-2798865;
CC       P0DTC9; P49841: GSK3B; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-373586;
CC       P0DTC9; P10412: H1-4; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-358163;
CC       P0DTC9; O14920: IKBKB; Xeno; NbExp=7; IntAct=EBI-25475856, EBI-81266;
CC       P0DTC9; Q92830: KAT2A; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-477622;
CC       P0DTC9; Q92831: KAT2B; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-477430;
CC       P0DTC9; Q07866: KLC1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-721019;
CC       P0DTC9; Q9H0B6: KLC2; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-726994;
CC       P0DTC9; Q9NSK0: KLC4; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-949319;
CC       P0DTC9; Q9NX58: LYAR; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-713507;
CC       P0DTC9; O43318: MAP3K7; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-358684;
CC       P0DTC9; Q9UBU8: MORF4L1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-399246;
CC       P0DTC9; Q15014: MORF4L2; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-399257;
CC       P0DTC9; Q9HCE1: MOV10; Xeno; NbExp=11; IntAct=EBI-25475856, EBI-1055820;
CC       P0DTC9; Q9HC36: MRM3; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-1045440;
CC       P0DTC9; O15226: NKRF; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-766011;
CC       P0DTC9; Q96P20: NLRP3; Xeno; NbExp=18; IntAct=EBI-25475856, EBI-6253230;
CC       P0DTC9; O15118: NPC1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-2368710;
CC       P0DTC9; Q96HA8: NTAQ1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-741158;
CC       P0DTC9; P11940: PABPC1; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-81531;
CC       P0DTC9; P62937: PPIA; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-437708;
CC       P0DTC9; O75569: PRKRA; Xeno; NbExp=8; IntAct=EBI-25475856, EBI-713955;
CC       P0DTC9; Q99873: PRMT1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-78738;
CC       P0DTC9; P61289: PSME3; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-355546;
CC       P0DTC9; P26022: PTX3; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-11574553;
CC       P0DTC9; P54727: RAD23B; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-954531;
CC       P0DTC9; O95786: RIGI; Xeno; NbExp=15; IntAct=EBI-25475856, EBI-995350;
CC       P0DTC9; P62899: RPL31; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-1053664;
CC       P0DTC9; P62753: RPS6; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-356625;
CC       P0DTC9; P37840: SNCA; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-985879;
CC       P0DTC9; Q96SB4: SRPK1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-539478;
CC       P0DTC9; P78362: SRPK2; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-593303;
CC       P0DTC9; P42224: STAT1; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-1057697;
CC       P0DTC9; P52630: STAT2; Xeno; NbExp=7; IntAct=EBI-25475856, EBI-1546963;
CC       P0DTC9; Q15633: TARBP2; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-978581;
CC       P0DTC9; Q14258: TRIM25; Xeno; NbExp=13; IntAct=EBI-25475856, EBI-2341129;
CC       P0DTC9; O60763: USO1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-356164;
CC       P0DTC9; Q93008: USP9X; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-302524;
CC   -!- SUBCELLULAR LOCATION: Virion {ECO:0000255|HAMAP-Rule:MF_04096}. Host
CC       cytoplasm {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:34341353}.
CC       Secreted {ECO:0000269|PubMed:35921414}. Host extracellular space
CC       {ECO:0000269|PubMed:35921414}. Note=Probably associates with ER-derived
CC       membranes where it participates in viral RNA synthesis and virus
CC       budding. When located inside the virion, complexed with the viral RNA.
CC       Can be secreted by unconventional protein secretion (UPS)
CC       (PubMed:35921414). When secreted, can bind to host glycosaminoglycans
CC       on infected and non infected cells (PubMed:35921414). Found in host
CC       cytoplasmic stress granules (PubMed:34901782). {ECO:0000255|HAMAP-
CC       Rule:MF_04096, ECO:0000269|PubMed:34901782,
CC       ECO:0000269|PubMed:35921414}.
CC   -!- PTM: ADP-ribosylated. The ADP-ribosylation is retained in the virion
CC       during infection. {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   -!- PTM: Phosphorylated on serine residues by host GSK3A and GSK3B
CC       (PubMed:34593624, PubMed:35728038). This promotes the solubility of
CC       homodimers that would otherwise aggregate (PubMed:32974389). Host
CC       phosphatase would dephosphorylate the protein during assembly at M
CC       bound membranes (PubMed:32974389). {ECO:0000269|PubMed:34593624,
CC       ECO:0000269|PubMed:35728038, ECO:0000305|PubMed:32974389}.
CC   -!- PTM: Proteolytically cleaved by host CASP6. The cleavage leads to two
CC       fragments and facilitates viral replication by inhibiting host IFN
CC       signaling. The two fragments may interact with IRF3 inhibiting its
CC       nuclear translocation after activation and reduce the expression of
CC       IFNB and IFN-stimulated genes. {ECO:0000269|PubMed:35922005}.
CC   -!- POLYMORPHISM: Variant Alpha/B.1.1.7 belongs to a lineage isolated first
CC       in United Kingdom (December 2020). It is also called Variant of Concern
CC       (VOC) 202012/01, Variant Under Investigation (VUI) 202012/01, 501Y.V1
CC       or 20B/501Y.V1. {ECO:0000305|PubMed:33413740}.
CC   -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC       isolated in South Africa (November 2021). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC       isolated in Nigeria (November 2022). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC       isolated in United States (November 2022). It is the result of
CC       recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC       express ORF8. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the betacoronavirus nucleocapsid protein family.
CC       {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43423.2; -; Genomic_RNA.
DR   PDB; 6M3M; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 6VYO; X-ray; 1.70 A; A/B/C/D=47-173.
DR   PDB; 6WJI; X-ray; 2.05 A; A/B/C/D/E/F=257-364.
DR   PDB; 6WKP; X-ray; 2.67 A; A/B/C/D=47-173.
DR   PDB; 6WZO; X-ray; 1.42 A; A/B/C/D=247-364.
DR   PDB; 6WZQ; X-ray; 1.45 A; A/B/C/D=247-364.
DR   PDB; 6YI3; NMR; -; A=44-180.
DR   PDB; 6YUN; X-ray; 1.44 A; A/B=249-364.
DR   PDB; 6ZCO; X-ray; 1.36 A; A=247-364.
DR   PDB; 7ACS; NMR; -; A=44-180.
DR   PDB; 7ACT; NMR; -; A=44-180.
DR   PDB; 7C22; X-ray; 2.00 A; A/B/C/D=248-364.
DR   PDB; 7CDZ; X-ray; 1.80 A; A/B/C/D=44-174.
DR   PDB; 7CE0; X-ray; 1.50 A; A/B/C/D=255-364.
DR   PDB; 7CR5; X-ray; 2.08 A; A=41-174.
DR   PDB; 7DE1; X-ray; 2.00 A; A/B=250-364.
DR   PDB; 7F2B; X-ray; 2.00 A; A/B=257-362.
DR   PDB; 7F2E; X-ray; 3.10 A; A/B/C/D/E/F/G/H/I/J/K/L=255-362.
DR   PDB; 7KGO; X-ray; 2.15 A; C=351-359.
DR   PDB; 7KGP; X-ray; 1.40 A; C=316-324.
DR   PDB; 7KGQ; X-ray; 1.34 A; C=222-230.
DR   PDB; 7KGR; X-ray; 1.55 A; C=159-167.
DR   PDB; 7KGS; X-ray; 1.58 A; C=138-146.
DR   PDB; 7KGT; X-ray; 1.90 A; C=226-234.
DR   PDB; 7LGD; X-ray; 2.88 A; E/F=105-113.
DR   PDB; 7LTU; X-ray; 1.12 A; A/B=217-222.
DR   PDB; 7LUX; X-ray; 1.30 A; A=217-222.
DR   PDB; 7LUZ; X-ray; 1.10 A; A=243-248.
DR   PDB; 7LV2; X-ray; 1.30 A; A=179-184.
DR   PDB; 7N0I; X-ray; 2.20 A; A/B/C/D/E/F/G/H=269-364.
DR   PDB; 7N0R; X-ray; 1.42 A; A/B=49-174.
DR   PDB; 7N3C; X-ray; 1.82 A; C=47-173.
DR   PDB; 7N3D; X-ray; 1.53 A; C=47-173.
DR   PDB; 7O05; X-ray; 1.94 A; A/B/C/D=247-364.
DR   PDB; 7O35; X-ray; 1.80 A; A/B/C/D=247-364.
DR   PDB; 7O36; X-ray; 2.00 A; A/B/C/D=247-364.
DR   PDB; 7PKU; NMR; -; B=191-263.
DR   PDB; 7QIK; X-ray; 2.01 A; E/F=193-200.
DR   PDB; 7QIP; X-ray; 2.65 A; C/D=201-210.
DR   PDB; 7R98; X-ray; 2.51 A; A/B/C=49-174.
DR   PDB; 7SD4; NMR; -; A=40-174.
DR   PDB; 7STR; X-ray; 1.50 A; C=47-173.
DR   PDB; 7STS; X-ray; 2.16 A; C/D=47-173.
DR   PDB; 7SUE; X-ray; 2.90 A; C/D/J/K=47-173.
DR   PDB; 7SUO; X-ray; 2.35 A; C/D=12-22.
DR   PDB; 7UW3; X-ray; 1.70 A; A/B/C/D=40-174.
DR   PDB; 7UXX; X-ray; 1.85 A; AAA/BBB/CCC/DDD/EEE/FFF=251-364.
DR   PDB; 7UXZ; X-ray; 1.73 A; AAA/BBB/CCC/DDD/EEE/FFF=251-364.
DR   PDB; 7VBD; X-ray; 1.94 A; A/B/C/D=48-174.
DR   PDB; 7VBE; X-ray; 1.59 A; A/B=257-364.
DR   PDB; 7VBF; X-ray; 1.30 A; A/B=255-364.
DR   PDB; 7VNU; X-ray; 1.95 A; A/B/C/D=47-174.
DR   PDB; 7WKJ; X-ray; 1.50 A; C=361-369.
DR   PDB; 7WZO; X-ray; 2.64 A; A=47-174.
DR   PDB; 7XWX; X-ray; 3.00 A; A/B/C/D/E/F/G/H=269-367.
DR   PDB; 7XWZ; X-ray; 2.25 A; A/B=48-172.
DR   PDB; 7XX1; X-ray; 1.90 A; A/B/C/D=49-173.
DR   PDB; 7XXK; X-ray; 2.00 A; A/B/C/D/E/F=248-364.
DR   PDB; 7YLB; X-ray; 2.41 A; A/B/C/D/G/H/J/K=247-364.
DR   PDB; 7YLD; X-ray; 2.80 A; A/B/C/D=47-174.
DR   PDB; 7ZIT; X-ray; 1.79 A; C/D=194-200.
DR   PDB; 8DNT; X-ray; 3.18 A; D/J/Q/X=222-230.
DR   PDB; 8FD5; EM; 4.57 A; A=1-419.
DR   PDB; 8FG2; EM; 6.00 A; A/B=1-419.
DR   PDB; 8IQJ; X-ray; 2.30 A; A/B/C/D=41-174.
DR   PDB; 8IV3; X-ray; 1.90 A; A/B/C/D=41-174.
DR   PDB; 8J6X; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 8TH1; X-ray; 1.80 A; E/F/G/H=1-25.
DR   PDB; 8TH5; X-ray; 2.62 A; K/L/M/N/O/P/Q=1-25.
DR   PDB; 8X1H; X-ray; 2.00 A; A/B/C/D=44-175.
DR   PDBsum; 6M3M; -.
DR   PDBsum; 6VYO; -.
DR   PDBsum; 6WJI; -.
DR   PDBsum; 6WKP; -.
DR   PDBsum; 6WZO; -.
DR   PDBsum; 6WZQ; -.
DR   PDBsum; 6YI3; -.
DR   PDBsum; 6YUN; -.
DR   PDBsum; 6ZCO; -.
DR   PDBsum; 7ACS; -.
DR   PDBsum; 7ACT; -.
DR   PDBsum; 7C22; -.
DR   PDBsum; 7CDZ; -.
DR   PDBsum; 7CE0; -.
DR   PDBsum; 7CR5; -.
DR   PDBsum; 7DE1; -.
DR   PDBsum; 7F2B; -.
DR   PDBsum; 7F2E; -.
DR   PDBsum; 7KGO; -.
DR   PDBsum; 7KGP; -.
DR   PDBsum; 7KGQ; -.
DR   PDBsum; 7KGR; -.
DR   PDBsum; 7KGS; -.
DR   PDBsum; 7KGT; -.
DR   PDBsum; 7LGD; -.
DR   PDBsum; 7LTU; -.
DR   PDBsum; 7LUX; -.
DR   PDBsum; 7LUZ; -.
DR   PDBsum; 7LV2; -.
DR   PDBsum; 7N0I; -.
DR   PDBsum; 7N0R; -.
DR   PDBsum; 7N3C; -.
DR   PDBsum; 7N3D; -.
DR   PDBsum; 7O05; -.
DR   PDBsum; 7O35; -.
DR   PDBsum; 7O36; -.
DR   PDBsum; 7PKU; -.
DR   PDBsum; 7QIK; -.
DR   PDBsum; 7QIP; -.
DR   PDBsum; 7R98; -.
DR   PDBsum; 7SD4; -.
DR   PDBsum; 7STR; -.
DR   PDBsum; 7STS; -.
DR   PDBsum; 7SUE; -.
DR   PDBsum; 7SUO; -.
DR   PDBsum; 7UW3; -.
DR   PDBsum; 7UXX; -.
DR   PDBsum; 7UXZ; -.
DR   PDBsum; 7VBD; -.
DR   PDBsum; 7VBE; -.
DR   PDBsum; 7VBF; -.
DR   PDBsum; 7VNU; -.
DR   PDBsum; 7WKJ; -.
DR   PDBsum; 7WZO; -.
DR   PDBsum; 7XWX; -.
DR   PDBsum; 7XWZ; -.
DR   PDBsum; 7XX1; -.
DR   PDBsum; 7XXK; -.
DR   PDBsum; 7YLB; -.
DR   PDBsum; 7YLD; -.
DR   PDBsum; 7ZIT; -.
DR   PDBsum; 8DNT; -.
DR   PDBsum; 8FD5; -.
DR   PDBsum; 8FG2; -.
DR   PDBsum; 8IQJ; -.
DR   PDBsum; 8IV3; -.
DR   PDBsum; 8J6X; -.
DR   PDBsum; 8TH1; -.
DR   PDBsum; 8TH5; -.
DR   PDBsum; 8X1H; -.
DR   BMRB; P0DTC9; -.
DR   EMDB; EMD-29002; -.
DR   EMDB; EMD-29072; -.
DR   SASBDB; P0DTC9; -.
DR   SMR; P0DTC9; -.
DR   BioGRID; 4383847; 1532.
DR   ComplexPortal; CPX-5686; SARS-CoV-2 nucleocapsid complex.
DR   IntAct; P0DTC9; 608.
DR   MINT; P0DTC9; -.
DR   ChEMBL; CHEMBL5169223; -.
DR   iPTMnet; P0DTC9; -.
DR   ABCD; P0DTC9; 27 sequenced antibodies.
DR   DNASU; 43740575; -.
DR   KEGG; vg:43740575; -.
DR   AGR; RefSeq:YP_009724397; -.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-168928; DDX58/IFIH1-mediated induction of interferon-alpha/beta.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-445989; TAK1-dependent IKK and NF-kappa-B activation.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-9020702; Interleukin-1 signaling.
DR   Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR   Reactome; R-HSA-9694322; Virion Assembly and Release.
DR   Reactome; R-HSA-9694614; Attachment and Entry.
DR   Reactome; R-HSA-9694631; Maturation of nucleoprotein.
DR   Reactome; R-HSA-9694635; Translation of Structural Proteins.
DR   Reactome; R-HSA-9694786; Transcription of SARS-CoV-2 sgRNAs.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9733458; Induction of Cell-Cell Fusion.
DR   Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways.
DR   SIGNOR; P0DTC9; -.
DR   PRO; PR:P0DTC9; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProt.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0044172; C:host cell endoplasmic reticulum-Golgi intermediate compartment; ISS:UniProtKB.
DR   GO; GO:0044177; C:host cell Golgi apparatus; ISS:UniProtKB.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0043655; C:host extracellular space; IEA:UniProtKB-SubCell.
DR   GO; GO:0043232; C:intracellular non-membrane-bounded organelle; IDA:DisProt.
DR   GO; GO:0042612; C:MHC class I protein complex; EXP:DisProt.
DR   GO; GO:1990904; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IPI:ComplexPortal.
DR   GO; GO:0019013; C:viral nucleocapsid; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0042288; F:MHC class I protein binding; EXP:DisProt.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; IDA:DisProt.
DR   GO; GO:0008266; F:poly(U) RNA binding; IMP:DisProt.
DR   GO; GO:0042803; F:protein homodimerization activity; EXP:DisProt.
DR   GO; GO:0140311; F:protein sequestering activity; IDA:UniProt.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProt.
DR   GO; GO:0035613; F:RNA stem-loop binding; IDA:DisProt.
DR   GO; GO:0039709; P:cytoplasmic capsid assembly; IDA:UniProt.
DR   GO; GO:0032688; P:negative regulation of interferon-beta production; IDA:ComplexPortal.
DR   GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; IDA:UniProtKB.
DR   GO; GO:0052572; P:response to host immune response; IDA:DisProt.
DR   GO; GO:0019074; P:viral RNA genome packaging; NAS:ComplexPortal.
DR   CDD; cd21595; CoV_N-CTD; 1.
DR   CDD; cd21554; CoV_N-NTD; 1.
DR   HAMAP; MF_04096; BETA_CORONA_NCAP; 1.
DR   InterPro; IPR044344; N_prot_C_CoV.
DR   InterPro; IPR044345; N_prot_N_CoV.
DR   InterPro; IPR043505; NCAP_bCoV.
DR   InterPro; IPR001218; Nucleocap_CoV.
DR   InterPro; IPR037179; Nucleocapsid_C.
DR   InterPro; IPR037195; Nucleocapsid_N.
DR   Pfam; PF00937; CoV_nucleocap; 1.
DR   PIRSF; PIRSF003888; Corona_nucleocap; 1.
DR   SUPFAM; SSF110304; Coronavirus RNA-binding domain; 1.
DR   SUPFAM; SSF103068; Nucleocapsid protein dimerization domain; 1.
DR   PROSITE; PS51929; COV_N_CTD; 1.
DR   PROSITE; PS51928; COV_N_NTD; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Host cytoplasm; Phosphoprotein;
KW   Reference proteome; Ribonucleoprotein; RNA-binding; Secreted;
KW   Transcription; Transcription regulation; Viral nucleoprotein; Virion.
FT   CHAIN           1..419
FT                   /note=""Nucleoprotein""
FT                   /id=""PRO_0000449656""
FT   DOMAIN          48..174
FT                   /note=""CoV N NTD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01276,
FT                   ECO:0000269|PubMed:32363136""
FT   DOMAIN          247..364
FT                   /note=""CoV N CTD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01277""
FT   REGION          1..51
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          41..186
FT                   /note=""RNA-binding""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   REGION          63..83
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          168..212
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          176..206
FT                   /note=""SR region""
FT                   /evidence=""ECO:0000305|PubMed:32974389""
FT   REGION          233..266
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          258..361
FT                   /note=""Dimerization""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   REGION          260..340
FT                   /note=""Putative NLRP3 binding""
FT                   /evidence=""ECO:0000269|PubMed:34341353""
FT   REGION          361..391
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          400..419
FT                   /note=""Tetramerization""
FT                   /evidence=""ECO:0000269|PubMed:32654247""
FT   MOTIF           256..264
FT                   /note=""Nuclear localization signal""
FT                   /evidence=""ECO:0000250|UniProtKB:P59595""
FT   COMPBIAS        1..11
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        21..31
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        367..378
FT                   /note=""Basic and acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   BINDING         92
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   BINDING         107
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   BINDING         149
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   SITE            399..402
FT                   /note=""Cleavage (by host CASP6)""
FT                   /evidence=""ECO:0000250|UniProtKB:P59595""
FT   MOD_RES         176
FT                   /note=""Phosphoserine; by host""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   MOD_RES         206
FT                   /note=""Phosphoserine; by host GSK3-alpha and GSK3-beta""
FT                   /evidence=""ECO:0000269|PubMed:34593624""
FT   VARIANT         2..3
FT                   /note=""SD -> Y (in strain: Eta/B.1.525)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         3
FT                   /note=""D -> L (in strain: Alpha/B.1.1.7)""
FT                   /evidence=""ECO:0000305|PubMed:33413740""
FT   VARIANT         12
FT                   /note=""A -> G (in strain: Eta/B.1.525)""
FT   VARIANT         13
FT                   /note=""P -> L (in strain: Lambda/C.37, Omicron/BA.1,
FT                   Omicron/BA.2, Omicron/BA.2.12.1, Omicron/BA.2.75,
FT                   Omicron/BA.4, Omicron/BA.5, Omicron/BQ.1.1,
FT                   Omicron/XBB.1.5, Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         31..33
FT                   /note=""Missing (in strain: Omicron/BA.1, Omicron/BA.2,
FT                   Omicron/BA.2.12.1, Omicron/BA.2.75, Omicron/BA.4,
FT                   Omicron/BA.5, Omicron/BQ.1.1, Omicron/XBB.1.5,
FT                   Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         63
FT                   /note=""D -> G (in strain: Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT  ",32908
GGACTG GACTGA ACTGAA CTGAAA TGAAAC GAAACA AAACAA AACAAG ACAAGT CAAGTA AAGTAT AGTATC GTATCT TATCTG ATCTGA TCTGAT CTGATG TGATGA GATGAT ATGATG TGATGG GATGGT ATGGTG TGGTGC GGTGCT GTGCTT TGCTTT GCTTTA CTTTAT TTTATT TTATTA TATTAG ATTAGC TTAGCT TAGCTA AGCTAT GCTATT CTATTA TATTAT ATTATT TTATTG TATTGA ATTGAT TTGATG TGATGC GATGCT ATGCTA TGCTAT GCTATT CTATTT TATTTT ATTTTA TTTTAG TTTAGC TTAGCT TAGCTG AGCTGC GCTGCA CTGCAA TGCAAA GCAAAT CAAATG AAATGA AATGAA ATGAAG TGAAGA GAAGAT AAGATA AGATAA GATAAA ATAAAG TAAAGT AAAGTA AAGTAA AGTAAC GTAACA TAACAG AACAGA ACAGAA CAGAAT AGAATA GAATAT AATATA ATATAA TATAAA ATAAAT TAAATC AAATCA AATCAG ATCAGG TCAGGT CAGGTA AGGTAA GGTAAA GTAAAG TAAAGA AAAGAT,3,97,GGAAGTAC C G GAGACTAGCT T A ACTG G CA TCTGTGA GC TGTGAGAAAA A G GAAGCTGGAA A A AAAAA ATACAC A AAAAGACATGCA A ACACACAAA C CACAAAAGAG G A AAAGTT A AGGACGTATA A G GTGTATATAT AG TATATCGAT ATATCCT  TCTCTCTGG CGAATGAA T TGTGAGATAT T G GAGATATGTG  AG ATATGGA A T TGTGAGATAT  GAGATATGTG G AAACATGAGGGG G T TGATAA TGT T G GGGGTTG T A GTGTGCA GC C T TG TAGCTCT  ATGA  TGCTTGTA CTCTTTTTTT  TTTATTTATA A T TTTTATATAT T T TATATATTTT  AT ATATTTTATA GGT TTTTATAGG T TAACTAGCC A AGAGCGCTCT T GAACGCTG ATA A C CTAT T T TATATATTTT T A ATATTTTATA  TTG ATATT AT T TATTTATTTT G GT GATTT ATG G T TTTTGTGAGA A T TGTGAC AAT T G GAGATATGTG G AGC ATGTGCGC C TGCTTGC AGCT  GA GCGCTCTATA A C CTCTATATAT T TTGCTATATTTT G CT AATTTTTTT T T TTTTTTTT GGT TAGATTTTAATA A T TTTAGAG  TATAGCTG ATC A AGAGCGCTCT T G GCGCTCTGTG T A CTCTGTGCGC C T TGGCACA A G GCGCACAAAA A C CACAAAAAAA A A AAAAAAATT A AAAATATGTG G A ATATGTGAGA A T TGAAATTAAA A GT G CAG A AAAAGGA A A AGAGAGATAAAT G GAGATATATA A A AT TATAAAA A T TATAAAAAA A AAAAAAAGAG G A AAAAGAGTGT ATAAGTGTATA A GGTATAAAA  CTTAAAACAC C A AA GCACACA A A TAAC CAGT TGAACAGGA A AGT  TTGAAA G GAGAAAATAT T A AAAATATATA A A ATATATATAT T T TATATATATA A A AT AGTAAAA A T TAAAAAA A A AATGAAATAT AT  AAAATATCTC  ATTCACA A TTCACAGAG G C CACAGAAAGG GCTAGGGGTGT T GTT GGTT CTA A G GTA AAA A T ACAAAA AAT AAGAG AAG AAAAGAGAGA GTA AGAGAGAT,GGAGACCT T G GAGACACTCTGTG G AACTTTGTGAGA A CATTCTGGAAAA A T TG TAA GCTTAA A G GAGAAAC C A AAAAAAACACACA A A AACAGACA TAGA  ACAAACAAAG G C CACAAAAGAGAGT T A AAAAGAGTTA A A AGG AGTATATAT AAC GTGTATATATCC T TATATATCGTACT T A ATATCCA CTGTG TCTCTGTGAGA A C CTCTGTGAGATAT T T TGTTGTG ATGTG G G GAGATATGTGAGA A A ATATGTGAGATCTTT T TGTGAGATATGTG G G GAGAT TGTGGGG G A ATATGGGTGT  AG TGTGGGGTGTGG G GGGGTGTGTGCGC TAGA GAT GCTCT T T TGTGCGCTAT TT T GATCGCTCTTACATT T C CTAAATTTTA TA TAA TTTTTTTATATGTGT T TTTTATATATTTT GATCTGTAT AATTATA  ATTA TTATTAAG  TTTTATAGAGCTCTC T TATAGAGCGCTCT  AA AGAGCGCTCTATA ATT GCGCTCTAAT T CT ATTAATTTT T TTGATAT CTTTATA A A ATATTTATTATAT T T TTTTATATTCAAT  TA AGATTCAATG G AATTTGAGA A T TTTGATGAGATAT T TC CTGAGATATGTG G GGATATGTGCGC C A ATATGGCTT TATGTGCGCTAAGAGGGAA GCAATCTATAT TAT C CTCTATATATTTT AGAAT ATTCAATT T A ATATTTTTTTTTT T T TTTTTA GA T TTTTTTTATAGAG G T TTTTATAGAGCGC TGGAGCGCTCT T AAGCGCTCTGG G GCGCTCTGTGCGC  TG CTCTGGCACA A T TGTGCAA A G GCCAAAAAAA AAC CAC TAAAAATT A AAAAAAATATGTG G AATTTATATGTGACTAA A ATATGTGAAA A T TGTGAGAAAAGAG G G GAGAAAAGAGAGA A AT AAAGAGAGATAT T A AGAGAGATATATA A G GAT TATATAAAA TAA ATATATAAAAAA T TA AAAAAAAGAG G A AAAAAAAG GCT A AAAAGAGTC TTA A AT TAGTGTATAAAA  GTGTATAAAACAC  TATAAAACACAGC A AT GACACAGAG G ATTTCAGT TA C CACAGAGAGAAAA A ATATAGTGAAAT T G GAGAAATATA A A AAAATATATATT TT A ATATAATAA T TATATATATAA ATATAAA A T TATAAAAATGCT AACAAATAAATC C AAATATCTCACA A A ATTCACAGAG  TCTT AGGGG G C CACAGTTAGGTGT G T AGAGGGTATA A GA AAA  GT GTGTATAAAAAA T TATAAAAAA AAGTAAAAGAGA A A AAAAGAGAGAT,GGAGACACTCTGAGAGACACTCTGTGAGA A A ACACTCTGC GGAAAA A CCAACTGTGATAAAAAAA A T TGTGATC AAAC G GAGAAAACACA ATA A AAGTAAACACACAAAA A A AAAACACATG AG CA  ACACA CTAAGGAATATAAGAGTGTAA A AAGCAAGTGTATATTATT A AGAGTTATATCT C GTGTATATGAATCTCT T T TATATATCTCTCTGTG G A ATATC TACTGTGCGA A T TCTCTCTGTGAGATAT T CCTGTGAGATATGTG G T TGTGAGATATGATAGA A GCTAGATATGTGAAAGAT T ACA ATGTGAGATATGAAGG T TGTGAATGTGGGG G G GAGATATGGGTGT  ATTGGGGTGTGTG  TGGGTGTGC GGGTGTGTGCGCTCT T G GT GATGCGCTCTTTT T T TGTGCAGACTTAC TT T G GCGCTCTTTTTTTATA A C CTCTT AATTATATAT T T TTTTTTTATATATTTT T TA AGC ATGATTTTAA T TAGCTATT ATTAGAG G A ATATTTTA TAAGCGC C TTGCTTATAGAGCGCTCT T TTCTTAGAGCGG CTATA T AAGCGCT GA TGAATGCT ATATT CTCTATATATTTGATA A T TATATTTACTG CT ATATTTTATATATTTT CAG TTTTAATTCAA AG TATATATTTTGTGAG AA A AAATTTTGTGAGATAT T T TTTTGTGAGATATGTG T GTGAGATATG TTGC C G GAGATATGTGATTACT T A ATATGTGCGCTCTATA A T TGTGCGCTCTATATAT T G GCATGTATATTTT GAA CTCTATATTT T T TATATATTTTTTTTTT T A ATATTTTTTTTTTATA A ATTTTTTTTAAG G T TTTTTGCTTAGAGCTTAC TAGATTAAGGAGCGCT TATAGAGCGCTCTGTAT AGAGCGCTCTGTGCGC AAG GCAT TATTGCGCACA A CT ACTGTGCGCAATAAA A T TGTGAAAGCAAAAAAA A G GCGCATTGAAAAT T C CAAAAAATATGTG  AAAAAAATACATTAGA  TT AAAATTATTGCAA A A ATATGTGAGAAAG G T TGTGAGAAGATAGAGA T C GAATAAAGAGAGATAT  AG AAAAGAGAGATCAATA A AAGAC GATATAAAA A GG TGATATATAAAAAAA A ATATTGATAAAAAAAGAG  GA TATAAAAAAAGAGTT AAAAAAGAGTGTATA A ATTTAAGAGTGTAAA A AAGTAAAGCTAACTTTAATGTATAAACAA T TATAAAACGA CAGAG G A AAAACACAAAACAAA A ACACACAGAGAGAAAA A C CACAGAGAGAAAT ATCG TAGAGAAAATGA TA A GGTG GCATACT AT T A AAAATTATTA A ATTAA GTATATATAAAA A T TAAT ATATAAAAAAA A A ATATATAAAAAAATAT T TTAGGATATCTC C AAAAAATATCTCAA A AAAATATCCAGAG G A ATT ATCACAGTAGGCTG T TCTCAT TAGGGGTGT T C CACAGGGTGAATA  AGAGGGGTGTATAAAA  GGGGTGTATAAAAAAA A G GTGTATAATG AG G T TATAAAAAC G TTGA A A AAAAAGCTGAT,GGAGACACTCTGTCTGA A GGACGATCTGTGAGAAAA A A ACACTGCTTGAATT TGAA A CCAACTGTGAGAAAAAAACAC  TGTGAGAAAACACACA AAA GAGAAAACACACAATA A A AAAACACAATTG A AAAACACACAAAAGAGTGT T A ATACA CTAAGGATGTATA A CCT CAAAAGAGTGTAAAAAT T A AAAAGAGT TGATCGT TCT AAGTATATATCTCTCT T G GTGTATATATCTCTACTTTAG TATGTATATCT GCTGTGAGA A ACTATGACTGAT T T TCC ACTGTGAGATATGGGTG C CTATTTGAGATATGGTGGA A TAG TGAGATTGAGATAT  GAATGTGAGATATGTG G A AT AGTGAGATATGTGGTATATA TGATGTAAATGTGGGT T GT GGATATGTGGGGTGTGTG G A AT TAAG GGTGTGTGCGC C TTGGGGTGTGGCT CAT G GGGGTGTGTGCGCTCTTTT T G GTTT GTAGCTCTTTTTTT T T TGAGCGCTCTTTTTTTATA TGC GCGCTCTTTTTTTATATAT  CTCTTTTTTATTGAT T TTTTTTTATATAT TA A T TTTTAATTTTATAGTGGG TT GTATGAATTATAGAGCGC C A ATATTTTATTGTGCGCTCT T T TTTAGAGCCTATA A TTAGAGCTAACTATATAT T A AGAGCTCTGG ATTAAATGA GCGCTCTATGAATTTTATA A C CTAAATATAG TTATATAT T T TATATTTATATTT ATA ATATTTATAATATTTTGG TTTATATATTTAGTGAGA A T TATATATTTTGTGAGATAT T A ATATTTTGGATATGTG G T TGTTGGATATGTGCGC  TGTGAGATATGTGCAAACT T G GAGATTATTGCCTGCTAAA A A ATATGTGCCTACTATATAT T T TGTGCGCTCTATATATTTT  TAAGAGCTGCTTATTAGATATT  CTCTATATATTTTTTTTTT T T TATATATTTTTTTATA A AATTCAGTTTTTATTATAGATTG T TTAATTTATAGAGCGC  TTTTTTTA GTAGCGCTCT T T TTTTATAGAGCGCTCTGTG G T TACTGGCTCTGTGCGC C A AGAGCGTACTGCA A G GCGCTTGC ATCAAAA A C CTCTGGCAAAAA TAACTGCGCACAAAAAAATAGAT G GCAGTCAAAATATGTG G C CACAAAAAAATATGTGAGA A AAGTAAAGATATGTGAAG AA A A AAAATTGAGAAAAGTAA ATATGTGAAAGAGAGA A TAAATGAGAAAAGAT GATAT GAAAAGAGAGCAATATA A A AAAAGAGAGATG TTAAAA A A AGGATATATAAAAAAA A G GAGATT ATAACTAAAGAG G A ATATATAAA GAAGAGTTC T T TATAAAAAAAGAGTGCTTA A A AATT AAGAGTTAAAA A A AAAGTA GTAAAACAC C A AGAGTGTAGCTAAC TACA A GTAGGTATAAAACACAAG G T GATAATATACACAGAGAGA A A AAAACACACAG GCGAAAA  ACACACAGAGAAGGAATTTTT C CACAGAGAGAATTTATATA A A AGAGAGAAAATATATATAT GGT GAGAAAATATATATATAA A AATATATATATATATAAAA A A ATATATATTTTTAAAA A TTTAATAAGGAAGAATAT T A ATATAGAATATATCTC C T TATAAAAAAATATCTCACA A A AAAAAAATTCACAGAG G A AAAATTCACAGGAAGG G AGATATCATTAGGGGTGT T T TCCAGAGGTG GTATA A C CACAGTAAGGTGTAAA A A AGAGGGGTGTAG GGCTAA A G GGGGTGTATAAAAAAAGAG AAT GTGTATAAAAAAAGAGAGA A T TATAAAAAAGAGCA,"ID   GATB_CAMFF              Reviewed;         472 AA.
AC   A0RP16;
DT   15-JAN-2008, integrated into UniProtKB/Swiss-Prot.
DT   09-JAN-2007, sequence version 1.
DT   27-NOV-2024, entry version 92.
DE   RecName: Full=Aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase subunit B {ECO:0000255|HAMAP-Rule:MF_00121};
DE            Short=Asp/Glu-ADT subunit B {ECO:0000255|HAMAP-Rule:MF_00121};
DE            EC=6.3.5.- {ECO:0000255|HAMAP-Rule:MF_00121};
GN   Name=gatB {ECO:0000255|HAMAP-Rule:MF_00121};
GN   OrderedLocusNames=CFF8240_0774;
OS   Campylobacter fetus subsp. fetus (strain 82-40).
OC   Bacteria; Campylobacterota; Epsilonproteobacteria; Campylobacterales;
OC   Campylobacteraceae; Campylobacter.
OX   NCBI_TaxID=360106;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=82-40;
RA   Fouts D.E., Nelson K.E.;
RT   ""Sequence of Campylobacter fetus subsp. fetus 82-40."";
RL   Submitted (NOV-2006) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Allows the formation of correctly charged Asn-tRNA(Asn) or
CC       Gln-tRNA(Gln) through the transamidation of misacylated Asp-tRNA(Asn)
CC       or Glu-tRNA(Gln) in organisms which lack either or both of asparaginyl-
CC       tRNA or glutaminyl-tRNA synthetases. The reaction takes place in the
CC       presence of glutamine and ATP through an activated phospho-Asp-
CC       tRNA(Asn) or phospho-Glu-tRNA(Gln). {ECO:0000255|HAMAP-Rule:MF_00121}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-glutamyl-tRNA(Gln) + L-glutamine + ATP + H2O = L-glutaminyl-
CC         tRNA(Gln) + L-glutamate + ADP + phosphate + H(+);
CC         Xref=Rhea:RHEA:17521, Rhea:RHEA-COMP:9681, Rhea:RHEA-COMP:9684,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:29985,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:43474, ChEBI:CHEBI:58359,
CC         ChEBI:CHEBI:78520, ChEBI:CHEBI:78521, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_00121};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-aspartyl-tRNA(Asn) + L-glutamine + ATP + H2O = L-
CC         asparaginyl-tRNA(Asn) + L-glutamate + ADP + phosphate + 2 H(+);
CC         Xref=Rhea:RHEA:14513, Rhea:RHEA-COMP:9674, Rhea:RHEA-COMP:9677,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:29985,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:43474, ChEBI:CHEBI:58359,
CC         ChEBI:CHEBI:78515, ChEBI:CHEBI:78516, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_00121};
CC   -!- SUBUNIT: Heterotrimer of A, B and C subunits. {ECO:0000255|HAMAP-
CC       Rule:MF_00121}.
CC   -!- SIMILARITY: Belongs to the GatB/GatE family. GatB subfamily.
CC       {ECO:0000255|HAMAP-Rule:MF_00121}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP000487; ABK83185.1; -; Genomic_DNA.
DR   RefSeq; WP_011731949.1; NC_008599.1.
DR   AlphaFoldDB; A0RP16; -.
DR   SMR; A0RP16; -.
DR   GeneID; 61064612; -.
DR   KEGG; cff:CFF8240_0774; -.
DR   eggNOG; COG0064; Bacteria.
DR   HOGENOM; CLU_019240_0_0_7; -.
DR   Proteomes; UP000000760; Chromosome.
DR   GO; GO:0050566; F:asparaginyl-tRNA synthase (glutamine-hydrolyzing) activity; IEA:RHEA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0050567; F:glutaminyl-tRNA synthase (glutamine-hydrolyzing) activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0070681; P:glutaminyl-tRNAGln biosynthesis via transamidation; IEA:TreeGrafter.
DR   GO; GO:0006412; P:translation; IEA:UniProtKB-UniRule.
DR   FunFam; 1.10.10.410:FF:000001; Aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase subunit B; 1.
DR   Gene3D; 1.10.10.410; -; 1.
DR   Gene3D; 1.10.150.380; GatB domain, N-terminal subdomain; 1.
DR   HAMAP; MF_00121; GatB; 1.
DR   InterPro; IPR017959; Asn/Gln-tRNA_amidoTrfase_suB/E.
DR   InterPro; IPR006075; Asn/Gln-tRNA_Trfase_suB/E_cat.
DR   InterPro; IPR018027; Asn/Gln_amidotransferase.
DR   InterPro; IPR003789; Asn/Gln_tRNA_amidoTrase-B-like.
DR   InterPro; IPR004413; GatB.
DR   InterPro; IPR042114; GatB_C_1.
DR   InterPro; IPR023168; GatB_Yqey_C_2.
DR   InterPro; IPR017958; Gln-tRNA_amidoTrfase_suB_CS.
DR   InterPro; IPR014746; Gln_synth/guanido_kin_cat_dom.
DR   NCBIfam; TIGR00133; gatB; 1.
DR   PANTHER; PTHR11659; GLUTAMYL-TRNA GLN AMIDOTRANSFERASE SUBUNIT B MITOCHONDRIAL AND PROKARYOTIC PET112-RELATED; 1.
DR   PANTHER; PTHR11659:SF0; GLUTAMYL-TRNA(GLN) AMIDOTRANSFERASE SUBUNIT B, MITOCHONDRIAL; 1.
DR   Pfam; PF02934; GatB_N; 1.
DR   Pfam; PF02637; GatB_Yqey; 1.
DR   SMART; SM00845; GatB_Yqey; 1.
DR   SUPFAM; SSF89095; GatB/YqeY motif; 1.
DR   SUPFAM; SSF55931; Glutamine synthetase/guanido kinase; 1.
DR   PROSITE; PS01234; GATB; 1.
PE   3: Inferred from homology;
KW   ATP-binding; Ligase; Nucleotide-binding; Protein biosynthesis.
FT   CHAIN           1..472
FT                   /note=""Aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase
FT                   subunit B""
FT                   /id=""PRO_1000015952""
SQ   SEQUENCE   472 AA;  53075 MW;  72E1DA6A3075AD9E CRC64;
     MFETVIGLEV HCQLNTKTKI FCSCSTSFGD EPNTHVCPTC LALPGALPVL NKEAVKKAIS
     FGKAINATVN KKSVFDRKNY FYPDLPKAYQ ISQFTIPIVE KGELFIKVGG EIKRIGITRA
     HLEEDAGKNN HETNKSLVDL NRAGTPLLEI VSEPDLRNSD EAVAYLKKLH SILRFLNISD
     ANMQEGSFRC DVNVSIRPKG DEKLYTRVEI KNLNSFKFIQ KAIEYEVERQ ILSWEDGKYD
     EEVYQETRLF DTNKLVTKSM RSKEDSAEYR YFPDPDLLPV IIPDKMMEEA SVLPELPDEK
     KARYVKDLGI KESDAEVIIS SYEMARYFED LIEAKNSPKL AVTWLCVELL GRLKNGVTIE
     TSPVDSKKLS NLINRIEDGT ISQKAAKDVL DYVMEHDEDV SSVIEKLGLK QVSDDSAILA
     IIDSVLSANS DKVAEFKSGK DKLFGFFVGQ VMKEGKGAFN PSKVNDLLKS KL
//
",31610
CGTGTA GTGTAC TGTACG GTACGC TACGCC ACGCCA CGCCAA GCCAAG CCAAGC CAAGCT AAGCTT AGCTTT GCTTTG CTTTGT TTTGTT TTGTTA TGTTAA GTTAAA TTAAAA TAAAAA AAAAAC AAAACA AAACAG AACAGT ACAGTA CAGTAC AGTACA GTACAA TACAAT ACAATT CAATTC AATTCT ATTCTG TTCTGT TCTGTG CTGTGA TGTGAT GTGATG TGATGC GATGCC ATGCCA TGCCAT GCCATG CCATGC CATGCG ATGCGA TGCGAA GCGAAA CGAAAT GAAATG AAATGC AATGCT ATGCTG TGCTGG GCTGGT CTGGTA TGGTAT GGTATT GTATTG TATTGT ATTGTT TTGTTG TGTTGG GTTGGT TTGGTG TGGTGT GGTGTA,0,67,CGTG GTGT TGTA GTAC TACG ACGC CGCC GCCA CCAA CAAG AAGC AGCT GCTT CTTT TTTG TTGT TGTT GTTA TTAA TAAA AAAA AAAA AAAC AACA ACAG CAGT AGTA GTAC TACA ACAA CAAT AATT ATTC TTCT TCTG CTGT TGTG GTGA TGAT GATG ATGC TGCC GCCA CCAT CATG ATGC TGCG GCGA CGAA GAAA AAAT AATG ATGC TGCT GCTG CTGG TGGT GGTA GTAT TATT ATTG TTGT TGTT GTTG TTGG TGGT GGTG GTGT TGTA,CGTGT GTGTA TGTAC GTACG TACGC ACGCC CGCCA GCCAA CCAAG CAAGC AAGCT AGCTT GCTTT CTTTG TTTGT TTGTT TGTTA GTTAA TTAAA TAAAA AAAAA AAAAC AAACA AACAG ACAGT CAGTA AGTAC GTACA TACAA ACAAT CAATT AATTC ATTCT TTCTG TCTGT CTGTG TGTGA GTGAT TGATG GATGC ATGCC TGCCA GCCAT CCATG CATGC ATGCG TGCGA GCGAA CGAAA GAAAT AAATG AATGC ATGCT TGCTG GCTGG CTGGT TGGTA GGTAT GTATT TATTG ATTGT TTGTT TGTTG GTTGG TTGGT TGGTG GGTGT GTGTA,CGTGTA GTGTAC TGTACG GTACGC TACGCC ACGCCA CGCCAA GCCAAG CCAAGC CAAGCT AAGCTT AGCTTT GCTTTG CTTTGT TTTGTT TTGTTA TGTTAA GTTAAA TTAAAA TAAAAA AAAAAC AAAACA AAACAG AACAGT ACAGTA CAGTAC AGTACA GTACAA TACAAT ACAATT CAATTC AATTCT ATTCTG TTCTGT TCTGTG CTGTGA TGTGAT GTGATG TGATGC GATGCC ATGCCA TGCCAT GCCATG CCATGC CATGCG ATGCGA TGCGAA GCGAAA CGAAAT GAAATG AAATGC AATGCT ATGCTG TGCTGG GCTGGT CTGGTA TGGTAT GGTATT GTATTG TATTGT ATTGTT TTGTTG TGTTGG GTTGGT TTGGTG TGGTGT GGTGTA,CGTGTAC GTGTACG TGTACGC GTACGCC TACGCCA ACGCCAA CGCCAAG GCCAAGC CCAAGCT CAAGCTT AAGCTTT AGCTTTG GCTTTGT CTTTGTT TTTGTTA TTGTTAA TGTTAAA GTTAAAA TTAAAAA TAAAAAC AAAAACA AAAACAG AAACAGT AACAGTA ACAGTAC CAGTACA AGTACAA GTACAAT TACAATT ACAATTC CAATTCT AATTCTG ATTCTGT TTCTGTG TCTGTGA CTGTGAT TGTGATG GTGATGC TGATGCC GATGCCA ATGCCAT TGCCATG GCCATGC CCATGCG CATGCGA ATGCGAA TGCGAAA GCGAAAT CGAAATG GAAATGC AAATGCT AATGCTG ATGCTGG TGCTGGT GCTGGTA CTGGTAT TGGTATT GGTATTG GTATTGT TATTGTT ATTGTTG TTGTTGG TGTTGGT GTTGGTG TTGGTGT TGGTGTA,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",36602
CACCTT ACCTTG CCTTGT CTTGTC TTGTCT TGTCTC GTCTCT TCTCTG CTCTGC TCTGCT CTGCTA TGCTAC GCTACC CTACCA TACCAA ACCAAT CCAATG CAATGG AATGGT ATGGTA TGGTAC GGTACT GTACTA TACTAC ACTACG CTACGA TACGAT ACGATG CGATGT GATGTT ATGTTT TGTTTG GTTTGA TTTGAG TTGAGA TGAGAA GAGAAC AGAACC GAACCC AACCCT ACCCTG CCCTGC CCTGCC CTGCCC TGCCCT GCCCTA CCCTAC CCTACC CTACCA TACCAT ACCATT CCATTT CATTTA ATTTAA TTTAAT TTAATG TAATGA AATGAT ATGATG TGATGT GATGTC ATGTCG TGTCGT GTCGTT TCGTTT CGTTTA GTTTAT TTTATT TTATTT TATTTT ATTTTG TTTTGC TTTGCT TTGCTT TGCTTC GCTTCC CTTCCA TTCCAC TCCACT CCACTG CACTGG ACTGGG CTGGGA TGGGAA GGGAAG GGAAGT GAAGTC AAGTCT AGTCTA GTCTAA TCTAAC CTAACA TAACAT AACATA ACATAA CATAAT ATAATA TAATAA AATAAG ATAAGA TAAGAG AAGAGG AGAGGC GAGGCT AGGCTG GGCTGT GCTGTA CTGTAT TGTATT GTATTT TATTTT ATTTTT TTTTTG TTTTGG TTTGGT TTGGTA TGGTAG GGTAGT GTAGTA TAGTAC AGTACT GTACTT TACTTT ACTTTA CTTTAG TTTAGA TTAGAA TAGAAT AGAATC GAATCG AATCGA ATCGAA TCGAAG CGAAGA GAAGAC AAGACC AGACCC GACCCA ACCCAG CCCAGT CCAGTC CAGTCC AGTCCC GTCCCT TCCCTA,1,145,CACC ACCT CCTT CTTG TTGT TGTC GTCT TCTC CTCT TCTG CTGC TGCT GCTA CTAC TACC ACCA CCAA CAAT AATG ATGG TGGT GGTA GTAC TACT ACTA CTAC TACG ACGA CGAT GATG ATGT TGTT GTTT TTTG TTGA TGAG GAGA AGAA GAAC AACC ACCC CCCT CCTG CTGC TGCC GCCC CCCT CCTA CTAC TACC ACCA CCAT CATT ATTT TTTA TTAA TAAT AATG ATGA TGAT GATG ATGT TGTC GTCG TCGT CGTT GTTT TTTA TTAT TATT ATTT TTTT TTTG TTGC TGCT GCTT CTTC TTCC TCCA CCAC CACT ACTG CTGG TGGG GGGA GGAA GAAG AAGT AGTC GTCT TCTA CTAA TAAC AACA ACAT CATA ATAA TAAT AATA ATAA TAAG AAGA AGAG GAGG AGGC GGCT GCTG CTGT TGTA GTAT TATT ATTT TTTT TTTT TTTG TTGG TGGT GGTA GTAG TAGT AGTA GTAC TACT ACTT CTTT TTTA TTAG TAGA AGAA GAAT AATC ATCG TCGA CGAA GAAG AAGA AGAC GACC ACCC CCCA CCAG CAGT AGTC GTCC TCCC CCCT CCTA,CACCT ACCTT CCTTG CTTGT TTGTC TGTCT GTCTC TCTCT CTCTG TCTGC CTGCT TGCTA GCTAC CTACC TACCA ACCAA CCAAT CAATG AATGG ATGGT TGGTA GGTAC GTACT TACTA ACTAC CTACG TACGA ACGAT CGATG GATGT ATGTT TGTTT GTTTG TTTGA TTGAG TGAGA GAGAA AGAAC GAACC AACCC ACCCT CCCTG CCTGC CTGCC TGCCC GCCCT CCCTA CCTAC CTACC TACCA ACCAT CCATT CATTT ATTTA TTTAA TTAAT TAATG AATGA ATGAT TGATG GATGT ATGTC TGTCG GTCGT TCGTT CGTTT GTTTA TTTAT TTATT TATTT ATTTT TTTTG TTTGC TTGCT TGCTT GCTTC CTTCC TTCCA TCCAC CCACT CACTG ACTGG CTGGG TGGGA GGGAA GGAAG GAAGT AAGTC AGTCT GTCTA TCTAA CTAAC TAACA AACAT ACATA CATAA ATAAT TAATA AATAA ATAAG TAAGA AAGAG AGAGG GAGGC AGGCT GGCTG GCTGT CTGTA TGTAT GTATT TATTT ATTTT TTTTT TTTTG TTTGG TTGGT TGGTA GGTAG GTAGT TAGTA AGTAC GTACT TACTT ACTTT CTTTA TTTAG TTAGA TAGAA AGAAT GAATC AATCG ATCGA TCGAA CGAAG GAAGA AAGAC AGACC GACCC ACCCA CCCAG CCAGT CAGTC AGTCC GTCCC TCCCT CCCTA,CACCTT ACCTTG CCTTGT CTTGTC TTGTCT TGTCTC GTCTCT TCTCTG CTCTGC TCTGCT CTGCTA TGCTAC GCTACC CTACCA TACCAA ACCAAT CCAATG CAATGG AATGGT ATGGTA TGGTAC GGTACT GTACTA TACTAC ACTACG CTACGA TACGAT ACGATG CGATGT GATGTT ATGTTT TGTTTG GTTTGA TTTGAG TTGAGA TGAGAA GAGAAC AGAACC GAACCC AACCCT ACCCTG CCCTGC CCTGCC CTGCCC TGCCCT GCCCTA CCCTAC CCTACC CTACCA TACCAT ACCATT CCATTT CATTTA ATTTAA TTTAAT TTAATG TAATGA AATGAT ATGATG TGATGT GATGTC ATGTCG TGTCGT GTCGTT TCGTTT CGTTTA GTTTAT TTTATT TTATTT TATTTT ATTTTG TTTTGC TTTGCT TTGCTT TGCTTC GCTTCC CTTCCA TTCCAC TCCACT CCACTG CACTGG ACTGGG CTGGGA TGGGAA GGGAAG GGAAGT GAAGTC AAGTCT AGTCTA GTCTAA TCTAAC CTAACA TAACAT AACATA ACATAA CATAAT ATAATA TAATAA AATAAG ATAAGA TAAGAG AAGAGG AGAGGC GAGGCT AGGCTG GGCTGT GCTGTA CTGTAT TGTATT GTATTT TATTTT ATTTTT TTTTTG TTTTGG TTTGGT TTGGTA TGGTAG GGTAGT GTAGTA TAGTAC AGTACT GTACTT TACTTT ACTTTA CTTTAG TTTAGA TTAGAA TAGAAT AGAATC GAATCG AATCGA ATCGAA TCGAAG CGAAGA GAAGAC AAGACC AGACCC GACCCA ACCCAG CCCAGT CCAGTC CAGTCC AGTCCC GTCCCT TCCCTA,CACCTTG ACCTTGT CCTTGTC CTTGTCT TTGTCTC TGTCTCT GTCTCTG TCTCTGC CTCTGCT TCTGCTA CTGCTAC TGCTACC GCTACCA CTACCAA TACCAAT ACCAATG CCAATGG CAATGGT AATGGTA ATGGTAC TGGTACT GGTACTA GTACTAC TACTACG ACTACGA CTACGAT TACGATG ACGATGT CGATGTT GATGTTT ATGTTTG TGTTTGA GTTTGAG TTTGAGA TTGAGAA TGAGAAC GAGAACC AGAACCC GAACCCT AACCCTG ACCCTGC CCCTGCC CCTGCCC CTGCCCT TGCCCTA GCCCTAC CCCTACC CCTACCA CTACCAT TACCATT ACCATTT CCATTTA CATTTAA ATTTAAT TTTAATG TTAATGA TAATGAT AATGATG ATGATGT TGATGTC GATGTCG ATGTCGT TGTCGTT GTCGTTT TCGTTTA CGTTTAT GTTTATT TTTATTT TTATTTT TATTTTG ATTTTGC TTTTGCT TTTGCTT TTGCTTC TGCTTCC GCTTCCA CTTCCAC TTCCACT TCCACTG CCACTGG CACTGGG ACTGGGA CTGGGAA TGGGAAG GGGAAGT GGAAGTC GAAGTCT AAGTCTA AGTCTAA GTCTAAC TCTAACA CTAACAT TAACATA AACATAA ACATAAT CATAATA ATAATAA TAATAAG AATAAGA ATAAGAG TAAGAGG AAGAGGC AGAGGCT GAGGCTG AGGCTGT GGCTGTA GCTGTAT CTGTATT TGTATTT GTATTTT TATTTTT ATTTTTG TTTTTGG TTTTGGT TTTGGTA TTGGTAG TGGTAGT GGTAGTA GTAGTAC TAGTACT AGTACTT GTACTTT TACTTTA ACTTTAG CTTTAGA TTTAGAA TTAGAAT TAGAATC AGAATCG GAATCGA AATCGAA ATCGAAG TCGAAGA CGAAGAC GAAGACC AAGACCC AGACCCA GACCCAG ACCCAGT CCCAGTC CCAGTCC CAGTCCC AGTCCCT GTCCCTA,"ID   SPIKE_SARS2             Reviewed;        1273 AA.
AC   P0DTC2;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Spike glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE            Short=S glycoprotein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=E2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   AltName: Full=Peplomer protein {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S1 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2 {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Contains:
DE     RecName: Full=Spike protein S2' {ECO:0000255|HAMAP-Rule:MF_04099};
DE   Flags: Precursor;
GN   Name=S {ECO:0000255|HAMAP-Rule:MF_04099}; ORFNames=2;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   FUNCTION (SPIKE PROTEIN S1), AND CLEAVAGE BETWEEN S2 AND S2' BY HOST
RP   TMPRSS2.
RX   PubMed=32142651; DOI=10.1016/j.cell.2020.02.052;
RA   Hoffmann M., Kleine-Weber H., Schroeder S., Krueger N., Herrler T.,
RA   Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A.,
RA   Mueller M.A., Drosten C., Poehlmann S.;
RT   ""SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a
RT   clinically proven protease inhibitor."";
RL   Cell 181:1-10(2020).
RN   [3]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, FUNCTION, AND MUTAGENESIS OF
RP   681-PRO--ALA-684.
RX   PubMed=32362314; DOI=10.1016/j.molcel.2020.04.022;
RA   Hoffmann M., Kleine-Weber H., Poehlmann S.;
RT   ""A multibasic cleavage site in the Spike protein of SARS-CoV-2 is essential
RT   for infection of human lung cells."";
RL   Mol. Cell 78:779-784(2020).
RN   [4]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=32366695; DOI=10.1126/science.abb9983;
RA   Watanabe Y., Allen J.D., Wrapp D., McLellan J.S., Crispin M.;
RT   ""Site-specific glycan analysis of the SARS-CoV-2 spike."";
RL   Science 369:330-333(2020).
RN   [5]
RP   GLYCOSYLATION AT ASN-61; ASN-74; ASN-122; ASN-149; ASN-165; ASN-234;
RP   ASN-282; THR-323; SER-325; ASN-331; ASN-343; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1194, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY.
RX   PubMed=32363391; DOI=10.1093/glycob/cwaa042;
RA   Shajahan A., Supekar N.T., Gleinich A.S., Azadi P.;
RT   ""Deducing the N- and O- glycosylation profile of the spike protein of novel
RT   coronavirus SARS-CoV-2."";
RL   Glycobiology 30:981-988(2020).
RN   [6]
RP   VARIANT GLY-614.
RX   PubMed=32820179; DOI=10.1038/s41598-020-70827-z;
RA   Isabel S., Grana-Miraglia L., Gutierrez J.M., Bundalovic-Torma C.,
RA   Groves H.E., Isabel M.R., Eshaghi A., Patel S.N., Gubbay J.B., Poutanen T.,
RA   Guttman D.S., Poutanen S.M.;
RT   ""Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein
RT   mutation now documented worldwide."";
RL   Sci. Rep. 10:14031-14031(2020).
RN   [7]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=32697968; DOI=10.1016/j.cell.2020.06.043;
RG   Sheffield COVID-19 Genomics Group;
RA   Korber B., Fischer W.M., Gnanakaran S., Yoon H., Theiler J., Abfalterer W.,
RA   Hengartner N., Giorgi E.E., Bhattacharya T., Foley B., Hastie K.M.,
RA   Parker M.D., Partridge D.G., Evans C.M., Freeman T.M., de Silva T.I.,
RA   McDanal C., Perez L.G., Tang H., Moon-Walker A., Whelan S.P.,
RA   LaBranche C.C., Saphire E.O., Montefiori D.C.;
RT   ""Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases
RT   Infectivity of the COVID-19 Virus."";
RL   Cell 182:812-827(2020).
RN   [8]
RP   FUNCTION.
RX   PubMed=32817270; DOI=10.1126/science.abd5223;
RA   Turonova B., Sikora M., Schuermann C., Hagen W.J.H., Welsch S.,
RA   Blanc F.E.C., von Buelow S., Gecht M., Bagola K., Hoerner C.,
RA   van Zandbergen G., Landry J., de Azevedo N.T.D., Mosalaganti S.,
RA   Schwarz A., Covino R., Muehlebach M.D., Hummer G., Krijnse Locker J.,
RA   Beck M.;
RT   ""In situ structural analysis of SARS-CoV-2 spike reveals flexibility
RT   mediated by three hinges."";
RL   Science 370:203-208(2020).
RN   [9]
RP   GLYCOSYLATION.
RX   PubMed=32929138; DOI=10.1038/s41598-020-71748-7;
RA   Grant O.C., Montgomery D., Ito K., Woods R.J.;
RT   ""Analysis of the SARS-CoV-2 spike protein glycan shield reveals
RT   implications for immune recognition."";
RL   Sci. Rep. 10:14991-14991(2020).
RN   [10]
RP   GLYCOSYLATION AT ASN-17; ASN-61; ASN-74; ASN-122; ASN-149; ASN-165;
RP   ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616; ASN-657; ASN-709;
RP   ASN-717; ASN-801; ASN-1074; ASN-1098; ASN-1134; ASN-1158; ASN-1173 AND
RP   ASN-1194, IDENTIFICATION BY MASS SPECTROMETRY, SUBCELLULAR LOCATION, AND
RP   SUBUNIT.
RX   PubMed=32979942; DOI=10.1016/j.cell.2020.09.018;
RA   Yao H., Song Y., Chen Y., Wu N., Xu J., Sun C., Zhang J., Weng T.,
RA   Zhang Z., Wu Z., Cheng L., Shi D., Lu X., Lei J., Crispin M., Shi Y.,
RA   Li L., Li S.;
RT   ""Molecular Architecture of the SARS-CoV-2 Virus."";
RL   Cell 183:730-738(2020).
RN   [11]
RP   VARIANT GLY-614, AND MUTAGENESIS OF ASP-614.
RX   PubMed=33106671; DOI=10.1038/s41586-020-2895-3;
RA   Plante J.A., Liu Y., Liu J., Xia H., Johnson B.A., Lokugamage K.G.,
RA   Zhang X., Muruato A.E., Zou J., Fontes-Garfias C.R., Mirchandani D.,
RA   Scharton D., Bilello J.P., Ku Z., An Z., Kalveram B., Freiberg A.N.,
RA   Menachery V.D., Xie X., Plante K.S., Weaver S.C., Shi P.Y.;
RT   ""Spike mutation D614G alters SARS-CoV-2 fitness."";
RL   Nature 592:116-121(2020).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Liverpool/REMRQ001/2020;
RX   PubMed=33082294; DOI=10.1126/science.abd3072;
RA   Daly J.L., Simonetti B., Klein K., Chen K.E., Williamson M.K.,
RA   Anton-Plagaro C., Shoemark D.K., Simon-Gracia L., Bauer M., Hollandi R.,
RA   Greber U.F., Horvath P., Sessions R.B., Helenius A., Hiscox J.A.,
RA   Teesalu T., Matthews D.A., Davidson A.D., Collins B.M., Cullen P.J.,
RA   Yamauchi Y.;
RT   ""Neuropilin-1 is a host factor for SARS-CoV-2 infection."";
RL   Science 370:861-865(2020).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH HUMAN NRP1 AND NRP2.
RC   STRAIN=SARS-CoV-2/human/Finland/1/2020;
RX   PubMed=33082293; DOI=10.1126/science.abd2985;
RA   Cantuti-Castelvetri L., Ojha R., Pedro L.D., Djannatian M., Franz J.,
RA   Kuivanen S., van der Meer F., Kallio K., Kaya T., Anastasina M., Smura T.,
RA   Levanov L., Szirovicza L., Tobi A., Kallio-Kokko H., Oesterlund P.,
RA   Joensuu M., Meunier F.A., Butcher S.J., Winkler M.S., Mollenhauer B.,
RA   Helenius A., Gokce O., Teesalu T., Hepojoki J., Vapalahti O.,
RA   Stadelmann C., Balistreri G., Simons M.;
RT   ""Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity."";
RL   Science 370:856-860(2020).
RN   [14]
RP   INTERACTION WITH HUMAN ITGA5 AND ITGB1.
RX   PubMed=33102950; DOI=10.1016/j.jacbts.2020.10.003;
RA   Beddingfield B.J., Iwanaga N., Chapagain P.P., Zheng W., Roy C.J., Hu T.Y.,
RA   Kolls J.K., Bix G.J.;
RT   ""The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2
RT   Infection."";
RL   JACC Basic Transl. Sci. 6:1-8(2021).
RN   [15]
RP   VARIANT GLY-614.
RX   PubMed=33184236; DOI=10.1126/science.abe8499;
RA   Hou Y.J., Chiba S., Halfmann P., Ehre C., Kuroda M., Dinnon K.H. III,
RA   Leist S.R., Schaefer A., Nakajima N., Takahashi K., Lee R.E.,
RA   Mascenik T.M., Graham R., Edwards C.E., Tse L.V., Okuda K., Markmann A.J.,
RA   Bartelt L., de Silva A., Margolis D.M., Boucher R.C., Randell S.H.,
RA   Suzuki T., Gralinski L.E., Kawaoka Y., Baric R.S.;
RT   ""SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and
RT   transmission in vivo."";
RL   Science 370:1464-1468(2020).
RN   [16]
RP   VARIANT GLY-614.
RX   PubMed=33417835; DOI=10.1016/j.celrep.2020.108630;
RA   Gobeil S.M., Janowska K., McDowell S., Mansouri K., Parks R., Manne K.,
RA   Stalls V., Kopp M.F., Henderson R., Edwards R.J., Haynes B.F., Acharya P.;
RT   ""D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease
RT   Cleavage at the S1/S2 Junction."";
RL   Cell Rep. 34:108630-108630(2021).
RN   [17]
RP   VARIANTS 69-VAL--PHE-70 DEL; LYS-144 DEL; TYR-501; ASP-570; GLY-614;
RP   HIS-681; ILE-716; ALA-982 AND HIS-1118.
RC   STRAIN=20I/501Y.V1, Alpha, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [18]
RP   VARIANT TYR-501.
RX   PubMed=32732280; DOI=10.1126/science.abc4730;
RA   Gu H., Chen Q., Yang G., He L., Fan H., Deng Y.Q., Wang Y., Teng Y.,
RA   Zhao Z., Cui Y., Li Y., Li X.F., Li J., Zhang N.N., Yang X., Chen S.,
RA   Guo Y., Zhao G., Wang X., Luo D.Y., Wang H., Yang X., Li Y., Han G., He Y.,
RA   Zhou X., Geng S., Sheng X., Jiang S., Sun S., Qin C.F., Zhou Y.;
RT   ""Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy."";
RL   Science 369:1603-1607(2020).
RN   [19]
RP   VARIANT GLY-614, AND MUTAGENESIS OF GLY-614.
RX   PubMed=33636719; DOI=10.1038/s41586-021-03361-1;
RA   Zhou B., Thi Nhu Thao T., Hoffmann D., Taddeo A., Ebert N., Labroussaa F.,
RA   Pohlmann A., King J., Steiner S., Kelly J.N., Portmann J., Halwe N.J.,
RA   Ulrich L., Trueeb B.S., Fan X., Hoffmann B., Wang L., Thomann L., Lin X.,
RA   Stalder H., Pozzi B., de Brot S., Jiang N., Cui D., Hossain J., Wilson M.,
RA   Keller M., Stark T.J., Barnes J.R., Dijkman R., Jores J., Benarafa C.,
RA   Wentworth D.E., Thiel V., Beer M.;
RT   ""SARS-CoV-2 spike D614G change enhances replication and transmission."";
RL   Nature 5920:122-127(2021).
RN   [20]
RP   MUTAGENESIS OF ASN-165; ASN-234; ASN-331; ASN-343; LEU-452; ALA-475;
RP   VAL-483; PHE-490 AND HIS-519.
RX   PubMed=32730807; DOI=10.1016/j.cell.2020.07.012;
RA   Li Q., Wu J., Nie J., Zhang L., Hao H., Liu S., Zhao C., Zhang Q., Liu H.,
RA   Nie L., Qin H., Wang M., Lu Q., Li X., Sun Q., Liu J., Zhang L., Li X.,
RA   Huang W., Wang Y.;
RT   ""The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and
RT   Antigenicity."";
RL   Cell 182:1284-1294(2020).
RN   [21]
RP   FUNCTION, CLEAVAGE BETWEEN S1 AND S2 BY HOST CTSL, AND INTERACTION WITH
RP   HUMAN ACE2.
RX   PubMed=32221306; DOI=10.1038/s41467-020-15562-9;
RA   Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Guo R., Chen T.,
RA   Hu J., Xiang Z., Mu Z., Chen X., Chen J., Hu K., Jin Q., Wang J., Qian Z.;
RT   ""Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and
RT   its immune cross-reactivity with SARS-CoV."";
RL   Nat. Commun. 11:1620-1620(2020).
RN   [22]
RP   INTERACTION WITH HUMAN ACE2.
RX   PubMed=33607086; DOI=10.1016/j.bpj.2021.02.007;
RA   Cao W., Dong C., Kim S., Hou D., Tai W., Du L., Im W., Zhang X.F.;
RT   ""Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2
RT   protein-protein interaction."";
RL   Biophys. J. 120:1011-1019(2021).
RN   [23]
RP   FUNCTION, AND CLEAVAGE BETWEEN S1 AND S2 BY HOST TMPRSS2.
RX   PubMed=33465165; DOI=10.1371/journal.ppat.1009212;
RA   Ou T., Mou H., Zhang L., Ojha A., Choe H., Farzan M.;
RT   ""Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated
RT   by TMPRSS2."";
RL   PLoS Pathog. 17:e1009212-e1009212(2021).
RN   [24]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH S PROTEIN.
RX   PubMed=33229438; DOI=10.1074/jbc.ra120.016175;
RA   Boson B., Legros V., Zhou B., Siret E., Mathieu C., Cosset F.L.,
RA   Lavillette D., Denolly S.;
RT   ""The SARS-CoV-2 Envelope and Membrane proteins modulate maturation and
RT   retention of the Spike protein, allowing assembly of virus-like
RT   particles."";
RL   J. Biol. Chem. 296:100111-100111(2020).
RN   [25]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, MUTAGENESIS OF ALA-684, AND FUNCTION (SPIKE PROTEIN S2').
RX   PubMed=32703818; DOI=10.26508/lsa.202000786;
RA   Bestle D., Heindl M.R., Limburg H., Van Lam van T., Pilgram O., Moulton H.,
RA   Stein D.A., Hardes K., Eickmann M., Dolnik O., Rohde C., Klenk H.D.,
RA   Garten W., Steinmetzer T., Boettcher-Friebertshaeuser E.;
RT   ""TMPRSS2 and furin are both essential for proteolytic activation of SARS-
RT   CoV-2 in human airway cells."";
RL   Life. Sci Alliance 3:1-14(2020).
RN   [26]
RP   CLEAVAGE BETWEEN S1 AND S2 BY HOST FURIN, CLEAVAGE BETWEEN S2 AND S2' BY
RP   HOST TMPRSS2, CLEAVAGE BETWEEN S2 AND S2' BY HOST CSTL, AND FUNCTION (SPIKE
RP   PROTEIN S2').
RX   PubMed=34159616; DOI=10.15252/embj.2021107821;
RA   Koch J., Uckeley Z.M., Doldan P., Stanifer M., Boulant S., Lozach P.Y.;
RT   ""TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect
RT   host cells."";
RL   EMBO J. 40:1-20(2021).
RN   [27]
RP   VARIANTS PHE-18; ALA-80; GLY-215; ASN-417; LYS-484; TYR-501; GLY-614 AND
RP   VAL-701.
RC   STRAIN=20H/501Y.V2, B.1.351, and Beta;
RX   PubMed=33690265; DOI=10.1038/s41586-021-03402-9;
RA   Tegally H., Wilkinson E., Giovanetti M., Iranzadeh A., Fonseca V.,
RA   Giandhari J., Doolabh D., Pillay S., San E.J., Msomi N., Mlisana K.,
RA   von Gottberg A., Walaza S., Allam M., Ismail A., Mohale T., Glass A.J.,
RA   Engelbrecht S., Van Zyl G., Preiser W., Petruccione F., Sigal A.,
RA   Hardie D., Marais G., Hsiao M., Korsman S., Davies M.A., Tyers L.,
RA   Mudau I., York D., Maslo C., Goedhals D., Abrahams S., Laguda-Akingba O.,
RA   Alisoltani-Dehkordi A., Godzik A., Wibmer C.K., Sewell B.T., Lourenco J.,
RA   Alcantara L.C.J., Kosakovsky Pond S.L., Weaver S., Martin D.,
RA   Lessells R.J., Bhiman J.N., Williamson C., de Oliveira T.;
RT   ""Emergence of a SARS-CoV-2 variant of concern with mutations in spike
RT   glycoprotein."";
RL   Nature 592:438-443(2021).
RN   [28]
RP   POLYMORPHISM.
RX   PubMed=34142653; DOI=10.2807/1560-7917.es.2021.26.24.2100509;
RA   Campbell F., Archer B., Laurenson-Schafer H., Jinnai Y., Konings F.,
RA   Batra N., Pavlin B., Vandemaele K., Van Kerkhove M.D., Jombart T.,
RA   Morgan O., le Polain de Waroux O.;
RT   ""Increased transmissibility and global spread of SARS-CoV-2 variants of
RT   concern as at June 2021."";
RL   Eurosurveillance 26:0-0(2021).
RN   [29]
RP   VARIANTS ARG-452 AND PHE-453, AND MUTAGENESIS OF LEU-452; TYR-453 AND
RP   ASN-501.
RX   PubMed=34171266; DOI=10.1016/j.chom.2021.06.006;
RG   Genotype to Phenotype Japan (G2P-Japan) Consortium;
RA   Motozono C., Toyoda M., Zahradnik J., Saito A., Nasser H., Tan T.S.,
RA   Ngare I., Kimura I., Uriu K., Kosugi Y., Yue Y., Shimizu R., Ito J.,
RA   Torii S., Yonekawa A., Shimono N., Nagasaki Y., Minami R., Toya T.,
RA   Sekiya N., Fukuhara T., Matsuura Y., Schreiber G., Ikeda T., Nakagawa S.,
RA   Ueno T., Sato K.;
RT   ""SARS-CoV-2 spike L452R variant evades cellular immunity and increases
RT   infectivity."";
RL   Cell Host Microbe 0:0-0(2021).
RN   [30]
RP   VARIANT 69-VAL--PHE-70 DEL, AND MUTAGENESIS OF 69-HIS-VAL-70.
RX   PubMed=34166617; DOI=10.1016/j.celrep.2021.109292;
RG   COVID-19 Genomics UK (COG-UK) Consortium;
RA   Meng B., Kemp S.A., Papa G., Datir R., Ferreira I.A.T.M., Marelli S.,
RA   Harvey W.T., Lytras S., Mohamed A., Gallo G., Thakur N., Collier D.A.,
RA   Mlcochova P., Duncan L.M., Carabelli A.M., Kenyon J.C., Lever A.M.,
RA   De Marco A., Saliba C., Culap K., Cameroni E., Matheson N.J., Piccoli L.,
RA   Corti D., James L.C., Robertson D.L., Bailey D., Gupta R.K.;
RT   ""Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in
RT   the Alpha variant B.1.1.7."";
RL   Cell Rep. 35:109292-109292(2021).
RN   [31]
RP   VARIANTS ILE-13 AND CYS-152, POLYMORPHISM, AND MASS SPECTROMETRY (SIGNAL).
RX   PubMed=34210893; DOI=10.1126/science.abi7994;
RA   McCallum M., Bassi J., De Marco A., Chen A., Walls A.C., Di Iulio J.,
RA   Tortorici M.A., Navarro M.J., Silacci-Fregni C., Saliba C., Sprouse K.R.,
RA   Agostini M., Pinto D., Culap K., Bianchi S., Jaconi S., Cameroni E.,
RA   Bowen J.E., Tilles S.W., Pizzuto M.S., Guastalla S.B., Bona G.,
RA   Pellanda A.F., Garzoni C., Van Voorhis W.C., Rosen L.E., Snell G.,
RA   Telenti A., Virgin H.W., Piccoli L., Corti D., Veesler D.;
RT   ""SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern."";
RL   Science 373:648-654(2021).
RN   [32]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF LYS-1269 AND HIS-1271.
RX   PubMed=34504087; DOI=10.1038/s41467-021-25589-1;
RA   Cattin-Ortola J., Welch L.G., Maslen S.L., Papa G., James L.C., Munro S.;
RT   ""Sequences in the cytoplasmic tail of SARS-CoV-2 Spike facilitate
RT   expression at the cell surface and syncytia formation."";
RL   Nat. Commun. 12:5333-5333(2021).
RN   [33]
RP   PALMITOYLATION AT CYS-1235; CYS-1236; CYS-1240; CYS-1241; CYS-1243;
RP   CYS-1247; CYS-1248; CYS-1250; CYS-1253 AND CYS-1254.
RX   PubMed=34599882; DOI=10.1016/j.devcel.2021.09.016;
RA   Mesquita F.S., Abrami L., Sergeeva O., Turelli P., Qing E., Kunz B.,
RA   Raclot C., Paz Montoya J., Abriata L.A., Gallagher T., Dal Peraro M.,
RA   Trono D., D'Angelo G., van der Goot F.G.;
RT   ""S-acylation controls SARS-CoV-2 membrane lipid organization and enhances
RT   infectivity."";
RL   Dev. Cell 56:1-18(2021).
RN   [34] {ECO:0007744|PDB:6M17}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.90 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), DOMAIN, AND INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1).
RX   PubMed=32132184; DOI=10.1126/science.abb2762;
RA   Yan R., Zhang Y., Li Y., Xia L., Guo Y., Zhou Q.;
RT   ""Structural basis for the recognition of the SARS-CoV-2 by full-length
RT   human ACE2."";
RL   Science 367:1444-1448(2020).
RN   [35]
RP   SUPERANTIGEN, AND DOMAIN.
RX   PubMed=32989130; DOI=10.1073/pnas.2010722117;
RA   Cheng M.H., Zhang S., Porritt R.A., Noval Rivas M., Paschold L.,
RA   Willscher E., Binder M., Arditi M., Bahar I.;
RT   ""Superantigenic character of an insert unique to SARS-CoV-2 spike supported
RT   by skewed TCR repertoire in patients with hyperinflammation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 117:25254-25262(2020).
RN   [36]
RP   INTERACTION WITH HUMAN BILIRUBIN, INTERACTION WITH HUMAN BILIVERDIN, AND
RP   MUTAGENESIS OF ASN-121 AND ARG-190.
RX   PubMed=33888467; DOI=10.1126/sciadv.abg7607;
RA   Rosa A., Pye V.E., Graham C., Muir L., Seow J., Ng K.W., Cook N.J.,
RA   Rees-Spear C., Parker E., Dos Santos M.S., Rosadas C., Susana A., Rhys H.,
RA   Nans A., Masino L., Roustan C., Christodoulou E., Ulferts R., Wrobel A.G.,
RA   Short C.E., Fertleman M., Sanders R.W., Heaney J., Spyer M., Kjaer S.,
RA   Riddell A., Malim M.H., Beale R., MacRae J.I., Taylor G.P., Nastouli E.,
RA   van Gils M.J., Rosenthal P.B., Pizzato M., McClure M.O., Tedder R.S.,
RA   Kassiotis G., McCoy L.E., Doores K.J., Cherepanov P.;
RT   ""SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity."";
RL   Sci. Adv. 7:0-0(2021).
RN   [37]
RP   BIOTECHNOLOGY, AND MUTAGENESIS OF 682-ARG--ARG-685 AND 986-LYS-VAL-987.
RX   PubMed=34322129; DOI=10.3389/fimmu.2021.701501;
RA   Martinez-Flores D., Zepeda-Cervantes J., Cruz-Resendiz A.,
RA   Aguirre-Sampieri S., Sampieri A., Vaca L.;
RT   ""SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of
RT   New Viral Variants."";
RL   Front. Immunol. 12:701501-701501(2021).
RN   [38]
RP   GLYCOSYLATION AT THR-676 AND THR-678 BY HOST GALNT1, AND MUTAGENESIS OF
RP   SER-673; THR-676; THR-678; SER-680 AND PRO-681.
RX   PubMed=34732583; DOI=10.1073/pnas.2109905118;
RA   Zhang L., Mann M., Syed Z.A., Reynolds H.M., Tian E., Samara N.L.,
RA   Zeldin D.C., Tabak L.A., Ten Hagen K.G.;
RT   ""Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [39]
RP   REVIEW, PROTEOLITIC PROCESSING, FUNCTION (SPIKE PROTEIN S2), AND FUNCTION
RP   (SPIKE PROTEIN S2').
RX   PubMed=34561887; DOI=10.1111/1348-0421.12945;
RA   Takeda M.;
RT   ""Proteolytic activation of SARS-CoV-2 spike protein."";
RL   Microbiol. Immunol. 66:15-23(2022).
RN   [40]
RP   INTERACTION WITH HOST MBL2.
RX   PubMed=35102342; DOI=10.1038/s41590-021-01114-w;
RA   Stravalaci M., Pagani I., Paraboschi E.M., Pedotti M., Doni A.,
RA   Scavello F., Mapelli S.N., Sironi M., Perucchini C., Varani L.,
RA   Matkovic M., Cavalli A., Cesana D., Gallina P., Pedemonte N., Capurro V.,
RA   Clementi N., Mancini N., Invernizzi P., Bayarri-Olmos R., Garred P.,
RA   Rappuoli R., Duga S., Bottazzi B., Uguccioni M., Asselta R., Vicenzi E.,
RA   Mantovani A., Garlanda C.;
RT   ""Recognition and inhibition of SARS-CoV-2 by humoral innate immunity
RT   pattern recognition molecules."";
RL   Nat. Immunol. 23:275-286(2022).
RN   [41]
RP   FUNCTION (SPIKE PROTEIN S1), AND INTERACTION WITH HOST INTEGRIN (SPIKE
RP   PROTEIN S1).
RX   PubMed=35150743; DOI=10.1016/j.jbc.2022.101710;
RA   Liu J., Lu F., Chen Y., Plow E., Qin J.;
RT   ""Integrin mediates cell entry of the SARS-CoV-2 virus independent of
RT   cellular receptor ACE2."";
RL   J. Biol. Chem. 1:101710-101710(2022).
RN   [42]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [43]
RP   SUBUNIT.
RX   PubMed=36735681; DOI=10.1371/journal.pbio.3001959;
RA   Shilts J., Crozier T.W.M., Teixeira-Silva A., Gabaev I., Gerber P.P.,
RA   Greenwood E.J.D., Watson S.J., Ortmann B.M., Gawden-Bone C.M., Pauzaite T.,
RA   Hoffmann M., Nathan J.A., Poehlmann S., Matheson N.J., Lehner P.J.,
RA   Wright G.J.;
RT   ""LRRC15 mediates an accessory interaction with the SARS-CoV-2 spike
RT   protein."";
RL   PLoS Biol. 21:e3001959-e3001959(2023).
RN   [44]
RP   VARIANT ASN-405.
RX   PubMed=36851546; DOI=10.3390/v15020332;
RA   Bugatti A., Filippini F., Messali S., Giovanetti M., Ravelli C., Zani A.,
RA   Ciccozzi M., Caruso A., Caccuri F.;
RT   ""The D405N Mutation in the Spike Protein of SARS-CoV-2 Omicron BA.5
RT   Inhibits Spike/Integrins Interaction and Viral Infection of Human Lung
RT   Microvascular Endothelial Cells."";
RL   Viruses 15:0-0(2023).
RN   [45]
RP   MUTAGENESIS OF GLU-484.
RX   PubMed=37421949; DOI=10.1016/j.cell.2023.06.005;
RA   Baggen J., Jacquemyn M., Persoons L., Vanstreels E., Pye V.E., Wrobel A.G.,
RA   Calvaresi V., Martin S.R., Roustan C., Cronin N.B., Reading E.,
RA   Thibaut H.J., Vercruysse T., Maes P., De Smet F., Yee A., Nivitchanyong T.,
RA   Roell M., Franco-Hernandez N., Rhinn H., Mamchak A.A., Ah Young-Chapon M.,
RA   Brown E., Cherepanov P., Daelemans D.;
RT   ""TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry."";
RL   Cell 186:1-16(2023).
RN   [46] {ECO:0007744|PDB:6VSB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.46 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN S1), SUBUNIT, AND
RP   GLYCOSYLATION.
RX   PubMed=32075877; DOI=10.1126/science.abb2507;
RA   Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.L., Abiona O.,
RA   Graham B.S., McLellan J.S.;
RT   ""Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation."";
RL   Science 367:1260-1263(2020).
RN   [47] {ECO:0007744|PDB:6VXX, ECO:0007744|PDB:6VYB}
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.80 ANGSTROMS), FUNCTION (SPIKE PROTEIN
RP   S1), SUBUNIT (SPIKE PROTEIN S1), INTERACTION WITH HUMAN ACE2 (SPIKE PROTEIN
RP   S1), MUTAGENESIS OF 679-GLN--ALA-684, GLYCOSYLATION AT ASN-61; ASN-122;
RP   ASN-61; ASN-165; ASN-234; ASN-282; ASN-331; ASN-343; ASN-603; ASN-616;
RP   ASN-657; ASN-709; ASN-717; ASN-801; ASN-1074; ASN-1098 AND ASN-1134, AND
RP   DISULFIDE BOND.
RX   PubMed=32155444; DOI=10.1016/j.cell.2020.02.058;
RA   Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D.;
RT   ""Structure, function, and antigenicity of the SARS-CoV-2 spike
RT   glycoprotein."";
RL   Cell 180:1-12(2020).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.45 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2.
RX   PubMed=32225176; DOI=10.1038/s41586-020-2180-5;
RA   Lan J., Ge J., Yu J., Shan S., Zhou H., Fan S., Zhang Q., Shi X., Wang Q.,
RA   Zhang L., Wang X.;
RT   ""Structure of the SARS-CoV-2 spike receptor-binding domain bound to the
RT   ACE2 receptor."";
RL   Nature 581:215-220(2020).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.68 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HOST ACE2, INTERACTION WITH HOST ACE2, AND MUTAGENESIS OF GLN-493 AND
RP   ASN-501.
RX   PubMed=32225175; DOI=10.1038/s41586-020-2179-y;
RA   Shang J., Ye G., Shi K., Wan Y., Luo C., Aihara H., Geng Q., Auerbach A.,
RA   Li F.;
RT   ""Structural basis of receptor recognition by SARS-CoV-2."";
RL   Nature 581:221-224(2020).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (3.08 ANGSTROMS) OF SPIKE PROTEIN S1 AND IN COMPLEX
RP   WITH HUMAN ANTIBODY CR3022, AND DISULFIDE BOND.
RX   PubMed=32245784; DOI=10.1126/science.abb7269;
RA   Yuan M., Wu N.C., Zhu X., Lee C.D., So R.T.Y., Lv H., Mok C.K.P.,
RA   Wilson I.A.;
RT   ""A highly conserved cryptic epitope in the receptor-binding domains of
RT   SARS-CoV-2 and SARS-CoV."";
RL   Science 368:630-633(2020).
CC   -!- FUNCTION: [Spike protein S1]: Attaches the virion to the cell membrane
CC       by interacting with host receptor, initiating the infection. The major
CC       receptor is host ACE2 (PubMed:32142651, PubMed:32155444,
CC       PubMed:33607086). When S2/S2' has been cleaved, binding to the receptor
CC       triggers direct fusion at the cell membrane (PubMed:34561887). When
CC       S2/S2' has not been cleaved, binding to the receptor results in
CC       internalization of the virus by endocytosis leading to fusion of the
CC       virion membrane with the host endosomal membrane (PubMed:32075877,
CC       PubMed:32221306). Alternatively, may use NRP1/NRP2 (PubMed:33082294,
CC       PubMed:33082293) and integrin as entry receptors (PubMed:35150743). The
CC       use of NRP1/NRP2 receptors may explain the tropism of the virus in
CC       human olfactory epithelial cells, which express these molecules at high
CC       levels but ACE2 at low levels (PubMed:33082293). The stalk domain of S
CC       contains three hinges, giving the head unexpected orientational freedom
CC       (PubMed:32817270). {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32142651,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32817270, ECO:0000269|PubMed:33082293,
CC       ECO:0000269|PubMed:33082294, ECO:0000269|PubMed:35150743,
CC       ECO:0000303|PubMed:33082293, ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2]: Precursor of the fusion protein processed
CC       in the biosynthesis of the S protein and the formation of virus
CC       particle. Mediates fusion of the virion and cellular membranes by
CC       functioning as a class I viral fusion protein. Contains two viral
CC       fusion peptides that are unmasked after cleavage. The S2/S2' cleavage
CC       occurs during virus entry at the cell membrane by host TMPRSS2
CC       (PubMed:32142651) or during endocytosis by host CSTL (PubMed:32703818,
CC       PubMed:34159616). In either case, this triggers an extensive and
CC       irreversible conformational change leading to fusion of the viral
CC       envelope with the cellular cytoplasmic membrane, releasing viral
CC       genomic RNA into the host cell cytoplasm (PubMed:34561887). Under the
CC       current model, the protein has at least three conformational states:
CC       pre-fusion native state, pre-hairpin intermediate state, and post-
CC       fusion hairpin state. During fusion of the viral and target cell
CC       membranes, the coiled coil regions (heptad repeats) adopt a trimer-of-
CC       hairpins structure and position the fusion peptide in close proximity
CC       to the C-terminal region of the ectodomain. Formation of this structure
CC       appears to promote apposition and subsequent fusion of viral and target
CC       cell membranes. {ECO:0000255|HAMAP-Rule:MF_04099,
CC       ECO:0000269|PubMed:32703818, ECO:0000269|PubMed:34159616,
CC       ECO:0000305|PubMed:34561887}.
CC   -!- FUNCTION: [Spike protein S2']: Subunit of the fusion protein that is
CC       processed upon entry into the host cell. Mediates fusion of the virion
CC       and cellular membranes by functioning as a class I viral fusion
CC       protein. Contains a viral fusion peptide that is unmasked after S2
CC       cleavage. This cleavage can occur at the cell membrane by host TMPRSS2
CC       or during endocytosis by host CSTL (PubMed:32703818, PubMed:34159616).
CC       In either case, this triggers an extensive and irreversible
CC       conformational change that leads to fusion of the viral envelope with
CC       the cellular cytoplasmic membrane, releasing viral genomic RNA into the
CC       host cell cytoplasm (PubMed:34561887). Under the current model, the
CC       protein has at least three conformational states: pre-fusion native
CC       state, pre-hairpin intermediate state, and post-fusion hairpin state.
CC       During fusion of the viral and target cell membranes, the coiled coil
CC       regions (heptad repeats) adopt a trimer-of-hairpins structure and
CC       position the fusion peptide in close proximity to the C-terminal region
CC       of the ectodomain. Formation of this structure appears to promote
CC       apposition and subsequent fusion of viral and target cell membranes.
CC       {ECO:0000255|HAMAP-Rule:MF_04099, ECO:0000269|PubMed:32703818,
CC       ECO:0000269|PubMed:34159616, ECO:0000305|PubMed:34561887}.
CC   -!- SUBUNIT: [Spike glycoprotein]: Homotrimer; each monomer consists of a
CC       S1 and a S2 subunit (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784). The resulting peplomers protrude from the virus
CC       surface as spikes (PubMed:32979942). Interacts with ORF3a protein and
CC       ORF7a protein (By similarity) (PubMed:32075877, PubMed:32155444,
CC       PubMed:32245784, PubMed:32979942). There are an average of 26 +/-15
CC       spike trimers at the surface of virion particles (PubMed:32979942).
CC       Binds to host MBL2 (PubMed:35102342). This binding occurs via glycans
CC       and inhibits viral infectivity. Inhibition is effective against alpha,
CC       beta, gamma, and delta variants (PubMed:35102342). {ECO:0000255|HAMAP-
CC       Rule:MF_04099, ECO:0000269|PubMed:32075877,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32245784,
CC       ECO:0000269|PubMed:32979942, ECO:0000269|PubMed:35102342}.
CC   -!- SUBUNIT: [Spike protein S1]: Binds to host ACE2 (PubMed:32075877,
CC       PubMed:32132184, PubMed:32155444, PubMed:32221306, PubMed:32225175,
CC       PubMed:32225176, PubMed:33607086). RBD also interacts with the N-linked
CC       glycan on 'Asn-90' of ACE2 (PubMed:33607086). Cleavage of S generates a
CC       polybasic C-terminal sequence on S1 that binds to host Neuropilin-1
CC       (NRP1) and Neuropilin-2 (NRP2) receptors (PubMed:33082293,
CC       PubMed:33082294). Interacts with host integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) and with ACE2 in complex with integrin alpha-5/beta-1
CC       (ITGA5:ITGB1) (PubMed:33102950). May interact via cytoplasmic c-
CC       terminus with M protein (PubMed:33229438). May interact (via N-
CC       terminus) with host bilirubin and biliverdin, thereby preventing
CC       antibody binding to the SARS-CoV-2 spike NTD via an allosteric
CC       mechanism (PubMed:33888467). May interact with host LRRC15, thereby
CC       allowing attachment to host cells (PubMed:36735681).
CC       {ECO:0000269|PubMed:32075877, ECO:0000269|PubMed:32132184,
CC       ECO:0000269|PubMed:32155444, ECO:0000269|PubMed:32221306,
CC       ECO:0000269|PubMed:32225",47675
AACATA ACATAG CATAGG ATAGGT TAGGTG AGGTGC GGTGCC GTGCCA TGCCAT GCCATG CCATGG CATGGA ATGGAT TGGATG GGATGT GATGTT ATGTTT TGTTTT GTTTTC TTTTCT TTTCTG TTCTGC TCTGCA CTGCAC TGCACA GCACAG CACAGA ACAGAT CAGATA AGATAA GATAAG ATAAGA TAAGAC AAGACA AGACAG GACAGG ACAGGA CAGGAA AGGAAC GGAACA GAACAC AACACT ACACTT CACTTA ACTTAC CTTACG TTACGC TACGCT ACGCTT CGCTTG GCTTGA CTTGAC TTGACA TGACAA GACAAG ACAAGA CAAGAT AAGATT AGATTG GATTGT ATTGTA TTGTAC TGTACT GTACTG TACTGG ACTGGA CTGGAA TGGAAA GGAAAG GAAAGG AAAGGC AAGGCA AGGCAC GGCACC GCACCT CACCTG ACCTGA CCTGAA CTGAAT TGAATA GAATAT AATATT ATATTT TATTTA ATTTAT TTTATG TTATGG TATGGC ATGGCG TGGCGA GGCGAT GCGATG CGATGA GATGAA ATGAAG TGAAGA GAAGAT AAGATG AGATGA GATGAG ATGAGG TGAGGA GAGGAA AGGAAG GGAAGT GAAGTA AAGTAC AGTACT GTACTG TACTGA ACTGAA CTGAAA TGAAAT GAAATG AAATGG AATGGG ATGGGC TGGGCT GGGCTT GGCTTA GCTTAC CTTACC TTACCT TACCTC ACCTCA CCTCAA CTCAAC TCAACA CAACAG AACAGT ACAGTT CAGTTA AGTTAC GTTACC TTACCA TACCAC ACCACC CCACCA CACCAG ACCAGA CCAGAC CAGACC AGACCG GACCGG ACCGGA,2,145,AACCA A A GAACACATAT T C CTCATATATA A A ATATATAGTATG T TATAGAGGGG G AAGGGGTGT TT GGTGTGTG G GTTAGTGTGCGC  TGT TGCCCC C G GCGCCCCACA CCAGA AT T C CACATATGTG G A TATGAGG ACC TGTGGGGAGTTA G GGGATAT T G GAT AATGTG G A ATATGTGTT T TGTGTGTTTT T G GTTTTTT TGC TTG TTTTT GT T TTTTTTTC ACC T TTTTCTCTCT T T TCTCTTG G C CTCTGTGCGC C T TGTGCGCACA A G GCGCACACAC C C CACACACACA A A ACACAAG AG  CA TGACAAGAA TAT T G GAGATATATA A A ATATATAAA T TATAAAAGAG G C AAAAGAGAGA A A AGGACAC C GCCAGACACACA A A ACACACAGG C CACAGGG G AGCTGGA AGA G GGGGACCTATTA G GATATAACAC C A AAAACACAA AA A ACAGGT AG AC C CACACCT GAT ACACTCTTTT T C CAT AC AACCA ATTATACAC C TTACACGCG G A ACACGCGCTTTC C CGAGGA AT G GCGCTTT T CCT CTTTG G T GGTTGTGAGA A T TGT AAGT GAGACACACA  AG ACCAAAA A C CACCAAAGAG CC  AAAAGAGAGA A AGA AGAGATAT T G GAGATATTTT AGT ATAA GA TG GC  TTTGTGT T T TGGTATA C G GTGTATACAC C T TATACACTCT  ACC G CGTG G C CTCTGTGGGG G T TGTGGTTTGA A G TTTGTGAA CCGAAAAAAA A A AAAG AAGAAAG A AAAAGTACGG G A AGAGGGGCGC C G GGGGCGCACA A G GCGCACACAC C CCTGCACACCCC C A ACACCCCTAAGT C CCGAACTGTG G C CTCTGTGACAT ATATTTGAC AAA A G GAGAAAATAT CT ATGATATA CA  ATATATATAT T TATGTATATTTT T A ATA ATTTTT T TG ATTATA A TTTAGAAAT T T TAATGAATAC  ATATGTGGGG G TGATTGGGGCGC A G GGCG G G GCGCGCGAGA A CCTGGATAT T G GAGATATGGGAAG TGGGA  TG TGTGACACAA A G GAGAAAAGAG G AGAAAGAA A AGAGAGATAT T G GAGATATGTG G A ATATGTGAGA  TGTGAAG G G GAGAGAGGGG  AGACAGGAGA A G GGGGAAA A GGAAAG G A AAAAGAGTGT T A CTAC GTATA A G GTGTATACAC C T TAAGGACTCT  ACACTTG G C CTCTGTGAGA A T TGTGAGAAAA A G GAGAATTAAA  AC AAAAAAATAT T A AAAATG AATGTGGGG G T TGGGGGG G GGGCGC G T GGGGCCT T G GCGCTCTTTT T C CTCTTTTATA A T TTCA TACAC  TATACACTG AAAA AC GTCCTCT T C CCCCTCTCTC C CGT CTCTCACA A T TCTCACAAAA CAAAACAC C A AAAACACAA T AC AGCAGG CG ACAGT AGT CTT AGAGTTT T GGTTTTATA A T TTACCTACAC C T TATAC GACC  ACCAATTAA C CCCACC C CACACACCCC GAATC AGACCACA A C CC GACAGAG G C CACAGAGAGA A ATG ACCGACAC C GGACACCCC C AA ACCGCG G CAA CCGCGGGG G CCGGGGA,AACACACATAT T A ACACACATCCGTA A C CACATGA TAGAG G A ATTAGAGGGG G T TATAGG AGGTGT  AGAGGGACGTGG G GGATGAC TGCGC C GC AGTGTGCGCCGAT TGTGCCCACA A G GCGCCCCACATAT T C CCCCACATATGG C CACTCATGTGGG A ATATGAA GGAGA A T TGT TGGAATTAT T GGGAGATATGTG G G GAGATATGTGTT A ATTGTGTTTT T TTGTGTTTTT GTGTTTTTTTTTT T T TTCTTTTTTTCTC C T TTTTTTTCTCTCT T T TTTTCTCTCTGG T TCTCTCTGTGCGC C CCC CTGGCACA A TT TTGCGCACACAC C G GCGA CACACAA CACACACACACAGAG G AATTACACAG GAA C CACAGAC GATATTAGAGATATAAATA G GAGATATATAAAA A AATATAAGGAAG G TC ATAAAAGGGAGA A A AAAA GG TA C AATGAGATGAACAA G AAGACACACAGAG G A ACG GC CG C CACAGAGGGGAGA A A AGAGGGGAGGGAA A G GGAAGGAAAACAC C GGTAGAAAACACACA A A AAAACACACACAC  ACACACACACTCT CG  CACACACTGACT AACTTGGTTATA A C CTTTTTTATACAC C T TTTTATACACGTTAG T TATACACGCGC TA ACACGCGCGCTCT T C CGCGCTGGTT T G GCGCTCTTTTGTG G C CTCTTTTGTGAGA ATA TTTTGGACGACGTGC T TGGACACACA A G GAGACACATGGAGAA A CACAAAAGAG  CACAAA TCCA AAAAGAGAGGCAT T A AGAA GATATTTT T G GACC TTGTG G A ATGATTTGTGTGT T T TTTTGTGTGTATA A T TGTGTGTATACAC  CT GTGTAAC ACT ACT TTACACTCTGTG ATATACAGGCTGCTTGACG C CTCTGTGGGGAA TGATGCTGAAAA A G GGGGAGAAAAAA G GAGAAAAACTGG A AAAAA TGAGGGG AGGT AAAGGGCGC C A AGGGCGCACA A GG AGC GCACACAC C G GCGCAACCTT GT  CACACACCCCTCT T A ACCCTTG TG G C CCCCTCTGTGAA CC GCTGTGAGAAAA A TC CTGAGAAAATAT T G ATAATATATA A A AAATAAT  ACATATAT ACTT TGGTATTTT CT ATT ATTTTTATA A T TTTTTTTATATAT T T TTTTAGAGATGTG G T TATATAGTA TGG G ACG ATGTGGCAAGC C T TGCAAGGCGCGT CG G GGGGCGCGCGAGA A G GCATGAGTGATAT T C CGACC TGGGTTG ACA GAGATGCGTGAGA A A ATATGTGAGAAAAGTGG TGTGAGAAAAGAG G G GAGAAAAGGA A A AAAAGAGAGATAT T A AGGATATGTG G G GAGAT AGTGAGA A ACT  GA TGTGAGAGAGGGG G G TAGAGAGGGGAGA A A AGGGAGAATGGA G GGAGAGAAAAGAG G GGA GAAAAGAGTGT T AAAGATGGTATA A A AGCCGTAC TCC G GT GA ACCT  TG TATACACTAAGTG G A ACACTCTGTGAGA A C CTCTGTGAGAATGGTT GAAAAAA G GAGAAAAAAATAT T A AAAATATGTG G A AAT GATG AGG A ATATGTGGGGGGG G T TGA TGGGGC C G GGGAAGGC ATT G GGGATGCTCTTTT T G GCGCTTTATA A CAACCTTGAATACC T TTTTATACACCCC AGG GATACCCTCT T A ACACCCCTTC C C CCCCTTCACA A C CTCTCTCAGGCAA A TTCACAATACC C CAACACA A A AA CTACACAG GGCT ACACGAGT T CACCCAGAGTGTTTT T A AGAGTGTTTTAA G GTGTTTACAC  TTTTATACCCACC C T TATACACCCCACA A AT AACC GACACAC  TG CCACCCACCGACC C C CACACACCA ACA A A AC CACCACAGAG G C CCCCACAGAGAGA A C CACAGAGAGACAC  GT AGAGAAA ACCCC C G GAGGTACCATACG G A ACACCCCGCGGGG G C CCGTAGGA,AAC GCCATATATA A A ACACA CTATATAGAG G C CACATATATAGGG G AGTAATATAGAGGGGT GTT T TATAGAGGGGTCAGTG  CA AGGAGGTGTGCGC C G GGGGTGTGTGCCC GT GTGTGCGCCCCACA A T TGTGCGCCCCACATAT T G GCGCCCCACATCTGTG  TG CCCCACATATGGG G C CACATGG CTGGGA TAA AATGTGGGGAAG AT T T TGAGAGATATGG G GGGGAGATATG CAGT T G GAGATATGTGTGTTTT T AACCATGTGTGTTTTTTT T T TGTGTACTTTTTTTT G GTGTTTTTAGAC TCACTTTTTCTCTCT T T TTTTCTCTCTGTG G T TTTTCTCTCTGTGCCC ACC TCTCTCTGTGCGCA TTA C CTTGCGCA TTAC C T TGTGCGCAGA CA A G GCTTACACGAGCAGTTAG C CACACACACAGAGAGA A A ACACACAGAGAGATAT T C ACAGAGATATATA A ATA AGAGATATATAAAA  GAGATATATAAAG G AGT ATATAAAGAGA A T TATAAAGATG AC C A AAAAGAGAGACACATACA A AGGACACACAGT CG G GAGACACACAGAGGGG G A ACCAGAGGGGAGA A C CACAGAACAA A A AGAGGGGAGAAAACAC C G GGGGAGATGGAACACA GAAACAATTAC C AGGCACCACACACACTT A ACCACTGGCTTTT T C CAAACACTCTTTTATA A A AC CGCTTTTAACAAC C C CTCTTAG ACGCAAG T TTTTAACGCGCGC C TAGATACACGCGCGCTCT T ACTGACGCGCGCTCTTTT T CTACCGCGCTCTTGGCTG G GGCTCTTTTGTGAACAA C CTCTTTTGTGAGACCA TGAGACACACA TAC TGTGAGACACAAA A G GAGACACAAAGAGAG A ACACACAAAAGAGAAGTA CCAAAAG TAGATAT T A AAAAGAGAGAATT T AAGAGATATTTTGTG G G GAGATATTTGTAC T A ATATTCGATGTTA A T TTTTGAAGGTAACTAC A G TGTGTGTA CCAGACT T G GTGTAGGCACTCTGGTTG T TATTAACTCTGTGGGCGG A ACACTTGGTGGGGAGA A C CTACTGGAGAAAA A T TGTGGGGAGAA CCAA A G GGGGAGAACA AAGAG G G GAGAAAAAGGCAGGGG G ACACAAAG TAGGTACGC C A AAAAGAGGGGCGCACA A A AGAGGGGCGCA GCAC C G GGGGCGCACACACCCC C G GCGCACACTTTCCTCT T C CACACAACCCTCTGTG G A ACC TCCTCTGTGATACA CCCTATGGAAAGTA C CTCTGGAAAATAT T T TGTGAGAAAATATATA  CA GAGAATATAT GAT AAATATATTT T A ATATATATATTTTTTT T T TATATATTTACTA A A ATAG TTATATAT T T TTTTTTTAATGAC G T TTTATATGTGGGG  TAATGATGTGGGGCGC C A ATATGTGGGCGCG  TGTGGGTAGA A G GGGGCATGCGACG AT T GGCGCGAGATCGGGACG C CGTTGGATTATTGAA G GAGATATGTGAGAAAA A A ATATGTGAGAAAAGT A TGTGAGAACCGA GGAAAAGAG ACTAT GAT AAGATATGTG G A AGTTCGATATGTGAGA A G GAGATATGTGAGAGAG G ACTTTGATACAGGAGGGGAGA A GCAGAGGAGGGGAGAAAA A A AGAGGGAAAAGAG G G GGCCAGAAAAGAGTCAGC A GAGAAAAGGA GTATA A A AAAAGAGT ATTACAC C AAGTCGATACACTCT GT  GTGTATG TG CAGTACG T TACA ACTCTGACCGA A A ACACTCTGTGAGAAAA A CCATGAAAAAAA A TG CTGAGAAAAAAATAT T G GAGAAAAAAATATGTG G A AAAATATGTGGGG  AAAATTGGGGGGG G A ATATGTGGTGAGGCGC C T TGTGGGGGGGCGCTCT T G GGGGGAAGGCTCTTTT T G GG AAGCTCTTTAC ATA GCACGCT ATTTATG C C CTCTTTTAA TCC C T TTTTATACTGACCTCT T T TAGA CAGCCTCTCTC C A ACACCCCTCTCTCATACA C CCCCTCTCTCACAAA C CTCTCTCACAAAACAC C T TCTCACAAACACA A CC TCAAT AACAACCAG AATAACAGT ATT A ACACA GAAGTGTTAG CAGAA GTTTTA AGA A AGAGTTTATACAC C G GTGTTTTATACACCCC C T AGTTAACCCCACA A TGA ACCCCACACAC T G ACACCGGACACACCCC C CAAACCA AAACCGCGAAAACA CACACACCCCACAGTTTG A ACACCCCAGTGAGAGA A CTACCCACAGAACGACT GC C CACAGGACACCGC  AGAGAGACACCGA TGAG G GAGACACCCCGATGGG G A ACTA CCGCGGGGA,AACACACATATATAGAG GT  ACACACATATATAGAGGGG G C CAA A TTTAGGGTGT GAT ATATATAGAGGGGTGTGTG G T TATAGAGGGGTGTGTGCGC  ACGGTGTGTGCGCCCC CGC GGGGTGCCCCACA A G GTGTGTGCGCCCCACATAT T TTGCGCCCCACA ATGTG G GAAGGCCG GCATATGTGGTATG C CCGCTCATATGTGGGGAGA A CGG CATATGTGGGATAT T AAA TGGGGAACTTG CAC TGGGAGATATGTGTGT T G GGGGAGATATGGGATT T G GAGATATGTGTTTTTT T A ATATGTGTGTTTTTTTTTT T T TGTGTACTTTCC G GTGTTTTTGC TTC GACT GGA TTTTTTTCTCTCTGAGAG TGACTTTTTCTCTCTG TGGC TGA TTTTCAG TACACTGCACATA T TCTCTTTAGCACACC C CTCTGTGCGCAGCTACACA A T TGTGCCTGCACACACAGTATG G TTGCAAAGCAGAAAGA A C CACACCAGACTGATAT  GC ACCGCCAGAGAGATATATA A CCAGAGAGATATATAAAA A A AGAGAT ATAAAAGAG G G GAGATTAACCAAGAGA A A ATATATAAAAGTG GACACCC T TATAAAAGAGAGACACAA A AAAAGAGATGAACACAGAG G AAGAGACACACAGAGGCACG G GACAGAGGGGAGA A AACACAGAGGGGAGAAAGAA C CACAGAGGGGAAAC AGC A AGAGGGGAGAAACCACAA G GGGGAGAATGAAC CACACAC G GAGAAAACCTTCACACTCT T A AAAACACAGG ACTCTTTT CAGTG ACACACCTTTTATATA C CACAGACTATATACAC C A ACAGACTTTTATACACGG C CTCTTTTATACACGT GC T GCTTAATAACGCGCGCTCT TTATACACGCGCGAACTTAGAT AACGGCTCTTTTGTG G C CGACAAT TTGTGAGA A G GCGCTTGA TTAC ACC CTCTTTTGTGAGACACACA A T TTTTGTGAACAGTTAA A TTGCTGAGACACACAAAGTAG G G GAGACACAGAAAAGAGAGA A A ACACACAAAAGCA GATAT T CCAAAAGGATCAATT C A AACACAGAGATATTTTGTG G A AGAGA AGATTTGTGT TTA GAGATATTTTGTGTGTATA A A ATATTTTG ATGTATACAAGC T CATTGTGTGTATACCAACT T TCGGTGTGTATACACTCTGTG G G ACGTATACACTCTGTGGGG G T TATACACTCTGTGGGGAGA A ACTGTGGGGAGAAAA A C CTCTGTGGCCAGAAAAAAA A T TGTGGGTTGAAAAAAAGG G GGGGAGAAAAAAGGGG G G GAGAA TAAAGAGGTACTTTC A AAAAAAAGAGGGGCGCAAGA AAAAG GGGGCGCACACAACATGGGCCACCC C GGGCGCACACACCCCTCT T G GCGCACACACCCCTGCATG G C CACACCAGCCTTGAGA ACCTCAC CCCTCTGGAAAA A CGG GCACTGAC AATAT T C CTCTGGCGGAAAATATATA A T TGTGAGAAAATTACGG AT  GAGAAAATATATATTT AC  AAAATATATATATTTTTTT T A ATATATATATTTTTTTATA A T TATATATTTTTTGCTA AT T A ATTTTT GTATATGTG  TTTTTTTATATATGTGGGG  TTTTAAG ATGGGCTGG TAAAGATGGC GCGCG G A ATATGTGGGGCGCGCGAGA A T TGTGGGGCGCGCGATG AT  GGGGCGCGCGAGATATGTG G GT AAACGATTGAA CCCACGAGATATGTGA GTA TACC GAGATATGTGAGAAAG G ATGT AGGAAAAGAGAGA A T TGTGAGAAAAG CAGATT G GAGAAAAGAGAGATATGTG G A AAAAGTT GATATGTGAGA A A AGAGAGATATGTGAAGAAG G GTCTGATTGGTGAGAGAGGGG  ATATGTGAGAGAGGT TGA AA  TGTGAGAGAGGGGAGAA ATA G GAGAGAGGAC CCGATTT GG AAGGGGA TAAAGAGTGT AG  GGGGAGAA GCAGTGTATA A GACCGAAAAGAGTGTAGGAC A AAAAGTATTACACTCT T AGATAGTGTATACACT ACCCA GTGTATACACTCTGC TGA A T TATACACTTGAGAAAA CAT ACTGCCTGCGAAGAAA A C CTCTGTGACTTAAAACCAT T T TGTGAGAAAAAAATATGGATG GGAAAAAAATATGGG G A AAAAAAATATGTGG CAG A AAAATATGTGGGGGGC C A ATATGTGGGGGCTCCACCT T T TGTGGGGGCTTTT T GAGGGGGGGCGCTGAATTATA A GGGCCCACTTTACT AC G GCGCTCTTTTATACACCCC  CTCTTTTATACACCCCTCT T T TTTTATACT ACCTCTCTC GAC TATAC GACCTGGCTCACA A A AC CCCCT ACCAAAA A C CCCCTCTCTCACAAAACAC C CTCACAAACACA  TCTCACAAAACACACAGTCTG C TTCAAAAC TGACCAGTG AT A AAACACAGGAAGTTTT T AACACACAGTGTTTTATA A C CAT AAGTGTTTTATACAC C A AGAGTAA TTATACACCCC C GGAAGTTTTATACACCCCACA A TATAT TGGCACC CGCACAC C TGAACTGCCACACCC C A ACACCGGACACACCCCACA A C CCCCACACAATCCAAG G C CAG TAC AAGCAGAGAGA  ACACCCCACAGGACAC C C CCCCACAGAGAGACACCCC C C CACAGGTTGACA GCCGCG AC AGAGACACCAGTACAACCGGG GAGACCCGGGA,"ID   ATMA_SALT1              Reviewed;         902 AA.
AC   D0ZTB2;
DT   11-JAN-2011, integrated into UniProtKB/Swiss-Prot.
DT   19-JAN-2010, sequence version 1.
DT   05-FEB-2025, entry version 83.
DE   RecName: Full=Magnesium-transporting ATPase, P-type 1;
DE            EC=7.2.2.14 {ECO:0000250|UniProtKB:P36640};
DE   AltName: Full=Mg(2+) transport ATPase, P-type 1;
GN   Name=mgtA; OrderedLocusNames=STM14_5349;
OS   Salmonella typhimurium (strain 14028s / SGSC 2262).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Enterobacterales;
OC   Enterobacteriaceae; Salmonella.
OX   NCBI_TaxID=588858;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=14028s / SGSC 2262;
RX   PubMed=19897643; DOI=10.1128/jb.01233-09;
RA   Jarvik T., Smillie C., Groisman E.A., Ochman H.;
RT   ""Short-term signatures of evolutionary change in the Salmonella enterica
RT   serovar typhimurium 14028 genome."";
RL   J. Bacteriol. 192:560-567(2010).
RN   [2]
RP   INDUCTION.
RX   PubMed=20813261; DOI=10.1016/j.cell.2010.07.046;
RA   Park S.Y., Cromie M.J., Lee E.J., Groisman E.A.;
RT   ""A bacterial mRNA leader that employs different mechanisms to sense
RT   disparate intracellular signals."";
RL   Cell 142:737-748(2010).
CC   -!- FUNCTION: Mediates magnesium influx to the cytosol. {ECO:0000305}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Mg(2+)(out) + ATP + H2O = Mg(2+)(in) + ADP + phosphate + H(+);
CC         Xref=Rhea:RHEA:10260, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:18420, ChEBI:CHEBI:30616, ChEBI:CHEBI:43474,
CC         ChEBI:CHEBI:456216; EC=7.2.2.14;
CC         Evidence={ECO:0000250|UniProtKB:P36640};
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane {ECO:0000305}; Multi-pass
CC       membrane protein {ECO:0000305}.
CC   -!- INDUCTION: By low extracellular levels of Mg(2+) and by low levels of
CC       proline; induction is higher in the absence of both. Also by osmotic
CC       shock (0.3 M NaCl). The leader of mgtA mRNA functions as a riboswitch;
CC       at low Mg(2+) stem loop 'C' forms which favors transcription of the
CC       full-length mgtA mRNA. Under limiting proline levels the 17 residue,
CC       proline-rich MgtL peptide encoded within the mgtA leader is unable to
CC       be fully translated, and the same stem loop 'C' is able to fold, again
CC       favoring transcription of the full mgtA mRNA. Osmotic shock induction
CC       also depends on MgtL translation. {ECO:0000269|PubMed:20813261}.
CC   -!- SIMILARITY: Belongs to the cation transport ATPase (P-type) (TC 3.A.3)
CC       family. Type IIIB subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP001363; ACY91682.1; -; Genomic_DNA.
DR   RefSeq; WP_001738655.1; NZ_CP043402.1.
DR   AlphaFoldDB; D0ZTB2; -.
DR   SMR; D0ZTB2; -.
DR   KEGG; seo:STM14_5349; -.
DR   PATRIC; fig|588858.6.peg.4845; -.
DR   HOGENOM; CLU_002360_6_3_6; -.
DR   BioCyc; SENT588858:STM14_RS23360-MONOMER; -.
DR   BRENDA; 7.2.2.14; 2169.
DR   PHI-base; PHI:8203; -.
DR   Proteomes; UP000002695; Chromosome.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:InterPro.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0015444; F:P-type magnesium transporter activity; IEA:UniProtKB-EC.
DR   CDD; cd02077; P-type_ATPase_Mg; 1.
DR   FunFam; 2.70.150.10:FF:000045; Magnesium-translocating P-type ATPase; 1.
DR   Gene3D; 3.40.1110.10; Calcium-transporting ATPase, cytoplasmic domain N; 1.
DR   Gene3D; 2.70.150.10; Calcium-transporting ATPase, cytoplasmic transduction domain A; 1.
DR   Gene3D; 1.20.1110.10; Calcium-transporting ATPase, transmembrane domain; 1.
DR   Gene3D; 3.40.50.1000; HAD superfamily/HAD-like; 1.
DR   InterPro; IPR006068; ATPase_P-typ_cation-transptr_C.
DR   InterPro; IPR004014; ATPase_P-typ_cation-transptr_N.
DR   InterPro; IPR023299; ATPase_P-typ_cyto_dom_N.
DR   InterPro; IPR018303; ATPase_P-typ_P_site.
DR   InterPro; IPR023298; ATPase_P-typ_TM_dom_sf.
DR   InterPro; IPR008250; ATPase_P-typ_transduc_dom_A_sf.
DR   InterPro; IPR036412; HAD-like_sf.
DR   InterPro; IPR023214; HAD_sf.
DR   InterPro; IPR006415; P-type_ATPase_IIIB.
DR   InterPro; IPR001757; P_typ_ATPase.
DR   InterPro; IPR044492; P_typ_ATPase_HD_dom.
DR   NCBIfam; TIGR01524; ATPase-IIIB_Mg; 1.
DR   NCBIfam; TIGR01494; ATPase_P-type; 2.
DR   PANTHER; PTHR42861; CALCIUM-TRANSPORTING ATPASE; 1.
DR   Pfam; PF00689; Cation_ATPase_C; 1.
DR   Pfam; PF00690; Cation_ATPase_N; 1.
DR   Pfam; PF00122; E1-E2_ATPase; 1.
DR   Pfam; PF00702; Hydrolase; 1.
DR   PRINTS; PR01836; MGATPASE.
DR   SFLD; SFLDS00003; Haloacid_Dehalogenase; 1.
DR   SFLD; SFLDF00027; p-type_atpase; 1.
DR   SMART; SM00831; Cation_ATPase_N; 1.
DR   SUPFAM; SSF81653; Calcium ATPase, transduction domain A; 1.
DR   SUPFAM; SSF81665; Calcium ATPase, transmembrane domain M; 1.
DR   SUPFAM; SSF56784; HAD-like; 1.
DR   SUPFAM; SSF81660; Metal cation-transporting ATPase, ATP-binding domain N; 1.
DR   PROSITE; PS00154; ATPASE_E1_E2; 1.
PE   2: Evidence at transcript level;
KW   ATP-binding; Cell inner membrane; Cell membrane; Magnesium; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Translocase;
KW   Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..902
FT                   /note=""Magnesium-transporting ATPase, P-type 1""
FT                   /id=""PRO_0000403461""
FT   TOPO_DOM        1..98
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        99..119
FT                   /note=""Helical; Name=1""
FT                   /evidence=""ECO:0000255""
FT   TOPO_DOM        120
FT                   /note=""Extracellular""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        121..141
FT                   /note=""Helical; Name=2""
FT                   /evidence=""ECO:0000255""
FT   TOPO_DOM        142..291
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        292..312
FT                   /note=""Helical; Name=3""
FT                   /evidence=""ECO:0000255""
FT   TOPO_DOM        313..321
FT                   /note=""Extracellular""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        322..339
FT                   /note=""Helical; Name=4""
FT                   /evidence=""ECO:0000255""
FT   TOPO_DOM        340..699
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        700..719
FT                   /note=""Helical; Name=5""
FT                   /evidence=""ECO:0000255""
FT   TOPO_DOM        720..728
FT                   /note=""Extracellular""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        729..748
FT                   /note=""Helical; Name=6""
FT                   /evidence=""ECO:0000255""
FT   TOPO_DOM        749..770
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        771..794
FT                   /note=""Helical; Name=7""
FT                   /evidence=""ECO:0000255""
FT   TOPO_DOM        795..803
FT                   /note=""Extracellular""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        804..822
FT                   /note=""Helical; Name=8""
FT                   /evidence=""ECO:0000255""
FT   TOPO_DOM        823..835
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        836..855
FT                   /note=""Helical; Name=9""
FT                   /evidence=""ECO:0000255""
FT   TOPO_DOM        856..870
FT                   /note=""Extracellular""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        871..890
FT                   /note=""Helical; Name=10""
FT                   /evidence=""ECO:0000255""
FT   TOPO_DOM        891..902
FT                   /note=""Cytoplasmic""
FT                   /evidence=""ECO:0000255""
FT   ACT_SITE        377
FT                   /note=""4-aspartylphosphate intermediate""
FT                   /evidence=""ECO:0000250""
FT   BINDING         335
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000255""
FT   BINDING         645
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000250""
FT   BINDING         649
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000250""
FT   BINDING         713
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000255""
FT   BINDING         738
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000255""
FT   BINDING         742
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000255""
SQ   SEQUENCE   902 AA;  99783 MW;  3D2712E9A074C957 CRC64;
     MLKIITRQLF ARLNRHLPYR LVHRDPLPGA QTAVNATIPP SLSERCLKVA AMEQETLWRV
     FDTHPEGLNA AEVTRAREKH GENRLPAQKP SPWWVHLWVC YRNPFNILLT ILGGISYATE
     DLFAAGVIAL MVGISTLLNF VQEARSTKAA DALKAMVSNT ATVLRVINEN GENAWLELPI
     DQLVPGDIIK LAAGDMIPAD LRIIQARDLF VAQASLTGES LPVEKVAATR EPRQNNPLEC
     DTLCFMGTNV VSGTAQAVVM ATGAGTWFGQ LAGRVSEQDN EQNAFQKGIS RVSMLLIRFM
     LVMAPVVLII NGYTKGDWWE AALFALSVAV GLTPEMLPMI VTSTLARGAV KLSKQKVIVK
     HLDAIQNFGA MDILCTDKTG TLTQDKIVLE NHTDISGKPS EHVLHCAWLN SHYQTGLKNL
     LDTAVLEGVD ETAARQLSGR WQKIDEIPFD FERRRMSVVV AEDSNVHQLV CKGALQEILN
     VCTQVRHNGD IVPLDDNMLR RVKRVTDTLN RQGLRVVAVA TKYLPAREGD YQRIDESDLI
     LEGYIAFLDP PKETTAPALK ALKASGITVK ILTGDSELVA AKVCHEVGLD AGDVIIGSDI
     EGLSDDALAA LAARTTLFAR LTPMHKERIV TLLKREGHVV GFMGDGINDA PALRAADIGI
     SVDGAVDIAR EAADIILLEK SLMVLEEGVI EGRRTFSNML KYIKMTASSN FGNVFSVLVA
     SAFLPFLPML PLHLLIQNLL YDVSQVAIPF DNVDEEQIQK PQRWNPADLG RFMVFFGPIS
     SIFDILTFCL MWWVFHANTP ETQTLFQSGW FVVGLLSQTL IVHMIRTRRL PFIQSRAAWP
     LMAMTLLVMV VGVSLPFSPL ASYLQLQALP LSYFPWLIAI LVGYMTLTQL VKGFYSRRYG
     WQ
//
",42282
CCAATA CAATAA AATAAA ATAAAT TAAATC AAATCC AATCCT ATCCTA TCCTAC CCTACT CTACTG TACTGA ACTGAC CTGACC TGACCA GACCAG ACCAGT CCAGTC CAGTCT AGTCTT GTCTTC TCTTCT CTTCTT TTCTTA TCTTAC CTTACA TTACAT TACATC ACATCG CATCGT ATCGTT TCGTTG CGTTGA GTTGAT TTGATA TGATAG GATAGT ATAGTG TAGTGT AGTGTT GTGTTA TGTTAC GTTACA TTACAG TACAGT ACAGTG CAGTGA AGTGAA GTGAAG TGAAGA GAAGAA AAGAAT AGAATC GAATCT AATCTG ATCTGT TCTGTC CTGTCT TGTCTC GTCTCT TCTCTT CTCTTA TCTTAT CTTATA TTATAC TATACC ATACCA TACCAC ACCACA CCACAT CACATC ACATCT CATCTC ATCTCC TCTCCG CTCCGA TCCGAG CCGAGC CGAGCC GAGCCC AGCCCA GCCCAC CCCACG CCACGA CACGAG ACGAGA CGAGAC GAGACA AGACAG GACAGG ACAGGC CAGGCA AGGCAG GGCAGA GCAGAA CAGAAA AGAAAT GAAATC AAATCT AATCTC ATCTCG TCTCGT CTCGTA TCGTAT CGTATG GTATGC TATGCC ATGCCG TGCCGT GCCGTC CCGTCT CGTCTT GTCTTC TCTTCT CTTCTG TTCTGC TCTGCT CTGCTT TGCTTG GCTTGA CTTGAA TTGAAA TGAAAA GAAAAA AAAAAA AAAAAA AAAAAA AAAAAA AAAAAA AAAAAA AAAAAA AAAAAA AAAAAA AAAAAA AAAAAC AAAACA AAACAA AACAAA ACAAAC CAAACA AAACAG AACAGC ACAGCC CAGCCA AGCCAT,0,145,CCAA CAAT AATA ATAA TAAA AAAT AATC ATCC TCCT CCTA CTAC TACT ACTG CTGA TGAC GACC ACCA CCAG CAGT AGTC GTCT TCTT CTTC TTCT TCTT CTTA TTAC TACA ACAT CATC ATCG TCGT CGTT GTTG TTGA TGAT GATA ATAG TAGT AGTG GTGT TGTT GTTA TTAC TACA ACAG CAGT AGTG GTGA TGAA GAAG AAGA AGAA GAAT AATC ATCT TCTG CTGT TGTC GTCT TCTC CTCT TCTT CTTA TTAT TATA ATAC TACC ACCA CCAC CACA ACAT CATC ATCT TCTC CTCC TCCG CCGA CGAG GAGC AGCC GCCC CCCA CCAC CACG ACGA CGAG GAGA AGAC GACA ACAG CAGG AGGC GGCA GCAG CAGA AGAA GAAA AAAT AATC ATCT TCTC CTCG TCGT CGTA GTAT TATG ATGC TGCC GCCG CCGT CGTC GTCT TCTT CTTC TTCT TCTG CTGC TGCT GCTT CTTG TTGA TGAA GAAA AAAA AAAA AAAA AAAA AAAA AAAA AAAA AAAA AAAA AAAA AAAA AAAA AAAC AACA ACAA CAAA AAAC AACA ACAG CAGC AGCC GCCA CCAT,CCAAT CAATA AATAA ATAAA TAAAT AAATC AATCC ATCCT TCCTA CCTAC CTACT TACTG ACTGA CTGAC TGACC GACCA ACCAG CCAGT CAGTC AGTCT GTCTT TCTTC CTTCT TTCTT TCTTA CTTAC TTACA TACAT ACATC CATCG ATCGT TCGTT CGTTG GTTGA TTGAT TGATA GATAG ATAGT TAGTG AGTGT GTGTT TGTTA GTTAC TTACA TACAG ACAGT CAGTG AGTGA GTGAA TGAAG GAAGA AAGAA AGAAT GAATC AATCT ATCTG TCTGT CTGTC TGTCT GTCTC TCTCT CTCTT TCTTA CTTAT TTATA TATAC ATACC TACCA ACCAC CCACA CACAT ACATC CATCT ATCTC TCTCC CTCCG TCCGA CCGAG CGAGC GAGCC AGCCC GCCCA CCCAC CCACG CACGA ACGAG CGAGA GAGAC AGACA GACAG ACAGG CAGGC AGGCA GGCAG GCAGA CAGAA AGAAA GAAAT AAATC AATCT ATCTC TCTCG CTCGT TCGTA CGTAT GTATG TATGC ATGCC TGCCG GCCGT CCGTC CGTCT GTCTT TCTTC CTTCT TTCTG TCTGC CTGCT TGCTT GCTTG CTTGA TTGAA TGAAA GAAAA AAAAA AAAAA AAAAA AAAAA AAAAA AAAAA AAAAA AAAAA AAAAA AAAAA AAAAA AAAAC AAACA AACAA ACAAA CAAAC AAACA AACAG ACAGC CAGCC AGCCA GCCAT,CCAATA CAATAA AATAAA ATAAAT TAAATC AAATCC AATCCT ATCCTA TCCTAC CCTACT CTACTG TACTGA ACTGAC CTGACC TGACCA GACCAG ACCAGT CCAGTC CAGTCT AGTCTT GTCTTC TCTTCT CTTCTT TTCTTA TCTTAC CTTACA TTACAT TACATC ACATCG CATCGT ATCGTT TCGTTG CGTTGA GTTGAT TTGATA TGATAG GATAGT ATAGTG TAGTGT AGTGTT GTGTTA TGTTAC GTTACA TTACAG TACAGT ACAGTG CAGTGA AGTGAA GTGAAG TGAAGA GAAGAA AAGAAT AGAATC GAATCT AATCTG ATCTGT TCTGTC CTGTCT TGTCTC GTCTCT TCTCTT CTCTTA TCTTAT CTTATA TTATAC TATACC ATACCA TACCAC ACCACA CCACAT CACATC ACATCT CATCTC ATCTCC TCTCCG CTCCGA TCCGAG CCGAGC CGAGCC GAGCCC AGCCCA GCCCAC CCCACG CCACGA CACGAG ACGAGA CGAGAC GAGACA AGACAG GACAGG ACAGGC CAGGCA AGGCAG GGCAGA GCAGAA CAGAAA AGAAAT GAAATC AAATCT AATCTC ATCTCG TCTCGT CTCGTA TCGTAT CGTATG GTATGC TATGCC ATGCCG TGCCGT GCCGTC CCGTCT CGTCTT GTCTTC TCTTCT CTTCTG TTCTGC TCTGCT CTGCTT TGCTTG GCTTGA CTTGAA TTGAAA TGAAAA GAAAAA AAAAAA AAAAAA AAAAAA AAAAAA AAAAAA AAAAAA AAAAAA AAAAAA AAAAAA AAAAAA AAAAAC AAAACA AAACAA AACAAA ACAAAC CAAACA AAACAG AACAGC ACAGCC CAGCCA AGCCAT,CCAATAA CAATAAA AATAAAT ATAAATC TAAATCC AAATCCT AATCCTA ATCCTAC TCCTACT CCTACTG CTACTGA TACTGAC ACTGACC CTGACCA TGACCAG GACCAGT ACCAGTC CCAGTCT CAGTCTT AGTCTTC GTCTTCT TCTTCTT CTTCTTA TTCTTAC TCTTACA CTTACAT TTACATC TACATCG ACATCGT CATCGTT ATCGTTG TCGTTGA CGTTGAT GTTGATA TTGATAG TGATAGT GATAGTG ATAGTGT TAGTGTT AGTGTTA GTGTTAC TGTTACA GTTACAG TTACAGT TACAGTG ACAGTGA CAGTGAA AGTGAAG GTGAAGA TGAAGAA GAAGAAT AAGAATC AGAATCT GAATCTG AATCTGT ATCTGTC TCTGTCT CTGTCTC TGTCTCT GTCTCTT TCTCTTA CTCTTAT TCTTATA CTTATAC TTATACC TATACCA ATACCAC TACCACA ACCACAT CCACATC CACATCT ACATCTC CATCTCC ATCTCCG TCTCCGA CTCCGAG TCCGAGC CCGAGCC CGAGCCC GAGCCCA AGCCCAC GCCCACG CCCACGA CCACGAG CACGAGA ACGAGAC CGAGACA GAGACAG AGACAGG GACAGGC ACAGGCA CAGGCAG AGGCAGA GGCAGAA GCAGAAA CAGAAAT AGAAATC GAAATCT AAATCTC AATCTCG ATCTCGT TCTCGTA CTCGTAT TCGTATG CGTATGC GTATGCC TATGCCG ATGCCGT TGCCGTC GCCGTCT CCGTCTT CGTCTTC GTCTTCT TCTTCTG CTTCTGC TTCTGCT TCTGCTT CTGCTTG TGCTTGA GCTTGAA CTTGAAA TTGAAAA TGAAAAA GAAAAAA AAAAAAA AAAAAAA AAAAAAA AAAAAAA AAAAAAA AAAAAAA AAAAAAA AAAAAAA AAAAAAA AAAAAAC AAAAACA AAAACAA AAACAAA AACAAAC ACAAACA CAAACAG AAACAGC AACAGCC ACAGCCA CAGCCAT,"ID   R1A_SARS2               Reviewed;        4405 AA.
AC   P0DTC1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1a;
DE            Short=pp1a;
DE   AltName: Full=ORF1a polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69;
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=RNA-capping enzyme subunit nsp9;
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=Non-structural protein 11;
DE              Short=nsp11;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [5]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [6]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [7]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (NON-STRUCTURAL PROTEIN 10),
RP   MUTAGENESIS OF ASN-4141 AND ASN-4142, AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [8]
RP   REVIEW, SUBUNIT (NON-STRUCTURAL PROTEIN 7), AND SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [9]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [10]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [11]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN
RP   COMPLEX WITH ALPHA-KETOAMIDE INHIBITORS, SUBUNIT (3C-LIKE PROTEINASE NSP5),
RP   ACTIVE SITE, AND ACTIVITY REGULATION.
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE APOENZYME AND
RP   IN COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5), AND CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7 AND NON-STRUCTURAL PROTEIN 8, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 7), AND
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [16]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7 AND NON-STRUCTURAL PROTEIN 8, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 7), AND
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [18]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7 AND NON-STRUCTURAL PROTEIN 8, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 7), AND
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION OF NON-STRUCTURAL PROTEIN 3.
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [20]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7 AND NON-STRUCTURAL PROTEIN 8 IN COMPLEX WITH ZINC ION, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), AND FUNCTION (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), CATALYTIC ACTIVITY (NON-STRUCTURAL
RP   PROTEIN 3), ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 3), AND MUTAGENESIS
RP   OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [22]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [23]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [24]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   AND INTERACTION WITH HOST TBK1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [25]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), AND SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [26]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [27]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [28]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9 AND NON-STRUCTURAL
RP   PROTEIN 10, AND SUBUNIT (NON-STRUCTURAL PROTEIN 8).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [29]
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
CC   -!- FUNCTION: [Replicase polyprotein 1a]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by nsp3 and nsp4, while nsp6 zippers
CC       ER membranes and connects to lipid droplets (PubMed:35551511).
CC       {ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [3C-like proteinase nsp5]: Cleaves the C-terminus of
CC       replicase polyprotein at 11 sites (PubMed:32321856). Recognizes
CC       substrates containing the core sequence [ILMVF]-Q-|-[SGACN]
CC       (PubMed:32198291, PubMed:32272481). May cleave human NLRP1 in lung
CC       epithelial cells, thereby activating the NLRP1 inflammasome pathway
CC       (PubMed:35594856). May cleave human GSDMD, triggering alternative
CC       GSDME-mediated epithelial cell death upon activation of the NLRP1
CC       inflammasome, which may enhance the release interleukins 1B, 6, 16 and
CC       18 (PubMed:35594856). Also able to bind an ADP-ribose-1''-phosphate
CC       (ADRP) (PubMed:32198291, PubMed:32272481).
CC       {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481,
CC       ECO:0000269|PubMed:32321856, ECO:0000269|PubMed:32680882,
CC       ECO:0000269|PubMed:35594856}.
CC   -!- FUNCTION: [Non-structural protein 6]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by nsp3 and nsp4, while nsp6 zippers
CC       ER membranes and connects to lipid droplets (LDs) (PubMed:35551511).
CC       LDs are consumed during DMV formation (PubMed:35551511). Binds to host
CC       TBK1 without affecting TBK1 phosphorylation; the interaction with TBK1
CC       decreases IRF3 phosphorylation, which leads to reduced IFN-beta
CC       production (PubMed:32979938). {ECO:0000269|PubMed:32979938,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 7]: Plays a role in viral RNA
CC       synthesis (PubMed:32277040, PubMed:32358203, PubMed:32438371,
CC       PubMed:32526208). Forms a hexadecamer with nsp8 (8 subunits of each)
CC       that may participate in viral replication by acting as a primase.
CC       Alternatively, may synthesize substantially longer products than
CC       oligonucleotide primers (By similarity). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32277040, ECO:0000269|PubMed:32358203,
CC       ECO:0000269|PubMed:32438371, ECO:0000269|PubMed:32526208}.
CC   -!- FUNCTION: [Non-structural protein 8]: Plays a role in viral RNA
CC       synthesis (PubMed:32277040, PubMed:32358203, PubMed:32438371,
CC       PubMed:32526208). Forms a hexadecamer with nsp7 (8 subunits of each)
CC       that may participate in viral replication by acting as a primase.
CC       Alternatively, may synthesize substantially longer products than
CC       oligonucleotide primers (By similarity). Interacts with ribosome signal
CC       recognition particle RNA (SRP) (PubMed:33080218). Together with NSP9,
CC       suppress protein integration into the cell membrane, thereby disrupting
CC       host immune defenses (PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32277040, ECO:0000269|PubMed:32358203,
CC       ECO:0000269|PubMed:32438371, ECO:0000269|PubMed:32526208,
CC       ECO:0000269|PubMed:33080218}.
CC   -!- FUNCTION: [RNA-capping enzyme subunit nsp9]: Catalytic subunit of viral
CC       RNA capping enzyme which catalyzes the RNA guanylyltransferase reaction
CC       for genomic and sub-genomic RNAs (PubMed:35944563). The kinase-like
CC       NiRAN domain of NSP12 transfers RNA to the amino terminus of NSP9,
CC       forming a covalent RNA-protein intermediate (PubMed:35944563).
CC       Subsequently, the NiRAN domain transfers RNA to GDP, forming the core
CC       cap structure GpppA-RNA (PubMed:35944563). The NSP14 and NSP16
CC       methyltransferases then add methyl groups to form functional cap
CC       structures (PubMed:35944563). Interacts with ribosome signal
CC       recognition particle RNA (SRP) (PubMed:33080218). Together with NSP8,
CC       suppress protein integration into the cell membrane, thereby disrupting
CC       host immune defenses (PubMed:33080218). {ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:35944563}.
CC   -!- FUNCTION: [Non-structural protein 10]: Plays a pivotal role in viral
CC       transcription by stimulating both nsp14 3'-5' exoribonuclease (By
CC       similarity) and nsp16 2'-O-methyltransferase activities
CC       (PubMed:35944563). Therefore plays an essential role in viral mRNAs cap
CC       methylation. {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:35944563}.
CC   -!- CATALYTIC ACTIVITY: [Papain-like protease nsp3]:
CC       Reaction=Thiol-dependent hydrolysis of ester, thioester, amide, peptide
CC         and isopeptide bonds formed by the C-terminal Gly of ubiquitin (a 76-
CC         residue protein attached to proteins as an intracellular targeting
CC         signal).; EC=3.4.19.12; Evidence={ECO:0000269|PubMed:32726803};
CC   -!- CATALYTIC ACTIVITY: [3C-like proteinase nsp5]:
CC       Reaction=TSAVLQ-|-SGFRK-NH2 and SGVTFQ-|-GKFKK the two peptides
CC         corresponding to the two self-cleavage sites of the SARS 3C-like
CC         proteinase are the two most reactive peptide substrates. The enzyme
CC         exhibits a strong preference for substrates containing Gln at P1
CC         position and Leu at P2 position.; EC=3.4.22.69;
CC         Evidence={ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481,
CC         ECO:0000269|PubMed:32321856};
CC   -!- CATALYTIC ACTIVITY: [RNA-capping enzyme subunit nsp9]:
CC       Reaction=a 5'-end diphospho-ribonucleoside in mRNA + GTP + H(+) = a 5'-
CC         end (5'-triphosphoguanosine)-ribonucleoside in mRNA + diphosphate;
CC         Xref=Rhea:RHEA:67012, Rhea:RHEA-COMP:17165, Rhea:RHEA-COMP:17166,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:33019, ChEBI:CHEBI:37565,
CC         ChEBI:CHEBI:167616, ChEBI:CHEBI:167617; EC=2.7.7.50;
CC         Evidence={ECO:0000269|PubMed:35944563};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:67014;
CC         Evidence={ECO:0000269|PubMed:35944563};
CC   -!- ACTIVITY REGULATION: [Non-structural protein 6]: Inhibited ex vivo by
CC       K22. It may shift NSP6 zippering activity towards the nuclear envelope,
CC       thereby impairing formation of the NSP6-compartment necessary for viral
CC       transcription/replication. {ECO:0000269|PubMed:35551511}.
CC   -!- ACTIVITY REGULATION: [Papain-like protease nsp3]: Inhibited in vitro by
CC       GRL-0617. {ECO:0000269|PubMed:32726803}.
CC   -!- ACTIVITY REGULATION: [3C-like proteinase nsp5]: Inhibited by pyridone-
CC       containing alpha-ketoamides compounds 13a and 13b. In turn, alpha-
CC       ketoamide 13b (tert-butyl (1-((S)-1-(((S)-4-(benzylamino)-3,4-dioxo-1-
CC       ((S)-2-oxopyrrolidin-3-yl)butan-2-yl)amino)-3-cyclopropyl-1-oxopropan-
CC       2-yl)-2-oxo-1,2-dihydropyridin-3-yl)carbamate) inhibits SARS-CoV-2
CC       replication in human lung cells (PubMed:32198291). Inhibited ex vivo by
CC       michael acceptor inhibitor N3 (PubMed:32272481). Inhibited ex vivo by
CC       compound 11a and 11b (PubMed:32321856). {ECO:0000269|PubM",22853
ACTAAA CTAAAG TAAAGA AAAGAA AAGAAG AGAAGG GAAGGT AAGGTG AGGTGC GGTGCC GTGCCA TGCCAC GCCACT CCACTA CACTAC ACTACT CTACTT TACTTG ACTTGT CTTGTG TTGTGG TGTGGT GTGGTT TGGTTA GGTTAC GTTACT TTACTT TACTTA ACTTAC CTTACC TTACCC TACCCC ACCCCA CCCCAA CCCAAA CCAAAA CAAAAT AAAATG AAATGC AATGCT ATGCTG TGCTGT GCTGTT CTGTTG TGTTGT GTTGTT TTGTTA TGTTAA GTTAAA TTAAAA TAAAAT AAAATT AAATTT AATTTA ATTTAT TTTATT TTATTG TATTGT ATTGTC TTGTCC TGTCCA GTCCAG TCCAGC CCAGCA CAGCAT AGCATG GCATGT CATGTC ATGTCA TGTCAC GTCACA TCACAA CACAAT ACAATT CAATTC AATTCA ATTCAG TTCAGA TCAGAA CAGAAG AGAAGT GAAGTA AAGTAG AGTAGG GTAGGA TAGGAC AGGACC GGACCT GACCTG ACCTGA CCTGAG CTGAGC TGAGCA GAGCAT AGCATA GCATAG CATAGT ATAGTC TAGTCT AGTCTT GTCTTG TCTTGC CTTGCC TTGCCG TGCCGA GCCGAA CCGAAT CGAATA GAATAC AATACC ATACCA TACCAT ACCATA CCATAA CATAAT ATAATG TAATGA AATGAA ATGAAT TGAATC GAATCT AATCTG ATCTGG TCTGGC CTGGCT TGGCTT GGCTTG GCTTGA CTTGAA TTGAAA TGAAAA GAAAAC AAAACC AAACCA AACCAT ACCATT,0,136,ACTA CTAA TAAA AAAG AAGA AGAA GAAG AAGG AGGT GGTG GTGC TGCC GCCA CCAC CACT ACTA CTAC TACT ACTT CTTG TTGT TGTG GTGG TGGT GGTT GTTA TTAC TACT ACTT CTTA TTAC TACC ACCC CCCC CCCA CCAA CAAA AAAA AAAT AATG ATGC TGCT GCTG CTGT TGTT GTTG TTGT TGTT GTTA TTAA TAAA AAAA AAAT AATT ATTT TTTA TTAT TATT ATTG TTGT TGTC GTCC TCCA CCAG CAGC AGCA GCAT CATG ATGT TGTC GTCA TCAC CACA ACAA CAAT AATT ATTC TTCA TCAG CAGA AGAA GAAG AAGT AGTA GTAG TAGG AGGA GGAC GACC ACCT CCTG CTGA TGAG GAGC AGCA GCAT CATA ATAG TAGT AGTC GTCT TCTT CTTG TTGC TGCC GCCG CCGA CGAA GAAT AATA ATAC TACC ACCA CCAT CATA ATAA TAAT AATG ATGA TGAA GAAT AATC ATCT TCTG CTGG TGGC GGCT GCTT CTTG TTGA TGAA GAAA AAAA AAAC AACC ACCA CCAT CATT,ACTAA CTAAA TAAAG AAAGA AAGAA AGAAG GAAGG AAGGT AGGTG GGTGC GTGCC TGCCA GCCAC CCACT CACTA ACTAC CTACT TACTT ACTTG CTTGT TTGTG TGTGG GTGGT TGGTT GGTTA GTTAC TTACT TACTT ACTTA CTTAC TTACC TACCC ACCCC CCCCA CCCAA CCAAA CAAAA AAAAT AAATG AATGC ATGCT TGCTG GCTGT CTGTT TGTTG GTTGT TTGTT TGTTA GTTAA TTAAA TAAAA AAAAT AAATT AATTT ATTTA TTTAT TTATT TATTG ATTGT TTGTC TGTCC GTCCA TCCAG CCAGC CAGCA AGCAT GCATG CATGT ATGTC TGTCA GTCAC TCACA CACAA ACAAT CAATT AATTC ATTCA TTCAG TCAGA CAGAA AGAAG GAAGT AAGTA AGTAG GTAGG TAGGA AGGAC GGACC GACCT ACCTG CCTGA CTGAG TGAGC GAGCA AGCAT GCATA CATAG ATAGT TAGTC AGTCT GTCTT TCTTG CTTGC TTGCC TGCCG GCCGA CCGAA CGAAT GAATA AATAC ATACC TACCA ACCAT CCATA CATAA ATAAT TAATG AATGA ATGAA TGAAT GAATC AATCT ATCTG TCTGG CTGGC TGGCT GGCTT GCTTG CTTGA TTGAA TGAAA GAAAA AAAAC AAACC AACCA ACCAT CCATT,ACTAAA CTAAAG TAAAGA AAAGAA AAGAAG AGAAGG GAAGGT AAGGTG AGGTGC GGTGCC GTGCCA TGCCAC GCCACT CCACTA CACTAC ACTACT CTACTT TACTTG ACTTGT CTTGTG TTGTGG TGTGGT GTGGTT TGGTTA GGTTAC GTTACT TTACTT TACTTA ACTTAC CTTACC TTACCC TACCCC ACCCCA CCCCAA CCCAAA CCAAAA CAAAAT AAAATG AAATGC AATGCT ATGCTG TGCTGT GCTGTT CTGTTG TGTTGT GTTGTT TTGTTA TGTTAA GTTAAA TTAAAA TAAAAT AAAATT AAATTT AATTTA ATTTAT TTTATT TTATTG TATTGT ATTGTC TTGTCC TGTCCA GTCCAG TCCAGC CCAGCA CAGCAT AGCATG GCATGT CATGTC ATGTCA TGTCAC GTCACA TCACAA CACAAT ACAATT CAATTC AATTCA ATTCAG TTCAGA TCAGAA CAGAAG AGAAGT GAAGTA AAGTAG AGTAGG GTAGGA TAGGAC AGGACC GGACCT GACCTG ACCTGA CCTGAG CTGAGC TGAGCA GAGCAT AGCATA GCATAG CATAGT ATAGTC TAGTCT AGTCTT GTCTTG TCTTGC CTTGCC TTGCCG TGCCGA GCCGAA CCGAAT CGAATA GAATAC AATACC ATACCA TACCAT ACCATA CCATAA CATAAT ATAATG TAATGA AATGAA ATGAAT TGAATC GAATCT AATCTG ATCTGG TCTGGC CTGGCT TGGCTT GGCTTG GCTTGA CTTGAA TTGAAA TGAAAA GAAAAC AAAACC AAACCA AACCAT ACCATT,ACTAAAG CTAAAGA TAAAGAA AAAGAAG AAGAAGG AGAAGGT GAAGGTG AAGGTGC AGGTGCC GGTGCCA GTGCCAC TGCCACT GCCACTA CCACTAC CACTACT ACTACTT CTACTTG TACTTGT ACTTGTG CTTGTGG TTGTGGT TGTGGTT GTGGTTA TGGTTAC GGTTACT GTTACTT TTACTTA TACTTAC ACTTACC CTTACCC TTACCCC TACCCCA ACCCCAA CCCCAAA CCCAAAA CCAAAAT CAAAATG AAAATGC AAATGCT AATGCTG ATGCTGT TGCTGTT GCTGTTG CTGTTGT TGTTGTT GTTGTTA TTGTTAA TGTTAAA GTTAAAA TTAAAAT TAAAATT AAAATTT AAATTTA AATTTAT ATTTATT TTTATTG TTATTGT TATTGTC ATTGTCC TTGTCCA TGTCCAG GTCCAGC TCCAGCA CCAGCAT CAGCATG AGCATGT GCATGTC CATGTCA ATGTCAC TGTCACA GTCACAA TCACAAT CACAATT ACAATTC CAATTCA AATTCAG ATTCAGA TTCAGAA TCAGAAG CAGAAGT AGAAGTA GAAGTAG AAGTAGG AGTAGGA GTAGGAC TAGGACC AGGACCT GGACCTG GACCTGA ACCTGAG CCTGAGC CTGAGCA TGAGCAT GAGCATA AGCATAG GCATAGT CATAGTC ATAGTCT TAGTCTT AGTCTTG GTCTTGC TCTTGCC CTTGCCG TTGCCGA TGCCGAA GCCGAAT CCGAATA CGAATAC GAATACC AATACCA ATACCAT TACCATA ACCATAA CCATAAT CATAATG ATAATGA TAATGAA AATGAAT ATGAATC TGAATCT GAATCTG AATCTGG ATCTGGC TCTGGCT CTGGCTT TGGCTTG GGCTTGA GCTTGAA CTTGAAA TTGAAAA TGAAAAC GAAAACC AAAACCA AAACCAT AACCATT,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",606
ACTATA CTATAG TATAGG ATAGGT TAGGTC AGGTCC GGTCCA GTCCAG TCCAGA CCAGAC CAGACA AGACAT GACATG ACATGT CATGTT ATGTTC TGTTCC GTTCCT TTCCTC TCCTCG CCTCGG CTCGGA TCGGAA CGGAAC GGAACT GAACTT AACTTG ACTTGT CTTGTC TTGTCG TGTCGG GTCGGC TCGGCG CGGCGT GGCGTT GCGTTG CGTTGT GTTGTC TTGTCC TGTCCT GTCCTG TCCTGC CCTGCT CTGCTG TGCTGA GCTGAA CTGAAA TGAAAT GAAATT AAATTG AATTGT ATTGTT TTGTTG TGTTGA GTTGAC TTGACA TGACAC GACACT ACACTG CACTGT ACTGTG CTGTGA TGTGAG GTGAGT TGAGTG GAGTGC AGTGCT GTGCTT TGCTTT GCTTTG CTTTGG TTTGGT TTGGTT TGGTTT GGTTTA GTTTAT TTTATG TTATGA TATGAT ATGATA TGATAA GATAAT ATAATA TAATAA AATAAG ATAAGC TAAGCT AAGCTT AGCTTA GCTTAA CTTAAA TTAAAG TAAAGC AAAGCA AAGCAC AGCACA GCACAT CACATA ACATAA CATAAA ATAAAG TAAAGA AAAGAC AAGACA AGACAA GACAAA ACAAAT CAAATC AAATCA AATCAG ATCAGC TCAGCT CAGCTC AGCTCA GCTCAA CTCAAT TCAATG CAATGC AATGCT ATGCTT TGCTTT GCTTTA CTTTAA TTTAAA TTAAAA TAAAAT AAAATG AAATGT AATGTT ATGTTT TGTTTT GTTTTA TTTTAT TTTATA TTATAA TATAAG ATAAGG TAAGGG AAGGGT AGGGTG GGGTGT GGTGTT GTGTTA TGTTAT GTTATC,0,145,ACTA CTAT TATA ATAG TAGG AGGT GGTC GTCC TCCA CCAG CAGA AGAC GACA ACAT CATG ATGT TGTT GTTC TTCC TCCT CCTC CTCG TCGG CGGA GGAA GAAC AACT ACTT CTTG TTGT TGTC GTCG TCGG CGGC GGCG GCGT CGTT GTTG TTGT TGTC GTCC TCCT CCTG CTGC TGCT GCTG CTGA TGAA GAAA AAAT AATT ATTG TTGT TGTT GTTG TTGA TGAC GACA ACAC CACT ACTG CTGT TGTG GTGA TGAG GAGT AGTG GTGC TGCT GCTT CTTT TTTG TTGG TGGT GGTT GTTT TTTA TTAT TATG ATGA TGAT GATA ATAA TAAT AATA ATAA TAAG AAGC AGCT GCTT CTTA TTAA TAAA AAAG AAGC AGCA GCAC CACA ACAT CATA ATAA TAAA AAAG AAGA AGAC GACA ACAA CAAA AAAT AATC ATCA TCAG CAGC AGCT GCTC CTCA TCAA CAAT AATG ATGC TGCT GCTT CTTT TTTA TTAA TAAA AAAA AAAT AATG ATGT TGTT GTTT TTTT TTTA TTAT TATA ATAA TAAG AAGG AGGG GGGT GGTG GTGT TGTT GTTA TTAT TATC,ACTAT CTATA TATAG ATAGG TAGGT AGGTC GGTCC GTCCA TCCAG CCAGA CAGAC AGACA GACAT ACATG CATGT ATGTT TGTTC GTTCC TTCCT TCCTC CCTCG CTCGG TCGGA CGGAA GGAAC GAACT AACTT ACTTG CTTGT TTGTC TGTCG GTCGG TCGGC CGGCG GGCGT GCGTT CGTTG GTTGT TTGTC TGTCC GTCCT TCCTG CCTGC CTGCT TGCTG GCTGA CTGAA TGAAA GAAAT AAATT AATTG ATTGT TTGTT TGTTG GTTGA TTGAC TGACA GACAC ACACT CACTG ACTGT CTGTG TGTGA GTGAG TGAGT GAGTG AGTGC GTGCT TGCTT GCTTT CTTTG TTTGG TTGGT TGGTT GGTTT GTTTA TTTAT TTATG TATGA ATGAT TGATA GATAA ATAAT TAATA AATAA ATAAG TAAGC AAGCT AGCTT GCTTA CTTAA TTAAA TAAAG AAAGC AAGCA AGCAC GCACA CACAT ACATA CATAA ATAAA TAAAG AAAGA AAGAC AGACA GACAA ACAAA CAAAT AAATC AATCA ATCAG TCAGC CAGCT AGCTC GCTCA CTCAA TCAAT CAATG AATGC ATGCT TGCTT GCTTT CTTTA TTTAA TTAAA TAAAA AAAAT AAATG AATGT ATGTT TGTTT GTTTT TTTTA TTTAT TTATA TATAA ATAAG TAAGG AAGGG AGGGT GGGTG GGTGT GTGTT TGTTA GTTAT TTATC,ACTATA CTATAG TATAGG ATAGGT TAGGTC AGGTCC GGTCCA GTCCAG TCCAGA CCAGAC CAGACA AGACAT GACATG ACATGT CATGTT ATGTTC TGTTCC GTTCCT TTCCTC TCCTCG CCTCGG CTCGGA TCGGAA CGGAAC GGAACT GAACTT AACTTG ACTTGT CTTGTC TTGTCG TGTCGG GTCGGC TCGGCG CGGCGT GGCGTT GCGTTG CGTTGT GTTGTC TTGTCC TGTCCT GTCCTG TCCTGC CCTGCT CTGCTG TGCTGA GCTGAA CTGAAA TGAAAT GAAATT AAATTG AATTGT ATTGTT TTGTTG TGTTGA GTTGAC TTGACA TGACAC GACACT ACACTG CACTGT ACTGTG CTGTGA TGTGAG GTGAGT TGAGTG GAGTGC AGTGCT GTGCTT TGCTTT GCTTTG CTTTGG TTTGGT TTGGTT TGGTTT GGTTTA GTTTAT TTTATG TTATGA TATGAT ATGATA TGATAA GATAAT ATAATA TAATAA AATAAG ATAAGC TAAGCT AAGCTT AGCTTA GCTTAA CTTAAA TTAAAG TAAAGC AAAGCA AAGCAC AGCACA GCACAT CACATA ACATAA CATAAA ATAAAG TAAAGA AAAGAC AAGACA AGACAA GACAAA ACAAAT CAAATC AAATCA AATCAG ATCAGC TCAGCT CAGCTC AGCTCA GCTCAA CTCAAT TCAATG CAATGC AATGCT ATGCTT TGCTTT GCTTTA CTTTAA TTTAAA TTAAAA TAAAAT AAAATG AAATGT AATGTT ATGTTT TGTTTT GTTTTA TTTTAT TTTATA TTATAA TATAAG ATAAGG TAAGGG AAGGGT AGGGTG GGGTGT GGTGTT GTGTTA TGTTAT GTTATC,ACTATAG CTATAGG TATAGGT ATAGGTC TAGGTCC AGGTCCA GGTCCAG GTCCAGA TCCAGAC CCAGACA CAGACAT AGACATG GACATGT ACATGTT CATGTTC ATGTTCC TGTTCCT GTTCCTC TTCCTCG TCCTCGG CCTCGGA CTCGGAA TCGGAAC CGGAACT GGAACTT GAACTTG AACTTGT ACTTGTC CTTGTCG TTGTCGG TGTCGGC GTCGGCG TCGGCGT CGGCGTT GGCGTTG GCGTTGT CGTTGTC GTTGTCC TTGTCCT TGTCCTG GTCCTGC TCCTGCT CCTGCTG CTGCTGA TGCTGAA GCTGAAA CTGAAAT TGAAATT GAAATTG AAATTGT AATTGTT ATTGTTG TTGTTGA TGTTGAC GTTGACA TTGACAC TGACACT GACACTG ACACTGT CACTGTG ACTGTGA CTGTGAG TGTGAGT GTGAGTG TGAGTGC GAGTGCT AGTGCTT GTGCTTT TGCTTTG GCTTTGG CTTTGGT TTTGGTT TTGGTTT TGGTTTA GGTTTAT GTTTATG TTTATGA TTATGAT TATGATA ATGATAA TGATAAT GATAATA ATAATAA TAATAAG AATAAGC ATAAGCT TAAGCTT AAGCTTA AGCTTAA GCTTAAA CTTAAAG TTAAAGC TAAAGCA AAAGCAC AAGCACA AGCACAT GCACATA CACATAA ACATAAA CATAAAG ATAAAGA TAAAGAC AAAGACA AAGACAA AGACAAA GACAAAT ACAAATC CAAATCA AAATCAG AATCAGC ATCAGCT TCAGCTC CAGCTCA AGCTCAA GCTCAAT CTCAATG TCAATGC CAATGCT AATGCTT ATGCTTT TGCTTTA GCTTTAA CTTTAAA TTTAAAA TTAAAAT TAAAATG AAAATGT AAATGTT AATGTTT ATGTTTT TGTTTTA GTTTTAT TTTTATA TTTATAA TTATAAG TATAAGG ATAAGGG TAAGGGT AAGGGTG AGGGTGT GGGTGTT GGTGTTA GTGTTAT TGTTATC,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",0
ATTCAA TTCAAC TCAACA CAACAC AACACA ACACAT CACATC ACATCG CATCGA ATCGAA TCGAAA CGAAAG GAAAGC AAAGCC AAGCCT AGCCTG GCCTGA CCTGAA CTGAAC TGAACG GAACGA AACGAA ACGAAG CGAAGA GAAGAA AAGAAA AGAAAT GAAATC AAATCA AATCAG ATCAGG TCAGGC CAGGCA AGGCAT GGCATA GCATAT CATATC ATATCA TATCAC ATCACG TCACGG CACGGG ACGGGG CGGGGG GGGGGT GGGGTG GGGTGA GGTGAA GTGAAT TGAATG GAATGT AATGTA ATGTAG TGTAGA GTAGAT TAGATG AGATGA GATGAG ATGAGC TGAGCG GAGCGC AGCGCA GCGCAT CGCATT GCATTC CATTCC ATTCCC TTCCCG TCCCGA CCCGAC CCGACA CGACAG GACAGT ACAGTA CAGTAT AGTATT GTATTG TATTGT ATTGTA TTGTAC TGTACA GTACAA TACAAC ACAACA CAACAG AACAGG ACAGGC CAGGCC AGGCCG GGCCGA GCCGAC CCGACG CGACGA GACGAA ACGAAG CGAAGT GAAGTG AAGTGG AGTGGT GTGGTG TGGTGA GGTGAA GTGAAC TGAACA GAACAT AACATA ACATAG CATAGA ATAGAC TAGACC AGACCT GACCTT ACCTTA CCTTAC CTTACG TTACGG TACGGC ACGGCA CGGCAG GGCAGA GCAGAT CAGATG AGATGA GATGAA ATGAAC TGAACT GAACTC AACTCA ACTCAT CTCATC TCATCA CATCAC ATCACC TCACCC CACCCG ACCCGG CCCGGC CCGGCT CGGCTC GGCTCA GCTCAA CTCAAG,3,142,ATTC TTCA TCAA CAAC AACA ACAC CACA ACAT CATC ATCG TCGA CGAA GAAA AAAG AAGC AGCC GCCT CCTG CTGA TGAA GAAC AACG ACGA CGAA GAAG AAGA AGAA GAAA AAAT AATC ATCA TCAG CAGG AGGC GGCA GCAT CATA ATAT TATC ATCA TCAC CACG ACGG CGGG GGGG GGGG GGGT GGTG GTGA TGAA GAAT AATG ATGT TGTA GTAG TAGA AGAT GATG ATGA TGAG GAGC AGCG GCGC CGCA GCAT CATT ATTC TTCC TCCC CCCG CCGA CGAC GACA ACAG CAGT AGTA GTAT TATT ATTG TTGT TGTA GTAC TACA ACAA CAAC AACA ACAG CAGG AGGC GGCC GCCG CCGA CGAC GACG ACGA CGAA GAAG AAGT AGTG GTGG TGGT GGTG GTGA TGAA GAAC AACA ACAT CATA ATAG TAGA AGAC GACC ACCT CCTT CTTA TTAC TACG ACGG CGGC GGCA GCAG CAGA AGAT GATG ATGA TGAA GAAC AACT ACTC CTCA TCAT CATC ATCA TCAC CACC ACCC CCCG CCGG CGGC GGCT GCTC CTCA TCAA CAAG,ATTCA TTCAA TCAAC CAACA AACAC ACACA CACAT ACATC CATCG ATCGA TCGAA CGAAA GAAAG AAAGC AAGCC AGCCT GCCTG CCTGA CTGAA TGAAC GAACG AACGA ACGAA CGAAG GAAGA AAGAA AGAAA GAAAT AAATC AATCA ATCAG TCAGG CAGGC AGGCA GGCAT GCATA CATAT ATATC TATCA ATCAC TCACG CACGG ACGGG CGGGG GGGGG GGGGT GGGTG GGTGA GTGAA TGAAT GAATG AATGT ATGTA TGTAG GTAGA TAGAT AGATG GATGA ATGAG TGAGC GAGCG AGCGC GCGCA CGCAT GCATT CATTC ATTCC TTCCC TCCCG CCCGA CCGAC CGACA GACAG ACAGT CAGTA AGTAT GTATT TATTG ATTGT TTGTA TGTAC GTACA TACAA ACAAC CAACA AACAG ACAGG CAGGC AGGCC GGCCG GCCGA CCGAC CGACG GACGA ACGAA CGAAG GAAGT AAGTG AGTGG GTGGT TGGTG GGTGA GTGAA TGAAC GAACA AACAT ACATA CATAG ATAGA TAGAC AGACC GACCT ACCTT CCTTA CTTAC TTACG TACGG ACGGC CGGCA GGCAG GCAGA CAGAT AGATG GATGA ATGAA TGAAC GAACT AACTC ACTCA CTCAT TCATC CATCA ATCAC TCACC CACCC ACCCG CCCGG CCGGC CGGCT GGCTC GCTCA CTCAA TCAAG,ATTCAA TTCAAC TCAACA CAACAC AACACA ACACAT CACATC ACATCG CATCGA ATCGAA TCGAAA CGAAAG GAAAGC AAAGCC AAGCCT AGCCTG GCCTGA CCTGAA CTGAAC TGAACG GAACGA AACGAA ACGAAG CGAAGA GAAGAA AAGAAA AGAAAT GAAATC AAATCA AATCAG ATCAGG TCAGGC CAGGCA AGGCAT GGCATA GCATAT CATATC ATATCA TATCAC ATCACG TCACGG CACGGG ACGGGG CGGGGG GGGGGT GGGGTG GGGTGA GGTGAA GTGAAT TGAATG GAATGT AATGTA ATGTAG TGTAGA GTAGAT TAGATG AGATGA GATGAG ATGAGC TGAGCG GAGCGC AGCGCA GCGCAT CGCATT GCATTC CATTCC ATTCCC TTCCCG TCCCGA CCCGAC CCGACA CGACAG GACAGT ACAGTA CAGTAT AGTATT GTATTG TATTGT ATTGTA TTGTAC TGTACA GTACAA TACAAC ACAACA CAACAG AACAGG ACAGGC CAGGCC AGGCCG GGCCGA GCCGAC CCGACG CGACGA GACGAA ACGAAG CGAAGT GAAGTG AAGTGG AGTGGT GTGGTG TGGTGA GGTGAA GTGAAC TGAACA GAACAT AACATA ACATAG CATAGA ATAGAC TAGACC AGACCT GACCTT ACCTTA CCTTAC CTTACG TTACGG TACGGC ACGGCA CGGCAG GGCAGA GCAGAT CAGATG AGATGA GATGAA ATGAAC TGAACT GAACTC AACTCA ACTCAT CTCATC TCATCA CATCAC ATCACC TCACCC CACCCG ACCCGG CCCGGC CCGGCT CGGCTC GGCTCA GCTCAA CTCAAG,ATTCAAC TTCAACA TCAACAC CAACACA AACACAT ACACATC CACATCG ACATCGA CATCGAA ATCGAAA TCGAAAG CGAAAGC GAAAGCC AAAGCCT AAGCCTG AGCCTGA GCCTGAA CCTGAAC CTGAACG TGAACGA GAACGAA AACGAAG ACGAAGA CGAAGAA GAAGAAA AAGAAAT AGAAATC GAAATCA AAATCAG AATCAGG ATCAGGC TCAGGCA CAGGCAT AGGCATA GGCATAT GCATATC CATATCA ATATCAC TATCACG ATCACGG TCACGGG CACGGGG ACGGGGG CGGGGGT GGGGGTG GGGGTGA GGGTGAA GGTGAAT GTGAATG TGAATGT GAATGTA AATGTAG ATGTAGA TGTAGAT GTAGATG TAGATGA AGATGAG GATGAGC ATGAGCG TGAGCGC GAGCGCA AGCGCAT GCGCATT CGCATTC GCATTCC CATTCCC ATTCCCG TTCCCGA TCCCGAC CCCGACA CCGACAG CGACAGT GACAGTA ACAGTAT CAGTATT AGTATTG GTATTGT TATTGTA ATTGTAC TTGTACA TGTACAA GTACAAC TACAACA ACAACAG CAACAGG AACAGGC ACAGGCC CAGGCCG AGGCCGA GGCCGAC GCCGACG CCGACGA CGACGAA GACGAAG ACGAAGT CGAAGTG GAAGTGG AAGTGGT AGTGGTG GTGGTGA TGGTGAA GGTGAAC GTGAACA TGAACAT GAACATA AACATAG ACATAGA CATAGAC ATAGACC TAGACCT AGACCTT GACCTTA ACCTTAC CCTTACG CTTACGG TTACGGC TACGGCA ACGGCAG CGGCAGA GGCAGAT GCAGATG CAGATGA AGATGAA GATGAAC ATGAACT TGAACTC GAACTCA AACTCAT ACTCATC CTCATCA TCATCAC CATCACC ATCACCC TCACCCG CACCCGG ACCCGGC CCCGGCT CCGGCTC CGGCTCA GGCTCAA GCTCAAG,"ID   KDPD_SYNY3              Reviewed;         370 AA.
AC   P73870;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   01-FEB-1997, sequence version 1.
DT   05-FEB-2025, entry version 126.
DE   RecName: Full=Putative sensor protein KdpD;
DE            EC=2.7.3.-;
GN   Name=kdpD; OrderedLocusNames=slr1731;
OS   Synechocystis sp. (strain ATCC 27184 / PCC 6803 / Kazusa).
OC   Bacteria; Bacillati; Cyanobacteriota; Cyanophyceae; Synechococcales;
OC   Merismopediaceae; Synechocystis.
OX   NCBI_TaxID=1111708;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 27184 / PCC 6803 / Kazusa;
RX   PubMed=8905231; DOI=10.1093/dnares/3.3.109;
RA   Kaneko T., Sato S., Kotani H., Tanaka A., Asamizu E., Nakamura Y.,
RA   Miyajima N., Hirosawa M., Sugiura M., Sasamoto S., Kimura T., Hosouchi T.,
RA   Matsuno A., Muraki A., Nakazaki N., Naruo K., Okumura S., Shimpo S.,
RA   Takeuchi C., Wada T., Watanabe A., Yamada M., Yasuda M., Tabata S.;
RT   ""Sequence analysis of the genome of the unicellular cyanobacterium
RT   Synechocystis sp. strain PCC6803. II. Sequence determination of the entire
RT   genome and assignment of potential protein-coding regions."";
RL   DNA Res. 3:109-136(1996).
CC   -!- FUNCTION: Member of the two-component regulatory system KdpD/KdpE
CC       involved in the regulation of the kdp operon. KdpD may function as a
CC       membrane-associated protein kinase that phosphorylates KdpE in response
CC       to environmental signals (By similarity). {ECO:0000250}.
CC   -!- SIMILARITY: In the C-terminal section; belongs to the universal stress
CC       protein A family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; BA000022; BAA17932.1; -; Genomic_DNA.
DR   PIR; S75070; S75070.
DR   AlphaFoldDB; P73870; -.
DR   SMR; P73870; -.
DR   IntAct; P73870; 2.
DR   STRING; 1148.gene:10498801; -.
DR   PaxDb; 1148-1653015; -.
DR   EnsemblBacteria; BAA17932; BAA17932; BAA17932.
DR   KEGG; syn:slr1731; -.
DR   eggNOG; COG2205; Bacteria.
DR   InParanoid; P73870; -.
DR   PhylomeDB; P73870; -.
DR   Proteomes; UP000001425; Chromosome.
DR   GO; GO:0016020; C:membrane; IEA:InterPro.
DR   GO; GO:0000155; F:phosphorelay sensor kinase activity; IEA:InterPro.
DR   CDD; cd01987; USP_OKCHK; 1.
DR   FunFam; 3.40.50.300:FF:000483; Sensor histidine kinase KdpD; 1.
DR   FunFam; 3.40.50.620:FF:000112; Sensor histidine kinase KdpD; 1.
DR   Gene3D; 3.40.50.620; HUPs; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   InterPro; IPR052023; Histidine_kinase_KdpD.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR014729; Rossmann-like_a/b/a_fold.
DR   InterPro; IPR003852; Sig_transdc_His_kinase_KdpD_N.
DR   PANTHER; PTHR45569; SENSOR PROTEIN KDPD; 1.
DR   PANTHER; PTHR45569:SF1; SENSOR PROTEIN KDPD; 1.
DR   Pfam; PF02702; KdpD; 1.
DR   SUPFAM; SSF52402; Adenine nucleotide alpha hydrolases-like; 1.
PE   3: Inferred from homology;
KW   Kinase; Reference proteome; Transferase; Two-component regulatory system.
FT   CHAIN           1..370
FT                   /note=""Putative sensor protein KdpD""
FT                   /id=""PRO_0000074775""
FT   REGION          1..22
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        1..12
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
SQ   SEQUENCE   370 AA;  41661 MW;  0A68AC7B831981B2 CRC64;
     MIHAGQSSSL TPAASPPHRR GKHKIFIGMA PGVGKTYRML EEGQQLKQEG FDVVIGLLET
     HGREETAQKA IGLEQVPLRT MIWQGRSLLE MDTGAILARS PQLALVDELA HTNIPGAERE
     KRYQDVELIL AAGIDVYSTI NIQHLESLND LVYKISGVVV RERVPDRLLD EADEVVVVDV
     TPETLQERLQ EGKIYAQDKI NQALQNFFKR QNLVALRELA LREVANNIEE NSRHDQQTNH
     CAVHERILVC ISTYPNSIQL LRRGGRIASQ MNGRLFVLFV APTNQFLSKV EALHVETCQH
     LTQEFEGEFI RQESDNVVGA IAQVATTYRI TQIVLGESRR SRWHLLIKGS IIQRLMRCLP
     TVDLHIIANG
//
",47112
ATGGAC TGGACC GGACCC GACCCC ACCCCA CCCCAA CCCAAA CCAAAA CAAAAT AAAATC AAATCA AATCAG ATCAGC TCAGCG CAGCGA AGCGAA GCGAAA CGAAAT GAAATG AAATGC AATGCA ATGCAC TGCACT GCACTC CACTCC ACTCCG CTCCGC TCCGCA CCGCAT CGCATT GCATTA CATTAC ATTACG TTACGT TACGTT ACGTTT CGTTTG GTTTGG TTTGGT TTGGTG TGGTGG GGTGGA GTGGAC TGGACC GGACCC GACCCT ACCCTC CCCTCA CCTCAG CTCAGA TCAGAT CAGATT AGATTC GATTCA ATTCAA TTCAAC TCAACT CAACTG AACTGG ACTGGC CTGGCA TGGCAG GGCAGT GCAGTA CAGTAA AGTAAC GTAACC TAACCA AACCAG ACCAGA CCAGAA CAGAAT AGAATG GAATGG AATGGT ATGGTG TGGTGG GGTGGG GTGGGG TGGGGC GGGGCG GGGCGC GGCGCG GCGCGA CGCGAT,3,85,ATGG TGGA GGAC GACC ACCC CCCC CCCA CCAA CAAA AAAA AAAT AATC ATCA TCAG CAGC AGCG GCGA CGAA GAAA AAAT AATG ATGC TGCA GCAC CACT ACTC CTCC TCCG CCGC CGCA GCAT CATT ATTA TTAC TACG ACGT CGTT GTTT TTTG TTGG TGGT GGTG GTGG TGGA GGAC GACC ACCC CCCT CCTC CTCA TCAG CAGA AGAT GATT ATTC TTCA TCAA CAAC AACT ACTG CTGG TGGC GGCA GCAG CAGT AGTA GTAA TAAC AACC ACCA CCAG CAGA AGAA GAAT AATG ATGG TGGT GGTG GTGG TGGG GGGG GGGC GGCG GCGC CGCG GCGA CGAT,ATGGA TGGAC GGACC GACCC ACCCC CCCCA CCCAA CCAAA CAAAA AAAAT AAATC AATCA ATCAG TCAGC CAGCG AGCGA GCGAA CGAAA GAAAT AAATG AATGC ATGCA TGCAC GCACT CACTC ACTCC CTCCG TCCGC CCGCA CGCAT GCATT CATTA ATTAC TTACG TACGT ACGTT CGTTT GTTTG TTTGG TTGGT TGGTG GGTGG GTGGA TGGAC GGACC GACCC ACCCT CCCTC CCTCA CTCAG TCAGA CAGAT AGATT GATTC ATTCA TTCAA TCAAC CAACT AACTG ACTGG CTGGC TGGCA GGCAG GCAGT CAGTA AGTAA GTAAC TAACC AACCA ACCAG CCAGA CAGAA AGAAT GAATG AATGG ATGGT TGGTG GGTGG GTGGG TGGGG GGGGC GGGCG GGCGC GCGCG CGCGA GCGAT,ATGGAC TGGACC GGACCC GACCCC ACCCCA CCCCAA CCCAAA CCAAAA CAAAAT AAAATC AAATCA AATCAG ATCAGC TCAGCG CAGCGA AGCGAA GCGAAA CGAAAT GAAATG AAATGC AATGCA ATGCAC TGCACT GCACTC CACTCC ACTCCG CTCCGC TCCGCA CCGCAT CGCATT GCATTA CATTAC ATTACG TTACGT TACGTT ACGTTT CGTTTG GTTTGG TTTGGT TTGGTG TGGTGG GGTGGA GTGGAC TGGACC GGACCC GACCCT ACCCTC CCCTCA CCTCAG CTCAGA TCAGAT CAGATT AGATTC GATTCA ATTCAA TTCAAC TCAACT CAACTG AACTGG ACTGGC CTGGCA TGGCAG GGCAGT GCAGTA CAGTAA AGTAAC GTAACC TAACCA AACCAG ACCAGA CCAGAA CAGAAT AGAATG GAATGG AATGGT ATGGTG TGGTGG GGTGGG GTGGGG TGGGGC GGGGCG GGGCGC GGCGCG GCGCGA CGCGAT,ATGGACC TGGACCC GGACCCC GACCCCA ACCCCAA CCCCAAA CCCAAAA CCAAAAT CAAAATC AAAATCA AAATCAG AATCAGC ATCAGCG TCAGCGA CAGCGAA AGCGAAA GCGAAAT CGAAATG GAAATGC AAATGCA AATGCAC ATGCACT TGCACTC GCACTCC CACTCCG ACTCCGC CTCCGCA TCCGCAT CCGCATT CGCATTA GCATTAC CATTACG ATTACGT TTACGTT TACGTTT ACGTTTG CGTTTGG GTTTGGT TTTGGTG TTGGTGG TGGTGGA GGTGGAC GTGGACC TGGACCC GGACCCT GACCCTC ACCCTCA CCCTCAG CCTCAGA CTCAGAT TCAGATT CAGATTC AGATTCA GATTCAA ATTCAAC TTCAACT TCAACTG CAACTGG AACTGGC ACTGGCA CTGGCAG TGGCAGT GGCAGTA GCAGTAA CAGTAAC AGTAACC GTAACCA TAACCAG AACCAGA ACCAGAA CCAGAAT CAGAATG AGAATGG GAATGGT AATGGTG ATGGTGG TGGTGGG GGTGGGG GTGGGGC TGGGGCG GGGGCGC GGGCGCG GGCGCGA GCGCGAT,"ID   ORF9B_BCHK3             Reviewed;          97 AA.
AC   Q3LZX3;
DT   12-JUN-2007, integrated into UniProtKB/Swiss-Prot.
DT   25-OCT-2005, sequence version 1.
DT   02-OCT-2024, entry version 58.
DE   RecName: Full=Protein 9b;
DE   AltName: Full=Accessory protein 9b;
DE   AltName: Full=ORF-9b;
GN   ORFNames=9b;
OS   Bat coronavirus HKU3 (BtCoV) (SARS-like coronavirus HKU3).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=442736;
OH   NCBI_TaxID=89399; Rhinolophus sinicus (Chinese rufous horseshoe bat).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RC   STRAIN=Isolate HKU3-1;
RX   PubMed=16169905; DOI=10.1073/pnas.0506735102;
RA   Lau S.K.P., Woo P.C.Y., Li K.S.M., Huang Y., Tsoi H.-W., Wong B.H.L.,
RA   Wong S.S.Y., Leung S.-Y., Chan K.-H., Yuen K.-Y.;
RT   ""Severe acute respiratory syndrome coronavirus-like virus in Chinese
RT   horseshoe bats."";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:14040-14045(2005).
CC   -!- SUBUNIT: Homodimer. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Host cytoplasmic vesicle membrane; Peripheral
CC       membrane protein. Host cytoplasm. Note=Binds non-covalently to
CC       intracellular lipid bilayers. {ECO:0000250}.
CC   -!- MISCELLANEOUS: The gene encoding this protein is included within the N
CC       gene (alternative ORF).
CC   -!- MISCELLANEOUS: Bat coronavirus HKU3 is highly similar to SARS-CoV
CC       (SARS-like).
CC   -!- SIMILARITY: Belongs to the coronavirus group 2 protein 9b family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; DQ022305; AAY88875.1; -; Genomic_RNA.
DR   SMR; Q3LZX3; -.
DR   Proteomes; UP000007450; Segment.
DR   GO; GO:0044162; C:host cell cytoplasmic vesicle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR   CDD; cd21955; SARS-CoV_ORF9b; 1.
DR   InterPro; IPR018542; Protein_9b_Betacoronavirus.
DR   InterPro; IPR037223; Protein_9b_SARS.
DR   Pfam; PF09399; bCoV_lipid_BD; 1.
DR   SUPFAM; SSF141666; SARS ORF9b-like; 1.
DR   PROSITE; PS51920; SARS_9B; 1.
PE   3: Inferred from homology;
KW   Host cytoplasm; Host cytoplasmic vesicle; Host membrane; Membrane.
FT   CHAIN           1..97
FT                   /note=""Protein 9b""
FT                   /id=""PRO_0000291325""
FT   DOMAIN          8..97
FT                   /note=""9b""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01268""
SQ   SEQUENCE   97 AA;  10723 MW;  1CAD2AFC3882E232 CRC64;
     MDPKVNVVPP ALHLVDPQIQ MTITRMEDAV VHDQNNAGPK VYPIILRLGS QLSLSMAKRN
     LDSLEARAFQ STPIVVKMTK LATTEELPDE FVVVTAK
//
",44777
CTCGCC TCGCCG CGCCGC GCCGCC CCGCCG CGCCGG GCCGGC CCGGCG CGGCGA GGCGAA GCGAAA CGAAAA GAAAAT AAAATC AAATCA AATCAC ATCACT TCACTA CACTAC ACTACA CTACAC TACACG ACACGC CACGCG ACGCGT CGCGTT GCGTTT CGTTTT GTTTTG TTTTGA TTTGAA TTGAAT TGAATT GAATTC AATTCA ATTCAA TTCAAC TCAACC CAACCG AACCGC ACCGCG CCGCGC CGCGCA GCGCAA CGCAAT GCAATC CAATCG AATCGA ATCGAG TCGAGG CGAGGA GAGGAC AGGACG GGACGG GACGGC ACGGCG CGGCGC GGCGCG GCGCGA CGCGAT GCGATC CGATCA GATCAC ATCACC TCACCA CACCAT ACCATT CCATTC CATTCT ATTCTG TTCTGC TCTGCA CTGCAG TGCAGC GCAGCC CAGCCC AGCCCG GCCCGA CCCGAC CCGACC CGACCT GACCTC ACCTCT CCTCTC CTCTCC TCTCCA CTCCAA TCCAAA CCAAAA CAAAAC AAAACC AAACCG AACCGG ACCGGC CCGGCG CGGCGG GGCGGC GCGGCA CGGCAT GGCATC GCATCA CATCAC ATCACC TCACCG CACCGA ACCGAA CCGAAG CGAAGC GAAGCG AAGCGC AGCGCT GCGCTG CGCTGC GCTGCG CTGCGC TGCGCG GCGCGT CGCGTC GCGTCG CGTCGC GTCGCC TCGCCG CGCCGC GCCGCC CCGCCA CGCCAT GCCATG CCATGG CATGGC ATGGCC TGGCCT GGCCTC GCCTCG CCTCGG CTCGGC TCGGCT CGGCTT GGCTTA GCTTAC CTTACA TTACAA TACAAA ACAAAC CAAACT AAACTG,0,145,CTCG TCGC CGCC GCCG CCGC CGCC GCCG CCGG CGGC GGCG GCGA CGAA GAAA AAAA AAAT AATC ATCA TCAC CACT ACTA CTAC TACA ACAC CACG ACGC CGCG GCGT CGTT GTTT TTTT TTTG TTGA TGAA GAAT AATT ATTC TTCA TCAA CAAC AACC ACCG CCGC CGCG GCGC CGCA GCAA CAAT AATC ATCG TCGA CGAG GAGG AGGA GGAC GACG ACGG CGGC GGCG GCGC CGCG GCGA CGAT GATC ATCA TCAC CACC ACCA CCAT CATT ATTC TTCT TCTG CTGC TGCA GCAG CAGC AGCC GCCC CCCG CCGA CGAC GACC ACCT CCTC CTCT TCTC CTCC TCCA CCAA CAAA AAAA AAAC AACC ACCG CCGG CGGC GGCG GCGG CGGC GGCA GCAT CATC ATCA TCAC CACC ACCG CCGA CGAA GAAG AAGC AGCG GCGC CGCT GCTG CTGC TGCG GCGC CGCG GCGT CGTC GTCG TCGC CGCC GCCG CCGC CGCC GCCA CCAT CATG ATGG TGGC GGCC GCCT CCTC CTCG TCGG CGGC GGCT GCTT CTTA TTAC TACA ACAA CAAA AAAC AACT ACTG,CTCGC TCGCC CGCCG GCCGC CCGCC CGCCG GCCGG CCGGC CGGCG GGCGA GCGAA CGAAA GAAAA AAAAT AAATC AATCA ATCAC TCACT CACTA ACTAC CTACA TACAC ACACG CACGC ACGCG CGCGT GCGTT CGTTT GTTTT TTTTG TTTGA TTGAA TGAAT GAATT AATTC ATTCA TTCAA TCAAC CAACC AACCG ACCGC CCGCG CGCGC GCGCA CGCAA GCAAT CAATC AATCG ATCGA TCGAG CGAGG GAGGA AGGAC GGACG GACGG ACGGC CGGCG GGCGC GCGCG CGCGA GCGAT CGATC GATCA ATCAC TCACC CACCA ACCAT CCATT CATTC ATTCT TTCTG TCTGC CTGCA TGCAG GCAGC CAGCC AGCCC GCCCG CCCGA CCGAC CGACC GACCT ACCTC CCTCT CTCTC TCTCC CTCCA TCCAA CCAAA CAAAA AAAAC AAACC AACCG ACCGG CCGGC CGGCG GGCGG GCGGC CGGCA GGCAT GCATC CATCA ATCAC TCACC CACCG ACCGA CCGAA CGAAG GAAGC AAGCG AGCGC GCGCT CGCTG GCTGC CTGCG TGCGC GCGCG CGCGT GCGTC CGTCG GTCGC TCGCC CGCCG GCCGC CCGCC CGCCA GCCAT CCATG CATGG ATGGC TGGCC GGCCT GCCTC CCTCG CTCGG TCGGC CGGCT GGCTT GCTTA CTTAC TTACA TACAA ACAAA CAAAC AAACT AACTG,CTCGCC TCGCCG CGCCGC GCCGCC CCGCCG CGCCGG GCCGGC CCGGCG CGGCGA GGCGAA GCGAAA CGAAAA GAAAAT AAAATC AAATCA AATCAC ATCACT TCACTA CACTAC ACTACA CTACAC TACACG ACACGC CACGCG ACGCGT CGCGTT GCGTTT CGTTTT GTTTTG TTTTGA TTTGAA TTGAAT TGAATT GAATTC AATTCA ATTCAA TTCAAC TCAACC CAACCG AACCGC ACCGCG CCGCGC CGCGCA GCGCAA CGCAAT GCAATC CAATCG AATCGA ATCGAG TCGAGG CGAGGA GAGGAC AGGACG GGACGG GACGGC ACGGCG CGGCGC GGCGCG GCGCGA CGCGAT GCGATC CGATCA GATCAC ATCACC TCACCA CACCAT ACCATT CCATTC CATTCT ATTCTG TTCTGC TCTGCA CTGCAG TGCAGC GCAGCC CAGCCC AGCCCG GCCCGA CCCGAC CCGACC CGACCT GACCTC ACCTCT CCTCTC CTCTCC TCTCCA CTCCAA TCCAAA CCAAAA CAAAAC AAAACC AAACCG AACCGG ACCGGC CCGGCG CGGCGG GGCGGC GCGGCA CGGCAT GGCATC GCATCA CATCAC ATCACC TCACCG CACCGA ACCGAA CCGAAG CGAAGC GAAGCG AAGCGC AGCGCT GCGCTG CGCTGC GCTGCG CTGCGC TGCGCG GCGCGT CGCGTC GCGTCG CGTCGC GTCGCC TCGCCG CGCCGC GCCGCC CCGCCA CGCCAT GCCATG CCATGG CATGGC ATGGCC TGGCCT GGCCTC GCCTCG CCTCGG CTCGGC TCGGCT CGGCTT GGCTTA GCTTAC CTTACA TTACAA TACAAA ACAAAC CAAACT AAACTG,CTCGCCG TCGCCGC CGCCGCC GCCGCCG CCGCCGG CGCCGGC GCCGGCG CCGGCGA CGGCGAA GGCGAAA GCGAAAA CGAAAAT GAAAATC AAAATCA AAATCAC AATCACT ATCACTA TCACTAC CACTACA ACTACAC CTACACG TACACGC ACACGCG CACGCGT ACGCGTT CGCGTTT GCGTTTT CGTTTTG GTTTTGA TTTTGAA TTTGAAT TTGAATT TGAATTC GAATTCA AATTCAA ATTCAAC TTCAACC TCAACCG CAACCGC AACCGCG ACCGCGC CCGCGCA CGCGCAA GCGCAAT CGCAATC GCAATCG CAATCGA AATCGAG ATCGAGG TCGAGGA CGAGGAC GAGGACG AGGACGG GGACGGC GACGGCG ACGGCGC CGGCGCG GGCGCGA GCGCGAT CGCGATC GCGATCA CGATCAC GATCACC ATCACCA TCACCAT CACCATT ACCATTC CCATTCT CATTCTG ATTCTGC TTCTGCA TCTGCAG CTGCAGC TGCAGCC GCAGCCC CAGCCCG AGCCCGA GCCCGAC CCCGACC CCGACCT CGACCTC GACCTCT ACCTCTC CCTCTCC CTCTCCA TCTCCAA CTCCAAA TCCAAAA CCAAAAC CAAAACC AAAACCG AAACCGG AACCGGC ACCGGCG CCGGCGG CGGCGGC GGCGGCA GCGGCAT CGGCATC GGCATCA GCATCAC CATCACC ATCACCG TCACCGA CACCGAA ACCGAAG CCGAAGC CGAAGCG GAAGCGC AAGCGCT AGCGCTG GCGCTGC CGCTGCG GCTGCGC CTGCGCG TGCGCGT GCGCGTC CGCGTCG GCGTCGC CGTCGCC GTCGCCG TCGCCGC CGCCGCC GCCGCCA CCGCCAT CGCCATG GCCATGG CCATGGC CATGGCC ATGGCCT TGGCCTC GGCCTCG GCCTCGG CCTCGGC CTCGGCT TCGGCTT CGGCTTA GGCTTAC GCTTACA CTTACAA TTACAAA TACAAAC ACAAACT CAAACTG,"ID   DGOD_RALPJ              Reviewed;         382 AA.
AC   B2UCA8;
DT   14-APR-2009, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-2008, sequence version 1.
DT   27-NOV-2024, entry version 104.
DE   RecName: Full=D-galactonate dehydratase {ECO:0000255|HAMAP-Rule:MF_01289};
DE            Short=GalD {ECO:0000255|HAMAP-Rule:MF_01289};
DE            EC=4.2.1.6 {ECO:0000255|HAMAP-Rule:MF_01289};
GN   Name=dgoD {ECO:0000255|HAMAP-Rule:MF_01289};
GN   OrderedLocusNames=Rpic_2990;
OS   Ralstonia pickettii (strain 12J).
OC   Bacteria; Pseudomonadota; Betaproteobacteria; Burkholderiales;
OC   Burkholderiaceae; Ralstonia.
OX   NCBI_TaxID=402626;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=12J;
RA   Lucas S., Copeland A., Lapidus A., Glavina del Rio T., Dalin E., Tice H.,
RA   Bruce D., Goodwin L., Pitluck S., Meincke L., Brettin T., Detter J.C.,
RA   Han C., Kuske C.R., Schmutz J., Larimer F., Land M., Hauser L.,
RA   Kyrpides N., Mikhailova N., Marsh T., Richardson P.;
RT   ""Complete sequence of chromosome 1 of Ralstonia pickettii 12J."";
RL   Submitted (MAY-2008) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Catalyzes the dehydration of D-galactonate to 2-keto-3-deoxy-
CC       D-galactonate. {ECO:0000255|HAMAP-Rule:MF_01289}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=D-galactonate = 2-dehydro-3-deoxy-D-galactonate + H2O;
CC         Xref=Rhea:RHEA:18649, ChEBI:CHEBI:12931, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:57989; EC=4.2.1.6; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_01289};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_01289};
CC       Note=Binds 1 Mg(2+) ion per subunit. {ECO:0000255|HAMAP-Rule:MF_01289};
CC   -!- PATHWAY: Carbohydrate acid metabolism; D-galactonate degradation; D-
CC       glyceraldehyde 3-phosphate and pyruvate from D-galactonate: step 1/3.
CC       {ECO:0000255|HAMAP-Rule:MF_01289}.
CC   -!- MISCELLANEOUS: Reaction proceeds via an anti dehydration.
CC       {ECO:0000255|HAMAP-Rule:MF_01289}.
CC   -!- SIMILARITY: Belongs to the mandelate racemase/muconate lactonizing
CC       enzyme family. GalD subfamily. {ECO:0000255|HAMAP-Rule:MF_01289}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP001068; ACD28113.1; -; Genomic_DNA.
DR   PDB; 3RR1; X-ray; 1.95 A; A/B=2-382.
DR   PDB; 3RRA; X-ray; 2.30 A; A/B=2-382.
DR   PDBsum; 3RR1; -.
DR   PDBsum; 3RRA; -.
DR   AlphaFoldDB; B2UCA8; -.
DR   SMR; B2UCA8; -.
DR   STRING; 402626.Rpic_2990; -.
DR   KEGG; rpi:Rpic_2990; -.
DR   PATRIC; fig|402626.5.peg.4126; -.
DR   eggNOG; COG4948; Bacteria.
DR   HOGENOM; CLU_030273_3_2_4; -.
DR   UniPathway; UPA00081; UER00518.
DR   EvolutionaryTrace; B2UCA8; -.
DR   GO; GO:0008869; F:galactonate dehydratase activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0009063; P:amino acid catabolic process; IEA:InterPro.
DR   GO; GO:0034194; P:D-galactonate catabolic process; IEA:UniProtKB-UniRule.
DR   CDD; cd03325; D-galactonate_dehydratase; 1.
DR   FunFam; 3.30.390.10:FF:000003; D-galactonate dehydratase; 1.
DR   Gene3D; 3.20.20.120; Enolase-like C-terminal domain; 1.
DR   Gene3D; 3.30.390.10; Enolase-like, N-terminal domain; 1.
DR   HAMAP; MF_01289; Galacton_dehydrat; 1.
DR   InterPro; IPR034593; DgoD-like.
DR   InterPro; IPR036849; Enolase-like_C_sf.
DR   InterPro; IPR029017; Enolase-like_N.
DR   InterPro; IPR029065; Enolase_C-like.
DR   InterPro; IPR023592; Galactonate_deHydtase.
DR   InterPro; IPR018110; Mandel_Rmase/mucon_lact_enz_CS.
DR   InterPro; IPR013342; Mandelate_racemase_C.
DR   InterPro; IPR013341; Mandelate_racemase_N_dom.
DR   PANTHER; PTHR48080:SF2; D-GALACTONATE DEHYDRATASE; 1.
DR   PANTHER; PTHR48080; D-GALACTONATE DEHYDRATASE-RELATED; 1.
DR   Pfam; PF13378; MR_MLE_C; 1.
DR   Pfam; PF02746; MR_MLE_N; 1.
DR   SFLD; SFLDF00003; D-galactonate_dehydratase; 1.
DR   SFLD; SFLDG00179; mandelate_racemase; 1.
DR   SMART; SM00922; MR_MLE; 1.
DR   SUPFAM; SSF51604; Enolase C-terminal domain-like; 1.
DR   SUPFAM; SSF54826; Enolase N-terminal domain-like; 1.
DR   PROSITE; PS00908; MR_MLE_1; 1.
DR   PROSITE; PS00909; MR_MLE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Lyase; Magnesium; Metal-binding.
FT   CHAIN           1..382
FT                   /note=""D-galactonate dehydratase""
FT                   /id=""PRO_1000140385""
FT   ACT_SITE        185
FT                   /note=""Proton donor""
FT                   /evidence=""ECO:0000250""
FT   ACT_SITE        285
FT                   /note=""Proton acceptor""
FT                   /evidence=""ECO:0000250""
FT   BINDING         183
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   BINDING         209
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   BINDING         235
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   SITE            258
FT                   /note=""Increases basicity of active site His""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   SITE            310
FT                   /note=""Transition state stabilizer""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   STRAND          3..11
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   TURN            12..14
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          15..22
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          27..30
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           38..48
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           49..51
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   TURN            52..54
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           60..69
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          71..73
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           77..98
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           102..105
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          114..119
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           125..137
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          142..147
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          150..152
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           157..172
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           175..177
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          178..183
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           190..200
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           201..203
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           218..224
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          231..233
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           240..249
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          253..255
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   TURN            259..263
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           264..276
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   TURN            277..279
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           290..302
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          309..311
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           323..326
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           330..333
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          345..347
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           354..362
FT                   /evidence=""ECO:0007829|PDB:3RR1""
SQ   SEQUENCE   382 AA;  42098 MW;  198F1A16BC5819F0 CRC64;
     MKITRLTTYR LPPRWMFLKV ETDEGVTGWG EPVIEGRART VEAAVHELSD YLIGQDPSRI
     NDLWQTMYRA GFYRGGPILM SAIAGIDQAL WDIKGKVLGV PVYELLGGLV RDKMRTYSWV
     GGDRPADVIA GMKALQAGGF DHFKLNGCEE MGIIDTSRAV DAAVARVAEI RSAFGNTVEF
     GLDFHGRVSA PMAKVLIKEL EPYRPLFIEE PVLAEQAETY ARLAAHTHLP IAAGERMFSR
     FDFKRVLEAG GVSILQPDLS HAGGITECVK IAAMAEAYDV ALAPHCPLGP IALAACLHVD
     FVSWNATLQE QSMGIHYNKG AELLDYVRNK ADFALEGGYI RPPRLPGLGV DIDEALVIER
     SKEAPDWRNP VWRHADGSVA EW
//
",260
GCGTTT CGTTTT GTTTTG TTTTGG TTTGGG TTGGGT TGGGTC GGGTCG GGTCGC GTCGCC TCGCCG CGCCGT GCCGTG CCGTGA CGTGAT GTGATG TGATGC GATGCG ATGCGC TGCGCA GCGCAT CGCATC GCATCG CATCGC ATCGCT TCGCTA CGCTAC GCTACA CTACAC TACACC ACACCA CACCAC ACCACT CCACTG CACTGA ACTGAT CTGATT TGATTT GATTTT ATTTTT TTTTTG TTTTGG TTTGGC TTGGCA TGGCAC GGCACA GCACAC CACACT ACACTG CACTGG ACTGGG CTGGGG TGGGGG GGGGGT GGGGTG GGGTGT GGTGTT GTGTTG TGTTGC GTTGCT TTGCTG TGCTGT GCTGTG CTGTGC TGTGCG GTGCGA TGCGAG GCGAGC CGAGCG GAGCGC AGCGCT GCGCTG CGCTGC GCTGCG CTGCGG TGCGGG GCGGGG CGGGGT GGGGTG GGGTGC GGTGCT GTGCTG TGCTGA GCTGAA CTGAAC TGAACC GAACCT AACCTG ACCTGG CCTGGG CTGGGT TGGGTA GGGTAT GGTATT GTATTG TATTGA ATTGAA TTGAAG TGAAGG GAAGGC AAGGCA AGGCAT GGCATC GCATCA CATCAT ATCATG TCATGG CATGGT ATGGTG TGGTGG GGTGGC GTGGCA TGGCAG GGCAGG GCAGGC CAGGCG AGGCGC GGCGCT GCGCTT CGCTTT GCTTTC CTTTCA TTTCAC TTCACA TCACAG CACAGG ACAGGC CAGGCT AGGCTG GGCTGG GCTGGC CTGGCT TGGCTC GGCTCT GCTCTC CTCTCG TCTCGG CTCGGT TCGGTT CGGTTT GGTTTA GTTTAT TTTATC TTATCT TATCTG,2,145,GCGT CGTT GTTT TTTT TTTG TTGG TGGG GGGT GGTC GTCG TCGC CGCC GCCG CCGT CGTG GTGA TGAT GATG ATGC TGCG GCGC CGCA GCAT CATC ATCG TCGC CGCT GCTA CTAC TACA ACAC CACC ACCA CCAC CACT ACTG CTGA TGAT GATT ATTT TTTT TTTT TTTG TTGG TGGC GGCA GCAC CACA ACAC CACT ACTG CTGG TGGG GGGG GGGG GGGT GGTG GTGT TGTT GTTG TTGC TGCT GCTG CTGT TGTG GTGC TGCG GCGA CGAG GAGC AGCG GCGC CGCT GCTG CTGC TGCG GCGG CGGG GGGG GGGT GGTG GTGC TGCT GCTG CTGA TGAA GAAC AACC ACCT CCTG CTGG TGGG GGGT GGTA GTAT TATT ATTG TTGA TGAA GAAG AAGG AGGC GGCA GCAT CATC ATCA TCAT CATG ATGG TGGT GGTG GTGG TGGC GGCA GCAG CAGG AGGC GGCG GCGC CGCT GCTT CTTT TTTC TTCA TCAC CACA ACAG CAGG AGGC GGCT GCTG CTGG TGGC GGCT GCTC CTCT TCTC CTCG TCGG CGGT GGTT GTTT TTTA TTAT TATC ATCT TCTG,GCGTT CGTTT GTTTT TTTTG TTTGG TTGGG TGGGT GGGTC GGTCG GTCGC TCGCC CGCCG GCCGT CCGTG CGTGA GTGAT TGATG GATGC ATGCG TGCGC GCGCA CGCAT GCATC CATCG ATCGC TCGCT CGCTA GCTAC CTACA TACAC ACACC CACCA ACCAC CCACT CACTG ACTGA CTGAT TGATT GATTT ATTTT TTTTT TTTTG TTTGG TTGGC TGGCA GGCAC GCACA CACAC ACACT CACTG ACTGG CTGGG TGGGG GGGGG GGGGT GGGTG GGTGT GTGTT TGTTG GTTGC TTGCT TGCTG GCTGT CTGTG TGTGC GTGCG TGCGA GCGAG CGAGC GAGCG AGCGC GCGCT CGCTG GCTGC CTGCG TGCGG GCGGG CGGGG GGGGT GGGTG GGTGC GTGCT TGCTG GCTGA CTGAA TGAAC GAACC AACCT ACCTG CCTGG CTGGG TGGGT GGGTA GGTAT GTATT TATTG ATTGA TTGAA TGAAG GAAGG AAGGC AGGCA GGCAT GCATC CATCA ATCAT TCATG CATGG ATGGT TGGTG GGTGG GTGGC TGGCA GGCAG GCAGG CAGGC AGGCG GGCGC GCGCT CGCTT GCTTT CTTTC TTTCA TTCAC TCACA CACAG ACAGG CAGGC AGGCT GGCTG GCTGG CTGGC TGGCT GGCTC GCTCT CTCTC TCTCG CTCGG TCGGT CGGTT GGTTT GTTTA TTTAT TTATC TATCT ATCTG,GCGTTT CGTTTT GTTTTG TTTTGG TTTGGG TTGGGT TGGGTC GGGTCG GGTCGC GTCGCC TCGCCG CGCCGT GCCGTG CCGTGA CGTGAT GTGATG TGATGC GATGCG ATGCGC TGCGCA GCGCAT CGCATC GCATCG CATCGC ATCGCT TCGCTA CGCTAC GCTACA CTACAC TACACC ACACCA CACCAC ACCACT CCACTG CACTGA ACTGAT CTGATT TGATTT GATTTT ATTTTT TTTTTG TTTTGG TTTGGC TTGGCA TGGCAC GGCACA GCACAC CACACT ACACTG CACTGG ACTGGG CTGGGG TGGGGG GGGGGT GGGGTG GGGTGT GGTGTT GTGTTG TGTTGC GTTGCT TTGCTG TGCTGT GCTGTG CTGTGC TGTGCG GTGCGA TGCGAG GCGAGC CGAGCG GAGCGC AGCGCT GCGCTG CGCTGC GCTGCG CTGCGG TGCGGG GCGGGG CGGGGT GGGGTG GGGTGC GGTGCT GTGCTG TGCTGA GCTGAA CTGAAC TGAACC GAACCT AACCTG ACCTGG CCTGGG CTGGGT TGGGTA GGGTAT GGTATT GTATTG TATTGA ATTGAA TTGAAG TGAAGG GAAGGC AAGGCA AGGCAT GGCATC GCATCA CATCAT ATCATG TCATGG CATGGT ATGGTG TGGTGG GGTGGC GTGGCA TGGCAG GGCAGG GCAGGC CAGGCG AGGCGC GGCGCT GCGCTT CGCTTT GCTTTC CTTTCA TTTCAC TTCACA TCACAG CACAGG ACAGGC CAGGCT AGGCTG GGCTGG GCTGGC CTGGCT TGGCTC GGCTCT GCTCTC CTCTCG TCTCGG CTCGGT TCGGTT CGGTTT GGTTTA GTTTAT TTTATC TTATCT TATCTG,GCGTTTT CGTTTTG GTTTTGG TTTTGGG TTTGGGT TTGGGTC TGGGTCG GGGTCGC GGTCGCC GTCGCCG TCGCCGT CGCCGTG GCCGTGA CCGTGAT CGTGATG GTGATGC TGATGCG GATGCGC ATGCGCA TGCGCAT GCGCATC CGCATCG GCATCGC CATCGCT ATCGCTA TCGCTAC CGCTACA GCTACAC CTACACC TACACCA ACACCAC CACCACT ACCACTG CCACTGA CACTGAT ACTGATT CTGATTT TGATTTT GATTTTT ATTTTTG TTTTTGG TTTTGGC TTTGGCA TTGGCAC TGGCACA GGCACAC GCACACT CACACTG ACACTGG CACTGGG ACTGGGG CTGGGGG TGGGGGT GGGGGTG GGGGTGT GGGTGTT GGTGTTG GTGTTGC TGTTGCT GTTGCTG TTGCTGT TGCTGTG GCTGTGC CTGTGCG TGTGCGA GTGCGAG TGCGAGC GCGAGCG CGAGCGC GAGCGCT AGCGCTG GCGCTGC CGCTGCG GCTGCGG CTGCGGG TGCGGGG GCGGGGT CGGGGTG GGGGTGC GGGTGCT GGTGCTG GTGCTGA TGCTGAA GCTGAAC CTGAACC TGAACCT GAACCTG AACCTGG ACCTGGG CCTGGGT CTGGGTA TGGGTAT GGGTATT GGTATTG GTATTGA TATTGAA ATTGAAG TTGAAGG TGAAGGC GAAGGCA AAGGCAT AGGCATC GGCATCA GCATCAT CATCATG ATCATGG TCATGGT CATGGTG ATGGTGG TGGTGGC GGTGGCA GTGGCAG TGGCAGG GGCAGGC GCAGGCG CAGGCGC AGGCGCT GGCGCTT GCGCTTT CGCTTTC GCTTTCA CTTTCAC TTTCACA TTCACAG TCACAGG CACAGGC ACAGGCT CAGGCTG AGGCTGG GGCTGGC GCTGGCT CTGGCTC TGGCTCT GGCTCTC GCTCTCG CTCTCGG TCTCGGT CTCGGTT TCGGTTT CGGTTTA GGTTTAT GTTTATC TTTATCT TTATCTG,"ID   TSGCD_HALVD             Reviewed;         329 AA.
AC   D4GPW1;
DT   06-FEB-2013, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 1.
DT   05-FEB-2025, entry version 57.
DE   RecName: Full=Putative glucose ABC transporter permease protein TsgC13;
GN   Name=tsgC13; OrderedLocusNames=HVO_B0314;
OS   Haloferax volcanii (strain ATCC 29605 / DSM 3757 / JCM 8879 / NBRC 14742 /
OS   NCIMB 2012 / VKM B-1768 / DS2) (Halobacterium volcanii).
OG   Plasmid pHV3.
OC   Archaea; Methanobacteriati; Methanobacteriota; Stenosarchaea group;
OC   Halobacteria; Halobacteriales; Haloferacaceae; Haloferax.
OX   NCBI_TaxID=309800;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 29605 / DSM 3757 / JCM 8879 / NBRC 14742 / NCIMB 2012 /
RC   VKM B-1768 / DS2;
RX   PubMed=20333302; DOI=10.1371/journal.pone.0009605;
RA   Hartman A.L., Norais C., Badger J.H., Delmas S., Haldenby S., Madupu R.,
RA   Robinson J., Khouri H., Ren Q., Lowe T.M., Maupin-Furlow J.,
RA   Pohlschroder M., Daniels C., Pfeiffer F., Allers T., Eisen J.A.;
RT   ""The complete genome sequence of Haloferax volcanii DS2, a model
RT   archaeon."";
RL   PLoS ONE 5:E9605-E9605(2010).
CC   -!- FUNCTION: Part of an ABC transporter complex involved in glucose import
CC       (Potential). Responsible for the translocation of the substrate across
CC       the membrane (By similarity). {ECO:0000250, ECO:0000305}.
CC   -!- SUBUNIT: The complex is composed of two ATP-binding proteins (TsgD13),
CC       two transmembrane proteins (TsgB13 and TsgC13) and a solute-binding
CC       protein (TsgA13). {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Multi-pass membrane
CC       protein {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the binding-protein-dependent transport system
CC       permease family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP001953; ADE01443.1; -; Genomic_DNA.
DR   AlphaFoldDB; D4GPW1; -.
DR   PaxDb; 309800-C498_02095; -.
DR   EnsemblBacteria; ADE01443; ADE01443; HVO_B0314.
DR   KEGG; hvo:HVO_B0314; -.
DR   eggNOG; arCOG00261; Archaea.
DR   HOGENOM; CLU_040769_1_1_2; -.
DR   PRO; PR:D4GPW1; -.
DR   Proteomes; UP000008243; Plasmid pHV3.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0022857; F:transmembrane transporter activity; IEA:InterPro.
DR   CDD; cd06580; TM_PBP1_transp_TpRbsC_like; 1.
DR   InterPro; IPR001851; ABC_transp_permease.
DR   PANTHER; PTHR43370:SF2; ABC TRANSPORTER PERMEASE PROTEIN; 1.
DR   PANTHER; PTHR43370; SUGAR ABC TRANSPORTER INTEGRAL MEMBRANE PROTEIN-RELATED; 1.
DR   Pfam; PF02653; BPD_transp_2; 1.
PE   3: Inferred from homology;
KW   Cell membrane; Membrane; Plasmid; Reference proteome; Sugar transport;
KW   Transmembrane; Transmembrane helix; Transport.
FT   CHAIN           1..329
FT                   /note=""Putative glucose ABC transporter permease protein
FT                   TsgC13""
FT                   /id=""PRO_0000420946""
FT   TRANSMEM        3..23
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        32..52
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        60..80
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        89..109
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        139..161
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        193..213
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   TRANSMEM        216..236
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
SQ   SEQUENCE   329 AA;  34876 MW;  68981A201C6F1177 CRC64;
     MSFAAGLLNA TVQAATVLLL AGLGELISER AGVLNLGVEG MMLVGALGGF VVTAVTGNYW
     LGFGVGIACG MALAAVHAFL CISLKSNQVI SGVMLTLLGT GLTTFFGSGW VQESITGFPQ
     MTFPIVGRYL VHLPLVGEAF FRSTATDYLA LLAVPVVWFF LYRSNLGLEI IAVGEDPEMA
     DTMGVPVFKF RYLAVIIGGG FAGAAGAHLS LAFSQLWVPG MTVGRGWIAV ALVVFAQWRP
     SRMLVGAYLF GLLDALQLRS QSLSLALDPN APLAGVLNPL VNTLMNPQIM STYPYLTTIA
     VLSYAVIRTE SVRLAVPSAL LQSYNREMD
//
",29343
GTTAGA TTAGAG TAGAGG AGAGGT GAGGTA AGGTAC GGTACA GTACAA TACAAC ACAACA CAACAG AACAGT ACAGTA CAGTAC AGTACT GTACTT TACTTT ACTTTT CTTTTA TTTTAA TTTAAA TTAAAA TAAAAG AAAAGA AAAGAA AAGAAC AGAACC GAACCT AACCTT ACCTTG CCTTGC CTTGCT TTGCTC TGCTCT GCTCTT CTCTTC TCTTCT CTTCTG TTCTGG TCTGGA CTGGAA TGGAAC GGAACA GAACAT AACATA ACATAC CATACG ATACGA TACGAG ACGAGG CGAGGG GAGGGC AGGGCA GGGCAA GGCAAT GCAATT CAATTC AATTCA ATTCAC TTCACC TCACCA CACCAT ACCATT CCATTT CATTTC ATTTCA TTTCAT TTCATC TCATCC CATCCT ATCCTC TCCTCT CCTCTA CTCTAG TCTAGC CTAGCA TAGCAG AGCAGT GCAGTG CAGTGC AGTGCA GTGCAA TGCAAA GCAAAT CAAATT AAATTT AATTTG ATTTGT TTTGTT TTGTTA TGTTAT GTTATC TTATCA TATCAG ATCAGC TCAGCT CAGCTA AGCTAG GCTAGA CTAGAG,1,100,GTTA TTAG TAGA AGAG GAGG AGGT GGTA GTAC TACA ACAA CAAC AACA ACAG CAGT AGTA GTAC TACT ACTT CTTT TTTT TTTA TTAA TAAA AAAA AAAG AAGA AGAA GAAC AACC ACCT CCTT CTTG TTGC TGCT GCTC CTCT TCTT CTTC TTCT TCTG CTGG TGGA GGAA GAAC AACA ACAT CATA ATAC TACG ACGA CGAG GAGG AGGG GGGC GGCA GCAA CAAT AATT ATTC TTCA TCAC CACC ACCA CCAT CATT ATTT TTTC TTCA TCAT CATC ATCC TCCT CCTC CTCT TCTA CTAG TAGC AGCA GCAG CAGT AGTG GTGC TGCA GCAA CAAA AAAT AATT ATTT TTTG TTGT TGTT GTTA TTAT TATC ATCA TCAG CAGC AGCT GCTA CTAG TAGA AGAG,GTTAG TTAGA TAGAG AGAGG GAGGT AGGTA GGTAC GTACA TACAA ACAAC CAACA AACAG ACAGT CAGTA AGTAC GTACT TACTT ACTTT CTTTT TTTTA TTTAA TTAAA TAAAA AAAAG AAAGA AAGAA AGAAC GAACC AACCT ACCTT CCTTG CTTGC TTGCT TGCTC GCTCT CTCTT TCTTC CTTCT TTCTG TCTGG CTGGA TGGAA GGAAC GAACA AACAT ACATA CATAC ATACG TACGA ACGAG CGAGG GAGGG AGGGC GGGCA GGCAA GCAAT CAATT AATTC ATTCA TTCAC TCACC CACCA ACCAT CCATT CATTT ATTTC TTTCA TTCAT TCATC CATCC ATCCT TCCTC CCTCT CTCTA TCTAG CTAGC TAGCA AGCAG GCAGT CAGTG AGTGC GTGCA TGCAA GCAAA CAAAT AAATT AATTT ATTTG TTTGT TTGTT TGTTA GTTAT TTATC TATCA ATCAG TCAGC CAGCT AGCTA GCTAG CTAGA TAGAG,GTTAGA TTAGAG TAGAGG AGAGGT GAGGTA AGGTAC GGTACA GTACAA TACAAC ACAACA CAACAG AACAGT ACAGTA CAGTAC AGTACT GTACTT TACTTT ACTTTT CTTTTA TTTTAA TTTAAA TTAAAA TAAAAG AAAAGA AAAGAA AAGAAC AGAACC GAACCT AACCTT ACCTTG CCTTGC CTTGCT TTGCTC TGCTCT GCTCTT CTCTTC TCTTCT CTTCTG TTCTGG TCTGGA CTGGAA TGGAAC GGAACA GAACAT AACATA ACATAC CATACG ATACGA TACGAG ACGAGG CGAGGG GAGGGC AGGGCA GGGCAA GGCAAT GCAATT CAATTC AATTCA ATTCAC TTCACC TCACCA CACCAT ACCATT CCATTT CATTTC ATTTCA TTTCAT TTCATC TCATCC CATCCT ATCCTC TCCTCT CCTCTA CTCTAG TCTAGC CTAGCA TAGCAG AGCAGT GCAGTG CAGTGC AGTGCA GTGCAA TGCAAA GCAAAT CAAATT AAATTT AATTTG ATTTGT TTTGTT TTGTTA TGTTAT GTTATC TTATCA TATCAG ATCAGC TCAGCT CAGCTA AGCTAG GCTAGA CTAGAG,GTTAGAG TTAGAGG TAGAGGT AGAGGTA GAGGTAC AGGTACA GGTACAA GTACAAC TACAACA ACAACAG CAACAGT AACAGTA ACAGTAC CAGTACT AGTACTT GTACTTT TACTTTT ACTTTTA CTTTTAA TTTTAAA TTTAAAA TTAAAAG TAAAAGA AAAAGAA AAAGAAC AAGAACC AGAACCT GAACCTT AACCTTG ACCTTGC CCTTGCT CTTGCTC TTGCTCT TGCTCTT GCTCTTC CTCTTCT TCTTCTG CTTCTGG TTCTGGA TCTGGAA CTGGAAC TGGAACA GGAACAT GAACATA AACATAC ACATACG CATACGA ATACGAG TACGAGG ACGAGGG CGAGGGC GAGGGCA AGGGCAA GGGCAAT GGCAATT GCAATTC CAATTCA AATTCAC ATTCACC TTCACCA TCACCAT CACCATT ACCATTT CCATTTC CATTTCA ATTTCAT TTTCATC TTCATCC TCATCCT CATCCTC ATCCTCT TCCTCTA CCTCTAG CTCTAGC TCTAGCA CTAGCAG TAGCAGT AGCAGTG GCAGTGC CAGTGCA AGTGCAA GTGCAAA TGCAAAT GCAAATT CAAATTT AAATTTG AATTTGT ATTTGTT TTTGTTA TTGTTAT TGTTATC GTTATCA TTATCAG TATCAGC ATCAGCT TCAGCTA CAGCTAG AGCTAGA GCTAGAG,"ID   NS7A_SARS2              Reviewed;         121 AA.
AC   P0DTC7;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 24.
DE   RecName: Full=ORF7a protein;
DE            Short=ORF7a;
DE   AltName: Full=Accessory protein 7a;
DE   AltName: Full=Protein U122;
DE   AltName: Full=Protein X4;
DE   Flags: Precursor;
GN   ORFNames=7a;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANT ILE-14.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION, UBIQUITINATION AT LYS-119, AND MUTAGENESIS OF LYS-2; LYS-32;
RP   LYS-53; LYS-72; LYS-85; LYS-117 AND LYS-119.
RX   PubMed=33473190; DOI=10.1038/s41423-020-00603-6;
RA   Cao Z., Xia H., Rajsbaum R., Xia X., Wang H., Shi P.Y.;
RT   ""Ubiquitination of SARS-CoV-2 ORF7a promotes antagonism of interferon
RT   response."";
RL   Cell. Mol. Immunol. 18:746-748(2021).
RN   [4]
RP   FUNCTION, INTERACTION WITH HOST BST2, AND SUBCELLULAR LOCATION.
RX   PubMed=33930332; DOI=10.1016/j.molcel.2021.04.008;
RA   Martin-Sancho L., Lewinski M.K., Pache L., Stoneham C.A., Yin X.,
RA   Becker M.E., Pratt D., Churas C., Rosenthal S.B., Liu S., Weston S.,
RA   De Jesus P.D., O'Neill A.M., Gounder A.P., Nguyen C., Pu Y., Curry H.M.,
RA   Oom A.L., Miorin L., Rodriguez-Frandsen A., Zheng F., Wu C., Xiong Y.,
RA   Urbanowski M., Shaw M.L., Chang M.W., Benner C., Hope T.J., Frieman M.B.,
RA   Garcia-Sastre A., Ideker T., Hultquist J.F., Guatelli J., Chanda S.K.;
RT   ""Functional landscape of SARS-CoV-2 cellular restriction."";
RL   Mol. Cell 81:2656-2668.e8(2021).
RN   [5]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [6]
RP   FUNCTION, SUBCELLULAR LOCATION, AND MUTAGENESIS OF 117-LYS--LYS-119.
RX   PubMed=36574644; DOI=10.1073/pnas.2208525120;
RA   Arshad N., Laurent-Rolle M., Ahmed W.S., Hsu J.C., Mitchell S.M.,
RA   Pawlak J., Sengupta D., Biswas K.H., Cresswell P.;
RT   ""SARS-CoV-2 accessory proteins ORF7a and ORF3a use distinct mechanisms to
RT   down-regulate MHC-I surface expression."";
RL   Proc. Natl. Acad. Sci. U.S.A. 120:e2208525120-e2208525120(2023).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 16-82, AND DISULFIDE BOND.
RA   Nelson C.A., Minasov G., Shuvalova L., Fremont D.H.;
RT   ""STRUCTURE OF THE SARS-CoV-2 ORF7A ENCODED ACCESSORY PROTEIN."";
RL   Submitted (MAR-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.20 ANGSTROMS) OF 14-96.
RX   PubMed=33615195; DOI=10.1016/j.isci.2021.102187;
RA   Zhou Z., Huang C., Zhou Z., Huang Z., Su L., Kang S., Chen X., Chen Q.,
RA   He S., Rong X., Xiao F., Chen J., Chen S.;
RT   ""Structural insight reveals SARS-CoV-2 ORF7a as an immunomodulating factor
RT   for human CD14+ monocytes."";
RL   IScience 24:102187-102187(2021).
CC   -!- FUNCTION: Plays a role as antagonist of host tetherin (BST2),
CC       disrupting its antiviral effect (PubMed:33930332). Acts by binding to
CC       BST2 and sequestering it to perinuclear region, thereby preventing its
CC       antiviral function at cell membrane (PubMed:33930332). May specifically
CC       downregulate MHC-I allele HLA-A*02:01 (HLA-A2) (PubMed:36574644).
CC       {ECO:0000269|PubMed:33930332, ECO:0000269|PubMed:36574644}.
CC   -!- SUBUNIT: Interacts with host BST2 (PubMed:33930332). Interacts with the
CC       spike glycoprotein (By similarity). Interacts with M protein (By
CC       similarity). Interacts with E protein (By similarity). Interacts with
CC       the ORF3a protein (By similarity). {ECO:0000250|UniProtKB:P59635,
CC       ECO:0000269|PubMed:33930332}.
CC   -!- INTERACTION:
CC       P0DTC7; P0DTD8: 7b; NbExp=5; IntAct=EBI-25475903, EBI-25475914;
CC       P0DTC7; PRO_0000449625 [P0DTD1]: rep; NbExp=3; IntAct=EBI-25475903, EBI-25475871;
CC   -!- SUBCELLULAR LOCATION: Host cytoplasm, host perinuclear region
CC       {ECO:0000269|PubMed:33930332}. Virion {ECO:0000250|UniProtKB:P59635}.
CC       Host endoplasmic reticulum membrane {ECO:0000269|PubMed:36574644};
CC       Single-pass membrane protein {ECO:0000269|PubMed:36574644}. Host
CC       endoplasmic reticulum-Golgi intermediate compartment membrane
CC       {ECO:0000269|PubMed:36574644}; Single-pass type I membrane protein
CC       {ECO:0000269|PubMed:36574644}. Host Golgi apparatus membrane
CC       {ECO:0000269|PubMed:36574644}; Single-pass membrane protein
CC       {ECO:0000269|PubMed:36574644}.
CC   -!- DOMAIN: The di-lysine motif confers endoplasmic reticulum localization
CC       for type I membrane proteins. {ECO:0000250|UniProtKB:P59635}.
CC   -!- PTM: Poly-ubiquitinated by host with K63-linked polyubiquitin chains.
CC       {ECO:0000269|PubMed:33473190}.
CC   -!- MISCELLANEOUS: Variant B.1.1.7 is also called Variant Of Concern (VOC)
CC       202012/01, Variant Under Investigation (VUI) 202012/01, or 20B/501Y.V1.
CC       {ECO:0000305|PubMed:33413740}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43421.1; -; Genomic_RNA.
DR   PDB; 6W37; X-ray; 2.90 A; A=16-82.
DR   PDB; 7CI3; X-ray; 2.20 A; A=14-96.
DR   PDBsum; 6W37; -.
DR   PDBsum; 7CI3; -.
DR   SMR; P0DTC7; -.
DR   BioGRID; 4383872; 1267.
DR   IntAct; P0DTC7; 128.
DR   MINT; P0DTC7; -.
DR   iPTMnet; P0DTC7; -.
DR   KEGG; vg:43740573; -.
DR   AGR; RefSeq:YP_009724395; -.
DR   Reactome; R-HSA-9694322; Virion Assembly and Release.
DR   Reactome; R-HSA-9694614; Attachment and Entry.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9727281; Translation of Accessory Proteins.
DR   Reactome; R-HSA-9733458; Induction of Cell-Cell Fusion.
DR   Reactome; R-HSA-9754560; SARS-CoV-2 modulates autophagy.
DR   PRO; PR:P0DTC7; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044173; C:host cell endoplasmic reticulum-Golgi intermediate compartment membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044178; C:host cell Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR   GO; GO:0055036; C:virion membrane; TAS:Reactome.
DR   GO; GO:0039587; P:suppression by virus of host tetherin activity; IEA:UniProtKB-KW.
DR   GO; GO:0039646; P:symbiont-mediated perturbation of host cell cycle G0/G1 transition checkpoint; IEA:UniProtKB-KW.
DR   GO; GO:0044071; P:symbiont-mediated perturbation of host cell cycle progression; IEA:UniProtKB-KW.
DR   GO; GO:0046776; P:symbiont-mediated suppression of host antigen processing and presentation of peptide antigen via MHC class I; IEA:UniProtKB-KW.
DR   GO; GO:0052170; P:symbiont-mediated suppression of host innate immune response; IEA:UniProtKB-KW.
DR   CDD; cd21684; ORF7a_SARS-CoV-2-like; 1.
DR   Gene3D; 2.60.40.1550; SARS coronavirus X4; 1.
DR   InterPro; IPR044390; ORF7a_SARS-CoV-2-like.
DR   InterPro; IPR014888; ORF7a_SARS-CoV-like.
DR   InterPro; IPR044871; ORF7a_SARS-CoV-like_X4e.
DR   InterPro; IPR036495; ORF7a_sf_CoV.
DR   Pfam; PF08779; bCoV_NS7A; 1.
DR   SUPFAM; SSF117066; Accessory protein X4 (ORF8, ORF7a); 1.
DR   PROSITE; PS51919; X4E; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Disulfide bond;
KW   G0/G1 host cell cycle checkpoint dysregulation by virus; Host cytoplasm;
KW   Host endoplasmic reticulum; Host Golgi apparatus; Host membrane;
KW   Host-virus interaction;
KW   Inhibition of host adaptive immune response by virus;
KW   Inhibition of host innate immune response by virus;
KW   Inhibition of host MHC class I molecule presentation by virus;
KW   Inhibition of host tetherin by virus; Isopeptide bond; Membrane;
KW   Modulation of host cell cycle by virus; Reference proteome; Signal;
KW   Transmembrane; Transmembrane helix; Ubl conjugation; Viral immunoevasion;
KW   Virion.
FT   SIGNAL          1..15
FT                   /evidence=""ECO:0000255""
FT   CHAIN           16..121
FT                   /note=""ORF7a protein""
FT                   /evidence=""ECO:0000255""
FT                   /id=""PRO_0000449654""
FT   TRANSMEM        96..116
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255""
FT   DOMAIN          16..81
FT                   /note=""X4e""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01267""
FT   REGION          16..80
FT                   /note=""Ig-like fold""
FT                   /evidence=""ECO:0000305|PubMed:36574644""
FT   REGION          83..95
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000305|PubMed:35108439""
FT   MOTIF           117..119
FT                   /note=""ER-retrieval motif""
FT                   /evidence=""ECO:0000269|PubMed:36574644""
FT   DISULFID        23..58
FT                   /evidence=""ECO:0000269|PubMed:33615195, ECO:0000269|Ref.7""
FT   DISULFID        35..67
FT                   /evidence=""ECO:0000269|PubMed:33615195, ECO:0000269|Ref.7""
FT   CROSSLNK        119
FT                   /note=""Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)""
FT                   /evidence=""ECO:0000269|PubMed:33473190""
FT   VARIANT         14
FT                   /note=""T -> I (in strain: Alpha/B.1.1.7)""
FT                   /evidence=""ECO:0000305|PubMed:33413740""
FT   VARIANT         82
FT                   /note=""V -> A (in strain: Delta/B.1.617.2 and
FT                   Kappa/B.1.617.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         120
FT                   /note=""T -> I (in strain: Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   MUTAGEN         2
FT                   /note=""K->A: No effect on ubiquitination.""
FT                   /evidence=""ECO:0000269|PubMed:33473190""
FT   MUTAGEN         32
FT                   /note=""K->A: No effect on ubiquitination.""
FT                   /evidence=""ECO:0000269|PubMed:33473190""
FT   MUTAGEN         53
FT                   /note=""K->A: No effect on ubiquitination.""
FT                   /evidence=""ECO:0000269|PubMed:33473190""
FT   MUTAGEN         72
FT                   /note=""K->A: No effect on ubiquitination.""
FT                   /evidence=""ECO:0000269|PubMed:33473190""
FT   MUTAGEN         85
FT                   /note=""K->A: No effect on ubiquitination.""
FT                   /evidence=""ECO:0000269|PubMed:33473190""
FT   MUTAGEN         117..119
FT                   /note=""KRK->ARA: Complete loss of MHC-I retention in ER.""
FT                   /evidence=""ECO:0000269|PubMed:36574644""
FT   MUTAGEN         117
FT                   /note=""K->A: No effect on ubiquitination.""
FT                   /evidence=""ECO:0000269|PubMed:33473190""
FT   MUTAGEN         119
FT                   /note=""K->A: Complete loss of ubiquitination. Partial loss
FT                   of interferon pathway inhibition.""
FT                   /evidence=""ECO:0000269|PubMed:33473190""
FT   STRAND          16..24
FT                   /evidence=""ECO:0007829|PDB:7CI3""
FT   STRAND          27..32
FT                   /evidence=""ECO:0007829|PDB:7CI3""
FT   STRAND          34..37
FT                   /evidence=""ECO:0007829|PDB:7CI3""
FT   STRAND          39..44
FT                   /evidence=""ECO:0007829|PDB:7CI3""
FT   STRAND          47..49
FT                   /evidence=""ECO:0007829|PDB:6W37""
FT   HELIX           50..52
FT                   /evidence=""ECO:0007829|PDB:7CI3""
FT   STRAND          53..57
FT                   /evidence=""ECO:0007829|PDB:7CI3""
FT   STRAND          60..66
FT                   /evidence=""ECO:0007829|PDB:7CI3""
FT   STRAND          72..80
FT                   /evidence=""ECO:0007829|PDB:7CI3""
SQ   SEQUENCE   121 AA;  13744 MW;  891E7EAB9E8A5BA9 CRC64;
     MKIILFLALI TLATCELYHY QECVRGTTVL LKEPCSSGTY EGNSPFHPLA DNKFALTCFS
     TQFAFACPDG VKHVYQLRAR SVSPKLFIRQ EEVQELYSPI FLIVAAIVFI TLCFTLKRKT
     E
//
",20476
TCCATC CCATCT CATCTC ATCTCT TCTCTC CTCTCG TCTCGC CTCGCC TCGCCT CGCCTT GCCTTT CCTTTG CTTTGC TTTGCA TTGCAC TGCACC GCACCG CACCGA ACCGAG CCGAGG CGAGGT GAGGTC AGGTCG GGTCGT GTCGTC TCGTCA CGTCAA GTCAAG TCAAGG CAAGGC AAGGCC AGGCCT GGCCTC GCCTCC CCTCCA CTCCAA TCCAAG CCAAGT CAAGTA AAGTAC AGTACC GTACCG TACCGC ACCGCG CCGCGA CGCGAG GCGAGC CGAGCA GAGCAG AGCAGC GCAGCT CAGCTC AGCTCT GCTCTC CTCTCT TCTCTG CTCTGC TCTGCC CTGCCT TGCCTA GCCTAC CCTACC CTACCT TACCTG ACCTGT CCTGTC CTGTCC TGTCCA GTCCAA TCCAAC CCAACC CAACCG AACCGG ACCGGA CCGGAT CGGATG GGATGC GATGCA ATGCAG TGCAGA GCAGAC CAGACT AGACTA GACTAT ACTATT CTATTG TATTGC ATTGCC TTGCCC TGCCCC GCCCCC CCCCCA CCCCAA CCCAAC CCAACC CAACCT AACCTC ACCTCA CCTCAC CTCACC TCACCA CACCAC ACCACC CCACCA CACCAT ACCATG CCATGG CATGGT ATGGTT TGGTTG GGTTGG GTTGGA TTGGAG TGGAGA GGAGAG GAGAGC AGAGCA GAGCAG AGCAGA GCAGAT CAGATC AGATCG GATCGG ATCGGT TCGGTG CGGTGC GGTGCC GTGCCC TGCCCG GCCCGC CCCGCC CCGCCT CGCCTT GCCTTA CCTTAT CTTATC TTATCC TATCCA ATCCAG TCCAGA CCAGAA CAGAAG,3,142,TCCA CCAT CATC ATCT TCTC CTCT TCTC CTCG TCGC CGCC GCCT CCTT CTTT TTTG TTGC TGCA GCAC CACC ACCG CCGA CGAG GAGG AGGT GGTC GTCG TCGT CGTC GTCA TCAA CAAG AAGG AGGC GGCC GCCT CCTC CTCC TCCA CCAA CAAG AAGT AGTA GTAC TACC ACCG CCGC CGCG GCGA CGAG GAGC AGCA GCAG CAGC AGCT GCTC CTCT TCTC CTCT TCTG CTGC TGCC GCCT CCTA CTAC TACC ACCT CCTG CTGT TGTC GTCC TCCA CCAA CAAC AACC ACCG CCGG CGGA GGAT GATG ATGC TGCA GCAG CAGA AGAC GACT ACTA CTAT TATT ATTG TTGC TGCC GCCC CCCC CCCC CCCA CCAA CAAC AACC ACCT CCTC CTCA TCAC CACC ACCA CCAC CACC ACCA CCAT CATG ATGG TGGT GGTT GTTG TTGG TGGA GGAG GAGA AGAG GAGC AGCA GCAG CAGA AGAT GATC ATCG TCGG CGGT GGTG GTGC TGCC GCCC CCCG CCGC CGCC GCCT CCTT CTTA TTAT TATC ATCC TCCA CCAG CAGA AGAA GAAG,TCCAT CCATC CATCT ATCTC TCTCT CTCTC TCTCG CTCGC TCGCC CGCCT GCCTT CCTTT CTTTG TTTGC TTGCA TGCAC GCACC CACCG ACCGA CCGAG CGAGG GAGGT AGGTC GGTCG GTCGT TCGTC CGTCA GTCAA TCAAG CAAGG AAGGC AGGCC GGCCT GCCTC CCTCC CTCCA TCCAA CCAAG CAAGT AAGTA AGTAC GTACC TACCG ACCGC CCGCG CGCGA GCGAG CGAGC GAGCA AGCAG GCAGC CAGCT AGCTC GCTCT CTCTC TCTCT CTCTG TCTGC CTGCC TGCCT GCCTA CCTAC CTACC TACCT ACCTG CCTGT CTGTC TGTCC GTCCA TCCAA CCAAC CAACC AACCG ACCGG CCGGA CGGAT GGATG GATGC ATGCA TGCAG GCAGA CAGAC AGACT GACTA ACTAT CTATT TATTG ATTGC TTGCC TGCCC GCCCC CCCCC CCCCA CCCAA CCAAC CAACC AACCT ACCTC CCTCA CTCAC TCACC CACCA ACCAC CCACC CACCA ACCAT CCATG CATGG ATGGT TGGTT GGTTG GTTGG TTGGA TGGAG GGAGA GAGAG AGAGC GAGCA AGCAG GCAGA CAGAT AGATC GATCG ATCGG TCGGT CGGTG GGTGC GTGCC TGCCC GCCCG CCCGC CCGCC CGCCT GCCTT CCTTA CTTAT TTATC TATCC ATCCA TCCAG CCAGA CAGAA AGAAG,TCCATC CCATCT CATCTC ATCTCT TCTCTC CTCTCG TCTCGC CTCGCC TCGCCT CGCCTT GCCTTT CCTTTG CTTTGC TTTGCA TTGCAC TGCACC GCACCG CACCGA ACCGAG CCGAGG CGAGGT GAGGTC AGGTCG GGTCGT GTCGTC TCGTCA CGTCAA GTCAAG TCAAGG CAAGGC AAGGCC AGGCCT GGCCTC GCCTCC CCTCCA CTCCAA TCCAAG CCAAGT CAAGTA AAGTAC AGTACC GTACCG TACCGC ACCGCG CCGCGA CGCGAG GCGAGC CGAGCA GAGCAG AGCAGC GCAGCT CAGCTC AGCTCT GCTCTC CTCTCT TCTCTG CTCTGC TCTGCC CTGCCT TGCCTA GCCTAC CCTACC CTACCT TACCTG ACCTGT CCTGTC CTGTCC TGTCCA GTCCAA TCCAAC CCAACC CAACCG AACCGG ACCGGA CCGGAT CGGATG GGATGC GATGCA ATGCAG TGCAGA GCAGAC CAGACT AGACTA GACTAT ACTATT CTATTG TATTGC ATTGCC TTGCCC TGCCCC GCCCCC CCCCCA CCCCAA CCCAAC CCAACC CAACCT AACCTC ACCTCA CCTCAC CTCACC TCACCA CACCAC ACCACC CCACCA CACCAT ACCATG CCATGG CATGGT ATGGTT TGGTTG GGTTGG GTTGGA TTGGAG TGGAGA GGAGAG GAGAGC AGAGCA GAGCAG AGCAGA GCAGAT CAGATC AGATCG GATCGG ATCGGT TCGGTG CGGTGC GGTGCC GTGCCC TGCCCG GCCCGC CCCGCC CCGCCT CGCCTT GCCTTA CCTTAT CTTATC TTATCC TATCCA ATCCAG TCCAGA CCAGAA CAGAAG,TCCATCT CCATCTC CATCTCT ATCTCTC TCTCTCG CTCTCGC TCTCGCC CTCGCCT TCGCCTT CGCCTTT GCCTTTG CCTTTGC CTTTGCA TTTGCAC TTGCACC TGCACCG GCACCGA CACCGAG ACCGAGG CCGAGGT CGAGGTC GAGGTCG AGGTCGT GGTCGTC GTCGTCA TCGTCAA CGTCAAG GTCAAGG TCAAGGC CAAGGCC AAGGCCT AGGCCTC GGCCTCC GCCTCCA CCTCCAA CTCCAAG TCCAAGT CCAAGTA CAAGTAC AAGTACC AGTACCG GTACCGC TACCGCG ACCGCGA CCGCGAG CGCGAGC GCGAGCA CGAGCAG GAGCAGC AGCAGCT GCAGCTC CAGCTCT AGCTCTC GCTCTCT CTCTCTG TCTCTGC CTCTGCC TCTGCCT CTGCCTA TGCCTAC GCCTACC CCTACCT CTACCTG TACCTGT ACCTGTC CCTGTCC CTGTCCA TGTCCAA GTCCAAC TCCAACC CCAACCG CAACCGG AACCGGA ACCGGAT CCGGATG CGGATGC GGATGCA GATGCAG ATGCAGA TGCAGAC GCAGACT CAGACTA AGACTAT GACTATT ACTATTG CTATTGC TATTGCC ATTGCCC TTGCCCC TGCCCCC GCCCCCA CCCCCAA CCCCAAC CCCAACC CCAACCT CAACCTC AACCTCA ACCTCAC CCTCACC CTCACCA TCACCAC CACCACC ACCACCA CCACCAT CACCATG ACCATGG CCATGGT CATGGTT ATGGTTG TGGTTGG GGTTGGA GTTGGAG TTGGAGA TGGAGAG GGAGAGC GAGAGCA AGAGCAG GAGCAGA AGCAGAT GCAGATC CAGATCG AGATCGG GATCGGT ATCGGTG TCGGTGC CGGTGCC GGTGCCC GTGCCCG TGCCCGC GCCCGCC CCCGCCT CCGCCTT CGCCTTA GCCTTAT CCTTATC CTTATCC TTATCCA TATCCAG ATCCAGA TCCAGAA CCAGAAG,"ID   NOP58_CRYNB             Reviewed;         565 AA.
AC   P0CP27; Q55Q74; Q5KFZ2;
DT   28-JUN-2011, integrated into UniProtKB/Swiss-Prot.
DT   28-JUN-2011, sequence version 1.
DT   05-FEB-2025, entry version 46.
DE   RecName: Full=Nucleolar protein 58;
GN   Name=NOP58; OrderedLocusNames=CNBF4620;
OS   Cryptococcus neoformans var. neoformans serotype D (strain B-3501A)
OS   (Filobasidiella neoformans).
OC   Eukaryota; Fungi; Dikarya; Basidiomycota; Agaricomycotina; Tremellomycetes;
OC   Tremellales; Cryptococcaceae; Cryptococcus;
OC   Cryptococcus neoformans species complex.
OX   NCBI_TaxID=283643;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=B-3501A;
RX   PubMed=15653466; DOI=10.1126/science.1103773;
RA   Loftus B.J., Fung E., Roncaglia P., Rowley D., Amedeo P., Bruno D.,
RA   Vamathevan J., Miranda M., Anderson I.J., Fraser J.A., Allen J.E.,
RA   Bosdet I.E., Brent M.R., Chiu R., Doering T.L., Donlin M.J., D'Souza C.A.,
RA   Fox D.S., Grinberg V., Fu J., Fukushima M., Haas B.J., Huang J.C.,
RA   Janbon G., Jones S.J.M., Koo H.L., Krzywinski M.I., Kwon-Chung K.J.,
RA   Lengeler K.B., Maiti R., Marra M.A., Marra R.E., Mathewson C.A.,
RA   Mitchell T.G., Pertea M., Riggs F.R., Salzberg S.L., Schein J.E.,
RA   Shvartsbeyn A., Shin H., Shumway M., Specht C.A., Suh B.B., Tenney A.,
RA   Utterback T.R., Wickes B.L., Wortman J.R., Wye N.H., Kronstad J.W.,
RA   Lodge J.K., Heitman J., Davis R.W., Fraser C.M., Hyman R.W.;
RT   ""The genome of the basidiomycetous yeast and human pathogen Cryptococcus
RT   neoformans."";
RL   Science 307:1321-1324(2005).
CC   -!- FUNCTION: Required for pre-18S rRNA processing. May bind microtubules
CC       (By similarity). {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleolus {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the NOP5/NOP56 family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AAEY01000033; EAL19927.1; -; Genomic_DNA.
DR   RefSeq; XP_774574.1; XM_769481.1.
DR   AlphaFoldDB; P0CP27; -.
DR   SMR; P0CP27; -.
DR   GeneID; 4937014; -.
DR   KEGG; cnb:CNBF4620; -.
DR   VEuPathDB; FungiDB:CNBF4620; -.
DR   HOGENOM; CLU_015495_5_2_1; -.
DR   OrthoDB; 8196at5206; -.
DR   GO; GO:0031428; C:box C/D methylation guide snoRNP complex; IEA:InterPro.
DR   GO; GO:0005730; C:nucleolus; IEA:UniProtKB-SubCell.
DR   GO; GO:0032040; C:small-subunit processome; IEA:InterPro.
DR   GO; GO:0030515; F:snoRNA binding; IEA:InterPro.
DR   GO; GO:0006364; P:rRNA processing; IEA:UniProtKB-KW.
DR   FunFam; 1.10.246.90:FF:000003; Nucleolar protein 58; 1.
DR   FunFam; 1.10.287.4070:FF:000001; Probable Nucleolar protein 58; 1.
DR   Gene3D; 1.10.287.4070; -; 1.
DR   Gene3D; 1.10.246.90; Nop domain; 1.
DR   InterPro; IPR045056; Nop56/Nop58.
DR   InterPro; IPR012974; NOP58/56_N.
DR   InterPro; IPR042239; Nop_C.
DR   InterPro; IPR002687; Nop_dom.
DR   InterPro; IPR036070; Nop_dom_sf.
DR   InterPro; IPR012976; NOSIC.
DR   PANTHER; PTHR10894; NUCLEOLAR PROTEIN 5 NUCLEOLAR PROTEIN NOP5 NOP58; 1.
DR   PANTHER; PTHR10894:SF1; NUCLEOLAR PROTEIN 58; 1.
DR   Pfam; PF01798; Nop; 1.
DR   Pfam; PF08156; NOP5NT; 1.
DR   SMART; SM00931; NOSIC; 1.
DR   SUPFAM; SSF89124; Nop domain; 1.
DR   PROSITE; PS51358; NOP; 1.
PE   3: Inferred from homology;
KW   Nucleus; Ribonucleoprotein; Ribosome biogenesis; rRNA processing.
FT   CHAIN           1..565
FT                   /note=""Nucleolar protein 58""
FT                   /id=""PRO_0000410170""
FT   DOMAIN          293..417
FT                   /note=""Nop""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU00690""
FT   REGION          430..565
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        471..481
FT                   /note=""Basic and acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        519..530
FT                   /note=""Basic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        531..541
FT                   /note=""Basic and acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
SQ   SEQUENCE   565 AA;  61979 MW;  41570781B93DEEF4 CRC64;
     MLVLTETSVG FVVFKLSSDA KIDNKDLWKE FETPEGANKA LKVQAIQRFT STASAVEDLT
     AVQDGRLTDS LSRFLLDTVG GADDGEKKKK KKKIEEMLVV SDPKLAGTIN KALSIPVLSD
     SSTQDLYRGI RQQLASLLGG VDQKDLNTMS LGLGHSLSRF KLKFSTDKVD TMVIQAIALL
     DDLDKEINIY AMRVKEWYGW HFPEMAKIIV DNIAFARVVK AMGFRTNAVT TDFSLLLPED
     LEATLKSAAE LSMGTEISDS DMTHIHSLCD QVISISEYRT QLSEYLRNRM QAIAPNLTAL
     VGELVGARLI SHAGSLMNLA KHPASTVQIL GAEKALFRAL KTKHDTPKYG LIYHASLIGQ
     APQKLKGKMA RMVATKAALS IRVDALSDAD SRSDVSAAEV GISNRVKLES RLRALEHQAG
     IQSVRKVVSA NGQQGRQQPR FEMSGVTGSY NAATDNVPLN GDLLPTQPAT EEVKEEKDEK
     KDKKKKRKSE VAEAGDVTMD GDADLSMVAG ETKEERRARK EAKKAAKAAK KAAEESGDGD
     KKSKKRRADE DEDSEKKKKK KKKDE
//
",38614
GCCTTG CCTTGA CTTGAA TTGAAT TGAATA GAATAC AATACA ATACAC TACACC ACACCA CACCAA ACCAAA CCAAAA CAAAAG AAAAGA AAAGAT AAGATC AGATCA GATCAC ATCACA TCACAT CACATT ACATTG CATTGG ATTGGC TTGGCA TGGCAC GGCACC GCACCC CACCCG ACCCGC CCCGCA CCGCAA CGCAAT GCAATC CAATCC AATCCT ATCCTG TCCTGC CCTGCT CTGCTA TGCTAA GCTAAC CTAACA TAACAA AACAAT ACAATG CAATGC AATGCT ATGCTG TGCTGC GCTGCA CTGCAA TGCAAT GCAATC CAATCG AATCGT ATCGTG TCGTGC CGTGCT GTGCTA TGCTAC GCTACA CTACAA TACAAC ACAACT CAACTC AACTCG ACTCGC CTCGCC TCGCCC CGCCCG GCCCGA CCCGAG CCGAGG CGAGGA GAGGAG AGGAGC GGAGCA GAGCAA AGCAAC GCAACA CAACAT AACATT ACATTG CATTGC ATTGCC TTGCCA TGCCAA GCCAAA CCAAAA CAAAAG AAAAGG AAAGGC AAGGCT AGGCTC GGCTCC GCTCCG CTCCGA TCCGAC CCGACG CGACGC GACGCA ACGCAG CGCAGA GCAGAT CAGATG AGATGG GATGGG ATGGGA TGGGAG GGGAGC GGAGCA GAGCAG AGCAGA GCAGAG CAGAGT AGAGTC GAGTCG AGTCGG GTCGGC TCGGCT CGGCTG GGCTGT GCTGTC CTGTCA TGTCAA GTCAAG TCAAGC CAAGCC AAGCCT AGCCTC GCCTCT,1,133,GCCT CCTT CTTG TTGA TGAA GAAT AATA ATAC TACA ACAC CACC ACCA CCAA CAAA AAAA AAAG AAGA AGAT GATC ATCA TCAC CACA ACAT CATT ATTG TTGG TGGC GGCA GCAC CACC ACCC CCCG CCGC CGCA GCAA CAAT AATC ATCC TCCT CCTG CTGC TGCT GCTA CTAA TAAC AACA ACAA CAAT AATG ATGC TGCT GCTG CTGC TGCA GCAA CAAT AATC ATCG TCGT CGTG GTGC TGCT GCTA CTAC TACA ACAA CAAC AACT ACTC CTCG TCGC CGCC GCCC CCCG CCGA CGAG GAGG AGGA GGAG GAGC AGCA GCAA CAAC AACA ACAT CATT ATTG TTGC TGCC GCCA CCAA CAAA AAAA AAAG AAGG AGGC GGCT GCTC CTCC TCCG CCGA CGAC GACG ACGC CGCA GCAG CAGA AGAT GATG ATGG TGGG GGGA GGAG GAGC AGCA GCAG CAGA AGAG GAGT AGTC GTCG TCGG CGGC GGCT GCTG CTGT TGTC GTCA TCAA CAAG AAGC AGCC GCCT CCTC CTCT,GCCTT CCTTG CTTGA TTGAA TGAAT GAATA AATAC ATACA TACAC ACACC CACCA ACCAA CCAAA CAAAA AAAAG AAAGA AAGAT AGATC GATCA ATCAC TCACA CACAT ACATT CATTG ATTGG TTGGC TGGCA GGCAC GCACC CACCC ACCCG CCCGC CCGCA CGCAA GCAAT CAATC AATCC ATCCT TCCTG CCTGC CTGCT TGCTA GCTAA CTAAC TAACA AACAA ACAAT CAATG AATGC ATGCT TGCTG GCTGC CTGCA TGCAA GCAAT CAATC AATCG ATCGT TCGTG CGTGC GTGCT TGCTA GCTAC CTACA TACAA ACAAC CAACT AACTC ACTCG CTCGC TCGCC CGCCC GCCCG CCCGA CCGAG CGAGG GAGGA AGGAG GGAGC GAGCA AGCAA GCAAC CAACA AACAT ACATT CATTG ATTGC TTGCC TGCCA GCCAA CCAAA CAAAA AAAAG AAAGG AAGGC AGGCT GGCTC GCTCC CTCCG TCCGA CCGAC CGACG GACGC ACGCA CGCAG GCAGA CAGAT AGATG GATGG ATGGG TGGGA GGGAG GGAGC GAGCA AGCAG GCAGA CAGAG AGAGT GAGTC AGTCG GTCGG TCGGC CGGCT GGCTG GCTGT CTGTC TGTCA GTCAA TCAAG CAAGC AAGCC AGCCT GCCTC CCTCT,GCCTTG CCTTGA CTTGAA TTGAAT TGAATA GAATAC AATACA ATACAC TACACC ACACCA CACCAA ACCAAA CCAAAA CAAAAG AAAAGA AAAGAT AAGATC AGATCA GATCAC ATCACA TCACAT CACATT ACATTG CATTGG ATTGGC TTGGCA TGGCAC GGCACC GCACCC CACCCG ACCCGC CCCGCA CCGCAA CGCAAT GCAATC CAATCC AATCCT ATCCTG TCCTGC CCTGCT CTGCTA TGCTAA GCTAAC CTAACA TAACAA AACAAT ACAATG CAATGC AATGCT ATGCTG TGCTGC GCTGCA CTGCAA TGCAAT GCAATC CAATCG AATCGT ATCGTG TCGTGC CGTGCT GTGCTA TGCTAC GCTACA CTACAA TACAAC ACAACT CAACTC AACTCG ACTCGC CTCGCC TCGCCC CGCCCG GCCCGA CCCGAG CCGAGG CGAGGA GAGGAG AGGAGC GGAGCA GAGCAA AGCAAC GCAACA CAACAT AACATT ACATTG CATTGC ATTGCC TTGCCA TGCCAA GCCAAA CCAAAA CAAAAG AAAAGG AAAGGC AAGGCT AGGCTC GGCTCC GCTCCG CTCCGA TCCGAC CCGACG CGACGC GACGCA ACGCAG CGCAGA GCAGAT CAGATG AGATGG GATGGG ATGGGA TGGGAG GGGAGC GGAGCA GAGCAG AGCAGA GCAGAG CAGAGT AGAGTC GAGTCG AGTCGG GTCGGC TCGGCT CGGCTG GGCTGT GCTGTC CTGTCA TGTCAA GTCAAG TCAAGC CAAGCC AAGCCT AGCCTC GCCTCT,GCCTTGA CCTTGAA CTTGAAT TTGAATA TGAATAC GAATACA AATACAC ATACACC TACACCA ACACCAA CACCAAA ACCAAAA CCAAAAG CAAAAGA AAAAGAT AAAGATC AAGATCA AGATCAC GATCACA ATCACAT TCACATT CACATTG ACATTGG CATTGGC ATTGGCA TTGGCAC TGGCACC GGCACCC GCACCCG CACCCGC ACCCGCA CCCGCAA CCGCAAT CGCAATC GCAATCC CAATCCT AATCCTG ATCCTGC TCCTGCT CCTGCTA CTGCTAA TGCTAAC GCTAACA CTAACAA TAACAAT AACAATG ACAATGC CAATGCT AATGCTG ATGCTGC TGCTGCA GCTGCAA CTGCAAT TGCAATC GCAATCG CAATCGT AATCGTG ATCGTGC TCGTGCT CGTGCTA GTGCTAC TGCTACA GCTACAA CTACAAC TACAACT ACAACTC CAACTCG AACTCGC ACTCGCC CTCGCCC TCGCCCG CGCCCGA GCCCGAG CCCGAGG CCGAGGA CGAGGAG GAGGAGC AGGAGCA GGAGCAA GAGCAAC AGCAACA GCAACAT CAACATT AACATTG ACATTGC CATTGCC ATTGCCA TTGCCAA TGCCAAA GCCAAAA CCAAAAG CAAAAGG AAAAGGC AAAGGCT AAGGCTC AGGCTCC GGCTCCG GCTCCGA CTCCGAC TCCGACG CCGACGC CGACGCA GACGCAG ACGCAGA CGCAGAT GCAGATG CAGATGG AGATGGG GATGGGA ATGGGAG TGGGAGC GGGAGCA GGAGCAG GAGCAGA AGCAGAG GCAGAGT CAGAGTC AGAGTCG GAGTCGG AGTCGGC GTCGGCT TCGGCTG CGGCTGT GGCTGTC GCTGTCA CTGTCAA TGTCAAG GTCAAGC TCAAGCC CAAGCCT AAGCCTC AGCCTCT,"ID   NCAP_SARS2              Reviewed;         419 AA.
AC   P0DTC9;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Nucleoprotein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=N;
DE   AltName: Full=Nucleocapsid protein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=NC {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=Protein N {ECO:0000255|HAMAP-Rule:MF_04096};
GN   Name=N {ECO:0000255|HAMAP-Rule:MF_04096};
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   SUBCELLULAR LOCATION.
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [3] {ECO:0007744|PDB:6WZO, ECO:0007744|PDB:6WZQ}
RP   X-RAY CRYSTALLOGRAPHY (1.42 ANGSTROMS) OF 247-364, AND SUBUNIT.
RX   PubMed=32654247; DOI=10.1002/pro.3909;
RA   Ye Q., West A.M.V., Silletti S., Corbett K.D.;
RT   ""Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein."";
RL   Protein Sci. 29:1890-1901(2020).
RN   [4]
RP   REVIEW.
RX   PubMed=32974389; DOI=10.3389/fmolb.2020.00219;
RA   Nikolakaki E., Giannakouros T.;
RT   ""SR/RS Motifs as Critical Determinants of Coronavirus Life Cycle."";
RL   Front. Mol. Biosci. 7:219-219(2020).
RN   [5]
RP   VARIANTS LEU-3 AND PHE-235.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [6]
RP   FUNCTION, INTERACTION WITH HOST NLRP3, AND SUBCELLULAR LOCATION.
RX   PubMed=34341353; DOI=10.1038/s41467-021-25015-6;
RA   Pan P., Shen M., Yu Z., Ge W., Chen K., Tian M., Xiao F., Wang Z., Wang J.,
RA   Jia Y., Wang W., Wan P., Zhang J., Chen W., Lei Z., Chen X., Luo Z.,
RA   Zhang Q., Xu M., Li G., Li Y., Wu J.;
RT   ""SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce
RT   hyperinflammation."";
RL   Nat. Commun. 12:4664-4664(2021).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 41-174, AND MUTAGENESIS OF
RP   TYR-109.
RX   PubMed=32363136; DOI=10.1016/j.apsb.2020.04.009;
RA   Kang S., Yang M., Hong Z., Zhang L., Huang Z., Chen X., He S., Zhou Z.,
RA   Zhou Z., Chen Q., Yan Y., Zhang C., Shan H., Chen S.;
RT   ""Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain
RT   reveals potential unique drug targeting sites."";
RL   Acta Pharmacol. Sin. 10:1228-1238(2020).
RN   [8] {ECO:0007744|PDB:6YI3, ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT}
RP   STRUCTURE BY NMR OF 44-180, FUNCTION, AND MUTAGENESIS OF ARG-68; ARG-92;
RP   ILE-94; ARG-107; GLN-163; TYR-172 AND GLU-174.
RX   PubMed=33264373; DOI=10.1371/journal.ppat.1009100;
RA   Dinesh D.C., Chalupska D., Silhan J., Koutna E., Nencka R., Veverka V.,
RA   Boura E.;
RT   ""Structural basis of RNA recognition by the SARS-CoV-2 nucleocapsid
RT   phosphoprotein."";
RL   PLoS Pathog. 16:1-16(2020).
RN   [9]
RP   MUTAGENESIS OF SER-188 AND SER-206, AND PHOSPHORYLATION AT SER-206.
RX   PubMed=34593624; DOI=10.1073/pnas.2113401118;
RA   Liu X., Verma A., Garcia G. Jr., Ramage H., Lucas A., Myers R.L.,
RA   Michaelson J.J., Coryell W., Kumar A., Charney A.W., Kazanietz M.G.,
RA   Rader D.J., Ritchie M.D., Berrettini W.H., Schultz D.C., Cherry S.,
RA   Damoiseaux R., Arumugaswami V., Klein P.S.;
RT   ""Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:1-9(2021).
RN   [10]
RP   CLEAVAGE.
RX   PubMed=35922005; DOI=10.1038/s41586-022-05148-4;
RA   Chu H., Hou Y., Yang D., Wen L., Shuai H., Yoon C., Shi J., Chai Y.,
RA   Yuen T.T., Hu B., Li C., Zhao X., Wang Y., Huang X., Lee K.S., Luo C.,
RA   Cai J.P., Poon V.K., Chan C.C., Zhang A.J., Yuan S., Sit K.Y., Foo D.C.,
RA   Au W.K., Wong K.K., Zhou J., Kok K.H., Jin D.Y., Chan J.F., Yuen K.Y.;
RT   ""Coronaviruses exploit a host cysteine-aspartic protease for replication."";
RL   Nature 0:0-0(2022).
RN   [11]
RP   MUTAGENESIS OF 203-ARG-GLY-204 AND ARG-203, AND PHOSPHORYLATION.
RX   PubMed=35728038; DOI=10.1371/journal.ppat.1010627;
RA   Johnson B.A., Zhou Y., Lokugamage K.G., Vu M.N., Bopp N.,
RA   Crocquet-Valdes P.A., Kalveram B., Schindewolf C., Liu Y., Scharton D.,
RA   Plante J.A., Xie X., Aguilar P., Weaver S.C., Shi P.Y., Walker D.H.,
RA   Routh A.L., Plante K.S., Menachery V.D.;
RT   ""Nucleocapsid mutations in SARS-CoV-2 augment replication and
RT   pathogenesis."";
RL   PLoS Pathog. 18:e1010627-e1010627(2022).
RN   [12]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=35921414; DOI=10.1126/sciadv.abp9770;
RA   Lopez-Munoz A.D., Kosik I., Holly J., Yewdell J.W.;
RT   ""Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive
RT   immunity."";
RL   Sci. Adv. 8:eabp9770-eabp9770(2022).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=34901782; DOI=10.1016/j.isci.2021.103562;
RA   Nabeel-Shah S., Lee H., Ahmed N., Burke G.L., Farhangmehr S., Ashraf K.,
RA   Pu S., Braunschweig U., Zhong G., Wei H., Tang H., Yang J., Marcon E.,
RA   Blencowe B.J., Zhang Z., Greenblatt J.F.;
RT   ""SARS-CoV-2 nucleocapsid protein binds host mRNAs and attenuates stress
RT   granules to impair host stress response."";
RL   IScience 25:103562-103562(2022).
RN   [14]
RP   FUNCTION.
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [15] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 191-263, AND INTERACTION WITH NSP3.
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
CC   -!- FUNCTION: Packages the positive strand viral genome RNA into a helical
CC       ribonucleocapsid (RNP) and plays a fundamental role during virion
CC       assembly through its interactions with the viral genome and membrane
CC       protein M (PubMed:33264373). Plays an important role in enhancing the
CC       efficiency of subgenomic viral RNA transcription as well as viral
CC       replication. Attenuates the stress granules formation by reducing host
CC       G3BP1 access to host mRNAs under stress conditions (PubMed:34901782,
CC       PubMed:36534661). {ECO:0000269|PubMed:32974389,
CC       ECO:0000269|PubMed:33264373, ECO:0000269|PubMed:34901782,
CC       ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: May block host chemokine function in vivo, facilitating viral
CC       replication and transmission (PubMed:35921414). Acts by being secreted
CC       into the extracellular space where it competes to host chemokines for
CC       binding to host glycosaminoglycans (GAG) (PubMed:35921414).
CC       {ECO:0000269|PubMed:35921414}.
CC   -!- FUNCTION: May induce inflammasome responses in cultured cells and mice.
CC       Acts by interacting with host NLRP3 to facilitate inflammasome
CC       assembly, which induces cytokine release that may play a role in COVID
CC       lung injury. {ECO:0000269|PubMed:34341353}.
CC   -!- SUBUNIT: Homodimer, homotetramer, homooligomer with RNA
CC       (PubMed:32654247). Both monomeric and oligomeric forms interact with
CC       RNA. Interacts with protein M (By similarity). Interacts with protein E
CC       (By similarity). Interacts with NSP3; this interaction serves to tether
CC       the genome to the newly translated replicase-transcriptase complex at a
CC       very early stage of infection (PubMed:35044811). May interact with host
CC       NLRP3 (PubMed:34341353). {ECO:0000250|UniProtKB:P59595,
CC       ECO:0000255|HAMAP-Rule:MF_04096, ECO:0000269|PubMed:32654247,
CC       ECO:0000269|PubMed:34341353, ECO:0000269|PubMed:35044811}.
CC   -!- INTERACTION:
CC       P0DTC9; P0DTC4: E; NbExp=3; IntAct=EBI-25475856, EBI-25475850;
CC       P0DTC9; P0DTC5: M; NbExp=6; IntAct=EBI-25475856, EBI-25475853;
CC       P0DTC9; P0DTC9: N; NbExp=105; IntAct=EBI-25475856, EBI-25475856;
CC       P0DTC9; PRO_0000449621 [P0DTD1]: rep; NbExp=15; IntAct=EBI-25475856, EBI-25492388;
CC       P0DTC9; P78563: ADARB1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-2967304;
CC       P0DTC9; O15145: ARPC3; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-351829;
CC       P0DTC9; Q13895: BYSL; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-358049;
CC       P0DTC9; Q16543: CDC37; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-295634;
CC       P0DTC9; Q92793: CREBBP; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-81215;
CC       P0DTC9; Q92499: DDX1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-358474;
CC       P0DTC9; Q9NR30: DDX21; Xeno; NbExp=12; IntAct=EBI-25475856, EBI-357942;
CC       P0DTC9; P26196: DDX6; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-351257;
CC       P0DTC9; Q08426: EHHADH; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-2339219;
CC       P0DTC9; P19525: EIF2AK2; Xeno; NbExp=8; IntAct=EBI-25475856, EBI-640775;
CC       P0DTC9; Q14241: ELOA; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-742350;
CC       P0DTC9; Q13283: G3BP1; Xeno; NbExp=71; IntAct=EBI-25475856, EBI-1047359;
CC       P0DTC9; Q9UN86: G3BP2; Xeno; NbExp=37; IntAct=EBI-25475856, EBI-1044298;
CC       P0DTC9; P57764: GSDMD; Xeno; NbExp=13; IntAct=EBI-25475856, EBI-2798865;
CC       P0DTC9; P49841: GSK3B; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-373586;
CC       P0DTC9; P10412: H1-4; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-358163;
CC       P0DTC9; O14920: IKBKB; Xeno; NbExp=7; IntAct=EBI-25475856, EBI-81266;
CC       P0DTC9; Q92830: KAT2A; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-477622;
CC       P0DTC9; Q92831: KAT2B; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-477430;
CC       P0DTC9; Q07866: KLC1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-721019;
CC       P0DTC9; Q9H0B6: KLC2; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-726994;
CC       P0DTC9; Q9NSK0: KLC4; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-949319;
CC       P0DTC9; Q9NX58: LYAR; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-713507;
CC       P0DTC9; O43318: MAP3K7; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-358684;
CC       P0DTC9; Q9UBU8: MORF4L1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-399246;
CC       P0DTC9; Q15014: MORF4L2; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-399257;
CC       P0DTC9; Q9HCE1: MOV10; Xeno; NbExp=11; IntAct=EBI-25475856, EBI-1055820;
CC       P0DTC9; Q9HC36: MRM3; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-1045440;
CC       P0DTC9; O15226: NKRF; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-766011;
CC       P0DTC9; Q96P20: NLRP3; Xeno; NbExp=18; IntAct=EBI-25475856, EBI-6253230;
CC       P0DTC9; O15118: NPC1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-2368710;
CC       P0DTC9; Q96HA8: NTAQ1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-741158;
CC       P0DTC9; P11940: PABPC1; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-81531;
CC       P0DTC9; P62937: PPIA; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-437708;
CC       P0DTC9; O75569: PRKRA; Xeno; NbExp=8; IntAct=EBI-25475856, EBI-713955;
CC       P0DTC9; Q99873: PRMT1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-78738;
CC       P0DTC9; P61289: PSME3; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-355546;
CC       P0DTC9; P26022: PTX3; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-11574553;
CC       P0DTC9; P54727: RAD23B; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-954531;
CC       P0DTC9; O95786: RIGI; Xeno; NbExp=15; IntAct=EBI-25475856, EBI-995350;
CC       P0DTC9; P62899: RPL31; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-1053664;
CC       P0DTC9; P62753: RPS6; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-356625;
CC       P0DTC9; P37840: SNCA; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-985879;
CC       P0DTC9; Q96SB4: SRPK1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-539478;
CC       P0DTC9; P78362: SRPK2; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-593303;
CC       P0DTC9; P42224: STAT1; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-1057697;
CC       P0DTC9; P52630: STAT2; Xeno; NbExp=7; IntAct=EBI-25475856, EBI-1546963;
CC       P0DTC9; Q15633: TARBP2; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-978581;
CC       P0DTC9; Q14258: TRIM25; Xeno; NbExp=13; IntAct=EBI-25475856, EBI-2341129;
CC       P0DTC9; O60763: USO1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-356164;
CC       P0DTC9; Q93008: USP9X; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-302524;
CC   -!- SUBCELLULAR LOCATION: Virion {ECO:0000255|HAMAP-Rule:MF_04096}. Host
CC       cytoplasm {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:34341353}.
CC       Secreted {ECO:0000269|PubMed:35921414}. Host extracellular space
CC       {ECO:0000269|PubMed:35921414}. Note=Probably associates with ER-derived
CC       membranes where it participates in viral RNA synthesis and virus
CC       budding. When located inside the virion, complexed with the viral RNA.
CC       Can be secreted by unconventional protein secretion (UPS)
CC       (PubMed:35921414). When secreted, can bind to host glycosaminoglycans
CC       on infected and non infected cells (PubMed:35921414). Found in host
CC       cytoplasmic stress granules (PubMed:34901782). {ECO:0000255|HAMAP-
CC       Rule:MF_04096, ECO:0000269|PubMed:34901782,
CC       ECO:0000269|PubMed:35921414}.
CC   -!- PTM: ADP-ribosylated. The ADP-ribosylation is retained in the virion
CC       during infection. {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   -!- PTM: Phosphorylated on serine residues by host GSK3A and GSK3B
CC       (PubMed:34593624, PubMed:35728038). This promotes the solubility of
CC       homodimers that would otherwise aggregate (PubMed:32974389). Host
CC       phosphatase would dephosphorylate the protein during assembly at M
CC       bound membranes (PubMed:32974389). {ECO:0000269|PubMed:34593624,
CC       ECO:0000269|PubMed:35728038, ECO:0000305|PubMed:32974389}.
CC   -!- PTM: Proteolytically cleaved by host CASP6. The cleavage leads to two
CC       fragments and facilitates viral replication by inhibiting host IFN
CC       signaling. The two fragments may interact with IRF3 inhibiting its
CC       nuclear translocation after activation and reduce the expression of
CC       IFNB and IFN-stimulated genes. {ECO:0000269|PubMed:35922005}.
CC   -!- POLYMORPHISM: Variant Alpha/B.1.1.7 belongs to a lineage isolated first
CC       in United Kingdom (December 2020). It is also called Variant of Concern
CC       (VOC) 202012/01, Variant Under Investigation (VUI) 202012/01, 501Y.V1
CC       or 20B/501Y.V1. {ECO:0000305|PubMed:33413740}.
CC   -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC       isolated in South Africa (November 2021). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC       isolated in Nigeria (November 2022). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC       isolated in United States (November 2022). It is the result of
CC       recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC       express ORF8. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the betacoronavirus nucleocapsid protein family.
CC       {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43423.2; -; Genomic_RNA.
DR   PDB; 6M3M; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 6VYO; X-ray; 1.70 A; A/B/C/D=47-173.
DR   PDB; 6WJI; X-ray; 2.05 A; A/B/C/D/E/F=257-364.
DR   PDB; 6WKP; X-ray; 2.67 A; A/B/C/D=47-173.
DR   PDB; 6WZO; X-ray; 1.42 A; A/B/C/D=247-364.
DR   PDB; 6WZQ; X-ray; 1.45 A; A/B/C/D=247-364.
DR   PDB; 6YI3; NMR; -; A=44-180.
DR   PDB; 6YUN; X-ray; 1.44 A; A/B=249-364.
DR   PDB; 6ZCO; X-ray; 1.36 A; A=247-364.
DR   PDB; 7ACS; NMR; -; A=44-180.
DR   PDB; 7ACT; NMR; -; A=44-180.
DR   PDB; 7C22; X-ray; 2.00 A; A/B/C/D=248-364.
DR   PDB; 7CDZ; X-ray; 1.80 A; A/B/C/D=44-174.
DR   PDB; 7CE0; X-ray; 1.50 A; A/B/C/D=255-364.
DR   PDB; 7CR5; X-ray; 2.08 A; A=41-174.
DR   PDB; 7DE1; X-ray; 2.00 A; A/B=250-364.
DR   PDB; 7F2B; X-ray; 2.00 A; A/B=257-362.
DR   PDB; 7F2E; X-ray; 3.10 A; A/B/C/D/E/F/G/H/I/J/K/L=255-362.
DR   PDB; 7KGO; X-ray; 2.15 A; C=351-359.
DR   PDB; 7KGP; X-ray; 1.40 A; C=316-324.
DR   PDB; 7KGQ; X-ray; 1.34 A; C=222-230.
DR   PDB; 7KGR; X-ray; 1.55 A; C=159-167.
DR   PDB; 7KGS; X-ray; 1.58 A; C=138-146.
DR   PDB; 7KGT; X-ray; 1.90 A; C=226-234.
DR   PDB; 7LGD; X-ray; 2.88 A; E/F=105-113.
DR   PDB; 7LTU; X-ray; 1.12 A; A/B=217-222.
DR   PDB; 7LUX; X-ray; 1.30 A; A=217-222.
DR   PDB; 7LUZ; X-ray; 1.10 A; A=243-248.
DR   PDB; 7LV2; X-ray; 1.30 A; A=179-184.
DR   PDB; 7N0I; X-ray; 2.20 A; A/B/C/D/E/F/G/H=269-364.
DR   PDB; 7N0R; X-ray; 1.42 A; A/B=49-174.
DR   PDB; 7N3C; X-ray; 1.82 A; C=47-173.
DR   PDB; 7N3D; X-ray; 1.53 A; C=47-173.
DR   PDB; 7O05; X-ray; 1.94 A; A/B/C/D=247-364.
DR   PDB; 7O35; X-ray; 1.80 A; A/B/C/D=247-364.
DR   PDB; 7O36; X-ray; 2.00 A; A/B/C/D=247-364.
DR   PDB; 7PKU; NMR; -; B=191-263.
DR   PDB; 7QIK; X-ray; 2.01 A; E/F=193-200.
DR   PDB; 7QIP; X-ray; 2.65 A; C/D=201-210.
DR   PDB; 7R98; X-ray; 2.51 A; A/B/C=49-174.
DR   PDB; 7SD4; NMR; -; A=40-174.
DR   PDB; 7STR; X-ray; 1.50 A; C=47-173.
DR   PDB; 7STS; X-ray; 2.16 A; C/D=47-173.
DR   PDB; 7SUE; X-ray; 2.90 A; C/D/J/K=47-173.
DR   PDB; 7SUO; X-ray; 2.35 A; C/D=12-22.
DR   PDB; 7UW3; X-ray; 1.70 A; A/B/C/D=40-174.
DR   PDB; 7UXX; X-ray; 1.85 A; AAA/BBB/CCC/DDD/EEE/FFF=251-364.
DR   PDB; 7UXZ; X-ray; 1.73 A; AAA/BBB/CCC/DDD/EEE/FFF=251-364.
DR   PDB; 7VBD; X-ray; 1.94 A; A/B/C/D=48-174.
DR   PDB; 7VBE; X-ray; 1.59 A; A/B=257-364.
DR   PDB; 7VBF; X-ray; 1.30 A; A/B=255-364.
DR   PDB; 7VNU; X-ray; 1.95 A; A/B/C/D=47-174.
DR   PDB; 7WKJ; X-ray; 1.50 A; C=361-369.
DR   PDB; 7WZO; X-ray; 2.64 A; A=47-174.
DR   PDB; 7XWX; X-ray; 3.00 A; A/B/C/D/E/F/G/H=269-367.
DR   PDB; 7XWZ; X-ray; 2.25 A; A/B=48-172.
DR   PDB; 7XX1; X-ray; 1.90 A; A/B/C/D=49-173.
DR   PDB; 7XXK; X-ray; 2.00 A; A/B/C/D/E/F=248-364.
DR   PDB; 7YLB; X-ray; 2.41 A; A/B/C/D/G/H/J/K=247-364.
DR   PDB; 7YLD; X-ray; 2.80 A; A/B/C/D=47-174.
DR   PDB; 7ZIT; X-ray; 1.79 A; C/D=194-200.
DR   PDB; 8DNT; X-ray; 3.18 A; D/J/Q/X=222-230.
DR   PDB; 8FD5; EM; 4.57 A; A=1-419.
DR   PDB; 8FG2; EM; 6.00 A; A/B=1-419.
DR   PDB; 8IQJ; X-ray; 2.30 A; A/B/C/D=41-174.
DR   PDB; 8IV3; X-ray; 1.90 A; A/B/C/D=41-174.
DR   PDB; 8J6X; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 8TH1; X-ray; 1.80 A; E/F/G/H=1-25.
DR   PDB; 8TH5; X-ray; 2.62 A; K/L/M/N/O/P/Q=1-25.
DR   PDB; 8X1H; X-ray; 2.00 A; A/B/C/D=44-175.
DR   PDBsum; 6M3M; -.
DR   PDBsum; 6VYO; -.
DR   PDBsum; 6WJI; -.
DR   PDBsum; 6WKP; -.
DR   PDBsum; 6WZO; -.
DR   PDBsum; 6WZQ; -.
DR   PDBsum; 6YI3; -.
DR   PDBsum; 6YUN; -.
DR   PDBsum; 6ZCO; -.
DR   PDBsum; 7ACS; -.
DR   PDBsum; 7ACT; -.
DR   PDBsum; 7C22; -.
DR   PDBsum; 7CDZ; -.
DR   PDBsum; 7CE0; -.
DR   PDBsum; 7CR5; -.
DR   PDBsum; 7DE1; -.
DR   PDBsum; 7F2B; -.
DR   PDBsum; 7F2E; -.
DR   PDBsum; 7KGO; -.
DR   PDBsum; 7KGP; -.
DR   PDBsum; 7KGQ; -.
DR   PDBsum; 7KGR; -.
DR   PDBsum; 7KGS; -.
DR   PDBsum; 7KGT; -.
DR   PDBsum; 7LGD; -.
DR   PDBsum; 7LTU; -.
DR   PDBsum; 7LUX; -.
DR   PDBsum; 7LUZ; -.
DR   PDBsum; 7LV2; -.
DR   PDBsum; 7N0I; -.
DR   PDBsum; 7N0R; -.
DR   PDBsum; 7N3C; -.
DR   PDBsum; 7N3D; -.
DR   PDBsum; 7O05; -.
DR   PDBsum; 7O35; -.
DR   PDBsum; 7O36; -.
DR   PDBsum; 7PKU; -.
DR   PDBsum; 7QIK; -.
DR   PDBsum; 7QIP; -.
DR   PDBsum; 7R98; -.
DR   PDBsum; 7SD4; -.
DR   PDBsum; 7STR; -.
DR   PDBsum; 7STS; -.
DR   PDBsum; 7SUE; -.
DR   PDBsum; 7SUO; -.
DR   PDBsum; 7UW3; -.
DR   PDBsum; 7UXX; -.
DR   PDBsum; 7UXZ; -.
DR   PDBsum; 7VBD; -.
DR   PDBsum; 7VBE; -.
DR   PDBsum; 7VBF; -.
DR   PDBsum; 7VNU; -.
DR   PDBsum; 7WKJ; -.
DR   PDBsum; 7WZO; -.
DR   PDBsum; 7XWX; -.
DR   PDBsum; 7XWZ; -.
DR   PDBsum; 7XX1; -.
DR   PDBsum; 7XXK; -.
DR   PDBsum; 7YLB; -.
DR   PDBsum; 7YLD; -.
DR   PDBsum; 7ZIT; -.
DR   PDBsum; 8DNT; -.
DR   PDBsum; 8FD5; -.
DR   PDBsum; 8FG2; -.
DR   PDBsum; 8IQJ; -.
DR   PDBsum; 8IV3; -.
DR   PDBsum; 8J6X; -.
DR   PDBsum; 8TH1; -.
DR   PDBsum; 8TH5; -.
DR   PDBsum; 8X1H; -.
DR   BMRB; P0DTC9; -.
DR   EMDB; EMD-29002; -.
DR   EMDB; EMD-29072; -.
DR   SASBDB; P0DTC9; -.
DR   SMR; P0DTC9; -.
DR   BioGRID; 4383847; 1532.
DR   ComplexPortal; CPX-5686; SARS-CoV-2 nucleocapsid complex.
DR   IntAct; P0DTC9; 608.
DR   MINT; P0DTC9; -.
DR   ChEMBL; CHEMBL5169223; -.
DR   iPTMnet; P0DTC9; -.
DR   ABCD; P0DTC9; 27 sequenced antibodies.
DR   DNASU; 43740575; -.
DR   KEGG; vg:43740575; -.
DR   AGR; RefSeq:YP_009724397; -.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-168928; DDX58/IFIH1-mediated induction of interferon-alpha/beta.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-445989; TAK1-dependent IKK and NF-kappa-B activation.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-9020702; Interleukin-1 signaling.
DR   Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR   Reactome; R-HSA-9694322; Virion Assembly and Release.
DR   Reactome; R-HSA-9694614; Attachment and Entry.
DR   Reactome; R-HSA-9694631; Maturation of nucleoprotein.
DR   Reactome; R-HSA-9694635; Translation of Structural Proteins.
DR   Reactome; R-HSA-9694786; Transcription of SARS-CoV-2 sgRNAs.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9733458; Induction of Cell-Cell Fusion.
DR   Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways.
DR   SIGNOR; P0DTC9; -.
DR   PRO; PR:P0DTC9; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProt.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0044172; C:host cell endoplasmic reticulum-Golgi intermediate compartment; ISS:UniProtKB.
DR   GO; GO:0044177; C:host cell Golgi apparatus; ISS:UniProtKB.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0043655; C:host extracellular space; IEA:UniProtKB-SubCell.
DR   GO; GO:0043232; C:intracellular non-membrane-bounded organelle; IDA:DisProt.
DR   GO; GO:0042612; C:MHC class I protein complex; EXP:DisProt.
DR   GO; GO:1990904; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IPI:ComplexPortal.
DR   GO; GO:0019013; C:viral nucleocapsid; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0042288; F:MHC class I protein binding; EXP:DisProt.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; IDA:DisProt.
DR   GO; GO:0008266; F:poly(U) RNA binding; IMP:DisProt.
DR   GO; GO:0042803; F:protein homodimerization activity; EXP:DisProt.
DR   GO; GO:0140311; F:protein sequestering activity; IDA:UniProt.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProt.
DR   GO; GO:0035613; F:RNA stem-loop binding; IDA:DisProt.
DR   GO; GO:0039709; P:cytoplasmic capsid assembly; IDA:UniProt.
DR   GO; GO:0032688; P:negative regulation of interferon-beta production; IDA:ComplexPortal.
DR   GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; IDA:UniProtKB.
DR   GO; GO:0052572; P:response to host immune response; IDA:DisProt.
DR   GO; GO:0019074; P:viral RNA genome packaging; NAS:ComplexPortal.
DR   CDD; cd21595; CoV_N-CTD; 1.
DR   CDD; cd21554; CoV_N-NTD; 1.
DR   HAMAP; MF_04096; BETA_CORONA_NCAP; 1.
DR   InterPro; IPR044344; N_prot_C_CoV.
DR   InterPro; IPR044345; N_prot_N_CoV.
DR   InterPro; IPR043505; NCAP_bCoV.
DR   InterPro; IPR001218; Nucleocap_CoV.
DR   InterPro; IPR037179; Nucleocapsid_C.
DR   InterPro; IPR037195; Nucleocapsid_N.
DR   Pfam; PF00937; CoV_nucleocap; 1.
DR   PIRSF; PIRSF003888; Corona_nucleocap; 1.
DR   SUPFAM; SSF110304; Coronavirus RNA-binding domain; 1.
DR   SUPFAM; SSF103068; Nucleocapsid protein dimerization domain; 1.
DR   PROSITE; PS51929; COV_N_CTD; 1.
DR   PROSITE; PS51928; COV_N_NTD; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Host cytoplasm; Phosphoprotein;
KW   Reference proteome; Ribonucleoprotein; RNA-binding; Secreted;
KW   Transcription; Transcription regulation; Viral nucleoprotein; Virion.
FT   CHAIN           1..419
FT                   /note=""Nucleoprotein""
FT                   /id=""PRO_0000449656""
FT   DOMAIN          48..174
FT                   /note=""CoV N NTD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01276,
FT                   ECO:0000269|PubMed:32363136""
FT   DOMAIN          247..364
FT                   /note=""CoV N CTD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01277""
FT   REGION          1..51
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          41..186
FT                   /note=""RNA-binding""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   REGION          63..83
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          168..212
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          176..206
FT                   /note=""SR region""
FT                   /evidence=""ECO:0000305|PubMed:32974389""
FT   REGION          233..266
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          258..361
FT                   /note=""Dimerization""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   REGION          260..340
FT                   /note=""Putative NLRP3 binding""
FT                   /evidence=""ECO:0000269|PubMed:34341353""
FT   REGION          361..391
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          400..419
FT                   /note=""Tetramerization""
FT                   /evidence=""ECO:0000269|PubMed:32654247""
FT   MOTIF           256..264
FT                   /note=""Nuclear localization signal""
FT                   /evidence=""ECO:0000250|UniProtKB:P59595""
FT   COMPBIAS        1..11
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        21..31
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        367..378
FT                   /note=""Basic and acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   BINDING         92
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   BINDING         107
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   BINDING         149
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   SITE            399..402
FT                   /note=""Cleavage (by host CASP6)""
FT                   /evidence=""ECO:0000250|UniProtKB:P59595""
FT   MOD_RES         176
FT                   /note=""Phosphoserine; by host""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   MOD_RES         206
FT                   /note=""Phosphoserine; by host GSK3-alpha and GSK3-beta""
FT                   /evidence=""ECO:0000269|PubMed:34593624""
FT   VARIANT         2..3
FT                   /note=""SD -> Y (in strain: Eta/B.1.525)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         3
FT                   /note=""D -> L (in strain: Alpha/B.1.1.7)""
FT                   /evidence=""ECO:0000305|PubMed:33413740""
FT   VARIANT         12
FT                   /note=""A -> G (in strain: Eta/B.1.525)""
FT   VARIANT         13
FT                   /note=""P -> L (in strain: Lambda/C.37, Omicron/BA.1,
FT                   Omicron/BA.2, Omicron/BA.2.12.1, Omicron/BA.2.75,
FT                   Omicron/BA.4, Omicron/BA.5, Omicron/BQ.1.1,
FT                   Omicron/XBB.1.5, Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         31..33
FT                   /note=""Missing (in strain: Omicron/BA.1, Omicron/BA.2,
FT                   Omicron/BA.2.12.1, Omicron/BA.2.75, Omicron/BA.4,
FT                   Omicron/BA.5, Omicron/BQ.1.1, Omicron/XBB.1.5,
FT                   Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         63
FT                   /note=""D -> G (in strain: Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT  ",10237
TATAAA ATAAAG TAAAGA AAAGAA AAGAAG AGAAGA GAAGAA AAGAAA AGAAAT GAAATT AAATTG AATTGA ATTGAG TTGAGC TGAGCG GAGCGC AGCGCA GCGCAT CGCATC GCATCC CATCCG ATCCGG TCCGGA CCGGAA CGGAAA GGAAAC GAAACG AAACGT AACGTT ACGTTT CGTTTT GTTTTC TTTTCC TTTCCT TTCCTC TCCTCC CCTCCG CTCCGC TCCGCT CCGCTT CGCTTG GCTTGT CTTGTA TTGTAA TGTAAA GTAAAG TAAAGA AAAGAT AAGATT AGATTT GATTTG ATTTGC TTTGCA TTGCAG TGCAGA GCAGAG CAGAGA AGAGAA GAGAAT AGAATA GAATAT AATATG ATATGG TATGGA ATGGAA TGGAAC GGAACC GAACCG AACCGC ACCGCC CCGCCA CGCCAT GCCATG CCATGC CATGCG ATGCGT TGCGTA GCGTAT CGTATT GTATTG TATTGG ATTGGC TTGGCA TGGCAC GGCACT GCACTA CACTAA ACTAAC CTAACC TAACCA AACCAT ACCATG CCATGG CATGGT ATGGTT TGGTTC GGTTCA GTTCAC TTCACT TCACTA CACTAA ACTAAG CTAAGC TAAGCG AAGCGA AGCGAT GCGATC CGATCG GATCGC ATCGCA TCGCAT CGCATC GCATCA CATCAT ATCATG TCATGA CATGAG ATGAGC TGAGCC GAGCCG AGCCGG GCCGGT CCGGTA CGGTAT GGTATG GTATGG TATGGA ATGGAG TGGAGA GGAGAC GAGACA AGACAC GACACA ACACAC CACACC ACACCC CACCCA ACCCAT CCCATG CCATGG CATGGG ATGGGA,3,142,TATA ATAA TAAA AAAG AAGA AGAA GAAG AAGA AGAA GAAA AAAT AATT ATTG TTGA TGAG GAGC AGCG GCGC CGCA GCAT CATC ATCC TCCG CCGG CGGA GGAA GAAA AAAC AACG ACGT CGTT GTTT TTTT TTTC TTCC TCCT CCTC CTCC TCCG CCGC CGCT GCTT CTTG TTGT TGTA GTAA TAAA AAAG AAGA AGAT GATT ATTT TTTG TTGC TGCA GCAG CAGA AGAG GAGA AGAA GAAT AATA ATAT TATG ATGG TGGA GGAA GAAC AACC ACCG CCGC CGCC GCCA CCAT CATG ATGC TGCG GCGT CGTA GTAT TATT ATTG TTGG TGGC GGCA GCAC CACT ACTA CTAA TAAC AACC ACCA CCAT CATG ATGG TGGT GGTT GTTC TTCA TCAC CACT ACTA CTAA TAAG AAGC AGCG GCGA CGAT GATC ATCG TCGC CGCA GCAT CATC ATCA TCAT CATG ATGA TGAG GAGC AGCC GCCG CCGG CGGT GGTA GTAT TATG ATGG TGGA GGAG GAGA AGAC GACA ACAC CACA ACAC CACC ACCC CCCA CCAT CATG ATGG TGGG GGGA,TATAA ATAAA TAAAG AAAGA AAGAA AGAAG GAAGA AAGAA AGAAA GAAAT AAATT AATTG ATTGA TTGAG TGAGC GAGCG AGCGC GCGCA CGCAT GCATC CATCC ATCCG TCCGG CCGGA CGGAA GGAAA GAAAC AAACG AACGT ACGTT CGTTT GTTTT TTTTC TTTCC TTCCT TCCTC CCTCC CTCCG TCCGC CCGCT CGCTT GCTTG CTTGT TTGTA TGTAA GTAAA TAAAG AAAGA AAGAT AGATT GATTT ATTTG TTTGC TTGCA TGCAG GCAGA CAGAG AGAGA GAGAA AGAAT GAATA AATAT ATATG TATGG ATGGA TGGAA GGAAC GAACC AACCG ACCGC CCGCC CGCCA GCCAT CCATG CATGC ATGCG TGCGT GCGTA CGTAT GTATT TATTG ATTGG TTGGC TGGCA GGCAC GCACT CACTA ACTAA CTAAC TAACC AACCA ACCAT CCATG CATGG ATGGT TGGTT GGTTC GTTCA TTCAC TCACT CACTA ACTAA CTAAG TAAGC AAGCG AGCGA GCGAT CGATC GATCG ATCGC TCGCA CGCAT GCATC CATCA ATCAT TCATG CATGA ATGAG TGAGC GAGCC AGCCG GCCGG CCGGT CGGTA GGTAT GTATG TATGG ATGGA TGGAG GGAGA GAGAC AGACA GACAC ACACA CACAC ACACC CACCC ACCCA CCCAT CCATG CATGG ATGGG TGGGA,TATAAA ATAAAG TAAAGA AAAGAA AAGAAG AGAAGA GAAGAA AAGAAA AGAAAT GAAATT AAATTG AATTGA ATTGAG TTGAGC TGAGCG GAGCGC AGCGCA GCGCAT CGCATC GCATCC CATCCG ATCCGG TCCGGA CCGGAA CGGAAA GGAAAC GAAACG AAACGT AACGTT ACGTTT CGTTTT GTTTTC TTTTCC TTTCCT TTCCTC TCCTCC CCTCCG CTCCGC TCCGCT CCGCTT CGCTTG GCTTGT CTTGTA TTGTAA TGTAAA GTAAAG TAAAGA AAAGAT AAGATT AGATTT GATTTG ATTTGC TTTGCA TTGCAG TGCAGA GCAGAG CAGAGA AGAGAA GAGAAT AGAATA GAATAT AATATG ATATGG TATGGA ATGGAA TGGAAC GGAACC GAACCG AACCGC ACCGCC CCGCCA CGCCAT GCCATG CCATGC CATGCG ATGCGT TGCGTA GCGTAT CGTATT GTATTG TATTGG ATTGGC TTGGCA TGGCAC GGCACT GCACTA CACTAA ACTAAC CTAACC TAACCA AACCAT ACCATG CCATGG CATGGT ATGGTT TGGTTC GGTTCA GTTCAC TTCACT TCACTA CACTAA ACTAAG CTAAGC TAAGCG AAGCGA AGCGAT GCGATC CGATCG GATCGC ATCGCA TCGCAT CGCATC GCATCA CATCAT ATCATG TCATGA CATGAG ATGAGC TGAGCC GAGCCG AGCCGG GCCGGT CCGGTA CGGTAT GGTATG GTATGG TATGGA ATGGAG TGGAGA GGAGAC GAGACA AGACAC GACACA ACACAC CACACC ACACCC CACCCA ACCCAT CCCATG CCATGG CATGGG ATGGGA,TATAAAG ATAAAGA TAAAGAA AAAGAAG AAGAAGA AGAAGAA GAAGAAA AAGAAAT AGAAATT GAAATTG AAATTGA AATTGAG ATTGAGC TTGAGCG TGAGCGC GAGCGCA AGCGCAT GCGCATC CGCATCC GCATCCG CATCCGG ATCCGGA TCCGGAA CCGGAAA CGGAAAC GGAAACG GAAACGT AAACGTT AACGTTT ACGTTTT CGTTTTC GTTTTCC TTTTCCT TTTCCTC TTCCTCC TCCTCCG CCTCCGC CTCCGCT TCCGCTT CCGCTTG CGCTTGT GCTTGTA CTTGTAA TTGTAAA TGTAAAG GTAAAGA TAAAGAT AAAGATT AAGATTT AGATTTG GATTTGC ATTTGCA TTTGCAG TTGCAGA TGCAGAG GCAGAGA CAGAGAA AGAGAAT GAGAATA AGAATAT GAATATG AATATGG ATATGGA TATGGAA ATGGAAC TGGAACC GGAACCG GAACCGC AACCGCC ACCGCCA CCGCCAT CGCCATG GCCATGC CCATGCG CATGCGT ATGCGTA TGCGTAT GCGTATT CGTATTG GTATTGG TATTGGC ATTGGCA TTGGCAC TGGCACT GGCACTA GCACTAA CACTAAC ACTAACC CTAACCA TAACCAT AACCATG ACCATGG CCATGGT CATGGTT ATGGTTC TGGTTCA GGTTCAC GTTCACT TTCACTA TCACTAA CACTAAG ACTAAGC CTAAGCG TAAGCGA AAGCGAT AGCGATC GCGATCG CGATCGC GATCGCA ATCGCAT TCGCATC CGCATCA GCATCAT CATCATG ATCATGA TCATGAG CATGAGC ATGAGCC TGAGCCG GAGCCGG AGCCGGT GCCGGTA CCGGTAT CGGTATG GGTATGG GTATGGA TATGGAG ATGGAGA TGGAGAC GGAGACA GAGACAC AGACACA GACACAC ACACACC CACACCC ACACCCA CACCCAT ACCCATG CCCATGG CCATGGG CATGGGA,"ID   ISPG_AKKM8              Reviewed;         585 AA.
AC   B2UKT9;
DT   24-MAR-2009, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-2008, sequence version 1.
DT   27-NOV-2024, entry version 94.
DE   RecName: Full=4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase (flavodoxin) {ECO:0000255|HAMAP-Rule:MF_00159};
DE            EC=1.17.7.3 {ECO:0000255|HAMAP-Rule:MF_00159};
DE   AltName: Full=1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate synthase {ECO:0000255|HAMAP-Rule:MF_00159};
GN   Name=ispG {ECO:0000255|HAMAP-Rule:MF_00159};
GN   OrderedLocusNames=Amuc_1388;
OS   Akkermansia muciniphila (strain ATCC BAA-835 / DSM 22959 / JCM 33894 / BCRC
OS   81048 / CCUG 64013 / CIP 107961 / Muc).
OC   Bacteria; Verrucomicrobiota; Verrucomicrobiia; Verrucomicrobiales;
OC   Akkermansiaceae; Akkermansia.
OX   NCBI_TaxID=349741;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC BAA-835 / DSM 22959 / JCM 33894 / BCRC 81048 / CCUG 64013
RC   / CIP 107961 / Muc;
RX   PubMed=21390229; DOI=10.1371/journal.pone.0016876;
RA   van Passel M.W., Kant R., Zoetendal E.G., Plugge C.M., Derrien M.,
RA   Malfatti S.A., Chain P.S., Woyke T., Palva A., de Vos W.M., Smidt H.;
RT   ""The genome of Akkermansia muciniphila, a dedicated intestinal mucin
RT   degrader, and its use in exploring intestinal metagenomes."";
RL   PLoS ONE 6:E16876-E16876(2011).
CC   -!- FUNCTION: Converts 2C-methyl-D-erythritol 2,4-cyclodiphosphate
CC       (ME-2,4cPP) into 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate.
CC       {ECO:0000255|HAMAP-Rule:MF_00159}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(2E)-4-hydroxy-3-methylbut-2-enyl diphosphate + oxidized
CC         [flavodoxin] + H2O + 2 H(+) = 2-C-methyl-D-erythritol 2,4-cyclic
CC         diphosphate + reduced [flavodoxin]; Xref=Rhea:RHEA:43604, Rhea:RHEA-
CC         COMP:10622, Rhea:RHEA-COMP:10623, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:57618, ChEBI:CHEBI:58210,
CC         ChEBI:CHEBI:58483, ChEBI:CHEBI:128753; EC=1.17.7.3;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_00159};
CC   -!- COFACTOR:
CC       Name=[4Fe-4S] cluster; Xref=ChEBI:CHEBI:49883;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_00159};
CC       Note=Binds 1 [4Fe-4S] cluster. {ECO:0000255|HAMAP-Rule:MF_00159};
CC   -!- PATHWAY: Isoprenoid biosynthesis; isopentenyl diphosphate biosynthesis
CC       via DXP pathway; isopentenyl diphosphate from 1-deoxy-D-xylulose 5-
CC       phosphate: step 5/6. {ECO:0000255|HAMAP-Rule:MF_00159}.
CC   -!- SIMILARITY: Belongs to the IspG family. {ECO:0000255|HAMAP-
CC       Rule:MF_00159}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP001071; ACD05212.1; -; Genomic_DNA.
DR   RefSeq; WP_012420427.1; NZ_CP071807.1.
DR   AlphaFoldDB; B2UKT9; -.
DR   SMR; B2UKT9; -.
DR   STRING; 349741.Amuc_1388; -.
DR   PaxDb; 349741-Amuc_1388; -.
DR   KEGG; amu:Amuc_1388; -.
DR   eggNOG; COG0821; Bacteria.
DR   HOGENOM; CLU_012689_0_0_0; -.
DR   OrthoDB; 9803214at2; -.
DR   BioCyc; AMUC349741:G1GBX-1474-MONOMER; -.
DR   UniPathway; UPA00056; UER00096.
DR   Proteomes; UP000001031; Chromosome.
DR   GO; GO:0051539; F:4 iron, 4 sulfur cluster binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0046429; F:4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase activity (ferredoxin); IEA:UniProtKB-UniRule.
DR   GO; GO:0141197; F:4-hydroxy-3-methylbut-2-enyl-diphosphate synthase activity (flavodoxin); IEA:UniProtKB-EC.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0019288; P:isopentenyl diphosphate biosynthetic process, methylerythritol 4-phosphate pathway; IEA:UniProtKB-UniRule.
DR   GO; GO:0016114; P:terpenoid biosynthetic process; IEA:InterPro.
DR   FunFam; 3.20.20.20:FF:000005; 4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase (flavodoxin); 1.
DR   FunFam; 3.30.413.10:FF:000006; 4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase (flavodoxin); 1.
DR   Gene3D; 3.20.20.20; Dihydropteroate synthase-like; 1.
DR   Gene3D; 3.30.413.10; Sulfite Reductase Hemoprotein, domain 1; 1.
DR   HAMAP; MF_00159; IspG; 1.
DR   InterPro; IPR011005; Dihydropteroate_synth-like_sf.
DR   InterPro; IPR017178; IspG_atypical.
DR   InterPro; IPR004588; IspG_bac-typ.
DR   InterPro; IPR045854; NO2/SO3_Rdtase_4Fe4S_sf.
DR   NCBIfam; TIGR00612; ispG_gcpE; 1.
DR   PANTHER; PTHR30454; 4-HYDROXY-3-METHYLBUT-2-EN-1-YL DIPHOSPHATE SYNTHASE; 1.
DR   PANTHER; PTHR30454:SF0; 4-HYDROXY-3-METHYLBUT-2-EN-1-YL DIPHOSPHATE SYNTHASE (FERREDOXIN), CHLOROPLASTIC; 1.
DR   Pfam; PF04551; GcpE; 2.
DR   PIRSF; PIRSF037336; IspG_like; 1.
DR   SUPFAM; SSF51717; Dihydropteroate synthetase-like; 1.
DR   SUPFAM; SSF56014; Nitrite and sulphite reductase 4Fe-4S domain-like; 1.
PE   3: Inferred from homology;
KW   4Fe-4S; Iron; Iron-sulfur; Isoprene biosynthesis; Metal-binding;
KW   Oxidoreductase; Reference proteome.
FT   CHAIN           1..585
FT                   /note=""4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase
FT                   (flavodoxin)""
FT                   /id=""PRO_1000097145""
FT   BINDING         492
FT                   /ligand=""[4Fe-4S] cluster""
FT                   /ligand_id=""ChEBI:CHEBI:49883""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00159""
FT   BINDING         495
FT                   /ligand=""[4Fe-4S] cluster""
FT                   /ligand_id=""ChEBI:CHEBI:49883""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00159""
FT   BINDING         526
FT                   /ligand=""[4Fe-4S] cluster""
FT                   /ligand_id=""ChEBI:CHEBI:49883""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00159""
FT   BINDING         533
FT                   /ligand=""[4Fe-4S] cluster""
FT                   /ligand_id=""ChEBI:CHEBI:49883""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00159""
SQ   SEQUENCE   585 AA;  64488 MW;  0CE70D2436BDA599 CRC64;
     MQSSYCPSPY RYTRRVTREV MVGNVGVGGS NPIRIQSMLT SDTRDTDACV KEALELAEAG
     CEIIRLTAQT KAYAANLENI ARELRAAGCH VPLVADIHFK PDAAMEAAKW VEKIRINPGN
     FVDKKKFEVR EYSDAEYREE LDRLKEEFTP LVLFCREHGR AMRIGSNHGS LSDRILNRFG
     DTPEGMVESA IEFAQIARDL DYHSLVFSMK ASNVKVMVAA YRLLVERMNA LGPDWNYPIH
     LGVTEAGGGE DGRIKSAVGI GSLLTDGIGD TLRVSLTEDA VREVPVAYRL SNPFQPSERS
     DDPVSFPEPE LSYDPLKFSK RQGGLAMYYG VRLGWEQPVR VAVPDAGFYA LQTEREAMGD
     MMPELSLGQL DAIEVDPRCD ADLEPLKELA EPSIVTVKNG LAMEPVYAFR LLAARIEDRH
     LILLKDTLVP GSVSGEDVPL TAARNIGSLL CDGIGDAVLI QGESDPRLAS FLGFNILQAT
     GTRLTRADYV SCPSCGRTLY NIQEATARIR KATEHLKGVK IAVMGCIVNG PGEMADADFG
     YVGGAPNKIN LYVKHTPVKF NIPQEEAVER LVDLIKEYGR WVDPK
//
",46497
CTTTCT TTTCTG TTCTGC TCTGCT CTGCTC TGCTCA GCTCAA CTCAAA TCAAAC CAAACT AAACTG AACTGG ACTGGA CTGGAA TGGAAT GGAATT GAATTG AATTGC ATTGCC TTGCCG TGCCGT GCCGTT CCGTTT CGTTTT GTTTTA TTTTAG TTTAGA TTAGAT TAGATA AGATAT GATATG ATATGT TATGTG ATGTGT TGTGTG GTGTGC TGTGCT GTGCTT TGCTTC GCTTCA CTTCAT TTCATT TCATTA CATTAA ATTAAA TTAAAA TAAAAG AAAAGA AAAGAA AAGAAT AGAATT GAATTA AATTAC ATTACT TTACTG TACTGC ACTGCA CTGCAA TGCAAA GCAAAA CAAAAT AAAATG AAATGG AATGGT ATGGTA TGGTAT GGTATG GTATGA TATGAA ATGAAT TGAATG GAATGG AATGGA ATGGAC TGGACG GGACGT GACGTA ACGTAC CGTACC GTACCA TACCAT ACCATA CCATAT CATATT ATATTG TATTGG ATTGGG TTGGGT TGGGTA GGGTAG GGTAGT GTAGTG TAGTGC AGTGCT GTGCTT TGCTTT GCTTTA CTTTAT TTTATT TTATTA TATTAG ATTAGA TTAGAA TAGAAG AGAAGA GAAGAT AAGATG AGATGA GATGAA ATGAAT TGAATT GAATTT AATTTA ATTTAC TTTACA TTACAC TACACC ACACCT CACCTT ACCTTT CCTTTT CTTTTG TTTTGA TTTGAT TTGATG TGATGT GATGTT ATGTTG TGTTGT GTTGTT TTGTTA TGTTAG GTTAGA TTAGAC TAGACA AGACAA GACAAT ACAATG CAATGC AATGCT ATGCTC TGCTCA,0,142,CTTT TTTC TTCT TCTG CTGC TGCT GCTC CTCA TCAA CAAA AAAC AACT ACTG CTGG TGGA GGAA GAAT AATT ATTG TTGC TGCC GCCG CCGT CGTT GTTT TTTT TTTA TTAG TAGA AGAT GATA ATAT TATG ATGT TGTG GTGT TGTG GTGC TGCT GCTT CTTC TTCA TCAT CATT ATTA TTAA TAAA AAAA AAAG AAGA AGAA GAAT AATT ATTA TTAC TACT ACTG CTGC TGCA GCAA CAAA AAAA AAAT AATG ATGG TGGT GGTA GTAT TATG ATGA TGAA GAAT AATG ATGG TGGA GGAC GACG ACGT CGTA GTAC TACC ACCA CCAT CATA ATAT TATT ATTG TTGG TGGG GGGT GGTA GTAG TAGT AGTG GTGC TGCT GCTT CTTT TTTA TTAT TATT ATTA TTAG TAGA AGAA GAAG AAGA AGAT GATG ATGA TGAA GAAT AATT ATTT TTTA TTAC TACA ACAC CACC ACCT CCTT CTTT TTTT TTTG TTGA TGAT GATG ATGT TGTT GTTG TTGT TGTT GTTA TTAG TAGA AGAC GACA ACAA CAAT AATG ATGC TGCT GCTC CTCA,CTTTC TTTCT TTCTG TCTGC CTGCT TGCTC GCTCA CTCAA TCAAA CAAAC AAACT AACTG ACTGG CTGGA TGGAA GGAAT GAATT AATTG ATTGC TTGCC TGCCG GCCGT CCGTT CGTTT GTTTT TTTTA TTTAG TTAGA TAGAT AGATA GATAT ATATG TATGT ATGTG TGTGT GTGTG TGTGC GTGCT TGCTT GCTTC CTTCA TTCAT TCATT CATTA ATTAA TTAAA TAAAA AAAAG AAAGA AAGAA AGAAT GAATT AATTA ATTAC TTACT TACTG ACTGC CTGCA TGCAA GCAAA CAAAA AAAAT AAATG AATGG ATGGT TGGTA GGTAT GTATG TATGA ATGAA TGAAT GAATG AATGG ATGGA TGGAC GGACG GACGT ACGTA CGTAC GTACC TACCA ACCAT CCATA CATAT ATATT TATTG ATTGG TTGGG TGGGT GGGTA GGTAG GTAGT TAGTG AGTGC GTGCT TGCTT GCTTT CTTTA TTTAT TTATT TATTA ATTAG TTAGA TAGAA AGAAG GAAGA AAGAT AGATG GATGA ATGAA TGAAT GAATT AATTT ATTTA TTTAC TTACA TACAC ACACC CACCT ACCTT CCTTT CTTTT TTTTG TTTGA TTGAT TGATG GATGT ATGTT TGTTG GTTGT TTGTT TGTTA GTTAG TTAGA TAGAC AGACA GACAA ACAAT CAATG AATGC ATGCT TGCTC GCTCA,CTTTCT TTTCTG TTCTGC TCTGCT CTGCTC TGCTCA GCTCAA CTCAAA TCAAAC CAAACT AAACTG AACTGG ACTGGA CTGGAA TGGAAT GGAATT GAATTG AATTGC ATTGCC TTGCCG TGCCGT GCCGTT CCGTTT CGTTTT GTTTTA TTTTAG TTTAGA TTAGAT TAGATA AGATAT GATATG ATATGT TATGTG ATGTGT TGTGTG GTGTGC TGTGCT GTGCTT TGCTTC GCTTCA CTTCAT TTCATT TCATTA CATTAA ATTAAA TTAAAA TAAAAG AAAAGA AAAGAA AAGAAT AGAATT GAATTA AATTAC ATTACT TTACTG TACTGC ACTGCA CTGCAA TGCAAA GCAAAA CAAAAT AAAATG AAATGG AATGGT ATGGTA TGGTAT GGTATG GTATGA TATGAA ATGAAT TGAATG GAATGG AATGGA ATGGAC TGGACG GGACGT GACGTA ACGTAC CGTACC GTACCA TACCAT ACCATA CCATAT CATATT ATATTG TATTGG ATTGGG TTGGGT TGGGTA GGGTAG GGTAGT GTAGTG TAGTGC AGTGCT GTGCTT TGCTTT GCTTTA CTTTAT TTTATT TTATTA TATTAG ATTAGA TTAGAA TAGAAG AGAAGA GAAGAT AAGATG AGATGA GATGAA ATGAAT TGAATT GAATTT AATTTA ATTTAC TTTACA TTACAC TACACC ACACCT CACCTT ACCTTT CCTTTT CTTTTG TTTTGA TTTGAT TTGATG TGATGT GATGTT ATGTTG TGTTGT GTTGTT TTGTTA TGTTAG GTTAGA TTAGAC TAGACA AGACAA GACAAT ACAATG CAATGC AATGCT ATGCTC TGCTCA,CTTTCTG TTTCTGC TTCTGCT TCTGCTC CTGCTCA TGCTCAA GCTCAAA CTCAAAC TCAAACT CAAACTG AAACTGG AACTGGA ACTGGAA CTGGAAT TGGAATT GGAATTG GAATTGC AATTGCC ATTGCCG TTGCCGT TGCCGTT GCCGTTT CCGTTTT CGTTTTA GTTTTAG TTTTAGA TTTAGAT TTAGATA TAGATAT AGATATG GATATGT ATATGTG TATGTGT ATGTGTG TGTGTGC GTGTGCT TGTGCTT GTGCTTC TGCTTCA GCTTCAT CTTCATT TTCATTA TCATTAA CATTAAA ATTAAAA TTAAAAG TAAAAGA AAAAGAA AAAGAAT AAGAATT AGAATTA GAATTAC AATTACT ATTACTG TTACTGC TACTGCA ACTGCAA CTGCAAA TGCAAAA GCAAAAT CAAAATG AAAATGG AAATGGT AATGGTA ATGGTAT TGGTATG GGTATGA GTATGAA TATGAAT ATGAATG TGAATGG GAATGGA AATGGAC ATGGACG TGGACGT GGACGTA GACGTAC ACGTACC CGTACCA GTACCAT TACCATA ACCATAT CCATATT CATATTG ATATTGG TATTGGG ATTGGGT TTGGGTA TGGGTAG GGGTAGT GGTAGTG GTAGTGC TAGTGCT AGTGCTT GTGCTTT TGCTTTA GCTTTAT CTTTATT TTTATTA TTATTAG TATTAGA ATTAGAA TTAGAAG TAGAAGA AGAAGAT GAAGATG AAGATGA AGATGAA GATGAAT ATGAATT TGAATTT GAATTTA AATTTAC ATTTACA TTTACAC TTACACC TACACCT ACACCTT CACCTTT ACCTTTT CCTTTTG CTTTTGA TTTTGAT TTTGATG TTGATGT TGATGTT GATGTTG ATGTTGT TGTTGTT GTTGTTA TTGTTAG TGTTAGA GTTAGAC TTAGACA TAGACAA AGACAAT GACAATG ACAATGC CAATGCT AATGCTC ATGCTCA,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",4988
ATCAGC TCAGCC CAGCCA AGCCAC GCCACG CCACGT CACGTG ACGTGC CGTGCT GTGCTG TGCTGA GCTGAA CTGAAC TGAACT GAACTA AACTAC ACTACG CTACGA TACGAC ACGACA CGACAT GACATC ACATCC CATCCC ATCCCC TCCCCT CCCCTA CCCTAC CCTACG CTACGA TACGAC ACGACA CGACAC GACACC ACACCG CACCGA ACCGAA CCGAAA CGAAAG GAAAGC AAAGCT AAGCTA AGCTAC GCTACG CTACGT TACGTC ACGTCC CGTCCA GTCCAC TCCACC CCACCG CACCGC ACCGCA CCGCAT CGCATC GCATCG CATCGG ATCGGC TCGGCC CGGCCG GGCCGC GCCGCA CCGCAC CGCACC GCACCG CACCGG ACCGGC CCGGCC CGGCCG GGCCGC GCCGCG CCGCGC CGCGCC GCGCCG CGCCGG GCCGGC CCGGCC CGGCCG GGCCGC GCCGCA CCGCAA CGCAAG GCAAGG CAAGGG AAGGGC AGGGCG GGGCGA GGCGAG GCGAGG CGAGGC GAGGCG AGGCGA GGCGAT GCGATC CGATCC GATCCT ATCCTG TCCTGT CCTGTT CTGTTC TGTTCG GTTCGT TTCGTG TCGTGG CGTGGC GTGGCC TGGCCC GGCCCC GCCCCG CCCCGC CCCGCG CCGCGC CGCGCG GCGCGA CGCGAG GCGAGC CGAGCG GAGCGC AGCGCG GCGCGG CGCGGC GCGGCA CGGCAT GGCATG GCATGC CATGCT ATGCTG TGCTGG GCTGGG CTGGGC TGGGCG GGGCGC GGCGCG GCGCGA CGCGAT GCGATC CGATCG GATCGA ATCGAA TCGAAC CGAACG GAACGC AACGCG ACGCGC CGCGCG,3,145,ATCA TCAG CAGC AGCC GCCA CCAC CACG ACGT CGTG GTGC TGCT GCTG CTGA TGAA GAAC AACT ACTA CTAC TACG ACGA CGAC GACA ACAT CATC ATCC TCCC CCCC CCCT CCTA CTAC TACG ACGA CGAC GACA ACAC CACC ACCG CCGA CGAA GAAA AAAG AAGC AGCT GCTA CTAC TACG ACGT CGTC GTCC TCCA CCAC CACC ACCG CCGC CGCA GCAT CATC ATCG TCGG CGGC GGCC GCCG CCGC CGCA GCAC CACC ACCG CCGG CGGC GGCC GCCG CCGC CGCG GCGC CGCC GCCG CCGG CGGC GGCC GCCG CCGC CGCA GCAA CAAG AAGG AGGG GGGC GGCG GCGA CGAG GAGG AGGC GGCG GCGA CGAT GATC ATCC TCCT CCTG CTGT TGTT GTTC TTCG TCGT CGTG GTGG TGGC GGCC GCCC CCCC CCCG CCGC CGCG GCGC CGCG GCGA CGAG GAGC AGCG GCGC CGCG GCGG CGGC GGCA GCAT CATG ATGC TGCT GCTG CTGG TGGG GGGC GGCG GCGC CGCG GCGA CGAT GATC ATCG TCGA CGAA GAAC AACG ACGC CGCG GCGC CGCG,ATCAG TCAGC CAGCC AGCCA GCCAC CCACG CACGT ACGTG CGTGC GTGCT TGCTG GCTGA CTGAA TGAAC GAACT AACTA ACTAC CTACG TACGA ACGAC CGACA GACAT ACATC CATCC ATCCC TCCCC CCCCT CCCTA CCTAC CTACG TACGA ACGAC CGACA GACAC ACACC CACCG ACCGA CCGAA CGAAA GAAAG AAAGC AAGCT AGCTA GCTAC CTACG TACGT ACGTC CGTCC GTCCA TCCAC CCACC CACCG ACCGC CCGCA CGCAT GCATC CATCG ATCGG TCGGC CGGCC GGCCG GCCGC CCGCA CGCAC GCACC CACCG ACCGG CCGGC CGGCC GGCCG GCCGC CCGCG CGCGC GCGCC CGCCG GCCGG CCGGC CGGCC GGCCG GCCGC CCGCA CGCAA GCAAG CAAGG AAGGG AGGGC GGGCG GGCGA GCGAG CGAGG GAGGC AGGCG GGCGA GCGAT CGATC GATCC ATCCT TCCTG CCTGT CTGTT TGTTC GTTCG TTCGT TCGTG CGTGG GTGGC TGGCC GGCCC GCCCC CCCCG CCCGC CCGCG CGCGC GCGCG CGCGA GCGAG CGAGC GAGCG AGCGC GCGCG CGCGG GCGGC CGGCA GGCAT GCATG CATGC ATGCT TGCTG GCTGG CTGGG TGGGC GGGCG GGCGC GCGCG CGCGA GCGAT CGATC GATCG ATCGA TCGAA CGAAC GAACG AACGC ACGCG CGCGC GCGCG,ATCAGC TCAGCC CAGCCA AGCCAC GCCACG CCACGT CACGTG ACGTGC CGTGCT GTGCTG TGCTGA GCTGAA CTGAAC TGAACT GAACTA AACTAC ACTACG CTACGA TACGAC ACGACA CGACAT GACATC ACATCC CATCCC ATCCCC TCCCCT CCCCTA CCCTAC CCTACG CTACGA TACGAC ACGACA CGACAC GACACC ACACCG CACCGA ACCGAA CCGAAA CGAAAG GAAAGC AAAGCT AAGCTA AGCTAC GCTACG CTACGT TACGTC ACGTCC CGTCCA GTCCAC TCCACC CCACCG CACCGC ACCGCA CCGCAT CGCATC GCATCG CATCGG ATCGGC TCGGCC CGGCCG GGCCGC GCCGCA CCGCAC CGCACC GCACCG CACCGG ACCGGC CCGGCC CGGCCG GGCCGC GCCGCG CCGCGC CGCGCC GCGCCG CGCCGG GCCGGC CCGGCC CGGCCG GGCCGC GCCGCA CCGCAA CGCAAG GCAAGG CAAGGG AAGGGC AGGGCG GGGCGA GGCGAG GCGAGG CGAGGC GAGGCG AGGCGA GGCGAT GCGATC CGATCC GATCCT ATCCTG TCCTGT CCTGTT CTGTTC TGTTCG GTTCGT TTCGTG TCGTGG CGTGGC GTGGCC TGGCCC GGCCCC GCCCCG CCCCGC CCCGCG CCGCGC CGCGCG GCGCGA CGCGAG GCGAGC CGAGCG GAGCGC AGCGCG GCGCGG CGCGGC GCGGCA CGGCAT GGCATG GCATGC CATGCT ATGCTG TGCTGG GCTGGG CTGGGC TGGGCG GGGCGC GGCGCG GCGCGA CGCGAT GCGATC CGATCG GATCGA ATCGAA TCGAAC CGAACG GAACGC AACGCG ACGCGC CGCGCG,ATCAGCC TCAGCCA CAGCCAC AGCCACG GCCACGT CCACGTG CACGTGC ACGTGCT CGTGCTG GTGCTGA TGCTGAA GCTGAAC CTGAACT TGAACTA GAACTAC AACTACG ACTACGA CTACGAC TACGACA ACGACAT CGACATC GACATCC ACATCCC CATCCCC ATCCCCT TCCCCTA CCCCTAC CCCTACG CCTACGA CTACGAC TACGACA ACGACAC CGACACC GACACCG ACACCGA CACCGAA ACCGAAA CCGAAAG CGAAAGC GAAAGCT AAAGCTA AAGCTAC AGCTACG GCTACGT CTACGTC TACGTCC ACGTCCA CGTCCAC GTCCACC TCCACCG CCACCGC CACCGCA ACCGCAT CCGCATC CGCATCG GCATCGG CATCGGC ATCGGCC TCGGCCG CGGCCGC GGCCGCA GCCGCAC CCGCACC CGCACCG GCACCGG CACCGGC ACCGGCC CCGGCCG CGGCCGC GGCCGCG GCCGCGC CCGCGCC CGCGCCG GCGCCGG CGCCGGC GCCGGCC CCGGCCG CGGCCGC GGCCGCA GCCGCAA CCGCAAG CGCAAGG GCAAGGG CAAGGGC AAGGGCG AGGGCGA GGGCGAG GGCGAGG GCGAGGC CGAGGCG GAGGCGA AGGCGAT GGCGATC GCGATCC CGATCCT GATCCTG ATCCTGT TCCTGTT CCTGTTC CTGTTCG TGTTCGT GTTCGTG TTCGTGG TCGTGGC CGTGGCC GTGGCCC TGGCCCC GGCCCCG GCCCCGC CCCCGCG CCCGCGC CCGCGCG CGCGCGA GCGCGAG CGCGAGC GCGAGCG CGAGCGC GAGCGCG AGCGCGG GCGCGGC CGCGGCA GCGGCAT CGGCATG GGCATGC GCATGCT CATGCTG ATGCTGG TGCTGGG GCTGGGC CTGGGCG TGGGCGC GGGCGCG GGCGCGA GCGCGAT CGCGATC GCGATCG CGATCGA GATCGAA ATCGAAC TCGAACG CGAACGC GAACGCG AACGCGC ACGCGCG,"ID   CSHA_BACC1              Reviewed;         525 AA.
AC   Q73EU1;
DT   06-MAR-2007, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   05-FEB-2025, entry version 120.
DE   RecName: Full=DEAD-box ATP-dependent RNA helicase CshA {ECO:0000255|HAMAP-Rule:MF_01493};
DE            EC=3.6.4.13 {ECO:0000255|HAMAP-Rule:MF_01493};
GN   Name=cshA {ECO:0000255|HAMAP-Rule:MF_01493};
GN   OrderedLocusNames=BCE_0267;
OS   Bacillus cereus (strain ATCC 10987 / NRS 248).
OC   Bacteria; Bacillati; Bacillota; Bacilli; Bacillales; Bacillaceae; Bacillus;
OC   Bacillus cereus group.
OX   NCBI_TaxID=222523;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 10987 / NRS 248;
RX   PubMed=14960714; DOI=10.1093/nar/gkh258;
RA   Rasko D.A., Ravel J., Oekstad O.A., Helgason E., Cer R.Z., Jiang L.,
RA   Shores K.A., Fouts D.E., Tourasse N.J., Angiuoli S.V., Kolonay J.F.,
RA   Nelson W.C., Kolstoe A.-B., Fraser C.M., Read T.D.;
RT   ""The genome sequence of Bacillus cereus ATCC 10987 reveals metabolic
RT   adaptations and a large plasmid related to Bacillus anthracis pXO1."";
RL   Nucleic Acids Res. 32:977-988(2004).
CC   -!- FUNCTION: DEAD-box RNA helicase possibly involved in RNA degradation.
CC       Unwinds dsRNA in both 5'- and 3'-directions, has RNA-dependent ATPase
CC       activity. {ECO:0000255|HAMAP-Rule:MF_01493}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + H2O = ADP + phosphate + H(+); Xref=Rhea:RHEA:13065,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=3.6.4.13;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_01493};
CC   -!- SUBUNIT: Oligomerizes, may be a member of the RNA degradosome.
CC       {ECO:0000255|HAMAP-Rule:MF_01493}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000255|HAMAP-Rule:MF_01493}.
CC   -!- SIMILARITY: Belongs to the DEAD box helicase family. CshA subfamily.
CC       {ECO:0000255|HAMAP-Rule:MF_01493}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AE017194; AAS39203.1; -; Genomic_DNA.
DR   AlphaFoldDB; Q73EU1; -.
DR   SMR; Q73EU1; -.
DR   DNASU; 2752637; -.
DR   KEGG; bca:BCE_0267; -.
DR   HOGENOM; CLU_003041_21_0_9; -.
DR   Proteomes; UP000002527; Chromosome.
DR   GO; GO:0043590; C:bacterial nucleoid; ISS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IEA:TreeGrafter.
DR   GO; GO:0005840; C:ribosome; IEA:TreeGrafter.
DR   GO; GO:0005524; F:ATP binding; ISS:UniProtKB.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:RHEA.
DR   GO; GO:0140849; F:ATP-dependent H2AZ histone chaperone activity; IEA:RHEA.
DR   GO; GO:0140665; F:ATP-dependent H3-H4 histone complex chaperone activity; IEA:RHEA.
DR   GO; GO:0140584; F:chromatin extrusion motor activity; IEA:RHEA.
DR   GO; GO:0061775; F:cohesin loader activity; IEA:RHEA.
DR   GO; GO:0003689; F:DNA clamp loader activity; IEA:RHEA.
DR   GO; GO:0003723; F:RNA binding; ISS:UniProtKB.
DR   GO; GO:0003724; F:RNA helicase activity; ISS:UniProtKB.
DR   GO; GO:0033592; F:RNA strand annealing activity; IEA:TreeGrafter.
DR   GO; GO:0009409; P:response to cold; IEA:TreeGrafter.
DR   GO; GO:0006401; P:RNA catabolic process; IEA:UniProtKB-UniRule.
DR   GO; GO:0010501; P:RNA secondary structure unwinding; IEA:InterPro.
DR   CDD; cd00268; DEADc; 1.
DR   CDD; cd18787; SF2_C_DEAD; 1.
DR   FunFam; 3.40.50.300:FF:000108; ATP-dependent RNA helicase RhlE; 1.
DR   FunFam; 3.40.50.300:FF:000783; DEAD-box ATP-dependent RNA helicase CshA; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 2.
DR   HAMAP; MF_01493; DEAD_helicase_CshA; 1.
DR   InterPro; IPR011545; DEAD/DEAH_box_helicase_dom.
DR   InterPro; IPR050547; DEAD_box_RNA_helicases.
DR   InterPro; IPR030880; DEAD_helicase_CshA.
DR   InterPro; IPR014001; Helicase_ATP-bd.
DR   InterPro; IPR001650; Helicase_C-like.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR000629; RNA-helicase_DEAD-box_CS.
DR   InterPro; IPR014014; RNA_helicase_DEAD_Q_motif.
DR   PANTHER; PTHR47963; DEAD-BOX ATP-DEPENDENT RNA HELICASE 47, MITOCHONDRIAL; 1.
DR   PANTHER; PTHR47963:SF5; DEAD-BOX ATP-DEPENDENT RNA HELICASE CSHA; 1.
DR   Pfam; PF00270; DEAD; 1.
DR   Pfam; PF00271; Helicase_C; 1.
DR   SMART; SM00487; DEXDc; 1.
DR   SMART; SM00490; HELICc; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   PROSITE; PS00039; DEAD_ATP_HELICASE; 1.
DR   PROSITE; PS51192; HELICASE_ATP_BIND_1; 1.
DR   PROSITE; PS51194; HELICASE_CTER; 1.
DR   PROSITE; PS51195; Q_MOTIF; 1.
PE   3: Inferred from homology;
KW   ATP-binding; Cytoplasm; Helicase; Hydrolase; Nucleotide-binding;
KW   RNA-binding; Stress response.
FT   CHAIN           1..525
FT                   /note=""DEAD-box ATP-dependent RNA helicase CshA""
FT                   /id=""PRO_0000280050""
FT   DOMAIN          33..203
FT                   /note=""Helicase ATP-binding""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01493""
FT   DOMAIN          214..374
FT                   /note=""Helicase C-terminal""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01493""
FT   REGION          428..525
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   MOTIF           2..30
FT                   /note=""Q motif""
FT   MOTIF           151..154
FT                   /note=""DEAD box""
FT   COMPBIAS        458..503
FT                   /note=""Basic and acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        515..525
FT                   /note=""Basic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   BINDING         46..53
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01493""
SQ   SEQUENCE   525 AA;  58583 MW;  1E3A8A3DB343AB11 CRC64;
     MTTFRELGLS DSLLQSVESM GFEEATPIQA ETIPHALQGK DIIGQAQTGT GKTAAFGLPL
     LDKVDTHKES VQGIVIAPTR ELAIQVGEEL YKIGKHKRVR ILPIYGGQDI NRQIRALKKH
     PHIIVGTPGR ILDHINRKTL RLQNVETVVL DEADEMLNMG FIEDIEAILT DVPETHQTLL
     FSATMPDPIR RIAERFMTEP QHIKVKAKEV TMPNIQQFYL EVQEKKKFDV LTRLLDIQSP
     ELAIVFGRTK RRVDELSEAL NLRGYAAEGI HGDLTQAKRM SVLRKFKEGS IEVLVATDVA
     ARGLDISGVT HVYNFDIPQD PESYVHRIGR TGRAGKKGIA MLFVTPRESG QLKNIERTTK
     RKMDRMDAPT LDEALEGQQR LIAEKLQNTI ENENLAYYKR IAEEMLEEND SVTVVAAALK
     MMTKEPDTTP IALTSEPPVV ARGGGSKKRG GNGGGYRDGN RNRSRDGRGG DGRNRDRNRD
     GRNRDGNRDR NRDGGNRGRR GEGQGRPGSS NGRGERKHHS RKPQA
//
",4693
TTGACT TGACTC GACTCA ACTCAC CTCACC TCACCC CACCCT ACCCTG CCCTGA CCTGAA CTGAAA TGAAAT GAAATC AAATCT AATCTA ATCTAT TCTATG CTATGA TATGAA ATGAAG TGAAGA GAAGAC AAGACA AGACAT GACATG ACATGG CATGGG ATGGGT TGGGTA GGGTAT GGTATT GTATTA TATTAA ATTAAA TTAAAC TAAACC AAACCA AACCAC ACCACC CCACCT CACCTA ACCTAA CCTAAG CTAAGG TAAGGG AAGGGT AGGGTG GGGTGT GGTGTT GTGTTA TGTTAT GTTATC TTATCA TATCAT ATCATG TCATGT CATGTA ATGTAT TGTATG GTATGG TATGGC ATGGCC TGGCCC GGCCCA GCCCAC CCCACC CCACCT,3,67,TTGA TGAC GACT ACTC CTCA TCAC CACC ACCC CCCT CCTG CTGA TGAA GAAA AAAT AATC ATCT TCTA CTAT TATG ATGA TGAA GAAG AAGA AGAC GACA ACAT CATG ATGG TGGG GGGT GGTA GTAT TATT ATTA TTAA TAAA AAAC AACC ACCA CCAC CACC ACCT CCTA CTAA TAAG AAGG AGGG GGGT GGTG GTGT TGTT GTTA TTAT TATC ATCA TCAT CATG ATGT TGTA GTAT TATG ATGG TGGC GGCC GCCC CCCA CCAC CACC ACCT,TTGAC TGACT GACTC ACTCA CTCAC TCACC CACCC ACCCT CCCTG CCTGA CTGAA TGAAA GAAAT AAATC AATCT ATCTA TCTAT CTATG TATGA ATGAA TGAAG GAAGA AAGAC AGACA GACAT ACATG CATGG ATGGG TGGGT GGGTA GGTAT GTATT TATTA ATTAA TTAAA TAAAC AAACC AACCA ACCAC CCACC CACCT ACCTA CCTAA CTAAG TAAGG AAGGG AGGGT GGGTG GGTGT GTGTT TGTTA GTTAT TTATC TATCA ATCAT TCATG CATGT ATGTA TGTAT GTATG TATGG ATGGC TGGCC GGCCC GCCCA CCCAC CCACC CACCT,TTGACT TGACTC GACTCA ACTCAC CTCACC TCACCC CACCCT ACCCTG CCCTGA CCTGAA CTGAAA TGAAAT GAAATC AAATCT AATCTA ATCTAT TCTATG CTATGA TATGAA ATGAAG TGAAGA GAAGAC AAGACA AGACAT GACATG ACATGG CATGGG ATGGGT TGGGTA GGGTAT GGTATT GTATTA TATTAA ATTAAA TTAAAC TAAACC AAACCA AACCAC ACCACC CCACCT CACCTA ACCTAA CCTAAG CTAAGG TAAGGG AAGGGT AGGGTG GGGTGT GGTGTT GTGTTA TGTTAT GTTATC TTATCA TATCAT ATCATG TCATGT CATGTA ATGTAT TGTATG GTATGG TATGGC ATGGCC TGGCCC GGCCCA GCCCAC CCCACC CCACCT,TTGACTC TGACTCA GACTCAC ACTCACC CTCACCC TCACCCT CACCCTG ACCCTGA CCCTGAA CCTGAAA CTGAAAT TGAAATC GAAATCT AAATCTA AATCTAT ATCTATG TCTATGA CTATGAA TATGAAG ATGAAGA TGAAGAC GAAGACA AAGACAT AGACATG GACATGG ACATGGG CATGGGT ATGGGTA TGGGTAT GGGTATT GGTATTA GTATTAA TATTAAA ATTAAAC TTAAACC TAAACCA AAACCAC AACCACC ACCACCT CCACCTA CACCTAA ACCTAAG CCTAAGG CTAAGGG TAAGGGT AAGGGTG AGGGTGT GGGTGTT GGTGTTA GTGTTAT TGTTATC GTTATCA TTATCAT TATCATG ATCATGT TCATGTA CATGTAT ATGTATG TGTATGG GTATGGC TATGGCC ATGGCCC TGGCCCA GGCCCAC GCCCACC CCCACCT,"ID   PRS4_CHICK              Reviewed;         440 AA.
AC   Q90732;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1997, sequence version 1.
DT   05-FEB-2025, entry version 120.
DE   RecName: Full=26S proteasome regulatory subunit 4;
DE            Short=P26s4;
DE   AltName: Full=26S proteasome AAA-ATPase subunit RPT2;
DE   AltName: Full=Proteasome 26S subunit ATPase 1;
GN   Name=PSMC1;
OS   Gallus gallus (Chicken).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Archelosauria; Archosauria; Dinosauria; Saurischia; Theropoda;
OC   Coelurosauria; Aves; Neognathae; Galloanserae; Galliformes; Phasianidae;
OC   Phasianinae; Gallus.
OX   NCBI_TaxID=9031;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8806779; DOI=10.1006/abbi.1996.0389;
RA   Singh I., Cai H., Wagner B.J.;
RT   ""cDNA cloning of a chick homologue of human ATPase complex subunit 4,
RT   quantitative tissue distribution and tertiary structure comparison of the
RT   ATPase domain to RecA."";
RL   Arch. Biochem. Biophys. 333:260-266(1996).
CC   -!- FUNCTION: The 26S proteasome is involved in the ATP-dependent
CC       degradation of ubiquitinated proteins. The regulatory (or ATPase)
CC       complex confers ATP dependency and substrate specificity to the 26S
CC       complex.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus.
CC   -!- SIMILARITY: Belongs to the AAA ATPase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U60187; AAC60013.1; -; mRNA.
DR   PIR; S74197; S74197.
DR   RefSeq; NP_990289.1; NM_204958.1.
DR   AlphaFoldDB; Q90732; -.
DR   SMR; Q90732; -.
DR   STRING; 9031.ENSGALP00000017347; -.
DR   PaxDb; 9031-ENSGALP00000017347; -.
DR   GeneID; 395804; -.
DR   KEGG; gga:395804; -.
DR   CTD; 5700; -.
DR   VEuPathDB; HostDB:geneid_395804; -.
DR   eggNOG; KOG0726; Eukaryota.
DR   InParanoid; Q90732; -.
DR   OrthoDB; 10255768at2759; -.
DR   PhylomeDB; Q90732; -.
DR   PRO; PR:Q90732; -.
DR   Proteomes; UP000000539; Unassembled WGS sequence.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0005634; C:nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0022624; C:proteasome accessory complex; ISS:UniProtKB.
DR   GO; GO:0008540; C:proteasome regulatory particle, base subcomplex; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:InterPro.
DR   GO; GO:0036402; F:proteasome-activating activity; IBA:GO_Central.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IBA:GO_Central.
DR   CDD; cd19502; RecA-like_PAN_like; 1.
DR   FunFam; 2.40.50.140:FF:000067; 26S protease regulatory subunit 4; 1.
DR   FunFam; 1.10.8.60:FF:000007; 26S proteasome regulatory subunit 4; 1.
DR   FunFam; 3.40.50.300:FF:000039; 26S proteasome regulatory subunit 4; 1.
DR   Gene3D; 1.10.8.60; -; 1.
DR   Gene3D; 2.40.50.140; Nucleic acid-binding proteins; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 1.
DR   InterPro; IPR050221; 26S_Proteasome_ATPase.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR041569; AAA_lid_3.
DR   InterPro; IPR003959; ATPase_AAA_core.
DR   InterPro; IPR003960; ATPase_AAA_CS.
DR   InterPro; IPR012340; NA-bd_OB-fold.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR032501; Prot_ATP_ID_OB_2nd.
DR   PANTHER; PTHR23073; 26S PROTEASOME REGULATORY SUBUNIT; 1.
DR   Pfam; PF00004; AAA; 1.
DR   Pfam; PF17862; AAA_lid_3; 1.
DR   Pfam; PF16450; Prot_ATP_ID_OB_C; 1.
DR   SMART; SM00382; AAA; 1.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 1.
DR   PROSITE; PS00674; AAA; 1.
PE   2: Evidence at transcript level;
KW   ATP-binding; Cytoplasm; Nucleotide-binding; Nucleus; Proteasome;
KW   Reference proteome.
FT   CHAIN           1..440
FT                   /note=""26S proteasome regulatory subunit 4""
FT                   /id=""PRO_0000084680""
FT   REGION          1..53
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          84..105
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        14..26
FT                   /note=""Basic and acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        86..103
FT                   /note=""Basic and acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   BINDING         226..233
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255""
SQ   SEQUENCE   440 AA;  49204 MW;  259F5CA691218527 CRC64;
     MGQSQSGGHG PGGGKKDDKD KKKKYEPPVP TRVGKKKKKT KGPDAASKPP LVTPHTQCRL
     KLLKLERIKD YLLMEEEFIR NQEQMKPLEE KQEEERSKVD DLRGTPMSVG TLEEIIDDNH
     AIVSTSVGSE HYVSILSFVD KDLLEPGCSV LLNHKVHAVI GVLMDDTDPL VTVMKLEKAP
     QETYADIGGL DNQIQEIKES VELPLTHPEY YEEMGIKPPK GVILYGPPGT GKTLLAKAVA
     NQTSATFLRV VGSELIQKYL GDGPKLVREL FRVAEEHGPS IVFIDEIDAI GTKRYDSNSG
     GEREIQRTML ELLNQLDGFD SRGDVKVIMA TNRIETLDPA LIRPGRIDRK IEFPLPDEKT
     KKRIFQIHTS RMTLADDVTL DELIMAKDDL SGADIKAICT EAGLMALRER RMKVTNEDFK
     KSKENFLYKK TEGTPEGLYL
//
",39038
ACTAAA CTAAAG TAAAGA AAAGAA AAGAAG AGAAGG GAAGGT AAGGTG AGGTGC GGTGCC GTGCCA TGCCAC GCCACT CCACTA CACTAC ACTACT CTACTT TACTTG ACTTGT CTTGTG TTGTGG TGTGGT GTGGTT TGGTTA GGTTAC GTTACT TTACTT TACTTA ACTTAC CTTACC TTACCC TACCCC ACCCCA CCCCAA CCCAAA CCAAAA CAAAAT AAAATG AAATGC AATGCT ATGCTG TGCTGT GCTGTT CTGTTG TGTTGT GTTGTT TTGTTA TGTTAA GTTAAA TTAAAA TAAAAT AAAATT AAATTT AATTTA ATTTAT TTTATT TTATTG TATTGT ATTGTC TTGTCC TGTCCA GTCCAG TCCAGC CCAGCA CAGCAT AGCATG GCATGT CATGTC ATGTCA TGTCAC GTCACA TCACAA CACAAT ACAATT CAATTC AATTCA ATTCAG TTCAGA TCAGAA CAGAAG AGAAGT GAAGTA AAGTAG AGTAGG GTAGGA TAGGAC AGGACC GGACCT GACCTG ACCTGA CCTGAG CTGAGC TGAGCA GAGCAT AGCATA GCATAG CATAGT ATAGTC TAGTCT AGTCTT GTCTTG TCTTGC CTTGCC TTGCCG TGCCGA GCCGAA CCGAAT CGAATA GAATAC AATACC ATACCA TACCAT ACCATA CCATAA CATAAT ATAATG TAATGA AATGAA ATGAAT TGAATC GAATCT AATCTG ATCTGG TCTGGC CTGGCT TGGCTT GGCTTG GCTTGA CTTGAA TTGAAA TGAAAA GAAAAC AAAACC AAACCA AACCAT ACCATT,0,136,ACTA CTAA TAAA AAAG AAGA AGAA GAAG AAGG AGGT GGTG GTGC TGCC GCCA CCAC CACT ACTA CTAC TACT ACTT CTTG TTGT TGTG GTGG TGGT GGTT GTTA TTAC TACT ACTT CTTA TTAC TACC ACCC CCCC CCCA CCAA CAAA AAAA AAAT AATG ATGC TGCT GCTG CTGT TGTT GTTG TTGT TGTT GTTA TTAA TAAA AAAA AAAT AATT ATTT TTTA TTAT TATT ATTG TTGT TGTC GTCC TCCA CCAG CAGC AGCA GCAT CATG ATGT TGTC GTCA TCAC CACA ACAA CAAT AATT ATTC TTCA TCAG CAGA AGAA GAAG AAGT AGTA GTAG TAGG AGGA GGAC GACC ACCT CCTG CTGA TGAG GAGC AGCA GCAT CATA ATAG TAGT AGTC GTCT TCTT CTTG TTGC TGCC GCCG CCGA CGAA GAAT AATA ATAC TACC ACCA CCAT CATA ATAA TAAT AATG ATGA TGAA GAAT AATC ATCT TCTG CTGG TGGC GGCT GCTT CTTG TTGA TGAA GAAA AAAA AAAC AACC ACCA CCAT CATT,ACTAA CTAAA TAAAG AAAGA AAGAA AGAAG GAAGG AAGGT AGGTG GGTGC GTGCC TGCCA GCCAC CCACT CACTA ACTAC CTACT TACTT ACTTG CTTGT TTGTG TGTGG GTGGT TGGTT GGTTA GTTAC TTACT TACTT ACTTA CTTAC TTACC TACCC ACCCC CCCCA CCCAA CCAAA CAAAA AAAAT AAATG AATGC ATGCT TGCTG GCTGT CTGTT TGTTG GTTGT TTGTT TGTTA GTTAA TTAAA TAAAA AAAAT AAATT AATTT ATTTA TTTAT TTATT TATTG ATTGT TTGTC TGTCC GTCCA TCCAG CCAGC CAGCA AGCAT GCATG CATGT ATGTC TGTCA GTCAC TCACA CACAA ACAAT CAATT AATTC ATTCA TTCAG TCAGA CAGAA AGAAG GAAGT AAGTA AGTAG GTAGG TAGGA AGGAC GGACC GACCT ACCTG CCTGA CTGAG TGAGC GAGCA AGCAT GCATA CATAG ATAGT TAGTC AGTCT GTCTT TCTTG CTTGC TTGCC TGCCG GCCGA CCGAA CGAAT GAATA AATAC ATACC TACCA ACCAT CCATA CATAA ATAAT TAATG AATGA ATGAA TGAAT GAATC AATCT ATCTG TCTGG CTGGC TGGCT GGCTT GCTTG CTTGA TTGAA TGAAA GAAAA AAAAC AAACC AACCA ACCAT CCATT,ACTAAA CTAAAG TAAAGA AAAGAA AAGAAG AGAAGG GAAGGT AAGGTG AGGTGC GGTGCC GTGCCA TGCCAC GCCACT CCACTA CACTAC ACTACT CTACTT TACTTG ACTTGT CTTGTG TTGTGG TGTGGT GTGGTT TGGTTA GGTTAC GTTACT TTACTT TACTTA ACTTAC CTTACC TTACCC TACCCC ACCCCA CCCCAA CCCAAA CCAAAA CAAAAT AAAATG AAATGC AATGCT ATGCTG TGCTGT GCTGTT CTGTTG TGTTGT GTTGTT TTGTTA TGTTAA GTTAAA TTAAAA TAAAAT AAAATT AAATTT AATTTA ATTTAT TTTATT TTATTG TATTGT ATTGTC TTGTCC TGTCCA GTCCAG TCCAGC CCAGCA CAGCAT AGCATG GCATGT CATGTC ATGTCA TGTCAC GTCACA TCACAA CACAAT ACAATT CAATTC AATTCA ATTCAG TTCAGA TCAGAA CAGAAG AGAAGT GAAGTA AAGTAG AGTAGG GTAGGA TAGGAC AGGACC GGACCT GACCTG ACCTGA CCTGAG CTGAGC TGAGCA GAGCAT AGCATA GCATAG CATAGT ATAGTC TAGTCT AGTCTT GTCTTG TCTTGC CTTGCC TTGCCG TGCCGA GCCGAA CCGAAT CGAATA GAATAC AATACC ATACCA TACCAT ACCATA CCATAA CATAAT ATAATG TAATGA AATGAA ATGAAT TGAATC GAATCT AATCTG ATCTGG TCTGGC CTGGCT TGGCTT GGCTTG GCTTGA CTTGAA TTGAAA TGAAAA GAAAAC AAAACC AAACCA AACCAT ACCATT,ACTAAAG CTAAAGA TAAAGAA AAAGAAG AAGAAGG AGAAGGT GAAGGTG AAGGTGC AGGTGCC GGTGCCA GTGCCAC TGCCACT GCCACTA CCACTAC CACTACT ACTACTT CTACTTG TACTTGT ACTTGTG CTTGTGG TTGTGGT TGTGGTT GTGGTTA TGGTTAC GGTTACT GTTACTT TTACTTA TACTTAC ACTTACC CTTACCC TTACCCC TACCCCA ACCCCAA CCCCAAA CCCAAAA CCAAAAT CAAAATG AAAATGC AAATGCT AATGCTG ATGCTGT TGCTGTT GCTGTTG CTGTTGT TGTTGTT GTTGTTA TTGTTAA TGTTAAA GTTAAAA TTAAAAT TAAAATT AAAATTT AAATTTA AATTTAT ATTTATT TTTATTG TTATTGT TATTGTC ATTGTCC TTGTCCA TGTCCAG GTCCAGC TCCAGCA CCAGCAT CAGCATG AGCATGT GCATGTC CATGTCA ATGTCAC TGTCACA GTCACAA TCACAAT CACAATT ACAATTC CAATTCA AATTCAG ATTCAGA TTCAGAA TCAGAAG CAGAAGT AGAAGTA GAAGTAG AAGTAGG AGTAGGA GTAGGAC TAGGACC AGGACCT GGACCTG GACCTGA ACCTGAG CCTGAGC CTGAGCA TGAGCAT GAGCATA AGCATAG GCATAGT CATAGTC ATAGTCT TAGTCTT AGTCTTG GTCTTGC TCTTGCC CTTGCCG TTGCCGA TGCCGAA GCCGAAT CCGAATA CGAATAC GAATACC AATACCA ATACCAT TACCATA ACCATAA CCATAAT CATAATG ATAATGA TAATGAA AATGAAT ATGAATC TGAATCT GAATCTG AATCTGG ATCTGGC TCTGGCT CTGGCTT TGGCTTG GGCTTGA GCTTGAA CTTGAAA TTGAAAA TGAAAAC GAAAACC AAAACCA AAACCAT AACCATT,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",606
GGCTTC GCTTCG CTTCGC TTCGCC TCGCCG CGCCGG GCCGGC CCGGCG CGGCGG GGCGGC GCGGCA CGGCAC GGCACG GCACGT CACGTC ACGTCG CGTCGA GTCGAA TCGAAT CGAATC GAATCG AATCGC ATCGCG TCGCGG CGCGGG GCGGGG CGGGGC GGGGCC GGGCCA GGCCAT GCCATG CCATGT CATGTT ATGTTC TGTTCA GTTCAT TTCATC TCATCA CATCAG ATCAGC TCAGCC CAGCCT AGCCTG GCCTGA CCTGAA CTGAAG TGAAGC GAAGCC AAGCCG AGCCGC GCCGCC CCGCCG CGCCGG GCCGGA CCGGAG CGGAGG GGAGGA GAGGAG AGGAGC GGAGCG GAGCGC AGCGCG GCGCGG CGCGGT GCGGTG CGGTGG GGTGGC GTGGCG TGGCGT GGCGTG GCGTGT CGTGTC GTGTCG TGTCGA GTCGAC TCGACG CGACGG GACGGC ACGGCG CGGCGG GGCGGA GCGGAC CGGACG GGACGT GACGTG ACGTGA CGTGAT GTGATC TGATCG GATCGA ATCGAC TCGACC CGACCG GACCGG ACCGGT CCGGTT CGGTTG GGTTGC GTTGCG TTGCGC TGCGCC GCGCCG CGCCGG GCCGGG CCGGGC CGGGCG GGGCGC GGCGCT GCGCTT CGCTTT GCTTTA CTTTAT TTTATC TTATCC TATCCG ATCCGG TCCGGT CCGGTG CGGTGC GGTGCC GTGCCG TGCCGG GCCGGG CCGGGC CGGGCA GGGCAT GGCATC GCATCC CATCCG ATCCGT TCCGTC CCGTCT CGTCTT GTCTTT TCTTTT CTTTTC TTTTCA TTTCAT TTCATG TCATGT CATGTT ATGTTT TGTTTG GTTTGC TTTGCG,2,145,GGCT GCTT CTTC TTCG TCGC CGCC GCCG CCGG CGGC GGCG GCGG CGGC GGCA GCAC CACG ACGT CGTC GTCG TCGA CGAA GAAT AATC ATCG TCGC CGCG GCGG CGGG GGGG GGGC GGCC GCCA CCAT CATG ATGT TGTT GTTC TTCA TCAT CATC ATCA TCAG CAGC AGCC GCCT CCTG CTGA TGAA GAAG AAGC AGCC GCCG CCGC CGCC GCCG CCGG CGGA GGAG GAGG AGGA GGAG GAGC AGCG GCGC CGCG GCGG CGGT GGTG GTGG TGGC GGCG GCGT CGTG GTGT TGTC GTCG TCGA CGAC GACG ACGG CGGC GGCG GCGG CGGA GGAC GACG ACGT CGTG GTGA TGAT GATC ATCG TCGA CGAC GACC ACCG CCGG CGGT GGTT GTTG TTGC TGCG GCGC CGCC GCCG CCGG CGGG GGGC GGCG GCGC CGCT GCTT CTTT TTTA TTAT TATC ATCC TCCG CCGG CGGT GGTG GTGC TGCC GCCG CCGG CGGG GGGC GGCA GCAT CATC ATCC TCCG CCGT CGTC GTCT TCTT CTTT TTTT TTTC TTCA TCAT CATG ATGT TGTT GTTT TTTG TTGC TGCG,GGCTT GCTTC CTTCG TTCGC TCGCC CGCCG GCCGG CCGGC CGGCG GGCGG GCGGC CGGCA GGCAC GCACG CACGT ACGTC CGTCG GTCGA TCGAA CGAAT GAATC AATCG ATCGC TCGCG CGCGG GCGGG CGGGG GGGGC GGGCC GGCCA GCCAT CCATG CATGT ATGTT TGTTC GTTCA TTCAT TCATC CATCA ATCAG TCAGC CAGCC AGCCT GCCTG CCTGA CTGAA TGAAG GAAGC AAGCC AGCCG GCCGC CCGCC CGCCG GCCGG CCGGA CGGAG GGAGG GAGGA AGGAG GGAGC GAGCG AGCGC GCGCG CGCGG GCGGT CGGTG GGTGG GTGGC TGGCG GGCGT GCGTG CGTGT GTGTC TGTCG GTCGA TCGAC CGACG GACGG ACGGC CGGCG GGCGG GCGGA CGGAC GGACG GACGT ACGTG CGTGA GTGAT TGATC GATCG ATCGA TCGAC CGACC GACCG ACCGG CCGGT CGGTT GGTTG GTTGC TTGCG TGCGC GCGCC CGCCG GCCGG CCGGG CGGGC GGGCG GGCGC GCGCT CGCTT GCTTT CTTTA TTTAT TTATC TATCC ATCCG TCCGG CCGGT CGGTG GGTGC GTGCC TGCCG GCCGG CCGGG CGGGC GGGCA GGCAT GCATC CATCC ATCCG TCCGT CCGTC CGTCT GTCTT TCTTT CTTTT TTTTC TTTCA TTCAT TCATG CATGT ATGTT TGTTT GTTTG TTTGC TTGCG,GGCTTC GCTTCG CTTCGC TTCGCC TCGCCG CGCCGG GCCGGC CCGGCG CGGCGG GGCGGC GCGGCA CGGCAC GGCACG GCACGT CACGTC ACGTCG CGTCGA GTCGAA TCGAAT CGAATC GAATCG AATCGC ATCGCG TCGCGG CGCGGG GCGGGG CGGGGC GGGGCC GGGCCA GGCCAT GCCATG CCATGT CATGTT ATGTTC TGTTCA GTTCAT TTCATC TCATCA CATCAG ATCAGC TCAGCC CAGCCT AGCCTG GCCTGA CCTGAA CTGAAG TGAAGC GAAGCC AAGCCG AGCCGC GCCGCC CCGCCG CGCCGG GCCGGA CCGGAG CGGAGG GGAGGA GAGGAG AGGAGC GGAGCG GAGCGC AGCGCG GCGCGG CGCGGT GCGGTG CGGTGG GGTGGC GTGGCG TGGCGT GGCGTG GCGTGT CGTGTC GTGTCG TGTCGA GTCGAC TCGACG CGACGG GACGGC ACGGCG CGGCGG GGCGGA GCGGAC CGGACG GGACGT GACGTG ACGTGA CGTGAT GTGATC TGATCG GATCGA ATCGAC TCGACC CGACCG GACCGG ACCGGT CCGGTT CGGTTG GGTTGC GTTGCG TTGCGC TGCGCC GCGCCG CGCCGG GCCGGG CCGGGC CGGGCG GGGCGC GGCGCT GCGCTT CGCTTT GCTTTA CTTTAT TTTATC TTATCC TATCCG ATCCGG TCCGGT CCGGTG CGGTGC GGTGCC GTGCCG TGCCGG GCCGGG CCGGGC CGGGCA GGGCAT GGCATC GCATCC CATCCG ATCCGT TCCGTC CCGTCT CGTCTT GTCTTT TCTTTT CTTTTC TTTTCA TTTCAT TTCATG TCATGT CATGTT ATGTTT TGTTTG GTTTGC TTTGCG,GGCTTCG GCTTCGC CTTCGCC TTCGCCG TCGCCGG CGCCGGC GCCGGCG CCGGCGG CGGCGGC GGCGGCA GCGGCAC CGGCACG GGCACGT GCACGTC CACGTCG ACGTCGA CGTCGAA GTCGAAT TCGAATC CGAATCG GAATCGC AATCGCG ATCGCGG TCGCGGG CGCGGGG GCGGGGC CGGGGCC GGGGCCA GGGCCAT GGCCATG GCCATGT CCATGTT CATGTTC ATGTTCA TGTTCAT GTTCATC TTCATCA TCATCAG CATCAGC ATCAGCC TCAGCCT CAGCCTG AGCCTGA GCCTGAA CCTGAAG CTGAAGC TGAAGCC GAAGCCG AAGCCGC AGCCGCC GCCGCCG CCGCCGG CGCCGGA GCCGGAG CCGGAGG CGGAGGA GGAGGAG GAGGAGC AGGAGCG GGAGCGC GAGCGCG AGCGCGG GCGCGGT CGCGGTG GCGGTGG CGGTGGC GGTGGCG GTGGCGT TGGCGTG GGCGTGT GCGTGTC CGTGTCG GTGTCGA TGTCGAC GTCGACG TCGACGG CGACGGC GACGGCG ACGGCGG CGGCGGA GGCGGAC GCGGACG CGGACGT GGACGTG GACGTGA ACGTGAT CGTGATC GTGATCG TGATCGA GATCGAC ATCGACC TCGACCG CGACCGG GACCGGT ACCGGTT CCGGTTG CGGTTGC GGTTGCG GTTGCGC TTGCGCC TGCGCCG GCGCCGG CGCCGGG GCCGGGC CCGGGCG CGGGCGC GGGCGCT GGCGCTT GCGCTTT CGCTTTA GCTTTAT CTTTATC TTTATCC TTATCCG TATCCGG ATCCGGT TCCGGTG CCGGTGC CGGTGCC GGTGCCG GTGCCGG TGCCGGG GCCGGGC CCGGGCA CGGGCAT GGGCATC GGCATCC GCATCCG CATCCGT ATCCGTC TCCGTCT CCGTCTT CGTCTTT GTCTTTT TCTTTTC CTTTTCA TTTTCAT TTTCATG TTCATGT TCATGTT CATGTTT ATGTTTG TGTTTGC GTTTGCG,"ID   MDTC_EDWI9              Reviewed;        1026 AA.
AC   C5BHN3;
DT   16-NOV-2011, integrated into UniProtKB/Swiss-Prot.
DT   28-JUL-2009, sequence version 1.
DT   05-FEB-2025, entry version 82.
DE   RecName: Full=Multidrug resistance protein MdtC {ECO:0000255|HAMAP-Rule:MF_01424};
DE   AltName: Full=Multidrug transporter MdtC {ECO:0000255|HAMAP-Rule:MF_01424};
GN   Name=mdtC {ECO:0000255|HAMAP-Rule:MF_01424};
GN   OrderedLocusNames=NT01EI_1169;
OS   Edwardsiella ictaluri (strain 93-146).
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Enterobacterales;
OC   Hafniaceae; Edwardsiella.
OX   NCBI_TaxID=634503;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=93-146;
RA   Williams M.L., Gillaspy A.F., Dyer D.W., Thune R.L., Waldbieser G.C.,
RA   Schuster S.C., Gipson J., Zaitshik J., Landry C., Lawrence M.L.;
RT   ""Complete genome sequence of Edwardsiella ictaluri 93-146."";
RL   Submitted (MAR-2009) to the EMBL/GenBank/DDBJ databases.
CC   -!- SUBUNIT: Part of a tripartite efflux system composed of MdtA, MdtB and
CC       MdtC. MdtC forms a heteromultimer with MdtB. {ECO:0000255|HAMAP-
CC       Rule:MF_01424}.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane {ECO:0000255|HAMAP-
CC       Rule:MF_01424}; Multi-pass membrane protein {ECO:0000255|HAMAP-
CC       Rule:MF_01424}.
CC   -!- SIMILARITY: Belongs to the resistance-nodulation-cell division (RND)
CC       (TC 2.A.6) family. MdtC subfamily. {ECO:0000255|HAMAP-Rule:MF_01424}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP001600; ACR68377.1; -; Genomic_DNA.
DR   RefSeq; WP_015870552.1; NC_012779.2.
DR   AlphaFoldDB; C5BHN3; -.
DR   SMR; C5BHN3; -.
DR   STRING; 67780.B6E78_16165; -.
DR   GeneID; 69538196; -.
DR   KEGG; eic:NT01EI_1169; -.
DR   PATRIC; fig|634503.3.peg.1059; -.
DR   HOGENOM; CLU_002755_1_2_6; -.
DR   OrthoDB; 9757904at2; -.
DR   Proteomes; UP000001485; Chromosome.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0042910; F:xenobiotic transmembrane transporter activity; IEA:TreeGrafter.
DR   FunFam; 1.20.1640.10:FF:000001; Efflux pump membrane transporter; 1.
DR   FunFam; 3.30.70.1430:FF:000001; Efflux pump membrane transporter; 1.
DR   Gene3D; 3.30.70.1430; Multidrug efflux transporter AcrB pore domain; 2.
DR   Gene3D; 3.30.70.1440; Multidrug efflux transporter AcrB pore domain; 1.
DR   Gene3D; 3.30.70.1320; Multidrug efflux transporter AcrB pore domain like; 1.
DR   Gene3D; 3.30.2090.10; Multidrug efflux transporter AcrB TolC docking domain, DN and DC subdomains; 2.
DR   Gene3D; 1.20.1640.10; Multidrug efflux transporter AcrB transmembrane domain; 2.
DR   HAMAP; MF_01424; MdtC; 1.
DR   InterPro; IPR027463; AcrB_DN_DC_subdom.
DR   InterPro; IPR001036; Acrflvin-R.
DR   InterPro; IPR023931; Multidrug-R_MdtC.
DR   PANTHER; PTHR32063; -; 1.
DR   PANTHER; PTHR32063:SF34; MULTIDRUG RESISTANCE PROTEIN MDTC; 1.
DR   Pfam; PF00873; ACR_tran; 1.
DR   PRINTS; PR00702; ACRIFLAVINRP.
DR   SUPFAM; SSF82693; Multidrug efflux transporter AcrB pore domain, PN1, PN2, PC1 and PC2 subdomains; 4.
DR   SUPFAM; SSF82714; Multidrug efflux transporter AcrB TolC docking domain, DN and DC subdomains; 2.
DR   SUPFAM; SSF82866; Multidrug efflux transporter AcrB transmembrane domain; 2.
PE   3: Inferred from homology;
KW   Cell inner membrane; Cell membrane; Membrane; Transmembrane;
KW   Transmembrane helix; Transport.
FT   CHAIN           1..1026
FT                   /note=""Multidrug resistance protein MdtC""
FT                   /id=""PRO_0000414033""
FT   TRANSMEM        16..36
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01424""
FT   TRANSMEM        333..353
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01424""
FT   TRANSMEM        360..380
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01424""
FT   TRANSMEM        387..407
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01424""
FT   TRANSMEM        435..455
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01424""
FT   TRANSMEM        459..479
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01424""
FT   TRANSMEM        528..548
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01424""
FT   TRANSMEM        853..873
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01424""
FT   TRANSMEM        897..917
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01424""
FT   TRANSMEM        953..973
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01424""
FT   TRANSMEM        984..1004
FT                   /note=""Helical""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01424""
SQ   SEQUENCE   1026 AA;  110510 MW;  DA954A51D0FB5932 CRC64;
     MSGFALFINR PVATSLLALA ITLVGLLGLR LLPVAPLPQV DFPVIMVSAS LPGASAETMA
     ASVAMPLERA LGRIAGVNEM TSSSSLGTTR IILQFNLDRN IDGAARDVQA ALNAAQSLLP
     SGMPSRPSYR KANPSDAPIA ILTLTSAQYS QGDLYDLAST RLAQKIAQIN GVGDVSVSGS
     SLPAVRIDLN PDALFNQGTS LDTVRQAIAS ANVRRPLGAV ADDGRRWQVQ SNDALMTAQE
     YRPLIIRYRD GAPLRLQDVA RISDGVEDVR NAGMSNGQPA ILIMIRRSAD ANIIETVDRL
     RSDLPALQAL LPGGVSLDIA QDRTPTIRAS LREVEQSLAI AIALVILVVF LFLRSARATL
     IPAVTVPVSL IGTCAAIYLC GFSLNNLSLM ALTIASGFVV DDAIVVLENI ARHIEDGLSP
     HRAALAGVRE VGFTVFSISL SLAAVFIPLL FMGGIPGRLF HEFAITLSAS IAISLLIALT
     LTPMMCARLL RPRHTDGGMR PTALRRLSAL LQRGYALSLN WTLDHARWVL LTLLAVIGLN
     IWLYISIPKT FFPQQDTGRL MGFIQADQSI SFQAMRGKLQ DFMHIVRADP DVDNVTGFTG
     GTRVNSGMMF IALKPLGERK QDAQQVIARL RTRLSHEPGA NLFLMAVQDI RAGGRQGNAS
     YQYTLLSDDL AVLRHWEPQV RKALAALPQL TDVSTDQQDK GTEMLLTYDR PAMARLGIKV
     SEVNTLLSNA FGQRQISTLY QPLNQYHVVM EVDPRYAQDE RALDKMFIIN QAGQPIPLSG
     FASWLPANAP LSVNHQGLSA AATISFNLPP GGSLSDASDA IAHAMTALGT PPSLRGTFAG
     TALLFQQAQS SQLLLILAAI ATVYIVLGIL YESYIHPLTI LSTLPSAGVG ALLALMLFNA
     PFSLIALIGI MLLIGLVKKN AILLVDFALT AEREQHLSAR DAIYQACLLR FRPILMTTLA
     ALFGALPLAF SYGDGAELRQ PLGITIVGGL LVSQILTLYT TPVVYLYMEK LRARFSRQKA
     LPPLAY
//
",23548
CTCGCC TCGCCG CGCCGC GCCGCC CCGCCG CGCCGG GCCGGC CCGGCG CGGCGA GGCGAA GCGAAA CGAAAA GAAAAT AAAATC AAATCA AATCAC ATCACT TCACTA CACTAC ACTACA CTACAC TACACG ACACGC CACGCG ACGCGT CGCGTT GCGTTT CGTTTT GTTTTG TTTTGA TTTGAA TTGAAT TGAATT GAATTC AATTCA ATTCAA TTCAAC TCAACC CAACCG AACCGC ACCGCG CCGCGC CGCGCA GCGCAA CGCAAT GCAATC CAATCG AATCGA ATCGAG TCGAGG CGAGGA GAGGAC AGGACG GGACGG GACGGC ACGGCG CGGCGC GGCGCG GCGCGA CGCGAT GCGATC CGATCA GATCAC ATCACC TCACCA CACCAT ACCATT CCATTC CATTCT ATTCTG TTCTGC TCTGCA CTGCAG TGCAGC GCAGCC CAGCCC AGCCCG GCCCGA CCCGAC CCGACC CGACCT GACCTC ACCTCT CCTCTC CTCTCC TCTCCA CTCCAA TCCAAA CCAAAA CAAAAC AAAACC AAACCG AACCGG ACCGGC CCGGCG CGGCGG GGCGGC GCGGCA CGGCAT GGCATC GCATCA CATCAC ATCACC TCACCG CACCGA ACCGAA CCGAAG CGAAGC GAAGCG AAGCGC AGCGCT GCGCTG CGCTGC GCTGCG CTGCGC TGCGCG GCGCGT CGCGTC GCGTCG CGTCGC GTCGCC TCGCCG CGCCGC GCCGCC CCGCCA CGCCAT GCCATG CCATGG CATGGC ATGGCC TGGCCT GGCCTC GCCTCG CCTCGG CTCGGC TCGGCT CGGCTT GGCTTA GCTTAC CTTACA TTACAA TACAAA ACAAAC CAAACT AAACTG,0,145,CTCG TCGC CGCC GCCG CCGC CGCC GCCG CCGG CGGC GGCG GCGA CGAA GAAA AAAA AAAT AATC ATCA TCAC CACT ACTA CTAC TACA ACAC CACG ACGC CGCG GCGT CGTT GTTT TTTT TTTG TTGA TGAA GAAT AATT ATTC TTCA TCAA CAAC AACC ACCG CCGC CGCG GCGC CGCA GCAA CAAT AATC ATCG TCGA CGAG GAGG AGGA GGAC GACG ACGG CGGC GGCG GCGC CGCG GCGA CGAT GATC ATCA TCAC CACC ACCA CCAT CATT ATTC TTCT TCTG CTGC TGCA GCAG CAGC AGCC GCCC CCCG CCGA CGAC GACC ACCT CCTC CTCT TCTC CTCC TCCA CCAA CAAA AAAA AAAC AACC ACCG CCGG CGGC GGCG GCGG CGGC GGCA GCAT CATC ATCA TCAC CACC ACCG CCGA CGAA GAAG AAGC AGCG GCGC CGCT GCTG CTGC TGCG GCGC CGCG GCGT CGTC GTCG TCGC CGCC GCCG CCGC CGCC GCCA CCAT CATG ATGG TGGC GGCC GCCT CCTC CTCG TCGG CGGC GGCT GCTT CTTA TTAC TACA ACAA CAAA AAAC AACT ACTG,CTCGC TCGCC CGCCG GCCGC CCGCC CGCCG GCCGG CCGGC CGGCG GGCGA GCGAA CGAAA GAAAA AAAAT AAATC AATCA ATCAC TCACT CACTA ACTAC CTACA TACAC ACACG CACGC ACGCG CGCGT GCGTT CGTTT GTTTT TTTTG TTTGA TTGAA TGAAT GAATT AATTC ATTCA TTCAA TCAAC CAACC AACCG ACCGC CCGCG CGCGC GCGCA CGCAA GCAAT CAATC AATCG ATCGA TCGAG CGAGG GAGGA AGGAC GGACG GACGG ACGGC CGGCG GGCGC GCGCG CGCGA GCGAT CGATC GATCA ATCAC TCACC CACCA ACCAT CCATT CATTC ATTCT TTCTG TCTGC CTGCA TGCAG GCAGC CAGCC AGCCC GCCCG CCCGA CCGAC CGACC GACCT ACCTC CCTCT CTCTC TCTCC CTCCA TCCAA CCAAA CAAAA AAAAC AAACC AACCG ACCGG CCGGC CGGCG GGCGG GCGGC CGGCA GGCAT GCATC CATCA ATCAC TCACC CACCG ACCGA CCGAA CGAAG GAAGC AAGCG AGCGC GCGCT CGCTG GCTGC CTGCG TGCGC GCGCG CGCGT GCGTC CGTCG GTCGC TCGCC CGCCG GCCGC CCGCC CGCCA GCCAT CCATG CATGG ATGGC TGGCC GGCCT GCCTC CCTCG CTCGG TCGGC CGGCT GGCTT GCTTA CTTAC TTACA TACAA ACAAA CAAAC AAACT AACTG,CTCGCC TCGCCG CGCCGC GCCGCC CCGCCG CGCCGG GCCGGC CCGGCG CGGCGA GGCGAA GCGAAA CGAAAA GAAAAT AAAATC AAATCA AATCAC ATCACT TCACTA CACTAC ACTACA CTACAC TACACG ACACGC CACGCG ACGCGT CGCGTT GCGTTT CGTTTT GTTTTG TTTTGA TTTGAA TTGAAT TGAATT GAATTC AATTCA ATTCAA TTCAAC TCAACC CAACCG AACCGC ACCGCG CCGCGC CGCGCA GCGCAA CGCAAT GCAATC CAATCG AATCGA ATCGAG TCGAGG CGAGGA GAGGAC AGGACG GGACGG GACGGC ACGGCG CGGCGC GGCGCG GCGCGA CGCGAT GCGATC CGATCA GATCAC ATCACC TCACCA CACCAT ACCATT CCATTC CATTCT ATTCTG TTCTGC TCTGCA CTGCAG TGCAGC GCAGCC CAGCCC AGCCCG GCCCGA CCCGAC CCGACC CGACCT GACCTC ACCTCT CCTCTC CTCTCC TCTCCA CTCCAA TCCAAA CCAAAA CAAAAC AAAACC AAACCG AACCGG ACCGGC CCGGCG CGGCGG GGCGGC GCGGCA CGGCAT GGCATC GCATCA CATCAC ATCACC TCACCG CACCGA ACCGAA CCGAAG CGAAGC GAAGCG AAGCGC AGCGCT GCGCTG CGCTGC GCTGCG CTGCGC TGCGCG GCGCGT CGCGTC GCGTCG CGTCGC GTCGCC TCGCCG CGCCGC GCCGCC CCGCCA CGCCAT GCCATG CCATGG CATGGC ATGGCC TGGCCT GGCCTC GCCTCG CCTCGG CTCGGC TCGGCT CGGCTT GGCTTA GCTTAC CTTACA TTACAA TACAAA ACAAAC CAAACT AAACTG,CTCGCCG TCGCCGC CGCCGCC GCCGCCG CCGCCGG CGCCGGC GCCGGCG CCGGCGA CGGCGAA GGCGAAA GCGAAAA CGAAAAT GAAAATC AAAATCA AAATCAC AATCACT ATCACTA TCACTAC CACTACA ACTACAC CTACACG TACACGC ACACGCG CACGCGT ACGCGTT CGCGTTT GCGTTTT CGTTTTG GTTTTGA TTTTGAA TTTGAAT TTGAATT TGAATTC GAATTCA AATTCAA ATTCAAC TTCAACC TCAACCG CAACCGC AACCGCG ACCGCGC CCGCGCA CGCGCAA GCGCAAT CGCAATC GCAATCG CAATCGA AATCGAG ATCGAGG TCGAGGA CGAGGAC GAGGACG AGGACGG GGACGGC GACGGCG ACGGCGC CGGCGCG GGCGCGA GCGCGAT CGCGATC GCGATCA CGATCAC GATCACC ATCACCA TCACCAT CACCATT ACCATTC CCATTCT CATTCTG ATTCTGC TTCTGCA TCTGCAG CTGCAGC TGCAGCC GCAGCCC CAGCCCG AGCCCGA GCCCGAC CCCGACC CCGACCT CGACCTC GACCTCT ACCTCTC CCTCTCC CTCTCCA TCTCCAA CTCCAAA TCCAAAA CCAAAAC CAAAACC AAAACCG AAACCGG AACCGGC ACCGGCG CCGGCGG CGGCGGC GGCGGCA GCGGCAT CGGCATC GGCATCA GCATCAC CATCACC ATCACCG TCACCGA CACCGAA ACCGAAG CCGAAGC CGAAGCG GAAGCGC AAGCGCT AGCGCTG GCGCTGC CGCTGCG GCTGCGC CTGCGCG TGCGCGT GCGCGTC CGCGTCG GCGTCGC CGTCGCC GTCGCCG TCGCCGC CGCCGCC GCCGCCA CCGCCAT CGCCATG GCCATGG CCATGGC CATGGCC ATGGCCT TGGCCTC GGCCTCG GCCTCGG CCTCGGC CTCGGCT TCGGCTT CGGCTTA GGCTTAC GCTTACA CTTACAA TTACAAA TACAAAC ACAAACT CAAACTG,"ID   DGOD_RALPJ              Reviewed;         382 AA.
AC   B2UCA8;
DT   14-APR-2009, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-2008, sequence version 1.
DT   27-NOV-2024, entry version 104.
DE   RecName: Full=D-galactonate dehydratase {ECO:0000255|HAMAP-Rule:MF_01289};
DE            Short=GalD {ECO:0000255|HAMAP-Rule:MF_01289};
DE            EC=4.2.1.6 {ECO:0000255|HAMAP-Rule:MF_01289};
GN   Name=dgoD {ECO:0000255|HAMAP-Rule:MF_01289};
GN   OrderedLocusNames=Rpic_2990;
OS   Ralstonia pickettii (strain 12J).
OC   Bacteria; Pseudomonadota; Betaproteobacteria; Burkholderiales;
OC   Burkholderiaceae; Ralstonia.
OX   NCBI_TaxID=402626;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=12J;
RA   Lucas S., Copeland A., Lapidus A., Glavina del Rio T., Dalin E., Tice H.,
RA   Bruce D., Goodwin L., Pitluck S., Meincke L., Brettin T., Detter J.C.,
RA   Han C., Kuske C.R., Schmutz J., Larimer F., Land M., Hauser L.,
RA   Kyrpides N., Mikhailova N., Marsh T., Richardson P.;
RT   ""Complete sequence of chromosome 1 of Ralstonia pickettii 12J."";
RL   Submitted (MAY-2008) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Catalyzes the dehydration of D-galactonate to 2-keto-3-deoxy-
CC       D-galactonate. {ECO:0000255|HAMAP-Rule:MF_01289}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=D-galactonate = 2-dehydro-3-deoxy-D-galactonate + H2O;
CC         Xref=Rhea:RHEA:18649, ChEBI:CHEBI:12931, ChEBI:CHEBI:15377,
CC         ChEBI:CHEBI:57989; EC=4.2.1.6; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_01289};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_01289};
CC       Note=Binds 1 Mg(2+) ion per subunit. {ECO:0000255|HAMAP-Rule:MF_01289};
CC   -!- PATHWAY: Carbohydrate acid metabolism; D-galactonate degradation; D-
CC       glyceraldehyde 3-phosphate and pyruvate from D-galactonate: step 1/3.
CC       {ECO:0000255|HAMAP-Rule:MF_01289}.
CC   -!- MISCELLANEOUS: Reaction proceeds via an anti dehydration.
CC       {ECO:0000255|HAMAP-Rule:MF_01289}.
CC   -!- SIMILARITY: Belongs to the mandelate racemase/muconate lactonizing
CC       enzyme family. GalD subfamily. {ECO:0000255|HAMAP-Rule:MF_01289}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP001068; ACD28113.1; -; Genomic_DNA.
DR   PDB; 3RR1; X-ray; 1.95 A; A/B=2-382.
DR   PDB; 3RRA; X-ray; 2.30 A; A/B=2-382.
DR   PDBsum; 3RR1; -.
DR   PDBsum; 3RRA; -.
DR   AlphaFoldDB; B2UCA8; -.
DR   SMR; B2UCA8; -.
DR   STRING; 402626.Rpic_2990; -.
DR   KEGG; rpi:Rpic_2990; -.
DR   PATRIC; fig|402626.5.peg.4126; -.
DR   eggNOG; COG4948; Bacteria.
DR   HOGENOM; CLU_030273_3_2_4; -.
DR   UniPathway; UPA00081; UER00518.
DR   EvolutionaryTrace; B2UCA8; -.
DR   GO; GO:0008869; F:galactonate dehydratase activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0009063; P:amino acid catabolic process; IEA:InterPro.
DR   GO; GO:0034194; P:D-galactonate catabolic process; IEA:UniProtKB-UniRule.
DR   CDD; cd03325; D-galactonate_dehydratase; 1.
DR   FunFam; 3.30.390.10:FF:000003; D-galactonate dehydratase; 1.
DR   Gene3D; 3.20.20.120; Enolase-like C-terminal domain; 1.
DR   Gene3D; 3.30.390.10; Enolase-like, N-terminal domain; 1.
DR   HAMAP; MF_01289; Galacton_dehydrat; 1.
DR   InterPro; IPR034593; DgoD-like.
DR   InterPro; IPR036849; Enolase-like_C_sf.
DR   InterPro; IPR029017; Enolase-like_N.
DR   InterPro; IPR029065; Enolase_C-like.
DR   InterPro; IPR023592; Galactonate_deHydtase.
DR   InterPro; IPR018110; Mandel_Rmase/mucon_lact_enz_CS.
DR   InterPro; IPR013342; Mandelate_racemase_C.
DR   InterPro; IPR013341; Mandelate_racemase_N_dom.
DR   PANTHER; PTHR48080:SF2; D-GALACTONATE DEHYDRATASE; 1.
DR   PANTHER; PTHR48080; D-GALACTONATE DEHYDRATASE-RELATED; 1.
DR   Pfam; PF13378; MR_MLE_C; 1.
DR   Pfam; PF02746; MR_MLE_N; 1.
DR   SFLD; SFLDF00003; D-galactonate_dehydratase; 1.
DR   SFLD; SFLDG00179; mandelate_racemase; 1.
DR   SMART; SM00922; MR_MLE; 1.
DR   SUPFAM; SSF51604; Enolase C-terminal domain-like; 1.
DR   SUPFAM; SSF54826; Enolase N-terminal domain-like; 1.
DR   PROSITE; PS00908; MR_MLE_1; 1.
DR   PROSITE; PS00909; MR_MLE_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Lyase; Magnesium; Metal-binding.
FT   CHAIN           1..382
FT                   /note=""D-galactonate dehydratase""
FT                   /id=""PRO_1000140385""
FT   ACT_SITE        185
FT                   /note=""Proton donor""
FT                   /evidence=""ECO:0000250""
FT   ACT_SITE        285
FT                   /note=""Proton acceptor""
FT                   /evidence=""ECO:0000250""
FT   BINDING         183
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   BINDING         209
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   BINDING         235
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   SITE            258
FT                   /note=""Increases basicity of active site His""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   SITE            310
FT                   /note=""Transition state stabilizer""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01289""
FT   STRAND          3..11
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   TURN            12..14
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          15..22
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          27..30
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           38..48
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           49..51
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   TURN            52..54
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           60..69
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          71..73
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           77..98
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           102..105
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          114..119
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           125..137
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          142..147
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          150..152
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           157..172
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           175..177
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          178..183
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           190..200
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           201..203
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           218..224
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          231..233
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           240..249
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          253..255
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   TURN            259..263
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           264..276
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   TURN            277..279
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           290..302
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          309..311
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           323..326
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           330..333
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   STRAND          345..347
FT                   /evidence=""ECO:0007829|PDB:3RR1""
FT   HELIX           354..362
FT                   /evidence=""ECO:0007829|PDB:3RR1""
SQ   SEQUENCE   382 AA;  42098 MW;  198F1A16BC5819F0 CRC64;
     MKITRLTTYR LPPRWMFLKV ETDEGVTGWG EPVIEGRART VEAAVHELSD YLIGQDPSRI
     NDLWQTMYRA GFYRGGPILM SAIAGIDQAL WDIKGKVLGV PVYELLGGLV RDKMRTYSWV
     GGDRPADVIA GMKALQAGGF DHFKLNGCEE MGIIDTSRAV DAAVARVAEI RSAFGNTVEF
     GLDFHGRVSA PMAKVLIKEL EPYRPLFIEE PVLAEQAETY ARLAAHTHLP IAAGERMFSR
     FDFKRVLEAG GVSILQPDLS HAGGITECVK IAAMAEAYDV ALAPHCPLGP IALAACLHVD
     FVSWNATLQE QSMGIHYNKG AELLDYVRNK ADFALEGGYI RPPRLPGLGV DIDEALVIER
     SKEAPDWRNP VWRHADGSVA EW
//
",260
ATGTTT TGTTTC GTTTCA TTTCAT TTCATC TCATCT CATCTC ATCTCG TCTCGT CTCGTT TCGTTG CGTTGA GTTGAC TTGACT TGACTT GACTTT ACTTTC CTTTCA TTTCAG TTCAGG TCAGGT CAGGTT AGGTTA GGTTAC GTTACT TTACTA TACTAT ACTATA CTATAG TATAGC ATAGCA TAGCAG AGCAGA GCAGAG CAGAGA AGAGAT GAGATA AGATAT GATATT ATATTA TATTAC ATTACT TTACTA TACTAA ACTAAT CTAATT TAATTA AATTAT ATTATT TTATTA TATTAT ATTATG TTATGC TATGCG ATGCGG TGCGGA GCGGAC CGGACT GGACTT GACTTT ACTTTT CTTTTA TTTTAA TTTAAA TTAAAG TAAAGT AAAGTT AAGTTT AGTTTC GTTTCC TTTCCA TTCCAT TCCATT CCATTT CATTTG ATTTGG TTTGGA TTGGAA TGGAAT GGAATC GAATCT AATCTT ATCTTG TCTTGA CTTGAT TTGATT TGATTA GATTAC ATTACA TTACAT TACATC ACATCA CATCAT ATCATA TCATAA CATAAA ATAAAC,1,97,ATGT TGTT GTTT TTTC TTCA TCAT CATC ATCT TCTC CTCG TCGT CGTT GTTG TTGA TGAC GACT ACTT CTTT TTTC TTCA TCAG CAGG AGGT GGTT GTTA TTAC TACT ACTA CTAT TATA ATAG TAGC AGCA GCAG CAGA AGAG GAGA AGAT GATA ATAT TATT ATTA TTAC TACT ACTA CTAA TAAT AATT ATTA TTAT TATT ATTA TTAT TATG ATGC TGCG GCGG CGGA GGAC GACT ACTT CTTT TTTT TTTA TTAA TAAA AAAG AAGT AGTT GTTT TTTC TTCC TCCA CCAT CATT ATTT TTTG TTGG TGGA GGAA GAAT AATC ATCT TCTT CTTG TTGA TGAT GATT ATTA TTAC TACA ACAT CATC ATCA TCAT CATA ATAA TAAA AAAC,ATGTT TGTTT GTTTC TTTCA TTCAT TCATC CATCT ATCTC TCTCG CTCGT TCGTT CGTTG GTTGA TTGAC TGACT GACTT ACTTT CTTTC TTTCA TTCAG TCAGG CAGGT AGGTT GGTTA GTTAC TTACT TACTA ACTAT CTATA TATAG ATAGC TAGCA AGCAG GCAGA CAGAG AGAGA GAGAT AGATA GATAT ATATT TATTA ATTAC TTACT TACTA ACTAA CTAAT TAATT AATTA ATTAT TTATT TATTA ATTAT TTATG TATGC ATGCG TGCGG GCGGA CGGAC GGACT GACTT ACTTT CTTTT TTTTA TTTAA TTAAA TAAAG AAAGT AAGTT AGTTT GTTTC TTTCC TTCCA TCCAT CCATT CATTT ATTTG TTTGG TTGGA TGGAA GGAAT GAATC AATCT ATCTT TCTTG CTTGA TTGAT TGATT GATTA ATTAC TTACA TACAT ACATC CATCA ATCAT TCATA CATAA ATAAA TAAAC,ATGTTT TGTTTC GTTTCA TTTCAT TTCATC TCATCT CATCTC ATCTCG TCTCGT CTCGTT TCGTTG CGTTGA GTTGAC TTGACT TGACTT GACTTT ACTTTC CTTTCA TTTCAG TTCAGG TCAGGT CAGGTT AGGTTA GGTTAC GTTACT TTACTA TACTAT ACTATA CTATAG TATAGC ATAGCA TAGCAG AGCAGA GCAGAG CAGAGA AGAGAT GAGATA AGATAT GATATT ATATTA TATTAC ATTACT TTACTA TACTAA ACTAAT CTAATT TAATTA AATTAT ATTATT TTATTA TATTAT ATTATG TTATGC TATGCG ATGCGG TGCGGA GCGGAC CGGACT GGACTT GACTTT ACTTTT CTTTTA TTTTAA TTTAAA TTAAAG TAAAGT AAAGTT AAGTTT AGTTTC GTTTCC TTTCCA TTCCAT TCCATT CCATTT CATTTG ATTTGG TTTGGA TTGGAA TGGAAT GGAATC GAATCT AATCTT ATCTTG TCTTGA CTTGAT TTGATT TGATTA GATTAC ATTACA TTACAT TACATC ACATCA CATCAT ATCATA TCATAA CATAAA ATAAAC,ATGTTTC TGTTTCA GTTTCAT TTTCATC TTCATCT TCATCTC CATCTCG ATCTCGT TCTCGTT CTCGTTG TCGTTGA CGTTGAC GTTGACT TTGACTT TGACTTT GACTTTC ACTTTCA CTTTCAG TTTCAGG TTCAGGT TCAGGTT CAGGTTA AGGTTAC GGTTACT GTTACTA TTACTAT TACTATA ACTATAG CTATAGC TATAGCA ATAGCAG TAGCAGA AGCAGAG GCAGAGA CAGAGAT AGAGATA GAGATAT AGATATT GATATTA ATATTAC TATTACT ATTACTA TTACTAA TACTAAT ACTAATT CTAATTA TAATTAT AATTATT ATTATTA TTATTAT TATTATG ATTATGC TTATGCG TATGCGG ATGCGGA TGCGGAC GCGGACT CGGACTT GGACTTT GACTTTT ACTTTTA CTTTTAA TTTTAAA TTTAAAG TTAAAGT TAAAGTT AAAGTTT AAGTTTC AGTTTCC GTTTCCA TTTCCAT TTCCATT TCCATTT CCATTTG CATTTGG ATTTGGA TTTGGAA TTGGAAT TGGAATC GGAATCT GAATCTT AATCTTG ATCTTGA TCTTGAT CTTGATT TTGATTA TGATTAC GATTACA ATTACAT TTACATC TACATCA ACATCAT CATCATA ATCATAA TCATAAA CATAAAC,"ID   NS6_SARS2               Reviewed;          61 AA.
AC   P0DTC6;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 24.
DE   RecName: Full=ORF6 protein;
DE            Short=ORF6;
DE   AltName: Full=Accessory protein 6;
DE   AltName: Full=Non-structural protein 6;
DE            Short=ns6;
DE   AltName: Full=Protein X3;
GN   ORFNames=6;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   FUNCTION, AND INTERACTION WITH HOST KPNA2.
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [3]
RP   FUNCTION, INTERACTION WITH HUMAN NUP98-RAE1 COMPLEX, AND MUTAGENESIS OF
RP   MET-58.
RX   PubMed=33097660; DOI=10.1073/pnas.2016650117;
RA   Miorin L., Kehrer T., Sanchez-Aparicio M.T., Zhang K., Cohen P.,
RA   Patel R.S., Cupic A., Makio T., Mei M., Moreno E., Danziger O., White K.M.,
RA   Rathnasinghe R., Uccellini M., Gao S., Aydillo T., Mena I., Yin X.,
RA   Martin-Sancho L., Krogan N.J., Chanda S.K., Schotsaert M., Wozniak R.W.,
RA   Ren Y., Rosenberg B.R., Fontoura B.M.A., Garcia-Sastre A.;
RT   ""SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and antagonize
RT   interferon signaling."";
RL   Proc. Natl. Acad. Sci. U.S.A. 117:28344-28354(2020).
RN   [4]
RP   SUBCELLULAR LOCATION.
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [5]
RP   FUNCTION, AND INTERACTION WITH HUMAN NUP98-RAE1 COMPLEX.
RX   PubMed=33360543; DOI=10.1016/j.bbrc.2020.11.115;
RA   Kato K., Ikliptikawati D.K., Kobayashi A., Kondo H., Lim K., Hazawa M.,
RA   Wong R.W.;
RT   ""Overexpression of SARS-CoV-2 protein ORF6 dislocates RAE1 and NUP98 from
RT   the nuclear pore complex."";
RL   Biochem. Biophys. Res. Commun. 536:59-66(2021).
RN   [6]
RP   FUNCTION, INTERACTION WITH HUMAN NUP98-RAE1 COMPLEX, AND MUTAGENESIS OF
RP   1-MET--LEU-16; 22-PHE--ASP-30; 38-LYS--ASP-61; 50-SER--ASP-61; MET-58 AND
RP   ASP-61.
RX   PubMed=33849972; DOI=10.1128/mbio.00065-21;
RA   Addetia A., Lieberman N.A.P., Phung Q., Hsiang T.Y., Xie H.,
RA   Roychoudhury P., Shrestha L., Loprieno M.A., Huang M.L., Gale M. Jr.,
RA   Jerome K.R., Greninger A.L.;
RT   ""SARS-CoV-2 ORF6 Disrupts Bidirectional Nucleocytoplasmic Transport through
RT   Interactions with Rae1 and Nup98."";
RL   MBio 12:0-0(2021).
RN   [7]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF 18-ILE--VAL-24.
RX   PubMed=35187564; DOI=10.1242/jcs.259666;
RA   Wong H.T., Cheung V., Salamango D.J.;
RT   ""Decoupling SARS-CoV-2 ORF6 localization and interferon antagonism."";
RL   J. Cell Sci. 0:0-0(2022).
RN   [8] {ECO:0007744|PDB:7VPH}
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 41-61, INTERACTION WITH HOST
RP   RAE1-NUP98, AND MUTAGENESIS OF MET-58.
RX   PubMed=35096974; DOI=10.3389/fmolb.2021.813248;
RA   Li T., Wen Y., Guo H., Yang T., Yang H., Ji X.;
RT   ""Molecular mechanism of SARS-CoVs Orf6 targeting the Rae1-Nup98 complex to
RT   compete with mRNA nuclear export."";
RL   Front. Mol. Biosci. 8:813248-813248(2022).
CC   -!- FUNCTION: Disrupts bidirectional nucleocytoplasmic transport by
CC       interacting with the host RAE1-NUP98 complex (PubMed:33360543,
CC       PubMed:33849972). Disrupts cell nuclear import complex formation by
CC       tethering karyopherin alpha 2 and karyopherin beta 1 to the membrane
CC       (PubMed:32979938). Retention of import factors at the ER/Golgi membrane
CC       leads to a loss of transport into the nucleus (By similarity). Prevents
CC       STAT1 nuclear translocation in response to interferon signaling, thus
CC       blocking the expression of interferon stimulated genes (ISGs) that
CC       display multiple antiviral activities (PubMed:33097660). Suppresses
CC       IFN-beta production possibly by blocking IRF3 nuclear translocation
CC       (PubMed:32979938). Might induce accumulation of host HNRNPA1
CC       (PubMed:33360543). {ECO:0000250|UniProtKB:P59634,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33097660,
CC       ECO:0000269|PubMed:33360543, ECO:0000269|PubMed:33849972}.
CC   -!- FUNCTION: May play a role in viral double membrane vesicles networks to
CC       enhance viral replication. {ECO:0000269|PubMed:35187564}.
CC   -!- SUBUNIT: Interacts (via C-terminus) with host RAE1 in the NUP98-RAE1
CC       complex (PubMed:35096974); this interaction disrupts the host nuclear
CC       import (PubMed:33097660, PubMed:33360543, PubMed:33849972,
CC       PubMed:35096974). Interacts with host KPNA2; this interaction may
CC       inhibit IFN-beta production by blocking IRF3 nuclear translocation
CC       (PubMed:32979938). {ECO:0000269|PubMed:32979938,
CC       ECO:0000269|PubMed:33097660, ECO:0000269|PubMed:33360543,
CC       ECO:0000269|PubMed:33849972, ECO:0000269|PubMed:35096974}.
CC   -!- INTERACTION:
CC       P0DTC6; O95870: ABHD16A; Xeno; NbExp=3; IntAct=EBI-25475897, EBI-348517;
CC       P0DTC6; Q15041: ARL6IP1; Xeno; NbExp=3; IntAct=EBI-25475897, EBI-714543;
CC       P0DTC6; P52292: KPNA2; Xeno; NbExp=2; IntAct=EBI-25475897, EBI-349938;
CC       P0DTC6; P52948: NUP98; Xeno; NbExp=11; IntAct=EBI-25475897, EBI-295727;
CC       P0DTC6; O75360: PROP1; Xeno; NbExp=3; IntAct=EBI-25475897, EBI-9027467;
CC       P0DTC6; P78406: RAE1; Xeno; NbExp=11; IntAct=EBI-25475897, EBI-724495;
CC       P0DTC6; Q96HR9: REEP6; Xeno; NbExp=4; IntAct=EBI-25475897, EBI-750345;
CC       P0DTC6; Q9UMX0: UBQLN1; Xeno; NbExp=3; IntAct=EBI-25475897, EBI-741480;
CC       P0DTC6; Q9UHD9: UBQLN2; Xeno; NbExp=4; IntAct=EBI-25475897, EBI-947187;
CC       P0DTC6; Q9NYU1: UGGT2; Xeno; NbExp=3; IntAct=EBI-25475897, EBI-1054215;
CC   -!- SUBCELLULAR LOCATION: Host endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:35187564}; Peripheral
CC       membrane protein {ECO:0000269|PubMed:35187564}. Host Golgi apparatus
CC       membrane {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:35187564};
CC       Peripheral membrane protein {ECO:0000269|PubMed:35187564}.
CC       Note=Localizes to virus-induced vesicular structures called double
CC       membrane vesicles.
CC   -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC       isolated in Nigeria (November 2022). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC       isolated in United States (November 2022). It is the result of
CC       recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC       express ORF8. {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC       isolated in South Africa (November 2021). {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the coronaviruses accessory protein 6 family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43420.1; -; Genomic_RNA.
DR   PDB; 7F60; X-ray; 2.85 A; E/F=1-61.
DR   PDB; 7VPH; X-ray; 2.80 A; I/J/K/X=41-61.
DR   PDBsum; 7F60; -.
DR   PDBsum; 7VPH; -.
DR   SMR; P0DTC6; -.
DR   BioGRID; 4383870; 1182.
DR   IntAct; P0DTC6; 111.
DR   MINT; P0DTC6; -.
DR   iPTMnet; P0DTC6; -.
DR   KEGG; vg:43740572; -.
DR   AGR; RefSeq:YP_009724394; -.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9727281; Translation of Accessory Proteins.
DR   SIGNOR; P0DTC6; -.
DR   PRO; PR:P0DTC6; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0044167; C:host cell endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0044178; C:host cell Golgi membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IEA:UniProtKB-KW.
DR   GO; GO:0005643; C:nuclear pore; IDA:UniProt.
DR   GO; GO:0140311; F:protein sequestering activity; IDA:UniProt.
DR   GO; GO:0039548; P:symbiont-mediated suppression of host cytoplasmic pattern recognition receptor signaling pathway via inhibition of IRF3 activity; IDA:UniProt.
DR   GO; GO:0039563; P:symbiont-mediated suppression of host JAK-STAT cascade via inhibition of STAT1 activity; IEA:UniProtKB-KW.
DR   GO; GO:0039564; P:symbiont-mediated suppression of host JAK-STAT cascade via inhibition of STAT2 activity; IEA:UniProtKB-KW.
DR   GO; GO:0039502; P:symbiont-mediated suppression of host type I interferon-mediated signaling pathway; IEA:UniProtKB-KW.
DR   GO; GO:0019049; P:virus-mediated perturbation of host defense response; IEA:UniProtKB-KW.
DR   InterPro; IPR022736; NS6_bCoV.
DR   Pfam; PF12133; bCoV_NS6; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Host endoplasmic reticulum; Host Golgi apparatus;
KW   Host membrane; Host-virus interaction;
KW   Inhibition of host innate immune response by virus;
KW   Inhibition of host interferon signaling pathway by virus;
KW   Inhibition of host STAT1 by virus; Inhibition of host STAT2 by virus;
KW   Interferon antiviral system evasion; Membrane; Reference proteome;
KW   Viral immunoevasion; Virulence.
FT   CHAIN           1..61
FT                   /note=""ORF6 protein""
FT                   /id=""PRO_0000449653""
FT   REGION          18..24
FT                   /note=""Important for host Golgi localization""
FT                   /evidence=""ECO:0000269|PubMed:35187564""
FT   VARIANT         2
FT                   /note=""F -> H (in strain: Eta/B.1.525)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         3
FT                   /note=""Missing (in strain: Eta/B.1.525)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         61
FT                   /note=""D -> L (in strain: Omicron/BA.2, Omicron/BA.2.12.1,
FT                   Omicron/BA.2.75, Omicron/BA.4, Omicron/BQ.1.1,
FT                   Omicron/XBB.1.5, Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   MUTAGEN         1..16
FT                   /note=""Missing: Retains interaction with human NUP98-RAE1
FT                   complex. Increases down-regulation of protein expression of
FT                   newly transcribed genes in host cell.""
FT                   /evidence=""ECO:0000269|PubMed:33849972""
FT   MUTAGEN         18..24
FT                   /note=""IMRTFKV->AAAAAAA: Complete loss of Golgi
FT                   localization.""
FT                   /evidence=""ECO:0000269|PubMed:35187564""
FT   MUTAGEN         18..24
FT                   /note=""Missing: Complete loss of Golgi localization.""
FT                   /evidence=""ECO:0000269|PubMed:35187564""
FT   MUTAGEN         22..30
FT                   /note=""Missing: Retains interaction with human NUP98-RAE1
FT                   complex. Increases down-regulation of protein expression of
FT                   newly transcribed genes in host cell.""
FT                   /evidence=""ECO:0000269|PubMed:33849972""
FT   MUTAGEN         38..61
FT                   /note=""Missing: Loss of interaction with human NUP98-RAE1
FT                   complex which suppresses the down-regulation of protein
FT                   expression of newly transcribed genes in the host cell.""
FT                   /evidence=""ECO:0000269|PubMed:33849972""
FT   MUTAGEN         50..61
FT                   /note=""Missing: Loss of interaction with human NUP98-RAE1
FT                   complex which suppresses the down-regulation of protein
FT                   expression of newly transcribed genes in the host cell.""
FT                   /evidence=""ECO:0000269|PubMed:33849972""
FT   MUTAGEN         58
FT                   /note=""M->A: Loss of interaction with human NUP98-RAE1
FT                   complex which suppresses the mRNA accumulation in the
FT                   nucleus, the down-regulation of protein expression of newly
FT                   transcribed genes in the host cell and blockade on nuclear
FT                   import on a broad range of host factors.""
FT                   /evidence=""ECO:0000269|PubMed:33849972,
FT                   ECO:0000269|PubMed:35096974""
FT   MUTAGEN         58
FT                   /note=""M->R: Complete loss of binding to the NUP98-RAE1
FT                   complex and IFN antagonistic function.""
FT                   /evidence=""ECO:0000269|PubMed:33097660,
FT                   ECO:0000269|PubMed:35096974""
FT   MUTAGEN         61
FT                   /note=""D->DYP: Does not affect repression of reporter
FT                   protein expression.""
FT                   /evidence=""ECO:0000269|PubMed:33849972""
SQ   SEQUENCE   61 AA;  7273 MW;  B21BD303F59A1D0A CRC64;
     MFHLVDFQVT IAEILLIIMR TFKVSIWNLD YIINLIIKNL SKSLTENKYS QLDEEQPMEI
     D
//
",13686
CGCCAC GCCACG CCACGG CACGGG ACGGGT CGGGTT GGGTTT GGTTTG GTTTGC TTTGCG TTGCGC TGCGCT GCGCTG CGCTGC GCTGCG CTGCGC TGCGCT GCGCTT CGCTTT GCTTTC CTTTCA TTTCAC TTCACC TCACCA CACCAA ACCAAA CCAAAG CAAAGC AAAGCA AAGCAA AGCAAC GCAACC CAACCA AACCAC ACCACG CCACGA CACGAG ACGAGG CGAGGG GAGGGC AGGGCG GGGCGC GGCGCG GCGCGC CGCGCT GCGCTG CGCTGG GCTGGT CTGGTG TGGTGG GGTGGA GTGGAC TGGACT GGACTG GACTGG ACTGGA CTGGAT TGGATT GGATTC GATTCA ATTCAC TTCACG TCACGA CACGAG ACGAGG CGAGGC GAGGCC AGGCCG GGCCGG GCCGGT CCGGTC CGGTCG GGTCGC GTCGCA TCGCAT CGCATG GCATGC CATGCA ATGCAC TGCACG GCACGC CACGCT ACGCTG CGCTGC GCTGCG CTGCGG TGCGGG GCGGGC CGGGCG GGGCGA GGCGAA GCGAAC CGAACT GAACTG AACTGG ACTGGC CTGGCG TGGCGG GGCGGG GCGGGC CGGGCG GGGCGT GGCGTG GCGTGG CGTGGT GTGGTG TGGTGC GGTGCT GTGCTC TGCTCA GCTCAA CTCAAT TCAATG CAATGC AATGCC ATGCCG TGCCGG GCCGGG CCGGGG CGGGGC GGGGCC GGGCCT GGCCTA GCCTAC CCTACA CTACAC TACACC ACACCC CACCCA ACCCAC CCCACA CCACAC CACACC ACACCA CACCAG ACCAGC CCAGCG CAGCGT AGCGTG GCGTGG CGTGGC GTGGCG,3,142,CGCC GCCA CCAC CACG ACGG CGGG GGGT GGTT GTTT TTTG TTGC TGCG GCGC CGCT GCTG CTGC TGCG GCGC CGCT GCTT CTTT TTTC TTCA TCAC CACC ACCA CCAA CAAA AAAG AAGC AGCA GCAA CAAC AACC ACCA CCAC CACG ACGA CGAG GAGG AGGG GGGC GGCG GCGC CGCG GCGC CGCT GCTG CTGG TGGT GGTG GTGG TGGA GGAC GACT ACTG CTGG TGGA GGAT GATT ATTC TTCA TCAC CACG ACGA CGAG GAGG AGGC GGCC GCCG CCGG CGGT GGTC GTCG TCGC CGCA GCAT CATG ATGC TGCA GCAC CACG ACGC CGCT GCTG CTGC TGCG GCGG CGGG GGGC GGCG GCGA CGAA GAAC AACT ACTG CTGG TGGC GGCG GCGG CGGG GGGC GGCG GCGT CGTG GTGG TGGT GGTG GTGC TGCT GCTC CTCA TCAA CAAT AATG ATGC TGCC GCCG CCGG CGGG GGGG GGGC GGCC GCCT CCTA CTAC TACA ACAC CACC ACCC CCCA CCAC CACA ACAC CACC ACCA CCAG CAGC AGCG GCGT CGTG GTGG TGGC GGCG,CGCCA GCCAC CCACG CACGG ACGGG CGGGT GGGTT GGTTT GTTTG TTTGC TTGCG TGCGC GCGCT CGCTG GCTGC CTGCG TGCGC GCGCT CGCTT GCTTT CTTTC TTTCA TTCAC TCACC CACCA ACCAA CCAAA CAAAG AAAGC AAGCA AGCAA GCAAC CAACC AACCA ACCAC CCACG CACGA ACGAG CGAGG GAGGG AGGGC GGGCG GGCGC GCGCG CGCGC GCGCT CGCTG GCTGG CTGGT TGGTG GGTGG GTGGA TGGAC GGACT GACTG ACTGG CTGGA TGGAT GGATT GATTC ATTCA TTCAC TCACG CACGA ACGAG CGAGG GAGGC AGGCC GGCCG GCCGG CCGGT CGGTC GGTCG GTCGC TCGCA CGCAT GCATG CATGC ATGCA TGCAC GCACG CACGC ACGCT CGCTG GCTGC CTGCG TGCGG GCGGG CGGGC GGGCG GGCGA GCGAA CGAAC GAACT AACTG ACTGG CTGGC TGGCG GGCGG GCGGG CGGGC GGGCG GGCGT GCGTG CGTGG GTGGT TGGTG GGTGC GTGCT TGCTC GCTCA CTCAA TCAAT CAATG AATGC ATGCC TGCCG GCCGG CCGGG CGGGG GGGGC GGGCC GGCCT GCCTA CCTAC CTACA TACAC ACACC CACCC ACCCA CCCAC CCACA CACAC ACACC CACCA ACCAG CCAGC CAGCG AGCGT GCGTG CGTGG GTGGC TGGCG,CGCCAC GCCACG CCACGG CACGGG ACGGGT CGGGTT GGGTTT GGTTTG GTTTGC TTTGCG TTGCGC TGCGCT GCGCTG CGCTGC GCTGCG CTGCGC TGCGCT GCGCTT CGCTTT GCTTTC CTTTCA TTTCAC TTCACC TCACCA CACCAA ACCAAA CCAAAG CAAAGC AAAGCA AAGCAA AGCAAC GCAACC CAACCA AACCAC ACCACG CCACGA CACGAG ACGAGG CGAGGG GAGGGC AGGGCG GGGCGC GGCGCG GCGCGC CGCGCT GCGCTG CGCTGG GCTGGT CTGGTG TGGTGG GGTGGA GTGGAC TGGACT GGACTG GACTGG ACTGGA CTGGAT TGGATT GGATTC GATTCA ATTCAC TTCACG TCACGA CACGAG ACGAGG CGAGGC GAGGCC AGGCCG GGCCGG GCCGGT CCGGTC CGGTCG GGTCGC GTCGCA TCGCAT CGCATG GCATGC CATGCA ATGCAC TGCACG GCACGC CACGCT ACGCTG CGCTGC GCTGCG CTGCGG TGCGGG GCGGGC CGGGCG GGGCGA GGCGAA GCGAAC CGAACT GAACTG AACTGG ACTGGC CTGGCG TGGCGG GGCGGG GCGGGC CGGGCG GGGCGT GGCGTG GCGTGG CGTGGT GTGGTG TGGTGC GGTGCT GTGCTC TGCTCA GCTCAA CTCAAT TCAATG CAATGC AATGCC ATGCCG TGCCGG GCCGGG CCGGGG CGGGGC GGGGCC GGGCCT GGCCTA GCCTAC CCTACA CTACAC TACACC ACACCC CACCCA ACCCAC CCCACA CCACAC CACACC ACACCA CACCAG ACCAGC CCAGCG CAGCGT AGCGTG GCGTGG CGTGGC GTGGCG,CGCCACG GCCACGG CCACGGG CACGGGT ACGGGTT CGGGTTT GGGTTTG GGTTTGC GTTTGCG TTTGCGC TTGCGCT TGCGCTG GCGCTGC CGCTGCG GCTGCGC CTGCGCT TGCGCTT GCGCTTT CGCTTTC GCTTTCA CTTTCAC TTTCACC TTCACCA TCACCAA CACCAAA ACCAAAG CCAAAGC CAAAGCA AAAGCAA AAGCAAC AGCAACC GCAACCA CAACCAC AACCACG ACCACGA CCACGAG CACGAGG ACGAGGG CGAGGGC GAGGGCG AGGGCGC GGGCGCG GGCGCGC GCGCGCT CGCGCTG GCGCTGG CGCTGGT GCTGGTG CTGGTGG TGGTGGA GGTGGAC GTGGACT TGGACTG GGACTGG GACTGGA ACTGGAT CTGGATT TGGATTC GGATTCA GATTCAC ATTCACG TTCACGA TCACGAG CACGAGG ACGAGGC CGAGGCC GAGGCCG AGGCCGG GGCCGGT GCCGGTC CCGGTCG CGGTCGC GGTCGCA GTCGCAT TCGCATG CGCATGC GCATGCA CATGCAC ATGCACG TGCACGC GCACGCT CACGCTG ACGCTGC CGCTGCG GCTGCGG CTGCGGG TGCGGGC GCGGGCG CGGGCGA GGGCGAA GGCGAAC GCGAACT CGAACTG GAACTGG AACTGGC ACTGGCG CTGGCGG TGGCGGG GGCGGGC GCGGGCG CGGGCGT GGGCGTG GGCGTGG GCGTGGT CGTGGTG GTGGTGC TGGTGCT GGTGCTC GTGCTCA TGCTCAA GCTCAAT CTCAATG TCAATGC CAATGCC AATGCCG ATGCCGG TGCCGGG GCCGGGG CCGGGGC CGGGGCC GGGGCCT GGGCCTA GGCCTAC GCCTACA CCTACAC CTACACC TACACCC ACACCCA CACCCAC ACCCACA CCCACAC CCACACC CACACCA ACACCAG CACCAGC ACCAGCG CCAGCGT CAGCGTG AGCGTGG GCGTGGC CGTGGCG,"ID   AROQ_ACISJ              Reviewed;         148 AA.
AC   A1W6C8;
DT   15-JAN-2008, integrated into UniProtKB/Swiss-Prot.
DT   06-FEB-2007, sequence version 1.
DT   27-NOV-2024, entry version 88.
DE   RecName: Full=3-dehydroquinate dehydratase {ECO:0000255|HAMAP-Rule:MF_00169};
DE            Short=3-dehydroquinase {ECO:0000255|HAMAP-Rule:MF_00169};
DE            EC=4.2.1.10 {ECO:0000255|HAMAP-Rule:MF_00169};
DE   AltName: Full=Type II DHQase {ECO:0000255|HAMAP-Rule:MF_00169};
GN   Name=aroQ {ECO:0000255|HAMAP-Rule:MF_00169};
GN   OrderedLocusNames=Ajs_1610;
OS   Acidovorax sp. (strain JS42).
OC   Bacteria; Pseudomonadota; Betaproteobacteria; Burkholderiales;
OC   Comamonadaceae; Acidovorax.
OX   NCBI_TaxID=232721;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=JS42;
RA   Copeland A., Lucas S., Lapidus A., Barry K., Detter J.C.,
RA   Glavina del Rio T., Dalin E., Tice H., Pitluck S., Chertkov O., Brettin T.,
RA   Bruce D., Han C., Tapia R., Gilna P., Schmutz J., Larimer F., Land M.,
RA   Hauser L., Kyrpides N., Kim E., Stahl D., Richardson P.;
RT   ""Complete sequence of chromosome 1 of Acidovorax sp. JS42."";
RL   Submitted (DEC-2006) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Catalyzes a trans-dehydration via an enolate intermediate.
CC       {ECO:0000255|HAMAP-Rule:MF_00169}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3-dehydroquinate = 3-dehydroshikimate + H2O;
CC         Xref=Rhea:RHEA:21096, ChEBI:CHEBI:15377, ChEBI:CHEBI:16630,
CC         ChEBI:CHEBI:32364; EC=4.2.1.10; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_00169};
CC   -!- PATHWAY: Metabolic intermediate biosynthesis; chorismate biosynthesis;
CC       chorismate from D-erythrose 4-phosphate and phosphoenolpyruvate: step
CC       3/7. {ECO:0000255|HAMAP-Rule:MF_00169}.
CC   -!- SUBUNIT: Homododecamer. {ECO:0000255|HAMAP-Rule:MF_00169}.
CC   -!- SIMILARITY: Belongs to the type-II 3-dehydroquinase family.
CC       {ECO:0000255|HAMAP-Rule:MF_00169}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP000539; ABM41803.1; -; Genomic_DNA.
DR   AlphaFoldDB; A1W6C8; -.
DR   SMR; A1W6C8; -.
DR   STRING; 232721.Ajs_1610; -.
DR   KEGG; ajs:Ajs_1610; -.
DR   eggNOG; COG0757; Bacteria.
DR   HOGENOM; CLU_090968_2_0_4; -.
DR   UniPathway; UPA00053; UER00086.
DR   Proteomes; UP000000645; Chromosome.
DR   GO; GO:0003855; F:3-dehydroquinate dehydratase activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0008652; P:amino acid biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0009073; P:aromatic amino acid family biosynthetic process; IEA:UniProtKB-KW.
DR   GO; GO:0009423; P:chorismate biosynthetic process; IEA:UniProtKB-UniRule.
DR   GO; GO:0019631; P:quinate catabolic process; IEA:TreeGrafter.
DR   CDD; cd00466; DHQase_II; 1.
DR   Gene3D; 3.40.50.9100; Dehydroquinase, class II; 1.
DR   HAMAP; MF_00169; AroQ; 1.
DR   InterPro; IPR001874; DHquinase_II.
DR   InterPro; IPR018509; DHquinase_II_CS.
DR   InterPro; IPR036441; DHquinase_II_sf.
DR   NCBIfam; TIGR01088; aroQ; 1.
DR   PANTHER; PTHR21272; CATABOLIC 3-DEHYDROQUINASE; 1.
DR   PANTHER; PTHR21272:SF3; CATABOLIC 3-DEHYDROQUINASE; 1.
DR   Pfam; PF01220; DHquinase_II; 1.
DR   PIRSF; PIRSF001399; DHquinase_II; 1.
DR   SUPFAM; SSF52304; Type II 3-dehydroquinate dehydratase; 1.
DR   PROSITE; PS01029; DEHYDROQUINASE_II; 1.
PE   3: Inferred from homology;
KW   Amino-acid biosynthesis; Aromatic amino acid biosynthesis; Lyase.
FT   CHAIN           1..148
FT                   /note=""3-dehydroquinate dehydratase""
FT                   /id=""PRO_1000023445""
FT   ACT_SITE        24
FT                   /note=""Proton acceptor""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00169""
FT   ACT_SITE        106
FT                   /note=""Proton donor""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00169""
FT   BINDING         80
FT                   /ligand=""substrate""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00169""
FT   BINDING         86
FT                   /ligand=""substrate""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00169""
FT   BINDING         93
FT                   /ligand=""substrate""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00169""
FT   BINDING         107..108
FT                   /ligand=""substrate""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00169""
FT   BINDING         117
FT                   /ligand=""substrate""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00169""
FT   SITE            19
FT                   /note=""Transition state stabilizer""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00169""
SQ   SEQUENCE   148 AA;  15696 MW;  614F5324D4F8418C CRC64;
     MTKTVYVLNG PNLNLLGTRE PQVYGSQTLA DVEQLCTAAC ARHGLALVFR QSNHEGALVD
     WIHEAGRLHA AGQLAGVVLN AAAYTHTSVA LLDAVKGTGV PVVELHISNV HARESFRHHS
     YLAGAARAVM CGFGVQGYAL AIDGLAQW
//
",33390
TTAAGA TAAGAT AAGATA AGATAT GATATG ATATGA TATGAT ATGATG TGATGC GATGCA ATGCAA TGCAAG GCAAGT CAAGTA AAGTAT AGTATT GTATTA TATTAG ATTAGA TTAGAC TAGACC AGACCA GACCAG ACCAGG CCAGGT CAGGTT AGGTTT GGTTTT GTTTTC TTTTCA TTTCAA TTCAAG TCAAGA CAAGAA AAGAAT AGAATC GAATCA AATCAT ATCATT TCATTT CATTTT ATTTTC TTTTCT TTTCTT TTCTTC TCTTCA CTTCAA TTCAAT TCAATG CAATGT AATGTT ATGTTC TGTTCC GTTCCC TTCCCC TCCCCT CCCCTT CCCTTC CCTTCC CTTCCC TTCCCA TCCCAC CCCACG CCACGA CACGAC ACGACA CGACAA GACAAA ACAAAG CAAAGT AAAGTA AAGTAG AGTAGT GTAGTG TAGTGT AGTGTT GTGTTA TGTTAC GTTACG TTACGT TACGTC ACGTCA CGTCAA GTCAAT TCAATG CAATGG AATGGC ATGGCA TGGCAT GGCATC GCATCA CATCAA ATCAAA TCAAAT CAAATG AAATGA AATGAA ATGAAG TGAAGA GAAGAA AAGAAG AGAAGA GAAGAT AAGATA AGATAT GATATT ATATTA TATTAA ATTAAA TTAAAA TAAAAC AAAACT AAACTA AACTAT ACTATT CTATTA TATTAA ATTAAA TTAAAA TAAAAA AAAAAT AAAATG AAATGA AATGAT ATGATG TGATGT GATGTT ATGTTT TGTTTT GTTTTA TTTTAA TTTAAT TTAATT TAATTA AATTAT ATTATT TTATTC TATTCA ATTCAT TTCATG TCATGG CATGGA ATGGAA TGGAAG GGAAGA,3,145,TTAA TAAG AAGA AGAT GATA ATAT TATG ATGA TGAT GATG ATGC TGCA GCAA CAAG AAGT AGTA GTAT TATT ATTA TTAG TAGA AGAC GACC ACCA CCAG CAGG AGGT GGTT GTTT TTTT TTTC TTCA TCAA CAAG AAGA AGAA GAAT AATC ATCA TCAT CATT ATTT TTTT TTTC TTCT TCTT CTTC TTCA TCAA CAAT AATG ATGT TGTT GTTC TTCC TCCC CCCC CCCT CCTT CTTC TTCC TCCC CCCA CCAC CACG ACGA CGAC GACA ACAA CAAA AAAG AAGT AGTA GTAG TAGT AGTG GTGT TGTT GTTA TTAC TACG ACGT CGTC GTCA TCAA CAAT AATG ATGG TGGC GGCA GCAT CATC ATCA TCAA CAAA AAAT AATG ATGA TGAA GAAG AAGA AGAA GAAG AAGA AGAT GATA ATAT TATT ATTA TTAA TAAA AAAA AAAC AACT ACTA CTAT TATT ATTA TTAA TAAA AAAA AAAA AAAT AATG ATGA TGAT GATG ATGT TGTT GTTT TTTT TTTA TTAA TAAT AATT ATTA TTAT TATT ATTC TTCA TCAT CATG ATGG TGGA GGAA GAAG AAGA,TTAAG TAAGA AAGAT AGATA GATAT ATATG TATGA ATGAT TGATG GATGC ATGCA TGCAA GCAAG CAAGT AAGTA AGTAT GTATT TATTA ATTAG TTAGA TAGAC AGACC GACCA ACCAG CCAGG CAGGT AGGTT GGTTT GTTTT TTTTC TTTCA TTCAA TCAAG CAAGA AAGAA AGAAT GAATC AATCA ATCAT TCATT CATTT ATTTT TTTTC TTTCT TTCTT TCTTC CTTCA TTCAA TCAAT CAATG AATGT ATGTT TGTTC GTTCC TTCCC TCCCC CCCCT CCCTT CCTTC CTTCC TTCCC TCCCA CCCAC CCACG CACGA ACGAC CGACA GACAA ACAAA CAAAG AAAGT AAGTA AGTAG GTAGT TAGTG AGTGT GTGTT TGTTA GTTAC TTACG TACGT ACGTC CGTCA GTCAA TCAAT CAATG AATGG ATGGC TGGCA GGCAT GCATC CATCA ATCAA TCAAA CAAAT AAATG AATGA ATGAA TGAAG GAAGA AAGAA AGAAG GAAGA AAGAT AGATA GATAT ATATT TATTA ATTAA TTAAA TAAAA AAAAC AAACT AACTA ACTAT CTATT TATTA ATTAA TTAAA TAAAA AAAAA AAAAT AAATG AATGA ATGAT TGATG GATGT ATGTT TGTTT GTTTT TTTTA TTTAA TTAAT TAATT AATTA ATTAT TTATT TATTC ATTCA TTCAT TCATG CATGG ATGGA TGGAA GGAAG GAAGA,TTAAGA TAAGAT AAGATA AGATAT GATATG ATATGA TATGAT ATGATG TGATGC GATGCA ATGCAA TGCAAG GCAAGT CAAGTA AAGTAT AGTATT GTATTA TATTAG ATTAGA TTAGAC TAGACC AGACCA GACCAG ACCAGG CCAGGT CAGGTT AGGTTT GGTTTT GTTTTC TTTTCA TTTCAA TTCAAG TCAAGA CAAGAA AAGAAT AGAATC GAATCA AATCAT ATCATT TCATTT CATTTT ATTTTC TTTTCT TTTCTT TTCTTC TCTTCA CTTCAA TTCAAT TCAATG CAATGT AATGTT ATGTTC TGTTCC GTTCCC TTCCCC TCCCCT CCCCTT CCCTTC CCTTCC CTTCCC TTCCCA TCCCAC CCCACG CCACGA CACGAC ACGACA CGACAA GACAAA ACAAAG CAAAGT AAAGTA AAGTAG AGTAGT GTAGTG TAGTGT AGTGTT GTGTTA TGTTAC GTTACG TTACGT TACGTC ACGTCA CGTCAA GTCAAT TCAATG CAATGG AATGGC ATGGCA TGGCAT GGCATC GCATCA CATCAA ATCAAA TCAAAT CAAATG AAATGA AATGAA ATGAAG TGAAGA GAAGAA AAGAAG AGAAGA GAAGAT AAGATA AGATAT GATATT ATATTA TATTAA ATTAAA TTAAAA TAAAAC AAAACT AAACTA AACTAT ACTATT CTATTA TATTAA ATTAAA TTAAAA TAAAAA AAAAAT AAAATG AAATGA AATGAT ATGATG TGATGT GATGTT ATGTTT TGTTTT GTTTTA TTTTAA TTTAAT TTAATT TAATTA AATTAT ATTATT TTATTC TATTCA ATTCAT TTCATG TCATGG CATGGA ATGGAA TGGAAG GGAAGA,TTAAGAT TAAGATA AAGATAT AGATATG GATATGA ATATGAT TATGATG ATGATGC TGATGCA GATGCAA ATGCAAG TGCAAGT GCAAGTA CAAGTAT AAGTATT AGTATTA GTATTAG TATTAGA ATTAGAC TTAGACC TAGACCA AGACCAG GACCAGG ACCAGGT CCAGGTT CAGGTTT AGGTTTT GGTTTTC GTTTTCA TTTTCAA TTTCAAG TTCAAGA TCAAGAA CAAGAAT AAGAATC AGAATCA GAATCAT AATCATT ATCATTT TCATTTT CATTTTC ATTTTCT TTTTCTT TTTCTTC TTCTTCA TCTTCAA CTTCAAT TTCAATG TCAATGT CAATGTT AATGTTC ATGTTCC TGTTCCC GTTCCCC TTCCCCT TCCCCTT CCCCTTC CCCTTCC CCTTCCC CTTCCCA TTCCCAC TCCCACG CCCACGA CCACGAC CACGACA ACGACAA CGACAAA GACAAAG ACAAAGT CAAAGTA AAAGTAG AAGTAGT AGTAGTG GTAGTGT TAGTGTT AGTGTTA GTGTTAC TGTTACG GTTACGT TTACGTC TACGTCA ACGTCAA CGTCAAT GTCAATG TCAATGG CAATGGC AATGGCA ATGGCAT TGGCATC GGCATCA GCATCAA CATCAAA ATCAAAT TCAAATG CAAATGA AAATGAA AATGAAG ATGAAGA TGAAGAA GAAGAAG AAGAAGA AGAAGAT GAAGATA AAGATAT AGATATT GATATTA ATATTAA TATTAAA ATTAAAA TTAAAAC TAAAACT AAAACTA AAACTAT AACTATT ACTATTA CTATTAA TATTAAA ATTAAAA TTAAAAA TAAAAAT AAAAATG AAAATGA AAATGAT AATGATG ATGATGT TGATGTT GATGTTT ATGTTTT TGTTTTA GTTTTAA TTTTAAT TTTAATT TTAATTA TAATTAT AATTATT ATTATTC TTATTCA TATTCAT ATTCATG TTCATGG TCATGGA CATGGAA ATGGAAG TGGAAGA,"ID   XYLF_PSEPU              Reviewed;         281 AA.
AC   P23106;
DT   01-NOV-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1991, sequence version 1.
DT   05-FEB-2025, entry version 102.
DE   RecName: Full=2-hydroxymuconate semialdehyde hydrolase;
DE            Short=HMSH;
DE            EC=3.7.1.9;
DE   AltName: Full=2-hydroxymuconic semialdehyde hydrolase;
GN   Name=xylF;
OS   Pseudomonas putida (Arthrobacter siderocapsulatus).
OG   Plasmid TOL pWW0.
OC   Bacteria; Pseudomonadota; Gammaproteobacteria; Pseudomonadales;
OC   Pseudomonadaceae; Pseudomonas.
OX   NCBI_TaxID=303;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND PROTEIN SEQUENCE OF 1-23.
RX   PubMed=1791759; DOI=10.1111/j.1365-2958.1991.tb02091.x;
RA   Horn J.M., Harayama S., Timmis K.N.;
RT   ""DNA sequence determination of the TOL plasmid (pWWO) xylGFJ genes of
RT   Pseudomonas putida: implications for the evolution of aromatic
RT   catabolism."";
RL   Mol. Microbiol. 5:2459-2474(1991).
RN   [2]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   DOI=10.1099/00221287-132-3-717;
RA   Duggleby C.J., Williams P.A.;
RT   ""Purification and some properties of the 2-hydroxy-6-oxohepta-2,4-dienoate
RT   hydrolase (2-hydroxymuconic semialdehyde hydrolase) encoded by the TOL
RT   plasmid pWW0 from Pseudomonas putida mt-2."";
RL   J. Gen. Microbiol. 132:2459-2474(1991).
CC   -!- FUNCTION: Catalyzes the conversion of 2-hydroxymuconate semialdehyde to
CC       2-hydroxypent-2,4-dienoate. {ECO:0000269|Ref.2}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(2Z,4E)-2-hydroxy-6-oxohexa-2,4-dienoate + H2O = 2-oxopent-4-
CC         enoate + formate + H(+); Xref=Rhea:RHEA:14549, ChEBI:CHEBI:11641,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15740,
CC         ChEBI:CHEBI:71198; EC=3.7.1.9; Evidence={ECO:0000269|Ref.2};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=30 uM for catechol {ECO:0000269|Ref.2};
CC         KM=36 uM for 3-methylcatechol {ECO:0000269|Ref.2};
CC         KM=10 uM for 4-methylcatechol {ECO:0000269|Ref.2};
CC         KM=15 uM for 3-ethylcatechol {ECO:0000269|Ref.2};
CC         KM=22 uM for 4-ethylcatechol {ECO:0000269|Ref.2};
CC         KM=5 uM for 3-propylcatechol {ECO:0000269|Ref.2};
CC         KM=23 uM for 4-propylcatechol {ECO:0000269|Ref.2};
CC         KM=37 uM for 3-allylcatechol {ECO:0000269|Ref.2};
CC       pH dependence:
CC         Optimum pH is 7-7.5. {ECO:0000269|Ref.2};
CC   -!- PATHWAY: Aromatic compound metabolism; benzoate degradation via
CC       hydroxylation.
CC   -!- SIMILARITY: Belongs to the DmpD/TodF/XylF esterase family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M64747; AAA26054.1; -; Genomic_DNA.
DR   PIR; S18245; S18245.
DR   RefSeq; NP_542864.1; NC_003350.1.
DR   RefSeq; WP_011005907.1; NC_003350.1.
DR   AlphaFoldDB; P23106; -.
DR   SMR; P23106; -.
DR   ESTHER; psepu-XYLF; Carbon-carbon_bond_hydrolase.
DR   BioCyc; MetaCyc:MONOMER-12763; -.
DR   SABIO-RK; P23106; -.
DR   UniPathway; UPA00156; -.
DR   GO; GO:0016020; C:membrane; IEA:TreeGrafter.
DR   GO; GO:0018775; F:2-hydroxymuconate-semialdehyde hydrolase activity; IEA:UniProtKB-EC.
DR   GO; GO:0052689; F:carboxylic ester hydrolase activity; IEA:UniProtKB-KW.
DR   GO; GO:0043640; P:benzoate catabolic process via hydroxylation; IEA:UniProtKB-UniPathway.
DR   Gene3D; 3.40.50.1820; alpha/beta hydrolase; 1.
DR   InterPro; IPR000073; AB_hydrolase_1.
DR   InterPro; IPR029058; AB_hydrolase_fold.
DR   InterPro; IPR050266; AB_hydrolase_sf.
DR   PANTHER; PTHR43798:SF31; AB HYDROLASE SUPERFAMILY PROTEIN YCLE; 1.
DR   PANTHER; PTHR43798; MONOACYLGLYCEROL LIPASE; 1.
DR   Pfam; PF00561; Abhydrolase_1; 1.
DR   PRINTS; PR00111; ABHYDROLASE.
DR   SUPFAM; SSF53474; alpha/beta-Hydrolases; 1.
PE   1: Evidence at protein level;
KW   Aromatic hydrocarbons catabolism; Direct protein sequencing; Hydrolase;
KW   Plasmid; Serine esterase.
FT   CHAIN           1..281
FT                   /note=""2-hydroxymuconate semialdehyde hydrolase""
FT                   /id=""PRO_0000207058""
FT   DOMAIN          31..261
FT                   /note=""AB hydrolase-1""
FT                   /evidence=""ECO:0000255""
FT   REGION          30..55
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   ACT_SITE        106
FT                   /evidence=""ECO:0000250""
FT   ACT_SITE        227
FT                   /evidence=""ECO:0000250""
FT   ACT_SITE        255
FT                   /evidence=""ECO:0000250""
SQ   SEQUENCE   281 AA;  30598 MW;  ED8D215E6DD47DF5 CRC64;
     MNAPQQSPEI GREILAAGYR TNLHDQGEGF PALLIHGSGP ASPPGPTGAG SFRSSQTRRV
     IAPDMLGFGY SERPADGKYS QARWVEHAIG VLDALGIQQG DIVGNSFGGG LALALAIRHP
     ERVRRLVLMG SVGVSFPITA GLETAWGYTP SLANMRRLLD LFAHDRTLVN DELAELRYQA
     SIRPGFQESF AAMFPPPRQN GVDDLASNET DIRALPNETL VIHGREDRII PLQASLTLAQ
     WIPNAQLHVF GQCGHWTQIE HAERFARLVE NFLAEADALH S
//
",40971
TCTCCT CTCCTG TCCTGC CCTGCT CTGCTA TGCTAG GCTAGA CTAGAA TAGAAT AGAATG GAATGG AATGGC ATGGCT TGGCTG GGCTGG GCTGGC CTGGCA TGGCAA GGCAAT GCAATG CAATGG AATGGC ATGGCG TGGCGG GGCGGT GCGGTG CGGTGA GGTGAT GTGATG TGATGC GATGCC ATGCCG TGCCGC GCCGCC CCGCCC CGCCCT GCCCTT CCCTTT CCTTTC CTTTCT TTTCTT TTCTTT TCTTTG CTTTGC TTTGCT TTGCTG TGCTGC GCTGCT CTGCTG TGCTGC GCTGCT CTGCTT TGCTTG GCTTGA CTTGAC TTGACA TGACAG GACAGG ACAGGC CAGGCT AGGCTG GGCTGA GCTGAA CTGAAC TGAACC GAACCA AACCAG ACCAGC CCAGCC CAGCCT AGCCTG GCCTGA CCTGAG CTGAGA TGAGAG GAGAGG AGAGGA GAGGAA AGGAAA GGAAAA GAAAAT AAAATG AAATGT AATGTC ATGTCT TGTCTG GTCTGG TCTGGG CTGGGA TGGGAA GGGAAA GGAAAG GAAAGG AAAGGC AAGGCC AGGCCA GGCCAA GCCAAC CCAACA CAACAA AACAAC ACAACA CAACAA AACAAC ACAACA CAACAA AACAAA ACAAAG CAAAGC AAAGCC AAGCCC AGCCCA,1,112,TCTC CTCC TCCT CCTG CTGC TGCT GCTA CTAG TAGA AGAA GAAT AATG ATGG TGGC GGCT GCTG CTGG TGGC GGCA GCAA CAAT AATG ATGG TGGC GGCG GCGG CGGT GGTG GTGA TGAT GATG ATGC TGCC GCCG CCGC CGCC GCCC CCCT CCTT CTTT TTTC TTCT TCTT CTTT TTTG TTGC TGCT GCTG CTGC TGCT GCTG CTGC TGCT GCTT CTTG TTGA TGAC GACA ACAG CAGG AGGC GGCT GCTG CTGA TGAA GAAC AACC ACCA CCAG CAGC AGCC GCCT CCTG CTGA TGAG GAGA AGAG GAGG AGGA GGAA GAAA AAAA AAAT AATG ATGT TGTC GTCT TCTG CTGG TGGG GGGA GGAA GAAA AAAG AAGG AGGC GGCC GCCA CCAA CAAC AACA ACAA CAAC AACA ACAA CAAC AACA ACAA CAAA AAAG AAGC AGCC GCCC CCCA,TCTCC CTCCT TCCTG CCTGC CTGCT TGCTA GCTAG CTAGA TAGAA AGAAT GAATG AATGG ATGGC TGGCT GGCTG GCTGG CTGGC TGGCA GGCAA GCAAT CAATG AATGG ATGGC TGGCG GGCGG GCGGT CGGTG GGTGA GTGAT TGATG GATGC ATGCC TGCCG GCCGC CCGCC CGCCC GCCCT CCCTT CCTTT CTTTC TTTCT TTCTT TCTTT CTTTG TTTGC TTGCT TGCTG GCTGC CTGCT TGCTG GCTGC CTGCT TGCTT GCTTG CTTGA TTGAC TGACA GACAG ACAGG CAGGC AGGCT GGCTG GCTGA CTGAA TGAAC GAACC AACCA ACCAG CCAGC CAGCC AGCCT GCCTG CCTGA CTGAG TGAGA GAGAG AGAGG GAGGA AGGAA GGAAA GAAAA AAAAT AAATG AATGT ATGTC TGTCT GTCTG TCTGG CTGGG TGGGA GGGAA GGAAA GAAAG AAAGG AAGGC AGGCC GGCCA GCCAA CCAAC CAACA AACAA ACAAC CAACA AACAA ACAAC CAACA AACAA ACAAA CAAAG AAAGC AAGCC AGCCC GCCCA,TCTCCT CTCCTG TCCTGC CCTGCT CTGCTA TGCTAG GCTAGA CTAGAA TAGAAT AGAATG GAATGG AATGGC ATGGCT TGGCTG GGCTGG GCTGGC CTGGCA TGGCAA GGCAAT GCAATG CAATGG AATGGC ATGGCG TGGCGG GGCGGT GCGGTG CGGTGA GGTGAT GTGATG TGATGC GATGCC ATGCCG TGCCGC GCCGCC CCGCCC CGCCCT GCCCTT CCCTTT CCTTTC CTTTCT TTTCTT TTCTTT TCTTTG CTTTGC TTTGCT TTGCTG TGCTGC GCTGCT CTGCTG TGCTGC GCTGCT CTGCTT TGCTTG GCTTGA CTTGAC TTGACA TGACAG GACAGG ACAGGC CAGGCT AGGCTG GGCTGA GCTGAA CTGAAC TGAACC GAACCA AACCAG ACCAGC CCAGCC CAGCCT AGCCTG GCCTGA CCTGAG CTGAGA TGAGAG GAGAGG AGAGGA GAGGAA AGGAAA GGAAAA GAAAAT AAAATG AAATGT AATGTC ATGTCT TGTCTG GTCTGG TCTGGG CTGGGA TGGGAA GGGAAA GGAAAG GAAAGG AAAGGC AAGGCC AGGCCA GGCCAA GCCAAC CCAACA CAACAA AACAAC ACAACA CAACAA AACAAC ACAACA CAACAA AACAAA ACAAAG CAAAGC AAAGCC AAGCCC AGCCCA,TCTCCTG CTCCTGC TCCTGCT CCTGCTA CTGCTAG TGCTAGA GCTAGAA CTAGAAT TAGAATG AGAATGG GAATGGC AATGGCT ATGGCTG TGGCTGG GGCTGGC GCTGGCA CTGGCAA TGGCAAT GGCAATG GCAATGG CAATGGC AATGGCG ATGGCGG TGGCGGT GGCGGTG GCGGTGA CGGTGAT GGTGATG GTGATGC TGATGCC GATGCCG ATGCCGC TGCCGCC GCCGCCC CCGCCCT CGCCCTT GCCCTTT CCCTTTC CCTTTCT CTTTCTT TTTCTTT TTCTTTG TCTTTGC CTTTGCT TTTGCTG TTGCTGC TGCTGCT GCTGCTG CTGCTGC TGCTGCT GCTGCTT CTGCTTG TGCTTGA GCTTGAC CTTGACA TTGACAG TGACAGG GACAGGC ACAGGCT CAGGCTG AGGCTGA GGCTGAA GCTGAAC CTGAACC TGAACCA GAACCAG AACCAGC ACCAGCC CCAGCCT CAGCCTG AGCCTGA GCCTGAG CCTGAGA CTGAGAG TGAGAGG GAGAGGA AGAGGAA GAGGAAA AGGAAAA GGAAAAT GAAAATG AAAATGT AAATGTC AATGTCT ATGTCTG TGTCTGG GTCTGGG TCTGGGA CTGGGAA TGGGAAA GGGAAAG GGAAAGG GAAAGGC AAAGGCC AAGGCCA AGGCCAA GGCCAAC GCCAACA CCAACAA CAACAAC AACAACA ACAACAA CAACAAC AACAACA ACAACAA CAACAAA AACAAAG ACAAAGC CAAAGCC AAAGCCC AAGCCCA,"ID   NCAP_SARS2              Reviewed;         419 AA.
AC   P0DTC9;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Nucleoprotein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=N;
DE   AltName: Full=Nucleocapsid protein {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=NC {ECO:0000255|HAMAP-Rule:MF_04096};
DE            Short=Protein N {ECO:0000255|HAMAP-Rule:MF_04096};
GN   Name=N {ECO:0000255|HAMAP-Rule:MF_04096};
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   SUBCELLULAR LOCATION.
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [3] {ECO:0007744|PDB:6WZO, ECO:0007744|PDB:6WZQ}
RP   X-RAY CRYSTALLOGRAPHY (1.42 ANGSTROMS) OF 247-364, AND SUBUNIT.
RX   PubMed=32654247; DOI=10.1002/pro.3909;
RA   Ye Q., West A.M.V., Silletti S., Corbett K.D.;
RT   ""Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein."";
RL   Protein Sci. 29:1890-1901(2020).
RN   [4]
RP   REVIEW.
RX   PubMed=32974389; DOI=10.3389/fmolb.2020.00219;
RA   Nikolakaki E., Giannakouros T.;
RT   ""SR/RS Motifs as Critical Determinants of Coronavirus Life Cycle."";
RL   Front. Mol. Biosci. 7:219-219(2020).
RN   [5]
RP   VARIANTS LEU-3 AND PHE-235.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [6]
RP   FUNCTION, INTERACTION WITH HOST NLRP3, AND SUBCELLULAR LOCATION.
RX   PubMed=34341353; DOI=10.1038/s41467-021-25015-6;
RA   Pan P., Shen M., Yu Z., Ge W., Chen K., Tian M., Xiao F., Wang Z., Wang J.,
RA   Jia Y., Wang W., Wan P., Zhang J., Chen W., Lei Z., Chen X., Luo Z.,
RA   Zhang Q., Xu M., Li G., Li Y., Wu J.;
RT   ""SARS-CoV-2 N protein promotes NLRP3 inflammasome activation to induce
RT   hyperinflammation."";
RL   Nat. Commun. 12:4664-4664(2021).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 41-174, AND MUTAGENESIS OF
RP   TYR-109.
RX   PubMed=32363136; DOI=10.1016/j.apsb.2020.04.009;
RA   Kang S., Yang M., Hong Z., Zhang L., Huang Z., Chen X., He S., Zhou Z.,
RA   Zhou Z., Chen Q., Yan Y., Zhang C., Shan H., Chen S.;
RT   ""Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain
RT   reveals potential unique drug targeting sites."";
RL   Acta Pharmacol. Sin. 10:1228-1238(2020).
RN   [8] {ECO:0007744|PDB:6YI3, ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT}
RP   STRUCTURE BY NMR OF 44-180, FUNCTION, AND MUTAGENESIS OF ARG-68; ARG-92;
RP   ILE-94; ARG-107; GLN-163; TYR-172 AND GLU-174.
RX   PubMed=33264373; DOI=10.1371/journal.ppat.1009100;
RA   Dinesh D.C., Chalupska D., Silhan J., Koutna E., Nencka R., Veverka V.,
RA   Boura E.;
RT   ""Structural basis of RNA recognition by the SARS-CoV-2 nucleocapsid
RT   phosphoprotein."";
RL   PLoS Pathog. 16:1-16(2020).
RN   [9]
RP   MUTAGENESIS OF SER-188 AND SER-206, AND PHOSPHORYLATION AT SER-206.
RX   PubMed=34593624; DOI=10.1073/pnas.2113401118;
RA   Liu X., Verma A., Garcia G. Jr., Ramage H., Lucas A., Myers R.L.,
RA   Michaelson J.J., Coryell W., Kumar A., Charney A.W., Kazanietz M.G.,
RA   Rader D.J., Ritchie M.D., Berrettini W.H., Schultz D.C., Cherry S.,
RA   Damoiseaux R., Arumugaswami V., Klein P.S.;
RT   ""Targeting the coronavirus nucleocapsid protein through GSK-3 inhibition."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:1-9(2021).
RN   [10]
RP   CLEAVAGE.
RX   PubMed=35922005; DOI=10.1038/s41586-022-05148-4;
RA   Chu H., Hou Y., Yang D., Wen L., Shuai H., Yoon C., Shi J., Chai Y.,
RA   Yuen T.T., Hu B., Li C., Zhao X., Wang Y., Huang X., Lee K.S., Luo C.,
RA   Cai J.P., Poon V.K., Chan C.C., Zhang A.J., Yuan S., Sit K.Y., Foo D.C.,
RA   Au W.K., Wong K.K., Zhou J., Kok K.H., Jin D.Y., Chan J.F., Yuen K.Y.;
RT   ""Coronaviruses exploit a host cysteine-aspartic protease for replication."";
RL   Nature 0:0-0(2022).
RN   [11]
RP   MUTAGENESIS OF 203-ARG-GLY-204 AND ARG-203, AND PHOSPHORYLATION.
RX   PubMed=35728038; DOI=10.1371/journal.ppat.1010627;
RA   Johnson B.A., Zhou Y., Lokugamage K.G., Vu M.N., Bopp N.,
RA   Crocquet-Valdes P.A., Kalveram B., Schindewolf C., Liu Y., Scharton D.,
RA   Plante J.A., Xie X., Aguilar P., Weaver S.C., Shi P.Y., Walker D.H.,
RA   Routh A.L., Plante K.S., Menachery V.D.;
RT   ""Nucleocapsid mutations in SARS-CoV-2 augment replication and
RT   pathogenesis."";
RL   PLoS Pathog. 18:e1010627-e1010627(2022).
RN   [12]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=35921414; DOI=10.1126/sciadv.abp9770;
RA   Lopez-Munoz A.D., Kosik I., Holly J., Yewdell J.W.;
RT   ""Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive
RT   immunity."";
RL   Sci. Adv. 8:eabp9770-eabp9770(2022).
RN   [13]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=34901782; DOI=10.1016/j.isci.2021.103562;
RA   Nabeel-Shah S., Lee H., Ahmed N., Burke G.L., Farhangmehr S., Ashraf K.,
RA   Pu S., Braunschweig U., Zhong G., Wei H., Tang H., Yang J., Marcon E.,
RA   Blencowe B.J., Zhang Z., Greenblatt J.F.;
RT   ""SARS-CoV-2 nucleocapsid protein binds host mRNAs and attenuates stress
RT   granules to impair host stress response."";
RL   IScience 25:103562-103562(2022).
RN   [14]
RP   FUNCTION.
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [15] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 191-263, AND INTERACTION WITH NSP3.
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
CC   -!- FUNCTION: Packages the positive strand viral genome RNA into a helical
CC       ribonucleocapsid (RNP) and plays a fundamental role during virion
CC       assembly through its interactions with the viral genome and membrane
CC       protein M (PubMed:33264373). Plays an important role in enhancing the
CC       efficiency of subgenomic viral RNA transcription as well as viral
CC       replication. Attenuates the stress granules formation by reducing host
CC       G3BP1 access to host mRNAs under stress conditions (PubMed:34901782,
CC       PubMed:36534661). {ECO:0000269|PubMed:32974389,
CC       ECO:0000269|PubMed:33264373, ECO:0000269|PubMed:34901782,
CC       ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: May block host chemokine function in vivo, facilitating viral
CC       replication and transmission (PubMed:35921414). Acts by being secreted
CC       into the extracellular space where it competes to host chemokines for
CC       binding to host glycosaminoglycans (GAG) (PubMed:35921414).
CC       {ECO:0000269|PubMed:35921414}.
CC   -!- FUNCTION: May induce inflammasome responses in cultured cells and mice.
CC       Acts by interacting with host NLRP3 to facilitate inflammasome
CC       assembly, which induces cytokine release that may play a role in COVID
CC       lung injury. {ECO:0000269|PubMed:34341353}.
CC   -!- SUBUNIT: Homodimer, homotetramer, homooligomer with RNA
CC       (PubMed:32654247). Both monomeric and oligomeric forms interact with
CC       RNA. Interacts with protein M (By similarity). Interacts with protein E
CC       (By similarity). Interacts with NSP3; this interaction serves to tether
CC       the genome to the newly translated replicase-transcriptase complex at a
CC       very early stage of infection (PubMed:35044811). May interact with host
CC       NLRP3 (PubMed:34341353). {ECO:0000250|UniProtKB:P59595,
CC       ECO:0000255|HAMAP-Rule:MF_04096, ECO:0000269|PubMed:32654247,
CC       ECO:0000269|PubMed:34341353, ECO:0000269|PubMed:35044811}.
CC   -!- INTERACTION:
CC       P0DTC9; P0DTC4: E; NbExp=3; IntAct=EBI-25475856, EBI-25475850;
CC       P0DTC9; P0DTC5: M; NbExp=6; IntAct=EBI-25475856, EBI-25475853;
CC       P0DTC9; P0DTC9: N; NbExp=105; IntAct=EBI-25475856, EBI-25475856;
CC       P0DTC9; PRO_0000449621 [P0DTD1]: rep; NbExp=15; IntAct=EBI-25475856, EBI-25492388;
CC       P0DTC9; P78563: ADARB1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-2967304;
CC       P0DTC9; O15145: ARPC3; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-351829;
CC       P0DTC9; Q13895: BYSL; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-358049;
CC       P0DTC9; Q16543: CDC37; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-295634;
CC       P0DTC9; Q92793: CREBBP; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-81215;
CC       P0DTC9; Q92499: DDX1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-358474;
CC       P0DTC9; Q9NR30: DDX21; Xeno; NbExp=12; IntAct=EBI-25475856, EBI-357942;
CC       P0DTC9; P26196: DDX6; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-351257;
CC       P0DTC9; Q08426: EHHADH; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-2339219;
CC       P0DTC9; P19525: EIF2AK2; Xeno; NbExp=8; IntAct=EBI-25475856, EBI-640775;
CC       P0DTC9; Q14241: ELOA; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-742350;
CC       P0DTC9; Q13283: G3BP1; Xeno; NbExp=71; IntAct=EBI-25475856, EBI-1047359;
CC       P0DTC9; Q9UN86: G3BP2; Xeno; NbExp=37; IntAct=EBI-25475856, EBI-1044298;
CC       P0DTC9; P57764: GSDMD; Xeno; NbExp=13; IntAct=EBI-25475856, EBI-2798865;
CC       P0DTC9; P49841: GSK3B; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-373586;
CC       P0DTC9; P10412: H1-4; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-358163;
CC       P0DTC9; O14920: IKBKB; Xeno; NbExp=7; IntAct=EBI-25475856, EBI-81266;
CC       P0DTC9; Q92830: KAT2A; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-477622;
CC       P0DTC9; Q92831: KAT2B; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-477430;
CC       P0DTC9; Q07866: KLC1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-721019;
CC       P0DTC9; Q9H0B6: KLC2; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-726994;
CC       P0DTC9; Q9NSK0: KLC4; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-949319;
CC       P0DTC9; Q9NX58: LYAR; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-713507;
CC       P0DTC9; O43318: MAP3K7; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-358684;
CC       P0DTC9; Q9UBU8: MORF4L1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-399246;
CC       P0DTC9; Q15014: MORF4L2; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-399257;
CC       P0DTC9; Q9HCE1: MOV10; Xeno; NbExp=11; IntAct=EBI-25475856, EBI-1055820;
CC       P0DTC9; Q9HC36: MRM3; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-1045440;
CC       P0DTC9; O15226: NKRF; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-766011;
CC       P0DTC9; Q96P20: NLRP3; Xeno; NbExp=18; IntAct=EBI-25475856, EBI-6253230;
CC       P0DTC9; O15118: NPC1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-2368710;
CC       P0DTC9; Q96HA8: NTAQ1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-741158;
CC       P0DTC9; P11940: PABPC1; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-81531;
CC       P0DTC9; P62937: PPIA; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-437708;
CC       P0DTC9; O75569: PRKRA; Xeno; NbExp=8; IntAct=EBI-25475856, EBI-713955;
CC       P0DTC9; Q99873: PRMT1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-78738;
CC       P0DTC9; P61289: PSME3; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-355546;
CC       P0DTC9; P26022: PTX3; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-11574553;
CC       P0DTC9; P54727: RAD23B; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-954531;
CC       P0DTC9; O95786: RIGI; Xeno; NbExp=15; IntAct=EBI-25475856, EBI-995350;
CC       P0DTC9; P62899: RPL31; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-1053664;
CC       P0DTC9; P62753: RPS6; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-356625;
CC       P0DTC9; P37840: SNCA; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-985879;
CC       P0DTC9; Q96SB4: SRPK1; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-539478;
CC       P0DTC9; P78362: SRPK2; Xeno; NbExp=2; IntAct=EBI-25475856, EBI-593303;
CC       P0DTC9; P42224: STAT1; Xeno; NbExp=6; IntAct=EBI-25475856, EBI-1057697;
CC       P0DTC9; P52630: STAT2; Xeno; NbExp=7; IntAct=EBI-25475856, EBI-1546963;
CC       P0DTC9; Q15633: TARBP2; Xeno; NbExp=5; IntAct=EBI-25475856, EBI-978581;
CC       P0DTC9; Q14258: TRIM25; Xeno; NbExp=13; IntAct=EBI-25475856, EBI-2341129;
CC       P0DTC9; O60763: USO1; Xeno; NbExp=4; IntAct=EBI-25475856, EBI-356164;
CC       P0DTC9; Q93008: USP9X; Xeno; NbExp=3; IntAct=EBI-25475856, EBI-302524;
CC   -!- SUBCELLULAR LOCATION: Virion {ECO:0000255|HAMAP-Rule:MF_04096}. Host
CC       cytoplasm {ECO:0000269|PubMed:33060197, ECO:0000269|PubMed:34341353}.
CC       Secreted {ECO:0000269|PubMed:35921414}. Host extracellular space
CC       {ECO:0000269|PubMed:35921414}. Note=Probably associates with ER-derived
CC       membranes where it participates in viral RNA synthesis and virus
CC       budding. When located inside the virion, complexed with the viral RNA.
CC       Can be secreted by unconventional protein secretion (UPS)
CC       (PubMed:35921414). When secreted, can bind to host glycosaminoglycans
CC       on infected and non infected cells (PubMed:35921414). Found in host
CC       cytoplasmic stress granules (PubMed:34901782). {ECO:0000255|HAMAP-
CC       Rule:MF_04096, ECO:0000269|PubMed:34901782,
CC       ECO:0000269|PubMed:35921414}.
CC   -!- PTM: ADP-ribosylated. The ADP-ribosylation is retained in the virion
CC       during infection. {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   -!- PTM: Phosphorylated on serine residues by host GSK3A and GSK3B
CC       (PubMed:34593624, PubMed:35728038). This promotes the solubility of
CC       homodimers that would otherwise aggregate (PubMed:32974389). Host
CC       phosphatase would dephosphorylate the protein during assembly at M
CC       bound membranes (PubMed:32974389). {ECO:0000269|PubMed:34593624,
CC       ECO:0000269|PubMed:35728038, ECO:0000305|PubMed:32974389}.
CC   -!- PTM: Proteolytically cleaved by host CASP6. The cleavage leads to two
CC       fragments and facilitates viral replication by inhibiting host IFN
CC       signaling. The two fragments may interact with IRF3 inhibiting its
CC       nuclear translocation after activation and reduce the expression of
CC       IFNB and IFN-stimulated genes. {ECO:0000269|PubMed:35922005}.
CC   -!- POLYMORPHISM: Variant Alpha/B.1.1.7 belongs to a lineage isolated first
CC       in United Kingdom (December 2020). It is also called Variant of Concern
CC       (VOC) 202012/01, Variant Under Investigation (VUI) 202012/01, 501Y.V1
CC       or 20B/501Y.V1. {ECO:0000305|PubMed:33413740}.
CC   -!- POLYMORPHISM: Variant Omicron/BA.1 and BA.2 belong to a lineage first
CC       isolated in South Africa (November 2021). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/BQ.1.1 belongs to a lineage first
CC       isolated in Nigeria (November 2022). {ECO:0000305}.
CC   -!- POLYMORPHISM: Variant Omicron/XBB.1.5 belongs to a lineage first
CC       isolated in United States (November 2022). It is the result of
CC       recombination between omicron BJ.1 and BM.1.1. Moreover XBB.1.5 do not
CC       express ORF8. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the betacoronavirus nucleocapsid protein family.
CC       {ECO:0000255|HAMAP-Rule:MF_04096}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; MN908947; QHD43423.2; -; Genomic_RNA.
DR   PDB; 6M3M; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 6VYO; X-ray; 1.70 A; A/B/C/D=47-173.
DR   PDB; 6WJI; X-ray; 2.05 A; A/B/C/D/E/F=257-364.
DR   PDB; 6WKP; X-ray; 2.67 A; A/B/C/D=47-173.
DR   PDB; 6WZO; X-ray; 1.42 A; A/B/C/D=247-364.
DR   PDB; 6WZQ; X-ray; 1.45 A; A/B/C/D=247-364.
DR   PDB; 6YI3; NMR; -; A=44-180.
DR   PDB; 6YUN; X-ray; 1.44 A; A/B=249-364.
DR   PDB; 6ZCO; X-ray; 1.36 A; A=247-364.
DR   PDB; 7ACS; NMR; -; A=44-180.
DR   PDB; 7ACT; NMR; -; A=44-180.
DR   PDB; 7C22; X-ray; 2.00 A; A/B/C/D=248-364.
DR   PDB; 7CDZ; X-ray; 1.80 A; A/B/C/D=44-174.
DR   PDB; 7CE0; X-ray; 1.50 A; A/B/C/D=255-364.
DR   PDB; 7CR5; X-ray; 2.08 A; A=41-174.
DR   PDB; 7DE1; X-ray; 2.00 A; A/B=250-364.
DR   PDB; 7F2B; X-ray; 2.00 A; A/B=257-362.
DR   PDB; 7F2E; X-ray; 3.10 A; A/B/C/D/E/F/G/H/I/J/K/L=255-362.
DR   PDB; 7KGO; X-ray; 2.15 A; C=351-359.
DR   PDB; 7KGP; X-ray; 1.40 A; C=316-324.
DR   PDB; 7KGQ; X-ray; 1.34 A; C=222-230.
DR   PDB; 7KGR; X-ray; 1.55 A; C=159-167.
DR   PDB; 7KGS; X-ray; 1.58 A; C=138-146.
DR   PDB; 7KGT; X-ray; 1.90 A; C=226-234.
DR   PDB; 7LGD; X-ray; 2.88 A; E/F=105-113.
DR   PDB; 7LTU; X-ray; 1.12 A; A/B=217-222.
DR   PDB; 7LUX; X-ray; 1.30 A; A=217-222.
DR   PDB; 7LUZ; X-ray; 1.10 A; A=243-248.
DR   PDB; 7LV2; X-ray; 1.30 A; A=179-184.
DR   PDB; 7N0I; X-ray; 2.20 A; A/B/C/D/E/F/G/H=269-364.
DR   PDB; 7N0R; X-ray; 1.42 A; A/B=49-174.
DR   PDB; 7N3C; X-ray; 1.82 A; C=47-173.
DR   PDB; 7N3D; X-ray; 1.53 A; C=47-173.
DR   PDB; 7O05; X-ray; 1.94 A; A/B/C/D=247-364.
DR   PDB; 7O35; X-ray; 1.80 A; A/B/C/D=247-364.
DR   PDB; 7O36; X-ray; 2.00 A; A/B/C/D=247-364.
DR   PDB; 7PKU; NMR; -; B=191-263.
DR   PDB; 7QIK; X-ray; 2.01 A; E/F=193-200.
DR   PDB; 7QIP; X-ray; 2.65 A; C/D=201-210.
DR   PDB; 7R98; X-ray; 2.51 A; A/B/C=49-174.
DR   PDB; 7SD4; NMR; -; A=40-174.
DR   PDB; 7STR; X-ray; 1.50 A; C=47-173.
DR   PDB; 7STS; X-ray; 2.16 A; C/D=47-173.
DR   PDB; 7SUE; X-ray; 2.90 A; C/D/J/K=47-173.
DR   PDB; 7SUO; X-ray; 2.35 A; C/D=12-22.
DR   PDB; 7UW3; X-ray; 1.70 A; A/B/C/D=40-174.
DR   PDB; 7UXX; X-ray; 1.85 A; AAA/BBB/CCC/DDD/EEE/FFF=251-364.
DR   PDB; 7UXZ; X-ray; 1.73 A; AAA/BBB/CCC/DDD/EEE/FFF=251-364.
DR   PDB; 7VBD; X-ray; 1.94 A; A/B/C/D=48-174.
DR   PDB; 7VBE; X-ray; 1.59 A; A/B=257-364.
DR   PDB; 7VBF; X-ray; 1.30 A; A/B=255-364.
DR   PDB; 7VNU; X-ray; 1.95 A; A/B/C/D=47-174.
DR   PDB; 7WKJ; X-ray; 1.50 A; C=361-369.
DR   PDB; 7WZO; X-ray; 2.64 A; A=47-174.
DR   PDB; 7XWX; X-ray; 3.00 A; A/B/C/D/E/F/G/H=269-367.
DR   PDB; 7XWZ; X-ray; 2.25 A; A/B=48-172.
DR   PDB; 7XX1; X-ray; 1.90 A; A/B/C/D=49-173.
DR   PDB; 7XXK; X-ray; 2.00 A; A/B/C/D/E/F=248-364.
DR   PDB; 7YLB; X-ray; 2.41 A; A/B/C/D/G/H/J/K=247-364.
DR   PDB; 7YLD; X-ray; 2.80 A; A/B/C/D=47-174.
DR   PDB; 7ZIT; X-ray; 1.79 A; C/D=194-200.
DR   PDB; 8DNT; X-ray; 3.18 A; D/J/Q/X=222-230.
DR   PDB; 8FD5; EM; 4.57 A; A=1-419.
DR   PDB; 8FG2; EM; 6.00 A; A/B=1-419.
DR   PDB; 8IQJ; X-ray; 2.30 A; A/B/C/D=41-174.
DR   PDB; 8IV3; X-ray; 1.90 A; A/B/C/D=41-174.
DR   PDB; 8J6X; X-ray; 2.70 A; A/B/C/D=41-174.
DR   PDB; 8TH1; X-ray; 1.80 A; E/F/G/H=1-25.
DR   PDB; 8TH5; X-ray; 2.62 A; K/L/M/N/O/P/Q=1-25.
DR   PDB; 8X1H; X-ray; 2.00 A; A/B/C/D=44-175.
DR   PDBsum; 6M3M; -.
DR   PDBsum; 6VYO; -.
DR   PDBsum; 6WJI; -.
DR   PDBsum; 6WKP; -.
DR   PDBsum; 6WZO; -.
DR   PDBsum; 6WZQ; -.
DR   PDBsum; 6YI3; -.
DR   PDBsum; 6YUN; -.
DR   PDBsum; 6ZCO; -.
DR   PDBsum; 7ACS; -.
DR   PDBsum; 7ACT; -.
DR   PDBsum; 7C22; -.
DR   PDBsum; 7CDZ; -.
DR   PDBsum; 7CE0; -.
DR   PDBsum; 7CR5; -.
DR   PDBsum; 7DE1; -.
DR   PDBsum; 7F2B; -.
DR   PDBsum; 7F2E; -.
DR   PDBsum; 7KGO; -.
DR   PDBsum; 7KGP; -.
DR   PDBsum; 7KGQ; -.
DR   PDBsum; 7KGR; -.
DR   PDBsum; 7KGS; -.
DR   PDBsum; 7KGT; -.
DR   PDBsum; 7LGD; -.
DR   PDBsum; 7LTU; -.
DR   PDBsum; 7LUX; -.
DR   PDBsum; 7LUZ; -.
DR   PDBsum; 7LV2; -.
DR   PDBsum; 7N0I; -.
DR   PDBsum; 7N0R; -.
DR   PDBsum; 7N3C; -.
DR   PDBsum; 7N3D; -.
DR   PDBsum; 7O05; -.
DR   PDBsum; 7O35; -.
DR   PDBsum; 7O36; -.
DR   PDBsum; 7PKU; -.
DR   PDBsum; 7QIK; -.
DR   PDBsum; 7QIP; -.
DR   PDBsum; 7R98; -.
DR   PDBsum; 7SD4; -.
DR   PDBsum; 7STR; -.
DR   PDBsum; 7STS; -.
DR   PDBsum; 7SUE; -.
DR   PDBsum; 7SUO; -.
DR   PDBsum; 7UW3; -.
DR   PDBsum; 7UXX; -.
DR   PDBsum; 7UXZ; -.
DR   PDBsum; 7VBD; -.
DR   PDBsum; 7VBE; -.
DR   PDBsum; 7VBF; -.
DR   PDBsum; 7VNU; -.
DR   PDBsum; 7WKJ; -.
DR   PDBsum; 7WZO; -.
DR   PDBsum; 7XWX; -.
DR   PDBsum; 7XWZ; -.
DR   PDBsum; 7XX1; -.
DR   PDBsum; 7XXK; -.
DR   PDBsum; 7YLB; -.
DR   PDBsum; 7YLD; -.
DR   PDBsum; 7ZIT; -.
DR   PDBsum; 8DNT; -.
DR   PDBsum; 8FD5; -.
DR   PDBsum; 8FG2; -.
DR   PDBsum; 8IQJ; -.
DR   PDBsum; 8IV3; -.
DR   PDBsum; 8J6X; -.
DR   PDBsum; 8TH1; -.
DR   PDBsum; 8TH5; -.
DR   PDBsum; 8X1H; -.
DR   BMRB; P0DTC9; -.
DR   EMDB; EMD-29002; -.
DR   EMDB; EMD-29072; -.
DR   SASBDB; P0DTC9; -.
DR   SMR; P0DTC9; -.
DR   BioGRID; 4383847; 1532.
DR   ComplexPortal; CPX-5686; SARS-CoV-2 nucleocapsid complex.
DR   IntAct; P0DTC9; 608.
DR   MINT; P0DTC9; -.
DR   ChEMBL; CHEMBL5169223; -.
DR   iPTMnet; P0DTC9; -.
DR   ABCD; P0DTC9; 27 sequenced antibodies.
DR   DNASU; 43740575; -.
DR   KEGG; vg:43740575; -.
DR   AGR; RefSeq:YP_009724397; -.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-168928; DDX58/IFIH1-mediated induction of interferon-alpha/beta.
DR   Reactome; R-HSA-389357; CD28 dependent PI3K/Akt signaling.
DR   Reactome; R-HSA-445989; TAK1-dependent IKK and NF-kappa-B activation.
DR   Reactome; R-HSA-5218920; VEGFR2 mediated vascular permeability.
DR   Reactome; R-HSA-9020702; Interleukin-1 signaling.
DR   Reactome; R-HSA-909733; Interferon alpha/beta signaling.
DR   Reactome; R-HSA-9694322; Virion Assembly and Release.
DR   Reactome; R-HSA-9694614; Attachment and Entry.
DR   Reactome; R-HSA-9694631; Maturation of nucleoprotein.
DR   Reactome; R-HSA-9694635; Translation of Structural Proteins.
DR   Reactome; R-HSA-9694786; Transcription of SARS-CoV-2 sgRNAs.
DR   Reactome; R-HSA-9705671; SARS-CoV-2 activates/modulates innate and adaptive immune responses.
DR   Reactome; R-HSA-9733458; Induction of Cell-Cell Fusion.
DR   Reactome; R-HSA-9755779; SARS-CoV-2 targets host intracellular signalling and regulatory pathways.
DR   SIGNOR; P0DTC9; -.
DR   PRO; PR:P0DTC9; -.
DR   Proteomes; UP000464024; Genome.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProt.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0044172; C:host cell endoplasmic reticulum-Golgi intermediate compartment; ISS:UniProtKB.
DR   GO; GO:0044177; C:host cell Golgi apparatus; ISS:UniProtKB.
DR   GO; GO:0044220; C:host cell perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0043655; C:host extracellular space; IEA:UniProtKB-SubCell.
DR   GO; GO:0043232; C:intracellular non-membrane-bounded organelle; IDA:DisProt.
DR   GO; GO:0042612; C:MHC class I protein complex; EXP:DisProt.
DR   GO; GO:1990904; C:ribonucleoprotein complex; IEA:UniProtKB-KW.
DR   GO; GO:0019028; C:viral capsid; IPI:ComplexPortal.
DR   GO; GO:0019013; C:viral nucleocapsid; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0042288; F:MHC class I protein binding; EXP:DisProt.
DR   GO; GO:0140693; F:molecular condensate scaffold activity; IDA:DisProt.
DR   GO; GO:0008266; F:poly(U) RNA binding; IMP:DisProt.
DR   GO; GO:0042803; F:protein homodimerization activity; EXP:DisProt.
DR   GO; GO:0140311; F:protein sequestering activity; IDA:UniProt.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProt.
DR   GO; GO:0035613; F:RNA stem-loop binding; IDA:DisProt.
DR   GO; GO:0039709; P:cytoplasmic capsid assembly; IDA:UniProt.
DR   GO; GO:0032688; P:negative regulation of interferon-beta production; IDA:ComplexPortal.
DR   GO; GO:1900227; P:positive regulation of NLRP3 inflammasome complex assembly; IDA:UniProtKB.
DR   GO; GO:0052572; P:response to host immune response; IDA:DisProt.
DR   GO; GO:0019074; P:viral RNA genome packaging; NAS:ComplexPortal.
DR   CDD; cd21595; CoV_N-CTD; 1.
DR   CDD; cd21554; CoV_N-NTD; 1.
DR   HAMAP; MF_04096; BETA_CORONA_NCAP; 1.
DR   InterPro; IPR044344; N_prot_C_CoV.
DR   InterPro; IPR044345; N_prot_N_CoV.
DR   InterPro; IPR043505; NCAP_bCoV.
DR   InterPro; IPR001218; Nucleocap_CoV.
DR   InterPro; IPR037179; Nucleocapsid_C.
DR   InterPro; IPR037195; Nucleocapsid_N.
DR   Pfam; PF00937; CoV_nucleocap; 1.
DR   PIRSF; PIRSF003888; Corona_nucleocap; 1.
DR   SUPFAM; SSF110304; Coronavirus RNA-binding domain; 1.
DR   SUPFAM; SSF103068; Nucleocapsid protein dimerization domain; 1.
DR   PROSITE; PS51929; COV_N_CTD; 1.
DR   PROSITE; PS51928; COV_N_NTD; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ADP-ribosylation; Host cytoplasm; Phosphoprotein;
KW   Reference proteome; Ribonucleoprotein; RNA-binding; Secreted;
KW   Transcription; Transcription regulation; Viral nucleoprotein; Virion.
FT   CHAIN           1..419
FT                   /note=""Nucleoprotein""
FT                   /id=""PRO_0000449656""
FT   DOMAIN          48..174
FT                   /note=""CoV N NTD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01276,
FT                   ECO:0000269|PubMed:32363136""
FT   DOMAIN          247..364
FT                   /note=""CoV N CTD""
FT                   /evidence=""ECO:0000255|PROSITE-ProRule:PRU01277""
FT   REGION          1..51
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          41..186
FT                   /note=""RNA-binding""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   REGION          63..83
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          168..212
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          176..206
FT                   /note=""SR region""
FT                   /evidence=""ECO:0000305|PubMed:32974389""
FT   REGION          233..266
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          258..361
FT                   /note=""Dimerization""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   REGION          260..340
FT                   /note=""Putative NLRP3 binding""
FT                   /evidence=""ECO:0000269|PubMed:34341353""
FT   REGION          361..391
FT                   /note=""Disordered""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   REGION          400..419
FT                   /note=""Tetramerization""
FT                   /evidence=""ECO:0000269|PubMed:32654247""
FT   MOTIF           256..264
FT                   /note=""Nuclear localization signal""
FT                   /evidence=""ECO:0000250|UniProtKB:P59595""
FT   COMPBIAS        1..11
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        21..31
FT                   /note=""Polar residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   COMPBIAS        367..378
FT                   /note=""Basic and acidic residues""
FT                   /evidence=""ECO:0000256|SAM:MobiDB-lite""
FT   BINDING         92
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   BINDING         107
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   BINDING         149
FT                   /ligand=""RNA""
FT                   /ligand_id=""ChEBI:CHEBI:33697""
FT                   /evidence=""ECO:0000269|PubMed:33264373,
FT                   ECO:0007744|PDB:7ACS, ECO:0007744|PDB:7ACT""
FT   SITE            399..402
FT                   /note=""Cleavage (by host CASP6)""
FT                   /evidence=""ECO:0000250|UniProtKB:P59595""
FT   MOD_RES         176
FT                   /note=""Phosphoserine; by host""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_04096""
FT   MOD_RES         206
FT                   /note=""Phosphoserine; by host GSK3-alpha and GSK3-beta""
FT                   /evidence=""ECO:0000269|PubMed:34593624""
FT   VARIANT         2..3
FT                   /note=""SD -> Y (in strain: Eta/B.1.525)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         3
FT                   /note=""D -> L (in strain: Alpha/B.1.1.7)""
FT                   /evidence=""ECO:0000305|PubMed:33413740""
FT   VARIANT         12
FT                   /note=""A -> G (in strain: Eta/B.1.525)""
FT   VARIANT         13
FT                   /note=""P -> L (in strain: Lambda/C.37, Omicron/BA.1,
FT                   Omicron/BA.2, Omicron/BA.2.12.1, Omicron/BA.2.75,
FT                   Omicron/BA.4, Omicron/BA.5, Omicron/BQ.1.1,
FT                   Omicron/XBB.1.5, Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         31..33
FT                   /note=""Missing (in strain: Omicron/BA.1, Omicron/BA.2,
FT                   Omicron/BA.2.12.1, Omicron/BA.2.75, Omicron/BA.4,
FT                   Omicron/BA.5, Omicron/BQ.1.1, Omicron/XBB.1.5,
FT                   Omicron/EG.5.1)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT         63
FT                   /note=""D -> G (in strain: Delta/B.1.617.2)""
FT                   /evidence=""ECO:0000305""
FT   VARIANT  ",11155
TCTTTT CTTTTG TTTTGA TTTGAA TTGAAG TGAAGA GAAGAG AAGAGT AGAGTC GAGTCA AGTCAA GTCAAT TCAATA CAATAA AATAAG ATAAGA TAAGAG AAGAGG AGAGGA GAGGAT AGGATT GGATTA GATTAC ATTACG TTACGC TACGCG ACGCGT CGCGTT GCGTTT CGTTTT GTTTTC TTTTCC TTTCCT TTCCTA TCCTAG CCTAGT CTAGTT TAGTTT AGTTTG GTTTGT TTTGTT TTGTTC TGTTCT GTTCTA TTCTAC TCTACA CTACAT TACATT ACATTT CATTTC ATTTCC TTTCCA TTCCAA TCCAAG CCAAGT CAAGTG AAGTGC AGTGCA GTGCAG TGCAGA GCAGAC CAGACA AGACAA GACAAT ACAATT CAATTT AATTTA ATTTAA TTTAAT TTAATG TAATGG AATGGA ATGGAA TGGAAT GGAATT GAATTA AATTAT ATTATT TTATTA TATTAT ATTATT TTATTA TATTAA ATTAAT TTAATG TAATGA AATGAT ATGATA TGATAG GATAGA ATAGAT TAGATG AGATGC GATGCA ATGCAG TGCAGC GCAGCA CAGCAA AGCAAA GCAAAA CAAAAA AAAAAG AAAAGA AAAGAG AAGAGC AGAGCA GAGCAT AGCATC GCATCT CATCTG ATCTGC TCTGCC CTGCCA TGCCAG GCCAGA CCAGAC CAGACA AGACAT GACATA ACATAT CATATT ATATTA TATTAC ATTACA TTACAG TACAGC ACAGCA CAGCAG AGCAGT GCAGTT CAGTTA AGTTAT GTTATC TTATCC TATCCC ATCCCT TCCCTC CCCTCA CCTCAC CTCACT TCACTC CACTCT,3,142,TCTT CTTT TTTT TTTG TTGA TGAA GAAG AAGA AGAG GAGT AGTC GTCA TCAA CAAT AATA ATAA TAAG AAGA AGAG GAGG AGGA GGAT GATT ATTA TTAC TACG ACGC CGCG GCGT CGTT GTTT TTTT TTTC TTCC TCCT CCTA CTAG TAGT AGTT GTTT TTTG TTGT TGTT GTTC TTCT TCTA CTAC TACA ACAT CATT ATTT TTTC TTCC TCCA CCAA CAAG AAGT AGTG GTGC TGCA GCAG CAGA AGAC GACA ACAA CAAT AATT ATTT TTTA TTAA TAAT AATG ATGG TGGA GGAA GAAT AATT ATTA TTAT TATT ATTA TTAT TATT ATTA TTAA TAAT AATG ATGA TGAT GATA ATAG TAGA AGAT GATG ATGC TGCA GCAG CAGC AGCA GCAA CAAA AAAA AAAA AAAG AAGA AGAG GAGC AGCA GCAT CATC ATCT TCTG CTGC TGCC GCCA CCAG CAGA AGAC GACA ACAT CATA ATAT TATT ATTA TTAC TACA ACAG CAGC AGCA GCAG CAGT AGTT GTTA TTAT TATC ATCC TCCC CCCT CCTC CTCA TCAC CACT ACTC CTCT,TCTTT CTTTT TTTTG TTTGA TTGAA TGAAG GAAGA AAGAG AGAGT GAGTC AGTCA GTCAA TCAAT CAATA AATAA ATAAG TAAGA AAGAG AGAGG GAGGA AGGAT GGATT GATTA ATTAC TTACG TACGC ACGCG CGCGT GCGTT CGTTT GTTTT TTTTC TTTCC TTCCT TCCTA CCTAG CTAGT TAGTT AGTTT GTTTG TTTGT TTGTT TGTTC GTTCT TTCTA TCTAC CTACA TACAT ACATT CATTT ATTTC TTTCC TTCCA TCCAA CCAAG CAAGT AAGTG AGTGC GTGCA TGCAG GCAGA CAGAC AGACA GACAA ACAAT CAATT AATTT ATTTA TTTAA TTAAT TAATG AATGG ATGGA TGGAA GGAAT GAATT AATTA ATTAT TTATT TATTA ATTAT TTATT TATTA ATTAA TTAAT TAATG AATGA ATGAT TGATA GATAG ATAGA TAGAT AGATG GATGC ATGCA TGCAG GCAGC CAGCA AGCAA GCAAA CAAAA AAAAA AAAAG AAAGA AAGAG AGAGC GAGCA AGCAT GCATC CATCT ATCTG TCTGC CTGCC TGCCA GCCAG CCAGA CAGAC AGACA GACAT ACATA CATAT ATATT TATTA ATTAC TTACA TACAG ACAGC CAGCA AGCAG GCAGT CAGTT AGTTA GTTAT TTATC TATCC ATCCC TCCCT CCCTC CCTCA CTCAC TCACT CACTC ACTCT,TCTTTT CTTTTG TTTTGA TTTGAA TTGAAG TGAAGA GAAGAG AAGAGT AGAGTC GAGTCA AGTCAA GTCAAT TCAATA CAATAA AATAAG ATAAGA TAAGAG AAGAGG AGAGGA GAGGAT AGGATT GGATTA GATTAC ATTACG TTACGC TACGCG ACGCGT CGCGTT GCGTTT CGTTTT GTTTTC TTTTCC TTTCCT TTCCTA TCCTAG CCTAGT CTAGTT TAGTTT AGTTTG GTTTGT TTTGTT TTGTTC TGTTCT GTTCTA TTCTAC TCTACA CTACAT TACATT ACATTT CATTTC ATTTCC TTTCCA TTCCAA TCCAAG CCAAGT CAAGTG AAGTGC AGTGCA GTGCAG TGCAGA GCAGAC CAGACA AGACAA GACAAT ACAATT CAATTT AATTTA ATTTAA TTTAAT TTAATG TAATGG AATGGA ATGGAA TGGAAT GGAATT GAATTA AATTAT ATTATT TTATTA TATTAT ATTATT TTATTA TATTAA ATTAAT TTAATG TAATGA AATGAT ATGATA TGATAG GATAGA ATAGAT TAGATG AGATGC GATGCA ATGCAG TGCAGC GCAGCA CAGCAA AGCAAA GCAAAA CAAAAA AAAAAG AAAAGA AAAGAG AAGAGC AGAGCA GAGCAT AGCATC GCATCT CATCTG ATCTGC TCTGCC CTGCCA TGCCAG GCCAGA CCAGAC CAGACA AGACAT GACATA ACATAT CATATT ATATTA TATTAC ATTACA TTACAG TACAGC ACAGCA CAGCAG AGCAGT GCAGTT CAGTTA AGTTAT GTTATC TTATCC TATCCC ATCCCT TCCCTC CCCTCA CCTCAC CTCACT TCACTC CACTCT,TCTTTTG CTTTTGA TTTTGAA TTTGAAG TTGAAGA TGAAGAG GAAGAGT AAGAGTC AGAGTCA GAGTCAA AGTCAAT GTCAATA TCAATAA CAATAAG AATAAGA ATAAGAG TAAGAGG AAGAGGA AGAGGAT GAGGATT AGGATTA GGATTAC GATTACG ATTACGC TTACGCG TACGCGT ACGCGTT CGCGTTT GCGTTTT CGTTTTC GTTTTCC TTTTCCT TTTCCTA TTCCTAG TCCTAGT CCTAGTT CTAGTTT TAGTTTG AGTTTGT GTTTGTT TTTGTTC TTGTTCT TGTTCTA GTTCTAC TTCTACA TCTACAT CTACATT TACATTT ACATTTC CATTTCC ATTTCCA TTTCCAA TTCCAAG TCCAAGT CCAAGTG CAAGTGC AAGTGCA AGTGCAG GTGCAGA TGCAGAC GCAGACA CAGACAA AGACAAT GACAATT ACAATTT CAATTTA AATTTAA ATTTAAT TTTAATG TTAATGG TAATGGA AATGGAA ATGGAAT TGGAATT GGAATTA GAATTAT AATTATT ATTATTA TTATTAT TATTATT ATTATTA TTATTAA TATTAAT ATTAATG TTAATGA TAATGAT AATGATA ATGATAG TGATAGA GATAGAT ATAGATG TAGATGC AGATGCA GATGCAG ATGCAGC TGCAGCA GCAGCAA CAGCAAA AGCAAAA GCAAAAA CAAAAAG AAAAAGA AAAAGAG AAAGAGC AAGAGCA AGAGCAT GAGCATC AGCATCT GCATCTG CATCTGC ATCTGCC TCTGCCA CTGCCAG TGCCAGA GCCAGAC CCAGACA CAGACAT AGACATA GACATAT ACATATT CATATTA ATATTAC TATTACA ATTACAG TTACAGC TACAGCA ACAGCAG CAGCAGT AGCAGTT GCAGTTA CAGTTAT AGTTATC GTTATCC TTATCCC TATCCCT ATCCCTC TCCCTCA CCCTCAC CCTCACT CTCACTC TCACTCT,"ID   KPRS_PORGI              Reviewed;         313 AA.
AC   Q7MT83;
DT   13-APR-2004, integrated into UniProtKB/Swiss-Prot.
DT   15-DEC-2003, sequence version 1.
DT   05-FEB-2025, entry version 120.
DE   RecName: Full=Ribose-phosphate pyrophosphokinase {ECO:0000255|HAMAP-Rule:MF_00583};
DE            Short=RPPK {ECO:0000255|HAMAP-Rule:MF_00583};
DE            EC=2.7.6.1 {ECO:0000255|HAMAP-Rule:MF_00583};
DE   AltName: Full=5-phospho-D-ribosyl alpha-1-diphosphate synthase {ECO:0000255|HAMAP-Rule:MF_00583};
DE   AltName: Full=Phosphoribosyl diphosphate synthase {ECO:0000255|HAMAP-Rule:MF_00583};
DE   AltName: Full=Phosphoribosyl pyrophosphate synthase {ECO:0000255|HAMAP-Rule:MF_00583};
DE            Short=P-Rib-PP synthase {ECO:0000255|HAMAP-Rule:MF_00583};
DE            Short=PRPP synthase {ECO:0000255|HAMAP-Rule:MF_00583};
DE            Short=PRPPase {ECO:0000255|HAMAP-Rule:MF_00583};
GN   Name=prs {ECO:0000255|HAMAP-Rule:MF_00583}; Synonyms=prsA;
GN   OrderedLocusNames=PG_2097;
OS   Porphyromonas gingivalis (strain ATCC BAA-308 / W83).
OC   Bacteria; Bacteroidota; Bacteroidia; Bacteroidales; Porphyromonadaceae;
OC   Porphyromonas.
OX   NCBI_TaxID=242619;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC BAA-308 / W83;
RX   PubMed=12949112; DOI=10.1128/jb.185.18.5591-5601.2003;
RA   Nelson K.E., Fleischmann R.D., DeBoy R.T., Paulsen I.T., Fouts D.E.,
RA   Eisen J.A., Daugherty S.C., Dodson R.J., Durkin A.S., Gwinn M.L.,
RA   Haft D.H., Kolonay J.F., Nelson W.C., Mason T.M., Tallon L., Gray J.,
RA   Granger D., Tettelin H., Dong H., Galvin J.L., Duncan M.J., Dewhirst F.E.,
RA   Fraser C.M.;
RT   ""Complete genome sequence of the oral pathogenic bacterium Porphyromonas
RT   gingivalis strain W83."";
RL   J. Bacteriol. 185:5591-5601(2003).
CC   -!- FUNCTION: Involved in the biosynthesis of the central metabolite
CC       phospho-alpha-D-ribosyl-1-pyrophosphate (PRPP) via the transfer of
CC       pyrophosphoryl group from ATP to 1-hydroxyl of ribose-5-phosphate (Rib-
CC       5-P). {ECO:0000255|HAMAP-Rule:MF_00583}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=D-ribose 5-phosphate + ATP = 5-phospho-alpha-D-ribose 1-
CC         diphosphate + AMP + H(+); Xref=Rhea:RHEA:15609, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:58017, ChEBI:CHEBI:78346,
CC         ChEBI:CHEBI:456215; EC=2.7.6.1; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_00583};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000255|HAMAP-
CC         Rule:MF_00583};
CC       Note=Binds 2 Mg(2+) ions per subunit. {ECO:0000255|HAMAP-
CC       Rule:MF_00583};
CC   -!- PATHWAY: Metabolic intermediate biosynthesis; 5-phospho-alpha-D-ribose
CC       1-diphosphate biosynthesis; 5-phospho-alpha-D-ribose 1-diphosphate from
CC       D-ribose 5-phosphate (route I): step 1/1. {ECO:0000255|HAMAP-
CC       Rule:MF_00583}.
CC   -!- SUBUNIT: Homohexamer. {ECO:0000255|HAMAP-Rule:MF_00583}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000255|HAMAP-Rule:MF_00583}.
CC   -!- SIMILARITY: Belongs to the ribose-phosphate pyrophosphokinase family.
CC       Class I subfamily. {ECO:0000255|HAMAP-Rule:MF_00583}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AE015924; AAQ67056.1; -; Genomic_DNA.
DR   RefSeq; WP_005873771.1; NC_002950.2.
DR   AlphaFoldDB; Q7MT83; -.
DR   SMR; Q7MT83; -.
DR   STRING; 242619.PG_2097; -.
DR   EnsemblBacteria; AAQ67056; AAQ67056; PG_2097.
DR   KEGG; pgi:PG_2097; -.
DR   eggNOG; COG0462; Bacteria.
DR   HOGENOM; CLU_033546_4_0_10; -.
DR   UniPathway; UPA00087; UER00172.
DR   Proteomes; UP000000588; Chromosome.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0002189; C:ribose phosphate diphosphokinase complex; IEA:TreeGrafter.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016301; F:kinase activity; IEA:UniProtKB-KW.
DR   GO; GO:0000287; F:magnesium ion binding; IEA:UniProtKB-UniRule.
DR   GO; GO:0004749; F:ribose phosphate diphosphokinase activity; IEA:UniProtKB-UniRule.
DR   GO; GO:0006015; P:5-phosphoribose 1-diphosphate biosynthetic process; IEA:UniProtKB-UniRule.
DR   GO; GO:0006164; P:purine nucleotide biosynthetic process; IEA:TreeGrafter.
DR   GO; GO:0009156; P:ribonucleoside monophosphate biosynthetic process; IEA:InterPro.
DR   CDD; cd06223; PRTases_typeI; 1.
DR   FunFam; 3.40.50.2020:FF:000007; Ribose-phosphate pyrophosphokinase; 1.
DR   Gene3D; 3.40.50.2020; -; 2.
DR   HAMAP; MF_00583_B; RibP_PPkinase_B; 1.
DR   InterPro; IPR000842; PRib_PP_synth_CS.
DR   InterPro; IPR029099; Pribosyltran_N.
DR   InterPro; IPR000836; PRibTrfase_dom.
DR   InterPro; IPR029057; PRTase-like.
DR   InterPro; IPR005946; Rib-P_diPkinase.
DR   InterPro; IPR037515; Rib-P_diPkinase_bac.
DR   NCBIfam; TIGR01251; ribP_PPkin; 1.
DR   PANTHER; PTHR10210; RIBOSE-PHOSPHATE DIPHOSPHOKINASE FAMILY MEMBER; 1.
DR   PANTHER; PTHR10210:SF41; RIBOSE-PHOSPHATE PYROPHOSPHOKINASE 1, CHLOROPLASTIC; 1.
DR   Pfam; PF14572; Pribosyl_synth; 1.
DR   Pfam; PF13793; Pribosyltran_N; 1.
DR   SMART; SM01400; Pribosyltran_N; 1.
DR   SUPFAM; SSF53271; PRTase-like; 1.
DR   PROSITE; PS00114; PRPP_SYNTHASE; 1.
PE   3: Inferred from homology;
KW   ATP-binding; Cytoplasm; Kinase; Magnesium; Metal-binding;
KW   Nucleotide biosynthesis; Nucleotide-binding; Reference proteome;
KW   Transferase.
FT   CHAIN           1..313
FT                   /note=""Ribose-phosphate pyrophosphokinase""
FT                   /id=""PRO_0000141172""
FT   ACT_SITE        195
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00583""
FT   BINDING         40..42
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00583""
FT   BINDING         98..99
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00583""
FT   BINDING         132
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00583""
FT   BINDING         172
FT                   /ligand=""Mg(2+)""
FT                   /ligand_id=""ChEBI:CHEBI:18420""
FT                   /ligand_label=""2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00583""
FT   BINDING         197
FT                   /ligand=""D-ribose 5-phosphate""
FT                   /ligand_id=""ChEBI:CHEBI:78346""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00583""
FT   BINDING         221
FT                   /ligand=""D-ribose 5-phosphate""
FT                   /ligand_id=""ChEBI:CHEBI:78346""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00583""
FT   BINDING         225..229
FT                   /ligand=""D-ribose 5-phosphate""
FT                   /ligand_id=""ChEBI:CHEBI:78346""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_00583""
SQ   SEQUENCE   313 AA;  34780 MW;  D8C34A7F336791FD CRC64;
     MNNENNFSVF SGTNSRYLAE KICNSLGCPL GRMNIEHFAD GEFAVSYEES IRGRDVFLVQ
     STFPSSDNLM ELLLMIDAAK RASAHYITAV IPYFGWARQD RKDKPRVSIG AKLIADLLSK
     AGITRLITMD LHADQIQGFF DVPVDHLYGS TVFMEYIRKN MPLENLVVAT PDVGGTKRAN
     SYAKHLGVPM VICHKSRLKA NEIAEMRIIG DVQDKDVLLV DDIVDTAGTI TKAADLMKEN
     GARSVCAIAS HAVMSDPASM RVDQSTLKEM IFTDSIPYPH KCEKVKILSV ADLFAEAIKR
     VCSHESITTL YYF
//
",31673
AAACGG AACGGG ACGGGT CGGGTC GGGTCT GGTCTC GTCTCC TCTCCG CTCCGA TCCGAT CCGATA CGATAA GATAAC ATAACA TAACAC AACACC ACACCT CACCTA ACCTAC CCTACT CTACTG TACTGG ACTGGA CTGGAA TGGAAG GGAAGG GAAGGA AAGGAC AGGACC GGACCT GACCTG ACCTGG CCTGGC CTGGCG TGGCGC GGCGCG GCGCGC CGCGCG GCGCGG CGCGGG GCGGGG CGGGGT GGGGTC GGGTCG GGTCGA GTCGAG TCGAGA CGAGAG GAGAGC AGAGCA GAGCAA AGCAAG GCAAGA CAAGAC AAGACG AGACGC GACGCC ACGCCC CGCCCC GCCCCG CCCCGC CCCGCC CCGCCT CGCCTG GCCTGC CCTGCT CTGCTC TGCTCG GCTCGG CTCGGC TCGGCA CGGCAG GGCAGC GCAGCG CAGCGA AGCGAC GCGACC CGACCT GACCTG ACCTGA CCTGAA CTGAAC TGAACG GAACGT AACGTC ACGTCA CGTCAG GTCAGC TCAGCC CAGCCG AGCCGC GCCGCC CCGCCG CGCCGC GCCGCA CCGCAA CGCAAG GCAAGG CAAGGA AAGGAG AGGAGC GGAGCT GAGCTG AGCTGT GCTGTT CTGTTC TGTTCT GTTCTG TTCTGG TCTGGG CTGGGG TGGGGC GGGGCG GGGCGC GGCGCG GCGCGA CGCGAT GCGATC CGATCG GATCGA ATCGAC TCGACA CGACAC GACACC ACACCT CACCTA ACCTAT CCTATG CTATGC TATGCC ATGCCC TGCCCG GCCCGG CCCGGG CCGGGT CGGGTT GGGTTC GGTTCA GTTCAG TTCAGC TCAGCA CAGCAC,2,142,AAAC AACG ACGG CGGG GGGT GGTC GTCT TCTC CTCC TCCG CCGA CGAT GATA ATAA TAAC AACA ACAC CACC ACCT CCTA CTAC TACT ACTG CTGG TGGA GGAA GAAG AAGG AGGA GGAC GACC ACCT CCTG CTGG TGGC GGCG GCGC CGCG GCGC CGCG GCGG CGGG GGGG GGGT GGTC GTCG TCGA CGAG GAGA AGAG GAGC AGCA GCAA CAAG AAGA AGAC GACG ACGC CGCC GCCC CCCC CCCG CCGC CGCC GCCT CCTG CTGC TGCT GCTC CTCG TCGG CGGC GGCA GCAG CAGC AGCG GCGA CGAC GACC ACCT CCTG CTGA TGAA GAAC AACG ACGT CGTC GTCA TCAG CAGC AGCC GCCG CCGC CGCC GCCG CCGC CGCA GCAA CAAG AAGG AGGA GGAG GAGC AGCT GCTG CTGT TGTT GTTC TTCT TCTG CTGG TGGG GGGG GGGC GGCG GCGC CGCG GCGA CGAT GATC ATCG TCGA CGAC GACA ACAC CACC ACCT CCTA CTAT TATG ATGC TGCC GCCC CCCG CCGG CGGG GGGT GGTT GTTC TTCA TCAG CAGC AGCA GCAC,AAACG AACGG ACGGG CGGGT GGGTC GGTCT GTCTC TCTCC CTCCG TCCGA CCGAT CGATA GATAA ATAAC TAACA AACAC ACACC CACCT ACCTA CCTAC CTACT TACTG ACTGG CTGGA TGGAA GGAAG GAAGG AAGGA AGGAC GGACC GACCT ACCTG CCTGG CTGGC TGGCG GGCGC GCGCG CGCGC GCGCG CGCGG GCGGG CGGGG GGGGT GGGTC GGTCG GTCGA TCGAG CGAGA GAGAG AGAGC GAGCA AGCAA GCAAG CAAGA AAGAC AGACG GACGC ACGCC CGCCC GCCCC CCCCG CCCGC CCGCC CGCCT GCCTG CCTGC CTGCT TGCTC GCTCG CTCGG TCGGC CGGCA GGCAG GCAGC CAGCG AGCGA GCGAC CGACC GACCT ACCTG CCTGA CTGAA TGAAC GAACG AACGT ACGTC CGTCA GTCAG TCAGC CAGCC AGCCG GCCGC CCGCC CGCCG GCCGC CCGCA CGCAA GCAAG CAAGG AAGGA AGGAG GGAGC GAGCT AGCTG GCTGT CTGTT TGTTC GTTCT TTCTG TCTGG CTGGG TGGGG GGGGC GGGCG GGCGC GCGCG CGCGA GCGAT CGATC GATCG ATCGA TCGAC CGACA GACAC ACACC CACCT ACCTA CCTAT CTATG TATGC ATGCC TGCCC GCCCG CCCGG CCGGG CGGGT GGGTT GGTTC GTTCA TTCAG TCAGC CAGCA AGCAC,AAACGG AACGGG ACGGGT CGGGTC GGGTCT GGTCTC GTCTCC TCTCCG CTCCGA TCCGAT CCGATA CGATAA GATAAC ATAACA TAACAC AACACC ACACCT CACCTA ACCTAC CCTACT CTACTG TACTGG ACTGGA CTGGAA TGGAAG GGAAGG GAAGGA AAGGAC AGGACC GGACCT GACCTG ACCTGG CCTGGC CTGGCG TGGCGC GGCGCG GCGCGC CGCGCG GCGCGG CGCGGG GCGGGG CGGGGT GGGGTC GGGTCG GGTCGA GTCGAG TCGAGA CGAGAG GAGAGC AGAGCA GAGCAA AGCAAG GCAAGA CAAGAC AAGACG AGACGC GACGCC ACGCCC CGCCCC GCCCCG CCCCGC CCCGCC CCGCCT CGCCTG GCCTGC CCTGCT CTGCTC TGCTCG GCTCGG CTCGGC TCGGCA CGGCAG GGCAGC GCAGCG CAGCGA AGCGAC GCGACC CGACCT GACCTG ACCTGA CCTGAA CTGAAC TGAACG GAACGT AACGTC ACGTCA CGTCAG GTCAGC TCAGCC CAGCCG AGCCGC GCCGCC CCGCCG CGCCGC GCCGCA CCGCAA CGCAAG GCAAGG CAAGGA AAGGAG AGGAGC GGAGCT GAGCTG AGCTGT GCTGTT CTGTTC TGTTCT GTTCTG TTCTGG TCTGGG CTGGGG TGGGGC GGGGCG GGGCGC GGCGCG GCGCGA CGCGAT GCGATC CGATCG GATCGA ATCGAC TCGACA CGACAC GACACC ACACCT CACCTA ACCTAT CCTATG CTATGC TATGCC ATGCCC TGCCCG GCCCGG CCCGGG CCGGGT CGGGTT GGGTTC GGTTCA GTTCAG TTCAGC TCAGCA CAGCAC,AAACGGG AACGGGT ACGGGTC CGGGTCT GGGTCTC GGTCTCC GTCTCCG TCTCCGA CTCCGAT TCCGATA CCGATAA CGATAAC GATAACA ATAACAC TAACACC AACACCT ACACCTA CACCTAC ACCTACT CCTACTG CTACTGG TACTGGA ACTGGAA CTGGAAG TGGAAGG GGAAGGA GAAGGAC AAGGACC AGGACCT GGACCTG GACCTGG ACCTGGC CCTGGCG CTGGCGC TGGCGCG GGCGCGC GCGCGCG CGCGCGG GCGCGGG CGCGGGG GCGGGGT CGGGGTC GGGGTCG GGGTCGA GGTCGAG GTCGAGA TCGAGAG CGAGAGC GAGAGCA AGAGCAA GAGCAAG AGCAAGA GCAAGAC CAAGACG AAGACGC AGACGCC GACGCCC ACGCCCC CGCCCCG GCCCCGC CCCCGCC CCCGCCT CCGCCTG CGCCTGC GCCTGCT CCTGCTC CTGCTCG TGCTCGG GCTCGGC CTCGGCA TCGGCAG CGGCAGC GGCAGCG GCAGCGA CAGCGAC AGCGACC GCGACCT CGACCTG GACCTGA ACCTGAA CCTGAAC CTGAACG TGAACGT GAACGTC AACGTCA ACGTCAG CGTCAGC GTCAGCC TCAGCCG CAGCCGC AGCCGCC GCCGCCG CCGCCGC CGCCGCA GCCGCAA CCGCAAG CGCAAGG GCAAGGA CAAGGAG AAGGAGC AGGAGCT GGAGCTG GAGCTGT AGCTGTT GCTGTTC CTGTTCT TGTTCTG GTTCTGG TTCTGGG TCTGGGG CTGGGGC TGGGGCG GGGGCGC GGGCGCG GGCGCGA GCGCGAT CGCGATC GCGATCG CGATCGA GATCGAC ATCGACA TCGACAC CGACACC GACACCT ACACCTA CACCTAT ACCTATG CCTATGC CTATGCC TATGCCC ATGCCCG TGCCCGG GCCCGGG CCCGGGT CCGGGTT CGGGTTC GGGTTCA GGTTCAG GTTCAGC TTCAGCA TCAGCAC,"ID   LPTD_ACISJ              Reviewed;         817 AA.
AC   A1WD88;
DT   20-MAR-2007, integrated into UniProtKB/Swiss-Prot.
DT   20-MAR-2007, sequence version 2.
DT   05-FEB-2025, entry version 80.
DE   RecName: Full=LPS-assembly protein LptD {ECO:0000255|HAMAP-Rule:MF_01411};
DE   Flags: Precursor;
GN   Name=lptD {ECO:0000255|HAMAP-Rule:MF_01411}; Synonyms=imp, ostA;
GN   OrderedLocusNames=Ajs_4112;
OS   Acidovorax sp. (strain JS42).
OC   Bacteria; Pseudomonadota; Betaproteobacteria; Burkholderiales;
OC   Comamonadaceae; Acidovorax.
OX   NCBI_TaxID=232721;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=JS42;
RA   Copeland A., Lucas S., Lapidus A., Barry K., Detter J.C.,
RA   Glavina del Rio T., Dalin E., Tice H., Pitluck S., Chertkov O., Brettin T.,
RA   Bruce D., Han C., Tapia R., Gilna P., Schmutz J., Larimer F., Land M.,
RA   Hauser L., Kyrpides N., Kim E., Stahl D., Richardson P.;
RT   ""Complete sequence of chromosome 1 of Acidovorax sp. JS42."";
RL   Submitted (DEC-2006) to the EMBL/GenBank/DDBJ databases.
CC   -!- FUNCTION: Together with LptE, is involved in the assembly of
CC       lipopolysaccharide (LPS) at the surface of the outer membrane.
CC       {ECO:0000255|HAMAP-Rule:MF_01411}.
CC   -!- SUBUNIT: Component of the lipopolysaccharide transport and assembly
CC       complex. Interacts with LptE and LptA. {ECO:0000255|HAMAP-
CC       Rule:MF_01411}.
CC   -!- SUBCELLULAR LOCATION: Cell outer membrane {ECO:0000255|HAMAP-
CC       Rule:MF_01411}.
CC   -!- SIMILARITY: Belongs to the LptD family. {ECO:0000255|HAMAP-
CC       Rule:MF_01411}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=ABM44213.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; CP000539; ABM44213.1; ALT_INIT; Genomic_DNA.
DR   AlphaFoldDB; A1WD88; -.
DR   SMR; A1WD88; -.
DR   STRING; 232721.Ajs_4112; -.
DR   KEGG; ajs:Ajs_4112; -.
DR   eggNOG; COG1452; Bacteria.
DR   HOGENOM; CLU_009039_0_0_4; -.
DR   Proteomes; UP000000645; Chromosome.
DR   GO; GO:0009279; C:cell outer membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:1990351; C:transporter complex; IEA:TreeGrafter.
DR   GO; GO:0043165; P:Gram-negative-bacterium-type cell outer membrane assembly; IEA:UniProtKB-UniRule.
DR   GO; GO:0015920; P:lipopolysaccharide transport; IEA:InterPro.
DR   HAMAP; MF_01411; LPS_assembly_LptD; 1.
DR   InterPro; IPR020889; LipoPS_assembly_LptD.
DR   InterPro; IPR050218; LptD.
DR   InterPro; IPR045659; LptD_2.
DR   InterPro; IPR007543; LptD_C.
DR   PANTHER; PTHR30189; LPS-ASSEMBLY PROTEIN; 1.
DR   PANTHER; PTHR30189:SF1; LPS-ASSEMBLY PROTEIN LPTD; 1.
DR   Pfam; PF04453; LptD; 1.
DR   Pfam; PF19838; LptD_2; 1.
PE   3: Inferred from homology;
KW   Cell outer membrane; Membrane; Signal.
FT   SIGNAL          1..45
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01411""
FT   CHAIN           46..817
FT                   /note=""LPS-assembly protein LptD""
FT                   /id=""PRO_0000281583""
SQ   SEQUENCE   817 AA;  92059 MW;  3227D4ED491CD302 CRC64;
     MDRLPLPHAL HVPTHRPFAA PLPPRRLLAR LAALMLCGVP LAVLAQAQPS QDAAPAEPPP
     ALRSSPRLQE VLPYGIRQQL PVFVRGDRVT GQPDIQATIE GNAELRRGDT VVHADRMQYD
     VADDRARASG NVLINRAGNR YEGSQLDLRV EAFTGFFSDA RYRFLETAAH GQASRVDFLD
     RDRSVVHNAT YTTCERTDEA SWQPDWILRA ERIHLDRVED VGTAENGVLE FKGVPVLPIP
     RITFPLSDRR KSGLLPPTLG LDSVSGFEYA QPYYWNIAPN RDATITPTVM TRRGVALGTE
     FRYLEPRYSG ELTADYMPND RLRDRDRWAY GIKHRATFDT PAGGVGLGID IKRVSDDNYW
     RDFSQRNSGR SGVNDQLTQR LLPGDATLNW ARGEHSLLLR TLKWQTLQDV NAPIIPPYDR
     MPQLRWEYRP LQLAGGLDAS VEADYTSFHA DRAYTGQPNA KRSYTMAQVS RPFLAPAGFI
     TPRVQLHSTH YEFDAPLANG QRTASRTLPT FSLDSGLVFE RDARYFGRDF LQTLEPRAFY
     TYTPYRDQRL LPIYDTAVND FNFASIYTEN AFGGQDRLAD NNLLTLGVTT RLLDPDTGAE
     AARFGVAQRV RFSDQEVTMP GGSPVNERLS DVLLGAGINW TPQWGFDSTV QYNPKTGRSL
     RTTVGARYSP GNYRTVSAAY RMQKVTGLIT EPSEQIDVGW QWPLNDLWGD RGDKPSSAGG
     RWYSVGRLNY SLQDRKLVDT VVGLEYESCC WIGRVVLERL QRSVTSSNTR LMFQIEFIGF
     SRLSLGSNPL SSLKQNVPRY QFLRESVSTP SRFTQYD
//
",45724
GTGCTT TGCTTG GCTTGA CTTGAA TTGAAG TGAAGT GAAGTT AAGTTG AGTTGC GTTGCC TTGCCA TGCCAA GCCAAC CCAACC CAACCT AACCTC ACCTCC CCTCCG CTCCGC TCCGCA CCGCAG CGCAGC GCAGCG CAGCGC AGCGCC GCGCCT CGCCTA GCCTAT CCTATG CTATGG TATGGC ATGGCC TGGCCG GGCCGG GCCGGA CCGGAT CGGATC GGATCG GATCGA ATCGAG TCGAGG CGAGGT GAGGTG AGGTGC GGTGCT GTGCTG TGCTGC GCTGCA CTGCAC TGCACG GCACGG CACGGC ACGGCG CGGCGT GGCGTC GCGTCA CGTCAA GTCAAC TCAACC CAACCT AACCTT ACCTTG CCTTGC CTTGCC TTGCCG TGCCGT GCCGTG CCGTGC CGTGCG GTGCGG TGCGGG GCGGGC CGGGCA GGGCAG GGCAGG GCAGGC CAGGCG AGGCGA GGCGAG GCGAGG CGAGGT GAGGTG AGGTGG GGTGGT GTGGTC TGGTCG GGTCGC GTCGCC TCGCCC CGCCCT GCCCTG CCCTGA CCTGAT CTGATC TGATCG GATCGG ATCGGC TCGGCT CGGCTC GGCTCC GCTCCA CTCCAA TCCAAC CCAACG CAACGG AACGGC ACGGCG CGGCGC GGCGCG GCGCGG CGCGGG GCGGGA CGGGAA GGGAAA GGAAAG GAAAGA AAAGAC AAGACG,2,118,CG TGCGC C T TGTGCGCTCT  GGGGCGC CTTTT T C CTCTTTG G TG TTTGTGAGA GCT TGAGTG CAA A G GAGAAAAGAG G A AATGAGT TGC AGCA GTTTT T GG CGTTTTGTG G T TTTTGTGCGC C T TGT AGCCC GGCCCCACA A C CCCCACAAAA A C CACAAAAC TG AAAACACCCC C A ACACC AGCT T C CCCCTCTCTC C CCGCCTCTCCCC C T TCTCCCCGCG G C CCCCGCGCC CAGC CTGCACA A G GCAG G C CACAGCGGC ACCTAGCGCGGTGG G GC GCCGCGC  CGCGCGCCCC C GGCCCCTCT T C CCCCTTA A C CTCTATATAT T T TATATATGC A ATATGTGGGG G T TGTGGGGCGC C G GGGGTGCCCC C G GCGCCCCGCG G C CCCCGCGGGG G C CGCG GGAGA A GG A GAGATAT AC ATCC A ATATCTCGCG CGG TCCGAGA A C CGGAGAG G G GAGAGAGGGG G ACCAAGGGGCGT T GGGTTG G G GTGTGTGCGC  GATGCGCTCT T G GCA TCTGTG CC  CTCTGTGCGC GCG TGA CGCAAGT GATGAGCAAC C C CACAGACGCG G AA GACGCGGG CTG CGGGC C G GGGGCGCGGTCAAC GCGCGCGTGT T C CGCGTCGGTC C G GTGTCTCACA A T TCTCACAAAA A C CACAAAACAC C A AAACCG CTG  ACCCTCT T C CCCCTCTTTT T C CTCTT TC TT TTTTG GCC T TGTGCGCCCC C G GCGCC GTG CT GCCGA GT C CGCGTGTGTG GCA GTAC G GC T TGTGCCG G GGC GCGCGGG CG GG TGGGGG G G GGGGGGGCGC  AC GGGGCGCACA A GGGCCACAG GAA CAAGGGG G A AGAGG CGGAA GGGGCGCGAACG G GCGCGCGAGA TGCCGAGAGAG G G GAGAGAGGGG G A AGAGGGGTGT T GTC GGTGTGG GGTGTCGGG G TCGCTGGGT T G GGGGTGTCTC C G GTTCGCG G T TCTGGCGCGC C C CGGTGGCCCC C G GCGCCC GC C CCCCCCGGCT  GG CCCCTCTG CGG C CTCTGTGAA T TGGATT GA GGATATC CCC A ATATCTCGCG G TTG CCTGG CCGCGGGCAGC  GC GGGGCGCTCT T G GCGCTCTCTC C C CTCTCCC C T TCTCCCCACA A C CC AGCAAAA  CACAA AAAACACGCG G A ACACGGC GG G C CGCGG GCGC CCC GGGGCGCGCG G G GCGCGCGCGC C C CGCGCGCGCG TGCC GGCGCGGGG G C CGGGGGG  CG GGGGGGGAGA  GCGGAGAACGT GAC GAAAAA  AAAAGAG T C AAAAGAGAGA A A AGGACT GC GC TGACACG, CG TGGCTCT TCCCA GCTCTTTT T GT ACTTTTGTG G C CTCTTTTGGA A T TTTTGTGAG TAA A T TGTGAGAAAAGAG G G GACGTAAGAGTGT T A AA CGTT T A AGAGTGTTTG G G GTCGGTTGTGCGC C T TTTTGTGCGCCCC C TCCTTGCGCCCCACGGA G GCCG CCACAAAA A C CCCCACAAAC C C CACAAAACACCGAG AAAACACCCCTCT T A ACACCCCTCTCTC C C CCCCTCTC TGCC C C CTCTCAAGCCGCG G T TCCA CCGCGCGC C C CCCCGCGCGCAC GA CCGCGCA GCAG G G GCGCACAGAGCGC  CACAGAGCGCGCG G A AGAGCGCGCGCGCAC AGCGCGCGCCCC C C CGCGCGCCCCTT G GCGCC TGCTATA  CCG CTATAT T CTGCGG ATGTG G T TATATATGTGGGG G A ATATGTGGGGCGC C TAC GGAGGCCC C G GGGGCGCCCCGGCCG G GCGCCCCGCGGCTA CCGCTCGGTGGGA A C CGCGG TCAT T G GGGGAGGGTC CA  GAGATTCGCG ATCGTCCGAGA A TTCGA C GCAG G C CGGAGAGGGG G G GAGAGATCGT GCTGTGAGGGGTGTGTG G GGGTGTGTGCGC C G GTTGCGCTCT T T TGTGCGCTCTGTG G G GCA GAAATGCGC C C CTCTGTGCCA A T TGTGCGCACACAC C GCAAGCACACACGCG G C CACACACGCGGGG G A ACACGCGGGGCGC C C CGCGGGGCGCGCG G G GGGGC TCCGTGT CGT GCGAAGTCCGTCTACGTTCGCA A G GTTCACAAAA A T TCTCACAAAACAC C C CACAAAACACCCC C A AAAACACCCCTCT T A ACACCCCTCTTTT T C CCGCTTTGTG G CTGCTTGTGCGC C T TTTTGGCGCC T TTGCTGCGCCCG  GCGCCCCGT GGT T C CCCCGCGTGTGTG G C CGC CGTGGTCGC C G GTGTG GCGCGCG AGG TGTGCGCGCGGGG G G GCGCGCGGGGGGG GTTGGGGGCAGGC G GGGGGGGCC GGCT GGGGCGCACAGAG G GGTCCAGG AGG G C CACAGCGCC GGC C A AGAGGGGCGCG GGG GCG GGCGCGCGAGA A GCTTGCGCGAGAGAG G C CGCGAGAGAGGGG G A GAGAGAGGGGTGT T A AGAGGGGTGTGTG G G GGGGTGTGTGGGG G G GT AGTGGGGTGT T TTGGGTCTC GGC GGGGTGTCTCGG G GTTGCGC C T TCTCGCTGGCCCC  CGCGCGGTCCCCC C G GCGCCCCCCCTCT T CAGACCCCCTCTGTG G C CACCTCTGTGAGA A C CTCGCTGAGAT TGGTGGATATCTC TTG GACGGATCTCGCG GAAATCTCGCGGGG G TGCGTCGCGGGGCGC C CCA GGCCCGCT T G GG GGCCTCTC AGC G GCGCTCTCTCCC CC C CTTCCA TTCCCAACCGA C CCCCACAGAACCGC CCCAAAACACGG AG A AAAACACGCGGTATCGC ACACGCGGGCGGC CC  CGCGGGGC CGCG G G GGGGCGCGCG GC C G GCGGC TGGCGCG GTGGCGGATGG G GG CGGGGCC CGCGGGGGGGAGA  GGGATGGAGAAAA A G GGGGACTGAA A G GAAAGAG G A AAAAAAGAGA A A AATCCAGAGACAC C ATC  CCGACACG,AA GCTCTTT T TGTGCGCTCTTTTGTG G G GCGCTTTGTGAGA A C CTCTTTGAGAAAA A T CCTTGTGAAAGAG G TGAAGT T G GAGAAAAGAGT ATTT T AAAGGTTTTGTG G AAGTGCCCG TGCGC C G GTGTTCCATGCATGCC C TG GTTGTGCGCCCCACA A T TG ACGCCCCATGCCGCA G GCGCCCCACAAAACCGCC CTGCCCACAAG GGTTCC C CGC CAAAACCG CCTCT GCG AAAACGCG CCCTCTC C A ACACCCCTGCGTCCCC C C CCC CTCCCCGCG  CG CTC TTCCCCGAC GC C T TCTCCTCCCGCGCAA C CCCGCGCACAGG CCCCCGCGCACAGAGCGC C G GCCAGAGCTGAG C CACAGAGCGCGG GGCGGTC AGAGCGCGCGCGCCCC C GGCGAA GCCCCTCT T CCGCGCCCCTCTATA A G GCCCTCTATATAT T CCCTTATGCCTG  CTCTATATATGTGGGG G T TAT GATGTGGGC ATGTGGGGCCAACC C T TG AAGCCCCGCG CTG GGGGCCGGGCGG GAGGGCCCCGCGGGGAGA A CGTTCCGCGGGATAT T CTGCCGGGGAATCTC C G GGGGATGCATCTCGACCGCGGATATCTCGCGAGA ACCCGATCGCGAGAGAG G T TCTCGCGAGAGAGGGG G CT GGAGACCGGTGT TAT GACA AGGGTGTG G A AGAGGGGTGTGCAAGC C GGGTGCTGG T G GTGTGGATGCTG CTG G TTGCGCTCTGTGCGC C G GC GCGCACA A C CTCTGTGCGCACACAC C T TGC TCACACGCG G G GCGCACACACG TGGG G C CACACACGG GCTGGC C ACGTACGCGGGGCGCGG C CGCGGGGCGCGCGTGT T G GGGGCGCGCGTGTCCC C G GCGG CGTGTCTCGA C CGCGTGTCTCACAAGTGA G GTGTCTCACAAAACAC C T TCTCACAAAACACCCC C C CACAAAACACCCCTAAAT AGGCAACACCCCTCTTCCGT A CGACCCCTTTGTG CTGATCAGGCTTTTGGC C C CTCTTTTGTGCGCCCC  TTTTGTGCGCACCGCG G TCGGTGCGCCTT CGTGT ATCCTGGCCCCGTGCGTGTG G C TTCCGCGTGTGTGCC CCGTGTG ACCA CG G G GTGTGGCGCGGGCCG T TGTGCGCGCGGGG CGC GCGCGCGGGGGTGGGG C C CGCGGGGGGGCGCACTTA G GGGGGGGCGCACAGAG  GGGGCGCACAGAGGGG  GCGCACAGAGGGGCGC C C CACAGAGGGGCGCGCG CTGAGGGGCGGTGCGGA A G GGGGCGCGCGAGAGAG  GCGCGCGACCTA GG C CGTTGGAGAGGGGTGT T GGAGGTGGGTGTGTG G A AG GCGGTTGGCT G G GGGGTGTGTGGGGTGT  GTTGGGGTGTCTC TCG TGGGCAACC AGAGCG  GGGGTGTCGCCCGCGC C GGTCTCGCGCGCCCC C T TCTCGCGCGCCCCCCC CGCGCC CGCCTCT T G GCGCCCCCCCTA CGAT CCCCCCCTTGAGA  CCCCT AGTGAGATAT T CG GCG ATCTC C T TGTGAGATATCTCGCG G G GAGATGGCTCGCGGGG G A AT CCTCGCGGGGCGC CTC TCTCGCGGGGCCT T CG CCGGGGCGCTCTCTC C G GGGGCAAGCTCCCGCAA GCGCTCTCTCCCCACA A C CTCTCTCCCCAC TAA A T TCTTGCAAAACAC C C CCCCAGG AACACGTTGG C CACAAAACCGGGG G A AAAACACGCGGATCC AACGCGGGGCGCGCG G C CGCGGGGCCGACGCGC C G GGGGCG GCGCGCGCG  GCGCGAAG CACGGGG G C CGCGCAGGCGGGGGGG GCG GCCTCCGGGGGGGAGA A CCGGGGGG GGAAAA GC GGGGAACT AA A G GGGGAGAAAAGAG  TTGAAAAAGCTAGAGA A A AAAAACGCAGAGACC AGGCAAGAGAGACACG,TC TGCGAGCGC CGGCTG TAA GCTCTTTTGTGAGA A G GCCGATTGTGAGAAA C CTCTTTTGTGAGAAAG G T TTTTGGGCGCCAAGAGTT TTGAGAAAGTGTTT GGAAAGTGTTTTGTG  GA AAAAGTG TTGTGCGC AC GCGAGTGTTTTGGCCGACC G GTGTTGGTCCTGCCCTTGGCGGCTTGTGCGCCCCACAAAA A T TGTGCGCCCCACAAAACCT C G GCGAACCACAAAACACCC C CCCAAAACACCCCTCT T C CAGCTAACACCCCTCTCGAT AAAACACCCCTCTCTCC ACACCT CCTCTCCCCGCG G C CCCGGCTCTCCCCGCGCGC C C CTCTCTCCCCGCTTGTGCA T G TCTCCCGCGCACAGAG G CCGGG GCGC TCCAGCACGC C C CGTATCAGAGCGCGCG G G GCGCACAGGCGCGCGC C C CACAGGAAGCGCGCGCCCC C A AGAGCGCGCGCAG CCTTCAAAAGGCGCGCGCGCCCCTCTATA A C CGCGCGCCCCTTATAT T GTGAGCCCCTGCAGAGTG G C CCCTATATATGTGGGG G CGGTCTATATATG GAGGC TATATATGTGGGGCGCCCC A G ATTGGCG G T TGTGGGCCCCGCGGGG G GGGCCCGGCTGGAGA A G GCGCCCCGGATAT T C CCCCGCGGGGAATCC C CGCGGC AATCTCGCG GTC GGGGAGATTCGCGAGA C ATGGATCGAGGCCG A ATATCTCGCGAGAGAGGGG G T TCTCGCGAATGAGGGT T CCGAAGGTTGGTGTG G G GAGCTAGGGTGTGCCCAC A AGAGGGGTTGCCGAAC T G GGGAAGTG GAGCTCTGGTTGAT GTGGTTGCTGGTGCGC C T TGTGCCTGTGCGCACA GTCTG CTGGCACACAC C C CTCTGGCACACACGCG G T TGTGCGCACACACGCGGGG CCG GCGCAAGCACGCGGGGCGC C C CACACACG GGGGCGCGGCGG A ACACGCGG TGCGTGAA CGCGGGGCCG G GTGATC C G GGGGCGCGGTCAGGGC A G GCGCGCGTG GTCAAA A CGGCCGTA GCAAAACAC C GCAA GGCCTAACACCCC C TGCATCACAAAACACCGAGCT TGC CACAAAACACCCCTCTTTT CCA AAAACACCCTTC GTG G A ACACCCCTCA TGGAGAC C CCCCTCTTTTGTGCGCCCC C C CTCTTTGCG CCCGG T TTTTGGCCCCGCGTGT T TGCGTGCGCCCGTGTGTG G GGGCGCCAGTCGTGTGTGCGC C C CCCCGCGTGTGGCGCG GCC CGCGTGTGTGCTCAGG G G GTGTGTGCG GCGGGGGGG G T TGTGCGCGCGGGGCCA C G GCGCGCGGGGG TTGCACA A C CGCGGGGGGGCGCAC GG G GGGGGGCACAGAGGGG CGTGTC GCGCACAG CCGGCGA AG  GCGCAGC AGGGCGCG G CAGAAGGGGCCGA AGAGGGGCGCGGAGAG G G GGGGCGCGCTTCCTAGGGG G G GCGCGCGAGAGAGGGGTGT T C CGGCTGAGCCGGGTGTGTG  GAGAGAGGGGTGCACTGGG G A AGAGGGGTGTGTTGGT  GGGTGTGGGGTGTCGTGC G GTTGGGGTGTCTCG GGG T TGTGGGTGGTCTCGCGCGC TTG GGGGTGTCTCGCGCGCCCC  GTGTCGCGCGCGCCCC C TTCGCGCGCCCCCCCTCT T CTTGCGGGCCCCCT GCTGTG G G GCGCCCCCCCTCTGTGAGA A CTCACCCCCTCTGGATAT T C CCCCTCTGTGAG GATCTC C C CTCTGTGAGATATCTCGCG G T TGTGAGATCGGAAACGGGG G G GAGATATCTCGCGGGC C A ATATCTCG CAGGCCGGCT T T TCCAACGGGGCGCTCTCTC C C CGCGGGCTCTCCC C GGGCCTCTCCCCACA A G GCGCTCTCTCCCCATCGAA A C CTCTCTCCACG GTAACC AC T TCTCCCCACAAAACACGCG G C CCCAGCAAAACCCA CCGG G C CACAAAACCGG GCGC C AAACACGCGGGGCGCGCG G AACGCGGGGC AGGC C CCGGGGCTCGCGCGCGCG GCG GGGGCCGCGCGCGGG G GCGCGGGGGG G C CGGCGCGGGGGGGAGA A G GCGCGATCGGGGGAAGCAA A C CGCGGGGGGGAACGAAAAA A GCGGGGGGGAGAAAAAAAGAG GGACG GGAT CCGCAAGTGCG AGAACCTAAGCGGGACC AAAAAAGAGACC GGT,"ID   MGLA_TREDE              Reviewed;         497 AA.
AC   Q73KK2; Q9ZGA2;
DT   28-NOV-2006, integrated into UniProtKB/Swiss-Prot.
DT   05-JUL-2004, sequence version 1.
DT   27-NOV-2024, entry version 129.
DE   RecName: Full=Galactose/methyl galactoside import ATP-binding protein MglA {ECO:0000255|HAMAP-Rule:MF_01717};
DE            EC=7.5.2.11 {ECO:0000255|HAMAP-Rule:MF_01717};
GN   Name=mglA {ECO:0000255|HAMAP-Rule:MF_01717};
GN   OrderedLocusNames=TDE_2216;
OS   Treponema denticola (strain ATCC 35405 / DSM 14222 / CIP 103919 / JCM 8153
OS   / KCTC 15104).
OC   Bacteria; Spirochaetota; Spirochaetia; Spirochaetales; Treponemataceae;
OC   Treponema.
OX   NCBI_TaxID=243275;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=ATCC 35405 / DSM 14222 / CIP 103919 / JCM 8153 / KCTC 15104;
RX   PubMed=11328650; DOI=10.3109/10425170009033992;
RA   Lepine G., Ellen R.P.;
RT   ""MglA and mglB of Treponema denticola; similarity to ABC transport and spa
RT   genes."";
RL   DNA Seq. 11:419-431(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=ATCC 35405 / DSM 14222 / CIP 103919 / JCM 8153 / KCTC 15104;
RX   PubMed=15064399; DOI=10.1073/pnas.0307639101;
RA   Seshadri R., Myers G.S.A., Tettelin H., Eisen J.A., Heidelberg J.F.,
RA   Dodson R.J., Davidsen T.M., DeBoy R.T., Fouts D.E., Haft D.H., Selengut J.,
RA   Ren Q., Brinkac L.M., Madupu R., Kolonay J.F., Durkin S.A., Daugherty S.C.,
RA   Shetty J., Shvartsbeyn A., Gebregeorgis E., Geer K., Tsegaye G.,
RA   Malek J.A., Ayodeji B., Shatsman S., McLeod M.P., Smajs D., Howell J.K.,
RA   Pal S., Amin A., Vashisth P., McNeill T.Z., Xiang Q., Sodergren E.,
RA   Baca E., Weinstock G.M., Norris S.J., Fraser C.M., Paulsen I.T.;
RT   ""Comparison of the genome of the oral pathogen Treponema denticola with
RT   other spirochete genomes."";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:5646-5651(2004).
CC   -!- FUNCTION: Part of the ABC transporter complex MglABC involved in
CC       galactose/methyl galactoside import. Responsible for energy coupling to
CC       the transport system. {ECO:0000255|HAMAP-Rule:MF_01717}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=D-galactose(out) + ATP + H2O = D-galactose(in) + ADP +
CC         phosphate + H(+); Xref=Rhea:RHEA:60156, ChEBI:CHEBI:4139,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:43474, ChEBI:CHEBI:456216; EC=7.5.2.11;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_01717};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:60157;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_01717};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=methyl beta-D-galactoside(out) + ATP + H2O = methyl beta-D-
CC         galactoside(in) + ADP + phosphate + H(+); Xref=Rhea:RHEA:72531,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:17540,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:43474, ChEBI:CHEBI:456216;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_01717};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:72532;
CC         Evidence={ECO:0000255|HAMAP-Rule:MF_01717};
CC   -!- SUBUNIT: The complex is composed of one ATP-binding protein (MglA), two
CC       transmembrane proteins (MglC) and a solute-binding protein (MglB).
CC       {ECO:0000255|HAMAP-Rule:MF_01717}.
CC   -!- SUBCELLULAR LOCATION: Cell inner membrane {ECO:0000255|HAMAP-
CC       Rule:MF_01717}; Peripheral membrane protein {ECO:0000255|HAMAP-
CC       Rule:MF_01717}.
CC   -!- SIMILARITY: Belongs to the ABC transporter superfamily.
CC       Galactose/methyl galactoside importer (TC 3.A.1.2.3) family.
CC       {ECO:0000255|HAMAP-Rule:MF_01717}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF082511; AAD05298.1; -; Genomic_DNA.
DR   EMBL; AE017226; AAS12735.1; -; Genomic_DNA.
DR   RefSeq; NP_972816.1; NC_002967.9.
DR   RefSeq; WP_002680067.1; NC_002967.9.
DR   AlphaFoldDB; Q73KK2; -.
DR   SMR; Q73KK2; -.
DR   STRING; 243275.TDE_2216; -.
DR   PaxDb; 243275-TDE_2216; -.
DR   GeneID; 2739492; -.
DR   KEGG; tde:TDE_2216; -.
DR   PATRIC; fig|243275.7.peg.2093; -.
DR   eggNOG; COG1129; Bacteria.
DR   HOGENOM; CLU_000604_92_3_12; -.
DR   OrthoDB; 304830at2; -.
DR   BRENDA; 7.5.2.11; 6426.
DR   Proteomes; UP000008212; Chromosome.
DR   GO; GO:0005886; C:plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0016887; F:ATP hydrolysis activity; IEA:InterPro.
DR   CDD; cd03216; ABC_Carb_Monos_I; 1.
DR   CDD; cd03215; ABC_Carb_Monos_II; 1.
DR   FunFam; 3.40.50.300:FF:000127; Ribose import ATP-binding protein RbsA; 1.
DR   Gene3D; 3.40.50.300; P-loop containing nucleotide triphosphate hydrolases; 2.
DR   InterPro; IPR003593; AAA+_ATPase.
DR   InterPro; IPR050107; ABC_carbohydrate_import_ATPase.
DR   InterPro; IPR003439; ABC_transporter-like_ATP-bd.
DR   InterPro; IPR017871; ABC_transporter-like_CS.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   PANTHER; PTHR43790; CARBOHYDRATE TRANSPORT ATP-BINDING PROTEIN MG119-RELATED; 1.
DR   PANTHER; PTHR43790:SF7; GALACTOSE_METHYL GALACTOSIDE IMPORT ATP-BINDING PROTEIN MGLA; 1.
DR   Pfam; PF00005; ABC_tran; 2.
DR   SMART; SM00382; AAA; 2.
DR   SUPFAM; SSF52540; P-loop containing nucleoside triphosphate hydrolases; 2.
DR   PROSITE; PS00211; ABC_TRANSPORTER_1; 1.
DR   PROSITE; PS50893; ABC_TRANSPORTER_2; 2.
DR   PROSITE; PS51260; MGLA; 1.
PE   3: Inferred from homology;
KW   ATP-binding; Cell inner membrane; Cell membrane; Membrane;
KW   Nucleotide-binding; Reference proteome; Repeat; Sugar transport;
KW   Translocase; Transport.
FT   CHAIN           1..497
FT                   /note=""Galactose/methyl galactoside import ATP-binding
FT                   protein MglA""
FT                   /id=""PRO_0000261376""
FT   DOMAIN          6..241
FT                   /note=""ABC transporter 1""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01717""
FT   DOMAIN          252..497
FT                   /note=""ABC transporter 2""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01717""
FT   BINDING         38..45
FT                   /ligand=""ATP""
FT                   /ligand_id=""ChEBI:CHEBI:30616""
FT                   /evidence=""ECO:0000255|HAMAP-Rule:MF_01717""
FT   CONFLICT        299
FT                   /note=""E -> G (in Ref. 1; AAD05298)""
FT                   /evidence=""ECO:0000305""
SQ   SEQUENCE   497 AA;  55284 MW;  D70DFF1DA2EF0500 CRC64;
     MSDVVLEIKN LSKSFGKNKV LDGINLTVRQ GSVMGLMGEN GAGKSTMMKC LFGIYTRDEG
     AISLLNKSIE FKNPKEALES GVAMVHQELN LCLDRTVTDN LFLGRYPTNF GIVDEIKMFE
     SASSLFSSLN MNVNPKTIMR TMSVSQRQMV EIAKAVSYNA KLIVLDEPTS SLTEREVKKL
     FSIIRALQKK GVSFIYISHK MDEVFEVCDE VAVLRDGKMI LSKPVAGTNM NEIISAMVGR
     SLDKRFPDVD NVPGEDFLKI ENLKTKYAPV LEDISFTVRK GEILGLYGLV GAGRSELLEA
     LFGIRTIESG SISINDKYLK FKSSKEAMAH GFALLTEERK LNGMFGKDTI EFNTVITNLN
     NYKTIGVLSK RKIREAANRE IETMRTRCLS ADQGISALSG GNQQKVIIGK WLERSPDVFL
     MDEPTRGIDV GAKYEIYQLI IKMAKEGKTI IVVSSEMPEI LGITNRIAVM SNRRLAGIVN
     TKETDQETLL RLSAKYL
//
",40337
GGTCCA GTCCAG TCCAGA CCAGAC CAGACA AGACAT GACATG ACATGT CATGTT ATGTTC TGTTCC GTTCCT TTCCTC TCCTCG CCTCGG CTCGGA TCGGAA CGGAAC GGAACT GAACTT AACTTG ACTTGT CTTGTC TTGTCG TGTCGG GTCGGC TCGGCG CGGCGT GGCGTT GCGTTG CGTTGT GTTGTC TTGTCC TGTCCT GTCCTG TCCTGC CCTGCT CTGCTG TGCTGA GCTGAA CTGAAA TGAAAT GAAATT AAATTG AATTGT ATTGTT TTGTTG TGTTGA GTTGAC TTGACA TGACAC GACACT ACACTG CACTGT ACTGTG CTGTGA TGTGAG GTGAGT TGAGTG GAGTGC AGTGCT GTGCTT TGCTTT GCTTTG CTTTGG TTTGGT TTGGTT TGGTTT GGTTTA GTTTAT TTTATG TTATGA TATGAT ATGATA TGATAA GATAAT ATAATA TAATAA AATAAG ATAAGC TAAGCT AAGCTT AGCTTA GCTTAA CTTAAA,0,85,GGTC GTCC TCCA CCAG CAGA AGAC GACA ACAT CATG ATGT TGTT GTTC TTCC TCCT CCTC CTCG TCGG CGGA GGAA GAAC AACT ACTT CTTG TTGT TGTC GTCG TCGG CGGC GGCG GCGT CGTT GTTG TTGT TGTC GTCC TCCT CCTG CTGC TGCT GCTG CTGA TGAA GAAA AAAT AATT ATTG TTGT TGTT GTTG TTGA TGAC GACA ACAC CACT ACTG CTGT TGTG GTGA TGAG GAGT AGTG GTGC TGCT GCTT CTTT TTTG TTGG TGGT GGTT GTTT TTTA TTAT TATG ATGA TGAT GATA ATAA TAAT AATA ATAA TAAG AAGC AGCT GCTT CTTA TTAA TAAA,GGTCC GTCCA TCCAG CCAGA CAGAC AGACA GACAT ACATG CATGT ATGTT TGTTC GTTCC TTCCT TCCTC CCTCG CTCGG TCGGA CGGAA GGAAC GAACT AACTT ACTTG CTTGT TTGTC TGTCG GTCGG TCGGC CGGCG GGCGT GCGTT CGTTG GTTGT TTGTC TGTCC GTCCT TCCTG CCTGC CTGCT TGCTG GCTGA CTGAA TGAAA GAAAT AAATT AATTG ATTGT TTGTT TGTTG GTTGA TTGAC TGACA GACAC ACACT CACTG ACTGT CTGTG TGTGA GTGAG TGAGT GAGTG AGTGC GTGCT TGCTT GCTTT CTTTG TTTGG TTGGT TGGTT GGTTT GTTTA TTTAT TTATG TATGA ATGAT TGATA GATAA ATAAT TAATA AATAA ATAAG TAAGC AAGCT AGCTT GCTTA CTTAA TTAAA,GGTCCA GTCCAG TCCAGA CCAGAC CAGACA AGACAT GACATG ACATGT CATGTT ATGTTC TGTTCC GTTCCT TTCCTC TCCTCG CCTCGG CTCGGA TCGGAA CGGAAC GGAACT GAACTT AACTTG ACTTGT CTTGTC TTGTCG TGTCGG GTCGGC TCGGCG CGGCGT GGCGTT GCGTTG CGTTGT GTTGTC TTGTCC TGTCCT GTCCTG TCCTGC CCTGCT CTGCTG TGCTGA GCTGAA CTGAAA TGAAAT GAAATT AAATTG AATTGT ATTGTT TTGTTG TGTTGA GTTGAC TTGACA TGACAC GACACT ACACTG CACTGT ACTGTG CTGTGA TGTGAG GTGAGT TGAGTG GAGTGC AGTGCT GTGCTT TGCTTT GCTTTG CTTTGG TTTGGT TTGGTT TGGTTT GGTTTA GTTTAT TTTATG TTATGA TATGAT ATGATA TGATAA GATAAT ATAATA TAATAA AATAAG ATAAGC TAAGCT AAGCTT AGCTTA GCTTAA CTTAAA,GGTCCAG GTCCAGA TCCAGAC CCAGACA CAGACAT AGACATG GACATGT ACATGTT CATGTTC ATGTTCC TGTTCCT GTTCCTC TTCCTCG TCCTCGG CCTCGGA CTCGGAA TCGGAAC CGGAACT GGAACTT GAACTTG AACTTGT ACTTGTC CTTGTCG TTGTCGG TGTCGGC GTCGGCG TCGGCGT CGGCGTT GGCGTTG GCGTTGT CGTTGTC GTTGTCC TTGTCCT TGTCCTG GTCCTGC TCCTGCT CCTGCTG CTGCTGA TGCTGAA GCTGAAA CTGAAAT TGAAATT GAAATTG AAATTGT AATTGTT ATTGTTG TTGTTGA TGTTGAC GTTGACA TTGACAC TGACACT GACACTG ACACTGT CACTGTG ACTGTGA CTGTGAG TGTGAGT GTGAGTG TGAGTGC GAGTGCT AGTGCTT GTGCTTT TGCTTTG GCTTTGG CTTTGGT TTTGGTT TTGGTTT TGGTTTA GGTTTAT GTTTATG TTTATGA TTATGAT TATGATA ATGATAA TGATAAT GATAATA ATAATAA TAATAAG AATAAGC ATAAGCT TAAGCTT AAGCTTA AGCTTAA GCTTAAA,"ID   R1AB_SARS2              Reviewed;        7096 AA.
AC   P0DTD1;
DT   22-APR-2020, integrated into UniProtKB/Swiss-Prot.
DT   22-APR-2020, sequence version 1.
DT   05-FEB-2025, entry version 26.
DE   RecName: Full=Replicase polyprotein 1ab;
DE            Short=pp1ab;
DE   AltName: Full=ORF1ab polyprotein;
DE   Contains:
DE     RecName: Full=Host translation inhibitor nsp1;
DE     AltName: Full=Leader protein;
DE     AltName: Full=Non-structural protein 1;
DE              Short=nsp1;
DE   Contains:
DE     RecName: Full=Non-structural protein 2;
DE              Short=nsp2;
DE     AltName: Full=p65 homolog;
DE   Contains:
DE     RecName: Full=Papain-like protease nsp3 {ECO:0000303|PubMed:32726803};
DE              EC=3.4.19.12 {ECO:0000269|PubMed:32726803};
DE              EC=3.4.22.-;
DE     AltName: Full=Non-structural protein 3;
DE              Short=nsp3;
DE     AltName: Full=PL2-PRO;
DE     AltName: Full=Papain-like proteinase;
DE              Short=PL-PRO;
DE   Contains:
DE     RecName: Full=Non-structural protein 4;
DE              Short=nsp4;
DE   Contains:
DE     RecName: Full=3C-like proteinase nsp5;
DE              Short=3CL-PRO;
DE              Short=3CLp;
DE              EC=3.4.22.69 {ECO:0000269|PubMed:32198291, ECO:0000269|PubMed:32272481};
DE     AltName: Full=Main protease;
DE              Short=Mpro {ECO:0000303|PubMed:32272481};
DE     AltName: Full=Non-structural protein 5;
DE              Short=nsp5;
DE     AltName: Full=SARS coronavirus main proteinase;
DE   Contains:
DE     RecName: Full=Non-structural protein 6;
DE              Short=nsp6;
DE   Contains:
DE     RecName: Full=Non-structural protein 7;
DE              Short=nsp7;
DE   Contains:
DE     RecName: Full=Non-structural protein 8;
DE              Short=nsp8;
DE   Contains:
DE     RecName: Full=Viral protein genome-linked nsp9 {ECO:0000305|PubMed:37794589};
DE     AltName: Full=Non-structural protein 9;
DE              Short=nsp9;
DE     AltName: Full=RNA-capping enzyme subunit nsp9;
DE   Contains:
DE     RecName: Full=Non-structural protein 10;
DE              Short=nsp10;
DE     AltName: Full=Growth factor-like peptide;
DE              Short=GFL;
DE   Contains:
DE     RecName: Full=RNA-directed RNA polymerase nsp12;
DE              Short=Pol;
DE              Short=RdRp;
DE              EC=2.7.7.48;
DE              EC=2.7.7.50 {ECO:0000269|PubMed:35944563};
DE     AltName: Full=Non-structural protein 12;
DE              Short=nsp12;
DE   Contains:
DE     RecName: Full=Helicase nsp13;
DE              Short=Hel;
DE              EC=3.6.4.12;
DE              EC=3.6.4.13;
DE     AltName: Full=Non-structural protein 13;
DE              Short=nsp13;
DE   Contains:
DE     RecName: Full=Guanine-N7 methyltransferase nsp14;
DE              EC=2.1.1.56 {ECO:0000269|PubMed:35944563};
DE              EC=3.1.13.-;
DE     AltName: Full=Non-structural protein 14;
DE              Short=nsp14;
DE     AltName: Full=Proofreading exoribonuclease nsp14;
DE              Short=ExoN;
DE   Contains:
DE     RecName: Full=Uridylate-specific endoribonuclease nsp15;
DE              EC=4.6.1.- {ECO:0000269|PubMed:33504779, ECO:0000269|PubMed:33564093};
DE     AltName: Full=NendoU;
DE     AltName: Full=Non-structural protein 15;
DE              Short=nsp15;
DE   Contains:
DE     RecName: Full=2'-O-methyltransferase nsp16;
DE              EC=2.1.1.57;
DE     AltName: Full=Non-structural protein 16;
DE              Short=nsp16;
GN   Name=rep; ORFNames=1a-1b;
OS   Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2).
OC   Viruses; Riboviria; Orthornavirae; Pisuviricota; Pisoniviricetes;
OC   Nidovirales; Cornidovirineae; Coronaviridae; Orthocoronavirinae;
OC   Betacoronavirus; Sarbecovirus;
OC   Severe acute respiratory syndrome coronavirus.
OX   NCBI_TaxID=2697049;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA].
RX   PubMed=32015508; DOI=10.1038/s41586-020-2008-3;
RA   Wu F., Zhao S., Yu B., Chen Y.-M., Wang W., Song Z.-G., Hu Y., Tao Z.-W.,
RA   Tian J.-H., Pei Y.-Y., Yuan M.-L., Zhang Y.-L., Dai F.-H., Liu Y.,
RA   Wang Q.-M., Zheng J.-J., Xu L., Holmes E.C., Zhang Y.-Z.;
RT   ""A new coronavirus associated with human respiratory disease in China."";
RL   Nature 579:265-269(2020).
RN   [2]
RP   VARIANTS ILE-1001; ASP-1708; THR-2230 AND 3675-SER--PHE-3677 DEL.
RC   STRAIN=20B/501Y.V1, B.1.1.7, VOC-202012/01, and VUI-202012/01;
RX   PubMed=33413740; DOI=10.2807/1560-7917.es.2020.26.1.2002106;
RA   Leung K., Shum M.H., Leung G.M., Lam T.T., Wu J.T.;
RT   ""Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-
RT   2 in the United Kingdom, October to November 2020."";
RL   Eurosurveillance 26:0-0(2021).
RN   [3]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=33479166; DOI=10.1073/pnas.2017715118;
RA   Lapointe C.P., Grosely R., Johnson A.G., Wang J., Fernandez I.S.,
RA   Puglisi J.D.;
RT   ""Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome
RT   inhibits translation initiation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 118:0-0(2021).
RN   [4]
RP   FUNCTION (2'-O-METHYLTRANSFERASE NSP16), SUBCELLULAR LOCATION
RP   (2'-O-METHYLTRANSFERASE NSP16), FUNCTION (HOST TRANSLATION INHIBITOR NSP1),
RP   FUNCTION(NON-STRUCTURAL PROTEIN 8), FUNCTION (NON-STRUCTURAL PROTEIN 9),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 8), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=33080218; DOI=10.1016/j.cell.2020.10.004;
RA   Banerjee A.K., Blanco M.R., Bruce E.A., Honson D.D., Chen L.M., Chow A.,
RA   Bhat P., Ollikainen N., Quinodoz S.A., Loney C., Thai J., Miller Z.D.,
RA   Lin A.E., Schmidt M.M., Stewart D.G., Goldfarb D., De Lorenzo G.,
RA   Rihn S.J., Voorhees R.M., Botten J.W., Majumdar D., Guttman M.;
RT   ""SARS-CoV-2 Disrupts Splicing, Translation, and Protein Trafficking to
RT   Suppress Host Defenses."";
RL   Cell 183:1325-1339(2020).
RN   [5]
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), AND MUTAGENESIS OF CYS-1674.
RX   PubMed=33727702; DOI=10.1038/s41564-021-00884-1;
RA   Liu G., Lee J.H., Parker Z.M., Acharya D., Chiang J.J., van Gent M.,
RA   Riedl W., Davis-Gardner M.E., Wies E., Chiang C., Gack M.U.;
RT   ""ISG15-dependent activation of the sensor MDA5 is antagonized by the SARS-
RT   CoV-2 papain-like protease to evade host innate immunity."";
RL   Nat. Microbiol. 6:467-478(2021).
RN   [6]
RP   DISORDERED REGIONS.
RX   PubMed=35108439; DOI=10.1111/febs.16379;
RA   Quaglia F., Salladini E., Carraro M., Minervini G., Tosatto S.C.E.,
RA   Le Mercier P.;
RT   ""SARS-CoV-2 variants preferentially emerge at intrinsically disordered
RT   protein sites helping immune evasion."";
RL   FEBS J. 289:4240-4250(2022).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.16 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3.
RA   Liu X., Zhang B., Jin Z., Yang H., Rao Z.;
RT   ""The crystal structure of 2019-nCoV main protease in complex with an
RT   inhibitor N3."";
RL   Submitted (FEB-2020) to the PDB data bank.
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (1.75 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH ALPHA-KETOAMIDE 13B INHIBITOR, SUBUNIT (3C-LIKE PROTEINASE
RP   NSP5), FUNCTION (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE
RP   PROTEINASE NSP5), ACTIVE SITE (3C-LIKE PROTEINASE NSP5), AND ACTIVITY
RP   REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32198291; DOI=10.1126/science.abb3405;
RA   Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S.,
RA   Rox K., Hilgenfeld R.;
RT   ""Crystal structure of SARS-CoV-2 main protease provides a basis for design
RT   of improved alpha-ketoamide inhibitors."";
RL   Science 368:409-412(2020).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 AND IN
RP   COMPLEX WITH MICHAEL ACCEPTOR INHIBITOR N3, FUNCTION (3C-LIKE PROTEINASE
RP   NSP5) (3C-LIKE PROTEINASE NSP5), CATALYTIC ACTIVITY (3C-LIKE PROTEINASE
RP   NSP5), AND ACTIVITY REGULATION (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32272481; DOI=10.1038/s41586-020-2223-y;
RA   Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L.,
RA   Peng C., Duan Y., Yu J., Wang L., Yang K., Liu F., Jiang R., Yang X.,
RA   You T., Liu X., Yang X., Bai F., Liu H., Liu X., Guddat L.W., Xu W.,
RA   Xiao G., Qin C., Shi Z., Jiang H., Rao Z., Yang H.;
RT   ""Structure of Mpro from COVID-19 virus and discovery of its inhibitors."";
RL   Nature 582:289-293(2020).
RN   [10]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), AND FUNCTION (RNA-DIRECTED RNA
RP   POLYMERASE NSP12).
RX   PubMed=32277040; DOI=10.1126/science.abb7498;
RA   Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q.,
RA   Ming Z., Zhang L., Ge J., Zheng L., Zhang Y., Wang H., Zhu Y., Zhu C.,
RA   Hu T., Hua T., Zhang B., Yang X., Li J., Yang H., Liu Z., Xu W.,
RA   Guddat L.W., Wang Q., Lou Z., Rao Z.;
RT   ""Structure of the RNA-dependent RNA polymerase from COVID-19 virus."";
RL   Science 368:779-782(2020).
RN   [11]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.5 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12 IN
RP   COMPLEX WITH REMDESIVIR ANTIVIRAL DRUG AND IN COMPLEX WITH ZINC ION,
RP   SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8),
RP   SUBUNIT (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12), AND
RP   ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32358203; DOI=10.1126/science.abc1560;
RA   Yin W., Mao C., Luan X., Shen D.D., Shen Q., Su H., Wang X., Zhou F.,
RA   Zhao W., Gao M., Chang S., Xie Y.C., Tian G., Jiang H.W., Tao S.C.,
RA   Shen J., Jiang Y., Jiang H., Xu Y., Zhang S., Zhang Y., Xu H.E.;
RT   ""Structural basis for inhibition of the RNA-dependent RNA polymerase from
RT   SARS-CoV-2 by remdesivir."";
RL   Science 368:1499-1504(2020).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.5 ANGSTROMS) OF 3C-LIKE PROTEINASE NSP5 IN COMPLEX
RP   WITH COMPOUND 11A AND COMPOUND 11B, FUNCTION (3C-LIKE PROTEINASE NSP5),
RP   CATALYTIC ACTIVITY (3C-LIKE PROTEINASE NSP5), AND ACTIVITY REGULATION
RP   (3C-LIKE PROTEINASE NSP5).
RX   PubMed=32321856; DOI=10.1126/science.abb4489;
RA   Dai W., Zhang B., Su H., Li J., Zhao Y., Xie X., Jin Z., Liu F., Li C.,
RA   Li Y., Bai F., Wang H., Cheng X., Cen X., Hu S., Yang X., Wang J., Liu X.,
RA   Xiao G., Jiang H., Rao Z., Zhang L.K., Xu Y., Yang H., Liu H.;
RT   ""Structure-based design of antiviral drug candidates targeting the SARS-
RT   CoV-2 main protease."";
RL   Science 368:1331-1335(2020).
RN   [13]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.9 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE NSP12, SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE), FUNCTION (NON-STRUCTURAL PROTEIN 7),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND CATALYTIC ACTIVITY (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=32438371; DOI=10.1038/s41586-020-2368-8;
RA   Hillen H.S., Kokic G., Farnung L., Dienemann C., Tegunov D., Cramer P.;
RT   ""Structure of replicating SARS-CoV-2 polymerase."";
RL   Nature 584:154-156(2020).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (0.95 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3 MACRO
RP   DOMAIN, AND FUNCTION (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=32578982; DOI=10.1021/acs.biochem.0c00309;
RA   Frick D.N., Virdi R.S., Vuksanovic N., Dahal N., Silvaggi N.R.;
RT   ""Molecular Basis for ADP-ribose Binding to the Mac1 Domain of SARS-CoV-2
RT   Nsp3."";
RL   Biochemistry 59:2608-2615(2020).
RN   [15]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.93 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8 AND RNA-DIRECTED RNA POLYMERASE IN COMPLEX WITH
RP   ZINC ION, SUBUNIT (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL
RP   PROTEIN 8), SUBUNIT (RNA-DIRECTED RNA POLYMERASE NSP12), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 7), FUNCTION (NON-STRUCTURAL PROTEIN 8), FUNCTION
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), CATALYTIC ACTIVITY (RNA-DIRECTED RNA
RP   POLYMERASE NSP12), ACTIVITY REGULATION (RNA-DIRECTED RNA POLYMERASE NSP12),
RP   AND MUTAGENESIS OF SER-5253.
RX   PubMed=32526208; DOI=10.1016/j.cell.2020.05.034;
RA   Wang Q., Wu J., Wang H., Gao Y., Liu Q., Mu A., Ji W., Yan L., Zhu Y.,
RA   Zhu C., Fang X., Yang X., Huang Y., Gao H., Liu F., Ge J., Sun Q., Yang X.,
RA   Xu W., Liu Z., Yang H., Lou Z., Jiang B., Guddat L.W., Gong P., Rao Z.;
RT   ""Structural Basis for RNA Replication by the SARS-CoV-2 Polymerase."";
RL   Cell 182:417-428(2020).
RN   [16] {ECO:0007744|PDB:6YVA}
RP   X-RAY CRYSTALLOGRAPHY (3.18 ANGSTROMS) OF NON-STRUCTURAL PROTEIN 3,
RP   FUNCTION (PAPAIN-LIKE PROTEASE NSP3), CATALYTIC ACTIVITY (PAPAIN-LIKE
RP   PROTEASE NSP3), ACTIVITY REGULATION (PAPAIN-LIKE PROTEASE NSP3), AND
RP   MUTAGENESIS OF VAL-1629; PHE-1632; THR-1638; CYS-1674 AND TYR-1831.
RX   PubMed=32726803; DOI=10.1038/s41586-020-2601-5;
RA   Shin D., Mukherjee R., Grewe D., Bojkova D., Baek K., Bhattacharya A.,
RA   Schulz L., Widera M., Mehdipour A.R., Tascher G., Geurink P.P., Wilhelm A.,
RA   van der Heden van Noort G.J., Ovaa H., Mueller S., Knobeloch K.P.,
RA   Rajalingam K., Schulman B.A., Cinatl J., Hummer G., Ciesek S., Dikic I.;
RT   ""Papain-like protease regulates SARS-CoV-2 viral spread and innate
RT   immunity."";
RL   Nature 587:657-662(2020).
RN   [17]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.6 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF LYS-164 AND
RP   HIS-165.
RX   PubMed=32680882; DOI=10.1126/science.abc8665;
RA   Thoms M., Buschauer R., Ameismeier M., Koepke L., Denk T.,
RA   Hirschenberger M., Kratzat H., Hayn M., Mackens-Kiani T., Cheng J.,
RA   Straub J.H., Stuerzel C.M., Froehlich T., Berninghausen O., Becker T.,
RA   Kirchhoff F., Sparrer K.M.J., Beckmann R.;
RT   ""Structural basis for translational shutdown and immune evasion by the Nsp1
RT   protein of SARS-CoV-2."";
RL   Science 369:1249-1255(2020).
RN   [18]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1).
RX   PubMed=32733001; DOI=10.1038/s41467-020-17665-9;
RA   Lei X., Dong X., Ma R., Wang W., Xiao X., Tian Z., Wang C., Wang Y., Li L.,
RA   Ren L., Guo F., Zhao Z., Zhou Z., Xiang Z., Wang J.;
RT   ""Activation and evasion of type I interferon responses by SARS-CoV-2."";
RL   Nat. Commun. 11:3810-3810(2020).
RN   [19]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 1), FUNCTION (NON-STRUCTURAL PROTEIN 6),
RP   FUNCTION (HELICASE NSP13), INTERACTION WITH HOST TBK1 (NON-STRUCTURAL
RP   PROTEIN 6), AND INTERACTION WITH HOST TBK1 (HELICASE NSP13).
RX   PubMed=32979938; DOI=10.1016/j.celrep.2020.108234;
RA   Xia H., Cao Z., Xie X., Zhang X., Chen J.Y., Wang H., Menachery V.D.,
RA   Rajsbaum R., Shi P.Y.;
RT   ""Evasion of Type I Interferon by SARS-CoV-2."";
RL   Cell Rep. 33:108234-108234(2020).
RN   [20]
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 1), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION (3C-LIKE PROTEINASE NSP5),
RP   SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 7), SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 8), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN
RP   9), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 10), AND SUBCELLULAR
RP   LOCATION (PROOFREADING EXORIBONUCLEASE).
RX   PubMed=33060197; DOI=10.1126/science.abe9403;
RG   QCRG Structural Biology Consortium;
RG   Zoonomia Consortium;
RA   Gordon D.E., Hiatt J., Bouhaddou M., Rezelj V.V., Ulferts S., Braberg H.,
RA   Jureka A.S., Obernier K., Guo J.Z., Batra J., Kaake R.M., Weckstein A.R.,
RA   Owens T.W., Gupta M., Pourmal S., Titus E.W., Cakir M., Soucheray M.,
RA   McGregor M., Cakir Z., Jang G., O'Meara M.J., Tummino T.A., Zhang Z.,
RA   Foussard H., Rojc A., Zhou Y., Kuchenov D., Huettenhain R., Xu J.,
RA   Eckhardt M., Swaney D.L., Fabius J.M., Ummadi M., Tutuncuoglu B.,
RA   Rathore U., Modak M., Haas P., Haas K.M., Naing Z.Z.C., Pulido E.H.,
RA   Shi Y., Barrio-Hernandez I., Memon D., Petsalaki E., Dunham A.,
RA   Marrero M.C., Burke D., Koh C., Vallet T., Silvas J.A., Azumaya C.M.,
RA   Billesboelle C., Brilot A.F., Campbell M.G., Diallo A., Dickinson M.S.,
RA   Diwanji D., Herrera N., Hoppe N., Kratochvil H.T., Liu Y., Merz G.E.,
RA   Moritz M., Nguyen H.C., Nowotny C., Puchades C., Rizo A.N.,
RA   Schulze-Gahmen U., Smith A.M., Sun M., Young I.D., Zhao J., Asarnow D.,
RA   Biel J., Bowen A., Braxton J.R., Chen J., Chio C.M., Chio U.S.,
RA   Deshpande I., Doan L., Faust B., Flores S., Jin M., Kim K., Lam V.L.,
RA   Li F., Li J., Li Y.L., Li Y., Liu X., Lo M., Lopez K.E., Melo A.A.,
RA   Moss F.R. III, Nguyen P., Paulino J., Pawar K.I., Peters J.K.,
RA   Pospiech T.H. Jr., Safari M., Sangwan S., Schaefer K., Thomas P.V.,
RA   Thwin A.C., Trenker R., Tse E., Tsui T.K.M., Wang F., Whitis N., Yu Z.,
RA   Zhang K., Zhang Y., Zhou F., Saltzberg D., Hodder A.J., Shun-Shion A.S.,
RA   Williams D.M., White K.M., Rosales R., Kehrer T., Miorin L., Moreno E.,
RA   Patel A.H., Rihn S., Khalid M.M., Vallejo-Gracia A., Fozouni P.,
RA   Simoneau C.R., Roth T.L., Wu D., Karim M.A., Ghoussaini M., Dunham I.,
RA   Berardi F., Weigang S., Chazal M., Park J., Logue J., McGrath M.,
RA   Weston S., Haupt R., Hastie C.J., Elliott M., Brown F., Burness K.A.,
RA   Reid E., Dorward M., Johnson C., Wilkinson S.G., Geyer A., Giesel D.M.,
RA   Baillie C., Raggett S., Leech H., Toth R., Goodman N., Keough K.C.,
RA   Lind A.L., Klesh R.J., Hemphill K.R., Carlson-Stevermer J., Oki J.,
RA   Holden K., Maures T., Pollard K.S., Sali A., Agard D.A., Cheng Y.,
RA   Fraser J.S., Frost A., Jura N., Kortemme T., Manglik A., Southworth D.R.,
RA   Stroud R.M., Alessi D.R., Davies P., Frieman M.B., Ideker T., Abate C.,
RA   Jouvenet N., Kochs G., Shoichet B., Ott M., Palmarini M., Shokat K.M.,
RA   Garcia-Sastre A., Rassen J.A., Grosse R., Rosenberg O.S., Verba K.A.,
RA   Basler C.F., Vignuzzi M., Peden A.A., Beltrao P., Krogan N.J.;
RT   ""Comparative host-coronavirus protein interaction networks reveal pan-viral
RT   disease mechanisms."";
RL   Science 0:0-0(2020).
RN   [21]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 3), AND SUBCELLULAR LOCATION
RP   (NON-STRUCTURAL PROTEIN 3).
RX   PubMed=32763915; DOI=10.1126/science.abd3629;
RA   Wolff G., Limpens R.W.A.L., Zevenhoven-Dobbe J.C., Laugks U., Zheng S.,
RA   de Jong A.W.M., Koning R.I., Agard D.A., Gruenewald K., Koster A.J.,
RA   Snijder E.J., Barcena M.;
RT   ""A molecular pore spans the double membrane of the coronavirus replication
RT   organelle."";
RL   Science 369:1395-1398(2020).
RN   [22]
RP   FUNCTION (RNA-CAPPING ENZYME NSP9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), FUNCTION (GUANINE-N7 METHYLTRANSFERASE NSP14), FUNCTION
RP   (NON-STRUCTURAL PROTEIN 10), FUNCTION (2'-O-METHYLTRANSFERASE NSP16),
RP   MUTAGENESIS OF ASN-4141; ASN-4142 AND ARG-5125, INTERACTION WITH NSP9
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND INTERACTION WITH NSP12
RP   (RNA-CAPPING ENZYME NSP9).
RX   PubMed=35944563; DOI=10.1038/s41586-022-05185-z;
RA   Park G.J., Osinski A., Hernandez G., Eitson J.L., Majumdar A., Tonelli M.,
RA   Henzler-Wildman K., Pawlowski K., Chen Z., Li Y., Schoggins J.W.,
RA   Tagliabracci V.S.;
RT   ""The mechanism of RNA capping by SARS-CoV-2."";
RL   Nature 0:0-0(2022).
RN   [23]
RP   REVIEW, FUNCTION (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT
RP   (NON-STRUCTURAL PROTEIN 7), SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT
RP   (RNA-DIRECTED RNA POLYMERASE NSP12), AND SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13).
RX   PubMed=34562452; DOI=10.1016/j.jbc.2021.101218;
RA   Perry J.K., Appleby T.C., Bilello J.P., Feng J.Y., Schmitz U.,
RA   Campbell E.A.;
RT   ""An atomistic model of the coronavirus replication-transcription complex as
RT   a hexamer assembled around nsp15."";
RL   J. Biol. Chem. 297:101218-101218(2021).
RN   [24]
RP   FUNCTION (RNA-DIRECTED RNA POLYMERASE NSP12).
RX   PubMed=33713597; DOI=10.1016/j.molcel.2021.02.036;
RA   Wang D., Jiang A., Feng J., Li G., Guo D., Sajid M., Wu K., Zhang Q.,
RA   Ponty Y., Will S., Liu F., Yu X., Li S., Liu Q., Yang X.L., Guo M., Li X.,
RA   Chen M., Shi Z.L., Lan K., Chen Y., Zhou Y.;
RT   ""The SARS-CoV-2 subgenome landscape and its novel regulatory features."";
RL   Mol. Cell 81:2135-2147(2021).
RN   [25]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 15).
RX   PubMed=35706445; DOI=10.3389/fgene.2022.904513;
RA   Liang J., Shi J., Chen S., Duan G., Yang F., Cheng Z., Li X., Ruan J.,
RA   Mi D., Gao S.;
RT   ""How the Replication and Transcription Complex Functions in Jumping
RT   Transcription of SARS-CoV-2."";
RL   Front. Genet. 13:904513-904513(2022).
RN   [26]
RP   FUNCTION (3C-LIKE PROTEINASE NSP5), AND MUTAGENESIS OF CYS-3408.
RX   PubMed=35594856; DOI=10.1016/j.molcel.2022.04.033;
RG   COVID Human Genetic Effort;
RA   Planes R., Pinilla M., Santoni K., Hessel A., Passemar C., Lay K.,
RA   Paillette P., Valadao A.C., Robinson K.S., Bastard P., Lam N., Fadrique R.,
RA   Rossi I., Pericat D., Bagayoko S., Leon-Icaza S.A., Rombouts Y.,
RA   Perouzel E., Tiraby M., Zhang Q., Cicuta P., Jouanguy E., Neyrolles O.,
RA   Bryant C.E., Floto A.R., Goujon C., Lei F.Z., Martin-Blondel G., Silva S.,
RA   Casanova J.L., Cougoule C., Reversade B., Marcoux J., Ravet E., Meunier E.;
RT   ""Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung
RT   epithelial cells."";
RL   Mol. Cell 82:2385-2400(2022).
RN   [27]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 6), FUNCTION (NON-STRUCTURAL PROTEIN 3),
RP   FUNCTION (NON-STRUCTURAL PROTEIN 4), SUBCELLULAR LOCATION (NON-STRUCTURAL
RP   PROTEIN 6), SUBCELLULAR LOCATION (NON-STRUCTURAL PROTEIN 3), SUBCELLULAR
RP   LOCATION (NON-STRUCTURAL PROTEIN 4), MUTAGENESIS OF 3675-SER--PHE-3677;
RP   PHE-3789 AND THR-3791, ACTIVITY REGULATION (NON-STRUCTURAL PROTEIN 6), AND
RP   INTERACTION WITH HOST ZFYVE1 (NON-STRUCTURAL PROTEIN 6).
RX   PubMed=35551511; DOI=10.1038/s41586-022-04835-6;
RA   Ricciardi S., Guarino A.M., Giaquinto L., Polishchuk E.V., Santoro M.,
RA   Di Tullio G., Wilson C., Panariello F., Soares V.C., Dias S.S.G.,
RA   Santos J.C., Souza T.M.L., Fusco G., Viscardi M., Brandi S., Bozza P.T.,
RA   Polishchuk R.S., Venditti R., De Matteis M.A.;
RT   ""The role of NSP6 in the biogenesis of the SARS-CoV-2 replication
RT   organelle."";
RL   Nature 606:761-768(2022).
RN   [28]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 2), INTERACTION WITH HOST GIGYF2
RP   (NON-STRUCTURAL PROTEIN 2), SUBCELLULAR LOCATION, AND MUTAGENESIS OF
RP   GLY-442.
RX   PubMed=35878012; DOI=10.1073/pnas.2204539119;
RA   Xu Z., Choi J.H., Dai D.L., Luo J., Ladak R.J., Li Q., Wang Y., Zhang C.,
RA   Wiebe S., Liu A.C.H., Ran X., Yang J., Naeli P., Garzia A., Zhou L.,
RA   Mahmood N., Deng Q., Elaish M., Lin R., Mahal L.K., Hobman T.C.,
RA   Pelletier J., Alain T., Vidal S.M., Duchaine T., Mazhab-Jafari M.T.,
RA   Mao X., Jafarnejad S.M., Sonenberg N.;
RT   ""SARS-CoV-2 impairs interferon production via NSP2-induced repression of
RT   mRNA translation."";
RL   Proc. Natl. Acad. Sci. U.S.A. 119:e2204539119-e2204539119(2022).
RN   [29]
RP   FUNCTION (HOST TRANSLATION INHIBITOR NSP1).
RX   PubMed=36534661; DOI=10.1371/journal.ppat.1011041;
RA   Dolliver S.M., Kleer M., Bui-Marinos M.P., Ying S., Corcoran J.A.,
RA   Khaperskyy D.A.;
RT   ""Nsp1 proteins of human coronaviruses HCoV-OC43 and SARS-CoV2 inhibit
RT   stress granule formation."";
RL   PLoS Pathog. 18:e1011041-e1011041(2022).
RN   [30]
RP   FUNCTION (NON-STRUCTURAL PROTEIN 9), FUNCTION (RNA-DIRECTED RNA POLYMERASE
RP   NSP12), AND INTERACTION WITH HOST SND1 (NON-STRUCTURAL PROTEIN 9).
RX   PubMed=37794589; DOI=10.1016/j.cell.2023.09.002;
RA   Schmidt N., Ganskih S., Wei Y., Gabel A., Zielinski S., Keshishian H.,
RA   Lareau C.A., Zimmermann L., Makroczyova J., Pearce C., Krey K., Hennig T.,
RA   Stegmaier S., Moyon L., Horlacher M., Werner S., Aydin J., Olguin-Nava M.,
RA   Potabattula R., Kibe A., Doelken L., Smyth R.P., Caliskan N., Marsico A.,
RA   Krempl C., Bodem J., Pichlmair A., Carr S.A., Chlanda P., Erhard F.,
RA   Munschauer M.;
RT   ""SND1 binds SARS-CoV-2 negative-sense RNA and promotes viral RNA synthesis
RT   through NSP9."";
RL   Cell 186:1-17(2023).
RN   [31]
RP   INTERACTION WITH HOST FBXO22 (3C-LIKE PROTEINASE NSP5), SUBCELLULAR
RP   LOCATION (3C-LIKE PROTEINASE NSP5), AND UBIQUITINATION AT LYS-3268 AND
RP   LYS-3353 (3C-LIKE PROTEINASE NSP5).
RX   PubMed=39223933; DOI=10.1002/jmv.29891;
RA   Zhou Y., Feng W., Yang C., Wei X., Fan L., Wu Y., Gao X., Shen X.,
RA   Zhang Z., Zhao J.;
RT   ""E3 ubiquitin ligase FBXO22 inhibits SARS-CoV-2 replication via promoting
RT   proteasome-dependent degradation of NSP5."";
RL   J. Med. Virol. 96:e29891-e29891(2024).
RN   [32]
RP   STRUCTURE BY ELECTRON MICROSCOPY (2.8 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   1, FUNCTION (NON-STRUCTURAL PROTEIN 1), AND MUTAGENESIS OF
RP   154-TYR--PHE-157; 164-LYS-HIS-165 AND 171-ARG--ARG-175.
RX   PubMed=32908316; DOI=10.1038/s41594-020-0511-8;
RA   Schubert K., Karousis E.D., Jomaa A., Scaiola A., Echeverria B.,
RA   Gurzeler L.A., Leibundgut M., Thiel V., Muehlemann O., Ban N.;
RT   ""SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation."";
RL   Nat. Struct. Mol. Biol. 27:959-966(2020).
RN   [33]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15 IN COMPLEX WITH UTP, CATALYTIC ACTIVITY
RP   (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), MUTAGENESIS OF HIS-6686 AND HIS-6701, AND ACTIVE
RP   SITE (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33504779; DOI=10.1038/s41467-020-20608-z;
RA   Pillon M.C., Frazier M.N., Dillard L.B., Williams J.G., Kocaman S.,
RA   Krahn J.M., Perera L., Hayne C.K., Gordon J., Stewart Z.D., Sobhany M.,
RA   Deterding L.J., Hsu A.L., Dandey V.P., Borgnia M.J., Stanley R.E.;
RT   ""Cryo-EM structures of the SARS-CoV-2 endoribonuclease Nsp15 reveal insight
RT   into nuclease specificity and dynamics."";
RL   Nat. Commun. 12:636-636(2021).
RN   [34]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 6453-679 IN COMPLEX WITH
RP   SUBSTRATE ANALOGS AND INHIBITOR, FUNCTION (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), CATALYTIC ACTIVITY (URIDYLATE-SPECIFIC
RP   ENDORIBONUCLEASE NSP15), SUBUNIT (URIDYLATE-SPECIFIC ENDORIBONUCLEASE
RP   NSP15), AND COFACTOR (URIDYLATE-SPECIFIC ENDORIBONUCLEASE NSP15).
RX   PubMed=33564093; DOI=10.1038/s42003-021-01735-9;
RA   Kim Y., Wower J., Maltseva N., Chang C., Jedrzejczak R., Wilamowski M.,
RA   Kang S., Nicolaescu V., Randall G., Michalska K., Joachimiak A.;
RT   ""Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU
RT   from SARS-CoV-2."";
RL   Commun. Biol. 4:193-193(2021).
RN   [35]
RP   STRUCTURE BY ELECTRON MICROSCOPY (3.3 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   7; NON-STRUCTURAL PROTEIN 8; NON-STRUCTURAL PROTEIN 9; NON-STRUCTURAL
RP   PROTEIN 10; RNA-DIRECTED RNA POLYMERASE NSP12 AND NON-STRUCTURAL PROTEIN
RP   13, SUBUNIT (NON-STRUCTURAL PROTEIN 8), SUBUNIT (NON-STRUCTURAL PROTEIN
RP   13), AND FUNCTION (NON-STRUCTURAL PROTEIN 13).
RX   PubMed=33232691; DOI=10.1016/j.cell.2020.11.016;
RA   Yan L., Ge J., Zheng L., Zhang Y., Gao Y., Wang T., Huang Y., Yang Y.,
RA   Gao S., Li M., Liu Z., Wang H., Li Y., Chen Y., Guddat L.W., Wang Q.,
RA   Rao Z., Lou Z.;
RT   ""Cryo-EM Structure of an Extended SARS-CoV-2 Replication and Transcription
RT   Complex Reveals an Intermediate State in Cap Synthesis."";
RL   Cell 184:184-193(2021).
RN   [36] {ECO:0007744|PDB:7PKU}
RP   STRUCTURE BY NMR OF 834-929 (PAPAIN-LIKE PROTEASE NSP3), AND INTERACTION
RP   WITH N (PAPAIN-LIKE PROTEASE NSP3).
RX   PubMed=35044811; DOI=10.1126/sciadv.abm4034;
RA   Bessa L.M., Guseva S., Camacho-Zarco A.R., Salvi N., Maurin D., Perez L.M.,
RA   Botova M., Malki A., Nanao M., Jensen M.R., Ruigrok R.W.H., Blackledge M.;
RT   ""The intrinsically disordered SARS-CoV-2 nucleoprotein in dynamic complex
RT   with its viral partner nsp3a."";
RL   Sci. Adv. 8:4034-4034(2022).
RN   [37]
RP   STRUCTURE BY ELECTRON MICROSCOPY (1.65 ANGSTROMS) OF NON-STRUCTURAL PROTEIN
RP   14, INTERACTION WITH NSP10 (NON-STRUCTURAL PROTEIN 14), AND INTERACTION
RP   WITH NSP14 (NON-STRUCTURAL PROTEIN 10).
RX   PubMed=36546776; DOI=10.1093/nar/gkac1207;
RA   Imprachim N., Yosaatmadja Y., Newman J.A.;
RT   ""Crystal structures and fragment screening of SARS-CoV-2 NSP14 reveal
RT   details of exoribonuclease activation and mRNA capping and provide starting
RT   points for antiviral drug development."";
RL   Nucleic Acids Res. 51:475-487(2023).
CC   -!- FUNCTION: [Replicase polyprotein 1ab]: Multifunctional protein involved
CC       in the transcription and replication of viral RNAs. Contains the
CC       proteinases responsible for the cleavages of the polyprotein.
CC       {ECO:0000250|UniProtKB:P0C6X7}.
CC   -!- FUNCTION: [Host translation inhibitor nsp1]: Inhibits host translation
CC       by associating with the open head conformation of the 40S subunit
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       The C-terminus binds to and obstructs ribosomal mRNA entry tunnel
CC       (PubMed:32680882, PubMed:32908316, PubMed:33080218, PubMed:33479166).
CC       Thereby inhibits antiviral response triggered by innate immunity or
CC       interferons (PubMed:32680882, PubMed:32979938, PubMed:33080218). The
CC       nsp1-40S ribosome complex further induces an endonucleolytic cleavage
CC       near the 5'UTR of host mRNAs, targeting them for degradation (By
CC       similarity). This inhibits the integrated stress response (ISR) in the
CC       infected cell by preventing EIF2S1/eIF2-alpha phosphorylation upstream
CC       of stress granule formation and depletes host G3BP1 (PubMed:36534661).
CC       Viral mRNAs less susceptible to nsp1-mediated inhibition of
CC       translation, because of their 5'-end leader sequence (PubMed:32908316,
CC       PubMed:33080218). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32680882, ECO:0000269|PubMed:32908316,
CC       ECO:0000269|PubMed:32979938, ECO:0000269|PubMed:33080218,
CC       ECO:0000269|PubMed:33479166, ECO:0000269|PubMed:36534661}.
CC   -!- FUNCTION: [Non-structural protein 2]: Enhances mRNA repression of the
CC       4EHP-GYF2 complex in the host, thereby inhibiting the antiviral
CC       response and facilitating SARS-CoV-2 replication. Possibly acts in
CC       cooperation with nsp1, which induces ribosome stalling on host mRNA,
CC       triggering mRNA repression by the host 4EHP-GYF2 complex which is
CC       enhanced by nsp2. {ECO:0000269|PubMed:35878012}.
CC   -!- FUNCTION: [Papain-like protease nsp3]: Responsible for the cleavages
CC       located at the N-terminus of the replicase polyprotein. Participates
CC       together with nsp4 in the assembly of virally-induced cytoplasmic
CC       double-membrane vesicles necessary for viral replication
CC       (PubMed:35551511). Antagonizes innate immune induction of type I
CC       interferon by blocking the phosphorylation, dimerization and subsequent
CC       nuclear translocation of host IRF3 (PubMed:32733001). Prevents also
CC       host NF-kappa-B signaling (By similarity). In addition, PL-PRO
CC       possesses a deubiquitinating/deISGylating activity and processes both
CC       'Lys-48'- and 'Lys-63'-linked polyubiquitin chains from cellular
CC       substrates (PubMed:32726803). Cleaves preferentially ISG15 from
CC       antiviral protein IFIH1 (MDA5), but not RIGI (PubMed:33727702). Can
CC       play a role in host ADP-ribosylation by ADP-ribose (PubMed:32578982).
CC       Plays a role in the formation and maintenance of double membrane
CC       vesicles (DMVs) replication organelles (PubMed:35551511). DMVs are
CC       formed by nsp3 and nsp4, while nsp6 zippers ER membranes and connects
CC       to lipid droplets (PubMed:35551511). {ECO:0000250|UniProtKB:P0C6X7,
CC       ECO:0000269|PubMed:32578982, ECO:0000269|PubMed:32726803,
CC       ECO:0000269|PubMed:32733001, ECO:0000269|PubMed:33727702,
CC       ECO:0000269|PubMed:35551511}.
CC   -!- FUNCTION: [Non-structural protein 4]: Plays a role in the formation and
CC       maintenance of double membrane vesicles (DMVs) replication organelles
CC       (PubMed:35551511). DMVs are formed by",33
